<SEC-DOCUMENT>0001213900-15-002253.txt : 20150331
<SEC-HEADER>0001213900-15-002253.hdr.sgml : 20150331
<ACCEPTANCE-DATETIME>20150331093516
ACCESSION NUMBER:		0001213900-15-002253
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		20
CONFORMED PERIOD OF REPORT:	20141231
FILED AS OF DATE:		20150331
DATE AS OF CHANGE:		20150331

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DanDrit Biotech USA, Inc.
		CENTRAL INDEX KEY:			0001527728
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				452259340
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-54478
		FILM NUMBER:		15736934

	BUSINESS ADDRESS:	
		STREET 1:		DANDRIT BIOTECH A/S
		STREET 2:		FRUEBJERGVEJ 3 BOX 62
		CITY:			2100 COPENHAGEN
		STATE:			G7
		ZIP:			0
		BUSINESS PHONE:		45 39179840

	MAIL ADDRESS:	
		STREET 1:		DANDRIT BIOTECH A/S
		STREET 2:		FRUEBJERGVEJ 3 BOX 62
		CITY:			2100 COPENHAGEN
		STATE:			G7
		ZIP:			0

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Putnam Hills Corp.
		DATE OF NAME CHANGE:	20110810
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2014_dandritbio.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>United
states</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><B>FORM 10-K</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&#9746;&nbsp;&nbsp;&nbsp;Annual
report under section 13 Or 15(</B></FONT><B>d<FONT STYLE="text-transform: uppercase">) of the securities exchange act of 1934</FONT></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">For the fiscal year ended <B><U>December
31, 2014</U></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&#9744;&nbsp;&nbsp;transition
report under section 13 Or 15(</B></FONT><B>d<FONT STYLE="text-transform: uppercase">) of the securities exchange act of 1934</FONT></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">For the transition period from</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">Commission file number <B><U>000-54478</U></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-bottom: black 1.8pt solid; text-align: center; font-size: 14pt; line-height: 115%"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>DANDRIT
    BIOTECH USA, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; font-size: 10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Name of registrant in its charter)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.8pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Delaware</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 49%; border-bottom: black 1.8pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">45-2559340</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">incorporation or organization)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</FONT><BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif">Identification No.)</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; font-size: 8pt"><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.8pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fruebjergvej 3 Box 62, 2100 Copenhagen, Denmark</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.8pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2100</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>+45 391 79840</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">(Registrant&rsquo;s telephone
number, including area code)</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>DanDrit Biotech USA, Inc.</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>375 Park Avenue, Suite 2607,</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>New York,
NY 10152</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>+1 (212) 763-0184</B></P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center">(Name, address, including zip
code, and telephone number, including area code, of agent for service)&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt">Securities registered pursuant to Section 12(b) of
the Act:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; margin-bottom: 8pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.8pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title of Class</FONT></TD>
    <TD STYLE="width: 2%; text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.8pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name of Exchange</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not applicable</FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%">&nbsp;</TD>
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not applicable</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Securities
registered pursuant to Section 12(g) of the Act: Common Stock, $0.0001 par value</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&nbsp;&#9744;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&nbsp;&#9744;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act
during the last 12 months (or for such shorter period that -the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect; 232.405 of this chapter) during the
preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;Yes&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller
reporting company.</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Large accelerated filer&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="width: 30%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accelerated filer&nbsp;</FONT></TD>
    <TD STYLE="width: 20%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-accelerated filer</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9744;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Smaller reporting company</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9746;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Do not check if a smaller
    reporting company)</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&nbsp;&#9744;&nbsp;Yes&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9746;&nbsp;No</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">On
June 30, 2014, the aggregate market value of the voting and non-voting common equity held by non-affiliates was
$24,956,260.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">Indicate
the number of shares outstanding of each of the issuer&rsquo;s classes of common stock, as of the latest practicable date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify"><FONT STYLE="font-size: 10pt">As of
March 30, 2015, the number of shares of the registrant&rsquo;s classes of common stock outstanding was 9,533,290.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: center; background-color: white"><FONT STYLE="font-size: 10pt"><B>DOCUMENTS
INCORPORATED BY REFERENCE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-align: justify; background-color: white"><FONT STYLE="font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">CONTENTS</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 10%; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"></td>
    <TD STYLE="width: 82%; padding: 0 0 1.5pt; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 8%; text-align: center; padding-top: 0; padding-right: 0; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 0; text-indent: 0; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Page</I></FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; text-align: left; vertical-align: top">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-align: center; text-indent: 0; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_021"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Forward-Looking Statements</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">i</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_022"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Part I</B></FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Business</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">1</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 1A</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_002">Risk Factors</A></FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">34</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 2</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Properties</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 3</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Legal Proceedings</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">50</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 4</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#a_005">Mine Safety Disclosures</A></FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">50</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_023"></A><A HREF="#a_023"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Part II</B></FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 5</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 6</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Selected Financial Data</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">51</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 7</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_008"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management&rsquo;s Discussion and Analysis of Financial Condition and Results Of Operations</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">51</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 7A</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_009"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quantitative and Qualitative Disclosures About Market Risk</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">58</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 8</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_010"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial Statements and Supplementary Data</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">59</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_011"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Changes In and Disagreements With Accountants on Accounting and Financial Disclosure</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">60</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9A</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_020"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controls and Procedures</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">60</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 9B</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_012"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other Information</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">60</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_024"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Part III</B></FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 10</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_013"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Directors, Executive Officers and Corporate Governance</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">61</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 11</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_014"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Executive Compensation</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">63</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 12</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_015"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">65</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 13</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_016"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certain Relationships and Related Transactions and Director Independence</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">66</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 14</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_017"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Principal Accountant Fees and Services</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">68</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_025"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Part IV</B></FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><A HREF="#a_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Item 15</FONT></A></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_018"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exhibits, Financial Statement Schedules</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">70</td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif"><A HREF="#a_019"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signatures and Certifications</FONT></A></td>
    <TD STYLE="text-align: center; padding: 0; text-indent: 0; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">72</td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_021"></A><B>Cautionary Language Regarding Forward-Looking
Statements and Industry Data</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">This Annual Report on Form 10-K contains
&ldquo;forward-looking statements&rdquo;. Forward-looking statements are based upon our current assumptions, expectations and beliefs
concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements
by the following words: &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo;
&ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;approximately,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential&rdquo; or the negative of these terms or other comparable terminology,
although the absence of these words does not necessarily mean that a statement is not forward-looking. This information may involve
known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be
materially different from the future results, performance or achievements expressed or implied by any forward-looking statements.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">Factors that may cause or contribute
actual results to differ from these forward-looking statements include, but are not limited to, the following:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#9679;</P></TD>
    <TD STYLE="width: 95%">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">all the risks inherent in the establishment
        of any new or early stage company</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">our history of losses</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">our ability to eventually generate revenues
        and achieve profitability;</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our limited operating history as a public company;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">emerging competition and rapidly advancing technology in our industry that may outpace our technology;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">eventual customer demand for the products we are currently developing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the impact of competitive or alternative products, technologies and pricing;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to manufacture, or to have manufactured, any products we develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">general economic conditions and events and the impact they may have on us and our potential customers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to obtain adequate financing in the future, as and when we need it;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; text-align: justify; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 2%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our ability to continue as a going concern;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%; line-height: 115%">&nbsp;</TD>
    <TD STYLE="width: 2%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="width: 95%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our success at managing the risks involved in the foregoing items; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%">&nbsp;</TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">other factors discussed in this report.</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">All
forward-looking statements speak only as of the date of this report. We undertake no obligation to update any forward-looking
statements or other information contained herein. Stockholders and potential investors should not place undue reliance on these
forward-looking statements. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking
statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or
expectations will be achieved. These cautionary statements qualify all forward-looking statements attributable to us or persons
acting on our behalf.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Information
regarding market and industry statistics contained in this report is included based on information available to us that we believe
is accurate. It is generally based on academic and other publications that are not produced for purposes of securities offerings
or economic analysis. Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications
and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and
services. Except as required by U.S. federal securities laws, we have no obligation to update forward-looking information to reflect
actual results or changes in assumptions or other factors that could affect those statements.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_022"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PART
I</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Unless
otherwise indicated or the context otherwise requires, all references in this prospectus to &ldquo;DanDrit,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; &ldquo;our&rdquo; or the &ldquo;Company&rdquo; are to DanDrit Biotech USA, Inc., a Delaware corporation (&ldquo;DanDrit
USA&rdquo;), together with its wholly-owned subsidiary DanDrit Biotech A/S, a Danish limited company, organized under the Danish
Act on Limited Companies of the Kingdom of Denmark (&ldquo;DanDrit Denmark,&rdquo; or the &ldquo;Subsidiary&rdquo;).</I></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_001"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
1.&#9;Business</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview
of Our Business</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
a biotechnology company seeking to develop what we believe could be the world&rsquo;s first vaccine approved for
the treatment of colorectal cancer. For more than a decade we have developed and patented vaccines successfully used in
initial clinical trials in Europe and Asia including<FONT STYLE="background-color: white">: (i) MelCancerVac&trade; (MCV)
for treatment of cancer (one phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), (ii)
Tolerogenic (producing immunologic tolerance) dendritic cell (TDC) (pre-clinical stage in Denmark) and (iii) Melvaccine (MV)
a melanoma cell lysate used as stand-alone vaccine (pre-clinical state in Denmark)</FONT>. We plan to continue our clinical
development program in  Europe and the United States. Springing from academic roots in Denmark, DanDrit has built upon its
scientific and medical skills to advance candidate therapies, targeted initially at non-small-cell-lung-cancer (NSCLC) and
colorectal cancer (sometimes referred to herein as CRC). <FONT STYLE="background-color: white">In 2001, MCV was developed as
a result of the combined efforts and research of DanDrit researchers and employees.</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
September 22, 2008, the Singapore government granted to DanDrit Denmark a named-patient compassionate use program of MCV. <FONT STYLE="background-color: white">DanDrit&rsquo;s
dendritic cell vaccine, MCV, was evaluated in</FONT> three single-arm Phase II clinical trials in cancer where
MCV demonstrated potential efficacy. However, these three clinical trials generated data <FONT STYLE="background-color: white">reported
in published papers which</FONT> indicated that the data needed to be confirmed in a larger, comparative randomized
clinical trial. As a result, DanDrit, with the assistance of experienced practitioners in colorectal cancer treatment, <FONT STYLE="background-color: white">designed
a randomized trial with 174 stage IV colorectal cancer patients and </FONT>plans to conduct this  randomized Phase III
trial to assess the ability of MCV to prevent relapse of stage IV NED colorectal cancer patients. Neither<FONT STYLE="background-color: white">
the US Federal Drug Administration (FDA) nor any other comparable governmental agency has reviewed MCV. Therefore,
any assessment of its safety or efficacy only reflects the opinion of the Company. Furthermore, it does not indicate that
MCV will achieve favorable results in any later stage trials or that the FDA or comparable agency will ultimately determine
that MCV is safe and effective for purposes of granting marketing approval.</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Biotechnology</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
</FONT>believe that DanDrit's next generation of dendritic cell vaccine technology may benefit of the following technological
competitive advantages over other cancer vaccines, such as Dendreon&rsquo;s FDA approved <FONT STYLE="background-color: white">Provenge&trade;
cancer vaccine</FONT>:</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The vaccine <FONT STYLE="line-height: 115%">is
    generated within eight days from a patient&rsquo;s peripheral blood draw. We are able to generate the vaccine quickly because
    only 250ml of blood is required to be drawn. Leukapheresis, a medical technology in which the blood of a patient is passed
    through a dialysis machine that separates out one particular constituent and returns the remainder to the patient&rsquo;s
    circulation is not needed</FONT>.</FONT></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The vaccine uses an allogenic (using cells, tissues, or organs, sourced from a genetically non-identical member of the same species as
    the recipient (&ldquo;Allogenic&rdquo;)) tumor lysate (a fluid containing the contents of lysed cells) as opposed to inconvenient
    autologous (from the patient) tumor lysate. Our cancer-specific antigens are off-the-shelf and therefore DanDrit does not
    need a patient&rsquo;s tumor cells to manufacture the vaccine.</FONT></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The vaccine ispolytopic (targets several cancer specific antigens). As a result, the risk of the tumor escaping is more limited and more
    T-cells can be activated than if the vaccine is targeting one antigen only. However, MCV has a focus on&nbsp;melanoma-associated
    antigen&nbsp;(&ldquo;MAGE&rdquo;)-A antigens that are only expressed by tumors and absent in normal tissues.</FONT></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fast track production
    in two days is possible.</FONT></td></tr>
</table>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">MCV
demonstrated efficacy in three separate Phase IIa clinical trials in colorectal and non-small cell lung cancer. Even if MCV can
be used for various cancers, DanDrit has decided to focus MCV&rsquo;s clinical development specifically on the treatment of advanced
CRC.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>History</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">DanDrit USA was originally
incorporated in Delaware on January 18, 2011 under the name &ldquo;Putnam Hills Corp.&rdquo; as a vehicle to pursue a business
combination through the acquisition of, or merger with, an operating business. We filed a Registration Statement on Form 10 with
the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;) on August 12, 2011.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the &ldquo;Share Exchange Agreement&rdquo;),
we completed the acquisition of approximately 100% of the issued and outstanding capital stock&nbsp;&nbsp;of&nbsp;&nbsp;DanDrit
Denmark (the &ldquo;Share Exchange&rdquo;) and as a result became DanDrit Denmark&rsquo;s parent company (the &ldquo;Parent&rdquo;).
In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares
of DanDrit USA&rsquo;s common stock, par value $.0001 per share (the &ldquo;Common Stock&rdquo;) for an aggregate of 6,000,000
shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies
Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange
and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder
prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2</FONT>) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of
Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA
prior to the Share Exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Emerging
Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a company with less than $1.0 billion in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company&rdquo;
as defined in the Jumpstart Our Business Startups Act, or JOBS Act, enacted in April 2012. An &ldquo;emerging growth company&rdquo;
may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include,
but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Reduced disclosure
    about our executive compensation arrangements;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No non-binding
shareholder advisory votes on executive compensation or golden parachute arrangements;</FONT></td></tr>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exemption from the auditor attestation requirement in the assessment of our internal control over financial
reporting;  and</FONT></td></tr>

<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reduced disclosure of financial information in this prospectus, limited to two years of audited financial information
and two years of selected financial information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; text-indent: -0.25in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a smaller reporting company, each of the foregoing exemptions is currently available to us. We may take advantage of these exemptions
until the last day of our fiscal year following the fifth anniversary of the date of the first sale of our common equity securities
pursuant to an effective registration statement under the Securities Act, which such fifth anniversary will occur in 2018. or
such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company if we have
more than $1.0 billion in annual revenues as of the end of a fiscal year, if we are deemed to be a large accelerated filer under
the rules of the Securities and Exchange Commission, or if we issue more than $1.0 billion of non-convertible debt over a three-year-period.
<FONT STYLE="background-color: white">The JOBS Act permits an emerging growth company to take advantage of an extended transition
period to comply with new or revised accounting standards applicable to public companies; provided, however, that an emerging
growth company may </FONT>elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. We have not elected to opt out of the transition period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because
we have elected to take advantage of certain of the reduced disclosure obligations and may elect to take advantage of other reduced
reporting requirements in future filings, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
Business Strategy </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
strategy is focused on conducting a Phase III<FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif"> </FONT> clinical trial in advanced colorectal cancer. DanDrit intends to conduct
a randomized multicenter Phase III clinical trial to determine the ability of MCV to prevent recidivism in stage IV colorectal
patients with no evidence of disease after resection of metastasis and chemotherapy. This comparative trial is planned to be enrolled
within two years. We believe that positive clinical data will be the catalyst to unlock commercial revenues for DanDrit through
either acquisition by a pharmaceutical partner or licensing arrangements that would yield upfront and milestone payments as well
as royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furthermore,
parallel to the previously described clinical trial, DanDrit may pursue a registration trial to support potential approval of
MCV in China. This trial would be conducted under China&rsquo;s State Food and Drug Administration (the &ldquo;SFDA&rdquo;) regulations
with a Chinese oncology pharmaceutical partner. China has recently put in place a drug approval system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
is headquartered in the USA and runs operations from Denmark. When clinical milestones are met (positive 12-month-interim results
from comparative clinical trial), DanDrit intends to establish a dendritic cell cancer vaccine good manufacturing practices (GMP)
laboratory in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
Proposed Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">DanDrit
intends to develop globally the use of MCV in the treatment of colorectal cancer, and to follow that expansion with the treatment
of other types of cancer. DanDrit currently intends to focus its development program, a randomized multicenter Phase III clinical
trial in stage IV colorectal cancer in Italy, known as VIVA (MelCancerVac vaccine in patients with stage IV colorectal cancer with
no evidence of disease after standard of care, a randomized Phase III adjuvant study).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">The
proposed study with an adaptive design plans to first enroll 174 stage IV colorectal cancer patients after resection of metastases
and chemotherapy. These patients have no evidence of disease but are not cured of cancer. Their Relapse Free Survival(the <FONT STYLE="color: #252525; background-color: white">endpoint
used to analyze the results of the treatment for the cancer which renders the patient apparently disease free, such as surgery
plus adjuvant therapy, where, in the Relapse-Free Survival, the event is relapse rather than death)</FONT> is only 24 to 26 months.
The objective of the VIVA Phase III clinical study is to lengthen the survival of these patients. Treatment will be randomized
against reference therapy. Patients will be included after resection of their primary tumor and metastases and after appropriate
peri-operative chemotherapy by stratification and random assignment to a non-vaccine control group or a vaccine group receiving
five vaccinations with 14-day administration intervals followed by ten vaccines with two-month intervals. Inclusion will take
place ten weeks after finishing the last round of peri-operative chemotherapy (FOLFOX or FOLFIRI) and after a negative tumor scan
(head, thoracic and abdominal cavities) and normal carcinoembryonic antigen (CEA) prior to inclusion in the vaccine or the control
groups. The control group will receive standard therapy. In the event of disease progression, as verified by tumor scan and biomarker
levels during the vaccination schedule, vaccinations will be discontinued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">D</FONT>anDrit
uses a dendritic cell technology similar to the Dendreon&rsquo;s FDA approved Provenge&trade; cancer vaccine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
MCV demonstrated potential efficacy in three separate Phase IIa clinical trials in colorectal and non-small cell lung cancer.
Even if MCV can be used for various cancers, DanDrit has decided to initiate MCV&rsquo;s clinical development with advanced colorectal
cancer. We believe that a maintenance therapy for advanced colorectal cancer represents a genuine commercial opportunity for MCV.<B>&nbsp;</B>A
clear and unmet medical need for a safe maintenance therapy offers the opportunity to confirm the potential efficacy of MCV in
a favorable setting. Neither the FDA nor any other comparable governmental agency has reviewed MCV.&nbsp;&nbsp;Therefore, any
assessment of its safety or efficacy only reflects the opinion of the Company.&nbsp;&nbsp;Furthermore, it does not indicate that
MCV will achieve favorable results in any later stage trials or that the FDA or comparable agency will ultimately determine that
MCV is safe and effective for purposes of granting marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">DanDrit plans to
conduct a randomized multicenter, company-sponsored clinical trial to determine the safety and efficacy of MCV as adjuvant therapy
in advanced colorectal cancer. The purpose of the study will be to determine the ability of MCV to prevent recidivism in stage
IV colorectal patients with no evidence of disease after surgical resection of liver metastasis and chemotherapy. Using an Adaptive
Design Clinical Study, which allows modification made to trial and/or statistical procedures of ongoing clinical trials based
on accrued data, the study will evaluate MCV with standard of care against standard of care alone in 174 colorectal cancer patients
using as primary endpoints Progression Free Survival at 18 months and Overall Survival. We anticipate that the first step of the
comparative trial can be completed within three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
has learned how to manufacture dendritic cells, immune cells forming part of the mammalian immune system with the main function
of processing antigen material and presenting it on the surface to other cells of the immune system, functioning as antigen-presenting
cells, <I>in vitro</I> from monocyte (a type of white blood cell) precursor cells taken from patients eligible for DanDrit&rsquo;s
therapies. The preparation of tumor lysate containing selections of cancer-specific non-self antigens allows DanDrit to sensitize
patients&rsquo; dendritic cells. The use of the patient&rsquo;s own monocyte cells from peripheral blood (autologous cell therapy)
overcomes the issues associated with non-self allergic reactions to immune therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">DanDrit&rsquo;s
intellectual property is protected with patents and trademarks. DanDrit&rsquo;s candidate vaccines are based on the MCV platform
that is protected by a family of issued or submitted patents. DanDrit&rsquo;s lead product has completed Phase II clinical trials
in Denmark and Singapore. Following the results of DanDrit&rsquo;s Singapore Phase II clinical trials, Singapore authorities allowed
the use of MCV for CRC on a humanitarian named patient basis.&nbsp;Outside the United States,&nbsp;named patient programs&nbsp;provide
controlled, pre-approval access to drugs in response to requests by physicians on behalf of specific, or &ldquo;named&rdquo;,
patients before those medicines are licensed in the patient&rsquo;s home country. <FONT STYLE="background-color: white">Governments
worldwide, such as Singapore&rsquo;s government, have created provisions for granting access to drugs prior to approval for patients
who have exhausted all alternative treatment options and do not match clinical trial entry criteria. Often grouped under the labels
of compassionate use,&nbsp;</FONT>expanded access<FONT STYLE="background-color: white">, or named patient supply, these programs
are governed by rules which vary by country defining access criteria, data collection, promotion, and control of drug distribution.</FONT>&nbsp;Through
these programs, patients are able to access drugs in late-stage clinical trials or approved in other countries for a genuine,
unmet medical need, before those drugs have been licensed in the patient&rsquo;s home country. In September 2008, DanDrit Denmark
and the National Cancer Centre of Singapore (NCC) entered into a collaboration agreement regarding a clinical named patient program
conducted in Singapore at NCC with the dendritic cell vaccine MCV.&nbsp;&nbsp;NCC has established a GMP approved laboratory in
which the manufacturing of MCV takes place. NCC has received approval from the relevant governmental authorities for the import
of lysate necessary for production of MCV. The clinical and research and development activities of the named patient program relate
to the Company&rsquo;s product, MCV. The purpose for the Singapore named patient program is to provide patients with advanced
colorectal cancer or other forms of cancer(s) with the presence of MAGE antigen expression an alternative treatment for the vaccination
with MCV, where there is no further indication for surgery or treatment with chemotherapy. Patients are recruited on named patient
basis according to the patient inclusion and exclusion criteria stated in the phase IIa study protocol. However, there may be
some exceptional cases where treatment will be made based on a doctor&rsquo;s discretion regarding the patient&rsquo;s quality
of life. An estimated total of 50 patients have been recruited for the Singapore named patient program and 8 patients are currently
still active in the named patient program. To date we have not received a detailed report regarding the final outcomes for patients
participating in the Singapore trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
colorectal cancer patients who are eligible for the humanitarian program in Singapore must present a profile similar to the one
of the patients who were recruited in the phase IIa clinical trial. Also, patients are monitored according to the previous phase
II study protocol.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
date, clinical trials of MCV have been targeted to patients in terminal stages of cancer with non-resectable bulky tumors who
failed to respond to surgery and chemotherapy. Several patients showed extended overall survival with good quality of life. Several
patients showed stable disease with no progression of tumors. There was evidence of tumor regression in some patients (see &ldquo;Clinical
Trials Data and Product Approvals&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">These
achievements have been built on a carefully executed R&amp;D program that generated practical solutions to scientific and medical
challenges. Through this development program, DanDrit gained advanced understanding of the role of dendritic cells in immunoregulation
and cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-core
applications of dendritic cell technologies mastered by DanDrit have applications in infectious diseases and auto-immune diseases
such as diabetes (seventh leading cause of death in the US). These other applications represent opportunities for out-licensing
and cooperation. Where other companies have non-core technologies of relevance to DanDrit&rsquo;s core business in dendritic cell
cancer therapy, we will pursue a policy of cooperation and in-licensing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>DENDRITIC
CELLS, THE THERAPEUTIC PLATFORM</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Summary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Early
academic work at the Danish Cancer Society was spun-out into DanDrit Denmark. None of the personnel at the Danish Cancer Society,
or any other third-party, retains any rights to the intellectual property underlying the Company&rsquo;s business, technology
or product candidates, including MCV.&nbsp;The fundamental scientific postulate of DanDrit is the fact that key cells in the immune
system can be sensitized to cancer cells that carry foreign (or non-self) antigens. These key antigen-presenting cells are the
dendritic cells. Dendritic cells encounter and recognize foreign antigens. Dendritic cells can assimilate and process the cells
expressing these antigens. The key components of these antigens (known as epitopes and several epitopes are known as polytopes)
are subsequently presented on the cell surface of the dendritic cell. Dendritic cells travel to lymph nodes and other lymphatic
tissues where the epitopes are presented to other immune cells, including cell-killing T lymphocytes. T lymphocytes sensitized
by dendritic cells can then recognize and kill tumor cells carrying tumor-specific antigens recognized by the dendritic cells.
The main aim is to kill tumor cells without killing normal body tissues.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Figure 1: Dendritic cell interacting with T-lymphocyte</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="(LOGO)" STYLE="height: 126px; width: 180px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
above photograph (courtesy Science Photo Library) illustrates a dendritic cell (blue/green) communicating with a T-lymphocyte
(gold). From DanDrit&rsquo;s point of interest, this might represent a dendritic cell instructing a T-lymphocyte to kill tumor
cells presents itself as a &ldquo;Cancer Vaccine&rdquo; company and its lead product, MelCancerVac&reg;&nbsp;(MCV), a polytopic
vaccine, targets colorectal cancer in the first instance. In addition, DanDrit has developed several technologies relevant to
dendritic cell production, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Generation of
    fast track dendritic cells</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Processing and
    presentation of protein antigen</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Characterization
    of DanDrit dendritic cells</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Analysis of lysate
    uptake by DanDrit dendritic cells</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MicroRNA profiling
    of DanDrit dendritic cells</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effect
    of Resiquimod (a drug that acts as an immune response modifier, and has&nbsp;antiviral&nbsp;and&nbsp;anti-tumoral&nbsp;activity)&nbsp;on
    production of Interleukin 12 (Il-12), a secreted protein factor that is naturally produced by dendritic cells in response
    to antigenic stimulation and Interleukin 10 (IL-10), a protein that inhibits the synthesis of a number of other signaling
    proteins.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Generation of
    tolerogenic dendritic cells</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Development of
    Il-12 based potency assay</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
vaccine candidates are based on the MCV platform and are protected by a family of issued and submitted patents. DanDrit&rsquo;s
lead product has completed Phase II clinical trials in Denmark and Singapore. DanDrit&rsquo;s Singapore Phase II data were compelling
enough for the Singapore authorities to make MCV available on a limited humanitarian named patient basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
date, clinical trials of MCV have been targeted to patients in terminal stages of disease who failed to respond to surgical resection
and chemotherapies. Some patients showed extended overall survival with good quality of life. Many patients showed stable disease
with no progression of tumor. There was evidence of tumor regression in some patients. (see &ldquo;Clinical Trials Data and Product
Approvals&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Scientific
and medical research is adding to DanDrit&rsquo;s clinical and pre-clinical development pipeline in cancer. Some of this research
in dendritic cells could have implications that reach beyond DanDrit&rsquo;s cancer vaccine vision.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Dendritic
Cells and the immune response</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dendritic
cells were first recognized by Paul Langerhans in the late 19th&nbsp;century. For this reason such cells in the skin may still
be referred to as Langerhans cells. The term &ldquo;dendritic cell&rdquo; was first used by Ralph Steinman and Zanvil Cohn in
1973. Steinman received the 2007 Lasker Award for this work and the 2011 Medicine Nobel Prize.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Like
macrophages, cells whose role is to phagocytose, or engulf and then digest, cellular debris and pathogens, either as stationary
or as mobile cells, dendritic cells are involved in the processing of antigens and their presentation to the cells that directly
carry out the immune response through antibody generation (B lymphocytes) or cell killing activity (T- lymphocytes). Like macrophages,
dendritic cells are mobile and once stimulated by an antigen, activated macrophages and dendritic cells move from their host tissue
(usually skin or epithelial tissue such as gut, mucous membranes, lung etc.) to lymphatic tissues where they encounter and stimulate
cells that mediate the immune response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Macrophages
and dendritic cells are closely related, in that both are derived from circulating blood cells known as monocytes, a type of
white blood cell which constitutes roughly 10% of all white blood cells. Monocytes, macrophages and immature dendritic cells
are all phagocytic cells, that is, they engulf and process foreign antigens. On activation by the uptake of antigen,
dendritic cells mature and become mobile. The mobile mature dendritic cells are capable of stimulating T-lymphocytes through
the expression of T-cell stimulatory antigens on their cell surfaces.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">It
is possible to force monocytes to differentiate&nbsp;<I>in vitro</I>&nbsp;into immature dendritic cells. This is the basis of
DanDrit&rsquo;s proprietary dendritic cell production process. As in nature, DanDrit&rsquo;s process involves a subtle communication
between monocytes and cytokines (small proteins that important in the communication process that governs basic cellular activities
and coordinates cell actions). Dendritic cells produced by DanDrit are functionally, morphologically and biochemically very similar
&ndash; if not identical &ndash; to natural dendritic cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Figure 2: Principle of Dendritic Cell cancer vaccines</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_002.jpg" ALT="(LOGO)" STYLE="height: 255px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
platform technology is based on isolating patient monocytes and transforming them into immature dendritic cells&nbsp;<I>in vitro</I>.
This is achieved by exposing monocytes to cytokines (interleukin 4, IL-4; and granulocyte macrophage colony stimulating factor,
GM-CSF). Still&nbsp;<I>in vitro</I>&nbsp;these immature dendritic cells are activated by exposure to a cancer cell line lysate.
This cancer cell lysate contains many &ldquo;non-self&rdquo; antigens of the cancer/testis family. Although coded by the human
genome, these antigens are not normally expressed in tissues other than cancer or testis (note that testis and immune system are
isolated from each other). Once sensitized&nbsp;<I>in vitro</I>, the immature dendritic cells are matured by exposure to a DanDrit
proprietary cytokine cocktail. The now mature dendritic cells can be re-injected to the patient via a simple 0.2 ml intra-dermal
injection and they will find their way to the lymphatic tissues. There, they will stimulate multiple cell killing (T) lymphocytes
which will become sensitized to the cancer-specific antigens present in the lysate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>The
Platform Technology, MelCancerVac&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MelCancerVac&reg;
(MCV) is a cellular immunotherapy for treatment of cancer. MCV has been studied in two cancers: non-small cell lung cancer
(NSCLC) and colorectal cancer (CRC). The use of MCV may be extended to other tumors in the mid-term such as the two types of
esophageal cancers: esophageal squamous cell carcinoma (EC) and esophageal adenocarcinoma (EAC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
platform technology comprises two arms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">autologous dendritic
    cells obtained by the activation of patient-derived monocytes; and</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">proprietary
    lysate from melanoma-derived cell line expressing a range of cancer/testis antigens, notably the MAGE-A family</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
melanoma lysate component of MCV is manufactured from a melanoma cell line established by DanDrit scientists. This cell line was
isolated from a melanoma tumor that expressed antigens found in a wide range of tumors but not in normal tissues (other than the
testis). These antigens belong to a family of cancer/testis antigens (including mostly MAGE-A antigens) found in many tumors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Antigen
characterization</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
a patient to respond favorably to MCV, it is necessary that the antigens presented by the patient&rsquo;s tumor show a significant
match with the antigens in the lysate. The level of expression of antigens in each batch of lysate is determined by a procedure
known as Reverse Transcriptase Quantitative Polymerase Chain Reaction or &ldquo;RT-QPCR&rdquo;. Clearly all patient cells will
present many thousands of antigens, as will the lysate. MCV&rsquo;s lysate component is isolated from a melanoma cell line that
expresses a great many cancer/testis antigens at significant level. This broad spectrum of cancer/testis antigens is what makes
MCV a good cancer vaccine. Figure 3 (below) shows how RT-QPCR can analyze levels of antigen expression as measured by messenger
RNA.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><B>Figure 3: Comparison of tumor antigen expression in MCV
with two patient biopsies</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="(LOGO)" STYLE="height: 114px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
this example, TA-1 to TA-28 are 28 known tumor antigens (antigens that are only expressed by cancer cells and not by normal cells).
We can see that 14 of these antigens are present in MCV. Twenty-one cancer-specific antigens are expressed by the tumor in patient
two, which indicates a good chance of promoting a cancer killing response. In patient one there is not a strong overlap of MCV
antigens and the five patient&rsquo;s tumor antigens. The chances of promoting a strong immune response are less but still significant
(TA-3, TA-9, TA-18, and TA-19 are shared).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By
analyzing patient&rsquo;s tumors by RT-QPCR, it is possible to select patients that have the best chance of success with MCV.
However, other uncharacterized antigens may also be present that might promote a response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Clinical
Trials Data and product approvals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Overall
clinical results</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">No
dendritic cell-based vaccination has to date demonstrated life-threatening side effects. The only potential adverse events
associated with dendritic cell vaccines identified to date are a flu-like symptom with fevers (up to 39-40 degrees Celsius),
chills, and headaches in some patients. The occurrence of these adverse events did not require additional treatment or
hospitalization. Some patients may also develop a vitiligo, a skin condition in which there is a loss of brown color
(pigment) from areas of skin, resulting in irregular white patches that feel like normal skin, when melanocyte
differentiation antigens are used as targets in immunotherapy. However, this has not occurred, to DanDrit&rsquo;s knowledge,
with MCV in clinical trials that have been conducted to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MCV
is produced according to the principles of Good Manufacturing Practice (GMP) in facilities approved by the Danish Medicine Agency
and EU regulation for the production of medicines from patient blood in aseptic conditions. No products of animal origin are used
during vaccine preparation. Quality control is performed for each individual batch of the vaccine as well as for the lysate used
in the loading of dendritic cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MCV
was originally developed in 2001 as a result of the combined research efforts of DanDrit researchers and employees and has been
tested in clinical trials for the treatment of colorectal cancer (CRC) and non-small-cell lung cancer (NSCLC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRC
Clinical Trials</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase I/II at
    Gentofte Hospital, Denmark (investigator-sponsored trial)&ndash; Completed, November 2004 &ndash; April 2006</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase
    II at the National Cancer Centre, Singapore (investigator-sponsored trial) &ndash; Completed, November 2005 &ndash; March
    2007</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NSCLC
Clinical Trials</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Phase II at Herlev
    Hospital, Denmark(Dandrit-sponsored trial) &ndash; Completed, January 2006 &ndash; September 2009</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>ColoRectal
Cancer (CRC) in Denmark</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
clinical trial using MCV at the University Hospital of Copenhagen, Gentofte, in Denmark was an investigator sponsored trial. The
principal investigator and sponsor of the trial was Dr. Anders Fischer, a recognized specialist in surgical oncology in Demark
and the department head of the Dept. of Surgical Gastroenterology at Copenhagen University Hospital in Gentofte, who received
a grant to fund the trials provided by the Aase&amp;EinarDanielsen Foundation. Dr. Jacob Rosenberg, a professor and surgeon, working
in the Dept. of Surgical Gastroenterology at Copenhagen University and Dr. Mogen Claesson, a director of DanDrit designed the
trial and proposed it to Dr. Fischer to act as sponsor and principal investigator. Enrollment of CRC patients started in October
2004 and the study ended in September 2006. Certain DanDrit staff, including Dr. Rosenberg and Dr. Claesson, as well as two other
employees of DanDrit Denmark at the time of the study&nbsp;&nbsp;closely collaborated with the researchers at Gentofte Hospital
responsible for the day to day work of the study&nbsp;&nbsp;with respect to the study design, analysis and interpretation of data
obtained in the Denmark CRC Trial.&nbsp;&nbsp;In addition, the patents and proprietary knowledge of DanDrit and its employees
were utilized in connection with the analysis and interpretation of the data that resulted from the study. The results and findings
of the trial were published in established scientific journals (Phase I study: J ExpClin Cancer Res. 2006 Jun;25(2):201-6., Phase
II study, clinical data: Oncol Rep. 2008 Dec;20(6):1305-11., Immunological data: ActaOncol. 2009;48(8):1157-64.), which were co-authored
by Dr. Rosenberg, Dr. Claesson and the two other DanDrit staff researchers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
data described in this prospectus with respect to the Copenhagen CRC trial have been obtained from the published papers issued
in connection with the study.&nbsp;&nbsp;Twenty patients with advanced colorectal cancer (Dukes D - not curable by resection and
no further conventional therapy options available) were included in the study (six patients in phase I and 14 in phase II).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
purpose of this open phase I/II study was to study the tolerability and effect of MCV given as intradermal injections to patients
with metastasizing colorectal cancer, where there was no indication for surgery or chemotherapy. The first part was a phase I
study to investigate whether treatment with MCV is in any way toxic. No toxicity was observed and the study continued into phase
II to study the effect and tolerability of MCV. At the completion of the study stable disease was observed in twenty percent of
the enrolled patients. This data was achieved with DanDrit&rsquo;s early MCV vaccine, which has since been replaced by an improved
MCV. The MCV was improved subsequent to the completion of the clinical trials described in this prospectus, but included the addition
of aza-cytidine to the DDM-1 culture to de-methylize the genome in order to optimize tumor specific antigen expression. The benefit
was marginal and did not justify switching to a different product during the trials. As a result, all trials we will present to
the FDA and EMEA will use the same cell line and the same manufacturing process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Inclusion
criteria:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Age 25-75</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>No chemo or
    radiotherapy within six weeks prior to inclusion</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Expected survival
    &gt; four month</I></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Performance
    status two according to the performing status of WHO</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Adequate hepatic
    and renal function</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Adequate hematopoietic
    and coagulation capacity</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Normal EKG
    or non-clinical significant abnormal EKG</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Preserved pulmonary
    function</I></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exclusion
criteria for the trial:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Uncontrolled
    serious infection</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Systemic corticosteroid
    treatment or other immune suppressive treatment in the last two months</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Participation
    in other clinical trials over the former six weeks</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>For women,
    pregnancy or lactation</I></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Study
design: dendritic cells were generated from autologous peripheral blood mononuclear cells (PBMC). In order to increase the level
of circulating leukocytes, patients exercised five minutes on a treadmill before 200 ml of blood was drawn. Patients were scheduled
for ten vaccinations consisting of 3-5x106&nbsp;dendritic cells. Vaccinations were given bi-weekly intra-dermally on the proximal
thigh with two injections each thigh. Adverse events were monitored and classified according to the National Cancer Institute&rsquo;s
Common Toxicity Criteria (NCI&rsquo;s CTC). Evaluation of responses was made according to the Response Evaluation Criteria in
Solid Tumors (&ldquo;RECIST&rdquo;) criteria and patients were CT scanned before entering the study, after five vaccinations and
after ten vaccinations. Quality of life was monitored by questionnaires bi-weekly. The study was performed at the Department of
Surgical Gastroenterology at Gentofte University Hospital, Copenhagen, Denmark according to ICH Guidelines for Good Clinical Practice
(European Directive on GCP 2001/20/EC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">RECIST
is a set of published rules that define when tumors in&nbsp;cancer patients improve (&quot;respond&quot;), stay the same (&quot;stabilize&quot;),
or worsen (&quot;progress&quot;) during treatments. The criteria were published in February 2000 by an international collaboration
including the&nbsp;European Organization for Research and Treatment of Cancer&nbsp;(&ldquo;EORTC&rdquo;),&nbsp;National Cancer
Institute&nbsp;of the&nbsp;United States, and the&nbsp;National Cancer Institute of Canada Clinical Trials Group. Today, the majority
of clinical trials evaluating cancer treatments for objective response in solid tumors are using RECIST.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
aim of the phase II CRC study in Denmark was to evaluate the effect of treating patients with advanced colorectal cancer with
a cancer vaccine based on dendritic cells pulsed with an allogenic tumor cell lysate. Twenty patients with advanced colorectal
cancer were consecutively enrolled, with 17 completed the full study. Dendritic cells (DC) were generated from autologous peripheral
blood mononuclear cells and pulsed with allogenic tumor cell lysate containing high levels of cancer-testis antigens. Vaccines
were biweekly administered intra-dermally with a total of 10 vaccines per patient. CT scans were performed and responses were
graded according to the RECIST criteria. Quality of life was monitored with the SF-36 questionnaire. Four patients of the 17 were
graded with stable disease, two of whom remained stable throughout the entire study period. Analysis of changes in the patients&rsquo;
quality of life revealed stability in the sub-groups: &ldquo;physical function&rdquo; (p=0.872), &ldquo;physical role limitation&rdquo;
(p=0.965), &ldquo;bodily pain&rdquo; (p= 0.079), &ldquo;social function&rdquo; (p=0.649), &ldquo;emotional role limitation&rdquo;
(p=0.252) and &ldquo;mental health&rdquo; (p=0.626). The median survival from inclusion was 5.3 months (range 0.2 - 29.2 months)
with one patient still being alive almost 30 months after inclusion in the trial. Toxicity and adverse events were graded according
to the National Cancer Institute&rsquo;s common Toxicity Criteria. At the first evaluating CT scan, four patients were categorized
with stable disease and at the second evaluating CT scan two of these patients still had stable disease and one of them received
additional monthly vaccines because of the remaining stability in the disease. DanDrit determined that treatment with this DC-based
cancer vaccine was safe and non-toxic. Stable disease was found in 24% (4/17) of the patients participating in the full study.
The quality of life remained stable for most categories&nbsp;stable throughout the study period. Stable disease is defined as
a tumor that is neither growing nor shrinking. Stable disease also means that no new tumors have developed and that the cancer
has not spread to any new regions of the body (the cancer is not getting better or worse) and quality of life, measured using
a global health score, was at the baseline with no or minimal variation. Variations in the patients' self-reported quality of
life during the study period, assessed by the SF-36 questionnaire, were estimated using Freidman's statistical analysis. There
were no significant variation in the patients' &lsquo;physical function&rsquo; (p=0.872), &lsquo;physical role limitation&rsquo;
(p=0.965), &lsquo;bodily pain&rsquo; (p=0.079), &lsquo;social function&rsquo; (p=0.649), &lsquo;emotional role limitation&rsquo;
(p=0.252) and &lsquo;mental health&rsquo; (p=0.626). There was a significant variation concerning &lsquo;general health perception&rsquo;
(p=0.006) and &lsquo;vitality&rsquo; (p=0.011).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Primary
endpoints of the study were tumor response according to RECIST criteria and quality of life (Burgdorf SK, Fischer A, Myschetzky
PS, Munksgaard SB, Zocca MB, Claesson MH, Rosenberg J. Clinical responses in patients with advanced colorectal cancer to a dendritic
cell based vaccine. Oncol Rep. 2008 Dec;20(6):1305-11. PubMed PMID:19020707) and secondary endpoints for the study were responses
measured by immunological parameters (Burgdorf SK, Claesson MH, Nielsen HJ, Rosenberg J. Changes in cytokine and biomarker blood
levels in patients with colorectal cancer during dendritic cell-based vaccination. ActaOncol. 2009;48(8):1157-64. doi:10.3109/02841860903099964.
PubMed PMID: 19863224).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As a<FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif"> </FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif">measure
of quality of life for the colorectal cancer trial in Denmark, DanDrit used the SF-36 Global Health Score questionnaire to
evaluate the patients' quality of life throughout the study period.&nbsp;&nbsp;At the time of the trial, this
questionnaire&nbsp;from the&nbsp;Medical&nbsp;Outcome Study&nbsp;(MOS), conducted by the&nbsp;RAND&nbsp;Corporation, was both
recommended and validated.&nbsp;&nbsp;All patients in the trial independently filled in the questionnaire every two
weeks.&nbsp;The SF-36 Global Health Score questionnaire consists of eight scaled scores, which are the weighted sums of the
questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question
carries equal weight. The lower the score is the more disability is reported by the patient. Higher scores reflect less
disability i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no
disability.&nbsp;The eight different aspects of quality of life reflecting different aspects of the
patient&rsquo;s self-reported quality of life are:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">vitality</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">physical functioning</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">bodily pain</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">general health
    perceptions</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">physical role
    functioning</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">emotional role
    functioning</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">social role functioning</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">mental health</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
fact that patients' SF-36 Global Health Score was high signifies that when entering the study the patients&rsquo; quality of life
was comparable to the healthy background population.&nbsp;&nbsp;The fact that it remained stable signifies that there were no
significant changes in the patients&rsquo; quality of life during treatment. This correlates with the fact that the treatment
was well tolerated by all patients and that investigators did not observe severe adverse effects from the treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
more in depth analysis of the components of the patients&rsquo; quality of life revealed a stability in certain parameters that
measure quality of life. The &ldquo;p&rdquo; refers to the p-value.&nbsp;&nbsp;In a statistical test, the p-value is the probability
of getting the same value for a model built around two hypotheses, one is the &quot;neutral&quot; hypothesis, and the other is
the hypothesis under testing. In the Friedman analysis that was used for QOL testing in this study, a p-value below 0.05 means
that the values varied throughout the observation period (but says nothing about increase or decrease). A p-value above 0.05 means
that the QOL values were stable throughout the observation period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
graph below indicates the specific p-values of &ldquo;general health perception&rdquo; and &ldquo;vitality&rdquo; throughout the
study:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_004.jpg" ALT="http:||www.sec.gov|Archives|edgar|data|1527728|000121390014006190|img012.jpg" STYLE="height: 311px; width: 499px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;The
Company does not believe that any significant information can be inferred from the variation observed, even if statistically significant,
with respect to these two parameters as it would have been anticipated that these extremely sick patients with a progressive disease
would have resulted in variations in QOL over the course of the study.&nbsp;&nbsp;For this same reason, it is, however, more significant
that 6 of the 8 parameters showed stability as it can be inferred that the treatment had a positive impact on the QOL of patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Non-small
cell lung cancer (NSCLC) in Denmark</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
sponsored and funded this MCV clinical trial conducted at Herlev Hospital, University of Copenhagen, in Denmark by Quintiles A/S
(&ldquo;Quintiles&rdquo;) and ACRO Nordic A/S (&ldquo;ACRO&rdquo;) as&nbsp;contract research organizations (CROs). The title of
the study is: &ldquo;Vaccination with Autologous Dendritic Cells Pulsed with Allogeneic Tumor Lysate (MelCancerVac) for the Treatment
of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer&rdquo;.&nbsp;The principal investigator was Dr. Anders Mellemgaard,
the head of the Department of Lung Medicine at Herlev Hospital.&nbsp;Dr. Claesson and three other DanDrit employees worked and
collaborated with the researchers at the Herley Hospital with respect to study design and the analysis and interpretation of data
obtained from the&nbsp;NSCLC Trial.&nbsp;&nbsp;The results of the trial were published in a recognized scientific journal (World
Journal of Vaccines, 2013, 3, 68-76) in a paper that was co-authored by Dr. Claesson and the three other DanDrit employees&nbsp;&nbsp;that
collaborated with the NSCLC Trial researchers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
NSCLC trial was designed as an open-label, phase II clinical study. Enrolled patients had disseminated, inoperable NSCLC after
chemotherapy; the patients did not want further chemotherapy: and no other systemic treatments could be offered to them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
primary objective was to measure the antigen specific immunological reaction between vaccine antigens and the patients&rsquo;
immune system in vivo and in vitro. The secondary objectives were to estimate the patients&rsquo; survival time, the tumor response
according to RECIST criteria, and the patients&rsquo; quality of life during the study period. Primary endpoint was tumor response,
assessed by clinical benefit rate, the percentage of patients with advanced or metastatic cancer who have achieved complete response,
partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents (CBR), however the study
also evaluated PFS and overall survival (OS) as secondary endpoints.&nbsp;<FONT STYLE="background-color: white">Complete response
(CR) is a figure representing the percentage of patients whose cancer disappears after treatment. Partial response (PR) is a figure
representing the percentage of patients whose cancer shrinks after treatment. PR&nbsp;describes a tumor that has decreased in
size by at least 30%. The term stable disease (SD) describes a tumor that is neither growing nor shrinking. SD also means that
no new tumors have developed, and that the cancer has not spread to any new regions of the body (the cancer is not getting better
or worse). T</FONT>he median overall survival was 7.4 months (95% confidence interval (CI), used to indicate the reliability of
an estimate, 4.5-17.5 months). Two patients were still alive at the time of analysis. An exploratory analysis showed that patients
with PR and SD had significantly better survival (median, 18.1 months) compared to those with progressive disease (median, 6.2
months; P = .007).&nbsp;&nbsp;Although the median time to tumor progression was short at 2.4 months (95% CI, 1.9-4.1 months),
five patients experienced a prolonged PFS of more than 6 months; and two of them (reviewed below) continued to be progression-free
at time of analysis (PFS &gt;27 and &gt;37 months).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
first patient was included in January 2007. A total of 28 patients were included in the trial. Treatments prior to DC vaccinations,
tumor histology, smoking status, number of vaccinations, age and gender were recorded.&nbsp;&nbsp;The median age was 58.5 years
(46-74 years).&nbsp;&nbsp;All patients received systemic anti-cancer treatment prior to inclusion. At the time of inclusion, 15
patients were in performance status (PS) 0 and seven patients were in PS 1. Fifteen months after termination of the trial, 4 patients
(patient number 1, 2, 12 and 13) were still alive.&nbsp;&nbsp;These four patients who remained in stable disease after more than
10 vaccinations had different histology subtypes: one broncho-alveolar carcinoma, one squamous cell carcinoma and two adenocarcinoma.&nbsp;In
this Phase IIa trial a 43% CBR (the percentage of patients with advanced or metastatic cancer who have achieved CR, PR&nbsp;and
SD to a therapeutic intervention in clinical trials of anticancer agents) was observed, with six patients showing stable disease.
Five of these patients were immunologically responding to the vaccine (ELISPOT &ndash;IFN Gamma positive) while eight of nine
patients with no clinical response had no IFN gamma response.&nbsp;&nbsp;Sixteen patients received at minimum six vaccines and
were evaluated by CT scans. Of those, nine patients showed progression on the 1st evaluation CT scan three months after initiation
of treatment, and seven patients had stable disease, representing a 43% CBR. For these 7 patients remaining in stable disease
(SD) for a variable period of time, the overall survival curve showed a plateau after two years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
this NSCLC trial, quality of life was measured by self-administered questionnaire using EORTC Quality of Life Questionnaire (QLQ)-C30
version 3 and QLQ-LC13. The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional
scales, three symptom scales, a global health status/quality of life scale, and six single items.&nbsp;&nbsp;Each of the multi-item
scales includes a different set of items - no item occurs in more than one scale. All of the scales and single-item measures range
in score from 0 to 100. A high scale score represents a higher response level. Thus, a high score for a functional scale represents
a high/healthy level of functioning, a high score for the global health status/quality of life represents a high quality of life,
but a high score for a symptom scale/item represents a high level of symptomatology/problems. Version 3.0 is currently the standard
version of the QLQ-C30, and should be used for all new studies.&nbsp;&nbsp;An essential component of the EORTC QLQ development
strategy involves the use of cancer-specific supplementary questionnaire modules which, when employed in conjunction with the
QLQ-C30, can provide more detailed information relevant to evaluating the quality of life in specific patient populations. The
additional QLQ-LC13 questionnaire is specifically designed for lung cancer patients. The QLQ-LC13 includes questions assessing
lung cancer-associated symptoms (cough, hemoptysis, dyspnea and site specific pain), treatment-related side effects (sore mouth,
dysphagia, peripheral neuropathy and alopecia) and pain medication. The questionnaire was filled by the patients at baseline,
and by the time of the 5th, 6th, 7th, 8th, 9th and 10th vaccinations. The data from the quality of life questionnaires was collected
and coded according to EORTC. An overall evaluation of general quality of life-score for the global question of &ldquo;How do
you rate your overall quality of life during the past week&rdquo; remained stable throughout the study period. More specific factors
such as anxiety and lung specific symptoms also remained unchanged during the study-period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
NSCLC trial in Denmark evaluated the clinical and immunological effects of dendritic cell (DC) vaccination in patients with NSCLC.
Autologous DCs were pulsed with a MAGE containing allogenic melanoma cell lysate (MCV). Twenty-two patients initiated the vaccination
program including a total of ten vaccinations. Seven patients remained in SD three months after the first vaccination.&nbsp;&nbsp;After
10 vaccinations, six months after vaccine initiation, four patients still showed SD and continued vaccinations on a monthly basis.
These four patients received a total of 12, 16, 26 and 35 vaccinations, respectively. Five patients showed unexpectedly prolonged
survival. The treatment was well tolerated and only minor adverse events were reported. Quality of life did not change during
the study period. In four out of seven patients with SD, vaccine-specific T cells were detected by interferon gamma (IFN&gamma;)
(a small protein that plays a role in immunity against infections and for tumor control mostly by activating microphages) EliSpot
assays, whereas only one patient with progressive disease (PD) showed vaccine-specific responses.&nbsp;&nbsp;This DC-based vaccine
trial has indicated a correlation between vaccine-specific immunity and sustained SD. The finding of a significant correlation
between prolonged disease stabilization and vaccine-specific cellular responses may support the latter notion and support the
hypothesis that immune responses may play a role in disease control even long time after the actual treatment. This is in sharp
contrast to the rapid effect of anti-cancer treatments such as chemotherapy and radiotherapy.&nbsp;Furthermore, the trial demonstrated
an unexpectedly prolonged survival in some patients, which may indicate delayed effect of DC vaccination after completion of the
treatment. In addition, the investigators reported that this kind of vaccine treatment was feasible and the logistics were manageable
in this patient group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
conclusion, 7 out of 22 NSCLC patients vaccinated with autologous DC pulsed with an allogenic Clinical Trial Authorization (CTA)
containing tumor cell lysate had prolonged disease stabilization. In the course of DC vaccination vaccine-specific IFN&gamma;
responses were detected in peripheral blood of four of patients with SD and one patient with progressive disease.&nbsp;&nbsp;However,
from this study it is not possible to conclude whether the vaccine treatment and the subsequent IFN&gamma; responses are involved&nbsp;in
the clinical cause of these patients. To elucidate the full efficacy of vaccine treatment of patients with NSCLC, the investigators
recommended that a randomized trial should be conducted.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Colorectal
Cancer (CRC) in Singapore</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
single arm phase II clinical study was also sponsored and funded by the Singapore National Cancer Centre (NCC) to investigate
the efficacy of intradermal vaccination with MCV in patients with advanced colorectal cancer. The principal investigator of the
Singapore CRC Trial was Dr. Han Chong Toh, a recognized specialist in medical oncology in Singapore. While Dandrit Denmark was
not sponsor of the trial, it assisted in the design and proposal of the trial to the SNCC and Dr. Toh. Dr. Claesson and two other
DanDrit employees collaborated with the researchers at the Singapore National Cancer Center, with respect to the study design
and the analysis and interpretation of data obtained from the Singapore CRC Trial. The results and findings of the Singapore CRC
trial were published in recognized scientific journals (Clinical results: Clin. Cancer Res. 2009 Dec 15;15(24):7726-7736., Immunological
data: Vaccine. 2009 Dec 11;28(2):542-7.) that was co-authored by Dr. Claesson and the two other employees of DanDrit Denmark that
collaborated with the researchers at the NCC in Singapore.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
study used DanDrit&rsquo;s patented procedure for generating dendritic cells. All included patients had tumors which antigenically
correlated with the vaccine, i.e. were MAGE-A positive. The purpose of the study was to investigate the objective efficacy and
specific immunologic response of the MCV vaccination. The first patient was enrolled in June 2005, and by June 2007 a total of
20 patients had been treated and evaluated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
vaccine was given to advanced colorectal cancer patients pre-treated with chemotherapy, where there was no further indication
for surgery or treatment with chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Treatment
with MCV did not appear to adversely affect the patient&rsquo;s quality of life, measured based on a global health score of 68.3
prior to treatment with minimal variation through the course of the treatment. The health-related quality of life&nbsp;assessment
quantifies how the individual's well-being may be affected over time by a disease, such as cancer.&nbsp; Health-related quality
of life is assessed using patient questionnaires. These questionnaires are multidimensional and cover physical, social,&nbsp;emotional,&nbsp;cognitive,
work- or role-related and spiritual&nbsp;aspects, as well as a wide variety of cancer related symptoms, therapy induced side effects,
and the financial impact of cancer. The questionnaire from the Eastern Cooperative Oncology Group (ECOG) is most commonly used
to evaluate the impact of&nbsp;cancer&nbsp;on sufferers.&nbsp;MCV induced objective responses in seven of 20 patients (six responses
were stable disease and one response was partial regression of tumor mass). Significant immunological and clinical correlation
was observed. Results from the trial were presented orally at the AACR meeting in Singapore in November 2007.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
CRC trial in Singapore evaluated the efficacy and toxicity of MCV in advanced colorectal cancer patients expressing at least one
of six MAGE-A antigens. Dendritic cells were cultured from peripheral blood mononuclear cells (PBMCs) and pulsed with allogenic
lysate and matured using cytokines to achieve high CD83 and CCR7 expressing dendritic cells. Each patient received up to 10 intradermal
vaccinations (3-5 x 106 cells/dose) at biweekly intervals. Twenty patients received a total of 161 vaccinations. Treatment was
well-tolerated with minimal adverse events. Quality of life measurement using global health score was high at baseline and did
not change during the duration of the trial. In this study, statistical testing was done with repeated t-tests comparing baseline
with each time point. or similar. A &ldquo;t-test&rdquo; is a statistical analysis used to determine whether there is a statistical
difference between averages or means of a group with a small sample size. The &ldquo;baseline&rdquo; is a starting point from
which a comparison can be made and is typically established prior to the beginning of a study as a point of comparison for monitoring
and evaluating data at various point in a study.&nbsp;&nbsp;The term &ldquo;<I>comparing baseline with each time point</I>&rdquo;
refers to the comparison of data at a defined point in time against the originally established &ldquo;baseline&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Since
the p-values did not change during the duration of the trial, we believe that there were no statistical differences regarding
quality of life in this study in any of the parameters at any time points.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
colorectal cancer patients who are eligible for the humanitarian program in Singapore must present a profile similar to the one
of the patients who were recruited in the phase IIa clinical trial. However, there have been some exceptional cases where treatment
has been based on a doctor&rsquo;s discretion on the patient&rsquo;s quality of life. Also, patients are monitored according to
the previous phase II study protocol. To date we have not received a detailed report regarding the final outcomes for patients
participating in the Singapore trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MAGE-A-expressing
metastatic colorectal cancer patients with prior progressive disease treated with MCV achieved a competitive Clinical Benefit
Rate of 40%. While patients with single metastatic sites in either lung or nodal regions tended to have more durable responses
(see patients 1, 2 and 9 in table below), Stable Disease was also attained in patients with bulky multiple metastases (see patient
6 in table below). Five patients notably remained progression-free for over six months and two patients with significant tumor
burden (see patients 1 and 9 in table below) were still progression-free for over 27 and 37 months respectively. We recognize
that adopting the primary endpoint of Clinical Benefit Rate using RECIST criteria has limitations. This study protocol was designed
in 2005 where objective response rate (ORR) and Clinical Benefit Rate evaluation as primary endpoints in Phase II cancer vaccine
trials were not uncommon. Nevertheless, the investigators&nbsp;&nbsp;did evaluate Progression Free Survival and Overall Survival
as secondary endpoints, which may better reflect true vaccine efficacy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
meta-analysis of 32 cancer vaccine clinical studies in patients with advanced colorectal cancer reported a Clinical Benefit Rate
in 11.2% of patients and an overall response rate (Complete Response and Partial Response) of 0.9%. The defined clinical benefit
rate (Complete Response, Partial Response, Stable Disease) was observed in 17% (12/70) of colorectal cancer patients who received
Dendritic Cell vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patients&rsquo;
Characteristics</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 5%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ID</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Age</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><br>
    <FONT STYLE="font-size: 10pt"><B>(years)</B></FONT></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 5%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Sex</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 5%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PS</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 17%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Site
    of disease</B></FONT></td>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>No.
    of</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><br>
    <FONT STYLE="font-size: 10pt"><B>Chemo-regimens</B></FONT></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Disease
    at Accrual</B></FONT></td>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>No.
    of vaccinations</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BOR</B></FONT></td>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Time
    to Tumor response (months)</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Duration
    of response (months)</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TTP</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><br>
    <FONT STYLE="font-size: 10pt"><B>(months)</B></FONT></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Survival
    Time (months)</B></FONT></td>
    <TD NOWRAP STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LN</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.7</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&gt;
    25.0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>*</B></FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&gt;
    27.7</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>*</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">39.7</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&dagger;</B></FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">67</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">35.6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, LN, Pelvic,
    Bone</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.7</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">43</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, Adrenal,
    LN</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">54</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liver, Lung, Ascites,
    LN</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ND&Dagger;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&gt;
    3.8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&Dagger;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&Dagger;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">76</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liver, Peritoneum,
    Pelvic, Lung, LN, Serosa</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bone</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">75</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">62</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LN, Lung and Pelvic</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PR</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&gt;
    35.4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>*</B></FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&gt;
    37.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>*</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&dagger;</B></FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">73</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liver, LN</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19.6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">64</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liver</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">12</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">57</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, Liver, LN</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">65</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LN, Pleural, Lung,
    Liver</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, Liver, Peritoneum</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7.2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">15</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">72</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LN, Pleural, Liver,
    Lung</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">77</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Liver, Bone, Lung</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">13.0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">75</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, Liver</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">17.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">54</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">LN, Lung</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">SD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.8</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6.7</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">23.2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">19</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">75</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">M</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, Liver,</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.0</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">20</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">41</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lung, Skin, LN,
    Bone</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PD</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.9</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.5</FONT></td>
    <TD NOWRAP STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*&nbsp;Indicates
that the patient has not progressed at the time of analysis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&dagger;&nbsp;Patients
who are alive at the time of analysis have their survival time censored at the time of last follow up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&Dagger;&nbsp;Patient
withdrawn due to poor performance status; survival time was censored at last date in the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Abbreviations:
PS, performance status according to Eastern Cooperative Oncology Group; CT, chemotherapy; RT, radiotherapy; BOR, best overall
response; TTP, time to tumor progression; LN, lymph node; F, female; M, male; SD, stable disease of at least 4 weeks; PD, progressive
disease; ND, CT scan not done; PR, partial response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; color: fuchsia; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ECOG
PERFORMANCE STATUS</B></FONT></P>
                                                                     <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P></td></tr>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 6%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Grade</B></FONT></td>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 93%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ECOG</B></FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fully active,
    able to carry on all pre-disease performance without restriction</FONT></td></tr>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Restricted in
    physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house
    work, office work</FONT></td></tr>

<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ambulatory
    and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours</FONT></td></tr>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></td>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capable of only
    limited self-care, confined to bed or chair more than 50% of waking hours</FONT></td></tr>
<TR STYLE="background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Completely disabled.
    Cannot carry on any self-care. Totally confined to bed or chair</FONT></td></tr>
<TR STYLE="background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dead</FONT></td></tr>
</table>
<P STYLE="margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of 2006, there were a total of eight clinical DC vaccination studies in patients with metastatic colon cancer, all with peptide-pulsed
DC. To our knowledge, this study which adopted an allogenic tumor lysate-based DC vaccine achieves the highest Clinical Benefit
Rate in advanced colorectal cancer patients compared to these previous Dendritic Cell vaccination clinical trials. The clinical
activity of this present Dendritic Cell-based vaccine might reflect its polytopic nature, its allogenic adjuvant-like components,
the quality of the Dendritic Cell preparation (i.e. high uniform expression of CD83, CD86, HLA class II, and CCR7), the intradermal
route of vaccine injection securing optimal lymph drainage to regional lymph nodes, the presence of MAGE expression in both patients
and vaccine and the increased frequency of delivery (ten injections).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quality
of life measurement using global health score was high at baseline and did not vary much across time. In this study, statistical
testing was done with repeated t-tests comparing baseline with each time point., Since the p. values did not vary across time,
we believe that there were no statistical differences regarding quality of life in this study in any of the parameters at any
time points.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Treatment
with MCV did not appear to adversely affect the patient&rsquo;s quality of life, measured based on a global health score of 68.3
prior to treatment with minimal variation through the course of the treatment. The health-related quality of life&nbsp;assessment
quantifies how the individual's well-being&nbsp;may be affected over time by a disease, such as cancer.&nbsp; Health-related quality
of life is assessed using patient questionnaires. These questionnaires are multidimensional and cover physical, social,&nbsp;emotional,&nbsp;cognitive,
work- or role-related and spiritual&nbsp;aspects, as well as a wide variety of cancer related symptoms, therapy induced side effects,
and the financial impact of cancer. The questionnaire from the Eastern Cooperative Oncology Group (ECOG) is most commonly used
to evaluate the impact of&nbsp;cancer&nbsp;on sufferers.&nbsp;MCV induced objective responses in seven of 20 patients (six responses
were stable disease and one response was partial regression of tumor mass). Significant immunological and clinical correlation
was observed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Compassionate
Use/Named Patient Approval</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Further
to the data emerging from the Singapore CRC trial, the Singapore government requested and approved (22 September 2008) that named
patients be offered MCV therapy at cost. This first compassionate use approval marked a significant milestone for the progress
and acceptability of the MCV therapeutic model. This compassionate program could be used as a model to initiate sales of MCV in
other countries of the ASEA such as Thailand or Malaysia. Outside the United States, named patient programs provide controlled,
pre-approval access to drugs in response to requests by physicians on behalf of specific, or &ldquo;named&rdquo;, patients before
those medicines are licensed in the patient&rsquo;s home country.&nbsp;<FONT STYLE="background-color: white">Governments worldwide,
such as Singapore&rsquo;s government, have created provisions for granting access to drugs prior to approval for patients who
have exhausted all alternative treatment options and do not match clinical trial entry criteria. Often grouped under the labels
of compassionate use, expanded access, or named patient supply, these programs are governed by rules which vary by country defining
access criteria, data collection, promotion, and control of drug distribution.</FONT>&nbsp;Through these programs, patients are
able to access drugs in late-stage clinical trials or approved in other countries for a genuine, unmet medical need, before those
drugs have been licensed in the patient&rsquo;s home country. In September 2008, DanDrit Denmark and the National Cancer Centre
of Singapore (NCC) entered a collaboration agreement regarding a clinical named patient program conducted in Singapore at NCC
with the dendritic cell vaccine MCV. NCC has established a GMP approved laboratory in which the manufacturing of MCV takes place.
NCC has received approval from the relevant governmental authorities for the import of lysate necessary for production of MCV.
The clinical and research and development activities of the named patient program relate to the Company&rsquo;s product, MCV.
The purpose for the Singapore named patient program is to provide patients with advanced colorectal cancer or other forms of cancer(s)
with the presence of MAGE antigen expression an alternative treatment for the vaccination with MCV, where there is no further
indication for surgery or treatment with chemotherapy. Patients are recruited on named patient basis according to the patient
inclusion and exclusion criteria stated in the phase IIa study protocol. However, there may be some exceptional cases where treatment
will be made based on a doctor&rsquo;s discretion regarding the patient&rsquo;s quality of life. Approximately 50 patients have
been recruited for the Singapore named patient program and 8 patients are still active in the named patient program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Future:
100% Off-the-Shelve Vaccines</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Autologous
(from the patient)&nbsp;</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">dendritic cells<FONT STYLE="background-color: white">&nbsp;cancer
vaccines are tailor made for each individual patient. This personalized medicine approach is appealing to the patients but may
present several drawbacks to a pharmaceutical company. Creating a new, unique vaccine for each patient may be perceived as complex,
time consuming, and expensive.&nbsp;</FONT>Therefore, DanDrit is pursuing two programs to offer in addition to its personalized
vaccine 100% off-the-shelve cancer vaccines: MCV2 and MelVaxin&trade;. These two programs presented below capitalize on the knowledge
and the expertise gained with DanDrit&rsquo;s proprietary lysate used for MCV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Allogenic
DC based vaccine: MCV2</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">First,
DanDrit is developing MCV2 a 100% off-the-shelf dendritic cell vaccine through collaboration with the EtablissementFrancais du
Sang (EFS) / GeniusVac (France) pursuant to a Confidential Disclosure Agreement entered into in March 2013, with a Materials Transfer
and Feasibility Study Agreement currently under negotiation. Through the proposed agreement, DanDrit would provide EFS with a
certain quantity of its proprietary DDM-1.7 lysate, for the limited purpose of EFS using its GEN-T plasmacytoid DC line technology
to conduct a feasibility study in collaboration with DanDrit, to demonstrate the potential efficacy of EFS&rsquo; technology and
evaluate prospects of further cooperation between the parties. The GEN-T cell line is generated by EFS&rsquo; R&amp;D laboratory
in Grenoble. This cell line, loaded with tumor-derived antigenic peptides (HLA-A*0201 restriction) is being used as a cellular
vaccine, to treat cancer patients. The DDM-1.7 lysate is produced by DanDrit to load autologous dendritic cells used to treat
cancer patients. In this context, the main objective of the project is to determine if DDM1.7 lysate and GEN-T cell line can be
combined to develop a new cancer vaccine. The main point is to validate that the GEN-T cell line, once loaded with the DDM1.7
lysate is able to present the DDM1.7-derived Ag to specific T lymphocytes. MCV2 is a cell-based immunotherapeutic product consisting
of an irradiated plasmacytoid dendritic cell line presenting DanDrit&rsquo;s proven lysate.&nbsp;<FONT STYLE="background-color: white">DanDrit
sourced the allogenic dendritic cells from EFS /GeniusVac. EFS/</FONT>GeniusVac produces an allogenic plasmacytoid dendritic cells
(pDCs) line that has demonstrated the induction of multi-specific and highly functional cytotoxic cell responses directed against
tumor targets both In vitro and in vivo. These irradiated antigen-presenting pDCs have a strong power to induce specific antitumor
response by cytotoxic DC8+ T-cells. The safety and efficacy allogenic pDC platform has been proven. Stimulation of PBMC from HLA-A*0201+
donors by HLA-A*0201 matched allogenic pDCs pulsed with tumor-derived peptides triggered high levels of antigen-specific and functional
cytotoxic T cell responses (up to 98% tetramer+ CD8 T cells (a group of white blood cells known as lymphocytes and play a central
role in cell-mediated immunity). The pDC vaccine demonstrated anti-tumor therapeutic in vivo efficacy as shown by the inhibition
of tumor growth in a humanized mouse model. It also elicited functional tumor-specific T cells ex-vivo from PBMC and TIL of stage
I-IV melanoma patients. Responses against MelA, GP100, tyrosinase and MAGE-3 antigens reached tetramer levels up to 62%, 24%,
85% and 43% respectively. pDC vaccine-primed T cells specifically killed patients&rsquo; own autologous melanoma tumor cells.
This semi-allogenic pDC vaccine was more effective than conventional myeloid DC- based vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">This
Allogenic approach offers multiple advantages:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&#9679;<BR>
<BR>
&#9679;</FONT><BR>
<BR>
&#9679;</td>
    <TD STYLE="padding: 0; text-indent: 0; text-align: left; vertical-align: top"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
                                                                                  vaccine could then be mass-produced in a unique manufacturing facility</FONT></P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Cost effective process</FONT></P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">All manufacturing process can then be out-sourced (DanDrit does not need to support its own GMP manufacturing facility)</P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"></FONT></P>
                                                                                  <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"> </FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P></td>
    <TD STYLE="width: 10%"><img src="image_010.jpg" alt="(logo)" style="height: 159px; width: 150px">&nbsp;</TD></tr>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<tr style="vertical-align: top">
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="padding: 0; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="padding: 0; text-align: justify; line-height: 115%; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The MCV2 vaccine could be more likely to have higher potential efficacy than MCV. The allogenic DCs are further
regarded as MHC-incompatible foreign invaders.&nbsp;&nbsp;Then, they induce an inflammatory reaction that further promotes the
recruitment and activation of endogenous DCs at the vaccination site. This hypothesis has now been verified in rat and mouse cancer
models in which tumor growth was significantly reduced by therapeutic vaccinations with tumor-loaded allogenic DCs.</FONT></td></tr>
</table>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MCV2 is still
    using the clinically proven lysate used in MCV as cancer specific antigen</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;One- To- Many&rdquo;: the same drug product could be used to treat several patients (consistent with current
pharma business model).</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Fully standardizable
    product</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Guarantee of homogeneity
    of the clinical trials</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Melvaxin&trade;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
second platform product, MelVaxin&trade; is also evaluated. MelVaxin&trade; is similar to the lysate component of MCV. DanDrit
proposed injecting MelVaxin&trade; into the skin to promote natural dendritic cell responses that will attack the tumor expressing
cancer/testis antigens. It is necessary to inject MelVaxin&trade; with an immuno-stimulator such as GM-CSF, BCG or novel adjuvants
(such as 3M&rsquo;s TLR7 and TLR8 agonists). A preclinical program has been planned in minipigs. These animals have immune response
profiles, particularly of skin injection, that are very close to human. This program, currently on hold, can be reinitiated when
staff is available to manage this program. This takes second place to the MCV2 program and illustrates DanDrit&rsquo;s professional
commitment to advancing lead clinical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Other
Future Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Other
cancers</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
has already made progress with clinical trials of NSCLC and CRC. DanDrit is now focusing its clinical development on advanced
colorectal cancer, but DanDrit may if opportunity arises extend its range of cancer targets to answer the desperate need for effective
new therapies.&nbsp;As an illustration, esophageal cancers may be one of these opportunities. The two types of esophageal cancers
the esophageal squamous cell carcinoma (EC) and the esophageal adenocarcinoma (EAC) expressed MAGE -A. Worldwide, EC is the most
frequent malignant esophageal cancer accounting for at least 10,000 deaths per year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">But
in Western countries, EAC is the most rapidly increasing cancer compared with other malignancies. Surgical resection is currently
the only potential cure with or without neo-adjuvant or adjuvant chemo-and/or radiotherapy, the five year survival rate is less
than 20%. At first presentation, approximately 50-60% of patients with esophageal cancer are not eligible for surgery and have
very poor outcome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Tolerogenic
Dendritic Cells</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Some
dendritic cells seem to instruct cell-killing T cell clones to abandon their mission by self-destructing through an apoptotic
pathway. This may offer the possibility of eliminating those T cells responsible for the manifestation of auto-immune disease.
In MCV dendritic cells are derived in such a way that the resulting dendritic cells promote an immune reaction. However, dendritic
cells may also be derived in such a way that they are tolerogenic, they promote immune tolerance. Promoting immune tolerance can
be used to treat autoimmune diseases such as early stage type I diabetes (where insulin secreting cells are still present) or
even to help prevent rejection of tissue transplantation. In this way the tolerogenic dendritic cells are used to turn off an
undesirable immune reaction. DanDrit has established methods to derive tolerogenic dendritic cells from peripheral blood monocytes,
similar to the approach used to generate immunogenic dendritic cells in MCV. Tolerogenic dendritic cells are easily distinguished
by their function in vitro. DanDrit has filed patents to cover the generation of tolerogenic dendritic cells.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Non-Core
Products &ndash; Out-licensing</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Non-core
patents are being developed for application in dendritic cell related applications that are not cancer-related. Revenues from
licensing such non-core products will support core product and core technology development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
principal non-core intellectual property relates to tolerogenic dendritic cells, their production and application in auto-immune
diseases to include type 1 diabetes. DanDrit&rsquo;s fast track production methods for dendritic cells might be out-licensed for
non-competitive applications in areas other than cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Fast-track
production of Dendritic Cells</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
generation of mature immunogenic dendritic cells from peripheral blood monocytes requires eight days of growth in culture. The
efficiency of producing MCV could be improved if the time required to generate dendritic cells could be significantly reduced.
DanDrit has tested many protocols for generating dendritic cells quickly. Two promising methods have emerged from intensive research
activities to generate dendritic cells in either two days or five days. The fast track methods for generating dendritic cells
produce immunogenic dendritic cells that are comparable to cells generated using DanDrit&rsquo;s standard technique. These new
fast track methods are covered by DanDrit&rsquo;s existing dendritic cell technology patent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
fast-track production technology could be of commercial interest for other companies working in non-competitive areas of dendritic
cell technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MicroRNAs
for dendritic cell quality control</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
patented a method using microRNAs to characterize dendritic cells and establish a basis for quality control. To date there are
few dendritic-cell specific antigens and those existing are covered by patents. DanDrit has patented its microRNA approach developed
with Bioneer (note that patents are 100% owned by DanDrit).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: small-caps 10pt Times New Roman, Times, Serif"><B>Proposed
Clinical Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">The
proposed Phase III study with an adaptive design plans to enroll 174 stage IV colorectal cancer patients after resection of
metastases and chemotherapy.Regulatory authorities in the United States and Europe have published guidance documents on the
use and implementation of adaptive design trials. These documents include descriptions of adaptive trials and a requirement
for prospectively written standard operating procedures and working processes for executing adaptive trials, as well as a
recommendation that sponsor companies engage with CROs that have the necessary experience in running such trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
</FONT>proposed patients in the trial will therefore have no evidence of disease. The clinical study is designed as a randomized
multicenter, Phase III clinical study. Patients will be included after resection of their primary tumor and resectable metastases
in liver and after appropriate peri- or post-operative chemotherapy by stratification and random assignment to a non-vaccine control
group or a vaccine group receiving five vaccinations with 14-day administration intervals followed by ten vaccines with two-month
intervals. Inclusion is planned to take place ten weeks after finishing the last round of peri- or post-operative chemotherapy
(FOLFOX or FOLFIRI) and after a negative tumor scan (head, thoracic and abdominal cavities) and normal CEA prior to inclusion
in the vaccine or the control groups. The table below summarizes the key features of the proposed clinical study<FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Traditionally
drug development has consisted of a sequence of independent trials organized in different phases.&nbsp;&nbsp;Full development
typically involved (1) a learning phase II trial and (2) one or two confirmatory pivotal phase III trial(s).&nbsp;&nbsp;The new
seamless phase II/III designs are aimed at interweaving the two phases of full development by combining them into one single,
uninterrupted study conducted in two steps. Adaptive seamless clinical trial designs have proved to be effective in several clinical
research areas, such&nbsp;as the development of Velcade intended for multiple myeloma and non-Hodgkin's lymphoma&nbsp;&nbsp;or
a long-acting glucagon-like peptide-1 analog (dulaglutide) in a randomized, placebo-controlled, double-blind study of overweight/obese
patients with type 2 diabetes: the EGO study.&nbsp;Adaptive seamless phase II/III designs enable a clinical trial to be conducted
in steps with the sample size calculation selected on the basis of data observed in the first step to continue along to the second
step. The main statistical challenge in such a design is ensuring control of the type I error rate. Most methodology for such
trials is based on the same endpoint being used for interim and final analyses. However, in some settings like our clinical trial,
the primary endpoint, overall survival, can be observed only after long-term follow-up.&nbsp;&nbsp;In this case the design includes
a shorter term endpoint data, in our case, progression free survival at 18 months. If short-term data are available for some patients
for whom the primary endpoint is not available, basing treatment selection on these data may lead to increase of the type I error
rate (false positive).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Phase
IIb/III Overview</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Purpose</B></FONT></TD>
    <TD STYLE="width: 80%; border: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To determine the safety and efficacy of our investigational vaccine in colorectal cancer and to determine its ability to prevent recidivism in stage IV colorectal patients with no evidence of disease (after resection of metastase and chemotherapy)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Study Type</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interventional</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Study design</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; line-height: 115%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Endpoint (primary)</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Efficacy : Progression Free Survival at 18 months and overall Survival</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Endpoint (secondary)</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 9pt">Carcino-Embryonic Antigen (CEA); Quality of Life</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">&nbsp;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intervention Model</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Parallel assignment 174 patients</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Allocation</FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Randomized</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Adaptive Design</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Purpose:</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;<FONT STYLE="font-size: 10pt">seamless Phase II/III clinical trial</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Treatment</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Five vaccines bi-weekly (intra-dermal administration) followed by ten vaccines every two months</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Location</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Italy and USA</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Expected Duration</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Three years</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; padding-left: 9pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Eligibility</B></FONT></TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid">
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 9pt">Stage IV colorectal cancer patients</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 9pt">After resection of metastase and no evidence of disease
        (CT scan and CEA back to normal)</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 9pt; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 0 9pt">Vaccine therapy given after FOLFOX or FOLFIRI &nbsp;</P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Critical
Success Factors</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
points below are a specific, focused list of critical factors and challenges that need to be considered for the project, during
the critical start-up phase and throughout the project life cycle. In addition to the sections noted below, during the course
of the study, DanDrit will be pro-active in discussing the Critical Factors with the investigators.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Oncology
studies by their nature have a degree of complexity not always encountered in other therapeutic areas. We believe success of the
CRC study will be related to these Critical Success Factors. Our approach to each critical factor is detailed below. DanDrit identified
the following key factors for success:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patient
    accrual and site selection</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assessment
    of patient response</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Study
    design and collection of patient data</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Vaccine
    supply</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patient
    safety</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Multinational
    regulatory requirements</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CRO
    previous experience</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Adaptive
    trial design experience</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Patient
accrual and site selection</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
proposed study is anticipated to enroll 174 patients at  30 sites in Italy. Although the number of potential
stage IV patients is significant, only a portion of these, approximately 10-20%, will have complete resections of their
primary tumors and metastatic disease with no detectable residual disease (i.e. clear resection margins). This coupled with a
competitive oncology vaccine research environment will put pressure on accrual milestones.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The selected
patient population will be easier to work with than the patients in Phase IIa. It is reasonable to expect the response rate
to be greater for MCV, or for any immunotherapy, in a patient population with No evident Disease (NED). Consequently in this
Phase III trial, patients will have to be NED, raising the likelihood that the immune system can generate a response against
cancer as it re-occurs. We believe this may ultimately lead to better data from the Phase III trial. Careful selection of
study sites using evidence based feasibility research, discussion with colorectal key opinion leaders (KOLs), contact with
investigators at key sites and our past clinical experience in this indication and with cancer vaccines will be required.
DanDrit will work with the GISCAD Foundation for Research on Cancer (GISCAD) in Italy and with IRCCS University Hospital San
Martino (Pr. Sobrero), all of which are recognized as among the world&rsquo;s premier cancer research and treatment
facilities. The GISCAD Group has conducted multiple clinical trials in colorectal cancer including most recently the TOSCA
trial, a clinical trial evaluating FOLFOX-4 3 months vs. 6 Months and Bevacizumab as adjuvant therapy for patients with Stage
II/III CRC.&nbsp; The network of Italian hospitals enrolled 3,800 patients in this trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accrual
rates are estimates and can be further refined. Inadequate enrollment is one of the biggest drivers of wasted cost and time in
clinical trials. Therefore, DanDrit has taken a very conservative position regarding site selection and patient enrollment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Assessment
of patient response</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
general, in oncology vaccine studies, the relationship between clinical response, survival (and other measures of efficacy) and
immune response may be unclear. Changes in patients&rsquo; immunological profiles during vaccination protocols, their response
to the vaccine components as measured by delayed-type hypersensitivity (DTH), used as the primary measure of the ability to immunize
a patient to a tumor cell or specific tumor antigen; the&nbsp;<FONT STYLE="background-color: white">enzyme-linked immunosorbent
spot&nbsp;</FONT>(ELISPOT), a common method for monitoring immune responses In humans; cluster of differentiation (CD) antigen
profiles,&nbsp;<FONT STYLE="background-color: white">protocol used for the identification and investigation of&nbsp;<U>cell surface
molecules</U></FONT>; and other strategies to attempt to correlate treatment outcome with the results of vaccination are variable.
The paper describing the Phase II study in CRC patients by Toh et al indicates that a plasma protein expression profile has been
identified for responding patients. Continued evaluation of immunological profiles of the patients and the collection of these
data and correlation with outcomes may be desirable but for this POC study will not be necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
a guidance document by the FDA, &ldquo;Clinical Considerations for Therapeutic Cancer Vaccines&rdquo; (September 2009), the agency
recognizes that immunological approaches to tumor control may require significant time to develop, and that careful clinical assessment
of patients must be performed as well as the use of methods that rely on radiological measurement of tumor size (e.g. RECIST).
The guidance indicates that for cancer vaccines, patients may be observed to develop indications of progressive disease based
on radiological measurement, but that these indications may also be transient and that tumor regression is still a possibility
as the immunological response develops. Methods to incorporate such an approach will help avoid premature termination of study
treatment for some patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Tumor
burden has also been a confounding problem for oncology vaccine development because of tumor-induced immune-suppression in some
patients and because of progression prior to immune response. These issues may be obviated in this study of no-evident-disease
subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Patient
safety</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
believes that MCV appears to be safe and well tolerated in studies to date. Adverse events related to the vaccine appear to be
Grade 1-2 and consist of mostly superficial toxicities as describe above. Patients in the proposed study will have recovered from
previous treatments and will be apparently disease free: thus, at this time, only general safety precautions and observations
related to the patient population are recommended.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Injection
site reactions and other toxicities expected in the class of DC vaccines will be included in site training. Some volume of Severe
Adverse Events can be anticipated in a population of advanced CRC patients. Discrimination of events related to vaccine against
a background of underlying disease and prior chemo or and/or radiotherapy will be necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IRCCS&rsquo;s
pharmaco vigilance scientists has prepared a Safety Management Plan to specifically outline the procedures to be followed
and will train the site personnel to obtain, collect, verify, transmit and coordinate a timely and efficient manner.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In addition
to reviewing assignment of causality, an Independent Data Management and Safety Committee (IDMSC) led by Pr. AvelGrothey
(Mayo Clinic) will assist in the proposed interim assessment for efficacy and safety<FONT STYLE="font: 10pt Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Regulatory</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">DanDrit will seek
scientific advice from the Italian Medicine Agency (AIFA) and the European Medicines Agency EMEA (ATMP) in connection with the
Phase /III trials in Italy and will request a pre-Phase II/III meeting with the FDA. GISCAD provides preparation and assistance
for the Scientific Advice process in EMEA including the following activities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Regulatory review
    of pertinent data</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Discussions/kick
    off meeting with DanDrit contact(s), for background, pertinent issues, proposed questions, strategic discussion etc.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prepare
    a briefing package for Scientific Advice includes QC (one review round with DanDrit) using the existing information in the
    Investigational Medicinal Product Dossier(IMPD)/Investigator Brochure(IB) as the basis for the package</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Set
    up and attend meeting with EU regulatory agency and conduct all associated administrative tasks (letters, post meeting minutes,
    etc.)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Upon
receipt of funding in connection with the initial closing of this offering, we anticipate seeking a clinical
trial authorization to commence a Phase III trial in Italy&nbsp;&nbsp;which we anticipate will run over a three year
period. DanDrit also has the option to evolve the Phase IIb to a Phase III trial through the use of an adaptive design.
Ordinarily a drug requires two Phase III trials before it can apply for FDA approval. Consequently the first patient for
Phase IIb could be considered commencement of &lsquo;pivotal&rsquo; trials for MCV. Also, DanDrit intends to move to a
pivotal trial in China with a Chinese partner. Currently, the China Food and Drug Administration offers a low-cost clinical
development pathway for cancer drugs developed, manufactured and commercialized in China. A separate local CRO will be
recruited for this Chinese trial. DanDrit intends to file an investigational new drug (IND) application with the FDA to
initiate the process to permit manufacturing capability of MCV in the U.S. and to include U.S. patients in the Phase IIb/III
trials initiated in Italy. Once an IND application has been filed in the U.S., we believe that we will be able to expand the
Phase IIb/III trials initiated in Europe to the U.S., however we cannot estimate at this time when we will be able to begin
enrolling U.S. patients in the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
Competitive Strengths</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
believe our following strengths position us to increase our revenue and profitability:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Cutting
    Edge Technology.&nbsp;</I></B>We believe immunotherapy is one of the waves of the future in cancer treatment.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Colorectal
    Market Potential.&nbsp;</I></B>Colorectal cancer is a large market with a well identified unmet medical need for safe maintenance
    therapy. The clinical data for MCV to date gives the potential for the vaccine to eventually become the standard of care for
    maintenance therapy. MCV has the potential to alter the treatment paradigm by prolonging periods of remission after response
    to chemotherapy. If MCV works as expected in colorectal cancer, we believe it would likely prove beneficial in other tumors
    that over-express MAGE-A including lung, breast and esophageal cancer.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Regulatory
    Precedent.&nbsp;</I></B>Dendreon with Provenge&trade;, its prostate cancer vaccine, pioneered the regulatory pathway for MCV.
    Dendreon worked with the FDA to develop the protocols allowing a cellular therapy such as MCV to be approved for clinical
    use. DanDrit could be the next generation of dendritic cell vaccine with several improvements over its competition:&nbsp;stimulate
    a cellular immune response rather than just an antibody response, no need for leukapheresis to produce the vaccine, intradermal
    administration, convenience of an allogenic vaccine, polytopic approach but with a focus on the MAGE-A antigen family and
    reliable manufacturing.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Successful
    Use in Singapore.&nbsp;</I></B>For the last five years, the Singapore National Cancer Center have provided MCV to colorectal
    cancer patients within an on-going compassionate use program in Singapore. Based on that experience, DanDrit is building a
    potential collaboration with a Chinese oncology pharma partner that may speed up large scale commercialization of MCV.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Strong
    IP Protection.&nbsp;</I></B>DanDrit owns 100% of the technology which is patented with a long patent life..</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
strategy is focused on conducting a Phase III clinical trial in advanced colorectal cancer that we believe may trigger a partnership
deal that may bring a significant return on investment (based on analysis of past acquisitions of peer cancer vaccine companies).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
intends to conduct a randomized multicenter clinical trial to determine the ability of MCV to prevent recidivism in stage IV colorectal
patients with no evidence of disease after surgical resection of metastasis and chemotherapy. The same need for a safe effective
maintenance therapy exists for stage III colorectal cancer patients with no evidence of disease after surgical resection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
comparative trial is planned to be completed within three years. DanDrit&rsquo;s management is confident that upcoming
clinical data will be the catalyst to unlock commercial revenues for DanDrit through either acquisition by pharmaceutical partner
or licensing deals that would yield upfront and milestone payments as well as royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are also considering a registration trial to support potential approval of MCV in China. This trial would be conducted under China
Food and Drug Administration regulations with a Chinese oncology pharmaceutical partner, such as the TASLY Group or 3S Bio. Contacts
with 3S Bio and the TASLY Group have already been initiated. China has recently put in place a drug approval system that includes
a low-cost first clinical approval pathway especially for Chinese biotechnology companies. The approval for local biotechnology
players is advantageous, since costs for a pivotal clinical trial in China are estimated at one tenth of EU or U.S. costs. Therefore,
we plan to collaborate with a Chinese company such as the TASLY Group to develop, manufacture and sell MCV in China. Several factors
are also making a partnership with a Chinese pharmaceutical company attractive:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
    registration, the clinical trial can only be performed in sites approved by the China Food and Drug Administration. By November
    2010, there were 112 oncology sites in Mainland China.</FONT></td></tr>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Screening
    for MAGE-A could be attractive to the China Food and Drug Administration, but tumor samples could not be shipped outside of
    China for genomic testing. Therefore a partner who can perform MAGE-A screening in China is valuable.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, the China Food and Drug Administration relies more than other agencies on risk benefit assessment. Risk benefit assessment
in China remains the &ldquo;heart&rdquo; of determining the value of products and is a more favorable assessment approach to MCV
as the vaccine is, thus far, well tolerated with what DanDrit believes to be a strong safety profile (due to dendritic cell technology).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furthermore,
due to high unmet medical need, the approval for cancer drugs is also more favorable than in other regions of the world. Because
cancer is the first cause of mortality in China, the approval process for oncology drugs benefits from easier rules than those
that govern drugs targeting other diseases. The State Food and Drug Administration (the predecessor of China Food and Drug Administration)
granted 114 CTA approvals for oncology global/regional trials from 2005 to 2010. Generally, in order to approve a cancer drug
in China:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Usually
    only one pivotal study is required</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With
    only 100 to 800 patients (most likely 300 patients)</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
    open-label study design is accepted (without placebo control)</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    statistical consideration are also attractive as relatively low statistical significance (P value 0.03~0.05) is required</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Overall
    additional flexibility exists for oncology drugs, driven by the benefit/risk ratio</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Furthermore,
a special review and approval procedure applies to oncology drugs. The review and approval procedure could shorten the review
time and can enhance communication with the China Food and Drug Administration. By the end of 2010, 28 drugs obtained approval,
and more than half were oncology drugs (ten chemical drugs, and five biologics).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
believe that it is important to take advantage of this development opportunity quickly as the paradigm for oncology drug development
is changing rapidly in China:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
    is an unprecedented number of anti-cancer therapies in development and the standard of care changes quickly</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&#9679;</B></FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    complexity of information concerning tumor genetics and signaling pathways is growing and will bring greater opportunities
    for personalized medicine</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Industry</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cancer
deaths remain constant, partly because people are living longer. DanDrit&rsquo;s lead products for NSCLC and CRC address about
40% of all cancer deaths. Other important cancers include Breast (8% of deaths), Prostate (6% of deaths) and Pancreas (6% of deaths).
Together these top 5 cancers are responsible for 60% of all cancer deaths.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Cancers
Diagnosed (deaths in parentheses) each year</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 16%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Region</FONT></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Population</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><br>
    <FONT STYLE="font-size: 10pt">1000,000s</FONT></FONT></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
    Cancer&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><br>
    <FONT STYLE="font-size: 10pt">1000s</FONT></FONT></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NSCLC</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><br>
    <FONT STYLE="font-size: 10pt">1000s</FONT></FONT></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CRC</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1000s</B></FONT></P></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Breast</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1000s</FONT></P></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prostate</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1000s</FONT></P></td>
    <TD STYLE="width: 12%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pancreas</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1000s</FONT></P></td></tr>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">USA</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">300</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1400
    (560)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">190
    (125)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>150
    (50)</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">185
    (40)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">185
    (30)</FONT></td>
    <TD STYLE="border-right: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">37
    (30)</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EU</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">500</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2300
    (900)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">315
    (205)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>250
    (85)</B></FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">305
    (67)</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">305
    (50)</FONT></td>
    <TD STYLE="border-right: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">60
    (50)</FONT></td></tr>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0 0 0 10pt; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Combined</FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">800</FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3700
    (1300)</FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">505
    (330)</FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>400
    (135)</B></FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">490
    (107)</FONT></td>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">490
    (80)</FONT></td>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">97
    (80)</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With
the 12,667,500 estimated number of new cancer cases in 2008, cancer remains a large market opportunity. Cancer is still the main
cause of death in developed countries &ndash; accounting for ~33% of death and remains an area of huge unmet medical need. The
cancer market has a high growth potential for the coming years with an expected 7% annual growth rate for the years 2011- 2018.
The American Cancer Society figured out 1,638,910 new cancer cases in the US for 2012 with 577,190 associated deaths.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
Europe the number of new cancer cases for 2012 was estimated at 3.45 million with a 1.75 million deaths. The cancer market is
the fastest growing pharmaceutical market with $83 billion expected growth of the cancer drug market by 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
per-treatment price of chemotherapy for CRC is approximately $30,000. We expect that, if our vaccine is approved for use in CRC
patients, the cost per-treatment will be approximately equal to the per-treatment cost of chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Due
to its safety profile, MCV should fit easily into the treatment paradigm of most cancers. The initial label of adjuvant therapy
for stage IV colorectal cancer with no evidence of disease after surgical resection of metastases could be a door opener for the
larger colorectal cancer market. DanDrit&rsquo;s pharmaceutical partner should be able to grow the label to the larger adjuvant
for stage III colorectal cancer market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Colorectal
Cancer</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
figure below presents the market opportunity for MCV in advanced colorectal treatment. The global colorectal cancer market peak
opportunity for MCV can be valued at US$4.6 billion using quite conservative assumptions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_006.jpg" ALT="(logo)" STYLE="height: 339px; width: 550px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Despite
numerous therapeutic advances, colorectal cancer continues to be associated with one of the worst survival rates of all cancers.&nbsp;<FONT STYLE="background-color: white">Metastatic
liver disease is found in 10% to 25% of patients having surgery for primary colorectal cancer instead of liver metastasis are
detected in 40-50% of patients with diagnosed colon cancer</FONT>. Then, standard of care &ldquo;treatment&rdquo; for colorectal
cancer patients after resection surgery and chemotherapy is only observation. When surgical resections of liver metastases are
possible, as in 20% of the affected patients, five years survival may approach 35%. According to the most recent papers, the median
PFS in patients receiving combined surgery and chemotherapy with No Evidence of Disease is 24-26 months. The same need for a safe
effective maintenance therapy exists for stage III colorectal cancer patients with no evidence of disease after surgical resection
and chemotherapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
believe that it is of great importance for colorectal cancer patients receiving surgery alone or surgery combined with peri- or
post-operative chemotherapy, that new and more effective therapies are developed and offered in the post-treatment period. The
aim of the proposed trial is to study whether our lead vaccine can increase the progression-free survival for these patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Licensing
Potential and Cooperation Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following discussion represents opportunities that we believe can expand the use of our technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Alliance
with Chinese Company</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition of the size of their national market, Chinese biotech firms currently benefit from a low cost first clinical development
path. The Chinese approval process is favorable for local biotechnology companies. With a Chinese partner, we plan to conduct
a Phase III trial in China for lower costs than in the U.S. and at a faster pace. A successful Phase III trial could result in
large scale commercialization in China and Southeast Asia.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
the domestic market in China for cancer therapies is expected to grow due to a large aging population, expanded insurance coverage,
higher government healthcare spending, rising disposable incomes and the high incidence of cancer among the population. In spite
of recent price cuts, we believe that the market for cancer therapies in China represents a long-term opportunity based on the
factors set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Alliance
Strategy</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to its lead compound MCV, DanDrit has built a pipeline of dendritic cell based cancer therapies, currently addressing
40% of all cancer-related deaths. MCV can be indicated to cancers over-expressing MAGE-A.&nbsp;&nbsp;Cancers over-expressing MAGE-A
include among others, lung cancer, colorectal cancer, breast cancer, and esophageal cancers.&nbsp;DanDrit intends to work with
strategic partners to strengthen the in-house pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
control key technologies with relevance outside our core business area and these we may out-license or co-develop with suitable
partners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MyTomorrows</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
December 2013, DanDrit entered an agreement with MyTomorrows (&ldquo;MT&rdquo;), a Dutch company, regarding a Patient Name Use
Program (PNU) for MCV. This program will allow DanDrit to sell MCV for one year of treatment (10 vaccines) to cancer patients
through MT. MT offers a worldwide online platform providing access to non-registered medicines for patients with life threatening
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MT
is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmacovigilance. DanDrit&rsquo;s potential
liabilities are limited to quality control of cGMP manufacturing of MCV. DanDrit expects several benefits from this agreement.
First, in 2014, DanDrit anticipates short term revenue generation as MT will transfer payment as soon as a patient orders MCV.
DanDrit also anticipates that this program may contribute to lowering the cost of manufacturing of the clinical lot through economy
of scale. This program may also generate real life data for MCV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Manufacturing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Since 2011, DanDrit has out-sourced the GMP manufacturing of its lysate. We believe that proving that our technology
transfer was possible was a key step in finding and working with a future pharmaceuticals partner. DanDrit evaluated several
possible EU-based contract manufacturing organizations (CMOs) and selected Cellin technologies, a CMO based in Tallin ,
Estonia. The collaboration with Cellin Technologies in Estonia demonstrated that GMP production of lysate could not only be
transferred but that the production could be scaled up. We consider that the potential economy of scale that can be expected
in the cost of lysate production could become a competitive advantage versus other cancer vaccine companies using recombinant
production of cancer-specific antigens (i.e. Mage-A3 from GSK). Also, the collaboration with the Estonian CMO is based on a
pure fee-for-services basis and can be discontinued at any time without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, DanDrit will spend a small part of the net proceeds on improving the manufacturing of the MCV vaccine. DanDrit intends
to establish a closed fully automatized manufacturing process. We learned from the Dendreon&rsquo;s experience that an&nbsp;efficient
manufacturing process should be in place before approval for commercialization. Cost saving should be expected from a fully automatized
vaccine production. We also assume that a fully efficient manufacturing process may increase the value of a deal with a pharmaceutical
partner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cell
Banking</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
melanoma cell lines used by DanDrit in the production of our lysate (MCL) are stored at ultra-low temperature in liquid nitrogen
at Symbion Science Park, Copenhagen, Denmark. Both master- and working cell banks are stored this way and the contents of the
cell banks (both master and working) are recorded in log books. Nitrogen levels are maintained by the staff of DanDrit Biotech
at least once a week and any activity in regards to storage (shipment of cells, nitrogen levels etc.) are documented in the appropriate
log book.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">Furthermore,
for security reasons, samples of the master cell banks are also stored at specialized cell storage facilities in England. In addition,
working cell banks from the DDM1.7 cell line are stored at PX Therapeutics in France and Cellin Technologies in Estonia for production
purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Sales,
Marketing and Distribution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
business model of DanDrit is to focus on early development of dendritic cell based vaccine. We have significantly reduced the
fixed costs linked with our operation and do not intend to build an expensive marketing, sales and distribution organization.
We will rely on pharmaceutical partners with demonstrated relevant experience in commercialization of cancer products to market,
sell and distribute MCV. Therefore, we have already identified and establish a communication line with several potential future
pharmaceutical partners. At completion of the comparative clinical trial, we plan to enter into a collaboration agreement with
a pharmaceutical partner regarding the regulatory approval, marketing, sales and distribution of MCV.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a company primarily focused on pharmaceutical research, we expect that our most valuable assets are our intellectual property.
This includes U.S. and foreign patents, patent applications, common-law trademarks, trade secrets and know-how. We are pursuing
an aggressive intellectual property strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
intends to aggressively defend its patents through legal process if necessary. Where appropriate, DanDrit may in-license intellectual
property that may add to the strength and defense of our core business. DanDrit&rsquo;s intellectual property comprises patents,
trademarks, copyright and secret know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
core business is cancer therapy. Where DanDrit&rsquo;s patents and secret know-how are applicable to non-core business areas we
will consider out-licensing for relevant non-core applications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
filed its first Patent Cooperation Treaty (PCT) patent application on November 29, 2002 with priority claimed from 2001 with the
Danish application, shortly after our formation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
may continue to patent its innovations, such as novel dendritic cell production systems or dendritic cell quality control. To
support potential income streams DanDrit may patent non-core applications of its dendritic cell technologies so as to secure future
revenue streams from out-licensing activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Patents</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Pharmaceutical
    composition for inducing an immune response in a human or animal (2001 Denmark (DK), 2002 PCT)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
    patent was first filed in November 2002. The patent covers and describes the usage of an allogenic melanoma cell lysate (MCL)-pulsed
    autologous DC vaccine expressing at least one of six MAGE-A antigens overexpressed by the cell line being the source of the
    lysate. The patent covers the antigen composition used in the generation of MelCancerVac and the claims for producing MelCancerVac.
    In this patent the antigens are specified to mainly belong to the cancer testis family. The family of antigens is expressed
    in a wide variety of cancer forms. In the International Preliminary Report on Patentability (IPRP) all claims were determined
    to be novel and inventive. The patent expiry date is November 29, 2022. This patent has been granted in: Europe, the USA,
    China, Australia, Singapore, Japan, Russia, Hong Kong. This patent is pending in: Israel and Norway. This patent is owned
    by the Company and was not licensed from third parties. The patent protection means that the cancer specific antigen-rich
    lysate obtained from our cell line cannot be commercially made, used, distributed or sold without DanDrit's consent. These
    patent rights can be usually enforced in a court, which, in most systems, holds the authority to stop patent infringement.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Protocol
    for generating dendritic cells&nbsp;(2005 DK, 2008 PCT)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
    patent covers the generation of dendritic cells based on a blood sample of 200 ml. The patent differs from other DC generating
    patents by the utilization of reduced temperature and a single blood sample.&nbsp;&nbsp;DCs exposed to tumor antigens followed
    by treatment with T(h)1-polarizing differentiation signals have paved the way for the development of DC-based cancer vaccines.
    Critical parameters for generation of optimal functional clinical grade DCs are a very competitive area. DanDrit has developed
    a method that covers the generation of immature dendritic cells under reduced temperature settings which by further activation
    has been shown to give a high yield of homogeneous and fully matured DCs. This patent was filed on December 7, 2006. In the
    International Preliminary Report on Patentability (IPRP) a large majority of claims were found to be novel and inventive.
    The patent expiry date is 2032. This patent was granted in 2012 in China, Eurasia, Russia, Europe, Israel, Mexico, Malaysia,
    New Zealand. This patent is owned by DanDrit and was not licensed from third parties. The patent protection means that the
    method that DanDrit use to generate dendritic cells cannot be commercially&nbsp;used, distributed or sold&nbsp;without DanDrit's&nbsp;consent<B>.</B>&nbsp;
    These&nbsp;patent<B>&nbsp;</B>rights&nbsp;can be usually enforced in a court, which, in most systems, holds the authority
    to stop&nbsp;patent infringement<B>.</B></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Method
    for generating tolerogenic dendritic cells&nbsp;employing decreased temperature (2007)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
    has expanded the method of development of mature dendritic cells to also include the generation of regulatory DCs. In addition
    to DCs used for cancer immunotherapy, DanDrit has developed an additional arm of DCs, namely regulatory/tolerogenic DCs to
    be used for treatment of various autoimmune diseases such as Type 1 diabetes and Multiple Sclerosis.&nbsp;&nbsp;This patent
    was filed on November 13, 2008. Patent pending:&nbsp;&nbsp;worldwide.&nbsp;&nbsp;1st Office Action received in Europe August
    25, 2010. This&nbsp;patent is owned by the Company and was not licensed from third parties. The patent protection means that
    the method that DanDrit use to produce tolerogenic dendritic cells cannot be commercially&nbsp;used, distributed or sold&nbsp;without
    DanDrit's&nbsp;consent<B>.</B>&nbsp; These&nbsp;patent<B>&nbsp;</B>rights&nbsp;can be usually enforced in a court, which,
    in most systems, holds the authority to stop&nbsp;patent infringement.</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Micro
    RNAs as markers of the functional state of a dendritic cell</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
    patent covers and demonstrates that functionally different DCs carry unique microRNA signatures.&nbsp;&nbsp;By examining a
    handful of microRNA profiles one can analyze the function of DC vaccines. We believe this is a valuable addition to other
    vaccine quality control measures that are currently used in studies that involve DCs.&nbsp;&nbsp;Critical parameters for assessment
    of the optimal functional state of DCs and prediction of the vaccine potency of activated DCs have in the past been based
    on measurements of differentiation surface markers like HLA-DR, CD80, CD83, CD86, and CCR7 and the level of secreted cytokines
    like interleukin-12p70. However, the level of these markers does not provide a complete picture of the DC phenotype and may
    be insufficient for prediction of clinical outcome for DC-based therapy. We have identified additional biomarkers by investigating
    the differential expression of microRNAs (miRNAs) in mature DCs relative to immature DCs. The patent was filed on November
    14, 2008.&nbsp;&nbsp;In the International Preliminary Report on Patentability, a large majority of claims were found to be
    novel and inventive.&nbsp;&nbsp;Patent pending: Europe and USA. 1st Office Action received in Europe on August 18, 2010. Follow
    up action on election restriction received in the USA on October 21, 2010. This&nbsp;patent is owned by the Company and was
    not licensed from third parties. The patent protection means that the method that DanDrit use to test and release its dendritic
    cells cannot be commercially&nbsp; used, distributed or sold&nbsp;without DanDrit's&nbsp;consent.&nbsp; These&nbsp;patent&nbsp;rights&nbsp;can
    be usually enforced in a court, which, in most systems, holds the authority to stop&nbsp;patent infringement.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
of the above patents are protected by relevant international extensions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Trademarks</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
policy of product trademarking and branding has been adopted by DanDrit. Trademarks have been obtained for</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MelCancerVac&trade;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>MelVaxin&trade;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>DanDrit&trade;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Commercial
Secrets</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">In
addition to intellectual property protected by patents and copyrights, DanDrit has commercial secrets relating to its products,
production processes, know-how and future strategies. Where it is expedient to share such secret information this will be done
under the protection of a confidentiality (or secrecy) agreement. Such agreements require the signing parties to keep DanDrit&rsquo;s
commercial secrets confidential unless<FONT STYLE="font: 10pt Times New Roman, Times, Serif">:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">at
    the time of disclosure the confidential information was already known to the recipient as evidenced by written record pre-dating
    such disclosure;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">at
    the time of disclosure the confidential information is generally available to the public or subsequently becomes available
    to the public other than by an act of omission on the part of the recipient; or</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    confidential information has been made available to the recipient (on a non-confidential basis) by a third party having the
    lawful right to do so.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Governmental
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Orphan
Drug status for MCV</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
United States and Europe may designate drugs for relatively small patient populations as orphan drugs. Orphan drug designation
does not convey any advantage in, or shorten the duration of, the regulatory review and approval process, but does make the product
eligible for orphan drug exclusivity, reduced filing fees and specific tax credits. Generally, if a company receives the first
marketing approval for a product with an orphan drug designation in the clinical indication for which it has such designation,
the product is entitled to orphan drug exclusivity. Orphan drug exclusivity means that the FDA will not approve another application
to market the same drug for the same indication, except in limited circumstances, for a period of seven years in the United States.
This exclusivity, however, could block the approval of our proposed product candidates if a competitor obtains marketing approval
before us. We plan to apply for orphan drug status for MCV to treat stage IV CRC with NED after  resection and chemotherapy
if we meet the eligibility criteria. However, note that, even if we obtain orphan drug exclusivity MCV, we may not be able to
maintain the status. For example, if a competitive product is shown to be clinically superior to our product, any orphan drug
exclusivity we have will not block the approval of such competitive product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Fast
Track designation for development of MCV</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
intend to request Fast Track designation for MCV. If a drug is intended for the treatment of a serious or life-threatening condition
and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA
Fast Track designation for a particular indication. Marketing applications filed by sponsors of products in Fast Track development
may qualify for priority review under the policies and procedures offered by the FDA, but the Fast Track designation does not
assure any such qualification or ultimate marketing approval by the FDA. Receipt of Fast Track designation may not result in a
faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures. In
addition, the FDA may withdraw any Fast Track designation at any time. We may seek Fast Track designation for our vaccine product
candidates or any other product candidates, but the FDA may not grant this status to any of our proposed product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Approval
for Commercialization</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MCV
and any future product candidates that we will be developing will require approval of the FDA before they can be marketed in the
U.S. Although our focus at this time is primarily on the U.S. market, in the future similar approvals will need to be obtained
from foreign regulatory agencies before we can market our current and proposed product candidates in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
process for&nbsp;filing and obtaining FDA approval to market therapeutic products is both time-consuming and costly, with no certainty
of a successful outcome. The historical failure rate for companies seeking to obtain FDA approval of therapeutic products is high
and, with the exception of Dendreon Corp.&rsquo;s dendritic cell vaccine for the treatment of prostate cancer, no cancer stem
cell or dendritic cell-based cancer vaccine has to date been approved by the FDA. This process includes conducting extensive pre-clinical
research and clinical testing, which may take longer and cost more than we initially anticipate due to numerous factors, including
without limitation, difficulty in securing appropriate centers to conduct trials, difficulty in enrolling patients in conformity
with required protocols in a timely manner, unexpected adverse reactions by patients in the trials to our proposed product candidates
and changes in the FDA&rsquo;s requirements for our testing during the course of that testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
time required to obtain FDA and other approvals is unpredictable but often can exceed five years following the commencement of
clinical trials, depending upon the complexity of the product and other factors. Any analysis we perform of data from preclinical
and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent
regulatory approval. We may also encounter unexpected delays or increased costs due to a variety of reasons, including new government
regulations from future legislation or administrative actions or from changes in FDA policy during the period of product development,
clinical trials and FDA regulatory review.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any
delay or failure in our clinical trial program and in obtaining required approvals would have a material adverse effect on our
ability to generate revenues from the particular product. Furthermore, any regulatory approval to market a product may be subject
to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for
the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Environmental
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are subject to a broad range of federal, state, local and foreign environmental laws and regulations which govern, among other
things, air emissions, wastewater discharges and the handling, storage disposal and release of wastes and hazardous substances.
It is our policy to comply with applicable environmental requirements at all of our facilities. We are also subject to laws, such
as the Comprehensive Environmental Response, Compensation and Liability Act (&ldquo;CERCLA&rdquo;), that may impose liability
retroactively and without fault for releases or threatened releases of hazardous substances at on-site or off-site locations.
We are subject to similar requirements in Denmark and other European countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development costs are charged to operations as incurred and consist primarily of clinical trial costs for the Company&rsquo;s
VIVA Phase III clinical trial, related party manufacturing costs, consulting costs, contract research and development costs, and
compensation costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Clinical
trial costs for the next three months are estimated at 313,104 Euros, and an average of 100,000 Euros per quarter for the year
2015 (calculated on an as-converted basis from Euro (EUR) to U.S. dollars ($) based on the currency exchange rate of $1.00 = EUR
1.2101, as of December 31, 2014).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
plan to have in the next 9 months over 30 clinical trial sites in operation in Italy in our Phase III trial with MCV. We expect
an increase in clinical lot manufacturing expenses in the next 9 months related to the ramp-up of our Phase 3 VIVA clinical trial
and the related enrollment efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Discovery
and preclinical research and development expenses include costs for substantial external scientific personnel, technical and regulatory
advisers, and others, costs of laboratory supplies used in our internal research and development projects, travel, regulatory
compliance, and expenditures for preclinical and clinical trial operation and management when we are actively engaged in clinical
trials. Because we are pre-revenue company, we do not allocate research and development costs on a project basis. We adopted this
policy, in part, due to the unreasonable cost burden associated with accounting at such a level of detail and our limited number
of financial and personnel resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
is extensive competition in the biopharmaceutical industry and the technology is developing rapidly. DanDrit is developing a vaccine
for the treatment of advanced colorectal cancer, where competing products may be introduced. If these newly developed products
are more efficient, cheaper, more patient-friendly, safer, or better placed than DanDrit&rsquo;s vaccine candidates, or if DanDrit&rsquo;s
competitors develop drugs that reduce or eliminate the need for DanDrit&rsquo;s vaccine candidates, such competition could reduce
or eliminate DanDrit&rsquo;s commercial opportunities. Many of DanDrit&rsquo;s competitors have substantially greater financial,
technical and human resources than DanDrit and significantly more experience than DanDrit with preclinical and clinical research
and development and in obtaining regulatory approval of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
drugs may face competition as a result of many factors, including the route of administration (e.g. oral administration vs. injection),
the availability and cost of production, efficiency of DanDrit&rsquo;s partners&rsquo; marketing and sales efforts as well as
the price of DanDrit&rsquo;s products. DanDrit has limited or no previous experience in these areas. DanDrit&rsquo;s inability
to compete effectively would have a material adverse effect on DanDrit&rsquo;s business, financial condition, results of operations
and future growth opportunities. At this time, Dandrit does not represent a significant presence in the biopharmaceutical industry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Several
companies are trying to capitalize on the growing interest for immunotherapy in the treatment of cancer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Two
Directly Competing Companies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
figure below outlines the competitive landscape for MCV. Note that colorectal cancer, while providing a large market opportunity
(it is the second most killer cancer after lung cancer), offers a more robust competitive landscape than other cancers. In the
colorectal cancer space DanDrit faces two main competitors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bavarian
    Nordic (&ldquo;BN&rdquo;): CV-301, BN&rsquo;s second compound, is in clinical development with advanced colorectal cancer
    patients</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Immatics:
    its second compound is in clinical development in early stage colorectal cancer patients</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_007.jpg" ALT="http:||www.sec.gov|Archives|edgar|data|1527728|000121390014006190|img008_v1.jpg" STYLE="height: 239px; width: 508px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Bavarian
Nordic (BAVA.CO) and CV-301</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_008.jpg" ALT="http:||www.sec.gov|Archives|edgar|data|1527728|000121390014006190|img008a_v1.jpg" STYLE="height: 44px; width: 88px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">With
its lead vaccine Prostvac&trade; from Therion Biologics and NCI, Bavarian Nordic (BN) also acquired Panvac&trade; vaccine. This
PANVAC&trade; vaccine failed to prove efficacy in patients with advanced pancreatic cancer who failed gemcitabine. BN is currently
focusing its efforts on Prostvac&trade; for treatment of prostate cancer, currently in Phase III. However, in 2012, BN re-initiated
the clinical development of Panvac&trade; (re-named CV-301).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CV-301
is a cancer immunotherapy product candidate incorporating two antigens, CEA and MUC-1, in a viral vector. CV-301 is an off-the-shelf
immunotherapy product candidate for the treatment of multiple cancers. It originates from the same poxvirus technology platform
as PROSTVAC&trade;. Both PROSTVAC&trade; and CV-301 are prime-boost vaccines sequentially combining two different poxviruses (vaccinia
and fowlpox).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CV-301
had been studied in different cancers in clinical trials led by the National Cancer Institute. One study was a randomized Phase
II trial in patients with metastatic breast cancer. The study enrolled 48 patients to receive CV-301 in combination with docetaxel
or docetaxel alone. The primary study endpoint was PFS, while secondary endpoints included overall survival and immunologic correlative
studies. A preliminary analysis of the study showed PFS of 6.6 months in the CV-301 group versus 3.8 months among those receiving
docetaxel alone. Final study data are pending results from five patients that remained on study at the time of the analysis. Because
of its size the study was not designed to reach statistical significance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">More
directly relevant to DanDrit was the colorectal Phase II study of CV-301 conducted by Morse at Duke University. The objective
of the trial was to determine whether one of two vaccines based on dendritic cells&nbsp;and poxvectors encoding CEA and MUC1 would
lengthen survival in patients with resected metastases of colorectal cancer. The studied patients were, disease-free after CRC
metastasectomy and perioperative chemotherapy (n = 74). They were randomized to injections of autologous DCs modified with PANVAC
(DC/PANVAC) or PANVAC with per injection GM-CSF (granulocyte-macrophage colony-stimulating factor). Endpoints were recurrence-free
survival overall survival, and rate of CEA-specific immune responses. Clinical outcome was compared with that of an unvaccinated,
contemporary group of patients who had undergone CRC metastasectomy, received similar perioperative therapy, and would have otherwise
been eligible for the study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
recurrence-free survival at two years was similar (47% and 55% for DC/PANVAC and PANVAC/GM-CSF, respectively). At a median follow-up
of 35.7 months, there were two of 37 deaths in the DC/PANVAC arm and five of 37 deaths in the PANVAC/GM-CSF arm. The rate and
magnitude of T-cell responses against CEA was statistically similar between study arms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a group, vaccinated patients had superior survival compared with the contemporary unvaccinated group. Both DC and pox-vector vaccines
had similar activity. Survival was longer for vaccinated patients than for a contemporary unvaccinated group.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
2013, Bavarian Nordic expanded its license with the National Cancer Institute (NCI) for CV-301 to include colon cancer. The original
collaboration agreement executed in 2011, involved multiple cancers including breast, lung, ovarian and other cancers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Immatics
Biotechnologies</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_009.jpg" ALT="http:||www.sec.gov|Archives|edgar|data|1527728|000121390014006190|img009_v1.jpg" STYLE="height: 51px; width: 100px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
second direct competitor is Immatics (previously known as Biomira), a German biotech company who currently focuses its
clinical efforts on a Phase III in Renal Cell Carinoma for its lead vaccine. However, Immatic also develops a vaccine in
colorectal cancer (enter Phase I in 2012). Note that Immatic&rsquo;s technology is peptide-based rather than a dendritic cell
approach and that Immatics is targeting its vaccine toward early stage colorectal cancer rather than resected advanced
colorectal cancer like Bavarian and DanDrit. This private German company only discovers and develops tumor-associated
peptides for the immunotherapy of cancer. Immatics reports that they raised &euro;53.8 million
to finance a Phase III pivotal trial of their lead product IMA901 which in data reported in June at ASCO demonstrated the
potential to confer an overall survival benefit in patients with advanced renal cell carcinoma.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Other
cancer vaccine companies</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following companies (by alphabetical order) are part of the competitive landscape but not direct competitors. They are presented
in this plan to illustrate the growing interest in cancer vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Agenus (www.agenus.com)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Argos Therapeutics
    (www.argostherapeutics.com)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>BioVest (www.biovest.com)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Celldex (www.celldextherapeutics.com)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>ImmunoCellular
    Therapeutics Ltd (www.imuc.com)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>North West
    Biotherapeutics (www.nwbio.com)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>Prima Biomed
    (www.primabiomed.com.au)</I></FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>TVax Biomedical
    (www.tvax.com)</I></FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>DanDrit Biotech A/S signs contract
for collaboration contract relating to VIVA Phase III adjuvant study</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In January 2015,
DanDrit Denmark signed a final contract of collaboration with the University Hospital IRCCS &ldquo;San Martino&rdquo; - IST - National
Institute for Cancer Research, better known as San Martino Hospital of Genoa (IST).&nbsp; The collaboration relates to the VIVA
Phase III adjuvant study of DanDrit vaccine in patients with no evidence of disease stage IV colorectal cancer (CRC).&nbsp;VIVA&rsquo;s
primary aim is to evaluate the efficacy of MCV in preventing relapse in stage IV CRC patients rendered Disease Free after completion
of standard treatment according to local practices.&nbsp;IST is acting as Contract Research Organization for DanDrit. Prof. Alberto
Sobrero is the Principal Investigator of this randomized multicenter study.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">In March
2015, DanDrit Denmark signed a contract of collaboration with the Fondazione Giscad per la RicercasuiTumori (foundation for
research on cancer) (GISCAD). GISCAD, the Gruppo Italiano per lo Studio dei Carcinoma dell&rsquo;Apparato Digerente(Italian
Group for the Study of Carcinoma of the Digestive Track) has conducted 46 phase II and III trials with the support and
collaboration of AIFA (Italian Drug Agency) and involves 160 oncology centers in Italy. GISCAD will assist DanDrit in the
identification, enrollment, compliance monitoring and management of the 30 clinical sites in Italy.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Negotiation with EtablissementFran&ccedil;ais
du Sang (EFS) regarding the GeniusVac Technology</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">DanDrit has
recently entered into a negotiation with the Etablissement Fran&ccedil;ais du Sang (EFS) regarding access to their GeniusVac
Technology. The GeniusVac technology is an Allogenic irradiated plasmacytoid dendritic cell line. This technology may allow
DanDrit to develop a 100% off-the-shelf cancer vaccine. DanDrit has conducted and completed due diligence under a CDA.DanDrit
and EFS are now working on a feasibility proof-of-concept test before establishing further collaboration.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company currently has 2 full-time employees and 1 part-time employee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Facilities
and Offices&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Our
corporate headquarters are located in Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen, Denmark and our U.S. mailing
address is </FONT><FONT STYLE="font-size: 10pt">375 Park Avenue, Suite 2607, New York, NY, 10152.<FONT STYLE="color: #1F497D"> </FONT></FONT>&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">We
lease approximately 1,108 square feet at our Symbion location which is used for work and storage of cells and biological
material in freezers. The lease is for a term of three years until March 2016. We also currently occupy approximately 1,620
square feet at Bredgade 75, 3rd</FONT>&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">Floor,
1263 Copenhagen K, Denmark, which is used for office space. The Company&rsquo;s lease can be terminated by either the Company
or the landlord with a three months&rsquo; notice of termination. </FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company gave a termination notice on February 28, 2015,therefore the lease will terminate May 31, 2015. The Company does
not anticipate renting additional office space in the near future</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_002"></A>Item
1A. Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>You
should carefully consider and evaluate all of the information in the risk factors listed below. If any of these risks occur, our
business, results of operations and financial condition could be harmed, the price of our common stock could decline, and future
events and circumstances could differ significantly from those anticipated in the forward-looking statements contained in this
report.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RISKS
ASSOCIATED WITH DANDRIT&rsquo;S BUSINESS AND INDUSTRY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
lacks an established operating history on which to evaluate its business and determine if it will be able to execute our business
plan, and can give no assurance that operations will result in profits.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
was formed in Delaware in January 2011 as a vehicle to pursue a business combination through the acquisition of, or merger
with, an operating business.&nbsp;&nbsp;On February 12, 2014, pursuant to the Share Exchange Agreement, DanDrit USA completed
the acquisition of approximately 100% of the issued and outstanding capital stock&nbsp;of&nbsp;&nbsp;DanDrit Denmark, a
Danish corporation formed in 2001, and as a result became DanDrit Denmark&rsquo;s parent company. &nbsp;&nbsp;DanDrit has a
limited operating history that makes it difficult to evaluate its business.&nbsp;&nbsp;DanDrit has not begun sales of its
products, and cannot say with certainty when it will begin to achieve profitability.&nbsp;&nbsp;No assurance can be made that
DanDrit will ever become profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
has incurred losses in prior periods and expects to incur losses in the future. DanDrit may never be profitable.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
had net losses at December 31, 2014 and 2013 of $2,370,883 and $2,147,361, respectively. DanDrit expects to continue to
sustain losses for the foreseeable future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
sales of DanDrit&rsquo;s products have generated minimal operating revenues, DanDrit has relied on loans and on sales of its debt
and equity securities to continue operations. If DanDrit is unable to raise funds through sales of its securities, there can be
no assurance that DanDrit will be able to implement its business plan, generate sustainable revenue or ever achieve profitable
operations. DanDrit expects to have operating losses until such time as it develops a substantial and stable revenue base. DanDrit
cannot assure you that it can achieve or sustain profitability on a quarterly or annual basis in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
may not be able to develop its vaccine candidates to yield satisfactory results and they may never be approved for use by regulatory
authorities. If DanDrit is unable to successfully commercialize its vaccines, its prospects, financial position, results of operations
and future opportunities will be materially adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">None
of DanDrit&rsquo;s vaccine candidates has completed full clinical development. Because DanDrit&rsquo;s vaccine candidates generally
belong to new classes of cell therapy, they will require extensive further development, testing and funding before we can seek
regulatory approval for any of these vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
prospects in the short term, including DanDrit&rsquo;s ability to generate revenue and make new strategic alliances, depend on
DanDrit&rsquo;s ability to develop, obtain regulatory approval for and commercialize its current vaccine candidates with satisfactory
results. If DanDrit fails to develop the medicines DanDrit has in its pipeline, it will have a material adverse effect on DanDrit&rsquo;s
business, financial condition, results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
can be no assurance that DanDrit will succeed in implementing its Phase IIb/III clinical trials for advanced colorectal cancer
so that the results of these clinical trials will support further preclinical or clinical studies, or that DanDrit will be able
to develop new vaccine candidates or successfully commercialize any of those cancer vaccine candidates at a later time. If DanDrit
does not do this, we cannot achieve our growth potential and this will have a material adverse effect on DanDrit&rsquo;s prospects,
financial position, results of operations and future opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Results
of our early clinical trials do not insure future success.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
results of early clinical trials may not necessarily be indicative of future results. Achieving positive results in preclinical
testing and early clinical trials does not constitute any assurance that in future clinical trials sufficient data can be obtained
to document a vaccine candidate&rsquo;s efficacy and safety. The safety and efficacy of a vaccine candidate in development must
be supported by extensive data from preclinical studies and clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
number of companies in the pharmaceutical industry and in the biopharmaceutical industry, including companies that have greater
resources and more experience than DanDrit, have achieved significant negative results in clinical phase IIb and III trials, even
after obtaining promising results in preclinical and early clinical studies. Results that are considered acceptable in early clinical
studies may not be confirmed or may be interpreted differently in subsequent studies. DanDrit cannot predict whether the clinical
phase IIb and III and other clinical trials that may be implemented will demonstrate sufficient efficacy and safety to obtain
regulatory approval to market any of DanDrit&rsquo;s vaccine candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Negative
or non-satisfactory results of clinical trials involving DanDrit&rsquo;s vaccine candidates could lead to DanDrit or its collaborators
having to perform additional nonclinical and/or clinical trials, which could result in higher costs and significantly delay the
marketing authorization application for such vaccine candidates by the regulatory authority, or could lead to an application for
a more narrowly defined use, or another indication for the vaccine candidate than originally expected. Such results could also
lead to the complete elimination of a vaccine candidate. If any of these risks materialize, it could have a material adverse effect
on DanDrit&rsquo;s business, financial condition, results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are a clinical-stage biopharmaceutical company which makes it difficult to assess our future viability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a clinical-stage biopharmaceutical company. We have not yet demonstrated an ability to successfully overcome many of the risks
and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical
area. For example, to execute our business plan, we will need to successfully:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">execute
    on product candidate development activities;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">obtain
    required regulatory approvals for the development and commercialization of our product candidates;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">maintain,
    leverage and expand our intellectual property portfolio;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">gain
    market acceptance for our products;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">develop
    and maintain any strategic relationships we elect to enter into; and;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td></tr>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></td>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">manage
    our spending as costs and expenses increase due to preclinical development, clinical trials, regulatory approvals and commercialization.</FONT></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we are unsuccessful in accomplishing these objectives, we may not be able to develop product candidates, raise capital, expand
our business or continue our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
will be dependent on collaboration and licensing arrangements to develop and commercialize its products. These relationships may
be unsuccessful and may not result in the development of vaccine candidates. In that case, our business, financial condition and
growth opportunities will be materially adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
expects to depend on collaboration and licensing agreements with third parties who we expect will provide additional personnel
and other resources and funding required to develop and commercialize its products. Until these relationships are established,
our plans for developing some of our vaccines may be uncertain. There can be no assurance that DanDrit will be able to enter into
or maintain these agreements, that the results of these agreements will further the development of a vaccine, or that DanDrit
will receive income from these agreements. Furthermore, collaborators that we anticipate may enter into agreements with us may
change their priorities; make reallocation of resources; terminate the agreements; end or further delay the development of vaccine
candidates; downgrade or change plans or strategies for regulatory approval or commercialization of the vaccine candidate; find
it difficult to retain key employees; or be taken over by companies that are our competitors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
expect that these collaboration and licensing agreements will entitle us to milestone payments and a percentage of sales related
to the vaccine candidates that are commercialized. If a third party with which DanDrit has established a collaboration or licensing
arrangement stops the development of a vaccine candidate, there can be no assurance that all rights in respect of the vaccine
candidate will be reassigned to us. A transfer of these rights may be delayed for various reasons, which may result in the delay
of all work performed for the vaccine candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Since
we are dependent on third parties to develop and commercialize our product candidates, any change in these anticipated relationships
will have a material adverse effect on our business, financial condition, and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Regulatory
requirements and regulations could have a material adverse effect on DanDrit.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
products are subject to extensive regulatory requirements, including public and/or regulatory limits set by the FDA and the European
Medicines Agency (&ldquo;EMA&rdquo;). These laws and regulations, including those relating to reporting on safety, product safety
and advertising and marketing of products cover all aspects of DanDrit&rsquo;s business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
and/or any future third party with which it has an effective collaboration or licensing agreement may be subject to changes in
applicable governmental regulations and/or regulatory framework and be subject to additional or more onerous restrictions, which
may make it necessary to make changes to personnel, facilities or procedures that could result in increased costs and adversely
affect DanDrit&rsquo;s business activities, including the development and commercialization of DanDrit&rsquo;s vaccine candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
DanDrit or its affiliates do not comply with applicable regulatory requirements or comply with significant legislative changes
DanDrit or its affiliates can be fined or risk having regulatory approvals suspended or withdrawn, risking recall or seizure of
products, restrictions on activities and/or civil or criminal prosecution, which could have a material adverse effect on DanDrit&rsquo;s
business, financial condition, results of operations and future growth opportunities. Furthermore, we cannot guarantee that our
vaccine candidates will be approved by the regulating agencies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
long as the relevant regulatory authorities have not considered and approved applications for DanDrit&rsquo;s vaccine candidates
(New Drug Application (NDA) or equivalent) DanDrit and its affiliates cannot commercialize DanDrit&rsquo;s vaccine candidates.
Production and marketing of DanDrit&rsquo;s products and DanDrit&rsquo;s ongoing research and development activities are subject
to rules set by numerous public authorities throughout the world. The regulatory authorities of each country can set their own
requirements and may refuse to approve a product or may require additional data before approving a product, even if the product
is approved by another regulating agency. Approvals may include restrictions on the marketing or use of products, which could
adversely affect the amount of DanDrit&rsquo;s revenue from the sale of those products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
are conducting, and may in the future conduct, clinical trials for MCV or any future product candidates in sites outside the United
States and the FDA may not accept data from trials conducted in such locations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have conducted, and may in the future choose to conduct, one or more of our clinical trials outside of the United States. Although
the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain
conditions imposed by the FDA. For example, the clinical trial must be well designed and conducted and performed by qualified
investigators in accordance with ethical principles. The study population must also adequately represent the U.S. population,
and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful.
Generally, the patient population for any clinical studies conducted outside of the United States must be representative of the
population for whom we intend to label the product in the United States. In addition, while these clinical trials are subject
to the applicable local laws, FDA acceptance of the data will be dependent upon its determination that the studies also complied
with all applicable U.S. laws and regulations. There can be no assurance the FDA will accept data from trials conducted outside
of the United States. If the FDA does not accept the data from our clinical trial conducted outside the United States, it would
likely result in the need for additional trials within the United States, which would be costly and time-consuming and delay or
permanently halt our development of MCV or any future vaccine candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>In
connection with the anticipated filing of our IND application with the FDA, we plan to submit trial results for trials we did
not sponsor, which the FDA may refuse to consider.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
was only a sponsor of one of the clinical trials completed to date for MCV while DanDrit Denmark employees and certain
affiliates were closely involved in the design of the studies and the analysis and interpretation of the resulting
data&nbsp;of all three studies. As a result, DanDrit intends to present all applicable data with respect to the current
trials that is available to it, regardless of DanDrit&rsquo;s specific role in any one of the trials.&nbsp;&nbsp;There are no
assurances that the FDA will accept any data that DanDrit submits in support of its IND application for any clinical trial in
which it was not a sponsor or principal investigator.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>There
can be no assurance that regulators will complete their review process in a timely manner, or that DanDrit vaccine candidates
will obtain regulatory approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
DanDrit or any third party with which we have an effective collaboration or licensing agreement experience difficulties or delays
in obtaining regulatory approvals, the development and commercialization of our vaccine candidates may be significantly delayed
or even discontinued. Such difficulties or delays could result in significantly increased development costs and/or a delay or
elimination of payments to us from our collaborators. This would have a material adverse effect on our business, financial condition,
results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
will be dependent on external suppliers of certain services and technologies.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
will be dependent on a number of external parties such as contract laboratories and clinical research organizations, and in some
cases our collaborators to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Implement
    preclinical studies (pharmacology, toxicology testing and safety pharmacological evaluations).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Provide
    DanDrit with vaccine materials and support DanDrit&rsquo;s activities related to preclinical and clinical studies.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Implement,
    inspect and/or monitor some or all aspects of the preclinical or clinical studies with DanDrit&rsquo;s product candidates.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Ensure
    compliance with regulatory requirements such as Good Clinical Practice (&ldquo;GCP&rdquo;), Good Manufacturing Practice (&ldquo;GMP&rdquo;)
    and Good Laboratory Practices (&ldquo;GLP&rdquo;).</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deliver
    IT services.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Produce
    vaccine drugs and vaccines in accordance with GMP.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
third parties DanDrit depends on may not be available when needed, or might not, if available, comply with all statutory and contractual
requirements, and/or otherwise provide their services in a timely manner or in an acceptable manner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
is dependent on its ability to recruit and retain qualified scientific and management personnel.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Recruiting
and retaining qualified scientific and management personnel for the planning and execution of research and development; preparation
of applications for intellectual property rights and regulatory approvals; and negotiating and maintaining cooperation with existing
and new partners is essential for DanDrit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
can be no assurance that DanDrit will be able to attract and retain such persons in light of demand for experienced employees
from numerous pharmaceutical companies, chemical companies, specialized biopharmaceutical companies, universities and other research
institutions. DanDrit&rsquo;s employment contracts contain no limitation on competition that would prevent DanDrit&rsquo;s current
employees from being employed by DanDrit&rsquo;s competitors or partners, if they choose to leave DanDrit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
may in the future require additional expertise and manpower in areas such as preclinical trials, management of clinical trials,
regulatory affairs, marketing, business development and management of partnerships. Inability to obtain or develop such expertise,
or hire the employees it needs, on reasonable terms, could have a material adverse effect on DanDrit&rsquo;s business, financial
condition, results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>If
our employees commit fraud or other misconduct, including noncompliance with regulatory standards and requirements and insider
trading, our business may experience serious adverse consequences.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
is exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply
with FDA regulations, to provide accurate information to the FDA, to comply with manufacturing standards we have established,
to comply with federal and state health-care fraud and abuse laws and regulations, to report financial information or data accurately
or to disclose unauthorized activities to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations
intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit
a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials,
which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct and
Ethics but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant
impact on our business, including the imposition of significant fines or other sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit&rsquo;s
products may not achieve market acceptance. This would have a material adverse effect on our business, financial condition, results
of operations and future growth opportunities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
drugs DanDrit or its collaborators may develop may not gain market acceptance among physicians, patients, third-party payers and
the medical community, even if they are approved for marketing. The degree of market acceptance of the products approved for sale
depends on a number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    ability of DanDrit or its collaborators to demonstrate the clinical efficacy, safety and benefits of the products.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    ability of DanDrit or its collaborators to demonstrate that the product has advantages over existing therapies or new alternative
    treatments.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    frequency and severity of any adverse effects arising from the use of the products.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    price of the products.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    subsidies DanDrit receives.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Efficacy
    within the therapeutic range for the illnesses the products are directed towards.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Patient
    comfort and user administration.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Requirements
    for marketing.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    level of support for marketing and distribution.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have no control over most of these factors. Furthermore, it may be difficult for us, to the extent that competitors are able to
commercialize competing products before our vaccine candidates obtain regulatory approval, to develop a market for a vaccine because
doctors, patients or third-party payers may have become accustomed to using a competing, existing product or for other reasons,
even though our drug may be more effective or has other advantages.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
any of the vaccines we develop fail to achieve market acceptance in the future, we may not be able to generate significant revenue,
which would have a material adverse effect on our business, financial condition, results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>The
use of DanDrit&rsquo;s drugs or vaccine candidates may lead to unforeseen side effects. If any of our drugs or vaccine candidates
is deemed to be unsafe, our business, financial condition, results of operations and future growth opportunities could be materially
adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
drugs are associated with a risk of allergic, immunologic genes or hyper-sensitivities. We test for allergic and immunological
genes actions in preclinical and clinical studies, but if any of our products cause other allergic or immunological reactions
than those considered acceptable by patients, doctors or regulatory authorities, we or our collaborators may be required to conduct
additional clinical trials that will cause delays and increase costs for the development of a product, or development may have
to be terminated or suspended on the grounds that participants will be exposed to unacceptable health risks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
in cases where pre-clinical or clinical studies have been successful, or received regulatory approval, a product can later prove
to be unsafe. The incidence of adverse events may make it necessary for us and for our collaborators to carry out further investigations
and studies. If a product is determined to be unsafe, we and our collaborators can be fined or risk having regulatory approvals
suspended or withdrawn, be required to cease selling activities relating to the product, be required to recall the product, be
subject to seizure of products, or be exposed to civil or criminal prosecution. Any of these results could have a material adverse
effect on our business, financial condition, results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Third
party reimbursement and reform measures on health care could have a material adverse effect on the commercial success of DanDrit&rsquo;s
vaccine candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Market
acceptance of DanDrit&rsquo;s vaccine candidates depends in part on the extent to which the public and private health insurance
and other third-party payers will subsidize DanDrit&rsquo;s drugs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Governments,
insurance companies and health organizations are increasingly seeking to reduce healthcare costs by limiting coverage, price and
reimbursement levels of new vaccine products as well as in some cases rejecting coverage. Reimbursement practices vary significantly
from country to country, and some countries require that products undergo a lengthy review by the authorities before they meet
the public support requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the United States, in Canada and in many other countries, pricing and/or profitability of some or all prescription pharmaceuticals
and biopharmaceuticals are subject to varying degrees of government control. Healthcare reform and controls on healthcare spending
may limit the price we charge for any products and the amounts thereof that we can sell. In particular, in the United States,
the federal government and private insurers have changed and have considered ways to change, the manner in which healthcare services
are provided. In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act, or collectively, PPACA, became law in the United States. PPACA substantially changes the way healthcare is financed by both
governmental and private insurers and significantly affects the healthcare industry.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, other legislative changes have been proposed and adopted since PPACA was enacted. These changes include aggregate reductions
to Medicare payments to providers of up to 2% per fiscal year, which went into effect on April 1, 2013. In January 2013, President
Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to
several types of providers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could
have a material adverse effect on our customers and accordingly, our financial operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
anticipate that PPACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous
coverage criteria and additional downward pressure on the reimbursement we may receive for any approved product. Moreover, payment
methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, the Middle Class Tax
Relief and Job Creation Act of 2012 requires the Centers for Medicare &amp; Medicaid Services, or CMS, to reduce the Medicare
clinical laboratory fee schedule by 2% in 2013, which in turn serves as a base for 2014 and subsequent years. CMS also recently
proposed to re-examine payment amounts for tests reimbursed under the Medicare clinical laboratory fee schedule due to changes
in technology and, in addition, proposed to bundle the Medicare payments for certain laboratory tests ordered while a patient
received services in a hospital outpatient setting. Such changes went into effect January 1, 2014. Levels of reimbursement may
be impacted by current and future legislation, regulation or reimbursement policies of third-party payors in a manner that may
harm the demand and reimbursement available for our products, which in turn could harm our future product pricing and sales. Any
reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private
payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate
revenue, attain profitability or commercialize our products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>There
may be delays or difficulties in the recruitment and monitoring of patients in clinical trials. Any such delays could have a material
adverse effect on DanDrit&rsquo;s business, financial condition, results of operations and future growth opportunities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
clinical development of new vaccine candidates depends on the recruitment of volunteer suitable patients for clinical trials.
The ability to recruit patients depends on certain factors, including the prevalence of the disease in the population. It may
be more difficult to find a sufficient number of patients to participate in clinical trials for drugs being developed for a disease
that is common among the general population. Even if a disease is frequent among the population, there may be a number of other
companies developing drugs that target the same disease who may eventually have more success in recruiting among the total group
of potential patients for their clinical studies. If we or our collaborators find it difficult to recruit a sufficient number
of patients to participate in clinical trials for one of its vaccine candidates DanDrit and/or its collaborators may have to postpone
or discontinue ongoing clinical trials. Delays may also result in increased costs for clinical studies and may affect the implementation
of studies required for a vaccine candidate&rsquo;s approval. Delay or complete termination of a clinical trial program could
have a material adverse effect on DanDrit&rsquo;s business, financial condition, results of operations and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
may not be able to make, or cause others to conduct, animal testing in the future. This could have a material adverse effect on
our research and development work.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
into dendritic cell vaccines does not generally involve animals. But, certain aspects of DanDrit&rsquo;s biotechnology research
and development may be carried out on animals. Changes to laws and regulations, recognized clinical procedures, or experimental
protocols may have a negative impact on this research and development. Pressure from society, which may lead to restrictions on
the use of animals or result in actions against DanDrit, its affiliates or its clinical research organizations from groups of
people or individuals who are against animal testing may also have a material adverse effect on research and development work.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
faces extensive competition. If our vaccine candidates cannot compete successfully, our business, financial condition,
results of operations and future growth opportunities could be materially, adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
is extensive competition in the biopharmaceutical industry and the technology is developing rapidly. DanDrit is developing a vaccine
for the treatment of advanced colorectal cancer, where competing products may be introduced. If these newly developed products
are more efficient, cheaper, more patient-friendly, safer, or better placed than DanDrit&rsquo;s vaccine candidates, or if DanDrit&rsquo;s
competitors develop drugs that reduce or eliminate the need for DanDrit&rsquo;s vaccine candidates, such competition could reduce
or eliminate DanDrit&rsquo;s commercial opportunities. Many of DanDrit&rsquo;s competitors have substantially greater financial,
technical and human resources than DanDrit and significantly more experience than DanDrit with preclinical and clinical research
and development and in obtaining regulatory approval of pharmaceutical products.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit&rsquo;s
drugs may face competition as a result of many factors, including the route of administration (e.g. oral administration vs. injection),
the availability and cost of production, efficiency of DanDrit&rsquo;s partners&rsquo; marketing and sales efforts as well as
the price of DanDrit&rsquo;s products. DanDrit has limited or no previous experience in these areas. DanDrit&rsquo;s inability
to compete effectively would have a material adverse effect on DanDrit&rsquo;s business, financial condition, results of operations
and future growth opportunities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>DanDrit
is likely to be exposed to product liability claims. If product liability lawsuits are successfully brought against us, our insurance
may be inadequate. If a judgment were to exceed our insurance coverage, our business could be materially, adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
will be exposed, by virtue of the nature of its business, to the risk of potential product liability claims, which is a natural
part of the clinical development, manufacture and marketing of drugs. Even in cases where DanDrit has granted licenses to third
parties to manufacture and sell its products, there can be no assurance that DanDrit will not be included in any product liability
claims relating to these medicines, or claims by third parties, including DanDrit&rsquo;s partners, for indemnity or other compensation
from DanDrit in connection with any such claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
plan to obtain product liability insurance coverage once our clinical trials commence. However, our insurance coverage may not
be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly
expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts
to protect us against losses due to liability. If and when we obtain marketing approval for our product candidates, we intend
to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain this product
liability insurance on commercially reasonable terms. On occasion, large judgments have been awarded in class action lawsuits
based on drugs that had unanticipated side effects. The cost of any product liability litigation or other proceedings, even if
resolved in our favor, could be substantial. A successful product liability claim or series of claims brought against us could
cause our share price to decline and, if judgments exceed our insurance coverage, could decrease our cash and adversely affect
our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have insufficient funds to develop our business, which may adversely affect our future growth, <FONT STYLE="background-color: white">and&nbsp;such
funding may not be available to us on acceptable terms,&nbsp;or&nbsp;at all, which would force us to terminate, delay, reduce
or suspend our operations, research and development programs&nbsp;and&nbsp;other commercialization efforts</FONT>.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
will need to raise substantial additional capital to fund our operations and to develop and commercialize our products. <FONT STYLE="background-color: white">As
of December 31, 2014 and December 31, 2013, we had approximately $5,038,333 and $96,262 in cash and cash equivalents, respectively.
</FONT>We may need to sell equity securities or borrow funds in order to develop these growth strategies and our inability to
raise the additional capital and/or borrow the funds needed to implement these plans may adversely affect our business and future
growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
future capital requirements may be substantial and will depend on many factors including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    clinical trial results, rates of progress and costs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    cost, timing and outcomes of seeking FDA and other regulatory authority approval of our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    cost of filing and prosecuting patent applications and the cost of defending our patents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    cost of prosecuting infringement actions against third parties;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">subject
    to receipt of marketing approval, revenue received from sales of approved products, if any, in the future;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    product liability or other lawsuits related to our products;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    expenses needed to attract and retain skilled personnel; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
    costs associated with being a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
on our current operating plan, we anticipate that our existing resources will be sufficient to enable us to maintain our currently
planned operations, including our continued product development, at least through December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not have any committed external source of funds or other support for our operational or development efforts. Until we can generate
a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash
needs through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing
arrangements and other marketing and distribution arrangements. Additional financing may not be available to us when we need it
or it may not be available on favorable terms. If we raise additional capital through marketing and distribution arrangements
or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable
rights to MCV or potential future product candidates, technologies, future revenue streams or research programs, or grant licenses
on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership
interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences
that adversely affect our stockholders&rsquo; rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take
specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to obtain
adequate financing when needed, we may have to delay, reduce the scope of, or suspend one or more of our clinical studies or research
and development programs or our commercialization efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Raising
capital in the future could cause dilution to our existing shareholders, and may restrict our operations or require us to relinquish
rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
the future, we may seek additional capital through a combination of private and public equity offerings, debt financings and collaborations
and strategic and licensing arrangements. To the extent that we raise additional capital through the sale of equity or convertible
debt securities, the ownership interests of our existing shareholders will be diluted, and the terms may include liquidation or
other preferences that adversely affect the rights of our existing shareholders. Debt financing, if available, would result in
increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take
specific actions such as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through
collaboration, strategic alliance and licensing arrangements with third parties, we may have to relinquish valuable rights to
our technologies, future revenue streams or product candidates, or grant licenses on terms that are not favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
depend on intellectual property and the failure to protect our intellectual property could adversely affect our future growth
and success. This would have a material adverse effect on our business, financial condition and results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
rely on patent, trademark and copyright law, trade secret protection, and confidentiality and other agreements with employees,
customers, collaborators and others to protect our intellectual property. However, some of our intellectual property is not covered
by any patent or patent application, and, despite precautions, it may be possible for third parties to obtain and use our intellectual
property without authorization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not know whether any patents will be issued from pending or future patent applications or whether the scope of the issued patents
is sufficiently broad to protect our technologies or processes. The patent position of biotechnology companies is generally uncertain
because it involves complex legal and factual considerations. The standards applied by the United States Patent and Trademark
Office and foreign patent offices in granting patents are not always applied uniformly or predictably. For example, there is no
uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in biotechnology and pharmaceutical
patents. Consequently, patents may not issue from our pending patent applications. As such, we do not know the degree of future
protection that we will have on our proprietary products and technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
endeavor to aggressively protect our technologies through patents covering compositions of matter, drug targets and aspects of
mechanism of action, drug product formulation, methods of use and methods of manufacture, and trade secrets.<B>&nbsp;</B>We have
filed patent applications and in-licensed others with respect to our technology both domestically and internationally and anticipate
filing multiple patent applications, in the future. While we believe that we will be able to secure adequate and enforceable patent
protection for our products and technologies, there is no guarantee that patent protection can be obtained, and even if it is
obtained that such patent protection will ultimately be deemed valid, sufficiently enforceable, sufficient to preclude competition
or not infringe upon the rights of other parties. Furthermore, the laws of some foreign countries may not protect intellectual
property rights to the same extent as do the laws of the United States and Denmark.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
patents protecting our proprietary technologies expire after a period of time. Currently, our patents have expiration dates ranging
from 2021 through 2026. Although we have attempted to incorporate technology from our core patents into specific patented product
applications, product designs and packaging to extend the lives of our patents, this approach may not be successful in protecting
our proprietary technology. If we are not successful in protecting our proprietary technology, it could have a material adverse
effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may not be successful in protecting our proprietary rights. Any infringement upon our intellectual property rights could have
an adverse effect on our ability to develop our products and sell them commercially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Issued
patents covering one or more of our product candidates could be found invalid or unenforceable if challenged in court. If that
were to happen, our business would be adversely impacted.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant
could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet
any of several statutory requirements, for example, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability
assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the
U.S. Patent and Trademark Office, or made a misleading statement, during prosecution. The outcome following legal assertions of
invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example,
we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution.
If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps
all, of the patent protection on one or more of our product candidates or certain aspects of our platform technology. Such a loss
of patent protection could have a material adverse impact on our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
may infringe the intellectual property rights of others, which may prevent or delay our product development efforts and stop us
from commercializing or increase the costs of commercializing our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
commercial success depends significantly on our ability to operate without infringing the patents and other intellectual property
rights of third parties. For example, there could be issued patents of which we are not aware that our products infringe. There
also could be patents that we believe we do not infringe, but that we may ultimately be found to infringe. Moreover, patent applications
are in some cases maintained in secrecy until patents are issued. The publication of discoveries in the scientific or patent literature
frequently occurs substantially later than the date on which the underlying discoveries were made and patent applications were
filed. Because patents can take many years to issue, there may be currently pending applications of which we are unaware that
may later result in issued patents that our products infringe. For example, pending applications may exist that provide support
or can be amended to provide support for a claim that results in an issued patent that our product infringes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Third
parties may assert that we are employing their proprietary technology without authorization. If a court held that any third-party
patents are valid, enforceable and cover our products or their use, the holders of any of these patents may be able to block our
ability to commercialize our products unless we obtained a license under the applicable patents, or until the patents expire.
We may not be able to enter into licensing arrangements or make other arrangements at a reasonable cost or on reasonable terms.
Any inability to secure licenses or alternative technology could result in delays in the introduction of our products or lead
to prohibition of the manufacture or sale of products by us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Unfavorable
outcomes in intellectual property litigation could limit our research and development activities and/or our ability to commercialize
certain products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
third parties successfully assert intellectual property rights against us, we might be barred from using certain aspects of our
technology, or barred from developing and commercializing certain products. Prohibitions against using certain technologies, or
prohibitions against commercializing certain products, could be imposed by a court or by a settlement agreement between us and
a plaintiff. In addition, if we are unsuccessful in defending against allegations of patent infringement or misappropriation of
trade secrets, we may be forced to pay substantial damage awards to the plaintiff. There is inevitable uncertainty in any litigation,
including intellectual property litigation. There can be no assurance that we would prevail in any intellectual property litigation,
even if the case against us is weak or flawed. If litigation leads to an outcome unfavorable to us, we may be required to obtain
a license from the patent owner in order to continue our research and development programs or to market our product(s). It is
possible that the necessary license will not be available to us on commercially acceptable terms, or at all. This could limit
our research and development activities, our ability to commercialize certain products, or both.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Most
of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to
sustain the costs of complex patent litigation longer than we could. In addition, the uncertainties associated with litigation
could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our
internal research programs, in-license needed technology, or enter into strategic partnerships that would help us bring our product
candidates to market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, any future patent litigation, interference or other administrative proceedings will result in additional expense and
distraction of our personnel. An adverse outcome in such litigation or proceedings may expose us or any future collaborators to
loss of our proprietary position, expose us to significant liabilities, or require us to seek licenses that may not be available
on commercially acceptable terms, if at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Changes
in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity. Therefore,
obtaining and enforcing pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the United States
has recently enacted and is currently implementing wide-ranging patent reform legislation. The United States Supreme Court has
ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances
or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability
to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once
obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. PTO, the laws and regulations governing
patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents
and patents that we might obtain in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Confidentiality
agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition to patents, we rely on other methods to protect our trade secrets, technical know-how, and proprietary information. In
the course of our research and development activities and our business activities, we often rely on confidentiality agreements
to protect our proprietary information. Such confidentiality agreements are used, for example, when we talk to vendors of laboratory
or clinical development services or potential collaborators. We take steps to protect our proprietary information, and our confidentiality
agreements are carefully drafted to protect our proprietary interests. Nevertheless, there can be no guarantee that an employee
or an outside party will not make an unauthorized disclosure of our proprietary confidential information. This might happen intentionally
or inadvertently. It is possible that a competitor will make use of such information in spite of any legal action we might take
against persons making such unauthorized disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trade
secrets are difficult to protect. Although we use reasonable efforts to protect our trade secrets, our employees, consultants,
contractors, or outside collaborators might intentionally or inadvertently disclose our trade secret information to competitors.
Enforcing a claim that a third party illegally obtained and is using any of our trade secrets is expensive and time consuming,
and the outcome is unpredictable. In addition, courts outside the United States sometimes are less willing than U.S. courts to
protect trade secrets. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Foreign
currency fluctuations could adversely impact financial performance.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
reporting currency is the United States dollar. Because of our activities in Denmark, the United Kingdom and continental Europe,
we are exposed to fluctuations in foreign currency rates. We may manage the risk to such exposure by entering into foreign currency
futures and option contracts. Foreign currency fluctuations may have a significant effect on our operations in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Assuming
that our vaccine candidates receive regulatory approval and we begin sales of these products, our results may fluctuate due to
certain regulatory, marketing and competitive factors over which we have little or no control.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Assuming
that our vaccine candidates receive regulatory approval and we begin the sale of these products, the factors listed below, some
of which we cannot control, may cause our revenue and results of operations to fluctuate significantly:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Actions
    taken by regulatory bodies relating to the verification, registration or health effects of our products.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    extent to which existing and newly developed products obtain market acceptance.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    timing and size of customer purchases.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Customer
    concerns about the stability of our business, which could cause them to seek alternatives to our solutions and products; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Increases
    in raw material costs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
will incur significant costs as a result of operating as a public company, and our management may be required to devote substantial
time to compliance initiatives.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a public company, we incur significant legal, accounting and other expenses which, to date, have been in excess of $300,000 annually.
In addition, the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC, have imposed various requirements on
public companies, including requiring establishment and maintenance of effective disclosure and financial controls as well as
mandating certain corporate governance practices. Our management and other personnel devote a substantial amount of time and financial
resources to these compliance initiatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
we fail to staff our accounting and finance function adequately, or maintain internal control systems adequate to meet the demands
that are placed upon us as a public company, we may be unable to report our financial results accurately or in a timely manner
and our business and stock pricemay suffer. The costs of being a public company, as well as diversion of management&rsquo;s time
and attention, may have a material adverse effect on our business, financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>A
significant portion of our assets and the majority of our officers and directors are located outside of the United States and
therefore it may be difficult for an investor to enforce within the United States any judgments obtained against us or such officers
and directors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
significant portion of our assets are located outside of the United States. In addition, the majority of our officers and directors
are nationals and/or residents of countries other than the United States, and all or a substantial portion of such persons&rsquo;
assets are located outside the United States. As a result, it may be difficult for an investor to effect service of process or
enforce within the United States any judgments obtained against us or such officers or directors, including judgments predicated
upon the civil liability provisions of the securities laws of the United States or any state thereof. In addition, there is uncertainty
as to whether the courts of other jurisdictions would recognize or enforce judgments of United States courts obtained against
us or our directors and officers predicated upon the civil liability provisions of the securities laws of the United States or
any state thereof, or be competent to hear original actions brought in other jurisdictions against us, or such officers and directors
predicated upon the securities laws of the United States or any state thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RISKS
RELATED TO OWNERSHIP OF OUR COMMON STOCK</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Our
majority stockholders will control our company for the foreseeable future, including the outcome of matters requiring stockholder
approval. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
officers, directors, and five percent stockholders collectively own approximately 48% of our outstanding shares of common stock.
In addition, these stockholders and previous stockholders of the Company&rsquo;s subsidiary, DanDrit Denmark entered into
a voting agreement in connection with the Merger, whereby they agreed to vote in favor of nominees for directors selected by the
parties to the voting agreement as described herein. As a result, such entities and individuals will have the ability, acting
together, to control the election of our directors and the outcome of corporate actions requiring stockholder approval, such as:
(i)&nbsp;a merger or a sale of our company, (ii)&nbsp;a sale of all or substantially all of our assets, and (iii)&nbsp;amendments
to our articles of incorporation and bylaws. This concentration of voting power and control could have a significant effect in
delaying, deferring or preventing an action that might otherwise be beneficial to our other stockholders and be disadvantageous
to our controlling stockholders. Certain of these individuals also have significant control over our business, policies and affairs
as officers or directors of our company. Therefore, you should not invest in reliance on your ability to have any control over
our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>An
investment in our company should be considered illiquid. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An
investment in our company requires a long-term commitment, with no certainty of return. Because we became a reporting company
other than by the traditional means of conducting an initial public offering of our common stock, we may be unable to establish
a liquid market for our common stock. In addition, investment banks may be less likely to agree to underwrite primary or secondary
offerings on behalf of our company or its stockholders in the future than they would if we had become a public reporting company
by means of an initial public offering of common stock. If all or any of the foregoing risks occur, it would have a material adverse
effect on our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>An
active, liquid trading market for our common stock may not develop or be sustained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Presently,
our common stock is traded on the Over-the-Counter Markets, or OTC.QB, and we are in our early stages, therefore, an investment
in our company will require a long-term commitment, with no certainty of return. Presently there is limited trading in our stock
and in the absence of an active trading market:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">investors
    may have difficulty buying and selling or obtaining market quotations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">market
    visibility for shares of our common stock may be limited; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a
    lack of visibility for shares of our common stock may have a depressive effect on the market price for shares of our common
    stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
lack of an active market impairs your ability to sell your shares at the time you wish to sell them or at a price that you consider
reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair
our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire additional
intellectual property assets by using our shares as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Even
if an active trading market for our common stock develops, the market price of our common stock may be significantly volatile.
</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Even
if an active market for our common stock develops, of which no assurances can be given, the market price for our common stock
may be volatile and subject to wide fluctuations in response to factors including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">actual
    or anticipated fluctuations in our quarterly or annual operating results;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes
    in financial or operational estimates or projections;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">conditions
    in markets generally</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes
    in the economic performance or market valuations of companies similar to ours; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">general
    economic or political conditions in the United States or elsewhere.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
particular, the market prices of biotechnology companies like ours have been highly volatile due to factors, including, but not
limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">any
    delay or failure to conduct a clinical trial for our product or receive approval from the FDA and other regulatory agents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">developments
    or disputes concerning our product&rsquo;s intellectual property rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">our
    or our competitors&rsquo; technological innovations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">changes
    in market valuations of similar companies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">announcements
    by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments,
    new technologies, or patents; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">failure
    to complete significant transactions or collaborate with vendors in manufacturing our product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
securities market has from time to time experienced significant price and volume fluctuations that are not related to the operating
performance of particular companies. These market fluctuations may also materially and adversely affect the market price of shares
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Penny
stock regulations may impose certain restrictions on the marketability of our securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
SEC has adopted regulations which generally define &ldquo;penny stock&rdquo; to be any equity security that has a market price
(as defined) less than $5 per share, subject to certain exceptions. Our common stock is presently subject to these regulations
which impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established
customers and accredited investors (generally those with assets in excess of $1,000,000, excluding the net value of the person&rsquo;s
primary residence, or annual income exceeding $200,000, or $300,000 together with the investor&rsquo;s spouse). For transactions
covered by these rules, the broker-dealer must make a special suitability determination for the purchase of such securities and
have received the purchaser&rsquo;s written consent to the transaction prior to the purchase. Additionally, for any transaction
involving a &ldquo;penny stock&rdquo;, unless exempt, the rules require the delivery, prior to the transaction, of a risk disclosure
document mandated by the SEC relating to the &ldquo;penny stock&rdquo; market. The broker-dealer must also disclose the commission
payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer
is the sole market maker, the broker-dealer must disclose this fact and the broker-dealer&rsquo;s presumed control over the market.
Finally, monthly statements must be sent disclosing recent price information for the &ldquo;penny stock&rdquo; held in the account
and information on the limited market in &ldquo;penny stocks&rdquo;. Consequently, the &ldquo;penny stock&rdquo; rules may restrict
the ability of broker-dealers to sell our securities and may negatively affect the ability of purchasers of our shares of common
stock to sell such securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>FINRA
sales practice requirements may also limit investors&rsquo; ability to buy and sell our common stock, which could depress the
price of our shares. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">FINRA
rules require broker-dealers to have reasonable grounds for believing that an investment is suitable for a customer before recommending
that investment to the customer. Prior to recommending speculative low-priced securities to their non-institutional customers,
broker-dealers must make reasonable efforts to obtain information about the customer&rsquo;s financial status, tax status and
investment objectives, among other things. Under interpretations of these rules, FINRA believes that there is a high probability
such speculative low-priced securities will not be suitable for at least some customers. Thus, FINRA requirements make it more
difficult for broker-dealers to recommend that their customers buy our common stock, which may limit our investors&rsquo; ability
to buy and sell our shares, have an adverse effect on the market for our shares, and thereby depress our share price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Investors
may face significant restrictions on the resale of your shares due to state &ldquo;blue sky&rdquo; laws. </I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Each
state has its own securities laws, often called &ldquo;blue sky&rdquo; laws, which (1)&nbsp;limit sales of securities to a state&rsquo;s
residents unless the securities are registered in that state or qualify for an exemption from registration, and (2)&nbsp;govern
the reporting requirements for broker-dealers doing business directly or indirectly in the state. Before a security is sold in
a state, there must be a registration in place to cover the transaction, or it must be exempt from registration. The applicable
broker-dealer must also be registered in that state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
do not know whether our securities will be registered or exempt from registration under the laws of any state. A
determination regarding registration will be made by those broker-dealers who agree to serve as market makers for our common
stock. There may be significant state blue sky law restrictions on the ability of investors to sell, and on purchasers to
buy, our securities. Our investors should therefore consider the resale market for our common stock to be limited, as
investors may be unable to resell their shares without the significant expense of state registration or
qualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>As
an &ldquo;emerging growth company&rdquo; under the JOBS Act, we are permitted to rely on exemptions from certain disclosure requirements.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
qualify as an &ldquo;emerging growth company&rdquo; under the JOBS Act. As a result, we are permitted to and may rely on exemptions
from certain disclosure requirements. For so long as we are an emerging growth company, we will not be required to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">have
    an auditor report on our internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">comply
    with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation
    or a supplement to the auditor&rsquo;s report providing additional information about the audit and the financial statements
    (i.e., an auditor discussion and analysis);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">submit
    certain executive compensation matters to shareholder advisory votes, such as &ldquo;say-on-pay&rdquo;, &ldquo;say-on-frequency&rdquo;
    and &ldquo;say-on-golden parachute;&rdquo; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">disclose
    certain executive compensation related items such as the correlation between executive compensation and performance and comparisons
    of the Chief Executive&rsquo;s compensation to median employee compensation.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
addition, Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition
period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words,
an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply
to private companies. We are not choosing to &ldquo;opt out&rdquo; of this provision. Section 107 of the JOBS Act provides that
our decision to opt out of the extended transition period for complying with new or revised accounting standards is irrevocable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
will remain an &ldquo;emerging growth company&rdquo; until the last day of our fiscal year following the fifth anniversary of
the date of our first sale of common equity securities pursuant to an effective registration under the Securities Act, or until
the earliest of (i) the last day of the first fiscal year in which our total annual gross revenues exceed $1 billion, (ii) the
date that we become a &ldquo;large accelerated filer&rdquo; as defined in Rule 12b-2 under the Securities Exchange Act of 1934,
which would occur if the market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last
business day of our most recently completed second fiscal quarter or (iii) the date on which we have issued more than $1 billion
in non-convertible debt during the preceding three year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Until
such time, however, we cannot predict if investors will find our common stock less attractive because we may rely on these exemptions.
If some investors find our common stock less attractive as a result, there may be a less active trading market for our common
stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have never paid dividends on our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have never paid dividends on our common stock and do not presently intend to pay any dividends in the foreseeable future. We anticipate
that any funds available for payment of dividends will be re-invested into the Company to further its business strategy. Because
we do not anticipate paying dividends in the future, the only opportunity for our stockholders to realize the creation of value
in our common stock will likely be through a sale of those shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>We
have the right to issue shares of preferred stock. If we were to issue preferred stock, it is likely to have rights, preferences
and privileges that may adversely affect the common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are authorized to issue 10,000,000 shares of &ldquo;blank check&rdquo; preferred stock, with such rights, preferences and privileges
as may be determined from time-to-time by our Board of Directors. No preferred stock is currently issued and outstanding. Our
Board of Directors is empowered, without stockholder approval, to issue preferred stock in one or more series, and to fix for
any series the dividend rights, dissolution or liquidation preferences, redemption prices, conversion rights, voting rights, and
other rights, preferences and privileges for the preferred stock. No shares of preferred stock are presently issued and outstanding
and we have no immediate plans to issue shares of preferred stock. The issuance of shares of preferred stock, depending on the
rights, preferences and privileges attributable to the preferred stock, could adversely reduce the voting rights and powers of
the common stock and the portion of the Company&rsquo;s assets allocated for distribution to common stockholders in a liquidation
event, and could also result in dilution in the book value per share of the common stock being offered. The preferred stock could
also be utilized, under certain circumstances, as a method for raising additional capital or discouraging, delaying or preventing
a change in control of the Company, to the detriment of the investors in the common stock being offered. We cannot assure you
that the Company will not, under certain circumstances, issue shares of its preferred stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1B.
Unresolved Staff Comments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">There
are no unresolved staff comments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_003"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
2. Properties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
corporate headquarters are located in Symbion Science Park, Fruebjergvej 3, 2100 Copenhagen, Denmark and our U.S. mailing address
is </FONT>375 Park Avenue, Suite 2607, New York, NY, 10152, USA.<FONT STYLE="color: #1F497D"> </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
The Company leases 2 locations as follows</FONT>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 24%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Location</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Terms</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Symbion Science
    Park,<BR>
Fruebjergvej 3, 2100<BR>
Copenhagen, Denmark</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,108 square feet
    used for work and storage of cells and biological material in freezers</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The lease is for
    a term of three years until March 2016.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bredgade 75, 3rd
    floor,<BR>
DK-1263 Copenhagen K</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,000 square feet
    used for office space</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The lease can
    be terminated with a three months&rsquo; notice from either party. The Company gave a termination notice on
    February     28, 2015, therefore the lease will terminate May 31, 2015. The Company does not anticipate renting additional
    office space in     the near future.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">375
                                         Park Avenue</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">Suite 2607</P>

<P STYLE="margin: 0">New York, NY 10152</P>


</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="margin: 0">Virtual office space.</P>


</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><P STYLE="margin: 0">On March 25, 2015, the Company entered into an agreement for use of virtual office space at a rate of
                                                                                                $375/month on a month-to-month basis, which can be terminated by either party on one month&rsquo;s notice.</P>


</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
</FONT>believe the property located in Symbion Science Park is adequate for our operations at this stage of our development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_004"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
3. Legal Proceedings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business.
We are not currently a party to in any legal proceeding that we believe would have a material adverse effect on our business,
financial condition or operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_005"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
4. Mine Safety Disclosures.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><A NAME="a_023"></A>PART
II</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><A NAME="a_006"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
5. Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Market
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company's Common Stock is traded on the Over-The-Counter Bulletin Board. The following table sets forth the range of high and
low bid quotations on the Common Stock for the quarterly periods indicated, as reported by the National Quotation Bureau, Inc.
The quotations are inter-dealer prices without retail mark-ups, mark downs or commissions and may not represent actual transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fiscal
    Year Ended December 31, 2014</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">High</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Low</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">First Quarter (1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Second Quarter (1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Third Quarter (1)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 76%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fourth Quarter (2)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)
Not available for trading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)
The common stock was available to be traded on the Over-The-Counter Bulletin Board, but there were no trades during the quarter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Holders
of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of March30, 2015 we had 9,533,290 shares of common stock issued and outstanding and approximately 99 stockholders of record.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company has not declared or paid any cash dividends on its common stock and does not intend to declare or pay any cash dividend
in the foreseeable future. The payment of dividends, if any, is within the discretion of the Board of Directors and will depend
on the Company&rsquo;s earnings, if any, its capital requirements and financial condition and such other factors as the Board
of Directors may consider.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Sales
of Unregistered Securities</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">All sales of unregistered
securities by the Company for the year ended December 31, 2014 have been previously disclosed in the Company&rsquo;s filings with
the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Securities
Authorized for Issuance under Equity Compensation Plans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2013, the Company did not have an equity compensation plan. On February 6, 2014, the Board of Directors adopted
and the Company&rsquo;s sole stockholder approved the DanDrit Biotech USA, Inc. 2014 Equity Incentive Plan. We have reserved 1,206,000
shares of our common stock for issuance in accordance with the terms of the plan. As of the date of this report, no awards have
been made from the plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_007"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
6.&#9;Selected Financial Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
registrant is a smaller reporting company and is not required to provide this information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_008"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
7.&#9;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>The
following discussion of our financial condition and results of operations should be read in conjunction with our financial statements
and the related notes to those statements included elsewhere in this report. In addition to the historical financial information,
the following discussion and analysis contains forward-looking statements that involve risks and uncertainties. Our actual results
may differ materially from those anticipated in these forward-looking statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
are a biotechnology company currently based in Copenhagen, Denmark. We are committed to developing what we believe could be the
world&rsquo;s first vaccine against colorectal cancer. For more than a decade, we have developed and patented compounds successfully
used in initial clinical trials in Europe and Asia including: (i) MelCancerVac<SUP>TM</SUP> (MCV) for treatment of cancer (one
phase I/II trial in Denmark and two phase II trials in Denmark and Singapore), (ii) Tolerogenic dendritic cell (TDC) (pre-clinical
stage in Denmark) and (iii) Melvaccine (MV) a melanoma cell lysate used as stand-alone vaccine (pre-clinical state in Denmark).
We expect to continue our clinical development program in the United States, Europe and Asia. Springing from academic roots in
Denmark, we have built upon our scientific and medical skills to advance a number of candidate therapies, targeted initially at
non-small-cell-lung-cancer (NSCLC) and colorectal-cancer (CRC). On September 22, 2008, the Singapore government authorized MCV
for a named patient compassionate use for CRC. We have conducted three single-arm Phase II clinical trials in cancer where our
dendritic cell vaccine, MCV demonstrated efficacy. The three clinical trials generated data indicating prospects in a larger and
different clinical setting. More specifically, this efficacy data needed to be confirmed in a comparative randomized trial with
advanced colorectal cancer patients.Neither the FDA nor or any other comparable governmental agency has reviewed MCV.&nbsp;&nbsp;Therefore,
any assessment of its safety or efficacy only reflects the opinion of the Company.&nbsp;&nbsp;Furthermore, it does not indicate
that MCV will achieve favorable results in any later stage trials or that the FDA or comparable agency will ultimately determine
that MCV is safe and effective for purposes of granting marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
a result, DanDrit Denmark, with the assistance of key opinion leaders in colorectal cancer treatment, has designed a randomized
trial with 174 stage IV colorectal cancer patients after surgical resection and chemotherapy. Using an adaptive design clinical
study that includes a prospectively planned opportunity for modification of one or more specified aspects of the study design
and hypotheses based on analysis of data (usually interim data) from subjects in the study (an &ldquo;Adaptive Design Clinical
Study&rdquo;), we significantly reduced the cost and duration of a Phase III study and we believe we can complete the study
within three years. Regulatory authorities in the United States and Europe have both published guidance documents on the use and
implementation of adaptive design trials. These documents both include description of adaptive trials and include a requirement
for prospectively written standard operating procedures and working processes for executing adaptive trials and a recommendation
that sponsor companies engage with CROs that have the necessary experience in running such trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">To
date, our operations have been funded by sales of our securities, loans and, to a lesser extent, by sales of our products. Sales
of our products alone will not support our current operations and we expect this to be the case until our MCV vaccine is approved
for marketing in the United States and European. Even if we are successful in having MCV approved for sale in the United States
and European, we cannot guarantee that a market for the product will develop. We may never be profitable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Share
Exchange</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 12, 2014, the Company closed the Share Exchange in accordance with the terms and conditions of the Share Exchange Agreement
and as a result became DanDrit Denmark&rsquo;s parent company. In connection with the Share Exchange, each outstanding share of
common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA&rsquo;s Common Stock for an aggregate of 6,000,000
shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies
Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange
and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder
prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors
and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit
USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Trends,
Events and Uncertainties</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Research
and development of new technologies is, by its nature, unpredictable. We cannot assure you that our technology will be
adopted, that we will ever earn revenues sufficient to support our operations, or that we will ever be profitable.
Furthermore, since we have no committed source of financing, we cannot assure you that we will be able to raise money as and
when we need it to continue our operations. If we cannot raise funds as and when we need them, we may be required to severely
curtail, or even to cease, our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RESULTS
OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Year-ended
December 31, 2014 compared to the year-ended December 31, 2013</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
following table sets forth our revenues, expenses and net income for the years ended December 31, 2014 and 2013. The financial
information below is derived from our audited consolidated financial statements included elsewhere in this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended<BR> December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net Sales</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,768</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cost
    of Goods Sold</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">295,661</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">109,299</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(295,661</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(76,531</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating Expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,644,918</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,233,683</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation and Amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,981</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,297</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consulting expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">469,666</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">390,437</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Operating
    Expense</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,133,565</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,662,417</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from Operations</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,429,226</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,738,948</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other Income (Expense)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest (expense)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(84,550</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(652,703</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on forgiveness of debt</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">49,016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain (loss) on currency transactions</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(40,583</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,541</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on derivative liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">175,732</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest and
    other income</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,937</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Other Income
    (Expense)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(119,196</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(408,413</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    Before Income Taxes</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,548,422</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income Tax Expense
    (Benefit)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(177,539</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,370,883</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BASIC
    AND DILUTED LOSS PER SHARE</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.321</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.40</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">WEIGHTED
    AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,500,142</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,332,721</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended<BR> 31-Dec</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Net
    Loss)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,370,883</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Currency
    Translation, Net of Taxes)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">306,439</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(219,470</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Other
    Comprehensive Loss)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,064,444</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,366,831</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>



<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"><B><I>Comparison of the year ended December 31, 2014 and December 31, 2013</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Revenues</I></B></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
net sales for the year ended December 31, 2014 were $0 as compared to December 31, 2013, net sales were $32,768, representing
a year over year decrease in sales of $32,768 or 100%. This decrease was due to the discontinuation of the Singapore compassionate
use program.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Cost
of Goods Sold</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
cost of goods sold increased by $<FONT STYLE="line-height: 115%">186,362 or 171% during the year ended December 31, 2014, to
$295,661, from $109,299 in cost of goods sold for the year ended December 31, 2013. The increase was due to additional costs
of technology transfer of lysate manufacturing</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Gross
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Gross
loss for the year ended December 31, 2014 was $295,661 compared to a loss of $76,531 for same period in 2013, representing an
increase in the loss of $219,130, or 286%. The increase in gross loss was due to no sales and higher cost of goods sold for the
year ended December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
operating expense for the year ended December 31, 2014 totaled $2,133,565, representing an increase of $471,148 or
28% compared to $1,662,417 for the year ended December 31, 2013. The largest contributors to the operating expenses for both
years were the increase in legal expenses, consulting expenses, and salaries of $155,501, $135,854, and
$100,549 respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;General
and administrative expense for the year ended December 31, 2014 was $1,644,918 compared to $1,233,683 for the year ended December
31, 2013, representing an increase of $411,235, or 33.33%. This increase was due primarily to costs associated with the audit
and the costs associated with becoming publically traded in November of 2014. General and administrative expenses include office
rental, website management, insurance, and salaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Depreciation
and amortization expenses for the year ended December 31, 2014 and 2013 were $18,981 and $38,297, respectively, representing a
decrease of 50.44%. This decrease was due primarily to the decrease in depreciable assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consulting
expenses for the year ended December 31, 2014 totaled $469,666 compared to $390,437 for the year ended December 31, 2013, representing
an increase of $79,229, or 20.92%. During 2014, we employed consultants to assist us with the valuation of DanDrit Denmark in
preparation for the Share Exchange, the preparation of the S-1 registration statement that was effective on August 12, 2014, and
consultants for our VIVA phase III clinical trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
income (expense) net for the year ended December 31, 2014 and 2913 were $119,196 and $408,413, respectively, representing an increase
in income of $289,217or 70.81%. This increase was due primarily to decrease in interest expense of $568,153 for the year ended
December 31, 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Net
Loss</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
loss for the year ended December 31, 2014 was $2,370,883 compared to $2,147,361 for the year ended December 31, 2013, representing
an increase of $223,522, or 10.4%. The increase in the net loss for the year ended December 31, 2014 is primarily due to the increase
in the general and administrative expenses of $411,235.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have historically satisfied our capital and liquidity requirements through funding from our largest shareholders, the issuance
of convertible notes (which over time have been converted into shares of our common stock) and the sale of common stock. At December
31, 2014 we had cash of $3,008,831and working capital of $3,288,685. At December 31, 2013, we had cash of $18,794 and working
capital deficit of $(1,993,145).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2014 and December 31, 2013, we received loans from shareholders for an aggregate principal amount
of $5,050,492. During 2013, $1,636,423 in principal amount and the interest accrued thereon were converted into 681,849 shares
of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
February 15, 2014 and March 18, 2014, the Company received DKK 2,500,000 ($424,110) and DKK 2,300,000 ($390,181) loans, respectively,
from PasecoApS, an entity owned by a shareholder of DanDrit USA (&ldquo;Paseco&rdquo;).&nbsp;&nbsp;The loans accrued interest
at 5% per year. On October 17, 2014 the Company repaid the loan and interest in its entirety.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
Denmark received an unsecured loan facility from Sune Olsen Holding ApS, an entity owned by a shareholder (&ldquo;Sune Olsen
Holding&rdquo;), with a goal of ensuring financing until new equity has been brought in. Under the loan facility DanDrit
Denmark has received the following amounts: On November 11, 2013 DKK 1,500,000, on November 20, 2013 DKK 405,000, and on
December 2, 2013 DKK 900,000. The loans accrued interest at 5% per year.&nbsp;&nbsp; On November 26, 2014 the Company repaid
the loan facility and interest thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
Denmark received an unsecured loan from Sune Olsen, in December 20, 2013. The loan was in the amount of DKK 1,000,000 and accrued
interest of 5% per year. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
March 2014, the Company received a 2,000,000 DKK letter of support from Paseco to ensure continued operations until February 1,
2015. The Company had an option to extend the loan for one year by giving notice to Paseco by December 31, 2014 whereby the interest
rate would increase to 7.00% per annum. During the year ended December 31, 2014, the Company did not give notice to Paseco to
exercise the option. The letter of support expires March 31, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
2012, <U>DKTI A/S</U>, a shareholder of the Company, which is controlled by officers and directors of the Company, agreed to
loan the Company up to DKK 5,000,000 (approximately $880,000) accruing interest at 6%.&nbsp;&nbsp;The loan was secured by all
the Company&rsquo;s intellectual property rights, including its patents and its patent applications credit
facility.&nbsp;&nbsp;During the year ended December 31, 2012 the Company borrowed DKK 4,431,862 plus DKK 71,563 in
interest.&nbsp;&nbsp;During the year ended December 31, 2013, the Company borrowed an additional DKK 310,000 (approximately
$55,000) on the loan and accrued interest of DKK 230,377. The principal amount and accrued interest were converted into
96,288 common shares of DanDrit Denmark on December 16, 2013, which were exchanged for 144,321 shares of common stock of the
Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the years ended December 31, 2013, 2012 and 2011 Sune Olsen loaned the Company DKK 1,267,724 ($232,841), DKK 338,719
($59,854) and DKK 143,750 ($25,019), respectively.&nbsp;&nbsp;The Company added the accrued interest at 6% and the Company
recorded interest expense of DKK 86,047 ($15,804), DKK 20,469 ($3,617) and DKK 2,689 ($468) during the years end December 31,
2013, 2012 and 2011 respectively.&nbsp;&nbsp;On December 16, 2013, the principal amount and related accrued interest were
converted into 59,620 common shares of DanDrit&nbsp;Denmark&nbsp;which were exchanged for 89,361 shares of common stock of
the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
July 26, 2013 and August 15, 2013, Sune Olsen Holding loaned the Company an additional DKK 1,000,000 ($177,239) and DKK 750,000
($133,343), respectively.&nbsp;&nbsp;The notes accrue interest at 5% per year. The principal amount and related accrued interest
of DKK 15,575 ($2,827) were converted into 33,705 shares of DanDrit Denmark common stock on December 16, 2013. Such shares of
common stock were exchanged for 50,518 shares of common stock of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
June 20, 2013, Sune Olsen Holding APS paid DKK 1,500,000, ($265,000) in accrued legal fees owed by the Company in exchange for
a DKK1,500,000 ($265,000) 5% note payable to Sune Olsen Holding APS. On December 16, 2013, the principal amount and accrued interest
of DKK 20,959 ($3,804) was converted into 29,036 shares of DanDrit&nbsp;Denmark&nbsp;common stock. Such shares of common stock
were exchanged for  43,520 shares of common stock of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">On
April 14, 2013, Sune Olsen Holding APS assumed DKK 4,375,932 (approximately$773,000) in&nbsp;&nbsp;liabilities owed by the Company
for past due rent from a vendor in exchange for a note payable. The note accrued interest at 5%. On December 31, 2013, the principal
amount and accrued interest of DKK 139,670 ($25,349), was converted into 86,204 shares of DanDrit Denmark.&nbsp;&nbsp;Such shares
of common stock were exchanged for 129,206 shares of common stock of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2014, the outstanding balance of $38,235 for professional fees paid by a shareholder and amounts advanced to the
Company are reported as loan payable - related party. The $38,235 loans payable were acquired in the reverse acquisition. The
amounts are unsecured, non-interest bearing and have no stipulated repayment terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">A
6% promissory note payable to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired
by the Company in the reverse acquisition,&nbsp;payable on February 12, 2014 upon the completion date of the Share Exchange.&nbsp;&nbsp;As
of December 31, 2014, the outstanding balance on the note, including accrued interest, was $42,753. During the three and twelve
months ended December 31, 2014 the Company recorded related party interest on the note of $213 and $619.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have no committed sources of capital but we believe that our cash together with available funds from other potential sources
of funds, such as loans from shareholders, will be sufficient to fund our anticipated working capital needs and capital
spending requirements for the next twelve months. However, if we were to incur any unanticipated expenditures, such
circumstances could put a substantial burden on our cash resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
may also need additional funds for possible future strategic acquisitions of businesses, products or technologies complementary
to our business. If additional funds are required, we may raise such funds from time to time through public or private sales of
equity or debt securities. Financing may not be available on acceptable terms, or at all, and our failure to raise capital when
needed could materially adversely impact our growth plans and our financial condition and results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash
Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><I>Year
ended December 31, 2014 compared to the year ended December 31, 2013</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash loss from
operating activities for the year ended December 31, 2014 was $2,034,175, representing a decrease in the loss of $96,453 compared
to the cash loss from operating activities of $2,130,628 for the year ended December 31, 2013 This decrease was primarily due
to a decrease in total interest expenses and an increase of in research and development income tax credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Changes
in assets and liabilities as of December 31, 2014 compared to December 31, 2013 included the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
total assets of $5,239,909 for the year ended December 31, 2014 increased by $4,789,442 or 1,063% compared to the total assets
of $450,467 for the year ended December 31, 2013 and the total liabilities for the year ended December 31, 2014 of $1,757,664
decreased $376,973, or 18% compared to the total liabilities of $2,134,637 for the year ended December 31, 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash
used in investing activities was $1,952,034 for the year ended December 31,2014, as compared to cash used in investing activities
of $105,015 for the year ended December 31, 2013. Cash used for investing activities increased during the year ended December
31, 2014 primarily due to an increase in the amount of $1,952,034 of cash held in escrow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash provided by
financing activities was $6,669,807 for the year ended December 31, 2014 as compared to cash provided by financing activities
of $2,439,526 for the year ended December 31, 2013. The increase of approximately $4,200,281 in cash provided by financing activities
in the year ended December 31, 2014, compared to the year ended December 31, 2013, was due to cash received in connection with
sale of common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Off
Balance Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of December 31, 2014, we had no off-balance sheet arrangements. We are not aware of any material transactions which are not disclosed
in our consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Significant
Accounting Policies and Critical Accounting Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
methods, estimates, and judgments that we use in applying our accounting policies have a significant impact on the results that
we report in our consolidated financial statements. Some of our accounting policies require us to make difficult and subjective
judgments, often as a result of the need to make estimates regarding matters that are inherently uncertain. In addition, Section
107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in
Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an emerging growth
company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.
We are not choosing to &ldquo;opt out&rdquo; of this provision. Section 107 of the JOBS Act provides that our decision to opt
out of the extended transition period for complying with new or revised accounting standards is irrevocable. As a result of our
election, not to &ldquo;opt out&rdquo; of Section 107, DanDrit&rsquo;s financial statements may not be comparable to companies
that comply with public company effective dates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
most critical accounting estimates include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Property
and Equipment</B> &mdash; Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend
the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs
are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the
estimated useful lives of the assets which range from four to six years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intangible
Assets</B> &mdash; Definite life intangible assets include patents. The Company accounts for definite life intangible assets in
accordance with Financial Accounting Standards Board, (&ldquo;FASB&rdquo;) Accounting Standards Codification, (&ldquo;ASC&rdquo;)
Topic 350, &ldquo;Goodwill and Other Intangible Assets&rdquo; and amortized the patents on a straight line basis over the estimated
useful life of twenty years. Costs incurred in relation to patent applications are capitalized costs and amortized over the estimated
useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs
are charged to expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenue
Recognition and Sales </B>&mdash; The Company&rsquo;s sales of its MelCancerVac colorectal cancer treatment have been limited
to a compassionate use basis in Singapore after stage IIA trials and the vaccine is not currently approved for sale for any other
use or location. The Company accounts for revenue recognition in accordance with Securities and Exchange Commission Staff Accounting
Bulletin No. 101, &ldquo;Revenue Recognition in Financial Statements&rdquo; (SAB 101), FASB ASC 605 Revenue Recognition. The Company
recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement,
product has been shipped or delivered to the customer, the price and terms are finalized, and collection of the resulting receivable
is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Value
Added Tax - </B>In Denmark, Value Added Tax (&ldquo;VAT&rdquo;) of 25% of the invoice amount is collected in respect of the sales
of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability
on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices.
These amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accounting
Estimates</B> &mdash; The preparation of financial statements in conformity with generally accepted accounting principles requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent
assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting
period. Actual results could differ from those estimated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recently
Enacted Accounting Standards</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
a description of accounting changes and recent accounting standards, including the expected dates of adoption and estimated effects,
if any, on our consolidated financial statements, see &ldquo;Note 1: Recent Accounting Pronouncements&rdquo; in the financial
statements included elsewhere in this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_009"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
7A. Quantitative and Qualitative Disclosures about Market Risk</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
registrant is a smaller reporting company and is not required to provide this information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><A NAME="a_010"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Item
8. Financial Statements and Supplementary Data</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT
BIOTECH USA, INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Index
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 90%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_001"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reports of Independent Registered Public Accounting Firm</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_002"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Balance Sheets at December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_003"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statements of Operations for the years ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_004"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statement of Other Comprehensive Income for the years ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_005"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statement of Stockholders&rsquo; Equity (Deficit) for the years ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_006"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Consolidated Statement of Cash Flows for the years ended December 31, 2014 and 2013</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#b_007"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes to the Consolidated Financial Statements</FONT></A></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">F-8</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="b_001"></A><IMG SRC="image_002.gif" ALT="" STYLE="height: 130px; width: 576px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 4pt 0 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4397
South Albright Drive, Salt Lake City, UT 84124</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(801) 277-2763
Phone &bull; (801) 277-6509 Fax</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Board of
Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DANDRIT
BIOTECH USA, INC AND SUBSIDIARY</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">P.O. Box
189</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Randolph,
VT 05060</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have audited the accompanying consolidated balance sheets of DanDrit Biotech USA, Inc. and Subsidiary as of December 31, 2014
and 2013, and the related consolidated statements of operations, consolidated other comprehensive income, consolidated stockholders&rsquo;
equity (deficit) and consolidated cash flows for the years ended December 31, 2014 and 2013. These consolidated financial statements
are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial
statements based on our audit.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
conducted our audit in accordance with standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements
are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal
controls over financial reporting for the year ended December 31, 2014. Our audit included consideration of internal controls
over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the
purpose of expressing an opinion on the effectiveness of the company&rsquo;s internal controls over financial reporting for the
year ended December 31, 2014. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in
the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates
made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audit
provides a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
our opinion, based on our audit, the consolidated financial statements audited by us present fairly, in all material
respects, the consolidated financial position of DanDrit Biotech USA, Inc. and Subsidiary as of December 31, 2014 and 2013
and the consolidated results of their operations and their consolidated cash flows for the years ended December 31, 2014, and
2013, in conformity with generally accepted accounting principles in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0">/s/ Gregory &amp; Associates, LLC.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 30,
2015</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Salt Lake
City, Utah</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 63; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><A NAME="b_002"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSOLIDATED
BALANCE SHEET</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    at<BR> Dec 31, 2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    at<BR> Dec 31, 2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">Assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Assets:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash (1)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,008,831</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,794</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash held in escrow (2)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,029,502</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">77,468</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other receivables</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,456</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,774</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Current Assets</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,046,349</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">141,492</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property and Equipment, net accumulated
    depreciation</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">OTHER ASSETS:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Definite life intangible assets</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">186,414</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">231,615</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred stock offering costs</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">67,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deposits</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,146</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,360</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Other Assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">193,560</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">308,975</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Assets</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,239,909</FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450,467</FONT></TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
accompanying notes are an integral part of these financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA, INC. AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>CONSOLIDATED
BALANCE SHEET</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>(Continued)</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    at<BR> Dec 31, 2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    at<BR> Dec 31, 2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Liabilities
    and Shareholder's Equity</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current Liabilities:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable - related party, current portion</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,951</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,001</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    Offering Escrow</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable - trade</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">711,449</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">548,501</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable -  related party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">212,438</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">733,826</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">858,135</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    income taxes payable</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Current Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,757,664</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,134,637</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long
    Term Liabilities</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable - related Party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable - Dandrit (3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Long-Term Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Liabilities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,757,664</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,134,637</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">STOCKHOLDERS'
    EQUITY (DEFICIT):</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock; par value 0.0001, 100,000,000 shares authorized, 9,533,290 issued and outstanding at December 31, 2014 and 6,000,000
    shares issued and outstanding at December 31, 2013</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">953</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">600</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,098,050</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,867,546</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    comprehensive income, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,249</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(31,190</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    Deficit</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(21,892,007</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,521,126</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Stockholders' Equity (Deficit)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,482,245</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,684,170</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; padding-left: 18pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Liabilities and Stockholders' (Deficit)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,239,909</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">450,467</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>The
accompanying notes are an integral part of these financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_003"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT
BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSOLIDATED
STATEMENT OF OPERATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Year Ended</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net Sales</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,768</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cost of Goods Sold</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">295,661</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">109,299</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gross
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(295,661</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(76,531</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating Expenses:</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">General and administrative expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,644,918</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,233,683</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation and Amortization</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,981</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,297</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Consulting expenses</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">469,666</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">390,437</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Operating
    Expense</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,133,565</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,662,417</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    from Operations</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,429,226</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,738,948</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other Income (Expense)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest (expense)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(84,550</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(652,703</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on forgiveness of debt</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">49,016</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain (loss) on currency transactions</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(40,583</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,541</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Gain on derivative liability</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">175,732</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest and other income</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,937</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total Other Income
    (Expense)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(119,196</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(408,413</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss
    Before Income Taxes</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,548,422</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income Tax Expense
    (Benefit)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(177,539</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,370,883</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BASIC
    AND DILUTED LOSS PER SHARE</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.32</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.40</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">WEIGHTED
    AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC AND DILUTED</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,500,142</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,332,721</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">WEIGHTED AVERAGE
    BASIC AND DILUTED LOSS PER SHARE</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.32</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.40</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
accompanying notes are an integral part of these financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_004"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSOLIDATED
STATEMENTS OF OTHER COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
    the Years Ended</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-weight: bold; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Net
    Loss)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,370,883</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="width: 1%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Currency
    Translation, Net of Taxes)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">306,439</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(219,470</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Other
    Comprehensive Loss)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,064,444</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,366,831</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
accompanying notes are an integral part of these financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="b_005"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSOLIDATED
STATEMENT OF STOCKHOLDERS' (DEFICIT)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For
the Years Ended December 31, 2014 and 2013</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD><TD STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Paid
    in</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Earnings</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Comprehensive</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Deficit)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income&nbsp;(loss)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font-weight: bold; padding-bottom: 4pt; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE,
    December 31, 2012</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,318,151</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">532</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,817,122</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(17,373,765</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">188,280</FONT></TD><TD STYLE="width: 1%; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    shares issued upon conversion of bond payable - related party and derivative liability at $9.00 per shares, December 2013</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">261,665</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,353,322</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    shares issued in payment of notes payable - related party at $6.42 per shares, December 2013</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">144,321</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">926,372</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    shares issued in payment of notes payable - related party at $6.42 per shares, December 2013</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,863</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">28</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,770,730</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    Adjustment for Foreign Currency Translation Year Ended December 31, 2014</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(219,470</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Loss for the Year Ended December 31, 2013</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,147,361</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 4pt; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE,
    December 31, 2013</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,000,000</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">600</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">17,867,546</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(19,521,126</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(31,190</FONT></TD><TD STYLE="padding-bottom: 4pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
    record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement where in the Dandrit
    Biotech USA Inc. (&ldquo;Parent&rdquo;) issued 6,000,000 common shares to acquire Dandrit Biotech A/S (&ldquo;Subsidiary&rdquo;)
    Dandrit Biotech USA Inc. (Formerly Putnam Hills Corp),</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,040,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">204</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(79,436</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
    record the issuance of 4,000 and 141,000 common shares on September 4, 2014 in connection Initial Public Offering valued at
    $5 per share or $4,000 and $141,000, respectfully. Net of stock offering cost of $67,000</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">145,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">657,985</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
    record the issuance of 100 common shares on September&nbsp;24, 2014 in connection Initial Public Offering valued at $5 per share
    or $500.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">100</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.01</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
    record the issuance of 889,690 common shares in October, 2014 in connection Initial Public Offering valued at $5 per share
    or $4,358,879 net of stock offering cost of $89,360</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">889,690</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">89</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,359,001</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
    record the issuance of 58,500 common shares on November 13, 2014 in connection Initial Public Offering valued at $5 per share
    or $292,500.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">58,500</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">292,494</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">To
    record the issuance of 400,000 common shares on December 31, 2014 in connection private placement valued at $5 per share or
    $2,000,000.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">400,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">40</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,999,960</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity
    Adjustment for Foreign Currency Translation Year &nbsp;Ended December 31, 2014</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">306,439</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Rounding</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net&nbsp;&nbsp;Loss
    for the year Ended December 31, 2014</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,370,883</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-indent: -7.5pt; padding-left: 7.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">BALANCE,
    December 31, 2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,533,290</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">953</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">25,098,050</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(21,892,007</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">275,249</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: red; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<B>The
accompanying notes are an integral part of these financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="b_006"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSOLIDATED
STATEMENT OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">For the Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">December 31,</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows from Operating Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net&nbsp;&nbsp;(Loss)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,370,883</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,147,361</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Adjustments to reconcile net&nbsp;&nbsp;(loss) to net cash provided (used) by operations:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Depreciation and amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">45,201</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">38,297</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(Gain)/Loss on sale of subsidiary</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accretion of discount on bond payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">502,465</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(Gain)/Loss on derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(175,732</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Changes in assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(Increase) decrease in account receivable,</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,440</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">56,346</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">(Increase) decrease in prepaid expenses &amp; deposits</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">22,988</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">4,183</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase (decrease) in accounts payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">162,950</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,674</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Increase (decrease) in accounts payable &ndash; related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">212,438</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Increase (decrease) in accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(124,309</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(406,152</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Total Adjustments</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">336,708</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">16,732</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net Cash (Used) by Operating Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,034,175</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,130,628</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows from Investing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceed from sale of subsidiary</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net decrease (increase) in cash held in escrow</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,952,034</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(77,468</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Purchase of intangible assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(27,548</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net Cash Used by Investing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,952,034</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(105,015</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash Flows from Financing Activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from notes payable - related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">814,291</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,754,662</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Proceeds from stock sales</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">7,377,089</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Payment of stock offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(89,360</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(67,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Payments on notes payable - related party</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(1,432,213</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(218,136</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net Cash Provided by Financing Activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">6,669,807</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,469,526</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">(Gain) loss on Currency Translation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">306,439</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(219,470</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net Increase (Decrease) in Cash and Cash Equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,990,037</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,413</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Cash and Cash Equivalents at Beginning of Period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">18,794</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">4,381</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Cash and Cash Equivalents at End of Period</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,008,831</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">18,794</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left">Supplemental Disclosures of Cash Flow Information:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Cash paid during the year for</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Interest</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">82,816</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">12,632</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Income Taxes</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><B>Supplemental Disclosure of Non-Cash Investing and
    Financing Activities</B></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Accretion of discount on bond payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">502,465</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Change in fair market value of derivative liability</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(175,732</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>The
accompanying notes are an integral part of these financial statements.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><A NAME="b_007"></A><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
1 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Business
and Basis of Presentation &ndash; </B>The consolidated financial statements include the accounts and operations of Dandrit Biotech
USA Inc and its wholly owned subsidiary DanDrit BioTech A/S.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
Biotech USA, Inc. (&ldquo;DanDrit USA&rdquo;, the &ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo;, &ldquo;our&rdquo;)
(formerly Putnam Hills Corp.) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue
a business combination through the acquisition of, or merger with, an operating business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
BioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (&ldquo;DanDrit Denmark&rdquo;).&nbsp;&nbsp;The Company
engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the
treatment of cancer in humans using the dendritic cell technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Reverse
Acquisition&nbsp;&nbsp;- On February 12, 2014, pursuant to aShare Exchange Agreement (the &quot;Share Exchange Agreement&quot;),
DanDrit USA completed the acquisition of approximately 100% of the issued and outstanding capital stock&nbsp;&nbsp;of&nbsp;&nbsp;DanDrit
Denmark (the &ldquo;Share Exchange&rdquo;) and as a result became DanDrit Denmark&rsquo;s parent company (the &ldquo;Parent&rdquo;).
Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the &ldquo;Common Stock&rdquo;)
of Parent outstanding.&nbsp;Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued
1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering.
At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares
of Parent&rsquo;s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent&rsquo;s Common Stock
outstanding immediately following the Share Exchange, <FONT STYLE="background-color: white">including 185,053 shares of Common
Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit
Denmark to the DanDrit Denmark shareholders who have not consented to the </FONT>Share Exchange (the &ldquo;Non-Consenting Shareholders&rdquo;)<FONT STYLE="background-color: white">,
and deemed issued and outstanding for accounting purposes</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Functional
Currency / Foreign currency translation</B>&nbsp;&mdash;&nbsp;The functional currency of DanDrit Biotech A/S is the Danish
Kroner (&ldquo;DKK&rdquo;). The Company&rsquo;s reporting currency is the U.S. Dollar for the purpose of these financial
statements. The Company&rsquo;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and
all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years 2014 and
2013. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in
stockholders&rsquo; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions
denominated in a currency other than the functional currency are included in the statement of operations as
incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash
and Cash Equivalents</B>&nbsp;&mdash;&nbsp;The Company considers all highly liquid debt instruments purchased with a
maturity of three months or less to be cash equivalents. The Company had balances held in a financial institution in the
United States in excess of federally insured amounts at December 31, 2014 of $2,508,759 and none at December 31,
2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Property
and Equipment</B>&nbsp;&mdash;&nbsp;Property and equipment are stated at cost. Expenditures for major renewals and betterments
that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance
and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis
over the estimated useful lives of the assets which range from four to six years (See Note 3).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intangible
Assets</B>&nbsp;&mdash;&nbsp;Definite life intangible assets include patents. The Company accounts for definite life intangible
assets in accordance with Financial Accounting Standards Board, (&ldquo;FASB&rdquo;) Accounting Standards Codification, (&ldquo;ASC&rdquo;)
Topic 350, &ldquo;Goodwill and Other Intangible Assets&rdquo; and amortized the patents on a straight line basis over the estimated
useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated
useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs
are charged to expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Impairment
of Long-Lived Assets &mdash;</B> Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment
whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances
which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant
adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history
of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will
more likely than not be sold or disposed of significantly before the end of its estimated useful life.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTES
        TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
        1 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Recoverability
of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future
cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future
cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value
of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying
amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired
and continue in use is their respective fair values.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenue
Recognition and Sales </B>&nbsp;&mdash;&nbsp;The Company&rsquo;s sales of its MelCancerVac colorectal cancer treatment have been
limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use
or location. The Company accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting
Bulletin No. 101, &ldquo;Revenue Recognition in Financial Statements&rdquo; (SAB 101), FASB ASC 605 Revenue Recognition. The Company
recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement,
product has been shipped or delivered to the customer, the price and terms are finalized, and collections of the resulting receivable
is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 18pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Value
Added Tax - </B>In Denmark, Value Added Tax (&ldquo;VAT&rdquo;) of 25% of the invoice amount is collected in respect of the sales
of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability
on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices.
These amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying
financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Research
and Development Cost</B>&nbsp;&mdash;&nbsp;The Company expenses research and development costs for the development of new
products as incurred and such costs are included in operating expense. There were no research and development costs for the
years ended December 31, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income
Taxes</B>&nbsp;&mdash;&nbsp;The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income
Taxes. This statement requires an asset and liability approach for accounting for income taxes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Loss
Per Share</B>&nbsp;&mdash;&nbsp;The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per
Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each
period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive
common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options
that have been granted but have not been exercised.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Derivatives
&mdash; </B>We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or
foreign-currency risks. However, we have entered into certain other financial instruments and contracts, such as debt
financing arrangements with features that are either (i)&nbsp;not afforded equity classification, (ii)&nbsp;embody risks not
clearly and closely related to host contracts, or (iii)&nbsp;may be net-cash settled by the counterparty. These instruments
are required to be carried as derivative liabilities, at fair value.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
estimate fair values of all derivative instruments, such as embedded conversion features utilizing Level 3 inputs (defined
below in Note 1: Fair Value of Financial Instruments). We use the Black-Scholes option valuation technique because it
embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to
fair value these instruments. Estimating fair values of derivative financial instruments requires the development of
significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related
changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to
changes in the market price of our common stock, which have historically had high volatility. Since derivative financial
instruments are initially and subsequently carried at fair value, our income will reflect the volatility in these estimate
and assumption changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>NOTE
1 &mdash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (continued)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
report our derivative liabilities at fair value on the accompanying balance sheets as of December 31, 2014 and 2013.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Fair
Value of Financial Instruments</B>&nbsp;&mdash;&nbsp;The Company accounts for fair value measurements for financial assets and
financial liabilities in accordance with FASB ASC Topic 820. The authoritative guidance, which, among other things, defines fair
value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category
measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the
amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market
participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants
would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier
fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 1. Observable
    inputs such as quoted prices in active markets for identical assets or liabilities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 2. Inputs,
    other than the quoted prices in active markets, that are observable either directly or indirectly; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Level 3. Unobservable
    inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Unless
otherwise disclosed, the fair value of the Company&rsquo;s financial instruments including cash, accounts receivable, prepaid
expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded
values due to their short-term maturities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accounting
Estimates</B>&nbsp;&mdash;&nbsp;The preparation of financial statements in conformity with generally accepted accounting principles
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures
of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses
during the reporting period. Actual results could differ from those estimated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Recent
Accounting Pronouncements</B>&nbsp;&mdash;&nbsp;In May 2014, the Financial Accounting Standards Board issued a new standard to
achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by
reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when
a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects
to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose
the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard
is effective beginning in the first quarter of 2017; early adoption is prohibited. The new standard is required to be applied
retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it
recognized at the date of initial application. We do not believe the new standard will materially impact our consolidated financial
statements.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the
Company&rsquo;s present or future financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Reclassification&nbsp;&mdash;&nbsp;</B>The financial statements for the period ended December 31, 2013 have been reclassified to conform to the headings
and classifications used in the December 31, 2014 financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
2&nbsp;&mdash;&nbsp;PROPERTY AND EQUIPMENT</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property
and equipment consisted of the following at December 31, 2014 and December 31, 2013:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Useful
    Life</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">31-Dec<BR>
    2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">31-Dec<BR>
    2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lab
    equipment and instruments</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 11%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">4-6</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">178,547</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">194,143</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Computer
    equipment</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">4-6</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,151</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,493</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">239,698</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">260,636</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    Accumulated Depreciation</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(239,698</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(260,636</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Property and Equipment</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation
expense amounted to $0 and $2,706, for the year ended December 31, 2014 and 2013, respectively. The Company&rsquo;s property and
equipment is held as collateral on the notes payable related party.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
3&nbsp;&mdash;&nbsp;DEFINITE-LIFE INTANGIBLE ASSETS</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">At
December 31, 2014 and December 31, 2013, definite-life intangible assets, net of accumulated amortization, consist of patents
on the Company&rsquo;s products and processes of $186,414 and $231,615, respectively. The patents are recorded at cost and amortized
over twenty years from the date of application. Amortization expense for the years ended December 31, 2014 and 2013 was $14,381
and $38,297, respectively. Expected future amortization expense for the years ended are as follows:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Year
    ending December 31,</U></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,381</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">14,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0; padding-right: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">114,509</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">186,414</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
4&nbsp;&mdash;&nbsp;NOTES PAYABLE &ndash; RELATED PARTY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
payable to related parties consists of the following as of December 31, 2014 and 2013:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Interest
    Bearing Loan Payable Sunrise Financial Group Inc.</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">38,235</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note
    Payable ML Group</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,963</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">21,557</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">6%
    Promissory Note payable to NLBDIT 2010 Enterprises, LLC</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,753</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">5%
    Note Payable - Sune Olsen Holding ApS</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">521,390</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5%
    Note Payable - Sune Olsen</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">185,054</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Notes Payable &ndash; Related Party</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,951</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">728,001</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less
    Current Maturities</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(99,951</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(728,001</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Note
    Payables &ndash; Related Party Long Term</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following represents the future maturities of long-term debt as of December 31, 2014:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Year
    ending December 31,</U></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,951</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2015</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2016</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 0; text-align: left; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,951</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 15, 2014 and March 18, 2014, DanDrit Denmark received DKK 2,500,000 ($461,084) and DKK 2,300,000 ($424,198) loans
(the &ldquo;2014 Loans&rdquo;), respectively, from PasecoApS, an entity owned by a shareholder of the Company
(&ldquo;Paseco&rdquo;).&nbsp;&nbsp;The 2014 Loans werepayable 14 days after the completion of the contemplated public
offering in DanDrit USA or February 1, 2015, and accrued interest at 5% per annum. On April 29, 2014, DanDrit Denmark and
Paseco entered into an amendment whereby the terms of the 2014 Loans werepayable on February 1, 2015 and couldbe extended at
the Company&rsquo;s option for an additional year with an increase in the interest rate to 7.00%.&nbsp;&nbsp;As of October
17, 2014, the outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange
rate of October 17, 2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DanDrit
Denmark has received an unsecured loan facility from Sune Olsen Holding ApS (&ldquo;Sune Olsen Holding&rdquo;), a shareholder
of the Company, with a goal of ensuring financing until new equity has been brought in. Under the loan facility DanDrit Denmark
has received the following amounts: on November 11, 2013 DKK 1,500,000</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">($276,651)<FONT STYLE="font-size: 10pt">,
on November 20, 2013 DKK 405,000 ($74,696), and on December 2, 2013 DKK 900,000($165,990). The loans weredue May 1, 2014 and accrued
interest at 5% per year.&nbsp;&nbsp;During March 2014, the Company extended maturity date of the loans with Sune Olsen Holdings
from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November
26, 2014, the Company repaid the loan facility and interest thereon.</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">DanDrit
Denmark has received an unsecured loan from Sune Olsen, managing member of Sune Olsen Holding, with a goal of ensuring financing
until new equity has been brought in. The loan in the amount of DKK 1,000,000 ($184,434) was issued on December 20, 2013. The
loan wasdue May 1, 2014 and accrued interest of 5% per year. During March 2014, the Company extendedthematurity date of the DKK
1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit
USA or February 1, 2015. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
March 2014, the Company received a 2,000,000 DKK ($368,868) letter of support from Paseco to finance operations until February
1, 2015 to be issued with terms substantially similar to those contained in the 2014 Loans. The Company has an option to extend
the loan for one year by giving notice to Paseco by December 31, 2014 whereby the interest rate would increase to 7.00% per annum.
The Company did not exercise the option.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
2012, DKTI A/S, a shareholder of the Company, which is controlled by officers and directors of the Company, agreed to loan the
Company up to DKK 5,000,000 (approximately $880,000) accruing interest at 6%.&nbsp;&nbsp;The loan is secured by all the Company&rsquo;s
intellectual property rights, including its patents and its patent applications credit facility.&nbsp;&nbsp;During the year ended
December 31, 2012 the Company borrowed DKK 4,431,862 ($783,139) plus DKK 71,563 ($12,646) in interest.&nbsp;&nbsp;During the year
ended December 31, 2013, the Company borrowed an additional DKK 310,000 (approximately $55,000) on the loan and accrued interest
of DKK 230,377 (approximately $42,000). The notes with related accrued interest were converted into 96,288 common shares of DanDrit
Denmark on December 16, 2013 which were exchanged for 144,321 shares of common stock of the Parent upon the closing of the Share
Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the years ended December 31, 2013, 2012 and 2011 Sune Olsen Holding&nbsp;loaned DanDrit Denmark DKK 1,267,724 ($232,841), DKK
338,719 ($59,854) and DKK 143,750 ($25,019), respectively.&nbsp;&nbsp;The Company added the accrued interest at 6% and the Company
recorded interest expense of DKK 86,047 ($15,804), DKK 20,469 ($3,617) and DKK 2,689 ($468) during the years end December 31,
2013, 2012 and 2011, respectively.&nbsp;&nbsp;The loans are payable upon three months written notice of Sune Olsen Holding.&nbsp;&nbsp;On
December 16, 2013, the notes with related accrued interest were converted into 35,106 shares of DanDrit&nbsp;Denmark&nbsp;which
were exchanged for 52,618 shares of common stock of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On April 14,
2013, Sune Olsen Holding, a shareholder of the Company, assumed DKK 4,375,932 (approximately$773,000) in liabilities owed by
DanDrit Denmark for past due rent from a vendor in exchange for a note payable. ) were converted into 86,204 shares of
DanDrit Denmark , which were exchanged for 129,207 shares of common stock of the Parent upon the closing of the Share
Exchange.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On June 20,
2013, Sune Olsen Holding paid DKK 1,500,000, ($265,000) in accrued legal fees owed by the Company in exchange for a
DKK1,500,000 ($265,000) 5% note payable to Sune Olsen Holding. On December 16, 2013, the note with related accrued interest
of DKK 20,959 ($3,804) was converted into 29,036 shares of DanDrit&nbsp;Denmark&nbsp;common stock. Such shares of common
stock were exchanged for 43,520 shares of common stock of the Parent upon the closing of the Share Exchange..</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July 26, 2013 and August 15, 2013, Sune Olsen Holding loaned the Company an additional DKK 1,000,000 ($177,239) and DKK
750,000 ($133,343), respectively.&nbsp;&nbsp;The notes accrue interest at 5% and are payable upon three months written notice
of Sune Olsen Holding. The notes with related accrued interest of DKK 15,575 ($2,827) were converted into 33,705 shares of
DanDrit Denmark common stock on December 16, 2013. Such shares of common stock were exchanged for 50,518 shares of common
stock of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2014, the outstanding balance of $38,235 for professional fees paid by a shareholder and amounts advanced to the
Parent are reported as loan payable - related party. The $38,235 loans payable were acquired in the reverse acquisition. The amounts
are unsecured, non-interest bearing and have no stipulated repayment terms.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
6% promissory note payable to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was
acquired by the Company in the reverse acquisition,&nbsp;payable on February 12, 2014 upon the completion date of the Share
Exchange.&nbsp;&nbsp;As of December 31, 2014, the outstanding balance on the note, including accrued interest, was $42,753.
During the three and twelve months ended December 31, 2014 the Company recorded related party interest on the Note of $213,
and $619, respectively.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
5&nbsp;&mdash;&nbsp;CONVERTIBLE BOND PAYABLE &ndash; RELATED PARTY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 1, 2011, DanDrit Denmark borrowed $1,500,000 from DKTI A/S and issued 6% convertible bonds. The bonds may not be converted
during the four weeks following the publication of the annual report. The bonds may not be repaid until the bonds&rsquo; expiration
on December 31, 2014.&nbsp;&nbsp;The bonds shall not accrue interest after expiration.&nbsp;&nbsp;The bonds and related accrued
interest are convertible into common shares of the Company at an initial rate of $9.58 per common share.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
conversion/adjustment features had an estimated fair value of $1,003,557 using the Black-Scholes pricing model using the
assumptions set forth below and were bifurcated and properly classified as derivative instruments required to be recorded at
fair value (Note 6). The proceeds from the bond have been allocated to the note and conversion/adjustment feature of the
convertible bond and recorded at a discount which was amortized to interest expense through conversion. During the years
ended December 31, 2013 and 2012, the Company recorded interest expense of $502,465 and $461,279, respectively, for the
accretion of the discount on the note.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 16, 2013, the $1,500,000 convertible bond, accrued interest of $179,612 and the $673,736 derivative liability were converted
into 174,578 shares of DanDrit Denmark common stock. Such shares of common stock were exchanged for 261,665 shares of common stock
of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
assumptions used to determine the initial fair value of the conversion feature of the convertible bond were expected volatility
of 65%, expected life of two years to twelve months, risk &ndash; free interest rates of .41%, and no dividend yield.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
6 &mdash; DERIVATIVE LIABILITIES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However,
the Company has entered into certain other financial instruments and contracts, such as debt financing arrangements with features
that are either (i)&nbsp;not afforded equity classification, (ii)&nbsp;embody risks not clearly and closely related to host contracts,
or (iii)&nbsp;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities,
at fair value.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
fair value of the shares to be issued upon conversion of the bond was recorded as a derivative liability, with the change in the
fair value recorded as a gain or loss in the accompanying statement of operations.&nbsp;&nbsp;During the three and nine months
ended September 30, 2013, the Company recorded gains of $4,180 and $45,823, respectively. On December 16, 2013, the $1,500,000
convertible bond, accrued interest of $179,612 and the $673,736 derivative liability were converted into 174,578 shares of DanDrit
Denmark common stock or 261,665 shares of common stock of the Company upon the closing of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
7&nbsp;&mdash;&nbsp;LEASES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Operating
Leases</B>&nbsp;&mdash;&nbsp;The Company leases laboratory and production space under operating lease agreements which can be
cancelled with 3 month notice.&nbsp;&nbsp;The lease calls for monthly payments of DKK 6,000 (approximately $967 at December 31,
2014).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 27, 2014 the Company entered into an operating lease agreement for office space from a related party. The Lease calls
for monthly payments of DKK 10,000 (approximately $1,612), increasing to DKK 20,000 (approximately $3,225) on July 1, 2014.
The lease can be terminated by either the Company or the landlord by giving the other 3 month notice. The Company gave
a notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31,
2015.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Lease
expense charged to operations was $32,297 and $65,702, for the years ended December 31, 2014, and 2013 respectively.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
8&nbsp;&mdash;&nbsp;INCOME TAXES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company
to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences
between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization
of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&rsquo;s
future earnings, and other future events, the effects of which cannot be determined.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2014 the Company had net operating loss carryforwards of approximately $2,380,106 for Danish tax purposes which
do not expire.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company files Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2007
for their Danish tax returns.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at December
31, 2014 and 2013:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Excess
    of Tax over book depreciation Fixed assets</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,711</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">87,578</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Excess
    of Tax over book depreciation Patents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">52,041</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">114,028</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Operating Loss Carryforward</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,380,106</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,642,598</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation
    Allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,444,858</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,844,204</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Deferred Tax Asset (Liabilities)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties.
The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step
approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first
step is to determine whether the tax position meets the more-likely-than-not condition for recognition and the second step is
to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization
of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&rsquo;s
future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management
estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets;
and consequently, a valuation allowance was recorded for all deferred tax assets.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company&rsquo;s effective rate
is as follows at December 31, 2014 and 2013:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Computed
    Tax at Expected Statutory Rate</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(866,463</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(752,882</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-US
    Income Taxed at Different Rates</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">255,356</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">199,292</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-Deductable
    expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,390</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">283,381</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation
    allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">436,631</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,209</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income
    Tax Expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
components of income tax expense (benefit) from continuing operations for the years ended December 31, 2014 and 2013 consisted
of the following:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    Tax Expense</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Danish
    Income Tax</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(177,539</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    Income Tax Expense (Benefit)</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Excess
    of Tax over Book Depreciation Fixed Assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,259</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,364</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Excess
    of Tax over Book Depreciation Patents</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">67,488</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(105,585</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Operating Loss Carryforwards</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(523,378</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">(190,988</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Change
    in the Valuation allowance</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">436,631</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">270,209</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Deferred Tax Expense</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
income tax expense/(benefit) results primarily from the reversal of temporary timing differences between tax and financial statement
income.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
9&nbsp;&mdash;&nbsp;LOSS PER SHARE</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of
shares of potential dilutive common stock for the years ended December 31, 2014 and 2013:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December
    31,</B></FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2014</B></FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2013</B></FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 78%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net (Loss)</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2,370,883</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD>
    <TD STYLE="width: 8%; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2,214,361</FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted average number of common shares
    used in basic earnings per share</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,500,142</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,557,893</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Effect of dilutive securities, stock
    options and warrants</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">-</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Weighted
    average number of common shares and potential dilutive</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><BR>
    <FONT STYLE="font-size: 10pt">common shares outstanding used in dilutive earnings per share</FONT></FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7,500,142</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: right; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,557,893</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the years ended December 31, 2014 and 2013, the Company had no options outstanding to purchase common stock of the Parent.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
10&nbsp;&mdash;&nbsp;STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Stock</B>&nbsp;&mdash;&nbsp;The Company has 100,000,000 authorized shares of Common stock $0.0001.&nbsp;&nbsp;As of December 31,
2014 there were 9,533,290 shares issued and outstanding.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Share
Exchange Agreement</B>/<B>Reverse Acquisition</B>&nbsp;- On February 12, 2014, in accordance with the terms and conditions of
a Share Exchange Agreement (the &quot;Share Exchange Agreement&quot;), wecompleted the acquisition of approximately 100%
of the issued and outstanding capital stock&nbsp;&nbsp;of&nbsp;&nbsp;DanDrit Denmark (the &ldquo;Share Exchange&rdquo;) and
as a result became DanDrit Denmark&rsquo;s parent company (the &ldquo;Parent&rdquo;). In connection with the Share Exchange,
each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA&rsquo;s common
stock, par value $.0001 per share (the &ldquo;Common Stock&rdquo;) for an aggregate of 6,000,000 shares, including 185,053
shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of
Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed
issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder
prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of
directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive
management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing
of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Common
Stock Issuances &ndash;</B> On<FONT STYLE="background-color: white"> December 31, 2014,</FONT> the Company received <FONT STYLE="background-color: white">$2,000,000
in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00
per share.</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2014, pursuant to <FONT STYLE="background-color: white">the Company&rsquo;s offering up
to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering
pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for
gross proceeds of $5,466,450 less offering costs of $156,360.</FONT></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 16, 2013, DanDrit<FONT STYLE="background-color: white"> Denmark</FONT> issued 174,578 shares of its common stock which
were exchanged for 261,665 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of a $1,500,000
convertible bond, $179,612 of accrued interest and the remaining $673,736 of derivative liability associated with the conversion
feature of the bond.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 16, 2013, DanDrit<FONT STYLE="background-color: white">Denmark</FONT> issued 96,288 shares of its common stock which
were exchanged for 144,321 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of $926,386
of notes payable and related accrued interest payable to DKTI A/S.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">On December 16,
2013, DanDrit<FONT STYLE="background-color: white"> Denmark </FONT>issued 184,051 shares of its common stock which were exchanged
for 275,863 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of $1,770,757 of notes payable
and related accrued interest payable to Sune Olsen Holdings ApS and Advance Biotech Invest AS.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Voting-</I></B>&nbsp;Holders
of the Company&rsquo;s common stock are entitled to one vote for each share held of record on each matter submitted to a vote
of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Dividends-
</I></B>Holders of the Company&rsquo;s common stock are entitled to receive ratably such dividends as our Board of Directors from
time to time may declare out of funds legally available.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Liquidation
Rights-</I></B> In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of
our debts and liabilities, the holders of the Company&rsquo;s common stock will be entitled to share ratably in the distribution
of any of our remaining assets.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.55in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
11&nbsp;&mdash;&nbsp;COMMITMENTS AND CONTINGENCIES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Shares
held for non-consenting shareholders </I></B><I>&ndash; </I>In connection with the Share Exchange agreement certain shareholders
of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the
Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange
the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to
receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled
to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding
in the accompanying financial statements.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Clinical
Trial Agreement</I></B>&ndash;On October 1, 2014 the Company&rsquo;s subsidiary, DanDrit Biotech A/S signed a contract of
collaboration with the University Hospital IRCCS &ldquo;San Martino&rdquo; - IST &ndash; National Institute for Cancer
Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San
Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III
adjuvant study of DanDrit&rsquo;s vaccine in patients with no evident disease (&ldquo;NED&rdquo;) stage IV colorectal cancer
(&ldquo;CRC&rdquo;). The primary goal of the study is to evaluate the efficacy of DanDrit&rsquo;s MelCancerVac&reg;
(&ldquo;MCV&rdquo;) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance
with local practices.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Patient
Name Use Program</I></B> - On December 16, 2013, DanDrit<FONT STYLE="background-color: white"> Denmark </FONT>entered into
an agreement with a Dutch company (the &ldquo;MCV Partner&rdquo;) regarding a Patient Name Use Program (PNU) for the
Company&rsquo;s MCV.&nbsp;&nbsp;This program will allow DanDrit <FONT STYLE="background-color: white">Denmark </FONT>to sell
MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner.&nbsp;&nbsp;The MCV Partner offers a
worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV
Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmacovigilance.&nbsp;&nbsp;
The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the
agreement. Either party may terminate the agreement with 180 day written notice.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Food
and Drug Administration (FDA) -</I></B> The FDA has extensive regulatory authority over biopharmaceutical products (drugs and
biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio
product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy
and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires
several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company
prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized
to produce the product. Accordingly, the Company&rsquo;s cell systems used for the production of therapeutic or bio therapeutic
products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Product
liability - </I></B>The contract production services for therapeutic products offered exposes an inherent risk of liability
as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause
adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the
Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be
successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the
Company against potential claims relating to such contract production services. The Company may also be exposed to potential
product liability claims by users of its products. A successful partial or completely uninsured claim against the Company
could have a material adverse effect on the Company&rsquo;s operations.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Employment
Agreements - </I></B>The Company and its Subsidiary have employment agreements with officers of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Contingencies
</I></B>- The Company is from time to time involved in routine legal and administrative proceedings and claims of various types.&nbsp;&nbsp;While
any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations
or financial position.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
12&nbsp;&mdash;&nbsp;DISPOSITION</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 16, 2013,DanDrit Biotech A/S sold its&rsquo; Dormant Singapore subsidiary DanDrit Singapore Pte. Ltd., for $1 resulting
in no gain or loss from the sale and discontinuing the operations. The Company had no sales or operations for the periods presented
in the accompanying financial statements.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
13&nbsp;&mdash;&nbsp;Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2014 and 2013, the Company entered into various notes payable with shareholders of the Company (See
Note 4).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See
Note 7). During the year ended December 31, 2014, the Company paid the related party DKK 130,000 or approximately
$23,152.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the year
ended December 31, 2014 and 2013, a law firm partially owned by the Company&rsquo;s Chairman of the Board of Directors provided
legal services to the Company. During the years ended December 31, 2014 and 2013 the Company recorded legal expense of $288,546
and $328,202, respectively. During the year ended December 31, 2013 the firm forgave $49,016 in legal services. At December 31,
2014, the Company had a payable to the firm in the amount of $212,438. During the years ended December 31, 2014 and 2013, the
firm held funds in trust on behalf of the Company in connection with stock offerings and to facilitate settling outstanding liabilities.
Balances held in trust at December 31, 2014 and 2013 were $2,014,909 and $14,593, respectively<FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA INC AND SUBSIDIARY</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></P>


<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOTE
14&nbsp;&mdash;&nbsp;SUBSEQUENT EVENT</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 40pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s management reviewed material events through March 30, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
March 13, 2015, the Company, DanDrit Denmark and Robert E. Wolfe entered into an Agreement pursuant to which Mr. Wolfe ceased
to be Chief Financial Officer of DanDrit Denmark effective as of the date on which a replacement Chief Financial Officer is
engaged (the &ldquo;Agreement&rdquo;). It is currently anticipated that Mr. Wolfe will continue to serve as the Chief
Financial Officer of the Company through a transition period that will end following the date that the Company files its
Annual Report on Form 10-K for the year ended December 31, 2014 (the &ldquo;Transition Period&rdquo;). In accordance with the
terms of the Agreement and except as amended by the Agreement, the CFO Service Agreement between DanDrit Denmark and Mr.
Wolfe, dated as of February 10, 2014 (the &ldquo;Wolfe Employment Agreement&rdquo;) will remain in effect through October 31,
2015 (the &ldquo;Termination Date&rdquo;). In addition, Mr. Wolfe is entitled to receive (i) all salary payable in accordance
with the terms of the Wolfe Employment Agreement, along with any unpaid accrued expenses, through the Termination Date; (ii)
attorney fees of up to a maximum of $4,000; (iii) a bonus in an amount equal to $10,000 following the filing of the
Company&rsquo;s Annual Report on Form 10-K for the year ended December 31, 2014; and (iv) a fee of $150.00 per hour for any
consulting services that Mr. Wolfe may provide in connection with the filing and completion of the Company&rsquo;s current
and periodic filings with the Securities and Exchange Commission; provided that the first 100 hours of consultant services
provided from May 1, 2015 through October 31, 2015 shall not be billable. Other than as described above, the terms of the
Wolfe Employment Agreement will continue to govern Mr. Wolfe&rsquo;s relationship with the Company and DanDrit Denmark in all
material respects through the Termination Date. In addition, Mr. Wolfe continues to serve as a director of the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
connection with Mr. Wolfe&rsquo;s departure as Chief Financial Officer of DanDrit Denmark, Lone Degn was appointed to serve as
Chief Financial Officer of DanDrit Denmark effective as of March 12, 2015. Subject to approval by the Company&rsquo;s Board of
Directors and Mr. Wolfe&rsquo;s resignation as Chief Financial Officer of the Company, it is currently anticipated that Ms. Degn
will be appointed to replace Mr. Wolfe upon the effective date of his resignation following the Transition Period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
accordance with the terms of a Contract of Employment, dated as of the Effective Date by and between DanDrit Denmark and Ms. Degn
(the &ldquo;Degn Employment Agreement&rdquo;), Ms. Degn will be employed by DanDrit Denmark for an indefinite term unless earlier
terminated pursuant to the terms therein. The Degn Employment Agreement provides that Ms. Degn will receive a salary of DKK 60,000
gross per month, to be paid monthly on the last business day of each month and subject to annual review and increases by the board
of directors of DanDrit Denmark, as it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to her salary, Ms. Degn will be entitled to receive reimbursement of all reasonable costs and expenses incurred in connection
with the performance of her duties in accordance with the terms of the Degn Employment Agreement In addition, DanDrit Denmark
has agreed to contribute an amount equal to 10% of Ms. Degn&rsquo;s yearly salary to a pension fund or bank account established
for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Either
DanDrit Denmark or Ms. Degn may terminate the employment in accordance with the Danish Salaried Employees Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
foregoing descriptions of the Agreement and the Degn Employment Agreement contained herein do not purport to be complete and are
qualified in their entirety by reference to the complete text of the <FONT STYLE="background-color: white">Agreement and the Degn
Employment Agreement, which are filed as exhibits to this report.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_011"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
9.&#9;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Not
applicable.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_020"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
9A. Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Report
on Disclosure Controls and Procedures</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Regulations
under the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;) require public companies to maintain &ldquo;disclosure
controls and procedures,&rdquo; which are defined as controls and other procedures that are designed to ensure that information
required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be
disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer's
management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
conducted an evaluation, with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial
Officer (our principal financial and accounting officer), of the effectiveness of our disclosure controls and procedures as of
December 31, 2014. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that as of December
31, 2014, our disclosure controls and procedures were effective at the reasonable assurance level.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Report
on Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange
Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, our Chief
Executive Officer and Chief Financial Officer and effected by our Board of Directors, management and other personnel, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles and includes those policies and procedures that (i) pertain
to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our
assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements
in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance
with authorizations of management and our directors; and (iii) provide reasonable assurance regarding prevention or timely detection
of the unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
management, including the Chief Executive Officer and principal Chief Financial Officer, assessed the effectiveness of the Company&rsquo;s
internal control over financial reporting as of December 31, 2014.&nbsp;&nbsp; In making this assessment, we used the criteria
established in&nbsp; Internal Control&mdash;Integrated Framework&nbsp; issued by the Committee of Sponsoring Organizations of
the Treadway Commission&nbsp;&nbsp;(&ldquo;COSO&rdquo;) and we performed a complete assessment as outlined in&nbsp; Commission
Guidance Regarding Management&rsquo;s Report on Internal Control Over Financial Reporting Under Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of
the Exchange Act&nbsp; (&ldquo;SOX&rdquo;).&nbsp;&nbsp;Based on this assessment we concluded that, as of December 31, 2014, the
Company&rsquo;s internal control over financial reporting was ineffective due to the limited number of Company personnel and the
inherent limitations on the segregation of duties and supervisory reviews which results in limited resources to identify, address
and review complex accounting and financial reporting matters.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">While
the Company has identified the material weakness described above, and believes it will need to expand staffing and perhaps
engage additional third parties to provide ongoing technical advice and continue to improve reconciliation and review
procedures, it will not be able to do so without additional funding or other financial resources. Management is committed to
continuous improvement of the Company&rsquo;s internal control processes and will continue to diligently review the
Company&rsquo;s financial reporting controls and procedures. As management continues to evaluate and work to improve internal
control over financial reporting, the Company may determine to take additional measures to address control
deficiencies.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Despite
the existence of the material weaknesses, we believe that our consolidated financial statements contained in this Annual Report
on Form&nbsp;10-K fairly presents our financial position, results of operations and cash flows for the fiscal year ending December
31, 2014 in all material respect.<FONT STYLE="background-color: white">&nbsp;</FONT>Because we are neither an accelerated filer
nor a large accelerated filer, pursuant to Item 308(b) or Regulation S-K, this annual report does not include an attestation report
of our registered public accounting firm regarding our internal controls over financial reporting.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Changes
in Internal Control over Financial Reporting</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">With
the addition of new processes and procedures associated with the Share Exchange, there were changes in our internal control over
financial reporting that have materially affected our internal control over financial reporting.&nbsp;&nbsp;These changes include
an increased requirement of business transaction review and an increased requirement of board oversight and review.&nbsp;&nbsp;The
acquisition of DanDrit Denmark also adds greater accounting and financial reporting resources, to manage these changes in our
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_012"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
9B. Other Information</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">None.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 82; Options: NewSection; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_024"></A><B>PART III</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_013"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
10. Directors, Executive Officers and Corporate Governance</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following table identifies our executive officers and directors, their ages, their respective offices and positions, and their
respective dates of election or appointment.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 20pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Name</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Age</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Position</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Officer/Director
    Since</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; width: 25%; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr.
    Eric Leire</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0%; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 10%; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">57</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 0%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive
    Officer and Director (Principal Executive Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 24%; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February
    2014</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert E. Wolfe</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">52</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial
    Officer and Director (Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February
    2014</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N.E. Nielsen</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">66</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the
    Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February
    2014</FONT></TD></TR>
<TR STYLE="background-color: white">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr. Jacob Rosenberg</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">50</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February
    2014</FONT></TD></TR>
<TR STYLE="background-color: #CCEEFF">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aldo Michael Noes
    Petersen</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">53</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">February
    2014</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Executive
officers are appointed by and serve at the pleasure of the Board of Directors. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
certificate of incorporation provides for the annual election of directors. At each annual meeting of stockholders, our directors
will be elected to serve until their respective successors have been elected and qualified.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
are no family relationships, as defined in subparagraph (d) of Item 401 of Regulation S-K, among any of our executive
officers and directors. To the best of our knowledge, none of our directors or executive officers has, during the past ten
years, been involved in any legal proceedings described in subparagraph (f) of Item 401 of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Background</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following is a brief summary of the background of each of our directors and executive officers.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dr.
Eric Patterson Leire, MD, MBA.</B>&nbsp;Dr.&nbsp;Eric Leire has served as the Chief Executive Officer and a director of
DanDrit Denmark since April 2011. Dr. Leire also served for two years as Chief Executive Officer and director of DKTI A/S, a
listed Danish investment company from September 2012. Prior to these roles Dr. Leire was a partner at BioFund Venture
Capital, a Finnish biotech venture fund, from August 2006 through September 2010 and a partner at Medwell Capital Corp., a
Canadian venture fund, from April 2010 through May 2011. Dr. Leire has worked globally for&nbsp;many international
pharmaceutical organizations, including Schering-Plough, Pfizer, Inc., Boots Pharmaceuticals Company PLC, Harvard AIDS
Institute and bioStrategies Group. Dr. Leire also served as the CEO of US biotech companies APT Therapeutics and Paringenix
and currently serves on the board of directors of Novicol Canada and DanDrit&nbsp;Biotech USA Inc. Dr. Leire received his
medical degree from the University of Medicine of Grenoble in 1980 and his MBA from ISA-HEC and the Kellogg School of
Management at Northwestern University in 1991. The Board of Directors believes that Dr. Leire&rsquo;s significant global
experience in the pharmaceutical and biotechnology industries will be a significant asset to DanDrit as it carries out its
business plan and for those reasons determined that he should serve on the Board of Directors.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Robert
E. Wolfe.&nbsp;</B>Mr. Wolfe has served as the Chief Financial Officer since January 1, 2014. Mr. Wolfe also serves as Chairman
and CEO of IProcess Manager Inc. from April 2010, and as a director of Iso-Ware A/S from February 2006. In addition, Mr. Wolfe
has served as Chairman, CEO and CFO of Advanced Oxygen Technologies, Inc., a publicly traded company, since December 1997, which
owns Anton Nielsen VojensApS, a Danish commercial real estate company. Mr. Wolfe has served as President, CEO and director of
Crossfield, Inc., Crossfield Investments, LLC, Drumbeg Ltd, Baldwin Construction Inc. and Ludlow Leasing, Inc. from May 1989 to
the present. The Board of Directors believes that Mr. Wolfe&rsquo;s experience with U.S. public companies and Danish entities
qualifies Mr. Wolfe to serve as a director of the Company.</FONT> On March 13, 2015, the <FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Company, DanDrit Denmark
and Mr.Wolfe entered into an Agreement pursuant to which Mr. Wolfe ceased to be Chief Financial Officer of DanDrit Denmark effective
as of the date on which a replacement Chief Financial Officer is engaged. It is currently anticipated that Mr. Wolfe will continue
to serve as the Chief Financial Officer of the Company through a transition period that will end following the date that the Company
files its Annual Report on Form 10-K for the year ended December 31, 2014. (See Note 14 to our financial statements &ndash; Subsequent
Event).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NE
Nielsen.</B>&nbsp;Mr. Nielsen is a lawyer and has been a partner at Lett Law Firm in Denmark since April 2011. His practice areas
are capital market conditions, securities law, boards of directors, managerial, finance and acquisitions. He currently serves
as the chairman and a board member of numerous companies, including as Chairman of DanDrit Biotech A/S since June 2013, director
of the board of Charles Christensen A/S since 1983 and as Chairman since May 2010, Chairman of Charles GulveEngros A/S since June
2002, Chairman of InterMail A/S since January 1995, Chairman of Gammelrand Holding A/S since December 2009, Chairman of GammelrandSk&aelig;rvefabrik
A/S since May 1995, director of the board of EjendomsaktieselskabetMatr. 43 EiAved&oslash;re since August 2000 and as Chairman
since February 2009, Chairman of GammelrandBeton A/S since April 2001, director of the board of P.O.A. Ejendomme A/S since July
1994 and Chairman since April 2007, and Chairman of KonveloutfabrikkenDanmakrs Fond and. Within the last five years Mr. Nielsen
has served as a board member or chairman in the following companies: Br&oslash;ndbyerns I.F. Fodbold A/S from June 2013 to April
2014, AmagerbankenAktieselskab now under konkurs from December 1999 to November 2010, Ambu A/S from February 1999 to December
2012, CarepointHaslev/Ringsted now under konkurs from June 2009 to August 2009, Cimber Sterling A/S now under konkurs from September
2000 to September 2010, Cimber Sterling Group A/S now under konkurs from September 2005 to September 2010, Danica-ElektronikApS
from March 1993 to September 2012, GPV Industri A/S now under konkurs from December 1986 to June 2011, GPV International A/S from
April 2009 to June 2009, Henrik Olsen Automobiler A/S from April 2010 to May 2010, Kirk &amp;Thorsen Invest A/S from February
2013 to April 2013, Olsen BilerAdministraton A/S from April 2007 to May 2010, Olsen Biler Ringsted-Haslev A/S from April 2007
to May 2010, Satair A/S fromNovember 1994 to October 2011, Satair Service A/S from May 1995 to May 2011, Torm A/S from September
2000 to January 2013 and Weibel Scientific A/S from January 1986 to September 2012.&nbsp;Mr. Nielsen&rsquo;s significant global
experience as a member of the board of directors or chairman of various entities led the Board of Directors to believe that Mr.
Nielsen is qualified to serve as a director of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 83; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dr.
Jacob Rosenberg.&nbsp;</B>Dr. Jacob Rosenberg currently serves as a director of DanDrit Denmark, a position he has held
since May 2012. Prior to this role, Dr. Rosenberg served as Chairman of DanDrit Denmark&rsquo;s board from 2003 to 2009 and
Chairman of T-cellic A/S from 2007 to 2008. Dr. Rosenberg is also currently Chairman of the board of DKTI A/S. Dr. Rosenberg
was appointed as a Professor of Surgery at the University of Copenhagen in 2003, where he also received his M.D. in 1991. He
also has a D.Sc. from the University of Copenhagen. During the years 1997-2003 he received 6 honorary research prizes.
Professor Rosenberg has overseen DanDrit Denmark&rsquo;s Copenhagen based clinical trials. The Board of Directors believes
that Dr. Rosenberg is one of the leading experts in research in cancer and dendritic cells and, as a result, that he has a
thorough understanding of our company and our technology. Because of his research background, the Board of Directors believes
that Dr. Rosenberg is uniquely qualified to serve as a director.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Aldo
Petersen</B>. Aldo Petersen has been chairman of LiqTech International, Inc. since August 2011. He has been the Chief
Executive Officer of APE Invest A/S, a private Danish investment company, since 2006 when he sold Telepartner A/S, a formerly
NASDAQ-listed company that he founded in 1986. Prior to Telepartner, he started and sold one of Denmark&rsquo;s first hedge
funds, Dansk Fromue Invest. Mr. Petersen was a major investor in Greentech Energy Systems A/S, a renewable energy company
that builds wind farms in Denmark, Germany, Poland and Italy. He is a private investor in wind farms in Germany and France,
and was also a major investor in Football Club Copenhagen (listed on the Copenhagen Stock Exchange). Mr. Petersen has a B.A.
degree in Economics from Copenhagen Business School. The Board of Directors believes that Mr. Petersen&rsquo;s experience as
a businessman and his knowledge of the capital markets qualifies him to be a director.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Compliance
with Section 16(a) of the Exchange Act</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Section
16(a) of the Securities Exchange Act of 1934 requires executive officers, directors and persons who own more than 10% of a registered
class of our equity securities to file reports of ownership with the Securities and Exchange Commission. Executive officers, directors
and more than 10% shareholders are required by regulations to furnish us with copies of all Section 16(a) reports they file.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Based
solely on the Company&rsquo;s review of the copies of the forms received by it during the fiscal year ended December&nbsp;31,
2014, the Company believes that the following person(s) who, at any time during such fiscal year, was a director, officer or beneficial
owner of more than 10% of the Company&rsquo;s common stock, failed to comply with all Section&nbsp;16(a) filing requirements during
such fiscal years:</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="width: 24%; border-bottom: Black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center; line-height: 115%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 24%; padding-bottom: 1.5pt; text-align: center; line-height: 115%; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Number&nbsp;of&nbsp;Late&nbsp;Reports</FONT></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center; line-height: 115%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 24%; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number&nbsp;of&nbsp;Transactions</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">not&nbsp;Reported&nbsp;on&nbsp;a&nbsp;Timely</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basis</FONT></P></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center; line-height: 115%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD NOWRAP STYLE="width: 24%; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Failure&nbsp;to&nbsp;File&nbsp;a&nbsp;Required</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form</FONT></P></TD>
    <TD NOWRAP STYLE="width: 1%; text-align: center; line-height: 115%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PasecoApS</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form 4</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"></P>

<!-- Field: Page; Sequence: 84; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Code
of Ethics</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">On
July 12, 2012, the Company adopted a formal code of ethics statement for senior officers and directors (the &ldquo;Code of Ethics&rdquo;)
that is designed to deter wrongdoing and to promote ethical conduct and full, fair, accurate, timely and understandable reports
that the Company files or submits to the SEC and others. A form of the Code of Ethics is attached as an exhibit to this report.
Requests for copies of the Code of Ethics should be sent in writing to DanDrit Biotech USA, Inc., <FONT STYLE="font-size: 10pt; line-height: 115%">375
Park Avenue, Suite 2607, New York, NY, 10152, USA</FONT>.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Corporate
Governance</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
Board of Directors has not adopted procedures by which security holders may recommend nominees to our Board of Directors and that
has not changed.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Insider
Participation Concerning Executive Compensation</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
registrant is a smaller reporting company and is not required to provide this information.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white"><B>Director
Independence</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Our
Board of Directors has determined that Messrs. Nielsen and Petersen are independent as that term is defined in the listing
standards of the NYSE MKT. In making these determinations, our Board of Directors has concluded that none of our independent
directors has an employment, business, family or other relationship which, in the opinion of our Board of Directors, would
interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Our other directors,
Dr.Leire Mr. Wolfe and Mr. Rosenberg, are not considered independent under these rules because Mr. Leire and Mr. Wolfe serve
as executive officers and Mr. Rosenberg serves as a consultant.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_014"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
11. Executive Compensation</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
following table sets forth certain information with respect to compensation for the years ended December 31, 2014 and 2013 earned
by or paid to our chief executive officer, chief financial officer, and up to two other most highly compensated executive officers
in 2013, (the &ldquo;named executive officers&rdquo;).</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    and Principal Position</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Year</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Salary<BR>
    ($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
                                         <BR> Awards<BR>
                                         ($)</FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Option
    <BR> Awards<BR>
    ($)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total<BR>
    ($)(1)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    Eric Leire, <BR></FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">341,275</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">341,275</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief
    Executive Officer and Director</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">169,442</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">169,442</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dina
    Rosenberg Asmussen,</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,444</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">93,444</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Former
    Chief Financial Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2013</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">99,132</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Robert
    Wolfe, <BR> Chief Financial Officer</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">2014</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">84,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1)
All values, except for compensation to Robert Wolfe, are reported on an as-converted basis from Danish Krone (DKK) to U.S. dollars
($) based on the average currency exchange rate of $1.00 = DKK 6.1534, for the year ended December 31, 2014. We do not make any
representation that the Danish Krone amounts could have been, or could be, converted into U.S. dollars at such rate on December
31, 2014, or at any other rate.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Employment
Arrangements</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Agreements
with Named Executive Officers</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have employments agreement with Dr. Leire and Mr. Wolfe and a consultancy agreement with Mrs. Rosenberg.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Leire
Employment Agreement</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
March 1, 2012, DanDrit Denmark entered into an Employment Agreement with Dr. Eric Leire, to serve as its Managing Director. Pursuant
to the terms and conditions of the Employment Agreement, Dr. Leire will be employed by DanDrit Denmark for an indefinite term
unless the agreement is earlier terminated as described below. The Employment Agreement provides that the Dr. Leire will receive
a salary of 2,100,000 DKK ($341,275 calculated on an as-converted basis from Danish Krone (DKK) to U.S. dollars ($) based on the
currency exchange rate of $1.00 = DKK 6.1534, as of December 31, 2014) gross per year, to be paid in equal monthly installments
on the last day of each month and subject to annual review and increases by our Board of Directors, as it deems appropriate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to his salary, Dr. Leire will be entitled to receive: (i) a company car at a value up of DKK 5,100 ($829) per month
(monthly lease value) and DanDrit Denmark shall defray all expenses in connection with the maintenance and use of the car;
(ii) coverage of all expenses relating to Dr. Leire&rsquo;s mobile phone, home computer, Internet connection as well as his
home phone; (iii) coverage of all the expenses relating to Dr. Leire&rsquo;s subscription to a fitness club; (iv) a bonus of
up to DKK 400,000 ($65,005) per year if Dr. Leire reaches certain conditions as specified in the Employment Agreement; and
(v) coverage underDanDrit Denmark&rsquo;s pension plan. In accordance with the pension plan, the Company pays a pension
contribution of 10% of Dr. Leire&rsquo;s salary, while Dr. Leire pays a contribution of 5% of his salary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 85; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">DanDrit
Denmark may terminate Dr. Leire&rsquo;s employment with 12 months&rsquo; notice to the end of a month. If DanDrit Denmark
terminates Dr. Leire&rsquo;s employment, he shall be entitled to be released from his duty to work (in Danish
&ldquo;fritstillet&rdquo;) during the notice period. Dr. Leire may terminate the employment at 6 months&rsquo; notice to the
end of a month. In case of material breach, the non-defaulting party can terminate the Employment Agreement without notice
and can claim damages in accordance with the general Danish law of damages. If Dr. Leire suspends payments, or insolvency
proceedings are commenced against his estate, DanDrit Denmark can terminate the employment without notice. The employment
shall cease without notice to the end of the month in which Dr. Leire attains the age of 70. The Employment Agreement
contains non-competition and non-solicitation clauses.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Wolfe
CFO Service Agreement</I></B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effective
January 1, 2014, DanDrit Denmark entered into a CFO Service Agreement with Robert Wolfe to serve as its Chief Financial Officer
and Chief Financial Officer of DanDrit USA following the closing of the Share Exchange. Pursuant to the terms and conditions of
the CFO Service Agreement, Mr. Wolfe will be employed by DanDrit Denmark for an indefinite term unless earlier terminated pursuant
to the terms therein. The CFO Service Agreement provides that Mr. Wolfe will receive a salary of $78,000 gross per year, to be
paid monthly on the last day of each month and subject to annual review and increases by our Board of Directors, as it deems appropriate
and a one-time sign on fee of $6,000.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to his salary, Mr. Wolfe will be entitled to receive reimbursement of all reasonable costs relating to his work for the
Company, including travel, accommodation and meal expenses incurred in connection with work outside the agreed premises, which
are to be paid by the Company according to vouchers submitted.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">DanDrit
Denmark may terminate the employment with three months&rsquo; notice to the end of a month during the first six months of the
term of the CFO Service Agreement. Thereafter six months&rsquo; notice is required for a termination. Mr. Wolfe may terminate
the employment at three months&rsquo; notice to the end of a month. In case of material breach, the non-defaulting party can terminate
the CFO Service Agreement without notice and can claim damages in accordance with the general Danish law of damages. If Mr. Wolfe
suspends payments, or insolvency proceedings are commenced against his estate, DanDrit Denmark can terminate the employment without
notice. The employment shall cease without notice to the end of the month in which Mr. Wolfe attains the age of 70. The CFO Service
Agreement contains a non-competition clause.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
March 13, 2015, the Company, DanDrit Denmark and Mr. Wolfe entered into an Agreement pursuant to which Mr. Wolfe ceased to be
Chief Financial Officer of DanDrit Denmark effective as of the date on which a replacement Chief Financial Officer is
engaged. It is currently anticipated that Mr. Wolfe will continue to serve as the Chief Financial Officer of the Company
through a transition period that will end following the date that the Company files its Annual Report on Form 10-K for the
year ended December 31, 2014. (See Note 14 to our financial statements &ndash; Subsequent Event).</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
foregoing description of the terms and conditions of the employment agreements provides only a brief summary and
are qualified in their entirety by reference to the full text of the employment agreements, which are filed as exhibits to
this report.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Outstanding
Equity Awards as of December 31, 2014</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2014, there were no outstanding equity awards to our named executive officers.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Board
Compensation</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
the fiscal year ended December 31, 2014, we did not compensate our directors, or issue any equity awards to our directors, for
their services other than to reimburse them for out-of-pocket expenses incurred in connection with their attendance at meetings
of the Board of Directors. In order to attract and retain qualified independent directors, we may in the future adopt a compensation
plan for non-employee directors that includes cash as well as equity-based compensation.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2014, Jaro Holding ApS was paid 200,000 DKK ($32,502 calculated on an as-converted basis from Danish
Krone (DKK) to U.S. dollars ($) based on the currency exchange rate of $1.00 = DKK 6.1534, as of December 31, 2014) for consulting.
Jacob Rosenberg, a director of the Company, is beneficial owner of Jaro Holding ApS.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 86; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_015"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">The
following table sets forth, as of March 18, 2015, certain information regarding the beneficial ownership of the shares in DanDrit
USA, of (i) our executive officers, (ii) our directors and (iii) each person known to us who is known to be the beneficial owner
of more than 5% of the shares in DanDrit USA. In accordance with the rules of the SEC, &ldquo;beneficial ownership&rdquo; includes
voting or investment power with respect to securities. To our knowledge, except as indicated in the footnotes to this table and
pursuant to applicable community property laws, the persons named in the table have sole voting and investment power with respect
to all shares of common stock beneficially owned by them. Unless indicated otherwise, the address for the beneficial holders is&nbsp;c/o
DanDrit Biotech USA, Inc., P.O. Box 189, Randolph, VT 05060.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beneficial
ownership of the common stock is determined in accordance with the rules of the Securities and Exchange Commission and includes
any shares of common stock over which a person exercises sole or shared voting or investment power, or of which a person has a
right to acquire ownership at any time within 60 days of March 18, 2015. Except as otherwise indicated, we believe that the persons
named in this table have sole voting and investment power with respect to all shares of common stock held by them. Applicable
percentage ownership in the following table is based on 9,533,290 shares of common stock outstanding as of March 18, 2015 plus,
for each individual, any securities that individual has the right to acquire within 60 days of March 18, 2015.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dandrit
    Biotech USA Inc.</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Name
    of Beneficial Owner</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">Number
    of Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">%<BR>
    Ownership</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Directors/Officers:</U></FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Eric
    Jean Marie Leire(1)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,615</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.09</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Robert
    E. Wolfe</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">NENielsen(2)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr.
    Jacob Rosenberg(3)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">31,476</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Aldo
    Petersen</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Directors/Officers
    Total:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">40,091</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.42</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-decoration: underline"><FONT STYLE="font-family: Times New Roman, Times, Serif">5%
    Shareholders:</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Bele
    Invest ApS(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">486,677</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">DKTI A/S(7)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">555,869</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.83</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Media-Invest
    Danmark A/S(5)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">793,923</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.33</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">NLBDIT
    2010 Services, LLC(8)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">600,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.29</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">PasecoApS(9)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">483,600</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.07</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Northern
    Biotech Fund SARL(9)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">369,300</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.87</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Roas
    Holding ApS(6)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">55,078</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.58</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sune
    Olsen Holding ApS(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">777,588</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.16</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sune
    Olsen(4)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">379,912</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.99</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: italic bold 10pt Times New Roman, Times, Serif; text-decoration: underline; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">5%
    Shareholders Total:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,501,947</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47.22</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-decoration: underline; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total:</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,542,038</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif">47.64</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%; width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%; width: 95%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    holder has an address of Hambros Alle 12, 2900 Hellerup, Denmark.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(2)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The holder has an
    address of Lett Law Firm, Raadhuspladsen 4, DK-1550 Copenhagen, Denmark.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares are owned
    by Jaro Holding ApS, a Danish entity with an address of C.F. Richs Vej 44, 2000 Frederiksberg Denmark. The voting and disposition
    of the shares owned by the company are controlled by Dr. Rosenberg.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares are owned
    by Sune Olsen Holding ApS, Biotech Invest ApS and Sardinian Solar Park ApS, all Danish entities with an address of Jagtvej
    169 B 4, 2100 Copenhagen, Denmark. The voting and disposition of the shares owned by the companies are controlled by Mr. Olsen.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares are owned
    by Media-Invest DanmarkApS, a Danish entity with an address of Ostergade 61 4, 1100 Copenhagen, Denmark. The voting and disposition
    of the shares owned by Media-Invest are controlled by Mr. Thomas Ulletved Rasmussen.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 87; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(6)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Shares
    are owned by Bele Invest ApS, a Danish entity and Roas Holding ApS, a Danish entity both with an address of Vermehrensvej
    7, 2930 Klampenborg Denmark. The voting and disposition of the shares owned by the Bele Invest ApS and Roas Holding ApS are
    controlled by Mrs. Dina Rosenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(7)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">DKTI A/S is a Danish
    public limited liability company with an address of Frederiksgade 21 1, 1265 Copenhagen, Denmark. DKTI was, until September
    19, 2013, listed at the stock exchange OMX Nasdaq Copenhagen. DKTI has 189 shareholders. Dr. Eric Leire as CEO of DKTI A/S
    has voting and dispositive power over the shares owned by DKTI A/S.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(8)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NLBDIT 2010 Services,
    LLC has an address of&nbsp;c/o Sunrise Securities Corp., 600 Lexington Avenue, 23rd&nbsp;Floor, New York, NY 10022. The voting
    and disposition of the shares owned by NLBDIT are controlled by Nathan Low, principal of the Placement Agent.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(9)</FONT></TD>
    <TD STYLE="text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">PasecoApS is a Danish
    entity which has an address of Naesset 26, Munkebo 5330 Denmark. Northern Biotech Fund Sarl is a Luxembourg entity and has
    an address of C/O Banque Havilland SA, 35A Avenue JF Kennedy, Luxembourg.&nbsp;&nbsp;The voting and disposition of the shares
    owned by Pasecoand Northern Biotech are controlled by Ole &nbsp;Abildgaard</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
know of no arrangements, including pledges, by or among any of the foregoing persons, the operation of which could result in a
change of control of DanDrit USA.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_016"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
13.&nbsp;Certain Relationships and Related Transactions and Director Independence</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Described
below are transactions or series of transactions that occurred from January 1, 2013 through the date of this report (the &ldquo;Reporting
Period&rdquo;) between us and our executive officers, directors or the beneficial owners of 5% or more of our common stock, and
certain persons affiliated with or related to these persons, including family members, in which they had or will have a direct
or indirect material interest in an amount that exceeds the lesser of $120,000 or 1% of the average of our total assets as of
year-end for the last two completed fiscal years, other than compensation arrangements that are otherwise required to be described
under &ldquo;Executive Compensation.&rdquo;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white">On
January 7 2015, professional fees of $317,613 were paid on behalf of the Company to Lett Advokat for services billed during the
Reporting Period. The chairman of the board of the Company is an employee of Lett Advokat.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the Reporting Period, professional fees of$125,765were paid on behalf of the Company by Sunrise Financial Group Inc. (&ldquo;<I>SFG</I>&rdquo;)
to Troutman Sanders LLP. The President of SFG was the Company&rsquo;s former President and sole stockholder.&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company engaged Samir Masri CPA Firm P.C. to provide accounting services to the Company. Samir Masri, the Company&rsquo;s former
Chief Executive Officer, Chief Financial Officer, President, Secretary and director, is the founder and President of Samir Masri
CPA Firm P.C. The Company agreed to pay Samir Masri CPA Firm P.C. for services rendered in connection with the preparation of
the financial statements required to be filed in the Company&rsquo;s registration statement on Form 10 and subsequent periodic
reports in an aggregate amount equal to $10,000 per fiscal year until the date that the Company consummates a merger or similar
transaction with an operating business. The engagement was terminated upon closing of the Share Exchange</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 12, 2014, in connection with the closing of the Share Exchange, the Company and NLBDIT 2010 Services, LLC (&ldquo;NLBDIT&rdquo;)
entered into a Share Cancellation Agreement pursuant to which NLBDIT agreed to the cancellation of an aggregate of 4,400,000 issued
and outstanding shares of common stock of the Company owned by NLBDIT prior to the Share Exchange, effective upon the closing
of the Share Exchange.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">During the
years ended December 31, 2013, 2012 and 2011 Sune Olsen Holding loaned DanDrit Denmark DKK 1,267,724 ($232,841), DKK
338,719 ($59,854) and DKK 143,750 ($25,019), respectively. The Company added the accrued interest at 6% and the
Company recorded interest expense of DKK 86,047 ($15,804), DKK 20,469 ($3,617) and DKK 2,689 ($468) during the years end
December 31, 2013, 2012 and 2011, respectively.&nbsp;&nbsp;The loans are payable upon three months written notice of Sune
Olsen Holding. On December 16, 2013, the notes with related accrued interest were converted into 35,106 shares of
DanDrit Denmark which were exchanged for 52,618 shares of common stock of the Company upon the closing of the Share
Exchange.</P>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
April 14, 2013, Sune Olsen Holding paid debt to Symbion on behalf of DanDrit Denmark (the &ldquo;Symbion Debt&rdquo;) of DKK 4,375,932
in payables equivalent to approximately $773,000. The Symbion Debt accrued interest at 5% from April 12, 2013 until repaid and
is payable on demand. DanDrit Denmark recorded interest expense of DKK 139,670 ($25,349) during the year ended December 31, 2013
for the Symbion Debt. On December 16, 2013, the Symbion Debt and accrued interest was converted into 86,204 shares of common stock
of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 88; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
June 20, 1013, Sune Olsen Holding paid debt to Lett Law Firm on behalf of DanDrit Denmark (the &ldquo;Lett Debt&rdquo;) of DKK
1,500,000 in payables equivalent to $265,000. The Lett Debt accrued interest at 5% per year and is payable on demand. DanDrit
Denmark recorded interest expense of DKK 20,959 ($3,804) during the year ended December 31, 2013 for the Lett Debt. On December
16, 2013, the Lett Debt and accrued interest was converted into 29,036 shares of common stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
July 26, 2013 and August 15, 2013 Sune Olsen Holding loaned DanDrit Denmark DKK 1,000,000, ($177,239) and DKK 750,000 ($133,343)
(the &ldquo;Summer 2013 Loans&rdquo; and together with the 2012 Loans and the Spring 2013 Loans, collectively, the &ldquo;Sune
Olsen Debt&rdquo;). The Summer 2013 Loans accrued interest at 5%, or approximately DKK 15,575 ($2,827) during the year ended December
31, 2013, to be repaid in full by the end of the calendar year 2014. The Summer 2013 Loans may be terminated by Sune Olsen Holding
with three months&rsquo; prior written notice. On December 16, 2013, the Summer Loans and accrued interest was converted into
33,705 shares of common stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the year ended December 31, 2013 the total debt due to Sune Olsen Holding under the Sune Olsen Debt, including accrued interest,
was DKK 9,641,065 (approximately USD 1,770,758). On the December 16, 2013, the full amount of the Sune Olsen Debt was converted
into 275,863 shares of common stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subsequent
to the conversion of the Sune Olsen Debt, DanDrit Denmark received a loan facility (the &ldquo;Subsequent Sune Olsen Holding Loan&rdquo;)
from Sune Olsen Holding to ensure financing until new equity is brought in. Under the Sune Olsen Holding Loan DanDrit Denmark
has received the following amounts: on November 11, DKK 1,500,000 ($276,651), on November 20, 2013 DKK 405,000 ($74,696), on December
2, 2013 DKK 900,000 ($165,990), in total DKK 2,805,000 ($517,337). The Subsequent Sune Olsen Holding Loan is to be repaid the
latest of 14 days after completion of the contemplated public offering of the Company or February 1, 2015.On November 26, 2014,
the Company repaid the Subsequent Sune Olsen Holding Loan and interest thereon.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">DanDrit
Denmark received an additional loan (the &ldquo;New Sune Olsen Loan&rdquo;) from Sune Olsen, managing member of Sune Olsen Holding,
to ensure financing until new equity is brought in. The New Sune Olsen Loan in the amount of DKK 1,000,000 ($184,434) was issued
on December 20, 2013. The New Sune Olsen Loan was to be repaid May 1, 2014 and carried an interest of 5% per year, or approximately
DKK18,966 ($3,498) as of March 31, 2014. During March 2014, DanDrit Denmark extended the maturity date of the New Sune Olsen Loan
from May 1, 2014 to the latest of 14 days after the completion of the contemplated stock offering of the Company or February 1,
2015.On November 26, 2014 the Company repaid the New Sune Olsen Loan and interest thereon.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
2012, DanDrit Denmark entered into a loan facility (&ldquo;DKTI Loan 1&rdquo;) of DKK 5,000,000 (approximately $880,000)
accruing interest at 6% per annum. DKTI Loan 1 was secured by of DanDrit Denmark&rsquo;s intellectual property rights,
including its patents and its patent applications. During the year ended December 31, 2012, DanDrit Denmark borrowed an
additional DKK 4,431,862 ($783,139) plus DKK 71,563 ($12,646) in interest (&ldquo;DKTI Loan 2&rdquo;). During the year ended
December 31, 2013, DanDrit Denmark borrowed an additional DKK 310,000 (approximately $55,000) plus DKK 230,377 (approximately
$42,000) in interest (&ldquo;DKTI Loan 3&rdquo; and together with DKTI Loan 1 and DKTI Loan 2, the &ldquo;DKTI Loans&rdquo;).
On December 16, 2013, the DKTI Loans, including accrued interest, were converted into 144,321 shares of common stock of the
Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of October 31, 2013, DanDrit Denmark had a $1,500,000 convertible bond issued to DKTI A/S. The principal amount including accrued
interest was $1,672,455 as of October 31, 2013. On December 16, 2013 the convertible bond, including accrued interest, was converted
into 261,665 shares of common stock of the Company.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 15, 2014 and March 18, 2014, DanDrit Denmark received loans (the &ldquo;2014 Loans&rdquo;) of DKK 2,500,000 and 2,300,000,
respectively, equivalent to approximately $461,877 and $424,927, respectively (based on the currency exchange rate of $1.00 =
DKK 5.4283). The 2014 Loans, evidenced by that certain Loan Agreement by and between DanDrit Denmark and PasecoApS, a shareholder
of DanDrit USA (&ldquo;Paseco&rdquo;) dated March 21, 2014, carry an interest of 5% per year and are payable on February 1, 2015.
On April 29, 2014, DanDrit Denmark and Paseco entered into an amendment whereby the terms of the 2014 Loans could be extended
at the Company&rsquo;s option for an additional year with an increase in the interest rate to 7.00%.As of October 17, 2014, the
outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange rate of October 17,
2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">DanDrit
Denmark received a loan commitment on May 2, 2014, for 2,000,000 DKK ($368,868) from Paseco, payable by February 1, 2015. The
Company has an option to extend the loan for one year by giving notice to Paseco by December 31, 2014, whereby the interest rate
would increase to 7.00% per annum.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Lease
Agreements</U></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8,
2013, the Company entered into an operating lease agreement for lab space with Symbion A/S, a shareholder of the Company. The lease
calls for monthly payments of 6,000 DKK (approximately$1,000) and expires on March 31, 2016 but may be terminated by the Company
with three month notice.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 27,
2014, the Company entered into an operating sublease agreement for office space with Paseco. The lease calls for months
payments of DKK 10,000 increasing to DKK 20,000 as of July 1, 2014 (approximately $1,842 and 3,684, respectively). The lease
can be terminated by either the Company or the landlord by giving three month notice. The Company gave a termination notice
on February 28, 2015,therefore the lease will terminate May 31, 2015. The Company does not anticipate renting additional
office space in the near future.</P>

<P STYLE="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>LETT
Advokatpartnerselskab</U></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2014 a total of $354,646 was accrued and due and payable to the Lett Law Firm for legal services provided for
DanDrit Denmark.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of December 31, 2014, the outstanding balance of $38,235 for professional fees paid by a shareholder and amounts advanced to the
Parent are reported as loan payable - related party. The $38,235 loans payable were acquired in the reverse acquisition. The amounts
are unsecured, non-interest bearing and have no stipulated repayment terms.&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Except
as otherwise indicated herein, there have been no other related party transactions, or any other transactions or relationships
required to be disclosed pursuant to Item 404 and Item 407(a) of Regulation S-K.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Approval
of Related Party Transactions</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company has not adopted written policies and procedures for the review and approval of any transaction required to be reported
under Item 404(a) of Regulation S-K. In approving these transactions, the Company follows the guidance of section 144 of the Delaware
General Corporation Law.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_017"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
14. Principal Accounting Fees and Services</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
following information sets forth fees billed to us by Raich End eMalter&amp; Co. LLP (&ldquo;Raich&rdquo;) during the fiscal
years ended December 31, 2014 and 2013 and Gregory &amp; Associates, LLC (&ldquo;Gregory&rdquo;) during the fiscal years
ended December 31, 2014 and 2013 for: (i) services rendered for the audit of our annual financial statements and the review
of our quarterly financial statements, (ii) services that were reasonably related to the performance of the audit or review
of our financial statements and that are not reported as audit fees, (iii) services rendered in connection with tax
compliance, tax advice and tax planning, and (iv) all other fees for services rendered.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Audit
Fees</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
aggregate fees billed by Gregory for such professional services were $67,835 for the year ended December 31, 2014 and
$48,927 for the year ended December 31, 2013. The aggregate fees billed by Raich for professional services rendered for the
audit of our annual financial statements and review of financial statements included in our quarterly reports on Form 10-Q or
services that are normally provided in connection with statutory and regulatory filings were $0 for the year ended December
31, 2014 and $0 for year ended December 31, 2013.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Audit-Related
Fees</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">There
were no fees billed by Raich or Gregory for assurance and related services that are reasonably related to the performance of the
audit or review of the Company&rsquo;s financial statements for the years ended December 31, 2014 and December 31, 2013.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 90; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Tax
Fees</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
aggregate fees billed by Gregory for such professional services were $0 for the year ended December 31, 2014 and $0 for the year
ended December 31, 2013. The aggregate fees billed by Raich for professional services for tax compliance, tax advice, and tax
planning were $0 for the years ended December 31, 2014 and December 31, 2013.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>All
Other Fees</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The aggregate fees
billed by Gregory for such professional services, including reading, consents and comfort letters associated with the Company&rsquo;s
S1 offering, were $22,380 for the year ended December 31, 2014 and $0 for the years ended December 31, 2013. The aggregate fees
billed by Raich for other products and services for the years ended December 31, 2014 and December 31, 2013 were $0 and $6,791
respectively.</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Audit
Committee&rsquo;s Pre-Approval Process</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Company&rsquo;s Board of Directors which acts as the audit committee approves all audit services.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 91; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><A NAME="a_025"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>PART
IV</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><A NAME="a_018"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Item
15.&#9;Exhibits, Financial Statement Schedules</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 10%; border-bottom: black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exhibit</FONT></P>
        <P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">No.</FONT></P></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 89%; border-bottom: black 1.5pt solid; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Description</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Placement
    Agency Agreement, dated August 12, 2014, by and among the Company and Sunrise Securities Corp. (1)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share
    Exchange Agreement dated February 12, 2014. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Share
    Cancellation Agreement dated February 12, 2014. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
    of Incorporation. (2)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Bylaws.
    (2)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Articles
    of Association of DanDrit Denmark, as amended, dated February 26, 2004. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Certificate
    of Ownership and Merger, dated February 12, 2014. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Form
    of Common Stock Certificate. (5)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Intellectual
    Property Assignment by and between DanDrit Denmark and Alexei Kirkin dated June 5, 2002. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Collaboration
    Agreement by and between DanDrit Denmark and National Cancer Centre of Singapore Pte Ltd dated November 11, 2008. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Master
    Services Agreement by and between DanDrit Denmark and Aptiv Solutions (UK) Ltd dated October 11, 2011. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Employment
    Agreement by and between DanDrit Denmark and Dr. Eric Leire dated February 5, 2012.(4)+</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Box
    Packing and Moving Agreement by and between DanDrit Denmark and Bryde&amp;Sonner A/S dated May 23, 2012. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.6</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Debt
    Instrument by and between DanDrit Denmark and Sune Olsen Holding ApS dated March 31, 2013. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.7</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lease
    Agreement by and between Symbion A/S and DanDrit Denmark dated July 8, 2013. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.8</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Lease
    Agreement by and between OrdnungApS and DanDrit Denmark. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.9</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Debt
    Instrument by and between DanDrit Denmark and Sune Olsen Holding ApS dated January 17, 2014. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10.10</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Early
    Access Agreement by and between DanDrit Denmark and Impatients, N.V. dated December 20, 2013. (4)</FONT></TD></TR>

</TABLE>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 92; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%; width: 10%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.11</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%; width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%; width: 89%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Consultancy
    Agreement by and between DanDrit Denmark and Dina Rosenberg dated February 4, 2014. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.12</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Consulting
    Agreement by and between DanDrit Denmark and PasecoApS dated February 11, 2014. (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.13</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">DanDrit
    Biotech USA, Inc. 2014 Equity Incentive Plan (4)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.14</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Loan
    Agreement by and between DanDrit Denmark and PasecoApS dated April 29, 2014. (6)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.15</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Letter
of Support of PasecoApS related to committed 2M DKK in additional financing, dated May 2, 2014. (6)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.16</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Form
    of Securities Purchase dated as of December 31, 2014. (7)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.17</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">CFO
    Service Agreement by and between DanDrit Denmark and Mr. Robert Wolfe dated February 10, 2014.(8)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.18</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Loan
    Agreement by and between DanDrit Denmark and PasecoApS dated March 21, 2014.(9)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">10.19</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Loan
Agreement by and between DanDrit Denmark and PasecoApS dated March 27, 2014.(9)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">14.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Code
    of Ethics. (3)</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">31.1*</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Certification
    of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">31.2*</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Certification
    of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">32.1**</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Certification
    of Principal Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18
    U.S.C. Section 1350.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">32.2**</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Certification
    of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C.
    Section 1350.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">101.INS</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">XBRL
    Instance Document*</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">101.SCH</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema*</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">101.CAL</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase*</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">101.DEF</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase*</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">101.LAB</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase*</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">101.PRE</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify; line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Presentation Linkbase*</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">+</FONT></TD>
    <TD STYLE="width: 93%; line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Agreement
    with management. &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">*</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    herewith. &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">**</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Furnished
    herewith. &nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1)<BR> </FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Filed
    as an exhibit to the Company&rsquo;s Form 8-K filed with the SEC on August 12, 2014 and incorporated herein by reference.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%">(2)</TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify">
Filed as an exhibit to the Company&rsquo;s Form 10 filed with the SEC on August 12, 2011 and incorporated herein by reference.</TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">(3)</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    as an exhibit to the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on July 17, 2012 and incorporated herein
    by reference.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">(4)</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    as an exhibit to the Company&rsquo;s registration statement on Form S-1 filed with the SEC on February 14, 2014. &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">(5)</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    as an exhibit to the Company's Current Report on Form 8-K, as filed with the SEC on May 16, 2014, and incorporated herein
    by this reference. &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">(6)</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    as an exhibit to the Company's Quarterly Report on Form 10-Q, as filed with the SEC on May 14, 2014, and incorporated herein
    by this reference. &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">(7)</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    as an exhibit to the Company's Current Report on Form 8-K, as filed with the SEC on December 31, 2014, and incorporated herein
    by this reference. &nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">(8)</FONT></TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify"><FONT STYLE="font: 10pt/115% Times New Roman, Times, Serif">Filed
    as an exhibit to the Company&rsquo;s Form S-1/A filed with the SEC on June 23, 2014 and incorporated herein by reference.&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: transparent">
    <TD STYLE="line-height: 115%">(9)</TD>
    <TD STYLE="line-height: 115%; padding: 0; text-indent: 0; text-align: justify">Filed as an exhibit to the Company&rsquo;s Form S-1/A filed with the SEC on March 31, 2014 and incorporated
herein by reference.</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 93; Value: 60 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a_019"></A><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date: March 31, 2015&#9;</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>DANDRIT BIOTECH USA, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 62%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 3%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 35%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Eric Leire&#9;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Eric Leire</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Robert Wolfe&#9;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert Wolfe</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 30%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Signature</B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Title</B></FONT></TD>
    <TD STYLE="width: 1%; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"></TD>
    <TD STYLE="width: 28%; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Dr.
    Eric Leire</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive
    Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2015</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr.
    Eric Leire</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Executive Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Robert
    E. Wolfe</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Financial
    Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2015</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Robert
    E. Wolfe</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(Principal Accounting
    Officer)</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;NE
    Nielsen</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chairman of the
    Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2015</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">NE
    Nielsen</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Dr.
    Jacob Rosenberg</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2015</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-top: black 1.5pt solid; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dr.
    Jacob Rosenberg</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center; line-height: 115%">&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/&nbsp;Aldo
    Michael Noes Petersen</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March 31, 2015</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Aldo
    Michael Noes Petersen</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; line-height: 115%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">72</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10k2014ex31i_dandritbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Eric Leire, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top">1.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">I have reviewed this Annual Report on Form 10-K of DanDrit Biotech USA, Inc.;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">4.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify">a)</TD>
    <TD STYLE="vertical-align: top; width: 93%; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">c)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">d)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">5.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">Date: March 31, 2015</TD>
    <TD STYLE="width: 60%; padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; text-indent: 0">/s/ Eric Leire</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Eric Leire</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><P STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt">Chief Executive Officer <BR>
(Principal Executive Officer)</P>



</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10k2014ex31ii_dandritbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">I, Robert Wolfe, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR>
    <TD STYLE="vertical-align: top">1.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">I have reviewed this Annual Report on Form 10-K of DanDrit Biotech USA, Inc.;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">2.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">3.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">4.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15-d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the registrant and have:</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 3%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 3%; text-align: justify">a)</TD>
    <TD STYLE="vertical-align: top; width: 93%; text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">c)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">d)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">5.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">a)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">b)</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">Date: March 31, 2015</TD>
    <TD STYLE="width: 60%; padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; text-indent: 0">/s/ Robert Wolfe</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Robert Wolfe</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10k2014ex32i_dandritbio.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">CERTIFICATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with the Annual Report of Dandrit
Biotech USA, Inc. (the &ldquo;Company&rdquo;) on Form 10-K for the year ending December 31, 2014 as filed with the Securities and
Exchange Commission (the &ldquo;Report&rdquo;), we, Eric Leire, Chief Executive Officer (Principal Executive Officer) and Robert
Wolfe, Chief Financial Officer (Principal Financial and Accounting Officer) of the Company, hereby certify as of the date hereof,
solely for purposes of Title 18, Chapter 63, Section&nbsp;1350 of the United States Code, that to the best of our knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">(1)</TD><TD STYLE="text-align: justify; width: 95%">The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of
1934, and</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 5%">(2)</TD><TD STYLE="text-align: justify; width: 95%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company at the dates and for the periods indicated.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 40%">Date: March 31, 2015</TD>
    <TD STYLE="width: 60%; padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; text-indent: 0">/s/ Eric Leire</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Eric Leire</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Chief Executive Officer<BR>
(Principal Executive Officer)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; border-bottom: Black 1.5pt solid; text-indent: 0">/s/ Robert Wolfe</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Robert Wolfe</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">Chief Financial Officer<BR>
(Principal Financial and Accounting Officer)</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    </TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>5
<FILENAME>pmhs-20141231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 7.2.0.0 [03/31/2015 08:23:24 AM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:pmhs="http://www.0001527728.com/20141231"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:net="http://www.xbrl.org/2009/role/net"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2012-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:us-types="http://fasb.org/us-types/2014-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="pmhs-20141231.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_As_Of_01_Dec_2011T00_00_00_TO_01_Dec_2011T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-01
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2011T00_00_00_TO_31_Dec_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:DktiAsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2012-01-01
</xbrli:startDate>
<xbrli:endDate>
2012-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:DktiAsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2012-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_26_Feb_2013T00_00_00_TO_01_Mar_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFiverMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-02-26
</xbrli:startDate>
<xbrli:endDate>
2013-03-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_14_Apr_2013T00_00_00_TO_14_Apr_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-04-14
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_11_Apr_2013T00_00_00_TO_14_Apr_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-04-11
</xbrli:startDate>
<xbrli:endDate>
2013-04-14
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-06-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_15_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-06-15
</xbrli:startDate>
<xbrli:endDate>
2013-06-20
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_26_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-07-26
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_21_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-21
</xbrli:startDate>
<xbrli:endDate>
2013-07-26
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Aug_2013T00_00_00_TO_15_Aug_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-08-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-07-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_11_Nov_2013T00_00_00_TO_11_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-11
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Nov_2013T00_00_00_TO_20_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-11-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_02_Dec_2013T00_00_00_TO_02_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-02
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_16_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-16
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:DktiAsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFiverMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSixMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanSevenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_ShortTermDebtTypeAxis_AccruedInterestMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">pmhs:AccruedInterestMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_ShortTermDebtTypeAxis_DerivativeLiabilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">pmhs:DerivativeLiabilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:DktiAsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-12-13
</xbrli:startDate>
<xbrli:endDate>
2013-12-16
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_20_Dec_2013T00_00_00_TO_20_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-20
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:DktiAsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFiverMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-01-01
</xbrli:startDate>
<xbrli:endDate>
2013-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanFourMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NotePayableMlGroupMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NotePayableMlGroupMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenHoldingApsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:FivePercentNotePayableSuneOlsenHoldingApsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:FivePercentNotePayableSuneOlsenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NonInterestBearingLoanPayableSunriseFinancialGroupIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-02-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_12_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_ParentCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">us-gaap:ParentCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-02-12
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-02-01
</xbrli:startDate>
<xbrli:endDate>
2014-02-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_15_Feb_2014T00_00_00_TO_15_Feb_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:PasecoApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-02-15
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_18_Mar_2014T00_00_00_TO_18_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:PasecoApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-18
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2014T00_00_00_TO_27_Mar_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedOfficeSpaceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LeasedOfficeSpaceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-03-01
</xbrli:startDate>
<xbrli:endDate>
2014-03-27
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_LoanThreeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:PasecoApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanThreeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2014T00_00_00_TO_01_Jul_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedOfficeSpaceMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LeasedOfficeSpaceMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-06-01
</xbrli:startDate>
<xbrli:endDate>
2014-07-01
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Aug_2014T00_00_00_TO_12_Aug_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-08-01
</xbrli:startDate>
<xbrli:endDate>
2014-08-12
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_04_Sep_2014T00_00_00_TO_04_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-04
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_02_Sep_2014T00_00_00_TO_04_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-02
</xbrli:startDate>
<xbrli:endDate>
2014-09-04
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_24_Sep_2014T00_00_00_TO_24_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-24
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Sep_2014T00_00_00_TO_24_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-09-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-24
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_02_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanTenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-02
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-10-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-10-01
</xbrli:startDate>
<xbrli:endDate>
2014-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_13_Nov_2014T00_00_00_TO_13_Nov_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-11-13
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Nov_2013T00_00_00_TO_13_Nov_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2013-11-01
</xbrli:startDate>
<xbrli:endDate>
2014-11-13
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:PasecoApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanTenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedLaboratorySpaceMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LeasedLaboratorySpaceMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:OtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SuneOlsenHoldingApsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NotePayableMlGroupMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NotePayableMlGroupMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenHoldingApsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:FivePercentNotePayableSuneOlsenHoldingApsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:FivePercentNotePayableSuneOlsenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">pmhs:LabEquipmentAndInstrumentsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NonInterestBearingLoanPayableSunriseFinancialGroupIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">pmhs:NlbditTwoZeroOneZeroEnterprisesLlcMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">pmhs:LoanTenMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_DanishTaxMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">pmhs:DanishTaxMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_13_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-13
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-03-01
</xbrli:startDate>
<xbrli:endDate>
2015-03-13
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Mar_2015T00_00_00_TO_30_Mar_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001527728</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-03-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw7;c444c555cT{h>=GF7<;=I1FHH<18=951EIFJ15;64<;884:F9 -->
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:unit id='DKK'><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">DanDrit Biotech USA, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">0001527728</dei:EntityCentralIndexKey>
<dei:AmendmentFlag contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">false</dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:DocumentType contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">10-K</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">2014-12-31</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalYearFocus contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">2014</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
<dei:EntityWellKnownSeasonedIssuer contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityVoluntaryFilers contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">No</dei:EntityVoluntaryFilers>
<dei:EntityCurrentReportingStatus contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityFilerCategory contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityPublicFloat contextRef="Context_As_Of_30_Jun_2014T00_00_00_TO_30_Jun_2014T00_00_00" unitRef="USD" decimals="0">24956260</dei:EntityPublicFloat>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_30_Mar_2015T00_00_00_TO_30_Mar_2015T00_00_00" unitRef="shares" decimals="INF">9533290</dei:EntityCommonStockSharesOutstanding>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">18794</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3008831</us-gaap:Cash>
<us-gaap:EscrowDeposit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">77468</us-gaap:EscrowDeposit>
<us-gaap:EscrowDeposit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2029502</us-gaap:EscrowDeposit>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">25456</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">8016</us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">19774</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">141492</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5046349</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">231615</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">186414</us-gaap:FiniteLivedIntangibleAssetsNet>
<us-gaap:DeferredOfferingCosts contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">67000</us-gaap:DeferredOfferingCosts>
<us-gaap:DeferredOfferingCosts contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">10360</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">7146</us-gaap:DepositsAssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">308975</us-gaap:AssetsNoncurrent>
<us-gaap:AssetsNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">193560</us-gaap:AssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">450467</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5239909</us-gaap:Assets>
<us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">728001</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
<us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">99951</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
<pmhs:StockOfferingEscrow contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<pmhs:StockOfferingEscrow contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">548501</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">711449</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">212438</us-gaap:AccountsPayableRelatedPartiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">858135</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">733826</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedIncomeTaxesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccruedIncomeTaxesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2134637</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1757664</us-gaap:LiabilitiesCurrent>
<us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermNotesPayable contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermNotesPayable contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2134637</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1757664</us-gaap:Liabilities>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">600</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">953</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">17867546</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">25098050</us-gaap:AdditionalPaidInCapital>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-31190</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">275249</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-19521126</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-21892007</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-17373765</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">12817122</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">532</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" decimals="0">188280</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-1684170</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-19521126</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17867546</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">600</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-31190</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3482245</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-21892007</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">25098050</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">953</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" decimals="0">275249</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">450467</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5239909</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_12_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">6000000</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">9533290</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="INF">6000000</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">9533290</us-gaap:CommonStockSharesOutstanding>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">32768</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:SalesRevenueGoodsNet>
<us-gaap:CostOfGoodsSold contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">109299</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">295661</us-gaap:CostOfGoodsSold>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-76531</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-295661</us-gaap:GrossProfit>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1233683</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1644918</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">38297</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">18981</us-gaap:DepreciationDepletionAndAmortization>
<pmhs:ConsultingExpenses contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">390437</pmhs:ConsultingExpenses>
<pmhs:ConsultingExpenses contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">469666</pmhs:ConsultingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1662417</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2133565</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-1738948</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2429226</us-gaap:OperatingIncomeLoss>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">652703</us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">84550</us-gaap:InterestExpense>
<pmhs:GainOnForgivenessOfDebt contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">49016</pmhs:GainOnForgivenessOfDebt>
<pmhs:GainOnForgivenessOfDebt contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">19541</us-gaap:ForeignCurrencyTransactionGainLossRealized>
<us-gaap:ForeignCurrencyTransactionGainLossRealized contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-40583</us-gaap:ForeignCurrencyTransactionGainLossRealized>
<us-gaap:DerivativeGainOnDerivative contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">175732</us-gaap:DerivativeGainOnDerivative>
<us-gaap:DerivativeGainOnDerivative contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:InterestIncomeOther contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5937</us-gaap:InterestIncomeOther>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-408413</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-119196</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-2147361</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2548422</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-177539</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-2147361</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-2147361</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2370883</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-2370883</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.40</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.32</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">5332721</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="0">7500142</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<pmhs:WeightedAverageBasicAndDilutedLossPerShare contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">-0.40</pmhs:WeightedAverageBasicAndDilutedLossPerShare>
<pmhs:WeightedAverageBasicAndDilutedLossPerShare contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.32</pmhs:WeightedAverageBasicAndDilutedLossPerShare>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">219470</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-219470</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">306439</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" decimals="0">306439</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-2366831</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2064444</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">5318151</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">6000000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_12_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_ParentCompanyMember" unitRef="shares" decimals="INF">8040000</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">9533290</us-gaap:SharesOutstanding>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_ShortTermDebtTypeAxis_ConvertibleDebtMember" unitRef="USD" decimals="0">1500000</pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_ShortTermDebtTypeAxis_AccruedInterestMember" unitRef="USD" decimals="0">179612</pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_ShortTermDebtTypeAxis_DerivativeLiabilityMember" unitRef="USD" decimals="0">673736</pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">2353322</pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">26</pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">261665</pmhs:StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_LegalEntityAxis_ParentCompanyMember" unitRef="shares" decimals="INF">174578</pmhs:StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">261665</pmhs:StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="USD" decimals="0">926386</pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">926372</pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">14</pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValue contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_11_Apr_2013T00_00_00_TO_14_Apr_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="shares" decimals="0">86204</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="shares" decimals="0">35106</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="shares" decimals="INF">96288</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">144321</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember" unitRef="shares" decimals="INF">25844</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="shares" decimals="INF">29036</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="shares" decimals="0">33705</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_LegalEntityAxis_ParentCompanyMember" unitRef="shares" decimals="INF">96288</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">144321</pmhs:CommonSharesIssuedInPaymentOfNotesPayable>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="USD" decimals="0">1770757</pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1770730</pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">28</pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableValueOne contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableOne contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">275863</pmhs:CommonSharesIssuedInPaymentOfNotesPayableOne>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableOne contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_LegalEntityAxis_ParentCompanyMember" unitRef="shares" decimals="INF">184051</pmhs:CommonSharesIssuedInPaymentOfNotesPayableOne>
<pmhs:CommonSharesIssuedInPaymentOfNotesPayableOne contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">275863</pmhs:CommonSharesIssuedInPaymentOfNotesPayableOne>
<pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-79436</pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue>
<pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">204</pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue>
<pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2040000</pmhs:ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">657985</pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">14</pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">145000</pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">500</pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="2">0.01</pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">100</pmhs:IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4359001</pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">89</pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">889690</pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">292494</pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">6</pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">58500</pmhs:IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne>
<pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1999960</pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue>
<pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">40</pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue>
<pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">400000</pmhs:IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares>
<pmhs:AccumulatedEarningsRounding contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">2</pmhs:AccumulatedEarningsRounding>
<pmhs:AccumulatedEarningsRounding contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<pmhs:AccumulatedEarningsRounding contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<pmhs:AccumulatedEarningsRounding contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_OtherComprehensiveIncomeMember" unitRef="USD" xsi:nil="true"/>
<pmhs:ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">9.00</pmhs:ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare>
<pmhs:NotesPayableRelatedPartyPerShare contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">6.42</pmhs:NotesPayableRelatedPartyPerShare>
<pmhs:NotesPayableRelatedPartyPerShareOne contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD_per_Share" decimals="2">6.42</pmhs:NotesPayableRelatedPartyPerShareOne>
<pmhs:ShareExchangeAgreementAcquisitionPercentage contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="pure" decimals="2">1.00</pmhs:ShareExchangeAgreementAcquisitionPercentage>
<pmhs:ShareExchangeAgreementAcquisitionPercentage contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="2">1.00</pmhs:ShareExchangeAgreementAcquisitionPercentage>
<pmhs:ShareExchangeAgreementSharesIssuedToParentCompany contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">6000000</pmhs:ShareExchangeAgreementSharesIssuedToParentCompany>
<pmhs:ShareExchangeAgreementSharesIssuedToParentCompany contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">6000000</pmhs:ShareExchangeAgreementSharesIssuedToParentCompany>
<pmhs:IssuanceOfCommonShares contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_24_Sep_2014T00_00_00" unitRef="shares" decimals="INF">100</pmhs:IssuanceOfCommonShares>
<pmhs:IssuanceOfCommonShares contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="shares" decimals="INF">889690</pmhs:IssuanceOfCommonShares>
<pmhs:IssuanceOfCommonShares contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_13_Nov_2014T00_00_00" unitRef="shares" decimals="INF">58500</pmhs:IssuanceOfCommonShares>
<pmhs:IssuanceOfCommonShares contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">4000</pmhs:IssuanceOfCommonShares>
<pmhs:IssuanceOfCommonSharesOne contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">141000</pmhs:IssuanceOfCommonSharesOne>
<pmhs:IssuanceOfCommonSharesValue contextRef="Context_Custom_02_Sep_2014T00_00_00_TO_04_Sep_2014T00_00_00" unitRef="USD" decimals="0">4000</pmhs:IssuanceOfCommonSharesValue>
<pmhs:IssuanceOfCommonSharesValue contextRef="Context_Custom_01_Sep_2014T00_00_00_TO_24_Sep_2014T00_00_00" unitRef="USD" decimals="0">500</pmhs:IssuanceOfCommonSharesValue>
<pmhs:IssuanceOfCommonSharesValueOne contextRef="Context_Custom_02_Sep_2014T00_00_00_TO_04_Sep_2014T00_00_00" unitRef="USD" decimals="0">141000</pmhs:IssuanceOfCommonSharesValueOne>
<pmhs:IssuanceOfPublicOfferingCost contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD" decimals="0">4358879</pmhs:IssuanceOfPublicOfferingCost>
<pmhs:IssuanceOfPublicOfferingCost contextRef="Context_Custom_01_Nov_2013T00_00_00_TO_13_Nov_2014T00_00_00" unitRef="USD" decimals="0">292500</pmhs:IssuanceOfPublicOfferingCost>
<pmhs:PublicOfferingValuePerShare contextRef="Context_As_Of_04_Sep_2014T00_00_00_TO_04_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">5.00</pmhs:PublicOfferingValuePerShare>
<pmhs:PublicOfferingValuePerShare contextRef="Context_As_Of_24_Sep_2014T00_00_00_TO_24_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">5.00</pmhs:PublicOfferingValuePerShare>
<pmhs:PublicOfferingValuePerShare contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD_per_Share" decimals="0">5</pmhs:PublicOfferingValuePerShare>
<pmhs:PublicOfferingValuePerShare contextRef="Context_As_Of_13_Nov_2014T00_00_00_TO_13_Nov_2014T00_00_00" unitRef="USD_per_Share" decimals="0">5</pmhs:PublicOfferingValuePerShare>
<pmhs:OfferingCostNet contextRef="Context_Custom_02_Sep_2014T00_00_00_TO_04_Sep_2014T00_00_00" unitRef="USD" decimals="0">67000</pmhs:OfferingCostNet>
<pmhs:OfferingCostNet contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00" unitRef="USD" decimals="0">89360</pmhs:OfferingCostNet>
<pmhs:IssuanceOfCommonSharesTwo contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">400000</pmhs:IssuanceOfCommonSharesTwo>
<pmhs:PrivatePlacementValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="0">5</pmhs:PrivatePlacementValuePerShare>
<pmhs:PrivatePlacementValue contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2000000</pmhs:PrivatePlacementValue>
<us-gaap:DepreciationAndAmortization contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">38297</us-gaap:DepreciationAndAmortization>
<us-gaap:DepreciationAndAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">45201</us-gaap:DepreciationAndAmortization>
<us-gaap:GainOrLossOnSaleOfStockInSubsidiary contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1</us-gaap:GainOrLossOnSaleOfStockInSubsidiary>
<us-gaap:GainOrLossOnSaleOfStockInSubsidiary contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:AccretionOfDiscount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">502465</us-gaap:AccretionOfDiscount>
<us-gaap:AccretionOfDiscount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:GainLossOnSaleOfDerivatives contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">175732</us-gaap:GainLossOnSaleOfDerivatives>
<us-gaap:GainLossOnSaleOfDerivatives contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-56346</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-17440</us-gaap:IncreaseDecreaseInAccountsReceivable>
<pmhs:IncreaseDecreaseInPrepaidExpenseAndDeposits contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-4183</pmhs:IncreaseDecreaseInPrepaidExpenseAndDeposits>
<pmhs:IncreaseDecreaseInPrepaidExpenseAndDeposits contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-22988</pmhs:IncreaseDecreaseInPrepaidExpenseAndDeposits>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-2674</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">162950</us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">212438</us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-406152</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-124309</us-gaap:IncreaseDecreaseInAccruedLiabilities>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">16732</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">336708</us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-2130628</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-2034175</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1</us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates>
<us-gaap:ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<pmhs:NetIncreaseDecreaseInCashHeldInEscrow contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-77468</pmhs:NetIncreaseDecreaseInCashHeldInEscrow>
<pmhs:NetIncreaseDecreaseInCashHeldInEscrow contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-1952034</pmhs:NetIncreaseDecreaseInCashHeldInEscrow>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">27548</us-gaap:PaymentsToAcquireIntangibleAssets>
<us-gaap:PaymentsToAcquireIntangibleAssets contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-105015</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-1952034</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2754662</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">814291</us-gaap:ProceedsFromNotesPayable>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">7377089</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">67000</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">89360</us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-218136</us-gaap:ProceedsFromRelatedPartyDebt>
<us-gaap:ProceedsFromRelatedPartyDebt contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-1432213</us-gaap:ProceedsFromRelatedPartyDebt>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2469526</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">6669807</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-219470</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">306439</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">14413</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2990037</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">4381</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">18794</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3008831</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">12632</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">82816</us-gaap:InterestPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<pmhs:AccretionOfDiscountOnBondPayable contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">502465</pmhs:AccretionOfDiscountOnBondPayable>
<pmhs:AccretionOfDiscountOnBondPayable contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<pmhs:ChangeInFairValueOfDerivativeLiability contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-175732</pmhs:ChangeInFairValueOfDerivativeLiability>
<pmhs:ChangeInFairValueOfDerivativeLiability contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 1 &amp;#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Business and Basis of Presentation &amp;#8211;&amp;#160;&lt;/b&gt;The consolidated financial statements include the accounts and operations of Dandrit Biotech USA Inc and its wholly owned subsidiary DanDritBioTech A/S.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;DanDrit Biotech USA, Inc. (&amp;#8220;DanDrit USA&amp;#8221;, the &amp;#8220;Company&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221;, &amp;#8220;our&amp;#8221;) (formerly Putnam Hills Corp.) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;DanDritBioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (&amp;#8220;DanDrit Denmark&amp;#8221;).&amp;#160;&amp;#160;The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the treatment of cancerin humansusing the dendritic cell technology.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Reverse Acquisition&amp;#160;&amp;#160;- On February 12, 2014, pursuant to aShare Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of approximately 100% of the issued and outstanding capital stock&amp;#160;&amp;#160;of&amp;#160;&amp;#160;DanDrit Denmark (the &amp;#8220;Share Exchange&amp;#8221;) and as a result became DanDrit Denmark&amp;#8217;s parent company (the &amp;#8220;Parent&amp;#8221;). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the &amp;#8220;Common Stock&amp;#8221;) of Parent outstanding.&amp;#160;Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share
 Exchange
 and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent&amp;#8217;s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent&amp;#8217;s Common Stock outstanding immediately following the Share Exchange,&amp;#160;&lt;font style="background-color: white;"&gt;including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the&amp;#160;&lt;/font&gt;Share Exchange (the &amp;#8220;Non-Consenting Shareholders&amp;#8221;)&lt;font style="background-color: white;"&gt;, and deemed issued and outstanding for accounting purposes&lt;/font&gt;.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Functional Currency / Foreign currency translation&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The functional currency of DanDrit Biotech A/S is the Danish Kroner (&amp;#8220;DKK&amp;#8221;). The Company&amp;#8217;s reporting currency istheU.S. Dollar for the purpose of these financial statements. The Company&amp;#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years 2014 and 2013. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&amp;#8217; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held inafinancial institution in the United States in excess of federally insured amounts at December 31, 2014 of $2,508,759 and none at December 31, 2013.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch:
 normal;
 margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification, (&amp;#8220;ASC&amp;#8221;) Topic 350, &amp;#8220;Goodwill and Other Intangible Assets&amp;#8221; and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Impairment of Long-Lived Assets &amp;#8212;&lt;/b&gt;&amp;#160;Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Revenue Recognition and Sales&amp;#160;&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company&amp;#8217;s sales of its MelCancerVac colorectal cancer treatment have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, &amp;#8220;Revenue Recognition in Financial Statements&amp;#8221; (SAB 101), FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of the resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal;
 font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 18pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Value Added Tax -&amp;#160;&lt;/b&gt;In Denmark, Value Added Tax (&amp;#8220;VAT&amp;#8221;) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices. These amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Research and Development Cost&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company expenses research and development costs for the development of new products as incurred and such costs areincluded in operating expense. There wereno research and development costs for the years ended December 31, 2014 and 2013.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Loss Per Share&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight:
 normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Derivatives &amp;#8212;&amp;#160;&lt;/b&gt;We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, we have entered into certain other financial instruments and contracts, such as debt financing arrangements with features that are either (i)&amp;#160;not afforded equity classification, (ii)&amp;#160;embody risks not clearly and closely related to host contracts, or (iii)&amp;#160;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We estimate fair values of all derivative instruments, such as embedded conversion features utilizing Level 3 inputs (defined below in Note 1: Fair Value of Financial Instruments). We use the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in themarket price of our common stock, which have historically had high volatility. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect the volatility in these estimate and assumption changes.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We report our derivative liabilities at fair value on the accompanying balance sheets as of December 31, 2014 and 2013.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant:
 normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own
 assumptions.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Unless otherwise disclosed, the fair value of the Company&amp;#8217;s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Accounting Estimates&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;In May 2014, the Financial Accounting Standards Board issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective beginning in the first quarter of 2017; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We do not believe the new standard will materially impact our consolidated financial statements.&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&amp;#8217;s present or future financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size:
 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40.5pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Reclassification&amp;#160;&amp;#8212;&amp;#160;&lt;/b&gt;The financial statements for the period ended December 31, 2013 have been reclassified to conform to the headings and classifications used in the December 31, 2014 financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 2&amp;#160;&amp;#8212;&amp;#160;PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Property and equipment consisted of the following at December 31, 2014 and December 31, 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;31-Dec&lt;br /&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;31-Dec&lt;br /&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Lab equipment and instruments&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 173px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4-6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;178,547&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;194,143&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4-6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new
 roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;61,151&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;66,493&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;239,698&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;260,636&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Less Accumulated Depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(239,698&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(260,636&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Net Property and Equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif;
 text-align: left; padding-bottom: 4pt; font-stretch:
 normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Depreciation expense amounted to $0 and $2,706, for the year ended December 31, 2014 and 2013, respectively. The Company&amp;#8217;s property and equipment is held as collateral on the notes payable related party.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 3&amp;#160;&amp;#8212;&amp;#160;DEFINITE-LIFE INTANGIBLE ASSETS&lt;/b&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;At December 31, 2014 and December 31, 2013, definite-life intangible assets, net of accumulated amortization, consist of patents on the Company&amp;#8217;s products and processes of $186,414 and $231,615, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the years ended December 31, 2014 and 2013 was $14,381 and $38,297, respectively. Expected future amortization expense for the years ended are as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Year ending December 31,&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1240.73864746094px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;114,509&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;186,414&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
<pmhs:NotesPayableDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 4&amp;#160;&amp;#8212;&amp;#160;NOTES PAYABLE &amp;#8211; RELATED PARTY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Notes payable to related parties consists of the following as of December 31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;38,235&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch:
 normal;"&gt;&lt;font style="font-family: 'times
 new roman', times, serif;"&gt;Note Payable ML Group&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;18,963&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;21,557&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;42,753&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5% Note Payable - Sune Olsen Holding ApS&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;521,390&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5% Note Payable - Sune Olsen&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;185,054&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;
 font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Total Notes Payable &amp;#8211; Related Party&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;728,001&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Less Current Maturities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(728,001&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Note Payables &amp;#8211; Related Party Long Term&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The following represents the future maturities of long-term debt as of December 31, 2014:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif;
 margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Year ending December 31,&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1367px; text-align: left; padding-left: 9pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;
 border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On February 15, 2014 and March 18, 2014, DanDrit Denmarkreceived DKK 2,500,000 ($461,084) and DKK 2,300,000 ($424,198) loans (the &amp;#8220;2014 Loans&amp;#8221;), respectively, from PasecoApS, an entity owned by a shareholder of the Company (&amp;#8220;Paseco&amp;#8221;).&amp;#160;&amp;#160;The 2014 Loans werepayable 14 days after the completion of the contemplated public offering in DanDrit USA or February 1, 2015, and accrued interest at 5% per annum. On April 29, 2014, DanDrit Denmark and Paseco entered into an amendment whereby the terms of the 2014 Loans werepayable on February 1, 2015 and couldbe extended at the Company&amp;#8217;s option for an additional year with an increase in the interest rate to 7.00%.&amp;#160;&amp;#160;As of October 17, 2014, the outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange rate of October 17, 2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;DanDrit Denmark has received an unsecured loan facility from Sune Olsen Holding ApS (&amp;#8220;Sune Olsen Holding&amp;#8221;), a shareholder of the Company, with a goal of ensuring financing until new equity has been brought in. Under the loan facility DanDrit Denmark has received the following amounts: on November 11, 2013 DKK 1,500,000&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;($276,651)&lt;font style="font-size: 10pt;"&gt;, on November 20, 2013 DKK 405,000 ($74,696), and on December 2, 2013 DKK 900,000($165,990). The loans weredue May 1, 2014 and accrued interest at 5% per year.&amp;#160;&amp;#160;During March 2014, the Company extended maturity date of the loans with Sune Olsen Holdings from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014, the Company repaid the loan facility and interest thereon.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;DanDrit Denmark has received an unsecured loan from Sune Olsen, managing member of Sune Olsen Holding, with a goal of ensuring financing until new equity has been brought in. The loan in the amount of DKK 1,000,000 ($184,434) was issued on December 20, 2013. The loan wasdue May 1, 2014 and accrued interest of 5% per year. During March 2014, the Company extendedthematurity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During March 2014, the Company received a 2,000,000 DKK ($368,868) letter of support from Paseco
 to finance operations until February 1, 2015 to be issued with terms substantially similar to those contained in the 2014 Loans. The Company has an option to extend the loan
 for one year by giving notice to Paseco by December 31, 2014 whereby the interest rate would increase to 7.00% per annum. The Company did not exercise the option.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During 2012, DKTI A/S, a shareholder of the Company, which is controlled by officers and directors of the Company, agreed to loan the Company up to DKK 5,000,000 (approximately $880,000) accruing interest at 6%.&amp;#160;&amp;#160;The loan is secured by all the Company&amp;#8217;s intellectual property rights, including its patents and its patent applications credit facility.&amp;#160;&amp;#160;During the year ended December 31, 2012 the Company borrowed DKK 4,431,862 ($783,139) plus DKK 71,563 ($12,646) in interest.&amp;#160;&amp;#160;During the year ended December 31, 2013, the Company borrowed an additional DKK 310,000 (approximately $55,000) on the loan and accrued interest of DKK 230,377 (approximately $42,000). The notes with related accrued interest were converted into 96,288 common shares of DanDrit Denmark on December 16, 2013 which were exchanged for 144,321 shares of common stock of the Parent upon the closing of the Share Exchange.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During the years ended December 31, 2013, 2012 and 2011 Sune Olsen Holding&amp;#160;loaned DanDrit Denmark DKK 1,267,724 ($232,841), DKK 338,719 ($59,854) and DKK 143,750 ($25,019), respectively.&amp;#160;&amp;#160;The Company added the accrued interest at 6% and the Company recorded interest expense of DKK 86,047 ($15,804), DKK 20,469 ($3,617) and DKK 2,689 ($468) during the years end December 31, 2013, 2012 and 2011, respectively.&amp;#160;&amp;#160;The loans are payable upon three months written notice of Sune Olsen Holding.&amp;#160;&amp;#160;On December 16, 2013, the notes with related accrued interest were converted into 35,106 shares of DanDrit&amp;#160;Denmark&amp;#160;which were exchanged for 52,618 shares of common stock of the Company upon the closing of the Share Exchange.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On April 14, 2013, Sune Olsen Holding, a shareholder of the Company, assumed DKK 4,375,932 (approximately$773,000) in liabilities owed by DanDrit Denmark for past due rent from a vendor in exchange for a note payable. ) were converted into 86,204 shares of DanDrit Denmark , which were exchanged for 129,207 shares of common stock of the Parent upon the closing of the Share Exchange.&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On June 20, 2013, Sune Olsen Holding paid DKK 1,500,000, ($265,000) in accrued legal fees owed by the Company in exchange for a DKK1,500,000 ($265,000) 5% note payable to Sune Olsen Holding. On December 16, 2013, the note with related accrued interest of DKK 20,959 ($3,804) was converted into 29,036 shares of DanDrit&amp;#160;Denmark&amp;#160;common stock. Such shares of common stock were exchanged for 43,520 shares of common stock of the Parent upon the closing of the Share Exchange..&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On July 26, 2013 and August 15, 2013, Sune Olsen Holding loaned the Company an additional DKK 1,000,000 ($177,239) and DKK 750,000 ($133,343), respectively.&amp;#160;&amp;#160;The notes accrue interest at 5% and are payable upon three months written notice of Sune Olsen Holding. The notes with related accrued interest of DKK 15,575 ($2,827) were converted into 33,705 shares of DanDrit Denmark common stock on December 16, 2013. Such shares of common stock were exchanged for 50,518 shares of common stock of the
 Company upon the closing of the Share Exchange.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform:
 none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As of December 31, 2014, the outstanding balance of $38,235 for professional fees paid by a shareholder and amounts advanced to the Parent are reported as loan payable - related party. The $38,235 loans payable were acquired in the reverse acquisition. The amounts are unsecured, non-interest bearing and have no stipulated repayment terms.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;A 6% promissory note payable to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition,&amp;#160;payable on February 12, 2014 upon the completion date of the Share Exchange.&amp;#160;&amp;#160;As of December 31, 2014, the outstanding balance on the note, including accrued interest, was $42,753. During the three and twelve months ended December 31, 2014 the Company recorded related party interest on the Note of $213, and $619, respectively.&lt;/font&gt;&lt;/p&gt;</pmhs:NotesPayableDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 5&amp;#160;&amp;#8212;&amp;#160;CONVERTIBLE BOND PAYABLE &amp;#8211; RELATED PARTY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 27pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 1, 2011, DanDrit Denmark borrowed $1,500,000 from DKTI A/S and issued 6% convertible bonds. The bonds may not be converted during the four weeks following the publication of the annual report. The bonds may not be repaid until the bonds&amp;#8217; expiration on December 31, 2014.&amp;#160;&amp;#160;The bonds shall not accrue interest after expiration.&amp;#160;&amp;#160;The bonds and related accrued interest are convertible into common shares of the Company at an initial rate of $9.58 per common share.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The conversion/adjustment features had an estimated fair value of $1,003,557 using the Black-Scholes pricing model using the assumptions set forth below and were bifurcated and properly classified as derivative instruments required to be recorded at fair value (Note 6). The proceeds from the bond have been allocated to the note and conversion/adjustment feature of the convertible bond and recorded at a discount which was amortized to interest expense through conversion. During the years ended December 31, 2013 and 2012, the Company recorded interest expense of $502,465 and $461,279, respectively, for the accretion of the discount on the note.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 16, 2013, the $1,500,000 convertible bond, accrued interest of $179,612 and the $673,736 derivative liability were converted into 174,578 shares of DanDrit Denmark common stock. Such shares of common stock were exchanged for 261,665 shares of common stock of the Company upon the closing of the Share Exchange.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The assumptions used to determine the initial fair value of the conversion feature of the convertible bond were expected volatility of 65%, expected life of two years to twelve months, risk &amp;#8211; free interest rates of .41%, and no dividend yield.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 6 &amp;#8212; DERIVATIVE LIABILITIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain other financial instruments and contracts, such as debt financing arrangements with features that are either (i)&amp;#160;not afforded equity classification, (ii)&amp;#160;embody risks not clearly and closely related to host contracts, or (iii)&amp;#160;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The fair value of the shares to be issued upon conversion of the bond was recorded as a derivative liability, with the change in the fair value recorded as a gain or loss in the accompanying statement of operations.&amp;#160;&amp;#160;During the three and nine months ended September 30, 2013, the Company recorded gains of $4,180 and $45,823, respectively. On December 16, 2013, the $1,500,000 convertible bond, accrued interest of $179,612 and the $673,736 derivative liability were converted into 174,578 shares of DanDrit Denmark common stock or 261,665 shares of common stock of the Company upon the closing of the Share Exchange.&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
<us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 7&amp;#160;&amp;#8212;&amp;#160;LEASES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Operating Leases&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3 month notice.&amp;#160;&amp;#160;The lease calls for monthly payments of DKK 6,000 (approximately $967 at December 31, 2014).&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On March 27, 2014 the Company entered into an operating lease agreement for office space from a related party. The Lease calls for monthly payments of DKK 10,000 (approximately $1,612), increasing to DKK 20,000 (approximately $3,225) on July 1, 2014. The lease can be terminated by either the Company or the landlord by giving the other 3 month notice. The Company gave a notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Lease expense charged to operations was $32,297 and $65,702, for the years ended December 31, 2014, and 2013 respectively.&lt;/font&gt;&lt;/p&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 8&amp;#160;&amp;#8212;&amp;#160;INCOME TAXES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&amp;#8217;s future earnings, and other future events, the effects of which cannot be determined.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;As of December 31, 2014 the Company had net operating loss carryforwards of approximately $2,380,106 for Danish tax purposes which do not expire.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company files Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2007 for their Danish tax returns.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at December 31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over book depreciation Fixed assets&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;12,711&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;87,578&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over book depreciation Patents&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;52,041&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;114,028&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Net Operating Loss Carryforward&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,380,106&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,642,598&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Valuation Allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(2,444,858&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(1,844,204&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Total Deferred Tax Asset (Liabilities)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meets the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&amp;#8217;s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company&amp;#8217;s effective rate is as follows at December 31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color:
 #cceeff;"&gt;&lt;td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Computed Tax at Expected Statutory Rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(866,463&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(752,882&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Non-US Income Taxed at Different Rates&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;255,356&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;199,292&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Non-Deductable expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;8,390&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td
 style="font-style:
 normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;283,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;436,631&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;270,209&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Income Tax Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing:
 normal; line-height:
 normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in; text-align: justify;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The components of income tax expense (benefit) from continuing operations for the years ended December 31, 2014 and 2013 consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Current Tax Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1068.49426269531px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Danish Income Tax&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(177,539&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Deferred Income Tax Expense (Benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size:
 10pt;"&gt;&lt;font style="font-family:
 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over Book Depreciation Fixed Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;19,259&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;26,364&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over Book Depreciation Patents&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;67,488&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(105,585&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Net Operating Loss Carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times
 new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(523,378&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(190,988&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in the Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;436,631&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;270,209&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Total Deferred Tax Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new
 roman', times,
 serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Deferred income tax expense/(benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:EarningsPerShareTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 9&amp;#160;&amp;#8212;&amp;#160;LOSS PER SHARE&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of potential dilutive common stock for the years ended December 31, 2014 and 2013:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="6"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1110px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Net (Loss)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 114.545448303223px; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;(2,370,883&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 113.636360168457px; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;(2,214,361&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;"&gt;Weighted average number of common shares used in basic earnings per share&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;7,500,142&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;3,557,893&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Effect of dilutive securities, stock options and warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Weighted average number of common shares and potential dilutive&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;common shares outstanding used in dilutive earnings per share&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;7,500,142&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;3,557,893&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;For the years ended December 31, 2014 and 2013, the Company had no options outstanding to purchase common stock of the Parent.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 10&amp;#160;&amp;#8212;&amp;#160;STOCKHOLDERS&amp;#8217; EQUITY&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company has 100,000,000 authorized shares of Common stock $0.0001.&amp;#160;&amp;#160;As of December 31, 2014 there were 9,533,290 shares issued and outstanding.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Share Exchange Agreement&lt;/b&gt;/&lt;b&gt;Reverse Acquisition&lt;/b&gt;&amp;#160;- On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), wecompleted the acquisition of approximately 100% of the issued and outstanding capital stock&amp;#160;&amp;#160;of&amp;#160;&amp;#160;DanDrit Denmark (the &amp;#8220;Share Exchange&amp;#8221;) and as a result became DanDrit Denmark&amp;#8217;s parent company (the &amp;#8220;Parent&amp;#8221;). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA&amp;#8217;s common stock, par value $.0001 per share (the &amp;#8220;Common Stock&amp;#8221;) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Common Stock Issuances &amp;#8211;&lt;/b&gt;&amp;#160;On&lt;font style="background-color: white;"&gt;&amp;#160;December 31, 2014,&lt;/font&gt;&amp;#160;the Company received&amp;#160;&lt;font style="background-color: white;"&gt;$2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During the year ended December 31, 2014, pursuant to&amp;#160;&lt;font style="background-color: white;"&gt;the Company&amp;#8217;s offering up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 16, 2013, DanDrit&lt;font style="background-color: white;"&gt;&amp;#160;Denmark&lt;/font&gt;&amp;#160;issued 174,578 shares of its common stock which were exchanged for 261,665 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of a $1,500,000 convertible bond, $179,612 of accrued interest and the remaining $673,736 of derivative liability associated with the conversion feature of the bond.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none;
 text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 16, 2013, DanDrit&lt;font style="background-color: white;"&gt;Denmark&lt;/font&gt;&amp;#160;issued 96,288 shares of its common stock which were exchanged for 144,321 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of $926,386 of notes payable and related accrued interest payable to DKTI A/S.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;On December 16, 2013, DanDrit&lt;font style="background-color: white;"&gt;&amp;#160;Denmark&amp;#160;&lt;/font&gt;issued 184,051 shares of its common stock which were exchanged for 275,863 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of $1,770,757 of notes payable and related accrued interest payable to Sune Olsen Holdings ApS and Advance Biotech Invest AS.&lt;/div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Voting-&lt;/i&gt;&lt;/b&gt;&amp;#160;Holders of the Company&amp;#8217;s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Dividends-&amp;#160;&lt;/i&gt;&lt;/b&gt;Holders of the Company&amp;#8217;s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Liquidation Rights-&lt;/i&gt;&lt;/b&gt;&amp;#160;In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company&amp;#8217;s common stock will be entitled to share ratably in the distribution of any of our remaining assets.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 11&amp;#160;&amp;#8212;&amp;#160;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Shares held for non-consenting shareholders&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;i&gt;&amp;#8211;&amp;#160;&lt;/i&gt;In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Clinical Trial Agreement&lt;/i&gt;&lt;/b&gt;&amp;#8211;On October 1, 2014 the Company&amp;#8217;s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS &amp;#8220;San Martino&amp;#8221; - IST &amp;#8211; National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit&amp;#8217;s vaccine in patients with no evident disease (&amp;#8220;NED&amp;#8221;) stage IV colorectal cancer (&amp;#8220;CRC&amp;#8221;). The primary goal of the study is to evaluate the efficacy of DanDrit&amp;#8217;s MelCancerVac&amp;#174; (&amp;#8220;MCV&amp;#8221;) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Patient Name Use Program&lt;/i&gt;&lt;/b&gt;&amp;#160;- On December 16, 2013, DanDrit&lt;font style="background-color: white;"&gt;&amp;#160;Denmark&amp;#160;&lt;/font&gt;entered into an agreement with a Dutch company (the &amp;#8220;MCV Partner&amp;#8221;) regarding a Patient Name Use Program (PNU) for the Company&amp;#8217;s MCV.&amp;#160;&amp;#160;This program will allow DanDrit&lt;font style="background-color: white;"&gt;Denmark&amp;#160;&lt;/font&gt;to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner.&amp;#160;&amp;#160;The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmacovigilance.&amp;#160;&amp;#160; The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 day written notice.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Food and Drug Administration (FDA) -&lt;/i&gt;&lt;/b&gt;&amp;#160;The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company&amp;#8217;s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.&lt;/font&gt;&lt;/p&gt;&lt;p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Product liability -&amp;#160;&lt;/i&gt;&lt;/b&gt;The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company&amp;#8217;s operations.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Employment Agreements -&amp;#160;&lt;/i&gt;&lt;/b&gt;The Company and its Subsidiary have employment agreements with officers of the Company.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&lt;i&gt;Contingencies&amp;#160;&lt;/i&gt;&lt;/b&gt;- The Company is from time to time involved in routine legal and administrative proceedings and claims of various types.&amp;#160;&amp;#160;While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.&lt;/font&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 12&amp;#160;&amp;#8212;&amp;#160;DISPOSITION&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On December 16, 2013,DanDrit Biotech A/S sold its&amp;#8217; Dormant Singapore subsidiary DanDrit Singapore Pte. Ltd., for $1 resulting in no gain or loss from the sale and discontinuing the operations. The Company had no sales or operations for the periods presented in the accompanying financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;div&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 13&amp;#160;&amp;#8212;&amp;#160;Related Party Transactions&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;During the year ended December 31, 2014 and 2013, the Company entered into various notes payable with shareholders of the Company (See Note 4).&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See Note 7). During the year ended December 31, 2014, the Company paid the related party DKK 130,000 or approximately $23,152.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;
&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;During the year ended December 31, 2014 and 2013, a law firm partially owned by the Company&amp;#8217;s Chairman of the Board of Directors provided legal services to the Company. During the years ended December 31, 2014 and 2013 the Company recorded legal expense of $288,546 and $328,202, respectively. During the year ended December 31, 2013 the firm forgave $49,016 in legal services. At December 31, 2014, the Company had a payable to the firm in the amount of $212,438. During the years ended December 31, 2014 and 2013, the firm held funds in trust on behalf of the Company in connection with stock offerings and to facilitate settling outstanding liabilities. Balances held in trust at December 31, 2014 and 2013 were $2,014,909 and $14,593, respectively&lt;font style="font-family: 'times new roman', times, serif;"&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;NOTE 14&amp;#160;&amp;#8212;&amp;#160;SUBSEQUENT EVENT&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The Company&amp;#8217;s management reviewed material events through March 30, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;On March 13, 2015, the Company, DanDritDenmark and Robert E. Wolfe entered into an Agreement pursuant to which Mr. Wolfe ceased to be Chief Financial Officer of DanDrit Denmark effective as of the date on which a replacement Chief Financial Officer is engaged (the &amp;#8220;Agreement&amp;#8221;). It is currently anticipated that Mr. Wolfe will continue to serve as the Chief Financial Officer of the Company through a transition period that will end following the date that the Company files its Annual Report on Form 10-K for the year ended December 31, 2014 (the &amp;#8220;Transition Period&amp;#8221;). In accordance with the terms of the Agreement and except as amended by the Agreement, the CFO Service Agreement between DanDrit Denmark and Mr. Wolfe, dated as of February 10, 2014 (the &amp;#8220;Wolfe Employment Agreement&amp;#8221;) will remain in effect through October 31, 2015 (the &amp;#8220;Termination Date&amp;#8221;). In addition, Mr. Wolfe is entitled to receive (i) all salary payable in accordance with the terms of the Wolfe Employment Agreement, along with any unpaid accrued expenses, through the Termination Date; (ii) attorney fees of up to a maximum of $4,000; (iii) a bonus in an amount equal to $10,000 following the filing of the Company&amp;#8217;s Annual Report on Form 10-K for the year ended December 31, 2014; and (iv) a fee of $150.00 per hour for any consulting services that Mr. Wolfe may provide in connection with the filing and completion of the Company&amp;#8217;s current and periodic filings with the Securities and Exchange Commission; provided that the first 100 hours of consultant services provided from May 1, 2015 through October 31, 2015 shall not be billable. Other than as described above, the terms of the Wolfe Employment Agreement will continue to govern Mr. Wolfe&amp;#8217;s relationship with the Company and DanDrit Denmark in all material respects through the Termination Date. In addition, Mr. Wolfe continues to serve as a director of the Company.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In connection with Mr. Wolfe&amp;#8217;s departure as Chief Financial Officer of DanDrit Denmark, Lone Degn was appointed to serve as Chief Financial Officer of DanDrit Denmark effective as of March 12, 2015. Subject to approval by the Company&amp;#8217;s Board of Directors and Mr. Wolfe&amp;#8217;s resignation as Chief Financial Officer of the Company, it is currently anticipated that Ms. Degn will be appointed to replace Mr. Wolfe upon the effective date of his resignation following the Transition Period.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In accordance with the terms of a Contract of Employment, dated as of the Effective Date by and between DanDrit Denmark and Ms. Degn (the &amp;#8220;Degn Employment Agreement&amp;#8221;), Ms.
 Degn will be employed by DanDrit Denmark for an indefinite term unless earlier terminated pursuant to the terms therein. The Degn Employment Agreement provides that Ms. Degn will receive a salary of DKK 60,000 gross per month, to be paid monthly on the last business day of each month and subject to annual review and increases by the board of directors of DanDrit Denmark, as it deems appropriate.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;In addition to her salary, Ms. Degn will be entitled to receive reimbursement of all reasonable costs and expenses incurred in connection with the performance of her duties in accordance with the terms of the Degn Employment Agreement In addition, DanDrit Denmark has agreed to contribute an amount equal to 10% of Ms. Degn&amp;#8217;s yearly salary to a pension fund or bank account established for such purpose.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Either DanDrit Denmark or Ms. Degn may terminate the employment in accordance with the Danish Salaried Employees Act.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;The foregoing descriptions of the Agreement and the Degn Employment Agreement contained herein do not purport to be complete and are qualified in their entirety by reference to the complete text of the&amp;#160;&lt;font style="background-color: white;"&gt;Agreement and the Degn Employment Agreement, which are filed as exhibits to this report.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Business and Basis of Presentation &amp;#8211;&amp;#160;&lt;/b&gt;The consolidated financial statements include the accounts and operations of Dandrit Biotech USA Inc and its wholly owned subsidiary DanDritBioTech A/S.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;DanDrit Biotech USA, Inc. (&amp;#8220;DanDrit USA&amp;#8221;, the &amp;#8220;Company&amp;#8221;, &amp;#8220;we&amp;#8221;, &amp;#8220;us&amp;#8221;, &amp;#8220;our&amp;#8221;) (formerly Putnam Hills Corp.) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;DanDritBioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (&amp;#8220;DanDrit Denmark&amp;#8221;).&amp;#160;&amp;#160;The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the treatment of cancerin humansusing the dendritic cell technology.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Reverse Acquisition&amp;#160;&amp;#160;- On February 12, 2014, pursuant to aShare Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of approximately 100% of the issued and outstanding capital stock&amp;#160;&amp;#160;of&amp;#160;&amp;#160;DanDrit Denmark (the &amp;#8220;Share Exchange&amp;#8221;) and as a result became DanDrit Denmark&amp;#8217;s parent company (the &amp;#8220;Parent&amp;#8221;). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the &amp;#8220;Common Stock&amp;#8221;) of Parent outstanding.&amp;#160;Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent&amp;#8217;s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent&amp;#8217;s Common Stock outstanding immediately following the Share Exchange,&amp;#160;&lt;font style="background-color: white;"&gt;including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the&amp;#160;&lt;/font&gt;Share Exchange (the &amp;#8220;Non-Consenting Shareholders&amp;#8221;)&lt;font style="background-color: white;"&gt;, and deemed issued and outstanding for accounting purposes&lt;/font&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;&lt;b&gt;Functional Currency / Foreign currency translation&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The functional currency ofDanDrit Biotech A/S is the Danish Kroner (&amp;#8220;DKK&amp;#8221;). The Company&amp;#8217;s reporting currency istheU.S. Dollar for the purpose of these financial statements. The Company&amp;#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years 2014 and 2013. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&amp;#8217; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.&lt;/font&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held inafinancial institution in the United States in excess of federally insured amounts at December 31, 2014 of $2,508,759 and none at December 31, 2013.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;&lt;b&gt;Property and Equipment&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).&lt;/font&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (&amp;#8220;FASB&amp;#8221;) Accounting Standards Codification, (&amp;#8220;ASC&amp;#8221;) Topic 350, &amp;#8220;Goodwill and Other Intangible Assets&amp;#8221; and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.&lt;/font&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;&lt;b&gt;Impairment of Long-Lived Assets &amp;#8212;&lt;/b&gt; Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"&gt;&amp;#160;&lt;/div&gt;&lt;div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"&gt;&lt;font size="2" style="font-family: times new roman,times;"&gt;Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.&lt;/font&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:RevenueRecognitionSalesOfServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Revenue Recognition and Sales&amp;#160;&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company&amp;#8217;s sales of its MelCancerVac colorectal cancer treatment have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, &amp;#8220;Revenue Recognition in Financial Statements&amp;#8221; (SAB 101), FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of the resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionSalesOfServices>
<pmhs:ValueAddedTaxPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Value Added Tax -&amp;#160;&lt;/b&gt;In Denmark, Value Added Tax (&amp;#8220;VAT&amp;#8221;) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices. These amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.&lt;/font&gt;&lt;/p&gt;</pmhs:ValueAddedTaxPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Research and Development Cost&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company expenses research and development costs for the development of new products as incurred and such costs areincluded in operating expense. There wereno research and development costs for the years ended December 31, 2014 and 2013.&lt;/font&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Loss Per Share&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.&lt;/font&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:DerivativesPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Derivatives &amp;#8212;&amp;#160;&lt;/b&gt;We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, we have entered into certain other financial instruments and contracts, such as debt financing arrangements with features that are either (i)&amp;#160;not afforded equity classification, (ii)&amp;#160;embody risks not clearly and closely related to host contracts, or (iii)&amp;#160;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We estimate fair values of all derivative instruments, such as embedded conversion features utilizing Level 3 inputs (defined below in Note 1: Fair Value of Financial Instruments). We use the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in themarket price of our common stock, which have historically had high volatility. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect the volatility in these estimate and assumption changes.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We report our derivative liabilities at fair value on the accompanying balance sheets as of December 31, 2014 and 2013.&lt;/font&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
<us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Fair Value of Financial Instruments&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times,
 serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#9679;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Unless otherwise disclosed, the fair value of the Company&amp;#8217;s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Accounting Estimates&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&amp;#160;&amp;#8212;&amp;#160;In May 2014, the Financial Accounting Standards Board issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective beginning in the first quarter of 2017; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We do not believe the new standard will materially impact our consolidated financial statements.&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&amp;#8217;s present or future financial statements.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Reclassification&amp;#160;&amp;#8212;&amp;#160;&lt;/b&gt;The financial statements for the period ended December 31, 2013 have been reclassified to conform to the headings and classifications used in the December 31, 2014 financial statements.&lt;/font&gt;&lt;/p&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Useful Life&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;31-Dec&lt;br /&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;31-Dec&lt;br /&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Lab equipment and instruments&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 173px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4-6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;178,547&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;194,143&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Computer equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;4-6&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;61,151&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;
 font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;66,493&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;239,698&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;260,636&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Less Accumulated Depreciation&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(239,698&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(260,636&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Net Property and Equipment&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt;
 font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family:
 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Year ending December 31,&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1240.73864746094px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2019&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;14,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-right: 0px; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;114,509&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;186,414&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
<us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: center; font-size: 10pt;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;38,235&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Note Payable ML Group&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;18,963&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font:
 10pt/normal 'times new roman', times, serif;
 text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman',;"&gt;21,557&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;42,753&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5% Note Payable - Sune Olsen Holding ApS&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;521,390&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;5% Note Payable - Sune Olsen&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;0&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;185,054&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch:
 normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Total Notes Payable
 &amp;#8211; Related Party&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times,; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;728,001&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Less Current Maturities&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(728,001&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Note Payables &amp;#8211; Related Party Long Term&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;u&gt;Year ending December 31,&lt;/u&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1240.73864746094px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2015&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2016&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2017&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt;
 line-height:
 normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2018&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 0px; text-align: left; text-indent: 0px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;99,951&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over book depreciation Fixed assets&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;12,711&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;87,578&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over book depreciation Patents&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;52,041&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times
 new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;114,028&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Net Operating Loss Carryforward&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2,380,106&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;1,642,598&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Valuation Allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(2,444,858&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(1,844,204&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt;"&gt;&lt;font
 style="font-family: 'times new roman', times, serif;"&gt;Total Deferred Tax Asset (Liabilities)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Computed Tax at Expected Statutory Rate&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(866,463&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(752,882&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Non-US Income Taxed at Different Rates&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;255,356&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;199,292&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Non-Deductable expenses&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;8,390&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;283,381&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;436,631&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;270,209&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times,
 serif;"&gt;Income Tax Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Current Tax Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2014&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1068.49426269531px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Danish Income Tax&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(177,539&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Deferred Income Tax Expense (Benefit)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-size: 10pt; text-align: left;"&gt;&lt;font style="font-family:
 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over Book Depreciation Fixed Assets&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;19,259&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;26,364&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Excess of Tax over Book Depreciation Patents&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;67,488&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(105,585&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Net Operating Loss Carryforwards&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(523,378&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal;
 font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;(190,988&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Change in the Valuation allowance&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;436,631&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;270,209&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;Total Deferred Tax Expense&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="6"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;2013&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1110px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Net (Loss)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 114.545448303223px; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;(2,370,883&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;$&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 113.636360168457px; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;(2,214,361&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 13.63636302948px; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Weighted average number of common shares used in basic earnings per share&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;7,500,142&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;3,557,893&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal;
 font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Effect of dilutive securities, stock options and warrants&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="padding-left: 10pt; text-indent: -10pt; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Weighted average number of common shares and potential dilutive&lt;/font&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;font style="font-size: 10pt;"&gt;common shares outstanding used in dilutive earnings per share&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;7,500,142&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;3,557,893&lt;/font&gt;&lt;/td&gt;&lt;td style="line-height: 15.3333330154419px;"&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
<pmhs:ValueAddedTaxPercentage contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="2">0.25</pmhs:ValueAddedTaxPercentage>
<pmhs:ValueAddedTaxPaidToVendors contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="2">0.25</pmhs:ValueAddedTaxPaidToVendors>
<pmhs:ProceedsFromSaleOfSubsidiary contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<pmhs:ShareExchangeAgreementCommonStockShares contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="0">5000000</pmhs:ShareExchangeAgreementCommonStockShares>
<pmhs:ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="6">1.498842</pmhs:ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany>
<pmhs:ShareExchangeAgreementNumberOfShareCancellation contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4400000</pmhs:ShareExchangeAgreementNumberOfShareCancellation>
<pmhs:ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1440000</pmhs:ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_12_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">185053</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">185053</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:CashFDICInsuredAmount contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2508759</us-gaap:CashFDICInsuredAmount>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember_RangeAxis_MaximumMember">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember_RangeAxis_MinimumMember">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember_RangeAxis_MaximumMember">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember_RangeAxis_MinimumMember">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">260636</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember" unitRef="USD" decimals="0">194143</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" unitRef="USD" decimals="0">66493</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">239698</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LabEquipmentAndInstrumentsMember" unitRef="USD" decimals="0">178547</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember" unitRef="USD" decimals="0">61151</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-260636</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-239698</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2706</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:Depreciation>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">14381</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">14381</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">14381</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">14381</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">14381</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">114509</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">38297</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">14381</us-gaap:AdjustmentForAmortization>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">728001</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NotePayableMlGroupMember" unitRef="USD" decimals="0">21557</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenHoldingApsMember" unitRef="USD" decimals="0">521390</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenMember" unitRef="USD" decimals="0">185054</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">99951</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NotePayableMlGroupMember" unitRef="USD" decimals="0">18963</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenHoldingApsMember" unitRef="USD" decimals="0">0</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_FivePercentNotePayableSuneOlsenMember" unitRef="USD" decimals="0">0</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" unitRef="USD" decimals="0">38235</us-gaap:LongTermDebt>
<us-gaap:LongTermDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" unitRef="USD" decimals="0">42753</us-gaap:LongTermDebt>
<us-gaap:LongTermDebtCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-728001</us-gaap:LongTermDebtCurrent>
<us-gaap:LongTermDebtCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-99951</us-gaap:LongTermDebtCurrent>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">99951</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">99951</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_11_Nov_2013T00_00_00_TO_11_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="USD" decimals="0">276651</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_11_Nov_2013T00_00_00_TO_11_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="DKK" decimals="0">1500000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_20_Nov_2013T00_00_00_TO_20_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="USD" decimals="0">74696</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_20_Nov_2013T00_00_00_TO_20_Nov_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="DKK" decimals="0">405000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_02_Dec_2013T00_00_00_TO_02_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="USD" decimals="0">165990</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_02_Dec_2013T00_00_00_TO_02_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="DKK" decimals="0">900000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_20_Dec_2013T00_00_00_TO_20_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanTwoMember" unitRef="USD" decimals="0">184434</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_20_Dec_2013T00_00_00_TO_20_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanTwoMember" unitRef="DKK" decimals="0">1000000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_15_Feb_2014T00_00_00_TO_15_Feb_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="0">461084</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_15_Feb_2014T00_00_00_TO_15_Feb_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="DKK" decimals="0">2500000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_18_Mar_2014T00_00_00_TO_18_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="USD" decimals="0">424198</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_18_Mar_2014T00_00_00_TO_18_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="DKK" decimals="0">2300000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="USD" decimals="0">368868</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="DKK" decimals="0">2000000</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">38235</us-gaap:UnsecuredDebt>
<us-gaap:UnsecuredDebt contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember" unitRef="USD" decimals="0">42753</us-gaap:UnsecuredDebt>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="pure" decimals="2">0.06</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_20_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="pure" decimals="2">0.05</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_26_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="pure" decimals="2">0.05</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="pure" decimals="2">0.06</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_15_Feb_2014T00_00_00_TO_15_Feb_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="pure" decimals="2">0.05</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_18_Mar_2014T00_00_00_TO_18_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="pure" decimals="2">0.05</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember" unitRef="pure" decimals="2">0.05</pmhs:AccruedInterestInPercentage>
<pmhs:AccruedInterestInPercentage contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember" unitRef="pure" decimals="2">0.05</pmhs:AccruedInterestInPercentage>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="USD" decimals="0">25019</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2011T00_00_00_TO_31_Dec_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="DKK" decimals="0">143750</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="USD" decimals="0">59854</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="DKK" decimals="0">338719</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="USD" decimals="0">880000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="DKK" decimals="0">5000000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_14_Apr_2013T00_00_00_TO_14_Apr_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="USD" decimals="0">773000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_14_Apr_2013T00_00_00_TO_14_Apr_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="DKK" decimals="0">4375932</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_20_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="USD" decimals="0">265000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_20_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="DKK" decimals="0">1500000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_26_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="USD" decimals="0">177239</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_26_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="DKK" decimals="0">1000000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_15_Aug_2013T00_00_00_TO_15_Aug_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="USD" decimals="0">133343</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_15_Aug_2013T00_00_00_TO_15_Aug_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="DKK" decimals="0">750000</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="USD" decimals="0">232841</us-gaap:LoansPayableCurrent>
<us-gaap:LoansPayableCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="DKK" decimals="0">1267724</us-gaap:LoansPayableCurrent>
<us-gaap:OtherShortTermBorrowings contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="USD" decimals="0">783139</us-gaap:OtherShortTermBorrowings>
<us-gaap:OtherShortTermBorrowings contextRef="Context_As_Of_31_Dec_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="DKK" decimals="0">4431862</us-gaap:OtherShortTermBorrowings>
<us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="USD" decimals="0">12646</us-gaap:InterestExpenseOtherShortTermBorrowings>
<us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="DKK" decimals="0">71563</us-gaap:InterestExpenseOtherShortTermBorrowings>
<us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember" unitRef="USD" decimals="0">15617</us-gaap:InterestExpenseOtherShortTermBorrowings>
<us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember" unitRef="DKK" decimals="0">86047</us-gaap:InterestExpenseOtherShortTermBorrowings>
<us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="Context_3ME_02_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember" unitRef="USD" decimals="0">213</us-gaap:InterestExpenseOtherShortTermBorrowings>
<us-gaap:InterestExpenseOtherShortTermBorrowings contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember" unitRef="USD" decimals="0">619</us-gaap:InterestExpenseOtherShortTermBorrowings>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_Custom_26_Feb_2013T00_00_00_TO_01_Mar_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFiverMember" unitRef="USD" decimals="0">14075</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="USD" decimals="0">55000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="DKK" decimals="0">310000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_15_Feb_2014T00_00_00_TO_15_Feb_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="pure" decimals="2">0.07</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_18_Mar_2014T00_00_00_TO_18_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember" unitRef="pure" decimals="2">0.07</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31_Mar_2014T00_00_00_TO_31_Mar_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="pure" decimals="2">0.07</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_NlbditTwoZeroOneZeroEnterprisesLlcMember_LongtermDebtTypeAxis_LoanTenMember" unitRef="pure" decimals="2">0.06</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_FYE_01_Jan_2011T00_00_00_TO_31_Dec_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="USD" decimals="0">468</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_FYE_01_Jan_2011T00_00_00_TO_31_Dec_2011T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="DKK" decimals="0">2689</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="USD" decimals="0">3617</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="DKK" decimals="0">20469</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_Custom_21_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="USD" decimals="0">2827</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_Custom_21_Jul_2013T00_00_00_TO_26_Jul_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="DKK" decimals="0">15575</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="USD" decimals="0">3804</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="DKK" decimals="0">20959</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="USD" decimals="0">42000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<us-gaap:DebtInstrumentIncreaseAccruedInterest contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="DKK" decimals="0">230337</us-gaap:DebtInstrumentIncreaseAccruedInterest>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_11_Apr_2013T00_00_00_TO_14_Apr_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="shares" decimals="0">129207</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="shares" decimals="INF">261665</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanFourMember" unitRef="shares" decimals="INF">52618</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember_LongtermDebtTypeAxis_LoanThreeMember" unitRef="shares" decimals="INF">144321</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="shares" decimals="INF">43520</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSevenMember" unitRef="shares" decimals="INF">50518</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember" unitRef="shares" decimals="0">275863</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_DktiAsMember" unitRef="shares" decimals="0">144321</pmhs:CommonStockExchangedDuringPeriodOfConversionOfDebt>
<pmhs:AccruedLegalFees contextRef="Context_Custom_15_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="USD" decimals="0">265000</pmhs:AccruedLegalFees>
<pmhs:AccruedLegalFees contextRef="Context_Custom_15_Jun_2013T00_00_00_TO_20_Jun_2013T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanSixMember" unitRef="DKK" decimals="0">1500000</pmhs:AccruedLegalFees>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanOneMember">2014-05-01</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember">2015-02-01</us-gaap:DebtInstrumentMaturityDate>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_SuneOlsenHoldingApsMember_LongtermDebtTypeAxis_LoanTwoMember">The Company extendedthematurity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_RelatedPartyTransactionsByRelatedPartyAxis_PasecoApsMember_LongtermDebtTypeAxis_UnsecuredDebtMember">The loans are payable 14 days after the completion of the contemplated public offering in DanDrit Biotech USA, Inc. or February 1, 2015, and accrue interest at 5% per annum.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:LoansPayable contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">38235</us-gaap:LoansPayable>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_01_Dec_2011T00_00_00_TO_01_Dec_2011T00_00_00" unitRef="USD" decimals="0">1500000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentFaceAmount contextRef="Context_As_Of_16_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="USD" decimals="0">1500000</us-gaap:DebtInstrumentFaceAmount>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_01_Dec_2011T00_00_00_TO_01_Dec_2011T00_00_00" unitRef="pure" decimals="2">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="Context_As_Of_01_Dec_2011T00_00_00_TO_01_Dec_2011T00_00_00" unitRef="USD_per_Share" decimals="2">9.58</us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1003557</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
<us-gaap:InterestExpenseCommercialPaper contextRef="Context_FYE_01_Jan_2012T00_00_00_TO_31_Dec_2012T00_00_00" unitRef="USD" decimals="0">461279</us-gaap:InterestExpenseCommercialPaper>
<us-gaap:InterestExpenseCommercialPaper contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">502465</us-gaap:InterestExpenseCommercialPaper>
<us-gaap:InterestReceivable contextRef="Context_As_Of_16_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="USD" decimals="0">179612</us-gaap:InterestReceivable>
<us-gaap:DerivativeLiabilities contextRef="Context_As_Of_16_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="USD" decimals="0">673736</us-gaap:DerivativeLiabilities>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="shares" decimals="INF">174578</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">The assumptions used to determine the initial fair value of the conversion feature of the convertible bond were expected volatility of 65%, expected life of two years to twelve months, risk free interest rates of .41%, and no dividend yield.</us-gaap:DebtInstrumentConvertibleTermsOfConversionFeature>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="2">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="4">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_3ME_01_Jul_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">4180</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:DerivativeGainLossOnDerivativeNet contextRef="Context_9ME_01_Jan_2013T00_00_00_TO_30_Sep_2013T00_00_00" unitRef="USD" decimals="0">45823</us-gaap:DerivativeGainLossOnDerivativeNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">65702</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_27_Mar_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedOfficeSpaceMember" unitRef="USD" decimals="0">1612</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Mar_2014T00_00_00_TO_27_Mar_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedOfficeSpaceMember" unitRef="DKK" decimals="0">10000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Jun_2014T00_00_00_TO_01_Jul_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedOfficeSpaceMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">3225</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_Custom_01_Jun_2014T00_00_00_TO_01_Jul_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedOfficeSpaceMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="DKK" decimals="0">20000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">32297</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedLaboratorySpaceMember" unitRef="USD" decimals="0">967</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeasedLaboratorySpaceMember" unitRef="DKK" decimals="0">6000</us-gaap:OperatingLeasesRentExpenseNet>
<pmhs:OperatingLeaseAgreementDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">The lease can be terminated by either the Company or the landlord by giving the other 3 month notice. The Company gave anotice terminatingthe lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.</pmhs:OperatingLeaseAgreementDescription>
<pmhs:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">87578</pmhs:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets>
<pmhs:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">12711</pmhs:DeferredTaxAssetExcessTaxOverDepreciationFixedAssets>
<pmhs:DeferredTaxAssetExcessTaxOverDepreciationPatents contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">114028</pmhs:DeferredTaxAssetExcessTaxOverDepreciationPatents>
<pmhs:DeferredTaxAssetExcessTaxOverDepreciationPatents contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">52041</pmhs:DeferredTaxAssetExcessTaxOverDepreciationPatents>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1642598</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2380106</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">1844204</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2444858</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsLiabilitiesNetCurrent contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredTaxAssetsLiabilitiesNetCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<pmhs:StatutoryIncomeTaxReconciliationRateExpenseBenefit contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-752882</pmhs:StatutoryIncomeTaxReconciliationRateExpenseBenefit>
<pmhs:StatutoryIncomeTaxReconciliationRateExpenseBenefit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-866463</pmhs:StatutoryIncomeTaxReconciliationRateExpenseBenefit>
<pmhs:OtherIncomeTaxReconciliationRateExpenseBenefit contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">199292</pmhs:OtherIncomeTaxReconciliationRateExpenseBenefit>
<pmhs:OtherIncomeTaxReconciliationRateExpenseBenefit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">255356</pmhs:OtherIncomeTaxReconciliationRateExpenseBenefit>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">283381</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">8390</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
<pmhs:IncomeTaxReconciliationValuationAllowance contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">270209</pmhs:IncomeTaxReconciliationValuationAllowance>
<pmhs:IncomeTaxReconciliationValuationAllowance contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">436631</pmhs:IncomeTaxReconciliationValuationAllowance>
<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-177539</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
<pmhs:ExcessTaxBenefitOverDepreciationFixedAssets contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">26364</pmhs:ExcessTaxBenefitOverDepreciationFixedAssets>
<pmhs:ExcessTaxBenefitOverDepreciationFixedAssets contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">19259</pmhs:ExcessTaxBenefitOverDepreciationFixedAssets>
<pmhs:ExcessTaxBenefitOverDepreciationPatents contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-105585</pmhs:ExcessTaxBenefitOverDepreciationPatents>
<pmhs:ExcessTaxBenefitOverDepreciationPatents contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">67488</pmhs:ExcessTaxBenefitOverDepreciationPatents>
<pmhs:IncomeTaxExpenseBenefitOperatingLossCarryforwards contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-190988</pmhs:IncomeTaxExpenseBenefitOperatingLossCarryforwards>
<pmhs:IncomeTaxExpenseBenefitOperatingLossCarryforwards contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-523378</pmhs:IncomeTaxExpenseBenefitOperatingLossCarryforwards>
<pmhs:ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">-270209</pmhs:ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount>
<pmhs:ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-436631</pmhs:ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_DanishTaxMember" unitRef="USD" decimals="0">2380106</us-gaap:OperatingLossCarryforwards>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" xsi:nil="true"/>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="shares" decimals="0">3557893</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="0">7500142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_12_Aug_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="0">156360</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="0">12000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">889690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">2400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="shares" decimals="0">400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD_per_Share" decimals="2">5.00</us-gaap:SharesIssuedPricePerShare>
<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_12_Aug_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="shares" decimals="INF">1093290</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_SubsidiarySaleOfStockAxis_PrivatePlacementMember" unitRef="USD" decimals="0">2000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="Context_Custom_01_Aug_2014T00_00_00_TO_12_Aug_2014T00_00_00_SubsidiarySaleOfStockAxis_IPOMember" unitRef="USD" decimals="0">5466450</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
<pmhs:ExchangedSharesOfParentSCommonStock contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00_LegalEntityAxis_ParentCompanyMember" unitRef="shares" decimals="INF">261665</pmhs:ExchangedSharesOfParentSCommonStock>
<pmhs:ExchangedSharesOfParentSCommonStock contextRef="Context_Custom_01_Feb_2014T00_00_00_TO_12_Feb_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1.498842</pmhs:ExchangedSharesOfParentSCommonStock>
<pmhs:TerminationOfAgreement contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00">P180D</pmhs:TerminationOfAgreement>
<pmhs:PaymentsForRoyaltiesPeriod contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00">P20Y</pmhs:PaymentsForRoyaltiesPeriod>
<us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue contextRef="Context_Custom_13_Dec_2013T00_00_00_TO_16_Dec_2013T00_00_00" unitRef="USD" decimals="0">1</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
<us-gaap:RelatedPartyTransactionDueFromToRelatedParty contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="DKK" decimals="0">130000</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
<us-gaap:RelatedPartyTransactionDueFromToRelatedParty contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">23152</us-gaap:RelatedPartyTransactionDueFromToRelatedParty>
<us-gaap:LegalFees contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">328202</us-gaap:LegalFees>
<us-gaap:LegalFees contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">288546</us-gaap:LegalFees>
<pmhs:ForgaveInLegalServices contextRef="Context_FYE_01_Jan_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">49016</pmhs:ForgaveInLegalServices>
<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">212438</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
<pmhs:AdditionalLegalServices contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">0</pmhs:AdditionalLegalServices>
<us-gaap:AssetsHeldInTrust contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">14593</us-gaap:AssetsHeldInTrust>
<us-gaap:AssetsHeldInTrust contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2014909</us-gaap:AssetsHeldInTrust>
<pmhs:AttorneyFees contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">4000</pmhs:AttorneyFees>
<us-gaap:AccruedBonusesCurrentAndNoncurrent contextRef="Context_As_Of_13_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">10000</us-gaap:AccruedBonusesCurrentAndNoncurrent>
<us-gaap:FeesAndCommissionsOther contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="2">150.00</us-gaap:FeesAndCommissionsOther>
<us-gaap:OfficersCompensation contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD" decimals="0">60000</us-gaap:OfficersCompensation>
<pmhs:PensionContributionsPercentage contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="pure" decimals="2">0.10</pmhs:PensionContributionsPercentage>
<us-gaap:SubsequentEventDescription contextRef="Context_Custom_01_Mar_2015T00_00_00_TO_13_Mar_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember">(i) all salary payable in accordance with the terms of the Wolfe Employment Agreement, along with any unpaid accrued expenses, through the Termination Date; (ii) attorney fees of up to a maximum of $4,000; (iii) a bonus in an amount equal to $10,000 following the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2014; and (iv) a fee of $150.00 per hour for any consulting services that Mr. Wolfe may provide in connection with the filing and completion of the Company's current and periodic filings with the Securities and Exchange Commission; provided that the first 100 hours of consultant services provided from May 1, 2015 through October 31, 2015 shall not be billable.</us-gaap:SubsequentEventDescription>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>pmhs-20141231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.0001527728.com/20141231" elementFormDefault="qualified"
xmlns:pmhs="http://www.0001527728.com/20141231"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2014-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.0001527728.com/role/Documentandentityinformation" id="Documentandentityinformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedBalanceSheet" id="ConsolidatedBalanceSheet">
<link:definition>002 - Statement - Consolidated Balance Sheet</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedBalanceSheetParenthetical" id="ConsolidatedBalanceSheetParenthetical">
<link:definition>003 - Statement - Consolidated Balance Sheet (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfOperations" id="ConsolidatedStatementOfOperations">
<link:definition>004 - Statement - Consolidated Statement of Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss" id="ConsolidatedStatementsOfOtherComprehensiveLoss">
<link:definition>005 - Statement - Consolidated Statements of Other Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficit" id="ConsolidatedStatementOfStockholdersDeficit">
<link:definition>006 - Statement - Consolidated Statement of Stockholders' (Deficit)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficitParenthetical" id="ConsolidatedStatementOfStockholdersDeficitParenthetical">
<link:definition>007 - Statement - Consolidated Statement of Stockholders' (Deficit) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows" id="ConsolidatedStatementOfCashFlows">
<link:definition>008 - Statement - Consolidated Statement of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>010 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/DefiniteLifeIntangibleAssets" id="DefiniteLifeIntangibleAssets">
<link:definition>011 - Disclosure - Definite Life Intangible Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/NotesPayableRelatedParty" id="NotesPayableRelatedParty">
<link:definition>012 - Disclosure - Notes Payable - Related Party</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Convertiblebondpayablerelatedparty" id="Convertiblebondpayablerelatedparty">
<link:definition>013 - Disclosure - Convertible Bond Payable - Related Party</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/DerivativeLiabilities" id="DerivativeLiabilities">
<link:definition>014 - Disclosure - Derivative Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Leases" id="Leases">
<link:definition>015 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>016 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/LossPerShare" id="LossPerShare">
<link:definition>017 - Disclosure - Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/StockholdersEquity" id="StockholdersEquity">
<link:definition>018 - Disclosure - Stockholder's Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>019 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Disposition" id="Disposition">
<link:definition>020 - Disclosure - Disposition</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>021 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/SubsequentEvent" id="SubsequentEvent">
<link:definition>022 - Disclosure - Subsequent Event</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies" id="SummaryofSignificantAccountingPoliciesPolicies">
<link:definition>023 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/PropertyandEquipmentTables" id="PropertyandEquipmentTables">
<link:definition>024 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsTables" id="DefiniteLifeIntangibleAssetsTables">
<link:definition>025 - Disclosure - Definite Life Intangible Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Notespayablerelatedpartytables" id="Notespayablerelatedpartytables">
<link:definition>026 - Disclosure - Notes Payable - Related Party (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>027 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/LossPerShareTables" id="LossPerShareTables">
<link:definition>028 - Disclosure - Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails" id="SummaryofSignificantAccountingPoliciesDetails">
<link:definition>029 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/PropertyandEquipmentDetails" id="PropertyandEquipmentDetails">
<link:definition>030 - Disclosure - Property and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/PropertyAndEquipmentDetailsTextual" id="PropertyAndEquipmentDetailsTextual">
<link:definition>031 - Disclosure - Property and Equipment (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Definitelifeintangibleassetsdetails" id="Definitelifeintangibleassetsdetails">
<link:definition>032 - Disclosure - Definite Life Intangible Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Definitelifeintangibleassetsdetailstextual" id="Definitelifeintangibleassetsdetailstextual">
<link:definition>033 - Disclosure - Definite Life Intangible Assets (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails" id="Notespayablerelatedpartydetails">
<link:definition>034 - Disclosure - Notes Payable - Related Party (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails1" id="Notespayablerelatedpartydetails1">
<link:definition>035 - Disclosure - Notes Payable - Related Party (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual" id="NotesPayableRelatedPartyDetailsTextual">
<link:definition>036 - Disclosure - Notes Payable - Related Party (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Convertiblebondpayablerelatedpartydetails" id="Convertiblebondpayablerelatedpartydetails">
<link:definition>037 - Disclosure - Convertible Bond Payable - Related Party (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/DerivativeLiabilitiesDetails" id="DerivativeLiabilitiesDetails">
<link:definition>038 - Disclosure - Derivative Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/LeasesDetails" id="LeasesDetails">
<link:definition>039 - Disclosure - Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>040 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Incometaxesdetails1" id="Incometaxesdetails1">
<link:definition>041 - Disclosure - Income Taxes (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/IncomeTaxesDetails2" id="IncomeTaxesDetails2">
<link:definition>042 - Disclosure - Income Taxes (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/Incometaxesdetailstextual" id="Incometaxesdetailstextual">
<link:definition>043 - Disclosure - Income Taxes (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/LossPerShareDetails" id="LossPerShareDetails">
<link:definition>044 - Disclosure - Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
<link:definition>045 - Disclosure - Stockholder's Equity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/CommitmentsandContingenciesDetails" id="CommitmentsandContingenciesDetails">
<link:definition>046 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/DispositionDetails" id="DispositionDetails">
<link:definition>047 - Disclosure - Disposition (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>048 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.0001527728.com/role/SubsequentEventDetails" id="SubsequentEventDetails">
<link:definition>049 - Disclosure - Subsequent Event (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="pmhs-20141231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="pmhs-20141231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="pmhs-20141231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="pmhs-20141231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="pmhs_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockOfferingEscrow" id="pmhs_StockOfferingEscrow" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConsultingExpenses" id="pmhs_ConsultingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="GainOnForgivenessOfDebt" id="pmhs_GainOnForgivenessOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="WeightedAverageBasicAndDilutedLossPerShare" id="pmhs_WeightedAverageBasicAndDilutedLossPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" id="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" id="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonSharesIssuedInPaymentOfNotesPayableValue" id="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonSharesIssuedInPaymentOfNotesPayable" id="pmhs_CommonSharesIssuedInPaymentOfNotesPayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonSharesIssuedInPaymentOfNotesPayableValueOne" id="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonSharesIssuedInPaymentOfNotesPayableOne" id="pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" id="pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" id="pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" id="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" id="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" id="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" id="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" id="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" id="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" id="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" id="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" id="pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" id="pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccumulatedEarningsRounding" id="pmhs_AccumulatedEarningsRounding" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" id="pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotesPayableRelatedPartyPerShare" id="pmhs_NotesPayableRelatedPartyPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotesPayableRelatedPartyPerShareOne" id="pmhs_NotesPayableRelatedPartyPerShareOne" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementAcquisitionPercentage" id="pmhs_ShareExchangeAgreementAcquisitionPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementSharesIssuedToParentCompany" id="pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonShares" id="pmhs_IssuanceOfCommonShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesOne" id="pmhs_IssuanceOfCommonSharesOne" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesValue" id="pmhs_IssuanceOfCommonSharesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesValueOne" id="pmhs_IssuanceOfCommonSharesValueOne" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfPublicOfferingCost" id="pmhs_IssuanceOfPublicOfferingCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PublicOfferingValuePerShare" id="pmhs_PublicOfferingValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="OfferingCostNet" id="pmhs_OfferingCostNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IssuanceOfCommonSharesTwo" id="pmhs_IssuanceOfCommonSharesTwo" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementValuePerShare" id="pmhs_PrivatePlacementValuePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrivatePlacementValue" id="pmhs_PrivatePlacementValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInPrepaidExpenseAndDeposits" id="pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NetIncreaseDecreaseInCashHeldInEscrow" id="pmhs_NetIncreaseDecreaseInCashHeldInEscrow" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CashPaidDuringPeriodsForAbstract" id="pmhs_CashPaidDuringPeriodsForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccretionOfDiscountOnBondPayable" id="pmhs_AccretionOfDiscountOnBondPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ChangeInFairValueOfDerivativeLiability" id="pmhs_ChangeInFairValueOfDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotesPayableDisclosureTextBlock" id="pmhs_NotesPayableDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LossPerShareAbstract" id="pmhs_LossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValueAddedTaxPolicyTextBlock" id="pmhs_ValueAddedTaxPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValueAddedTaxPercentage" id="pmhs_ValueAddedTaxPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValueAddedTaxPaidToVendors" id="pmhs_ValueAddedTaxPaidToVendors" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ProceedsFromSaleOfSubsidiary" id="pmhs_ProceedsFromSaleOfSubsidiary" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementCommonStockShares" id="pmhs_ShareExchangeAgreementCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" id="pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementNumberOfShareCancellation" id="pmhs_ShareExchangeAgreementNumberOfShareCancellation" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" id="pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LabEquipmentAndInstrumentsMember" id="pmhs_LabEquipmentAndInstrumentsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FivePercentNotePayablePasecoApsMember" id="pmhs_FivePercentNotePayablePasecoApsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" id="pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotePayableMlGroupMember" id="pmhs_NotePayableMlGroupMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" id="pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FivePercentNotePayableSuneOlsenHoldingApsMember" id="pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="FivePercentNotePayableSuneOlsenMember" id="pmhs_FivePercentNotePayableSuneOlsenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SuneOlsenHoldingApsMember" id="pmhs_SuneOlsenHoldingApsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PasecoApsMember" id="pmhs_PasecoApsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DktiAsMember" id="pmhs_DktiAsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NlbditTwoZeroOneZeroEnterprisesLlcMember" id="pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanOneMember" id="pmhs_LoanOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanTwoMember" id="pmhs_LoanTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanThreeMember" id="pmhs_LoanThreeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanFourMember" id="pmhs_LoanFourMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanFiverMember" id="pmhs_LoanFiverMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanSixMember" id="pmhs_LoanSixMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanSevenMember" id="pmhs_LoanSevenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanEightMember" id="pmhs_LoanEightMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanNineMember" id="pmhs_LoanNineMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanTenMember" id="pmhs_LoanTenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedInterestInPercentage" id="pmhs_AccruedInterestInPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockExchangedDuringPeriodOfConversionOfDebt" id="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedLegalFees" id="pmhs_AccruedLegalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="LoanOutstandingIncurredPenalty" id="pmhs_LoanOutstandingIncurredPenalty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="RemainingDiscountsOnBond" id="pmhs_RemainingDiscountsOnBond" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedInterestMember" id="pmhs_AccruedInterestMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativeLiabilityMember" id="pmhs_DerivativeLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LeasedLaboratorySpaceMember" id="pmhs_LeasedLaboratorySpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="LeasedOfficeSpaceMember" id="pmhs_LeasedOfficeSpaceMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="OperatingLeaseAgreementDescription" id="pmhs_OperatingLeaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" id="pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetExcessTaxOverDepreciationPatents" id="pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="StatutoryIncomeTaxReconciliationRateExpenseBenefit" id="pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OtherIncomeTaxReconciliationRateExpenseBenefit" id="pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxReconciliationValuationAllowance" id="pmhs_IncomeTaxReconciliationValuationAllowance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExcessTaxBenefitOverDepreciationFixedAssets" id="pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExcessTaxBenefitOverDepreciationPatents" id="pmhs_ExcessTaxBenefitOverDepreciationPatents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxExpenseBenefitOperatingLossCarryforwards" id="pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" id="pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="DanishTaxMember" id="pmhs_DanishTaxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxTextualAbstract" id="pmhs_IncomeTaxTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InitialPublicOfferingOneMember" id="pmhs_InitialPublicOfferingOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExchangedSharesOfParentSCommonStock" id="pmhs_ExchangedSharesOfParentSCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesTextualAbstract" id="pmhs_CommitmentsAndContingenciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TerminationOfAgreement" id="pmhs_TerminationOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PaymentsForRoyaltiesPeriod" id="pmhs_PaymentsForRoyaltiesPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsTextualAbstract" id="pmhs_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForgaveInLegalServices" id="pmhs_ForgaveInLegalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AdditionalLegalServices" id="pmhs_AdditionalLegalServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="SubsequentEventTextualAbstract" id="pmhs_SubsequentEventTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AttorneyFees" id="pmhs_AttorneyFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PensionContributionsPercentage" id="pmhs_PensionContributionsPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>pmhs-20141231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedBalanceSheet" roleURI="http://www.0001527728.com/role/ConsolidatedBalanceSheet"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_EscrowDeposit" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DeferredOfferingCosts" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsNoncurrent" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockOfferingEscrow" xlink:label="loc_pmhs_StockOfferingEscrow" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_pmhs_StockOfferingEscrow" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent" order="10" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfOperations" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfOperations"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_SalesRevenueGoodsNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsSold" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ConsultingExpenses" xlink:label="loc_pmhs_ConsultingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_pmhs_ConsultingExpenses" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpense" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_GainOnForgivenessOfDebt" xlink:label="loc_pmhs_GainOnForgivenessOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_pmhs_GainOnForgivenessOfDebt" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_DerivativeGainOnDerivative" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeOther" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementsOfOtherComprehensiveLoss" roleURI="http://www.0001527728.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfCashFlows" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationAndAmortization" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionOfDiscount" xlink:label="loc_us-gaap_AccretionOfDiscount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AccretionOfDiscount" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:label="loc_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable" order="70" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" order="80" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" order="90" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xlink:label="loc_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets" order="30" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromNotesPayable" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="40" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Definitelifeintangibleassetsdetails" roleURI="http://www.0001527728.com/role/Definitelifeintangibleassetsdetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Definitelifeintangibleassetsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="60" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Notespayablerelatedpartydetails" roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Notespayablerelatedpartydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="loc_us-gaap_LongTermDebt" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermNotesPayable" xlink:to="loc_us-gaap_LongTermDebtCurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Notespayablerelatedpartydetails1" roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails1"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Notespayablerelatedpartydetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" order="50" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#IncomeTaxesDetails" roleURI="http://www.0001527728.com/role/IncomeTaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:label="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:to="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:to="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" order="40" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Incometaxesdetails1" roleURI="http://www.0001527728.com/role/Incometaxesdetails1"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Incometaxesdetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xlink:label="loc_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xlink:label="loc_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxReconciliationValuationAllowance" xlink:label="loc_pmhs_IncomeTaxReconciliationValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_pmhs_IncomeTaxReconciliationValuationAllowance" order="40" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#IncomeTaxesDetails2" roleURI="http://www.0001527728.com/role/IncomeTaxesDetails2"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/IncomeTaxesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:label="loc_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExcessTaxBenefitOverDepreciationPatents" xlink:label="loc_pmhs_ExcessTaxBenefitOverDepreciationPatents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_pmhs_ExcessTaxBenefitOverDepreciationPatents" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:label="loc_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xlink:label="loc_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="loc_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" order="40" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#LossPerShareDetails" roleURI="http://www.0001527728.com/role/LossPerShareDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/LossPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="20" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>pmhs-20141231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfStockholdersDeficit" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#PropertyandEquipmentDetails" roleURI="http://www.0001527728.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Notespayablerelatedpartydetails" roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#NotesPayableRelatedPartyDetailsTextual" roleURI="http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#DerivativeLiabilitiesDetails" roleURI="http://www.0001527728.com/role/DerivativeLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#LeasesDetails" roleURI="http://www.0001527728.com/role/LeasesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Incometaxesdetailstextual" roleURI="http://www.0001527728.com/role/Incometaxesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#StockholdersEquityDetails" roleURI="http://www.0001527728.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SubsequentEventDetails" roleURI="http://www.0001527728.com/role/SubsequentEventDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_10" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_11" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_12" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_13" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_14" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_15" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xlink:label="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue_16" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xlink:label="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares_17" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue_18" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares_19" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne_20" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne_21" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue_22" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares_23" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne_24" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne_25" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue_26" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares_27" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_28" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccumulatedEarningsRounding" xlink:label="loc_pmhs_AccumulatedEarningsRounding_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_AccumulatedEarningsRounding_29" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_30" order="230" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_us-gaap_ParentCompanyMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPercentage" xlink:label="loc_pmhs_ValueAddedTaxPercentage_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ValueAddedTaxPercentage_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPaidToVendors" xlink:label="loc_pmhs_ValueAddedTaxPaidToVendors_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ValueAddedTaxPaidToVendors_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ProceedsFromSaleOfSubsidiary" xlink:label="loc_pmhs_ProceedsFromSaleOfSubsidiary_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ProceedsFromSaleOfSubsidiary_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonStockShares" xlink:label="loc_pmhs_ShareExchangeAgreementCommonStockShares_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ShareExchangeAgreementCommonStockShares_13" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:label="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_14" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany_15" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_16" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementNumberOfShareCancellation" xlink:label="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_17" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xlink:label="loc_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares_19" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_us-gaap_CashFDICInsuredAmount_21" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_8" xlink:to="loc_us-gaap_SharesOutstanding_22" order="130" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LabEquipmentAndInstrumentsMember" xlink:label="loc_pmhs_LabEquipmentAndInstrumentsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_pmhs_LabEquipmentAndInstrumentsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Notespayablerelatedpartydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayablePasecoApsMember" xlink:label="loc_pmhs_FivePercentNotePayablePasecoApsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_FivePercentNotePayablePasecoApsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xlink:label="loc_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotePayableMlGroupMember" xlink:label="loc_pmhs_NotePayableMlGroupMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_NotePayableMlGroupMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:label="loc_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" xlink:label="loc_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayableSuneOlsenMember" xlink:label="loc_pmhs_FivePercentNotePayableSuneOlsenMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_FivePercentNotePayableSuneOlsenMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_LongTermDebt_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_LongTermDebtCurrent_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_LongTermNotesPayable_12" order="30" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SuneOlsenHoldingApsMember" xlink:label="loc_pmhs_SuneOlsenHoldingApsMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_SuneOlsenHoldingApsMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PasecoApsMember" xlink:label="loc_pmhs_PasecoApsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_PasecoApsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DktiAsMember" xlink:label="loc_pmhs_DktiAsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_DktiAsMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:label="loc_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_us-gaap_UnsecuredDebtMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanOneMember" xlink:label="loc_pmhs_LoanOneMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanOneMember_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanTwoMember" xlink:label="loc_pmhs_LoanTwoMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanTwoMember_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanThreeMember" xlink:label="loc_pmhs_LoanThreeMember_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanThreeMember_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanFourMember" xlink:label="loc_pmhs_LoanFourMember_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanFourMember_14" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanFiverMember" xlink:label="loc_pmhs_LoanFiverMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanFiverMember_15" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanSixMember" xlink:label="loc_pmhs_LoanSixMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanSixMember_16" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanSevenMember" xlink:label="loc_pmhs_LoanSevenMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanSevenMember_17" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanEightMember" xlink:label="loc_pmhs_LoanEightMember_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanEightMember_18" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanNineMember" xlink:label="loc_pmhs_LoanNineMember_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanNineMember_19" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanTenMember" xlink:label="loc_pmhs_LoanTenMember_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanTenMember_20" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_UnsecuredDebt_21" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestInPercentage" xlink:label="loc_pmhs_AccruedInterestInPercentage_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_pmhs_AccruedInterestInPercentage_22" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_LoansPayableCurrent_23" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_OtherShortTermBorrowings_24" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:label="loc_us-gaap_InterestExpenseOtherShortTermBorrowings_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_InterestExpenseOtherShortTermBorrowings_25" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_26" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_27" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_28" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_29" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xlink:label="loc_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt_30" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedLegalFees" xlink:label="loc_pmhs_AccruedLegalFees_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_pmhs_AccruedLegalFees_31" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanOutstandingIncurredPenalty" xlink:label="loc_pmhs_LoanOutstandingIncurredPenalty_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_pmhs_LoanOutstandingIncurredPenalty_32" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_33" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_34" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_LoansPayable_35" order="150" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/DerivativeLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_5" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_5" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_us-gaap_ConvertibleDebtMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestMember" xlink:label="loc_pmhs_AccruedInterestMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_pmhs_AccruedInterestMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DerivativeLiabilityMember" xlink:label="loc_pmhs_DerivativeLiabilityMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_pmhs_DerivativeLiabilityMember_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_11" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_12" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_13" order="40" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/LeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LeasedLaboratorySpaceMember" xlink:label="loc_pmhs_LeasedLaboratorySpaceMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_pmhs_LeasedLaboratorySpaceMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LeasedOfficeSpaceMember" xlink:label="loc_pmhs_LeasedOfficeSpaceMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_pmhs_LeasedOfficeSpaceMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7" xlink:to="loc_us-gaap_SubsequentEventMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OperatingLeaseAgreementDescription" xlink:label="loc_pmhs_OperatingLeaseAgreementDescription_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0" xlink:to="loc_pmhs_OperatingLeaseAgreementDescription_10" order="20" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Incometaxesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DanishTaxMember" xlink:label="loc_pmhs_DanishTaxMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_pmhs_DanishTaxMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxTextualAbstract" xlink:label="loc_pmhs_IncomeTaxTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_pmhs_IncomeTaxTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_IncomeTaxTextualAbstract_5" xlink:to="loc_us-gaap_OperatingLossCarryforwards_6" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_us-gaap_ParentCompanyMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9" xlink:to="loc_us-gaap_ConvertibleDebtMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestMember" xlink:label="loc_pmhs_AccruedInterestMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9" xlink:to="loc_pmhs_AccruedInterestMember_11" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DerivativeLiabilityMember" xlink:label="loc_pmhs_DerivativeLiabilityMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9" xlink:to="loc_pmhs_DerivativeLiabilityMember_12" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_us-gaap_IPOMember_15" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_InitialPublicOfferingOneMember" xlink:label="loc_pmhs_InitialPublicOfferingOneMember_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_pmhs_InitialPublicOfferingOneMember_16" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_us-gaap_PrivatePlacementMember_17" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_18" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_19" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_20" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_21" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_22" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_23" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_25" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_26" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_27" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_27" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:label="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_28" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_28" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementNumberOfShareCancellation" xlink:label="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_29" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_29" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExchangedSharesOfParentSCommonStock" xlink:label="loc_pmhs_ExchangedSharesOfParentSCommonStock_30" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_ExchangedSharesOfParentSCommonStock_30" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_31" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_31" order="140" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_32" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_32" order="150" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_33" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_33" order="160" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_34" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_34" order="170" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_35" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_35" order="180" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_36" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_36" order="190" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_37" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_37" order="200" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_38" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_38" order="210" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_39" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_39" order="220" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_40" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_40" order="230" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SubsequentEventDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SubsequentEventTextualAbstract" xlink:label="loc_pmhs_SubsequentEventTextualAbstract_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_pmhs_SubsequentEventTextualAbstract_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AttorneyFees" xlink:label="loc_pmhs_AttorneyFees_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_5" xlink:to="loc_pmhs_AttorneyFees_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_5" xlink:to="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_7" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FeesAndCommissionsOther" xlink:label="loc_us-gaap_FeesAndCommissionsOther_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_5" xlink:to="loc_us-gaap_FeesAndCommissionsOther_8" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_5" xlink:to="loc_us-gaap_OfficersCompensation_9" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PensionContributionsPercentage" xlink:label="loc_pmhs_PensionContributionsPercentage_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_5" xlink:to="loc_pmhs_PensionContributionsPercentage_10" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_5" xlink:to="loc_us-gaap_SubsequentEventDescription_11" order="50" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>pmhs-20141231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DocumentAndEntityInformationAbstract" xlink:label="loc_6275329951G0_pmhs_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document - Document and Entity Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_DocumentAndEntityInformationAbstract" xlink:to="lab_8497541173I2_pmhs_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityRegistrantName" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_6275329951G0_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityCentralIndexKey" xlink:to="lab_8497541173I2_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_4HG8324JGII39406FJGK_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_AmendmentFlag" xlink:to="lab_6JI0546LIKK51628HLIM_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_6275329951G0_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_CurrentFiscalYearEndDate" xlink:to="lab_8497541173I2_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_4HG8324JGII39406FJGK_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentType" xml:lang="en-US">Document Type</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_DocumentType" xlink:to="lab_6JI0546LIKK51628HLIM_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_6275329951G0_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_DocumentPeriodEndDate" xlink:to="lab_8497541173I2_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_4HG8324JGII39406FJGK_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_DocumentFiscalYearFocus" xlink:to="lab_6JI0546LIKK51628HLIM_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_6275329951G0_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_DocumentFiscalPeriodFocus" xlink:to="lab_8497541173I2_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityWellKnownSeasonedIssuer" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityWellKnownSeasonedIssuer"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_6275329951G0_dei_EntityVoluntaryFilers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityVoluntaryFilers" xlink:to="lab_8497541173I2_dei_EntityVoluntaryFilers"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityCurrentReportingStatus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityCurrentReportingStatus" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityCurrentReportingStatus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_6275329951G0_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityFilerCategory" xlink:to="lab_8497541173I2_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_4HG8324JGII39406FJGK_dei_EntityPublicFloat" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_EntityPublicFloat" xlink:to="lab_6JI0546LIKK51628HLIM_dei_EntityPublicFloat"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_6275329951G0_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_8497541173I2_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Balance Sheet [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_6275329951G0_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AssetsAbstract" xlink:to="lab_8497541173I2_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current Assets:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AssetsCurrentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_6275329951G0_us-gaap_Cash" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_Cash" xml:lang="en-US">Cash (1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_8497541173I2_us-gaap_Cash" xml:lang="en-US">Balances held in financial institutions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_8497541173I2_us-gaap_Cash" xml:lang="en-US">CASH, BEGINNING OF PERIOD</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_8497541173I2_us-gaap_Cash" xml:lang="en-US">CASH, END OF PERIOD</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_Cash" xlink:to="lab_8497541173I2_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EscrowDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EscrowDeposit" xml:lang="en-US">Escrow Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EscrowDeposit" xml:lang="en-US">Cash held in escrow (2)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EscrowDeposit" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EscrowDeposit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_6275329951G0_us-gaap_AccountsAndOtherReceivablesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Accounts and Other Receivables, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AccountsAndOtherReceivablesNetCurrent" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_8497541173I2_us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_6275329951G0_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AssetsCurrent" xml:lang="en-US">Assets Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsCurrent" xml:lang="en-US">Total Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AssetsCurrent" xlink:to="lab_8497541173I2_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Net Property and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and Equipment, net accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_6275329951G0_us-gaap_AssetsNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsNoncurrentAbstract" xml:lang="en-US">OTHER ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_8497541173I2_us-gaap_AssetsNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Definite life intangible assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US">Finite-Lived Intangible Assets, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_6275329951G0_us-gaap_DeferredOfferingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred Offering Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DeferredOfferingCosts" xml:lang="en-US">Deferred stock offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DeferredOfferingCosts" xlink:to="lab_8497541173I2_us-gaap_DeferredOfferingCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DepositsAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DepositsAssetsNoncurrent" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DepositsAssetsNoncurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DepositsAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_6275329951G0_us-gaap_AssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AssetsNoncurrent" xml:lang="en-US">Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_AssetsNoncurrent" xml:lang="en-US">Total Other Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AssetsNoncurrent" xlink:to="lab_8497541173I2_us-gaap_AssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Assets" xml:lang="en-US">TOTAL ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_Assets" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_6275329951G0_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Stockholders Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Shareholder's Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDER'S DEFICIENCY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current Liabilities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_6275329951G0_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Notes Payable -Related Party, Current Portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Note payable - related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Notes payable - related party, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xml:lang="en-US">Total Notes Payable - Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:to="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockOfferingEscrow" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_StockOfferingEscrow" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockOfferingEscrow" xml:lang="en-US">Stock Offering Escrow</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockOfferingEscrow" xml:lang="en-US">Stock Offering Escrow</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockOfferingEscrow" xml:lang="en-US">This element represents stock offering escrow.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_StockOfferingEscrow" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_StockOfferingEscrow"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_6275329951G0_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable - trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccountsPayableCurrent" xlink:to="lab_8497541173I2_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccountsPayableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccountsPayableRelatedPartiesCurrent" xml:lang="en-US">Accounts payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccountsPayableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_6275329951G0_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_8497541173I2_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccruedIncomeTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccruedIncomeTaxesCurrent" xml:lang="en-US">Accrued income taxes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccruedIncomeTaxesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_6275329951G0_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LiabilitiesCurrent" xlink:to="lab_8497541173I2_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Long Term Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LiabilitiesNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_6275329951G0_us-gaap_NotesPayableRelatedPartiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesNoncurrent" xml:lang="en-US">Notes Payable, Related Parties, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesNoncurrent" xml:lang="en-US">Notes payable - related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:to="lab_8497541173I2_us-gaap_NotesPayableRelatedPartiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongTermNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermNotesPayable" xml:lang="en-US">Notes payable -Dandrit (3)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermNotesPayable" xml:lang="en-US">Note Payables Related Party Long Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermNotesPayable" xml:lang="en-US">Note Payables - Related Party Long Term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongTermNotesPayable" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_6275329951G0_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total Long Term Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total Long-Term Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_8497541173I2_us-gaap_LiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities" xml:lang="en-US">Total Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_Liabilities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_6275329951G0_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' EQUITY (DEFICIT):</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDER'S DEFICIENCY:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StockholdersEquityAbstract" xlink:to="lab_8497541173I2_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue" xml:lang="en-US">Common stock; par value 0.0001, 100,000,000 shares authorized, 9,533,290 issued and outstanding at December 31, 2014 and 6,000,000 shares issued and outstanding at December 31, 2013</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockValue" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_6275329951G0_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid In Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AdditionalPaidInCapital" xlink:to="lab_8497541173I2_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_6275329951G0_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated Deficit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_8497541173I2_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholder's Deficiency</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquity" xml:lang="en-US">Total Stockholders' Equity (Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockholdersEquity" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_6275329951G0_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Stockholders Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDER'S EQUITY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total Liabilities and Stockholders' (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_8497541173I2_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_6275329951G0_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_8497541173I2_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockSharesIssued" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_6275329951G0_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_8497541173I2_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Statement of Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncomeStatementAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_6275329951G0_us-gaap_SalesRevenueGoodsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SalesRevenueGoodsNet" xml:lang="en-US">Sales Revenue, Goods, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SalesRevenueGoodsNet" xml:lang="en-US">Net Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SalesRevenueGoodsNet" xlink:to="lab_8497541173I2_us-gaap_SalesRevenueGoodsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CostOfGoodsSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CostOfGoodsSold" xml:lang="en-US">Cost of Goods Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CostOfGoodsSold" xml:lang="en-US">Cost of Goods Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CostOfGoodsSold" xml:lang="en-US">Cost of Goods Sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CostOfGoodsSold" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CostOfGoodsSold"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_6275329951G0_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_GrossProfit" xml:lang="en-US">Gross Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_GrossProfit" xml:lang="en-US">Gross Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_GrossProfit" xlink:to="lab_8497541173I2_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OperatingExpensesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_6275329951G0_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">GENERAL AND ADMINISTRATIVE EXPENSES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_8497541173I2_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ConsultingExpenses" xlink:label="loc_6275329951G0_pmhs_ConsultingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ConsultingExpenses" xml:lang="en-US">Consulting Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ConsultingExpenses" xml:lang="en-US">Consulting expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ConsultingExpenses" xml:lang="en-US">Consulting expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ConsultingExpenses" xlink:to="lab_8497541173I2_pmhs_ConsultingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses" xml:lang="en-US">Total Operating Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OperatingExpenses" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_6275329951G0_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from Operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingIncomeLoss" xlink:to="lab_8497541173I2_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other Income (Expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_6275329951G0_us-gaap_InterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_InterestExpense" xml:lang="en-US">Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_InterestExpense" xml:lang="en-US">Interest (expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_InterestExpense" xml:lang="en-US">Interest (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_InterestExpense" xlink:to="lab_8497541173I2_us-gaap_InterestExpense"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_GainOnForgivenessOfDebt" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_GainOnForgivenessOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_GainOnForgivenessOfDebt" xml:lang="en-US">Gain On Forgiveness Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_GainOnForgivenessOfDebt" xml:lang="en-US">Gain on forgiveness of debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_GainOnForgivenessOfDebt" xml:lang="en-US">Gain on forgiveness of debt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_GainOnForgivenessOfDebt" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_GainOnForgivenessOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_6275329951G0_us-gaap_ForeignCurrencyTransactionGainLossRealized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ForeignCurrencyTransactionGainLossRealized" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), Realized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ForeignCurrencyTransactionGainLossRealized" xml:lang="en-US">Gain (loss) on currency transactions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:to="lab_8497541173I2_us-gaap_ForeignCurrencyTransactionGainLossRealized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeGainOnDerivative" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Derivative, Gain on Derivative</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainOnDerivative" xml:lang="en-US">Gain on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeGainOnDerivative" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainOnDerivative"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_6275329951G0_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest and other income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_InterestIncomeOther" xlink:to="lab_8497541173I2_us-gaap_InterestIncomeOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total Other Income (Expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_6275329951G0_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss Before Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">(LOSS) BEFORE BENEFIT FROM INCOME TAXES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Loss Before Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">(LOSS) BEFORE BENEFIT FROM INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_8497541173I2_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">BENEFIT FROM INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_6275329951G0_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NetIncomeLoss" xml:lang="en-US">(Net Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_8497541173I2_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_NetIncomeLoss" xml:lang="en-US">(Net Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetIncomeLoss" xlink:to="lab_8497541173I2_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerShareBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">BASIC AND DILUTED LOSS PER SHARE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">BASIC AND DILUTED LOSS PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_6275329951G0_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number Of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING- BASIC AND DILUTED</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares used in basic earnings per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average number of common shares used in basic earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_8497541173I2_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_WeightedAverageBasicAndDilutedLossPerShare" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_WeightedAverageBasicAndDilutedLossPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_WeightedAverageBasicAndDilutedLossPerShare" xml:lang="en-US">Weighted Average Basic And Diluted Loss Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_WeightedAverageBasicAndDilutedLossPerShare" xml:lang="en-US">WEIGHTED AVERAGE BASIC AND DILUTED LOSS PER SHARE</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_WeightedAverageBasicAndDilutedLossPerShare" xml:lang="en-US">The amount of net income or loss for the period per each share in instances when weighted average basic and diluted loss per share are the same amount and reported as a single line item on the face of the financial statements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_WeightedAverageBasicAndDilutedLossPerShare" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_WeightedAverageBasicAndDilutedLossPerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_6275329951G0_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_8497541173I2_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">Equity Adjustment for Foreign Currency Translation Year Ended December 31, 2014</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">Currency Translation, Net of Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">(Currency Translation, Net of Taxes)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">(Currency Translation, Net of Taxes)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xml:lang="en-US">(Currency Translation, Net of Taxes)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_6275329951G0_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">(Other Comprehensive Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">(Other Comprehensive Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_8497541173I2_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_6275329951G0_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StatementTable" xlink:to="lab_8497541173I2_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Statement, Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_6275329951G0_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_EquityComponentDomain" xlink:to="lab_8497541173I2_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_6275329951G0_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid In Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional paid-in capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid In Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_8497541173I2_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsMember" xml:lang="en-US">Deficit Accumulated During the Development Stage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Earnings (Deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RetainedEarningsMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_6275329951G0_us-gaap_OtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OtherComprehensiveIncomeMember" xml:lang="en-US">Other Comprehensive Income (Loss) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_OtherComprehensiveIncomeMember" xml:lang="en-US">Other Comprehensive Income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OtherComprehensiveIncomeMember" xlink:to="lab_8497541173I2_us-gaap_OtherComprehensiveIncomeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_6275329951G0_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SharesOutstanding" xml:lang="en-US">Shares of parent common stock outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_8497541173I2_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_8497541173I2_us-gaap_SharesOutstanding" xml:lang="en-US">Balance, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SharesOutstanding" xlink:to="lab_8497541173I2_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Stock Issued During Period Shares Value Conversion Of Bond Payable Related Party And Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Stock issued during period shares value conversion of bond payable related party and derivative liability.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Common shares issued upon conversion of bond payable-related party and derivative liability, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_6275329951G0_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Stock Issued During Period Shares Conversion Of Bond Payable Related Party And Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Stock issued during period shares conversion of bond payable related party and derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_8497541173I2_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xml:lang="en-US">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:to="lab_8497541173I2_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xml:lang="en-US">Common Shares Issued In Payment Of Notes Payable Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xml:lang="en-US">Common shares issued in payment of notes payable - related party at 6.42 per shares, December 2013, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xml:lang="en-US">Common shares issued in payment of notes payable - related party, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xml:lang="en-US">ommon shares issued in payment of notes payable value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_6275329951G0_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xml:lang="en-US">Common Shares Issued In Payment Of Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xml:lang="en-US">Common shares issued in payment of notes payable - related party at 6.42 per shares, December 2013, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xml:lang="en-US">Converted into common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xml:lang="en-US">Common shares issued in payment of notes payable.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xml:lang="en-US">Common shares issued in payment of notes payable - related party , Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:to="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayable"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xml:lang="en-US">Common Shares Issued In Payment Of Notes Payable Value One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xml:lang="en-US">Common shares issued in payment of note payable - related party at 6.42 per shares, December 2013, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xml:lang="en-US">Common shares issued in payment of note payable - related party,Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xml:lang="en-US">Common shares issued in payment of notes payable value one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xlink:label="loc_6275329951G0_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xml:lang="en-US">Common Shares Issued In Payment Of Notes Payable One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xml:lang="en-US">Common shares issued in payment of note payable - related party at 6.42 per shares, December 2013, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xml:lang="en-US">Common shares issued in payment of note payable - related party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xml:lang="en-US">Common shares issued in payment of notes payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xlink:to="lab_8497541173I2_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xml:lang="en-US">Share Exchange Agreement Common Shares Issued For Acquisition During Period Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xml:lang="en-US">To record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement wherein DanDrit Biotech USA Inc. ("Parent") issued 6,000,000 common shares to acquire a 100% interest in DanDrit Biotech A/S ("Subsidiary") DanDrit Biotech USA Inc., (Formerly Putnam Hills Corp),</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xml:lang="en-US">Share exchange agreement common shares issued for acquisition during period Value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xlink:label="loc_6275329951G0_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xml:lang="en-US">Share Exchange Agreement Common Shares Issued For Acquisition During Period Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xml:lang="en-US">To record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement wherein DanDrit Biotech USA Inc. ("Parent") issued 6,000,000 common shares to acquire a 100% interest in DanDrit Biotech A/S ("Subsidiary") DanDrit Biotech USA Inc., (Formerly Putnam Hills Corp), Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xml:lang="en-US">Shares of common stock of parent outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xml:lang="en-US">Share exchange agreement common shares issued for acquisition during period shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xlink:to="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xml:lang="en-US">Issuance Of Common Shares In Connection With Public Offering During Period Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xml:lang="en-US">To record the issuance of 4,000 and 141,000 common shares on September 4, 2014 in connection Initial Public Offering valued at $5 per share or $4,000 and $141,000, respectfully. Net of stock offering cost of $67,000, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xml:lang="en-US">Issuance of Common Shares in Connection with Public Offering during Period Value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xml:lang="en-US">Issuance Of Common Shares In Connection With Public Offering During Period Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xml:lang="en-US">To record the issuance of 4,000 and 141,000 common shares on September 4, 2014 in connection Initial Public Offering valued at $5 per share or $4,000 and $141,000, respectfully. Net of stock offering cost of $67,000, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xml:lang="en-US">Issuance of Common Shares in Connection with Public Offering during Period Shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xml:lang="en-US">Issuance Of Common Shares In Connection With Public Offering During Period Value One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xml:lang="en-US">To record the issuance of 100 common shares on September 24, 2014 in connection Initial Public Offering valued at $5 per share or $500, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xml:lang="en-US">Issuance Of Common Shares In Connection With Public Offering During Period Value One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xml:lang="en-US">Issuance Of Common Shares In Connection With Public Offering During Period One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xml:lang="en-US">To record the issuance of 100 common shares on September 24, 2014 in connection Initial Public Offering valued at $5 per share or $500, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xml:lang="en-US">Issuance Of Common Shares In Connection With Public Offering During Period One.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xml:lang="en-US">Issuance Of Common Shares In Connection With Initial Public Offering During Period Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xml:lang="en-US">To record the issuance of 889,690 common shares in October, 2014 in connection Initial Public Offering valued at $5 per share or $4,358,879 net of stock offering cost of $89,360 value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xml:lang="en-US">Issuance of common shares in connection with initial public offering during period value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xml:lang="en-US">Issuance Of Common Shares In Connection With Initial Public Offering During Period Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xml:lang="en-US">To record the issuance of 889,690 common shares in October, 2014 in connection Initial Public Offering valued at $5 per share or $4,358,879 net of stock offering cost of $89,360, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xml:lang="en-US">Issuance of common shares in connection with initial public offering during period shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xml:lang="en-US">Issuance Of Common Shares In Connection With Initial Public Offering During Period Value One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xml:lang="en-US">To record the issuance of 58,500 common shares on November 13, 2014 in connection Initial Public Offering valued at $5 per share or $292,500, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xml:lang="en-US">Issuance of common shares in connection with initial public offering during period value one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xml:lang="en-US">Issuance Of Common Shares In Connection With Initial Public Offering During Period Share One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xml:lang="en-US">To record the issuance of 58,500 common shares on November 13, 2014 in connection Initial Public Offering valued at $5 per share or $292,500, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xml:lang="en-US">Issuance of common shares in connection with initial public offering during period shares one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xml:lang="en-US">Issuance Of Common Shares In Connection With Private Placement During Period Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xml:lang="en-US">To record the issuance of 400,000 common shares on December 31, 2014 in connection private placement valued at $5 per share or $2,000,000.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xml:lang="en-US">Issuance of common shares in connection with private placement during period value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xml:lang="en-US">Issuance Of Common Shares In Connection With Private Placement During Period Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xml:lang="en-US">To record the issuance of 400,000 common shares on December 31, 2014 in connection private placement valued at $5 per share or $2,000,000, shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xml:lang="en-US">Issuance of common shares in connection with private placement during period shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccumulatedEarningsRounding" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_AccumulatedEarningsRounding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AccumulatedEarningsRounding" xml:lang="en-US">Accumulated Earnings Rounding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AccumulatedEarningsRounding" xml:lang="en-US">Rounding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AccumulatedEarningsRounding" xml:lang="en-US">Accumulated earnings rounding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_AccumulatedEarningsRounding" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_AccumulatedEarningsRounding"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" xlink:label="loc_6275329951G0_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" xml:lang="en-US">Conversion Of Bond Payable Related Party And Derivative Liability Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" xml:lang="en-US">Conversion of bond payable related party and derivative liability per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" xml:lang="en-US">Conversion of bond payable related party and derivative liability per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" xlink:to="lab_8497541173I2_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotesPayableRelatedPartyPerShare" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_NotesPayableRelatedPartyPerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NotesPayableRelatedPartyPerShare" xml:lang="en-US">Notes Payable Related Party Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NotesPayableRelatedPartyPerShare" xml:lang="en-US">Notes payable related party per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NotesPayableRelatedPartyPerShare" xml:lang="en-US">Notes payable related party per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_NotesPayableRelatedPartyPerShare" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_NotesPayableRelatedPartyPerShare"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotesPayableRelatedPartyPerShareOne" xlink:label="loc_6275329951G0_pmhs_NotesPayableRelatedPartyPerShareOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_NotesPayableRelatedPartyPerShareOne" xml:lang="en-US">Notes Payable Related Party Per Share One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_NotesPayableRelatedPartyPerShareOne" xml:lang="en-US">Notes payable related party per share one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_NotesPayableRelatedPartyPerShareOne" xml:lang="en-US">Notes payable related party per share one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_NotesPayableRelatedPartyPerShareOne" xlink:to="lab_8497541173I2_pmhs_NotesPayableRelatedPartyPerShareOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementAcquisitionPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementAcquisitionPercentage" xml:lang="en-US">Share Exchange Agreement Acquisition Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementAcquisitionPercentage" xml:lang="en-US">Share exchange agreement acquisition percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementAcquisitionPercentage" xml:lang="en-US">Share exchange agreement acquisition percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementAcquisitionPercentage"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:label="loc_6275329951G0_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xml:lang="en-US">Share Exchange Agreement Shares Issued To Parent Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xml:lang="en-US">Share exchange agreement shares issued to parent company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xml:lang="en-US">Share Exchange Agreement Shares Issued To Parent Company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:to="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonShares" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonShares" xml:lang="en-US">Issuance Of Common Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonShares" xml:lang="en-US">Issuance of common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonShares" xml:lang="en-US">Issuance Of Common Shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonShares" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonShares"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesOne" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesOne" xml:lang="en-US">Issuance Of Common Shares One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesOne" xml:lang="en-US">Issuance of common shares one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesOne" xml:lang="en-US">Issuance Of Common Shares One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesOne" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesValue" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesValue" xml:lang="en-US">Issuance Of Common Shares Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesValue" xml:lang="en-US">Issuance of common shares value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesValue" xml:lang="en-US">Issuance of common shares value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfCommonSharesValue" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfCommonSharesValue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesValueOne" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesValueOne" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesValueOne" xml:lang="en-US">Issuance Of Common Shares Value One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesValueOne" xml:lang="en-US">Issuance of common shares value one</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesValueOne" xml:lang="en-US">Issuance Of Common Shares Value One.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesValueOne" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesValueOne"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfPublicOfferingCost" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfPublicOfferingCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfPublicOfferingCost" xml:lang="en-US">Issuance Of Public Offering Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfPublicOfferingCost" xml:lang="en-US">Issuance of Public Offering cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfPublicOfferingCost" xml:lang="en-US">Issuance of public offering cost.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IssuanceOfPublicOfferingCost" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IssuanceOfPublicOfferingCost"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PublicOfferingValuePerShare" xlink:label="loc_6275329951G0_pmhs_PublicOfferingValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_PublicOfferingValuePerShare" xml:lang="en-US">Public Offering Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_PublicOfferingValuePerShare" xml:lang="en-US">Public offering value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_PublicOfferingValuePerShare" xml:lang="en-US">Public Offering Value Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_PublicOfferingValuePerShare" xlink:to="lab_8497541173I2_pmhs_PublicOfferingValuePerShare"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OfferingCostNet" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_OfferingCostNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_OfferingCostNet" xml:lang="en-US">Offering Cost Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_OfferingCostNet" xml:lang="en-US">Net of offering cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_OfferingCostNet" xml:lang="en-US">Offering cost net.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_OfferingCostNet" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_OfferingCostNet"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesTwo" xlink:label="loc_6275329951G0_pmhs_IssuanceOfCommonSharesTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesTwo" xml:lang="en-US">Issuance Of Common Shares Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesTwo" xml:lang="en-US">Issuance of common shares two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IssuanceOfCommonSharesTwo" xml:lang="en-US">Issuance of common shares two.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IssuanceOfCommonSharesTwo" xlink:to="lab_8497541173I2_pmhs_IssuanceOfCommonSharesTwo"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PrivatePlacementValuePerShare" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_PrivatePlacementValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PrivatePlacementValuePerShare" xml:lang="en-US">Private Placement Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PrivatePlacementValuePerShare" xml:lang="en-US">Private placement value per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PrivatePlacementValuePerShare" xml:lang="en-US">Private placement value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_PrivatePlacementValuePerShare" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_PrivatePlacementValuePerShare"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PrivatePlacementValue" xlink:label="loc_6275329951G0_pmhs_PrivatePlacementValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_PrivatePlacementValue" xml:lang="en-US">Private Placement Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_PrivatePlacementValue" xml:lang="en-US">Private placement value.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_PrivatePlacementValue" xlink:to="lab_8497541173I2_pmhs_PrivatePlacementValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By Used In Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash Flows from Operating Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net (loss) to net cash provided (used) by operations:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_6275329951G0_us-gaap_DepreciationAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DepreciationAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DepreciationAndAmortization" xlink:to="lab_8497541173I2_us-gaap_DepreciationAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">Gain (Loss) on Disposition of Stock in Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">(Gain)/Loss on sale of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xml:lang="en-US">(Gain)/Loss on sale of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_GainOrLossOnSaleOfStockInSubsidiary"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionOfDiscount" xlink:label="loc_6275329951G0_us-gaap_AccretionOfDiscount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccretionOfDiscount" xml:lang="en-US">Accretion of Discount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AccretionOfDiscount" xml:lang="en-US">Accretion of discount on bond payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccretionOfDiscount" xlink:to="lab_8497541173I2_us-gaap_AccretionOfDiscount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_GainLossOnSaleOfDerivatives" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">Gain (Loss) on Sale of Derivatives</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">(Gain)/Loss on Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GainLossOnSaleOfDerivatives" xml:lang="en-US">(Gain)/Loss on derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_GainLossOnSaleOfDerivatives" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_GainLossOnSaleOfDerivatives"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_6275329951G0_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_8497541173I2_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">(Increase) decrease in Accounts Receivable Dandrit USA</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">(Increase) decrease in account receivable,</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:label="loc_6275329951G0_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xml:lang="en-US">Increase Decrease In Prepaid Expense And Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xml:lang="en-US">(Increase)Decrease in Prepaid Expenses/Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xml:lang="en-US">The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services and deposits that bring economic benefits for future periods.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xml:lang="en-US">(Increase) decrease in prepaid expenses &amp; deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:to="lab_8497541173I2_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US">Increase (decrease) in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_6275329951G0_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xml:lang="en-US">Increase (decrease) in accounts payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:to="lab_8497541173I2_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US">Increase (decrease) in accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_6275329951G0_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Total Adjustments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:to="lab_8497541173I2_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By Used In Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">NET CASH USED IN OPERATING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash (Used) by Operating Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By Used In Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash Flows from Investing Activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Proceeds from Divestiture of Interest in Subsidiaries and Affiliates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xml:lang="en-US">Proceed from sale of subsidiary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xlink:label="loc_6275329951G0_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xml:lang="en-US">Net Increase Decrease In Cash Held In Escrow</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xml:lang="en-US">Net decrease (increase) in cash held in escrow</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xml:lang="en-US">Net increase decrease in cash held in Escrow.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xlink:to="lab_8497541173I2_pmhs_NetIncreaseDecreaseInCashHeldInEscrow"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PaymentsToAcquireIntangibleAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Payments to Acquire Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Purchase of Intangible Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US">Purchase of intangible assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PaymentsToAcquireIntangibleAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By Used In Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">NET CASH USED BY INVESTING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Used by Investing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By Used In Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash Flows from Financing Activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_6275329951G0_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds From Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from notes payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_8497541173I2_us-gaap_ProceedsFromNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xml:lang="en-US">Proceeds from stock sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromIssuanceOrSaleOfEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_6275329951G0_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of stock offering costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of stock offering costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_8497541173I2_us-gaap_PaymentsOfStockIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromRelatedPartyDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Proceeds from Related Party Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromRelatedPartyDebt" xml:lang="en-US">Payments on notes payable - related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ProceedsFromRelatedPartyDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By Used In Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">NET CASH PROVIDED BY FINANCING ACTIVITIES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used by) Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_8497541173I2_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US">(Gain) loss on Currency Translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_6275329951G0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET INCREASE IN CASH</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net Increase (Decrease) in Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_8497541173I2_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents at Beginning of Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents at End of Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_6275329951G0_us-gaap_SupplementalCashFlowInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Disclosures of Cash Flow Information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_8497541173I2_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CashPaidDuringPeriodsForAbstract" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_CashPaidDuringPeriodsForAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CashPaidDuringPeriodsForAbstract" xml:lang="en-US">Cash Paid During Periods For [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CashPaidDuringPeriodsForAbstract" xml:lang="en-US">Cash paid during the year for</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CashPaidDuringPeriodsForAbstract" xml:lang="en-US">Cash Paid During Periods For.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_CashPaidDuringPeriodsForAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_CashPaidDuringPeriodsForAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_6275329951G0_us-gaap_InterestPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_InterestPaid" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_InterestPaid" xlink:to="lab_8497541173I2_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxesPaid" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_6275329951G0_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Supplemental Disclosure of Non-Cash Investing and Financing Activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_8497541173I2_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccretionOfDiscountOnBondPayable" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_AccretionOfDiscountOnBondPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AccretionOfDiscountOnBondPayable" xml:lang="en-US">Accretion Of Discount On Bond Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AccretionOfDiscountOnBondPayable" xml:lang="en-US">Accretion of discount on bond payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AccretionOfDiscountOnBondPayable" xml:lang="en-US">Accretion of discount on bond payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_AccretionOfDiscountOnBondPayable" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_AccretionOfDiscountOnBondPayable"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_6275329951G0_pmhs_ChangeInFairValueOfDerivativeLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change In Fair Value Of Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change in fair market value of derivative liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ChangeInFairValueOfDerivativeLiability" xml:lang="en-US">Change in fair value of derivative liability.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ChangeInFairValueOfDerivativeLiability" xlink:to="lab_8497541173I2_pmhs_ChangeInFairValueOfDerivativeLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_6275329951G0_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_8497541173I2_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">PROPERTY AND EQUIPMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US">Definite Life Intangible Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_IntangibleAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US">DEFINITE LIFE INTANGIBLE ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_IntangibleAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NotesPayableAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NotesPayableAbstract" xml:lang="en-US">Notes Payable - Related Party [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NotesPayableAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NotesPayableAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotesPayableDisclosureTextBlock" xlink:label="loc_6275329951G0_pmhs_NotesPayableDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_NotesPayableDisclosureTextBlock" xml:lang="en-US">Notes Payable Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_NotesPayableDisclosureTextBlock" xml:lang="en-US">NOTES PAYABLE - RELATED PARTY</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_NotesPayableDisclosureTextBlock" xml:lang="en-US">Notes payable text block.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_NotesPayableDisclosureTextBlock" xlink:to="lab_8497541173I2_pmhs_NotesPayableDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Convertible Bond Payable - Related Party [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">CONVERTIBLE BOND PAYABLE - RELATED PARTY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US">Derivative Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US">DERIVATIVE LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LeasesAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LeasesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xml:lang="en-US">Operating Leases of Lessor Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xml:lang="en-US">LEASES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LossPerShareAbstract" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LossPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LossPerShareAbstract" xml:lang="en-US">Loss Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LossPerShareAbstract" xml:lang="en-US">nitial public offeringinitial public offeringLoss per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LossPerShareAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LossPerShareAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_6275329951G0_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">LOSS PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_8497541173I2_us-gaap_EarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockholdersEquityNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xml:lang="en-US">Disposition [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xml:lang="en-US">DISPOSITION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_6275329951G0_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_8497541173I2_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventsAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Business and Basis of Presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Functional Currency / Foreign currency translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IntangibleAssetsFiniteLivedPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionSalesOfServices" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RevenueRecognitionSalesOfServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RevenueRecognitionSalesOfServices" xml:lang="en-US">Revenue Recognition, Sales of Services [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RevenueRecognitionSalesOfServices" xml:lang="en-US">Revenue Recognition and Sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RevenueRecognitionSalesOfServices" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RevenueRecognitionSalesOfServices"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPolicyTextBlock" xlink:label="loc_6275329951G0_pmhs_ValueAddedTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ValueAddedTaxPolicyTextBlock" xml:lang="en-US">Value Added Tax [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ValueAddedTaxPolicyTextBlock" xml:lang="en-US">Value Added Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ValueAddedTaxPolicyTextBlock" xml:lang="en-US">Value Added Tax policy text block.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ValueAddedTaxPolicyTextBlock" xlink:to="lab_8497541173I2_pmhs_ValueAddedTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_6275329951G0_us-gaap_DerivativesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativesPolicyTextBlock" xml:lang="en-US">Derivatives</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_8497541173I2_us-gaap_DerivativesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_6275329951G0_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_UseOfEstimates" xml:lang="en-US">Accounting Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_UseOfEstimates" xlink:to="lab_8497541173I2_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recent Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_6275329951G0_us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US">Reclassification</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_8497541173I2_us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Summary of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_6275329951G0_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US">Schedule of finite-lived intangible assets, future amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_8497541173I2_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xml:lang="en-US">Summary of notes payable and related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of maturities of long term debt [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US">Schedule of maturities of long term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Summary of deferred tax asset (liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Reconciliation of income tax expense at the federal statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Components of income tax expense (benefit) from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of computing loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_4HG8324JGII39406FJGK_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_dei_LegalEntityAxis" xlink:to="lab_6JI0546LIKK51628HLIM_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_6275329951G0_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_dei_EntityDomain" xlink:to="lab_8497541173I2_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ParentCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ParentCompanyMember" xml:lang="en-US">Parent Company [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ParentCompanyMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ParentCompanyMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_6275329951G0_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_8497541173I2_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPercentage" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ValueAddedTaxPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ValueAddedTaxPercentage" xml:lang="en-US">Value Added Tax Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ValueAddedTaxPercentage" xml:lang="en-US">Value added tax percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ValueAddedTaxPercentage" xml:lang="en-US">Value added tax percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ValueAddedTaxPercentage" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ValueAddedTaxPercentage"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPaidToVendors" xlink:label="loc_6275329951G0_pmhs_ValueAddedTaxPaidToVendors" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ValueAddedTaxPaidToVendors" xml:lang="en-US">Value Added Tax Paid To Vendors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ValueAddedTaxPaidToVendors" xml:lang="en-US">Value added tax paid to Danish and EU vendors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ValueAddedTaxPaidToVendors" xml:lang="en-US">Value added tax paid to vendors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ValueAddedTaxPaidToVendors" xlink:to="lab_8497541173I2_pmhs_ValueAddedTaxPaidToVendors"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ProceedsFromSaleOfSubsidiary" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ProceedsFromSaleOfSubsidiary" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ProceedsFromSaleOfSubsidiary" xml:lang="en-US">Proceeds From Sale Of Subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ProceedsFromSaleOfSubsidiary" xml:lang="en-US">Proceeds from sale of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ProceedsFromSaleOfSubsidiary" xml:lang="en-US">Sale of subsidiary</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ProceedsFromSaleOfSubsidiary" xml:lang="en-US">Proceeds from sale of subsidiary.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ProceedsFromSaleOfSubsidiary" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ProceedsFromSaleOfSubsidiary"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockPricePerShare"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonStockShares" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementCommonStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonStockShares" xml:lang="en-US">Share Exchange Agreement Common Stock Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonStockShares" xml:lang="en-US">Shares prior to share exchange agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonStockShares" xml:lang="en-US">Common stock shares prior to the share exchange agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementCommonStockShares" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementCommonStockShares"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xlink:label="loc_6275329951G0_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xml:lang="en-US">Share Exchange Agreement Shares Held By Consenting Shareholders Of Company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xml:lang="en-US">Share exchange agreement shares held by consenting shareholders of company</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xml:lang="en-US">Share Exchange Agreement Shares held by consnting shareholders of comany.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xlink:to="lab_8497541173I2_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementNumberOfShareCancellation" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementNumberOfShareCancellation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementNumberOfShareCancellation" xml:lang="en-US">Share Exchange Agreement Number Of Share Cancellation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementNumberOfShareCancellation" xml:lang="en-US">Share exchange agreement number of share cancellation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementNumberOfShareCancellation" xml:lang="en-US">Share exchange agreement number of share cancellation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementNumberOfShareCancellation" xml:lang="en-US">Share exchange agreement number of share cancellation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ShareExchangeAgreementNumberOfShareCancellation" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ShareExchangeAgreementNumberOfShareCancellation"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xlink:label="loc_6275329951G0_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xml:lang="en-US">Share Exchange Agreement Common Share In Connection With Acquisition And Offering Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xml:lang="en-US">To record the issuance of 1,400,000 and 40,000 common shares in connection with the acquisition and offering valued at $5 per share or $7,000,000 nd $200,000, respectfully, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xml:lang="en-US">Common shares issued for legal and consulting services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xml:lang="en-US">Share exchange agreement common share in connection with acquisition and offering shares.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xlink:to="lab_8497541173I2_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock reserved for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_6275329951G0_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash insured amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash insured amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CashFDICInsuredAmount" xlink:to="lab_8497541173I2_us-gaap_CashFDICInsuredAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LabEquipmentAndInstrumentsMember" xlink:label="loc_6275329951G0_pmhs_LabEquipmentAndInstrumentsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LabEquipmentAndInstrumentsMember" xml:lang="en-US">Lab Equipment And Instruments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_LabEquipmentAndInstrumentsMember" xml:lang="en-US">Lab equipment and instruments [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_LabEquipmentAndInstrumentsMember" xml:lang="en-US">Lab equipment and instruments member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LabEquipmentAndInstrumentsMember" xlink:to="lab_8497541173I2_pmhs_LabEquipmentAndInstrumentsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ComputerEquipmentMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ComputerEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_6275329951G0_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RangeAxis" xlink:to="lab_8497541173I2_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RangeMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_6275329951G0_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_MinimumMember" xlink:to="lab_8497541173I2_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_MaximumMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful life (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Gross Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_8497541173I2_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_6275329951G0_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_Depreciation" xlink:to="lab_8497541173I2_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US">2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_6275329951G0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US">2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US">2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_6275329951G0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xml:lang="en-US">2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_6275329951G0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_8497541173I2_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AdjustmentForAmortization" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US">Related Party [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_6275329951G0_us-gaap_RelatedPartyDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyDomain" xml:lang="en-US">Related Party [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RelatedPartyDomain" xlink:to="lab_8497541173I2_us-gaap_RelatedPartyDomain"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayablePasecoApsMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_FivePercentNotePayablePasecoApsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_FivePercentNotePayablePasecoApsMember" xml:lang="en-US">Five Percent Note Payable Paseco Aps [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_FivePercentNotePayablePasecoApsMember" xml:lang="en-US">5% Note Payable Paseco ApS [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_FivePercentNotePayablePasecoApsMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_FivePercentNotePayablePasecoApsMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xlink:label="loc_6275329951G0_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xml:lang="en-US">Non Interest Bearing Loan Payable Sunrise Financial Group Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xml:lang="en-US">Non Interest Bearing Loan Payable Sunrise Financial Group Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xml:lang="en-US">Non interest bearing loan payable sunrise financial group inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xlink:to="lab_8497541173I2_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotePayableMlGroupMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_NotePayableMlGroupMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NotePayableMlGroupMember" xml:lang="en-US">Note Payable Ml Group [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NotePayableMlGroupMember" xml:lang="en-US">Note Payable ML Group [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_NotePayableMlGroupMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_NotePayableMlGroupMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:label="loc_6275329951G0_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xml:lang="en-US">Six Percent Promissory Note Payable To Nlbdit Two Zero One Zero Enterprises, Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xml:lang="en-US">6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xml:lang="en-US">6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:to="lab_8497541173I2_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" xml:lang="en-US">Five Percent Note Payable Sune Olsen Holding Aps [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" xml:lang="en-US">5% Note Payable - Sune Olsen Holding ApS [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayableSuneOlsenMember" xlink:label="loc_6275329951G0_pmhs_FivePercentNotePayableSuneOlsenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_FivePercentNotePayableSuneOlsenMember" xml:lang="en-US">Five Percent Note Payable Sune Olsen [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_FivePercentNotePayableSuneOlsenMember" xml:lang="en-US">5% Note Payable - Sune Olsen [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_FivePercentNotePayableSuneOlsenMember" xlink:to="lab_8497541173I2_pmhs_FivePercentNotePayableSuneOlsenMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US">Related Party Transaction [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_RelatedPartyTransactionLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_6275329951G0_us-gaap_LongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermDebt" xml:lang="en-US">Long-term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermDebt" xml:lang="en-US">Total Notes Payable - Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermDebt" xml:lang="en-US">Total Notes Payable - Related Party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermDebt" xlink:to="lab_8497541173I2_us-gaap_LongTermDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Long-term Debt, Current Maturities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtCurrent" xml:lang="en-US">Less Current Maturities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_6275329951G0_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US">2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US">2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_6275329951G0_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US">2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US">2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_6275329951G0_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_8497541173I2_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US">Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SuneOlsenHoldingApsMember" xlink:label="loc_6275329951G0_pmhs_SuneOlsenHoldingApsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_SuneOlsenHoldingApsMember" xml:lang="en-US">Sune Olsen Holding Aps [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_SuneOlsenHoldingApsMember" xlink:to="lab_8497541173I2_pmhs_SuneOlsenHoldingApsMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PasecoApsMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_PasecoApsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PasecoApsMember" xml:lang="en-US">Paseco Aps [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PasecoApsMember" xml:lang="en-US">Paseco Aps [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_PasecoApsMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_PasecoApsMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DktiAsMember" xlink:label="loc_6275329951G0_pmhs_DktiAsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_DktiAsMember" xml:lang="en-US">Dkti As [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_DktiAsMember" xml:lang="en-US">DKTI A/S [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_DktiAsMember" xlink:to="lab_8497541173I2_pmhs_DktiAsMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" xml:lang="en-US">Nlbdit Two Zero One Zero Enterprises, Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" xml:lang="en-US">NLBDIT 2010 Enterprises, LLC.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_6275329951G0_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_8497541173I2_us-gaap_LongtermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LongtermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_6275329951G0_us-gaap_UnsecuredDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Unsecured Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_UnsecuredDebtMember" xml:lang="en-US">Loan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_UnsecuredDebtMember" xlink:to="lab_8497541173I2_us-gaap_UnsecuredDebtMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanOneMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LoanOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanOneMember" xml:lang="en-US">Loan One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanOneMember" xml:lang="en-US">Loan One [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LoanOneMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LoanOneMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanTwoMember" xlink:label="loc_6275329951G0_pmhs_LoanTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LoanTwoMember" xml:lang="en-US">Loan Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_LoanTwoMember" xml:lang="en-US">Loan Two [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LoanTwoMember" xlink:to="lab_8497541173I2_pmhs_LoanTwoMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanThreeMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LoanThreeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanThreeMember" xml:lang="en-US">Loan Three [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LoanThreeMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LoanThreeMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanFourMember" xlink:label="loc_6275329951G0_pmhs_LoanFourMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LoanFourMember" xml:lang="en-US">Loan Four [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LoanFourMember" xlink:to="lab_8497541173I2_pmhs_LoanFourMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanFiverMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LoanFiverMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanFiverMember" xml:lang="en-US">Loan Five [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LoanFiverMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LoanFiverMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanSixMember" xlink:label="loc_6275329951G0_pmhs_LoanSixMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LoanSixMember" xml:lang="en-US">Loan Six [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LoanSixMember" xlink:to="lab_8497541173I2_pmhs_LoanSixMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanSevenMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LoanSevenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanSevenMember" xml:lang="en-US">Loan Seven [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LoanSevenMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LoanSevenMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanEightMember" xlink:label="loc_6275329951G0_pmhs_LoanEightMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LoanEightMember" xml:lang="en-US">Loan Eight [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LoanEightMember" xlink:to="lab_8497541173I2_pmhs_LoanEightMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanNineMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LoanNineMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanNineMember" xml:lang="en-US">Loan Nine [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LoanNineMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LoanNineMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanTenMember" xlink:label="loc_6275329951G0_pmhs_LoanTenMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LoanTenMember" xml:lang="en-US">Loan Ten [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_LoanTenMember" xml:lang="en-US">Loan ten.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LoanTenMember" xlink:to="lab_8497541173I2_pmhs_LoanTenMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_UnsecuredDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_UnsecuredDebt" xml:lang="en-US">Unsecured Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_UnsecuredDebt" xml:lang="en-US">Unsecured loan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_UnsecuredDebt" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_UnsecuredDebt"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestInPercentage" xlink:label="loc_6275329951G0_pmhs_AccruedInterestInPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_AccruedInterestInPercentage" xml:lang="en-US">Accrued Interest In Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_AccruedInterestInPercentage" xml:lang="en-US">Accrued interest in percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_AccruedInterestInPercentage" xml:lang="en-US">Accrued interest.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_AccruedInterestInPercentage" xlink:to="lab_8497541173I2_pmhs_AccruedInterestInPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LoansPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loans Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LoansPayableCurrent" xml:lang="en-US">Loans payable, current</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LoansPayableCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LoansPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_6275329951G0_us-gaap_OtherShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OtherShortTermBorrowings" xml:lang="en-US">Other Short-term Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_OtherShortTermBorrowings" xml:lang="en-US">Company borrowed loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OtherShortTermBorrowings" xlink:to="lab_8497541173I2_us-gaap_OtherShortTermBorrowings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_InterestExpenseOtherShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_InterestExpenseOtherShortTermBorrowings" xml:lang="en-US">Interest Expense, Other Short-term Borrowings</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_InterestExpenseOtherShortTermBorrowings" xml:lang="en-US">Interest expense, borrowing loans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_InterestExpenseOtherShortTermBorrowings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_6275329951G0_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Additional loan on borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_8497541173I2_us-gaap_ProceedsFromIssuanceOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US">Increased interest percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentIncreaseAccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentIncreaseAccruedInterest" xml:lang="en-US">Debt Instrument accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentIncreaseAccruedInterest" xml:lang="en-US">Accrued interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentIncreaseAccruedInterest" xml:lang="en-US">Accrued interest percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xml:lang="en-US">Common Stock Exchanged During Period Of Conversion Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xml:lang="en-US">Common stock exchanged during period of conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xml:lang="en-US">Common stock exchanged during period of conversion of debt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedLegalFees" xlink:label="loc_6275329951G0_pmhs_AccruedLegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_AccruedLegalFees" xml:lang="en-US">Accrued Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_AccruedLegalFees" xml:lang="en-US">Accrued legal fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_AccruedLegalFees" xlink:to="lab_8497541173I2_pmhs_AccruedLegalFees"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanOutstandingIncurredPenalty" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LoanOutstandingIncurredPenalty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanOutstandingIncurredPenalty" xml:lang="en-US">Loan Outstanding Incurred Penalty</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LoanOutstandingIncurredPenalty" xml:lang="en-US">Loan outstanding.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LoanOutstandingIncurredPenalty" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LoanOutstandingIncurredPenalty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentMaturityDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US">Debt Instrument, Maturity Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentMaturityDate" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentMaturityDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Extended maturity date, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayable" xlink:label="loc_6275329951G0_us-gaap_LoansPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_LoansPayable" xml:lang="en-US">Loans Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_LoansPayable" xml:lang="en-US">Loans payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_LoansPayable" xlink:to="lab_8497541173I2_us-gaap_LoansPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible bonds, amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Convertible bonds, amount borrowed</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentFaceAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Convertible bonds, stated percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Debt Instrument, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentDescription" xml:lang="en-US">Convertible bonds, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentDescription" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_6275329951G0_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US">Convertible bonds and related accrued interest, intial rate of conversion into common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_8497541173I2_us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xml:lang="en-US">Convertible bonds, after conversion estimated fairvalue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseCommercialPaper" xlink:label="loc_6275329951G0_us-gaap_InterestExpenseCommercialPaper" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_InterestExpenseCommercialPaper" xml:lang="en-US">Interest Expense, Commercial Paper</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_InterestExpenseCommercialPaper" xml:lang="en-US">Interest expense for the accertion of discount on note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_InterestExpenseCommercialPaper" xlink:to="lab_8497541173I2_us-gaap_InterestExpenseCommercialPaper"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_InterestReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_InterestReceivable" xml:lang="en-US">Interest Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_InterestReceivable" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_InterestReceivable" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_InterestReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_6275329951G0_us-gaap_DerivativeLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DerivativeLiabilities" xml:lang="en-US">Derivative liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativeLiabilities" xlink:to="lab_8497541173I2_us-gaap_DerivativeLiabilities"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_RemainingDiscountsOnBond" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_RemainingDiscountsOnBond" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_RemainingDiscountsOnBond" xml:lang="en-US">Remaining Discounts On Bond</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_RemainingDiscountsOnBond" xml:lang="en-US">Remaining discounts on bond</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_RemainingDiscountsOnBond" xml:lang="en-US">Remaining discounts on bond.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_RemainingDiscountsOnBond" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_RemainingDiscountsOnBond"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_6275329951G0_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xml:lang="en-US">Bond, related accrued interest and derivative liability, converted into shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="lab_8497541173I2_us-gaap_DebtConversionConvertedInstrumentSharesIssued1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Debt Instrument, Convertible, Terms of Conversion Feature</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xml:lang="en-US">Convertible bonds, conversion description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_8497541173I2_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_6275329951G0_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_8497541173I2_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ShortTermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ShortTermDebtTypeAxis" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ShortTermDebtTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_6275329951G0_us-gaap_ShortTermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ShortTermDebtTypeDomain" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_8497541173I2_us-gaap_ShortTermDebtTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_ConvertibleDebtMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_ConvertibleDebtMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestMember" xlink:label="loc_6275329951G0_pmhs_AccruedInterestMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_AccruedInterestMember" xml:lang="en-US">Accrued Interest [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_AccruedInterestMember" xlink:to="lab_8497541173I2_pmhs_AccruedInterestMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DerivativeLiabilityMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_DerivativeLiabilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_DerivativeLiabilityMember" xml:lang="en-US">Derivative Liability [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_DerivativeLiabilityMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_DerivativeLiabilityMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_6275329951G0_us-gaap_DerivativesFairValueLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DerivativesFairValueLineItems" xml:lang="en-US">Derivatives, Fair Value [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_8497541173I2_us-gaap_DerivativesFairValueLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeGainLossOnDerivativeNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet" xml:lang="en-US">Derivative liabilities gain</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DerivativeGainLossOnDerivativeNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LeasedLaboratorySpaceMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_LeasedLaboratorySpaceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LeasedLaboratorySpaceMember" xml:lang="en-US">Leased Laboratory Space [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LeasedLaboratorySpaceMember" xml:lang="en-US">Lab space [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_LeasedLaboratorySpaceMember" xml:lang="en-US">Leased laboratory space.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_LeasedLaboratorySpaceMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_LeasedLaboratorySpaceMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LeasedOfficeSpaceMember" xlink:label="loc_6275329951G0_pmhs_LeasedOfficeSpaceMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_LeasedOfficeSpaceMember" xml:lang="en-US">Leased Office Space [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_LeasedOfficeSpaceMember" xml:lang="en-US">Office space [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_LeasedOfficeSpaceMember" xml:lang="en-US">Leased office space.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_LeasedOfficeSpaceMember" xlink:to="lab_8497541173I2_pmhs_LeasedOfficeSpaceMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_6275329951G0_us-gaap_OperatingLeasedAssetsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingLeasedAssetsLineItems" xml:lang="en-US">Operating Leased Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_8497541173I2_us-gaap_OperatingLeasedAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_OperatingLeasesRentExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rental payments for Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OperatingLeaseAgreementDescription" xlink:label="loc_6275329951G0_pmhs_OperatingLeaseAgreementDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_OperatingLeaseAgreementDescription" xml:lang="en-US">Operating Lease Agreement Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_OperatingLeaseAgreementDescription" xml:lang="en-US">Operating lease agreement, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_OperatingLeaseAgreementDescription" xml:lang="en-US">Operating lease agreement description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_OperatingLeaseAgreementDescription" xlink:to="lab_8497541173I2_pmhs_OperatingLeaseAgreementDescription"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xml:lang="en-US">Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xml:lang="en-US">Excess of Tax over book depreciation Fixed assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xml:lang="en-US">Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="loc_6275329951G0_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xml:lang="en-US">Deferred Tax Asset Excess Tax Over Depreciation Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xml:lang="en-US">Excess of Tax over book depreciation Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xml:lang="en-US">Deferred Tax Asset Excess Tax Over Depreciation Patents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:to="lab_8497541173I2_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net Operating Loss Carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_6275329951G0_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation Allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_8497541173I2_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xml:lang="en-US">Deferred Tax Assets, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xml:lang="en-US">Total Deferred Tax Asset (Liabilities)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xlink:label="loc_6275329951G0_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xml:lang="en-US">Statutory Income Tax Reconciliation Rate Expense Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xml:lang="en-US">Computed Tax at Expected Statutory Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xml:lang="en-US">Statutory Income Tax Reconciliation Rate Expense Benefit.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xlink:to="lab_8497541173I2_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xml:lang="en-US">Other Income Tax Reconciliation Rate Expense Benefit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xml:lang="en-US">Non-US Income Taxed at Different Rates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xml:lang="en-US">Other Income Tax Reconciliation Rate Expense Benefit.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_6275329951G0_us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US">Non-Deductable expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="lab_8497541173I2_us-gaap_IncomeTaxReconciliationNondeductibleExpense"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxReconciliationValuationAllowance" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IncomeTaxReconciliationValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxReconciliationValuationAllowance" xml:lang="en-US">Income Tax Reconciliation Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxReconciliationValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxReconciliationValuationAllowance" xml:lang="en-US">Income Tax Reconciliation Valuation Allowance.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IncomeTaxReconciliationValuationAllowance" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxReconciliationValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_6275329951G0_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Current Tax Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_8497541173I2_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US">Danish Income Tax</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_6275329951G0_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_8497541173I2_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xml:lang="en-US">Excess Tax Benefit Over Depreciation Fixed Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xml:lang="en-US">Excess of Tax over Book Depreciation Fixed Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xml:lang="en-US">Excess Tax Benefit Over Depreciation Fixed Assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExcessTaxBenefitOverDepreciationPatents" xlink:label="loc_6275329951G0_pmhs_ExcessTaxBenefitOverDepreciationPatents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ExcessTaxBenefitOverDepreciationPatents" xml:lang="en-US">Excess Tax Benefit Over Depreciation Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ExcessTaxBenefitOverDepreciationPatents" xml:lang="en-US">Excess of Tax over Book Depreciation Patents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ExcessTaxBenefitOverDepreciationPatents" xml:lang="en-US">Excess Tax Benefit Over Depreciation Patents.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ExcessTaxBenefitOverDepreciationPatents" xlink:to="lab_8497541173I2_pmhs_ExcessTaxBenefitOverDepreciationPatents"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xml:lang="en-US">Income Tax Expense Benefit Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xml:lang="en-US">Net Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xml:lang="en-US">Income Tax Expense Benefit Operating Loss Carryforwards.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xlink:label="loc_6275329951G0_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xml:lang="en-US">Valuation Allowance Income Tax Expense Benefit Change In Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xml:lang="en-US">Change in the Valuation allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xml:lang="en-US">Valuation Allowance Income Tax Expense Benefit Change in Amount.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_8497541173I2_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xml:lang="en-US">Change in the Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xlink:to="lab_8497541173I2_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DeferredIncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total Deferred Tax Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US">Total Deferred Tax Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DeferredIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_6275329951G0_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_8497541173I2_us-gaap_OperatingLossCarryforwardsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IncomeTaxAuthorityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_6275329951G0_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_8497541173I2_us-gaap_IncomeTaxAuthorityDomain"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DanishTaxMember" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_DanishTaxMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_DanishTaxMember" xml:lang="en-US">Danish Tax [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_DanishTaxMember" xml:lang="en-US">Danish Tax [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_DanishTaxMember" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_DanishTaxMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_6275329951G0_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_8497541173I2_us-gaap_OperatingLossCarryforwardsLineItems"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxTextualAbstract" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_IncomeTaxTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxTextualAbstract" xml:lang="en-US">Income Tax (Textual) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxTextualAbstract" xml:lang="en-US">Income Taxes (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_IncomeTaxTextualAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_IncomeTaxTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_6275329951G0_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OperatingLossCarryforwards" xlink:to="lab_8497541173I2_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">LOSS PER SHARE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_6275329951G0_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US">Effect of dilutive securities, stock options and warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_8497541173I2_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted average number of common shares used in basic earnings per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_6275329951G0_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_8497541173I2_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsidiarySaleOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockNameOfTransactionDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_IPOMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IPOMember" xml:lang="en-US">IPO [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_IPOMember" xml:lang="en-US">Initial public offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_IPOMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_IPOMember"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_InitialPublicOfferingOneMember" xlink:label="loc_6275329951G0_pmhs_InitialPublicOfferingOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_InitialPublicOfferingOneMember" xml:lang="en-US">Initial Public Offering One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_InitialPublicOfferingOneMember" xml:lang="en-US">Initial public offering one [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_InitialPublicOfferingOneMember" xml:lang="en-US">Initial public offering one.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_InitialPublicOfferingOneMember" xlink:to="lab_8497541173I2_pmhs_InitialPublicOfferingOneMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private offering [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_PrivatePlacementMember" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_PrivatePlacementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_6275329951G0_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ClassOfStockLineItems" xlink:to="lab_8497541173I2_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Offering of common shares value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Offering of common stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_6275329951G0_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Offering of common shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Offering of common stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_8497541173I2_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SharesIssuedPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Offering of common stock price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_6275329951G0_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of stock common shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_8497541173I2_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Gross proceeds from share issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_6275329951G0_us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from Stock Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US">Proceeds from stock offering, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_8497541173I2_us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExchangedSharesOfParentSCommonStock" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_ExchangedSharesOfParentSCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ExchangedSharesOfParentSCommonStock" xml:lang="en-US">Exchanged Shares Of Parent S Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ExchangedSharesOfParentSCommonStock" xml:lang="en-US">Exchanged shares of parent's common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_ExchangedSharesOfParentSCommonStock" xml:lang="en-US">Exchanged shares of parents common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_ExchangedSharesOfParentSCommonStock" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_ExchangedSharesOfParentSCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_6275329951G0_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xml:lang="en-US">Business acquisition equity ownership, percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="lab_8497541173I2_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_CommitmentsAndContingenciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_CommitmentsAndContingenciesTextualAbstract" xml:lang="en-US">Commitments and Contingencies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_CommitmentsAndContingenciesTextualAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_CommitmentsAndContingenciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_TerminationOfAgreement" xlink:label="loc_6275329951G0_pmhs_TerminationOfAgreement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_TerminationOfAgreement" xml:lang="en-US">Termination Of Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_TerminationOfAgreement" xml:lang="en-US">Termination of agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_TerminationOfAgreement" xml:lang="en-US">Date of agreement termination.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_TerminationOfAgreement" xlink:to="lab_8497541173I2_pmhs_TerminationOfAgreement"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PaymentsForRoyaltiesPeriod" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_PaymentsForRoyaltiesPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PaymentsForRoyaltiesPeriod" xml:lang="en-US">Payments For Royalties Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PaymentsForRoyaltiesPeriod" xml:lang="en-US">Payments for royalties period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PaymentsForRoyaltiesPeriod" xml:lang="en-US">Payments for royalties period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_PaymentsForRoyaltiesPeriod" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_PaymentsForRoyaltiesPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_6275329951G0_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xml:lang="en-US">Gain or loss from the Sale and discontinue operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_8497541173I2_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_RelatedPartyTransactionsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="loc_6275329951G0_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xml:lang="en-US">Related party transactions amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:to="lab_8497541173I2_us-gaap_RelatedPartyTransactionDueFromToRelatedParty"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_LegalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LegalFees" xml:lang="en-US">Legal Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_LegalFees" xml:lang="en-US">Legal expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_LegalFees" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_LegalFees"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ForgaveInLegalServices" xlink:label="loc_6275329951G0_pmhs_ForgaveInLegalServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_ForgaveInLegalServices" xml:lang="en-US">Forgave In Legal Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_ForgaveInLegalServices" xml:lang="en-US">Forgave in legal services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_ForgaveInLegalServices" xml:lang="en-US">Forgave in legal services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_ForgaveInLegalServices" xlink:to="lab_8497541173I2_pmhs_ForgaveInLegalServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Due to Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xml:lang="en-US">Payable to related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AdditionalLegalServices" xlink:label="loc_6275329951G0_pmhs_AdditionalLegalServices" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_AdditionalLegalServices" xml:lang="en-US">Additional Legal Services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_pmhs_AdditionalLegalServices" xml:lang="en-US">Additional legal services</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_AdditionalLegalServices" xml:lang="en-US">Amount for for additional legal services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_AdditionalLegalServices" xlink:to="lab_8497541173I2_pmhs_AdditionalLegalServices"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_AssetsHeldInTrust" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Assets Held-in-trust</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsHeldInTrust" xml:lang="en-US">Balances held in trust</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_AssetsHeldInTrust" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_AssetsHeldInTrust"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventTable" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_SubsequentEventLineItems" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SubsequentEventTextualAbstract" xlink:label="loc_6275329951G0_pmhs_SubsequentEventTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_pmhs_SubsequentEventTextualAbstract" xml:lang="en-US">Subsequent Event Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_pmhs_SubsequentEventTextualAbstract" xml:lang="en-US">Subsequent Event (Textual)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_8497541173I2_pmhs_SubsequentEventTextualAbstract" xml:lang="en-US">Subsequent Event Textual.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_pmhs_SubsequentEventTextualAbstract" xlink:to="lab_8497541173I2_pmhs_SubsequentEventTextualAbstract"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AttorneyFees" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_AttorneyFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AttorneyFees" xml:lang="en-US">Attorney Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AttorneyFees" xml:lang="en-US">Attorney fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_AttorneyFees" xml:lang="en-US">The amount of expense provided in the period for attorney fees.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_AttorneyFees" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_AttorneyFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="loc_6275329951G0_us-gaap_AccruedBonusesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_AccruedBonusesCurrentAndNoncurrent" xml:lang="en-US">Accrued Bonuses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_8497541173I2_us-gaap_AccruedBonusesCurrentAndNoncurrent" xml:lang="en-US">Bonuses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="lab_8497541173I2_us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FeesAndCommissionsOther" xlink:label="loc_4HG8324JGII39406FJGK_us-gaap_FeesAndCommissionsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FeesAndCommissionsOther" xml:lang="en-US">Fees and Commissions, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_us-gaap_FeesAndCommissionsOther" xml:lang="en-US">Consulting fee per hour</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_us-gaap_FeesAndCommissionsOther" xlink:to="lab_6JI0546LIKK51628HLIM_us-gaap_FeesAndCommissionsOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_6275329951G0_us-gaap_OfficersCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_OfficersCompensation" xml:lang="en-US">Officers' Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_8497541173I2_us-gaap_OfficersCompensation" xml:lang="en-US">Gross salary per month</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_OfficersCompensation" xlink:to="lab_8497541173I2_us-gaap_OfficersCompensation"/>
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PensionContributionsPercentage" xlink:label="loc_4HG8324JGII39406FJGK_pmhs_PensionContributionsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PensionContributionsPercentage" xml:lang="en-US">Pension Contributions Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PensionContributionsPercentage" xml:lang="en-US">Pension contributions percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_6JI0546LIKK51628HLIM_pmhs_PensionContributionsPercentage" xml:lang="en-US">Pension contributions percentage.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_4HG8324JGII39406FJGK_pmhs_PensionContributionsPercentage" xlink:to="lab_6JI0546LIKK51628HLIM_pmhs_PensionContributionsPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_6275329951G0_us-gaap_SubsequentEventDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_8497541173I2_us-gaap_SubsequentEventDescription" xml:lang="en-US">Subsequent Event, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_6275329951G0_us-gaap_SubsequentEventDescription" xlink:to="lab_8497541173I2_us-gaap_SubsequentEventDescription"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>pmhs-20141231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Documentandentityinformation" roleURI="http://www.0001527728.com/role/Documentandentityinformation"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedBalanceSheet" roleURI="http://www.0001527728.com/role/ConsolidatedBalanceSheet"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedBalanceSheetParenthetical" roleURI="http://www.0001527728.com/role/ConsolidatedBalanceSheetParenthetical"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfOperations" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfOperations"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementsOfOtherComprehensiveLoss" roleURI="http://www.0001527728.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfStockholdersDeficit" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficit"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfStockholdersDeficitParenthetical" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficitParenthetical"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#ConsolidatedStatementOfCashFlows" roleURI="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#PropertyAndEquipment" roleURI="http://www.0001527728.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#DefiniteLifeIntangibleAssets" roleURI="http://www.0001527728.com/role/DefiniteLifeIntangibleAssets"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#NotesPayableRelatedParty" roleURI="http://www.0001527728.com/role/NotesPayableRelatedParty"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Convertiblebondpayablerelatedparty" roleURI="http://www.0001527728.com/role/Convertiblebondpayablerelatedparty"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#DerivativeLiabilities" roleURI="http://www.0001527728.com/role/DerivativeLiabilities"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Leases" roleURI="http://www.0001527728.com/role/Leases"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#IncomeTaxes" roleURI="http://www.0001527728.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#LossPerShare" roleURI="http://www.0001527728.com/role/LossPerShare"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#StockholdersEquity" roleURI="http://www.0001527728.com/role/StockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#CommitmentsAndContingencies" roleURI="http://www.0001527728.com/role/CommitmentsAndContingencies"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Disposition" roleURI="http://www.0001527728.com/role/Disposition"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#RelatedPartyTransactions" roleURI="http://www.0001527728.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SubsequentEvent" roleURI="http://www.0001527728.com/role/SubsequentEvent"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#PropertyandEquipmentTables" roleURI="http://www.0001527728.com/role/PropertyandEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#DefiniteLifeIntangibleAssetsTables" roleURI="http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsTables"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Notespayablerelatedpartytables" roleURI="http://www.0001527728.com/role/Notespayablerelatedpartytables"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#IncomeTaxesTables" roleURI="http://www.0001527728.com/role/IncomeTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#LossPerShareTables" roleURI="http://www.0001527728.com/role/LossPerShareTables"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#PropertyandEquipmentDetails" roleURI="http://www.0001527728.com/role/PropertyandEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#PropertyAndEquipmentDetailsTextual" roleURI="http://www.0001527728.com/role/PropertyAndEquipmentDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Definitelifeintangibleassetsdetails" roleURI="http://www.0001527728.com/role/Definitelifeintangibleassetsdetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Definitelifeintangibleassetsdetailstextual" roleURI="http://www.0001527728.com/role/Definitelifeintangibleassetsdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Notespayablerelatedpartydetails" roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Notespayablerelatedpartydetails1" roleURI="http://www.0001527728.com/role/Notespayablerelatedpartydetails1"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#NotesPayableRelatedPartyDetailsTextual" roleURI="http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Convertiblebondpayablerelatedpartydetails" roleURI="http://www.0001527728.com/role/Convertiblebondpayablerelatedpartydetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#DerivativeLiabilitiesDetails" roleURI="http://www.0001527728.com/role/DerivativeLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#LeasesDetails" roleURI="http://www.0001527728.com/role/LeasesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#IncomeTaxesDetails" roleURI="http://www.0001527728.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Incometaxesdetails1" roleURI="http://www.0001527728.com/role/Incometaxesdetails1"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#IncomeTaxesDetails2" roleURI="http://www.0001527728.com/role/IncomeTaxesDetails2"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#Incometaxesdetailstextual" roleURI="http://www.0001527728.com/role/Incometaxesdetailstextual"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#LossPerShareDetails" roleURI="http://www.0001527728.com/role/LossPerShareDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#StockholdersEquityDetails" roleURI="http://www.0001527728.com/role/StockholdersEquityDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#CommitmentsandContingenciesDetails" roleURI="http://www.0001527728.com/role/CommitmentsandContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#DispositionDetails" roleURI="http://www.0001527728.com/role/DispositionDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.0001527728.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="pmhs-20141231.xsd#SubsequentEventDetails" roleURI="http://www.0001527728.com/role/SubsequentEventDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Documentandentityinformation">
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DocumentAndEntityInformationAbstract" xlink:label="loc_pmhs_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_10" order="90" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_11" order="100" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_12" order="110" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityPublicFloat_13" order="120" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_14" order="130" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_Cash_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EscrowDeposit" xlink:label="loc_us-gaap_EscrowDeposit_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_EscrowDeposit_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_DeferredOfferingCosts_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaap_DepositsAssetsNoncurrent_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_DepositsAssetsNoncurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaap_AssetsNoncurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_9" xlink:to="loc_us-gaap_AssetsNoncurrent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockOfferingEscrow" xlink:label="loc_pmhs_StockOfferingEscrow_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_pmhs_StockOfferingEscrow_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccountsPayableCurrent_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrent_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableRelatedPartiesNoncurrent" xlink:label="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_NotesPayableRelatedPartiesNoncurrent_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_LongTermNotesPayable_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_24" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_Liabilities_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityAbstract_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_CommonStockValue_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AdditionalPaidInCapital_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_32" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_33" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_29" xlink:to="loc_us-gaap_StockholdersEquity_34" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_35" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedBalanceSheetParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfGoodsSold_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ConsultingExpenses" xlink:label="loc_pmhs_ConsultingExpenses_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_pmhs_ConsultingExpenses_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_OperatingExpenses_8" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_InterestExpense_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_GainOnForgivenessOfDebt" xlink:label="loc_pmhs_GainOnForgivenessOfDebt_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" xlink:to="loc_pmhs_GainOnForgivenessOfDebt_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossRealized" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossRealized_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainOnDerivative" xlink:label="loc_us-gaap_DerivativeGainOnDerivative_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_DerivativeGainOnDerivative_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_InterestIncomeOther_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_10" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_WeightedAverageBasicAndDilutedLossPerShare" xlink:label="loc_pmhs_WeightedAverageBasicAndDilutedLossPerShare_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_pmhs_WeightedAverageBasicAndDilutedLossPerShare_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficit">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_OtherComprehensiveIncomeMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_15" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_16" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue" xlink:label="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue_17" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares" xlink:label="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares_18" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue_19" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares_20" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne_21" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne_22" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue_23" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares_24" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne_25" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne_26" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue_27" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares" xlink:label="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares_28" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_29" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccumulatedEarningsRounding" xlink:label="loc_pmhs_AccumulatedEarningsRounding_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_AccumulatedEarningsRounding_30" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_NetIncomeLoss_31" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_StockholdersEquity_32" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_us-gaap_SharesOutstanding_33" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficitParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" xlink:label="loc_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotesPayableRelatedPartyPerShare" xlink:label="loc_pmhs_NotesPayableRelatedPartyPerShare_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_NotesPayableRelatedPartyPerShare_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotesPayableRelatedPartyPerShareOne" xlink:label="loc_pmhs_NotesPayableRelatedPartyPerShareOne_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_NotesPayableRelatedPartyPerShareOne_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:label="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonShares" xlink:label="loc_pmhs_IssuanceOfCommonShares_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_IssuanceOfCommonShares_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesOne_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesOne_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesValue" xlink:label="loc_pmhs_IssuanceOfCommonSharesValue_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesValue_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesValueOne" xlink:label="loc_pmhs_IssuanceOfCommonSharesValueOne_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesValueOne_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfPublicOfferingCost" xlink:label="loc_pmhs_IssuanceOfPublicOfferingCost_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_IssuanceOfPublicOfferingCost_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PublicOfferingValuePerShare" xlink:label="loc_pmhs_PublicOfferingValuePerShare_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_PublicOfferingValuePerShare_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OfferingCostNet" xlink:label="loc_pmhs_OfferingCostNet_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_OfferingCostNet_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IssuanceOfCommonSharesTwo" xlink:label="loc_pmhs_IssuanceOfCommonSharesTwo_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_IssuanceOfCommonSharesTwo_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PrivatePlacementValuePerShare" xlink:label="loc_pmhs_PrivatePlacementValuePerShare_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_PrivatePlacementValuePerShare_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PrivatePlacementValue" xlink:label="loc_pmhs_PrivatePlacementValue_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_pmhs_PrivatePlacementValue_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaap_DepreciationAndAmortization_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DepreciationAndAmortization_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainOrLossOnSaleOfStockInSubsidiary" xlink:label="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainOrLossOnSaleOfStockInSubsidiary_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccretionOfDiscount" xlink:label="loc_us-gaap_AccretionOfDiscount_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AccretionOfDiscount_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GainLossOnSaleOfDerivatives" xlink:label="loc_us-gaap_GainLossOnSaleOfDerivatives_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnSaleOfDerivatives_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" xlink:label="loc_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NetIncreaseDecreaseInCashHeldInEscrow" xlink:label="loc_pmhs_NetIncreaseDecreaseInCashHeldInEscrow_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_pmhs_NetIncreaseDecreaseInCashHeldInEscrow_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_21" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CashPaidDuringPeriodsForAbstract" xlink:label="loc_pmhs_CashPaidDuringPeriodsForAbstract_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_31" xlink:to="loc_pmhs_CashPaidDuringPeriodsForAbstract_32" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_CashPaidDuringPeriodsForAbstract_32" xlink:to="loc_us-gaap_InterestPaid_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_CashPaidDuringPeriodsForAbstract_32" xlink:to="loc_us-gaap_IncomeTaxesPaid_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccretionOfDiscountOnBondPayable" xlink:label="loc_pmhs_AccretionOfDiscountOnBondPayable_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_pmhs_AccretionOfDiscountOnBondPayable_36" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ChangeInFairValueOfDerivativeLiability" xlink:label="loc_pmhs_ChangeInFairValueOfDerivativeLiability_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_35" xlink:to="loc_pmhs_ChangeInFairValueOfDerivativeLiability_37" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/DefiniteLifeIntangibleAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/NotesPayableRelatedParty">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotesPayableDisclosureTextBlock" xlink:label="loc_pmhs_NotesPayableDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_pmhs_NotesPayableDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Convertiblebondpayablerelatedparty">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/DerivativeLiabilities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Leases">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/LossPerShare">
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LossPerShareAbstract" xlink:label="loc_pmhs_LossPerShareAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_LossPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/StockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Disposition">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SubsequentEvent">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RevenueRecognitionSalesOfServices" xlink:label="loc_us-gaap_RevenueRecognitionSalesOfServices_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionSalesOfServices_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPolicyTextBlock" xlink:label="loc_pmhs_ValueAddedTaxPolicyTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_pmhs_ValueAddedTaxPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/PropertyandEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Notespayablerelatedpartytables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/LossPerShareTables">
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LossPerShareAbstract" xlink:label="loc_pmhs_LossPerShareAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_LossPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_us-gaap_ParentCompanyMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8" xlink:to="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPercentage" xlink:label="loc_pmhs_ValueAddedTaxPercentage_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ValueAddedTaxPercentage_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValueAddedTaxPaidToVendors" xlink:label="loc_pmhs_ValueAddedTaxPaidToVendors_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ValueAddedTaxPaidToVendors_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ProceedsFromSaleOfSubsidiary" xlink:label="loc_pmhs_ProceedsFromSaleOfSubsidiary_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ProceedsFromSaleOfSubsidiary_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonStockShares" xlink:label="loc_pmhs_ShareExchangeAgreementCommonStockShares_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ShareExchangeAgreementCommonStockShares_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:label="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementNumberOfShareCancellation" xlink:label="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares" xlink:label="loc_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_us-gaap_CashFDICInsuredAmount_22" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract_9" xlink:to="loc_us-gaap_SharesOutstanding_23" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/PropertyandEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LabEquipmentAndInstrumentsMember" xlink:label="loc_pmhs_LabEquipmentAndInstrumentsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_pmhs_LabEquipmentAndInstrumentsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/PropertyAndEquipmentDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_Depreciation_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Definitelifeintangibleassetsdetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Definitelifeintangibleassetsdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_AdjustmentForAmortization_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Notespayablerelatedpartydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayablePasecoApsMember" xlink:label="loc_pmhs_FivePercentNotePayablePasecoApsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_FivePercentNotePayablePasecoApsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember" xlink:label="loc_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NotePayableMlGroupMember" xlink:label="loc_pmhs_NotePayableMlGroupMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_NotePayableMlGroupMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:label="loc_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember" xlink:label="loc_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_FivePercentNotePayableSuneOlsenMember" xlink:label="loc_pmhs_FivePercentNotePayableSuneOlsenMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_FivePercentNotePayableSuneOlsenMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_us-gaap_LongTermDebt_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_us-gaap_LongTermDebtCurrent_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_10" xlink:to="loc_us-gaap_LongTermNotesPayable_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Notespayablerelatedpartydetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaap_NotesPayableAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NotesPayableAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2" xlink:to="loc_us-gaap_RelatedPartyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SuneOlsenHoldingApsMember" xlink:label="loc_pmhs_SuneOlsenHoldingApsMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_SuneOlsenHoldingApsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PasecoApsMember" xlink:label="loc_pmhs_PasecoApsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_PasecoApsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DktiAsMember" xlink:label="loc_pmhs_DktiAsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_DktiAsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember" xlink:label="loc_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_3" xlink:to="loc_pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_8" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_us-gaap_UnsecuredDebtMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanOneMember" xlink:label="loc_pmhs_LoanOneMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanOneMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanTwoMember" xlink:label="loc_pmhs_LoanTwoMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanTwoMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanThreeMember" xlink:label="loc_pmhs_LoanThreeMember_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanThreeMember_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanFourMember" xlink:label="loc_pmhs_LoanFourMember_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanFourMember_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanFiverMember" xlink:label="loc_pmhs_LoanFiverMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanFiverMember_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanSixMember" xlink:label="loc_pmhs_LoanSixMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanSixMember_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanSevenMember" xlink:label="loc_pmhs_LoanSevenMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanSevenMember_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanEightMember" xlink:label="loc_pmhs_LoanEightMember_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanEightMember_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanNineMember" xlink:label="loc_pmhs_LoanNineMember_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanNineMember_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanTenMember" xlink:label="loc_pmhs_LoanTenMember_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_9" xlink:to="loc_pmhs_LoanTenMember_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaap_UnsecuredDebt_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_UnsecuredDebt_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestInPercentage" xlink:label="loc_pmhs_AccruedInterestInPercentage_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_pmhs_AccruedInterestInPercentage_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayableCurrent" xlink:label="loc_us-gaap_LoansPayableCurrent_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_LoansPayableCurrent_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_OtherShortTermBorrowings_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseOtherShortTermBorrowings" xlink:label="loc_us-gaap_InterestExpenseOtherShortTermBorrowings_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_InterestExpenseOtherShortTermBorrowings_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_DebtInstrumentIncreaseAccruedInterest_29" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_30" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xlink:label="loc_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt_31" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedLegalFees" xlink:label="loc_pmhs_AccruedLegalFees_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_pmhs_AccruedLegalFees_32" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LoanOutstandingIncurredPenalty" xlink:label="loc_pmhs_LoanOutstandingIncurredPenalty_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_pmhs_LoanOutstandingIncurredPenalty_33" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_34" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_35" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LoansPayable" xlink:label="loc_us-gaap_LoansPayable_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_21" xlink:to="loc_us-gaap_LoansPayable_36" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Convertiblebondpayablerelatedpartydetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentDescription" xlink:label="loc_us-gaap_DebtInstrumentDescription_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentDescription_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseCommercialPaper" xlink:label="loc_us-gaap_InterestExpenseCommercialPaper_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseCommercialPaper_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestReceivable" xlink:label="loc_us-gaap_InterestReceivable_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestReceivable_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_RemainingDiscountsOnBond" xlink:label="loc_pmhs_RemainingDiscountsOnBond_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_pmhs_RemainingDiscountsOnBond_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" xlink:label="loc_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/DerivativeLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_0" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_5" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_us-gaap_ConvertibleDebtMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestMember" xlink:label="loc_pmhs_AccruedInterestMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_pmhs_AccruedInterestMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DerivativeLiabilityMember" xlink:label="loc_pmhs_DerivativeLiabilityMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_6" xlink:to="loc_pmhs_DerivativeLiabilityMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativesFairValueLineItems" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_1" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_10" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_10" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_10" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_10" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentSharesIssued1_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/LeasesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LeasedLaboratorySpaceMember" xlink:label="loc_pmhs_LeasedLaboratorySpaceMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_pmhs_LeasedLaboratorySpaceMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LeasedOfficeSpaceMember" xlink:label="loc_pmhs_LeasedOfficeSpaceMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_pmhs_LeasedOfficeSpaceMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7" xlink:to="loc_us-gaap_SubsequentEventMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_1" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OperatingLeaseAgreementDescription" xlink:label="loc_pmhs_OperatingLeaseAgreementDescription_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_9" xlink:to="loc_pmhs_OperatingLeaseAgreementDescription_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" xlink:label="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" xlink:label="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Incometaxesdetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" xlink:label="loc_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" xlink:label="loc_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpense_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxReconciliationValuationAllowance" xlink:label="loc_pmhs_IncomeTaxReconciliationValuationAllowance_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_pmhs_IncomeTaxReconciliationValuationAllowance_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/IncomeTaxesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" xlink:label="loc_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" xlink:to="loc_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExcessTaxBenefitOverDepreciationPatents" xlink:label="loc_pmhs_ExcessTaxBenefitOverDepreciationPatents_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" xlink:to="loc_pmhs_ExcessTaxBenefitOverDepreciationPatents_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" xlink:label="loc_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" xlink:to="loc_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" xlink:label="loc_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" xlink:to="loc_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/Incometaxesdetailstextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DanishTaxMember" xlink:label="loc_pmhs_DanishTaxMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_pmhs_DanishTaxMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_IncomeTaxTextualAbstract" xlink:label="loc_pmhs_IncomeTaxTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_5" xlink:to="loc_pmhs_IncomeTaxTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_IncomeTaxTextualAbstract_6" xlink:to="loc_us-gaap_OperatingLossCarryforwards_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/LossPerShareDetails">
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_LossPerShareAbstract" xlink:label="loc_pmhs_LossPerShareAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_LossPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/disclosureGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/StockholdersEquityDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ParentCompanyMember" xlink:label="loc_us-gaap_ParentCompanyMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_us-gaap_ParentCompanyMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_8" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9" xlink:to="loc_us-gaap_ConvertibleDebtMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AccruedInterestMember" xlink:label="loc_pmhs_AccruedInterestMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9" xlink:to="loc_pmhs_AccruedInterestMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_DerivativeLiabilityMember" xlink:label="loc_pmhs_DerivativeLiabilityMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9" xlink:to="loc_pmhs_DerivativeLiabilityMember_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_13" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_us-gaap_IPOMember_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_InitialPublicOfferingOneMember" xlink:label="loc_pmhs_InitialPublicOfferingOneMember_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_pmhs_InitialPublicOfferingOneMember_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_14" xlink:to="loc_us-gaap_PrivatePlacementMember_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_19" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_20" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_CommonStockSharesIssued_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_22" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_23" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_26" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_27" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_28" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementAcquisitionPercentage" xlink:label="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_ShareExchangeAgreementAcquisitionPercentage_29" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementNumberOfShareCancellation" xlink:label="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_ShareExchangeAgreementNumberOfShareCancellation_30" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ExchangedSharesOfParentSCommonStock" xlink:label="loc_pmhs_ExchangedSharesOfParentSCommonStock_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_ExchangedSharesOfParentSCommonStock_31" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" xlink:label="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany_32" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_33" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability_34" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability" xlink:label="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability_35" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayable" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayable_36" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_37" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue_37" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_38" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne_38" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" xlink:label="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_39" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne_39" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_40" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_SharesOutstanding_40" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_41" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_18" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_41" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/CommitmentsandContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_CommitmentsAndContingenciesTextualAbstract" xlink:label="loc_pmhs_CommitmentsAndContingenciesTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_pmhs_CommitmentsAndContingenciesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_CommitmentsAndContingenciesTextualAbstract_1" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_TerminationOfAgreement" xlink:label="loc_pmhs_TerminationOfAgreement_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_CommitmentsAndContingenciesTextualAbstract_1" xlink:to="loc_pmhs_TerminationOfAgreement_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PaymentsForRoyaltiesPeriod" xlink:label="loc_pmhs_PaymentsForRoyaltiesPeriod_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_CommitmentsAndContingenciesTextualAbstract_1" xlink:to="loc_pmhs_PaymentsForRoyaltiesPeriod_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/DispositionDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedParty_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LegalFees" xlink:label="loc_us-gaap_LegalFees_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_LegalFees_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_ForgaveInLegalServices" xlink:label="loc_pmhs_ForgaveInLegalServices_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_pmhs_ForgaveInLegalServices_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AdditionalLegalServices" xlink:label="loc_pmhs_AdditionalLegalServices_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_pmhs_AdditionalLegalServices_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsHeldInTrust" xlink:label="loc_us-gaap_AssetsHeldInTrust_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_AssetsHeldInTrust_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.0001527728.com/role/SubsequentEventDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_SubsequentEventTextualAbstract" xlink:label="loc_pmhs_SubsequentEventTextualAbstract_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5" xlink:to="loc_pmhs_SubsequentEventTextualAbstract_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_AttorneyFees" xlink:label="loc_pmhs_AttorneyFees_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_6" xlink:to="loc_pmhs_AttorneyFees_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_6" xlink:to="loc_us-gaap_AccruedBonusesCurrentAndNoncurrent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_FeesAndCommissionsOther" xlink:label="loc_us-gaap_FeesAndCommissionsOther_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_6" xlink:to="loc_us-gaap_FeesAndCommissionsOther_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OfficersCompensation" xlink:label="loc_us-gaap_OfficersCompensation_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_6" xlink:to="loc_us-gaap_OfficersCompensation_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="pmhs-20141231.xsd#pmhs_PensionContributionsPercentage" xlink:label="loc_pmhs_PensionContributionsPercentage_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_6" xlink:to="loc_pmhs_PensionContributionsPercentage_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsequentEventDescription" xlink:label="loc_us-gaap_SubsequentEventDescription_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pmhs_SubsequentEventTextualAbstract_6" xlink:to="loc_us-gaap_SubsequentEventDescription_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`?@"T`P$1``(1`0,1`?_$`)$```$%`0$`````````
M``````,``00%!@('`0`#`0$!`0```````````````0(#!`4&$``"`0,#`P,"
M!`0&`04````!`@,`$00A$@4Q01-1(@9A%'&!D3*A(Q4'\+'10E(S\<'A8G(D
M$0`"`@("`@$#`P4!`````````1$"(0,Q$D$$46%Q$Z$R0H'Q(A0%8O_:``P#
M`0`"$0,1`#\`]7-6:"OZ&@!:VI@,;G0TABJ@D>Y_]J0#'72_2@0_YTQC$T@'
MU(H$-<T`('ZT#%<BF`]S2`;\]*8"W&@!7^NE`"!^M($*YH`5[40`CU!ZT"%<
MBB!G6NWZT`-_G0(5J`&-`Q=Z($.>M`QM/QH`>]`AJ!BI@.#^E(!KT`+2_P#E
M0`W>@!Z`&/\`@TP%VH`>@!C:_P!:`'_\T#%0(5P*!B'\*!#Z6^OI2`1ZZ=;T
M"%<_ZT#&^EZ`'[4`-VH`7^=`"I@-?2D`]^U`"UIA`J0"I@,;T`.*`&_P:`%:
M@!4#'M0(1/>@8U`A[GI2!"N;4P'L=O6D`M+Z_E0`@-30`W:@!4"%3&(G]:0'
M<,$\VX1(7*ZLJZFWX=33%9P6'].XZ%%3+R&CR@J.\0*!AN&XIL/NN!UO:FDV
M<]O829$R\6)09<.7[G%4J&<6NK,NX*UO4:@TFFC37L5N"+N`L;]?6@U'W#KV
M[F@!WW1Z2`K<"VX6ZZCK0`W44`*]("QX_A,O-B:962&$7VO(VT,0;6'?\Z))
M=T@')8_'\9'&,_DH(IYFVP1+N<$C]UV`TM^%JJM+6X1E?V:5Y8L;!:3)A0LK
MPR`R&2-@R^-1N;4=["DU!HMB:E$5I$+'9H"20/IVH+0B:`%0,5_T%`A'_`H&
M/?VTA"/6@0KWM0,1H`1H`6E`#&@"ZP#DX7'OD?T\Y$C[?MEA4-/(S:K9V)5$
MMU-J:4LY]UH6"I&/R>(G*YT&%)BY61$97Q9)`XLX*1_SW]FY-;*IZG4VK=M.
M%,GF];*6E!(7G^+X_C\/#F5266%9$9&E+RM?<[$W9P'N%O\`Y4NC<LTKO5$D
M-'GY:S,0O%X,TEU"RRK>0#HD:`NJ@]VJ>E?J5_LW?P@_%%\IAGOQR0%6V)BE
MUV;U.WR*H.J$CV]CUHM5<2:TWV:RB<N=S84-RC012R^6-<56BD/D`'B,:V([
MW-Z76KX$KW_E@B1X?%S0J\F<KY8TFBQ47861=TBIT4LJZFU2ZYPL&M-_^/,L
M%DP\4527"CFGQ=MY)VEC1!Z@FQ:ZCLJU2IX9-O:^,C3R\/\`*(S#Q_*+CRXL
M7ME3:XVC3IN30=[U:FGB3FM:NUX>3(9OQ3F<N`I_4<3,DQ))'BR0Q4K``I)9
M7`_W`Z+>ME?Z,XK:;/\`DF$_M[\KS'>9I\*1`28E3(6RV&F]-I*ZKU%3LJK(
MU]?>ZN.3T')8Y^)%&D@QHP060",[T_X[2%M]#7.DD>EV;AIF7S)XTS)(5``C
M.U0N@MV.I)I-'52THX5[ZTBSL,/QH`>]Q0`]_;^?2@#H^E`A7_A2!BL/UH`5
MZ8#?0T#.EVF1`URI87`ZD7Z4"?!J.9Y/QI!Q^+B+)BLEWD<JD:A;[5&HW&Z]
M!3I7S)Y^_;&$C)Y7R7/PX0JX'W6)+=4\3A\>-P"&(5QN'Y-71^-/R<=M]JJ(
MP9_*Y@S!<N;C\C&R,R3[.*.-7F)E8%5MM+%=ZCNPJ\(YVW;,$SC?BG!X@R3S
M\2<GEY9`:&0QA(2K7$J["RH0/1KGI46LWP::Z5I/8OL+D^"X[C%R>.D#JT9B
MCQ<AD20!9&2XD5;`"Q*@BH=;/DWKLI6LHB\@\/+0X\N/EQ8ZR,`7F1#D;K%"
MX=55=VTD"K2@SM=74IE!\KY;)XSB&;XWQN3/CX#&+QX\1D+.2#-,I7<SFY]Q
M7I36);$W,5IPAOBGS,K/F8_R"*/'EPHX93CRE)$,LI:UY%]ODC">X7N+T64\
M$Z]JK^[*.OFN-SD^-/+\<$$&1BJ)OLH`BG(BV7;%D1?<)1H4/Y$7I)P@NDVU
MQ]C+_'/F3Y28T<\$L,>.C32?<)M42EO<&OW'I6J<G-V=7]$:!><^.O`DN1C)
MBIBRV8PSM%N:0_MLQ/N+?MZ4FG\EJ];<K@L>;YOBHLO%Q<9<E?N"S-DJ7D4"
M)@IWR#VI^=JFJ?DZ;[5_$!%\@XSDY1D>61C;9N`%F`Z&]ZRO6#U-3<$R*;<+
MK<CL#Z?6LCHDD*U`T$!%(9U?VVTZT`$L=:`%K0`O6D`UZ8A;CUO0,Y9B!?H1
MT-^]`FL$WGN6X[$$F7G3"+(F@6#%PQ[W06)DE:,:J3TU[5M1-\<'E;[5K9ML
M\TOR"8TV5\9D7`E?(\N3,L6XRJZ_O,3$"5M/:&-M>U=%JGG=X?T!\)_?;+3Y
M;!\=R%GM(/M':6&)';(<A5/CBVA-O4ZUSMUF/)UU>Q5[8@]%DQOCN9A\BL65
M+,Z8\LL,L4J[WDC!W!259+W'3MWJF[$]*-/G@P7)9?Q7&X+'Q<*;)Y3(SX_+
MFQ3(Q"ON4+''%%9KWU8H3ZWJTWF3ELJPE3+9O_B?PB3!X!8ODN;C3Y$S%Y\6
M!?Y?O`/C8_OD*ZZM6#V-GH4]6M5#>"FYGFOC_`Q3?&>.2+AL#CXY,J'%",C9
M$8),DQD`)9+F[6]WK>KI7R8[[O\`:N%^I1XB8V?RD_-)OY)5,<L&"<.3'@BD
M_=YF!6/R:`6)7ZF]:QX\'-PYB61H\+%'RKD^5CR'7(S&1IUC8C8?&)-YO?W%
M1K_K358,[6=F4/SC!BCQ)>?P\A<&&=T!8KO659'%XWW;F&X_P[T6+K5.W$HJ
M)OD?%\;"[9J>=\*0Y6.F[S*K)[4=2?W*F[10=*5K)<A2EF\?;^Y>_"/D>2VP
MXD^5$N[R&65+K*7-R+*VX`'\:M1:H*:/G/T-1GY'"_=)-&7CR<R\LAC`?'O>
MQMM`=2Q]16-JL]CU]C:X)V-+[!:L&CL)J-VI%!U.M(#O<+=:!ABU`Q7/2@#D
MM;O>@0VX7I#%NM3`EO,,7!C:$JN?/=O(P#F.._MV*=`6&MZ:CR8;$[2DX14X
MN-@P8N9CS)YI,Y6$V5)9I=S'5BQUL>EA6GY7)SW].JHTN2OP^/PL"*7'Q4,:
M-MLANZA5/^TG0`=JZ)D\NVKI)CL.#&;^XN>5#$QK]Q&SQ':PCC"1B.4Z76P+
M>M5"X(?TX+3Y,G%?')CSO"<1$V+ELSYTP:=I_*;`2,PD"Q)IK:,Z]:RK5IR:
M;&HA%-@_)OCAR\AEAGXV;&A0>253(JI+TDQS;R>X=?;5JR.9ZVDH\DWG/FG,
MX?/8F%//)E<;-*(8II5\A,A0LD15![9&93?TI0E_4T[6M.>"F^UY'GOE&;G<
M]E9467XY,3'R`BQ8\$))81X^ZQFV:[B!KU[U*IR7LVS'P;3^W<W*\?'/@3\P
MW,<;-EN.-Y"-PRO'D(?*CD,Q'C9;>ZQ6Y%K5,8;-?R0TN"5)@#'Y$0\=_/`5
MTR)3M1BP2WCW7!:]QUK63GM6+0C.9WQSD>1DQ<)<^'"D@D67)O&,@D!?VH0W
MCU-K_G39-*I-R9_)FXODLF3&8/%-BDPI/#&5#2(Q0R1`A@4=>S=J:R3FKD29
M\/'3-CXT[39B-9F8`"+;8;=H"C]*IX.K3Z_;++GCYY993,[7=SN?2UR=36%C
MUZ*#2XLI(`_6L;(U+*)M.E26B0";>EJ0QO=N_P#C0(F,1^7K2*.";T`<E^PO
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MY?\`6,A>0Q_=+@.4"$;&W;%/I:M48=7YX,)_<WY/RO%?&<=,%@N1R+R8[9*L
M!)&-N]RBVU!7V@WT_.IW6=4='HZE=R_!Y)Q2YB3+(DDBR!MWD#'=?UN37/1N
M3UK5K'!MN'6<WDD+/(VK.Q)8GZDUT)F<&WXG=91^M)FB-/B`V`K*QHBTAZ6^
MFE04B2O2W>D4$MITH"`SZ$T@."10`)CU^M,0-VH`$[]^]`B3PO&_U3D4Q6E$
M,(!>:6V@5=38]`3]:5K0I`UF6F#B<=%QZHCPJ/8)R"TNTW]JV0$^I;J!7C>U
MN[<ET17S\IG99R(8,I46*(R,L6.XC5MH>\LS`1HNP:7_`(UR.][+#_0O",\>
M=Q.0?&QI\E<O)`/FA;'U<`>YH$`",O>ZNUZX[[FXR4DCSW^Y'QR;F53D,*:*
M#+PP[OQPU]Y.[R;%&Y9;#_;<^HKZ'TO?K:JI9_Y(\?V?6=;.R6&9?X=RF1\<
M\DV9RCPY$H67FL61"ZIY1>&1GMNLM_>X!`/736O7ICEGG;6[.*HG<WRGRCEE
M7-7+S>,,,;OY()EGQ944$QRK+'M4-T(6QOZ53E\8)K9+_P!%O#\WY'*X'C$;
M!BSQCOX>3S#%XI9&`5UE:!D4,UFZWIUG[BV63QP6B<VF'R.SPX\63FQ7.7"@
M7(95-_$Y[=`0*M)28][)#?'/G<'R/ALS'XN*9<Z"01209'[5N=70Z@W4=!K]
M*FME8WVUM10_)C_[B\`9\G$Y2/RRQ>(0S#QLL,3*QZ,3UD)U!`.E%ZSD[O2N
MNL%+@<1"G[1>^HO222.QLT''X.T@@:4#2-+@0;0#4MEI%]C"RBLS1%E&38?2
MH&2%)_.D,-N]MZ!A6.IM^=(`1-C0!PUK4"!/]*:`CN;==*9)HO@PMEY4LIW8
MVQ8W@OH[2'0E3U"@&N?V;))2-(J_F^9@>5^'S$5<G.R<<QY4DI822W*QQB*-
MD?:J-M+`$=:^>WVSU\R:HS/)<QS7+<A-NRYHN(3(\./CK*J^)\B+QM$ME):/
M<6%F'2W2L=FYL23*;"ECFQ87S89)<?'EC\19AC!'A#L8]SAMVY4V[0+::]*S
MK1IL:<\EIB9_\V>19K1Y#^2*='$T)-]JR*P6R;[[=!UITE,B_#//>8BAXCY1
M)P2<><S+GA<Y,KY#OLQY#ND557<JW/10M?9>OM5ZJ%X/#WZFDVW&21Q^?Q?Q
MG@Q)#"V=DOD;(H8Y1+)8W$2JX%E`OKI75^VIR63V7S@%F?+\',R)..G41,`Z
MY$0>XWVNY,I"WMT+`6TTI=TQ?@M'9%;)%S/+<SOAY/'3'VJR1XXWR(D*@!M`
MWO&EKMK4PV^31.M:YKDUF/@<W/B10XKIA8BO_.R"%6><VNTEELH=GZZ5JD<[
M\R:#DOD?$<;#)C9F"_(-F1F*=;JL3%;!B2;F^M]%ZT61W^HIE^3)OQ@QWC>)
MO+B3#=C3>H_XL.S+T(J&>C5ECAP6[=*1H7N+':U1)9:0#2H91.C&FM2-!TZ5
M(PUSLIC#.-3^-)#!,#3$<,#:W6D`%SU%-"(\G0TR21PG)QX'(B2601Q2HT+2
M,;*N_P#:Q'<*P!K+V-;M1QR-%ISF(`TLL6.)>2Q=V1A%D5T-UVMLT:P:Y-OS
MKY?:FF_DZ3"8<S_9YF=A^63(9TGS$956'*G0C^7XHSL&RYZ$$]ZQ[KA\$@^2
MEY%X/C:SRMDR31E7Q,NS1*V/&6=$<C<&DW"]KL-;@]2[633<\"^"'E9&&)H<
MC.@CC\#SRRSQ`JBE01NV;@%5"UE]:6I6O:*\LBT>3,\GRW$XTN7G')7(=P([
MHP,C!@=D05`3N.M?:^IK_'K2?*/GM];7OC@+Q6?!)E086#CG'+,8V"J"R$#<
M2UQ91?0UU)G,Z-/)2?T_X]R;9?@C@Y7DX6W<ECI,\*HBDEEAVJ?(1W]:SZI_
M4Z.UZ1,I>`G!X'Q_C6CY"*+D>/\`MHR7@7(4QL7L[@D1JS6N+ZBBE$N,"V[;
M7QAR;/S9.8I*R_;)(HB0PG5`>C!C:];+DY*XL97DLS*R.1=2I$6.3%&EST4V
M+:]V[U-F>UHUJM2ZX3*A:&;`R&$:S`/"7T59DZ:]MPTJ#=_)<XD!`UTJ6S5(
MM,>.H;+18Q*!4,9*0$?4TAH.FG:U2,+;V_\`I3&'8:GM2`&_>@&"86-``7%A
M]:8@)*!U\E]EQOV]=M];4R661Y#C<6,-A/'C1DDW8;YS8_[V8?P`M6E4H.+8
M]DD3'^9X\^7X,J7QS2NB8\S#0DMKY-1MOI8UY/O_`//E=M?)W:-C2BS(_+<7
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M+'J30V:I)&AP,-5()`)]#29:+O'AU%^M0V66$$1MI4-E$R)"!]:D:)*+8W(I
M,891;M^%(86PVTP#,"32&#8&@4`F'_F@`#WIB(TUQ?UJH$RFY!9F!"FU76"&
M9O+PY6)W$F_UK0@[R.9R<?C9H(GFDS,Q=F9F3R%SL!_ZX@;[0>YZU*UU64LD
M63?+P8KDURI(%QT9O"@90H)M9C=A]=:;JF"P9Z;BIMU[7J+4+5C7'/S</X3Q
M6'Q,0@DF:=,S)L"X=&O91T]RL#<UJFTL')^&MMCM;,&8PN"R\3(3)@=HIXSN
MCE0V8$]P?SK):X9U-A\?XVH(!6UO2J6M!V9I,C'.7C<;CLK!./QAC(I-Q<,6
M+*.U[C]*LSK6"1B\98^U:"T7>)QY%M/RI24D76+C6%JELI(LH8-`:S;*)L2;
M1TJ6,DH--:101>O2U(`RC2],9W==MN]`!V&M($<D>M`P;)0(`T=S3`!)%>F)
MH@9&,#VIIDE7DX0U-:)DP5&9QI<&J3):*F;B"#H*HF",>(%]5H%!(QL2:*"7
M'`!AF(+(PN`R]&7T8>HHD.GDXDP(855YF"*QVJ6TN3T'XT#@(F)AB9HS*GD2
MP=;BX)(%C^9%`02\>'!<J$FC8L_C47&KZG:/K932D<$N+[%6MYX]%WD7&BVO
MN/TM2[#2)L>5QJ&-6R8E,EC&"X!8$[1:_P!=*ELHF8.?@S/+$)$6:%Y5DB++
MN`A<HS'T'MO^%3(R6G*\6OA__3&?N',43*P(+@;B#;II4C)T69A.SJN1&S1$
M+(`P.TLVT7_%M/QJ1HD/EX<.DLZ1D':0S`6)%[:_36D,+'D8K/)&DJ-)%?RH
M""5MUW#M3&/][@A8F^XC`F7?"=PLZ^JGN*0PGW&'MOYD_;Y/W"VRU]WX6UHD
M"8P7N:`&L+]1>@!O;V-`'#"/6Y%``7$=SJ/QI@1I%@M^X?QH((DRX]M6'3ZU
M2$ROG7$U]X_C_I5B($JXFOO%OP/3]*:)P`9,/LX'IH?]*>0P(+B]G'X:_P"E
M&0P0^6CPVQHU:98W,BB!]LK.)-K6,8CLVZU_I:]]*`P#BQ8!ANOWR-A?<7+F
M)O+Y?*NY6(L/W^BT@!8^-Q/VL:29EXA/)]O(L<X8R,L@&P/N&Y2;C:+&U`R7
MAXF.O%YB1Y\;XA4#*D\+[A((4!(`(]I`5K6OZ4AG<D,;R9*R9,<6+]C`,I_'
M*7\?W#&Z!R7!O8:WJ1DW(QN*:!P^9LC+\AN98V)#/(?)V/\`UGK_`,A]*0$U
M,8?U)&.9'_4?N8V=5B?QFT#!4&O4QW:Y:D4#AQ,08N(/OT9!CQ#CF\3B\(RH
MV#2ZW+%]J'IZ^M("1RN/B,V09\M4=F_GA8Y2%OC[3^P]-ONUN.QI#"_;89ES
MPN8X8B7[PB.3<$,BEO'I;<`"&V#N/2F`ZXV!Y,7QYC;=U\&\;D`?<*UGL`A7
D>-HO8>E(83Q<']K_`-Z>#^H^3]K6ONOXO_KLTW?MM]*`/__9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.gif
M1TE&.#EA0`*"`/<``/______S/__F?__9O__,___`/_,___,S/_,F?_,9O_,
M,__,`/^9__^9S/^9F?^99O^9,_^9`/]F__]FS/]FF?]F9O]F,_]F`/\S__\S
MS/\SF?\S9O\S,_\S`/\`__\`S/\`F?\`9O\`,_\``,S__\S_S,S_F<S_9LS_
M,\S_`,S,_\S,S,S,F<S,9LS,,\S,`,R9_\R9S,R9F<R99LR9,\R9`,QF_\QF
MS,QFF<QF9LQF,\QF`,PS_\PSS,PSF<PS9LPS,\PS`,P`_\P`S,P`F<P`9LP`
M,\P``)G__YG_S)G_F9G_9IG_,YG_`)G,_YG,S)G,F9G,9IG,,YG,`)F9_YF9
MS)F9F9F99IF9,YF9`)EF_YEFS)EFF9EF9IEF,YEF`)DS_YDSS)DSF9DS9IDS
M,YDS`)D`_YD`S)D`F9D`9ID`,YD``&;__V;_S&;_F6;_9F;_,V;_`&;,_V;,
MS&;,F6;,9F;,,V;,`&:9_V:9S&:9F6:99F:9,V:9`&9F_V9FS&9FF69F9F9F
M,V9F`&8S_V8SS&8SF68S9F8S,V8S`&8`_V8`S&8`F68`9F8`,V8``#/__S/_
MS#/_F3/_9C/_,S/_`#/,_S/,S#/,F3/,9C/,,S/,`#.9_S.9S#.9F3.99C.9
M,S.9`#-F_S-FS#-FF3-F9C-F,S-F`#,S_S,SS#,SF3,S9C,S,S,S`#,`_S,`
MS#,`F3,`9C,`,S,```#__P#_S`#_F0#_9@#_,P#_``#,_P#,S`#,F0#,9@#,
M,P#,``"9_P"9S`"9F0"99@"9,P"9``!F_P!FS`!FF0!F9@!F,P!F```S_P`S
MS``SF0`S9@`S,P`S````_P``S```F0``9@``,P``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````````"P`````0`*"```(_P`!"!Q(L*#!@P@3*ES(L*'#
MAQ`C2IQ(L:+%BQ@S:MS(L:/'CR!#BAQ)LJ3)DRA3JES)LJ7+ES!CRIQ)LZ;-
MFSASZMS)LZ?/GT"#"AU*M*C1HTB3*EW*M*G3IU"C2IU*M:K5JUBS:EUZX,"*
M%3%DB!U+5L;7KEO3JEW+UNI7L5VZC"&#Z)'=NWCM(D)$)J[8%0?:"AY,N##-
M`V'EULV+U]%>,I#W.F+\")%?P(8S:][,F>(!&7$74W[4MXN5L5]7C.72A<QD
MQI;-=IY-N[9AU5U$PQ[3Q6Q@AI];C[:\PK;QX\BCKA`^FG0.&;\EJB8SF@R7
MZ,FS:]^N\T#NYHYZ%__'^%DW7C+0N:M?SUZE#.JCPZ?GN`(^Y2[M\^O?CW'Y
M:\KH8<>1=__AA8B`_"6HX((`O-<<(C@@V!&!C)$A(8,89IB=#.:=-QY)WE5X
MH88DEJB9`5T4V%@7(WX4XGDMFBCCC%NA^"!^*AU@'VDQTNCCCU#9.!P7+:T@
M&B(?`JGDDD_)H.)=$+[4!91),FGEE41Q&!^.+NFH5Y58ABEF3O4UQV),3E8&
MYIALMNF2D)0=*).-B,3@YIUXKI0F98[(0).12.8IZ*`AE5E=CRF)A2BAC#:Z
MT)3Q^>GHI)0:%4.'=W%9Z::<\C3EDX_TV>FHI-9D9',6EJKJJBS)T-PC.+#_
M*NNL(QD:YZ*TYJHK0ZZBBNNNP`8K4`ZACA:KL,@F>]`!8[RZIK+0[GKJ<,]&
M:ZVLO8YVYK7<YIKM?=V&.RNDHTDJ[KFCOE@NNNQRJBYEU1YDQ5[TUFOOO?CN
M%=>^_/;;1;SM!IS6NXP!3!"<KR;\JB,,-\RPF@)'/!C!!AI,$&[^9IQOO@^C
M:K'$($=%,94L>?46:WL!^''(+#=%KH@S?;:C762LW/+-2'V;5Z`>=8561%YZ
MB//04^E\UV0V.^3=7KSQ:ZY"+Y.6--%4^V0T7E/S"BK$"^%08,U5A[W4M)0]
MK5'41S]BA=8PBNWV44&7/2&HD/&XT)YVC=%C:GSW_[W0"E94T7=J3PSN4&I6
M))YX:A%]I?CB!@]N^$&`2UZEY6\GB':FOS*4PY-D-."JJ`KA_8C>?P>B^NJL
M*_XLX*S'+KOJ``,.B.J/6[&Z%1;#'DCNN%>[PNRKZ[&X0;K'KGN2OK.>-0".
M?Y6Y85?3W+E"!V"*WZF:4JX;Z@H!GKCJ@#B>/.T(I7;[[Y;KKD>\Y_/^H>.K
MQ^L[[Q??G[[BP:]01?Q@:I[\*)<\_$TD>7K`W?0(0[:";<1T>I'4E'B&D.SA
M!7P,&=[O+K8[^`6B?/L+1+4*^+KD"4]W("2@`A.BP;4-)'X((6%"=.?"`]+N
M*RM<(%M&9I?N6:19C.%2FO^.5<'O+:J%23J?!T4X0R;**WCA6UX(G=C$#:8O
MAP)1H@K9]\0:VK"&[M.A8*I7F>LMJT.D`T"(4E7$"QX1B@/1H!5CB+[]K:D*
MY(L<%0M2P`RN[W58A-[NKAA(01IP(KX;#PV?)\:Q[:ACCS`;13;'1H'T2I(#
ML>!=,)@Z+L:QCU5<D_2FZ,7PB;)^#0&E09!XL>15H8I[!(`4+0)*&C:R+9O+
M&WFT5Y`R^3"3!>)D^.`H$#DN\93/TB(MB:F0)Z!RE<PT9D)44$`5O#"6$\'C
M#6]7REMJY5*1NHB6=B;)"3Y+DWE[HR>SB#MKAE)>A^1C(26ROFZF[X^48Z8J
M"6G_Q>'9TX;DFR/T^!9/;T8EEW:KR.;&<!`M85*-+Q,F"W-X/X"1<'#'>Z)`
M$3G(AN@/FK]SYT<7XDSTS1(CYQ.H')]I4*F,DS%IE`@ZH?30*6VK(`8`8CH/
M5T_^%92.Y`.$4(7*S#@F$)N-ZV@JYRG'QZV3(04\J47^]\'=N1-Z`&QI51!*
MP8B\]"Z5Y&.HUI33__SRGKB#X5+9U[=%4NZHPK,<\Y2Z$&HR=7=J/5SK^D-"
M;:ITGEI]BJU@)I&9A>JLT*,.$0^FTT<@%J3XDR94Z\C!GV(5L,V+'2`X"-A5
M[C..4)2L0_S*R&*J,J_^#.Q5OIJ7+AB@<1WJJD&F%%:!_^04+X_M)>Y(P,ZG
M`G5-&45>9Q'7P2K1-7SXA*P[/_NWVZ6P(C*\)OK\65K5!@6ACB`21%(4Q+O5
MQ4XX;6QN.6O`IDX6J8"[JCP_6#L3:M2R($4O'$7K1]\V[K,5#:YUJ<+#RFBW
M(08P+"(>FDGJ^)!9N'T(*P6BS>?^-H-S[:QI*<M9I`IWHZ!=)P(_M@+GEK;#
M%"YF[*J[WZ`,=F?_]2YL>C1!`2%LO!D^Y$@?/,PJ*7.*R93PA"V\8.@=]9^K
MO-W[+#+C#&.XQ$7#E%Y2G!"T9;<A#L7ICF`LXJ?2]\(6C6533QAB(P.YMT#N
ML2Q9BES[1N3&!,DKDJO"6@,QV?\@<2,9<`Q<D)E269"^1?-Z/6C/+>-XHEV.
M\3"MK&?*)1>Z'22(7=<WQU&N&2H.VE+I.L10A[28(*:C,@YO6&&V]K*><F7N
MCGU;9,^J[I6]%/4GR8SG_E'.?ZL3')%3ZE3VQ6]\7WXT4OKKV`NA;<`/B?)`
MN)NI#*:4KL=F8F:))[LPCR^M_/L=?%MYT6=/>Z5[E:[SUCN[7$>QVQ]*-HEU
MK1,4*9DTX+U8;'_5+#*\%GKF&:_X")JX_/D-JX^3Z^18*+[<#5#!_<[WWZQ0
M.,35.X[[_F2^^TWD@/\TX.,F]TYDT-B=X2!)7%!1>"+RJ?%`\,X2#WE&#F`%
MPX+U0Q7_#U6Z#U<72<79L2*/N4FF`SJ/=RA5[W8(==CHM03+_.<C"0Y=BBT0
M)\<*-%W@@K]SUQL`?.X1XVD@R(%.]8E\!NGC>7FH`H/0O,S"M>#DTLNF7O6R
M6P2"I!'(N?G"ES&,0;MUD5.#?&[VNH?$R9)235G&$H/4^*SHH7*Y:,AN]\)G
M4,",U!(9ADUTPSL>(VBO=$7B'O5B$?[QF!<(Q6(ZD4_A*&B7S_SC3UQ&<<;]
M-[T*_7$B+OKD7$WUFH][WNL">^@](7&R_EN_'>W1W3/2?)![M5P]>N1>KJQR
M"-=WP@D8_(T,3@5\,^7P$0EQUA/M7:\A\'9[J'F;SMIXUAYA_ZW-3&U`/(Z;
MT]YBLTN9//,K3J@62]YDY:=\V$7]?.X_O_)82$,K_#CB_5=K]A.`X0<1XC,[
MQF-]-]-FM4416B)W,O!U%4%=<<1-P.5)I99F%IAJ.K9CO,-;ET5AYE-<'N5>
M_!=40[4Z0P4(>T!,ZI-6_E,%3U`%-$A#Z@5:,D8^&G&`_1,YS\96-I-5`Z5J
M6K4Y.:`1%@1L\'9YP^-@A@0FMB1/0$:$T856\G6%Z<=M7X9$J:%-]$<_!95(
M5]1GI*8Z'9$\3Q`1)%!4:V5945AB6O<(*W<1D,(E!R<1;YAF6M9EJ?5>"T&$
M8H@0SD2&(?40*24\&P5BW60%3AB(\/\$A4>F.V<8:`O1@1?F;!9F4%<C=QF1
M)IR(:'T6AH%VAQ767I1(A%AU2N079!F81=VDB-!T.29(0)!H3Z28$;/X$)9(
M7@.H@"&S.;5'$$FH?0[A5L8'6:_FAQG$AAHT9!RUBGRT-E080-SD61KU.DWT
M<`J8BPZQB]+E;6O60'<QAQ@!'[57A64&C4;6.ZPV9L5'?.KX0L4!8IFH0N#8
M6Z(TA6SH$=S8$-[8:K[X-E?3@.(T&;(E':UC,/BGD.VX1:5$C[^WC[$(9@98
MC<4XBF&6D"+1CPSQCZBH:P0S&<1H=76Q<1>!;5E(:TMTC^[XD`VI5_$H2S74
M0A5IAA<I0M#_UU9?!@6LHP>YQX^4J!`>^8_617J.$)#P09"-<U2QQF4:J8QM
MF$0O"8]9B&]\<VCU%0B&J(+=UDDJB&J36(\((9&F]H[D]GIFY#D1E!'+EGYM
M"8EFN5[Q5&@*1I9&UFP*=E1;*6W^%I<AF&@<P9&5&),AR)+[M3DC21'3$HRC
M%I0`H`)4=5PMN9=6H%YT"9-5N735=#AZ>9,!Y)>-Z807@882D4>'\Y'A&%L!
M"0`&L!A@XWQJECY5P)1S>#Z461"D-8%V*4APR6&=N5;`99@"%)A$"0"F>9.&
MJ5JOEW,>@0.-IQ%VY9BKME&Y:6R!=&4&N)MX!)?W2(][F8_W-95X_UB<NZF'
MH+E?"',7B3F!KZ&4#`$%.;9'@$-(\=2*NM5EJ`EH*4F(5>EC-@F<Z8-PF01?
M@@E06P@FQTE`I?ASXL@U(!%@=N$(R2EB_Z1!4GF#UU10&W9>MMB!\PE9]F-A
M!7HQZ_.=J3,_/":=$%&@PX.@JRA5(UI,J\DNP$@2V3(&S*F+%4IA4J6'K_B1
M$.F0?_AP=MFC`^&%'O6;YV51.;BC8KFB0=FC-#F&<AFB,WHN#1I)(+(8G`>/
M%\A^]K4""21*1P6698F(47ID+02"S`=HSA@^2OJ'CMF'5?:EN-F?UTA'KXA9
M1@J(1MI(FWBEFJ=3KUF7['6?-L9,=A5F]?]DCZ:(88X81Z2%H>R4D7;9/+VS
MF67I16*&9U)9G+YCIJQ99"M04F$8J=\80'GH37'H".3X$<[YG/#8@_UX:\25
M:_=#?P5HG=+F/XG#:$GT@S#X0L\&?L%*:S\5;7@5BL*JF4S)J0D)AHDJGM3&
M.OFGK%2$K4NW;0[).\HZH4,3:?>1EA#Q+8Z0`SGZ-_]S:_#%@X%@K(?#@^['
M>[TGK+UZIYIY?TN7).OJ;U"HF;=H6@`+L++X;/FGJI*Y/P/KK\2ZL+DS<,>F
M7SHD=.<6*GT!'5UA`.2Z+#/C"&00(3\#<(WS>_2JF()*%"5K:N`J$R?;+3)P
M")*A,%!B+V\&'&7_P1IC@`B@XACVPIBS\J>M!Q)M!E,.4[10(A&Y(1D-$Z$,
MPS$1>I#BLJI!*Q++T1KTDC&]L7=B@0-^(1UQ01?ZLB]C83)G<75_L;&S`CMX
M.K5L*Q+2UK9PZQ(M&[=T6[=V>[=XF[<!@S@_:12]<V\LP6&XRD)7,;=Q>SSB
MDWR`FW"8(Z/,,SG1Y[B+"SDIZZ/VEWP"*KF,@[FK1*\$E66BA#B7([KVMKF2
MZ[B<B[JR)#FMU+F/&W6-.U#(I[<;<5*.-F^NB(.7*[MCYC@X6%E9%&Y[-$L?
M:DBFE883-8^_$P`"X4SS(Y7F@Z(=RCP&%+"M!*D'-[NIF+NF=7_0*X\9_Q9N
M+L0XRU.\LM2(;SB[D25"LSM*:TN[J?-EI)@D&]2'PEM,1C5749=F[,>I_`M:
MB)B&%,B;F<M@XTM%+6IHP7HQX3.;FQ6-^2-BS$.L_!MN#XR__+L'L(O!,LG!
M8_:CV1I'$HS!U@N_1&:6B&L0]8M-C'@Y;_J$O'>+C"BC$$RA$^6MC8;`_%H^
MB0O`"OR[Q4C`0"Q<IP2M%LS`:8:[)1NP#&=\L[2GET.8)KR,\BL_!<4^2"6E
M\LE67N1_\A0]-8QO-ZR]0CQ0!%$%/!Q<"<R*/ER":@N\3W1*R#O"W.O!LF1(
M.8D\K[B[<61-4@3%EVBX04NG\&1-",H[>S"]NO^EOQ[LQ1I(P_]KPU<TQQST
M(27`KP<\D^CU7(2L$+J*P,7WIX2\QATLPFE&H<FZB#CTD/.X/("LLE.,4CH<
MR1X<"*_4IUK92QI<R?*B!V%LQG5,RM!$R6T,S,UK0#D\/Q6XP`7,1T-<RI`L
MS.)+RV.&Q"\4OGI\C-`<S8SXRJ:,5;%\DHA[AQV&/]"GR6O3R7PLR>RLA_-#
MO#,)?]N;C3$TDU_,Q_:;0E+5OFY87I35P]J;4>1<7O7I1+QGONILNP:$1S,Y
MEXNX4=DKR%/+NIIKNM%GNK([NK=;LI&;T1U-T?R6LH!;T:_[T9Y+NL)WNHI[
MJF"LN!S=T:H+R8K+N18<?=`:;=,8'<XZO=,\W=,^_=-`'=1"/=1$?2<!`0`[
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`_P(F`P$1``(1`0,1`?_$`+H``0`"`P$!`0``````
M```````%!@,$!P$""`$!``(#`0````````````````$#`@0%!A```0,#`@,#
M!P8("P8'``,``0(#!``1!1(&(3$302('46%Q,I,4%8&1T5(C5*&Q0E/3E1<8
MP6)R@I(S0R34%@BB-'24-E;PLF.T)76U<T0U$0$``@(`!`,&!`8"`@(#````
M`0(1`R$Q$@1!405A<2(R$Q2!H;'1\)'!0E(C<C/ALO$5\B0T_]H`#`,!``(1
M`Q$`/P#K6<#$J<M`;;0AI8[H;0+\/17-[_N;UGIB>$MSM=43QEJ>Z1/S#?\`
M03]%<KKMYRW<0\$.&D6$=H#^0GZ*==O.3$//=()6/L62H<NZB_XJCKGSE.(>
M^Y0]6HQVM7ET)^BG7;SDQ#WW2*?[!O\`H)^BG7;SDQ#2V])]PE1V9"&W"\I7
M-".0/G%=KL^ZMLF<\H<_?JBD0ZS$A8]V.A?NK/>`/]6CZ*W\RU6;X;CONK/L
MT_13JD/AN.^ZL^S3]%.J0^&X[[JS[-/T4ZI#X;CONK/LT_13JD/AN.^ZL^S3
M]%.J0^&X[[JS[-/T4ZI#X;C_`+JS[-/T4ZI#X=C_`+JS[-/T4ZI#X=C_`+JS
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MP['_`'5GV:?HIU2'P['_`'5GV:?HIU2'P['_`'5GV:?HIU2'P['_`'5GV:?H
MIU2'PW'?=6?9I^BG5(?#<=]U9]FGZ*=4A\-QWW5GV:?HIU2'PW'?=6?9I^BG
M5(?#<=]U9]FGZ*=4A\-QWW5GV:?HIU2.;Y)I369E)4+:B%"N3ZE7E+>[2><,
M5<IN/%(2JUQ>U!KM0FFU*LJY)U`&UZCDF65A3JD#J#OBX5;\%3!+Z6M#:%+6
M;)2+J)[`*G"$4B*X_N.*`+ITESA_&/#\5=;TRF(M/M:7=VXP[)`0416TGL`_
M%73:38H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`
MH%`H%`H%`H%`H-3*QER8J6TJ""EYATJ5RLR\APCY0F@I.8V#F\B_)BJ=B_"G
M93TM)7K+J_>'F75MJ3;2$I#:D\^-Q0:[?AA*B+6[#]T"=;SBXFDH:D`SQ*:9
M>LD]P-]SD;=@M4B>VCL]S#Y!^=)1'ZST5B.TF.DA+/3<><6AO4+A'VP`]%0+
M70*!0*!0*!0*!0*!0*"F[VP+KT=<F,I3;UCWT\[6K"^NMX^*,LZWF.2JPEK5
M%:*^*]-E$\R1P->=W4Z;S#JZ[9K$OMUK5=5U&PX(!TC\%4LVHMAU2@1'4DWX
MJZG&U1A+.B,XB1U`X5H*;*2:G'%&4=NEYU.+5':-G)2@TD]H!XJ_!6[V6OKV
M<?!K]Q;IJN6R-L%#")<DEQT@`*4.P"PKN4I%8Q#G6M,\U[2D)2`.RLF+V@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@T<Y&>DXJ1'93K<<2`E-[7[P/.@Y^8&\)4"6^W.ESV8\HPX2&'%H4['9+
MIZZEI=C$J4M:4%07PT7LH<*D8YV'WY*R4M+[$U6/?9?;>:1,!"E)+2X_24'&
MPG@A0X-I-S8E0-!8=IP=V-;AG/Y=QU493:TBZE=%2R[J:+:5/.^JUW5%*$<?
M+SJ!;W'$MH*U7TCG8$GYA<U,1D?'O+=FS9?VGJ]Q?^UP[ORU/3*<!DM`.&R_
ML^"OLU_[/#O?)3IDP],AL%`LN[GJ]Q?^UP[ORTZ3#PRFM*E679!L?LW+W\PT
MW/R4Z9,/KKHZB6[*U*&H=Q5K>=5K#Y:CI,/CWMKIE=G-(.G^K<O?^3IO;SU/
M1)A]>\-]7I67JM>^A>GE?UK:?PTZ>&3#&YD(K3(><4IMM2TMA2D+3WE$)3>X
MX7)M<U,:YF<0=,MBL$%`H-><P'HRT$<Q0<M6CW69*CJX(;5J!\@57&]1IBW5
MYNAVMLQ@$I@BX5<5SLMO#PRV0.T_)49,,I4G3J)LD"]_-4H1$NTW/1(@XH:1
MUO25&P_!77]-IPFS2[J>,0['C&`S$;0.0%=-I-J@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4`T%(R6XYR]Y'`
MMSFXD-#15(=2$EUM92E385J)T]6ZM!M;NGF:#?ERXT'$2Y4;/J6ME"EB1(<:
M?;04#4=8`0-(MQXCTT&[LS<)W%MJ!FNF&_>T*44I)*24K4C4DFQTJTW3YJ#8
MW#[A\/1[\7`Q[S%T]+UNI[PWTN?9U-.KS5?V_5U?#SQ;])S^3.F<\&UD\C#Q
MF/DY":YTHD1M3K[G$V2@7-@.)/D`YU56LVG$<Y8(S;.\L1N'WAN*E^+,B*2)
M6/FM*CRFPM(6VI32^]I6DW2?X:LVZ+4Y\8GQCDB)RW(&X,+/;D.1)C3K<1]<
M20O58(?0;*02;<;UA;7:.<<S+'%W)BI3^389<47<0\(TM)20>J64OA*+^N2A
MP<JF=4Q$3YF6ZQ.BO)9TK"5O(#B&5]URQ`5Q0>\+`\:PFLPED;>9<*PVM*RV
M=*PD@Z5#L-N1I@?=0-7*&8(9,-:&W^HU93M@G274ZQQ[2BX'GJS5T]7Q<N/Z
M,JXSQ;55L2@4'RX0$*)X"U!R_*6<S<M0XHTA)]-<OU*8X0WNTCFBWF2PX`D7
M;5R/D\U<?#>?-^%!FE.AQA+2.:[!5O)29X$-?2(FX8KQX(6T&P3Y4F]J[/IM
MOAF&AW4<8EV."X'(K:@;W%=-I,]`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%
M`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%!QO=TN%!WKN>7+Q*,DTEG&)4
MX0=;0+;WJJ19:;V[#4Q&6WVG;1MMTS.$?NS%['R?@SN'/XK'%IX0U@!YQUU3
M;B5)OI#JE6]-1,88=SV\ZK],NK;#;0C9F$2@!*1#9L!_(%&ND<NJ6F(DQ5-H
M=ZS`)>MIT%Y(<''\HHOI\]6ZL9X^4_HRKC/%I[QP;V<VW,QS"PW)<#;L92KZ
M.M'<2^TE=N.A2VP%6[*:-G1>)EA,*-NG'^(&9CQ5/0X^+R4Z6B`AN)JE.1\:
M^RIJ>Z[*`;3?B%-]T6*4\R:V]5M59GC,Q$9\N/AP_5C.4:]X9;F@Y%YR!B8$
M_'QY61$.!(?Z;+K&3:;2VZ1TUZ5QBWH((-TJ.DWJR.ZI,<9F)Q''W?N=++M;
MPJW9M^0X^N8,FHK;C!MUW2T6%8YJ,[+2"DJ]X2ZR$IU*_J[CFJHW=W2\8QC_
M`/+./=_4BLPL4784Y*7G%):9G.RHBTS4$%U#3.-;B+TJM>Z7$KL.T51/<1^&
M)_\`;*<-/PFV)N3;3[IS*@OHP8V.:>ZZ7>L8ZW%%U*$,LZ$*U\.H5+YW-9]Y
MW%-GR^<S_'$K&'2:T&2/SX8.-(?96^WUH_V;?K7ZZ-*N'8E5E'S"KM&>KA..
M$_I+.G-(52P*!05?<&ZV(S:F&3K>5P"1Q[*QM>*QF65:S,XA3F@[WW'C=UQ1
M4JWX!7G^ZW_4OGP=/3KZ*OI:$K3I4+BM=:U5Q'!ZO>%1AEEB<9<0+D6/9:H&
M',M+?B1W&%`/,+U#YN(K:[7N/IVS/BIW:^N%PVAO2,Y'3'DJT.)X65PKT%;1
M:,PY=HF.:[,3([R04+!ORXUDQ9J!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*`:#C^Y]T1<'O+>"7V%2%28F-#0T
MA204H=M>X/'R5-8RW>R[>=E^$XPID[%Y>3X7[LSRLBOX:Y#6A$&Q1Q!'K)\U
M9WEO^I[*Q'1CXO-W?8W_`$=A?^#9_P#(*K<-M;A]V]P1[PPY(;]YBV;:N%!?
MO#>A?#L0JRE>85?V^>KA..$_I+.F<O-R9UC`X61E'VU/)9T(0RBP4MQYQ+3:
M`3P&IQ:1<\JPU:YO;IA7,JKE?%*1C'IL9_`2%R\7$=R64:0\R0W$;=+:7&U$
MCJ%Q*5+";#@GCQL*V*=I%L3%N$SB/>CJ8_VHN3,4[E(>.=C8<J>,7,O*;4TM
M$64W'=*V@>HC6%**+CL[*G[3$XF?B\O?&3J>_M/EO3H+\3&!>#EXO(9,..NH
M9D$0G6VT#2X4(;U:^(6KA?C:Q%/M8B)B9^*+1'\SJ:6:\5'UX=Z9BP&'F%3V
MAP#[:UQL2[/;5J5TU!(4D?D\;6Y&]94[3XL3[/\`VPB;.@8.6],PN/F/6ZTF
M,R\[86&I;84JP])K3V5Q:8]K.&[6`T\L'C"/1DIB+ZC/VR[6MU4ZD\?KBZ1Z
M:LU8ZN,9Y_HRKS;E5L2@4'*2!K4JW>/,]M>8O>UIXR[%:Q')[6#(H%`H,+L5
MIPW/!7::C"8EK*Q$=3@6LDD<B.!_!6>J]J?++&]8MS;3+F4AD*AR"0GDASC\
MEZZ6KU&?[H:E^T\DI%WIF60$OL$^=-C^*MRO>:Y\5$]O:/!)1_$!G4`^A3=^
M=TVJZNVL\I5S28\$_CMPP9H!;<%_)5C!*@@BXXT"@4"@4"@4"@4"@4"@4"@4
M"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&*5*CQ(SLJ2X&H[*2XZXK
MDE*1<FIB,SB&5*3:8B.<JQLA_,91_(Y^:XM,">L)Q,4\`F,V5:7"CL4N_P#X
MX5=NBM<5CG'-T._KKUQ757YJ_-/M\OP5[)8:3EMW;TBQ%AN4F/BG65*M;4A#
MW.]4Q.):W:;HU[(F>2CY?=2_V2;LV[F)3:\PU'=+#3:>;8*;W4D6)O65H\6]
MZEV^9^I7Y<<7:=C?]'87_@V?_(*P<@WKG&\#MR3F'9`C,PE-.O+(U%38=3K;
M2+*[SB>XGSFMKLM$[=L4B,S;/Z<_PYK--.JV/-7-B8'+9G;&0G;L>=?_`,SK
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MF,?R]N?U.E9(D5F)$9B,#2Q';2TTDF]DH`2D7/F%46G,YE++4#1S:4*QY"XJ
MIB>JQ]@DD&X>19?#CW/7^2K='S<\<)_3^O)E3FWJJ8E`H.5'F:\L[14!0*!0
M*!0*!1+P@$6(N//QJ1KJ9>:7UH:RTZ/R1?2KT@5N=OWEJ<)Y-;;HB>,+EM+=
M`G-!I[NOI.E22>-Z[E;1,9AS[1A;!4L2@4"@4"@4"@4"@4"@4"@4"@4"@4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@H^ZY+NX\\ULZ+J$%&F1G92..EL=Y#/
MF*R!>MG5'17KGGX.OV=8T:YWS\W*D?U_!=6&6F&6V&4!MEI(0VA/`)2D6`'H
M%:TSER;6F9S/.7-=\,9C"9C)Y6,^F-$SD>.TN>XK0B.[$"TAMPCD'DN]U1L+
MBQ[*FO-L=K:D7CKY.;*7BI6TLMMU`9R>[\W_`'&(N#I<4`M21K-@1T@+E;G#
MR#C4VMEM>H=U&R8K2?@?H;;V.7C<%C\>XK4Y%CMM+5Y2A(!K%S%`RJE;_P!_
M-8=D];9VVU=7+J'%F5D!ZD8_DK2UP*AZ;]E=W5_^IV\WGANV?+YUKY_BW:_Z
MM>?[[<O9'FZ6(T8**@T@*4G0HA(N4\K>BN)U3YM/+SW.)H2WT4:$'4A.D6!\
MH%.N?,S+TQ8Q*R6D$NBSATCO#S^6G5/F9>>ZQK('219KBV-([O\`)\E.J?,R
M&)%/4NRC[7B[W1WNWO>6G5/F9E[[K&NV>DB[7]5W1W?Y/DIU3YF7AAQ"E:2R
MC2X=2TZ191\I\M.N?,S+WW=C6A?33K;%D*L+I'D![*CJDRR5""@4'*CS->6=
MHJ`H%`H%`H%`H%`J1I1Y1@[CC*3P1(MJMY178].V9K,-#NJ\<NN1'.I'0OR@
M&NBU&:@4"@4"@4"@4"XH/-0\M!B5.AI=#)>0'3R;N-7S4P,U`H%`H%`H%`H%
M`H%`H%`H%Q0*!<4"@4"@4"@4"@4"@4%<W?O3'[>:Z+NM>0D-*,%E*;ZW+A"4
MWY#O*!X]E7:M,W]S>[+L;;IS'RQ/%];)V[(PV*4J>L/9><X9.2D#CJ=5^3?R
M)'"HW;.J>'*.2._[F-M_AX4KPK'L6&JFD^76FW6U-N)"VU"RDJ%P0>PB@T,=
MMS`XQQ3F/Q\>(XOUELMI03\H%!2_$CQ/CXAQ[:N)2XYNV<EEG'HTGII,LE"7
M2L?4YVYWM7:]-],G9$;K_P#37,S^'A^+<[?MNKXY^2%DV'LV!M';C&(BDN.#
M[6;())+TA8'4<-_+;AYJT>_[RW<;9O/X1Y1Y*=^Z=ELRG79,=DI#SJ&RLZ4:
MU!-SY!?G6FI9*!0*!0*!0*!0*!0<J/,UY9VBH"@4"@4"@4"@\4I*?6-K\J#V
M@B,HK_Y;'`>MJ/S5U/3N<M3N_!V'%#_X]@WO=`KK-!MT"@4"@A,KF9J9B,;B
MT-.SE#J.%TD-MMWMJ5I%R2>``J8@:ZSN\)'4F0F4*(`7TEWN>0&IQ(N:G$(C
M,^"->WE,Q,\P,@42GI'=@!M)0XMT?V2DDJ3?B+&_XJ=)E@R>[<E`>;8FYG$P
MLB]936->6H&Q/`%S4./\VIC7:>,1,PB;P\R&[A,@J@Y)M6/DA:/>FBJVI@JT
ME;:T\T*5PN/P5C$$3GDWX^">9::1"RCD-F1<",LARP`[P:*^\#\]3,IB)8YN
M#QZ\1(8PCB1*C*2L/JNH]4*U!2EGO&^FQ-ZG+*^NU<9\4WMK,HR4$!8Z<R.`
MW,8OQ0X!Q'H[0:PE#8SV9BX3#RLK+2I4>(CJ.)1;41<#AJ*1V]IH(^#O/%2>
MGU3[L7M71*G&7$J*"00%LK=1?NDVOV4'J=[[=6%]*3U%)4$A(24Z@2T-:2JR
M2G^\(XW[:#U_>VVF%LI=F!"7]82X4+"06TI40HD"UPL6\O902T&=$G1Q)B.I
M>845)"T\KH44J'I2H$$4&>@\U#RT%?R?B%LC&2A$FYN(U*/]AU`M?RI1J(H-
M%?BWX<(6$*W!$"CRXJM\]J#8A^)NP)<I$9C/PB^Y_5H4Z$%7\DKT@_)069*T
M*2%)4%)5Q20;@^B@]H%!![VR,O';8FS8;G3DM=/IKL#;4ZA)X'S&@PQ-U1$P
MU@K5D)[3[S;L*'H=D(2E]2$J4T%!02E(3<T&KM_<N0E;BRD?)I$**AN*K'QG
M4]-:>NX\V`M1YN.=($)'+EY:"V4"@4"@4'A6@)*BH!*>*B>``'EH*U,\2]A0
MY2HCV>AB0D:EMI=#A`\^C5:@UOVM^'&K1_F")J',$J`^>U!NXSQ$V-DY/ND+
M.0W95K]#JI0LW\B5Z2?DH+#<>6@K6XMAXW<.:C9#)N+7'B-!MN(CNA2M94HK
M5SMR%A:KM>Z:5Q#H=MZA?3KFM.<SS61IIIEI#32`VTV`E"$BP`'```53,M"9
MF9S+ZH@H%!1,AX0;>R^]Y&ZLTM<UQ72$6!ZK"`R@)!7;O+.H:K7`\QKK:_5]
MFO1&G7\//,^/']&U7N[5IT5X+V;6\@KDM5%;B1MU>)?.>+`QJ4W>5)*0A-N(
M(*N2AV6X^2@KDGQ1QO0<7@<;/S[;(!7)BM:(UN1`D/EM"BGM";F@K>4\8-TM
M:5QL-C6TJ`LW*RC*7!?L4$\J&8;6/\7=QK92N1MUF8I2@`C&9".^OCVZ%%)I
M@RLT?Q,VR)"8>5<=P604H(3$RC9CE15R*'#=I:;\-254,+2VX%@$$*21=)'$
M$'EQH/N@4"@4"@Y4>9KRSM%0%`H%`H%$HW,[EV]A&PYE\E&@I4+I#[J4*(_B
MI)U'Y!6>O7:_*&-K17G+[Q^<Q>28]YQLA,Z/VNQKN@=O>T@V^6LITWSC"(O7
MS>-RT2`IQ*PML$I2!QL1Y:JF)9YAM,/(*+$\13$B,D#5NF`";ITW`_G&NQZ=
MREH=WSAV+#"V,8'\4_C-=.6FYMA<KNQG)8UUQ^=,3+<E"?%*BYTRTZ5,W;+2
M.BE2$%([RKDBH&V?$C="4.K.+0X8[3<CHH8E:I)=TGW1A5B$O,ZK+4;I/D%C
M8+#L;*9G(KRS^26%I,ADQ0AMQII+:HK2BE"7>_P63JO^5?ERH+0HV23Y!>@I
M^`2Q/8FY8O%,C(]]M95I*6T*/3;]'E]-93RA-+8MQ:$N89<S#Q,W/0S-#;SS
MF(2`XE_026E]1/!*@$\NWC6+H1BM+VI&8X?%Y*U-><?WC!R:KN1L<^H2G#ZB
M%R6RVV2?XE[J/8#5D3AS+1F'Y\WRK=$G<LP9IEYS(!U:.\A1*A?NZ;#O)M;3
M;LKU.B:1KB:3P4Q#M0C99O9^U(V343F2RI,QU?%;45Q.FSOF&I//M%>4O>+;
M+]/RY64AT2?U<IC(S&*?;BY&*M)0Z^3P:N-5B.=P/EI/-N]INI29ZHS68064
MR^X]MYU.)PF.9.W'%AV7/?=+CBPL6*475JN+6`M6/N;4VU7U3?9;_9CA$)O8
MCSK^6R,\C1&#+:'7#P2I:2M1X\NXE0!-3+EPG<KD-JYK&O8V5/;]UEMG4I+G
M3NA(#FI+G+EWK^3C4)1LK&;/>8:$O+.*6%?8RG)&EQ!U$$:[)";W4GCY;4'D
M?$;$;19$S4AT);2A3Y.D-%E0`'-/&.V>//\`G4&@[MOP]#ZL,]*==<;;,YR[
MI5W7"E(U*2.)]10!XFP-2+5@%X.-%;Q>,D(>$=(44I*2KO\`?NK0`G4K5J^6
MH&#=^\(&VL>)#R%2I;IT1,>S8OO+_BIYZ4CBI790<CR&4W1N24\G(SE>ZK`*
M<;'4MF$WQU!"NF"]-(X:^F0B_;644RPMLB/:UL=M?!0G$]5MU*RM2@TVVC',
MDJYZ`I*WO]JLXI"BVVZ,W%F=HXJ"B7/;DE,E3J(,..^LK<#"M*W''5WTIU]T
M`)K:T=G.V>"8O;S06V<?MS>Z<F(,:1CYF-BJE/(E.)EL.M"_<"BE+B%</+QJ
MKONWCM\9G/5.%U9E,8)6ZL,S'E[7S2H;*B%F`\5.P2HBP2M@ZEH!%AJ0;#MM
MSK6FJ8OEVK8_B`WGRO'Y&+\*S\=*5/P'%!274FX+T9=_M6[I/+EVU#)<:#0S
MN1&.Q;TLQU2BC2EN,BP4XXXL(0@%7`74H<3057)[Y9PJG'96'1[VF9'BR5Q7
MFG2EN2E2UO*4$I7]D&U%:5)'+A0;[6\,!+?S'O;26F,(Z-$ATI^W4PA3BE,I
MYJZ:D+`]%!D9W5EOAK>0?PKC<9^*93.AT.*3ZI0AX!(T%07?NZK6-!@>WT\V
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M@LHY.QZ+DX>:XIR,[PNI"'5]^.H`$HU=WAS[*PF%T7B79]F;\Q>Z8KG1!B92
M*0C(8IXCKL+-N?UT&_=6.!J$K-0*!0*!00N[=SQ=NXE<Y]!?7J2W&B-D=5]U
M9LEM`\O\%!RF6S/S+IEYF^3?6X2PAZRHT74-13%9N$E3?J]9RZ3^2%5C;,1P
M83LC.&[(BM2^F92E2#&LE*7?MR&QRLE=VQ8_516O;?T[,7X5G]416;4^'C*2
M;DH88TLO.IN.9<"+?S$!/#Y*LOW](G%?BGV*Z=K;G;@]8CM35J$MU;B3QZ+R
M$/-GTAU*K\JRU;^KFFVO$<'C^(:EX]>-2T%,<7%LA.M@K5S2Y'>*FSZ$%/FL
M:SILBW"(9XFO%AA3YVT5(7CTO3<>C1[UA4&[+#!OK<@)5=U);/>4RJ_=Y>6I
MF,,ZSET_'9"%D83,V$\B1%?2%M/-D%*@?(11+8H%`H%!RH\S7EG:*@*!0*#P
MU(IN[/$2/CU/8C"(3D=V+?$.#C.-B\IM+I6X;BS:$+U*-QY*VM7;3/Q6X44[
M-T1PCF^=M>'N-QKCV;RMLMNR8CJ3)TBSJ6W"+EN,DBS;:3P3VV[:C9W,V^&O
M"A35$<9XV;&\O$#=VT\5A&MKQ4-1)C27G9?0#O6DW(>:7Y]7RUZ_TKMM.S7\
M4N3W%K199,DU%B)1F):/A\B;C&IF2CM#@B8HC3I0>17WKBO.^IZZUVQ%?.6]
MV]IFLR@<`N3-0^^TA3<%"T%:R2LIY]O:36C>(CAXMG+"YDDJW%!Z:%)4VM39
M*N.JQY^;T5TNPKC+5[F<X=WQ2DG',6%NX+@>>M]J-L&_9:@4$+N7>6VML)B+
MS\Y&.9FN%B/(>NEHN@:@A3EM*21RU'C02K3\>2P'6'$/,N#NN(4%)(\Q'"@Y
MK)VON2*Z84&.M;+:BF.L.)"%-WN"LGO`IO8V'&I0@=T[?R&*EQ,KF%W<QX*H
MLMD*T66"%(<2-9X7NFF(E?3N+TI:D?+;FG]KC*-XZ8[+PC\B'DR'.]TTDM:`
ME)+:E!8*DBY%J6PIS$,V'Q#&1NUB,HZP(I*/<Y33:W6+?D`NH*TCR"_*L;4C
MQ\6'1$SE9,3L[&XU$AZ2ZY-D2`?>9,E6M2A;U>5@D=@`M4^R&4*;D\-)+BW]
MI1'I,,+*%H4X&V04\"65+/EX&W"LL^9.&CA<7.RV:^'Y52L?(2F[C"UE3RD'
MM;6`$V\XO4>&8(EU:'AX,7&?#F$=.-TRU9//21;YZA**F;#PLO&QL<\M\QXJ
M$MM66`KN1_=TDG3S"1?T_-0?$G8&&EXV7`ENR'T3W$NS72I"5N+2]UKG0A*1
MQ`'=`X4'K&R(<:8<@S,E'(KTA^25-A3R$=/2TX`V$A'V*;Z`#SX\:"I;=QFP
M7Y[^WOC74W'!*F\C$="$.K6IQ+R%!F2A6M"$I2ELBXT>7G077%[/Q^-R`G,O
M.J=#09`4&DC2$)1QZ:$$CN7"2;`WL!0<F>#VZ=]YC*/@C'L+7CV.^H7CQU]-
M;>GR.N(4I?$7!`\M9TKF5.[9B&CG3O1[!O0MGE*<JZZ\C.-A2&Y/N_*,F.I1
M3]D$<PCD:VM&S32\_5Y>'D4^7@AMGX?=F!AY!6^)2ABI+"FXF+?>]X?7*/%M
MQM(*U-E-CQK'O>[U;;173'&.<XQ&$S'!E.*>>Q+4.5"BY%C47NC+2K4VZL#7
MTG&U(4@*YD>6JZ[+5G-9F)5PDL6WDXF,=Q<&-"PF.?\`]Y3!;/6=%K$+><4M
M1!%47IUWZ[S-K>WP7=<XPVFW,4VA+*7D(*."2DV(JQ7A!;OR,K`Q863CMA2<
M?)3)A2FQ]JPK6%/)03>S;R-0<3RO8CMK&T+*2_0.T=P-;@V]$RS:=(D))4GR
M*!(5^$5BSEN9?%Q<KCGX$DK#+Z0"MI10M)!"DJ0H<E)4`0:"%;V#BS.7/ERI
M<Z:XME;CSZT=[W=#C;:="$(0$Z7U7`3QYT&QC-E;?Q\1,5+'O#26&X_]XLXK
M2VA2"K41?6L.*UJ[;T&O&V'CV66V5SIS[<9A4;']5U.J*A12?LEI0E14.FD`
MN%7`6\MPT<O$VIM!`W/GL@\A+,KK2<G(L077V4Q$EU++:4I0&P$BR0!VT%IQ
M65QF4AMS,;*9F170%(>86EQ!"A<<4DT&P\X&F5ND7"$E1`[;"]!P7:/OVXI<
M[<N3/?F/A2T$<@U<-,\2H%ML@$"UBH:C>PJW77/%K[]F.$+7)?6T/LVRZ5'[
M3B"KTDDB]9[)M$?#&6K7$SQDCKA.,-IZ0;5K/`J"%F_%6G2KO#R`5XSU#ON[
MT]Q,5Q7,<J\8_GYNYVW;Z;:\S/\`-77Y'6D%05U$\FNX6P$GL"3Q!\O&]>E[
M6.FG5:)BWC,\6A>,SB.3>A8I^1'<<.EL)L6UF]E=BDD75;TVKG]WZOKT;(B9
MZHGG'DV-7:VO'"&";C@A[H:?M!;J.6LC21>R0H=^]_16WV?>?<QUUX4_-7MU
M_3G$\U5SVZ,MM'-X3),,(*6'/=@ZA*4N+B'@8JE6[S239:0KBDBPX'AN3&$4
MG+]'8V>SD($>:P;LR&TN(]"A>H9-F@4$-N7=N!VS%8F9R4F!"?>3'$IQ*NDE
MQ8.D.+`(0#;@5<*"2A3H<Z,W*AOMR8S@NAYE06A0\RDDB@Y?XAH?R?B1B<4X
MZ40V(2WT(2;**W%+2YQ_D([./.W.LJ5S*O;;IKEN3\0&F$IB)"$)-U!-@#8<
M.`^:L.X[>+<8:^G=,<)04GWQ7!*EK<7P4DA*0GLN"!<_-7G^Y[7ZG#Y<><Y=
MSM>Z^E''C^#-"9)5=:$`V"$K(LX".!N0>/IM6QV>KZ<17,QGE[5/=;?J6ZL0
MW/>H\9?36#JTV[5'@>P5=LV],],Q%E=-6>,3A@&66DH#:5Z@;7]4@>?G>PKF
M;>^W:KXI&,^'-T-78Z]E.JT\GQ*0]E8SA2$J?L"R4A7$H.I'K%*N8_)(^:NK
MV\VFT3;JFT_R<[;B,Q&,-#_3UN%YK)9[9[BB8^/>6]#"KDINJS@]%U7M7159
M=OH%`H%!RH\S7EG:*@*!0*#YUI`)OJTBY`XGA673,<XPC,.0;*\))2MS/[UW
M9)<1EY,AV2UBV5E(;#AND/.(()L.&@</+Y*W]_>1%>BG\VMK[>9GJLZP@&ZG
M2FZ3R3R_%7.JVIY(R7ES#9TL,2&UI)59F0IM)X\RDI6D'T"_GK>U;KUCA9K7
MU1,YE]HC2'&([JXCJ1..J0B2M3[BE#@C4IVY(\G"N3W6[9.S.72[2FOHG+5S
MF-GS78</'OQ_=V]294%M]IM8=*NZHMW%^[\U;O:S,5F;1/4U-\UFW#DTY:L?
M$DP8S+[3CK;A4M:$J)4K@-"%GA8<SY:Z?9YZIEI]QR=;1MO$;EP<)O+-NN(8
M^T;2S(D1B%$6XJCK:4KAV&NDTVO^R/8OW:9^L\E_B*&3]D>Q?NTS]9Y+_$4,
MJKXA?Z=MK[IQ3&-ARI.*0EX//OJ?ESE*"`0E"6Y#ZFT^M<JM?R4$]X=>"VS]
MA-)&(7,?D`&[\J2ZL<18V924,#^A?ST%]`X4%=W<B,X[B6I>GW5R:V'-=M)5
MQ+8-_*NW"IB3#\Q>*OB5NB9NZ7':ER<<C&2'8[33#JVQ9M6D%021=7#MKT?9
M]IK^G$S$6ZH43'@ZALG,9&?@MK[DFDC-27519"QW%/L@K2%.)%M5DH2H'Z:X
M?<16NRU(Y1R3K^;'@Z)O+<4`;;R;<26VJ8&5H0A"P5%8%U)%CZP'9SJBL<87
M2X)XS^(.88F-;;Q3CD#&0T,N1WXRUM]9*V@H'4FUT\>RN]Z?VM+5ZYQ+6B9E
M(^&VY\YE=B9&7D%KD2L-);.-R#MU.DK*=38</$VO;G^56AZCKKKVQ%.4QR3'
M"T.^/XB#N#`,Q<HAQ3+R&UN(;==87J`N/M&5-K'SUSVPA_V1[%^[3/UGDO\`
M$4,G[(]B_=IGZSR7^(H9#X1[%M_NTS]9Y+_$4'/\G_I6VIF-X+S^1R4QN*-*
M8^.C..A24H%DE4I]Q]Y1[3:WFH.P8#`X[`XMG&8X."(P+(#SKCZ_27'E+6?G
MH.31'T83=>;VN\4ZU2',ACW$@W6S()=4A1^N@JMP[!Z:MUSX-7N*<<H_<RL>
MM$^7+0H1L1&]ZD%D6?7=02EM"K=VY]9795U*==HKYJZ3ASO%[TPF6W#%@1=N
M+;,AQ#29<>4\]*0DFQ40X%H4!S(L*W.X]/KJUS:;8Q_)=B718$1Y&2GXU;G7
M,!T-!\"VL%"5BX[#WN-<J+9C+*L-J<RAF6TAT!0#3KD9E9TMO24)NTRM7D4K
ML[>59TF,\2_+@Y>U-\8<EN1I:(#\5S6`Y'<C!J"A(/>UI6D-Z:ZVZ_:4USQK
M/ZL8PD_%//8B%'FX6$H/)RY9CL)0=;;;BC>2XT3<!"$\.=@37$K:9KQX,J<W
M=O!QAQK8D,J06TN+=6T@]C>JR?G`O1?*:S^RMOY]UEW*-/N+CI*&BS*E1@`H
MW-Q'=:"N7;1"*_9'L7[M,_6>2_Q%#)^R/8OW:9^L\E_B*&3]D>Q?NTS]9Y+_
M`!%#*#WCX$[6S>WY6)@+D8YZ6$H,QR5.EA"`H%5F79'343:PU<!08?#'_3QL
MW8:VY<63.GY%"@YUWGW&FM8%K^[LJ0V?Y^J@Z@^UU6'&KZ>HDIU>2XM>@X5L
M:=[M$F;>DJ0F?BY+J5I"AJ<2I9*G`/JA=[>06J_7/!I[Z<<I>9(5I-C8D&QY
MTM&8PPI#0QL6)(EH0\ZA32@4KZJP7;]FA7KI5?E;AYJX?J.VNJDVK6W5'E'#
M\70[>DVG$SP9Y>+CQ5-);<ZJ7E+2I;Q2FQ%N-KDKXGT51V'JD]UFN(I$?CE=
MN[7Z7&9RV(T&2RS]B4Q[FQ<T!2U#GZIL@?,:W-_IM-\QU_+'A']95T[B=?R\
MWRID%Y3BKE1.H$J4JQ/.P438>;LK<[3M:Z:],8X>QK[=LVG+G/B[D8CJ\/@F
MG4F8Y+3*D('$ML,B_>MZI<4H``\ZV+HU1+OFW]L1\AL+&XK--N:%,H6\TAUV
M.L*U=1(ULJ;<%K]BJK7,?[(]B_=IGZSR7^(H9/V1[%^[3/UGDO\`$4,J]OCP
M#VSN'`KQ$!Z1C#(6GKRG),V80V@ZM*&7I!;N2/64#:@V/#CP#V9L5MM<%Z;,
MFH(49#\EU+95Y1':4AG^DDT'UXI1_AN1Q.YH[05)CZX[ZU`Z.EI4I.M0]4#4
ML7/``D]E95MB<L-E.J,-V)D(^1Q_O,104%@=VX4I!("M*@DFQX_^!5]IS'!H
M]&)XH-Y2TK<3T++[-)XW[1\GFKD;+S&<UKAT:4B?&6JF<IQ]*DM#4E-E+'>-
MQRNA)[Q\M<.-V_JZ8X5S_&)=FVC3%.K/Q824?$NSG@2DJ*@"IX#2`3Y$\*ZF
MKM^KAB??ES[;<>*=5MF"E`4L7<[%GBKYS73IVM(C&(:-]]O-5=X9=C;4!\QE
M(<S,I!9Q491";OK!#:EGCI2#QO;C65-,:YGCP\F'7-_!!?Z9]NA$C.9Y4CWD
MEPQ$.$'OG5K6L7)-CV>:I;#O-`H%`H.5'F:\L[14!0*",W#,>B8J0ZRDJ6EM
M:M([2E)-OEKJ>D:*[-WQ>#6[O9-:<'*=H;LS>6W(U$D$Z7;@%`T%NW;P_AKV
M?<=M2NO.(PY%=ELNEMY^$P5L3279;;BVDICMK=6X$`$KT-A7!(5Q->.]0].C
M7L^#Y;1GW.MH[GJKQYLYW1B$E`!>4AUOK-K2P\4ENP)5J"+6`4+^2M#[>WL_
MFNG;#*_E8\>*C(,-ID(<2AQFZ`I)"AJ2KCYJPQ/*4SQY(7&ORD1,QE93RW,G
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ML9-C0L]!N1BW2XMAP`C7;J-A5TE-[#B/1RJ[7W%]?RSAJVU<?*5OVWX>Y!EM
MF(^Q&QF$84%C%QB7-:P=6MQU0"CQ`X53:TVMU6G-O--:8=':;2VA*$\$I``'
MF%8LWU0*!0*!0<A\9]ES79#.Y(3R6E1RV')"PL^[E)`U**.\EE0MK4.*#WN1
M54PQM#G$K=>3AR"<NPN/+`Z`G,H2\RXV\.\EYL]Q8\EAW^:16<^U1$1/)M[?
MG]5[J8>?BXKI2>HN)&:9DZ>T%*QJ3_1K';7K^:9G\66%TP$"+#;4A"]:W%%;
MKJE:E+4KB5$GB2:,VUN!_;[</1E9+#+:[A(><2DD@?DB^HGT5*',<IN/%277
M8.!;R&6D$I0`XM\1$ZN%W`I5^'8BUU=E(B/"&,QCF@<+MV;G-R-XP.MY#(K<
M;1D7FTGH1VT*!$9L@6N%#OZ>'#TUC*VC]>XF"F!C8T))!3';2V+<NZ*ADVZ!
M0*!0*!0*#B'BELO(X_.M;BPRE-J<<.E0T!M+K@45-.%0(1U%JU-K4-)4="N8
MK*K"_)54;^3&6F+GHCL:3J4V9#:-3:]'-10.\D_62-6GMK.9\U%:1/)-XW+0
MIJTN8Z:PXA)NI:%(4L'R:%>K\HO6ONT1MCIM/P>2ZEIKQCFL41"75MJ<=#NB
MX^TLM7>-R`3QYU7H[/7J^2,0LOMFW-]9C/8/'-_WR:Q'41<-E8*R!]5M.I9^
M05M0JF)<]R/B-+R3;D7:<)QZ05*0<C(T-QVM(N2-1(4;=A]4<5"IS/@PFL1S
M0FQ=J'=.[DAE7Q%UI[WC*9=0LVZZE5@EC_TDB_'M^:L)7UX/UL@:4A(Y#@/D
MJ$O:!0*!0:.:Q3&3Q[L1XE*5@%*P`2E2>*56/`\>P\#RH.*NX7/;7R[D7&.$
M+0W9N"NR5+:N"51'%ZDOH;_);7=2!W;#@JK8]C7OF/FC,-V%O>(ZZZWF8A;+
M"@&Y325MI<U=CC9*PR>/'J."J=NB+\X9:]F/EE*0=\;)>2LB.^DMFVIHQGKG
MRCHO+J+:JS&,<%D6MG.7K?BMLK&/JBA$C6#Q!+&J]K\&TNJ=O_,IKUQ6,07F
M9YHC,>)>[,NZ]#VOB51U`I#+TM.EYP'FKIK'V*1_ZB./8:OC*B9K'M<[R4B7
M+S:L9CWQN#=\QQ4=4QM.J+%#UTN],W4%KTJT:N(0GD2:PLNUQ.'Z)\-ME-;.
MVI%Q`4ER0+NRW4WLIU?.U^P<A6+-:*!0*!0<J/,UY9VCTU"7R7$`VO4X0PRI
M\.*P7Y+R66@I*2XLV3J6H(2+^=2@*F*S,X@F<("-N:/G\X]B\.IN5C\?<9J<
M+E*'CP;C-<@I9L2M7Y('E-;-(MICKY6\%,S%YQ')N#:D%#RW6W%-+7ZZD!(4
M?EKH_P#WNS&,1E3]E7/-]O85Z/,9F8KI-N-,*C+9>"M"DJ7KU73WM0/SUS;=
MQ.S/U)F<SE?]/IQTLC^-?>+*G7@IQ$5Z.XL)L%*?2D:@!R`*>581MB,^^)3-
M<_R1Q7*QF.A8V<I@N:6V(RF==U!E%B5:N7+LILB+1-J^^2G#$2UY8E2I&MU5
MUJNAM)]4-J`!2!\E1KM&$VKQ<P\;=I9-R1B,XIPQ,1C5L15R$=YU*Y#RBIU*
M;C@WI3S/$FNEVFVO&OC+4[BDYR[1.:D?`'/>"A<I+(+JV[A"EIM<I!XV/.M#
M1;_;'O;.R/@E??#Z2'<0UV]T&O0N6ME$%`H%`H*)OK,'&YR-)<"G&X<&9+:8
M']HZT@=WTA*B:NTUZIPJVSB'YKR?C/O=W<2\Q'R#S+.L+&/U$QP@<>F4=J>S
MRUZ"/3]45Q,<?-C$9AV.3D'"Y`D)2IB+F&8V0G1NQE25H*E#R!5^/HO7G9QR
M\IPG7,XF$_E,ID<A)1AI18F[<R276<FZ5:'6`02A2!]8*`MS';6$RZNC9JI7
MKB>G97E[6I`AXC;KN'AQ9"Y<#&N$+=<(+@ZRB$K-K"P4O38>6I\&MW/<3NVS
MLGA-G6`01<=M8J2@4"@4"@4'BDA7/EY*#F>Y_"=Y+C\W;;Z4)=4IYS"R1JBE
MTF^ME0*5L*)^H:RK>887UQ9R_);7R^/?=.9VE*2ZY8)FP%-N\`.U:51G#_.O
M64WB?!7&JT<I:R($=*-"(&30.TEFZN/GNH_[58YA9BS3?A"R6X>VI^2D-J!:
M<F!.@$'\GWA;UO2E%(DFDRL$'PS\1]TM(CSVDX/%.V#[+!)<=">(ZK[G?(_B
MBR?-2;S**ZHAVC8OAYA-HP0S!0"\I*0X[8`\!QM6*Q:J!0*!0*!0*!08941B
M4PY'D-I=CNI*'6E@*2I*A8@@\Z#E6X?";)PM;NVW43(G>+.*F%0]WU<Q&?04
MN(2?JFX\U91>85WU1;V.<3-NS(2UL9;:<V))6HK5(A%M39\ERTN/J^5%93:)
M\&,:[1XL?N$?IE`@Y-""+$]'O?T@=7^U6&86=,M-4247FCBMJRYDMLD>\S"A
M!L1;NK=5(<3_`#0*F+88VI,^*SX[P?WQNAUI.X%)Q.)U!Q6-C`I:4KGK=*BI
MQU7G546M,LJ:XJ[?M/:&(VSCDP\<V!8`+<(L56_@J&2<H%`H%`H%!HYG!XO-
M0'8&2CHDQG004+%R#]9)YI4.PB@Y_.\,]SP&RG#99O+0T^IC,VV'@D<@$2$V
M<X=EZRB\PPMJK/@J;V!\1L>5(:V)"=X^M#G.H0?YNOA2;$:XA@1B?$QZ0EQO
MP_A-.CD[+DJ>`O\`RG*CJ3T0WT>#?B%N8)3N[.H@P+C_`.,@)`;`'$=U.E'R
MF])M,IBL1R=.V7X?[<VA!$;$QP'5`!^6L`O.$?65_`*A*R4"@4"@4'*5J";D
MUY9VD=-R*&0>]RJVE,I5K([O984;N`6YW(K:IV^4X<]\3MQ3=Q86/M[$K*I$
MZ2A;BPO2A#3-U%2U=@U%/S5MZ-'1/5+7[FLS$5CQ7;PIP(VS@_ARLB9REKZJ
MB$);;2HCCI`&I5^U2B2:T^[GKMG#+5JZ(QET)*@H7%:.%CVH"B5.W!&?R6<`
M:)T0`"FWUSQ-=GLM,3JX_P!S0[C9\?N2L2RTI*AW@1>N+:)I:8;\3F,H7Q?C
M-R/"_.@B_3CAY!\BFUI4#6WVEO\`;"G?'P2MK0]YQC05QZS"+GSJ0*HSTWS[
M5F,U3/AC,+;:H:SWF3H(]!M7I:6S$2Y%HQ.'1:R8M.+F,3,4ZF)-8D*8_KTM
M.H646N._I)T\NV@^X.3QV0;4Y!E,RVT*TK6PXEP!7D)038T&S0?*W$(3J6H)
M'E)L/PT$)N+`MYN$V[%>2W*;LY$EILL64.(\BD+2;'RBD(F,N8/^%6.;RO77
MM&-)E:M1=0\I$<KO?7T"E5A?LO6S;O-\UZ8OP_-5&I>,3M9F&Q*RFY'F.H\W
MTW==D1V61P#:=9L$B_EYUK1[%M:X0TG:^WD+2ZYN=AB*^DN0SUF$+4GB`0[J
M^T2.5992D,1L`*F-R9$QF7%0H*/138.J0>Z5V4H=T\;#A>HR+Z!86[!4!0*!
M0*!0*!0<]D^*3D=$=#T-")(R1C9`%1TLP0L)$L<+G4EQ%A]:_DJ1*#?[#L9W
M3B)BI:$H>$`AH.*CN(6XAZY7H"5):5P)N#PM0:TC>.TRXI:\8IUBQ1'EAELI
M>D);2ZJ.CCJZFE?:+7N+\*@>RM[XG%1I&O#/1<DTTE;..*&DN/+*G$E+:DDI
M4$=(E2@;`<:#+#\2(SS3:W,;*2KW5,B2AK0\IIY4<2>AH0K6I734+*";7('.
M@GMNYYC.8[WUEI3&EQ;+K*U(44K;-E#4VI:3\AH).@4"@4"@4"@4%(R?B8QB
M<CE8LN`\\C'NJ"510%'HM1VI#KBPI2?5ZW`#G09GO$F(U$>D*Q4TF(ZIJ>T`
MUJ8*5)0"KOV5JZJ;!-_P4'P/$K$NRH\)^`^EYUXQ9#2RRKHR.LIA+:@%G5J6
M@]Y-P!S-2--S>VV6<8J=D,(8[S7NX?C]-I:DJE-K=19238]UOC4#?PN]\-(R
M$>"QBWH:GBEM:RAL!IUQOK-MN)0I2AJ;LJ]K"X!-Z#W_`#=E1D\MJ98^%XF?
M'@.I2'%2%^\I:LM)!T]U3XN+<A09(6Z\H<:QFY;3!QDUA4F+$8U^^)&G6A-B
M2'5%/K:0-//E036WLZQF\<)K+:F;.+:<:4I"RE;:M*AJ;4M"AYP:"2H%`H%`
M-!SZ5XFRV(T0^XH]Z.3]SGH*R$M1"XE*9([>^EU&F_;?R5(VV_$^&^PY(:QL
MA348J5+.ID]-GW9R4ASNK4%:TM$:0;@\Z@99OB?AHF07#5$DKZ+/O,EY*4:&
MF>DTZ5JNH'@'TBPXWH,TG>]]IY3-1X:VI6,"@N))M;6`E2>\V5)4DI6#=)\W
M.@.[CSC4UO"J;C'+ON(#4D)=$4-K:==NI).LJ`CJ%@KM%!]N;R]PDPH.18#L
MF0[T'I,52/=T*+G23_6*"M1/K-C4I/;06B@4"@4"@Y',64H41YZ\Q6.+M*+G
MI<EQT1XX!?>4&VTDV&HFW$UT=&O,LXA4Y&W8;V5:5(GE\1%A>1BN)Z3*D`@*
MT.@GN@D7U`<*Z]-45;<:.$2W,WCLE/QLHEIB+%CJ08;^A">GQX(2IH%124WX
M<:SFL2LOJKB(\6UM9W)PI*(LTH)6E+C3C:M:%H5R4#\E<SNM6&E>DUG#IL%W
M6T#Y17(NJ;55AP'$\AQ-$M38\!.0?EOJ%PZMP_)>PKTVFN*1'L<B\YF6M.B&
M%DW63P225)^>N/ZEKQ:+>;>[2V8P@/%183X7;@4?RHBA\Z@*I[3_`+*^]9O^
M25KQXTXZ(GR,-#YD"J;_`#2LKRAYM]]6.W0M)-FY)"T>D\Z[G8[.K7[G.[FN
M+.N-K"T!7EK<:SFHV;G7H4!A./3$=@0I[,IPN-#WOW@]R/=LJ^S7ZRE+M;YZ
M#;R^`STWKN8K&*P"EHC-]6*ZVE]T,H<.AP,NMIZ+:E)2G2L+_F\*#-O2!O\`
MF1,<G#E;$AB/U7ULOI3>6G1I;5J+04CUN\;C^+0:6X-J[DR#C:TIGK?3-:EO
M'WU*(]FI`*`PSK.DAK^2.'&YJ1DE8?Q$3#1$C.K#:8K*UO)D)#BI3R$,/MI]
M72AA*5NIL1J418BH&!.VM]?#$A$B4G(!2XBGU/A2C`]ZUBPZI^U+*K!17J%B
M-5[&@FAALXK;6'9R#*\I+@S4OR6'UM=1QE"W`WJ)46U+0E2%<5<;<[T'C>W)
M#S$9:L3'@E.8,U<9)2LI8[P+BS=2-:R=2DHX<?30>SH.?5A\GC(<>3%>?ENN
MLSHSK"#TG'PON7<2L'0>([IYV4#:@G-K-Y9K`Q&LN#\1;1I?)7U2;$A)*^TE
M-K\_2>=!*T"@4"@4"@4$,[L_;KKBG'(2%K6EI#A)4=2&'2\VE7'B`XHF@^<7
ML[!8QMQ$5E?V@TJ4ZZZZO0$%M*`MQ2E!"$*(2GD.R@PJV%M=3KKBHA/6:+*D
M=5W0`4);4M"`K2APH;2"XD:N'.@]:V5B42XSJP7FHC+[3*'2IQPJE_UZW'EE
M3BRL<.)H/EO8.VT)"`T\60Q[L63)?+92&^B%J3KLIP-]P+/>``X\!02>&PF/
MP\0Q8*%)0M:G75N+6ZXXXOUEN..%2U*-N9-!OT"@4"@4"@4"@A)FR]NS)$N1
M(BZW9P<3*5K6-8=;0RO@#PNAI(X4&1>T\$MN:VJ/=&07U)8UK[ZKI5?GPXMI
MY4&B_P"'>U79ZYQCNMR77Q+=4T^\VE;Z'"ZAQ:$K"5*2I1TW'"]!\2/#7:,A
M25/Q7'="0D)5(?(.C6$%0UV44I=4E)/)/#E02#>TL&UE&\FVRI,EL)L`ZYTB
MI#?20XIK5TU.);[H61>U!\(V;@D9MS-);=$UUP/N)Z[W04ZE'32X6-?2*@G@
M#IH,2-B[<0[)6&75)E)6@LJ?>4TT'5:E^[ME90R2H7NV!026&PL##Q#%A)4&
MU.+>=6XM;KCCCANM:W%E2E*)[2:#>H%`H%`H(&7L7:TM;RY$%+BI#33#]U+[
M[;#A=;2KCQLM1_%08(WAYMB.E:4M/K#H2'0[)D.:TMMK92A6I9ND-.*1IY6H
M(K-;8VCM?$R<HG&JEEP-PY"'7W7%.-RW&8Y"E.*7R"4?T:"PM[2PJ,-*PZFW
M'84W5[UU7G7'7"H`$J=6HN<D@#CPH,0V3@1C%X_3(*%NB09"I,A4H.I%DK3)
M*R\DI2+"RN7"@\.QMNGW+4RZH02DMI+[Q#A0YU4J?NL]90<[]W+F]!/T"@4"
M@4'(9Z"IM7RUYBO-VW.-ULRVP7XQ*7F2%MJ'8I)N*ZG;7Q+*LX5[`[H9G9"3
M$GPH\9XM*6V`2`^^DC2%=0E-OR@@<":[$3EO5VS?AR9,SN80\>W"R%WI#[I4
MIA@MI<0A";)4L)&GB38`CE4\EE[UI+=VL[*R,UN2MCW=EI"&H[`)4$I22;E1
MM<DFYKF]YLRT=NR;3EU3'MJ2TD'L%<6\J&Y58QR21&=(YA"C^`UE7G'O1/))
M>%+"?<DGM()O7J''EAWS"T95A:>&LD'YZT?4*=6N?8V>UMB[GWC0H,>%F;3?
MUFVVQZ5.I%<SLH_V0V^X^25UC)TQF4_5;0GYDBJ)YK8Y-#+DLR84M/\`9.A*
MSYE6K?\`3KXM,-;NJ\,NL8.2)$!M8-^%=ESDA0*!0*!0*#Y4;`\*"IS).%S#
MV38EST!,75&2VAU00T"@*ZSF@@7N?65P`'EHE$[/W,J+M^9`ENK5.Q[RV6RL
M$K4E1U"U^>D*L/11E6N92^V=SO.Y1>(G.]5Q;8D0I)&DN(_*00.&I!J9A-Z8
M6VH5E`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`/*@Y--Q&\
MXSD]R*]-<]S?>Q$)H%Q27(^347!*XGO&,7VTZ_R0VJI&X<UOJ)\1B1W5=!E"
M6\:Z]$?<4WTI/1/44EHWU,][5]I;UCPH)3;4S=3^39G21(:B3G&&Y,*0QI+?
M_P`>5J=U`G1]LV$V'"ZO+4"F?ZG=Y;JVGM_'R\?%9G868\AB>VX%!34AIU$B
M.M*T'DOI*001^&@Z=L6=G<AM/%Y#/-I8R\UA,B7'0DI2TIWOAL`DGN)('$T$
M]0*!0*!0*!0<I=3J!%>6SQ=I7<OB@Z%<+@BMK7LPRB5"S&Q(TEQ2M%E'MXUO
MZ^YF$Y:V/\/F&W0I0U>F]97[J3*Q1\CC\)G\=A'HSI<R8`C/-)U("@2"%\01
MZ:UK5F])MGDIMLQ:(GQ=#90$H%<Z99LE8C'(!5'=2.90H#Y0:RKS@GDD?"I\
M"*&CP4D$$><&O3Q.8<:6_OQK^\1'/(K\=4=U&=<K=$XO#D/CRX1X;3&Q_;2(
MK?SO)^BN3V$?[/PEN]S\GXN@I%DI'F'XJU,KVEF4:\:^?J#6/2DWJ_M;8V0K
MW1FLKWL.3UL6@WKT3DK10*!0?"WVT<5D)'E5P'SF@@LMOC`X]#EG%RW&N"VX
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M'TA]MJ/(>T%:0M(4IIM:02D@VO5M=%IC,<OP,L'[0MJ_GI/_`",W]#67VU_X
MF/W1D_:%M7\])_Y&;^AI]M?^)C]S)^T+:OYZ3_R,W]#3[:_\3'[F3]H6U?ST
MG_D9OZ&GVU_XF/W,G[0MJ_GI/_(S?T-/MK_Q,?N9/VA;5_/2?^1F_H:?;7_B
M8_<R?M"VK^>D_P#(S?T-/MK_`,3'[F3]H6U?STG_`)&;^AI]M?\`B8_<RR1-
M][8E3(\-J2ZF1*7THZ78TED+7I*M(6ZVA-]*2>=1/;WB,X_.$Y3]4A0*#77,
M90^6E<%``GT&X_@J.KCA.&P""`1R[*E#2R.6BP2VEU+CCKQ5TVF4%Q9"1=1T
MIXV'::)B,JGN!W;V\,9!Q&6A..8[+24JC$J1J#D577;4M%]2=73Y?(;5ETIF
MDQ"\``#@+#R5BQ>T"@4"@4"@4'*CS->6=IC<9"Q8U,6&D[C4J-ZSBZ<OEO&)
M2:F;CYR^$;GP%LI4&I*"EV)(MJ+;S1UM+L?(H5.O=TS[/%A>N8]IMW+N3XBV
MI80UEH:NCDHS9)"'.:2+_DK3923Y*C=JZ9X?+/)&N^8X\TK5+,H,>SY'N&XG
MHO)"^^B_D5QKT/:7ZJ1+F;ZXLM.^DZHK+MN"2#?Y15NZ,TGW*]<XM#BOCSQ\
M/EK_`"4S8:E'S=6N-V/_`&?A+?[GY/Q=$'(>@?BK2;#!D$ZH$D>5I?\`Y35F
MJ<7CWL;_`"RLOAD]JQJ1YOHKTSCKQ0>+6E"2I1L$@DGS"@@6Y^Y9:%/(CLX^
M,I.IKK*ZTA0(N#H24MH[.!4:QF<)A7<LC'I0AW.N*SJRI):CN*O';<Y!190E
M+7;VWKF]QW_TXSC.?)MZ>UF\\&3=45R9MJ9"8NONH=!60/ZM04;(%^%O+QKH
M>D]S6FZ,SX.9ZIHF^BT1S<SV^VY%W&N'(;4MF>C46VU65UQ?N&U^';_.K>[F
M*QLF:_+)Z7MM.N(M\T<)=%CPI\="6&66\>A7)(]<_P`WO+/S5KS,.E-H:^2R
M.U-NRFOBN4:;G+[P:<58JU</ZM(<?4./U*B95SLRB=YX.<VS+SF/BK@I9]W9
M8>6E(<*1KZBP%%1TJ"PGCQU6X5"OKE//[#7(P3,3$RC)AS5MOORI"M3H`4%D
MI-A<'3R[*93]2706&RVRAOGH2E-_0+45ON@4"@4"@4"@4"@4"@4"@4"@4"@4
M"@KNW/\`J3=?_&QO_P`^/5^SY*^Z?UD;,W>&WX60GX^7)Z,G&POB4I*DJL(M
MU)*TFUE:2GB!QXCRUC73:8B8CG./Q3AHQ?$?:\G%R<FTZ[[K$BQ9KY+2PH,S
M02R=)%[G3Q'96<]K>)B/&9F/Y&&WCMY8;(Y$0H@><2MQYEB;TE>[.NQB4OMH
M=Y704GGP-CI)M6-M%JQF?_/$PW,9GL9DH+TZ,[_=8[LAAUQP%`2N*XIIV^KL
M"FSQK"^N:SB>?[H1TS?NW(4'#SI;SC,7.OHC8YU;:P%+=!+:E\.XA83<*5Y1
M5E>WO,S$?V\TX9&M[;>=R2\<T^I<EN?\+59"M/O7NZI)1JM;@V@W/*_#G43H
MMC/LS^&<&&.7OK!QWQ'2'Y+Z4./OM1VE.*98:>4PIYP<#HZC:@+7)MP%37M[
M3&3"P@@@$&X/$&J$*YO'_>MM?_<-?^W?J_3RM_Q_K`L=QY:H&-<EA"PA2P%D
M%03YAPO49XX3A]A0(!';4H5;<<ER/++R1<H2.`[4@_P5KS?IVQGE*VL9JF8.
M4CN8U+^L!(1<GY*OO:*QF5>'/-V[M*9BW&LDF'F82-&,@(:4XJ5[R$A21?UB
M%)L-'(\ZSTQ,UCJA=2&SA\%M3$L(S./=?R.88+S45E];BK3U(4MX!@`:%FYO
MV`<JRF\VX2QM:9X2EMJ;LE97,^[,2%SX:(I5-=7'+'0E)6D!J^E/%5U72;D6
MK&U<0B](A=1RK%64"@P39/N["G+BXL!?SD#^&L;3B$Q&2+)2^DE)O:LD,]`H
M.5'F:\L[14!0><*#"9L,.]$O(ZU[=/4-7S5GT6QG'!&81>8QDU$]G,8AMM4]
MO[*8RKN>\QS^05\@ILG4@D>4=M6:[Q->FW+P]DL+UF)S7FF@>''Y:H6%[U(C
MGU&-FX<H<-=T*_`:ZOIM^=6GW=?%?MPH]ZV[K[0B]=.8:4.2^(V&<SGASEX3
M:=4CW<O,#MZC!ZB;?T:X=/@WX]KI6CJUIS;F69R^W\;E&3=$V,T^.-[%2`5`
MV\AX5K;:]-ICVK:3F,MV6+Q'QY6U_P#E-13YH]Z;<I3'A4N^/3Z*]/EQY7U^
M5&81J>=0TFQ-UD)Y"YYT0J.6W%)R3"V8#Z8\!]K6W-%EJ=:7=.I&KNH&H$<0
M302XF>_8J-+OHC2&@7&T`.\5#L*>=CVUK[^7L9TYHR&Q)>>M+;;9QT8'H(4H
M6+G8I:!?3P[+USM=+VF)O&*1R_=M7FM:_#.;2AMR[IVCB64QID]$IUPW1$@W
M<4KS=)C4NWDNH5??L\QTSRS[H_=A3?-9S'-`8=_>^7RWO>W\*<7CD!705-(8
M"]8&E;K;7VBM-CW2YQKHUC%8K_BU(KBTV\YRLL3PWW)*D&5G-SRCK!#D+&#W
M%BQ[/LSK5Z5*-2RF4]B?#G9.*0H0\/&2XL'J/+0%N+*AQ*EJN231"'S6QMT9
MF-'PTK,(8V_&4DK1';4F3(0V>XVZLJ*0!P]4<2*)RNT.*Q$C-1F$Z&64A#:1
MV`<!1#-0*!0*!0:N0RD''I85+=#29#R([)-^+KALE/#RT'U\0AE:$)>2HKUV
M*2%)NV`574.`M?MH/53X*4-N*D-!#MRTLK395N)TF_'Y*#0F;KP4;%Q\H9/7
M@RUAN,[&0N1U%*"E#2&@LG@@F@U)6_=K1H\=]4PNMR4*=;##3KR@V@Z5K<0V
ME2FPE7`Z@./"@FX\Z'(T]!]#I4A+@"5`G0L72JW.QH,U`H%`H%`H%`H%!7=N
M?]2;K_XV-_\`GQZOV?)7W3^LC4W)X?1<YFHV2>?T=%YHO-!%^M&2D]2,X;\4
M.+#:C_)K+5W,TK,?QGS3$J]^Q*`Y!E-2I#,B:Y!@0H<Q<?O1U0=5W$C7_::N
M5^'GJ_[^8F,<LS/\T]2R[;VIFL&\U$9RC:L!'?F2&H88L\1*<4ZAI;I61I:6
MXJQ";GA?EQU]NZM^./BX?DB986MJY"#@?@#.F9'R>1E/9&0H!"6X<N0Y)=1H
MU%2BI*^B+>75V6J9W1-NKEB(Q[XC'_DRV]W[*B;D8@Q7EI9B1"_=H(O?JQG(
MZ"BQ&@MJ<"TG^+6.G?.O,^,_ODB4*SX30?=,9#FR4SX\22S,G"0UJ,MYN,\T
MZXX=7K.NO]4GCY*NGO)S,Q&,QCW<8_\`@RV(_A_/Q4OWK;\]F"XN&K'J0M@N
M-H:$IR2RII(6FRFP^M'&X/`VX6K&>YBT8M&>.?RQ_0RNP%@!>]NT\ZU$*WO'
M_>MM?_<-?^W?J_3RM_Q_K`;F7DXQ$F*XO2``ID>KZ?36ELU6MQK;"RMH\85=
MW<,AUA<G6HOQ^):5ZP1?O<?)5%=MXW5B\>Q9T1TSA>-O3Q-QC3M[D\^VMZW-
MKOC/X]#S!?']8WQ]([156VD7K,2RI.)<XG91V'D$XB.XI75<)TWL$I)LE-O-
M6MVMIWXFWRU_.?-=>.GWRY=N[Q7W?B<X_C8GNZ%8R5U(SQ;^TU)24V*K\E!1
M!KT>GLJVIU>,LJ:XQEM#Q285BTS8\EYG.A]<R5D@M-UJ6WH]W2S:UN0XWMSN
M:HKVUIMB83CBF?!+Q4W;EMX0MMS76G($A,I]Y?3`>4X$EW45W[55EWG:5I7J
MC+#;3'%^C.0KG-=X%I/(TR/EQ]IM.I:TI'E)`_'43*<(#=4Y/NC:6U7"E!94
M.5D\?PFJ=L\:QYRSI'-][6EAR,>-SZ?/6QG/%AA/"]0A[0<J/,UY9VBH"@4$
M)F<7/D/OOP[)<,%QAE6K0KJJ=2L<>RX2>-;&K9$1B?\`*%=ZS,\/)%RL)N*:
M,@ZX5,+<ZJL>VF006W"EA+1)0;<"VX>T"_GJZNZE<1'Z*YUVEZG`[@;?6$*4
M4I>28#WO!*8[?6UN:D$W7K;X6X^2D[J3'Z\"-=ECQD0Q8:&U%1<-U.E2BLE:
MN)XJ)K5V6ZK974KB&MN#NQ6GAS:>0?D-Q6UV%L;%7<Q\#H>)4)NW2GG]GP^:
MNXYJEEHLRY,90NE)!L?(H5QO4=<1;/FZ':VS&%7V=@'MGQLGC''+[<8=7,Q<
ME:@5,M.=]UA8Y_9KNI*NT&J-UXV8G^[Q6:Z]&8\'K_B)@7VM&-ZN04\DA)90
M2D`@V)-N595[6T3FV(8SNB>$<6QL1WQ#R+'NV#+.,CJX*F2`%.I(YZ&P5<_.
M:[L<G.E=V_"*+.6)&Y,I+R<@VU(#A;:N!;B!Q/SU*,MYWP@V&Z&TNP%+;:!#
M;2G7"@`\P$ZK41E]2]G97%XU</9LEG&LN?\`]62@O--*)%ULIU#3?M3ROQK&
MT9YIB5?SFRL)%QPF>(.ZGCCV^\J,J0F#""^?!M&C7_.O44I%8Q!,Y:GAKXD>
M$>3W`G;6PH#DAYM"WI$QF*6V&FD#UU.+TJ[RK)38<36:'7!>W'G0>T"@4"@4
M"@4"@4%>WQMF1N/$-06'TQUH?0\5K!4"$I4FW`CZU!69?AK*Z3N-ANIC1Y,4
M-!YE`2AI;4=IGBF_>ZJF^-AZM!GQGAYDX2HZG#!EAUQ:IJ'VU+#`6Z'/[GP`
M![#<)%^/FH)#'[6S^*VOA<;CG(/O^'=*@I:'$QUM]-UOU4=X*(=!/GH-6#LG
M<N'E/Y#$3XBLEDTK^++E,KZ0<6\X\'(Z$*N-!>4-"CWN'&]Z#;P&SLGC=T2\
MF_)9?CR"ISJ:+/K<<0A*B>%D<47[JK'AW106^@4"@4"@4"@7%[4"@KNW/^I-
MU_\`&QO_`,^/5^SY*^Z?UD16X<MDV-V8V,S)<;CNY2$RXTDV2IMR',6M!\RE
M-I)]%6:J1-)G']L_K"80.3\3=PP]V9&`RN',:BS'H;>&0A0F!I&/$M,M2]=N
MFEP:%=WMYWJZO:UFD3QC,9SX<\83AAR'B-N&-CHRDYO%I#BIA.56A"V%^[1$
M24,Z6GU("BM13P<)TVX7J:]M69GX;>'#WSCR,-!O?>[69;TB9E6G'H[L]P0B
MT6D,-HQB)3770A96MI*EW%['NGCY,_MZ3&(CR_\`;'`PV!O[<<1C*!K.0I8;
MFRU,YAX-IAK]VB15(BM@O@)U*=45:5J5P58>3'[>LX^&8X1P\>,SQY&'78CJ
MWHK+JP$K<;2M21>P*@"0+V-<V8Q+%EJ`H*QOE!6YMU(<4T3EV?M$6U"T=\\-
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M+&+&H7Z4H6OQ_J36AZC_`-?XJM\\'Z]6H)02>%JX;4<_SNZG,,XI(<3=9LTC
MF02;FX^7E6A3N+6M].G&<\9\H;$:XQF7QCDY#+GWIZZD]BUF]O0#PK=C12O&
M>,^U7-_"$9G\D\^M&.B*UW5I6O\`!PJC5$;;]?\`;'"/:SGX8QXKUM/$JA8U
ML.>N1<UN6E2GJQ04'*CS->6=HJ`H%`H%`H%!JY-D/0'D'ZI(](XU;HMTWB6&
MR,UE9_#J5U\5HY]T#\%>D<F4=N6,8V;ZEK)>&GY;7K1[^F:9]K9[6V+-(@*2
M01<'@0:XKH,"(<1AM0890WP/J)`[/-675,SQ1B,-_P`)UW"[\]:OQUZ6O*'(
MMS=.K)B4'BT!0(/(@@VX<Z#A?B%_I/VONF6N=!S.0QDQU9<7UUJGLW/.R75A
MP?TZ"H;"_P!+>8VUN]4;/`YC;DYHH^*8V8_`>CNH!4GJLH4E2TJ/=X%5N=!U
M<?Z=_#NWK9;]:3?TM`_=W\.OK9;]:S?TM`_=W\._K97]:S?TM`_=W\._K97]
M:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=W\.OK9;]:S?TM`_=W\._
MK97]:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=
MW\._K97]:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?T
MM`_=W\._K9;]:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=W\._K97]
M:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=W\._K97]:S?TM`_=W\.O
MK97]:S?TM!<]I[1Q&UL4G%XHOF*EQ;H]Y?<D.:G+:N^Z5*MPY7H)J@KNW/\`
MJ3=?_&QO_P`^/5^SY*^Z?UD;T_/;:A2Q'GSHL>4!U`AYQ"%`)0M6KO$6[B%G
MT`UA77>8S$3@PC(VX?#N&7LBQDL>TJ>XXX])ZS=W'&VV^J2HG\EOIE78!8U9
M.K;/#$\$XE\2<KX::(<^1+QB6HRGS"=4XTEM*M"2^4BX3P0I)4>P$&D4V\8B
M).+8A;JVG,>D.*6RP^F2]"*WPVE3JHQ2VM2#<ZD?:I`/G\]1;3>/Y9,-W&R-
MKY%M3&.5#E-Q5!:VF.FM+:[E()2F^E5T$>7A6%HO7GF$)6JPH%!6]Y?[SMLG
ME\8:_P#;OU=IY6_X_L*=N5B5DY3B8(4R'3I2H`ZRD<+^:]:5=<[)ZK?+'*%_
M5TQB$CMKPMA1FPN6=;AXFXO6U-U.4O,\.,*^DZ!TU6X$"U1-R)5]W8>:Q#OO
M..DJ>0GB6%\0?0;FU:V_L]6V.,8E;3=,-AUAG+04AY):?:4"E8]9IU->?K>_
M:;<?Q,-J8B\*9XGNP%[%R;$F!':S+2D*5*2T@..(N>_U+:B#Z:]?Z=NB]JVK
M/!K5K-;8<K$:.?!>/)2T@2!F93:WM(UE(0T0DJYV%ZZ.O_\`HGW,X^=^BO!F
M'B&?#7;4TQF$2U0DDR0V@.DDD'OVU<:Y7<7Q><SXJ+<UCS6;6B(Z(R=12F]^
M/XA<UQ>Y[Z,]&OG/BMUZO&7,(F"RF8R1RF6O#A-JNPV^+.+X^MH/%-_/65>Z
MU=K3ICXKSY,[5M>?*%@G[OP<5A6.$M#9M;@I(MZ1<5K7W[M_]L]/L91KK7QX
MM';*8#3[LX3FII;[Y3;20.?85UT*]]TXKT6A5;5,^*S'Q"BN-),7IFYTJL=6
MGY!:K*;K6MC'3[V,ZXB,YRM>-E^]1P[:P5QM6S,84MN@Y4>9KRSM%0%`H%`H
M%`H/E:=2%)[""/GJ8GB2W_"UZR76C^2LI^8D5Z>LYB''M'%.;XQRG88?;L%M
MG4#Z*7IU1@K;$Y5-I:5MI6#<$7KS-Z],XEUZSF,ONL4OG8#@@9I^&H_EJ4GT
M*XBO1]MLZJ1+E;J]-L.KIX@&KU10*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!05W;G_4FZ_^-C?_`)\>K]GR5]T_K(C-T>'+N=DY)L9$1L9F$H5D
M6.@EUXNM,*8;+3JU:6TVTJ4-%S;F`HU9J[GHB.'&O),2Q0/#60C(2\KD,DB5
MD\@Q*8F+;CAIH^\,,1T%#>M>G0B-QN3J)[+5-NZC$5B,1&/ZS_4RQ[LV#F\G
MEXK^,F,1F5-3F9CSS75*$2XK$8!MO4C4JS)-R;#M!%-/<5K68F/+\IF2):CG
M@ZD-I99R7]W4Y($A#B';JCOK;6$)Z3S2=:>E:ZTJ2;^KPK+[WQQ_'\D]2R[2
MVI,P,K(NN9`3$91P2Y+?10UIF*)#JT%!]1:=`"3<C3>_$U1NW1>(X8QP_!$R
MLE4(*!05O>/^];:_^X:_]N_5^GE;_C_6!NS8T6&H2@V%K*@D^6QK4W;>BN65
M8S.&;%YF-."@V;*0;%/(BK/:C"1HAX0"#?E3.!3LXTU#EO+0-(=()MY:X/K4
MQ$U\V]V=9G*A^(\"1F=KR(\&.9,\V#*4D!1!X*'$@6JOT7OHT[XF\XIXMK;I
M\7/&MF;N1X8?`W,<L3AE'928^MN_3<0VG5?5;\FO1U]<[>.XF>KX.GG[5->W
MMG.'4?#X9#&[,P^,GW9D0HP:=:N#I(43:XX=M>3]1[J=N^W3.:9X+ZZ,5Y<6
M3+^(>&QJBRESJR!_9H[RK^@7M66CT_;LY1CWJ+WK'.5=5.W?NM]+4,+APE'B
M3ZZ@KAV>K\E=SM?2Z:^-_BLUK[Y\.2Y[>\'\=':"YH2XX>)O<F_GO71F_DU\
MY3$CPZ@(`<@GH/(]52;BJ[XM&)C@F+81$79>C*++S8!58J4D623VD6J*1B,>
M7),VRZ%!C(C,!M/(5+!L4'*CS->6=HJ`H%`H%`H%`H/KPX7T\M,9OR>5^$DU
MZ31.:1[G)VQBTND9-E+T-:5"_"KE;EL5KI+D(_)#JM(]-</U"(C9P\G2[;Y&
MQ6BV&@'3#W/$D<DO(*%>2Z>-=?TZ^:S5H]W7CEUZ&Z'8S:QQ!2/Q5TVFS4"@
M4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4%>E[-;>R<S(Q\MD<>Y.4
MA<EJ*ZVEM2VVTM!5EMN$'0@#G5T;L1$3$3A#X_R;)_[DS'MF/T%3]:/\:_G^
MX?Y-D_\`<F8]LQ^@I]:/\:_G^X?Y-D_]R9CVS'Z"GUH_QK^?[A_DV3_W)F/;
M,?H*?6C_`!K^?[A_DV3_`-R9CVS'Z"GUH_QK^?[A_DV3_P!R9CVS'Z"GUH_Q
MK^?[C%(VE*996X-PYEPI%PA+T>Y^=BHG?Y5K_'XIB%5ER'V7@VYN',1N/>ZC
MT=7#TABM39WNRL?]4?Q^*ZNJL^+Y@ZSD(TF=F)N33"?]Y@H?>:#1<"%(27$)
M:;)LEP_E5A'J])I,3$5M/">$IGMY;6<R^Z'^\U%6ZU>Z-`&GY+$FM7KKLY[(
MCV,XCI_M:V!?RCTE*YS#L&<@V0Z$G0L?QN'XZPC9.CA2T7I^<%HBW.,+BUGI
MC`TOH;61^4"1^"LH]5U>.6/V]IY/E_=R4H-D)U^DUAN]7UQ'P\96Z^RM//DJ
M&7RBWE*<6KB;DUYS?NMLMU2[';Z(KPA5I6YA'/`$CRGA5=:S+I5[3J9(.X4S
M#I]57DJ+1,(V=IT-G/N3AMN8[#N7T(N".8%[$_(#6]Z;6MMT1;DY7>SBG!,>
M&GA]B7,6B6\G6X3?C8FO:6L\_+IT/&PXB`EAL)`\PJO*,L[KS33:G'%!"$BZ
ME$V`%1,Q$9E,1E@C9&+(1K:7=/82+7'EXTB8F,DPR-KCO66@I6/K"Q%(G*&:
MI"@Y4>9KRSM%0%`H%`H%`H%!BV2KI[FFH/:X"/E%>A[2<ZX<O?\`-+J<L_W1
M9\U;*ERU']=(_P#Y37$]0_[/P=+M?D9*T&PCLXBT/W@>O&4'$D<[7L?P5M]C
MLZ=D>U1W%,U=&V;D4R\8V;W(2/Q5WW,6"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4'BDA0L>5!#Y#:V*F`]9L&_,VJ>J4Y<ZW#A
M<#C)"DLR'$E!)4EE13;S7K3V]Q$STUKU6]W!?6DXS,XA"N9K<4I*8V*:6EE'
M!*W%+5P\_&Y^4U57TR+3U;)CW0RG?CDR(F9G&V>R.0&H<?=XZ$E9/U2M5[?)
M5,Z-5IZ=5,^WP9Q:<9F<,G^=<U()+&->+=K`\*PMZ+:W&;1$IKW-8\&`[GF!
MP>]PW6DGFO3<#YKUK;/1-L<IB6W3OJ-F2^F1'4MM6H*2;6KC[-5J3TVC$NIH
MO$\84;/.J4Y9N_95O;QYNUV]6SMAEXOI4;V2;DUCW,P=S:.ETO%!"6[N$!!%
MB#R(/,573/AS>;[B4MB78<#_`/SI'0;)N6`06_YH/*N[J]6V5CXXRY-NWCP3
M:,W*4`"M)O\`E`#Z:LGU>)Y5PP^W57/9I1?*94Y(:OQ;-U'AYCI34T[V+3QB
MUY_)E&F<<.#5=S*]+/N2UR8JN#]E`D'EW@.-K5LZ-_U)_P!GP^4,+4Z8X<5[
MVVM+D1"]8((X)\GFKHXPUY3=0@H.5'F:\L[14!0*!0*!0*!1+5PBO=]VGR/!
M"A^$5W.PMG6YW<Q\3JKQU0B1VBMYJN8I_K7_`"]55<3U'_L_!TNU^1ZM>D7M
M<#G;LK0;#Q26WFRDV4VL$'S@U-;8G),9;?AYD3%ER,>X3=M>E/\`)_)_!7I-
M.SJI$N3LKBTPZ:""+BK590*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!
M0*!0*!0*!0*#F2]X[DAX_P",+FMS.I.R$1&(+2$%2(J7U(+:T=_4GH)U7OPO
MYJ"S[;EY%R3$]\S;.1,Z`F8(R&D(()4C[5I2/[+OZ;*N?/SH)S)-.NPW6V5E
MMQ0L%IYB_DK&]<QA-9XJ,SL-R5,+DH_8A5[7X\^VLJ4K2,596O,L6YYV.P>+
M+<$!*RKIZQQ5VWM6AMVVW7^E7EXRMUUBL=4M3:&T594IFSQ=L'@+]G.NC6L4
MB(CDIM:9G,NB1,)C(S80VRFP\O&HZF+U_"8MY)"V$D'S4RE2MR[4@8[5)BC0
MAV^IN_"_,$5RO6*5MIS/.);_`*=LF-F(4Q_;T22O6MOB>=C:O*Q:8Y/2U[JU
M8YMJ%AFV"$MITII/'FKV;YF.*$W"SE,IN-&WV7%,QD-I==TDI*RH\!<=ENRO
M4^C=K2-?U)C-I>>[W=,VPNL3PB7$C@Q);C3A'$)<)!](/"NI>E+_`#0THO,<
MF![96]8J^I&EI5H-P%)!O;T`5K6]/T3_`&K(WV0N:VPQ+G)RLQ*VI25!.08*
MRI''@E;8/+SU';3;3?Z4\I^64VQ:,PN./\.L2N,W)@K+:R`;I416Y;%N$QE3
M%ICDF<1ALE`D64YJ;/#\-84I%>7(M;*T)O87Y]M9,7M!RH\S7EG:*@*!0*!0
M*!0*"-?66-P8YWL6%)/R$&NMZ;;A,-+NXY.G094AYP,W'0+6L"W,6MS]-=N:
M5^GGQ:.>*AS`EC*R62;7.L?+PK@^I4XQ9T.TMPF'@(/(WKF-M\M-(0I6G@E1
MN1V5`CF)Z6,Y%DILE3JBVX!R.@\/P5U_3-LS$U\FGWE(S$NPX]WJQ&W+WN*Z
MC1;%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H%`H-5K%8Q
MEY3[,1EM]6HJ=0VE*B5>MQ`OQ[:!$Q>.AK6N)%:CJ<]=3:$H)[>-A0;5!IY?
MI#'2.HOIH+:@I8-K`CG>L-DQTSGA#*O-R27CW,UF&H[85[JV=0^DU7VE/[YC
M&>$>Y9LMX+?,S4/#LH:BN]4H3I=2CB@$?B-8;=DVG_7QG\BE>'%BQ6]Y,QSI
MA"A8V4H)4H#SDV`%5[.XVZXS:*Q^*?IUF>$I>1FIC:22H:>PVL#YZT+>KV\*
MPMKVT3SE0=P[XQ[KJDKE)DK02`RR2X0?0F_X:HOVO==S.;1B&YJVZM7+FKOQ
M3<N4<Z>/QSB&CZKCH(Y?Q4_36[I]#K'SV_DJV^H3/RPGL5B]V8Q(?RC77CKL
M2I*-)0#Z.8K+NO2:37.OA:/S5ZN\G/Q)9>*C3Y4?*PG4HFL(*./$+1>^DD<K
M'D:TNR[RW;YI>."=U.OC"[X3<3$Q(9?'0EHX+97P(_\`'EKT-9BT9KQAH3&$
MWS%2A7-S;;&0;4IGNN*%E$"]QY*QM2+8SX2SK;#>VY!=A00RX;D6M6<SE@E;
M"H"@4'*CS->6=HJ`H%`H%`H%`H(O-#2Y">_-O`7]-=#TZV+RUNZCX73MLZ7H
M+,B]UA!;^35>NYU?#ASI4W-IMG'3;\D<?EKE>I?+#=[3G*M;?F*DM9=84?LY
M;P:5Y`!PM6CNIT]/N;&NV<^]NC()8PWOKZBI*&M;B["_GX"JIIFV(9Q;$91:
MT7B(DV(T/-.-J/:%\/X:O].F:[,>:ONHB:9=BVP]U,2T3SM7?<M+T"@4"@4"
M@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4$%N:%+F-):;40
MR`2I`_*5PM?S"L+:XM,9Y0SK;$>U&0<='P3(ERT*6M1(*D`J(OY:G=MBL9Q/
MX%:S*'R4W#.1W9:@E#+(N6A8$W_`*U+][TQ$5K.9Y+:ZIGG*`Q^1DY%;C\=8
MAXJ*H*<=(XGMTM#R\.)-:G<:NGCM^/9;E'DLBWA7A"-R,O.[TR7N4!;D;#`:
M%H]4ND&]R1QT^;YZWNS[&-<=5^-_T5;-F>$<E^VYX6X7'LMEUI"U@"_IK=FZ
MG*WQ<1CXH`992BW:!6&3+8=8:=;4VM(*%"Q%$*3F]IS8;QFX<A`OJ6P;Z5>7
MAV&J-_:TW1\4<?-;3;-4?E9R6\2<LB.XMZ,`5]/^N0D'O$>73VBN+VT[-.WZ
M><?I+8M$6C+YQ7B6TY%0M#JW4D7&M(!_!7:F^V.$T4=%?-:-O[F<R:[+1IY\
MN5NRKJQ;'&.*NT862I8E`H%!RH\S7EG:*@*!0*!0*!0*".SP_N!5]1:%?AK;
M[*?]L*>XCX)7_8SNO%H!\A_'7?<M%;FQK[<IR4VC4+<:U.Z[>=L1CP;&C;T*
M&R@X/;TQU2;ON*=<2CRK7<)K1WZYONBOEAL:[177EARZI$;8:DJ!7(=80U8]
MJW5!/\-5ZXB=WX_HRM.-:2R04G'0XMK+6IE!'F0!>L^QKG;,H[B<4PZKM=HM
MXEH$6-J[3G)>@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@4"@4"@$`\Z#!+B-R&5-K]4TR.?9O9+DM]+5R(R25V3R])K'73%IM/-9-N&%
M?RF/6M]G#1N$=BR2!VDGB3\IJGMJ=5[;9\9Q#.\XB*NE;6VY%Q4)`2@=0\2?
MDK9M.5">J`H%`(!%J"D;L<<Q"9,MELK0`'B@6X\;*Y^:N9W_`&L;+5GE/)L:
M;X51UW;3'N^4;5[NS/[P[MF2L\;6MW2?)PJ.W[G?3X)CJZ?YLK4K/'DL^)W7
MAXNE*0A6K@"BYYUN4[N+3C$J[:ICQ72'+;E,AUOBDUL*6>@4"@X_+R+49Q2'
M6W;@\=*":X7V.SR=/[BK!\?A_FW_`&1I]AM\H/N:'QZ'^;?]D:?8;?*#[FA\
M>A_FW_9&GV&WR@^YH?'H?YM_V1I]AM\H/N:'QZ'^;?\`9&GV&WR@^YH?'H?Y
MM_V1I]AM\H/N:'QZ'^;?]D:?8;?*#[FA\?A_FG_9&GV.WR@^YH.2&\FPJ,RV
M[J61;4@I'.KNW[396\3,*]N^MJS$.B;5C-066XFLK=*;FR2`+C5SKMSJGIZO
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M-0=2DZE`I-E"P[1VB@^VMPX=UQQM$E"G&@HE`4"5!"=2BD#G84&-.Z,(38R$
MI5H0XE"^ZI25H"P4@\^ZH4&96?PH=Z1G,=2P.@.))L;6X`]MQ08QN7!EU+?O
MC5UIUMKU#0H>97*@DZ#!,"1&=5;CI-1/),*%A8S;N;=6L7.L$7K#M?\`JJSV
M?,Z(+=E6*R@4"@4$+N;%JG05-MVU$6-Q?A?B*KVZ^N/QAGKMB5'5M*5#@N`M
M>\0UB[T18U)('&X!Y&HW]OUSU5GIO'BRKLQPGC#0PN!QD>>VDW]T=)Z15ZR#
M]11J>W[B;<+1B\%ZXY<G6,?&9CQD(:]2PM5BILT"@4$+)A;=6X2Z\R%>0N)'
M\-!A^';4_/Q_:H^FB3X=M3\_']JCZ:!\.VI^?C^U1]-`^';4_/Q_:H^F@?#M
MJ?GX_M4?30/AVU/S\?VJ/IH'P[:GY^/[5'TT'GP[:?Y^/[5'TT0SQ86W4+NR
MZR5>1+B2?QT&TPTRG*E3:DD='U003>_T5?,_Z\>U'BD*H2&UN-!\:6;\Q>D`
M`U?A:]!]T"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4&CEXF.EQT-3E
M]-!=06E!PM*ZH-T:5`I-Z"+CXW:#4&6CK1W(CCZG)2EO)*`Z6])2HWLFR!R^
M7GQH,$+#;%9"S&?CJ26VTJ'O.L=-)'3YK/"X'IJ1L.8K:C:YB)3[2W%M-)E]
M=\%8;2[J05E2M7%P\SSY>:H&)[&;&5/?=<=BB6I?VZ3(`5KU$\4ZN!O4C??@
MX!4.1UG&_<5HZ<@*=LT`5WN3>P5JY&H$5(P6Q+K3*D,]0$-NEV6=?4"@H*45
M+OU+VXGCV5(^G,+L3W-;#K[!:+CO56J5WNJI8ZMUE=]6NU_(:#Z@X?8S>10_
M#?CF8@K[B9(7<EM25ZD:C<],JO\`/0>(PVQ6G$!3T=3MDJ;+DK4K00C0!J7?
M39*-/R>6@^<;B/#]N:7<<[%,CJ]Y#4D*^U*M7%(6>]<V'FX4'L7#;):0V(LA
MC0VX@\)*5A2PZ%I"M2E<2X`/P4%JJ!\/!):4%$`$<2:"OX_'8UN<MQJ0TI9-
MRA+B5&_GXWJ*XBOP\F4S/BL=2Q*!0*!0>*TV[UK>>@^5AHH(5;3VT2I&XL;"
MUZX,EGO.)U(#B>"AY./.JYK'7$Q\T?HSB?A6O"=<0&P]ZP`X^6K95M^H"@4'
"_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`<@(F`P$1``(1`0,1`?_$`*H```$%`0$!````````
M```````#!`4&!P(!"`$!``(#`0$```````````````0%`0,&`@<0``("`0,#
M`@,$!@D"!`0'``$"`P0%`!$2(1,&,0=!(A1183(50B,SXY15<8%28D,D-!8(
M@E.1@S47H:)C1<%RLW0EA381``(!`P($!0(%!0$!```````!`A$#!!(%(3%!
M!E%Q(C(389'P@:'1%+'!X4(C@O'_V@`,`P$``A$#$0`_`/JG0!H`T`:`-`&@
M#0!H`T!"?[X\-^H^F_/*'U!?M"'ZF+GSY<>/'EOORZ;:`F]`5F;W*\%AN96E
M)F:ZVL+&\V2AY?-$D8Y2'T^;@/Q<=]OCH"R12)+&DL9Y(ZAE;[01N#H"`\A]
MPO"?';+5,UF:U&VL/U'TTCCNF+EP#!!NQW;H!\=`3..R-')T*^0Q\Z6J5J-9
M:]B(AD='&ZLI'P(T`US7DWCN#[/YSDJV.%EBM?ZJ5(N;`;D+S(WVT`GXSY9X
MYY/CSD,#?BOU%=HGDB._%T)!5AZCTT`IF?),'A37&5N1T_JN[V6E.P/T\+V)
M3OZ`)%$S'?X#0#?Q;S+QSRFK-9P=P6HZ[B.=>+1NC,H9>2.%8!E.ZG;J/30$
MCDLEC\92EO9"Q'5IP@&6>5@J+N0HW)^TG;0$9AO./$\UEKN(Q64@N9''_P"K
MKQ-NR==OZ#L>AV]#H"8M68*M:6S.XC@@1I)7/HJH-V/]0&@&N%SN'SF.AR.)
MN17:4ZAXIX6#*0PW'IZ?T'0#[0%6@]TO;VQDJ^,@SU26[:F:O!"D@8F5#Q*$
MCH"6Z+OZGTT!:=`53->ZOMYA,T,+E<Y6JY+=0T#L?D+#<!V`*H=CO\Q]-`6I
M65U#*0RL-U8=00?0@Z`R?W=JY!_(*<WYI5;'"IP_([&<L8%A-W6/U0DKJQF!
M7Y.+?AVZ>IT!<?;.&_#X91COY2/,60TQ-R&PUQ.#3.T<7U+@/,8D(C+L-VVW
M.@$_<.-GIT-O*V\34609K*/60SQ<3SB!LI*O+X@[:`D/#%KKA%$&?D\EC[C_
M`/\`)S/!(Q._X.59(H_D]/P[Z`C?<^BUSQZ"$Y9,17%VN]N22U)1$T"L3)`+
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M`8E[IQ>3R>26*U7R2C'C++P234;&;EQ$L`CB90FT*,_%I&$I96W;;B1MH#6_
M&4G3Q[')/>7)S+7C$F00@K.P4;R`CU#?;H"G^?U[R>6XC(IY7'XS4KT;D8[D
MT866R\L!B,E:;9)HPJN&ZAAOT8:`L?A.2R60P[39#)XW+3K,\8N8D,M=E4#8
M%6DFXOU^8<SH"L^\-7-3P8HXSR2#Q[A)-W&L77HAV*`(X9%?N]OK^K;Y>N_P
M&@'7M!#<BP-T6,E!>1K9->"OD),LM5>U&&B-R4"1R[\I>)'R\^(Z#0$G[EID
M'\.NK0R,>+G+1;V9K!IJR=U>Y#]4H+0&9-XQ(HW4G<:`I_LWBK^/ORHWE%?*
MP257DM8N+)391HK$E@LC*\^[*D4.T?(;<SU(^)`TGR#O?D.2[%Q<=-]+/VL@
M^Q2NW;;C,V_3:,_,=_LT!A_ME8O3^1X._%FH15:S)4O6%SN0RIR<WTLK=KZ*
MU$D<#$KWPW38+LOKH#?9=NV^[<!L=W&PX]/7KTZ:`Q[Q#)5)K!O6/="WE(Z^
M5%..K%])V9.\Y%>&9?I$D!?B1NC\3MT;0&QZ`P/R3NNOG46-\^C@S\4UI[$4
MMNRT$>/8C]7V@-J\U,G@'K[^GS]6.P&\P;]B/<[GB.OV]-`9=YQ'3M^X<>+O
M>6RTA=HI'0\?K7IJ3RR\VWCD,2E0)_E"R<A(-B%Z;Z`MOME--+X)AVGR:YB8
M0!9,BK.XD925/SR!7?CMQY,-SMN=`4[WE5Y\G1H4/-YL!E[L#Q08,3I6AMAM
MU5C,89VA;FVVY&S?A&QZZ`M_MBD<7A&,JKE),Q-3C^DMW9G[C&S7_53Q\N*;
MB.1&4;C?IZGUT!">];RU\'0OP^41>+S5[$B169^Z8Y6L5I8.!$)#$Q]SNJ=B
M`R@D=-`>>T6,3%MF*,>8CR,6U*>.K%:LW5B$U8,9N]:+-_F6W?BIX@>G4G0%
M@]R9IH/",M/#E4PKQ0]S\QD=HDC"L"09$#.G/\/)02-^@T!GOM!;SEKR=LID
M\Y!.N9@LSUZ<&1L9%9TCF`!$<L<,5?Z8'@>`#-O\PT!L5I7:K,J'B[(P5M]M
MB0=COH#*?:C.96&GXWCY/,,=GJ%J)ZKQL)9KQN5JYDF6*V'X2H"O->Y&#V_0
MGH=`:WH#YQPUC-39SZG_`'K7O0T<K!%/;7+77^G:6X%/^3,2Q3K;'Z@)R[<9
M_">F@/H[0!H`T`:`-`&@#0!H`T`:`IR>%>V.,SZH^(QXR^:GENUEEK0N[30A
M7E>)BA*[$AO7U]-`7'0%$\H]OO;ZW3L8C,<XXO(KS2P()65EN21DR?3,.L?=
M5"77\+==QUT!>*\*P01PIN4B544GUV4;#?0%<SN!\3HW+OE.1;Z2>2&*O/=W
MZ1L"8H9D!#!95[W%7`^.@);Q[!X[`X2GA\:K+2I1+%`'8LQ`_29CZLQZDZ`;
M^3^+>.>0T5ASE**U%7;O02R*"\,B]1)&Q!*L/N_KT`S]O,+XSB/$Z5;QN3ZC
M%L'DBMD+SF+NS,[LJQACR)^&@%O+_!O&?+Z,=+/U#9AA9GA*R21.C.AC?9HV
M0_,C%2#T(.V@$_"\1XU6JV<G@YI+:9)U$MR61I6;Z1?IE0%_18^V1M]NY^.@
M)'R'`8[/XB?%9!6:M/Q)9&X.CHP9'1AZ,C`$'0%4]OO!/$\#E+[XW*7<MD*+
M/6F^NF$IJM8(L2HBJD:J92P9O70%UR%*&]0LTIB1#:B>&0J=FXR*5.Q^W8Z`
MIN(\`]N\3F\72H1&#.XBE"T9BEEADFKUU6LDEE(BD4Q^4`EU)T!>2`1L>H/J
M-`9M5]J_!,7Y#1IQY"^EF8_71XIK):&Q'CYDDA5U*_LZLLJ&-0P^&^^@-)T!
MGOD?MOX,,O/DLK>N5_SZ9ZB4UL%*_P!9?A%:1XE5>2RS0IP)+;;?`:`OM2K7
MJ58:E=!'7KQK%#&/140!5'7[`-`5_P`N\8\(N,GD?DM"K.N$KSRO9M0I,J5@
MA>4.'5]U4+R^T$=/4[@3>+HXNC0BKXNM#4H@<H8*T:Q1`.>6ZH@51N3OZ:`8
M>58/Q?*8]9?(Z=>Y1QC&\/J8Q(D9A4DOQ(/HN^^@'.`J8&OBH#@:U>KC+"BQ
M72I$L,3"4!^81`H^;??TT`GY+XSA?)<1-B<S52U2FV8HZJW%T.Z.O(,`RGJ.
MF@&_C%#PV%+,WC5&E543/6MO2@C@WE@8HZ/P5-RC;C0$K>HT[].>E=A2Q4LH
MT4\$@#(Z,-F5@?@1H"N>*^,>WV&N/CL'CJ4.4Q$4<4\L=>)+*)*O).<JHK'F
MOWZ`M1`(V/4'U&@*GA_$_;KQ_/BO0QM*MF[K3WZY$$0G"DJ)C'($Y*O)O3E\
M=`6S0%0D\*]M*.>,EG$8\Y7/67L1":M#([SQ1!I&C8H2#QCYMU]=SZG0%OT!
M4O)?%/;M<F?)?(<=2EL2I%0>>W!%,K\Y`(@>:,>7)N(.@+36K5JM>.O6B2"O
M$H2*&-0B(HZ!55=@`/NT!#^4>*>*YH5;F?HU[8Q+O9A>Q$DH0&-ED!#JP*E3
MU']!]0-`.?&ZWCL6'KS>.UJU;%746W7%.)((G690RR!$51\R[?#?0"/DOB7C
MGD<51<W1AN)0F%JMWHTD"NH(/1PP(93LPVZZ`Z\5K^++AX;?C%6K6Q60`M1-
M2A2".7FH`DXHJ;DJ!U(T`XSV"Q.>Q%G$9:LEO'VT,<\$@#*1Z@]?B#U!^!T!
M&^*XCPBE+;7QZC2@M47%#(35J\4,O<1$D[<C1HG+HZM]G70$U?HU,A1LT+D0
MFIVXG@LPM^%XY%*.IV^!4[:`I\/@O@X\FPJ++,_D/B]:*>!FE8RO6D6:K"UD
MD;2[;2*I/4=?AH"ZR1I)&T;@,C@JRGT((V(T!0['MW[?&]@<+(T@R6&?\QQ"
MF5N\(8921&S;?/"CR?*C>GPT!?M`4/R?VZ]OKE*3"9;N1)Y%D9IZB+*RNMV:
M)YK`K,`>V)5BD=U_"WS;^N@+VB!$5!Z*`!_5H"L>2>.^'Q29'/YO]77LU8ZF
M2YNPA=$D'9=E'I)&[?(Z_,OPT!(^)^-8OQGQZG@\5S_+Z2%:_=;F_$DMU;IO
MZZ`9^2>/^*F:UY#FAQABHR5<B78F"2IOW-IH^H;@V[*?4:`7\+\8POC7C\&+
MPK2-C@SSPM-(97/?<RDEV^9NK?'KH!SFO'<?EY,?-:[B3XRRMRG-"YC=9%!4
MC<>JNK%67XC0$1X/XUX=CY<IFO&-Q7S4H^H1')@5ZC/$5A0_LP'Y`J.GV;#0
M$SY!@<=G\18Q.15FJ65`<QL4=2I#*R,.JLK`$'0$!B/%/"SYM:S^.=V\@Q\/
MT&2XR'BS2JK\YH]N)E95!+CU^.@+>RJZE6&ZL-F!]"#H"A8+VX]OJ'E&/;&M
M,,WXI!\D9F=BM:ZLT5=9@PV<1QAXX3^)54+OL-`7[0&?7O;3VZYX7QZP94M5
MK4F4PL?=;NJM:PEF2)6(.\"2.GZMO3X:`T'0!H`T`:`-`&@#0!H`T`:`PO-9
M?W-?S3$CRJO<Q&'CO21K;PM1;$(@9E$'*VAGLQ]X@++^K5=M`;H-`8A[@9CW
M/'D<464K6\=XQ#D4$&0PM1;CBGOL9I)=Y;$,O$G?MP[;?'0&V5RA@C*,70HI
M5VWW(VZ$[_$Z`RGWCR?NI#]57P>-,OCY@5DM4:\5ZVTX.Y62&9UXHI`(:-&;
M0&@>'2P3>,8Z2"U:NQM""+5Y72RY^)E218V5M^FQ4:`AO<K(>X%.C5_VE22U
M'(SKDY%1)K44?'Y6KPRR0Q2-OZAVT!'^Q]F]8\/Y926\<RLSKD:=ZN:@K2!C
MQCAAX1QK&4V;]7R7<^N@)?W%O^=T\3#)XA2CN66DVN\@KS1P\3\]>-WBC>3E
MMT=MM`0?LC;R5C!W_P`XER`S*6Y1;HWZOT:0)WI?IS!$BK"!+%L[]MF'+?KH
M"X>6V/)J_C]N;QFM!<S:*#4KVF*1,=QON05_1WVZC0&<^T^0\HL^9YQ?*FR5
M3(E4>G1GII4J2QE$[LO*OW89723Y%)E+<?AH#6+C6EJ3-419+0C8P(YV5I`#
MQ#$>@)]=`8MXWE_<.Q[FXX>;Q7<3&]=UB6E444)+0D3MU_JX38D>%EYMM,R?
M,!H#;COMT]=`89)F/<N7W!P0\QAN8?'"Q)%WL3466J6:6$U8C<C,]@1SLI6?
MFJ+T'P.@-ST!B7NIEO<]<NT-BI9J>*PWJ[0Y'#U([LRU!MWIY&+23Q31[L4[
M4/\`7H#9<<8CCZQAD>:(Q(8YI=^XZ\1LS\@&Y$=3N-`9W[P9#W-AADK>-XX6
M<%-1E%N>O#%<N&PW)1%]/.\<9A9>/(@,W4]-`6?VWL"QX;CIC:N7)F5OJ9LC
M&\-D3<SW$>-UC*A'W51QVV`VT`P]U;?G%?Q[;Q6FMLR]Q,EQC2Q82`QG8UX)
M7CCE9GV!#G;;?IH#KVCL23^#TGL6+MBZ"RW5R,+5YHIU.SPK$R1\(X_1`HVV
M]#H"0\]N>9U,"9O$:<-W*=U%>*8]5@._<>-2T:M(.G%68#[=`5+V7NYBQ+G!
MGI<E'F%LEC0O5!2A6%NJRQ)$#`S.Y;FR2-\-]`7_`,@FS<.$NRX*"&SF$B8T
M:]EBD+RC\(=EZ@:`RSV[R?F5CW$M#S`9''VY*RM5J"FD%":0`B4&>N9UE[2\
M>WW)`WKTT!L3\N#<`"^QX@^F_P`-`8Y@<K[GV?<O%+Y=2FQU;C:0"G6C:@3M
M^J475>68\]MRL@0$Z`V30&&^4YGW./F.-C\B@MXGQR._(AOX6JME4J&*3M2&
MRIFLQN[]M)-HU7BS=>F@-RT!C?O'EO=>&>S!CL?)_MQ#7>"YC:L=ZR?G7OF9
M)&+Q]M=VC,43'<:`U3QYZTF#H/6L3VZ[0(8K5L,)Y%VZ-*'5&YGX[J-`53W1
MR'N'5@K)XO2^HQ\J2C*6((HK-V,_*(^Q7GDBB<$%N7(G[AH#KV8GFF\#I-;G
MNRY)=DR4%^%Z[5K*QH)*T,3)&%AC](^(X[?'0#CW(R'GU.I3/BE-;,+NXRLL
M:1S6XHMAQ:M!-)#%(^^_1VT!&^QMB[-X8/S.6\<Q'-V\E3O5VJ+5F6-!V*\/
M!$$(3BP[>Z[D]=`6CS2SY76\<M3>*58+F<7A]-7LDK&07`D/1DW(3<J.0W.@
M*%[0WO(+'DV?7R1\G7R;$20T+=-*=5HR$5YU,'<@DDY#AR[I;B!H#3\F]],;
M;?'1I-D%AD:G%*2L;S!28U=AU"EM@3H#'O$,KY]8]RZG^]4OXN66MPBAJTT3
M'S6$,K=EK<)G9XD1BZ"9E^;X:`VB4R")S&`T@4\`W0%MNF^@,0I9CW)F]P\-
M_O6&YAZI:1.6+J*])GY#LQ-=C,\_;D_3$H0;Z`W'0&'^>9CW-'DT,>9@N8SQ
MB#)M]/D<)46VRT>+H)WF!EL0S%6`;A%MLQZZ`V]./!>)W78;$_9H#*?>/)^Z
M<(LU\%C3-@#6#"S2KQ7K9L`[E)()W0+&-@0R*S:`O?A$T,WBN-EAM6KJ-"";
M-]7CLLWZ7=218V5@W38J-`4[W?R/N;7C:OXYCOJ,')5<VK-6"*Y<[^Y';^GG
M>.,Q%=MR`S?=H"S^VU@3^%XV4VKEN9HA]3)D$>*P)O\`$1HY$C90C;A1Q]-`
M<>X=[SJGAXY/$*45RV9=K8?9I4@XG=X(W>)'DWVV#L!H"O\`LC;REC$Y/\ZE
MR"YE+<HLT;U44HX8N]+].T$2*(?UL6SR&-F'+XZ`N?E=CR2OX_<F\:K06\VB
M;TZ]IBD3-N-^14@^GWC0&;>U61\JL^<9I?+#DJ=]HXWI4IJ:5:DJ<!WI.=?N
MPRM&^RH6FY<?AH#79"XC8Q@%P#P!Z`G;IOH#'?!\EYO8]T9!YJMO&6Y*J?1U
M*=;CC)YD$_<C:W&)3*D43*\?>=3S9MAT&@-DT!A5W,>Y<OGN#'F$%S#XL6I8
MOJ,146:MLTD?TJ&Y&9[*K.R\9^:HNVWPT!NN@#0!H`T`:`-`&@#0!H"*N>48
M:I<DIS2R&Q$%,B1P32\0W4;F-&&@,R\4J>88K'UJL_FCK#%/)(U-,-+87M/.
MT@C^HE1)&^1MN17IH#1QYG@.17N3EAMN/I;._7_R]`9]1A\KK6LD]?S*2C4M
MY"S;KTUP\MKA%-(753+*B-OMZC;8?#0%_3S'!JJ1O-.TG'J?I+(+$#J=NWH"
MD9+\^F\MR>6Q/E$F'Q]R*ND=?\KFN,7A0JS,)8T"?]).^@+=B_*J%3&UX<E?
MGO7$`6:Y]#/`)')VW[:QE5WW]!H"N>96;V6S>&O8'.2X9:`L"U*V/L6&<3(%
M4+"\80]1U)8;:`E_'/(&QU29<[G)LQ,6YI8_+):@1`/PE8T8'[=SH",\VNV,
MS;PEC`YF7$28^>66Q9:A9G)22!HPJQ-%P?JWZ1&WKH"1\:SL^/BG&=ST^:D<
MJ89!BY:G;4`\AM&C<M_OT`V\\RD.?\8EH86_)1ORR02P7'JVBJ".17+;+$W+
MY1T'H=`>>.Y7*T;SS9KRB;,5"A5*HPSU>+D@A^<:L3T^&@)?+^48>]B+U2M-
M,L\\$L,;FM:`5V0J"2(B1L3H"J>*/Y-BX\7'D_,9;M6G%%'9HKA9%#]M`I43
M\.YZC\6VYT!=F\RP)Y())^>WI]+9WV/Q_9Z`SSPZMY=A\;BJEWS.1X:7;%BD
MF'EE5HU?=HA9D1)3NOR\RN_QT!HG^\\!RX]R?EMOM]+9WV^W]GH#/(*_E4.4
MSMBEYA)C:62R$ENG47$37"D;PQ(.3S1H5/*,G@NZ_?UT!?X?,,+%!"D]B>28
M*J-+]'83FX'4A1'L-]M]M`4SR!LU=\U?-87R23#4'QL%-XCC9[;O-%//(S=N
M6-40<95'(-N?B.@T!9\+Y/5HXN.++Y.;)7(^1FO?E\]8,"Q(_5HA5=ATT!`^
M<6+N9RF`MX#-2X8XR:Q);G>A9G9DF@,:JL+1<'^8_I$;?#0$W@/)(J&,[6:R
M\V5MJSN]W\NFJC@>H';1"ORCXZ`C?.L@^;J8R/!Y27%6J=^*V]MZ5F7:)(Y%
M8+&8N+D\QT8@??H!QXUF;M!YSG/(I\TL@40*,3)4[9'KUC1N6_WZ`]\TS5+.
M>*9'&8JW+7O6H^%>R]:V$1PX/(E8F/3;[-`,O'<AG*-Z*7+^6396FB%7IC"O
M7W;;8-W44MT_HZZ`LLWF&"DBEB22?N%2/]+9Z%@=M]H]`4GP;_<6$KXZ'+^6
M27JE2,I-CDQ$NQ]>(%DH)3Q^TKN=`7K_`'G@.17N3\@-R/I;.^Q_\O0&>8.O
MY;0B:+_><E>L;4\R4TPTMD+%+.TBIWY41S\K?9T^&@-#/F>`!`,DX+=%'TMG
MKL-^GZO0%"L)Y&?)<UDL9Y9)B:&0>%Z]48F:XP[<7!BQFC3AN?@N^@+K1\LQ
M=:A!%>N3VK,:*D]KZ*Q$)'Z#EP6/9>1^`T!5O*YLGDO*\=EL%GY<+7JT+56R
M3CK%IY'GF@D3:&2,1[`0MN_+D/0#8G8"=\?\C3'8YH\YF9LM:[C/]9^6S5`$
M(`5."(5Z?;H"$\SGOY;/X/(8'.2X9<<EQ+<K4+-AG^H6,(JPM$(VV*'<LP(^
M&^^@)GQK/O0J2QYO-3YFR\G.*P,9+4X1\0.'"-&#?,"=_OT`Q\^R:>0>/)3P
M62DQ]X7:5F.Z]2TRHE:U'-)LHB(<E$("GHWH2!H#OQO+9.A;EES?DTV9KNG&
M*`8>2KP???GSC5B>G3;0#SRKR#&Y;Q?,XNA8EBNW:5FK7E:O;54FFA9$9F2)
MF79F!)`WT!!>,V/(\=+1.5\PER%.NBK8HKA7B#[)QV$P3GT;KOMUT!;;GEF%
MFJ3PQR3B22-E4FK:&Q92`3M'H"B^)1^5XFIC*]_S.2>O35%L4DPTC*ZKZQBP
MR+)_U%=]`7\^9X`,%,D_)MR!]+9W('K_`(?WZ`SO&5_+:DN1,7F<E.I:R5ZY
M7IKAY;7""U:DFC0RS(C[A'`(VV7T&XT!H?\`O+`HJAY9]SLNYJV1N3_Y?QT!
M1\K^>S^7Y#+XCR>3#X^W!7B2O^5SW&+Q!@S$2QHJ>OZ)._QT!;<5Y31IXN&+
M*9">_;B7_,7OH)X`Y'4MVUC*KH"KY^3,7/+WR^%\DDPU)J$=5XCC)[;O*DKN
M6X21JB#BXZ@[G0%EPGDU:EC(X<MDY\E<3D9KOY?/7##??]FB%5V&@(7S>[/F
MI\+-@<Q+B9:%EYY[34;,Y,;PLFRQ&+@^Y8?B(^W0#_QG.6*"6!G,]/FGD*F!
MQBI:G;`!Y#:-&Y<M_CH!#SS*P9_Q>UC<-?DI9"5XS#;>K;*QF.16)(6)M^B^
MF@./'LIEZ60:;,^4S9>H4*K5&&>KLY(V;N1JQZ?9H"?L^7X.6":%)9Q*R$#_
M`"MGH6!`)VCT!2_`3Y%@J6'K9KRR3(U:%2*O8QZ8F4*62$1CC:*"5@K#?DR@
MM\1UT!>#YE@22G<GYD;\?I;.^WIO^ST!G7B%7R_$8W'5+?FDAAJN#-23#RS*
M8^Z7,0LR(DIW0\>97?0&CCS+`<N/=F#<2P4UK`)`(!V!CZ[<AZ:`H6,]^JMX
M81?R>6*QE<L<7/"TJ$UXSV.%EMOQ(WUD70?VM`3]SW>\4[%>3$V$R;2WZ="1
M(VX<%NRF%)_F'S1\E/S#H=M`>8+W+M965;PP-F'Q2?ZGZ?/EXV3A4Y<I985/
M<CCDX-P/_B!N-`.['NQX#62)[.42`2H91W$=2L8F-<R."OR*)1Q);0#JQ[C>
M%UKUVE/E(HYL<)3=9@PCC,""256DVX<D1@67??KH!I8]U?"TH068+ZSS79Y*
M5&L%D[DER-`_TY4*65R&7U'H=]`,,9[O8F]%@IOIGABRF.GR=XL=S3C@D2#@
MZJ"6=YW,8`_LG0$E_P"ZO@79KRC+1D6#*%55=G7L2B&4R*%+($E8(2WQ.@$+
M_D%3QZSY=F[:L]?'P03NB?B;C&VRC^D]-8;HJGNW!SDHKFW0QR+_`)"^X29`
M7)H*,E'ER?%I&X;M_P!A9R_X]OTBNV_PU5+<_5R])W\^QJ6>$ZWJ?^?+_)N=
M?R?%G%6_)RS#%C'19%G(^80+&\I.WV\1JUKU/G^EUIU,-E_Y"^X+9`VXJ]&.
MERY+C&C=FX?V&L!_Q_W@NWW:JGN?JX+TGT&'8R=GU7*7:>'IKX?Y-R\=\BJ>
M1T\)FZ@*07Z[RB-NI5N@="?CQ8$;ZM8R354?/[MN4).,O=%T?Y&.>8>_OEIS
MUNOXX*M3&5)6ABDL0M/).8SLTC?/'Q0D=%]=OCJNR,_1/2ER.TV?M%9..KMR
M;CK58I>'B_V-*\%\[/F?A\61FA%>_5OP5+\2$F,3)+#)R0GKQ9)%;[M]M3;-
MU7(J2.7W+`EB7Y6I<7'KXI\B9GNY_*9FU2Q-B&CC\<5BN7'C[\DEAT#]F-.2
M!`B.K,S;[[[`?'6T@"*9/+(V5P>7,<]J*DUJM=@0QI+"P9#SC)?@ZL/@Q!'7
MIZ:`H_NM[O9GQN_5P.`BA%L5XY[EVPID5.>X2)(P4W;8<B2=@"/7X0\O*^*B
M7%LZ7M[M_P#GN4I2TVX\/JWX"_M)[LY;RFQ>PF=CA_,8:S6:UNNIC26-2$=6
MC8MQ=2Z^AZC?TVUG$ROE3\4:^X-A>!*-'JMSY>-5T9=+&4R45+"XO%+'^87X
M%/U$P+1011Q`O*R*07/H%7<;GU(U+.>/7M>1X:]3.1M0Y+&7)5K22+":\M>5
MQ\C]'D5XW<<?@5W'XNN@%,EF9<1A[MJ&$6+36_IZD!/%6FGE$<?)MCL@9MV.
MW10=1\O)C8M2N2]L54S%5="$GS'FV+A&1L6ZV3AA^>[1CKFNQCW^8P2&1_F1
M?0./F^U=<=A=XNY>4;D%&$G3@^*\_$D2QZ+@6"_E8ZJWLI$!-'!CS9B!/%7"
MAG4;D=.7]&NXDZ)UZ&FW;<Y**YR:7W,%J_\`(CSZ*Z+MNO2L4-^<N,BC='[?
MJ5CF+GYP/0LNQ/V:JH;E67%>D[^_V/ILMQFW=2Y4X/Z?Y/H&OD*UJQ7R$+<J
MTU$V(V'Q1BK@_P#AJV/GI5J><\RS%*/+4[E7'P6T6>A2DKM/^I<<HS/)W(SR
M=""0H^7^]KA<SO!V[[C""<(NG'FZ?T),<>JXDUC<XV9QV-M20_36H[I@N5@W
M(1SQ*ZNH;8;CX@_9KL\;(C>MQN1]LE4CR5'0XAN>1YR[<?&VHL;BJ<\M.-Y(
M._-/-`QCE?JZ+&BR*5`V);;?IK>8/!E+\V-S.+R@3\SQ\2L\T(*Q3P3!NU,J
MDL4Y&-U9"3L5/4C8Z`<9+(9J[FSAL/+%56K&DV2ORIW63N[]J**/DF[-Q+%B
M=@/@2=`-8\GEA%F<'F#'->JTC9BNP(8XYH)5=%)C+/P=7C8%>1^WXZ`[S^;R
MR7JV'PYBBL-!]3=NS*95@B+<(E6(,G-YF5]OF``4G[`:/?-Y6#;32U3ER7ES
M9MM6]3$,3GL[5SE7%Y:2*[6R(D6G=BC,+I-$AD,<J<G7BR*Q5P1UZ;?'478>
MX/YK<)QTS2KPY-&;MK3Q'5C*7:F.K5<=&DN2OV9(:W=W[<8#,SRR;=2J*/PC
MJ3L/O'3&D2N6?*<$U>[=N0Y3&/+#!=C2N8)8N_((A-&0\@9%=UY*1T7<\NFV
M@'&?ST.`IYK+RQM.M.")T@3\4C[,$C7[V8@:\SFHQ<GR1[MVW.2BN;=#-ZGN
MOYC4O17,K]+9QYD5;5"K"R-''(P7>*5G)=HR=_F4<A_9USV-OWR7E%QI!\/J
M=%D[!\=ER4JS7'Z&GY/*0XQLCDI5:2*K3$QC38L_'D0J;].3'H-=%)I)M\D<
MT5\9'S]X!=%NC'88"1<68':$#;?M&SS#[_#N=O\`Z=<%+O1_+PA_RKX^KS\/
MR)7\?ASXD]4RL65AP61B4QK9+.8GVY1MV'YQMM^DC;J?O&N\A-2BI+DU5$5F
M)^4_\@/+9,[:B\>6K5Q=2:2"%K$+323&)BC.WSQA%+*=@/AUWU79&X.$M*7(
M[G9^T%D6%=N3<=?))<O,TSPKSH^9>%ID9H%K7X+<-:]`A+()$GC(9">O%U(8
M;^FIUFZKD5)'*;E@3Q+\K,N<?U71DU/<SV4S%VCBYX\?3QCI#;M21=Z26>2)
M)^W$I9%55CE0ESON3L!TWUM((S?)9>),AA,TT4UM(!9IWH%,:6(.81^419^V
M\;,`WS$'<$?$`"F^[WO#F?'<TGC_`(\D"W(XTGOV["&4()-^$:1ADZD#?D3_
M`%:A9>7\7!*K9TW;_;SS]4I2TVXNGU;'GLY[KY7RJY:PN<BB&2@A^I@M5U*)
M+$&".&C)?BR%E^.QW^&O6)E?*GXHU=P;$\"<:2U0G6GCPYHE?+_-<AX_A<54
MQ<4;Y/(*Y2:<%HH8HMNY*R`J7.[JJKN.I]=M>-PS5CV]357R16;?A/)N:*T7
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MF^Q=`2DF0K/9H9`MPK-3L3EF_13]4Q)V^P:`CJ?^]<G27)I=K8WZA1+4QLE<
MS<(VZJL\O<0EV7;EQ&RG?\6@%ZV7DRF)HV9H?I[274@MUPW()-#*4<*VPW4D
M<E.P^4CH-`)1VO(\U;MMCK<6,QU.:2K&TD!GEGECZ-)U>-5C#=`!N6^T:`(<
MGDIL5G,;E5C_`#''PNK3P@K%/%)$6CF1&)*;]59=SLRG8D;'0#S(1^26\D8L
M?<KT<?"B]R4Q&Q/),VY*<2R+&JKP._S<M_AZZ`:ULEE.WE<1EA&]RK7,L5R%
M2D=B&16'+MDN49&&S#<_:#]@'EG)9B>]4P>(:.O*M2.U=OSH95CC<E(TCC!3
MF[%&WW8<1L>N^@%:EW-X[,U\=EIXKE7(!Q0NQQF%UGB4R&"1.3AN42LZN"/P
ML"/3<!&]E[M*M7IXZ-),ID[LT%3O$B).)>221]NI"1H6XCU]-`<7;GDN`[%W
M(78,EC&DCANA8/IY(C,XC66/9Y`R\V4%/7KOOH!]ELJN*;(7>V9W2*ND$"D`
MR32R&*&,$]!SD=5W/IOH"-OW/,,'2&:R-JM=IP`296A!"T;11[_.]>4NQ?M#
M]%E'/;]'TT!)9K*08NU-D)P3'7I._$="Q[BA5&_Q9B!H!FM?W`:E]<;E-;I'
M<&(,+=H=-^P;'/ER^'<X;?W=`,LEY34[.%\G[4GTOY;<O=C;]9Q[43\=OM^&
M@(^I[(^-5K-:RMFPTE84@O(KL?HK/U/V?XQ6-7^Y%T!YC/9+`8^G6IQ7)V@H
MV:<]#D$+QQ4)C-%`7(W=>1V._P`!H!9?:"E&LU6OG<I6Q'"V*&,@G[<=5[H(
MD9'4<VX<CVU8D+\-`(V?9;#VJ-VK8R-IVOXUL7/*.`/!YQ89QT/S<AM_1H!Y
M>]IL7=7-4YLE=7"9Q[,]K$QLJQ_46U422!^//HR<U7?8-UT`IBO:['4;N)OR
M79;%S%6K%M92B)W7L0"N0X4?HHO30#2/V;PT+>125<C=K2Y^1)`\3A#55++6
MS%!Q`VC>:1BZ_$';0">+]F:&)L&UB\U>I7)FL?6V83&'EBM6!:>/JI";2[\6
M'4`D:`E;&#I9Z]Y9A[P)J7X(()=O4!HVZC[P>NL-5X'J$W%IKFC)(_\`C?Y>
MU\59LK5&-WV>^BOWRF^W2(_*'V^.^V^JQ;8M5:^D[J7?-QV=*MTNT]U>'G0V
MNMX[C!1M>.F+?%_014#$?C`4>(KO]ZZM*'"5=:]3%9O^-_EJWS6@RM5L=RV2
M](K]\1[].48^4OM]AVWU5O;%JK7TG=6^^+BLZ7;K=I[J\/.AM6$P-+`5\-AZ
M((JT:[Q(3ZL0`68_>S;L=6:5%1'#3FYR<I<6W5_F9)Y;_P`?,]-G[5OQ^Y6_
M+KDK3"O9YJ\!<\F4%=^:<O3XZK[^`IRU)TJ=AM/=TL6PK4X:]/M=:</!FA^'
M>#1>&>(P8L3?56YKT%J_9"\1).\T2_*O7951%1?N&IMJTH144<SN&=/*O2NS
MYR_3P1+6\=G<?E;.0PRPVJ][BUS'S.8CWD7@)8I`&`+*`'##]$;:V$,0CP^3
M'YMF\N\1OSTWK5Z\&_;@KJ&?CR/5W9CNS;?<-`4[W0]GKOE-JKG,)9B@R*UT
M@M5YP1',J=4<,O57&^W7H1M]FHF5BJ[3C1HZ'8M_G@.2TZ[<N:^OBAQ[6>TE
MGQ&2]E\M:CLY6Q`U:&.`,(HH"5=NK=6=V0=?@!_3K.+BJTO%L\;[OL\^:X:8
M1Y+^[+98P]^UC\+D<7.L&3Q\2&,2@F&:.2,+)%+Q^;8^JD>AZZE%">G'>09B
M]3ERR14<?1D%@4X)#*\TZ@A.X^RKVUY<N.VY;;[-`*7\+^<8B[3$S5IQ;,]6
MPHW[<T$PEB8J?Q+R0<E^(W&M&3CQO6Y6Y^V2H93HZD-/XYYAE(?RZ\U6A5D`
M6[<JN[R2)^FL"L/U?+TW;?8:Y/"[/A:O*<YZXQ=4J?U-\LBJI0L%S&Q6GN8U
M3V89Z!K*R@'@KADW`/3Y=]=E)55#5;FX24ES3K]C#JG_`!N\L>\M6]E*J8L'
M::Y`'[[1^A"(W17(^))`U6QVU*56^!V]_OBY.RXQAINM>ZO#S2-VAHUJ]N"C
M"@2K%2,$<8Z`(K*H4?U:LSA2L5?&_,,357%8_P"CMTX`(L?;G9XVB@7I&DT:
M`\S&NR[J1OMN>NN,S.SXW;SG&>F$G5JG'ZT)$<BBI0F:.%7#X_&4S*;$YN=V
MU98;&6:179W('IN?_AKK<>Q&S;C;C[8JB-#=74X&/\BP]RV<1%7NXVY,]D59
MG:&2&:9N4Q#[.&1G+/L1N"=O3;6XP<C$WZV*R^0RDL<V5OQCO&$$11Q1`B*&
M/EU(7FS;GU9C\-M`.,GC,Q6S'YSANU*\T:PY"A,2@F5"3&Z2`'C(G(CJ-B-`
M-DQ&32#-9G+R1MD+=1H(X(`>U!7B5V2/D>KL6=F9C]NPZ#0'?D'C^2L6ZN7Q
M$D:WH8?I[%:?<16("0Z@LO57C;EP/I\S;^NJ?>=GAG6U%O3*/)FRW<TL0PWC
MV;FS%?+9HPP)25OHL?78OM+*G!Y)9#MRV0E54#;KOZ[:C;)V_'";DY:YOA7P
M1ZN7=0XM8>W?Q=>6A.*N3HV7GJ2N"T9/)E:.4#8E'4[';KKH32<S4/)\R]:O
ME(Z]#&PRQSVT@D:66=X'$D:*2%"1EU#-\2/E^)T`YS.#JYR#,XFT62&Y!'&9
M$Z,A(;BZG[5/4:\SBI)I\F>H3<9*2YHSJE[/^33WXJF9M5FQ2.KV+5;DLLZQ
ML&""-OV9<@<COT^&J+'V*-NZIZJQ7)%_D;_*Y:<%'3)]32[V-KY&;(8^P"*]
MJH(7*]&`;D-U/P8>H/VZOFDU1\F<\5]<'YTD`H"2D[`"-<N>8/`=.9KCIW./
M][CR^[7$R[+@[M5/_G7E3CY5)/\`(=.7$G:V+@Q46"QM<L\50M$LDAY._&NX
M+N?BS'JQ^W7:QBHI)<D1F8[Y7_QZSTF=M6?'KE8XV[,\ZP6N:O`TK%G7=>7-
M.1)'H?AJ!?V]3EJ3H=EM7=\\:PK4X:]/M=:?<T7Q'P6#PSPV/%K/]5:DMPV+
MMK;CW)GL1[\1\%4`*OW#4VU;4(J*.8S\V>5>E=G[I?BA+6L=G<=E[>1PZPVZ
M^1X27:$[&)A8CC6$2Q2[,`'CC164C]'<>IUL(@UEQ.4$.1S&8DB:]-"L%:O!
MR[=>`.&*AFZLSML7/IT&V@*G[L>S=WR?+)G<'8B@R)B$-RO8W$<RQ[]ME9=R
MK+OM]FVHF5BJ[3C1HZ'8>X)X#DM.NW+IUK]!U[1^TEKQ&U:RV7LQ6<K9B%>*
M.`$1P0DAW`9NK,[*NY]/E&LXV*K2?5LU[YOL\^:;6F$>2\^=22\K\(L^1X/&
M3T)TK96@K=AI@QBDCE`$D4G'Y@"55@1\0/AKSG84<BWH;IU17X&;+&N:TJ]&
M1/B7M=F(<[6RF>D@6OCV[U2G7+.S3@$+)(Y`&R;[J`/7UU"V[:%CRUMZI$[<
MMY>1#0HZ8]2WY'"'+T+D$<OT]N&W]12L[<NW-'ML=OB&!*M_=)U8Y6-&_:E;
MG[9*A2Q='4AIO&O+,Q`<7E4J4\?+^KR4]=WE:>$_M(X58+VQ(/E)8D@>G77*
MX':,;-]7)3U1BZI4^U3?+(JJ4+1F\2N6I7*+2O7:5$[5B/\`''(I+(Z[_%6`
M.NR(Y#W*WG62H/B+"U*@F4Q7,M"[,6B8;.8("-TD*^A9B`?MT!*O1K1W,?1X
M<JR5)X>#==T':79OMW&@(RG4\UQ5)<34%:_#"O:HY*S(ZR)$J@)]2@![CK\6
M4CE_3H!S!B!B<30IF9K,WUB2V;+@!I9I9"\CD#T')OE'P&P^&@$5Q_D>&NW'
MQ<<.1QUV9K"U9I.S+!-)^TXOQ96C)Z@;;C0'L.)R%7#9F[E)DGRE^*1Y^R"(
M8T2(I'%%R^;BHZ]?5B3H!YDO]S5L@;.-BKW:,J*):4C=B595)_6)+LP(92`0
MP_1&WQT`UJXC(Q19;*Y:6.3(7(&C2*$'M00(K%8T+=6))W9OB=`%G$Y5+=/-
MX=XVM?2I5N4Y]Q'-"N[IQ<?LW1F;8[;$'KZ#0"E+'9J[F(<KF1%7CIJXH8Z%
MC)QDE'%YI9"%#.$W5.(V`9OMT`E=P]N_3BL4)DKY3'W);%*652T9)9D>-P-C
MQD1BI(ZCU&@.+./\ESCUZV4AKT,7#*DMN**0SR66A8/&JDJ@CCY@,?TNF@'F
M5Q295LC1>1H3+#`T5A/Q12QN9(I5WZ;QR*K#?[-`1]K&^7YFJN(RPJ04'(3)
M68"[M:BW!:.*-MNUW!\K$DD==OAH"2RV.KY*[+0L;]FS1DC8CU&\B[,/O4]1
MH!B%\_6I^6K]'W@O!<X69ME].9K$?-+MU_%Q)^[0#7)>+XW;"^,_/^7?EURC
M^(\^WVXD_%]NV@+CH`T`:`K2^?X4>218">&U6L67GBI6YHMJL\E1#).D<H)&
MZ*C'Y@/0Z`6M>?\`AM::A`V7JR391Y8L>L4J.)G@C,DBJZG@"J_VB.I`]3H!
MY4\EPEB&M(UN&O+:K_5Q5I9HA+V0.3/LKL"JCU921]^@&F5\[\.Q=(7KN8JI
M4-F&EWEE5U$]A@L:,4+<?Q;G?T'4]-`>^1>;>.^/W,51R5@K<S-F*GCZ\:EW
M=Y76,,0/PH&<;L>G]>@(R0XB#-^1W\G&KP5(Z[LS#<@<&Z+]Y/0:`3:#,K3_
M`#+_`&W5:OMW#C%E;ZWM^NX/'MF7;_"]-^G/0#^G!XS,)\DL4/Y<:L5E9B/E
M$95F+?\`@-`1T<>:LT_S.KXW3%1AS@Q\\K)<DB(W#,0ACBD(ZB,[_>P/H!(4
M:_C^3;'7:E5/I[,<K<&4!E9?E9'`)V9&!4_?H"DYWW`HP9:U2PV`K6:U*0PR
M6[$AC$LB'9UB5%;Y0>G<)_Z=O6HS-YMV)Z*.3Z_0N<+9;E^&NJC%\BR8/(>/
M>28"._7QZU;$-V"M=J-LS0S"6,LG(=&5D=64_%6'0'IJQQ[\;L%./)E9D6)6
M9N$N:'MR*";*2XO#8NM+-657NV[/)88NYN8T55&\KGCN0&'$=2>H!W&D0B-.
M5<IB\CBX:>6JU7L)VF[L,T#*RK+&Q"L-F&S*PW!^T==`*6Q6-Z'$8C%5[-Y8
M([%RQ.3'!7BDW5-^(9I)'*'9!MT&Y8?+R`[I1U3;FQ66Q=>MD.R\]66`EX9X
M4V5V7D%9&1G7DA^T$$]=@$[7Y=1Q6*BK8J._E<@D<=2L2(D8K&'D>64AN"(O
M4D*3]@.@!(WH7ZM;-XFH*MY^S!>J%BJ3$%ECFC<`@-L0K@D$]"%W&X"]B'!8
MS&7KT]$3=JPT<4$:@R2222B.&)-R!R>1U5=R!N=`,[27L97_`#')X.DV/7YK
M<=21Y)ZZ?%_F11-Q^(4*=O3?0$H^-PR7)YDI)/$E42I'$H8OL21PZ[$M\.N@
M(F=,O5HG*V?':;4T7NST(96:Y'"!NS+N@2211U[8V^YB?4"6AQV`GN0V(8(7
MJ2U#,D@'RE2RD-_X'0%=BREC(*UW$X&DV,))IFS*R2VHP=NXO!'6)7]4)Y<A
ML3QUR^9W9CV+SMZ92TNC:Z?O^AOC8;526J#`Y:CCKE:D(>Y;[4]>10)(Y$5P
M\;C[0PUTEF]&[!3BZQDJHTM4X'+Q_77K5;"8FJ8*3F&>_:+!'F4`M'$B`EN.
M_%G+#9MQL=;#!P!CK>+RM>UBXZ&6H)M8K!A*O&0$Q2Q2;(6C?8@$JIW5AMTT
M`YRD=09./$8K&03WWC[\\TVZP5XM^(9^(+,S-^%!MOZ[@:`:I]%-6R^/OXN&
MEE:59I>,;=V*2%T81S1.0C;<E92K+N"/B.N@'.6CIUYZF.QF)ANY2TC2A9&[
M4,,,>P::9P'.W)@%4#=C]@#,`$Z2)!EXL5FL36B>V&./O52SPRM&I=XG1ARB
M<*.0ZL&`/4'H0"PN(QN)CD7&K<NV;#5Z55=E,LK,W$%ST10!NS'T`^)Z$!.1
M)\8]>7-8BE]!8DCADL4V=S6DF<1QAU=5[D9=@I==MM]RO'<@![<K>/8TY2]<
MK(*E.&.63BA=M@&)XJNY).W0#0$=,UBA53*Y;!UJ^++*)X(F,MJO&Y`6238!
M&X[CN*F_'X%MM`2=BCX_3LW;=F")*=:J)Y7XDA43DS-L-R?E'PT!&119F:I^
M9Q^-U%JL.Y'CGEVN-%Z@E@O960K_`(>Y&_3G\=`2$=3Q^^,-=IUHS6N%G7=>
M)XM`YV93U#`^H/H=`,8A8RDEB3!X>E^7UW:**W<=E^IDC)5Q&L:MPC#`KW"2
M=]_D^T!6!<5D<0[OC%HWZ]J&O=IMLS1R">/<!A^)&4[JVW53H!2Y#'-E)<9A
ML56E>JJF]=L$K#$\@Y)$J("TDG#9F&ZA0RG<[[:`:2?1207\;D,7#2RM>)9E
M[;=R*:$N%[L3$(W1NC*5^4D=3ZZ`C_.?*<-@+T>+Q^(AO9-XQ--W&[<,,9.R
MERH8LS;=$Z=.N^H&=N$,9+5Q;Y(L,#;KF2WIX)<V=^#>383R&Y/C+V(BHY2&
M/OQ*C=R*>$$*SQDA6!1F`=2.FXZG?6<'/ADQ;CP:YHQG[?/&DE+BGR8^OSXO
M&8O'15\7'>RM_=*M8GM)\@+/)+)L_!$7U/$G?8`;G6=PS[>):=RYR_5LA0@Y
M.B$Z-V&')5Z6:Q-6**Z_:J7:Q9D[Q&ZQ2(XW4MM\K!CN?@-5NT]Q6<R;@DX3
MYT?4]W+3CQ']J/!8RE=MS45G86>S7KQJ"\DDC!(XTW(]6;^@#J>@U?FH:61<
MQ=;\QS&$HKC4V:[]+*SRU8_TI&YHBS*@^9]N)`!(#>F@);*5O',74N7[=1/I
MZT:NX1.3'UV55'J6/0:`B)X\I3HG*W?'Z8I1J9;5*&4O:AA'5GY<>W*ZKU9!
MM]S-TW`E?RS!S7\?+#7B:M-7FE5@.A![14]?N.@,ZM>YE26U)+B/'*UG%*?\
MM+-,8Y+*?VU`1Q$K>J\N1(]>/IJER-\M6[FBC=.;_',O,?8;MRWKJE7DOQR+
MM1E\;SN$QN6Q]14ALV8PT<B!9$97*/&XZ]58$?9]G35Q":G%27%,IKD'"3C+
M@T#+]??MUL'BJAK47,,]^TS!6G7J\4<<8+'COLSLPV/H#KT>`C7&W,3EX;.+
MCHY7'QR):K@]Q`6BYQR12<4YHRGH>(Z[@@$'0#K(XZ4W_H\7AZW!(UDFO6BR
MQ`LQ"I&B`L[?*2VY7CT]=^@#:H*-F#)T;^*AHY:E"SO&C=V*2-U;A+"Y5"5.
MW4%05/3["0"Y]%%+2Q6,Q4-S*3P+/)W6[<,$/X>[*P#L>3;A%`^;8]1H#NC'
M%%EDQ6:Q-:"6PK/0N5V+PSF,;R1E7"M'(H^8+NVZ@D'H0`.;:XG&XXO'C%O7
MK%J2O1IILIDD+G8%COQ10-V;;H-`(RB?%RUY,WAJ0QUAUBEMU)&;Z:20A4$B
MR*G-"QX]P;'<CY-`/[M7Q_'29&Y:JI]-5KI*RJG)CMR^5%'5F;H%`]3TT!'3
MR3XZNF2S&!JP8IB#:$,ADGJ1D[=R4%5215Z&3@?E&^W/;J!)WJ&!I9!Y[%>-
M*L%.264\=^BNIWV'4G0$:L68EI_F</C=1JI7N18YI2MQXCU#;E>TLA7TC/3?
MH7&@$K]WQ5&Q.<1$7#2T;=N1PA^:)4B<;KZ[C[/MT!>=`&@#0%.R/MMB[,>5
MNUUBB\COQW(JV5F0VE@^KY#=:\K&+\!"L`HY?'0%3H>R65K7UR#Y.M)9-Z:X
MZF&1D"6<8<>ZJ7=FW4[2`[[?#8=-`-(O^/MF.NM=LI%,KT*]9Y9$G$D4]6E)
M41X#'+&.)[O+9]]NHV.^@)!O9&9*+0UKE:.11@7@4P'M&;!D%N:@K\LW';IU
M`T!=O,O%9/(8L.D<ZUSC,K2R;EE+<UIRB4QC;T+;;;Z`8VL0,Q?\IQI?MFQ'
M65'^`8*64G[N0&^@'1SWE9I_2C`2+F2O`S&2$T5<_+WNYW`YCW^;AQ[FW3C\
M=`>4/&:\>$L>,M(S5QC(L>\PZ,5:-XRP^_KH#J+.>5PU!5L8*6QED7A]1%)"
MM.5AL.\'9PZ(3U*E>8]`&]2`I@<1-B(,50GD$T\:6'GD7\)DF<RN%Z#Y0SD+
M]V@,QS/MYY7C,K:@Q^.?)8V61Y:$\+Q*RK(Q;LRK(Z$,A_3_``D?$'IKF=QV
M6Y<NN=MKU<_H=3MN]V[=I0N)UCR^I<_#/$[OCWCLAR/`9+)Y&M;M11MR2+9X
M(4C#?I%4B'(C](G;IMJ[P<7X+2A6M"BS\O\`D77.E/`F9AEL-F[EN"C)D<9D
M>$CBN4[T$\:\&)1V3G&ZA?PG=2/0@[B60QN*^6NSY/-7ZK8^%:,E6E2D:-Y2
MO5WEE[9=5Y'8*H8]/78]-`+2QY7%Y3\SITWR-"_!$ER"%D6>&6%2%E42,@=&
M392H/($`@'<[`>UH\ODLNV5N4VQU*G5E@J5YF1IY7F*L\KB-G5%58PJCEN=S
MN!L-P$[=+*_28'+8R(6I\=$.]0Y+&T\,T(5A&[[*'7HR\B`?0D:`]LR9G/6J
M=;\MFQN.KSI9NV+9BYN8OF2&)(W<[\]BSG8;#8<M^@"V1QEO(8JU'2=([T%X
M6JC2[]LRUYUE5'V!(23AP8@;@'<==`-[^2\DRE!\;6PLU"U:7M6+-MX&@@1Q
ML[@QR.93QWXJHZGUXZ`D8:CU)7J8\*'KT4BJ"4GCNFZQ\R.NW0;Z`829SRR:
ME])!@I:^7D7M_42R0-3B<@COEUD+.@/4(%YGT(7U`#VABH*'T>*A+?3U<=]+
M&QZMP3@@)^_8:`J^/J>2X2C%ASA9KWT,:UZ-JO+!VIXHEXQ%S(Z-$W`#GR7;
M?\.^OGF=VC?E?<K<HZ).O'I7^I+C?5.)-8?#6L7CJ$=QE:]:R#6[@C),:RS*
M[,J$@'BOIUUW.%C*Q9A:3KH5"-*574*HRGCUJ[7CQLM_%V[,MRM/5,9D22U(
M9)HY8W9#^U=F5EW''\6VW64>1-*.2:MG,WDH/H[.0KQ014>2NT->MW"@D9"R
M&1GG<MQ)`&PW.@'>0AR>+SKYBG4:_2NQ)#D*\)7ZA'A)[4L8<JKKLQ5EWW^(
MW]-`,_I,K:DS&=R-<T5>@U.E1=D>01H'=I93&60,[-T4,=@!\=QH!]E(,K3R
M=;-8^L;\?T_TM^DC(DQ3D'CEA,A5"4)8,A(W#;@[KLP"4:Y?,YNC:FHR8W&8
MTO,/J&C,UB9T:-5"(7X(@8L2Q!WV&VVYT!Q=QU^?'U+V-59+^-LR3Q5W/$3(
M2RR0\CT1G4_*Q^/W==`<Y";-9^&+&+B9\?6EEC?(6K;1`)%$ZR-'&L;R%W<K
MQW_"!NV^X`(#S,8N3*09G'Q2B&:>")892.05]F*DCXC<==`,;MKR3,8UL0V*
MDQMRR!%;MR/'+6CCW_6M$R,6DY#<1@JI_M<=`/[N)CN)?Q2N84FHBNDH'(IN
M&56V/J5]>N@&D6;\JAI+4D\?EDRJ+VQ(DT(I.P&W=[I;FL?QV,?/;]$Z`<T,
M8^,KX*C+*)YHGD[\P'$/*\,CR,J[GB"[$@;]!H!CBFS?CE>7%OBI\E52:62A
M<J-"2Z3R-+VY5D>(HZLY&_X-MOFWT`I4QV0AHW<ADD6*_E+U:>6O&W-8D22*
M**/D.C,J(.1'3?TT`K(F4PN:R%N"E)D<;E7CL3?3E.]!/'`D#;H[)SC>.&/;
MANP;?<;'<`,K%/)W+%[/9"J:"QU32H5&=7E[;RI)))-VRZ`LT:\5!.P]>IV`
M%>]R/"?(;&>_.\/5^O@LQ)%>K*ZI,CQ;\)$#E592O0KORW]-]4V[[;+(I*+]
M42[V?<XXVJ,UZ9>`K[9^%9RGFI,]F*WT!CKR5*55G1Y&69T>623MEU4?J4X#
MEOZ[@:SM.VRQTW)^J7Z&-WW..2TH+TQ_4G,IBLF]3$YC%P_5VJ44L,U+DJ--
M7GXLPC9R$$BO$C#D0"`1N-]]8WS:WFV-"=))U7@5-J>EU&T6,S>:RF.,U"7&
MX['V4N2S6&C[DLD0(2..-&D('(_,6VZ?AWU2=O\`;EW&O?+=:X+@EQY^)MNW
MDU1$MDL7;O5)WHE!D:-X6Z0E)$;21C8HY`)`=&9=]CMOOL=MM=H1AOE+F?SF
M.FP\.'L8U[T;5[=ZRT!CK)(NSLG!Y#*_$G@%''EMR(&@)/.X=\AB[5"JZP3B
M.,U)'!94DB):,L/4C=1OH"/MYCRB[CY*$.#FJ92=#"]F62%JD!<%3,'5^4BK
MZJH7D>FX7KL`^AQL-27&8X'E%#3GA)]-P.TI/J=M]`8_-[>^<XN3\MAQ3Y..
M#:.K>AE@2.6,=%9Q(Z-&W'\8VVW_``\M<ID[#<E<;@UI;^QUV+W!:5I*:>I+
M[FE^.^.3^/>,XS'VI$EN?6)-:>/?M]R60L53?KLHV7?X[;[#TUTN/95JVH+_
M`%1R^3>=VY*;_P!F.*QR^`N78!CILECK4\EJM9K&(O&TIW:&2-V1NC?A9=QM
MZ[:W&D\CIY)Z>=S&2@%6S>K&*"GR#M%6@C?MK*RDH9&:1V;B2!OMN=MR!(9'
M)Y>A?)3%R7L;(BD35&0S)*"0W<CD9-U9>/$IN=]]P!UT!'P5,G:FR>=R5;Z%
MFIO4HTF9'D2$;N[S&,LG)VV("L=A\=_0`L5<M2RM3.T*IR$,M**E=IHZ)*JQ
MN9(Y8NX41MNXW-2PZ;<=STT`K`,KF<U2N6*,F.QN,+SP"P4[\]B2)H`>",_"
M-(Y7WY?,6(Z;#J`GD,=D)H*N0QJK+?Q=Z:>.L[<%F1^<4L?(]%9D<\2>F_KH
M!/*/FO(H8L8F*GQU5YHI;]NVT(X+!(LO;B6-Y2[LR`;_`(-M_FWT`]S>*?*C
M(TXI!#8:*O+5F8<E2>"4S0LR@CDHDC4D;]1TT`PRDODF=Q<F%.)DQ\EL&OD+
MTDD3011GI(\!5B\I9>L?R#^_Q.XT!(YK&C(V)Z'/M&Q0D19-M^+=Q>)V^.Q^
M&@&D6<\KBHK4?`2RY>-!'W5EA%)W`X][NE^:Q$]2O#F!^B=`1N2\7D^EPOCW
MU1[_`-!<A^LXC]KQB/<X>GX^NV@+SH`T`:`A*WFOBMGR"7QV')0MFX>7.CN0
M_P`@W;CN`&XCUXGIH"4LWJ=4QK8F6-I>7:1C\SE$,C!5]6(12>F@/:5RO=J0
MVZS<Z\Z"2)]BNZL-P=F`(_K&@"U<JU(UEM3)#&SI$KR,%!DE8)&HW^+,P`'V
MZ`C<YYAXO@;5.KF,G!1L9!BE.*9N)D((!V^P;L!N>G70$=7C@_W'Y!//8>O#
M`E=Y)%;@H58V+,QV^`&@*2OOM[>F]V3:R:T2W'\R92(=M]N9_3X?WMO3KJ-_
M+MZM->)=/MW-5GYOC]-*_6GD:'6IUY+MB5+DQA,,,BRB0;%3R(.^WIMJ24IG
MMGWU]OX;[P+9R<U.-N#9&-2T)V.Q=?TF3^\!J,\NVI::\2ZM]O9L[/RJ'II7
MZT\B_10U+EC'6JEV:>K:A:6"=9-PR.H964[>A!U)*4I_E/NYX9X_F)<2]G(7
MK=8\;?TNSI$_]AF.P+CXJ/36B[DP@Z2?$ML#8\K+BYVHUBNKX?8L6.R>%\C\
M>IYG$7Y[%.Q8@"EF*LKK8171T(!5T;H0=;HR3545MVU*W)PFJ27-#;ROS'`^
M.78L=-/>N9*5.]])6/(I$3Q#R,=E0$@\=_74?)S+=A5FZ5-V+A7;[I!5H=8;
MR+"^287)24;-N.S4BD6U2L'A*FZ$J2NW5&^##H=>[&1"['5!U1KR,>=F6F:H
MQOYCYOXSX=6IKD[ER6Y:0-!2KGG(4`V+D;#BF_3<_'6;MZ-M5DR1@;=?RYZ+
M4=37V7YG7AGFWC/F56X,7<N1VZB[V*5@]N4*P/%P-OF0^G(?'6;5V,U6+,9V
MWWL6>B['2_T?D.<SG<%XMXG6R^8O68H.U"D<43%Y))&0<8XT`W)UZE)157R-
M%BQ.]-0@M4GT(;P_W3\/\GRRXF"S?I7Y06K16B$$O$;E48;@L!UX^NVM5K)A
M<=(LG[ALN5B)2NQI%]5Q1:&..QF-R.2R&0EJTJDDTEB=Y-E5%/4GIK>V5:3;
MHBD8GWM\#R&4AHO8R5*.PXC@N61PB+,=EYGU3E]K:CPR[<I:4^)<9/;^98M?
M+.%(?JO-%\GK5JMVU8L7)HJ]>KW9I6?\*(2S$]/0`;ZD%,9_6]]/;^;()7:S
MDX:<C<%R,BE81OZ.WZ2I_>(U&67;<M->)=7.W<V%GY7#TTK]:>1HGY=&<JG&
MU.0U=F#=SX<U^[4DI2@9GWK\%QF6GQXL9*XM60Q6+58<X@ZG9PAZ%^)Z'C\=
M1IY=N,J-\2YQ>W\R_:^6$*QZ<:5\D7*&7&Y;'XC)XV_-9HW9DD@F#]"I1^HZ
M=#\-24ZE/*+3HU1HKOF?NAXCXME3B;-F_<R,:J]B&M\PB#CDH=CL`Q&QV^S6
MB[D0M^YEGM^S9.6F[4:I=7P1)XO/8'RKQ*UE</>L2PJKQS0R-QDCD4`E)$(Z
M'8@_T:VPFI*JY$'(Q[EF;A<6F2Z'GG7FGC7AL4!REVW);MEOIJ4#<Y7"_B;;
M;Y4']HZ\W;L8*LF;L';[V5/1:CJE^B\V)X#ROQWR_P`:R-W$7;1>M%*EJI.>
M$L3=LD!U(]&'H1T.LV[D9JJY'C+P[N/<=N['3)#GS+RGQWP[&U[67O6^=D\*
MM6%N<LK*`6XKM^%=QR/H-+ER,%67(SAX5W)N*W:6J0P\&]Q/%?,+DU&A;O5L
MC`G=-6R>#/'OL6C(!5N)]=CTUYM7X7/:S=N&U9&(TKT=->3YK[DK=R&%\?\`
M')\OE\A-5I5W?DW/<LQ<A510-V9CZ`:V2DDJLA6[<IR48JLGR16?&/=_PO/9
MF'$K8R-&S:;A4:ULD<C_``3D-PK';H#ZZT6LJW-TB^):9VQ9>+#7=A2/BG6G
MF71JU6K8R-BS=EAKUXHY)IGD"JJ*KEF8D>@`U(*@I&&]YO!,KFX<9#;R$$=E
M^U7OV/U4+N>B#YOF',_A)&H\<JVY:4^);WMBR[5CYYPI#]?L7H8^),G89[<Z
M(D",\AD```+;[DCT&VI!4&>2>^GM^F0:NMG)R4U<QG(HA,)V.W,=.13^]MZ:
MC/+MJ6FO$NH=NYLK7RJ'II7ZT\B_R5JUB;$V*UV6:O89I(9ED#*R/`[*RD#T
M(U)*4IGD_N_X7@,Q/B6L9&]:JGC;-4<DC?U*<CQ#,!Z@:T7<FW!T;XEM@['E
MY4'.U"L5U?"OEXEDHY/"^1>-09C$9">Q2GFA4%FV96%A%9'4C=74^H.MT9)J
MJY%;=M2MR<)K3)<T1OG'N%XKX?:AI7[=VSD9D[HIUCS=8R=@\AZ!02#MOZ[:
MUW;\+?N9,P-JR,MM68ZJ<^B^Y[@_+?'?+_'+]O$7+1>KQ2W4G/"6-F.Z\EV]
M&V.Q'KKU;N1FJQ?`TYF%=QKGQW8Z9?CD*^=><^,>&F"/)W+DMVT"\%*N><A0
M'8N>@"KOTW.O-V]&VJR9LP-MOY<W&U'4US\%^9UX-YIXSYG'8&+N7([=3C]3
M3L'A*JOOQ<#;9D.Q&XUFU=C-5BS&=M][%GHNQTO]'Y,7R68P_CGCM:_DK=H"
M7:*O7A/.660[GA&@'4[`D_8.NEV[&W%RDZ11&M6I7)*,55L9^-^<X#-Y-,69
M+]&_*K-7CL$!90G5@CKNI8#KQ]=M1\;/LWZJ#JT2,K;[UBCFJ)DQ*V.Q=')Y
M'(7IJ]2M*S32F3I\`/AU))V`^)U+;2561$FW1<RMX[W-\8MWH:T[9.A#9<10
M6[0"1\V.R"3;<Q\CT'+XZ@V=SL7)Z(R]1.O;7?M0URCZ2Y6J].DEFW;O30UH
M(Q)-,\FRJJ\B23MJ>0"#;R*"*LF0M5LI6Q$FW^?EV`16]))8OVD:?WB.GQT!
M,2X]&RM+C:G97AG97$F_3>+T.WH=]`1/Y]',LUC'5LGD,?`S*UV`J4DX'9C`
M&V:8`@C=>A/IH!](M*]0Q]VE=FGK3V(3&_/^]L>FW1E/0CX'0"%K*0C(S8['
M)?R5JJ!]88'58XBPW"-(^R\R.O$==`"V:.5P&1GKSVXY*\<T5FK8/"6*58]R
MDB$=.A!^\'<:`5R-U:V1_+:D>0OWA$)Y4A8+''&Q*H7E<*@+E&XKZ]#H#FM;
MIY/&Y`1S7(+=2-TMTK!X2QL4)7DNW56'X6'0Z`+URKCH*%?G=M7[B#Z:G7;D
MY"*.3G<`(B\ANQ/QT!UC+\%K(-C;7UV/R*H9DKSL-I(U(#/$Z[JX4LO+;TWT
M!Y)+1Q>+EMVK-K@+#Q1Q1$O))(\A5$C0#=G8^@T`A'F$CMU:^3@R.-%YA'4G
MF96C:0]5C=DY=MV^`;0#^6O5J6KUFS=FAK5JZ2S3/(`%1>99F.WH`-`1L7D%
M,FM+9CR=/'W76.K>G'&,LYXIW!MRB#L0%+@;]-`2<U**++\I;<R1I4=WD:0#
MBJR*222.@T!GTOOK[?)?,`LY-Z:OP.1128=M]C(/TBGQY;>FHSR[>K37B72[
M=S79^90]-*_6GD7*^**Y?$6_KG-*2K;F^K,H*B,+$_-7]`"/CJ24I;-`&@#0
M&?Y?V[N3RW<Y#/)9SM89)O'Z$\[1TH)KJO'S_5@.I>-^IW.W([:`H>.]G?,$
MR%*_:IPN*.1LV*%8VV)K06L;V-XV557=;:K(5`^_[=`=1^T_N;M`;%Z22VF)
M@J5[<5P*8)$HRPS0N)(W:1)9G5BRL-_7X:`5O>S'DDV%FHR5X[L0EP%X4Y[D
MA66S1V&2V<\N#3+N.7Q]=`7'W0P/E&9MXVGCL%5RF$.QS7<LI5GEC2172JLA
MCE80ET#R`;%M@/MT`X\BP=O.P>:X>G)V;5VK#%!)OM\YC;8;_#?TUB2JJ&RU
M/1-2I6C3^Q\V#QGRLW1BQ@;WYD6[7TAKR!>?I^UX]KA_?Y<=M<]_"N:J4/L#
M[HPOA^37_P"?]J^'XX'TYAO%;5?PR3Q5[/\`FTPL..:WU.TA@>+G_43OKH4N
M!\>G*LF_%GS+/XMY94OG%38.[^9(W:^GBKR.C,.@[<JKVRA^#<MMO7;7/RPK
MBE2A]@L]SX3LJXYJ/#V]:^!]-^W_`(]>\=\<\<PU]@]RI6E$^QW`9V[A3?X\
M>7'^K5_".F*7@?(\FZKEV4TJ*4F_NSYY\Y\-\CP?E.1KV,?;L16+$D]2[#!+
M.LZ2N6#<HE?9^NS*>N^J;+Q;CN-I53/I?;N_8D<2-N<E"5M4=>OU_,V+V>\7
MS6!\'D;+0M5GR>6@N14Y/QQQ\J\*\QN=F?M<MOL(WZ[ZLL2TX6TGS.'[@SX9
M67*Y#V\$OK1<_P`="+]R\1DZ'EMK)259IL;D4A,-N"-Y@DD:E&BE$89D_M*3
M\O4^GQH]\P+MR2G!:E2A-V+/M6X.$WI=:CCVUP^3:3-YZ6K+5Q[X]J=9K"-%
M),P+2,XC<!@B^@+`;GTZ:E[)A7+,&Y\'+H1-\S;=^:4.*CU*W[\>)^0'/T_(
M*]2:[C)Z4-9Y*Z-,\$D98\61`S!&#;AMMM]]]OC(W#'E.CCQH77:&[V,;7;N
MO3K::E_;\?46]@_$\_%F[WD-JI+3QJT9:D1L(T4DTDCH_P`J.%;@HBZDCJ=M
MM]-OL2A5RX5,=W[M8R7"W:>K15M^?1$_[U^+9O,^%X"]BZ[W/RKC+:JQ`M*8
MY(`G.-!U8I\0.NWIK?FV7<A1<RJ[:W&UB92G<]K5*^!F_M;X?Y'E/-<58BH6
M*U/'6%M7+EB&2%$5`=D3N!.3N3ML/AOOJ#A8TU/4U1(ZSNC?,:>*[5N2G.=.
M73ZFV>X_CN2\A]O\YC<:IDO&R+$,&X'=-:PDW:W.PW<)LN_3?;5I>@Y0<5U.
M!VW*CCY$+LE51DF?.6/\/\JS&03$U,/<6W*XC?ZBO+#'%U^9Y)'4(`HZ^O7X
M;ZI;6'<UJJI0^H;CW)AK&DXR4W*+2CXU\?`^J+N/L?0W<="39L_E1KQER`9'
MX,@Y$^G(ZO9JJ:/DV-<5NY&3Y1:?V/E.#Q3RNQ<7#Q8.Z<DQ[)KR5Y40-Z'G
M*5[83[6Y;;>F^J".%<U4H?7[_<^$K+N*:EP]O7R/J_#XJ:C4Q^*EF[LU7%K5
M>P?5F0(A?^LC?70GQMGRE?\`#?*,%?;"6L5=EM5CVHY(:\LR6`.BR1NBLIY^
MOKT^.J"]B7-;HJU9]<VSN/#_`(T=4U!PBDT_HJ</$^BO;7QO*>/>$X*AE$[-
MYKC6):^X;M=X2,(R1TW4>NVKJS#3!1?0^8[GE1R,FY=BJ*<JF->ZWAWDF+\T
MRMN6E9M4,E9>U4NP123J5E^8QMVPY1H]^(#>H'359G8TW/4E5,[OM7>\:WBJ
MS<DH2BWSZU=2_>S'BF;Q/B/D.4R<$M-<LL7TM.8%)!'`K_K60[,AD,NW%NNR
M]=3<*S*W"DN9R_<VY6LO*UVO;&*C7QY_N1G_`"#\2STF?J>0U:TUW&M6%6<P
MHTK5W5RPW1`S<'Y?B`]1UUIW"Q*:3CT++L_=;.-.<+KTZZ4EY=#OV0\4SM''
M^2Y[(59J-6Y2%:I#80Q22B(2.TIC;9E7Y^*\@#Z_#7O!L2MQ>KJ1NZ]TLY=Z
M/Q>I05-7B//^0?BF<NG$YVA5DNU*<$E:W'`C22Q<V5UD$:[LRMMLW$=-A\/3
M&?8E.*T]#UVGNEG%O25WTJ:5)>%/W_L5KV-\2\AL>;U<V].>IC,:DW=L6(WA
M[CRQF-8XQ(%9OQ;D[;=/7?6G`QYQDY/@6G=V\X]ZU&S;:G+55M<E_P#2_P#N
M[XQF<]X`@Q,+6K%"Z;;TDVY2HK.K<`?5U#;@?_CJ;E6G.VTN9RVQ9T,7+A=N
M*L5^E>OY&+^&>'>2YSR7'5ZN.MP)#:@GM6YH)($@CAE61F+2JGS_`";*HW/+
M;X==5>+BW/D3:I0[[?\`?\1XDH0DIRN*B2_J_"GW/H[S?!W,]XYY/AZ17ZN]
M1$-<.=E+LC\58_83T.KJ<:IH^88]U6[D9-5TM,^9\9X7Y9E,Y7PB8FW6O/,@
MF^HA>..%48,[O*1V]E`Z%6.Y]-]4=G#N*XDU2G4^I[EW)B2PY2A+4YQHH]:O
MQ\CZBSN(L9+'9G$02\;%O%M5BF??;G(CH&;;<[;GKJ]:J?*+;TM/G0^53XKY
M9#>&)DP=X9)&$7TZUY&4MZ;K*!VBI_M<MM<_+"N:J4/L5ON?"=CY'.G#V_[>
M5#ZB\4PEO!^/>*XBXRM:I1]J?@=T#BNY*J?BJGY1]VK^"HDCY#D7/DN2FE35
M)NGFSYN\S\+\EP/DN1JV<?:GBGM3V*ENO!+/'-'/*THV,:OLPY\2IZZI<O%F
M[C:5:GTSMW?L6.)&W.2A*VJ-/^J-G]H_%LQ@?`I#E8FJV<CD(;:TW_'%&98D
M4./@S!>1'PWU:8MIPMJ+YG"[]G0RLN5V'M=$OR5*_F4+WS\2SU;S>UFXZ=BY
MC<JL+1SUXGF$4D4*PF%UC#,O[/F"1L>7VZA9^/.4M2XJAT_:.\X]BU*S=:A)
MRJF^3X+]B3]E_$\_3JYO/WZTU&E8K)5JPSJT;S$2!VE[;;,H7;B.0Z[ZW8%B
M4(O5U*SNW=+.5>BK3U*"?J\:_L)^_P!XCY!_NA/(*].:[C+%>.!WKHTS0R1D
M_*Z(&8*V^_+;;[=>-PL2G1QXT)?9^[6,;7;NO3J::?3E2@K_`,>_$\^GDMKR
M*U4FI8R.G)2B^H1XFGDEEC<LJ.%;C&(?Q$=>736=OL2@FY<*FON_=K.3*$+3
MU:*UEY]%]BU>Y6&RD^'P68IUY+E?'+-'<@A4R2I'.%VG2-06<H8^)"]>+';?
MTUXW?$G?LTAS3K3Q*'9\N%B]6?)JE?`K/AN'RF9\HQ$M2K/'4Q]I+ENY-%)#
M&JQJVT8[BH6=RWHH.WQVU4;-M]Z%[7):4DRXWO<;,[.B+U-T-!\\P>2R_B^1
MAQR&>U7NK:6H"%[XB(+1]2!OL>2@_I`?TZZ+,LN[:E!<VCF\*\K5Z,WR3,E&
M-R><)P]''VGMW`866>M-#'$&^5Y)GD5%54WW]=S^COKD</:K_P`RJG%1:J_V
M.QS-VQ_A=&I.2=%^YNGE.,MW<%=J55%FRL<3)#*0%F,3<NV_PV?CL==N<*,L
MEYGC+F(FJU:=NSD;<;UX\5)5F5NXZ\2DQ91$B#?YG+\=M^).@']3'RUABJ$D
MI,L5&:%I1U(8"%=Q_1\-`1N#\EH8;"5<3DX)ZF0QD$=:6K#6GD1S$H0-7:-'
M5T;CNNQW`_%MH!;$U+<&'K26X/I)KF1^J^BW!,*S2EE0\21RV^9]OTB?7UT`
MCC,K6\<NY*AE898!9N37*ER.&66*=)MF.[1*_&1?PE6VW_1WT![6::['Y'F_
MIY*M*W6$%-)5,<DR01/O9>-@&3F9.*AAOQ4;[>F@)7(>25,7DC6OPV(H)(UD
MAO"-Y868E@T6\8<H5"@_,`#RZ==`1%.1\MD,KGX8):V.^@:G6:9&A>R02[3=
MMPKJJ?A7D.O7X>H'=F9L/GJN:LPR2XRUCX:4L\*/*U>2)WE#2(@9N$@DVY*.
MA'7IH!878\_Y!C)<?'(:6)>6Q9O21O$K/)`\"UX^XJE]^[W&8?*.('4GH`CE
MH+*1T,M#7>XF*OSS6*D8W=HY`\3.B_I-'SYA?4[=.N@$L_F*GDE.+#8B.:S-
M:FKRS2O!-%%!%#,DS/(TBQ]?U>P3\6Y]-M`/_),=8R%?)UJR"6<15IHX&("S
M&"7O=EB>@67AP;[CH".\@\@@S^!L87&U;+93)QFLU:>O+&M8O\CO8=@$"Q=2
M>+'EM\G+0$AY5B[&4@R&-KOPL6\78AB=CL.3D`<B/@3ZZPUP/4):9)^#J?*A
M\6\LKVQBGP5[\S0B(54KR%2XZ?++MVN']_EMMKGWA7-5*?F?8H=SX7P_)KIP
M]O6OA3\(WG)>$YC_`&#A?#^ZGYM^17*7/<]KO=F(<=_7AO\`+_1J^T>G3]#Y
M+_)_[_+1>[53ISK0U;7LBAH`T`:`-`&@#0!H""FP663+6[^/R,=<7!&)(I*_
M=V,8(&S=Q/M^S0'?Y?Y7_.*_\'^^T`FN(\H6>289B#G(%5O\GTV7?;_&^_0"
MGY?Y7_.*_P#!_OM`)/A_*&GCF.8@YQA@O^3Z?-Z_XV@%?R_RO^<5_P"#_?:`
M2L8?R>=%23,0;*Z2#:G^E&X=?\;[5T`K^7^5_P`XK_P?[[0"<^)\HG@DA?,0
M<)59&VI]=F&Q_P`;0'28SRI$5!F*^R@`?Y/X#I_WM`>MC?*F4J<Q7V((/^3^
MW_SM`<5\3Y1!!'!'F(.$2*B[T^NRC8?XV@%/R_RO^<5_X/\`?:`3AQ'E$(?A
MF(/G=I&WI_%CN?\`&T`I^7^5_P`XK_P?[[0"0P_E`L&Q^<0=QE"'_)]-@=_^
M]H!7\O\`*_YQ7_@_WV@$_P`H\H^H%C\X@[@0QC_)]-B0?^]]V@%/R_RO^<5_
MX/\`?:`2GP_D\QB+YB#>%Q(FU/\`2`(_[W][0"OY?Y7_`#BO_!_OM`)6L/Y/
M9KR5Y,Q!VY5*MM3V.Q_\[0"IQ_E?\XK_`,'^^T`G8Q'E%BO+!)F(.W*C1OM3
MV.S#8_XV@.QCO*P`!F*^PZ?Z/]]H#W\O\K_G%?\`@_WV@$J^'\H@C[<>8@X[
MENM/XL=S_C:`5_+_`"O^<5_X/]]H!-,1Y0DTDPS$'.4*&_R?3Y=]O\;[]`*?
ME_E?\XK_`,'^^T`F,1Y0+#3C,0<V4(?\GTV!)_[WWZ`4_+_*_P"<5_X/]]H!
M*7#^3R2PRMF(.4#%D_R?Q92AW_7?8V@%?R_RO^<5_P"#_?:`2L8?R>Q%VY,Q
M!QY(_2GMUC<./\;[5T`K^7^5_P`XK_P?[[0"5K#>3V:[P2YB#A(-FVI['UW_
M`.]H!7\O\K_G%?\`@_WV@#\O\K_G%?\`@_WV@$Z^(\H@A2&/,0<$&R[T^O\`
M^MH!3\N\K_G%?^#_`'V@$H</Y1"9"F8@_6N7;>G\3_YV@%?R_P`K_G%?^#_?
M:`Y&-\J#EOSBONP`/^3^S?\`^M]^@.OR[ROU_.*^_P#^S_?:`2?#^3M8CL',
M0=R)71?\GTVD*D_XW]P:`5_+O*_YQ7_@_P!]H!*?#>3SB,29B#]6ZR+M3V^9
M#N/\;0"IQWE9_P#O%?\`@_WV@$[.(\HL5Y:\F8@[<R-&^U/KLPV/^-H!0X[R
ML^N8K_P?[[0'$V*\IFA>)\Q!PD4HVU/X,-C_`(V@/8\7Y3'&L:YB#BBA1O3^
M`&W_`'M`=#'^5C_[Q7_@_P!]H!.#$>40(RIF(-F9G.]/XL=S_C:`4_+O*_YQ
M7_@_WV@$UQ'E"SO.,Q!SD55;_)]-EWV_QOOT`I^7>5_SBO\`P?[[0"1PWD_U
M0L_G$'<"&,?Y/IQ)#?\`>^[0"OY?Y7_.*_\`!_OM`(28'R&6Y#<DRT)GK)(D
M!%38#NE>1([O7HF@+#H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T
M`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#
M0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`T`:`
M-`&@#0!H".S&>H8E818YR6++%*M2!3)-*RC<A$'V?$G8#XGKH!/$^24,E9DI
M]N:GD(D[KTK:=J7M[[=Q1N59=SMNI.WQT!(/;JI(T3S(LB)W'0L`P0?ID;_A
M^_0"B.CHKHP9&`*L#N"#Z$$:`2LW:=7M_4SQP=U@D7<=4Y.?15Y$;G[M`=QS
M0R%Q'(KF-N$@4@E6VWXMMZ'8Z`[T`:`-`&@#0!H"M7//\)7M3P116KJ5',=R
MS4A,L,+I^-6<'J5_2"[[>GKTU!O[GC69Z+ER,9>!Z4)/DB=Q^0I9&E#>HS+8
MJ6%#PS(=U93J<>1QH`T`:`-`&@#0!H#B>Q!!'W)Y%BCW"\W8*-V/%1N?M)V&
M@.]`&@#0!H`)`&YZ`>IT!2__`'>\*_-10[\W:,G9_,NTWT?<WX\>[][=.6W'
M[]1OYEK7\>I:_`E?PKWQ_)I>CQ+H#OU'IJ210T!S++'%&TDKB.-!N[L0%`'Q
M).@.8K5:9W2&9)'CX]Q48,5Y#DO(#TW'4:`4T`:`-`&@#0!H!.&Q7G#F&5)1
M&QCDX,&XNOJIV]"/LT`IH`T`:`-`5;RCW-\+\8N+2RV06.ZRB0UHU:214/HS
M!0>._P`-]:YW8P]SH2\7!OY%?BA*=/`FL%G\/GL;%D\1:2Y1FWX31[[;CU!!
MV*D?81OKVFFJHCSA*#<9*DET8Z^LJ=A['?C[$7+N2\EX+PZ-R;?8<=NNLG@[
M$L1B[P=>UQY]S<<>.V_+?TVVT`1R1RQK)&P>-P&1U(((/H01H#K0!H`T`:`X
M-B`3BN9$[Y4N(>0YE`=BW'UVW/KH#O0!H`T`:`-`&@#0!H`T`:`-`&@#0!H`
MT`:`K.5MUL1Y7'E<HW:QMBD*D-U^D-65)6DD$KGI&)U9-F/R[Q[$[E00$9,C
MC\_Y3AI<+,EV'%M//>OUV#P!)8'A6#O(2K.TC*_`;[!=SM\NX%']U?$?)K?D
MN4\BP=*6S=IX-ZE:)3LEI+)DCGK^OX@&5U^\:`]P<7NC4S.)J&*ZD=:6C#%'
MM%^6#$K446.]UY_4B4?_`)N7I\F^@'_N%@YG\QM9')^,6/+,3;PZ4<96KF/:
MO;$TC3*_<=.UWU>/]</3AM]FX$5@<-[@83R"6[3J7(ZMS-V/K,:)$DB-08:(
M1N)''S'ZJ(1K(WQ'IU.@([&GWFO9-:TQR]'$62)7DDX=^,M2<NG<W;H+(4#B
M%']E0-`/,CY3YG![C5,4N0F:>QF#6KTU>%ZAI)BI)HUE5&,JR?4#E)R`_P##
MCH"T^T;>X)CLGRQ[1D->L9HK<2+PO'G]3V)$D;E'^'Y0H4=./J=`:+H`T!XX
M)1@.A((!T!E^"SN%P6(JX;+W8<?E<?&(+5:RPBEEE3H\\2MLTRSO\X9-^7+K
M\VXU\DW;:LI94ZPE+5)M-)NM>7XZ$^W..DG_`!JGE8O#<K+&DM*:\]RUC(.W
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MWNO]GB=`/)(/>^S4C>&:[!;J8:_8HQL85[UM+O&A';]4,IIGDR[[%OQ?'0#O
M'2>Z40P\Q?)6ZT63/.C/"L,DE<Q("+%@SNX1'+,I9-FZJ1^$Z`00>ZG#.U)H
MLA>)O49:U^9(XE[8R2]Z**MRF'RUNI='X[?`-H!M9L>]ZXC(/72_^<_0W#D5
MD$)KK>%E!2_+.);=#%W.6_3CMR^;0&D^!Q>1UVS]3,RV)X*^4D7#V+1!D>FT
M,3`\AMR`E:0#0%JT`:`8YVG8NX6_4K-PL6*\L43;[;,Z$#K_`$Z,RN9\V%9#
M5'CXIR1YMH?I$P?$_4*X7M](QL>TIZ]P?+QZ[ZX1;;D?/IHZZO=T\ZG?/=,?
MX=552G+KY4-K\KI^6U/!,50PLDOYO%-C*UJ:ML7$`FBCM."WP$7([G7=G`OF
M42]![W4Z\WY3/>MV7&=K1BSVF"PU[$0QLB\N([LD)D*LQ^8[;]-#`T\DI^ZU
M_P`<LT)1E;>+LULE'2CABCCMFPRPK5CM=R5V>'K-LS;;G;D.BG0#VU_[J8S-
M6Y*-*\^*%2.O7BK+&3WOR?A$WS,I*I;'4D]#H!9*GNY8M0/-;R5=5DP$+K'V
M^/:FJ`99SN#\RR>K?HGJN@)F9O<X>UD"1_4MY`F1>&X^R_6'&)D73N)U4&0T
MPK;[\CZCYM`0D]_W(I_26KDN7-2MBLD]RRR100+.O=./:>,-+(62,?.RML?D
M+C?0#+"2^Z^7P&/:O;RT5#(38-I;\O9^J"30NV2>$KR'8_!L3Z'\.@']&+WB
M"9^&U<OPV5@N+%(M:.P@86%%.2JQGB!/T_+=0`3ZMLX&X'-BW[L#&^/V(:F5
M,M:>TEC'ATY6U$Z=B22RS<H04Y<4FC8<?Q'EMH!O?_\`>"*_FQ#!D(ZS6\A)
MX_\`0K"`UHR0_3?5\R/\L4Y[?#UWZ\=`3^#3W/7S*"SD);38^3,7Z]FMLIJ+
M0%9'@=`1RX]_D$8]=NF@-4T`:`-`?(_NKCLAA_/\V^7WC_,+4EJE8E.R2UW_
M`&81VZ'MK\I'Z.J/<+<ODKT/J?:&=CK$^.JC.+=:NE?K]OL:S_QOQN4K^/Y2
M_.CQ8W(6(WH*X([A1"LDZ`_H/\J@_'COZ;'5A@PE&W21R'=>59O9CE:=4HI-
MKJU7^U%^1$XO!>Y&)QN4@IQ7!%?C\GE-1@C1K.]IY,>T8/HTH?<?;OUU,.;&
M%_R'S8^04\%9NV&LW9WI/CH6@:L:@PLC+&Z*QD2?ZK\>X'7;X;:`O/M1CO-,
M5'-C<E]0<?#AL4]%;?'C'=,<JVHE*]0J<(MU^&@*L6][V\4I]HW_`/<AE=\D
MI$:(J")OJU1F:2,DGA]+P4`-]W+0#NIF?/+WGV2KXF;(RUJ&1JPM!,8_I(J$
ME#N3K+R/<[_<XD?'EZ=-]`,4K>]L&-P,C6\BT]NDUBXQ1)WARC3J%AFB#P?Y
M<0_HEN/XB3OMH"4E/NJ+GEE9),F4FBGDQN2$,7&NPL+VH8*IFVE)B9MI$D7Y
M1N5YD#0#&>;WADKTYZE&]`R49X;3.T4UIH_S&+>2)I..TS5>9B5SN-NO70'E
MY/>2:K>^DER<-2O2R4^"+=OZN62)T-%+?KN[?,-O5E_%H#:Z#6&HUVLC:PT2
M&8>FSE1R_P#CH!?0!H`T`:`-`&@#0!H`T`:`-`&@#0!H#F3\!]/^KTT!Y%^'
M]'U_0]-`=Z`-`&@#0!H""'_^N/\`Z;^P_P#['T'_`,F@)W0!H`T`:`2D_:#]
MG_U>N@%=`&@#0!H`T`QRWI4_TW^JB_U7]?[+_P"K_9T`^T`:`-`&@#0!H`T`
M:`3_`,;]#T_ZM`*:`-`&@#0!H`T`C>_T5C]G^S?]O^R_"?VG]W[?NT!SCO\`
M05OV7[)/]/\`L?PC]G_<_L_=H!QH`T`:`-`&@#0!H"/S/[!/]+^,?ZS\'Q]/
M[VAE#]/P+Z>GZ/I_5H8/=`00_P#]:?\`TW]B?3_U'X?_`":`G=`&@(_'?Z[(
E_P"E_:K_`*?]K^`?ZC^_]GW:`D-`&@#0!H`T`:`-`&@#0'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``34T`*@````@`!`$:``4`
M```!````/@$;``4````!````1@$H``,````!``(```$Q``(````0````3@``
M``````!@`````0```&`````!4&%I;G0N3D54('8U+C`P`/_;`$,``0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`?_;`$,!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`?_``!$(`3<!
M\P,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/[^*0YP<=<''U[4M(QPK$YQ@YQUQCG'O0!^:7Q\_:'^*O@3QI\7
M=#B\8>`_`V@>#])\"ZQX1UC6=)N-1GU>ZUU[BVN?#K"\F@LGUC4M0%O;V[HQ
MAM;61[@\Q\4OV<?VF_BQX_\`BS/X:^(=SX<DT^/3/%DNH^&?#UBCW_A.X\)0
M:<UO?SW\4CR7D&NM=SBQW*(;@1;K9Y0"1^@GB#P/X/\`%41B\3^$_#^OP326
MUQ+#K&D:?J2S26>3:NQNH)2&LP2T1.=I8A>:MZ7X,\)Z+?W&KZ/X9T+2M4OK
M:VLKS4-/TFRM+NZL;-=MI;7%Q;PI+)!`@`BC9B$```&*`/.G^/?@?>5CB\52
ME9#&ZQ^&=3D*NN"R/LB)5QD94\@$'`JS_P`+W\$_\^?B[_PE-6_^,UQGP(EN
M)/%OQWBGEN)H[3XIW4%L+JYDF6&*33K>0I:H3B*,GG:`!GGBOIN@#Q?_`(7O
MX)_Y\_%W_A*:M_\`&:/^%[^"?^?/Q=_X2FK?_&:]HHH`\7_X7OX)_P"?/Q=_
MX2FK?_&:/^%[^"?^?/Q=_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y\_%W_A*:M_\`
M&:/^%[^"?^?/Q=_X2FK?_&:]HHH`\7_X7OX)_P"?/Q=_X2FK?_&:/^%[^"?^
M?/Q=_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y\_%W_A*:M_\`&:/^%[^"?^?/Q=_X
M2FK?_&:]HHH`\7_X7OX)_P"?/Q=_X2FK?_&:/^%[^"?^?/Q=_P"$IJW_`,9K
MVBB@#Q?_`(7OX)_Y\_%W_A*:M_\`&:/^%[^"?^?/Q=_X2FK?_&:]HHH`\7_X
M7OX)_P"?/Q=_X2FK?_&:/^%[^"?^?/Q=_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y
M\_%W_A*:M_\`&:/^%[^"?^?/Q=_X2FK?_&:]HHH`\7_X7OX)_P"?/Q=_X2FK
M?_&:/^%[^"?^?/Q=_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y\_%W_A*:M_\`&:/^
M%[^"?^?/Q=_X2FK?_&:]HHH`\7_X7OX)_P"?/Q=_X2FK?_&:/^%[^"?^?/Q=
M_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y\_%W_A*:M_\`&:/^%[^"?^?/Q=_X2FK?
M_&:]HHH`\7_X7OX)_P"?/Q=_X2FK?_&:/^%[^"?^?/Q=_P"$IJW_`,9KVBB@
M#Q?_`(7OX)_Y\_%W_A*:M_\`&:/^%[^"?^?/Q=_X2FK?_&:]HHH`\7_X7OX)
M_P"?/Q=_X2FK?_&:/^%[^"?^?/Q=_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y\_%W
M_A*:M_\`&:/^%[^"?^?/Q=_X2FK?_&:]HHH`\7_X7OX)_P"?/Q=_X2FK?_&:
M/^%[^"?^?/Q=_P"$IJW_`,9KVBB@#Q?_`(7OX)_Y\_%W_A*:M_\`&:/^%[^"
M?^?/Q=_X2FK?_&:]HHH`\7_X7OX)_P"?/Q=_X2FK?_&:/^%[^"?^?/Q=_P"$
MIJW_`,9KVBC..3P*`/%_^%[^"?\`GS\7?^$IJW_QFC_A>_@G_GS\7?\`A*:M
M_P#&:]GW+G&1GKC(S^5+0!XO_P`+W\$_\^?B[_PE-6_^,T?\+W\$_P#/GXN_
M\)35O_C->T44`>+_`/"]_!/_`#Y^+O\`PE-6_P#C-'_"]_!/_/GXN_\`"4U;
M_P",U[1FB@#Q?_A>_@G_`)\_%W_A*:M_\9H_X7OX)_Y\_%W_`(2FK?\`QFO9
M\CGD<=>>GU]*"P!P2`?0GF@#QC_A>_@G_GS\7?\`A*:M_P#&:/\`A>_@G_GS
M\7?^$IJW_P`9KVC/Z]/>B@#Q?_A>_@G_`)\_%W_A*:M_\9H_X7OX)_Y\_%W_
M`(2FK?\`QFO9\CCD<]/?Z4M`'B__``O?P3_SY^+O_"4U;_XS1_PO?P3_`,^?
MB[_PE-6_^,U[110!XLWQX\%8.+/Q=_X2FK?_`!FKVA?&/PCK^JV6C64?B&WN
MKVY6W@;4=!OK"WDG92WEF>XC1`2`3@9)_&O6)3B-SDC"GD'&..N><8KY#_:0
MN+J'QI^S`+>ZN8DG^..EI.UO<36ZW$1TN]/D7$<95;B)C\VV7*DC=UQ0!]?T
M444`%%%%`!2'H?H?Y4M(>A^A_E0!\R_`;_D<_P!H'_LJ;_\`IKMZ^FZ^9/@-
M_P`CG^T#_P!E3?\`]-=O7TW0`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%,<$HP!P<<'`./?!X/T-/IDF3&X`R2I&#GN,=N?RYH`^9O%WQ&^*K_
M`!1NOAQ\.=!\'7YTWP[9Z[?:EXKO-2M-YNYFCCBMQIZD$*%[^]6CJ/[58&3X
M>^#8`[G5_$@'_HNO!?C=\+/'/Q?^)7C_`,#?#SXR>+/@3XIO_`GA9[7XA>"M
M/T[4]<TN*WNY3)%:6^KK);-%<9Q*T@)&.!BOEF?_`()D_MI30312?\%=?VH/
M+EBDB?'@SX>9`D1DR"+8$$;L@@@@C(Y%`'Z#Z5XT_:+UV74(-%B^`NKSZ5<M
M9ZI#IOBC6+Z73KM>6M;Z.V,C6MPHZPSA)!W6M=]0_:I92K>'O@WAAC_D,^)%
MS]#Y8Q]17\X'[%__``0G_;]^`'QC_:,\4ZI_P4S^+OA#PQ\0/%+ZGX>U?PK;
M:7K_`(A\9"9C/+K?BFQUX3:9I5Z7;R3#IR(NQ0.G3]4OA]_P3\_:V\">+-)\
M7>*_^"G/[0OQ-T3P_<OJ5]X#UOPKX'M=)\306\$Q_LB_N+"!;R&"=RNZ2!A*
M"HVG)H`^T;[QG^T9H\MA;ZK9?`NPN-4NEL-,CG\0^($>\NB"PMX=_#S%5+;%
MRV,G;CFMB35_VIEC9CH/P9*@<_\`$Z\1#(^NSTY^E?EGX9_9,^./Q:TOP[J.
MJZ)KOAC3-.\0Z[J^JVWB#QG?RZIXJUX76L#2/%%EB;[3HEO:*]G$+!3#YD0&
M%(`SWUA\#_V@-;F^(7POOO$/BZ\TCPGX$M=1TZYL-;O+2XU+Q[XAMK9=8T*+
M5KUHX+[3;&"U*VR^;L1YW'F*QS0!]_6_B7]I>\FN;.'2/@M)<6,D8N\:QXE'
MEAQE"6*;7.#C&2#QWJOK/C']H[0;;[=K%E\#[.V\Z"V:>ZUS7XHHI+F18H%=
MR!M:61E6-,AG8@`$G%?#G@O]GK]I/3])TV;QGH%UKN@0:EX<%]\.=(\;S:5/
M>06>F2V=M>'5#<%[5M'O3%?W]I]IECN&W!#)G%<K<_LI?M3^(OB]XNU[5Q<1
M>&=2FL1/9W7BV.ZT2_\`[+\1V&IZ/):6TDC71N]/TV!X)+AXH(W<$#<"#0!^
M@=MX^_:#N_$-WX6M(/@=<>(]-LK>_P!0TQ=<\0M>6=I=.?LTES&JD0+.@WP^
M8%9UR5!`KH_[6_:F?<BZ'\%V;;N*C6O$1.T_Q$!,[3Z]/>OD#XL?LY_%RR^*
MGQ,^+_PLT?[3XA\3W/A"VMH;/Q++IEQJVF6'A#4M&O1*9W:T@BT_6+J"[4&/
MYA%Y@&<5QVC?LI?M)Z:+GQ#!XNN[+QAJ>FZUI^I7LGB^^O;<:1)X5TVUL]-M
M;,2&U2:XUJ'48S>K&LD#7`NT8*,``^USXQ_:+M;I-/GT_P"!\-X98HH[,>(/
M$$]SBY9A%(T2!I(HY65A'(X5&(*ACTK<;6OVG@I(T;X,<-MR=9\1!0P(!4L1
M@$9Y!Y'I7Y^Z5^RW\7X?B-_PE7@[P3=?#J[UW0?`-M)JVH_$"ZUVXT./PM+J
MBZG97<+W$\=T]_/=0WT+Q+\\0V2'<H`PQ^R)^T9XAO@M_<:KX<\/Z98^)F;1
MI?'NI?\`$[^(*:.(M-\>QW-K<EX-/U75B+@:3(VV`*/,A`.*`/T@&I?M5-G;
MX?\`@VV#@XUCQ&<'T.(^#[4O]H?M6?\`0O?!S_P;^)/_`(U7L/@>PU72_"?A
M?3M<F%SK%CX?TFSU>=6W^;JEO8V\-[(TF292TZ2-YK_.^=QQG%=?N!Z$'!(/
M/0CJ/J._I0!\QZAK/[5-E87MY)X<^#[1VEI<W4BQZMXB+LEO"\KJ@:/;N94*
MC/&37BOCWQ?=_$+2OV,_&6H6$&F:AKOQHT2[N[*UGDEMK6>"SU:VEBMI),22
M1%H2<-R<\CBOO#7F']A:SR.=)U+'(YQ9S9QZX[XZ5^;Y_P"2?_L,?]EEM_\`
MT9X@H`_3>BBB@`HHHH`*0]#]#_*H)+NUB4M+<P1J"H+/-&B@L<+DLP`W'@9Z
MGI2K<02,\<<\,DB*"Z)(C.H8?*656+*&[$@9[4`?-?P&_P"1S_:!_P"RIO\`
M^FNWKZ;KYD^`O_(Y_M!?]E3<?^4NVKZ;H`****`"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBJ]S=VME!-=7ES!:VUNC23SW$J0PPQJ,L\LDC*J*H&2S$`"
M@"Q17,:/XU\'^(;E[/0?%&@:S=1(9)+;2]6L;Z>-!U=XK:>1U4=V(`]ZZ>@`
MHI,CU%&0.I%`"T4F1TR,XSU[>OTH!!Z$'Z&@!:*1F55+,0JJ"69C@*`,DDG@
M`#DDUR=MX^\#WM^NEV?B_P`-76I-*T"Z?;ZUITUXTR<-$+:.X:8R*>&0)N!Z
MB@#K:*3(]1QUI0<].?I0`44F1ZCTHR/4<]*`%HHS2%@.I`^I%`"T5R5_X]\$
M:7?-IFI>+_#5AJ*.L;V%WK>G6]VLCXV(UO+<+*K-D;5*@G(P*ZM)$D57C=71
MU#*R,&5E89#*02"""""."#0`ZBBB@`HHHH`****`"D/0YZ4M(>A^A_E0!\;^
M)/&GAGX;_''XC^.?%^H3:9X9\._##0[W5+V*VNKLVMI'<R>;<-;V4-Q=2!21
MN6*%VYX4\X^:OCM_P5Z_8^^%GP<^)'Q%T+QQ<>+=9\&^$]6U[3/#0\,^,+'^
MVKVQ@,EO8?;+G0HH+83R8#2RR(BKDEA7V-IL,%S^TIXPM[F**>";X?:$LD,\
M:2Q2QM<2@AXY`R.I]&!!]*]'\??!OX7_`!-\&>)?A]XS\'>']6\+>+])N]"U
MW3&TVRA%[IUXFRYMS)#`DJ;EZLC*P]10!_+K_P`$LO\`@YJTW]O3XT?$'P#\
M3/@KIOP8\%^`?!<OBR\\76^L:GXAN)`E_P#8H;8:996ES.XD&&=HHF\O/S8K
M]_\`P)^W]^RS\4?$UIX+\#?$*?5_$&I6]W/;61\,^*+%62UB:>5VN[[1K:!<
MHK85Y5+`$#DBO,?V7O\`@E#^P/\`L>^/-7^(W[/?P(\.>`_&&LZ7)HNKW]O+
M/>_:[)[@W+0R07DDT0^<[BFSC/3'7]`)/"GAI5N"GA_2K1C;RP--::?96TC1
M2QLDFV6"!)$RC,,JP*YH`^*;O]O?X86^C7^KQ:)XM%K96>JW<EU<Z0UO86%K
M9M>6FFZC?RM*7M]+UG4K-K6SN`C.H82/&%)(T_AC^V]\+/'OB_PC\.;BYDT[
MQGXDTJPN);%#'=6=GJ]_8)J2Z,UT&%S]L%HRR*S0K"P/WZZ'4OV/_@;X@L-*
M7^S]3?2[2SN]+;3[/6)5T_6K&2YN;DVVL+$'74(K.>XG>!&<;'QM.5Q6EX=_
M94^`_@7QUH_Q(TS1XM'U[2;&#3;"2XOK<6L\T%HMC;74HFB$UQJ"6BI#'*;@
M&-<+L-`'EGQ6_;O\'>!CXJM-*\'^*]4U+PYXL/@RV:YTN2UT_P`3:W875I!K
M.DZ#="8M>7]G#>17"#RT5\??P#75:;^W+\(-3T>34VB\2V=]:30V=QX?FT>4
MZXUT8+J:[-M;(S&Z2Q^QRQ7LR;HXG*J6!SBGX=_8V^&FH:_XP\5>*M:UGQI)
MXA\?:GXUTNR?5I/['\-ZC=W%K(?[*M8?EBNR;-8[NX5B)HQL8*:U;;]D#P59
M?%'P_P"-K.X>ST?P[X6\4:'I^E1L[WSZIXPO9+C5M3GOY%(;8DTBZ<#&WV5F
M('4T`84/[=/P\O+?PE?0:7X@\OQDNIP>'O#XTY)O$FNZI9W"6]OIVFQ6UP\/
MVFY=\F"XEBD50<A=N#7\>?MW?#GP=KY\&7.A>);/QI/X:OM6L-)U6R2TMAJN
MGZ8^JG0=2N$EDDMKXP*P^9/)?!42$G%=-:?L0_`;3[:WT](M>?6--N=0UG3-
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MH90-[_QD+GH*JWW[)'P9U2W:VNM%U"1'O;C5@&U&XW?:[JPT_2YCD*"`]KI5
MI$PR"Q0MD;L@`\$TO_@HS\,AIFA7/BCPKXO\*7OB'Q!JWA^QT^^M()9'>QU.
MZT;2]2\R*8N+'6[VU\NTE",T3.@GVYS5_P``_P#!0#P?XN\/S:Q?>"O&&DZJ
M+I8(_"(T^.X\0?8(+;4+[5=9FB67R!I^GZ?ITE[+,)/,:`_=S6^__!/KX%SZ
MI9ZC+'XNGDL=4;6TM9?$$DEBUS'J4FKVUIY,L#O#:6VH2-)#;P2QCG,K/71:
M9^P]\%])T:>QL(?%=K/<:H^JS:LGB.X.J@3PW-K>:8EUY0;^R;FSN[BSFL0O
MEM`VS)&*`)/AO^UO\,?C3K'B/PGX/_MV0#1/$<VD:Y?::UKHOB-=(@6/59-$
MN2[R7`LY+N"&X9TB0'<%)Q7C)_Y)_P#L,?\`99;?_P!&>(*^FO#/[-GPJ^%R
M'6?!6@S:7<Z-HWB^/3E-S(UM9P>)+83:K&D.`/\`2'M8F3)VH=V!SQ\RG_DG
M_P"PQ_V66W_]&>(*`/TWHHHH`*0\@C&>#QZ\4M%`'Y+_`+4/P,^,_B+XB>-?
M$?A/3/&7BKP-KP\&S2^&]*U^ZC6>ZT[3M4LW.D:=%<VCVT5GJ,UE>7@6:,.8
M3(PD`P;?[(_P:^/W@OXLMJ?Q&TKQ+"T/A[6X/$WB76-:N;_1_$AO+?3!X/LK
M&(W3QO/H*0W4-Z8[:%XV8AGD/-?J[2'H?H?Y4`?)/[,EMXCM==_:`A\3W^FZ
MGJG_``MV_?S]+MYK6%;22QMVM+=EF)+2PQX#OT;!]:^MZ^9/@-_R.?[0/_94
MW_\`37;U]-T`%%%&?YX_'T^M`!1110`4444`%%%%`!1110`4444`%%%)D>HX
MZ\]*``]#VX/-?G=_P4I\=:'I/[+'Q8^&5OXICT_XI?&#P1XF\'?"K0+6^-OX
MB\1>+-1TR:'3K#18;=UNS,\[(HF0JL18,SJ.:^Y/&.I:SI?A;Q%?^&M+&O>(
MK'2+^XT;1!<I;-J>IQ6[M9V)G?Y8/M$X2,R-PH8DU^:_[*O[(_Q"USXEW7[6
MG[8\EMXF^/>HO/!X&\%(PU#P;\%?#!F86^G>';>16MY?$-Q%M.HZSL\UWW")
ME44`?RG?\$"?^"</_!7WX!?M+?$+Q'\5_P#A/?@CI>I^![RSTWQ'\5$O/'>A
MW,[W0=;.WL+K5[A8;MEY67:"%XK^VCX(^!?VDO"^HZI+\;?B[X7^)&ESVZ)I
M%IH/@\^&;BPN03YDMS+Y\HG1QT4`8'3V^GZ*`/C/XJ_#3]K[Q!XQOM0^%7Q^
M\$^!/!TL$*V'A_6/AV->U"WN%SYLDFH-<()%<Y*C;\N17>?!#P5\?_"Z:POQ
MR^*7A_XF37+0'0Y_#WA7_A&!IB(I$XN@LT@N/-/*C'RU](44`?#GQ!^%O[:&
MK^,=8U#P!^T9X&\)^$+B42:1H%_\-_[9O[&$KRD^H-<1B?)ST48]*]I^"OA+
MXV>&]!U"T^-'Q'T/XC:U-=E]-U/0?#8\,P6=KMP(9K422"5@>IR,\]:]ZHH`
M_.CXN?!O]NS74\?MX)_:0\#:1H>J:=KT?AWP[+\./M6IP0W%A<1V=DVK"Y7%
MPS,L:W"J"KD-U`K^(W_@FI_P3(_X*Y?"G_@JMX#^*WQM^'_QHA^%&F_%#Q3?
MZYXNUGQ)J5[X5D@O+B\:UU,Z3+K$L+6,A=)(8C`51"%V\5_I$T4`?G[K/PB_
M;RNM:U6XTC]J/P#INCS7T\NE:>_PICNYK&R+L8+:YNC=+]H=$PK2`<D9XSFO
MJ/X<^'OBCI'@"/2/B)XWTWQ;X[\B\67Q1I>AKI%@9G#"UE32M[`"%BK,A;Y\
M$<YS7K]%`'YYW7P=_;]::Z>S_:J^'<%L]S<26D,GPHCEDAMGE9K>!Y?M0$DD
M4>%=PH#L">]?5V@^'_B=:?#,Z'X@\9Z=J_Q*.DRVY\96^AK::5_:S*1#>IHH
MD(\J)B&:$L-X&,UZ]44CJJ.=P!"D]>1COZX'?%`'YWGX-_\`!0/<Q/[5_P`.
M$0EMF?A0BE(S)D1LPNLEQ'\I<#KR!7TEX^N_B!X/^!/B&Z?Q!)J'Q`T#PG<7
M3^(=&\-'4S?:M:6Y<W&G^'5??=//(O[JR#9<L!3_``#\;_!'QGOOB9X6^'VM
MWK:OX`OYO#>MZJVDWD-E9:]);N@%E+>11PWYM)&5W\AGC#+M)YIGP$^%7CKX
M7>&;[2?'WQ6U_P"+>OW^O:AK,GB#7[.VLOL=O>3L\&EZ?;6GR+96<)$4?F9;
MY<F@#_-U_:@_8,_X+,?&/]NB;]I33O@Y^T=XB^'WB7XE>&_$]I/:7VI>&X+[
M1;/4;2:8OX8CUI(=+CD@B<_99(U`4[77M7^EU\(;C49OAEX`;5]+O/#^L?\`
M"*Z"FHZ+JH(U#3KR+3;>.[M;L[W#3Q3*X=O,;Y@3FO3;GS3;S"`(9O*?RA)D
M)YFT[-Y7D+NQG'.*_*7P)\0OB7^UGXD\<?#J[\:ZG^SY\:/V;OBV6US1/#[1
MZCIWB_P;+)OTNXO[6[`>[TW7],QB2'"V\^>2<T`?J]O3(&Y<GH-PR<],#/-.
MKQVZ^,/PXT/XB>&OA!KOBK2[7XD^(-&EU?1-"O'^S7^L6-CMBNKFQ4XCD9'R
MSPHS.BG.W%>PAE/1@?H0:`%HHHH`****`"FMG:<$`XZD9`_#O3J1NA^A_E0!
M\._%+2_BCK?Q.^+&F?!;Q'H/A/XG77PKT1/"'B#Q-I\NK:%INIFY;RKC4;"`
MK+<6RKO#1(0Q)4]`:[?61^T+X/\`V7?$4^I:SH/B_P#:'T+X<ZK+;ZOH&A7"
M^'M:\;6ME)+9R6&A,_VAH;BX5(UM_,5FW#G%%QXDT'PG^T'X[\0^)M7T_0M#
MTSX;Z%<:AJVJ74-G86<`N)!YMQ<SLD44>2!N=@,GK47C']N#]E3P?X4\1^*[
M[XZ?#:YL_#>BZEK=U;Z?XOT.YOI[?3+26[EAM+=;TM-<2)$4BB49=R%'6@#^
M>7_@C[\0_P#@LCJOQ)_:V\(_M@_"WQ;X'O\`XKG5/&GP;^*7C71C+X%\)^*5
M`M(M,&BQ74US;:/+`D=U#91[<DG(+;L_T9?`/PW^T3X?^$+:5^TEXX\(_$;X
MJ^3JZW.N^`M$N?#NAW<$Z2+80Q:;=2/(DT:LBO)O`)YP#7YE?L2_\'`/[!G[
M=7Q.\7?#'X8^(?%'AS4_!.CRZYKNL^.],3PWX=ALX;YK!&CU6ZN/L[F><'RM
MQ3S!C;DFOVMCUS2;W1?^$BL=0MKS1#8G5([ZTD6YM[BP6(W`N8)(2ZS1M$OF
M1E"P88VYS0!^+'@S1_VKO#/A>]T;3X_C!9^$+/5+Y_'L=U'&/%5A//KNHS68
M^&L@,AETA[62V>Y==S*"RD<FN=^)GAO]LGQ/J?@)-1L_B+=^,-&US2M3TA-'
M2)_`Y\)P+`HN?$7*)+XC9"7O(Y!N^T"0%<`5^DGQ+_;7^!WPQM-)O]4\1#4[
M?5+O3[18]&@FU&]5]6D2"Q*VMO&[O++*_P"\AQOA16=@,&CQ1^VI\#_#NMKX
M9A\1#4_%#7VE64NC1(\%Q&NHI*WVD/-&B/%:>4RWGE,WD-D2;<$``^0/@BO[
M17A'XF^"/A#JM_JECI?BK5-;^(GB*2Z<7%[X8TO1-1O%/A_<-Y%IXIGN4N(F
M8@QQQB-,@54TGQI^TEK7CCXY77@Z?XE^()O#^O?$?25M=0M8(/"$>DV-G9IX
M6A\(,ZJ9=;CN9+EYW&3($ZD@9^O?AA^V)^S[\3V\4Z_I.L6^F:AX5GN=(UJ[
MU+3VM+UXK*\M[.1+*^>%6O[/[=<Q)&+=I5+,,#T]`M/C+86_Q[M/@O8>`/$B
M1:CX1/CC_A.[331'X4D>XE6-K*XNHU5#J,BE9#YA,F.HSB@#\AO`>A_\%`/$
MVL"QU75/BGI7A`7.MR67B1[.+3]>>Q@5]0L--DN[X-??9'O%6!GDBY0XBX(-
M?MO\('\7'X<>!6\=13IXME\/Z9_;OVA5-Q_:8M$^VFY*XS*S#<[G`+D\5ZK1
M0`4444`%%%%`&3K_`/R`M:_[!.H_^D<U?F\?^2?_`+#'_99;?_T9X@K](=?_
M`.0%K7_8)U'_`-(YJ_-TD?\`"O\`]ACW^,MOCW_>>(/\#0!^G%%%%`!1110`
M4AZ'Z'^5+2'H?H?Y4`?,OP&_Y'/]H'_LJ;_^FNWKZ;KYD^`W_(Y_M`_]E3?_
M`--=O7TW0`5Q?C+QSX.^'6AR^(_&_B/2?">@6MQ;P2ZKKFH6VG6*SW4JPP))
M<W<D<2M)(ZHH+9+-BNR?.UL9'RGD=1P>1[CM7XK?\%J/^":OQ'_X*8?LXZ1\
M*_AC\8M;^%7B/P_XCL==6VM[N>V\/>)8A<1)/;:W]GD29VM(@UU:[3M$Z+@`
MG@`_:&TO;._MK>\LKJWN[2[ACN+6YMYHYH+B"9`\4T,L;,DD<B$,CH2&4Y!-
M6=PSC(R1D#V]:_G>^!7CO]K_`/X)0>`/!/P;_:MT/7_VD/V</"6G6>CZ'^TG
MX"M[S7O%WA:S6*()8>/_``TJRZB-+TUE=(=9@,NVUC!FP`:_<'X,_&WX5_'S
MPAIOC[X1^-M#\:^%]1@66'4-'U"WO#&SKNDM;RW1OM%E<PD[98+A(Y(V!5E!
M%`'L-%-W+@G(P#C\:=0`4444`%%%%`!113=R\#<.0<8/4#J1]/6@!&9=K?,`
M`"&.1\OU]/QKY>_:2_:*T7]GWPG:ZBVF:AXI\8^);Y-"\`>"-&@>;5O%/B*X
MPEM8VXC5MELKNLEY=282"$,Q8`9I?VB_VE?"G[/VAV+7-G=>*_'7BB^32/`?
MP\T0+-X@\5ZQ*XC2TL[==SI;HS![J]E40P1Y9F`%>M^'[`^*M-\)>)O&?@^P
MTWQ;;V=MJ*V5W!;7]WX8O[R!6N;:UO2C>3-`6,$TUNRERO7&*`/`OV7OAY\;
MM&LM=^('Q]\67&K^/OB!J":O)X,LIO\`BF?AUI6,V'AO1U50;B>VB91J=Y(2
M9[D,$PJYK[%HHH`****`"BBB@`HHHH`***3<OJ..O(H`6F%U(.&'"DG!!P/7
M@UFZKJNF:9;"34=0L;%)W2WA>\NH;9)9I3MCB1I'7?)(>$1<LQX`KYY\>^)/
MCW9?%GX<^'OAYX"T/4_AC?Q75Q\1?&^K:Q]DGTF!0/LUII.FQJSW=W._(<GR
MU2@#TO4/BK\/[#QQIWPRN?%F@P^/=7LI-4TWPI)?QG79].3(>]6Q#^?Y.>CE
M0N>*\]\(:%\?H?C)X[UOQGXH\.7?P<NK2QM/AYX2TG3G36[&>,?Z??Z]JDAV
MR>>_$4"+A0>37H,7PB^'`^(C?%9_"&CS?$5M+BT=?%TMG')K4&F(VX6<%VZE
MX8&)^9(BH;^(5ZC0!B:9HNF:09ETS2[+3UNYY+J\^Q6L%IY]Q)@M/.(8U\^9
MCPTCY<]236W110`U_NMUZ'IUZ=J^&O%'[+VM+^UYX,_:D\`^(+/PVDOA>]\'
M_%K0Y(YF7QKI"'S-#G(BQ&NH:5-NVW$H),1"=*^YZYGQIHD_B7PCXE\/6NIW
M>BW.M:'J>F6^KV+^7>:;/>VDL$-];/\`PS6TCK,A]4H`YS6?AMX#\1^*/#_C
MK6?#.B:IXN\*BY3PQX@N;.&75=&CO1MNHK*]`\R..<?>0-@GJ.N>#\&>-/BQ
M>?&'QMX+\4?"N;0_A_I-G:W_`(1^(]MJ]O=V'B,S<7%C/IP_TFSO[9N7W_NR
MN-IR:^4?^">?QF\9ZQHGQ`_9T^,>HSWOQG_9Y\6WGA?6]0U&0->^*/"]Q,]Q
MX8\4KOVM<)?Z>\:R3(&02JPW9S7Z57:B2UGCWLAEB>(.C['4R*5#(_.UQG*G
M'!&:`)O,3!.]2`<$A@1GICCOFG9!Z$&OE[X?^";?]F7P3X_UKQA\3_&GC/PR
MNK:UXTN]4\9,-3N/#.FW4AN9=,L'M(C/+I]AN988Q&S)$OMFO8OAW\0O!GQ2
M\)Z1XX\"ZU:>(?#&NPFZTW5[1G-O<H&*,45PCJ58;65@"&!4@8X`/0**0$'.
M"#@X..<&EH`*:^-C9Z8/K^'3GK3J*`/AWXF"RT[XR^)Y?&?PUU[QQX'\6>`M
M*T2YMK/PZ->TJ]DM;EVFL[NW<F-EQM.V1<'ZUXKXP^$/['?B[PIXC\+7O['-
MU;6GB+1=2T6YN+'X2:=;WL$&I6DMI+-:3I'OAN8DE+PR+RDBJPZ5^IE%`'\S
M?[%__!([_@G]^Q!\2O%OQ)^&OP/^/?B#4O&F@2^'=?T7QUH1UWPW<Z?<WAOU
M#:9*#$98YB6@.#Y6!CFOVSTWX[^'M'TRUT32OA#\3;+2K"SAL;33K;P;)!:V
MUE%'Y,5O#"KA%A2/"&/``08QTKZQHH`_&/Q1\!_A+K>GSPZ;X4^.VA7D_P`1
MM0^(=O?Q>$1>36.I74D'E:=$D\H5='M?*>.WM5PD8F9@.E<K>?LS_#?4_'S^
M/M9TSX\WUXMY>WL%NO@."*;S+\3>?Y][]I:6>!9;B3:@2+:H"C/WJ_<:B@#\
M,])^!&C^%M7^&^G:+X8^+FI>$?"7Q#O/'&L-J'@X6E_<:5<V<3+X7=;:4_VA
MID^J017@%QDQR1AL>OZ5#]HC2(IXI!\+/BF&\HVZR+X0F#(BD;4+"0%5`QC'
M7H*^HJ*`/F?_`(:.TW_HFGQ6_P#"3NO_`([1_P`-':;_`-$T^*W_`(2=U_\`
M':^F**`/F?\`X:.TW_HFGQ6_\).Z_P#CM'_#1VF_]$T^*W_A)W7_`,=KZ8HH
M`^9_^&CM-_Z)I\5O_"3NO_CM'_#1VF_]$T^*W_A)W7_QVOIBB@#Y5UC]H>RN
M=(U2V@^&?Q5:>XT^]@A4^%+D`S36\D48),N`"[+DGH,FO`=4TO5-$\'_`+$&
MFZQ8RZ7J,'QATXW5A>1&.ZMFN8=9N%A>,D^5*%F4NI.5S]:_2<]#]#_*OCW]
MI[_D=_V7/^R]Z/\`^FF^H`^PZ***`"BFAE;H0>_'IG'\QBD+*P(W`Y!&-V,Y
M'8_U'2@!0ZGHPZD=>XZC\*3>I7(8$$'!!Z]1Q^((^M>$?''XZ>"_@#X4M?%'
MCHWZZ?>:I'IMJEA;K<7$]R\9E<@;E'EPQ1-([E@3MP`3P>+^%W[5GPP^+7C*
M;P9X4?5);PV-Q?V6HW.GRP:7JT=DEM-J4%C<-@-<Z<EU`;I/E$1?J2:`-3X#
M`_\`"9_M!<'_`)*F_;_J%V]?35?,/[/MS;W7B[]H2:VGBGB_X6I(GF0R+(F^
M/2[=73<I(W(W##.0>#S7T]0`'H>,^U?)O[9/[7OPH_8@^`GC#]H#XP:FFF^#
M_"2VB2HDB?:[VZO[J*UMK.TB)WS3.9"XC0%MJL<8''UB<D$`X)!`/H<<'\*_
M/S]O;_@G;\#/^"C7PVT'X5?'^7Q;+X'T368]?&B^&M9GT5=1O[<&.!]2,(_T
MB.)BSHC?=/('2@#ZC^&7Q!\"?'?X4^%?'OAF\T_Q-X%^(WAJQUJPD/DWUG>:
M;K=E'<FUN$'F1,8UF:">*3.&#(Z\$5^<7Q>_X)JWG@KQ=??'7]@SXA77[-WQ
M;:22_P!4\&6JR7?P;^(LRY>2R\1^#@XM=-GO6^5M5TQ(I$9C*ZD+BOJ#X&_L
MCV'['O[+"?L\?LOZI=V">%=*UB/X?7?Q`O+OQ!%I5_>9DMH[^7<;B6PBEX2)
M<&./A<=N\\-?$3Q-\)?@'9>-OVK=;\,:%XBT'3PWCK7?#8NV\.0NDX@2^LXW
M1[F*"9"DLBE6\LLV3A:`/AKX1?\`!2G6/`?C33/@G^WQ\.+K]G'XG7+1V>A^
M.;EY+_X/_$"1I!$;S0_%<:?8].:XDP4L]3>"12P`.17Z[:7J^EZW86NJ:/J-
MEJ>FWT23V=_8W,5U:74,@RDL$\+/'*C@@JR,00>*\/\`&'@'X&_M7?"N'3?%
MF@>%OBG\,O&6E0W=BUY:0ZA97EC=1DQ7UE=LOG6\JY#PS6[QR(P#`@BORXU;
M]ES]L#]@K4IO%O[&?B?4OCW\"8IC>:O^S%\0M5DGU_0K$'=)!\,/%-TYDAC@
MA!$.F:@SHQ541N0:`/W'W+SR..O/3ZTM?GW^R]_P40^!G[2.HS>!Y[O4/A9\
M:-(Q;^)/A!\0K=_#OBG2[^,`7,%I#?+"FL6\;Y5+FQ::.3JIYY_0/<.N1CKG
M/;UH`6BDW`9Y''!Y''UII=?[RY[<CJ>GZT`.)'/(^E</K'C_`,&Z+K^A>$M1
M\0:;9>)/$[7$>@Z++<P+J6HFV0R3_9;4OYT@11EF5<*._2N+^./BWQWX)^&7
MB[Q/\,?!%Q\0?'5EITZ>&_"EM,EO+JFJN/+MA+/*P2.UAE=9)V^]Y:MCFOD+
M]CO]D[QUX5UV7]HC]IW7I?'O[27C2%[NX$K&;PU\*]+O#OB\(>#+)BT5J+6!
MU@U#4T`GNYD;D)T`/</`7[+N@:/\;?%GQ^\8:KJ_CKQUJDCV7A*77U22Q\!>
M'F`#Z/X7LN8K4SL/,NM0"BZE^YN"\'ZZHHH`****`"BB@G')Z"@`HI-RXSD8
M^HIN].FX9Y'!YR.N/<4`/SW[4FY?[P_,5YK\2OB?X*^#W@_5/'/Q!\1V?AWP
MGHJ^;JFKZ@3Y,"2-M0$H&.=Q"J`"2<`<UYGX_P#B#\0?%7P57Q_^S#IOASQ[
MXEU^RL;[P<GB74)=%T*[M+J1=UY<SF/S@JP,9$0(';`P*`/HZ[N;:UMY9[JX
MAMH(U)DFGD2*)!ZL\C*J^F217Y5^-O\`@J9\'+#]HGQO^RK\+/#^N?%_XZ>"
M[/0+NY\)>$9[.7S[76[A4GG2Y:X\I4TN%C<7Q&YDC'2OMCQ%\*+GXX?!NT\"
M_&P7-AJ&LZ78_P#"66G@C6[[2HTU.-5>YM['5[8I=FU\W*9^4O&!SZ_G'\"/
M^"'_`.R'^SY^U1'^U]X!NOB=;_%\75S+<7]_XSOK^PO;:XC\G^S[RWN=SW-I
M''A565VY`/)YH`_13XB_`OPE\<KCX;Z[\0;#6XI_!&J67BBQT&WUB\L;%-;$
M*2QIJT%G(BZE]@E)")(3"'7)4]_H2*((%1%V1(B(@QN`5!C&3GTQ_GBS10`4
M444`%%%%`!3)0#&X(R"#D9Q^M/I"2`2!DCMTS0!\NZ]\*?@U\./BEKW[4^N8
M\->*)/"UOX8\1:[)?&VTNZT:VG5K>;4X!M@EFA:14BN)OF12%#`5]&Z;?V6K
M6=GJ>GW$=Y8WL$%Q:7$#(\%Q;3HLL$\;#(9'1PRLIP0<YZ5RGQ'\`Z)\4O`/
MBSP#XDM4GT3Q=H>H:-?PR@,8TO('B6:,GI)!(4FC8='C!'K7QC^P7XM\8Z9X
M>\8?L\?$9+\^,O@%XAE\)VNKWD$PA\1>#"S2^&-5M[F1=EPS:<8H)F1FV/&0
MQ!H`_0:\MK:]M;BTO+>&ZM;F&2"XMKB-98)X9%*O%+$X9'C=25=74J02",5\
MZ_%RW^)OPX^&:0_LU_#WPIJVNZ1JFF21>#KMX]`TF;0Y;T-K<>G-;1K!!?K"
M[S6X*A))`=W6OI+(XYZ]/>D;.TXZXX[4`<QH-Y=W6F:1+JT*:7JEY:6]W>:7
M]I5Y+2X>%&N+8./]>L,Q9&=1M(&>*ZC<N0,C).`,CKC/\J^>?BU\"K?XH>)_
MAUXKB\8>,/!FK_#O6TU2WE\,ZFUK::W9.2;O1==LF)AO=/NN`Q*^9%@;#7GO
MQC_;C_9Q^`/Q,\,_"3XL>/+/P=XN\6S:-:>'+?5XIK2TUNZUR<V=G:Z=J$JK
M:SW?G+^]B60O&I4L`#F@#[(R,XR,GH.YI:I6TL$\<,T3;X9(DF@E#;E=)0&7
M#<@@@@@]P:NT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`"'H?H?Y5\>
M_M/?\CO^RY_V7O1__33?5]A'H?H?Y5\>_M/?\CO^RY_V7O1__33?4`?8=%%%
M`'AW[0/QO\&_LW_!_P`<_&GQT-1/A?P!H,^LZNFF6DEY?S0Q$*EM;6\2DO-+
M*RH#PJEMS$+DUX]^QA^VK\*/VV_`6H?$#X5'5HM/T6ZL],UBUUBS%M<6FH7M
MK]MBM5D1F@FD@A(CG$;DQR'8W-9?_!137KGPS^QO\;=7M?$?ASPU/:>&T6'5
M?%^F#6/#[F6_LXCI^H:6$?[>FLECIBP*N]GNQM(;::^=O^"3'Q.T3XA?!+Q1
MI.G^"?AQ\.KKP+XV_L/6O`_PX\/W7AI-(U*ZTV"_677M-O5$XN]31S>0$R28
MA(&X#`H`^W?VA_V>M)_:(\+:5X;U[5;K1(]&UDZO:W%I;0W8;=!+:RQ36MR?
M+D+P3/Y;CF*7:ZC(%>??!K]C[PQ\&_%T7B;1O$.OZG9:?IFJV&@Z%J2VRV^D
M-KWV5=:NVND/VBYGU%+2(E9?DB'RI7VG2'H?H?Y4`?)G[-?A[2?#?B#X_:;H
MUG#I]H?BY>7#P0/+(KW-S86\TUPS2M(P>5B24!"+GC%?6E?,GP&_Y'/]H'_L
MJ;_^FNWKZ;H`*KRW=K`0)[F"$L<*)98X]QQG"[V7)QSQFIV!*L!U((&?<5_(
M3_P=/W?[=EMX4_9:;]BF;XTQ7P\2^+/^$T3X/Q:HTWV4:5&=/;5FTZ-RD7G;
MA$9N"PP.:`/Z\DGBD3S(I8Y4YPT;JZG;U`*D@X/%8.LZ!H?B;3KO1O$.DV.M
M:/J5N]K>:7JEM#>V-W!)G?!<6LZ/%*IR?O`YZ5_,I_P1"O/^"M<_["?AB3XG
M66AWOBA_%?B9#-\?KK7(/'WV-+J+[,MTCQHPLV0L;9F&6`XR*_HWN#\58OAJ
MK6<7AM_BE_82?NIGN!X9'B+:"\9E`\\6`DR$8#=MH`YKXD_#+Q)<_"6]\`_!
M#Q%:_!W6K>RCM?"FL6&CVUUIF@BVF69(CIGR1&T=5:-HHU&$8@5D^/\`XL6O
M[/'P@T_QA\6)M8\4S:+;Z-IWBG6O"FA75]-=:E.(K>[UF'1[-99[>Q,S&:4*
M&$,62>!7@\=W_P`%*#)&)]&_9V,!D3S@FHZR7\K<-^W]W][;G&>,]>*^J/'U
MG\39_AE>1>#;'PC??$B;2;118^(Q,WA2;4RD9NXIRBM*UH'\P194D@+N&*`/
MF[]H/]BS]GK]LOP[X?\`%^OZ+<:%XOBLH-:\#_%?P>S^&?'OA^2]MH[BQOX-
M5M?L]S.%+)*]EJ'FQ,1L=>HKXB@^,/[;W_!/2_32/VA-#U?]JS]F:UD6'3OC
M7X-TYYOB=X,TI6"I)X^\.VV?[1M;.']Y<:E9*SL%9RN>*]E^*GPT_P""E_Q-
M\/Z3X<TGQ9\(?A4VG^(=$U1]<\&W>I-=2:9IMS#)=Z7);SQ^4UO=P++#Y2`#
M:5QCBO?OVOOBU\9/@O\`"GPE/\.?AQ)\5/%&N:SH'A76LZ9<:EI%A!?Q1VNI
M:MJ]C;*\SV#3LSN0C)'$27&!B@#V_P""'[1_P;_:+\&6GC_X3>/?#_BO0+M0
MI>TO8ENK&X_Y:VFI:=*R75E=Q'Y9(KB)'1@?2O$/VP/VQ/#?[,_AK2](T+3I
MOB-\9?B!/-HGPJ^%_AX&[U?Q)K4Y$<,\L,.]K72-/D=9M0U"7;%%$K?-FOYC
M_P#@L#^QC^V;\-/@5XL_:._9VT+3_A)\6-6U'27OM'_9B\0^(]*U#Q5%>-NN
M)+KP;`O]GS7,".9;JY@MHY%.YGS7C'_!"'X=?\%>_B#X/\?_`!4\47/AJ3QW
MX<\1P:-X9\4_M6:+KVI^+].TV\M&:[C\%7[HJPZ;,Z[;OR>6E!!<=``?V$_L
M@>#/C]X6^&37_P"TAXTB\5?$_P`7ZU<>*M6TZQ@6+1O!4&I()+;PCHKK\TUO
MI$;+!+.YS/<([#@XKZ[K\9V\,_\`!:=`6D^(_P"R0BC&6?2/$"*,],LS`9).
M,9ZU3O=*_P""R^F1I-J/Q4_8]T^&6011RWMAK5K')(WW8T>>5%9V[*"2?2@#
M]I**_$G7W_X+!^%=,&L^)?C'^QKH6DF2.$:EJMIK-E9-+,0(HUN)Y4B9I20(
MP&)<D;<U5\2:A_P5Y\'^'9/%WB?XS_L:Z+X8BCAFDUR_LM<@TT17&WR'^U%_
M+*S;E\LAOFR,=:`/V_+`=2!BDWK@G<,#.3GICK^5?AAXI\2?\%<?"?@2^^)&
ML_%O]D>'P?8Z8-8EUBST#Q1?Q3Z<T?G+<01P!Y)5,>"GEJQ;(QD\5YKXG^,7
M_!6C2?V>O$G[16F_$7]F+5?`.F>#]5\717-EX6\51ZE-IEC9S3NZ6%R$G23,
M890\?'4@4`?T+B6-@2LBD`X)#`X/I]?:JFHZEI^EVEQ>ZE?6NGV=M"\UQ=W4
M\4$$$*`EY9)966-$4<EF(`[U_!C_`,$=O^"KO_!6O]H;1_VK;WP'X=\!?M7:
MOIOB/4M0T+PQJ_B*/P[K?@^_N99UMY-,L9\277AE0BI';\2K(-I(/-?N'H/_
M``4>UW6?@M'\+/\`@HW^R?\`'?X?^)]8T^?3_B)>^&/!FLZGX'92V9!I^M:"
MTUTEB(3^\DR"0.3F@#]M?B'\3[?PK\-M5^(OAC1M3^)$=G9FYTW2O!:PZE>Z
M]E@D4%@T;F*4NY'SAMH&2>!SRNJ67CWXV?!.WCL+OQ)\"_&?C+18I6G>VMKK
MQ%X0DN!F6(PL6MQ=QPD#=N.'/J*^2_V=?V_O^">,7A7PU\._A7\8_"7@O2-`
MMHM/TGPQXJO+OPW>6L4>$6WD'B'R;B24D_QN68Y)/I^B?AWXA>!/%UI'?>%_
M&/AGQ!:3?ZJXTC6M/OXWSTVFWN)"?RH`X[PU\+[6S^'&B?#?QW='XHVMAI\%
MCJFJ^,K"ROY=>N("&-WJ-E)%);22._SCY,*<8'%>G:9IEAI-G;Z=IMI;V-C9
MPI!:V-G!%;6EO!&`(XX((E2*%4&`%0`````5I;AQR.>1R.1ZB@$$D`\CJ/2@
M!:*"<#)X%-#*>`PY[9&?RZT`.HHHH`****`"BBB@`HI`P/0@TN>W>@!K_<;K
MT/09_3O7SA\?OC)X<_9V\(+\3M:\-W5[I,GB#0M"\0:CI%K%]JTW3]3NEM!K
M.HS;1*VGZ>\BM<&1B(U.<@9KZ1.<''7M7GOQ%\`:+\4_`?BOP#XJL8[G1O%F
MC:AHNH02J'!BO('B2:,D$+)#(4FC88*N@(Z4`=7I6J6&M6&G:MIMPEU8:K9V
M]_9W$3!XI[>YC2:&:-QD$/&X((X(SVZZ]?)'[''@SXI_#/X0VOPX^+4D-SJ?
M@;6=4T#PQJZW'G/K7@RSN&7P]>7!R62X2R\NWE#?,6BR:^M\_P"-`"-]T\9.
M#@>I[#FOP/\`^"P?_!('XA_\%0_$?P9U3PY^T#%\&-+^#VHIX@T^UB\.2:CJ
M%UXD@N8[FUU`:A`T<\<<`B5%@#A<_,*_?&B@#XD_99\*?M2_#B(?#SXZZWX,
M\:^$O"7A?P]I?A?Q]H2W=CK>L76G626VHRZ_IMV66*0F)9!.DA#`DFOL;2]<
MT;7('NM&U73]4MXY9(7GL+N"ZB2:)BDL320NZK)&X*NI(92"".*O7423V\\$
MJ[HIHI(I$Y^=)%*NG'/SJ2I]C7SIX/\`A-X-_9X\'_$*\^%OA'6)SJ4VL>,I
M_"L6I7=X^I:T\<MW-9:6M[)(MFU_/D)#&XBWOP!0!]'^8F<;UR3@#(ZXSCZX
MYQ3Z\-^!?Q-O_B[\/M'\<ZKX&\2_#O4=0,D=YX4\6VHL]6TJ>VE:&1)HP<.A
M*YAF4X="#T.*]PWKD#<,GH,]:`'4444`%%%%`!1110`4444`%%%%`!1110`A
MZ'Z'^5?'O[3W_([_`++G_9>]'_\`33?5]A'H?H?Y5\>_M/?\CO\`LN?]E[T?
M_P!--]0!]AT444`?#'_!1.QU"_\`V./C19Z1X)T?X@WC^'H7;PGKLXMK._M(
M-3LFO6@F:2/R]0M+19;G3"LBNU_%;K&=Y%?+?_!(R+3/^$"^-=UX4^'4O@CP
M/+\4X(_"FI:YJ,NH^./%>/#]BNJWGC*6YGN+Q+S3=062QT_[2P860"*-HS7V
M5^VY\,?"'QG_`&8OBM\/?'OQ%D^$OA76O#T:ZK\08+R.QE\*M::A;7MK??:'
MD0!!/!$CH7_>;O+P=U?.?_!,#]G?X(_L^_#_`.(>G?!#XUW?QJT?Q9XVL-;U
M[7)M2DU&.SURUTE;>6-6>20PRWQ>6ZG13L.Y``-@P`?J;2'H?H?Y4M(>A^A_
ME0!\R_`;_D<_V@?^RIO_`.FNWKZ;KYD^`W_(Y_M`_P#94W_]-=O7TW0`51N$
MMYSMD2.0#[V^..08SR/G!X_^O5UONM]#_*OY9/\`@Y"_X*3?MD?\$[])_9SU
MO]DHQRW?CO6/%&G>+;.7PW-XBC:"RT^*XM)2L,4OE,9B5&X#)Z4`?U)(D,2"
M.)8D4;<1JH11Z8"X`]NU600>A[X_&OYCO^"/?_!9[4/C1^RMHOC3]NZ\U[P;
M\3-5\5>(K5/$]YX'U;2/!]UI\%U%#I]K%>):F"&:`,=WF[3W-?TE^'O$.C^*
M-%TCQ%HNIP7^CZQ90ZGI>H6[8M[VSN5#Q3*6V_+(""I/7(XH`Z>BFET&<L!C
M&>?7I3LYZ4`%-?.UL#)P>.F>.F:"RCJ0/Q]\?SXIU`'Y6_\`!6?X1_%?XD_L
ML>)M4_9\\+^,_$_Q_P#"D4D_PLL?!_B*3P_<)KFH1-9O<ZBV]+>_L+>%S)+;
M3@ARHQR:^)_^"/WP4_X*)O\`LO\`@3X=?MCZAXT^"?C;X-^/[Z^6[@?3=8F^
M*7A;5&;4(;#5+F5Y'A@LKIY(W93YFURJXQ7]%5%`'@_QK^"6E?&[PWI_AG6O
M$OC+PK:Z?K&GZW]J\&:S-HE]>RZ=,DZVMW-`-TEE,Z!9H,[9$)4CFL+XZ?LP
M?#']HGP?H'@GXEVNOWVAZ!J&G:K8MH_B#4]!OEO]+$8@EN;O3IH9IU;8/-C9
MBDAR2.37TK10!X9X^^`/PP^*?@32/AK\1/"]MXK\(Z.VE36.E:C<7;1F31!&
MFG23SQS1SR2Q")"[N[&1P6?.:[.^^''@O6/"UOX*UKPOI.J^%+.*VMX-`U&U
M2]TU+>S5!:1>1/YBRBWV+L9]Q!`->@4T,IQ@CG./?'6@#"71-'738]"&D:>=
M&AMH[=-->U@>PCMD4+';K:/&T'DH``J;=JCC'%8_B3P'X8\5>%-4\"ZWH=E=
M>$M9TNZT?4M$2%(;&XTZ\1HKBT\F`1(L,L3%&5`H()%=MD>H]>M4=3U33=&T
M^[U;5KZUTW3+&%[F\O[R>.WM+6WC&Z2:>>1ECCC102SLP``R30!\>?L]?\$_
MOV2/V4_%.K>,/V??@CX2^&'B'7;4V.M:GX;M'M'U*T>3S66Y02,D[B3+;R-V
M23WK[$N[&SU"%[>[M;:\@=2CP7-O%-$R,,%6CF5T8$<$,"#T(Q7#>$OC!\*_
M'M_+I7@GXA^#_%>I0P&YEL=`U_3=4NH[=>#,\-I<2NL8)P7(`'K7HVY>.1ST
MYH`^8_B/^QG^RW\6HYT^(7P'^&/B1YE(-U=>$]+@O%++M+I=64%O<*^.CAPR
MGD'/-?$_B'_@C1^RHMW+J7PHU3XN_`S5\M)#<?#+XC>(-.L()R0RRQZ1=7-Q
M981@"(\!"!M/%?KKG/3FDR/44`?C')^PK^WU\,!+-\"?V_M?UZT@W&U\/_&S
MPE9^)(YC&0R6\NIV9CN$CDQM:7E@.<56;XK_`/!87X0;1XP_9]^#?[06D6H=
MIM1^&GBR7P[KEQ&I&673-63RVE9`Q1`_+<9[U^TNX9`R,GH*3<OJ.N/Q]*`/
MQBM?^"MQ\&F2T_:+_9%_:/\`@U=6X<WFH_\`"'W7BC0(D0CS)SJ.B)<+Y"#+
M,^W`0$UPGPS_`.#A'_@G=\2?C=XF^#%G\2+C1+CPQI<.H-XFU[2+^QTNYNCQ
M<Z:L;P?:8KRVZ2+-&O(/IBOW$U6UL+FTN5U**VN+)H9/M"7<$$]N(0I,AF29
M70QA,^8'&W;G.:_+CX:_L=?\$P]`_:'\;?%[P;X:^!>K_&/XH3BPUZP^U>'-
M7:6[MR?M*V&@2&5+>[D<$W`B@5BP.>]`'H?_``]D_8$_Z.(\(_\`?%__`/(U
M'_#V3]@3_HXCPC_WQ?\`_P`C5]4_\,U?L[?]$3^%7_A$>'.W7_EP[5CZE\#?
MV5M'=8]7^%_P3TN1QE$U'PUX/LG<>JK<VT;,/<`T`?-W_#V3]@/_`*.(\(_]
M\7__`,C4I_X*Q_L"*0#^T3X1R>@V:AD\9XS:^G->ZZ)\+?V//%.H:GH_AOP#
M\"-?U32-HU33M(\/>#]0NK$OR@NH;6UE>+=VW`9KGK#P7^QMJOQ"U#X6:=\.
M_@W=>/M%LDU/4_#</@KP])>:=:/A4FN/^)8`@8=%)Y!_(`\I/_!67]@,9)_:
M(\(\$`_N]0ZG@?\`+MW[4+_P5C_8"D.W_AHCPB?F"GY-0&#Z$FV`!^M<1\<O
MC#^P5\"O&.I_#OQ+\#-%UKQSIVC#7#H'A7X)0:Y+>6GW@+>ZLM%DM6G&>(S)
MG/%=%^S1XB_96_:FL-8OO"W[*L/@ZTTJ11++\0_@WI/AEKQWP,6L=UID<DP&
M/O`=.OL`?.OCO_@OA_P3R\"_'7X8_`T_%JUU6^^),LB_\)/9QRIX>\.2!MMN
MNL7DZ1_9_M+'"L1L4<L>E?K)X,^-/PB^(MM;7G@KXD>#/%-O.B2PRZ/XCTN\
M)$BAT7RX;DODJ<XV].M?YS7_``5Z^.'C?X=_\%H++P7X5_9K^&=]X.\$^(?"
M/A'0I7^%L=WI<F@^([JQM]0GOA8V2V%W,B3RB&XE!DAX(.17]@>F?\$S_P#@
MG[\4%L_^$$EG^&7Q1LM'T:\\16_PC^(VK>&-3T35-1TV"ZE\W0;:^*1;GF=E
MC-OB-0`,`8`!^VJRQN`R.CJ1N#*P92OJ""01]#1N#`["&..,$?Y_.OQCC_X)
MS?M5?#)D;]G[_@H%\5M*MH0HM=!^*FG6/CK3!&G"0/<2;+TQ[<*"&SC);FHE
MN_\`@LO\*/WKZ=^SE^T1ID+A#%9W.H>"O$=[;QL5+J)Q):K.Z<X'RJQQ0!]2
M?MS_`!L^*'[.FB_"_P",/A*"VU#X9:#X^TS3/C7ITEKY]W%X-UJ1;$:Y:3#Y
MHET:\D2:X)&TQG+<#-?;GAW7M.\3:-H_B#2;N*\TW6M.M-3L+R!EDCN+.\B2
MXMY$V\%6C=?F7BOQ,^(7[>GQ;O/`OB[X8_M;_P#!/OXV:!X7\5^'M2T+6M3\
M#VEKX^T,V]Y#+:S7D?V#-P/)D*7,#;-X958"MC]D#_@I!^P[\-?AKX'^"6J?
M'#7O#^L^%-/32K*W^,6AZEX5UY;%97%M:7;ZC;QH8M.CVVIF+[%"#<U`'[?Y
MHKR#P/\`'WX*_$BV2Z\#?%'P)XE@D"&-M(\3:3=EQ)]PA([G?ENPVY->EWVN
M:-IL$-UJ&JZ?96UQ-%;P3W5W!##//.<0PPR2.J222GA$0LS'H#0!J4C$@$@9
MP#QZ\=/QI%=&QM8-D!A@YRIZ$8Z@]J=F@#QWXT^`_$GQ'^'/B+PMX2\;:M\.
M?$FJ0(=)\7:3#'<76CWD4B/%+Y$OR31_+M>(X#JQ'TPM7^)7A7X#^%_AY9_&
M+QU%'>ZM<:1X-A\3:C`;:'7/$LL,<(DN/*5H;1K^<%T+LL8D<(&R<5[\>AXS
M[>OYURGB7PIX:\862Z;XI\/Z7X@L([F*[@MM7LK>_@BN[5A+;W,4=Q&ZQ3Q.
MJM'(FUE(!4CB@#IXIX9E5HI%D5U5U*G(9&`96'J"""#Z5+7@7C:[^-&D?$7X
M;P>`?#_AO5/AC>7%S;?$>ZU"]>SUO1HTA`TZZT:(+Y5Q`K#9-$2#Z'BO<!J.
MGM<-9K>VK7:*KO:K/$;A48X5VA#&0*QX#%<'UH`NT4@8'H0<],$&EH`****`
M"BBB@`HHH)QR>@H`**3<.!D9/('<CU%+0`AZ'Z'^5?'O[3W_`"._[+G_`&7O
M1_\`TTWU?81Z'Z'^5?'O[3W_`"._[+G_`&7O1_\`TTWU`'V'1110!^;W_!5J
M'29OV"/C^FJV7B*\MQH&GM;P>%[5+S6'U&/6]-ETL0V[AHYH/MRP"X24/&8M
MPD&S-?,'_!$KXQ>+/C!\%?BE/XKT<Z#JGA3QUIFA"UF\+:=X9N%E71E-PMW#
MI=M;6MY>1F+;-,BOL,@!/(KW;_@J_K7QC\+?LP:SXX^$EI<WZ>$I)+WQ;IUK
M=1PRRZ-=/:V7FB&6WNDNH;&>7[;-F%O)CA>7`VUY'_P1N\;>+_&7PP^-<'C*
M]&LW'AWXFVUK9>)K-[2XT?7UO]`M[V:\TC4;.SL8KY;65OL5U)Y;%9T:,MD8
MH`_:7<O/(^4X/L?>HVEC`;+J.">OM7QK^V!^T1KO[/?@GPQJNAZ8FH:GXJ\2
MV_A^*YGMVN+73H?L\U]=7]S$A4-&EO;NNXL#G`7<QP?)OV>?VL?&7Q<^*A\.
MZA::"_A/4;77I]+_`+.@GBU?33X:CT]I;S4HY3S:ZS]M;[#%M!.PXSMH`^C?
M@,?^*S_:!]_BF^/_``5V]?3=?(/[,'B&#Q3KG[06K6EEJ5BH^,&H6CVFJ6KV
MMRLEC900&98W`8P7"CS(7Z,N".*^OJ`$;)4A3@D$`^AQP?P->?>+/AQX%\=B
MR7QIX,\->+3ITLTEB/$.B6&KBTED4+)+;B_@G$+28P2N,C]/0J*`/+E^$OPS
M7P^WA*+X=^$%\-9ED&AIX;TA-)%S(ZO-*MB;7[.LDA`W2+&&)'7-8WQ5^#>F
M?$_X:WOPUM];\0>`--ECMH;'4O`UX-$U324LV#0KITT"JD,2%5`B50A`V[<5
M[510!\_>)?#OQ1\!?!1/#?PBN;;QG\1/#>B6=GH-]\0[Y_+\07-H5#S:Y?PC
M<+JYBWAY<;1(58C'`^-?#W[<WQQ\$Z]I_A?]H_\`9)^(W@QM0O[;2;?QMX%5
M/&WA"ZNYI%B%P6L<W=G:%B&:2>,!5R6/%?J4>AXSP>/7CI59X?,5%:-&CQEX
MW&[#=B,YY':@#GKWQ9X<TJVTR\UO6=-T9-9DM[;33JMU!IQN)[H"6"TC%T\8
M-TP/$0.\G(`R*Z=98G572175AE65@RL",@J1D$$$8(Z]J\;^+/P2^'?QOT&P
M\.?$7PX-=TS3=6L];L!]HN;2YL=5L)?.L[VVGMI8I$DC=1P&*E>""#7)?'OX
M?_&GQ/\`#_3="_9_^)&G_"SQ9HUY82VFK:OHPUVPO;"Q14.E7L#,)%CN414E
MN`Q<9+<GF@#Z4R/44FY?4<G`]SZ5_-U_P4/_`."DO_!1+_@FO^SEXD^,'Q)^
M!/PJ^)FE^']0TO3(?'GAKQ!<6NG3M>SF%7O]`F7[3!(^,GRV95)QTK$_X(U?
M\%J/VB?^"FGAG4]?U+]FJTAT[2/B-9>$O$6M^&]52'3O".BW&EM>-K%]%>$3
M7DCSCRDC@!(!&>E`'],!=0,E@!ZYH+H.K`?4U\C?M,^$?VK_`!9:^&M/_9K^
M(7@?X=`7L\7BS5_%N@SZW>#3I(B()M'AB98_M,4I#%905)`'2O(/@G^R+\?_
M``E\0M*^)7QH_:Z^(/Q4O=-P[>#K33M/T#P/<3LC1R;[&!3<.J[@\89L;@#V
MH`^]]2\6^&-*U;3/#^I>(=(T_7-<,B:/I-U?VT.HZDT2EY!96DD@FN"B@LWE
MHV!R:^<?CU^V'\'?V<+_`$C1_B%=^(9?$&OI,^AZ)X9\-:IXAOM0:-2=L::?
M;RJDCMA5\QE&2,]:].\3?!#X<>+_`(@^$OBCK_AFUO?'7@=;A/"_B"1I_M.E
M?:U*3^2@D$#-(F58R1L1V///H5YX?TB\NK:]N])TR[NK;(@N[NPMKFZ@8\DP
M7$D3RP[CU$;K[^X!\9_`3]L/5_C]XSGT#2?@#\8?"/A-;$WJ>.O'6A+X?TJ9
MAN"VD=K.RW32/@8R@QQFN%_;@^'W[5OQ4^&/QY^'7P]T[PG<_#_Q5\%O%6C:
M%;Q7=U%XWU'QKJ.FSVUE;6TBM'#:VOF.@$F\,#DY&,U^D"H41%V+@8&U/E5>
M^<?Y`J>@#^!K_@A%_P`$@_\`@J=^RY^TEX^\7?%W6/$_P/T;6/!5YI^G^);[
M4$\9PRW4ER'2Q6PO;N=(F91GS0HP/K7]G'P=^%'Q[\$^(+W4/B9\>+KXIZ/-
M8F"UT>?PY9:,+>Z!!-R)[7YGXZ`]3S[U]6T4`>,2^"OB,WQ4M?%L7Q%GB\`)
MI!LY_A]_9D)AEOSR+\ZGS.&&?]7TSQFO,/C%\(?V@O&OBA-3^&O[0=U\,M`%
M@L!T"'PS9:MON@V3<&XN#N`8?PY]A7UM10!\J?!OX4?'OP3X@O-0^)OQXN?B
MCI$UD(+32)O#MGHRVUR#\UQYUN=S\=%.*[.W\!_%.#XMWOB^7XHW%Q\.YK(0
M6WPW.DVRQ0W94!KO^UA_I#<Y;RSUSUZU[Q10!\<?';X-_M!^.]5U&]^&OQ^N
MOAYX?FT*YLQX7B\-66JBYNV@D4L;J<[E$^[9@$8SD&OXF_V$_P#@CI_P4]^#
MW_!7KPU^T1\3/!GB63X)Z?\`%WQ/KU[XAF\4.UA<Z/>S3M;7YT5;QHHDN"XD
M$*Q`)NP!7^A710!\X>&?@5?:#\<?%OQFF^)?CO5;7Q3I%OI4/PYU'4%F\%:(
MUM]Z^TFQ`#P74V/WC,2#["O-/CU^P3^SW^T?XKT_QG\5M$\4ZSK&GB,6PT[Q
MEK^B6$8B;**;#3KJ""3IAMP((K[:HH`^8O@S^R-\!OV?];U?Q!\*?`-AX6UO
M7[>&WUK4X+J_NKO5(K=0L)NI;NXFW2J!R^-S'.>37M-KX(\*V.O7OBJR\.Z9
M!XEU&*."^U^'3[6+5KRWC^Y!<7R1+<S1ICA9'(]J[2B@#GY=!TM[W^TVTFPE
MU`Q^4;U[&V:]\L<[/M;1F8IVV%]O0>U:D<*11LL4*PY7(VQJB@X](U`S_A5R
MB@#R36?@S\+/$.M/XBUSX:>"]:UZ22">XUK4_#6D7FIW$EN08'-[<6DESOB9
M0T9,F05!'(!KY:^/G_!/OX3?&+7V^)'A"^\2_!?XRP*DEC\2OAWJ$NDWT\\*
M!;=-:TY'%EJUO'M5&BN(C^[^52.*_0"B@#Y7^#FE_&'X0?"*_P#^&@_&]G\2
M=8\))J%VWBC0]'FM[_4="L@7MI+O38=S3ZIY"_OA`,2/DJ.:]2^%7Q/\*?&/
MP?IWCKP1=RW>AZBTT<$UU:3V%Y%)!(T<T%Q:7*)+#+'(I#AE!KU*5%EC>-U#
MJZE64\AE(P5(P<@C@C!R.*X'Q'X.;4/!^O>&?"EZ_@B[U6RNX++6=!MK:&XT
MJ]N`2NH6UOL6W:99#O8NOSG.>M`':R(MQ"\<Z`D#'S!2K>@^;@@]\]OU_%C_
M`(*3_`SP/X-\=_!S]K[5/AQX8\9^#_!&JIX#^-/A74/#^GWNG7?P]\67D<+^
M()(C;?\`'UH6HR1S2W`(;R&;<P&17O&F^.OVS?V;-2TW1/BKX13]HWX9RWMO
MI\'Q(\$1_8_&NDV]U<K%#/XD\-'Y+J.V#!KF[M&SA2VW'7[X\5:7X1\=>%;C
MPUXQT[3=1T'Q7IHMKS0->$`@U&VG1)6MI+:=EWRJ2N8P"RLO3B@#\WM8_P""
M3O["WQ,TZP\7>"O`^I?#R[UVQMM7TSQ%\+/%6M>%08;R,75M/;PZ?=BT^5)5
M"8CV#/3BOR;_`."CW_!%_P#;H\7>#/A=H7[%W[97Q@N--T?X@:7J>N^%/B+X
MMN+B+1X+:Y62RUG3-5B9+N>#20O[VTG9OM`))SFOZ//AM\8OA'<_$+Q/^SOX
M3N!IGBKX3Z3HGVSPU+`UJD&BWMN/[-N-,#_\?-D$41>;%N167:2"*^C<]N]`
M'X0^!/VJOV\OV*_"OAWP?^V;\`-8^,GA#PUI>G:7<?'SX(>9XBN+JWM;9(GU
M#Q'X8"_;X[@;2]Q+"K+P7/6OT8_9]_;H_9?_`&D[6)_AC\4=#O-7)`O?"VL7
M0T3Q5IMQT>UO-%U(V]ZDD3_*X6-AN!QFOL">.&:)X)T26*96CDBD19$D0CYD
M='!5U(/S*P((KX'_`&@/^";/[*G[0-S)KFK>`(_!/CR-S/9?$/X:SR^"_%5I
M=#F.X:^T8VRW31R`2;+A'5SD,3S0!]^*ZL`596!Z$$$'/3!'4'L1UI<CU%?B
M*/@;_P`%.OV0Y5N?@A\7=(_:V^&&F_/_`,*]^+@72O'MO9J21:Z7XH@'E7DL
M4(\N)KH;G(&XY-=UX"_X*V_#.TUVR\#?M2_#?XB_LK^-WD6UE;XA:'=#P;>W
MP?RW_LOQ=!')ILEJ[9*22O&-A!)H`_7R95DB=#@AEZ>H^G4UX;+\!_")^,$/
MQQ@GUZ+Q<GAV3PW<VT6KW<>A7UB9-\<EYHQ<VKW4'(CG6,.%.,DFO0_!WCKP
M5X_TJSU[P5XHT/Q5HUU"D]GJ>A:G::C:RQRC(Q);2R`<'HV"/2NQ?!5A['@'
M!]?PH`^3O#G[4O@R?Q;\6O"_B[1/$?PZ'P<3[7K.O>+;%M-\-:AH$I3RM<TO
M692+.XLCN^93)YD9'S#FOI/P_P"(]#\5:98ZUH.L66KZ7J%M!?6-W87$-Q#<
M6MS&);>=7A9@8Y8V5T;HRG/0U^7W_!7W]E;]IG]LC]DCQ5\`_P!EWQ5X9\!^
M*?']Y9V'B[Q#KL\UF[>$X,2S6-I=VR^<))Y1M=2VTHH!'0CD/^".O["'QD_8
M4_9XC\!?'OQUJ'Q`^*,TR6FK:RGBS4O$6AR:38)Y.DII5MJ+'^S&BML))!`H
M4%!SB@#]B([RTE:5(KJWE:%MDRQS1R-"_P#=E5&)C;V<`TB7UG)*\,=W;O-'
MM\R%)HWECW?=\R-6+IGMO49KYZ^$G[.'A#X.>,/B9XQ\/ZYXRU74OBAK2ZYK
M-EXBUZ]U;3-/NL86+1;.X8PZ?;GO'"`.O<FE\`?LX^#_`(>?%GXC?&#2-:\8
M7OB'XF_9#K>G:QKU[J'A_3VM,%!HNE3M]GT]6V_,857/3I0!]"B]LVN'M5NK
M=KJ/!>V6:,SH&^Z7B#&10>Q*@&@7EH9Q;"ZMS<E=XM_.C\\ITWB'=YFW_:VX
M]Z^=M`_9N\(:!\>/%7[0%MK?C*X\7>+-'M=%OM'N]?O9_"=O9VQ/ES6.AN_V
M2VO&Z/,J[B/I4TW[.OA:3X_V_P"T6-;\7CQE;^&6\+?V'_;UXO@\V#=;AM!#
MBT-]CI<%2WYT`?0)O[%;D637EL+QAN%H9XQ<E<9W"'=YA7'.[;C'>H+W5M,L
M(Y6O-0L[;RK>6YD$\\2,+>!&DFEV,P9HTC5F9@"H`))%?-.L_LJ^"-8_:+TG
M]I>Z\1>.H_&6C:)_8=MH-OXEOX?!KVS1^7YUQX>1A:7%S@_ZQP3WSUS\K_\`
M!13]BCX@_M"^%=?\=?`'QCXA\(?M"V?@S4O!7@2:Z\6ZCI'@.R@UZ*6SU#5-
M9T>U?[/?W%O:S2B`RKN5V5E(*Y(!^AWP[^)'@?XK^'K/QG\//$6D^*?#-W->
M6MOK&DW4=Y:O<Z?<R6-Y`DL3,A>">)XI1G*.I!]:]"K\%_\`@A5^P;^V9_P3
MN^#OC[X%?M._$'PG\1O"UWXJG\6?#W4=`OKN^OM(NM8D:X\0V%W)==+6>Z;[
M7"$^59&?`.XFOWHH`0]#]#_*OCW]I[_D=_V7/^R]Z/\`^FF^K["/0_0_RKX]
M_:>_Y'?]ES_LO>C_`/IIOJ`/L.BBB@#X<_X*+:Q=:!^Q?\?=1LO'<'PVO5\#
M:E;6OBZZT_\`M2+3+B_:*R1'L0CB;[<\RV8.P^4TXD`RM?&__!$E/B/!^S1K
M=C\2?$,6MW5GXKBMM)L(?#<F@V^DV8TY&9%EEAADU5M4EVZ@]ULQ&Q\O/-?<
M?[=OP*U;]I?]F#XK?`_P_KNF^']9^(FB6VDV.JZK+LLHIH-2L]2$4P4AU2X2
MU:)GB(D"$E2&`->?_P#!/W]G;QA^SM\+=5\,>+M3\*:E+>ZU;7-M=>$-7U35
MM.>.SLX[-P\^ISW$L#AH^8HG50>-H.:`/M+Q5X&\+^-]/BTCQAX?T[Q'ID,\
M5W%9ZG;)<PBXC)<31J<%)4!V@@@$$J002*R=#^&'@/POKMYKV@>#]$T?5KVT
MCM;C4=/L8K>YEM4*A+<O&`JH"B[E4*=J#)/->F4AZ'Z'^5`'S1\!2/\`A,OV
M@_\`LJ+?^FFWKZ8KYD^`W_(Y_M`_]E3?_P!-=O7TW0`4444`%%%%`!1110`4
MAS@XZX./K2T4`>/?&;X%?"GX_P#@B\^'OQD\#Z'\0_!>H307-]X;\06:7NG3
MS6[;XG:W?`+(W(SG'O7+_`+]E?\`9_\`V7]*U;1/@)\+_"_PPTG7[R*_UC3_
M``OIZ:?;WUXD?EQ33)&,,R1_+DY_6OHFB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@!KYV-@9.#@'H3CBOG;XW_L
MZ^$_CS_PA[^*-1\3Z->>!?$%KXCT+4?#.M7>BSQ7MJRN8KI;5UCOK.XV[);>
M8%"I(P<U]%T4`?B_^WCX9^+GP*_:#_9Y_;"^!_PSUWQYI_AB&]\"_M"V_AA!
M<:]J/PVFB62SOQIBC?JE[I=RAFC(#.L98+Z5Z'JG_!9C_@GCX9L=%F\=?M!>
M'?`&K:Q;R3/X:\91W6C>(],FBXGM=1TZZCCFM9HG!0JPPQ!VDBOU9F4-%(K*
M'5D8%6&Y6!!X88((/0@@C'6OXE_^"EO_``23US_@L?\`M:>-/#%GK7@3]FSX
ME_L[F?3-6TRWT))9OB%X4UV7[9X=\7^?:I#YWGQ*8)696,<N1NR*`/[)_AE\
M2O!'Q@\$^'?B3\/->M?$G@WQ78Q:MH.N6;AK6_L9@#'<6['[T<B]",@\UZ)D
M<<]>GO7YG?L&_LM_'K]DSP#\-O@KXC^(/A?Q=\)_A[\--"\,:=:6NE2VNN0>
M(M-0+>7'VD,5ELI_O*K<CIBO8_%/[=W[.G@#XPW/P1^)'C-?A_XOBFMH--G\
M76L^CZ!X@DN8Q*B:+K=PJV5VZDA&1)-P8;30!]G,,@CCD=QD5YU\0_A1\//B
MKH=SX;^(G@KPUXST2Z@>";3_`!%I-GJ<+1R##JANHG>+/9HF1EXP17<V.HV&
MI6MO?:?>6][9W<*7%K=6TJ36]Q#(H9)8I4+(Z,I!5E)!!JYN'J.1D?2@#\</
M&/\`P2@LO!.LWGCG]BWXV?$/]F#Q:7:X3PYIFI7.O_#/49PWF+%=>%=1EE@M
M[=V^5Q:["J?='%<T?VM?^"@'[)SFR_:O_9V;XV^`K*(*_P`:/@`LE[>1VD&%
M:]USP9-_I44@3][.;4L,Y"#C%?MID>HJ*=(9XI(9526.565XW"NKJ1RK*V58
M'N&&".*`/SQ\#?\`!3_]B;QMX&U3QT_QU\+>$[3P]`MUXAT?QO<'PKXAT0ED
M1H;_`$75?L]X)8I&V$1HP)!(.*^U/"7Q'\!>.M`T3Q=X6\6>']>T#7K&'4=(
MUBPU2SFLKRRG3S(KB%DG(Q(A#`GUY`-?D]_P5"_X(S?LZ?\`!13X4ZMX>_LK
M2_A=\4Y&2[T7XD^%=/BTZ\:Y#KYEOKL-A]G35+.50WR3J^QN01UKBO@/_P`$
M+/V>?A/\*/`_P\U+XI?'C5K_`,,Z!8Z7?ZCIWQ0\1:38WES!$!-):Z?!<^7:
MPF7(CB3`5"`..``?N#_;NB?]!G2O_!A:?_'J/[=T3_H,Z5_X,+3_`./5^4`_
MX(V?LU'_`)GW]H/U_P"2O^)^G_@32G_@C7^S6!D^/?V@P!_U6#Q-_P#)5`'Z
MO?V[HG_09TK_`,&%I_\`'J/[=T3_`*#.E?\`@PM/_CU?E!_PYM_9JZ_\)[^T
M'_X=_P`3_P`OM--_X<W?LTX!_P"$^_:#P3@?\7?\3]?I]IS0!^L/]NZ)_P!!
MG2O_``86G_QZL[5_%_A;1M*U#5M3\1Z'8Z=IEG<7U]>76IV<=O;6EK&TUQ/,
MYG`6..)&9B3T%?EC_P`.:_V:SD?\)[^T'QU_XO!XG&/Q^TUQWQ!_X(B_LU>-
M/!/BOPBGQ*^/]E+XBT#4]*BNI/BWXFN4MY+RUDACGDMI+G9/''(RF2)OE=<H
M>M`'Z??!CXZ_"7X_^%(/'/P>\=>'O'OAA[VZTW^U_#NHP7]LEY9W3V]Q:R^3
M(YBECD1AAPI(&1G.:]GK\;_^"/W_``2ET#_@EE\)/$W@"R^(?B#XA:[XU\17
M>MZOJ&IW=P=(M(Q<R'3K?2=,DD:.VF%HR&\FC"F:;+L"37[(4`(>A^A_E7Q[
M^T]_R._[+G_9>]'_`/33?5]A'H?H?Y5\>_M/?\CO^RY_V7O1_P#TTWU`'V'1
M110!^$?_``7'\;>+O`OP;^$.M^!/'GB3PGXV/CWQ!9:%I'AZVU"9/$<DWA2Y
MM[TZ@--_?"'0[>8:G;*0Y>Z950;AD:__``1$\0Z]J_P+^)%KXF\3ZQ=>(-,\
M?:39ZW\/M;?4IKOX<7A\-VER\+7FJ/)=72^*%;_A(#$Q!MGNC$5&W%?;_P"U
MQ\4OV>OAO>?"4_'K3;2[&I^)/$FI^#-0OK:"ZAT+5?"7A:ZUW5[^X^T$(%_L
MJ*2/R5S]K95C(/%2_L+^!?"'A/X-P>*M!UWPYXIU3XK:M>?$OQ'XPT.VAMY/
M$K>*;F2_T.ZU."-Y'BNK709M/T](7(\B*WV(JJ<4`?<-(>A^A_E2TAZ'Z'^5
M`'S+\!O^1S_:!_[*F_\`Z:[>OINOF3X#?\CG^T#_`-E3?_TUV]?3=`!1110`
M4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1
M110`4444`%%%%`!1110`4444`%%%%`"'H><<=?3\^*_@@_X.,_\`@HA^UE^P
M/_P4>\*>(_V4[EO#FK:]\$M+TSQ%JUIH$FJIK"/=--$-0"0R1M-9L-L!8DJK
M$=,8_O?8D*<#)[#U]J\.\??L[?!+XG:FFN?$/X3^`_'&L0Q):IJ7B?PWIVKW
MR6RY(ACN+N!W6*,$[5#8'84`?G5^R!^V#^TIXT_8[_9J^*6K_!/Q3\9_&7Q(
M^'.E>(/&&MZ)<Z=HD=KK$R8EB>QO#&\3/UX4#/0#(KV6Y\(Z3^V5>S^$/VEO
MV,KCP]HEG8RW&F^*/%\^D:A=6EY(#'MTJZL";VRN4!WI.CKL.",5^@7ASPSH
M?A/1M/\`#_AO1[#0]$TR%+;3]*TRWBL[&RMHP/+AM[:%5CB1<?<50.E=!0!^
M7GAKPKXY_8I;5?A_\$?A%\9/C=X-U+R]3TNXUCQA::CI_AIQ$R+X?TJ35I#>
M0643A,*Q8!#QP!7LG[,WQT_:&^(EKXBD_:%_9TU#X%2:*]Y=65U-KUIKNFW^
MEQR.R3O+;?/!.EK'YLT1!5.>:^WZAN(DG@F@EB2:*:)X989!NCECE4I)&ZGA
MD=&*L#P02#Q0!^>NJ_MP7_B#Q-J6F?`KX4W?QST#3)/L<OB3P9XN\/%%OX7:
M.ZM)=,N)UO86MI%*R/)$`I'7BOH'X(?%7XA?$JWUC_A._@]XC^%,]A)%':#7
MK^POFU4R9+20FR9A'Y9^5MQ]J^>/BI_P39^!7C+5[GQA\.5U_P"`WQ"E>6YM
M_&/PHU2Y\/2_;Y'\WS]0TJW==.U!7ER\RS0_O<D-7T!9+X_^`_P+N)]4E\2_
MM`>-/!FB-<,UO#;67B3Q<UNX"PPQ@+:F\$/('!D93SEA0!_-Q_P<6?\`!4C]
MN+]A30OAF_[-7A?6_`EMJOB_4M*N/&MSIUIK^G>*K2&S68+8V,4<L]LL;G!:
M4+DY.>U?9_\`P;M?MO\`[3/[>7[&GB#XL_M/3S:EXVT[XD^(-`L]1;2ET=;K
M2[)(6@A2T*1L/*9BHD*X:OK?]L;]L#]C#X/_`+/GPW^/'[=G@>V\*>!_$6KQ
MV.D:%\1/"=MXBU;P_KU[;^9)936!CF$$VQ<221]5QS@UZ?\`\$_OVI/V,_VF
M/A%)XW_8VO/"]A\,I?$NH:6EGI&D6GA:.?6[,J-0>+2AY+2.^5RXC+,!DDB@
M#I?%7[2?QZT3Q+K&B:3^R5X^\2Z387\MM8:_9:WHL-MJ,,?$<\44SAT24<C>
M._MS[U\)?'?C?X@>$)-;\:?#/7/AAK"W5S;_`/"-:S>6M]=/%$?W<XFM&,>)
M<#:">"?3I[1N'J/S%-WI_>'4CKW`R1^`H`^"]9_:9_:$TS6]3L;']C[X@:K9
M65_=VEGJ=MKNBK;ZG:PW!2*[B21P\:SH!(JO@@$`U]+_``Z\;^,?%_@>/Q-X
ME^'&K>!_$!%Z6\(:G<VUQ?#R%<P)Y]NQA+3D`+S@%@3WKUX.IQAASTYZ_3UH
M+HO5@._X9QV]^*`/@*\_:D_:*MY[R)/V,_B)=)!>3V\$UOXAT,17=O'(4BO%
M+2!D650'V-R`W/-?)7_!7S]K[]H+]FO_`()?_$/]ICX2:/?_``V^-6AR^%_[
M/T._M(M<O='%_JSVM[:S0VZR1W):$!L@8`P3QU_:YIX@#\X/48'))'48]AR?
M;UKC_&7@KPA\0M$N?#'CCPYH_BOPY=/%+>:'KEA#J.G730-NMVFM;A'BD*,2
MR@J<9_,`_E'_`.#9O_@J1^V=_P`%#/%'[1NC_M7:V=:@^'^G>&]1\*RR>'GT
M-XY-2F>&Y10T,0E"A<G!('7M7]=U>0_#[X'?"'X375W/\,_ASX0\"3ZNL2:G
M/X5T.QT=[]+9B\45T;.&(RHF[(#'`[<BO7J`$/0_0_RKX]_:>_Y'?]ES_LO>
MC_\`IIOJ^PCT/T/\J^/?VGO^1W_9<_[+WH__`*:;Z@#[#HHHH`_$?_@M%H$F
MJ?"7X1RR?"*7XJ:7:_$75SJSV^GZEJ>H:4EQX;GL]/L+.'2V2>)?%5_-;:#<
M7;'RK2UDFDE^6MK_`((V^&_'_@[X3_%7P;XZ\"+X0C\,?$/2+#0)TM=4LK/4
M+23PQ;7=QINGVVJ2S.;7PE=3_P#"/QW416&\-J90N17[%W=C;WR`7,$<L8(;
M9)$DJ[P05812*R[@P!#XW*>0>*EAM;>W`$%ND`!:1EB01J7?K(50!7D)Y8GD
MF@"X748RP&[..>N.OY4TR)M/S#H>_L?\BOC+]M?7_CGH7PBN8?@+X:UG6_$>
MHR3PWE[HC6XU72+*.%YO,M(;DXEEN)E$/'*HQ(Z"OGO]EW4_CK?_`!MF3QQ_
MPG$:7?A[6)?%6F>(X9$T"P@@L-$/A$6,P_T?[>UR^H_;3;X+8/F=*`/KKX#<
M>,OV@#V/Q2=@?4?V7;C/Y_C7TW7R!^S#'XCCUS]H"/Q4^GS:S_PMS4F9](#Q
MV@LFM;<Z>F),DW*VV!<$<,V2!7U_0`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4U]Q4[>N..U.HH`_*3_@K/_P`$O_#/_!53X$^&
M_@;XP\?:I\/-.\-^+XO%L>KZ59Q7L]S/';FW^SF.7"JNW^(9/YU\I?L+_P#!
MO[^SY^QM\/-!\('XC_%#Q;KGAGQ1J'B72_$VF>*-6\+Q+)=SQ3BWET;3KA+.
M4H(MC22(QE4LI&*_H(HH`^?_`(U_"37OB?\`"V[^&_ACXB^+/AG?W4>G):>-
M/#$R#7K2/3W5C''+.&&;A%"S.^2V6)ZU?U_P5\1U^$\'@OP1X^?3/'5EHMMI
M5KX]U[3DU:XEO;6V2)M3O;4[(I9IW7?*0/FR3R3FO<:*`/R:TGX;_P#!6/PC
M;W#GXX?`;XESS:U8^3%KG@J[T/[%HD=ROVT1R6DK>9>O;;MFX;=^.U?;/QBU
M[X\>&OAWHM]\*?`_A_X@?$-;[0X];TC4=4?1=)^Q28_MR\LKD!F+1-N:WB<'
M<"H/<CZ,HH`^=?BM\3OB!\,O@U=?$32_A+K?Q&\96%C8W=Y\./"EW;_VO<7$
MRQ_;;;3[JZQ#(;5V*JS`&1`6-?BU^WG_`,%NO'W[(G[->I?&*X_8R^,V@>+-
M+BTB\GL?&NG1)X/LH-0NWM)[34O$%BY2WN6PIAPI(/0<U_1:_*L,$\'@=3[<
MUXE\>?V?OA1^TS\.M4^%'QJ\'V'C7P#KTEK)JOAS5$\RSNVL9?/MA,H.65'R
M0/[PSVR`#\(_^"%?_!;_`,;?\%<?%GQKTKQ'\)=(^&5A\*-'\.W5O_9VIRZC
M+?W6L3O#+O:11B,*H.>W&:_I+KXQ_9=_8`_9._8PU/Q+J/[-?P@\._#"X\9V
M]K;>(WT.-D.HQ6#F2V67<3]PDXXR,D`XS7V=0`AZ'Z'^5?'O[3W_`"._[+G_
M`&7O1_\`TTWU?81Z'Z'^5?'O[3W_`"._[+G_`&7O1_\`TTWU`'V'1110`444
M4`!YX/0\55,48E=TC42%`)&$8#.H'RJ9.IV^F>!5JD/0_0_RH`^9?@-_R.?[
M0/\`V5-__37;U]-U\R?`;_D<_P!H'_LJ;_\`IKMZ^FZ`"BBB@`HHHH`****`
M"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`$/0_0_RKX]_:>_Y'?]ES_LO>C_\`IIOJ^PCT/T/\J^/?VGO^1W_9
M<_[+WH__`*:;Z@#[#HHHH`***"<<GH*`"D/0_0_RHW#U'YTA8%2<C&#_`%H`
M^9O@-_R.?[0/_94W_P#37;U]-U\R?`;_`)'/]H'_`+*F_P#Z:[>OIN@`HHHH
M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@!#T/T/\J^/?VGO^1W_9<_[+WH_P#Z:;ZOL(]#]#_*
MOCW]I[_D=_V7/^R]Z/\`^FF^H`^PZ***`"@_E[T4'Z9]J`/-OB/\4/!/PHT.
M/Q'XVUJ'2-,ENH[-)V@EN#+<R`E55(4D8*BAGD?`CC12S$`&N:\&?'SX5?$3
MQ->>$?!_BW3M<URRLEOI+>VWF*:U*QRS?9I]@BF>U$L9N%B=FBW@,!FN=_:,
M^&?CKXJ?#V;PEX&U?1O#VJ7M[%]NU'6M,34HVT>3='JEA:(<FUFO;9FM3<(=
MRI(Y0@UXA\%OV.M2^%WQ&NO$MSK]A+X5MK'Q)%X<T'2+-[*XL)O&%M80ZU'=
M7F\O+;VAL1_99SOCW$DYH`]D^`Q`\8_M`,2-K?%-]K9&T_\`$KMQP>AYX^M?
M3=?&W[*WA#3_``3J7QW\-Z9/J5Y:6_Q=OK@7&K7DNH79>\LK>>56FG=V\N-C
MMAY^51C'05]DT`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`(>A^A_E7Q[^T]_R._[+G_9
M>]'_`/33?5]A'H?H?Y5\>_M/?\CO^RY_V7O1_P#TTWU`'V'1110`4444`%(>
MA^A_E2TAZ'Z'^5`'S+\!O^1S_:!_[*F__IKMZ^FZ^9/@-_R.?[0/_94W_P#3
M7;U]-T`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`
M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`(>A^A_E7Q[^T]_P`CO^RY_P!E[T?_
M`---]7V$>A^A_E7Q[^T]_P`CO^RY_P!E[T?_`---]0!]AT444`%%%%`!2'H?
MH?Y4M-)&.O4<9XZ].M`'S-\!O^1S_:!_[*F__IKMZ^FZ^9?@."/&?[061C'Q
M3?\`72K<_P`J^FJ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*
M***`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HH
MHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`$/0_0_RKX]_:>_Y'?]ES
M_LO>C_\`IIOJ^PCT/T-?'O[3O/C;]EPCD#X^:0#CL1I-]G-`'V'1110`4444
M`(WW3VX//IQUKXR^'?[3EYXV^.?B'X5WGA/^S=%TNZ\7Z=X=\1_VE'//J5[X
M)EM(=>&H6`7-O$_VI&LR"2VTX!K[-;)!`[@CT[>M>'^&_@'\./"GQ"USXG:!
MX:ALO%_B"6ZDU'4Y+BX=`VH%#JCV=HTK06\VH-%$UU,D:F;;S[`'S=\%OVBO
M@M8^-_VAXKKQ[IL3Q_%F>V<?8]8?;/;Z7!%-'NCTYU)CD4JQ!*Y'!-?1G_#3
M/P*_Z*)I?_@#K?\`\JZ]"TKP'X3T>;4I].\-:)9RZUJ$NI:O)%I]N'O;V10I
MN78QDM,V/F8]1[UN_P!@:%_T!],_\`;;_P"-T`>0']IKX%`9_P"%B:9^%AK9
M/Y#2\G\*0_M-_`H`,?B)I@!YYL-<'OT.EY_2O7SH&A@$C1],R`2/]"MNHZ?\
MLZ\V^)GC+X9?"/PW_P`)5XX%CIFD"_MK%'725O+B[U"_8K;VD$4%O)+)(Y5R
M%53PA).!F@#('[3OP(89'Q$TP@8SC3]=)Y]O[*S^G'>G?\-,_`K_`**)I?\`
MX`ZW_P#*NNT\(WG@KQEH&D^*_#T6EZGHFL6D>H:9?0:?#&+BVG+*H=&A##:R
MLK*P#`J0>0:ZO^P-"_Z`^F?^`-M_\;H`\@_X:9^!7_11-+_\`=:_^5E4Q^U5
M^SXUZVG+\3]$:_6W6Z:S6VU@W*VS2>4LS0C3#((S(-@8J`3[5[2_A_0BK#^Q
MM,.1C'V&VYS_`-LZYN'X?^$XM>F\0IX8T:/69[&'39-273X/-DL8Y#.MNQV;
M0J2="!G/7K0!PW_#3/P*_P"BB:7_`.`.M_\`RKH_X:9^!7_11-+_`/`'6_\`
MY5UZ_P#V!H7_`$!],_\``&V_^-T?V!H7_0'TS_P!MO\`XW0!Y%_PTO\``W_H
MH.F_^`&N?_*NF']IKX%K][XA:<OUT[71_P"XKBNT\9ZS\/\`X?\`AO5?%GBN
M+2M)T/1K8W5]>2V$3;(\A56...%Y)9I'*I%%&K.\C!0,UC_#OQ9\._BGX;MO
M%?@P:5JV@7LTL$=PVF_9[F.YMV"3V]Q!<0"6*:%R%ECD52IX-`&%_P`-.?`G
M_HHFE_\`@#KG_P`JZ=_PTU\"A_S432__``!UL_H-+S7KO]@Z/_T!](_\%]O_
M`/&Z4Z!H>#C2-.![%;*VW`]B/W?4=:`/%9_VJ?V?;6XM;2Y^)^AV]U>R-%9V
M\UMK$4UU*J[VC@C?30TKJGS,$!('6KG_``TS\"O^BB:7_P"`.M__`"KKL=6^
M&/@G7-7T'7-2\-Z;=:EX:O);W2+F6UB!M;F>,Q2.%5`)%>,]&!P?2NN_L#0O
M^@/IG_@#;?\`QN@#R#_AIGX%?]%$TO\`\`=;_P#E70?VFO@4!G_A8FE\?]..
MMG^6EUZ__8&A?]`?3/\`P!MO_C=8OB'_`(0OPOHVHZ_KUMHVEZ1I5I-?:A?W
M%C#Y-K:VZ&2::0I"Y"H@+'"DXZ`T`>;_`/#3OP(R!_PL33<GD#^S]=Z>O_(*
MX_&G_P##3/P*_P"BB:7_`.`.M_\`RKHT'XI_!#Q5KOAKP[X>U_POJVL^,-"D
M\2:!IUI;V[W5]H4/^LU.*(VX9+7MF78Q[+7K_P#8&A?]`?3/_`&V_P#C=`'D
M'_#3/P*_Z*)I?_@#K?\`\JZJ7G[5/[/NG6[7=_\`$[1+*V6183/=6VL01>:[
M!$BWRZ8JF1V(5$!+,3@`U[4=`T+!_P")/IOX6-MG\/W?6N4\2_#CP?XNTPZ/
MK_AG2]0T\7EK?+!-:P@?:+.99X)LHBE9(I%#*.AQZ4`<0/VG?@03@?$72S\J
MOQ8ZX?E?[K<:7T-/_P"&F?@5_P!%$TO_`,`=;_\`E77J\7AS1(E"KI&FB-46
M-56QMMVU```Q\OGI[]:L?V!H7_0'TS_P!MO_`(W0!Y!_PTU\"O\`HHFE_P#@
M#K?_`,JZ3_AIOX%8)_X6'IN`0"?[/UW@GU_XE7%>FZU;^%/#^DZAK>IZ=I=M
MI^EVDU[>3G3XI/*MX$+R/LBA>1B%'"HK,3@`5\TZ9^U?^S)J]YH6FV_B#1XM
M1\0ZD=)LM/N]$N+:YBO!((HTOX9K-'M%G8K]F:95$FY2#@T`>E?\-,_`K_HH
MFE_^`.M__*NC_AIGX%?]%$TO_P``=;_^5=>N+H>@/]W2-,/`/_'C;]",@_ZK
MN*?_`&!H7_0'TS_P!MO_`(W0!XW/^U#\!+6&6XN?B3H\$$"-+--+::S'%%&@
M+.[NVF!550"220`*9:_M2?`*]@@NK3XDZ1<VUS$L]O<066MR030M]V2.5-+,
M;*<<$-S7JVK^#?"^LZ7?Z5?Z!I-U9:A:S6EU;R64`2:"="DD;%4!`921P<U3
M\/\`@;PSX=TG3]#TO0M.MM,TRTCL[.U-K"\<-O%GRD7=&3E<X^8DX[T`>>_\
M-,_`K_HHFE_^`.M__*ND/[37P*`R?B)I?_@#K?\`32Z]@_L#0O\`H#Z9_P"`
M-M_\;I&\/Z%@_P#$GTW\+*VS_P"B^/K0!Y`O[37P*8$K\0]-(!(/_$OUSJ.2
M,?V5DGZ4T?M/?`=B0/B+IF1U']GZZ"/P.E9KF_&'[0O[//@J\U[3=7U_0IM5
M\,75I::]INF:8=2N],FO$+PFZ2TLYC&%C!=WR1&H.\K7LVB1>%/$>EZ7K^D6
MFEWVFZK90WVGWD=A`%N[2Z021.0T0;YE(/*CW%`'`?\`#3/P*_Z*)I?_`(`Z
MW_\`*NC_`(:9^!7_`$4/3#]+'6S_`"TNO7_[`T+_`*`^F?\`@#;?_&Z:WA_1
M"K`:1IH.#@K96P/3L?+[]*`/%++]JS]GO4D>73_B?H=[''-+;R26MKK,Z1SP
M-LFAD>/3&6.2-OE='*L#VJ]_PTS\"O\`HHFE_P#@#K?_`,JZ[/PM\-?!WA&W
MO;30?#.DZ=:ZC?W.JWL45M#MN-0O'WW,TBLAR7;GJ!GC`KK/[`T+_H#Z9_X`
MVW_QN@#R#_AIKX%?]%#TP_2PULG\AI>:4?M,?`PA3_PL'3@&SM)T_75!QUY;
M2@.*]<?0-#VMC2-,4XX/V*W&#]1'D?AS7SMXD_:'_9]\*>.-7^&VN:[H$7BS
MPYHA\1:]IJV<4RZ/I^W,3W1$1\J:X!`BA/[R0L,+DT`=4?VF_@2!D_$33,''
M/V#7.YP/^87Z]^E._P"&F?@5_P!%$TO_`,`=;_\`E775>"M<\"_$#PYIOBGP
MQ8V%WI.IQ^9:O+I:VI,18J2T,]O'(IR#@,@XYR:[7^P-"_Z`^F?^`-M_\;H`
M\?/[37P*`R?B)I?_`(`ZW_32ZJ)^U3^SY+=W-A%\3]#EO;,1&ZM([;6)+BV$
MR[XC/$FFEXO,3YEW@<5[1)X?T0HP31M,+8^4?8K8<_7R^,=:Y^Q\`^$[#5M1
MUJT\-:+!J.K>0NJ7B:?`ES??9T\N+S28RI1%.!@#/>@#@_\`AIGX%?\`11-+
M_P#`'6__`)5T?\--?`K_`**)I?\`X`ZW_P#*NO7_`.P-"_Z`^F?^`-M_\;I#
MH.AJ,_V1I8QSDV5L`,=S^[H`\A_X:9^!>,_\+#TP_2PUP^_0:632?\--?`O"
MG_A86G8<;E/]G:]@KZY_LKC\<4[6OBS\#/#E_P"--+U;7_"^G7_P]TNTUWQC
M#+;1K)H6F:AQ9W=T5M2/*N?^69B:0GH0*RO!_P`:_@GX[\92^`?#>H:9>^(8
M-.BU6.UETB2UM+VPECCE>33[FXM8HK\PQS1/((&?RPZ[ASP`:G_#3/P*_P"B
MB:7_`.`.M_\`RKH_X::^!0_YJ)I?_@#K9_EI=>O_`-@:%_T!],_\`;;_`.-T
MR30-%V-LT?3`V./]!M_Z1YY''%`'C$G[5/[/L5[;Z=+\3]#CO[N&6XM;)[?5
MUN;B"#_6S0PMIHDDBC_B=5*CUJW_`,-,_`K_`**)I?\`X`ZW_P#*NO0)?`?A
M&YUJPU^Z\+:+-K.G6T]G8:BVGVYGM+*YP9K:*1H_DC<@%D`.?:M_^P-"_P"@
M/IG_`(`VW_QN@#R#_AIKX%?]%$TO_P``=;_^5=*/VF?@6>GQ#TSG_IPUOZ?]
M`NO73H&A@9&CZ6,=S96V/_1=><^+?'7PE\&ZQI_ASQ'>>'M-U[5]*UC6]*TR
M:QC:[OM,\/P_:=7NK5(K=C(+&'YY$#"4\;$?-`&,?VFO@4#@_$/30<D8.GZZ
M,$=0<Z5Q^.*7_AIGX%?]%$TO_P``=;_^5=<+X+_:9_9T\?:YHOAOPWJ^G:EK
MNOWUU80Z6=!N(]0MKJU&5&KP26:MI9N$(>V^V"'SXR'3<N#7TQ_8.@YV_P!C
MZ9GT^PV__P`;H`\@;]IGX%%2/^%A::WLMAK98_0#2\DU\X_%_P"*_P`//B3\
M1?V:-%\&^*;/5]5M?C;9:M)I\5OJ%O.^G6>EW?VBY7[;:6R,D6]=Y#EN<`$F
MONUM`T0*VS1],#8."+*W'./41YK'G\$^%;V_T;4[SP[IDVH^'[LWVBWCV40F
MTRY:+RI);694#([HS+UP1G(ZT`=A1110`4444`%%%%`!1110`AZ'Z'MFO`OC
MW\(]7^+WA73M(T/Q"/"VNZ!XDTSQ/HFJSZ=!JMJ-1TU+B.-+JSG8(]N\5S*&
M!!(?8>U>_44`>7_!_P"'R_"WX=>%?`B7\^J?\(WIPM)-1F@2WEOIY;F>[NI6
MB1F1$:YN93&JG"QA0,`8KU"BB@`HHHH`*:X+(P'4J0.2.H]1R*=10!Y9\6_A
MZOQ-^'?B3P-*]O;MK^GO9QW-S;&\MK:;(>&:2'>CL(Y%5M\;JX(!5@0*Y/\`
M9U^"%E^S_P##G2_`%E?2:L;>\U+5K_4BLJ+<:EJLBS7K1QRRSR)!O4>2LLKL
M!UKW^B@`HHHH`****`$.2"!P<'!]#7.>*?#]OXG\-ZSX;NS_`*/K.F7FGRRF
M))A&+N!X2_E2#8^W=G:W!QS7244`?GU\'?V%=-^$?Q=\,?%FP^)/C#5+G1?#
MFH^&[OP[J2VLNC7,%X"L+6@$8GL((`0RPPN(\CH<5^@M%%`!1110`4444`8W
MB*QOM3T+5]/TRZ@L=1O=/NK:QO;FW6[@M+J6)D@N);9_EG2&0K(8FX;;@U^9
M-E_P3Y\2:CXG\'^,/&'Q(L-5\2Z)XC.M^(-5M?#%O8MK7EWHNK=K=$N0MK<A
M%2VEE*2*80%2-2,U^I]%`$$<9C14Y.!&I8=2%7!)QS4Q(`))``ZD\`?4FEJ*
M8J(96?.Q8W9\#)VJI8X'<X'`[T`.\V,KNW@+G&2<?SQ_GI3%GA<[5D4GGCD9
MQUQD<_AFOP9^)/\`P64B\)_&35_#NB_!O7KOX5>#M,\>OJOB74]5T&RU#Q;K
MG@J[2QFL_#UM+<F?2[9+@E6DU&`--@&&-Z]`^"7_``6<^#/QET7PM=67PX\:
M>&_$_CS4],TKP)X-U:?3[C5/%MY>ZJVFZF=%FA$:75OHCJUQJ+A$:*##$>H!
M^U'FQC'S=2`.O4].W'XU'=P_:;6YM]\L?VB"6'S(6V2IYL;)OB?^&1=VY6_A
M8`]J@MS-+%;RSPR6\A1))("PD9'=`61G7`8QL2I[<&K]`'YD+^P'XC\-7'Q&
MO?A_\:M?MKGXD7VG2ZT/&6D:;XA6#3K>YDGO]/L9]D5TAU%)#;2W3.9$A^5#
MQ7Z$^$O#O_",>'=!\/(L`ATC3;6P'V6-HH0;>-$'E*S,ZH2I8`DX)QTKKJ*`
M"BBB@`HHHH`CE4O&Z@L"1@%3M8'V;!Q]:_.;X\_L(-\</&WB?Q%=>+=.T'3]
M=M4G2+3O#EM;ZX=9B2)(O[6U^"6.ZUG1U\E673KEE\IB2C9K]':*`/!/@!\(
M]4^"_P`.M$\#W_B&7Q3<Z<\SW&IS"2!56:0NL%E%(\I2WA!"B.1V8#@&O>Z*
M*`"BBB@`IK@LC*`#D8P1D<]<@\'BG44`?,/C+]G#2O%OBCXI>(I[](%^)O@"
MQ\#WEHFGVTB6Z6*RA+\[EQ).!)B/?G:0K#!6N9^%'[.'BSP%\44\9Z_XUTSQ
M3X<T?PI8>%/!NB/X<M['4/#=M:VT$-S.-2A<FZN-0,(:ZE=<M@#M7V)10`44
M44`%%%%`#),[&PN\XX4\9]LGC/I[UX5\2_A"_CCQ=X(\:V>H1:;K7@:Q\96^
MDF;3+>\ADE\5:*-+B>[\P9DALIE6Z:`_++MVMPU>\44`?EC\.O\`@GQXG\+_
M`!?\/_&77_BI%JOB]=5M=7\:ZAIF@'1Y/$TNF37+V$2B*[^SVT<T5PMI?1^1
M)OMK>)864Y-?J4`04!R=JC+\<\8_S]?QJ2B@`HHHH`****`"BBB@`HHHH`**
M**`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHH
MH`****`"FL<*QQG@_P`OQHHH`^$/$?\`P3P_8L\9>*O&?C#7_@'X-U/Q+X[@
MO8O$^I317R2ZHM^RRWK&)+Q;:TEG=%=Y[2*&9W!8MDUP'@;_`()H_LW>!?CC
M\+?C#X1\/#P_9_!K2=8L?AW\.[5%D\+Z!J_B%E&J>)8I;A[B_GU*ZC`15GE:
M*,Y<?,<T44`?IA1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%
<`!1110`4444`%%%%`!1110`4444`%%%%`'__V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@!4P(F`P$1``(1`0,1`?_$`,D``0`"`P$!`0``````
M```````%!@,$!P(!"`$!``,!`0$!``````````````$"`P0%!@<0``$#`@,"
M!P@+#@4#!`(#`0(!`P0`!1$2!B$3,2*2%%46!T&1T3+24],546%2(Y.S5)16
M%QAQH4)RLC-SHS1TM'4V-X&Q8S4(8L(DP8*#=D.$\"5%)A$``@$"!`,%!00)
M`P4!`0````$"$0,A41(3,00406$R4Q5QD=$BDH&A!0;PL<%R@B.C-&3A0C/Q
M8J*R)%)C_]H`#`,!``(1`Q$`/P#IU][#)MSO=PN0WEMH9LAV0C2QR)11TU++
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MS2<DZ<"=)TZN,L*`4`H!0"@%`*`4`H!0"@-*]W,;7:I-P(%=2."GNTV*O<3A
MH"AL/:ZO+`7$+H$)M],6H[:+@@(JX+L0MM:QM-JIC.^DZ'OU;KSZ0?>7R*G8
M97J5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZM
MUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?
M(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D
M/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/
MO+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=
M2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/
MI!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-
MACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZM
MUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?
M(IL,=2LAZMUY](/O+Y%-ACJ5D/5NO/I!]Y?(IL,=2LCX;VM[,!7-ZY!<&8Z*
M3T0\40@[JXY4P5*B5II5+1OINA>[/<FKG:XT]K8+X(6&U,"X"3;AP$BUD;&Y
M0"@%`*`4!SP[OJS4)//VZ4-K@M.JVP*BN<\NQ54D0D7;W.Y6D+;D93O*+H>/
M5NO/I!]Y?(JVPRG4K(K^IKUV@V6?;+?&ENW6;=!DFRVT\Q&$`B(VKBD<G=C_
M`/F'!$6JRMM%XWDS+9;MKJY2KA#=N+D*9;&(S\IHW&WD3G8N&("XRA`2BC.U
M47#;16VR'>2,^GKCJN^VV#-C:AW;DZ#%N20C7%YIB8"DTIH(JFU1(<4V8BM2
MK39#OI=AIRKYKZ)=VHLJ3*8MC\MNW,WAS(+9RWBR-@+"IOU`SXJ.Y<G=QPJK
M@RRO*AZU'>.T*R*Z[SB5-M\-A9=TN#:@VU&CBA$1IO4$GR$&R(@:S$F";.,.
M,RMM$1O)D0/:'J4(;=QEW&3%M,V,Y,LD]5!U)S+>3:+3:$XPJHZ"X.HG#[2U
M&AEMQ$[8;AK^Y29T"9/=M5UMR,G+@/&V^HM24/<FCK"&T6?<GQ47%,-O"E3&
MVV5E>2((>T'5`1&YTR?)B6^=&6;8I*DV[S]G.TV)"#:$;"DLIG8\@X9MOBE4
M:&6W4>NNG:(MR?L@A++4<-I)<^T<XBHK$0L$"0LA5W!YE7#()9O:J%!C<7$M
M5KZWW2V0[G!U%O(4]AJ5%<42!2:>!'&R42#$<1)-BU=66U4S?,)=AL^K=>?2
M#[R^14[#'4K(^K+UM&%+0[,%TIRXQ[KM162!%<(,,NW,(8)L]FH=IUH65]-5
M.BUD;"@%`*`4`H!0"@%`*`4`H""US_25S_1?]R4!"Z7_`*=M_P"B_P"Y:[;7
MA//N^)DI6AF*`4`H!0"@(76U[E6+1]YO40`<E6Z&[)8!U%5M3;'%$)!45P^X
MM5DZ(M%5="/UIJ>\V:ZQ8-KB!,61!G2B%1(C%8C\-K>((JBF+3<MQTVQ3,>1
M!%45:JYLF,4SSI_4T]RVW"XW"YVRZ08;*NE)AMNV]QET45>;28LER2;1$FW$
MR$DX,G=J%-DRB>]':KNMVBJ%TMCD2Y`\V#[`CNU:9DQ!F-/.M/$+@@BF4;,B
M%F=`EP%,R!,9U(E&AFU/J.ZVN[6&)%A"<.Y7"/#FSW2XH"^CF#;("N8G?>L5
M4L!%,/&5<!3FT(Q30UAJ.[68K4D&"+[,RX08DR8\2(TRU*F-1B0!%<YO%OL1
M38*(BDJK@@%,I-$1BF1EWUA?8UQN\B,D5+18)T&W3(CC;A29)SAC%O6I".`#
M*!SX>*3)XY%VIFXM7-U+**H>=/:ROLZ;89$L8JVO4Y3`@16FW`D1.9MN.8O/
MDX8/YT95.*TWACCMPP6%<=27!8]QI:P[1+Y8H>I=0,LQ7K+I22U#EVPP<25+
M-UJ,YO&Y:.;M@4Y\*958/Q%V\;BS*;6(C!.BS,DS6>JK;<(UDEE!DW*[#!<M
M\YJ.\RQ'2?(*.B/1R?=-[=J&;$76\>#9PU#N,*">))1]9SHMENKEQ9:E7.TW
M5NR(L="CL29,GFR1SRFL@F&U.:`GQG%%$4DQ\6K*;*N.)BU'>];::TG>+I<'
M;;,?B-LN0Y3$>0T`DX^#1MN15>>-Q`$LZ$#R*2\7*F&*Q*31,5%LC+5VDW,Q
MEKF8OS(O,P&)L>%,L[35SDR&X[,.0W-.0YQM^CAN`GO8IM%5(:JKK+2MHN5D
M#5#1/-7QZ%+3`2CRX33L7%5Q0FSCNNR?%P0D-'=N;#*F7$M57M,G3L*?$[0;
MNYJ>3!*9;)#;=]*RA8&`-+H+&\1OGIGOS][;0LY_^.B94\9.&LMUFNVJ&U*[
M9=*QQQ5B7F)^1&:%U8D1'3AO$Q)W;DV1&:-&B0,<#VHX.7%1<1NSNHJK3)(.
MTG3+EMEW%@GWX\=N*\P+;>+LMN8`DT4-I51Q[QE%<$QS"2)BJ5.XAMLB7NUR
MTRCYI:A1+B$ZWL*S()AS/%E7%B$\Z@QGW3:($D)@+Z`:$J8@N!(D;E2=O,^L
M]MNBGV9;L=7I`L-[^*+!1'7);6]!K,RVW()QOC/!LDBTNW@Q0D1NH;3)5>T*
M"*E%.UW`+ZCHLCIY0C\])3:-\2%4?6+EW31GM?QP%=F."*W2NVS1^N'2`W9N
MV/*]&D;QN-,20L=DXLIU4$8[K!O#),LQBF=AIQM<V*&HXJD[JJ3M.A>%147!
M>%*T,SY0"@%`*`4`H"-U+_3]P_0%6=WPLTM>)$MH/^D;=^(7QA5Q'H$_0"@%
M`*`4!0='?[&/Z=_XQ:[+/A.&_P"(FZU,2FZ]TK-O-UL4YFSVV_1K:,T9%MNS
MB-M*4H64;<'&/,%2#=%PAW>&LIPJS2$J(UX5AU59I<N79[):Q:NT6*P_:PFG
M%8@K#%T$%@FX9H\)H]F_-MX+LP7'&H46F2Y)HL>E[5+LEEMEA)0?B6JWQ(C<
MY%43==8;W3BJQ@2-CE;$D7>%CBJ?@XEI%4P*2=74@[A%UD]JI9\VV0IFGK<N
M\M;0SG!=`@%5*2Y&YJ0NR-F#0[U!#N<;C51IUJRR:IAQ,-V<UO?XEE?B6:(5
MCEPV9MTM<R>[#?<?=`7$AO81'_>&\??1P17%XI8!G!PZM!47:0Q]F6I)M@MF
MGY3D2+&T]`>@V^<TX;Q3%<W.4G6%;:2,G_CIL1QSA]K;7;9;<7$L+/6&VW"Y
M:EN5N;Y[?)%IMJVN"^<H6&0D&P4E7U994D%)A&0[I$1`\;;B,Q36)5M/`KY]
MFNI9EEM=FE'$C,Z:M_J^V2VW3>*=E=B."X\TK;7-<WJ],40W<,_"N7C-#+:U
MQS-U-,ZW#6%RUHD&WE<;Q!"U/V=9SJ-,--$A#(&7S55=(E3#=[D</=K4*#3J
M-4:4+GINS^I=.6JS;[G'JN%'A<XRY-YS=H6L^3$LN;)CABN'LUK%45#*3JZD
MC5B#2G_M=M_>"_AW:K+BB\>#_3M+A7`>B*`4`H!0"@%`*`4`H!0"@(+7/])7
M/]%_W)0$+I?^G;?^B_[EKMM>$\^[XF2E:&8H!0"@%`*`TKW9X5ZL\VT3D(H5
MP9./(0"4"R.)@N4DX%J&JDIT=2"#1EU>E+/NNI),VYLL.1[;-9CL0RC(\XTZ
MZN5G8[G*,UBA[,J*/`2UFK;+N:R-9SLWYZX\]>[P[<WY2LM3%2,Q&:?AMN[X
MXKS+7$,7B\<UXV&RHVB=W)&];-!6>RWIFXZ>0;.PH&W<[?';%6YJ+M9)TC52
M$F"S*"C[HD[JU90H\"KFVJ,D[U8V;L5L)UXVO5D]FY-Y$1<YL"8H!8\`KO-N
M&VIE&I$94-"YV2ZWBY2H\]T6K)'D6F?:5:0%=61!D+)D`YW<IDTT*8]S'"H:
M;9*:2[S!<M"MSKG*?2XNL6RY2(\R[6L6VR21(AHTC)H^OOK2(D5K$0V+E_ZE
MHX584Z(QVS0:6R5%>:N+LF)9TDEI^W.-M@,5R4!@>=X??'T5'"3WS@QQ[E55
MNC)=RJ(USLUDWRSE%U'<#"/?&HLC5MGC@UNY%Q:89!PVI2>^-!GC-X"'%XO_
M`%+3;;XD[E'@;A]G)R3YY<+T_+O$=(XVNXHPRRD48CBO,IN`][>RF2JN?AIM
MC<[B2AZ,@A:)T"?(=GOW.3S^?/P2.X4L4;%M]D6N*R;7-VE#)P$.;AJRA@5<
M\36E:*GW&SS[=>M02K@4W<"+R,LQP:".^+XY6&_>U,B#`C7;AL[E1MOM)UTX
M(V[GHZV7&Y7":\XZ(W-MCG##:Y<DF(>>++8<\9IYG%<%'A7!5VBE-M$*XS9L
M=HNL$GG;I>7KQ)=00$C::C--@&*H@L,\3.JDN8^%4P3\%*M&+7$B33%BTY!L
M[]PD-8/2+A.D7`WS`$<`I*HI-":)FR#A@E(PH)2J0;O9PR$6$,&Y%&GP7+@3
M,UV,Q+3=726LQ]I6'D5O\X@()^,B#_U+57;+*YB;DO0-FERK5(D&ZZMKCE&4
MC5"=D#E7=$Z[L)#8,S<;4>`B6I=LA7&B'8[(X+<R'*=NTEXH`1V8S>Z9`$8B
M3HLYD%043,>:$@&XO&-"Q7:B5"MT+.Z9&^RJ,%K<M'K9Y+6#;+%OC-1V&E89
M8>;=`7'`3-))$8$4-S:FU>%:A6QN]Q(W?0HSM02=0Q+F];[PX;#D5\6FW@8)
MEAV,?O3G%<WC4@D7-XJ[4J7;(5RBH:T7L[./<BFI>Y+G.G@F79'&6"?DR@$!
MSA)5-[';RLMCN6^*@IE38JT5MU&YA2A<5VK6IF*`4`H!0"@%`1NI?Z?N'Z`J
MSN^%FEKQ(EM!_P!(V[\0OC"KB/0)^@%`*`4`H"@Z._V,?T[_`,8M=EGPG#?\
M1EU1>GK/:>=,-"]*>D18,47%5&T?G2&XK1.9>-D%QY"/+MPQPVU>3HC.*JRN
MZIEZVTQHV\W$[PW<WV1CK"EK";!]MQV2VRX",-^\NCD/$,>,I<.S"LGJ2+QT
MMD1:M=ZG;&7QY%S:YU&M34B[01M3D>YS)+4=ELF&L%=807=XX2;=B(/#58W&
M7E;1?-/V_4,5UQF[W0+NP:@K$E8X17A)55#`@9]Z4$3*HKXV*ECLPK552=3%
MM/@4/LUUS?;[,M(NW=N]%/;D%>H;45N.EJ5M"5E<[:(I[PT1OC*M9QFZFLX)
M(V)W;7;HK;9G:G6ED/RV(A3)+45M[U?(*/),'#0D41)6\NSC9B1/S959W"JM
M$K]:%H*"_):A23=W<)^UP"06Y4]N<**"QVBVXB:.-JA<)`53N$;3(>W=K[%W
MUI9-/0@&,<R1*62WO&Y!.1&(3[F)*")N'!>%K$%Q7A3N+4;E62[=$V>8O;M8
M9D67(AP')0MM`_`!E]LB?;<?:8'?;$2*2K(!4%Q?=)^#3=)VB8#M"N3EW>T^
MUIMX]3Q&AE3K5SN.@M1#5!!Y)*^]FI$N&1-M%=9#MX5J8+#VO6.\ZD"RQXKK
M6^==C,FZ2)(%]A"WH2(>&\802:,<Q+ABB>Z2IC<JR)6Z*I>ZU,S2G_M=M_>"
M_AW:K+BB\>#_`$[2X5P'HB@%`*`4`H!0"@%`*`4`H",U-;I%RL,V#'R[]]M1
M;S+@F.*+P_X4!3K9+O%IALVZ=99BN1P%`.,"/B2*JKM(%RHOM8K6\+R2HSFN
M6&W5&UU@?Z&N?S9?#5]]%.GD.L#_`$-<_FR^&F^AT\AU@?Z&N?S9?#3?0Z>0
MZP/]#7/YLOAIOH=/(=8'^AKG\V7PTWT.GD.L#_0US^;+X:;Z'3R'6!_H:Y_-
ME\--]#IY#K`_T-<_FR^&F^AT\AU@?Z&N?S9?#3?0Z>0ZP/\`0US^;+X:;Z'3
MR'6!_H:Y_-E\--]#IY#U^_T+<_FR^&F^AT\B(NG:1"@7:%9O4]TDWB?QV;<Q
M'%7T81<IR#$C'(R*[,R\*[$Q6F^AT\B7ZP/=#7/YLOAIOH=/(=8'^AKG\V7P
MTWT.GD.L#_0US^;+X:;Z'3R'6!_H:Y_-E\--]#IY#K`_T-<_FR^&F^AT\AU@
M?Z&N?S9?#3?0Z>0ZP/\`0US^;+X:;Z'3R'6!_H:Y_-E\--]#IY&G==:A:XJS
M)EFN@0FU_P#*D\VP;8;P55>=523!L<.,7X/C+@*$J-]#IY&X.H7B',-FN2BJ
M8H21E5,%X-N--]#IY#K`_P!#7/YLOAIOH=/(=8'^AKG\V7PTWT.GD.L#_0US
M^;+X:;Z'3R'6!_H:Y_-E\--]#IY#K`_T-<_FR^&F^AT\AU@?Z&N?S9?#3?0Z
M>0ZP/]#7/YLOAIOH=/(=8'^AKG\V7PTWT.GD.L#_`$-<_FR^&F^AT\AU@?Z&
MN?S9?#3?0Z>0ZP/]#7/YLOAIOH=/(T[M<;K<83EOA66;O98JTIOM*T(XIL7,
MN(]]4JL[R:HB]NPTZLNVG[<EMLL.%@J*RVB&A*BJA%QB3%-GC*M<YTDA0"@%
M`*`4!S:WAJ#3SKL"9;9$N*3AN,/Q1WJ(BKW$%/PEV\947VJVMW=.!A=LZL49
MKC/8N4)V%.L%R?BO)@8+',5V+BA"0D)`0KM$A5"%=J*BI6CO19DN7DB#.R-2
M;;,@W)K4ETY[N!<DR@;W@-QGA?;;;%EMEE$W@XJ2MJ:XX9L,,,]<>\OM2[C=
MGQ+9/N$^;)L-U([FPVQ.:1@A$UCDI1WD)%WC;K.8D;-LQPQQ\;!4G7'O(V9T
MXHR6(Y-J<=?=8U!=I;V1"DW!H")`;55!L08".R*(1DN.3,N.TE1!1)5U+,AV
M)/(S:?D!8K+"L\*T7<H<`-VPKS"D>&*EQE3*BKM]BD;L4)6)-]A4=52K'I'2
MZWHH^H[4W9BDDERAML))1NZ34>?959(&PK9R#`MHYDRBB%PYJN<2RM2[B>>M
MUFFG;)#UANSPP(SD9D'6C=WK+X9<'S-3=<4$55`L^(J1+W:EW(]Y"M361'0M
M'V>+J"SWY8.HI,ZQ-/1;8+XH3+<9YK<HQNA`1R-!L!4P)?PR/9A"G%/M)=N;
M5,#WU7@+;EM;L?4CMJ;%IJWV\Q%&8;+#K;K;3`B`J0IN`'%Y7"04V$BJ2J4X
M]XVY=QGN=CCS-0S-11XVH;9>)S34:3*A--(JQV47!E!>:?%!(L")43-BB8*B
M;*:X]X5J5*8'NS6B-9Y#7,8FH@MD8S=B64D4H;3SN97'<53G#A&3ADJ//&.8
ME7#%!RRIQ3[1*U)Y%BZP/]#7/YLOAJ^^BG3R-1RX7V3,:E#9906^">=S,VJ/
MFKC9-CE;7+C@IKCEQ_PJKO8]Q=6*)YG1:YSI%`*`4`H!0"@%`1M\U%:[)'%^
M>[E0URMMBF8R7NX#[7=H"#^M+2ONG_@E\-`/K2TK[I_X)?#0#ZTM*^Z?^"7P
MT`^M+2ONG_@E\-`/K2TK[I_X)?#0#ZTM*^Z?^"7PT`^M+2ONG_@E\-`/K2TK
M[I_X)?#0#ZTM*^Z?^"7PT`^M+2ONG_@E\-`/K2TK[I_X)?#0#ZTM*^Z?^"7P
MT`^M+2ONG_@E\-`/K2TK[I_X)?#0#ZTM*^Z?^"7PT!]'M1TJ1(.=Y,51,5:7
M!,>ZNV@([MJO2Q.RJ\2HL9VY,36FXCS43%7RC37!CO&PHH7O@MN$0*J*F*;4
M5*`Q=D]JN;;UYO5WL;L"ZWA\GY%TF/(<J0B&8BT,?C%%CLBB(RTKA8"NU<V*
MJ!T.@%`*`4`H!0"@%`%1"145,478J+P*E`?G>]W/7&E]9Z:?73TZVZ:M5Q-M
MQME!N3+46>V(*U&=;R*+69,$;5O%O@$LF`T!W&_:JLUC1OGSJH;J\1IM,YX)
MPDJ=Q.Y0$1]:6E?=/_!+X:`?6EI7W3_P2^&@'UI:5]T_\$OAH!]:6E?=/_!+
MX:`?6EI7W3_P2^&@'UI:5]T_\$OAH!]:6E?=/_!+X:`?6EI7W3_P2^&@'UI:
M5]T_\$OAH!]:6E?=/_!+X:`?6EI7W3_P2^&@'UI:5]T_\$OAH!]:6E?=/_!+
MX:`?6EI7W3_P2^&@'UI:5]T_\$OAH#-#[2-,RY;,5HW4<>)`%3#***OLJJ[$
MH"T"0D*$*HHJF**FU%1:`4`H!0"@%`*`Y;_R>_L9J?\`%A_QS%`=,A?L4?\`
M1A^2E`9J`4`H!0"@%`*`4`H!0"@%`*`4!1KK&:G:[=&6F^;@Q&W(S9891)PL
M"54PV\'=K6U%-F%^32P)#F4'Y,S\&'@KJTHX]3S',H/R9GX,/!32AJ>9K7-A
M6+;+>M]M8F3VF7#APR1MH7GA%5;;5PDP!#+!,R\%0XJA*D\SF5SU??[98;A<
M(DB!?9D3<))M;ML&TSX6^D`V#CL60[G)MT25$4LOX)#F''#"INE7,LL[M$TK
M!U4QIV=;TAR7W6HZ$\L1'$??P1L!BY^=.`ID@[YMLFN%<V"*J74ED4TRI6IJ
MO=J6E8T=N5.LS\.#)A.72!.=98W$B&AL-LNBX)*@*\4L.(YE)M.,Z@"J*LZE
MD-$LS$]VC6BXZ#U'?;#%C!<;$UB;)\UF-"X:(3?OL0W6'$4<<4!S$?PL*KJ3
M6`TM-)LF9^H(=DN-^CWF(R80VQG69MEIL7)48D%GFK6?+O922L`5!V>_,CPE
M5NPC%THS'*EWF-%T_9CCP%U3>&G2?F;C"&V41L77U1M4WBJ6=!`?NJJ[$QA]
MB"[77`A[K?-1V:X%:Y*VZ?)F#$3G+$-`;MCT^>Q!9;<',2R,PR''6\^[4T97
M8F*Y8I0LL<<3Q+O>L6#G6J-#C7"9:IG-G[I'M^??&Y#CRXS)0VR-6!=6231O
MYU%O)F+QL$AA4XU-ZQ:D>O\`!GOP5M4:XB@2K?:'!!PUALKE=-XA]]`9#B$V
M)[OB89D0L:E8D-4S++IJ=;[]I^WWINV)#9N3`26([X,$XC3J9FB+=*X''!4+
M#'9C@N"XI6D4FJT*2;3I4D^90?DS/P8>"K:45U/,<R@_)F?@P\%-*&IYF"=;
MK><*0)16E%6CX`%%V"JIM1$6HE!4+1DZ\3WV8/O.Z5;1PU)&G3;;1<.**8*B
M)A]VN$]$MM`*`4`H!0"@%`*`4`H!0%"&*Q-UA>9,L=^Y#)IB,AHBB`$WF5,,
M-NU5X?9K>S%-G-S$FJ(E.90?DS/P8>"NC2CEU/,<R@_)F?@P\%-*&IYCF4'Y
M,S\&'@II0U/,<R@_)F?@P\%-*&IYCF4'Y,S\&'@II0U/,<R@_)F?@P\%-*&I
MYCF4'Y,S\&'@II0U/,<R@_)F?@P\%-*&IYCF4'Y,S\&'@II0U/,<R@_)F?@P
M\%-*&IYCF4'Y,S\&'@II0U/,<R@_)F?@P\%-*&IYCF4'Y,S\&'@II0U/,<R@
M_)F?@P\%-*&IYCF4'Y,S\&'@II0U/,B]46V"=@FKN`!6VU=$@$17,&U-J)P>
MS5+D5I-+4GJ1;[#_`+';OW5GXM*XSO-Z@%`*`4`H!0'+?^3W]C-3_BP_XYB@
M.F0?V*/^C#\E*`S4`H!0"@%`*`4`H!0"@%`*`4`H"ER/Z\N/[BQ^6M;6.)S\
MSP1(UUG&*`Q2HS<J*]&<(Q;?`FS)IPVG$0TP50<;43`MNPA5%3N48*C<NS7U
MO'=;O6H+A<7MT3,*2XW":.*CCC3KA-HQ':`U-8[?YT2X-F&*UGM]YHKE.",T
MOLZ@R9B2#N4W<\_8O#D$#;!EVX,&V9/N90S%O=RB$"KD'Q@$2P6FV'<94;5H
M5QZ\PK9J.4U;@BV]R%8[/ZT:EOHQO6'HO-FA8A[(AP$7>&#IN\#A*(85FEC1
MEW+"J+@5@MEVL]\TU-U&]=YTUO=W5TGHW.6`3!$_\9@098P[OO29E\;%:NDN
M%2E6G6AOR[=IO5<BW71F0Q<!MLDG&W8ALR&W"RYECN$.\Q$7=T_DQ_.-ME^"
ME65']A&*-"_%"N2P]2V6ZPGG=/%(!QQ9+*Q4;E@+;Z./IO`:<`10@4T4?="N
M.RDZ/%$QPP:XD5'TI8K?8G#GZT<E6FX2!EQ+C+<MC8K<&WAD,RPD@RWOW6SC
MI@+A&&4<JBHC@D)*G$ER=>!/LZ,:;M%V@/W"3(EWQ?\`^VN;@L"^ZFZ".HY&
MVP8#_P`=M&N(VFSC>/QJOHP*Z\2/D:!:@R.>V)<7@<,X,&4:K$BOR64B2)F(
MISATN;[-T3N5>YE7C5#MY$JYV,G]-6,+#8(%E;E.S&;<R$9A^0C:.JTTF5H2
MW0-AQ`1!QR[<,5Q7%:O%45"DG5U)*K$"@,4O]D?_`$1_DK42X$KB:_97_2W_
M`.PY_D->>>F7"@%`*`4`H!0"@%`*`4`H"D0?ZFU'^G8^)KHY?M.3F>PJFJH5
MR]<7"Y//S9%MCB",2+7/>96UF+`G_P"9;VG66Y+8EC(,W"S9"0,A#A5IMIE(
M8HBM-:NU;%[,M,OH^U>K_>G'QAOJTX\Z\TVKKN=(Y/Q]\61M27W]I!#@1<N5
M84VD3*"<C#9>U_45YLCE\BQ(#,*+>(VG9#$@C1UV2X^R#DI@FW3;45;?XL=%
M(D\;>D(X+*N,.TE[JDWH?7^IK_=X)2K.L:Q787C@R2`&LB,HI#@ZLETI>=!_
M`CMY?&7917&R)VTD5C4M_OK/9E`FLW&2W,.;J8#D@\8N*,:)>B8%31<<&B8;
M4/<Y1PX$I5T]Y,4M7N_8=!U7<IT>U66-&>)@[S/AVQ^4/YUMJ2!DX;2KBB.<
M3!"5%PQQX<%JTY-(S@N)6-1MS+#S^79KU<B<M,&:_J.Y27')S##(Q'%B@W&=
M-(W.0>W1Y0$2(!7>%B?'JW1X,O%5XHPQ+9K$IMQTZT4B'(;9@W!RQNW>7,-^
M.Z[)9/=WEU$DQ5=-H>(V&`[O8OOI85J\<2V&#/&D=4C/=?B7VZRY8R!8L\:X
M0R-B.WOS4&'R<;-LT=FNX`R>[4QR+B0H52I9D.&1<]#W2\W2S\[N#K3H-O2X
M0F+:@Z;D"=(BD\XHKNO?6V6RR@`HA9L.*HB.L&9S23*5VKS+OI^"]J.TW22I
M.2AB.3TF$ZRRXX[NN8#;A1(J8#Q5?7WT%VKF+;64W3M-;:KQ1[OH72W:ID:-
MM<J?)BO.6\XMO>N$H)#YOQ[DZ\'K0R>EQPPMX.)E547)DP1'#6E613M?Z<#:
M9N5S?TM9K>[-D"4K4QV*X*#SB2&V&G9(%%"8A"^XK2L"'.<1<<PS+AF5*:G1
M8C3B\#5LW/;OJV?I.5<9Y6NT+="A@S-DLRL8KD$6=[*:<"2\@I+<V.&6.*8\
M`X$\5B&J*M"+M.H;_<M(2-82[C)];VUS3[,<FW39B9;A%MCLG>Q&U&*Z1G/>
M7%QM53%,,,HX-3)TJM/:=8U.B)8KFB<",.(G>K2?A,K7B19;%_L=N_=F?BTK
MB/1-Z@%`*`4`H!0'+?\`D]_8S4_XL/\`CF*`Z9!_8H_Z,/R4H#-0"@%`*`4`
MH!0"@%`*`4`H!0"@*7(_KRX_N+'Y:UM8XG/S/!$C76<8H!0"@%`<WUC=-$2-
M3CID9<.W7V3)AR[C<G%$9+9-N-%'884N,3SZ,@*@*H(MJJEM,<V$Z5-H5I4K
M6J)VE=0-76!H]V.S)LT2>S%A0UPFW!]QO(]@">^$RRBJ0F2KF+:.S;5/87BF
MN),W"X6>XCKIS2KS+T&[6-NW6-;=@+<BZ`Q<G7&(^[RH4A&R;)<O&PR^U5JX
M.F16CJJY_`B[I*L,V_P+M9U8>TM`&TC?I4412$V;4F04A).5$#$0,%/,G!AC
M573$LJT[S+:)NG(>K)-[NYQFM&3'+J-GF21%;<9.+;-SN$)%;Q)&)&7*GX)^
MW4JGV$.M*=O_`%.A]GL:?%T'IR-<6W&I[-MB-RVG\4=%T610Q/-MS(7#C6\.
M",9\66"K%10"@%`8I?[(_P#HC_)6HEP)7$U^RO\`I;_]AS_(:\\],N%`*`4`
MH!0"@%`*`4`H!0%(@_U-J/\`3L?$UT<OVG)S/88KIHS2MUN+5RN-L:DSF<N1
M\E,5XBXCF0"$3P_ZD79LX*V<$W4P4VCYU*TEZH*SI:F$M9/%)YH.801XBS$8
MX$A!BO"@JB4T(:W6I7Y?9/:I%[28#L>+:T=!Y+;&A-M.(0/I+XLE#Q'-*'>*
MJ-XX*H>+5=O$NKF!9H&EM.6ZZ/W6#;F8]QDXJ](!"Q7,N)9455$,>[D1*LK:
M11S;/C^E--/V\+:];6'(#9R'`C*BY$.8+H221,>%T93J%^.M3I0U,R7JQ1+M
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M#90+3:V9+`VH47<NC)1M$(RQ0\S>ZQ$L<VU=M0[9*FS+)T)HZ3;8UL?M+)P8
M9*49G$Q4"+A7.)(98]W,2_>J=M$:V9W]):9D76/=GK8P5QB"(1W\%'*(8H*9
M!5&URX[,1V;/82FA5&ITH9=2?T_<?W<_\J7/"R;7B19K%_L=N_=F?BTKA/1-
MZ@%`*`4`H!0'+?\`D]_8S4_XL/\`CF*`Z9!_8H_Z,/R4H#-0"@%`*`4`H!0"
M@%`*`4`H!0"@*5J^%=K?>6[];F#EM.MC'G1Q3,6`KQ%$1%23AX=OW,*M">EE
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MWCZ/R^2YZ*G4=PZ;O/AZAU!+`XL>PR!??%0;)Q#0454[JD`)P>R255WZK@2N
M6QXEOT=8W++86(;J_P#D*JNOICF1#+A1%P3@PK`Z2;H!0"@%`*`4`H!0"@%`
M*`H>HH]YLM_>N<&(Y.@7)!YPT"*1B\`X)XHJHIE39P]WVJO">DSN6U(TNM=X
M^C\ODN>BK;J.XQZ;O'6N\?1^7R7/14ZCN'3=XZUWCZ/R^2YZ*G4=PZ;O'6N\
M?1^7R7/14ZCN'3=XZUWCZ/R^2YZ*G4=PZ;O'6N\?1^7R7/14ZCN'3=XZUWCZ
M/R^2YZ*G4=PZ;O-2X:_FP'(3<BPRQ*X21AQ]A[73`W$QQ;39E:+@QIU'<.F[
MS;ZUWCZ/R^2YZ*G4=PZ;O'6N\?1^7R7/14ZCN'3=XZUWCZ/R^2YZ*G4=PZ;O
M'6N\?1^7R7/14ZCN'3=XZUWCZ/R^2YZ*G4=PZ;O'6N\?1^7R7/14ZCN'3=XZ
MUWCZ/R^2YZ*G4=PZ;O,<F?J*^LE:HUH>AG*XI2'D)&Q#\+,I-IPI[&WV*I.]
M54+0L4=:G1+9&<BVV)&<5%<89;;-1VIF`4%<,</8K$Z#9H!0"@%`*`4!RW_D
M]_8S4_XL/^.8H#ID']BC_HP_)2@,U`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@,<F2Q%CNR9!HU'8`G'G27`1`$S$2K["(E`<_:[1;EJRS1HVC@;AWJYL&\DJ
M=@;,)K,8MNF"*BNN.(&9MM.YQBXJ;0++HO1EKTG:5A0R.1*D.+(N=SD+GDS)
M1[7'WSX2(E_P1-B;*`GZ`4`H!0$??[!:-06B3:+O&&7;Y89'F3[Z*B\(D*[1
M5-J+0%%CWC4?9W;7;;>W3U'!;!SU!,$D&:60<68<K,O&,_$![#*JX(6"K0%W
MTO?H^H=-VN^QAW;%TB,RP:4D)01YM#R$H[,PYLJ^W0$G0"@%`*`4`H!0"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4!3.T7_<=$__`&)G^!ET!<Z`4`H!0"@%`*`4
M`H!0"@%`*`4`H#EO_)[^QFI_Q8?\<Q0'3(/[%'_1A^2E`9J`4`H!0"@%`15V
MU18[2^#%PD[EUP=X(Y'#Q'%4QQ`23A2@-+ZPM(?+_P!4]Y%`/K"TA\O_`%3W
MD4`^L+2'R_\`5/>10#ZPM(?+_P!4]Y%`/K"TA\O_`%3WD4`^L+2'R_\`5/>1
M0#ZPM(?+_P!4]Y%`/K"TA\O_`%3WD4`^L+2'R_\`5/>10#ZPM(?+_P!4]Y%`
M/K"TA\O_`%3WD4!%:IU!H74FGIUBF761'BW!O<O/1!>:>055%7(>[+#'#!=G
M!0%<TEIKL3TO+@W""X_(NT!'$8N<QR:^]F>#=.&J%[UF-O`54038B>Q0%X^L
M+2'R_P#5/>10#ZPM(?+_`-4]Y%`;]IU+9+NXXW;Y2/.-(A&"B0%E79BB&@XI
M]R@).@-2Z7:W6N+SJ>\C#.*"A*BJJDO`B"**2_X)0$1]86D/E_ZI[R*`J>N(
M'8_K44*^..%+;CO1(\YA9;#S34@<KB`H(@KBB\!B2+P*BILH#>T-/[.M%Z6@
MZ9M%Q>.W0-[N"D`X;J[YTWBS$+0(O&<7N4!/?6%I#Y?^J>\B@'UA:0^7_JGO
M(H!]86D/E_ZI[R*`?6%I#Y?^J>\B@'UA:0^7_JGO(H!]86D/E_ZI[R*`?6%I
M#Y?^J>\B@'UA:0^7_JGO(H!]86D/E_ZI[R*`?6%I#Y?^J>\B@'UA:0^7_JGO
M(H!]86D/E_ZI[R*`]L:\TH\\#(3TSN$@CF;=!,5X,2(4%/\`%:`GZ`4`H!0"
M@%`*`4`H!0%,[1?]QT3_`/8F?X*70%SH!0"@%`*`4`H!0"@%`*`4`H!0"@.6
M_P#)[^QFI_Q8?\<Q0'3(/[%'_1A^2E`9J`4`H!0"@%`<VTU:H-PA'=9[0RYD
MYQPW5=%%$50R3B#P)CPUTVH)JIR7KC4J(E_4%CZ/C_!CX*UVXY&.Y+,K^O3M
MFG-)S+Q%MT%7XYQ@%9+)&R*2)34<C,6L'"0!=4L!VKA5)Q27`M"<FZ596[)K
M33RQYLJZQ[9<+=&4&F[I:HCL=I9AGNTMZMS3S+(7QL<PBB;%P6LXM=J-9*78
MR5'6?9Z[!CR(MK.9(DOG$2W1X[!R0>;0%(#17$:S8/-X"+BJN=,$X<+UC3@4
M^>O$^1=<]EDFX#$;;9%DR)MNX&RV$<GFQ4C9P4M^AB@%BA-)XJ[:5CD'KS-*
M]ZVT[$@1)$'2LMYR7,A-,`[!%$?ARI+;)2&%%S`L4=%&\RHJF0<7#'"&U3@2
MM5<6>+OV@Z%9ML]Z!;F4E0U9<:&8R`MOQRELQWWFQ:(WL&P?0L#$2VIQ>%*-
MK(+5F28ZATQ)OUJMD6T-L))>DMW)N='1J0PVU#.6PZ@(I)E>1O%,?P>XBTJL
MA\R7$V=,:B[/]27`H%MAM[Y6U?BDZTR@R6$(15YG=FX61-X'CH*\9-G#A9:7
MV%9.:[2/2<[/TVFHK;;+1#M$G&1$F3F77B:A"F`N/L,*+AF\7``*F[3QLU4:
MPK1%ZXTJR-M&J'+A%2\'9+6S9XUTC6.9&W1E*<?E.L,A)8=0MV#.,QL]V8*>
M5%%2S<!+'@&VNUGR#JX7I*09%AM\:9(='*;S1-,P0!56:U,5U0WKD(=WO'&B
M$%5T,O=J%3(.N;+2+MJ8U$Y99=F8>*0V,VUO0FA-"AD\VP9/H2\563>$B(5P
M(-J)LVW5*\$4U.E:LGO4%CZ/C_!CX*TVXY%-R68]06/H^/\`!CX*;<<AN2S(
MZZ6Z%`FVB5!9&(_S]EE393)B#BX&*Y<,<43"LKT$E@;V)MNC.AUS'4<^U,(R
MNT&'$DHCT48JD+#G&!%47%5<J[-N5.]6EI5D9WFU'`]7RWV:W6.Y7%NVQ3<@
MQ)$H`-M,JDRT3B(6&"X*H[<*Z)127`XXSDWQ*=&UIIQ8MEDS[3#MX/G*;U`C
MH9DB\VMY3=XR2(F=L\J8$H[4QPVIC6=5D:-2S9(OZKT;'$&W]-SFKFZ^U':L
MQ06N?'OVWG&W1;1S)NB2(\F;/P@NRIK'(CYLS?.[:';TQ-U([`%N!;=XEQ9*
M./.&'&20'6G&D5??&R7C(A+5OEI6A%9UI4CVM9]G#EU9MW,-V;SH1U?=89;;
M;>>5$8;<$C1Y">0VR#!M=C@XX<;+'RUX$_/3B8W-<]G#;;CSEM,&-XK$-\HS
M0MRWDV[N.2FB(>7C97MVN%1JCD32>9E9U;H*5%9<MMH=N<MU71<MD&*R]+9Y
MNH(\KHHXC:("O-HN4U\<?\%8TX$?/F1EBU_I&;IH+Y,T^XR,F=-B08XQ&VS=
M9BOD`N>_N``J@94<0C1=YF045$HG&G`EZJTJ9HNN=#N7.X"=O:=LT=B%+8N,
M>/G%N-);)7I$HE5!!IMP<N(XK[2\-159"DLS*WJW2<2SQY=VM3//I<RY18\&
M&TTIDW;ISL0G??W&AP1`;S\?QBV)AP6^5+@165>)(M7#3UUN-NA:=A09038:
M75R<ZU[R,$C5H%;0<I&X;J9?8%-JXTP;HD*R2JVR`]97N'(O#<^W6&6S;WK?
M;&),.-(:!+G<I#;"`ZCKKBJ$87VW'!'!20QRDFVJI>PMJ>&+%PO\VWK)MSMB
MMK]SM\M(LN<Q&>*&X;D9F7'8:90B>!V0DC=`1&HH0JJ[%1*C[`FWC5DK:)[-
M\MTZ=;+-;0<:4#@6Z0H[]]AI4229&"\1"<S,MGDRB8*I9DPJR5>Q%7)KM9.V
M`=,7RVLW*':D;AR6F7XKC\<&]ZU(9!\#!$4MB"YE+V"14[F-:1C%]A24Y+M-
MF?IBR/PW6TB-L$HJHNM"(F*IM3!42DK<:$QNR3XDEV;W*3.TR'.%S%&<)@35
M555$4$DQQ]C/A]RN([RT4`H!0"@%`*`4`H!0%,[1?]QT3_\`8F?X*70%SH!0
M"@%`*`4`H!0"@%`*`4`H!0"@.6_\GO[&:G_%A_QS%`=,@_L4?]&'Y*4!FH!0
M"@%`*`4!0=&?TY&_&=^,*NRSX3@O^)DW6ID1FI+&%[M)6XWRCH3\21O1%"5%
MARFI2)@JIXRLY?:QQJLHU)BZ,A]0=G\6[R)[O.U:;G/1IW-761D1PG1-C;RM
M$0B8&/YUK9G7C9JS=HT5VAJRNSJ4]9&[<%TCB>\<<D"5M86"6]`0Q9AMFTK#
M@("9'!>4DS'MXR93MN@5S$QP.RN)$EO8S]_`D$^[(WD5A;DZ[+0M^KMRPSD!
M$X2Y4;3#8F.";6UB'=J9']`7M^T,VUW4I*W;SA%9T&$`ML);WVGV5>;WJ[]S
MW@0SY@V*6S;L;;&XLB+>[%8CRCFO#C6Z86&PXQ%9:?1E)$:0#CKR*IO2D6)@
M3Y^-CFRHJ+F*T3NDW&[/E]?-7VX71R;<4<<*2XC(LBZV4-R$T&5"/(0-NJI&
MGC%W!J5;(=S#@9-%Z#;TO(`FI++L:*P,2`RQ"9BN(R*CASI\%-R2X@MBF?B[
M<RJ*YN*C;H1.YJ,-ATUJ>VZ>A6.%<5M;UA_\>#<MVW*8FQE'8;T93;,7!X,,
MZ()>+G&JZ'2A+DJU-6U]EPVT$A,78RLCUP"\W""<<5=>N+;P2-Z$C/[TTKS#
M9;K(6Q%3-MQ2RMM,.Y7L)'4>A&[[/>N$B<J2Q2.-M%QI'HS`1\ZJ#L<B07T=
M-XU/:.*9$_`1:2MUJ1&Y0U;!HVXV^[,/LOE&BVF*MKAD_EDNRF'93<N2Z2(2
M(R)*WNV1Q501<53BBBQ&#J3*::+G6QD*`A]1?G+1_,XWY2UC?\)OR_B+W7(=
MIS^^_P!RXG[I_P!KM:6O$97_``LDKO;QN5HGVTG%:&?&>BDZB9E!'VR;4D1<
M,<N;'"NN2JJ'"G1U*I>.R>Q74H1/R'VMQ!*W3T9P%);:PC@MN%CCD<:!TE%4
MQ3:J8=VJ;9?=9L-:#F/7N'?KQ>.?7>))8>5YF*,5HV(K,MIIG=(X[@N:XNFK
MF;;Q4PV8T4'VAS[$9Y>AF)&F=06%9IB%_ERICDA&T4F5ENBZH".;`LF7!%54
MQIMX$:\4S"_V?L%JI^^,R66F9DL+A-9.$R]**0V(`B-37%4V6E1@$($!?PL"
M12Q$K=&6W,*$=,[*BFON/2[N+Q`X#\1#@M93=:4E;<N0(:!/(<Y<91;557%>
MXB5VF3O&ZQH&X0EBS+7>6X5Y8;?CNRDM[*Q%8DFVX;;4)MQH6N/'!4+.2^-P
MX[)VV5<T^PU6.RYQJ`U#<O9S$CS9LIER9%:D*K5R>1]\70,MVY(1S%6Y"BF3
M%>)@M-HG=[C6@]CP0K<_:VK[(6V3HL>WW.*3#>#T:.AIQ"0DW3Q;S#>)BB)^
M#[#:)W>XWIG9FR[&A[B8PLZ$_<G6GYT%J<QN[M,6:\'-G#!,PF@"#B'CE1=G
M&V3*W4A7*&_&TY,M&HK7<H.,^.$`+-,!Q6VG`:%Y7QE)E1MLL"7`P%$7+XJ*
MNRH<&F1J35#Z&AV`TLMCYX9/),6XMW$@13YT,WGS!N`I>^"T8@"BI<8!PQ3N
M6T8$:\:GN'I2<S;+TV[=B.\W]46X71IA&13*R$8=RP+A;M4CMH..\7C<?VJC
M;P&O$B$[/$LD[UG8464XUBD*`ZHM*+K[*13.1+QSG&!M=XK(MXY\3',6"5#M
MM.I;<JJ,LFE;$]8;%"LY3.>1[?'CQ(AJTC1(W'CML\?`CS*9@1X]S-E[F*Z1
M5$4DZNI*._FG/Q2_RJ60C1[*/Z:=_>C^+;KSSTRYT`H!0"@%`*`4`H!0%,[1
M?]QT3_\`8F?X*70%SH!0"@%`*`4`H!0"@%`*`4`H!0"@.6_\GO[&:G_%A_QS
M%`=,@_L4?]&'Y*4!FH!0"@%`*`4!0=&?TY&_&=^,*NRSX3@O^)DW6ID*`4`H
M!0'+M972\CJK4$@N=+9=,6^%.=DPK@Y#=ABZ+[CSHPQ;-B>2HPA(W)XG%R\!
M+7/*3J;PBJ'W3USO"ZC:NEU24W'N%^N-F@S6K@XZR^L>1*;9C.6LVTC,`+43
M:\T6\4@1?PSJ=6)#CA@?)MRN39S=0C.DI.C:L2Q-COW>:)!5X&=TL3-S93RF
MJ;Q6\^.W-C55)U)T]W81$BZ7FW632\N-<9F^U=:(DN[F[)>>0GI,^TL.%&1T
MC2+BW<GT1(^1$S)A@H!EE2PX_I44Q?=_J7_2&]B7[5%B&0^_!M$B$D(9;SLI
MX$DPQ><0GWR<>/$UQ3.2X<"8)5K;Q*36"+36QF*`4`H!0$/J+\Y:/YG&_*6L
M;_A-^7\1>ZY#M.?WW^Y<3]T_[7:TM>(RO^%D[7:<`H!0"@%`5*XG>&NTW3H'
M//U5,CW(0MK0Y`Q998+>/+BJNN9S++P"(X8#FQ)<9-J1HJ:2F3[W?--.NZ@N
M[3DJX7B3*8L$J%=)UPM?.%;-&VW+8R(`W':;:(W"'>F)(2IW,M=31II3P)K1
MVIY+W9=J*YQ[G(N$ZTN7XF[C,:('%6.](<C&0.-M!@C>[X@@@#XF5,,J6U?*
M4<?F1$7&3<+7<;%:8UQFI$U)$M3UR1Z7(>=4YEQCQGE8>=,W8^9MXA1&"'#'
M%,%1*IJ>9=1KV&[:F)=PUT]HJ3.N"V."_<"9`)LMN7@Q&M#K:.36W!EN")W)
M]<#<5.,B<`!ELW^GN*]E>W_J6_L[NLV[:$L-SG.[^9+AMN/O8(F<EQ3'`41.
MY6D'5&<U1LL-7*B@%`*`\N_FG/Q2_P`JADHT>RC^FG?WH_BVZ\\],N=`*`4`
MH!0"@%`*`4!3.T7_`''1/_V)G^"ET!<Z`4`H!0"@%`*`4`H!0"@%`*`4`H#E
MO_)[^QFI_P`6'_',4!TR#^Q1_P!&'Y*4!FH!0"@%`*`4!S*-/D:8EN66XQW#
MB-F11)8#F56B)5S$@\.*^QP<%;6[M,&<]VSJ=4;_`%QL?NG_`(!SP5MO1,=B
M0ZXV/W3_`,`YX*;T1L2'7&Q^Z?\`@'/!3>B-B0ZXV/W3_P``YX*;T1L2'7&Q
M^Z?^`<\%-Z(V)$7<Y&@+K.BS[C`65,AJBQGCCO8C@J$F*)@AHBIP$BI5'<@R
MRM31J7*/V?S'+E+;BN1;M<XKT1RYM1WMZ&_:5I7`%>(AHFW,B(OM[5J'.+)5
MN:$23V;1KQ%?5C>Z@CQ009)L.[\VFA1E7B;\7%5V*67''NT4H!VYLRQ6^S:(
MD](UK1M+HBC/1([RHX)*JJ.!8Y$Q+@##N>PF$ZX$;4S<LUTT79(20K3&.'%0
ME/=ML/+B2\*J19B7_%:F-R*(=F;XF]UQL?NG_@'/!5MZ)&Q(=<;'[I_X!SP4
MWHC8D.N-C]T_\`YX*;T1L2'7&Q^Z?^`<\%-Z(V)#KC8_=/\`P#G@J-Z(V)&D
M-V<U!<X$.#">18TQJ4X\XB"&Z9+C%[7#L[U97+NI4-[5IQ=6=+K$W*)K*',M
M^HHVI-R4F"VUN'0:\<"5"057'\%5/AJT)4=2ER.I4,3>L[*0"1H^!JB*0*R:
MY5]C%$P6NG?B<CY>1ZZXV/W3_P``YX*G>B-B0ZXV/W3_`,`YX*;T1L2'7&Q^
MZ?\`@'/!3>B-B0ZXV/W3_P``YX*;T1L2,#NHM+/38TYUIPYD-'1B2%CNYVT?
M1!=05P_#0$Q^Y57=B3LS-*#)T#`N[]XA0%CW.2BH]*".\A+FPS8#XHXX;<J)
M4*<*DNU.E#2OE\T)':M9/S'+3$C7;GR-JR8MRI,@7\[)YN'?')-Q4[JIP5#G
M%A6IHS1F.S2)$FPF+5NXUPV36N;OKO/:Q+$AP[F54PIK@-NX>7HG9B]:&+.Y
M:LUMC&KK$?</IE,L<2SHJ.+CCMQ+V/82FN%*#;N5J3;.J]/,M`RRCK3+8H+;
M81W!$138B(B)LJZO1*[$SUUQL?NG_@'/!4[T1L2'7&Q^Z?\`@'/!3>B-B0ZX
MV/W3_P``YX*;T1L2'7&Q^Z?^`<\%-Z(V)&O-U;'>9YM:V7Y$Z1BVR*M$*(1)
M@BKG1,4JDKRI@6AR[KB6S1]A*R6-J&XJ+()5=D8+BF<L$P3[@BB5S'835`*`
M4`H!0"@%`*`4!3.T7_<=$_\`V)G^"ET!<Z`4`H!0"@%`*`4`H!0"@%`*`4`H
M#EO_`">_L9J?\6'_`!S%`=,@_L4?]&'Y*4!FH!0"@%`*`4`H!0"@%`*`4`H!
M0%+<_O,Q_P#7'OXYJ@+I0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!R?_D=_3>F
M/_M%J_+.@.L4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`IG:+_N.B?_L3/\%+
MH"YT`H!0"@%`*`4`H!0"@%`*`4`H!0'+?^3W]C-3_BP_XYB@.F0?V*/^C#\E
M*`S4`H!0"@%`*`TKC>[3;,G/Y;<97<=VCA88X<.%`:7732G2D?ET`ZZ:4Z4C
M\N@'732G2D?ET`ZZ:4Z4C\N@'732G2D?ET`ZZ:4Z4C\N@'732G2D?ET!Q")K
MO57UVQ[6[,C.-Q&'1FZB,05H[0<IN2T`MM((@\2!N2)<<%7'AH#M_732G2D?
MET`ZZ:4Z4C\N@'732G2D?ET`ZZ:4Z4C\N@'732G2D?ET`ZZ:4Z4C\N@'732G
M2D?ET!NVZ]VBYJ:0);<E6L%<1LL51%X,>]0&[0&*3*C162?DNBTR"*1&:HB(
MB)BO#[24!%==-*=*1^70#KII3I2/RZ`==-*=*1^70#KII3I2/RZ`==-*=*1^
M70#KII3I2/RZ`==-*=*1^70'"/\`DWK.[H6GO4:QKU9O6$.2D5M#5UJ?#<<,
M!4P5,0D@X@X<*;M53AH#KVD=6,LV*/UEU!%F7AW%V230"PVVI[=R`)MP;\7$
MMJ]V@)GKII3I2/RZ`==-*=*1^70#KII3I2/RZ`==-*=*1^70#KII3I2/RZ`=
M=-*=*1^70&:)JC3LQ]&(UP8=>)%40$TQ7#AH"4H!0&"=/A0(Y29CP,,"J(KA
MK@F*K@B4!&==-*=*1^70#KII3I2/RZ`==-*=*1^70#KII3I2/RZ`==-*=*1^
M70#KII3I2/RZ`==-*=*1^70'(>V/7UQCWBRQK++CSW9-TC2=/N*"F$=\8S\:
M4,A&\J[MH7FY`9MIJICXHT!UF'K'3H1&`E7B,[)%L4?=%<HDXB(A$@]Q%7;A
M0&7KII3I2/RZ`==-*=*1^70#KII3I2/RZ`==-*=*1^70#KII3I2/RZ`==-*=
M*1^70&S`U%8[@ZK4*<R^Z*(J@!(JX+LH"1H!0"@%`*`4`H#EO_)[^QFI_P`6
M'_',4!TR#^Q1_P!&'Y*4!FH!0"@%`*`4!S&PVEN\@]>+PB2SEF2M-*IX-HAE
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MU4T[\A#E'Y5-J(WI9FE,MD.T7"TS+8"Q'CFM1W%;)<#:=7`Q)"S8\%97;:2P
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M#$E'`D7%.'BDB;=M<AW%CH#GT^%Z[U9<.?N*<2V$VTW#XV[+.VI(2\;82*2[
M42M;4-3,+UQQX&SU4T[\A#E'Y5=&U$YMZ68ZJ:=^0ARC\JFU$;TLRN:V>TQI
M6-:Y3UF25'G7!N!(5LS0F6W&7G3D8*6"BTC.8\51$#,6.RJ2A%=A>-R;[32<
MO^A6]57&S';AYE;HC3_K%LG7DD277D:2+%:95PWG!5<%$>-FXN6JTC7@3JG2
MM3?*Y]F81F9#C>[1TS;-DV98/L;I!5TY;!"CL9MH7`)QQX1`!(5)40AQMH@1
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MHTEV$IR?!DCIR1:]1-R%MM@:!8L7,Z[)>>!E9QD8M,`;8N8M*#>](U1"1MQD
MD!<^RR@GV%)3DNTE=.Q](WV*\]'MAL.Q'CB36'Q=%6I+*Y7FD<0E:=W9HHJ;
M1$.*<-6C"+[")7)KM);JIIWY"'*/RJMM1*[TLQU4T[\A#E'Y5-J(WI9D??M-
MVF-:9$N$RD65%'?M/@I9D4-N"8ELQ]FJ7+22P-+=V3DJE]M#SKUIA/.EG==C
MM&X:X;2($55V>W7*=AMT`H!0"@%`*`YG_P`E(DN7V(ZH9BLN2'4:CN*VT*F6
M1J6RXX6`HJY0`5(E[B(JT!T"SRXDRTPY41YN3%?8;-E]HD-LP(45"$A545%]
ME*`W*`4`H!0"@%`4/0XH5@ABO`IN(OPI5UVW\APWO&<N<[8-3!V>3'$5GK<!
M.G&D*TFXYF(/24=(?$WXQXSG$RY5)$V;:KK="VVJ]Q;9W:_9X&H9MMG0W&(<
M590C)`B=>(H;#DAS,RC:-"*MQW%!4?)5XN(HJJ@VW"BMU1YN7:SZISMW>R.P
MI"QF),;W]'6'>=O[E@4=;;4T3NN%NUR+LP+AINLG:[R<TUK>W7?3<J_2FRMT
M2WJ\D\W-X30#';1UQUMPVV2<:1LO&W:;4).Y5E/"K*2A1T(KLZUM.O#%P:O;
MT;G\5F/<%;C&V[NX\EA''17<$X.6._O&!QXZH&)9EVK$)YDSA3@2.D.T33VJ
MI=SB6TSWUN?-K`@='>-`C>#Z*;;:#B3N7(JYMF/!4PN5(G;<2(U/J+6#TF[L
M:=;D(EJE1K8ZD*.Q+D"4B.S-=FJW(41(&VG!9!M%3CFIEF1!1*SDZEHQ5,35
M@WZ_7.8-HA:@F-'%@RKA-F2(<$9J2(SX,E!?91HHX("'BJ@.;'\*J*3?:6<4
MNPTSUYKL(4"_G%`8ER@1'HL50;2VJ4Z(!-$4A224CXSG,K@9L@Q4)SQDQJ=;
M&B)-N:OEQX-EN%LGAJ%J5)8LTR*8A%(ICY+ED(:-@K>&"XBK>4AP441=M3K:
M*J&99=2M7D[:XMIEN1#:S./.QV&Y,LFP%20(S;^+.\,T$??$5,%7#`L"32=:
M%(TKB4)=3ZV9LT:^NW%59;F'!YNL5@(R`Q)2,1WE[*KK$@E51(8N`(XF5$PQ
M5<=3P-=,:T+?J^==&[C8K+;996X[U*D,.7`&VG7F0C1'97O8/"XTJFK.4LPK
ML5<,%VUI.3P,XI8LH]CUSJZ="O5W=N*(WIB_AIP[>C#"-3@YVQ%*4^>3>MO$
MDG-E9(`Q%.+ABBTU/[Z&C@N&:J3.E]3:BE2]+SIDWG$75B35*W*TR#</FC1N
MAN'``7CS9,J[TRV>W2,G4B45CW%IU%^<M'\SC?E+5K_A)Y?Q%[KD.TY_??[E
MQ/W3_M=K2UXC*_X606H=>2K!K\(4Y47316MMYY`!"D!,,YC@JWM3$29@GFQX
M%1,.%:Z')IG)&":(ZS]IMX8TG+N]YC-29I79^)&8:/<QVV$;;>:$G!!]U?>S
MX4;-5)<%P3:E5<:+.VJX&X/:VS)M#UTM=F?N+4&`Y<+JT#HMN,BV[(C(+(N`
MBO(K\%U")4#*"(>"XY:EW"-K&A[T7VMVS5=S8B0X+K<>:T;\*2BNFN5L<R\Y
M%66VV,4V#@X>*[*F-RK$K=$>KEKQ^-KYJUC*BC:&7XUNFMD0(]SJ:T\?B*N^
MS-NC$;'(.14D+FQRHH'/YB%#Y20OG:1INS:I@:<F.&DN8CBN.(V\0LJ(@32+
ME;)#WN\_!7BX<:I=RCH%;;53WJF_WF+=V;3:8Q/2@@R+PZVWD5V0W"=;;2$S
MG0@`Y#CPBKBHN`XY<"P)(E/(B,:E4@:CU4#<"TS+W<`O]SFQ(4D;A;H$1Z*R
M^S)<67%9:!P"!UR(38[Y3PP79CMK-2>9HXKC0]R-3=H2,24ADDEJS39L%V>K
M;`I(>B$"M^L,4`(\<VR)7'&$$D+#"IU,:8D_IG4K^I;;,:A79N/?7CYU$C$P
MF$6,9(45IP#$=YF:$>=(AD;9F8(0*@864ZIE)1HR5TA?Y&I-+0[T<7U<5Q:5
MQAH7$?407%`<QRHF*\.547#@7&KQ=45DJ.A7;(WJN7,U"+FL)!6F!NHD6Y.1
M+:V02F\'ICB*C"-&T#:@V)+LQ5S%,P(J9QKCB7=,,#%$O^J[;V93=1SYQ7":
M^XCUK*4PRP;<.3)!F,KK3`-"CNY<1PQ)%P/9XNRB;41I3E0QOWG5<?5G4CUT
M;CCLAD4U`4>*DL`=@RYA"C*-)%7C0D#%6L<I+W<%2%)\":*E30;UEJV=%O2M
MW+FIZ5M\R:9ML1R]8'#GW"(@R4<`T;$QM@D6XR;3+#!$'"7)^X:5[SI<224J
MTL2C%!.1&!XA''!%<:0U1,=N"8UJG5&7:8>RC^FG?WH_BVZX#TRYT!2(/]3:
MC_3L?$UT<OVG)S/82E=)S"@(+5NE6-2-6Z-)-$A199OS&>,BO,.PI,-QH2%1
M4%5)>.;N852<:EH2H5,>R26C&)7)EV2Y%W<X7&26-+DK,YTYOVL_[,ZB(!M#
MA[2U1VV:;JR(UK1-WT3(;E65IZ5*EO35+U3;&CCQ8TUN$CPML;Y@`=%R"BL*
M2&*CCO!(MJU<:$J2EQ,G9OV-.Z:9LSDMFT\YA99<J8D,7;FLHT4G&DEE[VC2
M&2H*@VAH*(B%PU,;;0G=J6>X]FUNO,Z\2[Y,EO>M"W.YA2I,%I8`!E:C2&V'
M`!Y0(W%S$FU"PJVW7B45RBP/5V[-['J)BQO:J8C76\6K<E*G+&:1)2MMF)M$
M!"N5@W'5<R)P+A4NW7B0IM5H2&KK++G6:(U;0!7[7-A7"/%)=V+J6]X74CH6
MU&\Z!E0L%1/8I.-5@(2H\2%NFC+SJAL&;S.!JR&DA^,V$9&+JV4V(]%W4@D(
MX^#+<PT1!;QQ$<Q%QE*NELLI)<"1L.FKW&NCMWNTN)(G!;PM4)N*RZW'1AMQ
M71)X73<,CS\.4D3#N8U*@^)$IJE$01=FTJ#,CWGGI39<=>?3W094YY26W"><
M&W&I@C?.@RQ'4<S*;`-ABF&-0X-8DZZX%CT39[Q:[?-&YJP+DZ?+N3<=C,2L
M).>*0;#CBKE=)LW%%#$114[E7MQ:6)6;3>!8:N4%`1VI/Z?N/[N?^54N>%E[
M7B19K%_L=N_=F?BTKA/1-Z@%`*`4`H!0%:[3O[;:L_DUP_A7*`T>Q?\`M+H_
M^4P_B1H"YT`H!0"@%`*`H6BB4=/1"3A0G%3_``=*NRTOE."]XV1B]EVDEMRV
M_(_N"@/VM5WJ9]Q(<5TRS9?SJ*JB)]P54>!:G:1&ZQ<NS73\MYR20O2%!R5)
MA6M]\TM[;TUEYN2.[`5)&Y)23)WQBQVCAP+#MA7&1%C[,)93)$_4,C"83#,>
M*[#E/2'FRCO;YB0+[[+&0V?$;%&E'#:6*U56V^)9W<BU)I.WK:"M<B1+F-NR
M&I<F3)>WC[[C+C;@HZ2B@J!;D0($%!4-F&U5K10HJ&;GC4R,Z5L,:Z1;G"B-
MP9$07@`88!':<1]!0M\#8BCBCD3)CXNVFVJC6Z4-^)`AQ"DE%:1I9CY2Y2CC
M[X^8B!.%BJ\91`4_PJ5%(AR;*_,T:3]WG/MRW(\.YN-S9#C#A-3(\^.P$5MZ
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M`UXO9GIR*ZBLNS!C&^,R?!5]%CS9H&CG.Y89,QO*X`&JB0IB*;*;9.XS;M.A
MK+:[@S,CN27`A[Q+9!>=0XT+?(HN<U!!$AS"2CQB+94JVDR'<;1L:B_.6C^9
MQOREJM_PFG+^(O=<AVG/[[_<N)^Z?]KM:6O$97_"Q>M%V*\R9,F<+JNRH\:(
MXH'EP;B2#DMY-BY24WC$E[HKEKJ<*LXXS:,3V@[$8N*R<F')*<]<V9L9U&WV
M)$EM&7MP2B0@!M)DRY5V*N%5VD3NLJM^[)G#C%9[`+,2R2HS\:<;TV4+Y#)D
M/R,";%EQ'AC.2C<80G17,JH:J-5E;["T;G:RV:?T5;;$Y'6++FO1X3>ZM\!Y
M[&)&'+E+<,HB88ILXY%AW*NK="DKC:/A:`TL5JDV]R&+BRDDH=P<$#G"LLS,
MR"40JX)`KJ[M?P$1,."FVAN,F3M\,Y4.8XTARX`.-PWR5<[8O"(NHFW\-`'&
MK:45U,B;]IA+C<XUQ;(5<&.[;9T9XC%MZWRC`I`"3>!MNBK8F!)PX95P0LR5
ME"N):,J*AJ_5Y:#;<.3.N,NYD;1LWJ0^)3F-QO-TC+B-B`H&_=PQ!?'+VL(V
ML"=QFUU*LBV%ZQNJ^]"F/+(N1..(KLPS)"=YR2"B$CV5$<04'%.#"IVU2A&M
MUJ8^J00),NY61S)=7=ZD'GADY%A+,>%Z:XPT*(6+SB;XQ(E0S1$Q`56H=OC0
M:ZT3-_2^GXNG++%L\)Y]^+#118*22&8CCB@(J(/%'\%.Y[-7C&BH1*574P#H
M^RCI67I=$=]4S&IC+R9_?<D\W''\IX;.,^679LHH84&MUJ>=0:>?O4F%&??Q
ML*,R&[I!550WS+=%$<$L%XS#C1%CCPKW:K*#;)C*GM-/ZO+0K9.'.N+EW5T7
MAOY/@MP`@;-H4%U&T;04:><##=\!+4;6!.XSR]V;:?<9%IM^;&$VCCW$F'T$
MK@TXXX\Z$U5`MXCCLAXRRY=KA>UA+MA7&67=-LQ-RT*`TTUD;!.`1$<!%/N(
ME7I1%%Q-3LH_IIW]Z/XMNO//3+G0%(@_U-J/].Q\371R_:<G,]A*5TG,*`4`
MH!0%"N=SURUJG44*(;4MSU(W)LEL;,66VS.8['1TGG<J*\K8YUS8"B\5,4XU
M8-NILE&B(@=8N:8M+\"Z72=%U$[(AQ7'=2/Q7VHP2`<+G8G'5(R(K3#SB,J[
MB1`(8HI#C$71$N-7AP)"'K"XO]B5LU%%GC)N;\*W-R9Z*)KSA]]B-*79L1T"
M</\`%-.#9A5G+Y45T_.T:SLJ_-:VZBI?)ZV\Y3:+<U<!;D@E;GYB@DC)ER[Q
M@4_-^+BG=JBK2A;"E:$:UJ74UPM>H9!7>5'=TE:Y<V$K!`*2G8L^Z1@Y\B@6
M^16[6UF0<N*J?NMDNM/9\1157?\`Z'683QO0HSQX9W66W#PV)F,$)<$^ZM;K
M@8,S5(%`*`4!':D_I^X_NY_Y52YX67M>)%FL7^QV[]V9^+2N$]$WJ`4`H!0"
M@%`5KM._MMJS^37#^%<H#1[%_P"TNC_Y3#^)&@+G0"@%`*`4`H#F=ON8Z;<.
MRW<"9:9=,8LY05&W!55+,NTO9QXN/#@M;V[J2HSFO66W5$CUOTSTBWWC\FMM
MV)ALRR'6_3/2+?>/R:;L1LRR'6_3/2+?>/R:;L1LRR'6_3/2+?>/R:;L1LRR
M'6_3/2+?>/R:;L1LRR'6_3/2+?>/R:;L1LRR'6_3/2+?>/R:;L1LRR,77G2/
M.TA^M&N=*TKZ-8.8[I"0%+'+AXRX4WHC9ED9>M^F>D6^\?DTW8C9ED.M^F>D
M6^\?DTW8C9ED.M^F>D6^\?DTW8C9ED.M^F>D6^\?DTW8C9ED.M^F>D6^\?DT
MW8C9ED.M^F>D6^\?DTW8C9ED.M^F>D6^\?DTW8C9ED:;ET8OUWMT&U"3XQYC
M4A^5@J-"+2*>&*(OC)CACAM2L;MQ-41T6;3BZLZ/6!T%`UDQ,M^JHM_*.;UN
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MG`(IC[=<IVD]0'/KK+.Q:LGN26S*W7%&GG):-ED9+#=BA%M%4V;>[M[^MJ>E
MF-ZWJ6!FZWZ9Z1;[Q^371NQ.79ED.M^F>D6^\?DTW8C9ED.M^F>D6^\?DTW8
MC9ED.M^F>D6^\?DTW8C9ED.M^F>D6^\?DTW8C9ED1LZ9V?3Y,B3,>8D.RX@P
M)&\WBB4<'">$,BIE11<-20D3,B]W8E5<X,LK<UV'VRSM"V8'AA3U)R2J+(DR
MGY,N0X@HJ`)R)"NND(9ERBI8#BN'"M%."#MS?81,U[03(V&VK=VV-/1(SMH:
MLY;\P?)P&EB8GM7/'&(1`98DBKBA(O#5RCG@2H3RQ,W,>S/F:QEF.*X3B/>L
M%F3EN&=!4$PGJ?.T3(2A@CF&553@5:G5`:)Y!^W]ESS<=I7D;;8;5DQ9?ELI
M(;4B,@F;L@YV)&X9$C^?,IFJ[3+%K@-%S(L`ZMTN(H(SVA$41!%$)$1$V(B(
M@U;=B4V9Y'WK?IGI%OO'Y-3NQ&S+(=;],](M]X_)INQ&S+(=;],](M]X_)IN
MQ&S+(=;],](M]X_)INQ&S+(T;O?XUTAN6NRXSY<L=VN[`E`!-<JJ9+ER^TJ[
M*SN74U1&MJRZU9T"V1W(UMB1G,-XPRVV>7:F8`05PX/8KF.LV:`4`H!0"@%`
M5KM._MMJS^37#^%<H#1[%_[2Z/\`Y3#^)&@+G0"@%`*`4`H#PXRR[AO`$\.#
M,B+AWZ`\<RA^8;Y`^"@',H?F&^0/@H!S*'YAOD#X*`<RA^8;Y`^"@',H?F&^
M0/@H!S*'YAOD#X*`<RA^8;Y`^"@*8Y%B_7(P&Y#+U=>7+E3#'GS7M4!<^90_
M,-\@?!0#F4/S#?('P4`YE#\PWR!\%`.90_,-\@?!0#F4/S#?('P4`YE#\PWR
M!\%`.90_,-\@?!0'MMEEK'=MB&/#E1$QP^Y0'N@!")"HDB**I@J+M146@,/,
MH?F&^0/@H!S*'YAOD#X*`<RA^8;Y`^"@',H?F&^0/@H!S*'YAOD#X*`<RA^8
M;Y`^"@',H?F&^0/@H#E'_(R-&#3>F%!H!5=46I%P%$Q3.>S@H#J_,H?F&^0/
M@H!S*'YAOD#X*`<RA^8;Y`^"@',H?F&^0/@H!S*'YAOD#X*`<RA^8;Y`^"@'
M,H?F&^0/@H#Z,2*)(0L@))M14%$5/O4!EH!0'PP`Q43%"%>$23%/OT!BYE#\
MPWR!\%`.90_,-\@?!0#F4/S#?('P4`YE#\PWR!\%`.90_,-\@?!0#F4/S#?(
M'P4`YE#\PWR!\%`4WM#BQ1N&BLK()CJ%E%P%-J<RE^U0%RYE#\PWR!\%`.90
M_,-\@?!0#F4/S#?('P4`YE#\PWR!\%`.90_,-\@?!0#F4/S#?('P4`YE#\PW
MR!\%`>VV&&U56VQ!5V*HBB?Y4![H!0"@%`*`4`H"M=IW]MM6?R:X?PKE`:/8
MO_:71_\`*8?Q(T!<Z`4`H!0"@%`*`4`H!0"@%`*`4!SYJ^V25VM19L:X1GX9
MV)V*$EMYLVB?6XM-HTABJBIYURY<<<=E`=!H!0"@%`*`4`H!0"@%`*`4`H!0
M"@%`*`Y'_P`BWV7+)IJ(VX)RF]36=QR.*HK@@ZZZ+9*"<9$,FR05[JHOL4!U
M.WW2V7)DG[=+9F,@X31NQW`=$7&UP,%(%5$(5X4[E`;-`*`4`H!0"@%`*`4`
MH!0"@%`*`4`H!0%%[1;A`]8:47G+6$#4;23ESC[PJ6V4\N]V\3WHQ/C?@JB\
M%`7AIUMUL'6C1QIQ$(#%442%4Q145.%%H#U0"@%`*`4`H!0"@%`*`4`H!0"@
M*UVG?VVU9_)KA_"N4!H]B_\`:71_\IA_$C0%SH!0"@%`*`4!59FO66[D];X-
MNDSW8ZF#RMH@HAMEE).-PU*39#DEQ//7:Y_1V9RF_#4Z'D4W8YCKM<_H[,Y3
M?AIH>0W8YCKM<_H[,Y3?AIH>0W8YCKM<_H[,Y3?AIH>0W8YCKM<_H[,Y3?AI
MH>0W8YCKM<_H[,Y3?AIH>0W8YCKM<_H[,Y3?AIH>0W8YG,(FD+HQVKOZJ6V3
MBTZ8+)9LBN`;27$GA=)Q0/%!3>`+P9.`Q2FAY#=CF=/Z[7/Z.S.4WX::'D-V
M.8Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-V.8Z
M[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-V.9[@Z[
M9<N;4"X6]^VF_@C+CV"BIDN`CB/!F[E0TUQ+*2?`M-06(#4FL(%D)ME067,-
M458C2IO$!4)<^"]S$<*`TNNUS^CLSE-^&K:'D9[L<QUVN?T=F<IOPTT/(;L<
MQUVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<QUV
MN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<SDO;MH.X]HZV>9!LDN%=8#PM2
MGT)D5<@D2D29EVJ3)8JTG!B14T/(;L<SI=AO*V&T1;1;-+R6(,-L6F6PW0)@
M*89E0<$Q+A6FAY#=CF;_`%VN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<QU
MVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<QUVN?
MT=F<IOPTT/(;L<S')[0)45I7Y5AELL"J(;A$&"8KAW*.+1*N1?!EHM\^+<(;
M4R*>\CO#F`OO*B^VB[*J7-B@*]?]91;3-;MX17IDYQ!)&6DP3(:J*+F79XPX
M42(;H:G7:Y_1V9RF_#5M#R*;L<QUVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/
M(;L<QUVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L<QUVN?T=F<IOPTT/(;L
M<QUVN?T=F<IOPTT/(;L<SG?:+9+_`*HU!9[A"M<N#$%]I-0MHK:NR(T<'T:%
MM2Q$?VIUMU.$P/#\%*:'D-V.9T%C5\V.PW'8TU*:89$6VFQ5M!$!3`11$7@1
M*:'D-V.9[Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::
M'D-V.8Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-V.8Z[7/Z.S.4WX::'D-
MV.9C>[0RBDT5PL\J''<-`5\U!4''VDJ'%HM&:?!EN9>;>:!YHD-IP4-LTX%$
MDQ14_P`*@L>J`4`H!0"@%`5KM._MMJS^37#^%<H#1[%_[2Z/_E,/XD:`N=`*
M`4`H!0"@*!HL4]0MN[5=?<<<>-555,T-1S$JKPX(E=EE?*<-]_,4O4][U)UT
MOT&U3[HMQ@QX!V"U18ZNVUV0^V9$,]Y&#%L#,4QSOM[,=O=JDFZDQ2IB;#_:
M[-&3=G8]A??M%O2Y"S*1J:B[RU@\ID^\49(0LFY%($)N098D.(8YD&^XRNWW
MF:X=IEYL[",WBT,>M93$61;6;>[(ELD,Q[<`CN$<9.83X1:9<7#@Q794;C"M
MI\&1+O:;K%+B5P=M(Q+9;K'>9TN#(67&60[;^;."ZR$F*R]N_?A:$C$<<75P
MX@9VMDZ%]Z)*Z=JEYM<I!EV$1995GG@`X_(<:YVHK'!QR*P_%9+*Z&\1]X.Z
MH9QR$1W"%;3[2,T[V@ZFC0+2EX!)MUGL2VH^21A&-\[TQ;HRO^\`8Y3?P4PQ
MP;3Q"(MD*;+2@NPG1UUJR1?6=-0[1;ROXN2FY^^FOA"'F[$.2"LNC&-T\S=Q
M#',T.!(7"F"K+FRFA<:GC4^K+A<NSVSWJQ\\B/W>X0(Z-1"CC+4'I6X=::-_
M%@2+!4$CV>SA43G5$QBE*C(^U:QU#;;//EDU-FX3`MT.!>W67+DW,`7')*.A
M;&WG"95D6R9!IDW5Q)Q1W*H:(R:1+BFS4B=K%[*ZW*[RH6[L-KL[KDJW"3PO
M\\CS2BF8,OL,NIF<3*@N92R;5!#XM1N.M2VTJ4):P:YU#J+5$;3TF"]8U98<
MN<J6#$QH)+4=YEL8S*W&-#=XQO8OENEP#`17$\P64VW0HX)*I'ZJO>K]+2I(
M>M),DY<4C%Z:#'-W'=]&;,K:RQF<CHQSHLPR27\#*IX%575,M%)HW)RZU8NE
MYT];KE/N42T'!??DHY$"[&U,9?50:?>%F(@@\RVI9P1=WG1,25*A-\"/EXGO
M2NJINH!?B3KWS*[3MS&MKT)DEA`['!#)P#<#=&<PQ<?;:WN=R&K9(@XJ56U8
M<0XT[/T_3[RT:'OT[4&EH%ZFQVHSLT2,&F#)P<B$H"2J0AE(LJJH[43V5K2$
MJHSFJ.AFU$JY[0G<]9QOREJE_@:\OXB]5R':<_OJJG:7$P^2?]KM:6O$97_`
MR,[3KI+M]MLW-YLV`W,N\>+,?MC6_F*P;+YD+3:-2")5)L?%;5<*Z+K.2VBO
M_6'J2SM,6TK?*NLM\I,JW/S8\U)#EK9<;::<D-0HDEX)!N.+^<8;'!-N"X8U
M4VL"[@GB2D?M$O;STJ:5E;C6&%,M\&4DA]P+H#MR9B&"%%W2LHK3EP`'$5_%
M,I88[$6VME-"S*U?.UK5%QTS=)-BM+L,#CN/6ZZN-S6Q9!HT12>==B<T4S3B
MMHRZZBKW43;57<;1=6TGB6(>T?4*Z<6[/6-AJ0[-=MT*.$AV0+KT5Y]N0X`,
M,.2C:1(W$1M@G<<Q&V#8[RK*;H5<%4KOUF:FGS+K,%E8EJB6QE"B`ZXQ(":%
MU.$\X(R(N<$(P(<'!0MVB8B)JJ#36RZMJA/77M4N%OM3M\<M+)6B2%R]3(,@
M^<F[:V9#QC*;5O=M`:0W$$FW'%VCLX<+;C*;:K0D)>J=0-6[4T"Y1XT"^6RS
M.76,_!><DQT;<"0#)9GFF#W@.Q251W:CAAM7:B'-T9"BJHA-`W;5#MYC,S'K
MN@!;QFW1J_/6XQ>9=9Q:=MW,\J['E3>$YQ1'BK@2I58-U+S2H1E[[6]4RH@Q
MK9;FX,R4[#DV^4X4L&BB+<(L=T5><B(PZ3G/&@S13=;R$9"?YO/+FV%;1(:B
M[9+G;7;LL2PNR8EMD.6\I"-3B$931HT;KCHQN9I'!Q=J\XSX<((NQ&ZR%:69
M/W$]56G4NDK>Y=!D6V3+?C3W2!.<2W>8S))*:(B`RTT;(;L!S*OX1<3CV5<"
MN#J0-NE:\5V2S.>N=MU1=&I3]IMDUZWOVM!!P3>:C+$WCJ%&9<06W'R',2H2
MCPHE,?M+_+]A]LFL[E$O:P-17%Z/`M>]WF\$'Y);W*(>L7X@NQ@&&*DLAQ%`
M`(V<2X4I&3[1**["UZ7N5Y=GW.T23"6U8I2PGKDZ2A)>SQ8TJ.1-`&[4LDD@
M=+,.*BA(*9E$=8M\#.27$L+XB3#HDB$*@2**IBBIAW46K/@57$U.RHS+3)H1
M*2#)-!155<$R`N"8\&U:\\],N-`4:&*%JS4#Q8DZVXRT!*JKE;)M"44]K,F-
M=%A<3EYE\"M]H=UD1=0:;@K<KK;;?-;N)RULD<I4HSCC'5K%L(\P\@[P\50/
MNK5[C=3*VE0BF^T[5-OYK;)UB?N%UAQV'[R,>/,=>5))&K(LC%8DL(ZK+:*2
M2'6DS+[&.6%-\"7;69(+VE7.&PY=;K:XX6!9MS@17(DDW9A.6OG9$3C+K3+(
MBX%O<PP>7!5'N8JEM;*Z$0TGM)UM<AM(0;1ZO5^Z6X3E/#/C1W8\I[)S93F0
MF2)P\<3W8D*#M0E795)3="\;:J2#G:CJ`XS;T6PMKSB3,8AB3LF0;C<"4<9U
M[F]OC39*`J[O`E:RH6834?>M[?<97;69%6KM.O4MV9>9+9A87KE:UMT9EY$?
M;C2K;SLFW0)G*J&*9C%'/'7!#RIBM-;J7VU0FI/:5?XS$)';1#6;>FH<JQ@,
MMU6E8FS(T-.=FK"$TX*SFRP;%Q-A;>#&VXRFVLR6/4]U>TUJOG#34"^Z>8D`
M\<9PGXZ/<P28RXR;@-&2"#P9LS:<9%3:FU9<G1D**JLF5+3&I]2PW><SW+L3
M4.U^LKK'O\FUH#[)LXM.6XXY-B/OZCO#=+*(\5<#5$K.,G4TE%&O=.UW4X2X
M0E;0A>K922;TTO/8^_@E!G/BVT,^'$=(O_`=)541',+8Y^,YDMK9"MHEV.TK
M45PC-Q4M)VN1<94.'#N9L3A8;&<XK>;"='@JX^VB9L@8AAMS]RCN.A&VB5EW
M'6%OUD,%DPN,4;#/D6RV$:`Y*DPW(8-.2I)"`BX\3Q!@(Y!3C8KFP&V*96B:
M^TA;6NM4@/VI9]\<U*#<63<(<YRV<X."9FVX];2CJ<5ETW@RH+[JX"*^RBKG
MB7^7CV&WHO6LN5<R8O\`<AS@(6Z*$=LEC./DXO\`Y#T@1-E">5`987>"CC@N
MB(ELJ\98XE91PP+#I*Y7AZX7NSSC"4S89#4-FY$2I)DJY&:E8OM""-HH-R`!
M3$N.2$64$5!J\&^!626#S)+4HB6G[@A(BHC!JF*8[438O^%+GA9-KQ(L]B_V
M.W?NS/Q:5PGH&]0"@%`*`4`H"M=IW]MM6?R:X?PKE`:/8O\`VET?_*8?Q(T!
M<Z`4`H!0"@%`4'1G].1OQG?C"KLL^$X+_B9(1K5!C7*=<F049EQ1@9;F8E0D
MC"0-8"JX#E$UX.'NU=15:F=<*$/([/=+2'99/,OFS,&0)PEDO\T;*6!MONL1
ML^Y9=<%US,XV*%B9KCB2XQMHMK9LW'1NG[BZ+TI@U?;C-PV'VW7&W&FV'-ZT
M31@2$VX![1<'C)[-'!$*;1HO=FVDWFD;>:DN*L>9$D.E+DJ[(:N+8M24E.*>
M=]2!IM$)Q54<@X894IMHG6S/=]!:6NTDI$Z*3A'NB<;%UUMLW8^7<OFV!(!/
M-B""+JIF0>+CA1P04VC2FZ*T+:K<]*FBXQ$CMOX/N2)!$PDB0W+)8ZH1&#B2
M&0<:W7&$_$VK4."2)4Y,RZ4MFB2"/?[,^<DXG.46Y2GI!OJKZ-"\LHI2HZ1(
M$5I!5[Q0$<O%PJ$HTJ1)O@1S%Z[*VM/18+4Y$M5CE,/Q6<)>]%]EY7FC`5#?
M/BCFU5%"'V=E16-"VF5:F2\R>S1PFY$N?S=R]DU*8DQ7)+1BZT*L#*1R/@L1
MU6S5DW24"4$R$N`*B2W%D)2]QNQ>S/1,92YM`R,.LOL'&%UQ8YM275?,59S;
MLD1TLX;.*OBX5;0B-R1]CZ#A6ZZQKS:9#Z7=K&/)F7!Y^>Y(A.&!.QG'7S-W
M`5;0V50N(?\`TD8E&W3@-=>)E9[/=*-(\"Q7'V'6R89C2'WGF(K1*A*W#:<(
M@BCB`8(R@X91]RE3MH:V;4#2=I@P9L1DY1%<!R3)SLN0[-,4%1!.=F9/INT)
M<F!\7%<,,:*"1#FV:DK0]K;<&796FK;<6`;""J"11&#;!(XR!AHHL+(;C)NF
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M2VXR$594C<1FW?S@PVL^2+FX/>4'9LJNVB=QFT.B;`%BC64!D!%ANG(BR`DO
MC,:>=,W''0EH?.!,U><0B0\5$B%=BK4Z%2A&MUJ14CLY[/;7!E276%M]M:CN
MI+09+S,8&%DK-+,`F@(@/DI!LXO`/L5#C%%E.3/,C2W9U)<8CON*X&I69(VN
MW%*?W)-R8YN27(,92R1U-@S4S;$5P(DQQ+!8I'WC5+W$CJI=&VQN9=-0.\V"
M\1@L<AW%XE=:+?F#``RAEG5'75S"./M[$J9T7$B-7P-%G4/9PY>;3&9EXW5J
M(W&@MHU+0EAR0RM-2%W:#NSR9A%]<,4S<.VJUC4FDJ$9;=)]DU]DRHMN-R1+
MC-<V4@D3&G&HPR&GVVHCI*&$=EZ*V32,%D;_``<$/C2E%DN4D3EU[-M*73G0
MRVI"M3%5QV,,E](R2%7'G21L^YYQGX^]RYE+:J[5J7;157&2C-G<D-VMZ].C
M-NMJ=-]F8T),BKI-.Q]XK:+ES$P\2$GBYE511-B)91S(<LC!:-'6&T3DFPVG
M=XV)-Q&GGW7F(K9X9FX;+A$W&`D%$46D%,$1.!$J%!!S;,$C0&EGVQ!V(1JA
MNN/N*Z[GD\X)">;F'FS26G%`<[;JD*H(HJ;$IMHG6S8L6F^8/.W"5).1=YKA
MR+D\V1M1W'G&VF>+'0LF5IJ.VVUFQ)!3%24B,BF,:$.528=_-.?BE_E4LA&C
MV4?TT[^]'\6W7GGIESH"D0?ZFU'^G8^)KHY?M.3F>PV7[5!?N<.Z.@JS;>#[
M45S,2((2D!'D447*6;=#P\'<KH<56ISUPH1]VT;8;K.6;,:=WC@BW+::?=98
ME-MXY&YC+9"W)`454071),%5.!:JX)DJ;1Z<T=IQR&Q">B(]$CS)-P!APB,%
MD3-_SA30E7.#G/'44"XO&X-B5+@AJ9H_5SIA6LCB3'C%QEUF2[.E.2&5C'O&
M09>-Q7&FQ/C9`5!Q[E5VT3N,V'M":8=BQXI1C%B.Y)<%`>=!3":\4B4PZ0DB
MN1WG"Q<9/$"P1%3!$J="(ULA9VE.S/2T5AV<AQHB'$1B,;LJ0!G`8YNSA&!7
M5/*RN4UR+BGCU62BBZE)F%8G95;G8(/3R=.445^V$])ERA8;CR`?8!LU5P8C
M&^9!5;)0!<F"IQ-D?*A\S+'<(>EHCDR)-<%EW5[JQGF2<-#E.K$2.H-(BXCA
M&91%RX(G#PK5W3AF55>.1'3?J\DWB-89CC3EQCQ2MP1CWJ@<8V\JQ7W<-RYL
M%"1IPU7-@6&;"J?+6A*U4J1-KTMV3WR=*9AN.7&X-.,N3W79$PGI*QTD,@3K
MSRHLMO=RW6C7,8DVHB7%R)4Q462Y21-/=G5EYL7-7I07%MQE^#<9,AZ8['<C
M$KC`ASDG/>1-<=UXGM8U+MHA7&2SU@@3G69=UCM2IJ07K=)1$+FYLRU;*2WN
M34T4'#8'!#Q7#9CM6K:<RNK(Q6G2=IM222C'*=D2V]P[-E2Y$F4+28Y6VY#Q
MFZV`D2D(B2(A+BFVH4$')LP-:%TNQ(AOL0T:*"+:--"9HRX3!*XRY(:1<C[C
M3A*X!N(I":J2*B[:;:&MF73NF_5;TZX29)R;O=B!ZZNB1A&)UL$;#<1U)0;0
M&Q%M%\<A$<Y$6VIC&@E*ILZD_I^X_NY_Y5%SPLFUXD6:Q?[';OW9GXM*X3T3
M>H!0"@%`*`4!6NT[^VVK/Y-</X5R@-'L7_M+H_\`E,/XD:`N=`*`4`H!0"@*
M#HS^G(WXSOQA5V6?"<%_Q,FZU,A0"@%`*`@=;PEEZ?/*U(==BR(TV.L0$>=;
M>B/@^V\C"JBOHT8(:LCQG$3*.U4JEQ51>#HRIV%)(6K42ZF63+76D]84#/$6
MVR96>TA'5LH[BJL552(Z`DZJ)L0^`DK)<,>TT?%4[""@1=3L]H.G]52VKG/L
M>G8,FWN`MH>BRV5?;5MIMM@5<=EHFS,ZV.5.'@JE,2[:TTKB>H]EOUOLVIHK
M]KFF[JZTRX=L!F.Z\B/29]VD-C,4$)(OO=S94E>RHF)(OB%A=K#V_$K557=_
MH=@AM&U#CM&F!MM-@2)M3$01%X/N5NN!SLRU(%`*`4`H"'U%^<M'\SC?E+6-
M_P`)OR_B+W7(=IS^^_W+B?NG_:[6EKQ&5_PLG:[3@%`*`4`H"'U?:8]TTW<8
MST9)9C'?<BL*BEC(%DT:P%/&7,6Q%QVU2:JBT'1E:C:<=:F=G<\;>:3HK0-7
M:0H$IL@W99#0@ZJ_FTWSF7#9B2ICMPK-1X%W+B9=7OV>XW1D\]]%_3[[L63)
ML`&;K#TJ.P^(FR#;QN(;)C@X`8!M153-M7!;P*[8X6KV'6L0O+6IKI*1V^1W
MQSV9R*ZN5]Y'D!6@<YOXC2NYA/\`![E42Q-)25"6T1#N93M)L.P)<5-+:?>M
M%S.4PXPUSIQ((",8W$$9`8PG..UB.&5<>,..EM?<9S?'O9T2MC(4`H!0"@/+
MOYIS\4O\JADHT>RG^FG?WH_BVZ\\],N=`4B#_4VH_P!.Q\371R_:<G,]A*5T
MG,*`4`H!0%>UG?Y=DAQY-OM<FXW-YQ6(KL:(]+2*AHF\?=1@3<0$3#BCM-=G
MLX9767@L>)3KI`;:T2&G[/;+SOI<9Q83A1'&FITA\GE.-=AR9H\=7GE4A?4$
MR%Q2P0EK/L-*X\2<OC$"^733=[M48I3\&_\`,YLM&SS,M01FL/HN/B-C(7!2
M3QMFU4RU>6+JBBP33R(:;:KL;TZP!;I2R96JPOS4C<GS)80OM/*92\-P+F5I
M?>U+-CLPQJB5&7KW]AM:(AW,INDF'H$N+U5T^]:+F<IAQAKG3B00$8QN((R`
MQA.<=K$<,JX\8<;VU]Q6;X][.BUL9"@%`*`4!':D_I^X_NY_Y52YX67M>)%F
ML7^QV[]V9^+2N$]$WJ`4`H!0"@%`5KM._MMJS^37#^%<H#1[%_[2Z/\`Y3#^
M)&@+G0"@%`*`4`H#G[^EM1V&1)=L3;4V')/,,4E)":VK@B(1HA8#@BDI8K[%
M7A<<>!G.VI<3'O\`M%Z&:[X^FJ^^S/IXC?\`:+T,UWQ]-3?8Z>(W_:+T,UWQ
M]-3?8Z>(W_:+T,UWQ]-3?8Z>(W_:+T,UWQ]-3?8Z>(W_`&B]#-=\?34WV.GB
M8G@UX^3)/V".Z4=Q'HZF@$K;J"HH88N\4D$R3%-N"K3>9/3K-F7?]HO0S7?'
MTU-]D=/$;_M%Z&:[X^FIOL=/$;_M%Z&:[X^FIOL=/$;_`+1>AFN^/IJ;['3Q
M&_[1>AFN^/IJ;['3Q&_[1>AFN^/IJ;['3Q&_[1>AFN^/IJ;['3Q&_P"T7H9K
MOCZ:F^QT\3:MMAU3=9T:1>D"#"B.B\,5O*IFZTN(+CB>`KFV\;N<'=JD[CD:
M0M*/`O54-"K:KTU.D3F;Y:2!+C$;458-%5'A[@8JN`\52[FW'A3AJ8RHZE91
M35&0F_[1>AFN^/IJUWV8]/$;_M%Z&:[X^FIOL=/$;_M%Z&:[X^FIOL=/$;_M
M%Z&:[X^FIOL=/$;_`+1>AFN^/IJ;['3Q&_[1>AFN^/IJ;['3Q&_[1>AFN^/I
MJ;['3Q,30:\9=>=:L$=MV22.2'`0!)PQ`6T(U1W$E0`$<5[B(E-]D].LV9=_
MVB]#-=\?34WV1T\1O^T7H9KOCZ:F^QT\1O\`M%Z&:[X^FIOL=/$;_M%Z&:[X
M^FIOL=/$;_M%Z&:[X^FIOL=/$;_M%Z&:[X^FIOL=/$;_`+1>AFN^/IJ;['3Q
M/HQ-?W->9/Q&[:R]L=F"J*0#W<$1PEQ7_P#BI42O-EHV(IU+O9[:S;+9&@,^
M)'!!QV[2X2+:JX8DJKPUD;&Y0%-U'IN\L71R^6-4=<=R\XMQ*2(X650WF*F(
MK@BILV<&-6C)Q>!2<%)8D;O^T7H9KOCZ:M-]F73Q&_[1>AFN^/IJ;['3Q&_[
M1>AFN^/IJ;['3Q&_[1>AFN^/IJ;['3Q&_P"T7H9KOCZ:F^QT\1O^T7H9KOCZ
M:F^QT\1O^T7H9KOCZ:F^QT\3%'#7D8";CV".R!&;I`V@`BN.DIN&J"ZG&,R4
MB7NJN--]D].N\R[_`+1>AFN^/IJ;[(Z>(W_:+T,UWQ]-3?8Z>(W_`&B]#-=\
M?34WV.GB-_VB]#-=\?34WV.GB-_VB]#-=\?34WV.GB-_VB]#-=\?34WV.GB-
M_P!HO0S7?'TU-]CIXGDK1KF^#S&;';MD,E17W47:0=T403<Q^YLJLKK9>%E1
M=3H,2,$6(S&;55!AL6P4N%4!$%,<,/8K,U,M`*`4`H!0"@*UVG?VVU9_)KA_
M"N4!H]B_]I='_P`IA_$C0%SH!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`
M4`H!0"@%`*`4`H!0"@%`*`4`H"M=IW]MM6?R:X?PKE`:/8O_`&ET?_*8?Q(T
M!<Z`4`H!0"@%`*`Q3#)N(^8+@8-D0K["H*JE`<OLNH];WAWLW@+*%F'>+"%Z
MO%S:<`)CS\9N+O&U:*,\SNC*6.9!42+%<"#)@X!>=<:B=TWI*Z7QIE)#L%E7
M`9(E$2+%!3%41=FV@(B0FH='P)NH+G>GK]:HD61,O4=]MAIQI([)/YK<+(!L
M4@4-R^9+@J+O44%1P#`?:-=+<%T8OEF$+E;X+5S:CVR0<UMR-(=)@%)QQF*8
M$)MDKGO9((<;%>"@(9OM#U;=-0:0;M[=J.VSKD_&N,JVW0)\1]L(+[RMM.C&
M0\[.ZWA(0M\9`%%42(@`L>J]<S[1<9L2WVUJ:-GMPWB\N2)!1E&&9/"G-A!F
M1OG?_$<XIJV/B\;:N4".TO?]3:BU[>!>=YE8+7%B.0(T=P")[U@RK@G*!R.2
MYQ3:F[=1!78J'PT!AM%EU'U_N%I>UE>9$&UP;9<`;<2V^^G*D3`=;=4(0+NU
M&&"<7*6TMO!@!KV;M'OD)Z>=WAG*M`Z@GVEFX(XV+R$+[B1VV8X"B&TV`9#-
MPQ+'@$TXU`8;;V[09ELNTQMFWRW8=DEZAAQK?<AEGS>&($K,]$:!8CY*\"(*
M(XFP]O%XP$KJ;M,NFGK=&GW.VP+6VZVY),+I=68IJT*JHL1Q$'M]+1I$)QM,
M&T(D$73X:`\0>U>9+>*0EC5JR-W./:"FG('?$].W"1E;80%Q1#DBC^8QR)M#
M><"`2NF-?+?IUOA,P=W)*"Y)OP;W-ZOE-R"B<UQ4!1_&3&E-YPV>]8\!BM`9
M^T^[7&S]G]^N=M?6-/B1#=C/H@DH&F&"X&A"O^*4!J=I5ZU-;&;(.G,KESFS
M);#,4T%0D.!9Y\F.R:DH8"4EAI55#'@\9$QH"`T_?+PMSW-JO\^ZR'(DDWK9
MJ*$<!Q9#;>+*0%6%;A=1'-CV)E@.'!PT!\['M37R[7.^1KS>GY$V(^33EHFQ
M18<:(&8QN+&-&X^9ME]YULTP<V*TN9,45P"2[0IU_LTMBYQ+U(%YZ0PS;;.,
M8$MQ`IM`_P`^DF!Y#P<,FR5]E%7*"(1(N8"-74.HCUY)?O#M\LVGF;FQ;+;N
M6[?ZMD.*0@&])T3GFDIUP0Q;;0!]WPJ@%CU:_=IFJK)IN'<Y%HCSX=PG/S82
M,+)SPG(C;;:+);D-(V22S4O>\<4'!4VX@<[C=H&L[GI6Z:I6Z'%D:?@0)3=O
MCMLI$E.2F4<<YTC@./*F*[-TZ&R@+)<M1:D&YWF\MW-UIBRZBMMA9LX@SS-Z
M/..`#CK^9M9"O)ZQ-14'A'$0Q%<"S`6?5]WN07:PZ>MCRQ9EX?<=>E917)#A
MH)R$;4D-$=+>`@X@J89N!<%H#GFD-6:DN*P)<>]7FXWIZYDU,M+]O1NSC"&>
M34D@EI"9!59B"1A_Y:XFB)QUXB@6>S]IFI+S:M/O0M/,L734L4[C;8<V<K;2
M1&&F"=-UYEB0HD3DI-T*`N8.,>[+WM`/#/;&R_;G9+-K+G4F+'?L$-QY!*<]
M(?YHK.=`(&<LI1;0C7;FS;$QH#)=^U^W6_5[MC+F&[BSHEKE,NSQ:NAR)R,J
MV<6!NRWS`\[;S&KHJF#G%7(F8#YI[M8DSX]JF7.R%;X-ZB2)5O()`R'26$UO
M7\X9&Q%LA_-%GS%^$`4!\C=K4EL%E7:R%%MIV"9JB/*CR!D$Y"B[@A:1LA95
M)"A(Q,5X@KE03/$E$"0T)VDQ]3W.;:E*W.S(;#4M7K-<!N<3=/&;8@;VZCJ#
MR$TJJ&14RX+FVX(!6>S_`%5JF9VAW.UZAN[L:6P#2E89$41C9G$D$01'T!O$
MD;::=3WUW$=YLV*H`>!UK?.M$*.%\-+U<KS<+1(T\ZRVY$@Q&4E\RE&V`-R&
MW'FXK+HH[(P>$C5M,N"@!8M)7"\,ZVGV%V[2KQ"8B*_)>N3+<9YN6CPADBB+
M47>1LBJN<1<%"V;S'90$9>-0ZD"Y7N\LW1UIFQ:@MEC8LX@RL-Z/.6`+KK^9
MLI"NIZR/*H/"/%#BK@68#1FZOU3&WVHPN;A"FH)EB&S$#/,4CQG'FP=1$!)&
M^5&455WV7''BX;$`D=(WO5:3[4T5P.\/:ATZ]?1C3U:9:9EME$1MAER.PA-L
M%SPD+.+IHB#@NQ<P%RU>+26)Y^1>I-@8CJCKUPA[A741-F[1)#,D2SJ2(@H&
M95P1-M`5+2UVU3I^UVN9JB3,G-7^>C!E/6,+EM;>0@A-J,5AE7B?=4!)5$<N
M;:@Y5H")OO:1JIQVW72'&"-IV;I[4%V'=R120\U#)I84IM#BNB!&P;3@"?!O
M20QQ;1#`F6>U&X;R&H697K7(NK%A6>4D4="41HV\XZUNQ3)BOO:@JJ2^,+:4
M!MQ^TL>N[&F9K,%AV:^Y%B1&KBT_=`-MAR2CLN"`Y6&7&F"(31XUXS>(IF7*
M!"=K>IM46?4%D:8N$FSV*4_%9Y]$C#)SNN&]S@'T5J1E!ML&C38&.)<9<.*!
MNR]:7Q_M"TK:+?*:>L>\-B^3&6TW<J4[;9,ID&#S/"@`D?>.#FS#F:VJ)+0&
MK%U'J3UK;;P5S=-BYZFGZ>=LY`SS-N-#>F--NM8-I(1Y4@@I*3Q#B1<5$P00
M)C5<V]3-9,Z?B761:(C5I?NQ/PA85YQUE\&A;,I#4@-UE-55!%"Q_"H"HVO7
M&K;IIY-8N7(X[L.78(2V9AMI+>\-VC6QV0XZA@Y)SB5T<R9'Q1,H8HN!9@-]
MS4NJ#F^MTNSS;3NISTUZK$&.:#&203"/CBVK^_01S8JZH9OP,-E`7/0EXN$Z
MWSH-T<1^ZV.:[;9LD41`>4`!]EQ,,N)%'?;WBY13>9LHH.%`66@%`*`4`H!0
M"@%`*`4`H"M=IW]MM6?R:X?PKE`:/8O_`&ET?_*8?Q(T!<Z`4`H!0"@%`*`\
M/M(ZRXTJX(X*BJIPIF3"@*]9=#0;46FB:DNN+IFU.6:-GR^^M.I%17',$3CI
MS(>#9M6@)JZVJWW:W2+;<6!DPI0*V^R:8B0K0%73LW;FL2(FH[O,O\$H[\2%
M'DY&^;LRF2CNKG9$#=>5@U;1YQ5-$4L%XY8@>X'9^\V<^7<+[,G7>;';A-W(
M$:B.,1F7%=;;;&,+8<5PR555,51<J[*`TX?9:3-T@WEZ^2'[S$FM2W9>YC-"
M\VRP_'1A66P%H$5J6ZBF(H6U-NQ*`D-4Z"&^3WI;-S?MO/X8VR\-L@TXDJ$!
M.D+.+HFK7[2[QV\"XWM)@!OV+24&RW6XW"*ZXJ7!J&PK!JBBV$%I66\JX9EQ
M%=N9:`V8]B88U)/OPN&K\^)$A.,KAD$(3DAP"'NXDLPL?N)0$&]V:VQZ`L)R
M6^K)7IV_'XB*KCSIN$SBB>)[XJ8^-[=`:L7LN!O3]TL$B]2I%LFVU^SPV4!A
MI(L5]O=?_B`=^X`"*";N8DV^Z+$#:U9V<0]0R7'UN$F`LJ"MLG\WR8O1DWBM
MB)&A*T0F\2J3>"EXI8I0$)IKLJEQI<KUE/>2VC=VI[%N`Q)I](01UA/%Q4)D
MQ=CYC%M40^`L4H"QZ0TP5KN5_N;T9F,[=9QG%9;P)6HH<`*:(B8/2"?EJ*<!
MO%CBN*T!.W2V0+K;I%NN#`284H%:D,.)B)@7"BI0%8'LX;EMO1M0WB9?82,/
MQ;>Q)4&RC-R6BCN$CK*`;KRL&K:/.*IHBE@O'+$#Y$[.WG)S<O4%\DWM8S#\
M:`V;3$5&&Y8;M[!8P-*:D"(B*7!ABFV@-;079@NE[Q<+E)N1W)QPG&K4A`+?
M-XCK<4";-0_.FO,&DSE[GV2+$"1U#H5R^3CYS>98V20XR].LB(V33CD=0)M0
M=(5>9',T!*+9(BKBO"18@>+KH63/N?.7;U+=MC<ENXM65S=DTDR.:.LF+ZCO
MP`70$MVA9>YA@JT!X/2FH;I:=/SYEU*U:RM\%(\VXQ&V'@4Y(,E-`6G@-K*;
MT<%0D'%,-FQ5H"./L<M+<9;;!N,J)8Y3#$6[VU-VXDMN,"`WB\X).M+E3!5;
M(:`DIG9TQ(O3\L;E(:M,V;'NMQLR"TK;\Z(K2LO;Y1W[:"41A<@$@KDX.,6(
M&UJ^Q7*5.LU\M"`5ULSY8-.%E%V))1!DM(JXB)$@`J$J+AA@G#0&]I;3<?3U
MA9LS#SC[+)/FCKN7.O.'C>7'*B)L5S!*`A%[.!CV?3L.TW:1;KAIF"EM@W06
MV7C*,3;0.B;3HFTJN<V;7-EQ3#9PK0'N-V7Z<C%I_<H2!I_-NP/*>_3,KH(\
M1(JJC<C!\,.`Q1>Y0&1[07__`$KUWB761#BS)#4VXVYH&O?Y++;;0GSA15]L
M5".T)`!H)(*HJ<8L0-:-V9VV';-/Q!D/R0TW$E1([9*`+(&4SN2WA"*95PX%
M'"@*WI3LWO4N6Z&IF'X]G;L<O3K,!Z:W)584PF,K;2QFV!;W3<=0)Q45QS,.
M*\1*`O.F-,3;.<AZ;>'[J^\@@&=MF,TVV.*H@L1@;;S8JN)JF94P3@1*`KNF
M^R5FS:Q=O97)R3;6-V=FMQ"B%&=1N2T9&]X[R9)KJ"A>ZVXY1P`DI/9XDR\\
M\FWF8_;VGG9<*WX@!,276W&MZ,L422N09#J-B1Y0Q3+AE'`#3DZ*U/;XMTN]
MNO#EVU>4$H-FE3@9:;9;4T<1LA:`1/CBBJ9HI4!N3^SIB7>7Y7K*0U:9TR/<
M[G9A%I6WYL3=;E[?**O-H*Q&.(!(*Y.#C%B!@=[+H+UQ<)VXR"L;DQVZ>I,&
MT!)SZF3CV_0=_@I.DN3/E3'##!*`PM:`O-EMLZ5:+JY/OL*TR;9I1)8,MM1`
M,0)IHMV`[U-Y'9Q-W,O%]M<0);6^CYFJ(<.*%X>M;,=X9#[33,=]N03:H38O
M!(!P2`"3-EPX<%[B4!%W[1VJI>DKC:G;R=ZN<LVO5LZ2U&BK`=$DR2V^;MAF
M-@L'1_"Q'!%2@-O4G9M;KP$%B-*<M4*#:[A9!B16VMVL.X,M-*"(8EDW7-VR
M#+AP8+LH"I_5YJ4]31HS#+T33\*[LW<7G)C3C+KK+B&ZXL=ML'5)_#BB;BBV
MNU$H"RP>RV##O\"Z-W.64:U3I%PMUM50W0.36GPD(98;QW,<HC!7%56_%'`5
M5*`\:_[-'-47*WW"'<SMC[+C(S\`%X7XK*NJC8B>*-GC(/CI[.W'!,`/9]CN
M@_7-CO#-L99G6-YMYM]`$G'U9C%&91YPD4RW?$,5QQS`-`9F.SEAN]M3"N3Y
MVF+/>N\*S96A;:GR2=-U_?(._-".2ZN0B44S<&`I0&HSHK4USAVVZW2[%:M7
M-1G85PE0VV'VG8SCRN;K=O`3:8Y07,(H5`?6^R:V1R9A0KA)C:<$X+TJR(@&
M+S]L;8:BN%(-"D#D&%'Q$31"R;?&+$#*[V;,A="F-SY#EL">5Z:L6#0MK<E-
M7=[SC+O\%<7')FR]S##90$IHBQ3K5;9+]S4"O-WENW&Z*VN((ZX@MMMC^#[U
M'::;511$)14L.-0%AH!0"@%`*`4`H!0"@%`*`K7:=_;;5G\FN'\*Y0&CV+_V
MET?_`"F'\2-`7.@%`*`4`H!0"@-69=;9"(1F2V8Q&BJ`NN""JB<*IF5*`U^L
MNG>E(GP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4B
M?#M^50#K+IWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY5
M`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50&Y$FPYC6^B/MR&L5'>-$ACBG"F(JJ4!F
MH!0"@%`*`4!IRKU9XCVYE3H[#R(A*VZZ`%@O`N!*BT!AZRZ=Z4B?#M^50#K+
MIWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY5`.LNG>E(G
MP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50
M#K+IWI2)\.WY5`98U[LTIX6(T^.^\6.5MMT")<$Q7!$55H#=H!0"@%`*`QR)
M#$=DGI#@LL@F)N&J"*)[:KL2@-'K+IWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4
MB?#M^50#K+IWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY
M5`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY5`.LNG>E(GP[?E4`ZS:
M<3__`%(GP[?E4!(@8F*&"H0DB*))M147@5*`^T`H!0"@-:9=+;"4$F2V8RN8
MJ"/."&;#APS*F.&-`:W673O2D3X=ORJ`=9=.]*1/AV_*H!UET[TI$^';\J@'
M673O2D3X=ORJ`Y_V[WF3([,[P6F;Q$YZPP\4J&KC)I*AN,.,26ES&&50;=5X
M<NW,")@N.%`>>P:Z,P^RZPK>;W$.0["CJQ&%X!;88!I`9!!)!-#R(BNXJO'Q
MPV4!T+K+IWI2)\.WY5`.LNG>E(GP[?E4`ZRZ=Z4B?#M^50#K+IWI2)\.WY5`
M;$.ZVN:9!#ELR3!,3%IP35$79BJ"JT!M4`H#A7:+<9A:DFLF\9BTZ0LH1*J`
M*H*J((OB[?8KGOS:HD?+_F7\3N\O&,+;TN=:ONX?9[453G#_`)PN^M<^N69\
M7ZIS7FS^I_$<X?\`.%WUIKEF/5.:\V?U/XCG#_G"[ZTURS'JG->;/ZG\1SA_
MSA=]::Y9CU3FO-G]3^(YP_YPN^M-<LQZIS7FS^I_$<X?\X7?6FN68]4YKS9_
M4_B.</\`G"[ZTURS'JG->;/ZG\1SA_SA=]::Y9CU3FO-G]3^(YP_YPN^M-<L
MQZIS7FS^I_$<X?\`.%WUIKEF/5.:\V?U/XCG#_G"[ZU&N68]4YKS9_4_B=#[
M)KS,"[)!XJQYB$KJ*FW,T"J)(OWJ[;,G*-6?HGX%SD^8Y93GXDVO;3]IUVM#
MV"L:YU).L+,&3%0#1QT@>;<3%"'(J\*;4PPH0W3$SZ<UM9KVT"`XD>66/_BN
M$F/"B(HEL0L<R>W4)U*V[D9Q4HNL7P98*DN*`4!^>-57:=+N\EQ]XC>5PQ4E
MV8"!*@BF'`B)[%<M^XTZ(^,_,WXK=M35JW)QPK*GW4?$AN</^<+OK6.N69\M
MZIS7FS^I_$<X?\X7?6FN68]4YKS9_4_B.</^<+OK37+,>J<UYL_J?Q'.'_.%
MWUIKEF/5.:\V?U/XCG#_`)PN^M-<LQZIS7FS^I_$<X?\X7?6FN68]4YKS9_4
M_B.</^<+OK37+,>J<UYL_J?Q'.'_`#A=]::Y9CU3FO-G]3^(YP_YPN^M-<LQ
MZIS7FS^I_$<X?\X7?6FN68]4YKS9_4_B.</^<+OK37+,>J<UYL_J?Q-VS7*9
M&GLOM'[ZT2.-D7&P(.,B[?N5K9N/51GT'Y<_%+\^8VYR<XR3\3K2BK@?HFU2
MCF6R'+<1!<D,-NF(\"*8(2HF/W:ZS[P@M=:EFV"/"E1D`Q<=('FW$V*.15X4
MVIA4-T*7+D81<I.D5Q9MZ?UC9KWE;CN;N6HYEC.;"V(BJH]PDVU)<G*`4!RC
MM<OF:<U;VQPYFB$9*FW.ZB+]Q4RHG^-9W9Z8U1Y7XUSTN6Y9SCXJI+N[\>/`
MYLLF1YPN^M<>Y+,_.7^*\TW7=G]3'.'_`#A=]::Y9D>J<UYL_J?Q'.'_`#A=
M]::Y9CU3FO-G]3^(YP_YPN^M-<LQZIS7FS^I_$<X?\X7?6FN68]4YKS9_4_B
M.</^<+OK37+,>J<UYL_J?Q'.'_.%WUIKEF/5.:\V?U/XCG#_`)PN^M-<LQZI
MS7FS^I_$<X?\X7?6FN68]4YKS9_4_B.</^<+OK37+,>J<UYL_J?Q'.'_`#A=
M]::Y9CU3FO-G]3^)Z;EOB2+G54[J*N/^=%=DL:FW+_C?-6YJ6Y*7<W7]=3K%
M@OD^W=G)SV#S.QY(BV+G&'=JX"*'M)@2\%>@F?JD)ZHJ6:3]Y-:;[0[5=!1F
M80PIB*@Y2+WLURXDHEW-J+L+VJ",D^#J6Q%14Q3:BT+"@%`?G[6MZF3;],-P
ME0D=)L<%54$&R4!$<57!-F/W5KFOW&G1'QWYE_%KMJ2LVWIP3<EQ]BR[R`YP
M_P"<+OK6&N69\IZIS7FS^I_$<X?\X7?6FN68]4YKS9_4_B.</^<+OK37+,>J
M<UYL_J?Q'.'_`#A=]::Y9CU3FO-G]3^)\YP_YPN^M-R68]4YKS9_4_B.</\`
MG"[ZTURS'JG->;/ZG\3[SA_SA=]::Y9CU3FO-G]3^(YP_P"<+OK37+,>J<UY
ML_J?Q'.'_.%WUIKEF/5.:\V?U/XCG#_G"[ZTURS'JG->;/ZG\2=TA>YUONS,
MEE4)P20%SIBBBXJ"2+6]B;=4SZ_\K_B-Z]KMW'JTJJ;X\<S]!UTGUHH#@':'
M_5=Q_3+^2E<G,\4?"_G#QV_W7^LK5<Y\<;LRWA'MEOF(:D4T7E(%3!!W3F1,
M%[N/#1\*G5=Y=1MPG7QU^YT-\M/Q6;E+9>><*)"C,2GB;`5>)'Q:XH"JH.PW
MTX5\5*MIQ?<=3Y&$;DE)O1"$9.G'YM/#[9>X^-66USI,9NW2W$1YPVG69(B+
MX[MO>*:"VI)E5.*G_51)/@(\E:N2BK<GBVFI>+!5[*X?M,&H;9`MT[F\20X\
MB"*N"\"`8J0":>*I"J*A]Q>XOM4DDG0QY_EK=J>F#;]JH^"?[3-`M-HG`,9F
M2^MP)LG-XK8I%0@;5T@4E7>8H@Y?%\;VMM$DS6QRMFXM*E+<I7A\O"M,^[AQ
M[C'"T^4BQR;H;NZW9MA'95-KF=P6R/'W(*6"X=VH2JJE;/(:K,KC=*4HL\:5
M]B/5VMEGA+)C-R)"SX;A-.*XT*,.&V>0T:(5(N'$DS(FQ/9J6DB>:Y:S;U14
MI:X.CJOE;6#I_KV=YYNU@<A1[=(9-9`3V6C5$':V\X*%NEP[JHN(^RE0XT2[
MRO-<@[<82B]6M+[&UP^'<>+_`&5+0]%95Y'G'HXONJB8(!J9@3?_`+%#!?;Q
MJ91H5Y[D]AQ5:MQJ^YU:I]E,>\C*J<)>.RK^I8GW'OBUKMY?PGZ3^5O[/^.7
M[#ME;'T10NUS_;+?^G+XM:,I<\+]C..L2763Q%>!<4]I47'%/86O.MW''@?E
M7X=^+7N4?R.L7Q3X?Z'1M+=JTI@$CW42F!BJ[Y%3?"BKP8;$)$V^W79;NJ7M
M/O\`\+_&K/-JGAN4QC\'VG4+?<X%QCI(A/@^TNS,"HN"\."^PJ8\%:GLFS0'
MYKO_`/NTK]*Y^6M<5_QGYO\`FK^\_AB1]8GSANQ+>#]LN$Q342A(RH@B8H6]
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M[FVV[&4`!8X[['(CA*2'LPXV`_<I%5IFSIM_A]MN$')[EQ)K#Y<>%>WVX&G8
M+&MU.2I.[AF,PZ\IJF.8P;)P&A[F8D`E_%$E[E(1J<O(\EO.5711BW[6DVE[
M71_8F?9%B)O3T2\-NYT?(QD,X;6T%Q0`\4_!)4PV]VHI\M2;G(TL1NIUK6JR
MQI7V/]8NMB*W6RW2W',7YJN[R/A@K2-HV0(6.W,0NH7W%3V:EQHD1S/);5J$
MV_FG7#*E*?:TZ^RA%54X38@?M(_<7_):UL>(][\L_P!['V2_]6?HS3O]/VS]
MT8^+&NX_33G_`&RR71<@L*:[A6C/=]S/B@H7>7"LKSI%GD_CMY6^3N-]JT^\
MYG%G/QR10)4PX%1514V8;%3:E<L+KB?!_AOXY?Y7!?-#)_L?9_H=,TKVJ$()
M'O.+S:94&2`\<41,%W@\)?='O5UPN*7`_0?P_P#%+/-QK!_,N*?%?$Z5"FQ9
ML9N5%<%UAT4(#%>%%K0]$XQVJ?U--_\`A^*2L.8\)\Y^:?[/^./[2D5QGYN;
MMFMX7">D4S5L5:><SHF*XLLFZB8+[*AA4Q570Z>4L*[/2W3"3]T6_P!@AV\'
M[9<)JFHE"1E1!$Q0MZYD7%>YA4+@V39Y=3MSG7P4^]T)([+8X[S4*9+D-S71
M:_\`(0&^:`L@!,%(R)#RBAIGV=Q<*M15I_T.Q\G8BU"<I*;IC1:%J55C6M%7
M'#,^Q]-P5L)W.7+-HBP5G(&=K!7393.N.;QFE\5%V*E%'"K)M_A\-C<G)K+#
M#BUCV]G81]HMT>6DIZ49A&AMHZ\+(H3I(;@M"@(2H/C&BKBO!C4)')RG+QGJ
M<F],%5TX\4L/?[B1/3]J;C+<W9$A+60-D`(`<Z0G7'6D0A4MVB9HY+XW`J>W
M5M*I7L.M\C:4=QREMT78M6+DL<:?[7V]J/*Z=A`XY(<D.K;@C,S!0`%9*A(/
M=@.55R9D+:7&X*BGZ>T>GP3<G)[>E2X?-1NB[O;B9(^E&)CYC%D&#;D%9L,7
MQ1'"))"1D9-!540C/')ACCB/LU*A7W$P_#(W)/1+!V]4:\?%ITOO;X>U&E:K
M`<V'<9;KBL-P67#$53:XZVF*MIC[E-I>PE54:IO(Y^5Y%W(3DWI4$_M:[/B1
M-0>>$X:A@OZOO-]G$5L#46WIY"Z*<!(+>=$7_P!PHM>FN!^R\O\`\4?W8_J1
M1DDF+ID/B$2JHKP*F-<"N-.J/S&W^,7;7,3NVG2,YN6E]N/:7?2?:7/MN6/)
MQEQ$RB+1EQP%-F#9+P_<+OUU6[REW,^V_#/Q^SS/ROY+F3[?W?TJ=6LNH+7>
M(PO0WA(L$5UA53>-JN.PQ[GBK6Q[Q(T!^;]3?[Y-_3O?&E7%?\1^<_FO^[7[
MB_::\Z`,:!;Y*&I+-9<=(53!!4'C:P1>[CN\:Q>"J>'>L*$(2KXTW_Y-?L):
M1INW0G9AS)#YQ8SK4<$CM@3RFZSOLRB1(*"B(J<-6<4JGH3_``ZW;<G.4M,6
ME@L:M5SX'FVZ=MURN;3466:P3:%T\1%9`9Y`QLI`*J"%G-#X?$]NIC%-E;'(
M6[MQ*,GHHG_W*LE#%<.+KQ\)$7*/%CS'&HKQ/,BJHA&.0T5%P423@Q3VEPJK
M//YFW"$VHNJ)"+:K/*9)F/)D'/%EQY7%;$8N+32O&&95WF.45'Q?&]K;4I)G
M7;Y6S.-(REKTM\/EP6IK/AAPX]QHVF"$Z>U&<?",V9(ANGW$543BCPD6W8*5
M"56<O*V%=FHMZ5G^G$WHVGVG9UTCE*%L;>,K=BN"NNE&!PT1!3@14:XQ<"<'
M"J5*C6IU0Y!.=R.JFC7[7I3?#[,7^VA\8M=I;@Q7[@](!R:!.LJPV)M@`NDS
MB[B2%XS:KQ479[=*+M%OE;2A&5QR3FJJBJEBXX]O%=G8>8U@YS8YMR9?SN0W
MD;1A!7WUO(IF8=WB".9<4\7&H4<*E;?(Z[,[D7C%\,UQ;7L6/L//J(ATV5Y<
M=RDLAMEJ-AQB;,7/?5_Z5)I1'VT+V*G3A4KT5.7WF_\`<DEW8X^RJHO8SQ8O
MVP/QV_RTK;EN+/HOR?\`\ES]U?K/TG76?=B@.`=H?]5W'],OY*5R<SQ1\+^<
M/';_`'7^LK5<Y\<3+90KE:H4-V6W!=M^]12?0U%P'3SX@K8FN8>#*J8>W4\5
M0].,H7K48.2@X5XUQJZX43Q[OO,JW*--OK\MJ8Y;'49;;@2\Q-H),MMLJ3JM
M(9BAM`6P<>,J)CABM6K5UX%GS$;E]R4G;>E*,N'!*.-*M5BGP[6EP-B3-@B[
M!*5<4?N`.F3MTMZ$!BTK:(WG<(&C-S>XD1J*EE7QEX*-]_N-IWK:<-4ZW*OY
MX884PJZ)MUXNC=.T]Z]G0Y$QAMMUF3*:15D2F$3*8FVUD0G,!)PD43Q4L>'A
M[B3==63^-WH3DDG&4EQ:[<(TQ[7QXF&SR(\&.KAW<7+<XVXLBT+OD,W3:4$S
M,X*P65S!4)3X$1=B[*A8=N!GRDXVHU=RMMIUA\V+:IX?"Z/MKP5<'@;(:@L!
MV23&YN_'>;CQF6&U>$P,FWA,C019'`E5,Q[>-]W;34J>XWCS]AV91I*+48I8
M\:23KX?M>.)ZO=Y:DA=GG;F$R+/S%;K:&\QCF;XNB9-$`-`2-H0D0*JJ1+PX
MJM3*5:XD\YS:FKC=Q2C/PPQ^5N2=:444Z53:JZOMJV?8^H+4VXVCRB^TQ!AN
M-B2*H\YBM92:1%%<"/Q<_M=VH4E]R]Y,.>M)JN*4(/\`BBN'#B^%2#O<UJ4U
M:U%U7G6H:-R27%2WN_=,LRKPK@:+C[=5;X>P\SG;RN*W1U:AC[=4G^TC*@X2
M\=E7]2Q/N/?%K7;R_A/TG\K?V?\`'+]AVRMCZ(H7:Y_MEO\`TY?%K1E+GA?L
M9QC!5+!-JUY:/QB*;=%Q)FR:7NUU?W<6.;JIPJ.P1X/&->*G#CAPUTPL-\3Z
MW\,_*]R3U7_D62\7^GZ_8=ATEH1BQO),=D&_-4%!4%5!I$7#9ACB>'_4N'=P
MQKK/O$J%JH2?FN__`.[2OTKGY:UQ7_&?F_YJ_O/X8D?6)\X2=HE1DBSK<^XC
M`SQ:0))(J@!,GG3.@HI92X%5,</86I7:CNY2['3.W)Z==,<J.N/Z?8;?.+<T
MEOMG/%48CDA_UC'S``OO@"-954=YD;-D%(LJ%M7!-B*MJK!&^NW'1;U>%R>M
M57S22T]E:)Q572O&BPQSSI<;F>%RN;=TE[YDH\J-O"D-@)*KV=YUMHRXN&3,
MI88=RC>;J;7KL-'\RXKDZJDHUU)=M922;[JUIW&WK&XP7K3`824$^40M.-RM
MAOHT*OH0OND(GF7.WQ55>!>#9C:XU1&OXM?A*U%:E.6#3XRI\WB?&N,<.[L[
M=?2U]L4-MB+,8>;42D.O2@>$0,C8)L!($:,E04V!QMA$J\"X5$))&7X;SMBV
ME&:DO$VZ\:QHL-+^S'!ML]PIUJY_9[N4QMINULLMNPC1Q9!*PJJJ!E!6RQQV
M8F/^%1%JJ>1I;OVMRW=UI*VE6..K#+"GWK[#'IJ^6&+'9B3([[9`,LWI(/"(
M.&[&)H!(-R:[$XH8EQ2(EX%PJ8225&9_A_.6(149J2\;;U<:Q:6&E^R..#DW
MP=#[;;O:PBVR$^XG-R8DLS!-%(6E-]7&C,<N!JB<&'L]RHBU@O:6L<W:4(0D
M\-,E+N^:J[,31OEW8N-OCDBY7UF37C855)6VW491H<V"(J(+:BF'<3N5#E5>
M\Y>=YJ-VVJ<=<W3)/33]5/L(6JGF&Q`_:1^XO^2UK8\1[WY9_O8^R7_JS]&:
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M2(3"&@M@R>?$U<$%S%P943#VZ<%0Z92A9M2@I*;G3A7"CKVI8]WWDC`DPVDC
MH5Y;=L8H"OVB7O'74'!%D"TWNB9`R7.C9@8K@OC)BM73[\#JLW(+36ZG9PK"
M56_^ZBTZ4WCI::>/%8FWINYVR/I^5SB7GCMD&^MDG!Q,5-W!8S1(0XJ)!B6*
M*BHNU$PQF$DDS?D.8MQL2U2^5<82Q[9>%<,L>-:D#IR6W'68'.D@S'V1"'/5
M3'<FCH&:YVT)P,S8D&(IMQP78M4@Z'E\A=47):M$I+Y98X.J?%8JJJL,Z<"6
MESX,RWN6QZYM.3C!@I%T=WQ-.FRZ^6UQ0)XB1M\`3,'X*IP(F-FTU2N)WW;T
M+D':E<3G2-9O51M.?;34\)16*[*<$CX%UA"Z4:-/&-+:@1XD:Z)O``7&7,SJ
M@X`[X1,.*BY=O`NRHKW]B)7-6ZZ8STR5N,5/&E4\:-+5BL.!XD7B."2L9V_N
M"6U&"N`*XJO2DG`^)"X2"XJBT@IF)$PRX)P)4N7?C0SGS<5J^?5/:IJQ^:6X
MI+%XX1IB\J9&:5J"U.'(%C+'8?@RS5L$5!YS+1%1I404Q)OQ,W=]JH<D_<_>
M:SYZTVTL$X3?\4NSAV<*E0JA\\$X:A@O;O\`;R!_,7/B5KTUP/V2Q_Q1_<C^
MHHF"XX8;>#"O-/QUP:>FF.1)6JQ7"XR!9CLFZXN&#8)BNU<-J\`I[:UM;LM\
M<#Z7\+_+=V]\UVMN'_D_A]ON.L:2[.$@.1KC<'SYVU@XW':)10%5%Q$SQ4BX
M4X,$[FU*[$J'Z#;MJ$=*K3O;?WNK+U4ES\WZF_WR;^G>^-*N*_XC\Y_-?]VO
MW%^TRBL&Y6V#'>F-P3MP.-'OD,MX#CIO9F\@EQDWBCE+!-B<;;LR>*H>9%V[
MUN"<E!VTUC7%:G+"G;C2CI[<<-SUHU-N,Z=#N9V:8Z8(!FXXVV<<&T%1)6!,
M\ZD(KE\7#&K5JVZT.GJ8W+DIPN.U-T[6DXT_[4W7AW&W;)UN#4\`QG#'D(#8
M29L/&-%==YRA*A((MY6UCX`N`"F=-NS$JLFM2-N6O6US,'KTRHJRC\L6]7L7
MRZ,."^98]K(;54N))NQ'&W:Y&Q;><9`6VS=''.8(*"F"^SE3&J3=6>=^)W83
MNUC3A1T5$WVM</U&W;7X\*$ZI7<7[<ZR[GM"[Y#)]QE6P(F5%6%R.Y20L_`*
M%P[*E.G;@='+SC;@_P"96VXOY/F\3C1?+X<)4=:\%7C@1$/=1KC#<)T";%QE
MUPQS*@IF0B1<41<1[N'^&-41Y]JD+D6VJ53_`$]A(L7"&.H;K*)U$CR&[B++
MF"X$K[3HM;,,>,II5D\7]IV1OP7,7)5^62N4_BC)+WU)"U7@4@6D`N@068&8
M9\4MZ#D@5D&\HIN@)'`5L\J"9(F..S;BME+!8\#KY7FUHMI7%!0\2QK+YG*F
M"Q5'2DG2M?:]>WWV!$CD8BA"MU20L-4RH<56W!(2P0ARJA95&JQE3W_<96.=
MMPBW_P#UKISC1U[J=E#Q=+I!<MUPALNH0-O06H2(BH)M16GFW'1'#B(X9[Q1
M]D^ZN*U+DJ/[#/F>9@[<X1>"E;4>]1C--]U6]5,Y=N)'V+]L#\=O\M*UY;BS
MVOR?_P`ES]U?K/TG76?=B@.`]H:+UJN*X;-\J8_^U*Y>9XH^(_.$):K<J?+1
MJO>5FN8^+%`*`4!\H#[0"@%`*`4`H"\]E2+UEB;%V"\J_!K7;R_A/TG\KK_X
MU^_+]AVNMCZ(HG:RV;EOMP-BIF4@D$1155?>U[B4*R54T0>ENRE]X`DW4BB@
MJ[8Z)[ZN!)PK^"B[?;K*W:4?:>5^&?@MGE%5?-<IC+X9?Z(Z?`M\&WQTCPF`
MCL(JJC;:8)BNU5K4]<V*`4!^;+^*^LY!=Q77,/\``UKBYA?,?GGYLM27,J3X
M2BJ?9Q(ZL3Y<4`H!0'R@/M`*`4`H!0"@-B!^TC]Q?\EK6QXCW_RRO_MC[)?^
MK/T9IY%2P6Q%3!4B,(J+L7\V-=Q^F%/[7(8O0H!-MYI)NDT)"BJ6505<NSN8
MI59QJFCFYVP[UF=M.FJ-"/TOV5.*HO7A=TPJ*JQ@+WTE44RJ1IXO"NQ.[40M
MJ/`PY#\,L\K&EM8OBWQ?Z9'2XD2+$8"/&:%EEM$$`!,$1$3!*N>@9:`XOVLQ
M7FM0O.FB9)`-&U@N*J(AD7'V.,*UAS'A/G/S2O\`X_XX_M*'7&?FXH!0"@/E
M`?:`4`H!0"@%`$X4J&#I<2.TYV6.&3:&ZU+%65PQ(2(P!<OMJ)*E>FN!^R\O
M_P`4/W8_J1K:8[-+A<E67*5848E0A,QQ<-"',B@*[,-J;5JD;23KVG!RWX/9
MM797::IRDY5?^VN7Q.I6:PVNSQ]S!91O%$WCG"9JB88F7=6M#U20H!0'YOU,
MB^NIA8<59#R(O_RE7'S"^8_//S9;DN94J?*XK'V5(NL#Y<4!\H!0'V@%`*`4
M`H!0$E8D59K:(BJJN-X(GXZ5T<MQ9]A^3U_,N?NK]9^DJZS[L4!2M7=G$6[N
MN3(1HU.=)"=!U5W1=Q5V(I"55E%/B<_,\K:OQTW(ZHE:^IV[^=B<M[R*KLQR
M.#T#DO+7OE\1]3MW\[$Y;WD4V8Y#T#DO+7OE\1]3MW\[$Y;WD4V8Y#T#DO+7
MOE\1]3MW\[$Y;WD4V8Y#T#DO+7OE\1]3MW\[$Y;WD4V8Y#T#DO+7OE\1]3MW
M\[$Y;WD4V8Y#T#DO+7OE\1]3MW\[$Y;WD4V8Y#T#DO+7OE\1]3MW\[$Y;WD4
MV8Y#T#DO+7OE\1]3MW\[$Y;WD4V8Y#T#DO+7OE\1]3MW\[$Y;WD4V8Y#T#DO
M+7OE\3Y]3UX[CL/EO>139CD/0.2\M>^7Q+[I324/3\8A;)79+R#OW51$3$>X
M&S%!_P`:T2/5A!1BHQ5$N!/4+'DFVR,3(44PQR$J(JIBF"X+W*`]4`H!0"@.
M8:^TI8&YG.`N#$5^0:D_%>S+AF3%"`60,A3B]U,%]FJRBGQ.;F>3M7U2Y%27
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M_*66<YB5N"$VX\=2Q7(2*JNB\`ED[GBX+[-6C!1X'7RG(6.7KM14:\>/[3J-
M6.P\DVV1B9"BF&.0E1%5,4P7!>Y0'J@%`*`KFM=-6R[V\GY;R13B@:A(7#(B
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M`4`H!0%&U3V91KH^[,@O(S(=+.;#B8-*6Q,44$Q'8BKP+BM5E%/B<W-<G:YB
M.FY'5%.O;Q^PKWU.W?SL3EO>15=F.1P^@<EY:]\OB/J=N_G8G+>\BFS'(>@<
MEY:]\OB/J=N_G8G+>\BFS'(>@<EY:]\OB/J=N_G8G+>\BFS'(>@<EY:]\OB/
MJ=N_G8G+>\BFS'(>@<EY:]\OB/J=N_G8G+>\BFS'(>@<EY:]\OB/J=N_G8G+
M>\BFS'(>@<EY:]\OB/J=N_G8G+>\BFS'(>@<EY:]\OB/J=N_G8G+>\BFS'(>
M@<EY:]\OB/J=N_G8G+>\BFS'(>@<EY:]\OB631W9T-EEC.F/`[(!"1MEM%5L
M57\+,:9E7#VDPJT8I<#OY;E;5B.FW'3$NU6.@4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4!X?>!AAQX\<C0J98;5P%,5H#\YWRYR)-Q??WI%OC)Q'"5<ZBJ
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M"2;%K:S<;=&?1_ES\7NSO;5QN>K@V^%%7W,_1==1]N*`4`H!0''^U>[RRO1Q
M,V5F*`"V**N"JX*&1*G!CMPK*[)QC@>/^.\[/EN6<X>)M1]E:X^TY_SJ1YPN
M^M<FY+-GY[ZOS?FS^ICG4CSA=]:;DLQZOS?FS^ICG4CSA=]:;DLQZOS?FS^I
MCG4CSA=]:;DLQZOS?FS^ICG4CSA=]:;DLQZOS?FS^ICG4CSA=]:;DLQZOS?F
MS^ICG4CSA=]:;DLQZOS?FS^ICG4CSA=]:;DLQZOS?FS^ICG4CSA=]:;DLQZO
MS?FS^ICG4CSA=]:;DLQZOS?FS^ICG4CSA=]:;DLQZOS?FS^IF1B7(1T<34D7
M9@JK4QNR3XG7R'XWS4;T:SE--TI)U6)W;L[GS)NFP.4ZKIM.FT!EPY`PRHJ]
MVN\_4&L2S4(%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0&K=?]KF?H'/R%H#\VSOSH_BI_E7%?\9^;_FK^\_@B:]8G
MSAN^KQ]2>LMXN;G7-MUALPW>\S8X_P"&&%33"O>=73K8W*_[M-/LJ;35A$W[
M<&^5`F0W)SRY4Q`&5>4Q!,>,62.N7'#:O^-2H\#:/(IR@J^*#F^Y1U5IGA'#
MAB9HUEL]P<%NVS74<0T1QN6V#9D*B1*K2-N.YLJ`N..'"E$D^!I#D[-UTMS=
M:_[DD_LHW7@:NH+9!MTWF\62<A$$5-'6]V8YP%Q,<%,<%0^X7<7'N8I*C,.>
MY:%F>F,M7M5'P3[UVYFQ#MFGY%NDR5E3&W8K*&[F8:W2O%@@M">]Q527%4Q3
M%415PV427>;6>6Y>=N4M4TXQQ^54KDGJ_1)GD+79F+;%D7*1);DRQ,PCL,MG
ME;%<`(E-QM<#X1V4HJ8D+EK,+<97)24I=BBN'9QDN)[@V*WNC;F9,EYN==D1
M88M-B;*(;Q,!O2(Q)/?`7'**\7V]E%%8=Y:QR5N6B,I-3N^&BP\3BJNM>*[$
M\##-T^Y'LD:Z"ZCB...MOM(BXM[MQ6Q/'W!*."*N&W94-85,[W(.%F-Q.M6Z
MK*CI7V,\W2Q';[9;I;KF+T[>YX^&"M(VC:BAX[<Q"YFPPX,%[M2XT2*\SR3M
M6H3;QG7#*E./>ZU]E,R+JIPFS;?VQO[O_I6MCQ'O?EG^]C[)?^K/TW7<?IHH
M!0"@%`<2[5/ZFF__``_%)6',>$^<_-/]G_'']I20',8CP9E1,?NK7&?G$55T
M)8;$"ZCEV??+EBG+!'LNTN:@X2<7'\+=^SLJVG&AWKDEU$K-?#KQ_=3_`%T/
M?JFRQVHHW"5("3*9;?'<--FT(/)B&8S<;+%/PN+4)+M+OE+,%%7)2U22>"5,
M>&+DOMP,EHTU'ENSUDR\(T$G&][%%'=X3;3S^8,Q-ID((QX+CPJ/MX6C"I;E
M?P^,W/5+Y8558XUI&4L.&%(/[B%<9!)),LNBZ&?*V]M`23'!"X^513\:J'G2
M@M6E.N/'A^LW+U:F[:Y%`)`R4D1Q?5P$P!%(S!1%5\9$R>-W?N5,E0Z.<Y56
M7%)ZM4:_>U^SB9XMLM`6MJ;<Y$EDY#C@L,L--N*K;:"F]7>.-\534A3#NBM2
MDJ59I:Y>RK2G=E).3=$DG@NW&2PK5?8SWZKLD>!'D3Y,IMZ5O#:8:9;)4:$L
M&S/.Z"IGX4P3"E%3$OTMB%M2N2FG*M$HKAV-UDN)D33T!22#SEWULL;G6&['
MFV7F_.LN\S[S'=;/$\;VMM3I[.TLN0M^#4]W3JX?+X=?&M?#W<>[$U9%C-O3
M\2\`[O!?)P7F<.,V@FH":X8\4E3#%>[LJM,*F-SDFK$;J=:UJLL:5]C_`%BZ
M6([?:[=,==17IRNYX^&"M(VC:BAX[<Q"YFPPX,%[M2XT2(YGDG:M0FWC.N&5
M*<>]UK[*9D:U^<'[J5"XF'+?\L?WE^L[IV7_`-,K^\N_^E>D?LLN);J$"@%`
M*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H
M#5NO^US/T#GY"T!^;9WYT?Q4_P`JXK_C/S?\U?WG\$37K$^<)>`[&E6<[2[(
M;B.I)YTV^]FW1>][M0)10B%>ZBX+CP;*E<*'H\O*%RSM-J#U:JOAPI3`RNRX
M+MQMS`R2:;M\?F[<]O$/?Q)QUMQ-BD((ZXB*O#E3-P[*FJJNXO.["5R$=5%;
MC34L/F^9I]RU-=]%7N)`IC`"!W.\!*GHZ"Q;E"(RDM)@2&KKQ@V9)M%!Q4L$
MQPPJ:YOW'8[L51W+BE.N$HUU+.LJ)OLIQHN!XU]+AOS6`!QA^8VBK)DQT14,
M3::R9W$1%<-"$\5+V4V^Q-UXF?XW=A*22<937%KMPC2K[76O$B),IANRPX<8
MT4GE.1/PQ0MZADVVV7`BB+8H8\."F7LU1O`X+EV*LQA%\:RE[:M)>Q)57[S)
MNT7AX6X)R[X)6B,`A)LY*X"FV&.9I&116G<?9(DS=VKQEPJ\,CT^5YII0<KO
M\J*588K#M6GPO[>/:8+:_`,[#.<G,,)9T!),=U31X]U*<D+NA$2$L0<1$Q)-
MM0GP[C+EYVV[5QS4=KBG6KI.4L,,GFL3-$O%K)F!%?='F[S<MN6)HJBTIR%=
M:,QP7-@G!A[-$UA7O_6:V^;M.,(R?RM23[OFJF\R.OMV8N-OC&)97EF37BCJ
MJDK33B,(R..")@(MY4P[B5#E5>\XN>YJ-VVFN.N;IDGHT_JI]A"54\PV;;^V
M-_=_]*UL>(][\L_WL?9+_P!6?INNX_310"@%`*`XEVJ?U--_^'XI*PYCPGSG
MYI_L_P"./[2D@64Q+ARJBX?<6N,_.(NCJ64YMN;NTO422FW$E\Y-NWCFYP+D
ML#!1/%,B"&\7C(JYL$V)FV7KC4]IW;:NRYC4GKU?+_NK--8]E%5X]N&"K@MS
MJ!$C@Q>6`M^05E6R>I&.]X75!G=N-</B%P_<J(\.)-B24%INK1VPG5X]ORT:
M]CXFQI69!;NET&%.6#'=22L:/))>;.,;A]&Q?%4<0R`B;7`L4PS<*X8VMO%E
M_P`-NP5VYHGHB]5%+PN.F=-2QJTW'!UPJ5V]/PI%WF/P01N&Z\91VT%`005>
M*F5-B?<JDFJX'D\Y.$KLI05(-NG9@;5T=C3%L[+3X#NX;3#SAYD!L]ZXJYU1
M%78A(JX(M'V>PWYF4;FTDUA!)]WS/B25CNDP(L$5OHQK=$+"3;")QM3;WJN.
M"@`)"[G$OPU3AR\"5:,GAB=G)<Q)1A6[IMQXPQ555MJBPE7O]G!&S"O1*['>
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M[R_6=T[+_P"F5_>7?_2O2/V67$MU"!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4
M`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!@N#1O0)++:8N.-&`)P;2%42@/S
M;<VG&I"MFF!!Q"[J9AV+M^ZE<7,>(_.OS7!KFJM8.*I]AJ5B?,B@%`*`^4!]
MH!0"@%`*`4!M6U%66"X;$X5K:POF/H?RQ"3YQ-+!*5>[!H_35=I^E"@%`*`4
M!Q/M41>LTS9YGXI*PYCPGSOYI7_R?QQ_:4>N,_-A0"@/E`?:`4`H!0"@%`*`
M]-?G!^[4KB;\K_RQ_>7ZSNG9?_3*_O+O_I7I'[++B6ZA`H!0"@%`*`4`H!0"
M@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4`H!0"@%`*`4!^?]78>O)^
M/-L-\7YK'=_^S#;]WV\:PO?8?._F#3I6K9I_WZM7'_;H^:F9!^]?Z7ZRL,.[
M[SY+^1_C_P!<>]?Z7ZRF'=]X_D?X_P#7'O7^E^LIAW?>/Y'^/_7'O7^E^LIA
MW?>/Y'^/_7'O7^E^LIAW?>/Y'^/_`%Q[U_I?K*8=WWC^1_C_`-<>]?Z7ZRF'
M=]X_D?X_]<>]?Z7ZRF'=]X_D?X_]<>]?Z7ZRF'=]X_D?X_\`7'O7^E^LIAW?
M>/Y'^/\`UQ[U_I?K*8=WWC^1_C_UR<TINO6D?'FF7>)ASG>;C-W-YAQN'@QV
M>SLKHL\.P^P_+VG9EIVZ:O\`9J_\M?S>SLXGZ`K8]\4`H!0"@.;=KGYV#^:_
M-N<'Y[_W?Z?L>WC4/@9WO^.5?_S+]7;W>PY8NZQ__%^LKA5/^W[S\T_D?X_]
M<>]?Z7ZRIP[OO'\C_'_KCWK_`$OUE,.[[Q_(_P`?^N/>O]+]93#N^\?R/\?^
MN/>O]+]93#N^\?R/\?\`KCWK_2_64P[OO'\C_'_KCWK_`$OUE,.[[Q_(_P`?
M^N/>O]+]93#N^\?R/\?^N/>O]+]93#N^\?R/\?\`KCWK_2_64P[OO'\C_'_K
MCWK_`$OUE,.[[Q_(_P`?^N9(V3><7=XX+XN?-_AF[M7M4U+A]YZOX+M=3'3L
M5[MW5_#KPK]YW_2/^R,_LG_Z/YO@3QO]3W5=9]T3-`*`4`H!0"@%`*`4`H!0
+"@%`*`4`H!0'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_
MVP!#`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0'_P``1"`#C`?P#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#^_BBBB@`H
MHHH`****`"BBB@#@O^%B>$AX^_X5K_:W_%:?\(O_`,)G_8WV#4\#PT-3_L;^
MT?[1^Q_V5_R$O]%^Q_;OM^/WWV7[/^^KYN^-_P"U?HWPE\1^)=/BM/!<NE?"
M;PYX$^(?QM\0?$+XF:=\)-)\(>!OBCK_`(P\&?#R;PUK7B70[KPIXI\6>*?&
M7@37="L_#NN^)_`NF0R)9M=^*(;W4])T[4OL1E16+GC:,DXYQCDXP6`[#MG`
M/-?FKXA^.O["'[4>L:SHGC*_\9V:^!98O"?CU?B;\/OVD_V=/!=W)XLCT'1]
M.^$_Q-U/X@^%OA=X(\=7'BF+XC>'[C0O@MXZN_$-QK\7B6T\0:-X.O(W_M&'
MSLPKU:5)4Z6.P6%Q5>I-85XF<<.JD*=.<W2BZBK\\J?NU:THTKN@JD8JA*<<
M13^RX-RO`9AF4L7C^&.)<_R'*\+@WGD<DPF(S:M@ZV,QV&PE+&5*6"J93*C1
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M^%/&OB>XE^&^E:AJ]]I=]>>$-/\`AQJWB*?0/"47B?Q?H6C?"^#5'UJRT3P)
M;V?8_`E/V7O`\.B_#;X(>*?`D;>%_#UA\)=+\)Z!\0_^$DU"RTWX.)J7AR/P
MQ?:?=^(M7U&\\0>!_L&J:+KEWJR77BRSET^]LO$%ZTUE*D.5&IB_K:C6S#!5
M*<:^/Y\/&I1==TZN(A'+Z:Y:=)PGAXPQ%&K"TJDYV@ZE2<9R79F&%X?ED-2M
M@.#^)\+CJN5\*O"YO4PF9T<IIXS!95B*W&&-JJMB<=#%4<XJ8O)\PR_%TYX;
M"8;#<]>E@\'AL30I2Q/'W[3-]X.^$'A[XBQ>`TU74/$?C77-)L?#,?B&_P![
M>!_"FK>*K_Q#XU%_IGA#6;A[RV^&GA+4/%UEX<71_(U+Q-=:5X`A\2)/J5IX
M@DP?B5^W=\(OA5\1;OP/XJT[Q2-!T>\O]"\1_%'33X3O/A]X9\2:1^S_`.-?
MVF]:T+6[E_%EOXFM+K2?@_X.MO$MS=+X8DTR9/&GA"/3[V]CF\13^'7:S\./
MV)/CQI7@7X1Z_8_!CXS6/PPD\1>%O"?P^\2Z[HOQ*71-9\,;_#WB>UNO#FM:
MIKCW_C3PR^@:AI&L:GK5K>>,M!N(_$EK<:A97.H^(%NOG#Q!^S]^SC;_`!_T
M7XS^._VC_AM=_".WMM3T?PM\(O%6OPLB>+O!/A2[_8P\8:8?%-]\3ET'Q+H^
MCWWQ2G^'7CRT\2?#K6_BNWQ6\8>$_"'BKXL2:=I?@#X=:3R8BMG,%"I1Q&75
M:;JX*$YJM1=.A3IPMF.(KJK"BN1U9QTHUI58QC14*5!SJ-_0Y+EWAMBY8C"Y
MID_%^!QE/+^)L7A<.\NS98K-<5C,9"7!F597+!5LSD\5#+L+B$JN8Y91R^KB
M:N93Q&-S6GA<%"'J?B#_`(*4?!73/AE\+?BQIWAOQWXJ\'_$?X6?%_XQ7-_X
M0D^'OB2W\$>"/@%XP\!^"OC%?>)=2TOQ_<:)K,W@;4_'0NKF+X=ZIXZCUZP\
M+>)AX1G\0:DWAO3O$?M?@/\`:V^'GQ!\4^!O"NCZ3XJMM2\>#]J(:7+J-IH\
M5G;?\,F?&WP]\!?B)]NDM-;O;J(Z[XN\2V.K>!Q%:3_VEX7@O+W7?^$<U6.'
M1;C@H_@]^Q/\4O"?PR^']G>>#_'&A^*/@)\8/`WP[LK'XM^(->U7QO\``CXJ
MWO@:3XSZKI>N6WC6Y\1^-[;Q'J^C>![OQ+\4IM1UCQ/9ZS=V]ZGBVRU'Q-?S
M:KZ]X0_9<^!W@;XEW/Q7\+>#IM+\9W,?Q!5+H>*O&5YH>G+\6-=\)^*?B.VA
M>#K_`,0W7@[P]_PFGBKP1H'BC7Y-`T#3C?\`BC^V_$+DZUXK\5WNM=&&6<N=
M.=3%9=B:#CA%65%.+C)0PT\74I2A"ISJLO;3H4YSC:-:C)3C"*4O&SN7AQ3P
MF-P^%R'C3)<VC7XAJ9;+,G&K"O1GB,VH</87,*.)Q.#>'EELU@:&:XO"X:JY
MU\MQ^'EA:F(JREA^U^"?QE\)?'WX8>%/BUX&CUR#POXQM[RZTN'Q)HUYX>UV
M&.PU6^T>YCU+1=05+W3;A+W3[A?LUU&DP0*SHA;:/6`0!@=N/QZ#/'Z]*\_^
M&7PQ\!?!_P`%Z5X`^&OA?2_!_@[1[C6;O3/#^C0M!I]I=>(=<U+Q+K=Q%$\C
MMYFIZ]J^IZK>,78R7=[<2'[W'H&!T^A[_AWZ<<#IQ7I898A8;#K%NE+%JA26
M*E04HT)8A0C[:5%3]]4G4YG34_>4.52UN?%9U/*:F<YM4X?I8ZAD$\SQ\\CH
M9K.C5S2CD\L76EEE',JN'_V>ICZ>"="&,J4'[&>(C5E2]R41:***W/."BBB@
M`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"
MBBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**
M**`*S3H"5+H#T///\_?]>:3SXA_$GXX)_3%?YOW[7'[57[4&C_M6_M-Z1I'[
M1_QZTC2-(_:$^,VEZ5I6E?%_X@Z?I>E:7I_Q'\26NGZ9IFGVGB&*TL=/L+2*
M&VL;*UABM;6VBB@@B2)$4?/7_#7G[6'_`$<_^T1_X>OXD].P_P"1E_SZ5_.V
M/^D3D>7X[&X"?#F;3G@L7B<).<,7@E"<\-7JT)3BG%249NDVE+5*6I_LCPC^
MQG\4^+^%>&>+,)XS^'V$PW$_#V2<0X?"8CAWBF>(PM#/,JP&:T<-7G2K^RG6
MP]/'PI59TU[.<Z<G"T6C_4&-Q'QEX^OM^0SG]*LC!';!';IC]*_R\1^UW^U@
M>1^T_P#M$`@;\_\`"ZOB3]X=Q_Q4O;UZ^]?Z5GP!O[[4_@5\%]1U*]N]0U#4
M/A-\.KV_OKZXEN[V]O;OPCI$]U=WEU.\D]S=7,SR37$\TCRS2N\DC,[,3][X
M>^)F`\0JF:4\#E>-RYY73PM2H\77P]955BIUXQ5-4(KE<'0;ES[\RMLS^3/I
M@_0>XM^AYA.`\7Q/QUPWQDN/,7Q!A<)3R#+,WRYY?+A_#Y5B*T\5+-*DU66)
MCFL(TE12=-T9NI?GAR](WP[\'GQX?B7_`&61XT_X1C_A#/[;%_J&?^$<_M/^
MV1IO]G&[_LG_`)"/^D_;?L']HD?N?M0MOW%?!?Q__8(N/C9X?_:4\/VOQEE\
M(K^T9\0;_P`;/,O@33M>7PW'??LG>&OV7)-$D-SX@L-5U`JN@-XZEU?P[K/@
MC4-06Y_X0'5?M_A"Z\36_BG[NN=$\6-XXEUT>+B?!+>$6T9?AX-"T]2/%9U3
M[9_PE_\`PE'G?VGQI0.C_P!C>7]DZ7@;S<BOPYUS]D?]M31;G4-7^'NEWNF7
M4X_X*$:QI%W;^,-*&OZ7<?'O]N7X4_$C1?#GAZ30?BU\+=8L;[XF?`;P#?:_
MX3U#2_B9X`D\)^,=4NT\4^-OAYKK6T\7UV=<DL-*A4R;%9C0K?7'7I8:;ISF
MI4J6'G)?5YQE.6+HXBM"//4IU+4IN?*DJD/YX\,ZF,HYY1S3!>)>1\'9KEJX
M:66X_/,/#&X2@\/F6,SC"8><<YPTZ-&EP]F>39;BZJPN"QV#Y\=AX4)UI2>$
MQ/TI\0/V#O'?QR\9?MIQ^,O%,7PX\(_%WQCXC;X9ZCI^DVVNZCJ<OC3]A/X;
M?LS7/C/53I?C72Y+WPIX=U"\^(=L_P`.?$=CIMUJWB'P[HWB:SO]-M(]&U2]
MZ;X7_P#!.FW^''[0GAKXUGXN)JT_A_XD^+_B(_A\^`X[&>]/BOQ%^W[KKZ0V
MN?\`"8730?9$_;AM+)M3.ES&[/PF6X;3K=?&T=OX+R_C;\,OVU9I_P!FB+P]
M?^+?%FI0^"?".F_'_P`0>"OBU:?#70(_%T5N/A/XJOK/PW?ZNU[>6\WACXY?
M$WXVV,NAW0OX_$_P`^'5JVJ77B6V\#[?(OCA^S+^U1=?M"?ME_$[X6>&]7TV
MZ\??!C]JG2?@YXMT'Q[X8\.:Y-X\\=_LT_\`!/#P3\-9-&O5\4:9K'A75[OQ
M[\!_B59Z=KM\=%CT&]\'0ZSJ&H:3I^J^%]1U;S:E'"4JU3%K(,RQ&*HXZGB/
M:3EB7*4L5[?,G6P_LN>A46%K/ZK*BER4ZGLZ52HXM2J?;X;-.(LPRW"9!5\7
M>"<FR',N%L3D_P!4PU/)?8TZ>1SR;@A9=F[QKH9M@9Y]EM-9]3S"I45;&8*&
M-Q^$P-*4)T,)[M\*/^"<]O\`#C]H#PA\=!\6TU=]!^(GC/Q__P`(X?`:6+W\
M7C#Q#^W[KDVB_P!MCQA=M";2/]N*VLCJ7]F3_:S\)_M!L8%\;16_@O+\5_\`
M!.'4]<\7^%;Z?XX6R>"O!GQ3^(?Q&\%>%)OADLVKZ>/BI^V3\`/VS_&NA:QX
MH'CR&TUJ*3QI\'/$?A/0+RW\+Z0-)\,^-M'FO[+7-4\':C=>..)D_9N_:QTG
M]KG3O%6A:AXON?@M\-]?^*4?@75/$GQ&L_%6N:I\./B(?^"?WC'Q'X!M]9UO
MQ@_C_2M*U[XA^`OVB[O0XKZ5;?PQ:^%(?"]M9:?\/M5\#Z%JGM'[8/PA^-OB
M[Q!KNO\`P_\`!?A7XN:YJ/A#PAHGP!B\=6&D-X5_9T^*_A[5/'VI^-?B;K5[
M'\2?AIX]TZ'XH>%/$'ACP%;>+OA3JFL^.O`5[X=M]9MO"_B#1;W6M)O+>&PB
MPN-A_J_C(0PN+FE15;%RCC?:TZ=2O6HN@Y5J]&5;"TJ,8^R<*E6.&K2C1HSJ
MU:/+'.,_J9]POBWXO\-U\7G?#^%G+,WEO#]*IPS'+\7B,%E65YC#,XX?+,KS
M3#Y9GN-S'$5UCH8G!8&IG66T:^8YI0P.!S&S\)O^">VD_#'XR^`OC$?BKXCU
M:;P/JGQYUD^&+;_A*O#_`(?U"\^+WQ<^.OQ*T'S_``_8?$"3P3<'P=I'[07C
M+PQJE_KW@WQ!K?B.\T;P?X@\.:M\/+73M9\-^(?T:B">6&4@@@D'[VX#)Y(Q
MN)VY;U))XSBORB^-_P`+_P!NS6?&/[;.H?#[Q/?+X,\:?LO>(_"OP#TK0_$<
M_AO5XOBG>^!K*P\'GP[K]Y\7(])\)>+]$\9IX^U'5?%$?PX^'):T\8_#N:Z^
M)_C1/#"Z5\.,[4_@K^V_HOQ]T'3OAQXR\20?`#PU^TPGBG2I/&_C;4O'.JW/
MPLUWX3_`S5?%HU&_NOC#X=UN7PBWCL_M,>$M`\,>,-!^*B^&O$GB7P-<^&?A
M?HG@GP[X0\=^`NVA767>VIX3(L?"E4QSA4]FHSE5J?6/J"QB4ZDE]7EAL-'$
MNI*K!QH>QO2<JRD?-YKE=7C*>6XWB/Q6X4Q.-PW"L*^$>.G4HPP.%_LC_6J?
M#LYX;#4I_P!KT\[SJODE/"4\%B(5<T69>SQT*&7RH/\`62UU&RNIM2@@N[6>
M?3KE;6_AAN(99K*Y>WANTM[N)':2VG:UN[>Z6*94<V]Q!,`8Y4=M/<"!R#D<
MXQTQSGT'X^WU_$#1?V3OVC?`7QL_X*G?$+PAI7B4Z3^T=?\`[)7B;X?ZAH_Q
M1<>.?&NE^#Y=9D_:*\"^%/$VK^.]#\0_#7Q3?:%J'B3PO\+]1O/$W@WPQX%7
MQ/X/C\&:YX?T3PL;3PY]XZEX2_:-/Q(_9!UG1]9O[?P;X:\*>-],_:(T.Z\:
M:3<P:EJ>K?#;1XO#6HWXA\'Z?-X[U31_'>F36UM>Z4G@G3T@UG5==N-(D7[!
MI5IOA<SQ56G4>*RC&8:K#'5<*J<5.M&=&&>XG**.,A.=&A>A4PE&AG,W]C`8
MA3C&<8JK4\C/N!N'LOQ>$IY)XA\/9W@,5POEV?3QE:6'R^IALRK^%.1^(F9<
M-U\+A\SS.<,UP7$68YGX:X>#M#$\590Z%6KAZ]>K@L)]H4445[)^;!1110`4
M444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!11
M10`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`445_-%>_M
MN_M<?!#QQ^T+X3\-_M$^']?_`&?/!'B#_@HE^TSH7Q_^-?[`VM_&2"Q^#7[.
MO[;6C^$/VP?!VG^(]+_X+'?"SXR>)?#_`/P3X\2?'^3X;6NG77[*GPPG\=_!
MOX`ZK:?LM^#_`(QR0_##1/B$`?TNT444`?Y?/[97_)WG[57_`&<E\<__`%9W
MB>OFVOI+]LK_`).\_:J_[.2^.?\`ZL[Q/7S;7^87$O\`R4.??]CG-/\`U88P
M_P"Z7P1_Y,WX3?\`9LN`?_6.X='+_%_NG^E?ZE7[.G_)OOP+_P"R._#+_P!0
MO1*_RU5_B_W3_2O]2K]G3_DWWX%_]D=^&7_J%Z)7]'_1G_WGBW_L&R?_`-/8
M\_Q<_;??\B?Z.W_8W\2?_5;P>>&?MGC]H#_A0G[2?_"K%!)_9I^*G_"`CP$/
M%Y^.?_"XSX9UW_A&_P#A#?\`A'^-H'V(^'O[#_XJ_P#X2_[%_9H_U-?&47C#
M]N7PKXQ^/ENEG\2[LV_Q1U>S^'EY=^&=4\1:3XV\1>$_V<?V6='^&NAVZ:CX
M)\:6'@CX"?%7QNOQBUWX@_$#PP_AZR\#^-(-9@_MRSU_4/$&/NS]JW]HW7_@
M?\(/CYXI\)^"M9OO%'PP_9[^(WQ@\.^)M=T"ZN_A7<:YX3T'6+S2O#&L:M8Z
MKIE[<ZQ)?6$&H7_A^SFL+N;P\9KJWU:UF,;Q_,WBK]MKXA?LY?%7PO\``?XU
M:7X2^+OB;5[_`.$=SJ'Q)^'6BZE\)O#\/AGXT_%6/X-:9'H?@+7?&'QBUC7O
M$'@3QOK?@>[\=K/XMT+PYI7@OQQX>UJ;7[?Q9XB\%>`/%W]%9O/"QQ4)5LQQ
M^!=J5'VE#F="%2M6Q4*4)*,N=3J2]K&$HTI0A"DO:U(QDHS_`,9_#VAGN(R+
M$4,MX,X0XI@JF88_ZGFZIPS3$X7+L!P]BLPQ%%UJ:PL\-@Z#P%2O1JYAA\7B
MJ^8R6!P6(K4:LJ'>_&OQ_P#M01>*?C=X3\!67Q"MM&\,>&_`^N^$/%WAGX:^
M&=9EN$^+/BKPEX-73?#&JZ_::EHFM>(/@W!X<^*WCKQHLWA7Q1?:#X9\4?#S
M5+CP=\1;BP3P?XR^6_C'H/[6'QXT+_@GUXMO=0^,GPKUR;]FCQI\2/VAK/P#
M:?%GP9=Z%\3[Z]_92C_L]O"_AGQ%H^C-\3/"Z>(?BAXA\`_#?XQ>&_B3X;U^
M#POXV\':O\.]5AO-6UC0?1_'?_!1_P`;Z'\./C9XGT[X.Z+X=OM"^$?[=7CO
MX-:]J7C&Z\8:9XEUK]B3XJ7WPA\31>.?"UIX?\&7VA:9KNKZEX'\0Z3;Z-XI
MU:[O+/4/%NB7-]HDOA[1M>\5>K>#OVE_C?X;_:O\,?L;?$'0?!'Q5\5:C\)-
M8^..M?&[P?I7B'X/>!-+\*V'CCPWX.N/"NG^#-8USXTW^M>-M)77$UK4[9_'
M.EVT6F:CX.N9OLL/BN5]"X\5+`8J;IULSS5T,=5PF'A",,1"E3Q-;,_K.!IQ
M@I0Q%.=18:6'A45%49X->UQ-:"J0E/W\BH\69%A:6-P'!/`-+,^%,%GV<8BO
MB,5D]?'XS)<NX*IY#Q3BJ^)J4\7E&+H82IG5'-JN%JYG_:.&XDK1P62Y=7K8
M3$4Z'T[\/-:^(]Y\9/C-I/B:37CX(TL>$)/A\U]X2MM)TF<W>G7#>+$T_P`1
MQ1+<^('L-6CA@B6ZBLC!;3*UJVLQF2_@^@L-T(&,9/Y^H_B]^3^-?E[^PM^U
MO^T!^TCXZ2W^(W@_X::/X$O_`-CK]DKX\VVL>%==\01:U%X[^.EI\19]<LX_
M"^J^'KF"V\-7U_X+\26%C83^/=9U#PQI_@WPYJ+:CXKN?B'KEE\./U$R.@(^
M[G/7GO\`4]Z^ARW$4L5A?;T9XBI3J5\5*,\33J4ZGO8B<N6*JMR="G[2,,.T
MW!T8PY=(V/Q_C;*,?D6?/*\SPV4X+&X3*LBIUL/DF*P>*PG[O**&'5:O/!0I
MTX9GBW@ZN*S>G4A#$+,JV)G77/43;J***[SY8****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`***
M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*_FA^.GBS_@E>GQ
M"_:$^(WQ)\->'[#]J/X=?&#XT?#OPY_P3WO_`/@HG\:?AG\9?VCOA[XE^)G@
MB[^/_AWPW_P35T3XGZ5\*?%WB#_@H/XI\"ZM\9/A5^RL/A/XN^&?_!3^#7_V
M<OB7\>?%VCZ[^T[XONOAG_2]7X`WW[1/Q3\5>,?B[=_&+]J#_@K_`/LS>+=#
M_:`_:+\`Z1\(?V7/^"3WB/XO?`G3OA9\,/CM\1/AO\#/&O@7XG^*?^"2O[5^
MI^.?^%O_``2\*?#[XP>)O$=K\>O&OAS4?&/CSQ#-X/LO!'A(Z)\/_"H!^_U%
M%%`'^7S^V5_R=Y^U5_V<E\<__5G>)Z^;:^DOVRO^3O/VJO\`LY+XY_\`JSO$
M]?-M?YA<2_\`)0Y]_P!CG-/_`%88P_[I?!'_`),WX3?]FRX!_P#6.X='+_%_
MNG^E?ZE7[.G_`";[\"_^R._#+_U"]$K_`"U5_B_W3_2O]2K]G3_DWWX%_P#9
M'?AE_P"H7HE?T?\`1G_WGBW_`+!LG_\`3V//\7/VWW_(G^CM_P!C?Q)_]5O!
MYZAXE\-:!XQ\.ZYX2\5Z+I7B3PQXETC4-!\1>'M=L+35=$UW0]6M);#5='UC
M2[Z*:QU+2]2L9Y[/4+"\AFM+RUFEM[B*2&1T;R/0/V8OV=?"WAW0?"GAKX%_
M"30/#?A;7K?Q3X;T'1_AWX1TS2-`\2V>LZ?XCM/$.BZ?9Z3#::9K=KX@TG2=
M=M]5LHH+Z#6-+T[4XKA;VQMIXO>*\A^.OQU^&O[-WPUU7XN?%O5==TGP3I&N
M^!/"\TOA?P)X^^)WB?4/$WQ.\?>&/A=X`\.^'?`'PN\,^,O'_BO7?%?C_P`9
M^&/#&D:1X8\,:OJ$]_J]NS6Z6R3SP_U6L+#$UJ<5AJ>(Q$[4**]A"M7G[2<6
MJ%-N$JCYZD8OV49)2G&,FN:*E'_`FAFF98.A4PN%S/,<)A*E6.)JX;#8_&8;
M"SQ%.E4H0Q-3#T,51P\\1"A6K485ZE*=6%"M5HPJ1I5:E.I/>_`_X.:AIDVC
MWWPL^'UWIEUH_P`1_#UYI]SX.\/S6=YH?QBUN'Q+\6]'O+62P:*ZTOXI^([6
MW\0_$:QG62U\;:Y;P:OXEBU/4(H[A:/@']GWX&_"N+1H?AI\'_AI\/D\.VGB
M.PT(>"_`_AKPNNCZ?XOOM%U3Q78Z8=$TVR-C9>)=3\-^'=1\06EJ8X-8OM`T
M6\U".YN-*L7@F^"_QT^&G[0'A:_\6?#/5=>N+71=>NO"GBCP]XT\!^/OA/\`
M$CP/XHM=/TS6QX;^(GPF^+/ACP3\4?ASKU_X8U_PSXTT32/'7@_P]J&O^`?%
MW@WQ_H<&H^#/&/AC7=5]>&`.I^I_^O2GAJ<*RE4PU.&(I7BI3H0C6IIN$N52
M</:03Y:<K*:C+EIR7,E"0+-,S^JU<$LSS'ZCB)^TKX-9AC?J=>HHUH>TKX58
ME8:M44,1B8*I5H5)QCB*\(RC&M5C/B/#7PV^'W@X:(/"G@GPKX:_X1KPKI_@
M7P]_87A_2=)_L+P3I)B_LKP?H_V"T@_LSPMIOV>#^S_#]GY&DV?DQ&VM(O+3
M;V_`S^??Z_Y%<!X.^*/@3Q]XB^*OA3PEKHU77_@GX\T[X9_$ZP&FZO8_\(UX
MXU;X8?#GXR:?HOVK4;"SL]9^T?#?XL_#_P`1_P!I:!<:KI$1U\Z//?QZ_I6M
M:7IA\//BAX%^*ND3ZQX(US^T1IPT"'Q)H.I:;J_A?QOX%U;Q1X(\*?$G1_"G
MQ-^'GBK3]$\>_"WQX_@/QUX-\57_`,/OB+X<\+^-]%TCQ/HMQK7A_3_[0MU>
MU3Y$XJDZ:BJ<I)4^10C5A"5*32BE&-6G*E*DVE&<)4W!N+@<U6K5KR=2O5J5
MZCO>I6J3JS;YIRE>=24YM\\ZDG>3O.<Y/WIS<O0****9`4444`%%%%`!1110
M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!
M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`5_,%^T9
M^SM^U/\`&36?"?Q?\(_M`?M`>*/$'[0WQ`_:K\&_L_ZU\"_^"G?Q%^"O[./Q
MOOOB!X[^&/[4O_!,SXL>'?A[\-OVJ/A%X7U3]D#X3?L,?#7XN_`;]M_3?V:O
M!FE_MD^/K5/B[\=_@G\-/CGX@B\*_MEZ;^WW[=W[-'_#7/[,_BCX)?V3\/\`
MQ/\`:OB!\`/BA_P@?Q9L/M_PL^*O_#/?[0GPL_:$_P"%,?$MO[!\7_V3\/\`
MXT_\*N_X51XR\4?\(-\1?^$0\.>,=2\5?\*S^)7]C?\`"">(?E_X_>*_VD?V
MS/@U\0OV8;']@7]I_P#9KU?XQ>'YO#?A[]I;XX>/_P!A>[\%_LU>*K>>#6_"
MG[1NBV?[/G[9?QR^,=]\8/@-XDTK2_BU^SU8^!?`^FZC??'WP?\`#.TO/BK\
M!M)FU#XY_#D`_5^BBB@#_+Y_;*_Y.\_:J_[.2^.?_JSO$]?-M?27[97_`"=Y
M^U5_V<E\<_\`U9WB>OFVO\PN)?\`DH<^_P"QSFG_`*L,8?\`=+X(_P#)F_";
M_LV7`/\`ZQW#HY?XO]T_TK_4J_9T_P"3??@7_P!D=^&7_J%Z)7^6JO\`%_NG
M^E?ZE7[.G_)OOP+_`.R._#+_`-0O1*_H_P"C/_O/%O\`V#9/_P"GL>?XN?MO
MO^1/]';_`+&_B3_ZK>#SVSGG`_\`KU\A_MR?"#XH?&_X`+X0^#-MX#U#XE>&
M_CO^R/\`&SPWI'Q-\6>(/`?@CQ`/V;OVL_@E^T/K'AG6_&?A;P'\4-=\,_\`
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MC]FKQ;KG[+7[*/[)?PMT?X(?'SXM?\$_OC1KOBSP)XFT']G34?B_\<YO`WP8
M_9!^-D?CB[^$WA7X5?'7PU8_"O6?&OQ*^N/C1_P3!^*?C_XY_M*_'#X4_$;P
M)^SW\5_VB/CIX]FN?VF/A]'XAL/VA?#/[,?BG_@D=:?L<>%O`<OB+PYIO@_Q
M+XC/P]_;9T#P-^U!H'PD?XG:-\/HKCP#X3^*.G>+]&^+.A:/IVF_$_Q(_P""
MIGQA\&_MZ>"]:\`?&WX3:G\+/VL?BU^Q;\$_A!^S+X[\)0OK4_[*>H_M?>)_
MV;&_;&^'WB?Q)^V_\*[;Q1K_`.U3XS\5?M%>/OA3XO\`V3_V;?VN=&\0?LI_
M![]COXF_'NV^$_AGQIIVJ3_;'PV_X*/?&CQ=^RI\7?CG?)\![OQ;X<'[,UWX
METS0O#/Q9M])_8(U;]H;XC:9X&^-_P`)OVU8]3UB7PIXJ\=_\$S/"M]=?&G]
MK&72OB_^SUXXU3P1HFM1?&3X&?L)^%+GP'\5?B#]C6EQ1AL%E<(3PM/".E"G
MAZ="GB5R?7YX"G4P.*HXF-2%:GA\1E^!PW+4IUL'B9X2,5+,\6I*>"5%RGNV
MFU)RM]GF?-%JUG)3DVU:4>:_N1:MP7PO_P""3!U?^P]&^-'[+_[!_@#X$7'_
M``4IU/\`;'\2?L??#)/^%M_L]Z3\,HO^"7FH?L9Z/H6B:!XI_9C^"GA#Q!X\
MOOVA8M+^-^I:7??"KPSX?TJUO+_Q%:^)]9\;Z=;6^J^O?\$??^"<WBO_`()S
M^#/BWX&\5?#W]FK1KKQWH7[(ERWQ&^!=SJ*^)_&WB?X3_L:?!3X(?%_1_'NE
MZA\'OA[)#H$/Q[^'WQ6^,_@'Q&WBWQ9J'CF__:!\?>*O$_A7X=^,M0\2'Q=X
M!9_MS_M3>/?VF?A#\(_@WXW_`&:;?Q%\?=!_9I\)1?'K4OAY^U!\4_@3XI\+
MS:#_`,%M_B!<?&'X4_`;7/V@_@5I.EZ#\9=)_84^&?B?P-XD\%^)O$%AJ7@_
MXG2K!^T7^V1\(O!W[/?Q2;U[]E3_`(*@?%']IOXS_LY:9_PKKP'X)\)?M`>`
MOA'XG/P",WB#Q)\?/"?PR^*?["OA_P#;%_X;B_X3[^T=`TW7OV3-"^,VN_\`
M#NT+_P`*!T;P_JO[1MK_`,)!_P`-$Z=XKN/^&;X>7&5.)YX''X7$8E/`XK"T
M,9C\*\5BFHPPM6.+I5IT:V)J<U:53"32J8AXJNXT9+&2P]:6'<JBJ2E%I>]%
MN,)62;NN5I.RM9/5)12O>*:YC]M:3//X$^W&/\_G7\Z/@;_@K?\`M%Z]\)/V
MROB,FA_`CXC^+/@I\"?V%/BS+\(/AEX=N]*\;_L6>-_VMOC-\<?AI\=O@=^V
M3>>/?VC]*\+>(O'7[`'A7X<Z=\2/CQ=>.-=_8/TBYTGPQXZ;XJ2_LN>%;N;Q
MSX`W?@W_`,%3/VF_B9J'@;Q_>:9^S3)\(=%\/_L%Z-\1_"G@BXT+XG^*/BIX
MH_;@_P""C/[3'_!/32_B/\.?CY\$/VIOC5\!?A5H/@V/X/>"?CWK7P7LT_:G
MU#2]1U?QC^S=JGQ\3Q#HA^+MCYE;AO-:%&M5JPP\(T*L*4U.OR5'4JX:CBJ4
M(T:E&%=^TIXBC&G5E0IX:<IQG#$3PTZ>*JTJL&TDW[R;6FEE)QWOR[IW5[JS
M3BFG%?T)4445XAJ%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44
M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`5^8'Q%_P""EFC?L]?M'0?LU?M(_"?^RO%OC#_A(O&G
MPGE_9O\`BQX$_:@\=^*/@G#=>+K+P;XKUC]D/1/^$$_X*#ZQ\0-8N/`GB27Q
MOX6_9K_8_P#VH/A%\,='AD\4ZM^T/JOA+P?\8==^%7W_`/%+XE^'?@_X$UWX
MB^+--^(&K^'_``[_`&6;_3_A;\)OBG\<?'=Q_:^L:?H5J-"^%OP4\&_$#XF^
M*/*O=3MI]3_X1KPCJ_\`8FCQZAXBUG[!X?TC5=3LOYHC^T1\0OAYIW[5GQ/^
M`-E_P4?^"?QD\3_M/_$WX@?#W]G3X.?\$4?B9X5_8E^/GB#QQXJ\/P_"WX[_
M`!WUS6/^"6MY^V'KOA_7O`=YX&NO^"A_BF]^.WAG]I_7O''P\_:/7]DC2]4\
M-G]F&W\4@']'OP4^._PS_:#\*ZAXM^&6J>()[;0_$%UX3\5>&O'/P_\`B%\(
M?B9X#\56NG:5KH\-?$GX0?%WPMX&^*WPU\0:AX6\0^%_'.AZ-X]\&>'-2\0_
M#WQCX)^(>@VVH^"?&GA77]7]@HHH`_R^?VRO^3O/VJO^SDOCG_ZL[Q/7S;7T
ME^V5_P`G>?M5?]G)?'/_`-6=XGKYMK_,+B7_`)*'/O\`L<YI_P"K#&'_`'2^
M"/\`R9OPF_[-EP#_`.L=PZ.7^+_=/]*_U*OV=/\`DWWX%_\`9'?AE_ZA>B5_
MEJK_`!?[I_I7^I5^SI_R;[\"_P#LCOPR_P#4+T2OZ/\`HS_[SQ;_`-@V3_\`
MI['G^+G[;[_D3_1V_P"QOXD_^JW@\]LP/3IT]J\!_:5^./\`PSU\.=`\?_\`
M",?\)=_;?QW_`&6?@G_9(UK^P#:_\-+?M.?"']G'_A)A??V3K7G'P5_PM;_A
M,O[&^QP_\)'_`&#_`,([_:V@_P!J?VYIWOU?,7[7NF_`>^^",FJ_M+_%;0O@
MC\'_``!\6?V</C)K7Q)\4^.?!WPX\,Z'XG^!O[1OPI^,?PQL/$?C#QY&_AG3
M="\5?%'P-X,\(:O:W4EGJ&MZ?KUQH/A_5-(\0ZGI6J6?]9X>,9XBA"=.=6$Z
MU.$J5*-2=6JIN453IPI)U9U)N4(PC23J2E[L$V[/_G\;LF]%9;NUEYN^EEUO
MYW/`OA#_`,%6OV(OC?XH\(>%/`7CSXL)<^.M!^%WBGPQXB\??LF?M=?"#X<7
M_AGXZ:AK.B?`?Q%<?%KXN?`OP/\`"[2="^//B?0-4\%_`G5]9\8:?I_QG\?0
M0>`/AC<>*O&E]8:%='P@_P""K7[$7QQ\4^$/"G@'QY\6$N?'6A_"[Q/X8\1^
M/?V3/VNOA!\.+_PS\==0UG1/@/XBN?BU\7/@5X'^%VDZ%\>O$^@:IX+^!6KZ
MUXPT^P^,_CZ"'P#\,KCQ3XSOK#0KKG_A+_P3S_9>N?A)\)5^&GQ1\>>.?AK9
M_`C_`()=^!OAQXWT3QK\/?$ND>-/AC_P30^,VJ_M-?LN^,K#Q)H/@MM!\1GX
MFZ]XL;_A9WB+00GA[QGX'ETW_A7EGX"O7.O7._X2_P""8_P&\&^"_!'@73/%
MGQ:FTGP!\)?^":?P;T>YOM=\&R:E=>&/^"5_QUUW]H/]GW4-3FMO`=K;SZ_X
MR\9^(;W3/C-=6EI9:?XA\,0VEEX(TOX>:M'+K4WI58<-1^L1I4\ZIS53V>%A
M6Q5&;I.+:G5Q#664O:MNT?JZCA_9NE-.M-U+4H7M-+^S?5VBU?RBN=VZW;NG
M=:*VN%XU_P""MO[)/@?P[XBUV[T3]K/4=1\)>/?V9O`GB?P&/V%/VRO"OQ/T
M@_M:?$[Q)\)_@_XQ;X>_$GX'>!_%.K>`]5\4^"/'=@?$/A_3=6_M;Q!X4'PS
M\'6?BKXS>,_AI\-?''K?@[]O?]GO7->T+P=XA\=Z!I?C3Q%\6?BY\*[2T\+Z
M9\5O%G@_PU?^`?VEOBG^R]X'7XM?$74_A-X-\+_!37OC#\4/A5XA^&GPPT[X
MI3>%_"_QA^.NC>,/@[^S/XY_:'N/#-EXJ\1_%'AG_@D'^S5^S;\(OVF-5UC]
MJSX[^&1\23^RU\6OBK^TWXZD_8Z\(^-O!FK_`+!/QFU_]J/P-\<?&WC?3_V7
M?"7@/XB>/+GQ[?:IXI^/GQO_`&H_#OQB\;_$G2+%;CQ_XPN/L<FHU];>!O\`
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M@RRN/%>L?`[X??LB^*M9_9:^&7A[Q[/XC^%7A_PSH/Q:M=1\6??>,Y]",8_/
M-?(7[*/['OA#]E$?%O4=&^('CSXE>+/C?X]N/B1\1_%OC+0/@C\/_P#A(/%U
MY]KFU3Q+=_#W]F?X._`#X,W7CSQ)J6I:EJ7COXPW_P`,[WXW?$XOX>T3XF?$
MOQAX5^&_PH\/^!/??#OQ7^%WB\>`_P#A%/B1X"\3CXJ>`[WXI?#'_A'O&'A_
M6_\`A8WPQT[_`(0W^T/B-X$_LS4+K_A+_`=C_P`+&^'WVSQAX?\`[0\/VO\`
MPG?@WS]10^*-$^V^=BY4ZF)K5*%;$8JA^[Y<3BG4J5YJ-"#FZLZE.G*R<*O)
MSTZ;5&*?*DI2=Q322:2>ND4K)WV25UU2T;U]=/0**,C_`#^7\ZX#_A:_PN_X
M2/\`X0__`(63X!_X2W_A//\`A5G_``B__"8>'_\`A(?^%G?\*Q_X7;_PKG^Q
M?[0_M+_A/?\`A3'_`!=W_A#_`+-_PD/_``K'_BO?[/\`^$4_XFU<]F[V3E97
M=DY62WD[)V2[NROU*._HHHH`****`"BBB@`HHHH`****`"BBB@#"\2Z_I?A7
MP]K?B?7KHV6A^'M)U#6]7O1#<7/V33=,M9;V^N!;6<,]W<>1:P2RB&W@FN)-
MNR*-Y&5&^5_CI^T1XH\*Z7^SQ%\%O`WA?XI:Y^T=X\3PEX,C\:^/M<^$_AFT
MTL_!_P")'QD/B'4]<L?AI\2M>A,FA?#FXL;72!X.6XDOM6MS=W-BEM,&^P)%
M5E(.""-I!Z;>^0?UW<>M?$G[:A_9KC\.?"<_M#/\38V3XH_\6E;X-']HL?$I
M?B3_`,*Z^(7G_P#",G]E['Q/`'PT_P"%B#5?+_XD/]B'41J@S]DKBQTJ\,-5
MG1Q-'#<JI6J5I1HJ#^LT/:.6(JTL52I^THRG0I\V#K-5JM.5GI$^CX3HY7BL
MZR_"YADF9YZJL\PY\!EM'$9E/$TUDF:/"1ADV!QN1X_&?4\RAA,SQCH<1Y:J
MF68'&47.E:IB'Y3XF_X*F?L\>"M-\CQ8=1A\9V'PY^.GCW7_``3H>K>%;S6;
M:Y_9WU;XF>'O'OA;0--\1ZYX1\2^*[Z]UCX,_%2W\-^(--\,Q>"YXO!LTOB3
MQ+X6;7_"<.O>UZ?^V%X/U"+6-`?P/X_L/B=I/Q;G^"4GPCU&'PA;^-KSQD/A
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M?CZ<,;6S&&.E5KRC+#9IBX36'P5*5"K_`&;ALNIXBCCX3J_7*6/RM8>&<4H5
M,;BZ7RMX,_X*Q?!BX^#&E?%_XC>#O$WPVT6YNO@QH6LWNK>)?ARGA6Q\9?%[
MX)?#KX_'PYH7B7Q)XN\'WOB1?"/P[\?2ZQJ4S>&M'U?7$\(Z]IWA?P]JWB6\
M\+^'O$/T=\9_VYOA'\$KWXF6OBC3_%-_;_"SPWXHU+7=1T-/#%Q;7WBWPI\&
M+S]H74/A9HUK?^*-.U:;XA7/P<L9?'6GVU_INF^&I=(:+[3XHM;AS`/+/`WP
MU_X)Z6#0?LV>"+CP?>O++<_$27PCH7Q"\::_+I,G[+_A[X6?LZZY_P`)!XHM
M?$VH2^''\(^&=-\"_"OQKX,\0>(-.;QKI0\8:-XMT#Q/;WOQ,%QV7B_3OV#_
M`(YZ_-9>(?&_PK\9:U^T!X"?PE9:/I_QD:)?B-X0^(?A3Q7X0M]6\*:#H/C.
MTL[_`%;Q/X)\,>-O#FB_$/PM8IXKN?#7AGQ)IFB^)/[-T'48;3&G/.E1J*6:
M9+5Q%Z=.G*\(Q5>*K1KQJ.*7,Y2JY?:$*<*J<JBLG4I1EZN+POAA4S'"U\/P
M#XFX');8S'8RC[/$5:]3**U3*ZF68G!>WE5>'A2P^7<:*IB<3CL3@JL:.#G&
MM.."QU7#?0GP6^.&A_%^/Q[I]OX>\4>#/%'PM\<W'P]\;^$_%\&CQ:OI6M-X
M:\,^-]&NHKCP_K7B#1;_`$OQ+X(\9^%/%6D3VFK27=O8:W%INO66B^)+'6=#
MTSV_>IS@Y&.H/Z=<Y_*ODCQW\4?V7?V3?$_C77/&VOVG@#Q!\7])^('[0'BV
MXEL_&?B"3Q%I?P&^'GPR\'>.O$UM;Z?::Y;6=QX4^'^G?#NR3PKH4-GJ.N16
MUQJ>B>']8U4>)+T^R:Q\;/@YX=/BY=<^*/P^T9O`5QX<L?&B:IXO\/V#^%+_
M`,8:E9:-X3LO$275_$^C7WBC5]1T_2?#UIJ"V]SK6I7]G8:;'<75S!"_LTJ]
M.$94\1BL-*O1G.-9JK2@XQO4K4G5I\T/95983V=:I'EC%6JU*:]@HR7YGCLH
MQ>(JT,;D_#^>4,IS+#X2IEJJ8#,,5"O65/`Y?F4<OQ4:&(>.P5/B-X[`8"K[
M6MB)0E@,)BI2S256A+U4]NHZ=,?K]._:EKYE^*_[8?[-GP6MM.O/B'\7/#&D
M1ZIHFL>);&WTU]0\5ZC<^&]!^'GC7XK:CXACTGPA9:[JO]B'P%\//&&MZ=JK
M62V.M2:2FC:+/?Z]J>D:9?\`MVC>.O!WB/5/$VB^'_%&@:YJ_@O4[?1/&&EZ
M1J]AJ5_X6UFZTNRUNWTCQ#9V<\UQHNK3:-JFF:M%IVHQVUW)IFHV%\L)MKRV
MEDTAB,/4G.E3Q%"I4A)0J4Z=:E.I3DX>T4)PC-RC)TTZBC)*3A>7+RJYPXG)
MLYP6%P^/QN3YK@\#C*4\1A,;BLMQV&PF+P]+$+!U<1AL37PM.C7H4\7..$J5
MZ52=&&*DL.ZOMFJ9UE%%%;'GA1110`4444`%%%%`!1110`4444`%%%%`!111
M0`4444`%%%%`!1110`4444`%?SP_%C_@J[^TKIWQ:^.?@OX7:#\'X=7_`&5?
M#_[77Q3^-OP!\5_`[XW^)_B9?Z=\./VA_AK^S?\`\$\OV4=+^+^E_%/P-X)\
M$_M/_P#!6NZTGXT?&K]EFXG^&7Q'\52_#WQ_\!M*\$_LR_&_2(M&^*GQ]_=[
MXI?$OP[\'_`FN_$7Q9IOQ`U?P_X=_LLW^G_"WX3?%/XX^.[C^U]8T_0K4:%\
M+?@IX-^('Q-\4>5>ZG;3ZG_PC7A'5_[$T>/4/$6L_8/#^D:KJ=E^$.@?M7_$
M+XO3^-_'GQ*_:7_X+/?LM:OJ'Q@^..C>%/@K\"/^"./Q,\0_#/0_@UX-^,OC
MOP7^S]XLTO5?C%_P1[_:,^),WB#XL?`GP_\`#GXN>/[;Q1\6M7GT[XA>.?%.
MFV'AKX::1::?\,?!P!_0]1110!_E\_ME?\G>?M5?]G)?'/\`]6=XGKYMKZ2_
M;*_Y.\_:J_[.2^.?_JSO$]?-M?YA<2_\E#GW_8YS3_U88P_[I?!'_DS?A-_V
M;+@'_P!8[AT<O\7^Z?Z5_J5?LZ?\F^_`O_LCOPR_]0O1*_RU5_B_W3_2O]2K
M]G3_`)-]^!?_`&1WX9?^H7HE?T?]&?\`WGBW_L&R?_T]CS_%S]M]_P`B?Z.W
M_8W\2?\`U6\'GMF!Z=.GM7P-_P`%,OAA\6_B[^R1K/A/X&Z'XZ\0_$O2_CM^
MQM\3-'T_X7:E\&]*^)D&E?!7]LKX!?&3QEK?P[NOVAK_`$WX'2^.O#/@GP'X
MC\1^$=-^*ES)X)UGQ!I6G:/KMAJMG?/I=Y]\_P!:3`Q@<#Z\CZ?Y_P`*_K3#
M5Y83$X?%0A3J3PU>EB(4ZR<Z525*7,H58K65.5VIQ6K3ZZJ7_/W)<T7%W2DF
MFUHTFNCZ-=//MN?RZ?M,_LB_\%(="_8*^%GP;^`'@7]I+Q7^T7K^O_\`!1OX
MRWWQ>\!?M4:7\'/'OPQ\7_M*_M!^-?CE\&/"?QR\&?`S]MO]@'X">*?BUK\?
MQ<M=0\??%?P>O[3GP*_9]^(_PF\?>&OA?^SO\8OAI\7M/U^'ZW_:J^`?_!0"
M]\4?'_3O!%G\6/B_^S]I&N>*/B=\`?AS\.?VK_'?P5^(U]XS^.^H?LH>&K&S
M;XC>%OV@?V8?B]XRT#]E3Q%I?_!0_P"/FO?LW?$#]J#X1?`OQKX!^-7[+WP,
M^#WQ&TN3P9X?T_\`8X_=,@9!YZ]O\\#C/XGUI3@@]_IU_P`\5ZKXAQ,O9<V`
MRJ3H8C&XER>&J*5:ICZM"O5YW"K!T84HT%A\,L+&BJ%&K7=.,*U64R/9+7WY
MZJ*W6G+%I-::MWN^:]VE>Z21_,E=?L:?\%*?'G[&/P]\(>*-<_:R\/?&CP#^
MR;_P6.O_``O;:!^V_P#$CX7^-X_VI/B!^TIX`\1_\$T=,\?^*_!O[;'Q/U'Q
MV=%^#,?C#3_"6B_%C]HW]HOX=_"[2$G\(_$[XEZQJ)LM6UK=\9?`C_@IQXA^
M/'_!1CQ+\-OA_P#M*?"'P7X\_8O_`."CWP\_9[L=0_;(\0^+_#'B']I3Q;XP
M^&=I^R7\2OA5J?B__@H1\5]*^'&O^,=*\/\`Q"^(?@9/#7[*'[#&@?LFZ?XX
M?X-WNN_$JVT?1_&UO_2CCC'3_/\`G^M(!CN>N3T_P_\`KT_]9,7[6M5>!RN7
MMJE>JJ<L-4="C]9Q=+&U:=*C[54U3=6E"$%-2E"ES1A.//44CV*5O>GHEK=7
M?+%Q3>F]G=VTOT>C7R!^RC\,_BC\([K]H[X=>+K[QWJGP?\`#WQVTX?LJ7OQ
M,^*?B#XU>-IO@AJO[//P"UOQ6NL_$SX@>+_'GQB\2K%^T[J7[1,&F#XQ^+-5
M\7:-I$5AX>\-?8?A)I/PUTZS_!/X#_\`!-?]OS]FGX>_L9>!_A=X?&@?";X1
M_P#!-<>&/'_@7PM\6?#6B_'SP1^T-\:OVG/^"?WQ=_X*,_LX_#;XF67B/P[9
M:9_PT=\./@C\=]1_9H^*FB_%9+KX4_M'?$/XGR1?M(?L]_">R_9GO/AS_592
M?GQ]3Z]>Y^E<V%SG&818N$(X>I1QL\+6Q.'KTI5*%7$8+!U<#0Q,J2G"+Q*I
M8G%U'B+>TC7QF*G3<(5ZE)N5.,E&[:<;J,D[22E)2<4_Y;QBN7:T8]8IGX5^
M)_V5/^"@?Q&\%?`JQL?B5\6/AKXW^'?[-'_!2/6/A3K&K?M.^.=*T[X7_'[Q
M;\=?@3KW_!+'PI^US%\-?'?B2/\`:MU[X%_`.Q\2>"/C=<_$73/VL?A7XV\3
M^$OB==?$/Q)\>;CX@:;XO^)OD7@G]EK]OO0/"7Q=N?V6?"'QV_90\4?$S]N[
MXQ_%?P,?VJ_VF?#7QZ\;:!X(OO\`@BAJG[-/PL\>_M!^,4^//[84_P`6/`>E
M?MZ^&_AQK&E_#O7_`!3\:M7T+2O#G@7Q)_PK6U\*>"].LM!_HR&.W;BD``!Q
M^7?T_7'XU4,[Q,(RIK#8"<)N[IU*$YTDO;U<4XRHN:I5HNK6NUB(U(KV<6HJ
M52NY#II]9)]T[/5*/G;16]VWF]$?(?[%WA;QSX3^%VO6'BSP7\=OAIX?N?'N
MIW_PO^&G[3'Q_P!'_:6^-W@;P._A[PQ:7^F>-OB?IGBCXM7MP-9^)%G\0?&7
MAO1/$'[2O[3^KZ1X2\3Z$D'Q-\#:!-HG[-OP'^O?P_'C_'/Z5PWAKXD_#[Q?
MX@\7^%?"GC;PIXD\2^`M2CTCQMH&A^(-*U76/".JS017<6F^)=-L;J>\T._D
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M,M-&\%_$_P`&>)]3N]3ET?7_`!#%IMM8Z-K-Y=3W\F@>%?%&NQV<43W#Z/X;
MU[4TB:RT?4)[?Z+!!Z'-94:]'$0]I0KT<13NU[2A5I5J=UNN>E.I"ZNKKFNK
MJZ5SMS#*\SR?$/!9QEF8Y1C5"%1X/-<OQN68M4JEW3J/"YAA,%B%3G9\E1T%
M"=FX2DDV`].>,<XZ_2C([=N./Y5@:3XJ\.:[J'B+2M&UW2=5U+PCJEOH7BFP
MT[4+6\O/#FMW>AZ-XGMM'UZVMY99M)U6X\.>(=`\00:??I!=RZ)KFD:JD+6.
MI64\^_D>OO\`S_P/Y5HFFKJS2;6EFKQ;35UI=---=&FG9IVXY1E!J,XRA)QA
M/EG%PER5(1JTYVDDW&I3G"I3E:TZ<X3BW&4926BBBF(****`,+Q+X?TGQ5X>
MUOPSK]I]OT3Q!I6H:+K%GYUQ;&[TW4[66ROK<7-G-!=6QGMII(Q/;3Q7$182
M0R1R(K+\0_M9?L>:1^T!X'^!WPZT"^^&.AZ/\$_'&G>+](\,?&+X2S_'OX=^
M(-+T[X7^//AE8^'/$?@J\^(?@&[U-=/M?&T7B'2]6NO$T]Q::]H&GW<UO>22
M-)%]N^)K'5M2\.ZWI^@ZR?#FN7VE7]KI.OBPM]6&BZI<VLD-CJITN\9+74AI
M]T\=V;"X9;>[$/D3D1R,1^67[0?[%Q\1_'KX:_&_0O@Y\.?B/\5=`_9S^-D/
MB+XN7F@_#'P;XB\0?M'Z1+^SA!^SUXMGU75/#OBF]T/Q5ID/@OQ^?!?C.'PQ
MXNL?A;I\'V6*)(+FPT;5_,S.FJM"4'E\<="H\/3KJ52=*7U=XJG4FH3H4L1B
M)SH3IT\2J+I1H34;2JQ;E&7W'`F-E@<VH8F/&%7A6M@H9QC<LG#"8;,*:S=9
M#BL)0EB:&;YAE&38>AF>&QV+R1YA''5<UPLZL98;`U8*%:CZ+X)_8)3P=\4O
MV8O'5C\5`-(_9ZM]5>S\#67@+3-*T'41J'A3]HWPS:Z9X;EL=<CO?"OA;P^O
M[0;6OA+PUK$OCG3?!_A;P+I?AOPLNCS^)?%NMZMS^I_\$\[C5_#7PQTC_A=+
MPOX!^.%O\3+VX@^&VA6R>(_"_AKXV?!GXB?#CX?R-IVM6.JZ=#\/_AU\#?!O
MP?T[4(M7N="URWM[7QQXE\&:IXA\.^%(-#^5_P!G+P]^V`OQIUGX;^*]>^)K
M>,OAQX8^!.IV%SK/Q;G\0>#O!WPLU?\`:\_;2#7/C/1G^)^L#X@Z_P#$?]F3
MPCX3\(Z1KE]J?Q#\9V>MV/@_6O'=WJ>L>'+S4K3B=?\`V;_^"C7AR;XH'X2M
MX^\.V=]K?[0VM^$=*T+XP>$=+T&YU_QA\1/^"GWQ3\(:W'X?O/&L>BVFL>(/
M&?CC]B^^U/4+ZPM;ZXL-1TO0/%$R^'_#7Q$TW0/FX/`RP4)T^&LTG3JRJ^VP
MT*F+]K1JTH8&G*$XW@E.*P5"ARQY53]@Z--IU\73A^VU:?%%+B3$X?&>-_`>
M&Q>`PV6/+\YQ6#X=>7YGE^/Q/%&-I8K#5^3$5*]&I/BG-<T]K456KCO[36.Q
MBE3RKA_'8K]!;#]@O^S+'3+2T^*[VMS:>$?V\O"T^H0?#_0[NYN)/VVOCKX<
M^,Z:O<V/B+4]?\/ZG+\+X/#D7A0Z9X@T/6](\?+)#J.IV6A:=;R^&KSSSP+_
M`,$ST\):-\0],N_C&-9U'QQXZ^!OC:/59?`,R7FBM\&_VY?C#^V?=:?;7&H>
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M9O$.B>9;:!IWPPU#1K[PV/+;Q)8>+[I5UW03IO\`Q,<3QG^P%!XOGFCF^*-U
M;:1HWQ$TSX@^"+!_#FH7]SI2ZA^U-\+/VJ/B)HWB>\O/&KVOC'^W/$/POM?"
M'P^U!]+T6/X4^%-:OM/T_3?$%@)=.NOBK0_V?/\`@I5I'PCT/PUX9\:>-K+Q
M1>_#W]BS6/&E[\0/BC>?$G4(?C-HFB_%W0OCU]@U&#XW^#M6MM(T/Q#9_L]^
M*O'NG6'C*Y\`>-M!TGQE+HW@[XO:[XD\;>$/&'[P6T5PD2>859]JJV3D%L`%
M?39S]WZ^IK7"8;"YE6QE?%9-B<%7KTL*\1/$5*D8XI-5(QHVA4@IO#PI4G5C
M*C#65'XW2BUYO$&=<0\%95PWE.0^)>2<395E689]')L)DN&PE6MD$HRP>(K9
M@Y8G"XBIAZ><8G'8^&"E3S#%.5.AF"_V>&/KT#\U?VJ/^">-[^T9KGC"[L?C
M*?!&D^-[OQUK>I:?=>!KKQAJ%GXE\;_LE>//V37N=,U6X\>Z)#I_AO3_``_X
MKT;Q:WA2QTNUM]0US1]>\W48+OQ?-J^C?5/P.^`MW\&-:^)\\/C%?$&A>-/%
MNK^(O#>ER>&;2QU;PQ9>(O%WC+XB:UI.K^+)=0U/6O&"KXW^(GBZ7P^LSZ+X
M?\*^$VT'PWH?AFUOK+Q!XC\5_2#<L/NGD#U/XC\_SIPX9CCCCG^?X>M>G2RW
M!4,34QE*BXXFM.=6I4]M6?-*<7"2Y)5'34&I.7LU#V?/:IRNI&,H_#YAQSQ3
MFF18/AG'YE3KY)@,+0P6#P3RW*J?L:.&JTJ]&<<52P4,9/%0E0IT_KM3$2QC
MPW/@W5CA:U:E5=1117<?+!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`<_XL\,Z=XT\*^)?!VL7/B"STCQ9X?UGPSJEYX3\6
M^*O`7BJUT[7=.N=*OKGPUXZ\"ZSX<\;>"_$$%M=2RZ-XL\'>(=!\5>'-22VU
MCP]K.EZO9VE]!_'%\6_"_P`,/A-X3^,OPV\$_LQ?M`?'K]DO7/\`AZS\4OB/
MK7QU_P""]/\`P4U^$-U=_"']EC]N+2?@=_P4,UWXN?L]?"7P/\1?A_K/P_\`
M#'Q`_:$\<^-O#^F:'KGQG^-G[1_[./@/Q+XY^).G^-_VM/'=U\-/'_\`9[7\
ML7[0VO?M/S?M*_%*PO?@?\8/'?Q6N?$'[6?QX^#/PD?_`()G>'_BC^R/X>_;
MS_9X^-_[-_@C_@CS\3;']K6V_9"\2:=8>(/VG?V+_".J>%OVH/V@/'7[94[_
M`+.>B>)/&GA*T^+/["GBGX=?#[1?A.`?U.T444`?Y?/[97_)WG[57_9R7QS_
M`/5G>)Z^;:^DOVRO^3O/VJO^SDOCG_ZL[Q/7S;7^87$O_)0Y]_V.<T_]6&,/
M^Z7P1_Y,WX3?]FRX!_\`6.X='+_%_NG^E?ZE7[.G_)OOP+_[([\,O_4+T2O\
MM5?XO]T_TK_4J_9T_P"3??@7_P!D=^&7_J%Z)7]'_1G_`-YXM_[!LG_]/8\_
MQ<_;??\`(G^CM_V-_$G_`-5O!Y[91117]7'_`#^A1110`4444`%%%%`#-N1U
MZMN_`UXBWP6_XR!'Q[_X69\5,'X4_P#"K/\`A4/_``E@_P"%*''BK_A*?^%B
M?\(*;#_DJ7_,M_\`"6_VI_R*G_$F^P<_:1[:2_.!WP/Z=>WO7EUUK/Q!\/7W
MQ0U_Q#8Z+JG@G0](L-6^'^E^%;/7-0\=:D^GZ%=7?B73]9L%AN+>]OKW5X8;
M;PO:^';>XN;F"3R;B&6^>*-LJJ@_9NI"4E&I[2+CS-4Y4X5)QJ3Y)1]U).-F
MIQ<YPBZ<KIQ[<!4Q4'C(X.O1HU*^"E@ZM.K*BIXRAC<3A,-4PF'5>C5C[:<I
MTJSE">%JTL/0KUH8JDJ=2-7X<\*_LM?M':)87OA*'XE^%;;P5X"_99\5?L\_
M#:75F7Q3X@^(GB;4+7PU+X<^-GQ(\4:-X)^'?Q6\%^(;RZTS5+7XG^#_``E\
M8O$^@^,[IM"\9Z%>^"O%VFW%S=?/O@7_`()S_';PU\$_VG/AT?&/@'2K[XL?
M#[P'X(\`V>BW]M=Z/8^'/`/[57[57QFMOAMK5KXD^$.M>#=&^'^L?"#XR^!/
MA,UK;_#+Q9X>T*QB\6:19_#J_P##&A:!9^(=[X:ZQ^VM?V?PC^%5]9?'OX%7
M7B[XY:[-\0?''B;2/AS\4==T3P%XL_9J^-'CB^OM-\177B#]HKP!H/A#2_VB
M_#NFZ=X-L-5U:TE\'V5]\/?AWJ7A:RT#5M)TSQ3\MZYXU_;O\/?%/X0_M0^*
MM?\`BIX;M?$7[,WPP\<^.?ASXGL4^'G[._A/Q]H7[(?[;^N^/-'^)]P/"45Y
M\./#7@CXM?\`"J-2UBW^)_B27[-XD^(=F-67Q(W@/X=:=\-?B:SRYT\)5EE>
M>2CRRRZ3G.4'A,)CZ%*CB?<J.G74,#".'HQ4:5.HFYSH*K45>K+^H,L_UQAC
M>(,NP_'?A;AZOUG"\94HT,%1Q<>).(>$<QQ>99'%8C!K&Y<Z_$^*JYMF%6K4
MS+&8.I3HT:&8RP&#>4X.A]J:M^P/\1;_`,36?C&\\7>&?%WC[P?X1_X)\>&O
M!7Q.\2WFH6GCBVO?V;/CG\0O%G[1&M?:-*\.M!I-S\5_A!X[U'P=8)I4T</B
M>77O%/A/Q+!X<\)ZC/>7_O/[#W[.GQ0_9T\-_%;0/B!KWA/4SXQ^)]IXZT&W
M\%W6NRZ#I\-[\*OAAH'C":.P\0VD6H:1>>*/BGX=\?\`CJ\M)]5\6ZI?S^*F
M\0>*O&GBSQOK7B;6[OXF^'G[0W[:^O\`Q5T#0/A]J7C?XO\`PML_VB_#?A75
M_&'Q&^'-E\,?%[_#6]_9U_9F\8:C#XU\+Z!\`!'H@>\\=_&WQG)<:V/@E):_
M$3PUX;\#-XS@6ZTWX1>*/IK]G_QK^UHWQ=\/GXG7_B_7?`7CZ7]MX:AHNN_#
M?1/#FC_#8_!C]JS2_!O[/2:9XBT?PIH6I2#XG_!CQ5J6JZ</%FJZXWCGPQX(
MT3QAX5*&#QCK7B3TL#++)XZEB,-@,QA7IXBOAI5I1A]7]I65*E4K5*BJ2ABX
M2=:G1^L4IUY+V-YM*@Y1^+XKH\=87A;&Y-GG%O!N*RO&Y3E><0R^AB*\LW>%
MRF6,QN!RW"8*6`HXCA_$T(Y=B\<\IQV&RJG46/:PT)5,SA3J?+W[*W_!.KXU
M_"SX@?L6>,O%=IX*\+#]F&SNM%\<"T_:.^.7QY'Q&@D_9Y^(/PIB\1^`-"^*
MG@G0=(^":-XH\36-Y=_"_P`!K8^"YO#]R\D^KS7'@KPEHTZ^*/V,?B[X3\3?
MLY:=J7A?PI\7[&3XVV*^)M%OFU.Y\`^(YO"O[*_[7FC:U\??C?JVE?#B-O"?
MC'XO>(/&W@[2/&KMI/B'PY;Z[HW@C2=-U2^O-9%O)V_A:Q^(;?\`!37XR:IX
MK^(_QNTGP_9>)K1/AA\.[OX:?ME:[\,=:\(G]DGX?G4=:\+_`!!\/?$6S_8X
MT+3['XB3>-I5T'QY\)_&&N:CX[TK4["PO(_&6O>$)]"7XE_'C]K?0KS]FWPO
MHFN>+X?B1XT^%'[5WBS5?`L_PKT*U/C;XA?#GXF?L\Z!\(="\0QP^%/%VH>#
MO`=[I_C_`%73]?\`%.B7:6UKI/B.\UO4[RTOM,TY=!\JG@<IPF$JTW@<=2I4
M,RG2@XUL)BI5?J-?)LII3J4W3IT:+Q5'`X54\*Z4I5*,*E>I&M6K)2^\QO%'
MB%Q!Q'@,9'BKA7'8[-^"\)C,2J^6Y[D$,$N*LK\1O$7&T<-C*6.QF88^.19I
MQ3G[QN>T\?2IX/,,5@LJPM7+,MP%2I1;;?\`!/+XW:-XGU#Q1I7Q$\&ZOX[F
M\4WS2_$WQ%>>*K?Q)XC\#W/_``3C\/\`[+MQIOBH^$++POJSMKO[17@[P9\4
M?$OA;P[XE\/Z7>:%X6\.^*;#Q'IWCCPYX>TG2N1\8?\`!,_XI^,/@#X1^%>I
MW_PKO-4\#_`S_@HO\+_",=_J&K2Z%X7UK]I_XM>#?%'[//\`9,=IX#LK72?"
M_P`-OA_X8/AG7$T3P_IZ^"Y+?2=)\`^&]8T6U@FL/4M$^(G[>=IXA_9\U!;?
MQ'XHT;Q_^U5^T/X<^)NEZ_X6TGPK9^"_@WX+^/WB_P`*?#6..'1?@GK>IS>%
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MQWX%_L;_`!J^%>G?M;Z?+XO\(1Q?&CP+XL\/_"V"/7/'&I:7X5UR_P#C3^U]
MXL\+7NO:?9?\(EJ6FZ=I/PJ^+WP*\%W/_"'^([+68(_A]?\`AO1]5L-)\+>$
M->U'Z8_8W^"7B[X`?`+PW\*O&5YH=YJ?AWQ9\6KS3(_#=S+<Z%I7@WQ1\7O'
MGBWX>>&M,#:%X8M["T\)^`==\->&8]%TO0-+T#0/[).A^';5=!T_36;U[X*Z
MSXV\0_"/X9:[\1](O-`\?:SX#\(ZKXUT34;.TT[4-(\4ZAH&GW6OZ9?:?87N
MHV%C>6.J2W5M=6=EJ-_:6T\3PVU[=0(D\GJ`QVXP<>G^?6O>P.6X+#?5,1AJ
M=6G[+!U:%&$Y<KA0QM:ECJL:E/E5JOMHQ;O9P:G!IO5?DO%?&W%&=O/\HSS&
MX+'+'<29=FF9XG"TH5/K.:<+Y7C^%L!7PN.C5FZF#>7U*]G'FCB^?#XGVBC*
M,&M%%%>H?#&'XE_X2`^'M;'A/^RO^$I_LC4#X=&N_:_[#_MS[)-_90UG[!_I
MITO[?Y`OQ9?Z6;3S?LW[[97PS^V'J7[1+_"OX8^&/AYX`\>>.?B1J5];^)/&
MJ_!+5=,\.:=8:EX)T%M8MH9O$/CCXE?"?3E\$ZC\2)?"T.J>%M1\676M>-O`
MT'B'P])X8UK39_$,^E_<OB/6SX=\/ZWK_P#9FJZU_8NC:CJ_]CZ%:?;];U4Z
M?:2W?]G:/8^9%]MU2]\G[-I]H)8OM-W+%#YB;]R_(WQ]_:9\2?"QOV4]7TGP
MLR:!\:OBF/#_`,0=)\5:;>VOBGPGX#@^`OQ=^+VMWEO96FHQ1Z;XK\-S?#ZQ
MDU*SODU>V:PM==TF.V6_N;+5=/\`-S/V3PM>-7$XC#1G"C"53#)2JTX5<51H
M\].,J<X\\IU8TY2M*4:;E)0?*Y+[+@?^T(Y]E-?`9)DV=UL/B\?B\/@\ZG['
M!8JOE^19EF,J&+JPQF&K?5J.&P-?&TZ5Z-*KBZ5&E+$QE55,^*_BK^U/^TK>
M?M*Q>&_@S?ZS=WS:M<Z%I?P/O?".DGPY+%=_L'_%SXZ>%;#XA>-=2^'_`/PD
MG@'XEW_QKM_#6G^)/!,GB=]3T7P5H_PRURZ\/:+IWQ(FM_%M+X@?%'_@H-<?
M`7X+>*O#Z>.='^(>F_LT_M9_%#Q9I6D?"ZR\8W7C[XC_``L\9_!NX_9T\'>,
M+37O@EX"UK1O%WQ;\$W_`(NBUCP'H/P[^$/B[5I-5\9VGA[PEX6U[PKIDOA3
MTGX0_M.^"/$]O^SY^T-XG^`/@"]^,OQ#_9W_`&8=7^+GQB\.>'Y-*\6^'+7]
MIW6T\.>$_!?@&:;PWXD\1^*O!=A\0K34-2\9^'[WX@64/P\\(G3O%FLR:L)T
MFE\E\8_\%&/VHUD_8L\:^&/@A\*/#/PW_:>\!^`O'6HZ;XA^)'B/Q9XJL=/\
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M+^TMIHY(;:]NH42XD_/VZ_X*076F67PUN=1^#NDV>N_$#Q/\0O`EUI5Q\7--
MLK?3_&?PN\??%?X(^*4T>[U/P=8:GXF\*7/Q\\)_";X<>'-?CT'3-;U*U^.?
MA_6]6\(:!JFD#PEKWU5X2_:GT?Q5^U?\3/V7(O".OVE_\//!NG^)#XSN-+\7
M1Z'JVHFQ\$ZOK>BQ:G=^#++P3(;'2/B5X(GTTZ'X^\1:_>W;^*K?7/#'A6ST
M+2=1\4>S@\=@(5M<VK8F=6I0P=.AB(5J:5;%4EBL)#DJPO[:IA\-5DZMU&HW
M6YN6;43\RXFX5XLKY6VO#[+,EPN`P69\1XK,\GQ&68N=3+LCS!Y)GN(EBL'B
MG'^S<+F^>9?2C@O9U*^%A#+G1=?"QJ5W]7@_+R1[>G&,9].?I[4PM\V>>/\`
M#M['@^]?F)IW[:_Q.^)FE_L">.OA-X`\(V?@G]IOXT^/?A[\5--\9>.TDU_P
M=IW@CP1\9-4UG3]"O/!_ACQ?X?U36=)N/A5XFUZYF.M6,2ZOX3TKX?7`@MO&
M>L^.?A_\Q?M6_MZ?ME?!CQC^U_XH\"^!O`FI?`S]FB]L/#=GXAU[P!:7^ER^
M*-7_`&=_AO\`%'2;+Q=XOMOVG/#GCV.]N/&7Q$L+"#3?"?[.6O:)<Z/)I.FZ
MAXY\.O>^(/%WA%XGB7*\+@IYC)XJI@H>SE*O1P=:4/85<J><_6ESJE?#T\O3
MJU9V4J<U[&<%4:B&2>"''>?<3X;@W#PX?P?$N*>,H4LKS+B3*\/6>9X+C^'A
MG_8<G0EC(1SC&<7U(8'+L,Y2I8_#2688;$RP:=0_=L$;CTXQSW_^O^F.E.KY
M/^%_[3UO\1?B?>^!G\'W6C:-J*_%A_`OB9K[4KJYUU/@C\0=*^&/CYO$^BW/
MAG2K?P8UWXEUBRO/A\IU[7_^$^\*)?>*---I8V;H_P!6B1&Y##U_`=_\\^U>
MU1K4Z\7.DW*,9.#;C.+4HVOI.,6TTXRC)*TXRC.+<9)O\RS'+,;E%>GALPHQ
MH5JE"GB815:A74J-652$9<^'J5::E"K1K4*U)R57#XBA6P]>,*U*I"+Z***U
M.$****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@
M#X@_X**?'[4?V9_V5=?^*=A\0O#_`,(+:?XP?LJ?"?Q1\8O$TWA6UT[X-?#W
M]H7]J[X)_L_?$WXPVVH>/8+_`.'>D^(/A3\._B?XH^('A/6_B5HOBCX9Z)XJ
M\.:-JWQ&\&^-/!%EKWA36?R`_:%_:F_X)7_LR_`+XX?M$_LE_P#!5CP_XL_:
M6^!OP?\`B7\6/@GX"\6?\%I?C3^U;X5^*7Q"\!>"];\3:!\'O$W[/7QL_;$^
M+?@GXG^'_C%=::/A?K.B6'@U?B9::=XMN=:^"/C+X9?&G2_`'Q+\(_N_^T[\
M;=8_9W^$5W\6-&^%'Q`^-']C_$#X)^'?$'@GX6^%?'?COQW:>!/B-\;/A[\-
MOB/\1="\#?#'P-\2/B!XU_X4U\/_`!=XF^,.I^$?"?@W5=8\3:/X$U#1+:?1
M_MS:YIOQ_P##3_@KC^R[\4?#FI>)="^&7[?]O9:9\0/BS\.IT_X=?_\`!1+Q
M1NUGX/\`Q3\9?"7Q%/\`VE\.?V9?&WA^V^T^(/!.IW/_``CNH:S9>._"'F_\
M(G\4O"/P_P#B;HGB[P'X;`/T_HHHH`_R^?VRO^3O/VJO^SDOCG_ZL[Q/7S;7
MTE^V5_R=Y^U5_P!G)?'/_P!6=XGKYMK_`#"XE_Y*'/O^QSFG_JPQA_W2^"/_
M`"9OPF_[-EP#_P"L=PZ.7^+_`'3_`$K_`%*OV=/^3??@7_V1WX9?^H7HE?Y:
MJ_Q?[I_I7^I5^SI_R;[\"_\`LCOPR_\`4+T2OZ/^C/\`[SQ;_P!@V3_^GL>?
MXN?MOO\`D3_1V_[&_B3_`.JW@\]LHHHK^KC_`)_0HHHH`****`"BBB@")F;'
M"YY]>@]?\&Z>E<%HNM>,+SQAXTTK5/!?]C^&M'_X1_\`X17Q5_PD&G:A_P`)
MA]OTZ6XUO_B26\27V@_V#?)'IW_$P>7^U/,^U6FV%2I]!X`]1G].O/H!^6*C
M`4,QYYQCI^GO_=QVJ6FW%J4H*$G*48J+55.,H<D^:,I**E*-1.G*G+FIQ3DX
M.<)U"<*<,1&6'HUY5Z,:5*K5EB(U,%4CB*%=XG"JC7I4IUYTJ-3!RCC*>*PZ
MP^*KRC0CBXX7%8;\)OV1OV@/VZ=8\%?LFZC\1_$#W]A^UIK_`,.['0_%?QJ\
M$_"B]U>WAN?V6?CA\=?'GB+P1I7[./B3P9H\7P]U[5/`?@.W^&NF_$BUT_XF
M:;:S^/(_&=B8[_PM+HOTQX1_;1\8:I\%_C3\5/B3X6\/6_A#X3^'?AYXU^(,
M-OHE[<1>$_"WB*^\0'XT?!WQ)9:=XF\77&K?&'X&>#=!DUKQ;):6MMH.OW'B
M'P_I%GX>L8[JZO8/T\2-%6`!0H3[O``'R@<=.P[8X'<C-(\49BE7:N')+#`P
M?PSR3[DC@^U>-A<JQN$P]&@LYQ>(G2H2INOBXRQ$JE5X6G25:K&5=<]L7"IB
MW!U&W"J\-[1**JGZ;G_'W#/$&<YCFE3PUX?R;#8_,Z&,CE?#56EDM#!8"EG^
M*S"IEV!JT,M?U6=7(*N%R!8JGA%"&(P:SEX*4Z\\$_R!^$?[0/C_`.$6M_&K
MX%^"/V4?#GA#PO\``S]FR/XV^'/`7PD\.>$?"6A7WCR_\-Z7XTNM!T*PT[QE
M+K<]A\0O$OB;Q%X3\.7NI_"GP5I][XG^%7Q`O[?Q?XMU"]U30_`N-^TM^UK\
M<OAQ\+/V!/V@/!OCWX=>)_AEXA_:5T#PA^T7XB\*^!O%L'@#Q9\)-<M/&NDZ
MQ\6+#6-9\2K+X`^&F@>'=(U/QZEYJ,_B[P\=8E\$ZW8_$WQ#X#T"\F^)7[-^
M6N20OWL*3CG&,8./8#\,>M56MXC!%'L0JKDA2!@9)SQV/?CIQZU,LIQKPM7"
MTLWK4HN[PLH8>%)X3DQ^&Q>&ITXX6>&C*C2H8=X"=)I>UP]6<4Z<74IU-*'B
M%PTL_P`!GV.\/,MS"K!0CGN'Q&:U\;'B%XCA+..',YQ6)KY[A<ZKX?,\PS/-
M8<4X;'4ZE1X#.,%0JSCC,13PN,P?YS>&_P!LGXAZO\%_@C\4=/\`"'A[Q';_
M`!*_;.^(7[/?B"72=.\821Z/\,M$_:#^,/P@\+>,=/M-'L_$\KZ\^E^"O!UY
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M9UI?[)&<(TGZJ<X[9XSU_'&.?T-'3`X'I_\`6_\`U5X!I_[2'P\N4\=27\?B
MG15\!>--!\!:A:W_`(4UN[UK5/$'B#X9^#/BM;6VB^%=#M-7\5SO:>&/&UDN
MK6=WHECJFE7VC>(_MNGPZ;I?]HW%70OVH?A)KOBKQOX4CUF[L9O`MY!!<:WJ
M&F72>%=<M)?A9X1^,+:IX>\36BW>CW-K%X,\86EY]CU"[T[6YCI&OW5MI$^D
M:?%JEWLZM-2474IJ3=E%SBFW>:MONW":7=QE:]CY.7$F00G1ISSG+:=3$8J>
M!HPJ8NA"=3%PECH2H1A.<9>T<\MQ\()I1J2PE:-.4W"S^B3SR#]!V/UQ^GH:
M`<\\=/R]B?\`/TKYG\<_M8?"#X>^&?A#XT\0:AKZ^$OC1X_T[X9>%=6MO"?B
M%KNP\7:QI?B:]TS3O$WA2XTZV\9Z-<S:KX7NO"=YITGAR;6M%\47EG9ZYI.F
MV4&KZCI6[;?M-?!"_P#A]J?Q0T[QS:ZGX'TGQ!X.\*WNLZ7I'B'4FCU[X@W/
M@^W\$V4>EV.D7&L7*>)A\0/!=[I-[;:?-8W&D>(],US[2NCS&^0]M1YG'VU+
MFC%3E'GCS*FXJ:J-7O[/E][F^&VMS/\`UIX:]MB,-_;^31Q&%P:S#$4)9E@X
M5:.7RP:S"./E"5:,OJ#P+^MK&)/#>P4ZGM>6G/E][R#UQ[\YQ1\IXX/MP:\.
MT?\`:.^"^O\`@JX^(6B^.M/U3P?;^+/`W@J;6;*PUF>)/$OQ*O?!ECX$L&MH
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M@EE\FU@FN)=@2&*21E4_*7QC^*^B:S<_!;0OAM\.?`GQB^*OC[PYXL^+WP;L
MOB5J^H^`O"^E^%_#VF^%_!?C3QLOC/\`X5M\2=:\*:Z?#OQRTSPU8VEEX+EU
MO6-.\9:WI%S)IVC2:_<0?2'@CX@^$?B7HUWK/@[5&U73+34[S1KB673-5TF1
M;RR,;DK::U9:?=S:??6D]IJNB:M!!)I/B'0=0TOQ!H5[J6AZKIVH77._%GX/
M>"/B[X=@T;QA;>((A83?:=,UKP9XX\<?#/QAI4CO$UPFC^.?AOXB\)^,M(M;
M]8(8=5LM-UZUL]7MHUM-3@N[8>56.(A7K46L-4I>\J;IMJ/O.-6$Y2A6E#$T
M8\U).-*<L)75.JXU7&:BH'U_#>9</*O@\?CH5L?@)QQ51XK`8EXG"5<+7R[$
M4,.UA<#C<GQ6.I1QE2%?%0PO$F6/'8!5<!3Q&%J5/K9\]_#?XB?L^>*U_9Z'
MA3X,V-K?VB_%+X;?"R72_`WA_P#LKX0ZA\#M8USX8?$;P9HVK&"P_P"$2T'0
MM3\':IX<T>;1;.RTGQ#I5A9IHD-Q:S0VR?-OPB_:F^`_Q6TO0_"_C?\`9.MO
MA5H/P8^*>F_#?PCI7B?3_@AKFD?!NXT?XPW/P3^#FN6NG>$O$NM1^!_^$@^/
M_P`*]8^&_@*Q\!VVNC3_`!;\,H=4L+V/PU:^%?$UY^C47P8^&MM?^!-0M?"]
MM9W?PUMM1@\$26=WJ=JN@+JUM+:ZO)!%;WT<5Q<ZS!/.NM75\ES<ZNTTLFI2
MW4DCNW"Z-^R[\$-`U/1-7TGP;)9WNC>+/%_C>%5\2^+Y+"]\4>,O'_B;XK:Q
MJFO:3-KSZ5XE-O\`$3QAXE\6^&;3Q#9:G8^"M6U:>3P9:Z!'';Q0^=+!9DY4
MG&I@8TXMJM16'H<F)C['+8P=7FP<Y)T:V'Q4X1I2I\U/ZK#GBX4Y87[JEQ-P
M3##YA&M@>+:N,Q$:4LLS'^VLR6)R2I'-.,:V+A@?99_1HU(YCE><9)A:U7'T
M,6J.+EGN)5'$4\1BZ>>?"4_[57[-7BSX?_"#XA>&?V1;37$U_6OV>/%VF6?B
MWPM\(=)NOAOX>_;,_:5\`R>'OB1J3Z=JGB[4M,U+QA\6+74/BFEOH^GW=UXM
M^)WPHDUK7M4T34H]"\8UZ!^UY^U0/V7OBQ\-9/`/[.N@_$KXA_&[P1X]O?$W
MC"&+XI0>)(/"?P3U7P#;Z/X>U-_@?^S=^T5X]UO2%U#XS:C>Z<=8T71O"7AN
MX.H*^I#4_$MK;7/TC/\`L<_L\-X:^%GA-/`EQ;^'_A#IWPNTCP-I=GXT\>V=
MM9:=\%_$.A^*_A=;:W]D\40/XS'@SQ!X=TS4M*D\9OX@G,IU*.YEN+?7=<BU
M'H/B_P#LQ_"'XT^)?`'BSQUIGB[_`(2/X=VOB73O"FL>"_BG\5?AA?6FE^+[
MSPI?^)M'U&;X8^-/"!\0Z-K%YX)\+7%[I'B(:KIK/HUN4M4#W(FB>"SEX2O&
MGB,#3S"7]F.AB8T*"A"6'D_[1ERRP4U%U:,YT<,Y*JX)MP>%]HU'MH<3>&<<
M_P`LJXO)N*L9PI27'-/-LGQ.:YK.OBZ.:X:#X,I>VH\3T)3C@<TPV$S/.XT)
M8"E7JJG&O1SM8.$JGR/\.?VV_@5XJ_9W^$_Q7\7_``ATSPSI.J>(/C_XZTSP
MAI$O@+Q'8?#?PG^S9\7M=\`^./CI<7US+X6TBWTG0;JYT3Q-KE_X-MM:US2K
MGQJEKHJ^)5$VL7?,^'/BY^P%\=OVB]9\/ZU^S1X;O/C9\0O$?C[X-:YX[\:_
M!SX<ZE>>-H?"O_#0/PXOK'6O%L$VMZMJOA7Q7HG[*'QBTC2K;7"/M'A?PC8:
M5XATO1DUC0M-O/LK1_V0OV>M%\`>#?AMI/P]BTSP5X'UKQIK_AW0=/\`$7BZ
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M6)QT,;BL)7Q%>>/Q$,-BSQ'X3?M??LO_`!!T2_\`C#\$?"]AXC\6_%'XF3_"
M2:V\$I\,KGQI\0?%WA;PKJ/CFV6\\0Z/XNDT35%L_A1IUY\1(M*UWQ3%XKT'
MPN;C2=;\-Z)XOM-2\*6?+?`O_@HWH/Q:^&%MXWU3X5>(]&USQ'XM^$O@OPAX
M$\):W8^.->\1:G\2OV6?AG^U-K4EC]OL?!*W$/P_\%^-O%L^J:?IT.H>(?$6
MA_#C4=1\*Z%JGB?Q!I/@4?7EE^S'\%=(\$IX"TOPA<Z=X>@\4S^-+1+'Q9XT
MMM9T_7YEEM%ETOQ/%XA3Q-I>F6>C2GPKI7A_3M7M?#^B^"([;P'I&EV7@VSM
M-"AX/0_V(/V9/#GP\N_AIHWPU^P>#I=5\$:Y_9B>+O'<DXU#X>_#?PA\(/#6
M-8G\3R:Y]@/PO\"^'O`GB/1_[2.C^-O#2ZYIGC6Q\00>+/%BZWO"CGT%AK8C
M+ERT9/%0I4G2I5\7.-Y5*<98>K4IQ]LYS]I*H[\T95*%24:D:WFXG-?"*O4S
MKFR;C:K'$9GAUD.)S#'0Q^8Y7P_A:W)#"8NO2SG!83%55EE/#X186&#C[/V-
M2EA<SP5.KA:F`[?3_P!HWP7<?M%:G^S3=:=XDTWQS!X$NOB%INIWMC9Q>&O$
M.CZ-=^$K+Q);Z/<C47UF2X\/R>/O!GVJ^O=#L_#NJ3ZU=:7X:US7-;\)>/-,
M\*_0X9<':1CG'7KS]1CZ?EDUXG8?L^?"'3?C/J/Q\L?!UO:?%;5-&UG0]3\5
MP:CK<?\`:%AXAL?AQIFL/>Z,NI?\(]<ZC>Z7\(OAMIAUJ;27UF#2_"6F:=;7
M\-BUU!<^VA5QP!CK_GO^%>GAUB5[?ZTZ+;Q-9X?V'-981N'L%5YHQ_?I<ZJ.
M*<;<EI3:E)_!9O+(IRRO^P*694H1R3+89RLR=%\_$4(5UFU7+U1K5VLKJ3^J
MRPBKRA7YOK+E1H4W1HP=11170>4%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!7X`_%__`()?_%/QSK'QYTNV_9B_8`\<_$WXO?$#
MX[^(_`7_``56^(GCKQ'8_P#!03]GS_A=7COQIXO^$GC_`.'_`(4C_8U\<>()
MOB!_P3_\/^,/"?PU_9AL]&_;B\!?VMX8_9[^%<GAGQK^SA97FF>&_AI^_P!7
MXP:9^V;^UQ\.OBU\6_V;M<\6?\$H/C-\5O!OQ@\>:SIFA^./^"GFM_`OX^Z!
M\&OCE^T/';_LC^$_B3^SIX1_X)Z?$*Z\">(+'P3\;_V=/@3H=S-XF\43_$SQ
MIK7@F]M_$WBCQ3\2],FU@`_9^BBB@#_+Y_;*_P"3O/VJO^SDOCG_`.K.\3U\
MVU])?ME?\G>?M5?]G)?'/_U9WB>OFVO\PN)?^2AS[_L<YI_ZL,8?]TO@C_R9
MOPF_[-EP#_ZQW#HY?XO]T_TK_4J_9T_Y-]^!?_9'?AE_ZA>B5_EJK_%_NG^E
M?ZE7[.G_`";[\"_^R._#+_U"]$K^C_HS_P"\\6_]@V3_`/I['G^+G[;[_D3_
M`$=O^QOXD_\`JMX//;****_JX_Y_0K^3?_@ZE_Y)E^QU_P!CU\7/_4>\#5_6
M17\F_P#P=2_\DR_8Z_['KXN?^H]X&K]5\"O^3M\%?]AV._\`5+FQPYE_N.(_
MPP_].TS^,>BBBO\`4,^-/Z^_^#4OK^WE]/V7OY_M$5_8(O0?0?RK^/O_`(-2
M^O[>7T_9>_G^T17]@B]!]!_*O\QOI`_\GBXT_P"OF0_^LMD!]AE?^X8?_N+_
M`.GJ@M%%%?D!Z`4T'M\Q]R#Z^O'3^7'-5+_4;/2["]U._G%O8Z=9W-_>SLKN
M(+2SA>XN9BD2O(XBAC=RL:.[!<*K,0#\^C]K#X"'/_%?1CL/^*?\6'VS_P`@
M+@\>I//K6%;$X;#\JQ&(H4'._)[:M3I<UK)\O/*/-;F5[7M=7M='I9?DF=9P
MJKRC)\US58=P6(>69?C,>J#J\WLU6>$H5_9.I[.?L^?EY^2?+?E=OHW/0X;G
MM@8_'_\`7BE_$_B/_K#^?]*^<O\`AK'X"<_\5[%SW_X1_P`69_#_`(D56[#]
MJ/X&ZI?V6F67CJ*:\U"[M[&TB_L+Q1%YMU=S)!;Q&271$BC#RR(GF2ND:;MT
MC*H+#%9CE\FDL?@FVTDEB\.VV[622J7;;:LEJ[KN>A/@WC"G"=2IPEQ/3ITX
MRG.<\@S:$(0BG*4YRE@E&,8Q3<I-I))MNQ[7K6AZ)XBTRYT?Q!I.G:WI-WY/
MVK3-5LK?4=/N?L\\5S`9[.[26WF$-S##<1&2,^7/%'*F)$1AX[\=?A?\/O&?
MAN\U[QMXA@\#6?ACPSXILM<\:3P>"9M/M?AKKL>EWOQ)\+^*!\0_#WB?PDW@
M'Q3IWAG3!XQBU73`@L-(M[N+4--GLXKV'TWQGX5_X3'PYJ'A[^W_`!'X9%_]
MC(UOPEJ7]C^(+,VE];7W^@:CY-Q]G^T_9OLET?*?S;*>Y@POF;UX7]H?X>ZU
M\5O@+\9?AAX<N=.M-?\`B%\+?'O@K1;O69KFWTJVU;Q3X7U31-.FU2>SM+^\
M@TZ*[O89+V:TL;VYCMEE>"TN)0D+]=17A-<O/[C:C?E<Y14Y1A=6E'WE%*7-
MI[1N-FI7_/\`/:#KY;G$?[)IYC-97.KAZ#J<DLPQ>&IXO$87!>THNEB:$H8J
MGA_8UX5HNG4Q3J4'3J4Y2E\L_!SX8_LE:QI<?AS]GSXW:-JVIV?B+2?&G@_4
MO`'Q#\!^-O$G@>Z^&WP4^'G[/-XGAF26S\2![*U^&P\.Z1XFN-<M-;OX;OQ_
M+/-J-G_;^AP0=#JW[)W[-_@2PUJ7Q;KW]B_#3Q/>:;HMGX&\4:QX4TKP/IGB
M#6?@IX>_9=TBR\,W-UH]EK<.KZM\.K#_`(133=+;7[Y[[4?$FK1PVD[W.FVE
MAY!X-_8^^*I\?ZGX^74['X60Z]^S]\7?A-;VEI\;/BC^T)XO\*^(_'6M?#N[
M\.^)M)^(_P`7_#.G^(+O3+.W\,7]TWA:YBAT+PMK$$%_HEAJDWBSQ-<VW=>*
M/V7?&_B'X2:EX6TS2OA5IFL7_P`0KSQ/X8\$:DE]K?PO^&.DZY\.+KX6:[!X
M;B'AK3F\16VH6]_XD\8>(?"OB+PTFE>-%\9>,_`%[JN@V7B&W\8Z'Q\E1TY.
M>!@YTW5<*<7*,6J32I)0<ERNK&52T'9)I0::]ZG^6X3!XRIE%1XOPWRNIB\!
M4QN*RVAA88S#9=B'1HPE3Q&&RW&*GB*+QL,9B:,\#BUAJ]:4<OPLZ%2E@ZE7
M*/1=7_8M^$E]\-O@)\+TO?$&C>'_`-G3XM>&?C5X3/A^'PAH#:UXS\.:IK^N
M/_PD>F:5X4M?#<&B:_K/B;5]2UK2?".A^%($FG2'0WT2SB6UK-\/?LP?!3X5
M_#S2/@LWC+Q/#8>//B+\#]9\-#6=4T(Z[KOBS]G#P9\+;_PGHFG/;^';2SNH
MM3\+_LSZ=K?BNT2R%W?1GQC/H]WHL=QI<&C^9_'']D/XE_$WXX:OX]L=7\$1
M^"M;D^&D.JZ==7_B"UUG5M&\"?&3]E_XCPZ?K=L=*UBTU.?2M.^%_P`9E\-^
M3JFF:%8WWCW3;.T\.Z1?^(/B+XTUOB/C/^P#K_Q'_9_^$_P\L#\.QXF^#'QP
M^*WC?PBNK6.DW^DP?"3Q=XQ^*&J>%OA7I5_XJ^'7CS2_#>G6GAG7?AMI>H:5
M/\/_`!1X4T>3P38V=AHFM6?A_P`/W-.:J4HU9T,OA*5)*-*/M%&5:-)TJ<(P
M2A)0B\.Y.G>6DH*FX\MYDYAAL9@:F>5LH\),)BJV2Y7]0RNI+,XT)9Y@,'5P
M/#_]FX.$,))8>G5X3JXJ>#E4J5'">$6`G0G&:Q#^G_"G[&'PW\'?![Q'\&]$
M\1>.TT;7=6^$OB&V\17%_P"'Y?$_A_Q)\$O"'PB\)?#[7M(D'AM-"FO-,D^"
MO@SQ/=VFM:!JVBZGXA_M>.^TN;PY?IX>MHM`_8L^'&A:?XMLQXF\>ZE+XR\2
M?#SQ3K-Y?W_ATW#ZK\-_VD_'W[4FD&);3PQ:0QVVH_$'XC:WI&M0^4SS>#[;
M2M/T^73-9@N]?O?H_P"&_AK5/!W@#P5X3UK7KGQ/J_AGPIX?\/ZGXDO5C6]U
M_4-(TFSL+S6;I88;>(7.I3V\E[/Y5O!&)9F"01KA!V^.,?\`Z_K]>^:Z(TJ2
MY)*E&,E%)*WP)VDXV4N2ZDY)M1;>MI<KL?HN%X0X;E3P&)EP_A<)7H975P-.
M@W*3P6%Q\<35QN!7LZ\J$KU,PQM.K4BI\SJUN2K[.21X?\!/V?/AS^SEX2U#
MP9\-M+CTS2-4\1ZAXGNT6PT/3F>]O+>RTVVB,/A[2-$LIDTO1-*T?1(-0O+6
MZU_5+;2X=2\3ZSK_`(CN]4UN_P#<![@#G/KSZ]/_`*]'`_+J>N!_GFEJH0A3
MC&%.,80@E&,(I*,8K:,4M$EV^;U/?R[+L!E&!PN699A*&!P&"HQH83!X:FJ5
M"A2A?EITX15HJ[DWNW*4I2;E)ME%%%6=P4444`%%%%`!6->^(O#VF:MHF@:C
MKNC:?KOB4ZB/#FBWNIV5KJVOG1[9;W5QHFFSSQWFJG2[-TN]1^PPS_8;9UGN
MO*B8,=FL:]\.^'M3U;1-?U'0M&U#7?#1U$^'-;O=,LKO5M`.L6RV6KG1-2G@
MDO-*.J6:)::C]AF@-];(L%SYL2A``?'/[=W[>OPE_P""?7P\^&OQ'^+^A>(-
M=TCXJ_%^R^"OAN/1O'/[/'PQTZP\57OPT^)_Q52_\6?$3]J3XX_L\?!SPEX?
M_P"$<^$WB2PMKO7?B59ZCJ_BF_\`#7AC0=*U;5M=M;<<E^SW_P`%-/V:_P!H
M?PAXC\9Z.OCWP3IWA;XBZ-\-=2B\3:#HWBZ"74-5^!/P+_:#OO&]AXG^!GB7
MXP^`[[X)^'/!W[0G@&RUK]H&'Q<?@A-?S/K_`(?\?Z[\.->\">//&.;_`,%(
M?^%-6?A[]EWQ)\3_`(Y_M/\`P"\;>$?VGY-9_9T\5?LA_`V?]H[XRZ[\9;[]
MF+]IGPKK7A.Q^$47[+O[7L?B30+G]G[Q'\==>UVXNOA!+!H4'AZ+75\2Z)<Z
M=;B\^3O@3\`O^"9GQ'T[X_Z]X,^./BS5+GXR_M*>//AK^T1_PNS2O#GPV\5^
M,OB?^U#^S5^R#_PT%^R)K?@WXT?!3P)K6BVGQZ\"_##X!^-?B_\`"CPEX;T#
MQ]X5^)[>)?`NB:C\-KKPG?\`PP\$@'ZQ_$[]HKX-_!Y-67X@>,1I>I:/::/=
MGPUI>@>*?%OC76Y/$FF^.=4\+Z3X+\"^#]$U_P`9>/\`Q-XN@^&OCNS\'>$O
M`^A>(?$_B[6_#5_X<\-Z1JGB#[/IDVK-\=/@];^+/A)X$F^(_A-/&'QY\/>*
MO%OP:\._VM;MJGQ*\,>!]*\/ZYXNU[PC;H6.K:7X>TCQ7X:U#5+RW)AMK;7=
M,=F_TN(-\D?MR?LI_LF?M%Z+XB\0_M2_$FU\)>`/!/P7\<>&O&6E^+/$_P`*
M%^#6BV%QXF\`_&KPU\;?B;X%^-'A3QG\+/$/BOX$7_P.U3Q'\-M2^*N@>(/A
MGI/A3Q)\9M.\=>"?&?A'Q/K=E:^Q6W[.?[.WA[6_V0;30[@^#&_93\/:OX=_
M9M\#^&?'E[X7\.?\(G??"H_"5]"NO!6F:E::7X_\/Z)X$^S+H6FZII^IZ?X>
MU&QTW7]-BM=1L+2ZB`)?V0?VN/A[^VC\,/$GQ6^&GACXL>$]!\,?&?XV?!*]
MTWXQ?"7XC?!WQ+<>(/@C\2_$7PWUK5;'P[\2_#'A;6+K1]4NM`^U[HK)KWPG
MK<FM_#'Q]:>%OB[X!^(O@/PG]3UY-\'/@UX2^!GA[Q/X4\#S:S_PC_BCXL?&
M7XRS:?K%Y;Z@-*\7?'OXI>+/C3\2HM*NDLK:^_L?5?B9X[\8>);*SU2YU2?2
M/[=ET;3[R#P_I^C:5IGK-`!P?\_YYK(U77=%T/[`=8U;3-*.J:E;:/IG]I7U
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M%IU_YCXX\'_!&X^/VA^(]?\`%_Q,M?BD^H^&;C2&TK7OB0GPYT.33H[?2M$\
M,>(-.T>W?X.VVH>*#K5['86OQ!AF\=:Q_P`)->/X2U"!;71GTCQKQAX'_9/T
M.36/!?BCXP^.[+4OV=];U_\`:4\7V+WVHZI]@T_2/'7@'XZ7=G<6P\):CI>N
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M5TQ<FFY6OS3MR[<JG)0OJ_>Y.7GUMS7LDC[O`5,74H2EBWA75>)QJIO"2<J3
MPL<77C@VVZE3]]]5C1^LVERK$^U4(PBE&-+4=2T_2-/OM6U:^M-+TO3+2YO]
M2U+4+F*RL-/L;*%[F\O;Z\N'CM[2SM;>.2>YNIY(X8((WEE=$5F'D'QC^.'A
M_P"$GPI'Q7CT77OB1I=_KGPP\.>&M%^'5QX3N]6\7ZO\7_B!X1^&O@:+P_J'
MBKQ3X2\'M9ZGXB\;Z'-)JNJ^*]*TF#27GU`WK+&B2^OZCIMAK&GWNDZM96FI
MZ7J=I<V&I:=?VT-Y8ZA8WD+VUY97UG<)+;W=G=V\DD%S;3QO#/"[Q2H\;LI^
M9OVI?!_P!U;X'6/P[^-Z+H_P>OO'GP4T]?#VC^%EUS1]2N?!OQ1\%>+_``?X
M*U#PO9>%O%-B_@'5M5\(Z;HOC:VN-"BT2P^'\GB"74-3\.:9;3:[IG9@J=*M
MBL)2JT\15A4Q=&%6CAH.I6J8>4E[2%&G!QJSKR7NPC"4;WLI1E>2];#1I3KT
M(U(U)QE7IJI"G%SE*FY+GC",6IRFU=12:OHDT]3B/"'[?'P1\9^%M=\0:5IO
MQ+@U;P9\6_AY\"_B+X-U+P'J5AJ_P]^*'Q"^*7PZ^$MIX9USQ-)*WPPU>70]
M?^)WAK5M7N_`WQ!\766H^%1J.O>#KCQ5!:)'/Z7\&OVMOV?/C[J&GZ5\)_B)
M!XGU35?"O_":Z?ID_A[Q=X<O[GPS_9?@77&U(6?BK0-#N$,.B?$[X<:S<V4D
M::A:Z1XZ\)ZG<6L5CK^F3W/F6O\`P'_9=^&W@[XI:+J'C+P[\)/`>J?&'X%?
MM`^)-+M]>\`>`_"GPXU3]G_2_@IJ/@/0M)L9=)L=(\(_#FXT3]F#P[>ZQIE[
M$US)I(\;W.BZUHMF+!_#^-\`OV3OV=OV<_&'P]\0^"_B;K6IZW_PK9O`_@G3
M_%'C#P3>1>*/#&H_"G]E#X51ZOI]KI/A_1+O6KR;PO\`L@_#34X+[2IAI\FL
M^(/'5XMF^G:KX>T[PQZM6EP_.AC*F'I9S1J2O++8U'"K2NL)AZM2EB:BPL5.
M,,0Z\8RI3C*&&]E5JSJ\RF^^=/*Y4:\H1QL*CN\,FE.FW["G*4*C]DKJ-5U(
MIQ:DJ7+*;E=,F^*G_!17]GCX9?#G1_B997^I^//#^L?&`_!`G3=0\!?#2+2?
M&;?#O7?BI;7.O:_^T3XX^"?@S2?#.K^!M%M]>\+>([KQ.NG>.=-\4^"-1\#R
M>(]+\6Z+?W6_X&_;K^"GC733J+6_C7P_"?`/PS^(%K'-H$'C.YU:S^*OB7XT
M^%]`T?PO!\)M4^(DGC74;6;X#>.==OM5\%CQ!X*OO!SZ-XQ\,>+?$/AR[O-1
MT_E=*_X)^^!_".AV-IX`^,?QR\$^)=(^.=M\?M(^(-EJ'PO\4^,[3QG'^ST/
MV9;VVN[CXC?"KQMH'B/3M<^'#WEWK^I>*_#^O>,=8\9:C?\`BN]\52:A<?+T
MUM^PY\-M,U=_%VB^-?B7I'CN"S\*-I7CBSOO!4NO:)XB\-Z_^T9X@U'QEI,%
M_P"![W0;3Q%XS;]JCXOZ-XI0:*V@1Z#J^GZ?X6T+PPU@T]S53_554:E.D\PE
M-5G*E7E*I&M*BYP:A6IJC+#4[0YHJK2C5J<RG.5"5J4)N:R=4W&#Q#ES-PJ2
M<E4:<H^[4BH.E&*C=*I!3G?G;IZ0C+@?VAO^"F'P._9VUKQ/I&N>#?B]X_M_
M"_[/OA/]I2?Q#\+_``SX:\1^&]4\`>,OB4OPWTBQTK4]2\9Z"S^)<QZOXZN+
M:]M[#1E^'?AKQ+XA@UV>XTF?2S]5_P##0WPD^R?$:\/BB;ROA3JEAHOC4)X;
M\6O+;:IJ=]_8^G6GA^"/0S<>.?M_B*.\\)6=QX%C\1VMSXUTK7/!,,[^*]`U
MO1]/^4?BW_P3&_9X^+B:?:WVK?$CP;HVE_!7PK\`M-T#P-KGAW3-&LOAUX-\
M$?'+P+H&GQP:MX2UR>6XL=/^/.N:K&+JXN=/&O\`@WX>Z@FG+'HNK6NO^HZ1
M^PW\#?#LOQXN_#VGWNAZI^T#X^\*_$_Q5K>F:=X)L]8TKQMX(\;S_%'PEKFD
MWT7A!6UK4/#_`,4;[5?'VEZA\0T\<ZG::IJC:)'?+X*TCPSX6T.JL.$GE^#5
M&MF\<R5WCI2I0^KU.;$X.FHTTY3]G[/!+&XARIJ:EB*E.CK"G%U":R5T*"A/
M&1Q"=ZSY(\DTZN'BTKMJ#C1^L5%R\RE-PA>T?>]R^#'Q@\+_`!T\"CX@^#K3
M7K306\8?$SP5'%XDTS^QM5DU'X5_$KQ;\+=>NWTMIY[FSL;_`%WP=J5_H\6H
MK9:Q_8]S8-K.DZ-JK7FD67JU>3_!;X2Z-\$O`B^!-#UOQ)XCM'\8?$SQS>:W
MXMN-)N==O_$'Q7^)7BSXI^*9;J;1-'T'3?(7Q+XRU6+38K?2K=K?2X[.WN)+
MRZBFO+CUBO"Q/U?ZSB/JG.\)[>K]6=2[J.ASOV//>,&Y\B7,Y1BV]XQ=U'S*
MWLO;5?8<WL?:3]ESN\O9\SY.9V6O+:^BUZ+8****Q,PK^2+]H?X9^-+_`,0?
MM%^*O#5Q\8+G_@F%X4\/_P#!7+X"?M!?'JP_9H^`7B'4?`WP:_;+_:?L?BC_
M`,%7?$>E>/?$'_!3CX6_'&]\0?LY?'#X)?%_PA\%/$^@?\$U/'D_A[PKX6NH
MM"^#'[;BGP9X[^)?]3OQ2^&GAWXP>!-=^'7BW4?B!I'A_P`1?V9_:&H?"WXL
M?%3X'>.[?^R-8T_7;7^POBE\%/&7P_\`B;X7\V]TRV@U/_A&O%VD?VWH\FH>
M'=9^W^']7U73+W^2+Q_\%OV2[KXA?'?1/B#_`,%)?V8/V$M73]I_Q3J/B/\`
M9A_;6_;G_P""GGBS]H>?Q5^S1\3-+^'OP`_:9^*FL:W_`,%U?V5;GQ-X@^*G
M@GX!?`W]I;]GCQA??`S0M1\%_"75/@/9^"O&/CW2/`WA#XI>(P#^QVBBB@#_
M`"^?VRO^3O/VJO\`LY+XY_\`JSO$]?-M?27[97_)WG[57_9R7QS_`/5G>)Z^
M;:_S"XE_Y*'/O^QSFG_JPQA_W2^"/_)F_";_`+-EP#_ZQW#HY?XO]T_TK_4J
M_9T_Y-]^!?\`V1WX9?\`J%Z)7^6JO\7^Z?Z5_J5?LZ?\F^_`O_LCOPR_]0O1
M*_H_Z,_^\\6_]@V3_P#I['G^+G[;[_D3_1V_[&_B3_ZK>#SVRBBBOZN/^?T*
M_DW_`.#J7_DF7['7_8]?%S_U'O`U?UD5_)O_`,'4O_),OV.O^QZ^+G_J/>!J
M_5?`K_D[?!7_`&'8[_U2YL<.9?[CB/\`##_T[3/XQZ***_U#/C3^OO\`X-2^
MO[>7T_9>_G^T17]@B]!]!_*OX^_^#4OK^WE]/V7OY_M$5_8(O0?0?RK_`#&^
MD#_R>+C3_KYD/_K+9`?897_N&'_[B_\`IZH+1117Y`>@</\`$/\`Y)_XZ_[$
MWQ1_Z8[ZOY^AT_[:M_,U_0+\0_\`DG_CK_L3?%'_`*8[ZOY^AT_[:M_,U^=\
M>?Q,M_PXS_TK#']F?1*_W;C?_K_P_P#^F,W):ZCP-_R._@[_`+&C0/\`T[V5
M<O74>!O^1W\'?]C1H'_IWLJ^#P?^]X7_`+"*/_IR!_67$G_(@SO_`+%&9_\`
MJ%B#]XO&?_":#PYJ/_"`?\(Y_P`)9FS_`++_`.$L_M'_`(1__C_M?MW]H?V3
M_I^?[-^U_93!\QO?LWF_N/,KS#]J/_A,?^&;?CT/A^/$1\>'X.?$D>#1X/\`
M[2/BS_A)_P#A#M8_L#_A%_[%_P")O_PD/]J_9?[$_LK_`(F7]I?9OL/^E>37
MOA[\<=\C@_K^IH(!!';V]O2OW^2YHRC=QYH.%XNSC>,X\T>TESW3OO&&UC_&
M_,<O^OX/,L)]:Q.'_M'+Z^7^UHS][">VH8JC]:PRLN3$Q^M<ZJ<VLJ&'TC[.
M[_*[0O$_[8_AWXRS:%;Z%XFUGPGJ'[2VG>']>U?7UUD:1>?#_1?@I^S]HUSK
M&@+-X!\8V-EX+UV4?%[QV+G3M=^&FB1_$_1_["F\:W.O:O?^"/&'MG@?QG\>
M[G]I_P`1>"=?A\<CX7Z==^(18ZO?_#[1]/\`"5\GARUGU[_0_&<5A'<7UKXB
MM/C=\.O#V@^7Y%S/JG[/'CA%O9[G_A,6U;[CV@DD=P!VP1[<'T_"C:`V<$DY
MR>._KQT_'MWKG5":<;8K$V56-1Q<HR4HJ+BZ,KJ[IS;YI7]Y22<6M4_E,)P7
MC,'7C6CQ=Q)5A#B&.=PP];%0EAXX5PK1Q&2SA%0=;`8JI5>(JNM*<H5XQG0C
M2O.,OQ]_9\;]K6[\*?#/PKX@\2?&;P;>^,/B+\-=*\:^+?$OAN3Q%XG\/^%H
MO^"<OA+7-;U$GXI>&_%.GZ-;K^T3I#6NM:K>Z;]EF^+%QKFA:T;K7-:U_2[_
M`-D_9!\8_M+^*/%FNZ_\:M(\2:-HOC"R\&ZW-HVL:%K^CIH7B^?]FO\`9FU#
M7=+TS3/$%I*/#WA*'QG>_$BVBTK2KNPCLOB#:>--.U>*_P!:%^+/YX_;NN[J
M'XZ;(KF>)!X-\/D)%-(B`FXU0DA58+DG[W')SFOC+[???\_MW_X$S?\`Q=?R
MWQA])?!\'\49MPU4X5S''SR/&_4I8N.?4J%/%.G23=1X>67UN2,_:MSA[1MR
MC%N;LD?G%EPSFF"P;SCB?'?V!FE7$2C5S>7U;,HO"+#0PV(PLX5J4,/!U\7B
M)1I*,Z];$*5:<E0H*'Z]^$-3^*UG\?O#=EK_`(6\;:IK^I^)/BC#\3_$5AXG
M\<Z;\)?"'PQMCXYO_@/<Z'X<U;PQJGPJ\3:CJ.C6GAO1O'9\)>)?"_Q-T3QS
M>6=YK,>N^#9#:V/SC<_$W]OG4O`EQK=[I?BCPYXET'P-^T[XSLM)T+P-9>+H
MO%'B[X?7GP-U+X;^`;XZM\(/"EZ;76M=U3XN^!/"VE^'-.76?'/@;3'USPQX
M\\=:E9Z9\3)/A+[???\`/[=_^!,W_P`77[/_`+"4LMQ\"@\TKRLOC+Q#AIG:
M1@HATL@*S$G(.2OH68]Z^C\,/'7#^*'$N)R"CD..R5X?*<9FGMWFU+$0E&CB
M,!A?8J%+!8:KSN>*=6-7V^C4X.+A-17HY;A\1Q97KY71XAXDR:DJ>88Q/+<;
MA\*Y1K5,AA2A5K82A0QM>O2JX#$8RIBYXM5L3B\VS+GY,#4I9?1\B_:!N?VL
M/'-_^US\-_"MGXCT/P6O[/>J77PKU[PHUK%KFI>,QX>TB]TO2M`N]4^&@L(]
M6\:ZO+X^\'^(ULOB3KWB'0]'T7PSJNB:!\+=8U;1_&GBC1^$>N_M`Z+X:_9\
MTO6M4^+.LVFJ?&#]HVU\9^)O$W@G^U/&'B/3[7X_ZY:_#.U\<V.J^&]#A\"^
M`-7^$=YXE\7V/B#3%\`Z=HC>&/`&A^$K/4=.UC2?AQXG_1\J,=CGDDGDX].W
M0GVZ9IJJNU..%)Q@=,GD\]!QSZYY[U_07U?]Y*K[>MS2<U9R=HPG75=0BE-1
M4(6]DO=<O9RLY6O"7V4>!JT<YQ6=2XIXAJXG$T:V&]G4QE18;#X.?$]#B*CA
M,-AZ%6A0A##TJ=;)X5JE*KBIY=7E1EB/91>'J>#_``+UOXLZJWQ7M?BKIMS9
MOH?QB\9:/X"O)]#LM#@UGX;Q+IEYX6U"PCL]5U5]2M(H;ZXTQ];O3I]YJE]I
MUY<OI5E`UO&WO>2`>,`$]`.@_'\?P]Z=ZY_R/?\`6O./BMX^7X9^!-<\9MI;
M:Q_8YTU?[.%XM@;@ZCJ^GZ4#]J-M>"(1&^$Y_P!&DWB+RQL+AT\W/\^RGA7(
M,YXCS[&K!9+P_E699WF^85:=:LL)EF68:OC\=B9T\-2K5ZD</A:56?)1HU*T
MU3C"G3G-I/[S(\HQ<GE^2X6MBLTQV)Q4,%A)8JK3GBL5B,;BY1PU"=:;IP<E
M/$4\/3J5)02IPINI/24WZ-D9Z_K^7&>^?\\49'J/S%?GO_PW0G_1,W_\+"/_
M`.9FC_ANA/\`HF;_`/A81_\`S,U_*O\`Q/K]$W_H\.4?^&/BW_Z'/Z^3/U3_
M`(@IXI?]$CC/_"W*?_GEY_U9GZ$'V/;/'/'L/ZXHQZ8'7''3-?'7PJ_:O3XD
M^.M&\&?\(,^CG5DU$C4?^$C74!`=/TN\U(AK4:'9>8)1:&($7"!&<.`P4J?L
M0-D9QQ_G_P"MTSS^=?OOAEXL>'_C!P[4XI\..(\/Q/D%',L3E%3,<-A<QPE.
M.88.EAJV)PKI9E@L#B.>E3QF&DY*BZ;51*,Y.,E'XKB#AO/.%<>LKXAR^IEF
M/EAZ6+CAZM3#U9/#UI5(TJG-AJU>G:4J51*+GS+E=XI-7=7&ZWX`\(^(O%O@
MGQSK.D_;/%7P[/B,^#=4^WZG;_V.?%FF1:/X@_T&UO8-.U#^T-.@CM_^)I9W
MWV7;YUE]FG+2GLJXW6]%\77WBWP3K&C>-O["\+:&?$?_``F/@[_A&],U/_A.
MAJ6F16OA\?\`"0W4J:CX8_X1G44EU3.E13'6?-^Q7OEP1JQ_1SQ3XS_X*#_L
M1?\`#<?@WX$^&_[0^`'_`!9#X_Q_'/\`X1+]J/\`9G_X:U^!/Q#Q\"_CI\$O
M^$6\=?!K_A;WP2_M,:;_`,+K_P"$^\,ZW_PFO_$A\8>"O#]Y_9%_]^V^:_AA
M_P`$B=&^%VC_`!OT+0_C4VGZ-\>?$_Q5L]=\.>$O`OB/X?>$?AY\$/CG^SS^
MR'\!_B#\(_@GX:\'_%_3;7X<:IX+M_V1?#$W[,GQ%2;6KW]G;P%KTGPUT3PY
MXF33[[Q5XBZ7_@K-^SQ^TU^T$G_!-Y_V8K'Q=+J'P6_X*G?LQ?&?XYZWX&^*
M&G?"7Q)X3_9;T[P?\9OA]\?]9M_$EQXQ\%:YJ6G7_@7XC7?A+Q#X1\%W^J>+
MO%7AWQ/JND6'A[6+&XU.!?'?@G\(?^"G.J_L3W'@3X_:S\48OV@=0_:=_P""
M6/B6[U'3?C7X.T?QG#\'-`\._P#!,[Q-_P`%#+:Q^(7PX\=6,>GZ`_Q/T']O
M2UUGPI8>(H)_%'AZ76?"?PRT?6OA[XE^'&CZN`?8'[:'[!<O[7.MZ=JUM\8M
M8^%D&E_#V?3XK/PYI?BO2M8OOC)X*^(/A'QY^SM\5+GXH?"OXG?!OXV^'=%^
M$5N_QV\$^(?!'PO^)_PXUWXB^#OVB/&-K9_$KP#J^C:3K$GN/A7]F31/!,/[
M*VF^'_$VHW&C_LI^!&^'OAAO%MA;^-_%OB;13\/=,^'0NM<\?^);B]\60ZW-
MI>CV-_JFMVE__:GB'4UGD\17>JPW$L)_,G]F3X?_`/!4OPM\-OV;O$W[0\7Q
M1\:>-_AG^U1\`/'/Q=\`6'QB^%DGBCX@_"/QI_P2.\%_!?X]Z5]KL?B%HWPW
M\4>%OA[_`,%+_B?\3/C3K7@3Q9XNLK.#1?A;J7BKX(Z'XI30O@/X4\28'PT_
M9W_X*3:;X8_9E\1>+_$GQU;XF?"[]EW_`((5>%O%=G?_`+3B:OH.L?&3P+^T
M9\7-!_X*SW7Q'\-_\+5O_`WQ;\1W7[+'CRVN/&'C#QEIWC"+XD:U9>#/$?PE
MUKQ9\8/AOX)U/PH`?OG4%U=6UC;7%[>W,%G96<$UU=W=U+';VUK;6\;2SW%Q
M<2LD4$$$2/+--*RQQQJSNRJI(_+WP?X/_;J\"_`_XUZ]-;>(OB%\8_"OPV^%
M_BKP7\.=1^(^FZ(_[0/[5OPONO%WBOXW3>!O&GBOXG?%CPW\&?V9_P!JXP?#
MCX:_#?X;^(D\(K\$K!/&^NZAX<T2?5+'4K?Y,_:V_8N_;H_:#A_:O^`[>)/B
M'K?P8^,G_!-3]HKX$Z#XGU']I/5=`\,^,OVE[#P5^RE<?LV>(O$/AKP;J_@G
M6?AJ/$7Q,U7]L*Q^+&C>&/!'B/PI\3_AP3X?^//CWXA?"_Q3\)_V=_@Z`?OY
MZ\8Y_/WKE/%'@KPWXR_L(>(M-&HCPWXAT[Q7HV;N^M/L>O:093I]\?L-S;?:
M1`9YLVEWY]E-N_?VTNU<?E)\"?V??VH/@-^P]H?PS^&OA?XC^'/B9:_MI_M:
M:G;>%_$GQP\.^*/'MI^SQ^U'^W?^T/<:3\5/''Q7\9^*?BY%\0?&GPG^`WQM
M\._M5W$'B'QEXI^)7CSQM\-K?P3KNM7_`(T\2:[IM_\`2W_!/+P/^UW\/_@E
MXFT?]M'QAI/C+XI7?Q=\=:OI-[I.GZ]8PV_AB\&D1ZE/;GQ%\?/VCM0E\-^*
M_B1;_$'X@_#:SC\<^&+#PQ\)_&/@+P78?!']GJV\-1_`[P`K75FD^ZMH]GL_
M-+[D95J-*O3E2KTJ=:E*W/3JPC4A+EE&<>:$E*,K2A&2NG:48M:I,]&\5_LW
MWVK^/W\4^&/B-KG@70]<^)7@OXN>.=(\.OXFL/$'BCQAX&TKP=X7LK`^(M)\
M;:1HY\`>(O!7@O3_``KXU\!>)/!OBW1]=AE;6+)]%UV"WU%,GXK?LPZM\2]4
M^.TR_$R30-%^,_P9\5?"P:':>$+&6/2M5\5^'-,\-2>+M>NX-7L)O&+>'[/1
MK=_#&FRIHNHV,>M^+=/U'Q+JVEWOA:R\%_7Q!R/J#W/3UY`'Y'/--;[W\1!'
M09_3IG]16<J-*?-SP;YI.4ESS2<I1J0DU%322E&M54DDE)S<FFU%KYW$\(</
MXJEC*-;`S=+'8JIC,52IXW,*-.I7K8?'X>M+DHXNG&G"M3S/'NK2I*%*K5Q,
MJ]2$J\:=2'#>!/!,?@.SU'1=.OY;CPZVIS7^@:;<I<37&@V]\JW.H:<-3NKZ
M[N-2M9-7DO\`4+,RI#+917OV(M<)!'+7>#/(/X<<8Z8Z=O\`]6:,#K^7H/I_
MC_2EK1)12C%6BE9+HET2[););)62LDDOH,/AZ.%HT\/AZ:I4*4>2E2A=0I03
M;C3IIMJ%*"?)3IQM3ITU&G3C&G",5C>(M`TGQ7H&N>%]?M/M^A^(])U'0M9L
M?/N;7[9I6KV<UAJ%J+FSFMKNW^T6EQ-$)[6X@N82_F031RJKK\Q?'3]E6S^,
M7@SX??#;1?B5XL^$G@;P#I6MZ3:V'@S0_`GB;5]0M-1\#W?PXT_3YK_XM^%O
MB1H\6EV7@[7/%&EW[_\`"-S^)]0?5[>XLO%>B_9+^+6OK:DX.>`3R.1W]ZZ<
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M#7;-%C/U^0.,$`'W(S],$9_S^+O\/Q_.NIYSF4L/2PCQ$/J]%5_94UAL)'E^
MM4,1AJR<X8>-2:E0Q5>C!5)S]E":5+V:ITN39X_%.E"C[2/LX<[C%4J*M[2%
M2E*\E3YG^[K3A'FD^2+2AR\L>4HHHKS3D"BBB@`HHHH`****`"OYP=:_:*^+
M'[%_C']H#PGX6_:G_P"%>_!_Q)^U_P#%7Q%X/\+>/_\`@WG_`."O7QD\.>`?
M'?[2/QVE-U\.O!7[1'P]^/7A#P;\;O\`A;?[1OC[6_$OASQ=I%SK>C_$;XI_
M&.]T;X%P>&_@_J/P=^$?@C]_OBEXR\1?#_P)KOB[PE\)_B!\<?$&D?V9_9_P
MM^%NH_"S2/'?BC[?K&GZ9=?V%J'QK^)?P?\`AE;_`-B65[<^(M3_`.$E^(OA
MWS='TC4(-&_M?Q!)I6A:G_/#^U!\7_BEJWBI/@Q^TEX,_P""SUUX(_;*\0>-
M/AUHO[#D?BK_`(-V!!\<?AGXTU&Q\/\`Q3^"?@/2?A_\5%_;#U3X0>$_`?CV
M'2/BU\4?!'Q9@^(7P.^#5SJ7QA^('QT\!VWAW5OBSI(!_2]1110!_E\_ME?\
MG>?M5?\`9R7QS_\`5G>)Z^;:^DOVRO\`D[S]JK_LY+XY_P#JSO$]?-M?YA<2
M_P#)0Y]_V.<T_P#5AC#_`+I?!'_DS?A-_P!FRX!_]8[AT<O\7^Z?Z5_J5?LZ
M?\F^_`O_`+([\,O_`%"]$K_+57^+_=/]*_U*OV=/^3??@7_V1WX9?^H7HE?T
M?]&?_>>+?^P;)_\`T]CS_%S]M]_R)_H[?]C?Q)_]5O!Y[91117]7'_/Z%?R;
M_P#!U+_R3+]CK_L>OBY_ZCW@:OZR*_DW_P"#J7_DF7['7_8]?%S_`-1[P-7Z
MKX%?\G;X*_[#L=_ZI<V.',O]QQ'^&'_IVF?QCT445_J&?&G]??\`P:E]?V\O
MI^R]_/\`:(K^P1>@^@_E7\??_!J7U_;R^G[+W\_VB*_L$7H/H/Y5_F-]('_D
M\7&G_7S(?_66R`^PRO\`W##_`/<7_P!/5!:***_(#T#A_B'_`,D_\=?]B;XH
M_P#3'?5_/T.G_;5OYFOZ!?B'_P`D_P#'7_8F^*/_`$QWU?S]#I_VU;^9K\[X
M\_B9;_AQG_I6&/[,^B5_NW&__7_A_P#],9N2UU'@;_D=_!W_`&-&@?\`IWLJ
MY>NH\#?\COX._P"QHT#_`-.]E7P>#_WO"_\`811_].0/ZRXD_P"1!G?_`&*,
MS_\`4+$']"%%%%?T`?Y`A1110!^)_P"WC_R78_\`8F^'_P#THU6OB^OM#]O'
M_DNQ_P"Q-\/_`/I1JM?%]?Y/^-'_`"=7C?\`['E3_P!,T#^=N*?^2AS?_L+G
M_P"DP"OVG_8,_P"2$C_L<_$7_HG2Z_%BOVG_`&#/^2$C_L<_$7_HG2Z_2OHI
M?\G)S+_LD,S_`/5EDQ[WAU_R/:__`&+<1_Z>PI]LT445_HL?M85\Y?M5_P#)
M#/&O_77PQ_ZF/A^OHVOG+]JO_DAGC7_KKX8_]3'P_7XM](G_`),)XU_]FG\0
MO_64S4^FX'_Y+?@[_LJN'_\`U;80_'RBBBO^1`_U2/H7]EG_`)+IX-_W/$O_
M`*BVM5^Q"=#]?Z"OQW_99_Y+IX-_W/$O_J+:U7[$)T/U_H*_Z*/V67_*-^:?
M]G/XI_\`55PP?P-])7_DX=#_`+)O*O\`U(S0?1117^F!^`!7Y\?$G_@IO^RU
M\*?'GBOX;^+M5\:P^)O!NLW6A:W%8>#KN^LTU"S8+,MM=I<JEQ$"1MD50&]*
M_0>OXM_VZO\`D\']HC_LIWB#_P!&QT`?T%?\/>/V-_\`H-?$#_PA+[_Y+H_X
M>\?L;_\`0:^('_A"7W_R77\HM%`']Y?@+QKH?Q(\$>$OB#X8>YE\.^-O#NC^
M*="DO;=K2[DTG7;"#4;![FU9F:WG:UN(FE@9BT;DHQR":ZVOG#]CS_DU#]F[
M_LB'PQ_]0_2*^CZ`"BBB@!"`?4?3C/UHQ]?S/\SS^7\J_.#_`(*0?MF>._V,
MOAQX!\9>!/#/A3Q-?^+?&\GA>]M_%BZK]CMK1="U+55N+8Z3?V$OG^=9)&3*
M\D?EN_R;L,/QZ_X?P?M%]_A/\&/_`"\OYCQ"#^7\J\/,.(\IRS$2PN,Q$Z=>
M,(3<(X>O47+-<T7STX2CJO/0_`^/_I+^$7ACQ)6X4XPS['X#.\/A<)C*N&P^
M19MCZ4:&-INKAYK$87#SHR<X)R<8S<H;2L]#^J/..>3GMW^N/Y@<>U*.?49]
M>HZ?EZX]Z_E</_!>#]HK/_))_@OPI;@^,\'_`&?^1A^]Z#\C7Z7?\$V_^"A/
MQ-_;/\3?%#1/'O@WP/X:M_`V@^&=6TZ7PC_;GG74VN:AJMG/#?#5M3OU"PKI
MZ-&L,:,&D8O(P*@1@N)LFS#%4L'A<3.IB*[DJ4'AL134N2$JD[SJ4XPC:$)/
M5ZVLM78Y."OI2>#/B%Q/E?"'"W$&88W/LXEBH8##5N'\WP5*J\'@L3F%=3Q.
M)P\*-+EPV%K27M)1YI04(^]*-_UVHHHKWS^APHHJO=7"VMK<W3*76V@FG95X
M++#&TA4$\`D+@$\9H`L>GT]_\/YX/MZ)GI_]?W]A^N/\?YI#_P`'+GP`!(_X
M9Q^,?!(_Y#_@OL?^OZD_XB7?@!_T;C\8_P#P?^"O_DZOT;_B$'B7_P!$AF7_
M`('@_P#YM/IO]3N)?^A3B/OI>7_3WS_/LS^EWI17\X7A/_@X\^`_BWQ5X9\*
MVO[/'Q=M;GQ-X@T;P_;W-QKW@UK>WGUG4K;38;B98[QI'BAEN5DD6,%RBL%!
M;`K^CE)%9`WJ/Z?Y]J^9X@X4XBX5GA:7$64XC*JF-A5GA88F5&3KPHN$:LH^
MRJU5:$JD$^9J_,K71Y68Y1F.4RI1S'"5,+*LI2I*IR/G4&E)KDE+9R2=[$E%
M%%?/GG!1110!X_\`'[PK\9?'/P:^(7@[]GSXO>'_`(`_&/Q+X?FT;P+\:/$O
MPL@^-FG?#34;Z>""[\66WPNOO&?@'2/%GB#2](;4)?"=MXB\0R>%=/\`%1T;
M6/%?AKQQX;T[5/!/B'\X?@7^PK^VO^SA_P`)3>_"?]H_]@#3O%OC[^Q/^%E_
M%;QA_P`$^?VN_BO\=OBS_P`(K_:\7@W_`(7%^T!\6/\`@L%XW^-OQ>_X0/3-
M<U+PY\/O^%E^/_%7_"`>#GM?!7@W^P_"6G:;HMI^OU<1\2/'-E\-?`WB;QUJ
M.G:CJUGX:TU]0ETS2?L8U&^821P16UJVHW=C9(\LTT:F2YNX8HT+.68J$8`[
M>BO!/^%H?%O_`*-H\=_^%_\`!G_YOZ/^%H?%O_HVCQW_`.%_\&?_`)OZ`/\`
M-U_;*Q_PUY^U7C_HY/XY\=\?\+.\48KYLK^ACX^?\$-?V]OBI\=/C3\3]#\%
M^$++1?B/\6?B-X^T>SU3X@>#EU.STOQAXPUGQ#I]KJ"6NM7-LM];VFHQ0WB6
M]Q<0+<+((II8]LC>3_\`$/S_`,%"O^A3\`\<_P#)0O"W?_N*\_3M7\"9YX5^
M(&+SK-\30X7S&I0Q.:9A7HU%]7M4I5L;B:E.:OB$[3A4C)72=I:I6=O^N?PJ
M^GK]$/(/##PYR/-O'7@[!YID_`?!N59G@YO-Y5,)F&7<,Y+@<;A:DJ>43IRG
MA\5AJ]&;A.<'*FW&<HN+?XA#OT^X>G]??UK_`%*/V=#_`,8^_`L?]4>^&>/K
M_P`(7HV?Y9_'Z5_$G_Q#]?\`!0O_`*%3P%TQ_P`E!\+?G_R%.OO7]COPJ\1?
M&?P+\,?ASX)U']G'QG=:AX/\!^$?"U_<V?C[X.FSN+WP_P"']/TJZGM3-X\B
MF-M-/:220&6..0Q,I=%;Y1^W^`O"7$G"^(XEEG^48K+(XRAED<*\1[.U:5&K
MC955'V=6IK"-2#?-;XE:]]/\M/VLOTAO!;QUROP1I>$GB%D?'%7AS,^.JV>4
M\H>-4\MI9G@.&:6`GB(XS!81VQ53!XF%/V?M-:,^;EM[WUY17@G_``M#XM_]
M&T>._P#PO_@S_P#-_7.Z%\>_B!XCOO%>G:1^SCX_N+OP5XB7PKXAC?QM\(8!
M9ZT_A[P_XI6VC>;QVB749T7Q/HUS]HMFEM]]R]OYGGV\\<?]&'^,9].=<@CV
M^HK^3C_@ZE_Y)G^QU_V/?Q<_+_A'O`^!^'2OZ3?^%H_%O_HVCQW_`.%_\&?_
M`)OZ_%/_`(+,?L2?M:?\%'?"/P(\/_"KX.?\(;<_"WQ'XXUC69O'/Q!^&J0W
MUOXFTOPY8V<6G?V)XKU-VEADT>X>X^T+"@22+8SDL%_1/"+-\NR'Q)X5SC.,
M72P&6X'%XNIB\76YO94(3RK,*$)3Y(SD^:M5I0246[S734Y,?3G5PE:G3BY3
MDH*,5N[5*;>_DF?P345^]/\`Q#E?\%&_^A:^'7_AQ?"__P`LZ/\`B'*_X*-_
M]"U\.O\`PXOA?_Y9U_H#_P`1K\*_^BVRO[L;_P#,G]?]NL^7_L[&_P#0//[X
M_P"9^B7_``:E_>_;R[\?LO?S_:(K^P0<@'N0/\_K7\VO_!%_]@K]KO\`X)N'
M]I(_%?X11>,_^%S?\*>_L#_A!?B#\.'_`+-'P[_X6E_:G]J_VYXITO'VS_A.
M=.^Q?9?/S]EO/.\K$/F?N@/BA\6\#_C&CQV?^Y_^#/\`\W]?P-XSYSEG$7B;
MQ3G628VEF.5XZ>3O"8RASJE76'X?R?"5G%5(PFO9XC#5J4N:*]ZF[73BW]-@
M*<Z.#HTZD7&<54YHO=7JU)+:ZU33^9[W17S%KWQZ^('AJY\,VFL?LX^/K>?Q
M=XBB\*Z$J>-OA#.+K6YM)U?6X[:1H/'<BVT;:?H>I2_:+@QP!H5B:022QJW1
M?\+0^+?_`$;1X[_\+_X,_P#S?U^9G:>B_$4?\4!XY'7'@SQ/[X(T.^_PS]:_
MGX7OU_US?S[>W_UZ_:+Q3XX^,&N^&?$>B6_[-OC>&?6=!U?2H)9O'WP<,4<V
MH:?<6<<LNSQ\S^6CS*[A`S;0VT,<"OS$'[,/[4(SCX(:G]\N?^+@?"OO_#_R
M.?W?8\^]?$<89;CL?+`/"8:IB/91Q*J<G+[G.Z'+S<TEO:5K=KG]2?1OXUX5
MX/H<6QXESO"91+'ULEE@UB?:OZPL/3S&-9P]E2J?PW5I<W-R_&K7MIX[74>!
MN?&_@X8.?^$H\/\`T_Y"]GQ]?P^O:N[_`.&8OVHO^B(:G_X<#X5__-G6UX;_
M`&=/VG-'\0Z#J]Q\#=5D@TO6=+U"=(_'_P`*C(\-E?07,J1AO&@7S&2)@FY@
M-Q&2!S7R&&X>SJGB*$Y8"NHQK4I2;<-(QG!M_'T2N?T9G7C)X98G)LVPU#C#
M*ZE:OEN.HT8)8J\ZM7"5H4X*^%2O*<XQ6J5WJU9V_;NBO!/^%H?%O_HVCQW_
M`.%_\&?_`)OZ/^%H?%O_`*-H\=_^%_\`!G_YOZ_9C_,\][HKYA\)?'SX@>./
M#VG^*/#G[./C^[T;4_M?V.XE\;?""T>3[%>W.G7&ZWN?'<4\>R[M)T&]%WA`
MZY1E)Z/_`(6A\6_^C:/'?_A?_!G_`.;^@#\ROV\?^2['_L3?#_\`Z/U2OB^O
MT"_:2^#7[2'QE^(__"8Z!\!]9TZP_L'3-*^SZIX_^%"W7GV,MZ\DA^S>-9HQ
M&PN$"9DW95L@<5X!_P`,B?M5?]$6N?P^('PQ/_NX5_G+XJ>$7B1GGB'Q;FV4
M\)YAC<NQ^:U*^$Q=*>$5.O1E2I14X*>*A.S<7'WHIZ;'XEQ#PWGF+SK,<3A\
MNKU:%;$RG3J1=+EG!J%FDZB?3JD?/E?M/^P9_P`D)'_8Y^(O_1.EU^;?_#(G
M[573_A2UQ^/Q`^&`_GXPK]`/V;;3XZ_!KX;CP=KW[/'BO4;_`/M_5=6^T:9X
M_P#A";7R;Z.S2*/_`$GQU#+YBFV8O\FWYEP3R:^\^CIX;<<<(\=8[,^(^',=
ME.`J\-8_!4\3B)865.6)JYAE56G12HUZLN:5.A6FKQ4;0=W>R?L<$9'FV6YQ
M5Q&.P-7"T)8"M2C4FZ;3J2K8>2C[LY.[C&3VMH]3[]HKP3_A:'Q;_P"C:/'?
M_A?_``9_^;^N<G^/?Q`MO%NE>!YOV<?'R^(]:\.Z]XJT^S'C;X0M'-HOAK4O
M#FDZQ<M=KXZ-K$]O?>*]$B2WEE2XG6Y>2".2.WN&B_MX_53Z>`QP*^<?VJ\?
M\*+\;>GF>&?R_P"$P\/UI_\`"T?BW_T;1X[_`/"_^#/_`,W]>5?&?5?C5\2/
MAQXA\'Z5^SIXQLK_`%=M(:WN;SQ]\'C;I_9^NZ9JDOF&'QX\GS0V4J)M1OWC
MINPNXC\K\;LDS7B/P<\5L@R3!5<RSC._#CC;*<JR_#N'UC'9CF'#>987!82@
MJDZ<'6Q.)JTZ--2G"+G-*4XIW7O\(XK#X'BSAC'8RK"AA,'Q#DF*Q5>HWR4,
M-A\RPU:O6J64I*-*E"4Y-)M*+LF]'^8.[_97\J-W^ROY5ZO_`,,Z_M-_]$,U
M'_PO?A9_\VE'_#.O[3?_`$0S4?\`PO?A9_\`-I7_`#6?\2/_`$JO^C,<4_\`
M@>4>7_4V_KY,_P!"_P#B,?AG_P!%;E?W8G_YG.L_99_Y+EX,'<)XE_\`45UF
MOV'3[I[\GC\/ZXK\F_@U\*OVB_AU\1M!\8:K\!==O+'2EU836]EX^^$_VF0Z
MAHU_IT8C\[QO%'A);M)&W./D5L9.!7W6OQ/^+8R/^&:/'><_]#]\&1_/Q_TZ
M\_7%?[:?L]/"_CWPI\#,PX9\0N&<=PMGM7Q`XAS2GEV83PSKSR_%Y;P_3P^*
M7U;$8BG[.K4PV(A']YS*5*?-%6U_CGQVXAR;B?C:EF60YA0S/`QR++L-+$X?
MGY%7HXC'RJTOWD*<N:$:M-OW;6DK,]]HKYB\7?'KX@^!?"?BCQMXE_9Q\?67
MASP=X=UOQ5K][%XV^$-W)::+X>TVZU?5;F.TM?'<UU=/!86D\J6]M%+/,R".
M*-Y'53T7_"T/BW_T;1X[_P#"_P#@S_\`-_7]YGXV>]U_%O\`MU?\G@_M$?\`
M93O$'_HV.OZS?^%H?%O_`*-H\=_^%_\`!G_YOZ_`C]HS_@G=^V'\8_CG\4?B
MCH7PHM--T?QSXOU/Q#IUAJGQ"^'8U"UMKUU:.&[%MXHGM_.3!W>5+(G/#&@#
M\>:*_1S_`(=1_ML_]$UT7_PX7@'_`.:.C_AU'^VS_P!$UT7_`,.%X!_^:.@#
M^DW]CS_DU#]F[_LB'PQ_]0_2*^CZ^+O@5JGQM^%OP6^%'PUUC]G+Q??ZMX"^
M'OA'PAJ5[IWC_P"#YL+N^\/:'9:7=7-F;CQU#.;:::V>2'SHHY/+9=Z*V17J
MW_"T/BW_`-&T>.__``O_`(,__-_0![W17S#I?Q[^(&LZ]XG\-V'[.'C^75_!
M\^E6VO0/XV^$$26LVLZ7!K.GK'/)X[6&Z$MA<PRLUN\BQ.QBD*R*RCH_^%H?
M%O\`Z-H\=_\`A?\`P9_^;^@#\E_^"\W_`"0?X,_]E=EZ]/\`D3=?Z_U__77\
MM1ZG^G3\*_K;_P""DOP%_:6_;+^&_@'P;X"^!NI>&[_PIXXD\3WUSXJ^('PL
M6TN+-M!U+2E@MO[+\8WTK7'G7J.WF)'&(U;#EB!7XY_\.<OVYQ_S3WPP?^Z@
M^"3_`"U^OR_BO),VQV<U<3@\%5KT)4,/%5(.FDW&G:2]^:>CTV/\G?I<>!?B
MUQ[XRYGQ#PCP1FV>9+5R/(,-2S#!RP4:$Z^%P4J>(II5L71J<U*;497A:^S9
M^67_`'S]W_/_``*OZ`O^""XQX_\`VANASX+^'WOC.M^)>OTZU\E?\.<OVY^?
M^+>^&.5Q_P`E"\$<>_\`R'\;O>OTT_X)L?LD_M4?L9^)_BEK?C[X+R^)+;QQ
MH'AG2=.B\*>/_AH9K670]0U:[N);S^U?%UBFR9-1C6,PM(=R-N51RW-PUD.<
M8+/,!BL5@:M'#TIUW4J2=+ECS86M"-U&HY:SE%:+=G@?1D\`?&'@SQOX(XDX
MGX#SC)\CRZKG;QV8XJ6"=##+$\-YSA*#J>RQM6K^]Q.(HT8\M.7O5(WLKM?O
MK17@G_"T/BW_`-&T>.__``O_`(,__-_7.^(_CU\0?"D6CS:W^SAX_MDUWQ%H
MOA733'XW^$%QYNM>(+M;'2[9Q!X\D,4<]RRH]S(%@A!WRNJ`M7ZR?[`GT[6=
MK'_()U3_`+!U[_Z32UXK_P`+0^+?_1M'CO\`\+_X,_\`S?U5OOB3\7;JQO+9
M/V:?'2O<6MQ`A;Q_\&L!I87C4G'C[H"PS0!_F'/]]O\`>;^9IM?MJ?\`@@)_
MP4)8DCPEX%Y)/_)0_"7<_P#86I/^'`7_``4)_P"A1\"_^'#\)?\`RVK_`$@_
MXB_X:_\`17Y9]V+_`/F;^M.TK_TDN,>&K+_A7PNR^S7_`/E1^2WP7_Y+%\)_
M^RE^!/\`U*=*K_4DC&$7.3A57W)*XZ?G^/KS7\./@'_@A%_P4`\)>.O!?BJ\
M\&>"KFT\,^+/#GB"[M[?XA^#_M$]MHVL6>HSPP>9JZQ^=+%;.D7F,J;V7<P7
M)']BZ?$SXMJJ@_LT^.VPH&?^$^^#//&,_P#(_GD]>_\`6OYB^D#Q7P[Q5CN&
M:W#V:X;-:>"PF94\5+#JJE0G6KX.=*,U5I4W><83:LG\+O9GYCX@YMEN:U\L
MGEV+IXJ-&EB(U734_<E.=)Q3YH1W47:U]CZ`HKP3_A:'Q;_Z-H\=_P#A?_!G
M_P";^N]^&?CV'XD^$H_%$6B:IX;F3Q!XT\+:EH6M2Z9<:AI>N^`O&>O^!/$%
MI+<Z-?ZGI=U$FN>'-0^R75E?3PW5F;>=2AD,:?SX?G9WU%%%`!67K.BZ3XBT
MN]T37=.M-6TC48?L]]IU_`EQ:74.Y7\N:&0%'4.B.N1E7164AE!&I10`5Y_\
M6/BEX$^!WPL^)?QK^*6N_P#"+_#+X/\`P_\`&7Q2^(OB7^S-8UO_`(1WP)\/
M_#FI>+/%^N_V-X=T_5_$&K_V1X?TG4+_`/LS0M*U/6+_`.S_`&73-/O;V:"V
MD]`KX@_X*;>$_%7CW_@FW_P4&\"^!?#/B#QIXV\:?L0?M7^$_!W@[PGHVH^(
M_%7BSQ5XC^`_C[1_#WAKPSX>T>VO-7UWQ!KNKWEII>C:-I=I=:CJFHW5M8V-
MM/<SQ1,`?;]%?E!^T_\`&K1/V[_V+_V\/V8_V=/AM^T_=_&3XG?L0?M0^$_`
M6B_&O]C7]KC]E#PKXF\4^-/A3X@^'_A;PSI_Q3_:M^"7P5^%(\0:SXI\8:':
M6NC7/C:#41IS:MXCFMHO#?ASQ%JVE?$'[15E??ML_%?]J?Q%\./A%^U_;_#+
MQA_Q#S_#2XUWQ%^SK^V3^R)X[O?^%/\`_!7KX]?%+X_:E\.M3^(7P[^"'Q@T
MW_A3?P?\?>'_`(C>+OBQ\,9[+_A56CWT'BY?&7AV]T2;4--`/Z/J*_GA\<_L
MZ:=\/+WXD_#77_V8/$&H?\$XOA3_`,%7]#\3>*/V7_`W[-_BGXG_``0U3]D?
MQ#_P1^\$VMA;?#;]CGX:^`_%B_&7X/V__!3WQ_H7Q,USPG\(/A'XYT3PQ^TK
M8>-OV@O$NC:3K_PT^(WQ!\*_;_\`P1[L_P"SOV(HM._X1OX@>#OL'[7_`/P4
MPL_^$1^+/C7_`(65\4_"OV7_`(*5_M;P?\(W\2_B-_PG_P`5_P#A/OB!H>S^
MS/&7C7_A:7Q*_P"$J\16NI:[_P`)_P",?M__``D6H@'Z?UX9\6_B[\'?V9_#
MUSXX\=/JFE?\)[XSLM,L=!^'OPY\?_%CXH?%'X@7'AIF&E>!/A%\'_"OCCXK
M_%+Q7IWP_P#`NI^)]<TSP+X,\2:IX>^&?P_\6>/M?M].\#^!O%&O:1[G7P!^
MTO!K/PI_:G_9R_;#U/PA\0/&OP?^%GP`_:Q_9[^)%E\'?AUX[^-'Q3\+:Q^T
M;\1?V-_'WP_\>6OP;^&'AWQ3\3?'GP_M+W]F'7?`?C!OA;X8\=>._"WB/XB_
M#[Q1J'@3_A3^F?%[XH?"D`^O_A;\4O`GQH\":%\2?AMKO_"0>$O$']IP6US/
MIFL^']8TK6/#^LZAX:\6>$?%WA/Q+I^C^+?`GQ`\">+='USP3\1?AUXVT/P_
MX[^'7COP_P"(O`WCGP[X?\6^']9T:Q/&7Q2\"?#_`,1_"?PGXNUW^R?$'QQ^
M(&I?"WX6Z?\`V9K%_P#\)1X[TGX5_$OXUZAH7VK3-/O;+1/L_P`,O@_\1?$O
M]I^(KG2-'F_X1W^QH-0D\0:OH6E:G^4'[3NCZ=\9/`_P7^+/Q$_8X\0+^R=X
MH_;?G^*O[4_PCG^!7BKXS?$S]H[]GBV_8E^,'P8^#7Q9_:A_8K\'_"SQ'\4?
M&GB"?]I&U_98U+PC\$==\!_&/XM?![X>_#3]G[XN?&OPY\#?&/PC^(/PV_9N
M^0/CS\`?VN/$7_!/[]F;P3^SO\/?C!X:^*UA^U!_P5F\3?LQ:/X?AUOX4^*O
M@1\&OBQ^QG_P6>\/?\$Z[99=6G\)7/[)?A_PEX(^+7[*?PN^&/A/Q_/\)Y_V
M;]1U;X<?!?7M&^&'BGPU#X.T4`_I>HK^<'QI\&?#NN?LL?\`!:/3?V'/V5_B
M!\&OV9?BK_P3`N?AI\'/@-X<_9"^*G[(W_">?MDP?#K]O"#XTZEX`_9*\<?"
MKX0_$#7/B!XW^'_CS]D'P;>?%C1?A//8_%[_`(1[P5\--!\9>,-:^#6J^&_!
M'`?\%"?V*_&-A\;+SX?_``G\&_V%\,K[]D#P#X!_8X\:#]@7X[?\%$OC9\,?
MVR=9^+O[6/BGXZ_&[]GO]H?1_P!H[X3^'_V"OVO_`!9X@^)/[-WQ/\=?MQ_M
M??$CPG8_'OXNVG@/XO?$'X[37O[.OQ3\5Z"`?T^UY_\`"?XI>!/CC\+/AI\:
M_A;KO_"4?#+XP?#_`,&_%+X=>)?[,UC1/^$B\"?$#PYIOBSPAKO]C>(M/TCQ
M!I']K^']6T^__LS7=*TS6+#[1]EU/3[*]AGMH_S`T#X)^!/%7[>W[55E^T3^
MS%\0/BOXM^*_Q`%O\)?BMJ?P]UC7/A%IW_!/O7/V#_@O\+?'GP8^*7Q@U*[T
M[X6^*OV?_%7[5NG?M!1:A_P3ZU[7O'WB?4?C9X^T+]KR\_9;3PDD?[2?A7\X
M?#/P.G/_``2Y_P""2/PBLOV#/#^O6WA']F"'PSXQ^'7[1W_!/#XR_M'^%O"'
M[86G^&?A?H?B'X>^+_\`@GYK'Q%_9,\*^"?B_P#'_P"*[?';Q5I'_!2;]I'Q
M5X(^!GP5T[P[\2AXF^+^B>"?VY9?B+K(!_24/''PN\7?%G7/@X]Y::O\4_A#
MX3^&7QLU;P]=:+JI;PMX:^+NJ_&;P#\-_%UGK5UIJ>'[F[U_4?A!\8=%6STG
M5;S7-&AT*>XUNPTNRUWP]<ZMZG7XP?\`!+CPG\?;/Q5X-\=?'_PS\8+7QMXC
M_P"",/\`P1C\)?$'QC\8=&\:0>*M=^/O@O4?^"@.L?'/PUXR\0^-;9-7U3XO
M^$]7\>^'-4^*^C:W=S^--"U'QIHE]XOMK6Y\1V,MY^S]`'Q!XY_X**?LK?#C
MXF?$GX5^+=?^,%GJ_P`&/$&A^&OC-XXTS]E3]J[Q+\`O@[J.N_#WP3\6DN?B
MU^T_X8^">L?LW?#/P_H'PN^(O@SXA^//%GCCXK:#X5^&O@O6X_$GQ#UGPOI%
MGJ-W9_;]?RQ?MK_#/XR^-O$O_!:SX&>#OB7_`,%'_`GC?]K+Q!J7AGX`?!'X
M-_L2P>.OV1_VD=1^(7_!+G]D;X%^'+GQ]^UCXP_8,^+OA;X9^'_&GQ6\.^(?
M@Q\4/%DO[7OP0\*_"[1/!M[XCUC6?A7<V.M_$&Z^W_%W[+GQ3U./_@OC\4O@
MWX&^(&A?M=?&3_A8'PT_8\^(J^)O$?@'6)O[9_X)4?L2^'?#&H_L]^+_`!1X
M@\/^#/AO_P`)+^T;X,LM"\=_%CP#J/A/_A*/'?P0\!Z9\4/&6I2_LZ^!(/A^
M`?M]17\T/P1^!_B#PQ^SQ^W3J7P\^!_A_P`3_!OQ[X?_`&3_``I#^SW\+?\`
M@EM^U!_P3%_9JM]1\*_%KX@7O[27Q>O/V$/&_P"T#J7[2W[8OB#2_@MXW\#^
M)OVF_A7X2\%?#SPK^WY\$/@Q\,_V$O!GC/XP>)-4^('@SX8\!\-/@?\`$*__
M`&.?VA/"?Q<^!_B#P=\&_!W_``4?T7QE\&O@SHW_``2U^)FN?L9ZM^SQKG[#
M?P.MM!UOQ;_P1Y\,_M`^-OCCXO\`V8/%_P`<?&WC/XM6WP>^%GCK4?BU\*?^
M"@.H^&OVF/VB?A/\(?$GPA_:;^'WPP`/Z7=-^*7@35OBIXR^"FGZ[]H^)OP_
M^'_PT^*7B[PU_9FL0_V3X$^,'B/XL>$_AUKO]LSZ?'X?O_\`A(O$'P.^*6G_
M`-F:9JM[K&D?\(O]JUW3],LM;\.W.K^@5^`/_!,7X&^'?AQ^VO\`%/XB:I^Q
MI_PH#Q;\2OV`/V=-,\%?$72/V=_BIX.\'>)?#G@#]KO]NCP[XD@T3Q=X^TCQ
M)J?[-'_"P_@D/V'?B!X6_P"">GQ*^*G_``M/]EOX$V'P+_9AC\*W7A+]D"SA
M\#?O]0!\E_&/]JC]GG]DG5_AK\+?%MA\5!XA^(WA_P"(_BSX??#[X"_LP?M)
M?M(Z_=>%?AEK/@&Q^(_B6[\,?LT_"+XKZGX7\/Z!K_Q?^'UC?:SXFLM%TZZU
M;QEIMI8W-W=RSQP^Z?"WXI>!/C1X$T+XD_#;7?\`A(/"7B#^TX+:YGTS6?#^
ML:5K'A_6=0\->+/"/B[PGXET_1_%O@3X@>!/%NCZYX)^(OPZ\;:'X?\`'?PZ
M\=^'_$7@;QSX=\/^+?#^LZ-8_`'[5'P(^+WQ@_;Z_9`UGX=?%_\`:`_9U\/^
M$/V/_P!OS3/%/QK^!?@SX)^)/L^L^+/C1_P3?NO"GPM\4ZK^T/\``;]H#X9:
M/_PG5CX2\7>+-$T^#PUHWCO6_P#A5VKW/AW75\/Z%XTT^]X#]LG]G+P[\)_V
M-OA[\%_#OPH_X:"^'[?M`>(/'GQN\2?&7X'_`!3_`&U?#D7B/XJWWQI^,GQ)
M_:%^-_[!'[-6I?#76OVS?^%G?M->-H`GP)^'6@>'OA9\!/BG\7_"7[57A'X;
M^#/A_P#LFZ#HOA@`_7ZBOYH?V0OV.?%7QTU7]@3PO^W/^R_X@U7P3\+_`(/_
M`/!;KPYXL^#GQ/\`A5J/AGX!>#8+[_@I=^RW#^RI\&/%?P3M/B1\:O@<?@_H
MWP.\'QZ]^R9\!-<^)OQY^#7A?P7\'OAWX]^`GB?QO;?`WX;?%31?0/V6?`'Q
M"N_%7_!/_P`;_MG?`C]I_P"+OQ6N_P#@G!_P2QT;X)>-]6\+?$S5_B9\"OVN
M/!FH_&G7_P#@H;XL^(GQCU35-`N?V5/$&N>"?%/[/TW[6%M\8_B!\,]<_;B^
M'O@W5_V;=.\-?M2^*?#NL_`6<`_H>HK^>']I']DSXA^(;?\`X*]_%KP/\,/$
M#?%CX@?MO_L8:?H/B/QC\//B9\7O"WBO]B;PG\&O^"2VM_M@:5X.^`6F>*_"
MMS\=?A!\2?!/PH^,?@?]IGX*_`:[TOQO^VWIWP?T[]F'Q!=_$#Q3X!^&/A#P
MOY_HOP/U_P`/?L+^+M!O?@AX?^)7P)\=_MNVOC'1_A]K'_!+7]J#X=_LK?L^
M_!NS_9P\->%IM;\)_P#!$+P_^T#XH_:>^.OP@UK]ISP=JBW7P>\<VWPXGTK]
MJSXV^)?^"CUG\*;_`.&_P=\'_&'QV`?TO5ERZ+I$VM67B*73;237M.TS4]%L
M=7:!#?VNDZQ=:5?:IIT-SM\Q+2_O-#T>YN80VR2;3K5R-T0K^7:T^!_Q"UC]
MAO\`9,M_VKO@?X@M=6^'/QA_X*&^#6^!WQN_X):_$S_@H;^RC\.O#^H_MA^-
MD^`&BR_\$\_V;OV@?'?Q*^&&O>`O@7X/T?PC^PI\8/AQ\3/C=^S%^S]^RS=_
M%[X):=\5M>TGXZ?`77_%_P#1[^SU'XJB^`7P/B\<^`O$'PK\;1_"#X:Q^,/A
MAXL^+6I?'SQ3\./%*>#-%7Q!X#\2_'76-2UK5_C1K_A#5A=^']8^+&J:QJNH
M_$74=/N?%]]J5]<ZQ+=2@'D'QB_;G_9_^!WQ3N?@KXNA^/\`XH^)NG^`/"'Q
M1UCPS\#/V._VO_VF_P#A'O`GC_Q%\0/"?@G7?%&L_LW_``+^*V@>%O\`A*/$
M'PJ^(FGZ)IGB+5=,UB__`.$2U>Z@T]K**.YD^G_"7BWPKX^\*^&O'7@7Q+X?
M\:>"/&GA_1O%G@[QCX3UG3O$7A;Q9X6\1:=;:QX?\2^&O$&CW-YI.NZ!KNDW
MEIJFCZQI=W=:=J>G75O>V5Q/;3Q2O^8'C?\`9O\`C=\3_P#@I'^T+XZ\&?M%
M_M/_`+*O@EOV(/V&/"=KXQ^"G@/]FK6?"WQ5\5:#\>/^"C6L>(O#.H>(?VG/
MV8?VA=(N/$'POTCQ7X2U6ZT;X>W?A;4M)T[XIZ5?>-[?5;77/!4M@>)/V+_A
MGIG[9W_!-#P5H/P@\07'[-_['O[$G[6'A3X<V4E]\0M<^&?@+Q3X!^*G_!,F
MT_9M\->/=4U#5[_2/'.O^'])^&VN_$'X3:-\7K[Q9J"_$+X.Z;\</#=M)\4/
M@WX?\<^$P#]7Z\_\9?%+P)\/O$7PG\)^+]=_LC7_`(X_$#4?A;\+;#^S-8O_
M`/A*/'>D_"WXE?&G4-"^U:9I][9:+]G^&?P@^(GB7^T_$5SI.CR_\(]_8T.H
M2>(-6T/2M3_GB_9$_9[\51>%_"7A?PG\#OVG_@M\9++_`()2_M#?!?\`X*@?
M$GX/_#34OV6?CY\>/^"B/BS3OV4]/\"_$?P=^TK\:-$^%OPI_;,_:>L?%/A/
M]MG7?A1^V/HWQ-^,_P`,/`WC/QSK7CWQ+\:_#_AS]H#1_$'Q#\>^%/[-OPZ;
MX_?L-^/F_8*\`3_#+X3_`+?WPWU.Q^+_`,#O^"47[4W[$'@;PWXB\;?LB?MU
M:!=SW?[!'QJ7XL^.?A,?AM\>-+_8D\:_$W_@H5IMEX0^%GQ0UC6?V;O#GC?Q
M5I][^P'I7B'PB`?U?5Y_\)_BEX$^./PL^&OQJ^%NN_\`"4?#+XO^`/!WQ0^'
M7B7^S-8T3_A(?`OC_P`.Z=XK\):Y_8WB+3](\0:3_:V@:MI]_P#V9KFE:9K%
MA]H^RZGI]E>Q3VT?\\5S\%/B%XP_X*;_``ZFU']CKP_HOP\^('[4'[6OP[_;
M*\03?L:_$SQ7XJ\??LT^,OV7?VPM/^$?A[]I_P#X*-_$GXSZQX(_:_\`V8/V
ME+G2_A+\2/"7[*O@/X%^*/@E^QWJ.G_`#]DGXL^+?A-\0O@;\#?`GQ6\`TO]
MGC7X/V#/^",7A[4OV=/#_AG]GSX4?L2_$?P)^T1\#OVC?^"1O[3_`.W)X5\.
M_ML7R_LLI:^)_%__``3T^%5[\(?C'HOQ>U'Q'X/_`&S=8TC]L+6_!VL>![33
MO&GQ)B/B>^?]K'P9K_C,`_K(UO1=)\2:-J_AW7].M-7T+7M,O]%UK2=0@2YL
M-4TG5+66QU+3KVVD!CN+2]LYYK:YAD4I+#*Z,"K$5J5\_?LF^$?'?P__`&6/
MV:O`?Q1\1?$#Q?\`$SP3\`?@YX1^(GBSXL3:/<?%/Q/XZ\-_#OP[H_BWQ#\2
MKCP]\1?C!H$_C_6M?L]0U+QC-H?Q:^*.CR>(;G47TSXB>-;,P^)=3^@:`"OF
M"S_;/_9@U+X-_M$_'W2OB_X?U?X5?LE^(/V@/"?[1_B#1K+7]7U'X0^*?V6Y
M]>C^.?AKQ9X.TW1[KQM!X@\%VOAV]UNVT:T\.7>H>,/"U[X:\7^!K;Q+X6\8
M^$M8UOZ?K^8/X^_LJ_M'>&_^">G[?GQ(^!GP8^('BCXP?')O^"T/[/GQV^!R
M:!=-\1/C)^SA\0/VLO\`@J-XZ_9.\=_!KP1XE&B7NH_$#X??$S]H_2/B;X2;
MPOX@TNU^,?[+?QH^-K:+X%_:%^+T7[)6@>'`#^CS3?BEX$U?XI^,?@KIVN_:
M/B;X!^'_`,-?BEXM\-?V9K$7]D^!/B_XB^*_A/X=:[_;,^GQ>'[_`/X2'Q!\
M$/BA8?V9IFJWFL:3_P`(Q]JUS3],LM:\/7.K>?\`@;]J/X$_$GQCX?\``'@K
MQS_;7BWQ2?VHAH.D_P#",^,=.^WG]B_XY^&?V:_VEO\`3]6\/6&F6O\`PK;X
MU^,?#G@O_3+VW'C'^T?^$C\`_P#"4^$[2_UVU^'_`!I^S=\;_B=_P4A_:"\<
M^#/VB_VG_P!E3P2W[#W["WA.U\8_!3P'^S5K/A;XJ^*M!^/'_!1K6/$7AG4/
M$'[3G[,'[0ND7'B#X7:3XJ\):I=:-\/;OPMJ6DZ=\4]*O?&]MJMKKG@J6P^(
M?V=E\8_L;_%C]EKQE\=_`W[8'CKP_P"'9/\`@X4\!>(?B7X=_9`^.OQQ\=Z[
MXB^-/_!7/X#?%?X.^-?B+X-_9)_9]U>R\)_\+_\`AGX%\4_%?PCXDTOX:>`_
MA9XKT>*?4?`-G8>'[S0].(!_1]17G_PM^)GASXP>!-#^(OA/3?B!I/A_Q#_:
M?V#3_BE\)OBI\#?'=O\`V3K&H:'=?VY\+?C7X-^'_P`3?#'FWNF7,^F?\)+X
M1TG^VM'ET_Q#HWV_0-6TK4[WT"@#,L]%TFPU#5M6LM.M+74]>EM)]9OH842Z
MU.6PLXM/LGO)@-\YM;*"*V@WDB.%`J@<YTZ**`/(/C5\=_AG^S[X5L/%WQ-U
M37X+76]?M/"?A;PWX'\`?$'XN_$OQWXIN].U77/^$9^&WPA^$7A;QS\5OB5X
M@L?"_A_Q/XVUK1?`7@SQ'J7A_P"'_A#QI\0=<MM.\%>#/%&O:1Y]X?\`VR?V
M>/$?PS_X6U!XQ\0:)X6M_B[\,O@+K>E>.?A9\6_AO\3/!?QB^,OQ`^'/PS^%
MWP_^)'P5^(/@7PS\9/ACKWC?Q'\7_A7J6AQ?$/P'X9M[CX??$7P7\67N(_A7
MXCTKQG=>0_\`!0?2/.\&_`KQA_8?Q_L_^%9?'^+QA_PO3]EWPO\`\+3^.O[+
M/]I_`WXY?#G_`(7'X%_9[_X49^TQ_P`-%'Q;_P`)[_PS3XE^'O\`PH?XC?\`
M"(>$/V@O$'QZ^R^&/^%-?\)WX5_/_P`5^$/VCOBC^Q9\9%\!Z1\0?$WBSQ+_
M`,%-?^"=?C7X$?'KX\_LC77P[_:!^-/@?X>_M,_\$Z]2\4_M%_M>_LT>`/`'
M[(7BV]'P,\6>`_BQ\.KN34OAA^S7K&K?LB?LV_#C7WUG_A$QIGQV\6`'[O7/
MB;3K3Q3HW@^6V\0/JVO:!XE\26-W;>$_%5[X6@T[PIJ'A33-4M]9\<V>C3^"
M?#FOW5SXRTB3PUX4\0^(-+\4>,].L_%>K^#]'UW2O`GCB]\.]!7\LOQV_9[^
M/NH_!_X]^%=1^!_Q?\:?M!V7_!*K_@OA\$OCU\5-/^&GC37=0_:O_::\?M_P
M3^TGX(_&32M9TC1=4\-ZSKW[87P>\!>&?&GP6^!/PV\3>-=`_9]\+Z%=?L-_
M#N6S3]D76_`'@/\`7C]EWX`Z?^SI^V;^T]X/^%OP\\0>`?V?M>_9<_8M\96-
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MPYXMT;PA\1K;PI-X$\5^(O`_C_PUX>\1:EK_`(!\9:;H?`?MS_"WQW\7/V?D
MT3X;:'_PE7BWP/\`'O\`9`_:`M?!\.IZ/H^K^-](_9;_`&N_@;^TKXK\"^$M
M1\2ZAHOA.W\?>-_"?PFUOPI\.U\:^)/!W@6?QUK'AZW\<>.?`OA.;6?%^B?,
M&H^#O!G_``42^/MGXPU#X5_&"#]E'0_V)?VT/V._C#:?'WX0?'S]E'Q3\4]1
M_;,\8?LH:EJ_@[X>^!_BSX5^$WQT;0/"?PX_9\\31_$#XI1>'_!GA1-0^*7P
M^TCX-^._'_C#0/C)8_!P`_5ZBOQA_96^&G[6W_#-W[8WQS_:/\%>(/C9^V9X
MT^$%G^S5HGAOPSXXUS]DWQG\8=,_8U^"FM?"V7PWX/\`B'X?T/X46'P4\/\`
M[0G[=6N?MH?M`_LW?M(>&],T+Q5;?`;]IWX-?$.?5O!FG>&_"'PM^$_Y?_#[
M]G/XM^*O#/[5WPJ\/?L_>(/AY^S7XY^+'_!"WQ#\.--_95_8(_:'_P""5'P_
M\3W6A?\`!4'Q!>?M:_&3P'\!YOC=X\^.OPU^,/@'X;^#_"$?QF^/NKS?`7XQ
M:;\-/A3\)?B)!X:T_P"#'ACX'_&[X@`']7VC>)M.UW4O%FE6-MX@@NO!>OVW
MAK6)=9\)^*?#NFWFHW?A;PUXPBN?">L>(-&TS2/'N@)I/BO2[2Y\5^!K[Q%X
M7LO%-KXD\#WFL0>-?!OB_P`/Z'T%?SQ?&7X!W'@GPG^W%X#L/V3M`U7]GS4O
M^"B_P&?P]X<\2_LJ?&7]I/\`9Y\$?`3P1_P2@_8W^&_A?QY;_P#!/K]G[5O`
MGB7]N/X0^&_C#\/M+_9_\+?"3P,^I>#O@C\69M'_`&EKS38)/V0-0_L/SW]D
M+]CGQ5\=-5_8'\+?MR_LO^(-4\#_``P^$_\`P6T\/>*O@Y\3?A3J7A;X!>#;
M6^_X*1?LO0_LK?!KQ5\$K7XD?&KX(#X/:1\$O"*:[^RC\!-=^)OQW^#GAGP;
M\(?A[X[^!/B7QM;_``0^'/Q0T4`_I?K,TG1=)T&UFLM%TZTTNTN-3UK6I[:R
MA2WAEU;Q'K%]X@U[47CC"JUYJ^N:GJ.JW\Y&^YO[VYN9"TDSL?E+_@GL/BF/
MV!_V(A\<AX_'QK'[(O[-X^+_`/PM@>(A\4A\4!\'?!H\??\`"R1XO_XJS_A/
M?^$J&J_\)@/$Y_X2+_A(?[0_MK_B9?::^P*`"BBB@`HHHH`****`"BBB@#Q_
MXU_L]?`+]I3PKI_@7]HSX'?!_P"/W@G2?$%KXLTOP=\:_AIX+^*GA73?%5CI
MVJZ/8^)M/\/>.M%U[2+/Q!9Z1KNN:7:ZS;V<>HV^G:SJMC#<I;:C>13>@>$_
M"?A7P%X5\,^!?`OAGP_X+\$^"_#^C>$_!W@[PGHVG>'/"OA/PKX<TZVT?P]X
M9\,^'M'MK/2-!\/Z%I%G9Z7HVC:79VNG:7IUK;6-C;06T$42E%`'04444`%%
M%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110
3`4444`%%%%`!1110`4444`?_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X``02D9)1@`!`@$`2`!(``#_X0=U17AI9@``34T`*@````@`!P$2``,`
M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q
M``(````;````<@$R``(````4````C8=I``0````!````I````-````!(````
M`0```$@````!061O8F4@4&AO=&]S:&]P($-3(%=I;F1O=W,`,C`Q-#HP,CHQ
M,R`Q-CHP-#HQ-````````Z`!``,````!__\``*`"``0````!````6*`#``0`
M```!````+``````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0``
M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```8_````
M`````$@````!````2`````'_V/_@`!!*1DE&``$"`0!(`$@``/_M``Q!9&]B
M95]#30`"_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\,
M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`+`!8`P$B``(1`0,1`?_=``0`
M!O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$`
M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$%
M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D
M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F
M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B
M$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D
M154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=7
M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))))2DDDDE*3%)(I*>2^M/UP
MNZ?DGI_3FM.0P`W7/&YK"1+:V,GW6;5CX/U\ZQ1>UV=LRL>?TC6L#'@?O5EG
MM_LO5#ZTXUV-]8,P6@CUG^M4X\.8X"-O]3Z"RB8'CY=SY*C/-D$SK5&J=O#R
MF`X8^D2XH@F7Z7J\7V7'OJR**[Z7!]5K0]CAW:X;FE)4OJYB78?0\+&O$6UU
M`/:>03[MG]C=M25RSPW6M73C\,?<X>+T\7#Q?U;^9__0]522224I))))2DQ3
MIBDIX;K'U[SZNH6T=.KJ%&.\U[[07%[FG:\^US-E>[Z*Z;ZN]9;UGIK<O9Z5
M@<:[JYD![?I;3^XZ=S5S?6?J'F79]F1TZZL4Y#R]U=L@L<XR_86!WJ,W>Y=)
MT+I%/0^FC%%F\@NLNN=[07'Z3OY#&M"AQ^[QRXOE_E\K<YC[K[,/:_G-+_>_
MK<;#K]'0,EE&/UC8#D/]/%+B6O\`4/YM5C?<Q#Z=]4.A]/O&352;;F&6/N<;
M-I_>8UWM:[^4J_3>J]%ZMU)U6/E.R'ML.177>R8+0*_U%]@VLI;])W^%5CI6
M!U^GK&;D9^6+L"V?LM,\2=S/9M'I>FSV?2_2)WI)$N$2UKB&M>;&3DA`PXY8
MZ'$<<C*/'Q?NQ=H)))*1KO\`_]'U'UZ-VSU&[IV[=PF?W8_>3BZDNVA[2=Q;
M`(G<!N<S^LN<;^P/V@_TO7^U?:[/H_Z?:[U=F[_HH='_`#4]-_V'U9V5SZ6_
M?ZVX_9=GJ^[]I?SO_">EZOVC]$DIZ?UJMP;O;N)(`D22WZ8']3\Y-]HQSH+6
M=_SAV^E_FKG7_P#-;UJ?I_:?T/V+;NWSN.S[-'MW_:/5^V>I_A?5^U*#?^:>
MU_I[Y]/*];;OG9N/VO=N_P"%^AZ:2GIC;6'%A>W<T;G-D2!^\1^ZDVZI[0YK
MVN:X;@X$$%O[P_DKGK/^;OV^S=ZO[2W7?:/I^IL]/]/ZL_H_LGV?TO1_,_F/
M0_2HN%^P_6R/L?J>G]F.[9/H;-/6^S?X/UOH>OZ/Y_\`POJ)*=O[1C^GZGJ,
M],MW!^X;=O[^[]U"LMPLK'>PVL=38#4\AP_.&K)_>VK"/_-W]+Z7J^ELJCTO
MYG?ZM7I_9O\``^O]H^S_`&CT_P!#_IO\*B9G["]=W[2]7UO7HW^I^_Z=WV7^
MB^S9Z?K?^C$E"[T:W1/JKT[HW4&YSL\7;&N;C-<6,@'V/<YV[]*YO\VNF?DX
M]3=UMK&"8ES@!,;H_P`U8./^QMOZEZVW[/;]#9'H>J_?_2/^&]39_A$2G]C>
MKC_8_6]:?T&R)C[/1N_I'LV_9?L_\O>F8^#A]'RVS<Q[W'^NOCH;_N_X+NLL
M98P/K<'L=PYID'X$)*OT[TOL=?I;MGNC?MW3N=NW>G[/I_NI)["__]G_[0P@
M4&AO=&]S:&]P(#,N,``X0DE-!"4``````!``````````````````````.$))
M30/M```````0`$@````!``$`2`````$``3A"24T$)@``````#@``````````
M```_@```.$))300-```````$````'CA"24T$&0``````!````!XX0DE-`_,`
M``````D```````````$`.$))300*```````!```X0DE-)Q````````H``0``
M```````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F9@`!`*&9
MF@`&```````!`#(````!`%H````&```````!`#4````!`"T````&```````!
M.$))30/X``````!P``#_____________________________`^@`````____
M_________________________P/H`````/__________________________
M__\#Z`````#_____________________________`^@``#A"24T$"```````
M$`````$```)````"0``````X0DE-!!X```````0`````.$))300:``````-)
M````!@``````````````+````%@````*`&D`;0!G`#``,``X`&$`7P!V`#$`
M```!``````````````````````````$``````````````%@````L````````
M``````````````$`````````````````````````$`````$```````!N=6QL
M`````@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L
M;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<````L`````%)G
M:'1L;VYG````6`````9S;&EC97-6;$QS`````4]B:F,````!```````%<VQI
M8V4````2````!W-L:6-E241L;VYG``````````=G<F]U<$E$;&]N9P``````
M```&;W)I9VEN96YU;0````Q%4VQI8V5/<FEG:6X````-875T;T=E;F5R871E
M9`````!4>7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S
M3V)J8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F
M=&QO;F<``````````$)T;VUL;VYG````+`````!29VAT;&]N9P```%@````#
M=7)L5$585`````$```````!N=6QL5$585`````$```````!-<V=E5$585```
M``$```````9A;'1486=415A4`````0``````#F-E;&Q497AT27-(5$U,8F]O
M;`$````(8V5L;%1E>'1415A4`````0``````"6AO<GI!;&EG;F5N=6T````/
M15-L:6-E2&]R>D%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0``
M``]%4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N
M=6T````115-L:6-E0D=#;VQO<E1Y<&4`````3F]N90````ET;W!/=71S971L
M;VYG``````````IL969T3W5T<V5T;&]N9P`````````,8F]T=&]M3W5T<V5T
M;&]N9P`````````+<FEG:'1/=71S971L;VYG```````X0DE-!"@```````P`
M```!/_`````````X0DE-!!$```````$!`#A"24T$%```````!`````$X0DE-
M!`P`````!EL````!````6````"P```$(```M8```!C\`&``!_]C_X``02D9)
M1@`!`@$`2`!(``#_[0`,061O8F5?0TT``O_N``Y!9&]B90!D@`````'_VP"$
M``P("`@)"`P)"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,
M#`P,$1$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(
M`"P`6`,!(@`"$0$#$0'_W0`$``;_Q`$_```!!0$!`0$!`0`````````#``$"
M!`4&!P@)"@L!``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($
M`@4'!@@%`PPS`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#
M!R624_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$
MU.3TI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&
M!P<&!34!``(1`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S
M-/$E!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/54DDDE
M*22224I))))2DQ22*2GDOK3]<+NGY)Z?TYK3D,`-USQN:PD2VMC)]UFU8^#]
M?.L47M=G;,K'G](UK`QX'[U99[?[+U0^M.-=C?6#,%H(]9_K5./#F.`C;_4^
M@LHF!X^7<^2HSS9!,ZU1JG;P\I@.&/I$N*()E^EZO%]EQ[ZLBBN^EP?5:T/8
MX=VN&YI25+ZN8EV'T/"QKQ%M=0#VGD$^[9_8W;4E<L\-UK5TX_#'W.'B]/%P
M\7]6_F?_T/54DDDE*22224I,4Z8I*>&ZQ]>\^KJ%M'3JZA1CO->^T%Q>YIVO
M/M<S97N^BNF^KO66]9Z:W+V>E8'&NZN9`>WZ6T_N.G<U<WUGZAYEV?9D=.NK
M%.0\O=7;(+'.,OV%@=ZC-WN72="Z13T/IHQ19O(+K+KG>T%Q^D[^0QK0H<?N
M\<N+Y?Y?*W.8^Z^S#VOYS2_WOZW&PZ_1T#)91C]8V`Y#_3Q2XEK_`%#^;58W
MW,0^G?5#H?3[QDU4FVYAEC[G&S:?WF-=[6N_E*OTWJO1>K=2=5CY3LA[;#D5
MUWLF"T"O]1?8-K*6_2=_A58Z5@=?IZQFY&?EB[`MG[+3/$G<SV;1Z7IL]GTO
MTB=Z21+A$M:XAK7FQDY(0,..6.AQ''(RCQ\7[L7:"222D:[_`/_1]1]>C=L]
M1NZ=NW<)G]V/WDXNI+MH>TG<6P")W`;G,_K+G&_L#]H/]+U_M7VNSZ/^GVN]
M79N_Z*'1_P`U/3?]A]6=E<^EOW^MN/V79ZON_:7\[_PGI>K]H_1)*>G]:K<&
M[V[B2`)$DM^F!_4_.3?:,<Z"UG?\X=OI?YJYU_\`S6]:GZ?VG]#]BV[M\[CL
M^S1[=_VCU?MGJ?X7U?M2@W_FGM?Z>^?3RO6V[YV;C]KW;O\`A?H>FDIZ8VUA
MQ87MW-&YS9$@?O$?NI-NJ>T.:]KFN&X.!!!;^\/Y*YZS_F[]OLW>K^TMUWVC
MZ?J;/3_3^K/Z/[)]G]+T?S/YCT/TJ+A?L/ULC['ZGI_9CNV3Z&S3UOLW^#];
MZ'K^C^?_`,+ZB2G;^T8_I^IZC/3+=P?N&W;^_N_=0K+<+*QWL-K'4V`U/(</
MSAJR?WMJPC_S=_2^EZOI;*H]+^9W^K5Z?V;_``/K_:/L_P!H]/\`0_Z;_"HF
M9^PO7=^TO5];UZ-_J?O^G=]E_HOLV>GZW_HQ)0N]&MT3ZJ].Z-U!N<[/%VQK
MFXS7%C(!]CW.=N_2N;_-KIGY./4W=;:Q@F)<X`3&Z/\`-6#C_L;;^I>MM^SV
M_0V1Z'JOW_TC_AO4V?X1$I_8WJX_V/UO6G]!LB8^ST;OZ1[-OV7[/_+WIF/@
MX?1\MLW,>]Q_KKXZ&_[O^"[K+&6,#ZW!['<.:9!^!"2K].]+['7Z6[9[HW[=
MT[G;MWI^SZ?[J2>PO__9`#A"24T$(0``````4P````$!````#P!!`&0`;P!B
M`&4`(`!0`&@`;P!T`&\`<P!H`&\`<````!(`00!D`&\`8@!E`"``4`!H`&\`
M=`!O`',`:`!O`'``(`!#`%,````!`#A"24T$!@``````!P`(`````0$`_^$8
M`6AT='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN
M/2?ON[\G(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX*/'@Z>&UP
M;65T82!X;6QN<SIX/2=A9&]B93IN<SIM971A+R<@>#IX;7!T:STG6$U0('1O
M;VQK:70@,RXP+3(X+"!F<F%M97=O<FL@,2XV)SX*/')D9CI21$8@>&UL;G,Z
M<F1F/2=H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S`R+S(R+7)D9BUS>6YT87@M
M;G,C)R!X;6QN<SII6#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]I6"\Q+C`O)SX*
M"B`\<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TG=75I9#HU,38R-6,T9"TY
M-#EA+3$Q93,M.&,V.2UD,#9B-&(T,S(V-F,G"B`@>&UL;G,Z97AI9CTG:'1T
M<#HO+VYS+F%D;V)E+F-O;2]E>&EF+S$N,"\G/@H@(#QE>&EF.D-O;&]R4W!A
M8V4^-#(Y-#DV-S(Y-3PO97AI9CI#;VQO<E-P86-E/@H@(#QE>&EF.E!I>&5L
M6$1I;65N<VEO;CXX.#PO97AI9CI0:7AE;%A$:6UE;G-I;VX^"B`@/&5X:68Z
M4&EX96Q91&EM96YS:6]N/C0T/"]E>&EF.E!I>&5L641I;65N<VEO;CX*(#PO
M<F1F.D1E<V-R:7!T:6]N/@H*(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T
M/2=U=6ED.C4Q-C(U8S1D+3DT.6$M,3%E,RTX8S8Y+60P-F(T8C0S,C8V8R<*
M("!X;6QN<SIP9&8])VAT='`Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\G/@H@
M/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70])W5U:60Z-3$V,C5C-&0M.30Y82TQ,64S+3AC-CDM9#`V8C1B-#,R-C9C
M)PH@('AM;&YS.G!H;W1O<VAO<#TG:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T
M;W-H;W`O,2XP+R<^"B`@/'!H;W1O<VAO<#I(:7-T;W)Y/CPO<&AO=&]S:&]P
M.DAI<W1O<GD^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TG=75I9#HU,38R-6,T9"TY-#EA+3$Q93,M.&,V.2UD
M,#9B-&(T,S(V-F,G"B`@>&UL;G,Z=&EF9CTG:'1T<#HO+VYS+F%D;V)E+F-O
M;2]T:69F+S$N,"\G/@H@(#QT:69F.D]R:65N=&%T:6]N/C$\+W1I9F8Z3W)I
M96YT871I;VX^"B`@/'1I9F8Z6%)E<V]L=71I;VX^-S(O,3PO=&EF9CI84F5S
M;VQU=&EO;CX*("`\=&EF9CI94F5S;VQU=&EO;CXW,B\Q/"]T:69F.EE297-O
M;'5T:6]N/@H@(#QT:69F.E)E<V]L=71I;VY5;FET/C(\+W1I9F8Z4F5S;VQU
M=&EO;E5N:70^"B`\+W)D9CI$97-C<FEP=&EO;CX*"B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TG=75I9#HU,38R-6,T9"TY-#EA+3$Q93,M.&,V.2UD
M,#9B-&(T,S(V-F,G"B`@>&UL;G,Z>&%P/2=H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O)SX*("`\>&%P.D-R96%T941A=&4^,C`Q-"TP,BTQ,U0Q-CHP
M,SHR,"LP-3HS,#PO>&%P.D-R96%T941A=&4^"B`@/'AA<#I-;V1I9GE$871E
M/C(P,30M,#(M,3-4,38Z,#0Z,30K,#4Z,S`\+WAA<#I-;V1I9GE$871E/@H@
M(#QX87`Z365T861A=&%$871E/C(P,30M,#(M,3-4,38Z,#0Z,30K,#4Z,S`\
M+WAA<#I-971A9&%T841A=&4^"B`@/'AA<#I#<F5A=&]R5&]O;#Y!9&]B92!0
M:&]T;W-H;W`@0U,@5VEN9&]W<SPO>&%P.D-R96%T;W)4;V]L/@H@/"]R9&8Z
M1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70])W5U
M:60Z-3$V,C5C-&0M.30Y82TQ,64S+3AC-CDM9#`V8C1B-#,R-C9C)PH@('AM
M;&YS.GAA<$U-/2=H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C`O;6TO)SX*
M("`\>&%P34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W`Z-3$V
M,C5C-&,M.30Y82TQ,64S+3AC-CDM9#`V8C1B-#,R-C9C/"]X87!-33I$;V-U
M;65N=$E$/@H@/"]R9&8Z1&5S8W)I<'1I;VX^"@H@/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70])W5U:60Z-3$V,C5C-&0M.30Y82TQ,64S+3AC-CDM9#`V
M8C1B-#,R-C9C)PH@('AM;&YS.F1C/2=H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R<^"B`@/&1C.F9O<FUA=#YI;6%G92]J<&5G/"]D8SIF;W)M
M870^"B`\+W)D9CI$97-C<FEP=&EO;CX*"CPO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@"B`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`*("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@(`H@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@"B`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`*("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@(`H\/WAP86-K970@96YD/2=W)S\^_^X`#D%D;V)E`&1``````?_;`(0`
M`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0("
M`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$!`0$!`@(!`@(#`P,#`P,#`P,#
M`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#_\``$0@`
M+`!8`P$1``(1`0,1`?_=``0`"__$`:(````&`@,!``````````````<(!@4$
M"0,*`@$`"P$```8#`0$!````````````!@4$`P<""`$)``H+$``"`0,$`0,#
M`@,#`P(&"74!`@,$$042!B$'$R(`"#$403(C%0E10A9A)#,74G&!&&*1)4.A
ML?`F-'(*&<'1-2?A4S:"\9*B1%1S148W1V,H5597&K+"TN+R9(-TDX1EH[/#
MT^,I.&;S=2HY.DA)2EA96F=H:6IV=WAY>H6&AXB)BI25EI>8F9JDI::GJ*FJ
MM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?H1``(!`P($!`,%
M!`0$!@8%;0$"`Q$$(1(%,08`(A-!40<R811Q"$*!(Y$54J%B%C,)L23!T4-R
M\!?A@C0EDE,88T3QHK(F-1E4-D5D)PIS@Y-&=,+2XO)59756-X2%H[/#T^/S
M*1J4I+3$U.3TE:6UQ=7E]2A'5V8X=H:6IK;&UN;V9W>'EZ>WQ]?G]TA8:'B(
MF*BXR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:``P#`0`"$0,1
M`#\`W^+?\5_XC_>O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=1Y7(X^
MGI)^I]5O[-A8@DCW4T[%888T_P!GK1&HH-8&<CS(\Z=:\W\T7^<#N[XW]E9#
MXV_&/&[8K>TMO8_%5_9?9F\**3<>W]@UN<H1D<5L[;FV:7(4,.9WB<9-!5U=
M162FAH(9TB,4T\C""'/<'W,?E6Y;9MBMA)N6@,SL=2+4GM/J?/CY]9A_=^^[
M':^X>VV_///LUW!RG)))';0P42:X9,:UD<%%0/5?A9V930!14UO=&?SX_F%L
M'>N-K^__`.Z'>75\M4J[MQ&%V5B-A;]Q6(*_Y3E-E9+`STF%R63QZ7G%!7TQ
M2L53"D\4CK(`7LWO)O5M>V[\Q);W&SN0DC0+1H2:4)R:TX$$Y\B.ISYI^YI[
M>[ELUTG)FYWNW<R*X$)NY1)`TFDD0L-`</)P#"J`THK"HZW#^OM[;7[(V-M'
ML'9.8IL_M#>^W,-NS;&;I"WV^4P.?Q\&4Q==$LG[L0GHZE"8W"R1M=6`(]Y(
M6DEO-;6\UI(6MG4,IXU5LC/Y_;]GES4O]NOMGO[[:MTB\/<[>5XY5H01(C%&
M%#6F5.*D#R/7_]#?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW71-OKQ[UG'KU[KB&
M6]M:W^GU'U^GT_U_?@020&%1_JSUNA].L,I6X!'-B1P;7L38D?I^GOPX>(N3
M_L_ZATVP+-1>(!_F*<?+K0._FB];;RZP^?\`\E:7>-%5P1]C;XD[<V/DZB*<
M4FY-B;PH<?\`85>*JID6.LCP&1I*C%5"1D_:U%)H>VI0<,?<>QN]OYYYB-[A
M9YDDC)X%=`4`>39!K2M#Y==B_NZ<Q;9S1[)\BG;*']VV[6MP/X)8W9];*/@U
M(X;4VFM>->!`ZJ=*:-W>.2=B4B2FIX7GJJRHJ9%AIJ"DIH@9ZNOKJF18H(54
MO+*ZJH)('L%'Q5;P[4?KR(XH!YU`';YD_94=3./!=X)YP&M$&MV.5"J]=6NM
M!BM&J*=?0@_ET=5;QZ1^#WQDZM[`IIJ'>>T>JL!2[BQ=3Y!5X7(9$SYI\!5Q
MRI')#68"/)K1S1V_;D@*?B_O-[DRQNMMY5V&RO:_5);KJK@U-33\@0/E\NN*
M_N_S%M7-GN?SQS#LBTVFYW"0Q4((95HFJHP=94MC^+CU_]'?X]^Z]U[W[KW7
MO?NO=>]^Z]U[W[KW4><\!0P!8V%Q^?P/H?K[JRF160,P)!R.(^?56+`#01K\
MOGYD?LZU3OF!_/5[VVG\@M_]??&?:/5]#UMU7N[,;(EW)V-A,[NC.]A[BVOD
M9L5N7)4D.+W#@*3;6TURM+)2T2J)ZZ9(6GD,6M(EQYYF]X=SL]VNMKY:VJ*1
M89`ADEJ#,5-'7-.-.VO<>L_?;#[H7+N[\D;1S+SOONX1[MNL`N(X+81U@@<5
M1I!)6K,M&511=.37CU>?_+Q^96.^<OQOP_<PVT-E;KH<]F-A]C;.BR'\4QV"
MWSMC[5LG_`<BZPU59MO,4-?35U"U1'%41PU(BE!>-F,P<H<T6W-^QVV\6\)C
M8DI(G\,B_$/VG_4:]8G>[7MG>>TW/&Y\H7-X+FW15F@E%"7@F&J,G22`PH5(
MJ:$$B@(`3GSUV/\``OL_%]2]9_->38U#7=J;X3K[H7)9G(5VW=^/V+FDA7^%
M]>[OPB+F<!65R_;K/>:.AFD:%)PQ:-3[F;;>5]QBL[?F:*%E>0+"7'<';AH-
M,&M..*D"M:=*O:S?O='EJ]WK?_;26Z#6%LT]Z$TM!],H[OJ(G.B10*DJRDTJ
M5_$0B/CM_*(^#OQLWW1=F[1ZZS6\=]X.JIJS;&>[;W9DNPWV=D*8NT>3VQB\
MJ%P>)S,)<&.M%.]7$R*T<J%;DNV7V\Y1Y?N)+ZTLM4NLM61M05B<LI8"G^JE
M.C[G7[QGNOS[M/\`5_=N8EM]E(),%I&MNCAN(=4HQ4TRE=%#@4QU9[`NF,"X
M)NY)O?DLQ_K8GGV.*#'<2*<3_J_9U!48TJ0`HR>&1Q^?\_G7K__2W^/?NO=>
M]^Z]U[W[KW7O?NO=>]^Z]U'G5W4".VH-J!:]@5^G(/'NZ4#U8]M,]>H"P#?`
M:UIQ%1Q'Y]:M_P`QOY$';N^N^]Y=E?&/L/K2AV)VMNW+[TSVTNT6W!B*[K?<
M.XJTY#<:[=K]N8G-Q[LVQ7Y2HGK:>"5*.JI&F:#R2)H=8!YK]G+[=-[EW/9=
MXBA@FF\1U<,:')[:`TR3DT^?6=GMQ][_`&S9.2=NY=YZY:O+R_VVW6&!H&C4
M3QQJ$A28LRE=`!^$G4/0XZNQ^#7Q)VE\!_CA1=20[O&XZBGR>X^PNR.Q,Q2T
M^W:/-[JS*QSY[,_:/4U$.W]N8;%8Z"FI8IJB4PT=('ED9R[&5>4^7;;E#8K?
M:H9E9H]<DC?""68LS?8":9^WSZQ;]U_<7=O=KGF[YHO;)+?QUBM[>"`%BB(*
M1**99N/`98GY=%!^./RH^&'S#^26;VEUUWGG.V\SA-_97O7:&T>Z.NYJXX[*
M;8Q.&VI%5?%7=.Z\-08W;W6F*I:>:NK:2"GFSDU17"LIZN*E+H239^8^4N8]
MX>RL]S-S?PRF94<5*L!IU0E@`(US^8P>AASM[;>Y_MSRCM>[;]RTECM-]9_2
MRR6TQ76&=FT;A&KM^L:%:/I72M"K&G0O_%;HOY\[$^8?RB[(^0?R$H>Q/C3O
M>6O'1G7<%=4U3X%*S<4>4V_/2;;DP6/I.OEVEM=7Q55%!6UXR\S_`'#D%0?:
M_9]NYMM.8-_O=XW:&ZV2;08(E!!3R(SVX'$@FIR:G/1+SQS'[4[O[>>WVS<F
M<HSV'.-K"1N%RV!-)0U\R2-5"E::5[108ZM#0>D7`!_(_P`?Z_['V,NHATA>
MT<.O_]/?,&_-D-DEPPWCM8YA\H^$7$C<&).3;-1H\DF(6@%7]T<I''&S-3Z/
M,JJ25L"??NO=9H-Y[2JJQ<?2[GV_4U[9K(;;6BI\QCIZIMQXFA?)Y7;RP0U+
MRMG<;C8VJ)Z.WW$,"F1T"#5[]U[KFF[]JR5])BH]R8&3)Y"KS./Q^.CS&.>O
MK\AMS_CX:"AHUJ#45=;@/^4Z)%9Z0G]T+[]U[J$G86PI7>*+>VT9)(XLG/+'
M'N3#/)%#A7$>9FD1:PE(<0[!:IC9:<D"323[]U[ISEW/MR#)5^&FS^&CRV*Q
M4>=RF+DRE"F1QF$F>HCBS&0H6G%518F62DE5:F15A+1N-7I-O=>ZP8W=^T\Q
MCZ/+8G<V`RN*R.&&XZ#)XW,8^OQ]?MTA#_'J*MI*B:FJ\+:1?\JC=H`&'KY]
M^Z]U"7L#8)P<.Z$WKM)MLU.%_O)3[C7<6(;`S[<5HHSGHLP*PX^3"B2HC7[L
M2>#5(HU787]U[I#;@W1TQVQU_NC`UF_=F9O8^\L=F^M\]4XW>&$%-*=TX.KI
M*_`?Q"&M=:7,U>&JI)(X;B?Q_N*I47]LW$*7,%Q:S?[CRH58>=""#0_,$_Y.
ME>WW]WM6X6&YV)`N[:=)D)X!XR'4D>8U`8ZIH^%'\J_XY_!KO[&?(#+?+7']
M@+MW;N\,/TMA-R5VP=GT^+PV;C;:NX,YG<M2YN0;WRN%QZ38H301T5)%(SO+
M'Y[+'''*/MAMG*F\W&[Q;@\K,&5%(II4UJ">)XFGGUDE[J_>BYC]S^2%Y-GY
M<@M4GFBGOI0P8W,L3$H8Q0>"JX)%34XJ>/5XV;[%Z_VECADMT[WVCMZ@^\AQ
MPKLSN'$XVD>OJ*&/)T]#'+5UD:25D^*F2I6-27:G<2@:"&]R;4,6]*^?6,$8
METKXKZI/,CI383.X3<N*HL[MS,8K<&#R41GQV9PF0I,KBJ^`.\7FHLC0S3T=
M5%Y8V75&[#4"/K[]U;K_U-C6@_V0C_9@=T?W._T[?Z:?]F\[<\G\!\?C_P!F
M)_NWNG^_']V_XY_DW\/^Q^[^Q_W3]QX]'IO[]U[I$[(_X:D_N[NC_0#_`*4_
M-_=+J/[O_1?_`*1O[[_Z:O[U97_09_=[^^_^Y3_9U/O_`.\'C^W_`-RW\"_B
MG]X/]Q5O?NO=*_,_\-=?WSZX\G]^_P#2SHZ(_P!ED_@G]^?[Y?>?WQR']VO]
M"?V7^X7^\7^EW^/_`.D;^+?Y=_'/XM_>C_)+>_=>Z8J'_AJ#['<O]V/[Z?<_
MW#^9/^D?^$?W_P#XI_<K^^F3_P!F)_C'\4_R/P?WYM_#_P""_NZO!XO\CO[]
MU[I?9[_AN[_3QO3^)?Z6_P#9L?[R?(;_`$P_\?\`?Z4O[E_Z*T_TI?W_`/O_
M`/?D_P"R\_Z)/X!_=G[;_<5?^"_P3_<K;W[KW2]Z5_V1_P#OCW%_H6_TB?W6
M_P!EARG\>_NS_%?]EY_N-X<=_I'_`-"OVO\`OTO])%_X5_>K^[7^X_\`BNCS
M?[D_OO?NO=!)4_\`#=VOL'^Z7^E?^Z/]S.E_!_HW^X_T)_WQ_P!-W4G]U?\`
M0GY_^,9_Z4?]+7]SO[W_`,(_W[/WG_%V_P`I_B?OW7NEGVY_LBW]]\[_`+--
M_I3_`+]?Z?/CM_>?_2!]KJ_OY_HD[B_T$?<_Z"/]^W_=W^Z7]YM6C_*OOO%]
M_P#M_;>_>OIUK'4787^R;?8Q_P"@W_31_"/]ER[I\?\`<W_1_P#PO_9>?]F`
MWU_>3P_Z8_\`*/!_I*_BW\*M_N:^QT_=<^+WX?T?3RZWTKMF_P"R=?WIZ;_T
M(?Z8?[__`,1JO]%G]TOX;_&?X3_LH?07\;U?Z8?]^W_!O]`O]SO/]U_N4_B?
ME^W_`'/NO?NO=6!?'/\`NQ_H=VC_`'._O%_=_5N+[7^]W]V_[S?>_P!ZLY_'
:/XQ_<_\`WZ_W/\>^YM]A_D^C3I]^Z]U__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`,P!D`P$1``(1`0,1`?_$`*P````&`P$!`0``````
M``````0%!P@)"@(#!@$+``$``00"`P$```````````````,$!08"!P$("0H0
M```%`P(#!04%!P,%``````$"`P0%$08'$@@`(1,Q(A05"4%1%A<883)"(S2!
M,R0U-C<*<5)'@D-41481``$#`@4"`P4'`P4```````$1`@,`!"$Q$@4&00=1
M(A-A<8$R"/"1H;%"(Q3!<@GA\6(S%?_:``P#`0`"$0,1`#\`OT!^6`))%$:F
MJ(U`0"O9VC[.')\RO><A7%G9QVL9"X9]:WZP[]!K0G;[Q[!X1)``7(FD8G,D
MN3HRI/KEN>U+8:/I2[;EM^VXJ/=HD=.YJ79Q[)LZ>%*=F2476<)D9`L4"B3J
M"6H#4.%GW@:TL:%.G2N"#W^%/]EV+D4]])#QX&XEG<^31'$Y[TR<0>J(ATCH
M:$PMQP%SLQF[?FXJ;B%RF*WFH&39R\8)A*!1(1S'.'"9>\/=U4'AO$'L1KFH
M"0I\?%,%%15]M=Y:[L^&ZM)[;=H<W2$("!J5T:ZAABA%=3%-@08():CJ`3J4
M.<XJ',!E#B`B<1&M:_LX4OKDLE+]).5/H;J6ZC$\TD<LCAB]@TM/N'1,O:0M
M!I:3CX5H[E))VWBXQ@F"\E*2,DVBHUDW*%17=O'ATVZ2)`'O&$P`'#6WN)+Q
M_IMC<`J#(DD^`&)HD=A7&6WES%%Y2)HBU,J8WO.14J<D1;EZVM,2!2`-.XSB
MY%RY4*42CWJ<.9=KOK9XGDBE8T#]3'#XJ16#)&H@<%I2DP$#'*8"]TP:`()N
M04#D>O*O^GLX9OO':M`8[5\*5U$YD5J<@&I,13,H;O"4I>792M1'NA^WA..U
MC<3<77ETX@X@#W@9TVGB,KFID/\`2N=>W%;T<X!.1N**BW0`'\/(RC,#)5[#
M$2653TB/9]H<5.Z[G\+VZ^=M][?VK)]2$&4`_$(M2<-G,(?(QS@F8%&S%VV>
M&!1LJ5^DHCU"R+91%1HJ`G``3(=%0Y!-SKQ/[>_C^YN=?[5.R5SPAT/+L#BO
MA3>6W<WYQI=[1C1L4I0+V\AI7]G$C#`+745P-8+I0>%9<M-*\O?^VO"GKL^=
M1I\:%*K6HX5`:&3*(^VM!#_2G"Q*-4@D"D)&W,C-+2B^^HR/4%]07"NR*$L>
M"RE>5Q6;,9J>7);$-=UL1!+C?8\9MHQ1N?)3F(,59-^RMJ2>(`+<$E%53F#\
MHP`(\,W2,9*PSNT-D=I!Z-Z:G*0$!SK</:'LUR#N'-=LV>)T_P#&A$CV_N+(
MF)AC+893ZCFCRH,2F>-0$0FR;=279MZF%S.<L$WYP.XNV,9RN(;LL:YYJ_[N
MNR2MZ=5E)B94M8@+(63<S.`D$5%HI,3F(!!3"H%`.(N_CFVZ"\CD>V4EH,;F
M.52"N!4(XC!,/ZUWCL-][4;9WCX%M$FWW'')[&U$6Y1[I!;V+7O+"PZW2B-L
ML<CQY)7)J=F0Y0(1]G6^3<SL`R^SD[6F[Y96Y;5SLX[+&#KA>2K5E,L6@`HY
MCY*U)U(SRWY5]&F46(X23(=,Z6C6`"`<0.U\E?MTRSG7"YI!#SJ3^W4X(_JN
M.2CQKOYW-^G+MCWYXSN>S;!9;<;N%SGQ7>VQ6P<9!&2P/N(H)'%A&+D4D##Q
MKZ/&+LN63D7"%J9IMZ0D/@*\\>-\E-91RH37'02\026<%454$H)KMD1.'>`"
MU3$1XOUI?,W>Y8(@SU7Z0`@3$@!0%]BU\Z6[<0NNWVYW/#;_`-7^5M\\D;B\
MN+B0XG-S6.(*JU6CRD5\M[U:_6&W1>J?NDE<78RNJ]H';@RR`OC3!&W2P)&3
M8RN3'!9,(&+G+P&%607GKEO.2#J`F\4%NS3,1-(AB@8P[RV7B%CL]F+Z]+'R
MJIR34W47!FIK4&!0>#25(-5^:<N.&7VSI;,P>EKF+9'L.VLPCC:GN8LWU9=R
M.XJ02L._L0Y#N.=):6,HU..:0N.[P7L.;=6U;DM<KZ3!UT!ZJS8&9E55TT^H
M4L9N&_;5N.X>@ST#8"+2,!J,@\WF<I;Z>G`E"%7KA31\SHG:'`B3/'P)3`'$
MN6K?WHF;T-ZTS,Y`].+U0+3<VAO8V^6):>0[?NF1E+=D5\TX*N17RV/N0TK:
M;EQ;LQ<-K2:8,G[IDJKUA"JP$6*I6C[YM]C#IW.Q+7V;U5""`['II``Z$*H*
M$X$5*VSG$:9%U?C4D6^;<K<6$;2B;?LDR09`O)%[TW@J:TX*';+)MEI'HA41
M54ZQNF8*&*)/?3CSN^L;ZASVKMMHVG9W$3[DRZ)(Z-C]-@"MF8027*`C@B(1
M5JV6R;>/=K'REJ?'X5!=)O'UP/'4C<,K,W&YD!`#3CB8=F<'<:A664T+.#*%
M1*8U"CV<>,/)^Y?/>2[L_=HKV[8[63I:^<*.F4AQK8$.T-$0T-PZ_9*<)M\W
M+WU@F[X589V0FL>E<-H^Z89\\<N^C$/G:"`/(\BZBB9';5P<HB8H`8$]7LXW
MOV!^IGFO!N6Q#D-Q=2;3<0F!)'RN`<H(/[D[6C`%3B4Z5%7^RM?&XO`'@4Q_
M*K'$/(LYABTEV2@K(2C!L\;K%,84E6:Z8*MU4RZA(43D/SIS]_'O/PS?F<LX
MG:[TS_KGC4'#'[B[\S6M+]G\>8Q=11QSI3[.S_IXE/2=Z7I_JKE1HU=$K09.
MI`(`F$:C4PAS&O8'9V!Q*V[R02_&F=Y-+(0("YGNPJGK_E!67<:UP[3LD':.
M%;*@/CFRI1XS:*="(N:0=1LW$/9$2@*:3=[',5A`QC`4QD]/:/%6YDV:.P9-
M`XM4.&'0_C@?Z5ZR?XS)-ICY/=V^[RL+A+%)YW-1P+=*D$C!A"'PU"F%[>,F
MWCC3T4,YWC@*\I_'F0\;[[+*N"X[DL:Z)6WI^+C%[&AVD7*NC(+!UX-\[4`J
M[<!!NN9$`,4P`(#7(II!L3`'$21Z`X@]<<<?$X$IAT(*&NP_=3AW"N:_7I9;
M)RG8=GO>$NX1=A;R+5')=LN2]DK/5'HR2,:Y`6N5@/E"D&CG$.1[0]7>SKAP
M7G%K;5K^HS;5KS4EMZW`LH=K;+'<C$6Y'.W3G%.3$&0)-$;M33*=1FN<`,N0
MU2&KJ(=4QP<F#8;AL<.XMB5KFCS2AJ!RAP365S\,"N!%:W&/G_T7]QX>XG"+
MC<;SL"998=PL9)',MK:6]`A9,RUB8KX+8$.:/5\A0H02:M";=]NV8X?T?8O;
MA<[1W:^:G&U2_;&-'/DR'>0EQW#`7`6.B%46I@(NLQ-(IM04*-1$*]H\7WC5
MO#M]U%J:DK7!7)CBB+\:\J?J.Y1L'..\N_<IXLAV.]N&/C0:0OI1AZ`$H-8<
MF)PS-4LO2:W);M\Q3^U/8MLJ]/O9O#[A]CUTR]SYKW.YAMF$E[J3L^"OY>!N
M&5</GD46>LVZG#QXH@9XB=R]%=-$&Q4BB(FW)NMS=.VV3U;N46LC&1EKWJT`
M8*P-!<9'@%=7B<P"FA2PDA!Y@I">/15P04X[U]_7LW;1&=[RV-[>H'*&S24V
MX97;R%\Y1B[N8J7[E%N2.:2UN+1B$&VZ+.QI>,FDI<Z)')U':)TR+@'>3XYX
M1Q&/<89-PG:'VHD#0Y&%I`0N`:X.11Y7*ASTD'&HV\!:YNL!,2A+M2]"3ACA
M@F'B*"?XTF5-VN^KU;<L[R-P5^7)E=[CS;(^L^]K^FT463)LWN6091MAVG#Q
M4>W;,(955!@J].R('4-WUA*&JHO.X@V6WV;_`,^P@@BE5K2(VZ0JEQ(;J<02
M/F)SPQIUMWK&57N<6J<RI\,\B%P'A5G3U,K?F(_)=F72JWZT-+6<ZA(LZ;D[
M90)*(DR.'#,'`?EI"^3?%*8!^^4@>[CP$_R`<3W2YY%QFX.IUJ8;P`.Q9@^(
M*?+@1@1CTK;7&9;5D,ID`]74WICE34KZVO9EQWCF$RU/0L,O:LNS;F681T@"
MTU$>=*@JQ3D#")"JMTDU"@D!=6A01KQU;W/Z:^YNV<(/<%IM(N/^D9-0NV:M
M#,_V@T%7'_DI&`RJ79?RSW)M[69P<W-JD#\D('L5.M(.FB]5*W9L6BCI205*
MQ91W-:04?KJ$9$Z!`#4<2JK`8W;2E>-&<9V_=.5\@MMIM7227'KL?@I:&@@D
MY%,%&52=UA9B60J=28U:7Q+%24%C:Q8*7U%F8BSX)E)D`#=,CE%DD0Y*CR%8
MIB4-]H<?3#V;VR;9^UVU64V$C;?XKGX#H1TK3N]>>Y>]G5WV_&E+H;I=O>I]
M[V]GOXN7[O\`'53K55ZTWQ]-/960FY@`]@]@_;R]W$RU@8W"LM#)&:FYTV[<
MIMIQ5NRQC=6%\S6W'7#9MT,=+Q-5,XR4;)MS">*FXIPDHF9M(1JH`HD:HAJ"
MA@,41`6EVWU[<P2^:%P^+3XC+\ZM7;WN3RCM_O\`'NVQ3/@O8E'E<$<UV;2"
MUP0X$%"0<14".VST4+WVU7[N#PVOD"WLT[*]SV)Y6P+L:7*#Z$RU95PQR[ES
M8=SL6)DEK:DY"'67`'#LBB2JH@!NCRT\0S>*W5O;R/\`5U6=T6ZFH%:!BTY9
M#-/FS"XK7=/N3]9L/=SBO'=SVRUN++N!Q3=[5KY&RN+9X&L#;X:W1M8!*T-U
ML],ZOT.4*"WT_O0#:[?,HP.:MR>7FU[W%C2[&L]CG'F,TY:,MX[NW7@*VK=%
MR7$X\'-24TS23346CFZ)&9E`$#G5+R!;:^+,MKKU[MPD>&^0C``A1J\5+?*A
M]Z#*K7WS_P`B^Y=UN(WW9GB-B+#:+P,%R]\CW%S8_-I,;XP`7#2'.;+I"8-/
M2T*U,@Z0!5$P&J8YBJ%`Q!*H!S:NX8QC$$AZ@8@]@\A#B<,?HR.D?UKS1M7Q
M2P-EA"1E4P3J5P..=5^MV/HWY2A]U5P>H+Z6.X"V-G>[^](EQ!Y:M:\K1^)M
MO>X-F^%!9RZO.#9LG+NV;F.Z;)N#NV39X#ITD54R:2@G4-/V>]1.C-O<M,EN
M=.I5(1ORZ@H)TJ2'`AV0=J`%<O9U;@ZJ\%R_XN'JM[N]R%\YKWC[HMO\5-9$
MN)&6OO),>K<]VW;+I"W:Q8)6U:<7$QL&V/%1#))!DD[=-D&Z*:8!6@E#8^V\
M_P!OV387[78`D.E)#6AS=((Q<KU!Q&6?LJ,FMG/G!DZCQS^['[9U<W].3TYM
MNGIDX";8!V]P[]9)S(%N/(N1KG5:OK^RK>[EL1)[=%WR39%`#&33#HLF9"E;
ML&H`FD`]\Y]1[ENTNXW/J2Y*<%)13BI.))ZG[@!4JR%L;0GV2G+9OPM9.=+-
M<V->T<+I@N8SM@^;*"E*PLHF`>'DHY<3`"9DZ]\!J!@[0'C3W=WM%Q[NUQD[
M5NC&#<H&N-M*6ZG1/<`ND%[1YB&KJ48=*>6MV87D-<5*8>/^U1X91VO[L;QM
M&.Q;\U;0O['T&Y0\M;/%36M*`>,TDC6]QN6;=8),T:B4ITP*):G"IJ\=%^9_
M2[]25YP=W!MKWR[GX[I+?0+K%D;HR?D(<X.`/]U66VW""V6X^6<A"X`JGW>R
ME#V^;`87'EP1&1,GS+:];MMO6[@HF-;K$@(*15.0XR"`F.121?`4!)50!)0P
MC3BV_3Y]$=KVVL6;[R%PEY7+(0]A:S]N-$T"2.=S7`XG)>@PKC<.2"Y@%K",
M`5U?ADE21MR'U$,L":8"0W02J;JDJ!>H)^]I,-*<OP^SCT)M8(;"QCM&8!C4
M]F'WU5)?,O7&AM`TZ?;QEZ1]'VYTV4?)7O13H`4Y`(B',>T>WV\.2]QSZTI"
MT0-TQ8`T6JJ)G,8AEB(A4I5"Z5"J!S[I5G"1P`@B`5`*A]O"88T9"LU(.KK6
MCPZ!S'4.@X1*0ITCE.<QR.BJ#J'25$YP*H!^TU`-PX$\H((.(I&&"*WN3=PC
M3.223[RIPR_"O4FS4HD*4@I`WJBFH5<ZYND(:C`*AJ&1YCVC4.7;QP9GN)<<
MW%3]NE<RPQ37PW*0+>@$:O8<PF5"2*HG$2$,852")S)M_P`V@%"ND5#$*G57
MM]@C7E[^$G_N#2_$4N9'G,U@<05.<3=%02B3H%(DFH]9&,%%3J@94Y:$$/PE
MK3W\)LB9&=3`CO?6!QSKPQ4-:;GICJ(F*R2="%4,8Q2]PQ!(!DE3=4"C[>0<
M92,;*09,2,JP,;"\2$><95@S<ME3N4&CYNNX:GZ#@!<(N3INC%U]%X"0@HDN
M@'($Q,4VGG2G&`@B;\H_&E-1(0UM.8IU#=BKE$O6(B504R"!1`IA!<":25/V
ME,)A`.WA&>QM;B:*>9JRPKH*D(N>`*'+K6`:!CXUB<!7$A3)D;D5(93K)+%6
MJ80`!U$%(6YR@'M/R]W"LMO#.X.E"N&6)I34XX')*V&$42%!`J2JZPZ6VHYP
M2/H+K-U%$RF(F;IE,8*`!>5`X4:QK7:F_,B?"DFQL8[6T>:A#=1-P!543%61
MH<H+#J`X*%/I.0"F*4P%"GV<8NB8XZG#&LUH5I#A3HG2L=#57K67!65,!REE
MB_8/?_M9P]'W0XB\:W_B'/5R7+;I61%$)ZZ;-<VPWMM5U)&2.9,&Z,HN/0UE
MZH@6G,M."BF4>JUD[/%LWM;\/AS/^3\'QEE;;LQYMDD,9QT`_4O"ZK*NFR(.
M(C;D6FXF33)")(W*Y,X33TG4.0!#[E1**<7Z:]]YBN&-W*8GS%EBZ,T/<$9Y
M1L>V<A7A`Q<5=\U:D[CVU;X397*I#-6D5*E8O+@601>))EUHE(41U`/!14.%
MX9PWH)!/98A]\F:X4YHC?'DR-Q^-EV9(6`U>;6]P]OXRLJRVK%:!)-GM23M&
M3.>2*JMK<&$K@AAI3@HJ=[>)GYIB/9!?V9)UYD6/?'L"S1/)X65AV-]1=P7P
M,&S8R$%*3[5Q!6Z@C*2A3KO7Y#-6S6JBE`#@HIO7I&9_R]FNQMQ\%E6]IG(I
M\);A)+&UI75<D_95V7"[MP+5MN:4C9J],>-VUFWB^BG\BJ4L@S#2J!@((U+P
M45P'IQ6V[L_>3ZD5KW'N2R->=PL]P,G<45@B_';,R-LV=<,7'/H+(L0S<,49
M!Q$/S&.R:KLS^$Z2)0.3J"`@44]/&&4K\G]]V[?$4I/.Y#'>/<2;<+CM:VQC
MD$FD+-WFCD$]T'9/2HD4=GG213<RA%%#],2%T@%>913:(3*]RWQZI>4\7W?N
MEN3&MJXCMW&X8AVSQ*,-`Q>9C7+:PR-YW',/9*+7>72T@Y8H(IH,UTE&]1$W
M<H`E%!/6"S3E;`>(L2Y(LW/3G"M@P>4F[_.<%9*UK-\YW[C9M#R'CV&#QO!!
MQ&S5Q6ZY*G*.H=),',BQ;JD2/J&@E%2IV#,,KCM2S+B8KRDBSG+0@Y:,EIAH
MHQE'\=)1K1ZT>RS11-N+.7>H+E4<(],HIJ"8*`'("BN[X**_<%%)=,:_F/:5
M/E_I\LG-/G'A_F%^^;:_@K7^9Y73^::_Q=/1P443Y+U>(_XMT_#<[3X_Z?WO
M',=76K^;\)TIYI7N=7H4YUX**&6'3Q=^T^6O\VCO[?Z_,]/E;?\`K;7_`.V[
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MW.T\NQOTOI@_N&2GU25Z>KH+U^57C?\`[RO[G5W>EJIRX**<S'??:Z=.CPYM
8/6KUONDIT>I_$=G^[_LZ/;P44?<%%?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````/```_^X`#D%D
M;V)E`&3``````?_;`(0`!@0$!`4$!@4%!@D&!08)"P@&!@@+#`H*"PH*#!`,
M#`P,#`P0#`X/$`\.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-#`T8$!`8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\``$0@`GP"6`P$1``(1`0,1`?_$`)4```$%`0$!````````
M```````!`@0%!@<#"`$!``,!`0$```````````````(#!`$%!A```@$#`@,%
M!0<$`@(#`````0(#`!$$$@4A,1-!47$B!F$R4A0'D;'10L(C,X&ADA7!<N%B
M\206$0`"`@$$`0(&`04``````````1$"`R$Q$@1!41-A<8$B,@6QD<'10A3_
MV@`,`P$``A$#$0`_`/EJ663J/YVYGM/?0#>K+\;?::`.M+\;?::`.M+\;?::
M`.I-\;?::`L=CV[*W7-&,LIBC16ER)B2=$2"[-;M\*JS95CK+(9,G%2#8&2<
M;-S<>0O@XLJQB21M#MK)"62_.PN1V5WFI2>[0YJ4GNRN,DO/4?M-6$PZTH_.
MWVUV0'S$OQ'[320*<B7XS]I_&D@3KR_&WVG\:<@'7E^-OM/XTY`.O+\9^TUV
M0'7E^(_::2`ZTGQM]IJ(#K2_&WVF@#K2_&WVF@')++I?SMR[S\0H!LO\K^)^
M^@&&@$H"Z])[=BYV^XF/E@G&D?2>8#/I)1"1\1%JH[5[5QMU_(JS6:JXW-DO
MTNW+=O461(%CAVL$'5'IBMP'[83\MN^U8:_L*UQ+S8H782I\3=[3]*1M6):)
MUB_<,IRF8*Y5N2..)95'$<KGF*Q9NT[ZV]-O[E5[NVXDWTSQ63*A4C)7,*9$
MT,EE4NG`2V4J5YV*]M17:MI&ZT^A#W&HCP8KU)]+XTS\B8S+@PZ3($1-8%A;
M2(T`(Y7O<UMP?L'"37)E^/LN-=68/>_3^3M)A68ZS*I;6H.BX/`*3S\MC_:O
M1PYED3:--,BML557%@4`4`4`4`4`4`4`4`].3^'ZA0"R_P`K^)^^@&&@)&WX
M&3GY<6)BIKGE-E7L]I)[`.VHWNJJ6<M9)2SO_I3Z=[>T<4\T,7[*J5\I3C$G
M%U\PU$$DAFXU\]D[-FWKZGG^XV=)P_3^#A0&1>,D@4K<ZK\/+P]E9':")._V
M42=*$P1223%FS&E34JC\J@&_9VBH>X)'LF"F"[&<8\;6C1H4#2$\39!V$6Y6
MKBL@5&X;1)N<.1H_D9+P$`Z&MS95D\Z.O-A>U6*R8.>^N/I_+N6#/!'(8!'*
MMYA"G[R@W-AP;VBQK7UNQ[=IB=#N._!R<FW#Z?/'&^1@9\.1BJQ0F>^.X=>#
M(0UUN#[:]2G?6UDT_P"II797E,R+"Q(K>:1M`%`%`%`%`%`%`/3D_A^H4`LO
M\K^)^^@$1'D=412SL;*H%R2>X48.D?2[T_NCO\PT:_*S&\<9'G=U.@:F').)
M.F_&U>3^PRUV\F/L73T\GT5M6RXAEC?*US6BTZ(A:X5M=A;F7?37DR9R4),H
M(>LB=4V#*C`Z/_0VX%E'.W;6>SU#9Z29ZM+)C+`@P0H2-RMY-5KF3L/XU!W*
MW<\%CB!8PRB2)ATWD8,@#-QX@CFMKBU<DYR)W7DE=8H[75K8JJFEC?@/$U.M
MB:M)69NTR-')#DK&N5$FN:!+/(AY6UCRV86L#RJ]$FCA?U1V'*R-I0X,<L[Q
M2ZI<9T_=13?S"W=:S<Z]+H9%6[G30MP-*VIQYU96*L"K#@0>!!%>X;QM`%`%
M`%`%`%`%`/3D_A^H4`LO\K^)^^@).TY$N+N&/EQQ&9H)%<1\>-CR-N^J\M%:
MKJW$HA>LJ#O_`--<&.:&&:!6ABSE.0T;<7$K6UL>P<^'LKYWL.W*'XT^AYUT
MYA^#JD,P2*1(<D0DQ]/0$.I1P_/>ZL;VX=G&LMF='X.(H;IHRPB-2SR.2%1>
MTD\>^JXDBSVQL6*42&.>$S1D]*.;4(I`!P8MP\OLM4$D501XQEXZ8"N5D?(G
MDCSX8Y-<#*3Y2J<KJ#P-<G0YX1%GC5)A'AGJ9$;=2%64CSBX.I5/,6YBH3J$
MR1EF"8]<N6R'5@TC*%(9@/*"#YA?C<UHI8N3DRWJS:L?+VS(ZBLDT2([2!/+
M&SD>8-^:Q-S[*TU>J.P?-7JF3T[D94TNVSY$LP>TDLX!$]_>D6UM/+D:^AZ]
M<B462CX>#?C5EN9^M):)0!0!0!0!0!0#TY/X?J%`.<7E>_Q'[Z[`+'8MTR-M
MSHGC%XY&5)HOC2X_OW51FQ*]6F5Y:*R/HST9/&F+'*J@SH)$!4601HW[C$#A
MK*`6KYN^AYZ1T#'BF9CD/J;'.I3,6U",`>\;FX6L]I.DK%C;*,>*DL<7$SRL
MZ:@=(U`/>Q.GNKB4Z")(^9&_5#]=,M)?=9`5]@&G[JJLBBR(D@6/B%LR\O\`
MFQ%0:(L\/W)LD+"K.Y1BR*;>4#43[;6KD'#RA3+R,Z.**6.(>^LTQ>PTD-PT
M$7+`6XU;CW+*%UNJ8F7CJ(XQT<YQ&0S6#*!=F6W:;>5:UU?H7GR5ZRV38SE9
MV=L^9BQQ0,`^TAB)(^2-H;W9//\`";U]#ULEX2LG\S9CN]FC''G6LN$H`H`H
M`H`H`H!Z<G\/U"@'2']U_P#L?OJ38"*0QRI(5#Z&#!6%P;<;$=U1B0U)WSZ=
M[WDR8&-*<>+'9](/1*E#$20RK;W/:M?-]FBK=I-OYGEVA6:W.K;9E/()%BEZ
MD<ZZ7!!#63CQN.5QS%8K(Z6T>3'%$)4E9LF-2HC9;J+]QORJ,P<$W!L,31*8
MBD>A)9I(1H#!@?XCR\:BUJ0=2'+MV%)B29>!),D<3`O!,`Q+-Y5">TM8&]1X
M+P<X$>3#W"+'3-..RRSR&%(473*7N05103P(XGERKO`[P'IA!'?#'#-X)/I?
M4HN.*GN(/,"IUI!.M23OVC`]/290F1,+$CD<2D!;ND>I2I/NA-+'E6FM=4BR
M#YNR-GFW7<&Q\784RAO4<N4V>76,0SY+%D8S-Y46%O>OS'97K8\OEWB'$%M;
MQJV<QR(6AGDA8@M&Q1BI#+=38V8<"/;7J3)K/*@)&)M^9EN4QHFE8<[=GB37
M55LX[);B96#EXDG3R8FB<BX#"UQ[*--!-/8\*X="@"@'IR?P_4*`67^1_P#L
M?OH!#R%`:GT3ZHR=ORH\"5XQ@3-YS,=(COQ)#`$VX<N^L/<ZJNN2_)&?/B34
M^3Z%]-[Z-$:K*&B(*%R?,`P!`]MQ7@61AJS71SK)Q282+^5RMB+<+&W"J6B8
MW)R]P/2ZEG1T>2(DJ`&5M+J!PXC@UJXP>SX#E4Z$*2R2A3D28KLW4''4S(Y`
M#+SOVUT"3PC<I8V3):.,QMT4CN7C*"RJWPZ_BJ4'3QGQYL=,?(FD.+"%5LN/
MRAA<:>BE[:F;D.VY_K5B1U(@[]E0#U?'@B4IB++-MLC3Q7@DD>+3TE(NUPI\
M[&U^0JY5C4FT<?WO9-OV/<MS],[U`\OI[67Q<J&2V1C*6,0\_`-H<%"&!U6K
MTZ8KMK)3?R=:C[J[F&R_0>WO,O\`K=T:?')*ZI8-#7![`&8'A[:]C%BM92]"
MQ=CX$'<?I_O^(!)"@RH".$D9`/'LLU2>"R)USU9YX4DN)C)`RE&N>HAX6:_:
M#5E%"*LCEDO=I4FV&;JBYC=#`2;V8FQ`_IV4RJ:C#I8R-936%`%`/3D_A^H4
M`LO\K^)^^@&&@%5B#?@?8:`Z%Z5]>XN%C3G.F>'+GE5084)41A=*G1?2`OLX
MFO+['1LVN'XI&/)@<Z;'9/3GJ5,F)XEZDLT27,FE49@O`O87'ML:\>^,SHWZ
MPX>YX6/CA9S&(U8"/]JTK<V(<6:WC5;H2@GXFSY6'TXUD0JA7C*M]7&X)MR(
MYV[Z*C'$\9MOPEB`S7DZ9#%EBEZ!)_+8)JX=GF;OIHMP]"!ONS;2F(FX8DAB
ME$2M>>5I%QF)U1B*(>5B[\6+&^GQK=T^L\KT\;DJP<@P_4/J3=X]PVO-ROG]
MUE"M#D2V4-D8I/2;RZ?/)[NOG:W=5CBF5*RTF"R[@@9N;NWK/%EAS]$?J#%<
M9>)"NDB5E0*\#D#C(P4,I/Y_&O1]Q=?/Q?X6_DXK*K^9FGS<B7/BR2W5<."P
M/`@CFK+PM:UJ^AT@SM[FVVZ3`8QY$),>*[R#*PI21Q<:@PU\M+7X5V#.\CDS
MWK/Z<0+-\_A"2/J^<QL24((N;<R*J=)9JIFA'-?4>)FX>2D$I/19=<2D6'<;
M]YO67,FG!MPM-24XJDN"@$H!Z<G\/U"@%E_E?Q/WT`PT`E`*O.@.B;3E[SG1
M8F^;++*,["*1;CCQ/HUQA@S`L>`#`7X^WNKRW6N.SI?\;;?,R0JMU>S.W[)Z
MBS9/3>3N46=",E8I&Z&*>J%E4A=()+AG46U#A?G7F9*<;05JL,M=D^IN'+FX
MFQ9:9>5NV4A3%;*Z3-*UM1#K``L>I`2#R'(FBQMIV6R)P:3(BCW6)?E6AAF;
MRG'9]+!APY,/[5FMJ46,_N6WY_\`J-SVIT*YMNM%&5#,S16;2HO8F0`J/&MO
MZ_/[>1/P]R54</\`36\OE9,V3T1CRHX94'`Z6)TD^T$$5M_<X=59>3N5?:>/
MK67)VOU:F7AVCQ]UC7+#7"A)3PD4$?F61=0\:MZT=K`E;\JZ2=Q5FLD?;ML;
MU%Z@AA!*Y>:UI$B-E9SQ:3_UX<6KV^KCM6O%N2O-;B=5R?HSLLVU_*X&YS)N
M$%S$\C*T>OX9!STW[>=:X9B>2K9F,;UF<21MIWW!ECSMO_\`JRMJ\P`\I!5O
M*P[5/=7"3;KH4WKW:]FW5,>/%!5)@9L?*4#RL!9D9.R_LJO)3DC7@R\68_9V
M_P#S68IDA2;K`CYADU`CX0#>U5*BJ:7DY:FBWC9MCWKT_D9F'C119:H9$DC4
M(VI1J*D#F"*Y>B9REW)RH\ZRFL<G)_#]0H!9?Y7\3]]`,-`)0"T!)P]QSL03
M+BY$D"SH8IQ&Y4.C<U:W,5QU5MSC29V/T=]0_2/IST9A)M;33[I%D(LFV3*&
MFD>9E,[H5&CIZ0=%^-^=>7GZF3)EE_C!1:C=M=AOJV()ZL8[+N;XLX@E!S<6
MS`Q9,94KP-AK1K<#4>ACM]TK0A2T&H]-;@=T](PQR+)\YM17#R9I+ZI;)=)&
M)]H(_H*S=_KK'D5O];&;-I8E^@_7#[EDY&SYI4Y.WNYVO(=RTDB1M^Y"2>>G
MWHQV"X[JT_L^FDEEHM-G_DYE4/0RGK;`_P!;]1=UR,<K'#ND,65"IX*>K;7:
MW`6E5JU=;`NUUTF]:LG>VB+$[.V5MCPY"+D*%XDGOXG2.7_->MT^A7#2$9GF
M=7"/7Z5^FXH-UR,GB9E4I"YYHA]X`^WMK=2B1D['8LSH.5OR[7E?+)@R9TC7
M+(D8TFY_,Q!O5L'F>XTS-?5'TG@[VNU^JNLVT02L-LW:`PEW64<89%OI'F4%
M;GV50ZQ:)/3Z^::2U+,MF>@MUQVAGVS>XLO;EN?ELJ)>0^%D)]X?97+X[3*9
MKQ9:1#6I2[QZ:R>A)$^*\"N6!4L'47]UT:H-2B]7UDA;&$V;:)WSAKE@)<(A
MU"X4@>4=_P#:JFFD6IIO0Y8YNQ/*YO;QK&;Q4Y/X?J%`++_*_B?OH!AH!*`*
M`6]`2MLS)L+.Q\N%0\L#AXU8774.5Q0XU)M9]T:9W<)T#)8L!8BX',@CB*OX
M09D_4O=A]0G!V7<V#$!\>+0A/)EDN3_6LG;P\E5?$IR*;P0=NSVP\K#W1<5'
MEC:+(6=KZ[W#$ZN8\*NR8^6/B7I*R@V/U$&/N$&WYZN%R,4O'CMV212><(3_
M`$NOC6#]5]MFC/&D,G^G=Q2;;8F!#W&EE-KJ>ZOIJN4>9D4,NM@S$VC.>>0Z
M<<AFE=^2C_YJ:1GO633Q[IM>ZQ"3'D212.-B.==,ML1%]31[8_H_<]CR,A^M
MNMOEV&IS%*EC')VV4,OFMV57>LFOK-4>IBMKE>##:#*4PY>-(F%/`W$]290;
MFW-;I<-4O!>]#<G:</+QM3Q],QD$J.3`IYQ<<.=56+*VB#EFX>G!'O63#M\R
M38L3L)C(ZZE?400+<2`.=0;@TTU.1>J/3N?LNZ2PY<(BCD9VQRI#(R:N%B.Z
MO/NH9ZF.THJ$Y/X?J%0)BR_ROXG[Z`8:`2@"@%6@-;+C108\<:BR(HL+6N;7
M)_\`-;4DD8;-ML9CS*X,3O;C[W'B#P'&N"#0>EMCCW#/RFRW+X<2QI)"IL#=
MK\^RUJ@Z2R3LDOB:#>=MP\=.E&QZ&DA=8TZ1;R_W%JFZD,>;4]-XCDG^G<>4
MRZVQ(HI38V),3V/$=NF]>'6W#.T237N0)Z*WC:?];E3)C39;NP&0$C=FB")P
M8E+<[\+FOH,-Y,7<QNMH9>[UD-'Z?E^:)V[YV+7C3;C^S%*HXE!(!Y7TBZJ1
M<UIM=)&2F)V9FMJFW#"U''G,9`X21]H''CWCQJ2V(62+F'UMFQE4DQY,O-)\
MICMQ[N'9478XD0=[@]2X.>-]S()<=,XMDEYEU1"8+I50P_,`/=-1U1.ME8G-
MZY]20[`<G#-S)$TFIP2XX%?*.2MQN+U&UM"['76&8''WR?I)F126G2X94+6=
MF/`&Y-S<W)%5-R;>,,]]XWK&W7T_E1Y8/S$<740L+@,#8&_8;W^VJLBT+\;A
MHYTGNO\`]?U"LAL%E_E?Q/WT`PT`E`%`**`ML;>E..F/EH7T6"2@^;3W,.VW
M95U<GAE-L6LHL<***?<L:!9`69P"`IMI'?5ZW*7M)V/9_1PVE1FP3M/CW$6;
M&I\XC8>;2U[<.8O5U3%EL4OJS<ML2,X>W97SC1+QCE4AE0]A/>*6(XDSVQ3C
M3?3:2`R!2S28:H?*5DD;4`1Q/)KBOF^QAM;MI>I.]XM/H:/T]M^!'L\&THJQ
MX,"<$&E'>0$?N-S/F/Q&OJJ455"/&S]EWNVSU]6;<N\[%/L&[#4S6?`RN2Q3
MZ"(F?3Y2`I(O4<N-64&CJ]ATLF8C'&1G[5(<:(KOFW$P[G@J07E2(:=<=N;)
M;B![R\:^?ZW>MULCPY7]OAF[+A5M5]"X^GP3*62:.S3W!5B/9R-?1T<J4>1V
M$ZN#HN+NN/\`*''W&<)!*=.1A3*),9QVC2P-=:3W,V.]DY15^J_1FU2X46X[
M',/]?,3'TWN_1DXV0<FTM[>55M^&>KAVE'$-WVO_`%V:!I98X'8N`/*Q/(J>
MZJ&CTZ6<&<]4Y[ME_*)Y88PI;LU%E!X^%ZS9K:P;,%$E)1IR?P_4*H+Q9?Y7
M\3]]`,-`)0"T`E`6.U[7\VK2R-HAC(4D<26/&PJRE.17?)Q-?M6WQQQI,4(<
MV8%18BWNDUKJC%>TG2?37JN&'%C2506),>2@(NH>XU>%6HR66IG_`*@X^T`I
ME;:G[<@\XO;2Z\QP\;URQ.E3);3%F94Z9`)6"#R*`3YKG2/\>^JJUER2S62K
M'EG0=FRSA/'.\!GCGD$;LQ(55N0S:>9*D<:V)G@6Q:LN?5FYO\ABXT>E9&="
MR@DGIJ2;^SCRI9E^"C*':=LBBSMQFS9NED.R96T;G"K=1D-]4<B"[,8V3M%Z
M\_L=*F>K5_H>E>Z2KQ^31!VKU'\IO<V9#C-!UI",R(#2CR`V$Z(3Y==O,*H_
M6XLV":7^ZBV9'M8U=+74Z.N[;-N^!:6+5(;`E20P/>1VVKU^1YRZ[/>.%WV#
M+]/AVQE9&E.:;EEF/N>6_%;<#_:Q%5Y7Y1Z/6IX:.0[]=<@XF60T@'2F?F-0
MX*P)YFJGJ;:J#F.ZOKW"?C?2VBY_]!I_XK#D<LWT4(C)R?P_4*@3%E_E?_L:
M`\Z`44`&NL"5P&F](1"6+*34!9HVTGG:Y!/A5^%F;L;&O:4XR)90\,K:&%^7
M$V(ORK6CSY)8@(4'%`U31_N,>*JH][4>WCP%JZ@4F1G2?,-BY;$X6H`R'B8[
M7%^'&UN=<98EH:'T\N)AY"03:2<=>NS!=:_+S"T<RZ;\`7JRJ1DS<MV62;KL
MJY3XN+N1A96U&)U(6]O>4LO]^%2E%"PN)@@[]G3X6*VXF8%G0B#(<JPD9A8!
M2>#6JN]D:L.)SL0]BSLZ3"7<,S(>3.+)'$Q-K)JTC2!R`O>E'H69**="5NN(
M,_)7*B+1>71/<BQL38^/&I05MP"OZAQ1#!A99B=C:.6RZRUO*A=@>=4YLBQU
MY6T1W'KX&/Z[]6>?;LW)Z<H#?-?MJ);7L@(L+&USY:A2];J:N4:$O)F,[-'6
M5Y"=1),8)+-?B2;FNMEM4S.9F",M)<J)>G*EVD^![<21;D?95%ZSJ::7\%.G
MNO\`]?U"J"X67^5_$_?0'G0"B@`T8$H"9M6:</.AGU$(K#7I-KK?B*E5PR-Z
MRH-Q)G0Y$.F*1&#<5=6%O82#6M71@>)FD].GYC:)9(2ID3]N=`00C6O:POS)
MO4ZV(6HT0TV>!LDC(>RKP%A>Y;ON1^-315=LU&S[AL>P]2+*D4S9$<$,*LRN
M42.7^-U!LB-?R%B`#SJU-(RNMF-RGWB?>A)#M#*CZVXR0RR,L9XM&T8TD6X%
M0>7*NRSC54HF2@F^F\.[9^1N&7>*,AI!!'P6PXE@!R\!5-L%6Y-6/MVK6$2<
MC;<O!$**@4P0]4HH-V`'"]^'#G4H.*\C]QO\OAQ,0D4IZLHO\)OKO^-=3.-2
M1?46;AC'6+;MSCT,JV<,I*A>.I?$]IJK-6MZP]46XZP9:?=LH1$[A/%G0KRG
MD!69;<M+CG7E?\2QN<;X_P`&FJ3V*3YV#*EZOS`Z@`55?R\/_-;*W]2UT:#-
MR(L/!>(.KY$P*C20;*>9-O[5R]M(.XZRRA3W7_Z_J%4&@67^5_$_?0'G0"B@
M`T`E`+0`";T!T?Z:[]C;/A,9P7Q\IF7)4"]BI&DD>!K1BV,F;<M-YSMKR\Z-
M\'("QJ=2@-QL>5Q5ZL4<#P@PW.1$^2X.&)>K+D*5=R=8)OIXZ=/?X595E5ZE
M_B8.WX>_Y&?U#"FUY4DZE.-]+%D*CEYKK5LZ&;633Y/JOT]NT$63!+'BY4XT
MYN#&R@B8CS:!^53S`[JKY^"WV9(F5F`N)Y$U0Z#$22";&XXU+D0]MHS7KN2&
M?9\3'Q)4O(TBRD$!M"JA`/'EJYU"[1=A3W.<RXKA5)6S7(8>''^M4&JI'W*Z
M;:686:1U5?:`+U5D>A=C6I1W-4&@+T`Y.3^'ZA0"R_ROXG[Z`8:`2@"@"@"@
M"@)6%N.3B,3$WD)NT;"ZGQ%2K9K8C:J>Y=;;N)R4E9D$9CL2([CR\K\2>35?
M2\E&2D$Z%F3(BG0E)%(;J1^4EN8;A5A3:LFAF]:QXD3Y&;C*K995&">>_36V
MK2;<[<>-'E@A7!R>A0R[UM>8TDF+"5!-V54"GO'(]]<5^1:\7$EXGJK*11C/
M=H@!:YNU=DYPDS_JW.:?*A2P`52_`\;N>W[*HSN6:,%815XVZYV.NF.4Z>Q6
M`8#PORJM6:+'1/<9F9^5EL&R)"Y7@HY`#V`<*XVV=54MB-7#H4`].3^'ZA0#
MY8VZK\1S/YAW^-`,,;=X_P`A^-`)TV[Q_D/QH`Z;=X_R'XT`=-N\?Y#\:`.F
MW>/\A^-`'3;O'^0_&@#IMWC_`"'XT!*P#FQ3B3%77(H)*BS`KVW`[*ZI\'+1
M&I;#<LS0.GMY$G?<E;>P<_[U=S?H4/&O4J]Q;<)90^4N@D>1390![`:JLWY+
M:I+8=M<F1#.62+K(1:1%(O:_`@CD:[1M,72:+D9F(NIEQY6FL?V](!_J;U<[
M_`HX?$H<\Y,V4\DZB.1N.@D"P[``:HL]316(T(W3;O'^0_&HD@Z;=X_R'XT`
==-N\?Y#\:`.FW>/\A^-`/2-M+\1R^(?$/;0'_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EXIAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases (Details)<br></strong></div>
        </th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="4">1 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Lab space [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Lab space [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2014

</div>
          <div>Office space [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 27, 2014

</div>
          <div>Office space [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Jul. 01, 2014

</div>
          <div>Office space [Member]

</div>
          <div>Subsequent Event [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Jul. 01, 2014

</div>
          <div>Office space [Member]

</div>
          <div>Subsequent Event [Member]

</div>
          <div>DKK</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rental payments for Operating Leases</a></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 32,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet" onclick="toggleNextSibling(this);">$ 65,702</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LeasedLaboratorySpaceMember]" onclick="toggleNextSibling(this);">$ 967</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LeasedLaboratorySpaceMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LeasedLaboratorySpaceMember]" onclick="toggleNextSibling(this);"> 6,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LeasedLaboratorySpaceMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LeasedOfficeSpaceMember]" onclick="toggleNextSibling(this);">$ 1,612</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LeasedOfficeSpaceMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LeasedOfficeSpaceMember]" onclick="toggleNextSibling(this);"> 10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LeasedOfficeSpaceMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LeasedOfficeSpaceMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 3,225</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LeasedOfficeSpaceMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingLeasesRentExpenseNet[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LeasedOfficeSpaceMember;us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);"> 20,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLeasesRentExpenseNet<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LeasedOfficeSpaceMember<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_OperatingLeaseAgreementDescription', window );">Operating lease agreement, Description</a></td>
        <td class="text">The lease can be terminated by either the Company or the landlord by giving the other 3 month notice. The Company gave anotice terminatingthe lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_OperatingLeaseAgreementDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Operating lease agreement description.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_OperatingLeaseAgreementDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41499-112717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVOAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>DKK</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty', window );">Related party transactions amount</a></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" onclick="toggleNextSibling(this);">$ 23,152</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_RelatedPartyTransactionDueFromToRelatedParty" onclick="toggleNextSibling(this);"> 130,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal expense</a></td>
        <td class="nump"><a title="us-gaap_LegalFees" onclick="toggleNextSibling(this);">288,546</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LegalFees</span><span></span></td>
        <td class="nump"><a title="us-gaap_LegalFees" onclick="toggleNextSibling(this);">328,202</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LegalFees</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ForgaveInLegalServices', window );">Forgave in legal services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ForgaveInLegalServices" onclick="toggleNextSibling(this);">49,016</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ForgaveInLegalServices</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Payable to related parties</a></td>
        <td class="nump"><a title="us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" onclick="toggleNextSibling(this);">212,438</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_AdditionalLegalServices', window );">Additional legal services</a></td>
        <td class="nump"><a title="pmhs_AdditionalLegalServices" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AdditionalLegalServices</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldInTrust', window );">Balances held in trust</a></td>
        <td class="nump"><a title="us-gaap_AssetsHeldInTrust" onclick="toggleNextSibling(this);">$ 2,014,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsHeldInTrust</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsHeldInTrust" onclick="toggleNextSibling(this);">$ 14,593</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsHeldInTrust</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_AdditionalLegalServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for for additional legal services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_AdditionalLegalServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ForgaveInLegalServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Forgave in legal services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ForgaveInLegalServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_RelatedPartyTransactionsTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_RelatedPartyTransactionsTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldInTrust">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The total amount of cash and securities held by third party trustees pursuant to terms of debt instruments or other agreements as of the date of each statement of financial position presented, which can be used by the trustee only to pay the noncurrent portion of specified obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(b))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsHeldInTrust</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of obligations due all related parties.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 17<br><br> -Article 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(3),(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 3, 4<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LegalFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedParty">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedParty</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>23
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#XP*0N&0(``+@>```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,F4]OTS`8QN](?(?(5]2X
M_L,8J.T.`XXPB?$!3/*VB9K8ENV-]MOCI%LU3:55126>2Z,F]OO\XL/OD&=V
ML^F[XI%";)V=,U%.64&V<G5K5W/V\_[KY)H5,1E;F\Y9FK,M17:S>/MF=K_U
M%(N\V\8Y:U+RGSB/54.]B:7S9/.3I0N]2?EO6'%OJK59$9?3Z16OG$UDTR0-
M,]AB]IF6YJ%+Q9=-OKTC"=1%5MSN%@Y9<V:\[]K*I$S*'VW]*F7RE%#FG>.:
MV+0^OLL8C!],&)[\/>!IW_=\-*&MJ;@S(7TS?<;@FX[_=F']R[EU>7S(`4JW
M7+85U:YZZ/,)E-$',G5LB%+?E>.U[$UKG[F/Y(^+(Q\OXL(@P_N-@\_DD"`<
M"H1#@W"\!^&X`N'X`,)Q#<+Q$81#3%%`4(PJ4)0J4)PJ4*0J4*PJ4+0J4+PJ
M4,0J4,PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<PJ4<RJ4,RJ4,RJ4,RJ
M4,RJ4,RJ4,RJ4,RJ4,RJ4,RJ4,RJ4<RJ4<RJ4<RJ4<RJ4<RJ4<RJ4<RJ4<RJ
M4<RJ_Y=94^[EB(^__ZZR<<R)8BBF;4?QPA]S=T-/)3<F4/TCA=Q@7AS@Y>P3
M')7IJMLF5WD7/H3]W&/YN5^\"\['W+0&.A_@N4H==D]\'D0AM;0O4P^5DOO$
MW-*>'_BJ%:6A!ZZI/I#-Q]YY\0<``/__`P!02P,$%``&``@````A`+55,"/U
M````3`(```L`"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``",DL].PS`,QN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DIC
MV]'VY\\_6][NYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=
MWFQ?>*24FV+7^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&
MOQY0+3S5P6H(!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:
M0LM)@Q7SG-,1R?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]
MSCSBIX3A363X8<'%#U1?````__\#`%!+`P04``8`"````"$`*2A#!DH"```#
M'@``&@`(`7AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````O)G-;MLP$(3O!?H.`N^QS%W*
M28K(.:0HD&N;/@`ATY816S)$]L=O7\(-Y!IHISX(<S%`"EX-%K/?DJN'QY_[
M7?$]#'';=[6QL[DI0M?TJVVWJ<W7ET\W=Z:(R7<KO^N[4)MCB.9Q^?[=P^>P
M\RG_*;;;0RQRE"[6IDWI\*$L8].&O8^S_A"Z_&3=#WN?\G+8E`??O/I-*&4^
M7Y3#GS',\B)F\;RJS?"\LFJ*E^,AO_K_P?OU>MN$CWWS;1^Z])=WE#_ZX36V
M(:0<U`^;D&HS;L7R],3J+&LVY3_DY'QPY=PA.;(@RY$%DJ/W9#EZC^2()<L1
MB^2H(\M1A^0X(<MQ`N7<LN7<(CE5)N%TA9XR$$,.^,:<T[(\_4+'L%,",\*V
M"W2+98//0O`)&WP"P6?9X+/0QL(&GT#P*=O)"JVL["I76.9N4O"-IZLS_,:M
MMP.7FR,.NVI*#H_O!G(J)*>:]#C:^%WSU/IM=Y8S;D$5Y)S`E%BV82PTC&6C
MV$(4*QO%"E'LV"AV$,75I"B.K1_"ZDL:\NTUGDOJ8AN5%3TW2`S;QM#%EIT:
M"VTCD]KFBJ8@L(,+NX,+[.#*!K)"("N[@RML5V[2#GZ%=QP<*#GV0,G!@1);
M#1133=H[8SKN\O1RO(3_7B,$LYT"C6+9S+.0>9;-/`N9)VS("(2,TJT#O:/L
MLE98UXX]O'%X>,/NEP+[I9N4>M<T*'AC8*N!8MC&@;ZQ;.98R!QA,T<@<X3-
M'(',4;9U%'K'L:]W;KS?E1>?;I>_````__\#`%!+`P04``8`"````"$`L-:M
M`!($``#*#@``#P```'AL+W=O<FMB;V]K+GAM;)27;6^;,!#'WT_:=T"\WP@/
M(6O5M%J;3JM4;=62K2^1"TYB%6QFFR;Y]CL3E9TQ1>FK]`#_N8??W96+JWU5
M>B]4*B;XW`\_3WR/\EP4C&_F_N_5MT]??$]IP@M2"D[G_H$J_^KRXX>+G9#/
M3T(\>R#`U=S?:EV?!X'*M[0BZK.H*8<[:R$KHL&4FT#5DI)";2G551E$DTD:
M5(1Q_ZAP+D_1$.LUR^E"Y$U%N3Z*2%H2#>ZK+:N5?WFQ9B7]<XS((W7]@U3@
M][[TO9(H?5LP38NY/P53[*AU03;U=<-*N'L63V(_N.R"?)!>0=>D*?4*PGM5
MAWQ%212EYDF3BC^,[M3_0\;T]H^,%V)G'H74'CHK!@=V[:U'5N@MW)],)MVU
M[Y1MMOKU(L@'2+_-(+RG_?5X&]YK1C*H5';+-=.'[(X?L\\$E-!D_0XB"WU/
MGC/X0]X5H7$<J]Q`$D7)"@(IRJY)27A.LZ4YBA0BI!"=KI`]$(E48J32IOI-
M/Y8:W#'5SL0Z^UE3K)(@E634ETY%M3)ZBWR!M'<YF9ZF8D266N1()44J+1*G
M1614H"CMPZ9`,R0S.]V9&Z)P2-"U74A?^BK+IJJ(/+0QL`UGT%($TOLUST7#
M<:FG@&PG<]:7>9#0Y!)`:YG[V[#:5`F%,K5@F_3/+^B:<>C&[)ZM*=`*4V;#
MGDJ:?57*(FZ*D0L=:G\(317@=2#F\"\S#0!?P$T?L#.8N'`(7)B"NGW_M8`F
MLO2P#F8N=-!=4,E>8!R]F+#($RN99C`R_]=WBFD+'6CO*5'V\YBKT,'S#H9U
M1;,5V=NG,$:A@^.]4)`Q*J&YB:38.PQ.Z/!G8'W>BK*`\9K=0LGM%)\A7$('
MNQM154P;1E2+#$P;#6L&UHV=H113%SK8+9BJA8*T"E@=7=NDF#48M;W)9E&1
MK23ABN3MTL`:F+/(X6S9/"GZMS&3Z/;%)CW%<$4.7.,-A[L_Q71%#EW#+0?5
M!_(Q9"F&+'(@&^\\RQ],7^30-])ZX!1.+>;QN#'Q>,04#T2#H8P<*&V8!XYC
M+",'R_'B`!(=8Y$EY(#Y1G$65!-6XNK$&'`P>JR.Z^#JQ&!T\QF,GM!XF7%D
M,28?C'<)`?M=BF+<"&#TA,9X6>`Y%.,^`.-=.E:*<"?`/UWO$L(IFEE%<R8J
M#+.1_6%YA%LA=F@>7B#9`$6X*V('Z^,B&3@WLZ!Q*+9:T7UK@M,`1B^?0Z<S
M''V"WP[&*>=Q&1),*ABGG%_1O6X(?`!TF"884S!Z*KV),I`%C&?BX#FP)@<*
MD6`TP>@Y,;HN,QP,GM&)0R;:ET-.8!H3A\:W]Z;10D[,K+HX-/9WYY`G>+HF
M+9=!6S#XU,E)F<,WF/EI/V*2:7K<S\'K9^CE/P```/__`P!02P,$%``&``@`
M```A`!+CX//T!```7A(``!@```!X;"]W;W)K<VAE971S+W-H965T-"YX;6R4
MF%UOJS@0AN]7VO^`N$_`QGQ%28X*57>/M$=:K?;CFA(G00TX`MJT_W['C`/8
M-#WA)FW@S?CQS/@U9OWMO3Q9;[QN"E%M;+)T;8M7N=@5U6%C__/WTR*RK:;-
MJEUV$A7?V!^\L;]M?_UE?1'U2W/DO+4@0M5L[&/;GE>.T^1'7F;-4IQY!7?V
MHBZS%K[6!Z<YUSS;=3\J3PYUW<`ILZ*R,<*JOB>&V.^+G#^*_+7D58M!:G[*
M6N!OCL6YN48K\WO"E5G]\GI>Y*(\0XCGXE2T'UU0VRKSU?=#)>KL^03S?B<L
MRZ^QNR^3\&61UZ(1^W8)X1P$G<XY=F('(FW7NP)F(--NU7R_L1_(*J6^[6S7
M78+^+?BE&?UO-4=Q^:TN=G\4%8=L0YUD!9Z%>)'2[SMY"7[L3'[]U%7@S]K:
M\7WV>FK_$I??>7$XME!N'V8D)[;:?3SR)H>,0I@E8N3B!`#P:96%;`W(2/;>
M_;T4N_:XL;U@Z8>N1T!N/?.F?2ID2-O*7YM6E/^AB$BH/@A503R@5_?IDD8^
M\8.?1W&0J)O@8]9FVW4M+A9T#8S9G#/9@V0%D:\S0XY^KK>F"G@RR(.,LK&A
MW6$6#=3G;1M$:^<-4IHK23*5$%V17A6R$D#7(\+$QXB?)_U*(L621&9.HB5X
M`6+W:-08]Q-%V$LT$DC0_212#(4>#1S$?5AD0PGK8=/1!6U@-F=@*=[8,*M^
MQJ%K#(R2H*N4<2\=W_-H."JDA@2->W\NI-A`,JJ?H"3LD&CL!X$A2,<"XL8T
M'K*I@05SP*38`#/:(T$)@BT^)=,48>![`[I&%LXADV*]?4+/J")*1NTSNJ`-
M+/>AT2+_>@5)L9$29@R,$DP)"1B+B;':4TU!/2^(!G@-+9Z#)L4&FF^@H42A
M17$TE*);<NGXOA?1^,9*)[!'W)^R3FV`!0:8TB`9"^(@,!2IIO!BEWFWX*13
MWEU/@KZJ^<$0&(U(:1".$L_S`R.QJ28A04`9&:)H)2724._'0_O5\(QN2KJ(
M&QOQ%I31F-))]C".TI#0BV(VQ-$!I<W>#XBF#)^#GP[6H_(W,F[L,S*ZH@\^
MR\O)U,PCP[`3I5$SCYCO&XI45P0^A4>/OCUUNEFV+I^!C`5I+KA$:6`>??J\
M87"5K+&WL]@E0W%UNEG>3J;F'IGFKC0J=\SU1SZEV,;N3F*?#8ZBL\UR=X)6
M/>YZ<^1$:;[.',9!?A+ZH3?,4,>;M0>0Z280F9N`TN#0?CPR*Y4XC,&Z'?U6
MTF;9/YGZ?V385*(TJJ"$Q"0>FDF!C?>`!7,C1H:&U))&9^T"G5K?!2)C[$1I
M%![U6<3H4#'D,S2$A=[H84@'G+43T.E.$`T>W@V>*,TU?V'H>X;9I4IRHR]U
M/FG*=SLM10O7%L5@X8H/-?CHNJ!>Z$;FPDE5G*OFRP1*F[X?$$U=`S2RDU#4
MQ%W;+]SE:$&J\AJ"85WIJ9/./R*3)S,&/OGUPQN5O])[,#9V@T1IL,2A[[J$
M35H0PZ#$]^`80&^L8'GT-#$]6#8_P9QN'/$P@*HT:KY(I"$P$XG'>3SMEKP^
M\)2?3HV5BU=Y5*=0H/YJ_QKA@<K#F'$]@=<+W5G<Z6_`Z?Z<'?B/K#X456.=
M^!Y"NLL0D&I\/X!?6G'NSMC/HH5S???O$=[C<#B9NDL0[X5HKU_DN;=_,[3]
M'P``__\#`%!+`P04``8`"````"$`'P^$.%<$```4$```&0```'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6R45UV/XC84?:_4_Q#E?0G.)R!@-<29=J6M5%7=
M]CD$`]$D,8K#,//O>V\<B#^V`\-#("<GAW/OM7WMY=>WNG)>62M*WJQ<,IFZ
M#FL*OBN;P\K]\??SEYGKB"YO=GG%&[9RWYEPOZY__65YX>V+.#+6.:#0B)5[
M[+K3PO-$<61U+B;\Q!IXLN=MG7=PVQX\<6I9ONM?JBO/GTYCK\[+QI4*B_81
M#;[?EP6CO#C7K.FD2,NJO`/_XEB>Q%6M+AZ1J_/VY7SZ4O#Z!!+;LBJ[]U[4
M=>IB\>W0\#;?5A#W&PGSXJK=WUCR=5FT7/!]-P$Y3QJU8YY[<P^4ULM="1%@
MVIV6[5?N$UED9.9ZZV6?H']*=A'*;T<<^>6WMMQ]+QL&V88Z806VG+\@]=L.
M(7C9L]Y^[BOP9^OLV#X_5]U?_/([*P_'#LH=0408V&+W3IDH(*,@,_$C5"IX
M!0;@ZM0E#@W(2/[6?U_*77=<N4$\B9)I0(#N;)GHGDN4=)WB+#I>_RM)9)"2
M(OX@$H+[X7DT"?THF7U&!?ZOMP+?5Y7X815/QM6GB>9=OEZV_.+`V`/GXI3C
M2":+_\T+)`2Y3TA>N3`W(&0!Q7Q=1T&T]%ZA`,7`V4@.7&\<$DQU3FISPH3H
M'&ISHB#6.9G-&54\"/`6)53@\2B1C%'B:,"P-Q)00PH37[>2VIPH2'0.?8"3
MV1Q_E-%B"CX3$Y)A["I5B8*9;F\C.>$M[M0$J`ED"J!Y@Y'^>+Z1O'(A\-N(
MB8*YX4UR%&\2B/M!&)*9,<*H]CB:^8&NEREZFG&8`JIQ7"["N],"7S("4(HF
MQY#D)+U?DH0P]W5'J22,$5(3R!1`\QSKGG^^M%VG,)(-KZ&1O(WDC%92$Z`F
MD"F`YBWYC#<DWQNDDJ-X,P%J`ID":-ZPQRM+WV.UQI?,_(V+CJRUY`RUCJ;X
M,8HM&6,4U`0R!=!,SW73'Q<;R:998^':2,YH)34!:@*9`FC>"+1G-:,?F^O9
M]\H]D!1[%D(M)%,1W2%VC$_7G,@^HZU0H5GT@72=X?.8&)E.!\88"[603$5T
MY]@8%.=W<BO;B.[86`,W1))&/ZF%4`O)5$1WB,W@<8>R=<!56?6--7%#E/[2
M3ZW40JB%9"JB.\157W'XV(PGLE?HN;2J+TFR^G$2).9>)1UDQFQ3"\E41'>.
M:[_B_$[U9:=0'8=!J"]!&]P%P^(P^DDMA%I(IB*Z0^P`CSN4_>).]96F,E3?
M1"@QD4Q%=(?8!Q2'6/T85JP[N93=0\TEF1K[T`V1)%E]/R9Q;.R*TX$Q9IM:
M2/:1BAX)-@<CDON[%#AFV=W`&L=*WQER;B)T$!ICP1,<2LO=F#]F1[J6AS-Y
MZJA9>V`IJRKA%/R,!R\"6Z(;>CL4/OFX#?5N#^!,=LH/[(^\/92-<"JVAU>G
MDP0&<2M/=?*FXZ?^3+/E'9S&^I]'.'TSV,9/)T#><]Y=;_`/;N?Y]7\```#_
M_P,`4$L#!!0`!@`(````(0#EPPJLW`,``*0-```9````>&PO=V]R:W-H965T
M<R]S:&5E=#,Y+GAM;)17VZZJ2!!]GV3^@?!^N`EXB7JR%;DD9Y+)9"[/"*V2
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MI.047W/^![V%)#M?.%3;@81$7JOTRR,L`4-!1K,<H930'"8`GTJ1B94!AL2?
M&]6"@;.47S;JS-6<N3$S@:X<">-^)B15);DR3HM_),F\2TF1V5T$ON\BIJ59
M"\=TW)]0L>\J,&ZKLOQY%?>N,N]4+%-;.([M+N;3,X+=T=BR?*C,-=,V)N2C
M2X>;@GDQC[?KFMX4V`3@(:MBL:7,%>BVE9*^=K7[K])!S83(FU#9J#`_J`J#
MY?:Q=6Q[K7_`&DGNG-TSQQPR]BU#+`@AZV'@@`&_!1X#FS,D&[2<5C;$0-0#
M=/"E,P?67]^<\>7;>B#(PH-VF)T$0+LSQ4()CS#F0XHW0ADR#O_+\)\9L/"&
M*L$$3CC&60QUHM><@;NP,:>[*\@#=R70=]>>SX:3V4_@>,\<QW:&.H<)''^,
M@XH93."$$SC1:\[`9#B_IILLR`.3)2#/5;$C]QCP6N"QR)_*<!CC(&O\,0XJ
M9S#&03KA,\>QE\-R1J\Y`_O@<)YNGR`/[)-`SSX,>!@X8,#'0("!L`5>E"`:
MXSRL&Z0,=]7TE`49;N?>&><XQM#NG>38W<&XQX"'@0,&?`P$&`@Q$/6`07YP
M!T_/3Y";/J0[PQT'W2\[R7&;:V]F6<N'K\TMMN^_=Z&+0;>`UW^_=%'T0;Z=
M-^JN82!S_7ZPZ9I(.^A'FQ"-PL-^.,P='7Q1/QQ:Z%[XP%+1MN,FPH`E]_K"
M%%'86S3_G>3`ANWYCXZ%?<MI+UX/`P<,^!@(,!!B`-IE,=MF%<O<9?<KFZF"
MU&>R)WG.E(1>16<[@X)U:-=TOS7=+L)WY@H:&Y@]PGUHTAM<[UY`DUS%9_);
M7)^SDBDY.<%0AB9ZR%JVV?*!TZII[8Z40WO<_+S`OR$"1[BA`?E$*6\?8&"]
M^W^U_1<``/__`P!02P,$%``&``@````A`!G>RY*]`@``6`<``!D```!X;"]W
M;W)K<VAE971S+W-H965T-#`N>&ULG%7+;MLP$+P7Z#\0O$<2];9A.X@=I"W0
M`D71QYF6*(N()`HD'2=_WR7I*+*<I$DOMJF='<[.KE>+R_NV07=,*BZZ)29>
M@!'K"E'R;K?$OW[>7.08*4V[DC:B8TO\P!2^7'W\L#@(>:MJQC0"ADXM<:UU
M/_=]5=2LI<H3/>L@4@G94@U'N?-5+QDM;5+;^&$0I'Y+>8<=PUR^A4-4%2_8
MM2CV+>NT(Y&LH1KTJYKWZI&M+=Y"UU)YN^\O"M'V0+'E#=</EA2CMIA_V75"
MTFT#==^3F!:/W/9P1M_R0@HE*NT!G>^$GM<\\V<^,*T6)8<*C.U(LFJ)K\A\
MDV%_M;#^_.;LH$:_D:K%X9/DY5?>,3`;VF0:L!7BUD"_E.81)/MGV3>V`=\E
M*EE%]XW^(0Z?&=_5&KJ=0$&FKGGY<,U4`88"C1<FAJD0#0B`3]1R,QE@"+VW
MWP=>ZGJ)H]1+LB`B`$=;IO0--Y08%7NE1?O'@<B1RI&$1Y((U!_CH1?F"4G2
M?[/X3I$M\)IJNEI(<4`P-'"GZJD903('YN<K@E(,]LJ`;0J(5="%NU62Q`O_
M#JPKCICU.28\16R>060#Q`==@S@H^>WB#!B,Q6@0%\ZB@=<6L':8V/IJ*MJ,
M'IS<##3CFTW#(QB;U^TQ24L,E(."*`@F"APFM>:1,"/D-+X9Q_,LR?(A?J(O
M_A]])FFJ;W+_VF$RU]PPB"?QS3A.2!R$+PB$N1X;^+IQ!CP5-IF:M<,X86&4
M!R1(!VML<S=C!$GC,)F]H"U]CS8#GFJ;CI7#.&T781S'>?)TM1-W`B%Y'(.W
M@_Z3UF;O46?`4W437]8.`XU[&LM)`;`[#<T+$*?.+4>W.WJZ8]^HW/%.H895
MP!MX&=@OW6IT!RUZNRNV0L-*LS]K>(,Q^-L%'H`K(?3CP2S?X9VX^@L``/__
M`P!02P,$%``&``@````A`&E,MV`-`P``.`@``!D```!X;"]W;W)K<VAE971S
M+W-H965T-#$N>&ULE)5;;YLP&(;O)^T_(-^78SA%(55#U:W2)DW3#M<.&+`*
M&-E.T_[[?<8)IW1==I,$\_KU\QWR>7/[TM3&,^&"LC9!CFDC@[09RVE;)NCG
MCX>;"!E"XC;'-6M)@EZ)0+?;CQ\V1\:?1$6(-,"A%0FJI.S6EB6RBC18F*PC
M+;PI&&^PA$=>6J+C!.?]IJ:V7-L.K`;3%FF'-;_&@Q4%S<@]RPX-::4VX:3&
M$OA%13MQ=FNR:^P:S)\.W4W&F@XL]K2F\K4W14:3K1_+EG&\KR'N%V>%L[-W
M_W!AW]",,\$*:8*=I4$O8XZMV`*G[2:G$(%*N\%)D:`[9YU&R-IN^OS\HN0H
M)K\-4;'C)T[S+[0ED&PHDRK`GK$G)7W,U1)LMBYV/_0%^,:-G!3X4,OO[/B9
MT+*24&T?`E)QK?/7>R(R2"C8F*ZOG#)6`P!\&@U5G0$)P2_]]Y'FLDJ0%YA^
M:'L.R(T]$?*!*DMD9`<A6?-;BYR3E39Q3R8>T)_>NZ8;^8X?_-O%TD1]@/=8
MXNV&LZ,!30-GB@ZK%G36X'R.3',,L?XM5(A1F=PIEP1!MT,4`LKSO/5]?V,]
M0TZSDV9WJ7'FBO2L4*4`O($1(I\ROIWU,XH2*Q15!<6VTPO@/;"YBW/?4(2#
M9$8"&;J>1(FATM.#8V_PU7!:LQIHT\G"[.35_&15)P_Z^/U<J$T)@O"&T#T[
M7A!H3=`7[28*@E6P8$QGBM!WHVA,X(P1>GF:G>L8U:8%HS/ZZRQI3=@SNK[O
M^<$\B'0J<.+8C4>'&6$P)WP_>TJ\)%OD9J<UFBSR8GO!-7WM1IX7C2T_XPK_
MATN)EURK^<$[K=%<*R\(O/'@/J7I5."&MCOIBQF9NL$F\^']C"GQDFPY!K3F
MU&].&/K>HB-AD"L7Z+JQ:\>T:S@]J?4@:P@O24KJ6A@9.Z@I[$*C#*O#!7'G
MJG_98GT'%T<_9JWA!0SN#I?D*^8E;851DP(L;3.$'N-Z].L'R;I^?.Z9A)'=
M_ZS@AB8P<VP3Q`5C\OR@)MIPYV__````__\#`%!+`P04``8`"````"$`?2\\
MK<L$``"2$0``&0```'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6R<6%UOJS@0
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MTO)XZJ'<`3CBQE;[SX1V!6049"PWX$H%JR``>#7JDK<&9"3_&-XOY;X_;4QO
M806AXQ&@&SO:]5G))4VC>.MZ5O\C2&24$B+N*`+OHP@)+-\-PN<?4?%&%7C_
M_Z'XH\A"BA#7<I\#$BSN&[)%<H9<)WF?;]<MNQC0P&"_.^=\.Y`5*%^3+%(B
MT_Y?68=T<Y$7KK(Q8>=!0CMHE?=M0)[7]CN4MQ@YD>#`J^00S]$Y\5R'Z(SD
MRN#UYE^=8B`3P%!&&TQ*IU!"U>GWV^AJB).YH>O71`(`;1F]'[IZ;/&<@QC)
M=QBA+I+.*;Z+.-F<$Y"EU-%<0\NIKGE]/=B*M]WS1<!3S+JA)_6'O$>"X\L,
MQ1A(,)!B(%,`+6AH=37HV\%R\L:$E,C*!"[JJTAP%D-GDL#A/[J=6#`F.PD&
M4@QDMT0U.W#</&Z'D[$=M`DBP9F"C3&08"#%0"8`X@PY<2QG(1.BQ0YG@AH[
M[Q\?EMXN"5^$/:"M$`F.X@$#"092#&0"6`X6EE8PG3B:A7!NX?X6X(NP!;P%
M!$>Q((!0M)GC>$&`=FZ"EZ08R!1`<\$?:]!!?=\%7X1=^++08B,+CN("`XD`
MA*W`<?U%H$ND*L%?$#><#J/A.S)%4C.UU$W=[BI.QF90))'@C!4(EQ"+'FHL
M")/;!`,I!C(%T(*'O:.5Y';T`QN'/VTZ48N1)`ZJ1>B%'F+$(T,Q,$/2&9*I
MB.Z!3\L?;BLB9JQVYA)\2(TD40MW01:X;>*1H7H1PA.2SCB9BNA>^%A$7NZ?
M540,4\T+'KC12+KVE0_/?ZBO1L84>3)#TAF2J8CNA8]&Y(4X=P]>(B:J;@:%
M&HVD*=18(NH,17LXD:3K,U$Z0S(5T?WP8:GXN;-7Q&C5;.!GQ8C@@1Q+9++A
MH3,[D9S)!=;)5([N@@_-QUV($:N[F.T205*+(1#8LOPYVK'PMDGX)0@.PFE)
M.D,R%=$M\)GYN`4Q874+Z$B-")[+\8B,%GR+#$]<\L5+GV9EP1KI3#53$=T3
MGYF/>Q(35O>$XHG@8JOG.);(U%R!AV9I(DE3=V$A?F>6TL*&N`*+:UE-VR.-
M:55U1L'>^/76A3Z0J+QZO[C\R1OA,5G!?0AP6_X!;L3G_$A_R]MCV71&10\@
MZ5@A]%`K[M3B0\_.PV5PQWJX"P^_GN!_'Q2N6(X%Y`-C_?4#_P+YWY3MOP``
M`/__`P!02P,$%``&``@````A`"ZY*4RO$@``=&L``!D```!X;"]W;W)K<VAE
M971S+W-H965T,S8N>&ULG)W9<MM($D7?)V+^0:'WE@CN5-B>*.[[OK_),FTK
M6A(=HMSN_OM)$`6RD*<D0]T/;OOP(EE`WDP40"P?_O?WX\/%7[OGP_W^Z>-E
M<)6YO-@]W>V_W#]]^WBYF#?_*%]>'%YNG[[</NR?=A\O_]D=+O_WZ;__^?!K
M__SGX?MN]W(A$9X.'R^_O[S\N+F^/MQ]WSW>'J[V/W9/\LG7_?/C[8O\\_G;
M]>''\^[VRW&AQX?K;"93O'Z\O7^ZC"+</*>)L?_Z]?YN5]_?_7S</;U$09YW
M#[<O,O[#]_L?ASC:XUV:<(^WSW_^_/''W?[QAX3X?/]P__+/,>CEQ>/=3>?;
MT_[Y]O.#K/??0?[V+HY]_`?"/][?/>\/^Z\O5Q+N.AHHU[ER7;F62)\^?+F7
M-0@W^\7S[NO'2Q/<F&TV<WG]Z<-Q"RWO=[\.SM\O#M_WOUK/]U_Z]T\[V=R2
MJ#`%G_?[/T-IYTN(9.%K+-T\IF#\?/%E]_7VY\/+=/^KO;O_]OU%\EV050K7
M[.;+/_7=X4XVJ82YRA;"2'?[!QF`_'GQ>!]Z0S;)[=_'__^Z__+R_>-EKGA5
M*&5R@<@O/N\.+\W[,.3EQ=W/P\O^<16)`ALJ"I*U0>3_-DA0N,IG"Z7R>Z+D
M;!3Y?QPE>Y4M%X)"\1UCR<<K=!Y,[E^$">+1A'_Y]ULFB(>3*YW#_(OAY*1@
MCWD*__+OAY.KV#!Y&9<-D\U<E8),)5=*G^^\2(^C"?\2YZK\_HSGBS9.(?1]
MY"P9SGOM5XA-7'!RGMK%UU%%'`NL?OMR^^G#\_[7A;0MB7KX<1LVP>`FC!R7
M5E0(IV)[K=:DR,(H)@SS\5+2)F5TD`[QUZ=\*?/A^B\IZCNKJ48:^?.D"7)*
M4XLU80V'@>LQ>&.A1JR)%VK&P%DH.996I"@?"SS\GK8&'0VZ&O0TZ&LPB(#\
M>5[CY#B&>I&1!F-/#+W5)O%"KW[/-%;$FVBFP5R#A09+#58Q<+Y6#VT=:^(O
MWL3`62BY3;:Q(E[$>-P%YQAKKW-*C3630ZR;'&*]XQ!K'H?`+`9N,;"+@5\,
M#&.L8V2%7S.(L1YRA@//&)C&6-<X2YT\<MJJ\(0YF<(9CDZH@5',R2G.8LF4
M&GC'G,QS&@^L8JQ7W,V3+P4JM+6+*SI+KJ7+G5J==+=$J_//'N*.%JK#CA:/
MKQJ#\UKF2]GD8&J1QAV+4M2I0)0&-2I*\[>*%A7Y4C$YVG8*3<>G*2?C=%-H
M>CY-)1FGGT(SH$9MFR$5^?+9$<>]RBB%9NS1Z'Q//)IL*;E6TQ2:F4=3SB7C
MS%-H%M3HX2Q_+UE1`H^N/9IR(3GB#35Z--O?2XRA!L,QMCK=RJ/(4Y[YLDJ7
M\54H1)X2S9=561A/E5+D+51E:>.KU(J:.AE?J4+DJ]6*J@[C*U:(/-6JA^TI
MUGPEGS2)\=4K1+Z"K2B[&5_%0N0KV8IJC,97LQ#YBE8W"..K6HA2E*U)4;?&
M5[BZXHRO<B'RE&Z^HMJU'/(?=Y%NS9T=D-CSRM%E8L\;'F3DY&CH[3UPN%1B
M#ZQ!+0+N`/(EU3;K/HWR8".%IIE"TTJA::?0=%)HNBDTO12:?@K-((5FF$(S
M2J$9I]!,4FBF*32S%)IY"LTBA6:90K-*H5FGT&Q2:+8I-,:D$573B+REJLK0
MI*E5DZ9839IJ-6G*U:2I5Y.F8$V:BC5I2M;X:K9R;KW1&1E?T4+DJUJ(?&4+
MD:]N(?(5+D2^RH7(5[H5/0'SU2Y$ON*%R%>]$/G*%R)?_4+D*>!"1L_W/!7L
MBA([8#D1FM@!O[WC#=6)':\&M0A$Y\>/I^DT:&C0C(%[^*QF<*T4FG8*32>%
MIIM"TTNAZ:?0##R:LDKG,(5FE$(S]FE4;YBDT$Q3:&8I-/,4FD4*S3*%9N73
MJ)W,.H5FDT*S3:$QQB?2!QO5-*)3Q3GE4]:1ZFDBG2KSK4B^:L77^<JUK`\2
M?/4*D:]@(?)5+$2^DH7(5[,5==Q@?$4+D:]J(?*5+42^NH7(5[@5?0+#5[D0
MG4HW/KUI?(6*Q7R5"I&O5"'RU2I$OF*%R%.MA8P^I>$I5U>4V%G*SWWOV%F&
MZL3.4H-:!)R=I08-#9H:M&+@%*T^TFW[-,H<'9]&.;_KTZ@X/9]&Q>G[-"K.
M(-;$-AS&X(T5'?DT*O`XUL2!)S%X(_#4IU&!9SZ-6O.Y3Z/B+'P:%6?ITZ@X
MJU@3K^@Z!F^LZ":%9NO3J"\WQB=2:V&J/I&.=*J2-X9MZFDBG:KIK4BG"G-%
M>DRGJHNWK?'6F%Y?;Y'IV-XJTY&\9:8CG>KL-,I35;DKIV-[*TW']I::CG2J
M-??K=*0T]6?2%*`Y5>!I?4_U=B)IJLND*2]SJB]WY?06\-:<W@)IBLYXJ^[\
M=8G]E%Q7\H[]5*B6LZ[.3\WYHMI+5B--_O2;9TV#N@8-#9H:M#1H:]#1H*M!
M3X.^!@,-AAJ,-!AK,-%@JL%,@[D&"PV6&JPT6&NPT6"K@3$@R)U!\@RR9Y`^
M@_P9)-`@@P8I-,BA01(-LFB01H,\&B32(),&J33(I4$R#;)ID$Z#?!HDU""C
M!BDU;DX352V7T+VCJD/UQTOY(>9T`4DAHX[VJY'&J>H(%(^7:>7*V9PZ#5/7
M"S0T:&K0<D,&Q4)%__#8C@2EXW=6,N%_R=\!.VZ$4KZH?V[KN@'R&3G3I0+T
MW`#94K%84-VM[T8(P@`ZQ"!2G+?4T(T9E//YG#J;,$K$/(94PQKKF!,-IAK,
M-)AKL-!@J<%*@[4&&PVV&A@#`B^9&C2PCX%_#`QDK(/.V]Y8RSC$>L0AUA4.
ML39PB,V[0VR>HP+(9_,!3L#:Q$=VS>8\7C$V]39(,<B4E3>,3;T-XC.<L6:P
MI5@LEXOZ'+9UAPWB<YB!7PP,8^`8`\L8>,;`-`:N,=8V\<8L%5Z9K807X[L7
MFKY]"CI4Z[YV#GS\A:,::<YYK6E0UZ`1@2!S;$.9JXSJ?,W??-[2`=L:=#3H
M:M#3H*_!0(.A!B,-QAI,-)AJ,--@KL$B`N>MI<XW+G_S^4H'7&NPT6"K@3$@
MR+NQB3\/5*756".\+K#&.'O)6"LX!,DW-ONOA[5N>%T`=QC8P\`?QAKD];#6
M,*\+K(%>%UA#O2Z`P0P<9F`Q`X\9:S)G.UM;.<0:Z3P8941CC?6Z`$8SKM,2
M\R^Y>>`=?2I4ZSZE]@/52'->GYH&=0T:&C0U:&G0UJ"C05>#G@9]#08:##48
M:3#68!*!:`=6J)0+:O-,W<]SN7(I4#\AS%Q!5L[:JL_G[N=!7F[Q4%.PA2O(
MYK+EO)H9+EU!D"V62EDUR%6D..=PK<%&@ZT&QH#`&L9ZP^[NBYSF&FN62.&=
MQAIKGTA2*H73E^1DVU@_18IPDU5RZJC!P&'&6LQ^LVRDG,J$L9ZS"N]DQ;K0
M2G*Y7%[MUHVU9:209'+T\*F!40V<:F!5`Z\::]9SGHVUIT.L'QUB'>@0:SF'
M6(\YQ'HJ6L]RV;.>UF21(IH_ZD3"=L;U7:*Q27=\3V<[RG5K4SO6JA6=UZH&
M4@=I@#1!6B!MD`Y(%Z0'T@<9@`Q!1B!CD`G(%&0&,@=9@"Q!5B!KD`W(%D3N
MK0EM\?'RG$*YDP:(:37,JV%B#3-KF%JYGP;?R.3*'350,;UR3PU43+!AAN4N
M&BS('!LFV3#+<B<-8C'/<N,,5,RTW"D3J6Q#+.<"]-TX]Y%$3E,$Y:+NYW2#
M2=@AV2ODFMIWS(*"4*Y[A9JD5:WH;+0:2!VD`=($:8&T03H@79`>2!]D`#($
M&8&,028@4Y`9R!QD`;($68&L03:61`Z2FY$#]?/%-B$H%S-Y)9!.$KG@G&#I
M)$!,NG02J)AVZ210,?'22:!BZJ630,7D2R>!BNF73@(5#2`WY$%%"T@G@8HF
MD#OPH*(-Y)8[J&(CV"1GBWE5HR8VANTUX@,].XN-DC^>0LD&^O/8)]'G16>R
MGFPPX;T#Z4\'!=&M!LGSW,J`52LZ^Z\&4@=I@#1!6B!MD`Y(%Z0'T@<9@`Q!
M1B!CD`G(%&0&,@=9@"Q!5B!K2ZS3\IF2FCENL,@61#I*E/9S1J6C`#'+TE&@
M8IZEHT#%3$M'@8JYEHX"%;,M'04JYELZ"E3,N'04J)ASZ2A0,>O24:"*\QYE
ML.`Y$(U]$"ER@><`AL:0#H.OHA=D9N*HDHTCO-O@'8TCNCE!HCD_D*ES[-7P
MZ1>)*7`-I`[2`&F"M$#:(!V0+D@/I`\R`!F"C$#&(!.0*<@,9`ZR`%F"K$#6
M(!N0+8AT"IU"Z11`3*MT"JB86.D44#&UTBF@8G*E4T#%]$JG@"I.L!P.A,_7
M*%V%!>?\5VK\H>?\L0/>L4ALD7<L$GOH'8O$)GO'(K$+W[$(;2J=#MN51I6Y
M$U2TJK0RJ&A6:661RHY;?G0Z3[J2G2V\>OL=G2VZV#O9V=0)N6KX9![5V32I
M0],`:8*T0-H@'9`N2`^D#S(`&8*,0,8@$TOL#@N'.-/$Y]F,7(20/&TZ.X4\
M/N!&_U8[3RY?U->=+TZ+Q]>I+4%6(&N0#<@61#IBE&B[LN6,.J,M_=$59#.5
M@EI;>7Z*]HJT2R"Z1=HE5/2+M,O$`,JX"3GV3[0*0:&@)Y'22_%%-)3T4JAH
M*9EU0453R:P+JMA6SBPU=I*#SMZ)DR^]"+%BBT2KG)?GS.D3OK%E(H5<FI#+
MJ>,@.6&$N#21/%P%JH2-DKTIO/#V';TINDXWT9L"M2;5\`%NJC=I4H>F`=($
M:8&T03H@79`>2!]D`#($&8&,+;'%60B<?<+QVH8)%IF"S$#F(`N0)<C*$NNH
M@ESFE&Q[:RRR`=F"2`>*TFGC5C*Y\XXOND4UML#KBAK#TA-RWMG])CGUB687
MFR3Z)I\B-DVDD*+2UX9(O]+VE*<^`=%&\MPGJ&@D>=`35+22G*2&*C:3TVQH
M'SD0Q((TD+2D2!5MA4HQBX>:T%$R6T+HV%/.F.@B:4%8,.&C9`L*+WEU6U"Z
MAT@$T96RR5:D?O^M6I'U83&0BP>3)5"SBO/ZU)/+E`IE?:JL@66:("V0-D@'
MI`O2`^F##$"&(".0L271MBEDBX$Z>IY@D2G(#&0.L@!9@JQ`UB`;D"V(]*;(
M%M%:Y7.%K-H[R?3H=PIZ0J9'T4)GFTAO<N,$V4HVH_?7L2VBP7@EL4]L%C(%
MG07I3OAJ&D<F3%#1.C)A@HKFD0D35+2/3)B@HF.D.T$5>\9N%?E1*ZO*5KI5
MM-0;$KI*VA6^B[Z2@SNHZ"PYN'-4R7857A?KMJN_O<^JC9\V%T27T2;;E#J<
MKUK1V5TUD#I(`Z0)T@)I@W1`NB`]D#[(`&0(,@(9@TQ`IB`SD#G(`F0)L@)9
M@VQ`MB#2=W"Y-+,J!UZ1*O)UUGL54$+RRF5`_#*F7GZ.QY"8?)GI0,7TRTP'
M*AI`9CI0T0(RTX&*)C!T@?02+$@?2.^`BDZ07@$5O2"]`BJZ07J%HTKVBO`:
MUW?TBNB2V&2O4+_#50-]W6P-I`[2`&E:4CB><\P'I:+:4;:P2!ND`](%Z8'T
M008@0Y`1R!AD`C(%F8',018@2Y`5R!ID`[(%D=:A,RIS%"!F628E4#'/<LX&
M*J969AE0,;DRRX"*Z9591J2RULKR^)#YEDD'0C/C,NF`BCF71@$5LRZ-`BKF
M71H%5,R\-`JHF'MI%(XJV2C"*TC=1A$>`U7D\J#?3"ZB"T^3#4,=Y%<#?75J
M#:0.T@!I@K1`VB`=D"Y(#Z0/,C@1Y_>^0!W,#4^B^%3<"&0,,@&9@LQ`YB`+
MD"7("F0-L@'9@DC3T%F5I@'$3$O3@(JYEJ8!%;,M30,JYEN:!E3,N#2-6.4F
M6)]8.ML@SK`TCGC!$V+6I7%`Q;Q+XX"*F9?&`15S+XT#*F9?&@=4S+\T#D>5
M:!SR<HYDXWB[81SEZGH^?4%8U8J<HQ%+[-ULGAM+L4@#I`G2`FF#=$"Z(#V0
M/L@`9`@R`AF#3$"F(#.0.<@"9`FR`EF#;$#"][4D3[_+@Y:!F&13HZI.Q,3*
MXY`1GJF51QU#Q>0:9E<>6HP%F5_#!,L#B+$@4RP/%X:*298'!T/%-,M#@:%B
MHN6)OU`QU?(X7ZB8[./;>4[9CCI#]+*=Z%T@C[OG;[O:[N'A<'&W_QF^2$>.
M53Y].&'[FI^1O.='WBP@#51_,I%/Y'T"GD]F\HF\,L#SR4(^D6?^\Y-J]D8>
M&4,N"\A[!,A7P8TWSB:XD9<#4"][Q9OPA0V>3[KRB;RFP?/)0#Z1-R]X/I$/
M?*-M!3?RF@CJ.\&-O!J"O!?<R.L@R(?!C;S?@5PV>;1=KT_)D%<>_;C]MAO<
M/G^[?SI</.R^2B;EQ3=REOTY>FE2](^7_8_CBU\^[U_D94?'OWZ7MUOMY#TH
M\EZ:RXNO^_U+_`_YXNO3^[(^_5\`````__\#`%!+`P04``8`"````"$`$]DD
M!8("``#>!@``&0```'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6R455UOFS`4
M?9^T_V#YO1@(D`^%5*VJ;I4V:9KV\>P8$ZQBC&RG:?_]KNV$LJ3KDA>(<\\]
MYYY[;;.\?I8M>N+:"-65.(EBC'C'5"6Z38E__KB_FF%D+.TJVJJ.E_B%&WR]
M^OAAN5/ZT32<6P0,G2EQ8VV_(,2PADMJ(M7S#B*UTI):6.H-,;WFM/))LB5I
M'!=$4M'AP+#0YW"HNA:,WRFVE;RS@43SEEJHWS2B-P<VR<ZADU0_;OLKIF0/
M%&O1"OOB23&2;/&PZ92FZQ9\/R<990=NOSBAEX)I951M(Z`CH=!3SW,R)\"T
M6E8"'+BV(\WK$M\DB]L9)JNE[\\OP7=F]!N91NT^:5%]$1V'9L.8W`#62CTZ
MZ$/E_H)D<I)][P?P3:.*UW3;VN]J]YF+36-AVCD8<KX6U<L=-PP:"C11FCLF
MIEHH`)Y("K<SH"'TV;]WHK)-B2=%E$_C20)PM.;&W@M'B1';&JOD[P!*]E2!
M)-V3P'M/DJ11.LN3O/@_"PD5>8-WU-+54JL=@DT#FJ:G;@LF"V!VSB;0G[>=
M@267<^.2?"J@#4SC:945\R5Y@A:R/>;V%),."`+B0P6@>GD%+@DJQ6BH(,WR
M@=]7>1LPF9_L6!"RQH+O6W7@$J?>9!HGV9%&"!<^/)_/\V2(_^4QNT32@4>2
MQ[9"&)Z#]<GD;5786^<;=>"1:C%0AF:&\#FJQ26J#CQ2G1ZIAO`YJM-+5!UX
MI#H[4@WA<U3=_3XZ/>]O)0=VJJ^#2[/7R84V!\R_]U.XHL()[NF&?Z5Z(SJ#
M6E[#=HBC*<Q)APLJ+*SJ_4E=*PL7B__9P'>$PS&.(P#72MG#PEV!PY=I]0<`
M`/__`P!02P,$%``&``@````A`!@=U+-!!```NPX``!@```!X;"]W;W)K<VAE
M971S+W-H965T,2YX;6R4E]^/HS80Q]\K]7]`O"=@\NL2)3DM1-N>U$I5>]<^
M$V(2M(!3[&QV__N;P=C8YKHE+TD8OAY_/..9V-O/;U7IO=*&%ZS>^60:^AZM
M,W8JZO/.__;U>?+)][A(ZU-:LIKN_'?*_<_[GW_:WEGSPB^4"@\\U'SG7X2X
M;H*`9Q=:I7S*KK2&-SEKJE3`8W,.^+6AZ:D=5)5!%(;+H$J+VI<>-LT8'RS/
MBXP>6':K:"VDDX:6J0!^?BFN7'FKLC'NJK1YN5TG&:NNX.)8E(5X;YWZ7I5M
MOIQKUJ3'$M;]1N9IIGRW#P/W59$UC+-<3,%=($&':UX'ZP`\[;>G`E:`8?<:
MFN_\)[(YD)4?[+=M@/XNZ)T;OSU^8?=?FN+T6U%3B#;D2:3'OVA),T%/D#G?
MPXP<&7O!H5_`%,(DO!7@)/Q?-<U3A+,$>AKSMYKRN4W;'XUWHGEZ*\6?[/XK
M+<X7`3,M(`P8C<WI_4!Y!FF`N:;1`KUFK`07\.E5!>XG"&/Z)NF*D[CL_-ER
MNEB%,P)R[TBY>"[0I>]E-RY8]8\4D<Z5=!)U3N#[+M]'RRF9A\L'?,PZ'_#=
M^2#1PR#SS@E\:R?_MXI`1J0-]B$5Z7[;L+L'6QW6S*\I%@[9@$,561D''>O_
M"C7$&)T\H9>=#S4*4>20[]=]N`U>(:-9IXBE`CZU@MB*1"DP?>CT8!@"H-7(
MD``3^<>;0)&A&,F4UU@:3)#(`1DJ9K;B,%3,M<)"A3R;J!C=&93,Q\@X"'1&
MJ!;:>QN96"KF>E&):S@8!@L(4FP"?0R"XIT/B]4Y6SH@4@&?6K&R%8E2J/@?
M#(-%!H4XG@S%-MDG>]Y8*N;M7B2+:+6*'$6B%)K,,%ADRT?(4&R3K1TRJ9`Q
M._ZH5A*ET&2&P2);/4*&8IN,N$4J)1BT?#^9D&@R@R+-L9PGQ%E&HK0:TC!8
MD/C/;728C[<<BAU(IT_$4F+N.>)6L))H-L-@L:T?84.QP^8TAEA*%FU6YW"R
MZ-M"6[B)?-\7[L$P6&`$NL3XJ+5J!\V9.NXTLB*BD#CO$_U>!\VTV'#8F4>G
ME,@^;K81XC:T3F,EU>DUB=;T@-)S&TX;$!OT>$#9SBU`IXW%1&HL0+>A:$T/
MJ$:!Q0;$_CP>4'9S"]`IQYBHCM^W8C(`5)H>T+#8@+#2!P!1;>^_R.TM1&K,
M"$9.:2=:TP.J48,(8K<>'T'9V\T(1D[3B/%`"8NP`)WZ3K2F!U2C!H#8M,<#
MRA9O`3H5&A/C;T"VDX'ET%F6;0>*YNO%,EKVF;!3C`W;`!QW.(&[P2#5@VHV
M_@HZ4&E9M5CKQ6P6K7NJ5H*7#AE^'4AY-9"GU8HV9YK0LN1>QFYXU"?@2UOU
MW:6[5.@7<`NXIF?Z>]J<BYI[)<UA:#A=0=8:>8^0#X)=V[/PD0DX_[<_+W!)
MI'`.#:<@SAD3Z@$!];5S_QT``/__`P!02P,$%``&``@````A`,Y\SP3&`@``
M!P@``!D```!X;"]W;W)K<VAE971S+W-H965T,S(N>&ULE)7);MLP$(;O!?H.
M!._1+GF!Y2!QD+9`"Q1%ES,M4181211(.D[>OD..X\I6G,876]3\_/7-#)?%
M]5/;D$>NM)!=3D,OH(1WA2Q%M\GIKY_W5U-*M&%=R1K9\9P^<TVOEQ\_+'92
M/>B:<T/`H=,YK8WIY[ZOBYJW3'NRYQU$*JE:9F"H-K[N%6>EF]0V?A0$F=\R
MT5%TF*OW>,BJ$@6_D\6VY9U!$\4;9H!?UZ+7+VYM\1Z[EJF';7]5R+8'B[5H
MA'EVII2TQ?S+II.*K1O(^RE,6/'B[08C^U842FI9&0_L?`0=YSSS9SXX+1>E
M@`QLV8GB54YOPOEJ1OWEPM7GM^`[/7@FNI:[3TJ47T7'H=C0)MN`M90/5OJE
MM*]@LC^:?>\:\%V1DE=LVY@?<O>9BTUMH-LI)&3SFI?/=UP74%"P\:+4.A6R
M`0#X):VP*P,*PI[<_TZ4ILYIG'GI)(A#D),UU^9>6$M*BJTVLOV#HG!OA2;1
MWB0&^GT\\J)I&J;9_UU\)'()WC'#E@LE=P06#7Q3]\PNP7`.SC:S&.KS>F:0
MDIUS8R>YJ:#6T(W'99)F"_\12ECL-;=C372L6+VBF!PD/O`=("'URR'M)$B&
MD@-D%$\/_BZ16]0DKLXVL]7@Q1$!V`P)WBZ/%><T<H6)@C`]^2B&,Q<.DW@:
M'L=7&'=01PS))0Q6/&`X[0Z&)V<9,#YF@.7Z_CI8\8#A7W.Q^!@^SX#Q,4-V
M"8,5#QA.%P"&SS-@?,PPN83!B@<,L^-^WV+X/`/&QPSV<AELW;?7I!5;AL%N
M2.(3$-3L0<(D#4Y(5R@8D\PN(;'B8Y(D/5T:J-EOD6F6A,DQ*ASVU@0%41QF
M@TV&>P;/<CSJ>K;AWYC:B$Z3AE=P'@3>!%:7PI,<!T;V[DA;2P,GL'NLX<+E
M<"H$'H@K*<W+P-X5ARM\^1<``/__`P!02P,$%``&``@````A`"Q>MUZE`@``
M708``!D```!X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC)5=;]L@%(;O)^T_
M(.YKQU]I$L6IVE3=*JW2-.WCFF!LHQIC`6G:?[\#)-1)NJXW28"7U\][.#C+
MJV?1H2>F-)=]B9-H@A'KJ:QXWY3XU\^[BQE&VI"^(IWL68E?F,97J\^?ECNI
M'G7+F$'@T.L2M\8,BSC6M&6"Z$@.K(>56BI!#`Q5$^M!,5*Y3:*+T\ED&@O"
M>^P=%NHC'K*N.66WDFX%ZXTW4:PC!OAURP=]<!/T(W:"J,?M<$&E&,!BPSMN
M7IPI1H(N[IM>*K+I(/=SDA-Z\':#,WO!J9):UB8"N]B#GF>>Q_,8G%;+BD,"
M6W:D6%WBZV2Q+G"\6KKZ_.9LIT>_D6[E[HOBU3?>,R@V'),]@(V4CU9Z7]DI
MV!R?[;YS!_!=H8K59-N9'W+WE?&F-7#:!02RN1;5RRW3%`H*-E'J,*CL```^
MD>"V,Z`@Y-E][WAEVA)GTZBXG&0)R-&&:7/'K25&=*N-%'^\*+%0P23=FV1`
MOU]/HW16),7T_RZQ)W(!;XDAJZ62.P1-`\_4`[$MF"S`^9#,<X2L_XH*>-;D
MVKJ4&+H=4F@XGJ=57LR6\1/4E.XU-^>:Y%BQ/BCL40!>8(3D8\:WJWY`L6*+
M8DMGV6[\!'@'MO3DN6\H+H/DB`0J-":QU<J@F]XGLIM`-P;(3HOC-7F@7H\F
MC@CR8X+WGVS%)89X(7I>O";SY?&:J3NT9#;-DSQ$=X+U6)!FR30I@N"(##IY
M7)OWR:SXE&P>?#V9U^S)\FQVVB[C]6R6SE^3>2Y_G7VW"Z8:MF9=IQ&56WM5
M4T@<9L-;Y#JU1W`R?P-O%W<7X[``MWL@#7L@JN&]1AVKP7(270*3\N\'/S!R
M<'=L(PW<:_>SA=<X@\:<1""NI32'@6W[\,>P^@L``/__`P!02P,$%``&``@`
M```A`!FD]B[1`P``*@X``!D```!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL
MG%?;CMHP$'VOU'^(\KXD3DBX"*A*5MM6:J6JZN4Y)`:B3>(H]BZ[?]^Q)X!M
M6`+[`L0YGCES\?$P^_12E<XS;7G!ZKE+!K[KT#IC>5%OYNZ?WP]W8]?A(JWS
MM&0UG;NOE+N?%A\_S':L?>1;2H4#%FH^=[="-%//X]F65BD?L(;6\&;-VBH5
M\-AN/-ZT-,W5IJKT`M^/O2HM:A<M3-MK;+#UNLCH/<N>*EH+--+2,A7`GV^+
MAN^M5=DUYJJT?7QJ[C)6-6!B592%>%5&7:?*IM\V-6O350EQOY!AFNUMJX<3
M\U61M8RSM1B`.0^)GL8\\28>6%K,\@(BD&EW6KJ>NY_)-`E\UUO,5(+^%G3'
MM=\.W[+=E[;(OQ<UA6Q#G60%5HP]2NBW7"[!9N]D]X.JP,_6R>DZ?2K%+[;[
M2HO-5D"Y(XA(!C;-7^\ISR"C8&801-)2QDH@`)].5<C6@(RD+^I[5^1B.W?#
M>!"-_)``W%E1+AX*:=)ULB<N6/4/0:0SA4:"SD@([+OWP2`81R2*^ZUXR$@%
M>)^*=#%KV<Z!K@&?O$EE#Y(I6):1A9"?\Y%!2'+/9[E);04TAW(\+X:Q/_.>
M(859AUF>8@(3D9Q!C`X0#_@=2$+H.LG+Y"08@G`=C1PYV%4!+!$S5/F5$27:
M@N$9S%SO68+G+IC2/%M!+Q$3JZ1-)I/(8I;H[T?!V/>/`(/8\!9B$FP2"Z+8
M2@EB1HK8W3EF!N`2-6AI/6?7M93<9%(<QJ%%$3'`XY#?T((D%R%&`N/WL)2;
M;)9#BR5BM-[2%@P&(Y/!Y:Z6X+ZN1HSF65LP/,M[23OTESU+L!VSW=6(P>8)
MQT$8F3E)\/T;E3.H36ZA)L$V-<OU$C%:4K0%PS,!V;L^*PK=5Y`.I#G75TSO
MEA!?K@E![;PL-1T(JT+&$_L\)08@(%'TAOP2J8Y:OUQWHM4NNSJVZG0@/4-O
M23&Y28L5NK<^J+:Z=VW%K(^4/RT'/?5!L>RI#X*P/L-@%-EB1A``G^<$SZ3W
M+M&5,\S)`3HV`=Z5'4A/TEYEY<RDW]/$$M6>)*$P0L8/X0WCXW77>=?44ZTD
MRLG<57Q,[S<)*D%Q["G17D'EC&--.$EG`>L7!22<'!$F,4MOKSP_YX1W;`KK
MDNR550Z=:I+15TP6-TDK09GL*8ZFI9UW;<7P#N/Y#>='H6WML"^=#H2SU#'U
M2,1X2<:1'QWO:22&TSX.PTVZH3_2=E/4W"GI&OK1'XR@RUN<]?%!L$8-O2LF
M8$97/[?PGXS"_.@/`+QF3.P?Y,DX_,M;_`<``/__`P!02P,$%``&``@````A
M`*V&2)8W`P``50D``!D```!X;"]W;W)K<VAE971S+W-H965T-#(N>&ULG%9=
M;YLP%'V?M/^`>`^?`9(HI&I2=9NT2=.TCV<'3+`*&-E.T_[[W8L3`D[;I7LA
MP3X^]]QS+UR6-T]U93U2(1EO4MMW/-NB3<9SUNQ2^]?/^\G,MJ0B34XJWM#4
M?J;2OEE]_+`\</$@2TJ5!0R-3.U2J7;ANC(K:4VDPUO:P$[!14T4W(J=*UM!
M2=X=JBLW\+S8K0EK;,VP$-=P\*)@&;WCV;ZFC=(D@E9$@7Y9LE:>V.KL&KJ:
MB(=].\EXW0+%EE5,/7>DME5GBR^[A@NRK2#O)W]*LA-W=W-!7[-,<,D+Y0"=
MJX5>YCQWYRXPK98Y@PS0=DO0(K5O_<7&]VQWM>P,^LWH00[^6[+DAT^"Y5]9
M0\%MJ!-68,OY`T*_Y+@$A]V+T_==!;X+*Z<%V5?J!S]\IFQ7*BAW!!EA8HO\
M^8[*#!P%&B>(D"GC%0B`JU4S;`UPA#QUOP>6JS*UP]B)$B_T`6YMJ53W#"EM
M*]M+Q>L_&N0?J31)<"0)0?UQ/W""6>1'\;]97*VH2_".*+):"GZPH&L@IFP)
M]J"_`.939EI'G^MKJ4*.2'*++*D-[0Y92*C/XRJ*XJ7[")YF1\SZ$N./$9L3
M`DL!\GJ-D/E0X\NNGZ0@&*5@%5#;6B\`=Z\M,.*^@$AZR$@).'2]$@1#I0>!
M0__,J\5IS+17NQDLC")/WQ,9P:D-:?4IA_ZLSTA'UIBX*];$3Y(HG(\1&XV`
MZYDE["$C<=#$U]N"8,.6P.MYM3B-&=@R6!A%CL>1L7U#>+S?;A$\9-@3&+VX
MUIBDL\>?!Y%ISG`_B,-XVF<PTI?\CSX\9.HS>G:M,5I?G$QG1GDWP_V)[T71
M+'I9(<ZHP0O@;><0;"H[9ZYKIS%:V20*PC`QM8T0_MR;#]2/W)N_1QN"36WF
MXZ8Q6MLTC./0*/MF"`@2+_#.=1\I@VGS#MLZM*G-<&5]!+WRO'7>XI##)%_!
M:(5ZBNF7?$W%CFYH54DKXWN<4`%T=+_:3\_;`-]`QOH:IRJNN_T&#+66[.@W
M(G:LD59%"Z#TG`0>3Z''HKY1O.U&RY8K&&?=WQ(^7RB\CST'P`7GZG2#`?H/
MHM5?````__\#`%!+`P04``8`"````"$`;]-E,3,"``#V!```&0```'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6R4E,N.VC`4AO>5^@Z6]Q,G@3`0D8P&(=J1
M6JFJ>ED;QTDLXCBRS>WM>VP#8J!J9S9)#/_Y_G-+YD\'V:$=UT:HOL!)%&/$
M>Z8JT3<%_OEC]3#%R%C:5[13/2_PD1O\5'[\,-\KO3$MYQ8!H3<%;JT=<D(,
M:[FD)E(#[^&?6FE)+1QU0\R@.:U\D.Q(&L<3(JGH<2#D^BT,5=>"\:5B6\E[
M&R":=]1"_J85@SG3)'L+3E*]V0X/3,D!$&O1"7OT4(PDRU^:7FFZ[J#N0S*F
M[,SVASN\%$PKHVH;`8Z$1.]KGI$9`5(YKP14X-J.-*\+_)SDBS$FY=SWYY?@
M>W/UC$RK]I^TJ+Z(GD.S84QN`&NE-D[Z4KF?()C<1:_\`+YI5/&:;CO[7>T_
M<]&T%J:=04&NKKPZ+KEAT%#`1&GF2$QUD`!<D11N,Z`A].#O>U'9ML"C290]
MQJ,$Y&C-C5T)A\2(;8U5\G<0)2=4@*0G"-Q/D"2-TFF69)/_4TC(R!>XI):6
M<ZWV")8&/,U`W0HF.9!=92/HS]\K@Y)<S+,+\J&@-C"-79EECW.R@Q:RDV9Q
MKTDO"@+FEPS`]3J#?SL[<8'A>N4\O7!]=HN@\>OPRFCT'B,GAE:\,IK=&`7-
MO='X/49.?%/1)+XQ"IJ)[W0ZFL9)/+DH0HEA=<-D!]KPKU0WHC>HXS5T*HX>
M8<]T6-QPL&KP$UPK"POG'UOXOG`8;QR!N%;*G@_NU;A\L<H_````__\#`%!+
M`P04``8`"````"$`*%?*5^`"``"O!P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970T-"YX;6R<55UOFS`4?9^T_V#YO7P&2**0JDG5K=(F3=,^GAUCP"I@9#M-
M^^]WC1,*I$N[O21@CH_/.?=R65T_U15Z9%)QT:38=SR,6$-%QILBQ3]_W%W-
M,5*:-!FI1,-2_,P4OEY__+`Z"/F@2L8T`H9&I;C4NEVZKJ(EJXER1,L:>)(+
M61,-M[)P52L9R;I-=>4&GA>[->$-M@Q+^1X.D>><LEM!]S5KM"61K"(:]*N2
MM^K$5M/WT-5$/NS;*RKJ%BAVO.+ZN2/%J*;+^Z(1DNPJ\/WDSP@]<7<W9_0U
MIU(HD6L'Z%PK]-SSPEVXP+1>91P<F-B19'F*;_SE-L'N>M7E\XNS@QI<(U6*
MPR?)LR^\81`VE,D48"?$@X'>9V8)-KMGN^^Z`GR3*&,YV5?ZNSA\9KPH-50[
M`D/&US)[OF6*0J!`XP218:*B`@'PBVIN.@,"(4_=_X%GNDQQ&#M1XH4^P-&.
M*7W'#25&=*^TJ'];D'^DLB3!D20$]<?G@1/,(S^*WV9QK:+.X"W19+V2XH"@
M:>!,U1+3@OX2F$_.K([>Z]^L@D=#<F-84@S=#BX4E.=Q'<7^RGV$3.D1LSG'
M3!#;$\*4`N3U&L'Y4./KJ9^D&+"18JI@M&WL`G#WVH*QLNTKB*2'C)1`0N]7
M8L!0Z<'!83@Y>F,QLU[M=K`P.GGV+R<;<(K!5F_9CV:](QN+Q<1=L:Z",/'F
M\W`,V8XA_BP)!T4=J8,N'N9BNBB$M^QRI<RFL<HPG(\E;"PFZ50FD>?YLTF"
MVR$B@H"3X*6M1AKC_]%H-DTU+B8:+0;"ZM,.ITE>A(Q4)N<JXS>3-)O&*F$F
M3%1:S*4DAX@PBI+YXL6&U6@'I)T?-9,%V[*J4HB*O1E^`52I7^WG\DU@FGNR
MOH%YW4TWMW\`\[(E!?M*9,$;A2J6`Z7G)%!?:2>NO=&B[:;63FB8E-UE"1]&
M!J^ZYP`X%T*?;LP@Z3^UZS\```#__P,`4$L#!!0`!@`(````(0!\$TT88PL`
M`,EC```-````>&PO<W1Y;&5S+GAM;-Q=;8_BR!'^'BG_P?(FT9V4&<"8`>:&
M.2W,.%EI,SG=3I1(N2@R8&9\XQ=BF]V9.^6_IZK]5@W8;D-#KW+H=K"AJYZJ
MI[JZN]PV-]^_^I[VV8EB-PPF>N^RJVM.L`B7;O`TT?_V:%V,="U.[&!I>V'@
M3/0W)]:_O_WM;V[BY,US/CT[3J*!B"">Z,])LK[N=.+%L^/;\66X=@+X9!5&
MOIW`8?34B=>18R]C;.1[':/;O>KXMAOHJ81K?R$BQ+>CE\WZ8A'Z:SMQYZ[G
M)F],EJ[YB^L/3T$8V7,/H+[V3'N1RV8'.^)]=Q&%<;A*+D%<)URMW(6SBW+<
M&7=`TNU-L/$M/XFU1;@)DHEN%*>T]),/RXE^I6NIR;-P"2#^\)]-F'SWN_3/
MNS^^>]?]][??_?-'9_FOG[[9_>RG;_5.KH;(!`[J95YV:\7"QZGD3F;![<TJ
M#(@A`)HYZ/HE"+\$%GX&P0#FX==N;^)?M,^V!V=Z"&\1>F&D)<`RV,?.!+;O
MI-^8V9X[CUS\VLKV7>\M/6W@"188V?=\%VC"DYU4PWGUS!%-;M,(87`V]?$,
MM<D'DVP\66^3_?,>FSA=@V9=Q_B/T\6LJ+=+FJ[=N-CQX3&Z"JZ(GNAI/M$M
M"W)(K]M%MU+"3J1L/.N"OK,INQJ<S;*^U;>&4BWC8G&7-U38MV2ZLD&A]7YX
M=S9WRE=695V6AL_5`[##R?6B"UVWIG\/+7R=(T[./*"=AC$FE4OZK.O)RHU<
M%)Y8UZ8B,$[!$]K%Z3NQ;:B/"_P3ZSNGKJ(S-]KTZ/I.K#TX7[0?0]\.L)/3
M"1:+7&Y^V"[\6HAG6F)0[WI>,;WO#W`"#&=N;V"ED3A18,&!EKU_?%O#]#>`
M11'B[J3?:_CV4V2_]0PV"11K$(>>NT043S,VZ<XF/;.K>VMVS_029*(H*H1:
MUFQX`J'WT_%,/M+9>"Q;J&'!2[+0]P-\219JP7\S:3[-TJDI"V0A3TM<7"1W
M+X?C\7C4NQJ-1F.SWS--YN1Y%M%NL'1>'5PW2W/3+H(!(!CW1^,K`X!TS1%3
M=58$?0`P'`Q&@][8,.%_EMM.CT"V3P>Z:E8)`D6L$@2*6&7KM(Z$S)_U%*C^
M*.ZK!($B5@D"1:P.)6?@H7)6"0)%K!($BEAEU46)?15*P8K[*D&@B%6"0!&K
MTB:?608>*V>5(%#$*D%P;E;S9=7L_MYBM:;=F9FT^7&F"R?Q[76Q52.L4^=A
MM(1K=OF%J%X?UHCIN=L;SUDEL"*-W*=G_)N$:_AW'B8)7.&ZO5FZ]E,8V!Z\
M[>0M\K\U+>$:(%SNF^C)L[MX`65<B2GU3:KB5!J*K&?B:L(<FMVA.3"NT@6;
M)-6^LW0W_JYUA>Z]<0EN1-\V&TY\&!1*LG`HRYP=9"&C3[`%HYHQ+=@`8B(/
M"<$6,FPL2_ZB-I(68C:2!H(VDA:B-D+7V=>Y<D\NPPU<?MXFV+)&W6Y:T1+5
M4R^0`-\3,?M!D#:[_FQLLL>CC6W:V@KY9:=O3`U\L=GQ'DL;6NS:V=!@CY4-
M+41MY.,F9Y<37I0N,#WO0;+E;^[KA\$`16E#@H=D^"P]X46?]+*/<+:KM+96
M^AZ;P4&U30ZS6]1<`@@LVC=Z9L,HC,H+Q_,^X3CYCU4Q-$.UZ_;F=44V<\`.
M&]SM@'M%\"V4E+.WZ3"<'H"NJD9&92/-7J^]MX>-/W<BBVV[82K862Q=ET=3
M-G\HC]][[E/@.ZQ>IZ=B?HC"Q%DD;%L0J^17X>E7X.EE@D3P'*/?K-`/?A+V
MQS'ZH1ZTET3PBU+]$%S"^F7&`U12<G\`!32HZ_#(1`"K_AP!D*`"`6[8RCHV
MA*<*!+":RA%`@)8(`$Y-5!S3#WHDFT$,E"I!_ZE40H[)K>14GM#*JO0+^FNL
MM+CT>Y2;2;Z%0"_=#`<U`(Y2695B5:480COTM-(%<%#C`@M&73E#7J\JYRMS
M"$FZ@*'T"*2!.H_(BTJ2<T%G":#>(U.)\Q`2%)B*5$,`.$H@$")ZBL;?'L6@
M:`2FT:!H"*80N#'XC'V",L&-D(HP`!XEO:*<)_2X$>.,;B`05&5($@V&JA1)
M,:C*D245AJH422"HRI"4"54IDF)0E2,)%:I2)($`'E&2(2D3JE(DQ:`J1Y94
M]%6E2`)!588D3/1/G"([M&R:%E%)_71@'E0_U5Y7C8747M6B"7C/FZ>KIW3E
M"%RPM1192N,M<G9>.]6>P\C]!1:9>*O<`HJI3J3CK96)NZ!GOD3V^M%YA:5H
M>CGH=55=ZP4D>7UC.QAYA)682OU0R=:U-LJE^^<(+,<[HM%RMJAO+,QO109?
MW&Z,D$80&)*J,6"!234&Y#O#(#T,)753&"1SB,+1*3M<6,WU_YFKQ@Y#`P49
MR:KN<)J;1?'9T@*78?IMR.=ME`N'0&6F/J^V(W*Q]`[9QO(>S`N_!I+[VZNV
MK0ACE56I$8:%B]SR)NU<?%N2L##>\Z0L#F9_SN.[H"R(^X>N!F]5`)3D-0*I
M!8,5F$["*TFA)(OUMTL"YPWP!NTG<41E@->#.2=7))K$N:H`>.(`_WJ<1@*<
M=D$X?=XYPOG'+BZBA4?.BGCA^IR4:0P6H?,A[?QLB`]A!PU6=)F!^Q9;+KX)
M.BFNH7#RXD2;B9<!DYFO@BOIWF!;1`]GIVF@Y+J-X$2'DG5<[)P:W0'.(YV^
M869V@+=$\9Q_(*6<BJ)$5T'\;.T5Y;V&-8"ZN=DTVV,A=3%2R:$T-!+=53\3
M.2#(=KNDAO>QIT4%V+K;J:OITBG(J7OG<4"KZN-[..:2G'#$48X/&9,J*Q'P
MH+KM/J$&(>TG4L*PS9!=J1PW!BE-&9PK]H03MS01#J=&WX@D_5W?5$R'#\-(
M0UYT%!""O3,**(>-X9<-7KC-0MGD$1ZX(U<YY?#G39RXJ[=VTT?2,>%MS2*T
M<I5U-`0#NJ!41H01L>N]<(67W"_#WRU37`_6\+%E\)C5[N^U"^W]`D>((J_C
M6GJ^<3VX&1YG1WBM?@%4A/XT/9E=7:V3521!`SH8E06N:2L+)*0)U<#]&P07
M+./:R@+UJ:P^6$MDP:U$K65!Z&>R<'=-B<N$L;TM+FB2R>)]/Q#TO;F/1[8/
MK<2%)HO@HK)*'G%8(;+`Y+:R2AZ!."H+3&XKJ^01$!)9)BAI*ZOD$5B@LB#<
MVLHJ>#0Q^93^&@CZ_FHOCWRLXJ81$5Q45LDC'ZM]P5BELDH>^5A%D]OB*GD$
MJ<1?)GS05E;)(Y\G3,$\06TL>>1]/Q#T_79&Y2/>$(SX5$K)';PC/L*EJHB/
M4BDE:WR4]P6C/)52\L7'MRD8WZF4DBF01RPRX0-QBPJ.^KQW34'O3NUEGG7Y
M@,%Q1@0&/)![L?'@0>DA/F:=;8K"Q1$Q".=F0I*>G<6+-H-[7`M!?'_`851$
MT/WKVK,#.PFC-PTW0A7B>-('@N+^%(:%CW@)!AR*`/HS/)0>GG>O@5]2#_$Q
MC*O,-F**OL"[!^^*:",&6J=H^/C#\D$;,=`Z%<,G59P_B8CY$*PW!4-\+L6A
M6T3$1S=X<99\Y/`>QLFHB*0'9Y-$=A%_?)<R!!WS@'=&%S+X%)$^LC2_C3N;
M?S[`C="Y$W&3&.D[N'05`?[734+<B*V($*RLBPAY=!-XKD3>B3D1"$M(1`B;
M$PL16QE%4,;?[2C`WL)UW:T8K;"HW.H)L__E:WF7//-[@C_;P.Z?+]8#X*BE
ML[(W7O)8?#C1R_=_84]L@6#*OO6#^SE,F(B)7K[_B(_"@5X,E3E(-Q]C>+P*
M_-4VD3O1?[V?#L=W]Y9Q,>I.1Q=FWQE<C`?3NXN!.9O>W5GCKM&=_1=<AK]Q
M<0T_DG#$;TBPW[J`S9X]\SKVX)<FHLS8#/RG\MQ$)P<I?/;\"X`-U<7<B$Y<
M_`;'[?\```#__P,`4$L#!!0`!@`(````(0#VZF[#R5\``'DY`0`4````>&PO
M<VAA<F5D4W1R:6YG<RYX;6SLG>MN'%>VW[\'R#L4!$Y"`4V*W<WKV*.`(BF;
M8YID1,H3(\B'9G>1['&SNZ<ODC6?Y@WR(0&"`R2`G\6/XB?)[[_6WG5OBIKQ
ML0;)`<[Q4%U5N_9>U_^Z[%U?_J<?'T;)NW0V'T[&?WC6WMQZEJ3C_F0P'-_]
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MW#)(?TR^23]4[SN$M`,C[^M1[ZYZ]6@YFS%"\GHX[S/*]VEO)G(FQ[U%?6J1
M3]<?IK6+[:V-;ZJ#9[2Z3&?#B7C[D8&+LWC-V^8K1PQWAH$;[WW]??7I0+(_
MI:/1Q@_CR?MQ<I7VY@C^(#F=SY?IK/K`^:3Z2QCBN\EH.5[T9A\@W`CU6G%;
MI.Z;=#J9+5"ZY&K16]27]7VZ:@0;/CF"&W>368VW5P^]$:]/\O&/)@_3WKAV
M8YCVY?)F-.PGKT>3WF+5E"</#^C<U6+2_R&YNN_-TGERL5R8D6`!U:>.)N/Y
M9#0<,,%!\JHWZHW[*8]A"5:I;5$ON[7A@C@>SN?I8O[[VN7>_#Y9;S]O_/T^
M'0V2X3A)Y_W9Y'VRWJG==K&XAUBSM)\.W_5N1G6B7\[2:6\X2-(?,7+S^O6?
M?_KYI^J[KR<+%"=RVB=>O>=RAM6<8=;,POUE.9Q*(5O)&#+U^EB_Y<@(.$BQ
MI/UA;X'9JXYQ<?WUR9OD\.KJY/JJ1ICC]'8X'B[29#2\32$")OUNR`J3GA&R
M.A:WI^C]`-LO-D]N^:>DLS^9+VJ2>(SPSH?UWWWA3M/F9?L=S=<BP<Z&O9OA
M:+@8IG5VGV,"Y\FT]T',2C;@G)-IVH.6K:0?A,5TJTXP%^&+N+83$XLJ)0[[
MYJ.*;\&<#FKFK>&^TFP:QITM(?`J26(\NS[$&S^DR:+W8[[2ZEAE"2L0K'KC
MV00>7J>SA^21F\Y7$/521*V.6+D9YS20<UKOUG3+)ZD9;'QL!N'6G/'5MUY=
M7QQ]\_7%V?')FZO_F)S\Y[>GU]\GZ\<GKT^/3J^?UX0?FR>39;+\!>(R2][U
M1LLTV=K<VMH"`+2WMEK\I?]/YF[1>LO%_60V_&LZ:"4'K9UNM]4YV$J&<@(#
M4]));O*2WB+!:*4/-QB/""CLIMWJL$\?H&;Y#@<#E&`RQI;(!&U@R/J]Z1#;
M4J6.:QQB@ZVXQTP-WTGC)49F4*JW(VF9?9&9Z`]KIM\98OIR/QD-\&=0'2N%
MP5H/CZSB=\Y$HTAYC)4//^8UD$-LXWVZ&`)(GJ_R(F57LQIT%66CE<M&E4CE
MVVI"\J3;G?E/NK4@7?7["PY5:"$U[#:Y32YP(>89YJN(LNKVU>0YQP%=]1H\
MX1&>`+^0?#69#.;)%5)1G>A7L\E\GISQG^J5,%%LT4GPHS65_2H=LYB1R4QO
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M4YDIN,F%BQVFJ^`(C,0K`F:F?7WR[<GY-8MXG3B>9&V7;TZ^/CF_.OWNQ*>R
MVEJL1V+7N+#N<`X!O)8``M,0P%:B^Q%@8W+]F57SK]W93`.-O,+?K#*0)JQ5
M%@7;;T-5KQ6\\J4"@],QL5BC5RZZV9/>;`R<QDZO\IY-2X_:8TI=G<@KL@9C
M#9H%68Y*LA1'YZ-/M&(X][$G`T&"%PR89CF5F9F,0S))Q+^98!L".M\HH6&S
MSTUF1ECJ`%B6X,L"%FOEX(I,3;>5?"?P5EW-9YZ3!\)/FA0F')I$ISU>@;8M
MA!$U=C>W.[\.-7[E%_]#2XYB40W:_K57_(^\MWG!`0<?#OZ\G"^,J[BOY#4N
M;'B',;`0M&SVLB0:H40M;JB*4,2Q%9VLA0?AOE4Z7+O_>D*TW)_,!@F>67^Z
MU0IPR4SG\F8^'`R5PT)RT.QQ:K`A>3]<W-M3K].;V5+7VQW/HKH!P2?W[\DO
MI,GAW2QU>/J>Q$K*,`W92WGZS63]F>/Z9\]CE)4'3_T0OWEHMIB0$B'X`"/T
M%+K]3ND,!TX-+SA\<<785]E:&'_5'%K).FQ[2&>C#\GE<C'N/21?#T>C>7(T
MF4V?MZJ<^3<*%G/0QL6/4##XE\<)*7=B24(<R+:%Y$*8[>VV_5T6!3S.53HE
M`E+DO1UDL"RLIV2]A@02(;.997LL`T`HOTC6=G+SFJ"Z:_E;U\)K6RC(?(KX
MWRY'HP^;$;;,Z\DQ*<[:[I[%_<V.JBPV_P^MMMD\KEXNJHM5\<R,:W:)G9U?
MC9\[I'8^E1>_[>0^E73[^P>M7?)19?(A^!?]Q01=^/4TH;NSW]K?.[!$-**]
M2N*93W=WR]-J3U?O?])EM`+P?/I"(!)"5F$'TGP^>>>V2;!59<:*)_T[C%/G
MH*-WM3Z5UI]CBG-3ZZ>3<3OD8,MB#1UK**E"QZGE*])D.NJ1AB4[Z-1I-N^=
MF)2M54Q7VZK?>&:K)/`-M7&5YJLD70$2MU?<MPHDUN[_.^+JIV5GMY+'*O/M
M1Z_B\3>3K>`=JBO$`&81;VTY]F3T*]4GT=7-).II]6*65ZGG%`+^7YT4@8@K
M8F)01:%>M3HFSF+AZK3.2\%C>;1_["%RAK40V[P4Z=>^@_M>!NX-CE,!)*4C
M*-5'`7MW3W_<S42$_8L),9JU'&`&I@VEZM,"0"Q9BBIU5M[8M+C5-QM2?/K8
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MKY84!+(ZKC+FI@7K;Z/LY26J7`FJCU45YQ2?-+?R5_Y,K0A'5TH_1<Q-U3XN
MBII:)'6R/LRXKX!<:E/NOZG.\'(YP[',3=P_VI^244%$D/XUK:?ZABH-7@_'
M)!J4,O\X#4*);UQRN)6&D^K[`OG"HQXZB8JU<M9EG@YN"+!6W4Z)9YQ\TH0R
MJC$S-V!0SN0($CZG4ZU.C^J:W'(D*D'H]4WIS>HC>FNN5$#Y8!00"^.(TCOV
MAY`43@[T4%ORRAN5P,E+'YC`2^LDK,[AT>?5=?CXD];S-5A:"Y32I1_4!4F:
MM_J:6!2M_PY065'+O%I.IR,+6LA2'6/`H>V2W"8S.I^,-VSFN72+6$_ADYMK
MV;O;WG"6//1F/\"&@$U4,?YXA?=J^<!CN#:J:*2RAW2&J"<5AR,7([6YI+&O
MC^FO+O?I3R:K8?/5VV^_/7SSO2J15Z=?G9_2VW-X?IT<'AU=O#V_IKB:7%Z<
MT>]S<E5]_?G%]4G23G[YV_],_MY!9FH[?K6<#ZW$+J*_ZLV'5E2])!4H@&L^
M]Y>__8_8\,<C^K]+_C/_JRA-6W/[V8N77_8G([**B,T#_=/VR^PU;<E^RU%O
M-+R9#77?;>]A2.;9GNSH!VNH3OT'.B`F,_WXPMZP>'F-&`)3\MY*^OMDS1"B
M>6P*D;?NCY8#VL>X.W-\6DZ.5\3?V+95Z"F6RIJ+I[$O>4_7#U.C(19KFV.1
MF$GGL6NU(I-K#S$U1"@T8C<DW+UE.5G_Y6__.UY]>W7XR]_^3\OFRL]'CO[M
M)_[Y/HU_+>?QK\ERQI^T`*&**]+VF\^3]SWX-AM2'J475K4,JAYT!%H_)?HA
MTAC%C!`$9.^)/F3;_M@;>W%CWW(W;7`/!8=WZ?VP#RA3F+*<T0[&;S=14-#R
M&UYCHK&XGTV6=UXH*09(D]N6LLS,]XZDM6HI+>@<&8)6Q=%JZ8E`J`*U>5(\
M&.)<5:/0HH0$M>+2,OGMD!S)*+%N]ZUVB>['Z5CF093<5/^J)"L0G[T`=T1R
MAOI$)XE^#S=M@C%(WZ6C26A4?8!8M[W^PFVD)*P_HFFGCS@N9@BEJ<Z4?-`#
M&9JEM6[9(#=#M./.[@-5#Y9]I`UN&E<6.`JOJ"&BV)X^1FN<W"]YUUP4O[.[
M!JFU'-*UW*=M.UD@B&.-^:%&OS=,>`;`.%3UR,-5K7<CN1@GM5(6O6!BKRP>
MK.Y=*9755-A:%UV>K;K\[#G5Z]"PCWPK0XBQ5RNT'BN+1=*;0H(?A^R:2)%3
MJVRQ<-TX;.X[##4[S\IJ*9-;_3>^,#`VL2FB0N5)FN:(42;6<)9VJ.2&.B".
MJC+"+W_[%_6_%H/R;%#/]YCP)$2,8MW$YEQ^FWZ"@._UGYV8@(O-EF&5$"=K
MTRRTXB5KUJ:9QYW9NY'2K!7=EL-`/I^DT$"'4(<?;;7T?_](,YG$9RZF>D-C
M8MD,V#)Q21M13HI)/[O-!%BVL/A2-Y#.G'9K>[O40LID2O=*K$?I'1IAZI$W
MH,W3V;MA'RV+"9QF"MKLD]LE.D:FTQOU8[2_F1PBITC*8@C[`CTK'$A[*&Z!
M+KY\W5PDO%G!(+%1@&1/8MJ':(!UM#>W#_;W:4S(:1,%`5$I+KME]_<@K+K@
M>5E>UO5GK;866O%0[_W65HV,6MB*X4L+&CX\I!2L37UN\5B3]]%(E$G1^ODG
M=XRZW-Y''G>ZA944IV\F;_9.01#+EAY:;9*)RIW.!O8O*XA?A>KXWE:D/UKD
MEEEI+&`2AF=AO-=Z#FE-Q(^86-$`/PE-_4WD#^)04<JB])J'3NY[=$>.)R0I
MD"T@BJR,Z>+//Y77GRF0`4R_6:2PNT*#K_1)CFD`5@2YL'&BV0:)+`%9:`B,
M)M%X.J\87_#`XN7KY=@:")"#+&YXD75*]&.GA'4H>H.8(SO!JM\06?W\$\C1
MW>!M/N-L>HAPY`2>6.XF48\!X%!L#3S_9D;^=.9N]IMOW#I><QG10A8^F$$E
MFQ'V_&1C8Y?NT[>;5YO),>+K,88-&\@:)`L?UH3V-I/J*V["?AO;>1?9!(K!
M@$0JB[-CQ,3>.K"W<H,;$W):[,K:P,%FZI\(-W&#_`;>=H9+'0L#V2V^)^;)
MPR.N,]!%=>PI@_;8\8$T54*NN=?0]#)U@K'>O)<PN2-QYA-3<*HYLLI!W,=B
M$RXTNIO3P^Y-X9/R9;>AAU4_5;OF(9"[V$PU_B5)K?L]S`#<(]A5F\'B'D+V
M9D/Q2PW"T88:$9/;$6AGZ4E#OVX\\<'F3'T\`?5'F-K+6W@G"(D0$JB1O_`(
MF5IE@J2UNXDS_MI]65A@J\WRE?+_W"KM&P2M+:)WT]R5X?/G5M"@3V;QR,C.
MX#I2>3^\NP=!C=A.2DOF@.YH5DC_^%*E09!,R#0-O).I1W0LW,IF!L0`V)ZF
M";!"^T;-8Y/I0#]N"+>4Q!+C0Y*BI&]87Q)1KF_SF.KJY6JJ"0P7(%\$!7D2
MX]YJ0];`=OPAKOR(?(2.[MN4Q81P98Z_1]L>%'6SOJ:])LQ[367A_=;>SH$I
MXQBY;KJWNXK%I(00B>H.M,_)W]*,1'8+-4RM392AB5S=G(*?==2S/09*>?CP
MT/LSO`.PIN\5>TC[;]+%@IU/)@&FF.F/"UDV<6(Y3^GL06!(BDH(P.$Y,<JO
MSOKDX(FUO-[0UH;?4\U#IC0):*YQ4EC:5%&Z&TQ+9TMD4=8^4/2.`9"TT/Q?
MTDLJX)BEB!'P-;)32TF/_&\N9;F.1T>L2+:'^9KU4(K%!F8U14PMEX'YM=4K
M$:R@@P55Z"#:A&S_>\+>>PR7VOK,F-T2?6NZ\^&/E@^C9G.%YISC$I/N\U5B
M1H8L[CPL;OO[/"Y>S=>/;(J$FYX]F4(<=*^L[UDZ11S`SWQDI!I>?)WE:P[S
MC-H5U!GT9H-Y\FK"_]!/1]SV^O#JE84WC3<>L5E?J3E9%K__\.K(;K^>3(F*
MNSLTBS"*-NJ\IYW1E,';RVO,X#&['"I4DD<D("R_+$DHRY,DZ=;#D?<0\(/+
MR28HB%VDHJXY'2F-13XRC0B4OT[1,-G%X!Y-16*'*M.2VE=F2JO-2G$.D\C6
MLIF<WB9L4T21!D3C,_RLK57N.K[?:#4&36/Y'?MZ:BH&:3,..X#GTGT3C^*$
M;7ZK%'NE:@`-AV:@9()LH^09!FF0N*(HG_F9S+'-1<81DVO;A>E/66(-0`[1
M4A*OL[5[X1%#P6)B8*/XB(=`NV'ZGG$LFLH73'OP6-F91'@2V4"EL(C8&O.+
M_>&,+8K8-BRG?AA(+I34A%\2T'YO-OL@3KB3%/G`1C95?/L'BXG@HNJZ@ISL
M%48&2V.Z=2.QS0YQ\E5W2LWUPFRC&6B1F4,^6(6D8C1\,.^]F/P>$YBGQP>A
MOF$3U^1"ZIWT&V:?F64V]8O2<[T!4P,H%I:M.V,R4.DTV6B')$HB*-LVF<V_
MR'<Y&UIWE')+[*M;0YH7T@10C-\@0PD#+&;M`96H.'F2/]S!4SVQATP0.L:$
MB2;)EBQ%WXBL0[P:A]%$<1V5U<GI.B!=F$_KAYQYQC9GD.D9%7%M3?]!B2\#
MMD'Q2&^3J\:^#N<**_F;6GA.;>Z^\=UBFH*\.=>5I&EP:;=I@^(M7KZ)0J$]
MYH8`7<0#YK.:I5;"^G#O<_*V/0=DE,[`Y(KG`/A8KL#:QV11SCWWM8CQW$HI
M#!RR.H8PQ3OE6]1OS"4>0G;OT`]/6?/>3(3,CNE?C[U5J#+%HU3H\NCKI<?)
M,-=/AR=:OY0(:6=CM,JN-A-#IOJ7:]&*^623-IBK">D7JTYE9:GL'O)99FC"
MZHOL?V]*"DGF',4@DB`$4Z_)B$,.K2N!+_SS:)L[@LV`R.CX*J:!J50V\XF1
MI1'@DL\2WB'+[&;.9S*>H!98JIG81"\"!%(*:N!H(?Z@\PD"[,(XA;5Y>(A[
M,4)K;E(95S?%;Z94T!RR,!G6*)'`#!<FUYAH4:);4;ED&UY9S*&AKU1\_DSU
MJD)6)01ME@2Q>GC4VF_3T9%L_.R['ME\E<U8+Z;.<_\8YE@/L$S739J."V8X
M:N-<1QG)4LHB.<FAY!7FJS>5E>G=XO!5\0'(GIX>QO*$Z`.I97<L#Q]3?M&"
M::+FM4C?A%R!F3QRNA-'*8_`PY@F"<H3@T!!R&(*4>)/&E&QJ-*%FM))[+:#
M:`_`$&&DJT7O]I9D8E:'?<6N!'J`U&],"Z-.-`#O-0D!M^2PDV%\[[CJ:8#W
MPU=ZEJ2?\";GB!PENUL[R%!-ELH+#6OZ*Q..RY0W3_"B]VB,%H&!U!DB5C^<
MS>^'4T]53J4'9N"T<`[S65`DIW?='N<GF`5'",1(NMHA!H`'LB+N1N7@9Q:.
M**0#?GCUB)'G*"+OUWNF#"_OD0J\*(I&?\OOTK_<-6NB@H(.VX#S5&;M^`==
M0!A'TCURI=%F>,5$7A$*A$XF-Y`Z,0B0@7\@9:JL"H614-H2>N!U8`*5>N,4
M7U^\\K\UVG1"E"@K%:RI$OID#I`^HY?9H.(:&KR:Y6R^LR,NV)_*LME?FVQ\
M)L4_5?NV51C#)HPDGY.BF^\.KRU:03XZ.[^+U!V.WTT$F`*B0PX""U@-4AQL
M8;P[LR)W=AH!.G*3WO=&2!QXB[6'TSRD52Z\O+0XH.M]%-_@%(*9^H+WS1<<
M7^;P/Y^0!'\FZEHN,7;"81R:7-`2#$5E7JA9[Y9<:[MPD,?2_'0]$(/;2%\H
M)/)[0W;9#,-;2M'C`0A0+PSD\M5A]WR6+LHS<AL$E?)`%KA+>`J^Y$Z8>"PE
MPM+&B?A!1,45>M(Q%_4,W\J(X;_&!L"E-M4FA%4"^B8M%)./,3.AF&SAX6>*
M=++,?V!^3,;(MA5F6RA](T8"!HIG1-CB%9A(_BE:)I@AFID_<4]OTN"/8Q="
MLL'$.X?M(1ED4HOM4/T4P/'$R:A-"22IP^\:ME!(BBR-GM$Z:]DP`W):.X#A
M\V1IKB%K9(>$#55R>D,Q=56AX!XF5MUIYL<\$;*WO55TFN)8<8DB,?H&,`@G
MJLP4QD)I7)@L.>U3HEBNYP835%/52&%B,N#Z9W%JJ^3_3#UTEV"1*Y6A,R:(
MR+]5$U$=E(&U1GT[;`S!":<4O`@MT'AB+SJRO'HZ*X*&#OO`3N+Y!MGR-JV!
MJI^-:=5\V&<%?^NM6#^YO'INX36@#8$-9O0]VZCO@=-)K!:-E[;;$^4J/HX5
M+!S(%.I&5O%FUA2QJ*@-1Y8PC:NJST#..7OW7),JC[K."SWIBB9C4@7Y`2;]
MQ&>.<$Q)?F+H+7$_T/L$UDO3!`O$>\H7)#)JU3+]-TO2-%^;5<8C@<'P&/^[
MP5,;T#,%6/C&U*D#%@NX<\A\!VH2097-R$K&!IG2']F\0;5J91WH&%KZP3!S
MI:,^$Z+X4PR'U<XUH"\?S"XL#D/BL36Y'RH6?O"V]^D`W(]5M29+`U,*NC<4
M=+=BK@8%1HFU?W_#X3_[]X5A<:]?$S;B+P&IJ1,/?ANR!+31.D(%A:1@B`^:
M)^%P4F=RTNN4)]*L2A6>P(@4L"W%?6VXOR7X`4TJ&E2:$EE-^1D97!\^__DG
MT8"HP`&)#!>YC/X(LU7,#0]U)QL2)X.P'B,=70@];7FWB9'A44`=DYRBF%*M
M"DK#A"'.^M!&4FKMQC9);%CB`A,)3,WR`I[;F$UU;)SY+UA4Y(:6$&RL`2&&
M4AIC*%U77C9C9C2YH#<"[T4A^FTPK8N7B$?,LA1N-=RNXF!AX,)L<D9HPZ:!
M9M:LE)R4+*,]&DU4("M_)L"2=%D1)H':AU4`M'A@S'M^]4)(^_?):R42'(QC
MLUYG`.DTKT@^WTR8M$18BO^*4M(/&U=]JLTR0*;$EHGPYCYK<--!N;RJW]-#
M)+*-J18SLD)>HW&,MK2Y60EG^1",@?KRL3-:`ARU_WTW&3&TTE^MC')9+(15
ML_#M5F51*_X_!]6H3JG>8.2CD"CAK64>4P3S?)?YQ2RC8KPH\*%943+_J\54
M<%4A!VAR2T_JGT-N)##$M`0)]52-9"VF%R<<#.D[V+*2`?["B1M(EPN&ZUY4
M!W_.H"_Z#FP69(9"*B7:/T*R-^1F2<_A*,.Y?71]&@LVW,5D;'20'DK6@16P
MC%'IX5&7(BY$IB5/AT./:E)9M;CH9V3[%42K7F?VW7.\ZK%$LU6FULN2G.N;
MRH[TGV`_1465N=S!V139EX2UP0@R=*:]115EV<R-\075+-=+/*)8VF0TGX14
MQN4G4UZ]0"&TBVZD0-#Y>,RS0=4&1W2C!NK?H`^[\.H,/IL-\H2CK;X@Z@5;
M5C9E$>^4PJE2&M,""`3TN/&HR0*2+Y'F">;GGP5ZEL!]P:R$E+N7[H6N<WMA
MN%P(G11Z9EF+-$:J/A(6['>VS#MEL2^6`)6[HW5$N<B@29@1H-5=\.R+>PP:
MSLB-/M%(9MK,@A)KT_BGR$&.DUJ[4"'!-ZVU[R>S'RQ"\$65[6*P)5.6@P/,
MMX)HS89EO:VA*1A104P'0.?UB9*CE'0%N*"REE"-7LVX-(KD_Q:<!>28S'CN
MFX@H>C:<LBPQW;,+3YFI<W.J4-1W@^ABR(Z8\?7T>'@KSMUS![A(K)F2Z*PV
MQ%5,@^LQR8%;&L]O`3:]0K`E/H*KR+<(JM@MH>N*OH[WRO=%DPC<8%,*-%3!
M_I"`CIP+3:@9AY1[4<N/-L0$6UP0,)8(X>;WL<A0*`]GH4%NDP(8:WAUXJLW
M]\RF:(I_HG=QQ5%*P4;,DDT$HKV)ALF,;`9/A#IK-(+(G,@<A5/NNB!LUKNT
M09:K5+ZXY]]JVL<5NE-@-NR'X&1,`Y,RZ09AF*L%'\V2J:FIHS;N;\7N%NS=
M+__KO[L5B;9G\=(!4GLSN<!%S.PX[?BFL*CD+TMB(:(FE4;-J8JEZ)[3,P3Y
M9'S#=@&OFB`LD70`GB^:7]N1Z]6J<#\03+D9:"_2?>2=HF^`UY-\WD&(!Z0#
M^O)TS$%5:/_7%[!UT#R-[B9-7H5Q`J41YJQ4)I<Z9T6"SJZ/49('O44OLBQ@
M(5N!.Q8)AR@#SD>?`CRR&I^.K2^(:,5?+EZ^'5M!R^CR7KV)P=+HJ&-1J*`J
M`0X=>8+/"C:YF<U!DN6U`JA4)("QC'D:5WHE'Y6B+Q^>WH*(VH5JAKWP3#@Q
MT'XI;98%N'D/"'WTME,4.WMGP,U=P!AQ4F+5CP,O;*<PRV4EM)"R->.&:0-%
M0SU6S464?K;8`,@]P`%"+2O"5*AG:.,PK[P$>!NWP"EW\WG2-T;;',3F7,KR
M6:9@F!:<"9T+%&L55'I96;@0CNDD+1!7OCH4DV0N&U:4_@S),#;?4#D3RT2Y
MA]X/>;3E3"B(7M`E#E@/<,]%5R\)W8P(F'DS?[2@URZ*N0^TD('94^5BSHL5
M3\7B+JJ3=2,TDD*`0;)>F9!"IU`%\!F%]*LDQ<QQ_HST+Z:6#M7'JV9H[:%1
MI4)M)'1ER8F%E#MA=1Y;!:$JFE`3K#<@.]96D"\*1V,2GGZH3=AG^7F$['2<
M?$N\KT.,G#>O,[Q5F"\UQ6+_&J;-#TRW1#BB:!<E..1-AT309814:/DJ<`*Z
MYF5L22WF4WQ0QWIE\PB-CO`%0QI+.0\3:G]Z'_C"1D?V:%3(32AA"5!!D;,G
M]*P-_JE:(>N.G[;9*--O;].4\OGF`I5,:#\G'6_5375S>[DSF=PH922I(<4R
ML>B=6B:U7J8:REG8IKA%R'%0$6:%<,K!680.'LVR[LS/1&?A?27<;30Q#Z*<
M#>-FW>F"FYQ^C\36WE^):,4&+3SC;&8FS(LVD3DZ&R>:I;0P]&8.D"N:JL9W
M_!OUE-1;-@U;5:"B+A7:9-1\(U4T-3,2*JWFQBV2&!QX79TH/C<UNR2\<9.=
MG1M$ZW8X(^GUER58$O;R=L1^[PLEKV4I!R$GPQAPZGYXHT:PYG<$>ACF+8@@
M)W9P.'KHYA">I3%(E01#9@7I=`,CQQGV\\"9ZK-FQ\4(6N24N->"?&F:>"%<
MIY_2:G3`]R"A:N(![.CA:#'#_<5F1DM.#3S-2G;+U+;&>._BPNQJLR<K4DL+
M1M_S$A_9I<P&/8=/18.X>.D]JDS5['W1*Q5M8C0Q:+4F936?`=52L(#@E%(6
M^C-,W+2_[,(L16)[`&SNV<S=R!2A3V"#A@W]6DV^I0DQO$G+N=A0=\E6+9/^
M6]5\KJ%2T[PM]!`)@]`UEPV[GE*R<@&L"1EFY`@11OT$+O2GQKFG9HYJNB.-
M=\:&WAALZ,9Z0J-I?@U.<_$2_\ATL1`R"R=QCX#3-0]%FN]ZY.R!RS<7G`//
M-T5T/+P^+W*I4]&KPY[KG(%.X.73'BG-1)#*]S28V29+0-7+<[<>:\FPH9]U
M^FBUU5^[M>-;WGHW_QE?_*E._:QW8SM9PI8*ABN@^>K-:]4?I!34TDA*Q!54
M[SA3RQRXH/!A$;0G[%^HWKS>Z>HXR_WJ[[5SFM:I+;9VN[O5&W7"2(FR*R5A
MH_IH:5]%0'O!';E0KVV9;+&]9F]KUS>S2F;M!)!F%=FV!Y2/,W2267GW$&6#
M4I#>C):*![WMU)M>9%1!EZ$>.B[%.#$Q[466^N)0)!4`)`($Q.`O_^C3H872
MGWC[(_JB+^^<GZ(-9Z>O3Y+3<SY_\-7IJ[,3NLCT-:KRBPSJFNYT@^[$QS<>
M>_PWA[T^Z[)/.GRR-H;D(-1GSPW4IUX0J>\1CW_<"WTGX,K4!""4?;*$:->3
MAS(*4Z3`&N.;W%)L+D.-ISJR">Y:O+36WM]M;;==(-<Z?)IHM[W3))1Q="_)
MQ;8FE?V`03(V85XR4-3$$C)NV7:.&.'D&*(`X\EM%5:DNJL^FY:YFJ<UJ-AY
M%AS%W.KN<P@'LUGK[O,YIKWJ2DYBRW3PSD5B/OIJ+9OL9CG!E;N/[\%]ZJ*1
M.2Y:W;)8VY$L=*BJO;1ZY=R4EF.>E`CAY+`WX=S'2]5&/^GF1Y10*L7W2PZ_
M/Y3F\9*3,S[G<<PO>++:2^2[MH/^E9_D3)N//%LR07C[HA52*!7DUF10QK+@
MS>RW(A$MHLPL9LV'%6^MK8'CD3!JE-^1TE<P20PZFY#HBY2^6HZ)#T"%6:S*
M1XF64TQAOP+3%B_%H^S!;\\2N[/ZRMW?R=&H$5>Y=GLDIIN@P_G9J^/3:ZV(
M%AA-##R/*K:2L[.CZD@[O_/'XU0W$B:;)A<CD#Y=!B.3ML-IQ78N7C[V7/4=
M?IB<9DFC41`^X^YCXF>N^\@VXR\(^6,BK#KV^L%!ZV"G7?MYK\,)#ENUWS6)
M.`?UCB!BQ4G8=J?DFMQ;=<#KDOP047HLY.%N4/0\72=3J6Y\3^-93P6*S8]%
M.3*1JTG:1?$0&*RD,ATFE]_:B3=M/P6(Y,=Q^70,!2C$7`"R;[Y)_&QF?4=N
M?6U[ER/K][>?VR!^L1L...8BQ]"V#_:?,UNJ'=F!#/92B;!ZLFG%9K$9?@!\
M:!/Y)9G/_@3)4)@<HWH_F8D8B`R(&I=\IWI$DP%SV&9"?URC9X?]Y"^U_L(H
MT"Q_T/L`?+>&>>EQ']RG1G.@""3U7Q!S?L0[X7O*9Y(HIQ!I]9:S;PB;\E-V
MC+Y0V9Q+]JG#H,M@7L0<8,]EVKTH(8S#^46=`V=,C0LVD*]--,E;<J`19;?P
M@5MR+[,T1(K<0Z]W6,<*$K#0ZI3M19;A(Y[W+<0L/43117`7D@1*IF@.^=?[
M##I:U,[O)%CQ&9BHD'FPM@+9,[5:*)+:X_";WQFKJ!(QVW#">]+&_6G6GHPK
M-K_%HC&3%XL*2^-E(4L/Y@A?EPPDUQ$O:_O=W=9^=RMO@C,6FRF@`RK+#]G4
M&J9B?*K.S^80!1#UM4YFIB6Y-UIF*X8"MD6)'"\YCOKQ35&6CKV;G$!4:>F@
M?`RV!%F088,;-C8]&+ZER[2FV;B:1M0ON>X]IDK4990^[Y$A$S2_1>;FGB$.
MH2N>:,E"1I8>$[0G1LVV)MS8R6`+>%[,()9G_>AJQ9>"4_5D^N\5(N0GSMM1
M7^VNF:6V'1F/65I?Z^SMMG9WM,VC>'?'OW3M=V]OV0E-F+"];>*R7>Z5FG)_
M9D7]>R]^^X$;M?6U]NY.Z^!@BVZFZ\!@$G'21*HLRAW[C-RHU@0PUWGIAPG\
ML5/4[6\NZU&8,N4+YI]>0.E,T&A1,^0!ZPP&Z\F4%B>%JGVRP0MMEO$#LKPY
M<FV%O3,-R5C4(9ZL+ZNJ(YD<BP>9LB`!LW0RKJ&8.(&G*HG(D--''9"4=X2C
M'M0'9[G/_'+$);^>]$=!B>8/R([:B(=RF/;)%QT6ABBV]SF0JXLWM</MO*Q0
MDL@@P;GPZ<XGB1YO"^[&1"]YHMS!@D;)*\^\60[_F<1OE86NV-.GB=_C*IN;
M:Y`2?#7>BE[K:]U=/C2R*T!DYW1(!.:<C$HX7(0]\HAN85%T`$(H_KJIK;EJ
M;L9)AQJ4Y\G-Z>L$RP4-(IZJGE-TT%E+W.U5#\(7E61P),$IYRZTE,,Q@X[C
M"9Z>YPM'BK@UQ_GK(!9S^>`./MHIW1I/Z&@P[QX0"Y<RTYI]0+@(5C*]-]_K
MO249=.#%AA**B$F*%0UE3(?']FYCN$^Z;C^<@:P8$W_\S?5IPN%6V/]'8&7L
M42!M)<I1PPI-P!Q.QS(I>4ETO%O"MBLY=`RS8VQ]1\`2R$8SU"J;.:$:BY.`
MY&<&KA?J^A0:UO;W38R`V<(T(F]&+'S*KF.GW,[0$!10@M`R74B%]UF#@YZV
MS7XJZ9).\?RR[V94QT*$4,(J6=Y$ICG[=[%X`DUP@)1<HADO>C:]VD2C.9'8
M*<Z-\]QG?+4>0HD<LH5M]*4C)[W?;;6[!\\Y@6$YMZM[^/O=KHQFI[6[O6O'
MGD>B?,+[NXXMHQAE$Q!PR^&LIM-MNRI7>;-C;'LNZ*"U&G\E##7O'PQ^I[O5
MZN[M)=5QMLU:!&"!]A#/FCK'Q$-M/,$.22/)*D4F+'Z2'.RV.OO["F*R32<>
M&I;CN1+.:;N+[H8ZJ@T;<3`MAZAW>YN\5*?M^F'CQ1>$CX/9RDGT$)7X@4&B
MA`YYEJBR;OWSRG;`Q+V^JY0RBLNJ+5WP2WIKZL8?[8)CCY[[YY_$`PE19='B
M8KO5X<ME>YUM)*?3[;3VMP43C;\DW/;:!_R^<]#:WRG$M.WM+F=.R4%WX'7[
M@`>*,:M)VS4KC$*$X$C7^:7&,]-6F[PNQP=P&;ZI(0IPELD+,D.*<VL;D5DC
MM;F_M1UF#*#=WM6$N^0\]XHQ^.Z^?MZ6JRDT=4@-C:XU0UREZHH%BJY8.L0N
MQL]V.E3I.+'W]!21QHWVGP74L951[*(`M:,(NC+^O<+?W6FUMW8+4AH$X.>?
M`E+\^2=O%6@0\1VL2'N_\&R3A$=^A55_JHBSXD.R99Q03$2+\$+U.FT^YH>L
M]2BSD-T]PI$N%K+D,-;V]KJ"'684"PU';$[G23GBBF9(R:<Z"D58TK38P)M.
M@M;V6V&$:!',(/3$WDP*-A,0:X,Q0FH[6]L%FE9?&[UJ`S_:9$$Z6WN%AYL8
M\H^9'/CQ1^4C8V#8Q`[(0J'=+8<^229`)T-`&!@)')7<S[V]33'<D<Y%):_3
MD%&SH+4X)D"]2%[!@[J<6)B5`:JZ`GW$>41GM$6"TTV([(H%'A67`B.VNH]K
M59$U;+30!G#+T-5=10.G,:X[G:U5#P3G\6F,KCD7XS1`*D2C7;/`A\L[^I,2
M58M6*:-Y\V#+H_+7D4$IA-O;:U'JS8TQCL,B`&QWM]OJ;G=7>0^W>BY,)7B'
M.!B>^,?-KK<(/0%:!.F`-#M[.Q+-UGX'!].DY"QJCR,T<GY7E;PH'(VXXY,E
M!HKN_&O;:D]$9OH5`Y9',I$<3ZF277?'+"2@^I8:)6GD'L=8R2:8(1$>=UJ%
M[+5Q-C2*<CR6=F-8F"#+$81>_M:[S+A$/M`09G3`E<^S>.P6)^+^.MYJW+/C
MV)4_#&&?F@AU)%?AF'8?P[,4[NVS*)EZ+O6H#*7<A'J4%A%VV=(F-YRJ18M7
M*,OCWP"W/'1-*P^)7!1]Q%)3U>@]5FI2NBX6!LH169F^P7X$Y<7A0,",!G"C
M8J'USP:2<)AVI.*DF"[W%.%V`?/FU8-BHJZ"?76`_:<+F,<7(E(Q1(O>)S+%
METCM!<C:94>XQ[I:E\,T\8K2]H@..D($'0#;')AMETB3(=08C4Q5U<W-%%31
M*\Z%"B#Y6D?@1J]:VVT?5-#DER\6+XO[*HX\A!FJ;/QJPC.73ZLA/_6Y1\K)
M1Q?GW]$#96T<KR[H@_J4RO).J"RO'.2C16;<4F9A/'',?ZOV,PM)UW*P8.@L
M9BZ,SB$!A$(%]VWDO(&<<]=G^Y/49W928+@//2V$"';@*5N-?HB=`@K@Q%FO
M>WG+;=`IU:TP;FZ:5KPD)'H]=Z5Q;!KD(!3A##VU57(*T=!F097/&_="&@/9
M#R%5+GE>N<M'JSPH&8PR6U651):U2"X+H:._"F<CE!(YJH%A=V(#:2P2K1UL
M[NQ;9JKX<,W>7;-^?YW\PHO>X,_@#]MED.V]ULY5&3;?40QORAM5$(&M+?#2
MSAX[J2-KRGNI"3#ZNN)=X?E=%C>$_=$ZYP/(3W'GQG9RBTCF'6Z&MYP;;<9;
MOWEF"-P4.QN9$/9SD&;;U@L==9"9$I!<"WCU1F8T[[$IK&+=;,1NR'/P!C^X
MSR0Z"H@[$^N_A.TZ>LQ'U75D`&_%Y!ZE9$PZ%+DK2;(GBS/KV<X@2\B'V%`.
MPOMY_*71L&8Q.7;4/GJ33Z!D9K,HF\<S[0YB[<!3"8QRVBF;4>UE,J8[6QT"
M_1V;NU7<.WL5FYKW[$G&2]5K]:)[O2'W'S7)+!FBD`[R&1:,3I66&/AJA56S
M;3.YW9"A$</X4CP0D0BB(#8Q)OW0""G;E.1V]HK!>-4F1C53^NF3X6.'GH5=
MR)E#UN)P47*.;-/$AX)K_Z1TEG2]J'+6"XQB9'LMS:I&0U+0CV!<<^&*!S/$
MB579X"14UYD=I?DN.^A`#^SN_([=NO&:->GI!>\G?DRQU0.*8`!7K7/LY+GL
M,(1,'F7J+)S;W&XSI!20,YH&Y/H'X(?DPS`=Q1-5\J:RX]Q0G`U[-RI5TSI5
M]?_-=SWBM8]/WIQ^=WA]^IUZ,0]?G9Z=7J_Z0MJNCG!)GO:`6!:Y/IBP6KD;
M^%84W%#YQNT5+1]\_=7.7)'*Q%FHF$Y*5>5E.;Q_.WOE,YV]DDNT9*2NK,&2
MN-\+2,QRA`4M#GIM3DA!2&;RY6^*(I;91I"\^B\D$'T_RR/$;(4)E$?1QSG4
M@H2ELIV0>A0;[99,H("*8#CXB^GDM47#3(V1`F=_5^($OB_.$"J;4\<(B9.B
MS&8STF3,8JS1!;8?.LRWR5]W"`U*^7.U/F6>LIS)^N=W/Z+W;^)1SM1"53.>
M_NLCQO+LY/!JQ><C]T(`TW2+-;!?>/49P2F^O*E)?4N?;;33;"6OO^I'(,,D
MKPMVT79&DPCI$1OU[&CO@%;U;3UU[LVG?*DB['8,8LXB[#$OQ=IV[%#PXN1=
MX54[@-?*NJ9V70^/Y00H\&91A8^A8V84(?&)0\70(.20Z3"!5[;8O@!62<LG
M:P>[>PHA,F&/T4[3IR38'*;MJ/H282?TP9DMB,ZAY!A8PLIUVCR]3AT($Y+[
M,2ZR6-X#..,SI/C8\E;40M5\WR'!&<KV%J%X;9L<._GR&D&ZK4YGQVJG?UQ"
MQ=`]Y7.)I#;NX`3CAX+(VH2S"HIV!U[HGQS0/^!,9:MRA$X$_>P')%1X:NG0
M2,X[?5C,ZAK6MA!>%V.LBN@H9,TZ,0)W=O1^Z[R$KNAJ?#2^((MP?"Q&4&M6
MD("=&B0_LXY)03=M)L`!Q$^GY&;;DEEK%#'9)^#!`56)/8(%X[B6_5@L0@U*
M6J/4=]D<5_'9:>&,S$<,S>GYT<6W)\GUX7]986[V@R8_=N-U0<OEN4@<N)XA
M49]X#F:KN,=<JEI<QQ=!]PM[>7/8A1\G+A6RE4`0*W,Z3*I/1_DYNW9,)N-E
MCEI;Q$"$/"::9V@[-&[K;-X;3K:_I4&"IR)'A0?H*L:`S8I[M7U'O0Z`UA'/
M?NK+S63R@_'*COG--XF*?3JIN_>.3XG9KHN"#;"/5Z,3O#UT9]CY^1(-/OX:
MLT)Y+YH&TQ<*:?=2[*Z#H4O9GK`$N*%V.BVT3I4JJ_05*OM2GK9[<4J\,HTZ
MQQJ4(IO3RH,K39.OTAIJ\8V]I0#93^7PKT*2<]872>8NOJ[8@=3DLI$7?])'
M,7OL@3WV78`>2Y_%8/6(Y=`-.!VW#G%B.Z?6&Q59.1I)18781MY(7<5>I9*L
MOEW5I8M'!6H)(Q&MOINH=6=$\GD.?!<R<D(RI686B@IR.]2I%6&D7$'@WF(Y
M&P<",7,DA$17ON$_/\T_'"EGHLM,TA_Y/+-_VM=9Z?:#E!(S1KP[6U1D-7L&
MY3"1PAK"*QNGFXMY0;AA4B:9`&"$KRR>?&@.>VP;6X)>Y;W`=<%+UJ,R$E]2
M>VMPL9FQJVV*H"5%.SGAV#53LKU?IG'QLP:&*%X/?T3_?5=;U4`^:8!+]`KA
MK#ZK;9T7.<R2UA[I2R]!D*JWZXQ%5\M#'52D<E'UEG621?3K[._4]IJNTTW%
M%6KRU6=\$\UQ-'.BPZ&9N?5"W%[;JGI*CQ36J'BZ_Y3B2?BN83#?<H/Q**>2
M3LLF%%.&"ASLHQO&J>P(!1FX@FSG)R;`:<<)<?1HM!5/D>'88*_QU)50QPX@
M1;_=&[1HR71^S)2D/3.ANE006'P1#3,--E</83_)FH`6(%>V>%^XG^!@R^0B
M"\P,FT9$1QT2E49Y2%,\*M=`KC-MV]3G:#A5MS?>&&,="5AIY-/KI.:!8/9O
MS5F/:6,.?S:^5=>#1V$V(0<</Z1"]&+]];JI<(P#GO;&4T,JQJ&Y-)K8IUQV
MV!)B".W_+Q]E#HIC=8:<4+TH,]6M)$A_#%2&NEF58!,HF9U8%'\5ER$GJ`/A
M$+,1N?*WA^RZV!$]6_8Y,/<52K0/A&WX0PX/5@%B3-*4%M.3=5/,QYILGOKB
M;C@T$T]=.-M5&7TS7`9?LW2!Y(U+32/6O,JA22;'-J%$)IS8[H*-B!"+U6N.
MM_Z=24M^+"U:M+H-$KKZF4`1PQWY&2KV'-0D9>/>B#\_R=5H6#N@6Q:61T]B
M9O:*Q(S/[0W4KIKG]?U=]CCO=FN_[]&VMK_?J?ZN3QZ_O2H"7EP7$[73FO!"
MB5Y2=T4\=<Q&EKZ.VW,<"P]KM^4N*.-D]?VG6<3@7ZV<UU9T+2,`,>S+M.9[
M&WBQ'@SF<\><V!U.QK+NYT(,%.#(XZ%.YOQEX.RL2DR15_8R6%'#!7%_J'@E
M1D&,ZD(#`LK76[UAO4T_T$[WH/I[YFKS1^,[DO57'BW4_&T#SGBET*!TOH,#
M%?/>-=8]:8`50&6]S8ZIG?V=ZDH^`F!J<UC?(?_7W6L`)P?THNW7?C\JI3Z?
M('P-6&85]R+>J<O>BUSV2%7:B6>@8,YLU"=ML@C(.T4(_21+63#G!SR%L]'*
MD9Q<L:QC7D;(,[(^B9JM.VOX@D*>CRY??20Z/[NX8M_\R9ODZNO#-R<U)FJG
M_$%,!SYZJS0WTQGM1E._C3[F)E/KKAJ@$H[9E(ISG+AR;UH&.->K;D8$/1`/
M<;)-H@KP(\QXY),((=L.S:?4@FV'"\2N?(C`&M,_S3;4#(!$>UT4KFDB&+N[
MMX7I[58IR96.3G'8K>T._]-3/_(0B:?#4OOECTG8TJNO//&S!Z%'1@7;_F'%
M-LY\]Q[]4/H7?8G_]7F$FFH^>88:I$[[ZKQ@?G$30N'3%7&%V7QC3)]+2'6P
MUQYU/M',EP.-_\O>N>[&<5QY_%4:AHS0`$63EBA;R:X`BJ1L)A1%<"@'V"`?
MAC,C:I(1AYB+90'[&/L`?H)]"#_9_O[G5%575W</*3NVL(O]DEB<[NI3ITZ=
M^\4,]GDH84+89)"@!,1)V9)'!F^[IJ%U*0=ZQC/X_K"TGDSM%A?9,\L_A&<\
M0>IO!Y1F:=+`W\M=#BY?'?[ENU>G!"P'O$-3IIZN%GN[X;+F;RBMINL=\^4?
M^NX,*O_LI_?C*[ZY%Y*JY1T.DYG4LJV^Y`%P)^,'NY2*[^Z9.WZ#KP9EU_)9
MGB)[<3$_3>G%(3@G`L[(()PO"$GM?@UG@T;)2G6@(BY%#CX)_KYL?;71_OTW
MC,!<A!S1@Q$)/FZ-MF!);>A_0SA^_NFA0H7)\:XL&MS7.+)Q*):>"$D7!0V"
M<RG:M:9K#HMBI/IDO4G%9WT'_QFQC?<8P-8B0OY@R;P:*VVO']3]>=0TNVD/
MO]?M5&/)C,"5&3I_H_]%M3RBE`;ESN;*I>X93=!LJIRHF9NDIN=253`-1[2#
MD'LN7\%L&=RNTO^U`SE6MK0!YM.=VY^M8096@Y1DQE^8995"T,WODE0BITIV
MAX)@1PJQ>(./%G"8V8>1;WI=J"_;>8SF]_BK[-;'ER@R-\#S1>FR3"FKM3>N
M'A@_J.5&VM)AQN\,2V9@0B?7W&(:*EN>JD7I+#"UM'0_BUR%]A%[WU#BL?\H
M@RE?4KBF7RDTH'5UM-Y(OX,2!P&57^]&2F!S<OZR'J>@9D(TUTV:SX%ZN\NQ
M"RI1X^>AH9S^&9$2:`(IYR&'XN\.LHLGB@C?*D_'FT7*^M'YA_>:9VH0C,7A
MR#8)/6V;?-+VFOGUHN>ZZ)@*#NZFH&IK[PN[/TM&P.00XV8([F819PEBJJ/U
M<*V*1$.)M9^@T)139>/,4@<9[I4NS=97#L*5YM#KS;J`5S]32SQ">U6F=.U>
M:1^#$33.?LVT%$]0YW\H0U=2.[`A]W9ZUDM=U<'W65S=%6K/0ZHX@^P8V92\
M'OJ`(3#4(?L9A@_E)*/E&HB]3W5F2R`VL'D2B-Y:'7TB@?#J1L5]1;2&;'WA
MQ:^7@FO>/^7GGXC!H#W8?>^@T:$0Q.0O<0;B?;):..PV>8UR_H9;1;'W^`(K
MD'C`:P_V84PU6^K0,%;/LHP;!5I(]1I#/^WM2$45?]&];6S-.&/ZMA>2JQXZ
M;E*A@,;M(-)>\.=[PF\2MDY\+KL@90":&+IF'`C.,DO%2"E'-37C7H[%5TF$
MYR<&18_5&.-I0W<K01?CO:;%L'4H=I^Q(1Y/&=XRZG5AHN*BX2Q]"*6>V-M_
M@H&VV]+JT2T2\NLTI,!<LR+2P!S;::IRCC:HH[?<M)TQU+A:0"E\N%BNHZ0;
M[ZR.*-;;\/Z0?<:..&+'E/FL4DW`=IVFJT?+-%[Q)WU_0?,/4E2Y""F)E\?'
M=59G#&(080R2"@).*H-_-1\N)O+3PLJ"^SCT!Y'W\T\!^:'0O6;Z]\=]NYK]
M7XW[!T\I-'STS1-M]P8?A8J_PKP&,!O3;EIHCP\A06)MQ\<AJ8-&Z2BSNY]7
M[M\?3U]16_S-DUX%*!SEKZ%1*/1KW"A?4\[PBS'5KHQ%G;H=F"`\\(*ZZOF4
M0T!=/;%1'#1L+=!JQM[W)'K15.\3";+O8'EJ(Q*P"D7>HJ"W5-]*D7SYO&P(
M(82BSBL_J"1"W-!T<KL2WER7Q3R^HGRE,%R)XGR<<.LKYF,$;87@C!;@83-!
M@MZ8J\*ZLN0TN47`<TE-\AR,L6<L>)-QK`KK(R(]*/9\M0^DC-3.E<*)M#2.
MHY!AOMPXVOLW-#I_Z<$$K4,][@BG,*Y45=$Q7QX5D*->+[J40_<NVT1TM'O]
MOXJVQNI#SMFCV^JD-.V:!$@,&9MK$A.`^K!XRBQ%1GV90+ZPF?6?BLY/O`K%
M,G6T$5FALQHZ.@K#X.=RYD*RD/1[S2#B6J+<Z.DWRGTN;PE4:.T;<^E'))'G
MA6(UR'25.THK+"YW$$83B2=%XKV7SN*B5\V+Y]<LGBZR5RL`_&HQ9>BL0>^[
M"V#4LA1120R^XZA6SR2(ICXKR!C8H86\B,:.@-DY4^W[W_CPAE``:7HO3R[5
M['U@O=^I7[P\.?OV^.RPKXIB;R]X&S_BU=J!%CI]BT&I>ABM0#:HM`K#83B$
M;#X"K]JD@&D^WO`WO.)4NW1\_??P:'$;0,<=OI8Z8SG-WLT1)SI'1QWGSB+W
M>,L31&*)*G16C,A%->,(>EP!T2&CU6QUDFN`KO2J_9:^#.Z/`M?0?*2/@9PR
M\9):MD*$/H&K6U>Z/U2'F!4GPR[>JQT0></&A#=]1$3JVQ<B,J:@8@QX2L$$
M(I-WTZOM,1KEIF)S01;']G*)+='0#U48LV?BU0XTE_\1@BG'EOIN.,JHHK0J
M26&3[2./M1_#*;'FD?G?/,.F`+S^4IB[P]O(JZ!YRSC(/2R!]8E23&?1Q>Z(
M;W8Q/.,1AS-,##+.JTN-5:E=L9]$$8,58`6F_J[N7\[IP#0R]=:;CJ=D[M;E
MVE''I)4<`YJN17`V&1,[&.<>9S^B9YP7+$@X)"/I]0T.)B8P0[#?,2['7,$G
M%X>'`_EE!_@6*`&`6<[Q8=+O_&1P:<5Y9R;+0=<)$Y:GI(ZX`G@H)^2BNL`W
MJ<*![>J?-SXISX^^7JW^%I!].[F9#ZEA7=#)?D9E#Y0RF%\M)@NF"(MDOF/(
M2;P.+VGTIL-Z18K';'[]@>E0<J;AFA!M=7P`/5(&.M%MYE7.,%(U#4\3[;AI
MX480C!S3!$)A'Z;[J-Q"-6]HH^LQ@R,O6;B).S>@+`]I6)T31&+NP\D)N4K_
M6--`@\F6>E&+!\9@9_8#!*IB)LCU%N3QB=!?C6S8B54QDN=-)W.MM@7JSXZ/
MS&U,@/Z:];\7#"11D1PS\U(11H3SV.'%H;O-!2;;)$6`%HBA8:YPXL!X?AZY
MD4K?]-0IW"%@DI[#!:`O)S,_QN^'HY__VS[R\O![@P78$SA\N-X(3GVL!_`7
M=V#%FWU-K5DCS"@CYS!H&RQ=\GH57JL[(/3+D?3>7_)%A,WJ3#&'UV#O?#&_
M9@SL)[F_(41T+S>.41DXL\I**-=Z-%HYOEW.(;TS5C#FP-928('#D&-F=3-9
MV*$HFK"0CLI][\-%M75^]IHT)FA>-('FEJP[E@O%179/#'4N:RR]*M)P\G]P
M.6VPK,#0>D,+B=M5BJ>):WV7\(C1.]G0,L2<+R3"CR7L`B;;3ZIRRO[&RCC0
M4*`10XO9^+VJ(DA`U%522W1`>`>-J%K"4,"$19QN?%*J'JC17&`1)D$%]27`
M%2*@$R"&:2M+5G<2KH9YFP(5+_WRY\`H^:Y2=OL_R6I?1CM!(BF*9P@9T4:Q
MC%`"`.I%PQP#E1RJ=::1^S;I*()L.EJZ!7O+&^^&(W9Q324%/-0PT:@/LO6Q
M,.P`<Y`(N\T_#&?P;]BZ6/Z:_J`\IEE1_I_UU%OZ7'E*/8]JC>50@1[V0>U%
MFK*7Z)#)\A2`P@EO(3>F'NOCL0S*P$A/NCA1E27=[*MF"[X.0\/D[HOY'!$%
MYHX6Z^OJ8$SF?^VUW7IQ=/!%]:F,Q$O($@!08*A_9NP\*7LJ!DB'&1,%A'.$
M9W4UG8<3G&!Z.=<*\V*VQNS.S3^>TK'G/Q/.);2SIF\I-"7ZA9))[9A3W"?,
M\"_:,:V)N=@_=5MX-)2Q2Y*X?Y>_@_2@'M;K:5[>`>:MA@?R;:VFY$KQ&_?T
MZR:0"J.%WJYY3RJ67#/_0,J(?O"CS&DUP762R`2ZD"[OQ8M,GV-\H:FU`DSX
MLML$M&H%H`7B%Y.HT::6PS=TGB>&BN?<',*K^8]<37!IO^I^NZ>>ZZ=%K8P%
MP96XET#F;A7;8KY#JK/A-SL6Q<!H&3\9?Q%!9W_ZB=78F%P8+%2?\"UW-&J#
M<<\"*OVQUA[0H:P5KS!:(V%YRY^9^ZR3]"L="2)R<42TF#!,E*MG.P[;$0X#
MOCBVJ)E+^+L2%-&P).:`DE%_4SA"NR%J['*])H!`4,81H4LJJG@K'8L_77_2
M*BEX9<;9")A<2(PT2GSY`5Y*/@,`>]0Y`SGX&_C+8GAK>Y:M)ZK+_Q0^!C7C
M2<H(3?HJ!B)2@ID,?LNT(`:3/J$-UMSI1<BF%OM`^Q7OT!$=SI?O)MP]A;+A
MJ7P"*AUS!9(:T$RM.0^7(?ID/E2?RL%WR18QPEU/#QC2[A7$E=X3Z3XA-F'1
M)"-G0;XY-U$\`D)0#:C0J#8:$'>]/W!2GH?L"'0Q?:2F&HVH#OJT[CM7WQ`,
MW>@P=+?MJ.1BLNN3)H!JEI:&\L)6)LO)Q+R.HZ'(F\9RB/#L7FO/@;[8I[H]
ML;P/::W5(':N4K\NW*1OLN'QY!W$8U,W10BJ"/`Q4@(W?L16DJ^O3AO,,`.R
M=%?L(;-BA3T3_M`I5"FS&S7=F(G0M5V1<2H^HIL2<!6_%/DPZ^CBO5G+Y@A[
MTT=L_20XDU,Z5!"*-VA%>RKNC8MA#KWL+?O*,!1'X-V%)H@PN!44(1E:!P3*
M)OC)LU1QX4ZYP&:_"!:Q(1GM72B.Y.<Z4%Q3.L!PMO2YMD9VSE'2)P)Q9G07
M/LIEAA3<=ZH84*1BF)V`B+B2JB$S'$2,T%)I5$]]$->?7@YBY.H$-7T'C1`7
MA##S(W;B\R``Y(RFHG6:I"<5*7O'X]=>_08U]_&*8^"8>R/!@YB"M_RD_"(>
MAPA>R!PDAP`Z"ZJ*Q@4%B!M$0SL/F`9<I>7#[ML[WC")?O<`?R(OY<.&(HR.
MT@Y1()CGM!24,54AV0&9<B-%)XQW#3/E$NQ`>@K7LRW7JP*%PBU_(,'>%)X/
MMQB<2H/[ZUN*7%G$KEAZ2]1IA*B;(U(4[R6N9-8;ZZSE!M$/4G1@K7&:>VKK
M`\O6=>T<B:N@`1S4DOY9*ZLUX;.U9RL6YG6<'*D=4U21/%6R=MMG/VUPTA^=
M#,Y?#6AL].K,)6B]P)F2]??B3-8-#[[JRF>(SM+G(29J_BH9(-`Q][$ZPJ"3
M'C#@>(:W*AN3E')O5S1&LQ_/5Y.=ZG0UWO&F`P_V`NK$WJ`%N+98A=B)50`X
MY4B.1?4+6T^'&`I[Q!QJA#=Y7TCCUIL(/KQ'B7%$$:U\F^D<K?)6$M"4-+ZM
M->_KG:RQ?-$8W7:)SK>4(P0V59Y'_Y,;SK<QN+"ZO#@X&QP<ZK0'Y?)^W'&,
M:/_'RO?NF5UD%]3['V><63%F%!G=9X14O)8WB!F0&W(9S-HP9WETT7-;\C6V
M!I/0$O1Q;'!2XQ?B_$V;FV2`20_KANMKVA#>$T\-I1P<D%&I-4V6@R<WT:U/
M.'V1E,P.A98=`)AAL?]5X!<U)NX)0'900_5*@!7)]>+R&AF=@AS95DW`'KXE
M9LJ=CFCH2$B$(\L%2E6R\>RH>TA!R59KX:J_=ZP$HW46R5X'5Z$CI']%/)A0
MC\!ZP-"*[?W'3VR/=#2AC[+:F`13%N-_AB/X?GAZ9!`;;E"$K8O`@\>T,-][
M(G[4W)\9>LE7&)OQ-$]:7(?,P$#S`2&V?&0M:9P376])N'OT30O4N_'DW[1E
M;2RRQ_?UA<4:/0NUZ6I""U2D49.4>0+NV0@@>J%$3'MS"0O8P7$A[S/AYQ5F
M-NF-625,5,>MK/[YT+Q@(7*;P$`Q;F$KD:577"C%DHS\I[M/_2SY[WW2^)I'
M6;(JJ4]>+%P=JX7'7;\O-S#6P>OG`XI@B&Y7Q]_SO^5:SD[C5-B[GK[DB@=E
MS^Y2IDM0_#>=:)Y"TG6Q2!15B,Y59V^A2UJ[P4]B@&J5S%W9;]!="BP=A?Q_
MW:B+N:(SU?%.]=?Y[(WE(]1,F@N>M.,\8S0XJ5X2W?&W1HIQF-F`677X=CIY
MD\V.?>7JJ>@L:@H1@CI_$U,VT"$Y)5S@Z`A3!0).8=)Q043OTBB0$W2+:V"(
M]0<)<(^EG*SD"1OY?%98&_H('BJ<Q@);YEF]&3/$@@*!1Z7(O=ZPNYPQQ1/#
MM2PY[PT07)?P[]E7,&M1-%2]KKNC]VWW+0O4V[+(+#CP#LD7$_0HN\0OY"W?
MVWWXEZ2Q;$K\3>@Q[<.A.C<-)Z"I';,15/(1IP-*F+7K2-B<]GV9>R;Z>-)C
M@0A?O*H&[O_(B"KV(RH)0Z293H0,'CLGIY&Z5L>;!3)V1R`2.'-:[#+M+*IB
M&/><&?%MI[UTM6*`-G;/2JM>QKY=T.01<-2("L.<MFM(16/0:4JE0SQIR&VU
M-?W".A&@:"J8%UD_4)01LA:V^S>%3T<S>]U%*W-F?6,Z!$O:D-(@#)?"O[<7
MUN+E=OX$<()N14CC!J>S#QO!WK$98K)F?IR^6[\SD4KBY^ZNO:`WE'*[-F\'
M?")TU(#E8J!Q9QZ$=FY-ZH:.34@T)(YQP5])U]XA8FOZ@^!B"P;NWKY*^RQC
M_JTL,#G'A2?NMDPQ05*K)4T>(*=(T&!$*Z5`%"+#7D2IP:TA%U]3F-K6`M.Q
MV^(<`)^FOQWBQ5J.-!CB!6IF:P_&;`J)"@TS8.T_18@"QW(@%LAR2L)P7ZW=
M`Q!V)X,K[2XI8V8LO61SWH5J/Y%&B_Q1=G$0HY[+4T:?7>L&QH08OFH.+8Y<
M#;B6(Y+3X*&D(?P0W-H-9M%/OA[>R/GLM2(OZ/!1K!CV3!N6C?1V>NNDKGWG
MWI*2=^A6`7J2H4'EJZ6H%BBO@:<F==SH"*#Y,X50+#^.B+`XESO+.`@0M53Q
MDS;U-#=(3R@4;CQA6G>#="FVR71T)>H>3:X1E8*HLUKH_NMEE4&L!AF[KA$*
M(O?5$CM%D6+@(K+ZL'<[KPY3H,',PZ'6)4>;=YT=-FD?=PKQ)8JR822$SAI8
M"9I$36!U&42MB+CZ\:9Z"RN'<E)E5).1M<1GU[EOY.U#:#A$"$!V+;2:PD[;
M/R9:CIL`PI/X$<Z%T(V2,Z(A2D;#2?V-6@!+F"&_XO,F(KGO[FSD6O.Q@NX"
M%X4KXI97LW'7#A`^5AM#DM!L*@X1H\K8L3"F4&ID*H[S!W:VF&B2\R5;[(4O
MLCQ=7BEI#4"C=*5=A,M5$&F-4MU:#H4\`&,=51&#YN,V&6E_D87KOIR9!I5=
M:;*!4@T4\&8ISV[GD!A8#<+Q6<4H:AI3(77=?B1:1ZZ!(C9@3(?64?\GZ)KU
MLTAPY*>:02H(9[>*8"*'W$E-@3EI&^+!ON>NP^M00$#UNRO.(;DSQ2$%,<.$
MU)G'*YFTS:@U<,`FN.2OZ91_B#($*M;+R*2M0!KCI04%8L!%$S>AI"$7^D\<
MAAG'9":+!0+QDF6%[X=UP:9ND'*CY<YMJ2![NY\;'PLT8XQ'NC'''N@%3&*'
M*Q<`.I!]+`_+U?"&UIC`OT:"$BH#/U36<A>D/EAL)=2HM@XII%84AZPU$]VV
M$R[\JIEUTX,WUE-I[T`TKHQ;O\>:_T1@M`6$KA.03JZI';T.`CHTZH``=0Y)
M,3?*U5_Z#T/2#V<K7_7K6HV],,-0@`'B5VH4PCJVH`+!T@(]/9@]\04Z.THM
MIJ4C7<94/OF&RR_"X7T!D!98$;D/.A3SC&)DYFY`R:5].R7LI8_+6$(A01/_
M\>WT2D:3?<7XN:RF%LH&ZW>68P=^!EG8^L!I0&@\G\^P%L'X5ORO5O^6YY%[
MZ!(]I\^*"=%S]QI;L*]T&[P@I"#O+PKSH=FE).Y]6;W@[``BF*K\R>S'6<<*
MGG+S"Q=10GS(B?^(K/1+:D>6U1E,[V+.S5>'[C?T]^1&D<WQ[Y_MZ0]?6J+]
MZEG([[\4/=9`NC)L*8KQGN1A`[!F!.DD_Y<%*HXG1<+7W?#2>KF^@5#G3'5(
M:6ERCMY.7N\,T`64(.N*OY8-%S<0&'[".O3"/2<3`B*%6Y2?N'+7%5G<=#J,
MK`$^!*W%PX'@S*UM7QW;5WF`^Z&OFGW]4+9^RC&GR`-$BE2<$>/F68N)9?SW
MOLL3'%PHG[18^[9NFSG&L``_@L53Q=3APCXF?RK[E8?"*<Q"*PZ8@BN"D5VF
MEGP&\"C68-DE4WI::+HFO'KS7/V)-/N0984D41\F6$%>#08_5I=CLH0"!!X+
M:4-@DA_6I_-2]D!CH]6;V9I,*[L>,8J8!58`_88\8*K;[81@]XE*'%(6=Q6@
MBT:U]Y"'8V)0&$R$8KOE;,.G)<F#Q`P,AON5$E2HPQG"PX4_^X]C-LZ5$;TU
MV8)=ZO,X/EO/Z]%;4:8_^+M=W`80.B@#PNC!<,#IKTQO(*=0;G>:?&+$<`;(
MNW?#?_"_L/C)>U(+;-OHJU(`M&,HD5>SH>]D$2BI8H:.:UP3<Q7$AO2QYJ=#
M:Q/E/85>SU=HD>1FR4=HAQ2,WDZH+$_.-!9A%M9AI5\ZYI$E>&)9:QJ]5`(S
MQ]*)(B(AZ-@W`RXE"K>VB]IN!QN)O(;]H)E`-8NABN3HCHK1YMF;EF<HDE(J
MGJQ5,C8+1.A7K^T*\@W2YJK;-;"Y:H"[G/X8KG4=''L4@V--&CQ!F-]<6X;>
M@56,==!>SS._&]G1QM"M"DOAY<`BQ`$/X3[B0UNUN'7-FW4JR3[I7:FEIKZ`
M4U!5@$3.A/\`$,;J;^ZEE<SJQ=?XXF#PW+R*G0\>SNE+'7)\_/F#@27U5Y?S
M6[P_CY@W*H_EMV2\F<TE<G372@O_?,4N$!XVY)SE^T$58?M-ZN(&W8NZ\/-+
M%WP/`C\X[>P@4Y?<S$CP8M;1\Z([X9^3B8(B%#F>KHUW&C*P9$,4D&XB\0!$
MV@L>&%JNKN1"34V'@Z=+P3*=MKN,;MPGY;5#[ER.(=.Z(K(-L/$JEV?MR][)
MLD](J2?,J0^#+MPMUP]/85%C;V3=Q;CO>(,C_Z_?B8M7/[Z;_=%FEOS[9W`N
M<UQ]]LPW(3XKV:V:49KY*5T,Z169+FF\1.J4<0E-9LR7?T6B$\-,L2I=-1*'
M(Z;4>%IY=%3`Z'[*^@'=<"VS"T?3!=H#\@/E7W\8BYI0HR00Q.RL8[OX>=ZA
MV4%%J*1!D[!BD99,5RBWL6;(&+:T18S#ZVM`41#)3/7`/+:Q]2%5=B%:FDTI
MD`4AJ_D?K<PJIJV.R>YWF]Z-&`!8_!,%$!,=RT47*'+G/S7>B_EIV;;U9'(O
MD'HL;B_,>.R8."J.1+H<NV["%TQC!!FH#&\(#NG1D)H":H)BA@2Z,LLLE);@
ML&(5\UR$)W@+9SCV!`L9"0=?IO`;M;N.'AL(H6)WHH0(FZ3C"&59)G,Z-J,E
MOYV=;:&OT)N4$`1$).<HM97_IKRPMK8P(:XF@M6P*EV9WV6[=0C'-]$_TI1N
M%Z(XM.@+B(/D8\^O9"$,YW:E\_>436$*C\=`0C?>IB!</;O@QMB<'&W]B(5G
M<U=_Q":;#P/$ZME):D\</_7+!.8A=O/58EH:5E_I#\N1QB"YI85*.U_T6%N'
MJ"8*<P0?AFMD4/Y'#CO)1:#N>+Y%V4CP:=,#C3^FH2=HTTX,0EQ,``"66]B+
MVKMII0"8R%#_S$'KX,.&WU/UY#GG*@_0TT+/Y$^/X=%P-K+!U)!I&"'RY99N
MUA<6=%H*5DE2;3@?:2#EH4(C8,K7;G4<WJRWMV/^@U%:TQ;C^*P%GJVY=7P^
M(-+%ZJB2NDMNPVSH<)N_#E/.LC2"=6C>3F<\V,WJ?<NZ<5=M"!K?MHTV5]WB
M@ZX@(UKPK'%TTGI'E4,.<:0<9JY^ZMK:`','OXO$OO2QQ@\B&15')*/,WB_A
M=?3',Q*_"J_Q_XPGF#P$GRKY\N:LP4=F+*VN5DZ%&<@+^ZL$AE=,_SA9C+!)
MN\H12-:$@]/W2P9-![?(?I5*\(ER</^:#W`9NU]/O)^S"K!GAHURLQ?K8+[]
M"V=3OI^$].8\.7#DF;;!F5!;5SD0)I-"!"738M2:(X(M-4)MB:_=L>/1PS07
MV4Y:9#SQBCAB]#__I..E(PBW5=1DWHDTJ=CU7M1YXN4__\0TG_E8C6F6E#KH
M-1HLFF_9`(,)*,D]ZJ5HT&^E'4L`J_@5@&%\+*25I-=<V3B$AR;Q+9>*SX=(
M@CFB)XM;%>R)[R*9(.#Z-+2%?.@)2TF+DJ>8JY<=9N3&^#%1[L`2*INDR;I;
MG+[0SRXF$<6U9712?[M)VJMGF2UT'&S:@OPE656+G0L7'`TW.-L]Q:?K>:(S
MRV1.E=_D[=I7<)S<%%N74@[;;;8S7V]4>)N*;KE^LD=/IU@L+>NLZOT0TGJ\
M)K0"\MRBQ?;W=/;"I"7-V<=0!0O/=:O@A2C!.;-\V?/N<?;]P-0>[IM&PJV(
M-1*I*`S:*+\XR#:"WHHOT8(\;,NR3U8X=:"RJT(K:JI$]P$L.1FMH[V,D^8(
MIA(NJ7F_;EY'N>(A(@N18%8+RF?2F))'J.[@;QZ83)VN$\?+19N:2S\B,BR[
MZ(Q:>JU*E$MGM'QGW.)H0AQGAF*R]7IP5#UHA2_(JMJA`L"[4Y0?(D-S)XX5
M;$T&B5"\ND?TY!*G'Z&AUM>=S1#V@VGI^+G1XA*XM4M06D]:UC3=[3QB('H^
M?EUA"(RQJ,J790F8W9'*#\HG(`%I60/3"8+9[)$_N1MDM;;>D)$&/\;W"<.U
MQ-W6(_FB?WMI<^#^7CYDBJVL\%A,:HI>\G5;T%/BM_.]VB>>GHL]9RSW%U$"
ML:I^051EBE&68"]ZPV"X]\HW:YMD!P>(*A9X(=`BBZM<)"#4'L3@]Q[`TOK=
M]`U2O$S'*E<)R.&+,"EVD=1!U]UJ;;9\L7&>$?75?\8VF/QLIE+\I7R]3[C<
M=9OB>]O5N7PI)F%JV?2W4[GI3E1YVR*#;ZW[:'R_^6()W2G)"G^4)%W3XP2/
M@BS56ZQ]GV#4>GIX5;AS<BVB#P.G]WH+C+[$:ZL\P;Z%HD*0.;F1IUL6D&KQ
M@\?NE?QE6Q`P(6FQ#Y@GW>N+'+![\%TE/:)OA0V/W@,9=[Q]!_3=U%%M!:JL
M(I?MX_4YE4395J+Z3K7GKBN`PHA7+3A,6VK3-D'D%BN[[S?OW."!N\I_C2)U
MU_8N^FJYJDVWVP<)G6W2X<J#T,.P*^OU2H5JU?RPG-*@8Q%:X]050/3^DK)*
MF@5FQW,L$S'^TSGNF:@[TN748JJU9@_O(>OWY&;4>XES8*J7IY6_T7='GGRN
MQCW*7I5?TMZ-F<\81&>GSX].+E6F@`]$D"+Z"#B3UWAZV`O`_N>^3MS$0](2
MX:6O9L@V&E#-QMJF>K7VP;1Q@;Z7!#KNISZE.]X[NL_W:%?W7"!>W'_[<M6(
M'3^J7F(XOF4LC/H?E+^:=A:;2Y<_2MO;:JM[G5BC!J9'.3'">06B^QXP&%1?
MI8R"$@9R-\H_G<U_V.'9[N?MQSW/4&XM9J!<OI]O!J5O:7O[A9+!-^XD%`&T
M!B[YZYAQO:^3-;M3[6Z"?4"\MN_C?UZ3$-D'^\$M2VLT21>.#;*!/.`;%I^Q
M^)/N]VF>SN(4#'4M?HZ3<33G7MU!(7W;,J3L?6.+/RY)P2T/_W+K1WLS5M&5
M;SHIT.2I_SABT^M>I`PFMY@VH9*D_,#9[(JLADK4]A^TKJ-#W<3_H\FO9J/>
MY1W$#8?R&JV<T`JZVPSF7`*`;F>E'-/(R7$F]]M&^EBJI:5UAQ<[E6M&G?=J
MOEC0\L(_W#*5DNP(?@A"9O:\6Z5\IUR64(J%7(;D<4C,('_2&ZV'D3$66I,#
M-\BH_FVUD-#_Z*$WI6=3K*MN6;7/O`4#>#"'NID0T<ZBV0@.#F0(WZ#L6\8B
MAA.A1J6(MK8<3N?4*EQ?D)%9/G$D;V3M,"-9UQTHRJINS^0\5E\JF<#!S8)?
MG*=(@K4J"W-0EQ_`'1BSX=#D_'5<VXT%M`G^9JG13$`(TQMT2*'\)!,&17W(
M8\7^]QXK(YK(N75$UDK@]98V'G*IA[7E"E$F*_"2*>U669R2P"-8YT?XC:K7
MC`S!]JM+N(PEM`L9M2T'4-[-J#1\-"#E3`EN3X0D)AT"T;94GITNN#P&/K1C
MKBD5URE:!`2"=88IO%.>2>,:EC\&"K4<G.>:>GR75M&K4[C(=4G3$E3Y9RC3
M&LOCZT7%\=IO`BR\8>$]`C6]SIC65\Q>C?Y$QUM]Q:G?\%B.DA^;-^M>U[4Y
M;T([,H*$],+]S&+%\FV;:[O<9LG7+`(IF@9:H@Z!I*V#Q%IY'^HWT;ZI)4LJ
MOW)4AU"BU[WE7M'IJXC9[TR)+,/DN&,9M60R3$0FYZZ5$H+6T<3W+-?=Z[9Z
M.0K^]O6[$!`C(J34B#HGQWB)C#N%Y>H80L8)XG&$4$OSEWIBB%=W>SX!WZ#;
M"P;;3%WCX!A/]C]G()CE&O";97")U2")/845B,A?HC^,%W=`#8K$D!F',I!D
MBF?9\M[.XSV6D[.)[B&Q8W[U83J9Q?!=;3D=QX\VGU/7_9;S+SV;`=_UW$4W
M;.6AI>60B2V+[JMNGT5&:J=3GWINB>IW&;!/-]H4N5KTJ`2S_B1HS\)$FRS?
M^IV4%2`PU<FE7#XG71.@?6IEE.#RE";?HHVURG@"IR]V%H4(#43]PED\;<,M
MZ^0>\=XG+M('6K;=>"H?^I5$SS**_IN6-TP^.$OEZEW!U.2OONY6L+W^_HX5
M_KS&.`AV2TL++YLI],+Q"EG!)9:K07N*F7(;?2(7^'/A)`AYCR[+.5RLT]*K
MZM\)NA(/35[O.Y4E?SXT@%MQS4)N.![R$`>6,("R;I5"`RCZ)S[<,9V:+21[
MS?00]J<_>P;Y(^=`DA/DA>WDU0.0-PQJZ+^DDCA>MT6;D$O4)+TH'.6^/K.8
M`!M4R^/QPQ$\T];JM5A!I;VQ@KVEF*#F*`>(=">N2Z*V/I]%Y]-5OX^C^WG&
MX?7X1+J?CRX0X/.(#M`F<MM&@>P*7G4\6C*5YM?B5\JG-)XYA/(X8V7R>$:B
MM`1&'(];A%A&]^[BNK]R'G+3HFFD\9B<1L%-J32-W!U3$LK=6I3+XT!IY/#=
M=.&>@IY(X:%B]9+?'D';)!%@2Z@WH)FGH<MDBY&1:@R]A!:BMV<:W%[VL#,.
M+7-C?KIH+CQ,RI7Q^FU/9OB%RT;Y@0>V(4&V+2!9+GH2U*/2`.D3%_VXZ!1#
M?8^'U%29)MT''N.?9J!%I'=B&\>M6N.%DIJF1;=-,]Y5N>7S<M!AWUX]PG7;
M7%\P6'2P*\1ZSH_HXA"`,>6^A8_3`%@G(%&$APNA[KA9[;P$_==25K7M:8DM
M[G#/A?MHJPO.WE$^]<7]R-?Z>.%E$([!)$HBMEP^M`AO;1[#MA;HWL]<&A_$
MB6.E7"1V,2__GG<VO%-B?8LR*9%M?#O)1@OZ2_6OVP(BNEU1^;C6>PF`$LJ+
MOF`08K8/O?$=UT/)"DO-`'NR"-S+)),(EV$)P8O0EPP$>&`]5$%UG8H5?&,_
MY7RL(^\G=^@U6KB5W^[N[%4^U=(A$S:KK=9O\8KW"7QW*#]R[]'=7^H[@X.\
MZ4VY#/8Y,K6%0*R3F*V@/C/BM6J]4K[M7&X9^OWP$+)K];9\ZEP5DJAMV"M>
MR,X_[(KT9+^4B-JH[OY_TR%7TSN;#B$2_F^V')*L<\>_&;?.;O_W-ARJ;\R7
MR^7JV?\(````__\#`%!+`P04``8`"````"$`QZQY[X,"``"O!@``&````'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;)2576_:,!2&[R?M/UB^)Y\D%$2H6KIN
ME39IFO9Q;1R'6(WCR#:E_?<[MH&2T#'*18CCQ^]YS_&),[]^%@UZ8DISV18X
M#B*,6$MER=MU@7_]O!]=8:0-:4O2R)85^(5I?+WX^&&^E>I1UXP9!`JM+G!M
M3#<+0TUK)H@.9,=:F*FD$L3`4*U#W2E&2K=(-&$217DH"&^Q5YBI2S1D57'*
M[B3="-8:+Z)80PSXUS7O]%Y-T$OD!%&/FVY$I>A`8L4;;EZ<*$:"SA[6K51D
MU4#>S_&8T+VV&YS("TZ5U+(R`<B%WNAISM-P&H+28EYRR,"6'2E6%?@FGBUS
M'"[FKCZ_.=OJHWND:[G]K'CYE;<,B@W;9#=@)>6C11]*^P@6AR>K[]T&?%>H
M9!79-.:'W'YA?%T;V.T,$K)YS<J7.Z8I%!1D@B2S2E0V8`"N2'#;&5`0\NS^
MM[PT=8'3/,@F41H#CE9,FWMN)3&B&VVD^..A>"?E19*=2`KN=_-)D%QE<9;_
M7R7TCER"=\20Q5S)+8*F@9BZ([8%XQDHV\Q2J,_;F4%*=LV-7>26`JUA-YX6
M>3(/GZ""=(?<GB(#8OD&,3F(A&#OX!$R/_9XWIN%(0>,7KVE!UEG_]8C8U==
MF\_RZ$$O,*A<'MC"!0:IU\#C06"/3%W%XD^CP?3RG],]4^/WF++PP%0V,.61
MB3<5[7Y]9GF>Z=F#AKZ\9A8>V,O[H6\]XNU-LS1-IE&?6!X3N?=_('K6\O=8
ML_#`VFM[^C[RR#EKQ\3;UOR9XU_)CJS9-Z+6O-6H817T411,(#OE3QP_,+)S
MK]Y*&C@IW&T-'P8&?1P%`%=2FOW`GFF'3\WB+P```/__`P!02P,$%``&``@`
M```A`-T"HF&2!0``A1<``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R4
MF%F/HS@4A=]'FO^`>*^`;<P2)6DUE&JFI6EI-)KEF2(D015"!-3V[^>:ZXH7
M*E1XJ>[`Q_7QL7T,7GU[JX_.2]EV57-:NV3ANTYY*IIM==JOW7_^?KB+7:?K
M\],V/S:G<NV^EYW[;?/K+ZO7IGWJ#F79.U#AU*W=0]^?EY[7%8>RSKM%<RY/
M<&?7M'7>P\]V[W7GMLRWPT/UT:.^'WIU7IU<K+!L;ZG1['954=XWQ7-=GGHL
MTI;'O`?]W:$Z=Q_5ZN*6<G7>/CV?[XJF/D.)Q^I8]>]#4=>IB^6/_:EI\\<C
M]/N-!'GQ47OX,2I?5T7;=,VN7T`Y#X6.^YQXB0>5-JMM!3T0MCMMN5N[W\DR
M8X'K;5:#0?]6Y6NG_=_I#LWK;VVU_:,ZE>`VC),8@<>F>1+HCZVX!`][HZ<?
MAA'XLW6VY2Y_/O9_-:^_E]7^T,-P<^B1Z-AR^WY?=@4X"F46E(M*17,$`?#7
MJ2LQ-<"1_&WX][7:]H>UR\(%CWQ&`'<>RZY_J$1)URF>N[ZI_T.(R%)8A,HB
M#-3+^W1!8TYX^'45#Q4-';S/^WRS:IM7!V8-M-F=<S$'R1(J?]XCZ(I@OPMX
M>`3$=C`,+QL:KKP7<*Z02/H)8A+9)T1T03R0==$&/;Y=FX#!5]=1VN)+V4%^
MBL@P3X8+F7;!:!BJW-ZP@-<NE%(-)U;#B(2#8\SWXY@1D\AT@L11$ESN&\*"
M.<($;`IC_J4L.H)(A$/ITX3[U"0RG8BB(%2>&L)@&M_NF(`M898?*2(H+/:)
M-<LR_3;E`5?W#57A'%4"ME199J2(@"67H6;,\@L1%$X2<.QRWU`6S5$F8$N9
M*HL#B0@VR_T@9($U!S.=(`$)$M4Y0YG8L[1`$%''(#"G@T$\9"GDEXZC0D0F
MO9M$#)&)*7):G(#-9&!JOJ`X1+1DT"X8#1.P0K=GNN6!MGQ168=-2T;.F#B$
MH3&=RPR",A(2Y:TI;EZ88Q#KP<74ZI;BD)D<-8(,=B",?%^%C*E.I*TVL[ZP
M#K/94&=-Z90@@RU')+!&-3/N$Y^%UY3-RGLR#OQ`%9:^(2,'-6%<:WH@,ED%
M">;'271M4$4"WVZ;H,T9%]C92I#!ICEE2>);SF8&$HA`4=/6'-19P2_>F:RE
M&*@8DM8AHZU%^=1PQ6S<RO?;LHJ,@SZP4CR5#%J4)`FW/,P,(**Q[RO"U#@K
MZ<DXZ@,K#E+)3*])K'.%,05:@?_%LAPG?:`FKAQ!9-"\B)!@M!<1G>!!S*^Z
M-ROH"::VGAEV)J2207&4T,#.O$P2MWA'9^T&`VVM3;6LT#O)2.\8B^T7[,P@
M8AX3IOPW!I;.V@T&VA)G[P:2N>(,YMHT8PH4\7USLE$,>V-PK=A*)8/ND8A'
M86BMGLQ`*&'PJJ3&P)0W:U>@F/CP]_)NR.U=03):M.E7S,;!Y!G>"-H</#NQ
M4HK,].!-,J;`6<$O/E!M@7;P2V9:X,?FH%S6WL!-@=;F,)UK=+PI<'M3D,RT
M0*QSA3$%SMH9Z'AGX-;<3B4S.?VQS$?\34W_6?L"Q40WIK_*)9EMR.C37[MB
M>F/EOMC9DR^_0N@X_[4O0RD"F6#XY$WL,<YD";P=7GN5%1]$MZ_.@;96I\H<
ME"49.2[<3V+?CH_,8$@4AQ'7MC?#/S8K^P?:$FAGOV2DP(C3T:9N$'>,D$3E
MGREN5NZS<>YS._<E@^+N*(D3.""U+,Y,B"2<$J+MKJ;$6=G/,/OUK<E^WT\E
M@Q)9$%-JOS=E!G)'PC@@T34+15!K6^=M;[YP1&JG<*A>6^5$1`;/JC[_.)!E
M$/GTXP`/4O&<\9SORY]YNZ].G7,L=["0_44$,=[B,2K^Z)OS<*[XV/1P_#G\
M]P#'W24<.OH+@'=-TW_\$`>UEP/TS?\```#__P,`4$L#!!0`!@`(````(0#[
M8J5ME`8``*<;```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW
M('1O;2>V&P=UBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PK
MT`*[=)\F6X>M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';
MJUVN>HC$/A_3.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;
MN.V%2B6;E8KT81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![
M>S*A/D%#3=+;RHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D
M#Y2'&)8*)MI>U?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V
M<OH&P-0RKM?K=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4E
MF5N=3J?12F6Q1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK
M67?Q!A0R&D^7T-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN
M^@#00(85C9&:)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+
M>J^>?__J^5/TZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^
M\_+Q%^5X6<3_^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&
M1*);Y`@=\`AT,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H
M`UZ?W7=D'81BIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+
M8\>UO5D"53,+2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%
M'4Q+33*D(R>0%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$Z
MGBD<E9$<XH@5#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU
M^QZ;1RY2*#HMHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX
M`<<KW7V7$L?=IQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW9
M9A3JMN7PKFRWO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7
MY?+%U^5%*88JK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+
M0GC4F0P,'%P@L%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>
M-AOZ'&(KA\1JCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV9
M6\V(9HJBPRU769O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86
MXX6+=)$,\9BD/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HK
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MI>UQH4(.52@)J=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0
MH+`?J5`0L@]ER43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ
M25H&#.YD_+GO:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CL
MJG:]69[MO45%],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>
M$"5PD83T']C_J/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@
MTJ2L:=/625LMVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@
MV9,I"D.3["!C'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*M
MOP```/__`P!02P,$%``&``@````A`$Z"'(S+`@``R@<``!D```!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&ULE%5=;]L@%'V?M/^`>*\_$MNIHSA5NZI;I56:
MIGT\$XQM5&,L($W[[W>!QG.<IFI>+(,/YYQ[@.O5U;-HT1-3FLNNP'$08<0Z
M*DO>U07^_>ONXA(C;4A7DE9VK,`O3..K]>=/JYU4C[IAS"!@Z'2!&V/Z91AJ
MVC!!="![UL&72BI!#`Q5'>I>,5*Z1:(-9U&4A8+P#GN&I?H(AZPJ3MFMI%O!
M.N-)%&N)`?^ZX;W>LPGZ$3I!U..VOZ!2]$"QX2TW+XX4(T&7]W4G%=FT4/=S
MG!"ZYW:#(WK!J9):5B8`NM`;/:XY#_,0F-:KDD,%-G:D6%7@ZWAY$T<X7*]<
M0'\XV^G1.]*-W'U5O/S..P9IPS[9'=A(^6BA]Z6=@L7AT>H[MP,_%"I91;:M
M^2EWWQBO&P/;G4)%MK!E^7++-(5$@2:8I9:)RA8,P!,);H\&)$*>"SP#85Z:
MIL#S+$@7T3P&.-HP;>ZXI<2(;K61XJ\'Q<Z4YW+6;HDAZY62.P3[#6C=$WMZ
MXB40[SUYAL'E*9/@SI)<6Y8"PT$%?0W)/JW3/%N%3Y`&?<7<>`P\!TP\CP9,
M"'X&4V!D;.KM@/;:%FRU;6#6S(V?&`NE^>)MH?DY0A;LTA\*2)-\X/7:'I.X
MR,<5)><(63!L[BBI-+^<"'G,L1"<A(]'9\&3BO)I11Z3N4U-HNC$CF7GR%KP
MH6PVXO5!>LS"R<8@>T)W<8ZN!4]UXTFN'I-XW?2$JNW(HTOS_OFTX*GJ;*+J
M,3YDR.)4M?DYNA8\U9U/=#T&FIZ]LE'P/XR#ZPC?#^JU36(>P>3[A;ME4P?)
MQ,$K"([S<*NR*!U`WH=OJ;YO":9J]H6UK494;FV[C,'],#NT\NN9NX3#!^BD
M/:G9`U$U[S1J605+HV`!YUOY7NP'1O:N*VZD@1[J7AOX9S+H+%$`X$I*LQ_8
M;C_\A=?_````__\#`%!+`P04``8`"````"$`55^R7%,#``#J"0``&0```'AL
M+W=O<FMS:&5E=',O<VAE970T."YX;6R4EEUOFS`4AN\G[3\@[ALP'PF)0JH2
MU*W2)DW3/JX=,,$J8&0[3?OO=XP#`:?;DEZDX?#R^CGGV)RL[U_KRGHA7%#6
MQ#::N;9%FHSEM-G']L\?CW>1;0F)FQQ7K"&Q_4:$?;_Y^&%]9/Q9E(1("QP:
M$=NEE.W*<416DAJ+&6M)`W<*QFLLX9+O'=%R@O/NH;IR/->=.S6FC:T=5OP:
M#U84-",IRPXU::0VX:3"$OA%25O1N]79-78UYL^']BYC=0L6.UI1^=:9VE:=
MK9[V#>-X5T'>KRC`6>_=75S8US3C3+!"SL#.T:"7.2^=I0-.FW5.(0-5=HN3
M(K8?T"I%KNULUEV!?E%R%*/OEBC9\1.G^1?:$*@V]$EU8,?8LY(^Y2H$#SL7
M3S]V'?C&K9P4^%#)[^SXF=!]*:'=(62D$EOE;RD1&504;&9>J)PR5@$`?%HU
M55L#*H)?N_]'FLLRMGU_%GCA(D*@MW9$R$>J/&TK.PC)ZM]:A4Y>VL4[N02`
M?[KOS;PH1.'\_RZ.1NHR3+'$FS5G1PNV#:PI6JPV(5J!<Y^:YAB2_5NND*0R
M>5`NL0W[';(0T*"731A%:^<%BIJ=-,FE!DT5VUZA*JAL4QWHRN``[P`-I1A#
MO]^'GDV)%5OOFN@`>`^PG@'RCF(QE:3O2`;%A-6_A56))ZPZ,&8-%OZP4%>E
M[16:]#W-.:4),.R"ZXNKQ+"=1[4,H^64+]&:8&C`U@RDH\`$!0[']2A*'-O0
MEZ&MX=(U4+1FWNU0ST>AV7A]_XR:ZL"B>P#Y+OP-CA/2^2VD2FR2&F<AT1J]
ML!=%83`?%M9='PM\+_)<(Y=4"[I<)JB+6U"5V$0U%DJTYERTK0YH]F#I(@,]
M'3TP(5/S<O0N^O>Q5F*3S#@9B=:<BHB\P#?>25LM.*.GH\`$;7D+FA*;:,&T
M?8G6!-W&.N\IW=K^7O_&2D>!"14,O1LJUJE-KM#@.HE.1\1%T#_C/&\G$A2$
M2Z/L:A:K`HRVGAZM>O#4A._)EE25L#)V4&/3@RH,T6&D/_CJC6'$$[2",0%Q
M9[@!D[;%>_(5\SUMA%61`BS=V0*.+M>S6E](UG;C;L<DC-CN:PF_J0@,&G<&
MXH(QV5^H!89?:9L_````__\#`%!+`P04``8`"````"$`><$8TU8"```M!0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6R45,N.VC`4W5?J/UC>3YP`
MX27""(IH1^I(5=7'VC@WB44<1[:!F;_O=0P14T85W22Q?>XY]W&<Q>.+JLD1
MC)6ZR6@2Q91`(W0NFS*C/W]L'Z:46,>;G->Z@8R^@J6/RX\?%B=M]K8"<`09
M&IO1RKEVSI@5%2AN(]U"@R>%-HH[7)J2V=8`S[L@5;-!'(^9XK*A@6%N[N'0
M12$%;+0X*&A<(#%0<X?YVTJV]L*FQ#UTBIO]H7T06K5(L9.U=*\=*25*S)_*
M1AN^J['NEV3$Q86[6]S0*RF,MKIP$=*QD.AMS3,V8\BT7.02*_!M)P:*C*Z2
M^7I$V7+1]>>7A).]^B:VTJ?/1N9?90/8;!R3'\!.Z[V'/N5^"X/93?2V&\`W
M0W(H^*%VW_7I"\BR<CCM%`OR=<WSUPU8@0U%FFB0>B:A:TP`GT1)[PQL"'_I
MWB>9NRJCPW&43N)A@G"R`^NVTE-2(@[6:?4[@)(S52`9G$GP?29)TF@T2"?3
M.UA8R*@K<,,=7RZ,/A$T#6K:EGL+)G-D?K\B+,5C5QZ<430U)FMQ"L=E.ATO
MV!%;)\Z8=<#@L\<DP[C',)3MM5'O?FT/]MJ^NSZ9==BX%AI-!N\+#?]'R(-Q
M0%<%#,>SGC=H!TSGN#<5C=X*>9\,T6W_[JH/RBB6TW<LG4[^$@R8<=?SI#\+
MVL&V8:H*3`F?H*XM$?K@+9E@3+_;WY;5H#-\?X!N;7D)S]R4LK&DA@)#XVB"
M]C3![V'A=-MY9J<=^K3[K/"W!#B0.$)PH;6[+/R-ZG]TRS\```#__P,`4$L#
M!!0`!@`(````(0`V&6X>Q`(````'```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0V+GAM;)2576^;,!2&[R?M/UB^+]\D-`JIVE3=*FW2-.WCVC$&K&*,;*=I
M__V.<:"0;%U[$X)Y_?HY[S%F??4D&O3(E.:RS7'H!1BQELJ"MU6.?_ZXN\@P
MTH:T!6EDRW+\S#2^VGS\L#Y(]:!KQ@P"AU;GN#:F6_F^IC431'NR8RT\*:42
MQ,"MJGS=*4:*?I)H_"@(%KX@O,7.8:7>XB'+DE-V*^E>L-8X$\4:8H!?U[S3
M@YN@;[$31#WLNPLJ10<6.]YP\]R;8B3HZKYJI2*[!NI^"A-"!^_^YLQ><*JD
MEJ7QP,YWH.<U7_J7/CAMU@6'"FSL2+$RQ]?A:KO`_F;=Y_.+LX.>_$>ZEH=/
MBA=?>,L@;&B3;<!.R@<KO2_L$$SVSV;?]0WXIE#!2K)OS'=Y^,QX51OH=@H%
MV;I6Q?,MTQ0"!1LO2JT3E0T`P"\2W.X,"(0\]=<#+TR=XWCAI<L@#D&.=DR;
M.VXM,:)[;:3X[43AT<J91$<3N!Y-PM1+HG29O<<E/KK`=7")O"A+PW3Q?Q;?
MU=7'=$L,V:R5/"#8>D"N.V(W<K@"YR$?5\V8V+\"@Z2LR;5UR3&\,Y"%AB8_
M;M(L6/N/T!EZU-PX#?R.FC`^T6P'C6TI`(Z4D-R4\N_=&V"LV,+8;EJZ&S<P
M73E91G.Z[;GF13%#@9"F*#:P&+;EZTAV$N@FM:=9.">X<9IDQ-Y.!F8$R9S@
M]96M.,=0W9AZ$K]4YO)QFLG*;F#9-S+,TB"-1]89";P"TRQ>)['B.4F:G9(X
M#2P_TJ;9R]H][7;0G.Z1Q7M@K/@4)AF+=+$XS1PFG6O@Z+(^?70N&7<2N5=,
M,%6Q+6L:C:C<VU,FA$C'T?$`O(YLT_WQ`1Q`':G85Z(JWFK4L!*F!MX2*E?N
M"',W1G;]"[R3!HZ>_F\-7QH&>S[P0%Q*:88;N\#X[=K\`0``__\#`%!+`P04
M``8`"````"$`T!B8@SL*``#\-0``&0```'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6R<FUMOXDH6A=]'FO^`>.^`KT"4Y*AQ7>9(,])H-)=GFC@)ZH`CH"_G
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M'__5_/A;O7E].[KI+IPC;^S^^0]5'];NC+HR=VGA*ZV;=W<`[N_1=N.7ACLC
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M7NRV%'(BBK+@OWL9-/GY[%42*`FT!$8"2P`[>K<M##]Z+WX<NW-SGD9Y_I=!
M0@X^@$5[+23ZDY@O)?5:`G.Y@"5Z9LSM5,.->;$P)F<E2(BQ`&;!V#3^X5.I
MY"`M@1E0Q9)!S*+;1H=;]&)A45P7RR`A%@,(%A=%EJ4+L4\I.41+8&B-,IPE
M?I(L&<+LN5UXN#TO%O;$-;T,$F(O@$OVY!`M@:$U^NV1(<R>3YRDX5S>4;V8
MVRM*.7U!0_P%$/S-YXL29D^.T!(8"2P!S,V"N_'M,W/A[;(K/XB[2G*QPI9!
M0UP%D$S#A<?7DI)J+8&1P!+`'+G?P"9HF*5VE/24\*-<1A$Q%4F8J]YUI&"0
M!F*`6$JX/=_I!Z^_).0"NO7GF>C/RRBBML*P8"N9%]-"A"$%8S00`\12PEWY
MQDU<#9RTT.ZINZ*4VT<21&6[[A9IF<W%!5A%1>=?`=%`#!!+"7?GN_CM[D+O
MY^[F<DD&49RIV6PZ*\0)J!*2(=HXJ8!H(`:(I83;\[V<V+N\>22A\W-;"VF+
MQ(/VF*LXC$Z2U&C0&""6$N["M^OA+D)S=Z?VG*DP$?H;6+=1=L=<`5%`-!`#
MQ%+"7?BN/-Q%Z.%L+F9R)T](HX]S$4A<=.Z=$O^'SZ"*HZ+&W4V50J&AK@%B
M*>$^?7L>[C,T<^83^G!".G[T&4CPD.:]-N4@#64,$$L)M^7[-+$U<!\,W9W9
MFT'S(A$@V@LD[(PB-ZM$RC40`\12PHWY=DV,7=DC0G/GAJ!MD000#4FBDD#B
M*IPN,`KK*.DN4@/$4L)LI2)L7+;5JGG(*&:BLRZCJ#N>"HB*)-@J\K+,"WEU
MP2`#Q%+";=T4,E(,&<5,W#`NHXC:"L,ZHD"C@1@@EA+NPJV?X6LN]>IK]_A1
MU!US!40!T4`,$$L)=^';]^`K)PW-GETYL--%$741AH4%U;O1P1@-Q`"QE'!7
M(C,,V^C2GNP`&UT447=A6/]&!W(-Q`"QE'!C-\4(_R:LN)4J9F(K7D81-12&
MQ<;4]B5Q_2L8I($8()82;NNF7)'VY`JX0XPB:DLF#04:#<0`L91P%[Y;#[^6
M0F^_G/%2&0`J(`J(!F*`6$JX"]^:B0M_[>1N15QI/J&ALYTAER$A#:+8+XN>
MQ%-%23=M"H@&8H!82K@]W[.)O2NV0H?GMF142&4PJ(`H(!J(`6(I82[\NRC#
M7;3J:\TGBKHS7P%10#00`\12PEV((#!LJ64]@0"66A3%I39;E(F8M2HJ.K\*
MB`9B@%A*N#O?\@>OM,RK17K+97J+HNZ8*R`*B`9B@%A*N(N;`D(6.OWE32V*
MJ(LPK",*-!J(`6(IX2YZ`L'U32WK"02XTH(HK+1RELTR^0Y0+$/=A3$=T:`Q
M0"PEW-U-J2#K2P7BF)=1U!UA!40!T4`,$$L)=W%3",A"-[^RTF3+K^*PSI<"
MHH$8()82[D*$@&'1,PM]GO69F7BK;1E%,9>522D_)*RB@KJ3`4*#Q@"QE'!W
M/>&@O/J.?H;A()G"BF/A8):[[T7P-WVJ6(:Z"V,ZHD%C@%A*N#N1#0;.74]&
MD,>^S((HS-VB3.=@3H8(%8=0<U)C0&,I8>9R$1F&F6M'B;8TD^^G1E%LMO-\
M6HCD5T5%YT4!T4`,$$L)=R>BQ.58EV.$R#/YGD(4=<=<`5%`-!`#Q%+"7=P4
M&?(0&2YO@5%$781A'5&@T4`,$$L)=^&[^>#@DX?>3[<^_/Y`T'2'7,51'5%`
M="1_]BT#`R,L)=Q23W[PL?;*,L/\@!]EYC(+5$`4$!V)^R#/?YU(7&X&])82
M[DQDAX';`F:(/)/]R@<L_@$%$`5$1Q(VD[SOW2(#@RPEW)X(%0/MA=Q`UV0!
M[3B'<`%$`=%GTL[;7;Z8SW-Q:V+.FM-7I2PEW-\OQ8T<XT8"P3:*NDNL`J*`
MZ$C"]/5^9FU@D*6$VQ-YX\KUACD#/X_.96:H@"@@.I)3B\//K`V,L91P5[Z/
MDPW2+TJ_@J^X"]V?+4J<-!D1JEP2!40#,6?BEZG\KIP]_Z_\0F#1$S*NY\-V
M%`\9F`^C*,Q`VI=^HZ);L`J(!F*NUK5T#)O'0H2.89M+.XJ[A:R[C**XWG*W
MC,4>7T4%=1M234<T:,S5NI:.X6Y];A"K]GH/+/PHX1:^11%%W9%70!00#<2<
M2;NYBD!GS_\+JU8$EH'SB,&E@&A<!%%<M;-B+K_X6T5%YUT!T4#,U;J6CN'S
M^$M9IL`L4Y3B)F8919V7"H@"HH&82,)'*JGX+9;JN;-?RC)%7Y:1MSA11)V%
M86%F^[\'"8,T$!-)*-/;+RV3%%DR3\C]%3\!OY1V"DP[+G?QF^]E%-$3(/./
M`HT&8H!82K@;D6TNM\<B9!IWO5WXSDP441=A6$<4:#00`\12PEV("#-P<^F+
M,K`H(<JXAVAXY%9`="1AQ<VG;<+FDVU@D'\ZYUPXV`L/VX2G);;U_K6NZO?W
MPVC=?/,/TJ3NON1,SP_Y?$[]]]<%5\F];I^4F9S_PSU[\[%ZK?^QVK]N=H?1
M>_WB2D[O9NZ2VX>G=\(/Q^:C?4;C2W-T3]VT_WQS3UG5[JF&Z9T3OS3-\?2#
MW_3/SVT]_1\``/__`P!02P,$%``&``@````A`%4*T9%;!```X!```!D```!X
M;"]W;W)K<VAE971S+W-H965T,S`N>&ULG%A=CZ)*$'W?Y/X'PON(#0U^1-V,
M3N;N)KO)S<W]>$9HE0S0AL9QYM]O=1<RW8T+.B\J[:GR]*FJ`^WBZUN1.Z^L
M$ADOERX9C5V'E0E/LW*_=/_]Y_EAZCJBCLLTSGG)ENX[$^[7U1]?%F=>O8@#
M8[4#&4JQ=`]U?9Q[GD@.K(C%B!]9"=_L>%7$-5Q6>T\<*Q:G*JC(/7\\CKPB
MSDH7,\RK6W+PW2Y+V!-/3@4K:TQ2L3RN@;\X9$=QR58DMZ0KXNKE='Q(>'&$
M%-LLS^IWE=1UBF3^?5_R*M[FL.\W0N/DDEM==-(765)QP7?U"-)Y2+2[YYDW
M\R#3:I%FL`,INU.QW=)])/.-3UUOM5`"_9>QL]`^.^+`SW]66?HC*QFH#762
M%=AR_B*AWU.Y!,%>)_I95>"ORDG9+C[E]=_\_(UE^T,-Y0YA1W)C\_3]B8D$
M%(4T(S^4F1*>`P%X=8I,M@8H$K^I]W.6UH>E&T2C<#(.","=+1/U<R93NDYR
M$C4O_D<0:5)A$K])`N]-$A*-J!].IO=D"9HL\'[)XH_\:4C":)B+A_M2,CW%
M=;Q:5/SL0.\!<W&,92>3.62^Z(.[:17[G6"@E$SR*+,L71@:T$)`E5]7E)*%
M]PJ521K,&C'PVF(LQ.:"D`4%>BU'T$WG>+UV%RH2+*G(6DIN:US0?]<WF6VN
M("8MQ&`""NE,I%H!]&0_(QD$.&WCE%H4UHA1@Z!8;[0%@P$U&?3_L@0O7=A>
M*SFE0;LSE`<Q$U4T/YA%LZD)V"`@0D`TCH*H!1C,8!YT;?J92;#-C+9YD1EB
MD-G#56HFHH=;=`\W"3:Y^8'-#3$@3:ML8`F[Z848RDU,=K=UE0PR65(:6@HB
M1NLJ;<%@(&]WE@L,][4,&NIKQ&@,M`6#P<QDT-\]$FSOW9)_C1CL'C*9AO1C
MI''"#,",$FTR#&8$!OQ^<524S?%C<K##&Y`FC[YBLI#F>'>)"%IJO_<T()T%
MAJD5DX6T2HU%?YD(&JOI/U89U@U('R5*;0]J0?:M@4B?U`C=-CLJRB[.S!J>
M!J3+\CM3)M(C[V>!SCI0'`3I++05LSAW.;!\"NH,4:<X"()?;'V.AF-3J$V3
MZ4JWW&6[I.N[-+0>$=8-2)?CXK.=UOB4K1*TR(&B:#Z*9M*$7='`LM:!B4%[
M-"?&=C:"(+2VB!!;I$T#P%MV%-'91P:S82S3O7%XKKAO:#_/$`3I==)6#!;^
MI_Q510W=?1J0QD)?,5E8_MI?)Q\-TJR3/3P-R!B>CK.U(+M]?6F>=WN*BK*<
M+?PH/]YV&I`NB_RQI=MM7_]3_JJB!HNCN2D.41-VA86T/$V+@>*@00X4!T%&
M<3K.!B=32Q8\:.()JF#5GFU8G@LGX2=YB"3PD-RNM@?<1U\=4=LOX'QYC/?L
M9USMLU(X.=M!Z'@T`:^M\(2*%S4_JO/9EM=PLE0?#_!/`H-#S7@$X!WG]>5"
M=D_[W\3J%P```/__`P!02P,$%``&``@````A`,-HB,5Z`@``M@4``!D```!X
M;"]W;W)K<VAE971S+W-H965T,S$N>&ULE%1=;YLP%'V?M/]@^;T8:$C:**1J
M4G6KM$G3M(]GQUS`*L;(=IKVW^_:3E#2=%KW`M@^/O><^\'BYEEUY`F,E;HO
M:9:DE$`O="7[IJ0_?]Q?7%%B'>\KWND>2OH"EMXL/WY8[+1YM"V`(\C0VY*V
MS@USQJQH07&;Z`%Z/*FU4=SATC3,#@9X%2ZICN5I.F6*RYY&AKEY#X>N:RG@
M3HNM@MY%$@,==ZC?MG*P!S8EWD.GN'G<#A="JP$I-K*3[B604J+$_*'IM>&;
M#GT_9Q,N#MQA<4:OI##:ZMHE2,>BT'//U^R:(=-R44ETX--.#-0EO<WFZPEE
MRT7(SR\).WOT36RK=Y^,K+[('C#96"9?@(W6CQ[Z4/DMO,S.;M^'`GPSI(*:
M;SOW7>\^@VQ:A]4NT)#W-:]>[L`*3"C2)'GAF83N4``^B9*^,S`A_#F\=[)R
M;4DOITDQ2R\SA),-6'<O/24E8FN=5K\C*-M319)\3W*)ZO?G>9)?%5DQ_3<+
MBXJ"P3ON^')A](Y@TV!,.W#?@MD<F0_.HH[1Z]^LHD=/<NM92HK=CBXLEN=I
M.2DF"_:$.15[S.H<DYTBU@>$+P7*&S6B\V.-;V?](,6#O11?!:]M%3>0>]26
MOXK[!F(V0DZ48(;>K\2#L=+'@?-7H5<1$UHWJ%T?;9Q$GOQ/9`\N*=H:+4^*
M8G04TQ(QTU"L]/0,1\G?CV?Y+)V.QU%2G)/81@I,`VOH.DN$WOH9R)%RW!W'
M\S;W%7FUO\*Q#4W.Q@,<FX$W\)6;1O:6=%`C99K,<$Y,'+RX<'H(S;O1#@<F
M?+;X?P2L>)H@N-;:'1:^G\8_[O(/````__\#`%!+`P04``8`"````"$`&>(O
M8B`%``#4$@``&0```'AL+W=O<FMS:&5E=',O<VAE970R."YX;6RLF%V/HS84
MAN\K]3\@[C>$CWR`DJPF(7Q$K515V_::(4Z")N`(F,G,O]]CC!WLDXXR56^6
MG<?'+SZOCXV=Q??W\FR\D;HI:+4T[='8-$B5TWU1'9?F7S^B;W/3:-JLVF=G
M6I&E^4$:\_OJUU\65UJ_-"="6@,4JF9IGMKV$EA6DY](F34C>B$5M!QH768M
M_%D?K>92DVS?=2K/EC,>3ZTR*RJ3*P3U(QKT<"AR$M+\M215RT5J<LY:&']S
M*BZ-4"OS1^3*K'YYO7S+:7D!B>?B7+0?G:AIE'F0'BM:9\]GR/O=]K)<:'=_
M(/FRR&O:T$,[`CF+#Q3G[%N^!4JKQ;Z`#)CM1DT.2_/)#G:V;5JK16?0WP6Y
M-H/_&\V)7N.ZV/]65`3<AGEB,_!,Z0L+3?<,06<+]8ZZ&?BC-O;DD+V>VS_I
M-2'%\=3"=$\@(Y98L/\(29.#HR`S<B9,*:=G&`#\:Y0%*PUP)'OOGM=BWYZ6
MINN-9O;8=V>@\DR:-BJ8I&GDKTU+RW]X4)>1%'%Z$7@*D>EH,AN[-KSS41&(
M[$8"SU[$'\TG$V\Z_\)(IKT(/'L1^\O9P-+H!@+/7@/R>M`)O^\+S_^>A`U5
MP">%E4-O^*-I6'R"NWH)LS9;+6IZ-6`1PA0VEXPM:3M@;Q"5PN=5ULZ_E0[4
M#%-Y8C)+$[R!JFB@WM]6GN,NK#>HT;R/6>,86XW8B`A6D$PVU,%6!Y$.8ATD
M.DAUL!L`"VR1WL`$_Q_>,!GFC<AJ+<#-+$<S0D2(+J$.MCJ(=!#K(-%!JH/=
M`"A&N)H1][<140LL&C:,02VXKC;3:QYCN]*4#2(A(EM$(D1B1!)$4D1V0Z*D
M[FFI\_4Q8IM/>RKRES7E^^`=2UQ8!WQU,!%88/`8+`]/G?,U#_)NCN@@[`&,
M5<HXGJ_*;&60J)T(D1B1!)$4D5U/V``5B\`*O$Q@I^\=^D$OW3;SN%U,L+-+
MI+#F9."-#L(>>-W>XXQMS=VM;!>:D2X1ZR"1?=A^!IK:AI;*=J&Y&T@H%L&'
M!ULTN561\.A.%<&W4I014U%]Z<EL4!&N.U$K8B.#Q#!#1+:<N*K05!6*9+=!
M_;G:UA7+(/&V1))!-V>N:J=W!S!3@W;WE`8#4"R'5)#E+GS@/K>8]5(MYL2!
MK5$N.M?51K^102+I$)$M)^Z\J]#99`PUJGD7H4XQ(@DBJ2+L3B:SN:]5ZF[8
M27&)'?CUS[\[OA7F0]L;$U%-ZPF\=F":ME-M9)`TC1/7EWO@EA,/YDT*.7J!
M1T@H1B1!TNDCTKNAD&(<'.4^->ZQ%<U45.<X\>!((A-VO;&Z#C9]$#^Y=P>E
MGDQOSO7DLW)#,C$B"1).%>'[Y3:445QC)TQDF\/*Y.%O:2>A>M8C3UFCGG;D
MV(BH@6L"S6ZV"72KP4B@6\<8HT2@FU8JT$UK)U"GI5K#3J'Z4K2__(V`6Z5>
M4@(-#EL8A1AM,8HPBC%*,$HQ8A?@;JC=N+@7_$+++R@EJ8]D0\[GQLCI*[NL
MVC/8.R7F-^F=#S?I[C*L-<`5^\EA\ZKQ-;MZW^-.`.??._%N`*=#S)^\X`DR
MP`UK6U[NM5>'7@#'*MPCG`1P/L$\F01PQL!\XP>LFG%#Z`?AW8:M'VSO-D1^
MP.H;2\5^P*H<-R1^P&H=-Z1^P"H>&BR9-_RF<,F.Y/>L/A958YS)`::1?UYJ
M_JM$_ZWISXC/M(5?$V"FX2(*OQX1N`..V4'R0&DK_F`OD+]'K7X"``#__P,`
M4$L#!!0`!@`(````(0!YMG$2)P4``$`4```9````>&PO=V]R:W-H965T<R]S
M:&5E=#$Q+GAM;*R86X^K-A#'WROU.R#>3[CFAI(<;0*T1VJEJNKEF25.@A9P
M!.QF]]MW!AMB,YP<5NK+LOEE9C)_C^TQWGQ]+W+CC55UQLNMZ<QLTV!ERH]9
M>=Z:?_\5?UF91MTDY3')><FVY@>KS:^[GW_:W'CU4E\8:PR(4-9;\](TU\"R
MZO3"BJ2>\2LKX9L3KXJD@8_5V:JO%4N.K5.16ZYM+ZPBR4I31`BJ*3'XZ92E
M+.3I:\'*1@2I6)XTD']]R:YU%ZU(IX0KDNKE]?HEY<450CQG>=9\M$%-HTB#
M;^>25\ES#KK?'3])N]CM!Q*^R-**U_S4S""<)1*EFM?6VH)(N\TQ`P4X[$;%
M3EOSR0EBUS:MW:8=H'\R=JN5_XWZPF^_5-GQMZQD,-I0)ZS`,^<O:/KMB`B<
M+>(=MQ7XHS*.[)2\YLV?_/8KR\Z7!LH]!T4H+#A^A*Q.840AS,R=8Z24YY``
M_#6*#*<&C$CRWCYOV;&Y;$UO,9LO;<\!<^.9U4V<84C32%_KAA?_"B-'AA)!
M7!D$GB-!'CAZTA&>TM%U9TO'7GM+^/4'CKYTA*=T]&>K^=Q?K'[@"&%;O?"4
MCLYJFN=">L)S4JZ6&.FV<&'2)+M-Q6\&K`88R_J:X-IR`@C654RH[6OXO1)"
M[3#($T;9FK",H3HUS+NWG>LM-]8;S)54VNRIC:-;'#H+G!@8-AR":`AB!5B@
MJ)<%Q?\?9&$4E-4EM.^`HG.@H;/H7,(AB(8@5H"F`>;A4(,'2W)\,7650"=8
M-EHE5GJ.>V'C>+VN`R$A(1$AL4JTS&$A##/';>"3DPJCP+2$AS*KU@,MT@BB
MWXU\6S<Z]$9]50B)"(E5HLF#'U/E/2X(&K<JNM_>2Z(,/R$A(1$AL4JT_&`=
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MP2PY.+W!O0X$19W5@SJH3KH&;%C3-<CVIFJ0J*_#X#!U@`*0.A`42:M'=5"=
M=`W8J*9KD&U-U2`0U$%9LKXW7!2]U;T8!$6.1+(8CC^W!R,2=R;M3J<KP98V
M78EL@*H2@3SQ]HKO.P='6JGKH$>*7KI%":NN)*N%[_CZD,1:;$T)>'U"26NM
MM^`.*;V-HI"BB"*\GFBG8!M+I"FN&\1;:\&J,SNP/*^-E+_B50+L"KM-C\4]
MQWX5P(D(2C_DZP!.(B/<L0-L_F/?P)4)]-N1;USP@6SI-]`+`VQ^]!NX?WD:
MXWO\D1'[O0L_,<:]`%Z^1N+[$'\LI;T?P.L,==C/`WB-&.&+`([O(WP9P+$9
MN-6/+-S?7),S^SVISEE9&SD[05'L&1Z8*W$#)#XT_`K%@EL<WL#-3?OO!6[J
M&,Q[>P;&)\Z;[@/^0'_WM_L/``#__P,`4$L#!!0`!@`(````(0!JO="Y4`\`
M`&U<```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*R<VV[C.!*&[Q?8
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M/]L_;;_KW>;A;YO7-66;ULFOP"_;[:_>U3YX1(,O8+3J5^`?N[.']>/JV_/A
MG]OO9KWY^G2@Y5Y01#ZPFX<_Q'I_3QFE:<Z;A9_I?OM,.T#_GKUL?&E01E:_
MWTX:VO#FX?!T.YFUYXOEY6Q*[F>_K/<'M?%33L[NO^T/VY?_#DY]1,=)9F$2
M^@R3--?G5XO%O+U:TBPG1L[#2/H,(]OS>;-87O6;/S&0INWWFS[C)IN/;;(-
M(^DSC%R<3^>7K8_WQ`:781A]Q@U^,$9JM7Y7Z7-<C-=A('W&3;8?V=4I55&_
M1?^?#\1X,=1$7V)B=5A]_K3;?C^COJ55W[^M_%%@>N/GBL4UI.E8;G]6;51F
M?I8O?IK;"85/A;2G%OGM<S.??[KXC<KZ/OC<H<^4>W31P]>PGU:40)9`E4"7
MP)3`EL!EX(+2<LP--<S_(S=^&I^;&-5=!%FRBD1$CSA$E$"60)5`E\"4P);`
M98`E@IH>$C&C8JD?@6)-^%%TK&$UL>"!W@T^T]DQ.1T0`40"44`T$`/$`G$Y
M82F@HQ=+P>G0O3=U%'UD_=`6L0].#6^:)7?JCD['4@`B@2@@&H@!8H&XG+!T
MT(%T1#J\=Y^.&,1=(-FZ`Q%`)!`%1`,Q0"P0EQ,6*)U"1@3JO7F@`VF6J<"!
M""`2B`*B@1@@%HC+"0N43GHC`O7>/-!`LA4%(H!((`J(!F*`6"`N)RQ0ZK<1
M@7IO'NA`:$7SWKXJVO;H%"M>`)%`%!`-Q`"Q0%Q.6.PD,T;$[KUY[(%DBPQ$
M`)%`%!`-Q`"Q0%Q.6*!>RHR(M'?GH0:4=RXB@4@B4H@T(H/((G(,\9B]CLFU
MW.ESU'20/722BC5Z%U&VOH@$(HE((=*(#"*+R#'$8_:2943,@\)A,0?4'-/0
M30-JCT@$5)RLKWG7R^054ZH0:40&D47D`IKV^\73X'7+B#0$F9,O?4!Y&@+*
MTS`@2D,O\2^GA<:7I.3\,8,<4@9@&AV\AD!ZI6_2P##SC.?6)H<XLV/3\'QX
MX3(B'X/.86414)X/0,(K/`IWEKPD(A40+5_<=8W(X$"+R+&!/&:O8?*8_:5<
MT_I[`N\(=7\SH3C01T1GDJ1@%Y=\3;KD%0,3"64#F^+T*(-7,^WK:';5S(H+
M`Y7FB5-K1":A$UNS5:]RBRYYT19Y9KUHRC/[SH%UT%BT4G'7[ZC2^[:@5LC2
M"9>_1Z\X4*2!$<F(VCYWTZOKMF@5%3W285PC,HAL1,/4S72Q*"Y'7/3HI^9)
M\H(K3]+'RR](M3Q?`?'R:\KR.WK%Y(@I(!E0J+5YLUQ`OF"0QGD,(IM0MJQ8
M6/GT/&=>J.4Y>Z>P!EW'"FM`#2^L(L!N>O1*B0(DDY<_!!>]KI(USJ$1&40V
MHJ&H%LUT=EW,[:)+I:J\PAN1H2`(\U(*B.+-6J\X;W73HU>,3B"2"54S!'/H
M-"!.:Q#9@$*%3J\6EXMB_QP;Q6JH&:=T>W>N=`,J:J@X('?)*X8B$,F(AL6^
MOKY>%`<Y%3VR@Q,B@\A&-$R];*XN+XNY773!.J+<CJFCWKW(4I#+O(Z*>SI=
M')CTCT`D$\IKLCC6JJK7K#@(ZN05U\4@L@GE6RQ.RZ[JE6V1%]XXZ=V@]`ZH
M*+Q"5'?)*P8H$LJB`9%1]2J/SBIYQ>DU(I/0B2W:JE>Y19>\:(L\I5XJ?_QH
MYQ-7Z+:(4G=UB`0BB4@ATH@,(HO(,<1C]A)Z1,Q!A&='^&9`[([,K#P%)J>X
MS`*11*00:40&D47D&.)9*,7[:27@-7VY\@'E*P](Q(')2R)2B#0B@\@B<@SQ
MF,?)Z@9E=4!LY9NV4!==\DI+'Y1VNBTKT4LATH@,(HO(,<33X.7AB`8(:C)O
M@(#2HG8^);Y`$A*()"*%2",RB"PBQQ"/V:O/$3$/8C47OOY.#`5(FXB+VB$2
MB"0BA4@C,H@L(L<0C]G+PQ$Q!S69KW-`:5&[!I!`)!$I1!J10601.898S/Y+
MPA$Q]^Y<=@4T8Q<X\T($=7%@NL,BXL"4/XE(L8%\U\<IQAG>38WHSVZ6=<DA
MUK!(Z(3.D,&+Y)J_#JFI[#0/3<WC&B?;Z-96>:8)B$[IX59=>:F0'%)<PS0T
M)B*9O+)02[&DDA<$,DXL^0HJ3ID1'1>H5//)(>ZU0"03.AE(V'Y_9<!79)P"
MFJ$""BBM2'$IT26'%$A03?F*'-')0(Y>L"+C1,P,14Q$QQ4IKE"ZY)`""=.D
M2RZ9O$X&D@_D*S).F<Q0F03D96^ZZS`O16GR2M$$99(ORQ%E<V&C'+U@6<8)
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M%I%CB.?'RYL1-3&H(583`>4U`4C,`4E$"I%&9!!91(XA'O,XX39'X190MH(=
M(H%((E*(-"*#R")R#/&8QTF\.4J\B/)U#EX)"?22B!0BC<@@LH@<0SSF4N+]
M:.^C]IL/J.C]\CHD>:7>/PZ,2**70J01&406D6.(Y6<Q3@[V[EP.1I0*H$,D
M$$E$"I%&9!!91(XA'G,I!T]_(>#/%,7=C8#RWD<D$$E$"I%&9!!91(XA'O,X
M?;=`?1=1OLZH[]!+(E*(-"*#R")R#/&82WWG>W]VU3^U-?+4OT#M%U#1_L7#
M!5WRBKTN$$E$"I%&9!!91(XAGJ)Q<G"!<C"BO"R"5T("O20BA4@C,H@L(L<0
MC[F4@^^T/ZJ^!8BW#I%`)!$I1!J10601.89XS%YZ?5SB+8)22S?X[R)*B]HA
M$H@D(H5((S*(+"+'$(^YE'@_?M6_0/D74-'^Y>WZY)7:?Y@K.W=(]%*(-"*#
MR")R#/$4C5.$"U2$$>5E@8H0O20BA4@C,H@L(L<0C[E4A.^T/PJ_!>BW#I%`
M)!$I1!J10601.898S.TXE=>[<Y474;;.B`0BB4@ATH@,(HO(,<1C+E7>#RK_
M%N5?0$7OE]]P):]C[R.2B!0BC<@@LH@<0SP_XQ1ABXHPHKPF4!&BET2D$&E$
M!I%%Y!CB,9>*\'3OMZCZ`LJ.WATB@4@B4H@T(H/((G(,\9C'2;P6)5Y$^3JC
MQ$,OB4@ATH@,(HO(,<1C+B6>[_UF<4YXI/!O4?T%5'1_^;5P\DK=#[)1HI="
MI!$91!:18XAG:)P@;%$01I171?!*2*"71*00:40&D47D&.(QEX+PG>Y'T=>"
M=NL0"402D4*D$1E$%I%CB,<\3N&UJ/`B2HO:(1*()"*%2",RB"PBQQ"/N51X
M/W[=WZ+Z"ZAH__)ABN25VA]DHT0OA4@C,H@L(L<02]%RG"#LW;D@C"@K"T0"
MD42D$&E$!I%%Y!CB,9>"\'3[+U'W!92?_!$)1!*10J01&406D6.(QSQ.Y"U1
MY$64KS.*//22B!0BC<@@LH@<0SSF4N3]>/LO40`&5+1_^<.*Y'5L?T02D4*D
M$1E$%I%CB*=HG"9<HB:,*"\+U(3H)1$I1!J10601.89XS*4F?*?]4?CYQT6*
MYZ(1"402D4*D$1E$%I%CB,<\3N4M4>5%E*\SJCSTDH@4(HW((+*('$,\YE+E
M_;#V7Z(`#(AW_[+\543R2MT/RE&BET*D$1E$%I%CB&=HG"9<HB:,**^*X)60
M0"^)2"'2B`PBB\@QQ&,N->$[W8^Z;PGRK4,D$$E$"I%&9!!91(XA%O/5.)'7
MNW.1%U%:U`Z10"01*40:D4%D$3F&>,RER/OQDS^]=[+\WC>@HOW+1_V2U[']
M$4E$"I%&9!!91/ZMF>ED-:1H>`OF\(K"E_7NZ[I;/S_OS^ZWW_P;+DDX?_YT
MQ,/K-^^N+NG]F_TK-,%R?#-G:5G.;_QIF&('RX(L_6LTP=*2I7\9"EB69.E_
MB026*[+T#S*#Y9HLU[4]:&D,73A6]JVE,72]5+$L*0>4G)J%<D#:NV9IR-+_
M8@;V;4:6OI]*2TMCZ-9E9;:6QM`-OIJ%<DVWP6H6RC7=_JE9*-=TDZ1FH5S3
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M%GJK$XVIQ6'(XE_*A+/1SPUO_.\+T7+74)#TZ]^:A<(<[M/`HE.@]$O2VABJ
M.OJ])5DNCH/H9<]OJZ_KOZ]V7S>O^[/G]2.=*B_[7P[LAM=%#W\<MF\DG>B5
MS]L#O>:Y_^\3O=9[36_:O?1?.SQNMX?XA]_`\47AG_\'``#__P,`4$L#!!0`
M!@`(````(0#(DOL1=0,```4,```9````>&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;)166V_:,!A]G[3_$.6]!(=+"B)4=%6W2ILT3;L\F\0A5I,XLDUI__V^
MSPXAMQ9X`?)Q?,YW\7&\NGO-,^>%2<5%$;ID-'8=5D0BYL4N=/_\?KRY=1VE
M:1'33!0L=-^8<N_6GS^M#D(^JY0Q[0!#H4(WU;I<>IZ*4I93-1(E*^"?1,B<
M:GB4.T^5DM'8+,HSSQ^/YUY.>>%:AJ6\A$,D"8_8@XCV.2NT)9$LHQKR5RDO
MU9$MCRZARZE\WI<WD<A+H-CRC.LW0^HZ>;1\VA5"TFT&=;^2*8V.W.:A1Y_S
M2`HE$CT".L\FVJ]YX2T\8%JO8@X58-L=R9+0W9#EO>^[WGIE&O27LX-J_'94
M*@Y?)8^_\X)!MV%..(&M$,\(?8HQ!(N]WNI',X&?THE90O>9_B4.WQC?I1K&
M/8.*L+!E_/;`5`0=!9J1/T.F2&20`'PZ.<>M`1VAKZ'K@S"/=1JZD_EH%HPG
M!.#.EBG]R)'2=:*]TB+_9T'$)&6Y3&H/5-/U2HJ#`_,&M"HI[AZR!.)C3I:A
MSO*])"$[)-D@2^C"1@5]!9U]6?N!O_)>H!M1A;FW&/BL,:1&>)!-G1*DT4QI
MN#U'902C,K8+4[FW@:;,*9&6S*0M@Y5/8*8?R^$BP#6*\(-)78;-P&*FINW-
MNJ9]07^.HSZCB>M@//!5=\X/IAW1"C1O@68UJ%4Y*%[>8`0;];K#-M*O#[0O
MIT5PF[:*&`.VT@VNX45PF]=&^NGBL=K;^9-1<'8>N+`M445@ZS4F-!]N_J(M
M^_%V0W!;RD;ZU1#8NLUR/N8UZ#;Q,=3O/T'G-CIUAKKRN4G1&L(0A.Y`TAVK
MHP?]\?2"&9#*YDV5*M2>0C`\!=)Q_YF:K*7!@K4)#,%@31V;GV&NS7UBKD(#
M@[C*N/AJZ6R>*C0PB(YWS6N`S$9GO4#Z/CZ&VG.X?6<.5YF;]-U=A09*ZOC[
MS!SZIB8#KIZ<SOK6$46N<K5!=]SWGJ_]CJ]Q,D%PP5O#+&R+'$/MR2R&)^-?
MY7J#[JC9@Z`_&;AC77&>&'2'&0D@-#^]8NVER]YL<B9W[`O+,N5$8H\7*A^N
M)'6TONQMC,.Z\>ER`Y+@1J_^!RYA)=VQ'U3N>*&<C"7`.3:GE+37./N@10E9
MP55,:+A^F9\I7+<97$O&:*5$"'U\0('Z`K_^#P``__\#`%!+`P04``8`"```
M`"$`J!N%)N`"``!'"```&0```'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6R4
M5EMOFS`4?I^T_X#\7FXA:8)"JG15MTJ;-$V[/#M@P"I@9#M-^^]WCDTHE*A)
M7R`^?/Z^<_-QUC?/=>4\,:FX:!(2N#YQ6).*C#=%0O[\OK]:$D=IVF2T$@U+
MR`M3Y&;S^=/Z(.2C*AG3#C`T*B&EUFWL>2HM64V5*UK6P)=<R)IJ6,K"4ZUD
M-#.;ZLH+?7_AU90WQ#+$\A(.D><\97<BW=>LT99$LHIJ\%^5O%5'MCJ]A*ZF
M\G'?7J6B;H%BQRNN7PPI<>HT?B@:(>FN@KB?@XBF1VZSF-#7/)5"B5R[0.=9
M1Z<QK[R5!TR;=<8A`DR[(UF>D&T0WP8A\39KDZ"_G!W4X+>C2G'X*GGVG3<,
ML@UUP@KLA'A$Z$.&)MCL37;?FPK\E$[&<KJO]"]Q^,9X46HH]QPBPL#B[.6.
MJ10R"C1N.$>F5%3@`#R=FF-K0$;HLWD?>*;+A(1+=SF?1XOE-=#LF-+W'#F)
MD^Z5%O4_BPHZ+LL2=BSP[EAF"W=^[<\"$#U#XEF/3(!W5-/-6HJ#`UT#DJJE
MV(-!#,2G(X)0$+M%<$*@J\%7!65XVH1+?^T]0>K2#G-K,?#L,4&/\$"T5P:U
MRY41C,J86W3EUAJ&,N%IF=E'9!"<$'CVSH?+5_>MLL5$IF&&\40?$4(PI!Q>
M`Z77"*Q2!UJ,0+/384('7)Y-!!OU/IW6,@T*M"^G1?"8MK.8HSDJ_O5'>!$\
MYK66J;LX<`?=;,[I`@[)N<;&?6.%S@)M-BA0=#KWJ['J^V<(P6,I:YD&$\"<
M&D;S/J]!CXF/IFGZ`SRE@T2=H>[.M''1MJ8A2,@)I]\<:RQ!Z$<NSKDS*MV1
M'JITIG$5YF^J8,>VG6HUDP7[PJI*.:G8XT@.84[UUOZZV)J<O+5'\=9>(U[_
M!<9X2POV@\J"-\JI6`Z<O@E'VHO`+K1H(?DPAH6&^6U^EG!A,YA5/O9?+H0^
M+O"JZ?\";/X#``#__P,`4$L#!!0`!@`(````(0`<EC[A6P<``!(B```9````
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;*R:6V^C.!3'WU?:[Q#E?4*`7!K4
M=C7A?EEIM=K+,TU(@R8)$=#IS+??8\#!]I_)%&E?FN3GXV/\][$YMOOXV[?S
M:?(U*ZN\N#Q-]=E\.LDNNV*?7UZ?IG__Y7UZF$ZJ.KWLTU-QR9ZFW[-J^MOS
MK[\\OA?EE^J89?6$/%RJI^FQKJ^6IE6[8W9.JUEQS2Y4<BC*<UK3S_)5JZYE
MENZ;2N>39LSG*^V<YI=IZ\$J/^*C.!SR7>84N[=S=JE;)V5V2FMZ_NJ87RON
M[;S[B+MS6GYYNW[:%><KN7C)3WG]O7$ZG9QW5OAZ*<KTY43]_J8OTAWWW?P`
M]^=\5Q95<:AGY$YK'Q3[O-$V&GEZ?MSGU`,F^Z3,#D_3S[J5&,94>WYL!/HG
MS]XKX?ND.A;O?IGOD_R2D=HT3FP$7HKB"S,-]PQ190UJ>\T(_%%.]MDA?3O5
M?Q;O09:_'FL:[B7UB'7,VG]WLFI'BI*;F;%DGG;%B1Z`_D[..0L-4B3]UGR^
MY_OZ^#0UC=G"6*X?=+*?O&15[>7,YW2R>ZOJXOQO:Z5WOEHO1N>%/KF7U6RY
MGIN-DSL5S:XB-=55U"DR[U18=17HD[<T>U@N%ZN'-?FX4W'=5:1/WM)RMM;G
M&_,G%>EY&H7HD[=XMZ%-9T^?O*'[7=)IT-LQ8*/?#<+'.J7?AH^^\-8^UBV=
MCQG[PEL=ZIC61DP3@$Y:I\^/9?$^H5E-35;7E*T1NL6<\-!K!^$6C#^*10I"
MYN4S<_,T)8DHRBJ:0%^?#4-_U+Y2T.\ZFRW:*!8VMV`1SMPZ*G!5X*G`5T&@
M@E`%D0IB%20"T$BXFWHDV/^A'G/#U./]WG(@R"F+:7,+7L51@:L"3P6^"@(5
MA"J(5!"K(!&`)!4M$I)4PVL;CR=F3:N8%$^&+,&VM='-FVPV$`>("\0#X@,)
M@(1`(B`QD$0DDCR+4?(P:YJQ]"',-U/1IS4RY$FYD(WLF]$MD("X0#P@/I``
M2`@D`A(#240B24:OBA$1Q:P;R7A'MQT1X@>(`\0%X@'Q@01`0B`1D!A((A))
M#'J5CA"#6<MBM,18]Y,)B`/$!>(!\8$$0$(@$9`82"(220Q*#T:(P:QE,3HB
M1`80!X@+Q`/B`PF`A$`B(#&01"22&#3_1XC!K&4Q6D*1(:XU2V49N1GQV>4`
M<8%X0'P@`9`02`0D!I*(1-*'4KP1^C!K69^.",$"Q`'B`O&`^$`"("&0"$@,
M)!&))`9+8T>HT9C+<G1(7$D0.8A<1!XB'U&`*$04(8H1)1*2E6$YH)@IWT]@
M6%*O!`I'0J0@<A"YB#Q$/J(`48@H0A0C2B0D*\-2OA'*M!DB)2]\K=BRC0>)
M)<5,A_JDV.%6-).%K&<EKT1N;\7=>QQMFHW)PC!7&[F2WUOP2@%'_0.$B"*.
M?N@Z[BVXZX2CQK4L)<L/1TC9I9.BE"V2I.Q0WQ.'DN9&\!ZYB+P>-1NZN:XD
MCWYOP/L6(`H113WJ/"NY:]P;<,^)A&356(HX0K4VHY0"L$-R:*WE*+%9OLWF
M=*^:PQ$??WT^ERNYW**OY/5(#.0'N:+?61EZ$[7Z^F&Y4!XHZ!UQE4)$48_N
M-!<KS6T6^D(9E*1W1,W)(\#RTA$CT*6Q8MRVR*#`%":W,D]M=BC&%HI^"74X
M6G23>V`$H)+'*_5^?(Y6C9^5KB^5TXF`6_250D01HIBCSO5JL0%EQ4>4E65)
M[@AEVYR81HI'Q%;O4!^`-B('D8O(0^1WJ`M3P]RL-DHD!U@K1!0ABA7?J_G*
M5);[1*HE*\<RXA'*=0FTJ%R+Y)@TE0ENZS<K+KF#R$7D(?)[),P"$P+QUJ)H
MI1R/A+TO_EP1HKA'HB^(SY^T*`O/4NT1PK>9N12R'9*68U-Y^]CLD%E=C@&Y
M:.7U2.BSH42M/VAE*AN?H+?B*H>(HA[=:3$>M%);3'HK:E$6GJ7U(X3O=@%B
MQ(L;@^8(UM8!.8A<1!XB'U&`*$04(8H1)1*2E#'&;6L:<WE;TR$QKT+D('(1
M>8A\1`&B$%&$*$:42$A69MRVAI;Y9LX),<-1_UJT$3F(7$0>(A]1@"A$%"&*
M$242DI51MS7L:L18SNA5/?)RA*X.0;3;CD=8$-27F]U5%(+.0>0B\A#YB`)$
M(:((48R(78\VF5ES@-CJV%YWMK=-YZQ\S>SL=*HFN^*-7672N?3SXPVW]ZQ;
M?6ZQ+3@M;%!"5["T!1TJV5#)9JC$(&\4^0-U#':A.^C-,/A5K_H$"XN.H@=\
M+2TZE1W@*XL.*`?XVJ*SN@'^8-$9U0"G[@WUCC:H%MMM80W:IUILTX4EM%VU
MV(9TJ,2DDJ$ZM%LE?8=*Z%;\\Y"O+1NJ@3:V3-HA;EIT+X+/]'E!_@<KT"-M
M!Q_)IA)[L(1.#RRV[<5FZ,3`8KM?+*&#`XL=#0R5F%32U-%N<4(W\M?T-?L]
M+5_S2S4Y90<*\_F,W4R7[9U^^Z,NKO1NH6OYHJ:K^.;KD?[W(J,+SSE;70Y%
M4?,?U+1V^V^.Y_\```#__P,`4$L#!!0`!@`(````(0"?J#$7&`X``%!-```8
M````>&PO=V]R:W-H965T<R]S:&5E=#DN>&ULK%Q=;^LV$GU?8/^#X??&EK\=
M)"EN1'2WP!98+/;CV==1$J-Q'-B^O>V_WS,4*<YP9FTQV)>F]\R0/#X<'4F4
MJ+L??]^_#7YKCJ?=X?U^6-V,AX/F?7MXVKV_W`__]<^??E@-!Z?SYOUI\W9X
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MX!?S9R$??V-^;[*C]H=['=WFO'FX.QZ^#U"=^&FGCPW5>G6+CJ.`+>U.TO^E
M**2D3KY0+_=#'%80ZX0Z^.VA6JWN1K]AZK8AY]'(D1EUS*!YHFX=`T;@VY&&
MTO\'TM0+D8[#/48@_8I)QC!FQ":.`8(AYC1G.$5UVW495:1&J$"AXEHR>&QS
MJFG'NE:(XXA@A0FV6!5.-O6"<L&?--OK<<8S).$(8$F53*J[I$Y/C@CJZ(A3
MORPD)7N&L=_'@##9%.(X(L9>E(Q-R7+L@+3^0W5=*\1Q1(R]+!F;DN78`6&_
M6R&.(V)L.DUFWK!`$1>6"_4B204$>K/:R`^U+BG.H>.(X+F6/"_7!B5+.@%A
M&BG$<42,74$0+M+EP7VV'#U";'@-.0%)`F22;):N$&@M%0=OE/6Q"A`GH""<
MQEO=?)8D0![("-`I9%U>)KA,R"<F0L(1U]/,1%)6_$E.0)(L>2,C>T6MX*1<
M+6ZN_BQ5PXP]\R2@$Y`D0`[7GT#P0TX@0&FTFJR8:CI!3D"2`-E<?P+!%#D!
M[I-!`04YN@KK.$D"Y'6,P&?K)5@F9Q8@S`<SEEE>+UU6JA<.2;)DCHSLE7H)
M5LHY<7<-:BG(51R2!,CU^A,('LD)!"@51UTIR`E($B#KZT\@&"4GP+TS**`@
M5W%($)AD#DOU,EVBO`K/0[X?Z;T1D@4SSPHF974%(R#)EGRRMUR3X*I,K@BQ
M^=*0$Y`DD-GQY8J=:->-$"<0LA+D1)8D0';87X%@GER!`*71ZHF"G(`D@<QB
MJ6`FZ5ZL]TW-1)MOA%!]S&$6><&$ANF*SZ6&J"')EHRROUS!5KE<`>)R*<C1
M[[?]>$+FUY]`L$I.@+MG>X#[/N4924!2`3*__@2"57("W#T#`06Y"8<D@<QC
M/WE&FFCSC1#$9_6RS.LE-.3UPB%)EHRROUK!5KE:W&F#6@IR$PX)`G0?VY^`
MSY:N&R%6L!IR`I($BBQVJBTV0IQ`R$J0$UF20&:Q5"_5%'-<>$:::O.-D"R8
M;"FE3EG=&4E`DFV1'T^U'T<H:5-KR`E($LC\^/(9::I=-T*<0,A*D!-9D@!Y
M7^]#AB8RNT.,4!JMUI`3D"206:POF,4G"D:;[S1`LF"R5:,Z9:6"Z1KF9Z0I
M&65_N8*M,H?Q'0CWKS7D!"3EROSX2L%HVYT&B,^7@IS(D@3(_/HK$*R2*\#=
ML_78J8*<@`2!6>:QOF#6Y07C^Y'N&R%>,'ALD9V24E97,`*2;(L,>:8-.4)L
MOC3D!"0)9(9\N6!FVG8CQ`F$K`0YD24)%'GL3'MLA-)HM8:<@"2!S&-]P:S*
M5V%FVGTC!-+=-<QDK)9RM2&GAKG#S%!\_8\OGYT5,74@'29F)06=@*1<F2%?
M*1AMN[,`I=%J#3D!20)%'CO3'ALA3B!D)<B)+$D@\U@JF`D=XH77,#/MOA&2
M#I.O[Z:LY#"A+W\=+-D6&?),&W*$DC:UAIR`!(%Y9LB7"\9GRXJ-$".@(2<@
M2:#(8^?:8R/$"82L!#F1)0ED'NL=ABYY"@MFKMTW0K)@\G7>E-45C(`DVR)#
MGFM#CE#2IM:0$Y`DD!GRE8+1MCM7AEIKR`E($B"+['T-,Z?LK&(#Q!50D(L-
M?98DD'DL%<PGENWFVGPC!#;LC)2O\Z:L5"^A+VTP\R(_]MF96LI\ZYB5!'0"
MDFIE?GRE7K3KS@.41JLUY`0D"119[%Q;;(0X@9"5(">R!`%ZM,@+ENKE$X\;
M?3=R;B(DZR5?YDU97;T(2)(MLN.%MN,()6EJ#3D!20*9'5^NEX4VW0AQ`B$K
M04YD20)%#KO0#ANA-%JM(2<@22!S6']"HA-HX0EIH;TW0K)@\F7>E)4*)O2E
M#8;N]GEU7YDORLZ*.$!<+@4Y/PP:^BPI5V;'5PAHUUT$B!-0D!-9DD"1Q2Z"
MG[*;Z@AQ`LIUG<B2!#*+_>P5S$*;;X0P(>R,E*_SIJQ4,*$OHV"*_'BA_3A"
M7"[MQR)+R+7,_/ARP?AL6;$18@0TY`0D"11Y[%)[;(0X@9"5(">R)(',8ZE@
M)L2WT&&6VGTC!%MD!9.O\Z:LKF`$)-D6&?)2&W*$DC:UAIR`)`'3D,O5TGZ\
M#)!4*U_D3%E)K:XA($F6O+/WY3%=MV9^'"&NEO9CD24)9'Y,Q44+%J6UI8UZ
MV;DRJZTJ7^%+64FMKJ%2J\B[E]J[(\35TMXMLJ1:F7=?,2/MT,L`<0(*<B)+
M$BBRXZ6VXPAQ`MJ.198@0(MYO&"]&='=5V'!^'ZD44<(G24SJO(5OI35%8R`
M)-LB[UYI[XX0DTM#3D"20.;=EPMFI1TZ0IQ`R$J0$UF20)$=K[0=1RB-5FO(
M"4@2,.R8GCA<44*[[RI`_CW^]F%&@GC%9$M\SLY*ZSJ2+IEG;T->4796Q0'B
M>BG(Q88^2Q+(#/F*3MIW5]P^@TX*<B)+$B@RV94VV0AQ!;3)BBQ)(#-9LI@>
M%:/-=A4@7C$==+%BS*RTLB/I%EGR2EMRA+A>VI)%EB!`;[GV+UF?+4LV0HR`
MAIR`)($BEUUKEXT0)Q"R$N1$EB20N2Q5S+RZH:N>RX?/6AMNA%C1).A2T=A9
M:7E',BZRY;6VY0@E?6H-.0%)`IDM7]%)V_$Z0)R`@IS(D@3(%'L;+3UTSHPV
M0IR`-EJ1)0ED1DM%0S5>>"&SU@X<(<P:NY#)UVU25G<A(R!)MLB4U]J4(\35
MTJ8LLB0!LD0V7:06O5Q=JE9P5K:>L@X05VN:SL[M&2PE);&Z=OEMPKK(D7UV
M9HC*?NN8E?1S`A)B5>/,DKU:]+9NH5QM1Y)<AT%]5E[Y*@]+ZR236$:YR,2K
ML7;Q#DL:U0:&323<VS,6F9-?MJ5JK/V[PP2+D)<PL.!8QJ+(G:NQMN<.2R-"
MBY"7,+#@6,8BLV@JHBE55G$1:?>NQ@&3192O_+`T5D1=T_S`J\9DP,PEKDT?
MI>?5';`D$H13&(3C6"9<YNS76&@'K\8!$RP4!A8<RU@4678UUI[=88*%=FV9
ME[$P?)N>)Q77D#;N:MPY,#>B?#V,I;$:ZIKJ&BIR[VH<O)J=43I,Z*8\';/'
M,:F;W^G6OY+CQCC.(F)^4;T]C54:PY8V.EGXLZG2PF]W*V!AF++8,1=9<`/V
M&%AP+-,B,V4RHL_44-P/)T0*+HRC.9W,)ODJ(>W>3QI%QAQK&;<[]-N=Y?OF
M^-+4S=O;:;`]?*/=]_0;'^XZO/TXP"/J$Y\'0"U#?1U;4VQMQJHQ?5;`?QE`
MM:O\)P?\!GT=FW2?(U"Q,<5P9C*Y3"GF:UJWFU',"ZMC<XKY*M2Q!<46]GA+
MBBVMV!K-<+%JL%RC$:XBK0ADQF6<%8'(N)@R(KA@(0ZVQF/2&-<21KL5>L0-
MLQ%9HT-<Y5L1=(=;3"L"X7$G944@.VYQK`A$Q[V'$5EA'"P86A%,/E;RK`@8
M8(G-BF`<+"99$<P15GFL".8(RR]&9(G><-=L1=`;UNJM"'K#BKD5P8QC*=N*
M8'ZPQFQ$5I@?K.<:D07:X#&A$5FB#9Z'61%HC0=K5@1:XR&6%8'6>+ID13#;
M>+IC1!9H@U<$K`C:X`F]%8'6>$YN1:`U'F!;$6B-)\M6!%KCP:X1F:,-7OBQ
M(FB#-W&L"+3&*S)&9`&MX?U6!%KC11$K`JWQ!H<1F:,-WO6S(FB#]^JL"+3&
M"V]6!%KC330K`JWQD,**0&N\HF5$9FB#)V%6!&WP3JT5@=9XV=6*0&N\:VI%
MH#7>^#0B<VB--TF,R!1ML"1J1&9H@_=GK0BTQKOK5@1:XZ5R*P*M\;:W%8'6
M>+/:B$S1!KMPK`C:8'N,%8'6>(G3BD!K;!NQ(M`:FS>L"+3&K@HC,D$;;,"S
M(FB#;7)6!%IC&YH1F4)K[`^S(M`:&[>L"+3&)BDC,D$;[*>U(FB#C:Y6!%IC
M!ZH5@=;8[6E%H#6V85H1:(W]D4:D0ANL]E@1M*GL-M`:&\JM-M`:.[VM"+3&
M%FPC,H'66$`Q(FABMO"79V:+]N+,ZJN"TKC4-$:IH'3[.I.ZAH+2[8<LL@@^
M._7%[@L-K#%HFBV<#B@#_S*[_1(^:Y6-_$@'I]'B$=-HSB(FT9Q#3*$Y@YA`
M/W^C;F!\SNIC\]+\LCF^[-Y/@[?F&1?<8[\$?VP_B-7^XWSXP(4X/FIU..-#
M5OY_7_'EL@;?HQG?X";@^7`XQW]@&D;=M]`>_@L``/__`P!02P,$%``&``@`
M```A`'M3L91;!@``=AH``!@```!X;"]W;W)K<VAE971S+W-H965T."YX;6R<
M65V/HS84?:_4_X!X3X)M/D>364U8;;M2*U55/YX90A(T(43`[.S^^UYS#;9O
M2";T)3,AA\OQN1_'<1X_?:^.SK>B:<OZM';9TG.=XI37V_*T7[M___5E$;M.
MVV6G;7:L3\7:_5&T[J>GGW]Z?*^;U_90%)T#$4[MVCUTW?EAM6KS0U%E[;(^
M%R?X9%<W5=;!VV:_:L]-D6W[FZKCBGM>N*JR\N1BA(?FGACU;E?FQ><Z?ZN*
M4X=!FN*8=<"_/93G=HA6Y?>$J[+F]>V\R.OJ#"%>RF/9_>B#NDZ5/WS=G^HF
M>SG"NK\S/\N'V/V;B_!5F3=U6^^Z)81;(='+-2>K9`61GAZW):Q`RNXTQ6[M
M/K.'5,3NZNFQ%^B?LGAOC?^=]E"__]*4V]_*4P%J0YYD!E[J^E5"OV[E);AY
M=7'WESX#?S3.MMAE;\?NS_K]UZ+<'SI(=P`KD@M[V/[X7+0Y*`IAECR0D?+Z
M"`3@U:E*61J@2/:]__M>;KO#VA7A,H@\P0#NO!1M]Z64(5TG?VN[NOH704R%
MPB!<!1'`7GW.ESP.6!!^'&6%C/H%?LZZ[.FQJ=\=J!IX9GO.9`VR!X@\K`QY
MC&N]ME18HPSR+*.L72AW6$4+^?GVQ`+^N/H&FN8*LYG`V(AT0,A4`+V1(ZS<
MY#BM^D!%@B45F07);8,7(/;(C3!+)Q#12,UB`@K=ST2"(=/&@UD@QKA(#C'^
MR#8U+EA/]N<\68+7+BQK7#(+?/)DQ(1]LA9<1%X<$W*I#6%^)$(V1K'8016;
MNL@J\J_VQY`I>1/5)QCCHSZ(,?0Q+E@,0IO![1J18*I/2)Z,F*C7QP^XIU?>
M,TO-ST7,DRL5$\WA)<&4EXZ+BB`&4C/F5M"\#1#9APO-V])+6I/1][?UDF#*
M*R9Z(>8F+X2@I(''_5!GV^*6S.$FP91;0K@AYB8WA""W!8N"2.@I89%CX![W
M*]>C29&''J&G0$:5FU?LI\L9:>1-=IH`1K?SQW"R6@/!:&4L+`5""5CD^X1F
M:@&"4/BZ96R.<I[.YXA3V.:H<Z`X(@@Y<I[$I`I39@)\9HPTFZ(<L_,IXG"V
M*9+FVS`$*1E#G@07.IJ(!0\C/9IMDG+^SB<I[R(-$>HG*!T1I'1DW!<70B("
M7J?FC,U3SN3Y/'&2VV+J@:!X(@AY+B1/C_1V*O=AL%X%\;W0W'G8/&=Y!)LP
MB5!7O.)GN8`(P47MWDY5F*$<KH^564;!)IPBI$ZA0$H9[@D?YAJEAX$&#!->
MR/42;/EF60;#80^E/M8/"W5D)=]@&L-F+56W]:/0?OHL4V`3KA"2RMDHT)42
M[QFF(Z;?TX[B6=0X<83[9G)_%^G3B(R*C0*I]+`$]B&"]')J8Z+(-V2V>1+O
MN.T9?,(S(KV9P`0JT$T)%68HL2CP=1G8_.3L-N;(!_QPTEOS(Z)^P1%T6S\;
MXP4>TUUB$Y2#^WZ"..:M#HBH6W`$&=9O7K&?+B>R\?0[RTS>1<N,E-"&(PAE
MBIG/$Y+HU$)PR&$8:JUMFL0-/LCBA`O0(;617V_'$1^)"*8LZ>540:X4HDUP
ME@WP"1N(J`THD"JS.!%TBY?:"/`)3[>ZS8[XP)U9GO"#B/H!MV8]\P7GC-1C
M:F,XBYG0B[6)$CNXDRA.?+MK]3Q04P5!*&<8ADGLD;6DW(3`-PF8C-=XSC(.
M/F$<$2FVC0(A/W!,7Q!$:B$6G"6^,=HM&>7F?7Y7]W>1KHYU1:&,"H0T>9)X
MGJ`R6A#F^T8]V"R)==R7;#%A(3&9+!L%0I8LCA(RG%(+`!M5'<"F*,?X[/$H
M</A;]1CKR::$1-"0;WE2HDGTD%3%F5J%S7*6A8@)"S&^TBAV%Q:B;KO<1`EB
M(;=G<X^F14:RLU$@7'C,8Z;;4"EC>@OCX;7OU6*6;_1HRDW;ME(&?>.**2AZ
M-S%V[HAQW-D$:""0)+T1CHE(&X$@8QM@7K%9$(/X((<3QA#0>2L0=%LGTSQN
M'=[`.?S_Z<,)7XC)M-KTH>%DT9#RXNQ+8=2YYN1!#A[SXREX533[(BV.Q];)
MZS=YA,_AQ&^\.OZ\\,SE$2VYOH&?'?HS^M7X`9SZG[-]\7O6[,M3ZQR+'83T
MEA%468._&^";KC[W9^\O=0?G_?V_!_A]IX`#:V\)X%U==\,;>1P^_F+T]!\`
M``#__P,`4$L#!!0`!@`(````(0!<`S3X)@4``&H4```8````>&PO=V]R:W-H
M965T<R]S:&5E=#<N>&ULE%C;CN(X$'U?:?\AROL0#(2;@%&3VXZT*ZU6,[O/
MZ6`@:A*C)-UT__V64[G8989)]T,#)Z=.<EQEN^+-U_?L8KWQHDQ%OK79:&Q;
M/$_$(<U/6_O']_#+TK;**LX/\47D?&M_\-+^NOO]M\U-%"_EF?/*`H6\W-KG
MJKJN':=,SCR+RY&X\ARN'$61Q17\+$Y.>2UX?*B#LHLS&8_G3A:GN8T*ZV*(
MAC@>TX3[(GG->%ZA2,$O<07/7Y[3:]FJ9<D0N2PN7EZO7Q*174'B.;VDU4<M
M:EM9LOYVRD41/U_`]SN;Q4FK7?\PY+,T*40ICM4(Y!Q\4-/SREDYH+3;'%)P
M((?=*OAQ:S^Q=<26MK/;U`/T;\IOI?+=*L_B%A7IX<\TYS#:D">9@6<A7B3U
MVT%"$.P8T6&=@;\+Z\"/\>NE^D?<_N#IZ5Q!NEUP)(VM#Q\^+Q,849`935RI
ME(@+/`#\M[)4E@:,2/Q>?][20W7>VM/YR%V,IPSHUC,OJS"5DK:5O):5R/Y#
M$FND4&32B,!G(\+<T6SB+I:?49DV*O#9JH#@P$>8-<'PT%WP:+)TF3O_A)%Y
MHP*?O<IG1V/1B,!G+S+T41S,3YUN/Z[BW:80-POF$&2@O,9R1K(U*,L\3Z%:
M,"M=YG^6>,BX%'F2*EL;)C^$EU"M;SLV66V<-ZBPI.'LD0/_>\YTK'.\.SI3
MIG/\EB.+3MX\:`%%6`\)6T8;$B%05YL#`]&-!A2&.AKWJ[TU+<G2=*NZ1P"T
M%8<3_5&\>YRISO'O<68Z)S`YY$ZAR6!35U>)3,YDT5&TD8'9HXY,6R>/1T@&
M03UI`S+O].OL[9$SZT;1HX!/@8`"(04B!=!<P'3^O`L9M+5AJ)2T]J.$+I"C
MN*"`3X&``B$%(@3F]7SJ9Y-F"-8EU=#C=$@R-;(DZ4".8H0"/@4""H04B!!8
MU4;FL()W]]2\P.JH>AE68C*(>NK'"I.#',43!7P*!!0(*1`A\"M/L*1^WI,,
M(IYF9*7<(T?Q1`&?`@$";(SK<Y>#>HQ"RHX40,N2[/#N;!B/*T\&44=D7=\C
M1W%$`9\"`0(+K*MQ_4=LT9!(`31;*]W68SN23.WT18U%AQS%#@+XL,OE:KXB
M*?7;B'K[').K@1H^`ZO$J'K97;KT>M2*PV:E^89RT/+YV'C-IL[)]K5O2(IU
M`_$-)&@0'!\V8Z9%(R92$=V5W."5*OV%*VP'M!5^1C;</4,2KL9F`KSF>N_:
MUR*,C`1&0&@@D8KH!N7./=P@[O.Z0=(+[!F2?IX`KV&H%C&F1P*#$QI(I"*Z
M*[EO#W>%N[SNBK873&D%ZHGI-0CZG$W=Y7)!-@S?"`H,)-1D)JN)D>!(C=%M
MRHU]N$UL`W2;M/]@:J]`,NL]NN@_NA@T%_O\AH_HD4K7'<L.8+AC[!=TQ[11
MD6^CL`AC&N<+8[GP-,)R-9V3)=-O"+VYP$!"`XE41/<H.X+A'K%_T#V2.MPS
MVG5X!N(;2-`@38'?VQ6-F$A%=%>R#QCN"KL&S95+QGW/E-:BF9(4\0U.T""X
M_I(*#PUZI"*Z(=D!##>$_8)NB'8N<!`C2[$O),]`?`,)&@0-P?&6_".;NA$D
MSWRZ6Z$M/,+!=_J,%R?N\<NEM!+Q*H]GIM`;=6AW=/0TD:];!/?8&MZM33Q@
M:WB!EGU#%P`G/=?XQ/^*BU.:E]:%'^%6X]$"IF2!9T7XHQ+7^H3A651PQE-_
M/<.9'H>W]O$(R$<AJO:'O$%W2KC['P``__\#`%!+`P04``8`"````"$`O3OO
M,"8'``"P'P``&````'AL+W=O<FMS:&5E=',O<VAE970V+GAM;)Q9VVZC2!!]
M7VG_`?$>FV[N49+18&!WI%EIM=K+,[%QC,8V%I#)S-]O=5=#N@L&XTFD."Y.
M%9RJZNIC]\.';Z>C];5LVJH^/]ILY=A6>=[6N^K\\FC_\W=^%]E6VQ7G77&L
MS^6C_;UL[0]/O_[R\%8W7]I#67861#BWC_:AZR[WZW6[/92GHEW5E_(,5_9U
M<RHZ>-N\K-M+4Q8[Z70ZKKGC!.M349UMC'#?+(E1[_?5MDSK[>NI/'<8I"F/
M10?/WQZJ2]M'.VV7A#L5S9?7R]VV/ET@Q'-UK+KO,JAMG;;WGU[.=5,\'X'W
M-^85VSZV?#,*?ZJV3=W6^VX%X=;XH&/.\3I>0Z2GAUT%#$3:K:;</]H?V7WN
M.O;ZZ4$FZ-^J?&NU_ZWV4+_]UE2[S]6YA&Q#G40%GNOZBX!^V@D3.*]'WKFL
MP)^-M2OWQ>NQ^ZM^^[VL7@X=E-L'1H+8_>Y[6K9;R"B$67%?1-K61W@`^&N=
M*M$:D)'BFWQ]JW;=X=%V@Y4?.BX#N/5<MEU>B9"VM7UMN_KT'X*8"H5!N`H"
MKRH(<VX.XJH@\-H'\58\\ID?W/`HGHH"KRH*=U<A<V(W7,X'D#(I\-H'B6X.
M$J@@\*J"N.[2I*RQ2K+H:=$53P]-_6;!2H(ZM)="K$MV#X%%M:&[?E!M*+/P
M^2B<I"N@6VC1KT]Q^+#^"EVU59!D`A*9D,T$)#8AZ1C"',?$9%,89F+R*0P?
M,&O(Q9`0:#D](=-MWR="@!]M^#LD@CGN$%<F*T&,)_M;9&^#AD#FS7??'T/"
M4_TJXQ$+&2>03(?<L="%W\`W[YKK&!9%/'I/FT$7%H=.=UG]A1.E[9D/D"!&
MHXV&4-%F$?-)E5+JDE%#KAD,%K`X*8O@:A<+)\J"I#%!C,:B-XBFYX').<6+
M2)&[ONN.2M>[OS>,2_HEGX48K&&:W,Y:.%'6A$>"&(TU&A2Q@`6TW5+JD5%#
MKAD,$C!T*`D/L//K3CA1$G0"(48CT1M$Z1AIUQ0O(L.8!VY(%UWO/5.Y68A!
M.OP9TL*)DB8S-4&,1AH-R(MYGLOIHJ,>&37DFL$@(10?V3JN5TXX41)DZB>(
MT4CT!KGH".44+RJ&8>B$[ONHDR,UZ]UG2C<+,5C'/\-:.!'6C#QE@AB--1K4
MH@O]*""3(J4>&37DFL$@P6`XWEX[Z45ID'Y*%$@]-HN]D!#=*`3,N6'7I$,P
M78#)%F!RXVGNN/DX9DJ$1M#:>7X`,504L,L.'"+2F(G"8";@WE[H!B1;&X69
MSP7>:PZ3+;A7/G\O,QE"/BQ/!HH-/1F,D?F9,`2I;+`@\MBX,Q#C28T04*67
M&B%8&`6A[Y&M*S,P=RSV.3P*`>4FR&4L?N]1,P]"<"S/`\H3,P]DT29,TS!R
M/&V4!3,#K,4/$18CIVQDR76+24(H"HV$_$3G7MUCF7"CJYULFXD":5-KL,AA
M[1"'5%U6;1#&GDN*DPT!WI<6'0_Y/,9D+X3'3[!'O6+6DJI#\;D84J2S1PO2
MXXXW54OJE(W"Y+K%9",T!F$37U6Z#)6)28;D/5$@G4PO:"85D\*KMO7#."+I
MR8:(<Y7L[S&),;D+(7([=Y0O)G>J%9FF<=2B1`NR8YX_L2:I3S:*DNL6DXL0
M'(3+]4\L#&6*R66T[?1:1GPW(S]P*C<<J\[*(9M0:EP'IN;PR8;+DR62M\CG
M,29U(4INIXY2QJ1.A2/3](ZBWEMD"U-JZ<@A&UERW6(0X1,B2GPG-*\<I!<9
MJYRD/%$@;2T.%D$D(L13=16[U7/]V*%%SH8`,U6<QYCDB5P2F\H"\F/9Q.@G
MDH3W>F=H8&5!>E$4!]I^+>N<CGRRD277+287Z"K:D0NX""]:2*IZ.(+T0O86
M44@R@U,%1Z(\YEY,]L]L"#A7QOX6DQB3.A$X"\LX(70X%3I\)'24!=GYT6C2
MI".7;&3)=8M)94+F7!^I?$+E<)+T1('T*J(;CE2/+-]4X9$HB^$G()!L"#E9
M(QRJ\QB3O!`59*@N:&&4(M`NPZ<8^);>'/^)^*[<%#G*@O2DQ"'LTI%/-K+D
MNL7D,J%QKG^QP*<T#MGI$@7")W>=P'/))-TH!)1W2`E5G^D"3+8`D\\]C9D1
M(36TZE[985"8F%4EDR;A5+UL!LL<\][KQYALB",&')F'^7!Q,H!)FDBD*Z3'
MTFCT@9PC!JM_Q]W0B2(RM38*,U__7F%-DI!K-UMPKWS^7F8RB&BZDHP)L<2I
MYN4(PG,(UXLX]\C2WQB0V">Y2HW+W'?BR/')),@,#'P)$L5PGDL>)3=`//1A
MWQN&D)$&<32U?"%(--VAJ5Q6(&VV*PNV";!V^4ANC)RRD44<T@YS$TG@F2L>
MOUV*E_*/HGFISJUU+/<P;)R5&-@-GKCBFZZ^R&.VY[J#DU+Y[P%.QDLX18+C
M4-O:UW77OQ%GNL-9^]/_````__\#`%!+`P04``8`"````"$`JG_'_,@"``#^
M!@``&````'AL+W=O<FMS:&5E=',O<VAE970U+GAM;)2576^;,!2&[R?M/UB^
M+]^!$(54+56W29LT3?NX=L"`58R1[33MO]\Q#BR0KNMRD<3F]<MS/CALKY]X
MBQZI5$QT&?8=#R/:%:)D79WA']_OK]88*4VZDK2BHQE^I@I?[]Z_VQZ%?%`-
MI1J!0Z<RW&C=;UQ7%0WE1#FBIQU<J83D1,-2UJ[J)27E<(BW;N!YL<L)Z[!U
MV,BW>(BJ8@6]$\6!TTY;$TE;HH%?-:Q7HQLOWF+'B7PX]%>%X#U8[%G+]/-@
MBA$O-I_J3DBR;R'N)S\BQ>@]+"[L.2ND4*+2#MBY%O0RYM1-77#:;4L&$9BT
M(TFK#-_XFSS&[FX[Y.<GHT=U]A^I1AP_2%9^9AV%9$.93`'V0CP8Z:?2;,%A
M]^+T_5"`KQ*5M"*'5G\3QX^4U8V&:J\@(!/7IGR^HZJ`A(*-$ZR,4R%:`(!O
MQ)GI#$@(>1I^CZS438;#V%DE7NB#'.VITO?,6&)4')06_)<5^2<K:Q*<3$*@
M/UT/G&"]\E?QOUU<2S0$>$<TV6VE.")H&KBGZHEI07\#SF-DEF.*]6^A0HS&
MY,:X9!BZ':)04)['71ILW4=(:7&2W%Y*_+DB'Q6F$D`W(4+@YX@O)WTD,6)#
M8HI@T&[M!GA/:`NR_`5%,J'-2"!!YR0F62$TT^M$YA#HS@#2<+*WC%823=#Y
MV<8,()H#O'YC(\XP1#=%GD:+&UM)/%3L*@@3;[U>L.5SB1\E8?RG<#,X:.7S
M[+P.9\0+N-4"SDH2"Q=Z<12F<T4^4P1^&B7>I)BAQ?^#9L0+M'BRM06SDC%O
M@`:?N03&D7$9)6$<K\-EWNR\L8\CI[*F.6U;A0IQ,+,D@,"GW6G,W02F2Q;[
MMS#^AF'A3A=@_/2DIE^(K%FG4$LKL/2<!%(F[0"S"RWZ80CLA8;!,_QMX#U#
MX='Q'!!70NAQ81[,Z<VU^PT``/__`P!02P,$%``&``@````A`$_H(+!E!0``
MPQ4``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&ULG%C9CJLX$'T?:?X!
M\=X!LV13DJL&W#-7NB.-1K,\T\1)4(<0`;W]_90I(&4[G>7V0Y;#J<IQN>SC
M]N+;1[&WWD15Y^5A:;.1:UOBD)7K_+!=VO_\_?0PM:VZ20_K=%\>Q-+^%+7]
M;?7K+XOWLGJI=T(T%F0XU$M[US3'N>/4V4X4:3TJC^(`3S9E5:0-?*VV3GVL
M1+IN@XJ]X[GNV"G2_&!CAGEU2XYRL\DSD939:R$.#2:IQ#YM0'^]RX]UGZW(
M;DE7I-7+Z_$A*XLCI'C.]WGSV2:UK2*;?]\>RBI]WL.X/UB09GWN]HN1OLBS
MJJS+33."=`X*-<<\<V8.9%HMUCF,0);=JL1F:3^R.?="VUDMV@+]FXOWFGRV
MZEWY_EN5KW_D!P'5AGF2,_!<EB^2^GTM(0AVC.BG=@;^K*RUV*2O^^:O\OUW
MD6]W#4QW"".2`YNO/Q-19U!12#-"&5FY!P'P:A6Y;`VH2/K1OK_GZV:WM/WQ
M*)RX/@.Z]2SJYBF7*6TK>ZV;LO@/24R*&I)X71)X[Y*P\2CPPLGTGBQ^EP7>
M^RSA_5F"+@NH[[-X(V\:LG!\?40.5J<M=I(VZ6I1E>\6=#",OSZF<CVP.63N
MJXPU&>K^5=FA5#+)H\RRM&'I045KZ)6W%11IX;S!_&8=)T(.O`X<IC+B,PS?
M53E)SY&S)'^:$\"!,0T#@RFC`SO?-KU^29;Z^ZP1`E2LIPJ)34;@C55.8G*\
MB4KA)B4@'&5$T#YT1'*J?%A6ET<F@X!'JAYX4U5#A)Q@&'VL`XD.<`(H&J%)
MJ<;+VB1Y:4,%AHX(O)FF#3G,;9M*+G7U>8S/3]H3'>`$4*1"MU.IMY53!FF2
M]1:-D/.U9'Q.).L`)X`B>:Q*OEQ=2=:E:BLN0@Y4:)@!W]<*W%/ZI9'H`">`
MHG:BJKVMP#)(5<T";0^(D-,56!M2C`])=76`$T#1*T\.VE9X?7W)(%VO)BE"
MSJ1MX;';_FE%1@81K0.<`(KHF2KZ<DM(LBIV'*A*(J3,6JV,/VB/8WQ,A%[F
M<\)79,/D*<6^K+MEJ\(#7]N0HXZ$96;3T`WU5NX81+V!<(JHBJ71D/:XHAAM
M2=G;]*45,22-VV)[H3N=A-KV%W<4*AF#3@BG'%6R-)?;):,5J9*U^8\8DDZ_
M'AM(8B"<(JI"Z2-$X6U[!$/W@==AVS)-K2-1I<2TVK-#8G`X152ETD;N5XKF
MH]94L["($8=J=<4=@JT<GMLQ$B.(4T25+NWD?NEH0E2ZN1/+`SGL*+3(B,`R
MDJ=`;2=,##ZGB*I:VHJF.H#D5]8=FA%5'?C:L2QBQ+&Z@O=(*WH4S*;30-M?
M$B.*4T35+BU&TW[=2A@:$]7.`JV"44>B%<>P"_:2&$&<(JIT:33W2T=[HM(#
M7SOJ1HQX6%=V1%!Z$)QQQL0(XA11I4NS(=*O=`I:$Y5LF"$C]M4I1N0K?TR,
M"$X11:ZG6>!M>U\;I5NA?J#O2*1).J0S1RRUZOR)$<0IHDJ_RPN]<UZHK:ZH
M(U')&-9)/N/GB1'#*:(JAGFFO7%CL6647FS-HB,/2:AS%OJ^-],.K'%'.0TN
M48+.G@FY0@E]-F7A:3-0!_=3+NJA'=(%`'VA-D74D4[*8P-)#(131%7Z4R[J
MH4%>]ON.1)7JOIH8'$X15:GT,;*9W-@PZ'Y*37VC89!$E2*"+31UVXU0G8A$
M7O$H3BLOWP8$I>-=&E[O%*+:BECL][65E:_RGHR!(P_H<(?WZ+6W<,,#N$([
MIEOQ1UIM\T-M[<4&0MW1!'ZLPDLX_-*4Q_;RZ+ELX/*L_;B#RU(!5S+N",B;
MLFSZ+_"OHS-<OZ[^!P``__\#`%!+`P04``8`"````"$`P&U+HA4#``#'"0``
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6R45EMOFS`4?I^T_X#\7@PD
MS4TA5;JJVZ1-FJ9=GATPP2I@9#M-^^]WCDT8A+1)7K@</K[O7#DL[U[*PGOF
M2@M9Q23T`^+Q*I&IJ+8Q^?WK\69&/&U8E;)"5CPFKUR3N]7'#\N]5$\ZY]QX
MP%#IF.3&U`M*=9+SDFE?UKR")YE4)3-PJ[94UXJSU+Y4%C0*@@DMF:B(8UBH
M2SADEHF$/\AD5_+*.!+%"V;`?YV+6A_8RN02NI*IIUU]D\BR!HJ-*(1YM:3$
M*Y/%UVTE%=L4$/=+.&;)@=O>#.A+D2BI969\H*/.T6',<SJGP+1:I@(BP+1[
MBF<Q68>+^W!"Z&II$_1'\+WN7'LZE_O/2J3?1,4AVU`GK,!&RB>$?DW1!"_3
MP=N/M@(_E)?RC.T*\U/NOW"QS0V4^Q8BPL`6Z>L#UPED%&C\Z!:9$EF``W#T
M2H&M`1EA+_:\%ZG)X6KBA^-@`FAOP[5Y%,A(O&2GC2S_-IB&R7%$#0><&X[1
MQ+^=!J/P/`EU_MCP'IAAJZ62>P]Z!B1US;`#PP40GXX'`D'L&L$Q@9X&7S44
MX7D5S29+^@R)2QK,O</`L<6$+8*":*L,:I<K(QB5,;/HRKTS=&6BTS*C:V00
M'!,XMLY'LVG+ZY0=9FS;I1O/^!HA!$/*X=11FATI-:!)#S1O0;UL0AM=GDT$
M6_4VG<XR#`JT+Z=%<)^VL42#9$VOX45PG]=9AN[BY[;3S3BE<YCU][L:7^K3
M-Y9>XN?!Z<3/^Y+O2R&X+^4LPTA"<+L;RON\%MTG/IB&N0]Q1#M9.D/=#+1U
MT4V`)8C)":>/9MI])4?^%-KKC$HSSUV5Q@2G_S,R?^-C$EXUYA9]E*ZWQAIG
M](ILM8/=CI8E`+$3A;AJ:''='#5/8SI1B*.YQ4*,H-7.%&$XP+!3K6B_",>?
M6K<VW5XIN=KR3[PHM)?(':[$"#9%:VW7]=KFX]@^7JS=&J?M$UBC-=OR[TQM
M1:6]@F?`&=B>4FX1NQLC:\@R;%-I8(/:RQQ^F#ALB\"'W&52FL,-%(>VOV"K
M?P```/__`P!02P,$%``&``@````A``74HQ0A!P``,Q\``!D```!X;"]W;W)K
M<VAE971S+W-H965T,3<N>&ULK)G=;N,V$(7O"_0=#-^O;4FVDPA)%K'UCQ8H
MBFU[K=A*+,2V#$G9[+Y]9R12(GFTKKWHS7KS<3CB'`[)H73_^=MA/_J:E55>
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MO^YJFNX%1<2!N=OO7E9M2%%R,[$7[&E3[&D`]._HD'-JD"+IM^;W(]_6NX>Q
M[4RL^6Q)UJ/GK*J#G#V.1YOWJBX._[0VEO#4^K"%#_H5/ISE9'$S<ZPKG#C"
MR;QS8EO=0,X\G(;9!$"_,@![<KM8S)>W-\3.]%R*GO0KAWU9QQO1D7[E(R\:
M*JVY9JCT*_K->YG.#/1.]*-?^;P+0[0HG]KIY<1JY\XY&^2TS8\FW;RT3A_O
MR^)C1&N84J`ZI;PC6"Z[E8G6CKM+O1]E'J4<>WEB-P]C4H"RJJ+E\O71<6;W
MTZ^4XAMALT(;2[=82PO.9W;KF<`W06""T`21"6(3)`J8DBR=-I3X_X<V[(:U
MD5&M).C%L@TAI(7LXIG`-T%@@M`$D0EB$R0*T(2@1:P),;P+R5Q@ZX<Q_:OD
M@C'3J];&<CI1UD`\(#Z0`$@()`(2`TE4HH5.^Y86^D^N#W9#2XQ^%%&,65\)
M(]K>%"/'2(W.J,L-(#Z0`$@()`(2`TE4HNE$@]9T.I\B;-W((8-8":(D!!`/
MB`\D`!("B8#$0!*5:('2L7)%H&RM!RJ($B@0#X@/)``2`HF`Q$`2E6B!TC%X
M1:!LK0<JB!(H$`^(#R0`$@*)@,1`$I5H@7+-;!Z!#AV%5QZ![$970!#:6Y3U
M/#?6<V<DEX('Q`<2``F!1$!B((E*-%&H*-%$.;^>V5J/71!E]H%X0'P@`9`0
M2`0D!I*H1`N4BYXK(FW,]5`E4F)%Y"'R$06(0D01HAA1HB$]9JYXU)0_/[M6
M6R#1Z25S="61&K.PZI&'5CZB`%&(*$(4(THTI,?,Q8T:<WN23_@V4>_RS=NJ
MH%5*,0QHX5!%*^K<MD32I&A1+\[:,HDGB;H5V/,[?2OP>RNI<X`H1!0ABA$E
M$O$LZM)P]0/2T%U/*/.E.#7*7"&3J*=Z4594Z_$>T9,U$$^2>7.#L&>6L5GZ
MO4&OD.DWE$9=MD:2='Z-HBKN#:3?1")4BVL@4&O1)Y*4:R"1Z.+<99(HI7I!
M5EP>\C9*)Y5R8"ST+%GW5G*L'B)?($?WM=1]!7W'_HFV8]2E86\EGQCU2.EH
MW^KNX^%!W.A6R:`O91!ZKG)A9JK/I_5_J"WJ.57M%M%;G#X$QS%"6/-+%YJ3
M]EV/N)0"\H65<]LD[LUB1JEKJ!B@IQ!1A"C6G3N+Q<WMG9'`B=9-%XP+/!2L
M3]?+]CU1)JKZ":1GF+&GK:W.2N:.)Y!SURU07Z`YS6.7^;9C9'Z`OD)$$;J/
M+W*?:+YT#;EV/*?AA4N>W1BU0XOF=.YT@3MSX\W)FG<$WCO;-WWMFQ&!EHJ(
M`IU-0O`4HO-(HMYY+%'K_`=)J#K7!>0ZTQ30)O,KCA11JJH9V**YMH+GQJN&
MM26L5/$$NE'$$ZA/R@`[AH@BB7I?L42]KT2B9A"Z-%R9FM)8UQ\GHL!5Y5%K
MWF;K6EN`/$0^H@!1B"A"%"-*-*1I85]7BS?F^GJ2J"]"UX@\1#ZB`%&(*$(4
M(THTI,?,9;,Z_^</,EM4V<H\2Z3&+*QZY*&5CRA`%"**$,6($@WI,7.!K,;\
MDV_5^.PV-E2)J"I4-E3C+%[W5MVIA,A'%"`*$46(8D3\_:@9?3-)K3[M]Z#V
M!?TA*U^S=;;?5Z--\<[?>FS>?#O<?HA:V?PEJOEP`RVV_$9EMMRZ=/&GR$U^
MY](]>8!;,Y=ODT,M]'2Z<PVUD#-:Z0,M-GFC]8`MB75#?89&1I_;GIJO;>:(
M^?$#GE8<^A!W7'K5BT]^FI/_P0YSE]YY8H?5PJ57A`-\Z=(;M0%.D34GA!$`
MW0Q=OJMA#[H,N7S?P1:ZSE"?H18J%%P^[["/1RW>8(M/+?Y@2T`M?`BB-ZH9
M7#X+L85*!Y>/1&RA"H)&W;1,.Q'HD^4I?<U^3\O7_%B-]MD+I?FLJ4W+]J-G
M^T<M;J#/14U?*YO+Z(X^3F?TC6C&U]27HJCE'_3H:?>Y^_%?````__\#`%!+
M`P04``8`"````"$`SU.M2A<.``"?3P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6RLG-MNXS@2AN\7V'<(?#^))=G.`4D&'8E'[`*+Q1ZNW8G3,2:)
M`]L]/?/V6Y1(D\6?[43!WK0['XM%5JDH_:(M7?_ZQ\OSR>^K[6Z]>;V95*?3
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MAENTP<+5JG/;Y4#D0.9`Y4#GP.3`)N",TG+(#2V/_T=NG!N7FQ#570`Q6766
MB&`1NG0Y$#F0.5`YT#DP.;`)8(F@)<X243Y9A5IPUC<3^O=0"_5EPP.\&VRJ
MYI"4%D@'1`"10!00#<0`L2EAH=,YBH7^R?7AW-`2HX\D*;,L*=Z(3DZ)4;:*
MVH/1H3:`""`2B`*B@1@@-B4L3S1IEJ?C)>*L^W2$(.X\20H"2`=$`)%`%!`-
MQ`"Q*6&!TK5D1*#.F@?J21(HD`Z(`"*!*"`:B`%B4\("I:O?B$"=-0_4DR10
M(!T0`40"44`T$`/$IH0%ZJ1U?@E<T*5PY"70N>$9\(3.+<EZ7O!%WQZ,PE+H
M@`@@$H@"HH$8(#8E+"FD2%A2CJ]G9\UC]R0Y^D`Z(`*(!**`:"`&B$T)"]2)
MGA&1]N8\U("26!%UB`0BB4@ATH@,(LL0C]DIGK3DCQ_=:A!(=/4*-7H74!JS
MMXJH0RN!2")2B#0B@\@RQ&-VXB:-^9-7\FH022P9'O&%?IXM]-`QS<^A8TBL
M0"N)2"'2B`PBRQ#/CY-`:7[>J0FOF-*:\"@&V)+`ZT\,$76(!"*)2"'2B`PB
MRQ"/V<F9$3%[]9/&[%$,L'4BSYT,(^H0"402D4*D$1E$EB$>LU,V(V+V0BB-
M.=5&_7U:ZW8P\I@!";22B!0BC<@@L@SQF)W(26/^[-KW8BE-QD$_I1?YBWSM
M'ZS"0N\J0`*11*00:40&D66(Y\=IHS0_[ZQ]+Z72-*3JRM<$H*X")!!)1`J1
M1F00689XS$[ZC(C9*Z4TYE0\^9@!=14@@4@B4H@T(H/(,L1C=BIH1,Q>-*4Q
MISK*QPRHJP`)1!*10J01&426(19SG>N[3Z[]W@\7?@'112X1^)?9VH]6A[6/
M2""2B!0BC<@@L@SQ_(S3@C5JP8#B!:]%U"$2B"0BA4@C,H@L0SSF7`L>/]_5
M*/D"2F,&,=>AE4`D$2E$&I%!9!GB,3LI]O&U7WOEEJS]@-*84=^AE4`D$2E$
M&I%!9!GB,>?Z[K-K'X5?[5%]N"=J/8H9ZX)1T^^(U],JV_$3T2"<&R1X44!T
M[.9VVLEOMKUJHD'P:U,O/$E.J*6%X9+4T%GSG47A]5T,]\Y]K>)4(%WE#^?#
M9CK-SX<'JS"WKM2QKC,1);P5G<KZ[Q?J\ZKBKF7T$UPK1#JB.$T8S?#1+L[I
M>RT^FHU^:#2>4J?M/I%2+PG3E`[(+>LDI5G<;7VP"G%WB$1`\SY_\WHZR_S(
M8!&+6B'2B$Q`@^N*OF/+CYX-)KUOGBVG"M-LO5-X7D2F6?*(%QY\J7*PBED"
M).H!^2JKFXMI-<WV[*2WH4(/GA0BC<APY]6"OBZ]A+)*Y\03Y:3DB$1YY9DF
M:D!9.65GC[8^6(7P.D0BHK0TLS.<+%G5379H5+0*(VI$)J)TQ.P+$ENR2D?D
M*75*=41*O;!-4^H1';5DA685T]8'JQ!@%U'L"*<A4;1JLIAEM`KN%2(=T9$1
M3=$J']%&*QJ1I=1=.D:DM#?GNCJ@1&@@ZA`)1!*10J01&426(1[S.!'=H(@.
M*(W96T74H95`)!$I1!J10609XC&/$]$-BNB`8H`MH@Z10"01*40:D4%D&>(Q
MYR+:::5+*OB1WQ4UJ*X#HI;D/))O(D>KL-`[1`*11*00:40&D66(YR<7W,<O
MY0WJZH#2FO!6$75H)1!)1`J11F00689XS+E^?B=FU,V-1S'`%E&'2""2B!0B
MC<@@L@SQF'.!^T[,*&P;C]*8`75H)1!)1`J11F00689XS$Z7I5+ADS>3C==W
MB88(B*_]3!BVT2JN?>\K9E&@E42D$&E$!I%EB.=GG#IM4)T&%*-I$76(!"*)
M2"'2B`PBRQ"/>9Q\;%`^!I3&[*TBZM!*()*(%"*-R""R#+&89^/T76_.]5U`
M,<`648=(()*(%"*-R""R#/&8<WWWR;4_0^$74+SG;CV*)X@N&/UT(RD:A'.#
M!"\*B([=?K*1%`V"7YMZX4G*!>''-I)F*`P#XO=4^<9ZM`ISZR**(@KOJ4I6
M397M4\F257H?V7_[H:)5F(2.Z,@D3,FJR7>T;,DJG00_`"5UZFY:CE^=9RA&
M/>+[!%5VU]Y&JQ![AT@$-.P-U?-Y,\_NCF4PB6M`(=*(3$!^W^GRLK[,)FF#
M">X[S<:)U=X\.Y%Y9<KJ--^,;4/'N%O4(1(>^7VGB^82ZO$P6,BV0C<:D>&>
MZXNFN<@V_BSKQ6MJG+J=H;KU**NE;)^HC58AN@Z1"&@XWK-FL6BR4&0P26MI
MF!3-(/C6:&4"\G5Z/JVGV1G'!I-"+8T3Q#,4Q`'Q6LHV>MIH%4+I(CIRNA%%
MJWQ71T:KX%XATA$=&=$4K?(1;;2B$7GE.6V;ZNUWSF+./%N>'J4Z`U`W`R00
M240*D49D$%F&>,SC-/0,-71`:<S>*J(.K00BB4@ATH@,(LL0CWF<AIZAA@XH
M!M@BZA`)1!*10J01&426(1;S/-?0G]23O1]>]`&Q>\DJN^*VT2HL]`Z10"01
M*40:D4%D&>+YR?7V\;4_1UD=4%(3B#I$`I%$I!!I1`:198C'G,OG=V)&V3SW
M*(T94(=6`I%$I!!I1`:198C'G"O6=V)&I3KW*(T94(=6`I%$I!!I1`:198C'
MG,O.SZY]KP?C;>+=?$#T;]Q"KO(MY(-17/G>TT_O+GV7Y">M$KPH(#IV^\G=
M930(<[&I%YZV<4)TCD(T(+K>)^G)=]FB59A3%U'LB'>5):NFRB2D+%FE-W3#
M766T"I/0$1V9A"E:@>B*5N2>9WF<CIVCCO6(R_TZNYEI@U5<MIU'M.D<8A8!
M+0Y(!A2M%/K2:&4"BKYL0+TOG@:G"5/M^;&MC+F7DNF2](@579W=M+2A8W*+
MB$AX%'X`<TD_'N`_29'822'2B`QW72^:17:#9EDGGJQ<M'XP62A>YP/*:B>[
MHV^C52B4#I$(:+B=6YS/+K*5+H-%O"U4B#0B$U%<BDV=_8K"EJS2E<YS.$X$
MSU$$!\0++3N*;;2*N?.^8NV):)4&F-V+RI)5&J`_E8%['3N&29B(TA$SU6I+
M5NF(+*7N$3ZVAH]KB]Z<2VF/LG+,KZ?1*D33(1(!'=FY""9)/2+2B$Q`1W8N
M@@GN7"S&2>W>/$N35]^\\K+5UH:.L<RZB.)!Q^MJT2J_I,EH%8Z"0J0C.C*B
M*5KE(]IH12/RRANGY!>HY`.*E\<648=(()*(%"*-R""R#/&8QRGY!2KY@-*8
M4<FCE4`D$2E$&I%!9!GB,3O=G*J$=\XP7F8GZF!Q4-ZA:EM$'2*!2")2B#0B
M@\@RQ&/.9?@G[U[H'3OY=EU`=-"C/J\SB=-&JY"R#I%`)!$I1!J10>3>$!2?
M=QOR,[SQ9WBWRLMJ^VW5KIZ?=R?WF^_N;3YT.WA[?<##JX;N%@V]:Z@O=VB9
M44M?)]`R#^\GREMFEU=NQXFRDK?,IU=NKZ740F\[HAV)4DM-+?W5`KS1K"F<
M0I\%]:$S1*&E.;]ROQPHM5Q02_]NE'R<AN*A;Z$+?684#WU76VJA<6AWM=1"
MX]`>9*&EIAS0HR*E%HIG^-(@GUM-.:#'#@I]&IH;?>56:J%QZ-=TI18:AWYS
M5FBIZ&C38XVEE@6U]/<R^=PJRL'PRV1HH1S0PV$E;Y1K>H2JT%)3/'3#46BA
M+L4>%?6@1\\+/2K*`#V@76JA#-"CR:46RO2P[P#1T!JAQURQ#[W"ZTO9%W4H
MV-^YPUSB-'3I&'^977VA$P`.?$<S*DWHCHYBT9Z.8?$0TA$L%C$=O]+AH^=,
MKMRC)#@C>E+DRCT,@BWTDX(K05_E8PO]*.#*%%NZ.8U#&S2%/M1BBBUWC<MB
M*8UW#:6+?E:'WNX:2MBP#Y`?](921C_1HCYGAR9Z/=K;\MOJ[\OMM_7K[N1Y
M]4@GW.GI.9VCM\,+UH8_]ILW$J[TDK3-GEZ,UO_WB5Z$MZ(734U/R?AQL]F'
M/]P`AU?KW?X/``#__P,`4$L#!!0`!@`(````(0#=:$#J_P,``)$-```9````
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;*Q7VXZC.!!]7VG_`?$^X9I+HR2C
M$&!FI%UI-)K9?:;!25`#1MCI=/_]EFWL8#S=HJ5]">&X?').E2^5[>>7IK:>
M44\JW.YL;^':%FH+7%;M>6?_^IE]VM@6H7E;YC5NT<Y^1<3^O/_SC^T-]T_D
M@A"U@*$E._M":1<Y#BDNJ,G)`G>HA9$3[IN<PFM_=DC7H[SDDYK:\5UWY31Y
MU=J"(>KG<.#3J2I0@HMK@UHJ2'I4YQ3TDTO5$<G6%'/HFKQ_NG:?"MQT0/%8
MU15]Y:2VU131MW.+^_RQ!M\O7I@7DIN_&/1-5?28X!-=`)TCA)J>'YP'!YCV
MV[("!RSM5H].._O@19GGV\Y^RQ/T3X5N9/3=(A=\^])7Y5]5BR#;4"=6@4>,
MGUCHMY)!,-DQ9F>\`M][JT2G_%K3'_CV%57G"X5R+\$1,Q:5KPDB!604:!;^
MDC$5N`8!\&DU%5L:D)'\A3]O54DO.SM8+99K-_`@W'I$A&85H[2MXDHH;OX5
M0=Y`)4C\@02>`XD?+D)_N=Y\A"4<6.`I668K`*W<!CR'N>NY+AR1$9[@)*?Y
M?MOCFP6K%CR3+F=[P(M6MB4S*_*@<OU6JB''C.3`6'8V;#?((H'U\;P/O7#K
M/$--BR$F-F,\/>(H(U@!&6TR!=(ID(T`!QPI6U"D_\$68V&VI*!8`G>?_L2#
MC)!3DBF03H%L!&@>`M-#`%OG]XM>5H)-@N4]JH0?;'2-L8CQ`N7K:"")@:0&
MDHT133DL[G'VWU?,@F'UP6.T>)83R2*(V5=!?CC-_<#$#R*Q@`3BKY73U$"R
M\2S-!6RS^2Y8,'<A"Q\/R)IO!]_U)I:.:ES.2!0R,NE/BI>*(-_EM%X8;":[
M*%,LP*OY@>T]WP\+UOT(Q/>EGY5>HJ,:5WX,)!V0Y9OBQU,T\>N/B&?!NO@!
M4<583\2K<27>0%*!O)/Y\11-/.M#1H?L^_N!!>OB!7+/_&1)'-6X$F\@Z8"\
MG?GQ%$W\PT?$LV!=_("HS#],,J_&E7@#207R3N;'4S3Q'IP8\U//HW7Y`P3)
M'VW*,)B8N$<I%R:42F@H@A<NW4DV,AG"SS#=";OJ9B\B3UR,<*I*0?$`!:*K
M8??K44;=S\?D#HW\&H?0$"4KLED9UWUV)P(%NA-VX<UW(JY'S<D`C2XPZ#[Y
MPKM#B0FE)L3:UOM$(5.TH:)+:E!_1D=4U\0J\)6UF&PA*U2TOTD8P;T"-B<X
MM,4'7L@)'K-V^3?QL1]!,V#RQ$$$=ZV)'\+H`/K-@=@#)C'BJ-^&AKC+S^CO
MO#]7+;%J=`(W[F(-]T4O6FKQ0G$'6P":4DRA%>9?+_#7!\&"<1<0?,*8RA?X
M:4?]F=K_!P``__\#`%!+`P04``8`"````"$`#H:*#]D&``#='```&0```'AL
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MNPF=*(YY-5E-P--V?2@A`I+V45,<-]:K[>V=F379KOL$_5,6'ZWR_Z@]UQ]Q
M4QY^*Z\%9!O6B:S`6UU_(=+T0!`83Y!UU*_`'\WH4!RS]TOW9_V1%.7IW,%R
MNQ`1"<P[?`^*-H>,@INQXQ)/>7V!"<#?4562TH",9-\VE@,#EX?NO+%FB[&[
MG,YLD(_>BK:+2N+2&N7O;5=7_U*1S5Q1)W/F!#Z9$W#WI"V,TD\`/IGM\FG;
M!;.%3V9K#YX[;(1^?/@<//<5LX5/9@M>GHS;AJ7N!R;_#)W]A*YB7Q1!UF7;
M=5-_C&"GP3JUMXSL6]LCCGDYT,43!?*C^H#"(%Y>B9N-!<'`TK=0U%^W<WNQ
MGGR%0LR99H<UMJ[PN8)4'7$;F"`T062"V`2)"5(3[!4P@;2(W$!-_A^Y(6Y(
M;GA4.PYDLAPC$5S!30(3A":(3!";(#%!:H*]`K1$S.XD8@;%<O_,X#5!K.!T
M4&K"F;MZH#NJL?OSKE]R'Y$`D1"1")$8D021%)&]2K04P$FEU<+CT(D:=A1\
M*/MA:<3.1(XH#)^1A2`!)8ZZL9SY2G<4"A$OEPB1&)$$D121/25V/R$M'7#X
M#D@'4??IX!/<,:+$SH@2.R40.SE.G*D]-\(6U[G7"/F($4F$%?,ZT[VFXCKW
MNE=]:$F`N\B`)!"UG@1&E"0@$E`RDYH0D0A9Q8@DR"I%9*]::8'"#58+E-PD
MG`7I#WYR!!!#/69&M()VI_H:^$+$UR`01&XHQWG1S4(J<NR^8&8OSLPX;2+A
MA?N-$4D$>3!2>D]DCK87(AA-2R<$KZ7S\5E"U'H.*8$F49FB:]Y+A8C'&B`2
M,K+H$V:_K!;&9HB028Q(@DBJN75LUS5.OKUJHF4&^B(M,T\7&C'4D\0(#"6.
M8,<U[[-"))*$2$@)JZJYLW3-)"&3&)$$D50097ZHA(3(+"'2JFF9>EQ#O5S/
M#T-&%1FQ^5(E,H11*!$Y5(W=',FKW$>,48)1RA&M3]>Q9RO#]YY+^@9"*R6;
M='5J9_N3#-$F$&[9?)*[W@,D32\AXR[D2Q4W##`*);J;(3:X[!%C:<#=)ABE
M#+'BM%_<J6O,;Z]9Z1DB[=Z`#-'N4,L0148-&:>N;PL5#R7`*.2(+O9JM3)/
MM(@K9+,88Y1@E')$72^=E^G4."WW7'*GCDA+."!+K(-4ZX@AO8Z,7T<^],#]
M$29K(,`HE$@Y-LSS-;JKFAF'7RQ5?%T2C%*)U!&-6^_^KDH942\\TE8.2"GK
M0M64LE85<J:<[D9?[)/^&^X*4)X\P$`BQ1`U$G=5YN$<215W'V.42/1@Q/2N
MRAQQ+U4PHIY2TJ0.2"GK:2%!(G]SVUC4'7DL!/DCO_2$RID;9>0S%>P@GH:`
M&\H5"S&*-$,]&M*)#HB&-:YRN!W\9.EWT_('/QY\*9"S%C9*N+@VJ,J9]I[O
MGE/"#UHETA(.B(MUD&I<%#D.CPL=MD(@XT(HM`520C7++9(J%`CIX`8$0N1&
M^\&06"!T'@J!#`2AD-R<B6>(1Y8H#D2H4""DPQH0"&O(U!6A2*Z(T>SZMA#(
M0!`*I>IA(*JAMF6@'H<$TLOU%>%(K(AQ'/A2(`+!*)3H42!29:X(]#*#`L%]
M6^\!CGUH.V1-S,W.5JID--07&'(42I7B"]675*%H2._S?'V1.1L;A:$9?8!.
MGHKZ7+44\PPD4N:)SBZF@N23+O3>V27]H$A(?S(@$M;.*#N%M(DD.'D[]C$*
M,`HQBC"*,4HP2C$B;UODO.BFHF]/Z(/RJFA.A5]<+NTHK]_)FQ&(8+L66+RV
M>>WKQN`[>)W3+YW)'7C-0];/Y#,/'D)B_CKW7N'V?^>"[7JO$`*^LG/`U]TK
MP=R#AWW8(G"]L'_G8TPJ<3UX+G9'O_#@<13FR<*#QTN80V/@D4X`KDS$$/!R
MZ9:=BM^SYE1>V]&E.$**I^,E-!\-?3U%OW3U#5(/KTOJ#EXK]?^>X35B`3MB
M.@;QL:X[_H4,(%Y,;O\#``#__P,`4$L#!!0`!@`(````(0!O4_D"/@@``.0D
M```9````>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*Q:VV[C-A!]+]!_,/Q>
M6Y1\1Y(BUEUH@:+HY=EK*XFQMF58RF;W[SN4.+S,:+UQT)<X/CIS2!X.J9',
MNU^_'@^#+^6EWE>G^Z$8><-!>=I6N_WI^7[X]U_)+XOAH&XVI]WF4)W*^^&W
MLA[^^O#S3W=OU>5S_5*6S0`43O7]\*5ISJOQN-Z^E,=-/:K.Y0FN/%67XZ:!
MKY?G<7V^E)M=&W0\C'W/FXV/F_UIV"FL+N_1J)Z>]MLRJK:OQ_+4="*7\K!I
MH/_UR_Y<H]IQ^QZYX^;R^?7\R[8ZGD'BT_ZP;[ZUHL/!<;O*GT_59?/I`./^
M*B:;+6JW7YC\<;^]5'7UU(Q`;MQUE(]Y.5Z.0>GA;K>'$4C;!Y?RZ7[X*%:%
M/QN.'^Y:@_[9EV^U]?^@?JG>TLM^]]O^5(+;,$]R!CY5U6=)S7<2@N`QBT[:
M&?CC,MB53YO70_-G]9:5^^>7!J9["B.2`UOMOD5EO05'06;D3Z72MCI`!^#O
MX+B7J0&.;+[>#WUH>+]K7NZ'P6PTG7N!`/K@4UDWR5Y*#@?;U[JICO]V)*&D
M.I&)$H%/)0)R[XR%5MH.P*>*78X6T^EDMIB_OP,S)0*?2D2,YL);!C=HP(IH
M.P*?-P]BJ6+A\^.#$##Y;0_D/[<.8]S-:YLFT:;9/-Q=JK<!K#V8N?J\D2M9
MK*0P)D@WG3IEOI<QD"I2Y5'*W`_!&TB&&M+\R\-$+._&7R`UMXJSYASA,D)D
MR#R4LA$%8@HD%$@ID%$@IT!A`6.P17L#6?I_>"-EI#<XJC4"QBR?&($,#(DH
M$%,@H4!*@8P".04*"W","(@1_;L'YH)DPSYAY8*_#-P!KCN."+0I(4,BAL0,
M21B2,B1C2,Z0PD:<H<.>]7_D@)2!)08?9H'X'C%%D7QC2H=,-!`I2M`N,=\3
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MF"=K`9+T"#4)1Q9IQ(3QC:R/%)#!)IJ$VBE#,HU<:2WO(]'6"DV"UAP?965Y
M@Y$MW742(:MBX%#$H9A#"8=2#F4<RCE4.)`[9EE6VHOPHZ5U5YZ2VH%LP&NA
M6%;QH""K>D#2=\L'0\!\29A*RI#,A'VGA#`$U"UL%=<W6852WWY<18BN>`6;
ML(DU0N[R(X\EH6%A8&2@*TLB[F,%@I0I21_+WF_:!YW4L+`3F8&N="+O8P6T
MIBGZ6'8GW`F0Q?`')D#5T/8$=)!['Q%D9P_A*4#NF\#"L4<<BA'J:A!_.@VF
M9"--D&*$4@YE',H1ZK3%<NDO22<+I+3:KEVR&K;MNGZSE>N8W"40<O*4EN&A
M81F;E-9<.Q<KEJI'%L&2Y2.+2;ERQJ'<5?870;`@FU#A1+DFR5KW!I-4:6SG
MDBJGG6*6/O^$\MT6S24&Q<CJYGL2S&8!&4J"%#N7F%#&63E"*D_GGN^1':=`
M2D\NR7KW!INZ\AALQY18"P6YN43*@M"P,#`RT)7M)NYET3H@,2R43SF4&>A*
MBWDOB[98&!:TZ&8>.'&+I9).2@\%V:4'@R+!H)A#"8=2#F4<RCE4.)`[9EGC
MVFGTT=*CJY7ELM;UZ\0G6^-:="R;%(BY6W6'FH09$2D$-E95-)#'@M@0,"9A
M*BE#,A/VO6)$C<K,9V&KN$[*DM9V\@>;NZJ`[06IBV+C82#(DUPH-`O'&AG(
M!/*G@#Y60%^])GTL^_ZOBA#6B:PWD#ZEY[TLOD9M><=EN%O=XG)+=]>H@MQ*
M@[Y@"Y%E9CY24-#]^"%?.L<(M3_+M,XD"!E6RK4RSLH1,EH%0JV6:T/?$\./
M*U]?/R!@[JP1@CU)+]S`)_>XT+`P,.)0K"#HMEQ/8@GO(=RUG?"@E$,9AW)7
MVI\%,[('%$Z0:];''A-DAI#]74$D=\@N%QJ6,:O3@BL(Q<CJ[OZS^61!5GJ"
M#!.4<BCC4&X@>T[)2YFBCV6O=-=#6NE?W]U\7N$CY"8:F<70L-"HB$.Q@>P!
MDM(EZ6/9`^RV,L/"%C,.Y0:R6R2/%44?RV[1M526U^^_8?BJ&K=N&`J2$VFM
M77H_-2P<8,2A&*$KA2Y2['SL.@4]0.V,LW*$KA2Z2&F%7)MD+7V#35WI;1>Z
M\O=GN9#=S".K+30L'$ID(.,OOZ_VLN@M+3$LE$\YE!GH2HMY+XNV6!@6M.A:
M>MNS`YPZ8!NA@LSM,426@2(.Q1Q*.)1R*.-0SB%Y0*+M:MN);LS=@8?NE^QC
M>7DNP_)PJ`?;ZE4>9H"G@8<[#>-)"[%ZA&P!V\B5M9BO9#'-KSR*Q>H16N=7
MUOX,#VX0-3C1\=CF.\'7<-*C/19!<1^$^EH(5O"K)&_Y<0+#:`]]4"'A00M]
M5Z+)"GX8Y%+99`4_[G$\$F(5P_LY?@7>]*WRWBM0SD-,^R,WZ1<4Y!#37AGK
M2W#&Y+QY+G_?7)[WIWIP*)]@VKR1/(]QZ4ZI=%^:Z@S3":=%J@9.E[3_OL!I
MHA+J-&\$Y*>J:O`+='>LSR<]_`<``/__`P!02P,$%``&``@````A`-%_I`TO
M"@``-S```!D```!X;"]W;W)K<VAE971S+W-H965T,C,N>&ULK%K;;N,X$GU?
M8/_!\/O$ULV)C20#RT3O#K`#+!9[>78[2F*T;066T^G^^STE4F)5D6-'QKQ,
MI@^+U*F+3E$T[W_]L=^-OE?'9EL?'L;)S70\J@Z;^FE[>'D8_^??7WZY&X^:
MT_KPM-[5A^IA_+-JQK\^_O4O]Q_U\5OS6E6G$58X-`_CU]/I;3&9-)O7:K]N
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M/TW5;!!1+'.3%K32IMZ!`/X[VF^I-!"1]8_V[\?VZ?3Z,,YF-\7M-$M@/OI:
M-:<O6UIR/-J\-Z=Z_S]KE+BE["*I6P1_W2)$X<R$S$W`W^ZI-TD^G=$SSTS+
MW33\[:9]FNS$.M[&T:Q/Z\?[8_TQ0G'"M>9M3:6>++!P%T!+HP_I'T44H:1%
MEK3*PQAO%8+5H`R^/V;SY'[R':G;.)LRM%$6J\Z"\D3+&@9,P+<GC4C_":1I
M%2+=/:[L`.]%*GU8=1;=%,,`P1"IU0PS5'>\+KLHTB14((MB<C>7#$IKD[3O
M5!ND58`8C@A62+!F-0.K@<FF55`N^,.RK2)5.B-4=&^4S)71JC?JX\D101T+
M<>KG`TG&+<-NW=(A+&P!8C@BGCT;\FPREL]V"'MV@!B.B&??#GDV&<MG.X0]
M.T`,1\2SJ4LJ;9@/+Q=:19)RB"CT>28+?=4;=3DT'!$\YY+G^=H@8TG'(2Q&
M`6(X(IZ=("`\2.<?WEK+IW<0>WP(&0%)`B22+$L7"%A)Q<O;A;5,',0)!)`1
M5I(`:2`C0"WDBC))K)0*9@Z2A9*K0NDF>OY&0)(L:2,C>R%:3DEYM!SDG[:"
M&+<EY2$C($F`%.[S!)P><@(.\D];D11337O("$@2()G[/`$GBIP`UTG;@FB_
MHPEP2!(@K6,$J%ZR6Y@/;$.)TTQ.K9=1WG4*73"]5?<.F&ZM-H*2+:FC8IL4
MR/A0ME9E4=%]/\RTYI6)-2KP^C&KH.![*\^?0Y(_J:;B?\W;:<57TE>!+1.G
MT,AE3S^9W^KP]U:>/H<D?1)>1?]N3IOYP0FP$LX]2%.U`RT3:Z02,-,>]%;>
M`PX)#U+5(-H==GI[,]R#=J6',?<@T]$MG9'RX$YYX*UZ#P0D/:!NH'*`SY5K
MDI"ZQ@+!ZBLDF^L]KK,2/N33J?;!K@4K[P.'I`^(&O?AO.ZG9"W;M(.*M'_:
M*H2,@"0!:A)_4A!=OV'"EUJ(=*F/:SI5U;WR5CYB_41`DC`U%44XS8=O_U+;
MG'C5YII9Z8RHCS#^^G/!6WG^KO6U'_>2/];2_)/LBK>.UI%O73Y5S$K2(RH8
M_&'\]9;66WG^_<0@_I$V>4673&VSD^%7Q$IGI.CKON.M/'W72B/AIXZDRH=>
MZ(%M,[6-C=-/[G3?Z8S01?KHY].`OEO*?_`;/S&(/G4D13])\IMK,F";&W<A
MRY28E:DSDBXH1U?>RF>@GQBX0"U)NS`%C:$IL*V-=I0LNJHGEJFU(H;,2O=^
M;^4=Z"=J!^C`A#MP7K-;:ZG9'>3WQ:L0,@(2$I)1.V$1O$#`-A_^`=,N`.VX
M]4TCA(R`)`%D:P`!LE81<!"/0`"9C$.2`+4'%H%V\S)/KFG]F>TT(CP6HK>P
MKYETJO<J;B(+HA&0)*RZUH64N>[!.FGF(!ZQ`#+"2A(@06<1NT#`R3\G8"&\
M2-TKLJ*N12W(0T9`DH#J&Q<(.`'G!!S$(Q!`)N.0)!!1_K2X8K^;6<$6%>,T
M7%1,HL1TY2:*BNDG!BI#`LH21B6>%HCX0)G,K!`KF53%7'966-^7?*(W:MZJ
MJP$C(!EOI?,7$MZK>;=TF3F()SR`C+`2!&A3R"-XGD!K+56J@QB!$#("D@0&
MZ70>ZG0'<0+.RD-&6$D")*"JABA>%R+A9)>]>[F#V%>&AWC%J`VHB5OY?9ZD
MJU3]`LU0N','^>"L0L@(2!(8I-)YJ-(=Q`F$*BVL)`%25):P"Q&P^LN%*'<0
M)Q!`1EA)`B2?C$!["':Y8ISH\HIQ$*^8'CI;,5$KOVF6=$D^&=T+\;)B*^+E
M(!ZO`#(YAR0!I=(7"/1:W(M<[B!.((",L)($2!$_'P&GGSQ1#N($`LCD'!($
M"J6R5#%%TGZ0G`]&.U$*;@>QHO'0N:*)6_G/%,EXD"S3QZ':O780"UD(&0%)
M`DJ6+\0IE&.<]K2<.($`,L)*$A@DM'1ZHR,0"FUGY3D9`4D"2FBI:*XX_2U"
M!>X@$&0;&?55N/)6W8MH!"3)*E$FL@D=2P[<B='FC;;+C%D^U6>,SD@>>23Z
M>]5;>?Y.YL,CCX(4E4E$J^G3*_@[94;0^]#F>I-;MD]#@$"GMTH3M=]<>2OO
M@%L^X@#)+W/@POOBQ)II7,'UV_XT%$)&0+("!JE\$:I\!_F78Q5"1D"2`,GO
MYR/@Q)I'@.NWBT``F8)#@@!=Q^`$J(:NN*+1+B,UOX/D"ZM>BY6WZNM%0)*L
M$GA;\(/?UUFO_+Z2<_U-5'96HMY3_>GGK3Q_MWQ8[S/2\D]GN[56,77-H%W:
M9KNS\I`1D`P@R?OG";AFP,H-=^O:EN&?M@HANH'GK2P!>Z/.W@3;5\>7:E7M
M=LUH4[_3;;E9@3M</>RN\LV2Q=+>Y5,C2$UWRT^/%-F"NA-R$8SD&&D]"48*
MC+0.J9%E,0.#]D*@&H$88LXL^IQ;C+3G;\&<.XRT1RK!R!PC\]AJLRD\C3+(
MP1K;_8BG.1A@8QL;`0/L.&,C8("M8&2D0*RQXXF-I!AI=W3:GPS<<&`4F9,A
M;CC)B8V`-<Y1PI%E=K=8QC.'$3JG".?@B`$C47]R1!1?]I$Y.3S%)W=L!%6%
MC\O8"*H*7WV1D12>X@>,V`@\M4=%.FXI_+&';FIDF<X7RVAT<`Z..5%/,WB*
ML^8(@PR>XA`X-H*<XG0V-H(8X!@T-H(8X'PR'%FF>(/Q&V`X4F+$X%?7V`@8
MX%?-V`@8_,%J8(#?ZF)S4(GX%2PRDF`$>YG8"#*'^QFQ$60.5R9B(\@<;B/$
M1I`?_,H?&4F1'^PV(R.8$IV18`8N9D5F)(@G;DS%1A!/7$^*C2">]@J/JK8R
M03SMQ[0:P?7J97PM3(@]@Y(9PZF8(O@R7RSCH:?W+#*A1!:C240.HRE$!J,)
M1/[:]$UZCW%M^VW]4OV^/KYL#\UH5SVC44W;[]^CO?AM_W&JW]"D<7F[/N'"
M=ON_K[B@7^$^\90.H9_K^M3]`UF8]%?^'_\/``#__P,`4$L#!!0`!@`(````
M(0""7RW__@0``"(3```9````>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;*R8
M7X^R.!3&[S?9[T"X?T4*XDC4-Z.(@FZRV>R?:P:KDA%J@!EGOOV>`JVTQYV,
MR=Z(_CSG:?OTM!2F/S_RL_%.RRICQ<RT!T/3H$7*]EEQG)E__1G^>#*-JDZ*
M?7)F!9V9G[0R?\Y__65Z9>5K=:*T-D"AJ&;FJ:XOOF55Z8GF235@%UK`/P=6
MYDD-/\NC55U*FNR;I/QLD>'0L_(D*\Q6P2^_H\$.ARRE`4O?<EK4K4A)STD-
M_:].V:42:GGZ';D\*5_?+C]2EE]`XB4[9_5G(VH:>>I'QX*5R<L9QOUANTDJ
MM)L?2#[/TI)5[%`/0,YJ.XK'/+$F%BC-I_L,1L!M-TIZF)G/MK^SAZ8UGS8&
M_9W1:]7[;E0G=EV7V7Z7%13<AGGB,_#"V"L/C?8<0;*%LL-F!GXOC3T])&_G
M^@]VW=#L>*IAND<P(CXP?_\9T"H%1T%F0$9<*65GZ`!\&GG&2P,<23Z:ZS7;
MUZ>9Z;B#T7CHV!!NO-"J#C,N:1KI6U6S_)\VR.ZD6A'2B<"U$R'>@#R-[)'W
M@(K7J<!5J'R[!^,N%ZY=+A3X-WL/D8T%<.UR[8<=@"GN?.0SV'H$;GRS![:<
M!?CR</]M83__\N@(K+8>FO(*DCJ93TMV-6#-0D^J2\)W`-OGPJ*PVC*0I?9?
ME08EQE6>N<S,!&NAB"I8'N]SUR93ZQU*.NUB%CC&5B.6(H+7+Y<-=+#20:B#
MM0XV.HAT$.M@JX-=#UA@G'0/#/L_W.,RW#TQ[H4`-SLU,Y<B0J0$.ECI(-3!
M6@<;'40ZB'6PU<&N!Q2K',VJ^SN7J"<>#7M4KYX(T2Q8M#&V(VU;(A(@LD(D
M1&2-R`:1")$8D2TBNSY1['$?LH='PXJ%2V^].>IJ6K1!9'SSIR.W0@LDN0D1
MXJE"*QDDBBWLR*1=Z<3Q)FK*6@:(E`T2B1")95:S@6#9K0P0LKN^B&(HW-:4
MI?EUO?'HQE`AO&A)W[V.]-Q#9(5(*`D?$QG:KN:4_%^TO$$D0B26I%/5YGXK
M_Q>JNSY1C(+[\`-&\6C5J([T]WY"QNHHES)(]"?HB"@A>SA44U8H)92D7ZQ/
M:MJZ#2)V4YKV^&GD:GW92!G1EPB16)(OFMJJ34U<V]6F82=EH"G%=#C`/&`Z
MCU9-;PF![41N`(1HBW`I@\1`@XZXW;K%IJ.4$)%U1[Q&Q+/MD78;WZ"4")$8
MD:TJZ[D3W<Q^BF(FE-X#9O)HU<R.W!;V$I$`D14B(2+KEG3%2)R)-]'*=8-R
M(D1B1+:JKC?T'&W/WO5S%+,F#YG%HU6S6J)6GJ.MW:4,DI6'R`J1$)&U)+TR
M=_1RNQND'18B&21Z%".RE:3?FEZ%=X-NK2E>\\>%!RJS"5?=%@BF\[;0'>T>
MLKQ%B=$%&*TP"F^H)T^T&EW?C7)&ZL:[N46)3D08Q3?T18O;NU%ZB_R!NZG.
M9N&VQK</T.T33D[+(UW2\[DR4O;&'XYMOF=)W#ZY;UP?[KC098U'K@_W7<QC
MUX=CR!T^\N&NB_G.]>'>BSF\,7@F=_B"OTFXQXD/9VNLLW!\.%5B_NSZSV`0
M_F/A^G"XP7SI^LM[/'#]X!Y?N3X<=[!.Z/IP_+O#1_ZZB;>DT_"&XI(<Z6])
M><R*RCC3`TS2<#"&LTK9ON-H?]3L`I,'S]FLAG<3S=<3O(NB\(@X'$#P@;%:
M_("&+?EV:_XO````__\#`%!+`P04``8`"````"$`N<O0$B,#```C"@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R45EMOFS`4?I^T_X#\7AS(A28*
MJ=)5W2IMTC3M\NR`"58!(]MIVG^_<VR"(*1-\L+E\/%]Y\IA>?=:%MX+5UK(
M*B:!/R(>KQ*9BFH;DS^_'V]NB:<-JU)6R(K'Y(UK<K?Z_&FYE^I9YYP;#Q@J
M'9/<F'I!J4YR7C+MRYI7\"23JF0&;M66ZEIQEMJ7RH*&H]&,EDQ4Q#$LU"4<
M,LM$PA]DLBMY91R)X@4SX+_.1:T/;&5R"5W)U/.NODED60/%1A3"O%E2XI7)
MXFE;2<4V!<3]&DQ8<N"V-P/Z4B1*:ID9'^BH<W08\YS.*3"MEJF`"##MGN)9
M3-;!XCZ("%TM;8+^"K[7G6M/YW+_58GTNZ@X9!OJA!782/F,T*<43?`R';S]
M:"OP4WDIS]BN,+_D_AL7V]Q`N:<0$0:V2-\>N$X@HT#CAU-D2F0!#L#1*P6V
M!F2$O=KS7J0FC\EXXH>WTV`Z`[RWX=H\"N0D7K+31I;_'"IHN!Q+V+#`^<`R
M\Z?1:!R<)Z'.(QO@`S-LM51R[T'7@*2N&?9@L`#BTQ%!*(A=(S@FT-7@JX8R
MO*S&T7A)7R!U28.Y=Q@XMIB@15`0;95![7)E!*,RYA9=N7>&KDQX6F9\C0R"
MH3@=Y\?1I.5UR@XSL0W3C6=RC1""(>5P:M,TCJ9'2@UHU@/-6E`OF]!&EV<3
MP5:]3:>S#(,"[<MI$=RG;2SA(%G1-;P([O,ZR]!=_.!VNAGG=!KX$43W<6/C
M>WV%Q@)MUBE0=#KW\[[JQU(([DLYRS"8`+Y3W6@^YK7H/O'!-$Q_@%/:2=09
MZF:FK8MN""Q!3$XX?3366((Y!')&H1GGKD)CZE?@]G0%@JNFW**/4O7>5..(
M7I&I=J[;R;($(':B"%?-+.Z;H\9I3">*<#2V6(1P`B&>J<)P@(-V@KMS,'^G
M"E=--2SL04"#N78KV6VLDJLM_\*+0GN)W.&Z#6$'M=;V5V!M4WULGRS6[A>!
MMD]@1==LRW\PM165]@J>`>?(?BZ46_+NQL@:"@A[6AK8S?8RAY\Q#GMHY$-9
M,BG-X0;J3MO?N]5_````__\#`%!+`P04``8`"````"$`5)9%)*`$``#:%```
M&0```'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6R4F%MOZC@0Q]]7VN\0Y?T0
M<H$"`H[:K;I[I%UIM=K+<QH,1$UB%(?2?ON=&9LTMA."7[@,X__<_".)U]\_
MRL)[9[7(>;7QP\G4]UB5\5U>'3;^/W^_?%OXGFC2:I<6O&(;_Y,)__OVYY_6
M%UZ_B2-CC0<*E=CXQZ8YK8)`9$=6IF+"3ZR"7_:\+M,&OM:'0)QJENYH45D$
MT70Z#\HTKWRIL*KOT>#[?9ZQ9YZ=2U8U4J1F1=I`_N*8G\15K<SND2O3^NU\
M^I;Q\@02KWF1-Y\DZGMEMOIQJ'B=OA90]T>8I-E5F[Y8\F6>U5SP?3,!N4`F
M:M>\#)8!*&W7NQPJP+9[-=MO_,=P]93,_&"[I@;]F[.+Z'SVQ)%??JWSW>]Y
MQ:#;,"><P"OG;^CZ8X<F6!Q8JU]H`G_6WH[MTW/1_,4OO['\<&Q@W#.H"`M;
M[3Z?F<B@HR`SB2B-C!>0`+QZ98Y;`SJ2?M#[)=\UQXT?QY/%;);,%P\@\\I$
M\Y*CIN]E9]'P\C_I%6)6K4JD5.#]JC*?S!ZF<0A!1T0"F1$5^)PVZ79=\XL'
MNP9"BE.*>S!<@7!_19`$^CZB\\:'70VY"AC#^S9.XG7P#JW+E,^3]('7UB=L
M/0((VD:&:/='1F>,C/W`5)ZDH1LFZ@\3NX1!9QA.)_DX25I=&5GZ)+1ANO4D
M+H'0&5H.;VV;XF1F1%).<\UIWCIIW80=<'\WT9FBM^V4%KLHB'V_+#KKLLH2
M6<UZ<-%%9UU76NQT\0^WLYN1TWDR@>)N[VM<I@=0%KWU#_VM7^I!;X="9SV4
MM-BUA/`WU2WFMBYYZ\)7D]W]$"'M]&E$6B%-*4H&2&#C]R1M4(T32*;+"31R
M)(@"NAM$F?0A+/J'$#IQ3MY&MX:X1D@=FM62W;)%`A"L9PY.U.(5Q]@[RM0S
M!R2O,^%[20AQG=$89=+'L!P8@Q/8H4VV,O549+`]LIULI$-EZAF#$\&AC;`R
MV4E'!L-TXQ`M\"YAA`=:J0_B:@(LOBX:LVG_("(GQ,G;B":I[ZG)0/SV("*;
MZZO)'D3D!#%Y&TD/01P9$#L,P@::Q""P/HBAVQPGQG%C&/PI4\\@#,9'!F&3
M'2E3SR"<,(YLC)6I)VD#8QK$-)K@??!(`3;248MTEXB!&\'(B7+R-C;7T)4Z
M-BB_70=YZ\I7DSV(V`EC\C:DAS".#8QI$.%L_&:)%AI!%.0Z$%]/!MJ=:NP$
M.7D;T88@CPW(1^9@@TT"$*QG#DX4QS;%RF0#$1L4XQR6L*%&DK=I)J&-/X.U
MG<O#U].+/@0GP&,;<&7JJ<<`?*0.&^JXA1KNH/2DG0B.[>NT,ME))P;!.(1[
M'AQHG;X[E<D8P]>CG591XH0W>1O1AO!.#+QOCX&\#>66:7,,B1/`Y&U(#P&<
M&`#?QP*M,B)(MHTA##PZP\F1=J\\TBJ;;1+0GH;D29(\:"E9?6"_L*(07L;/
M>$H4P=%):VU/L![I7\>T)ZM'>;(5M+_`R=(I/;`_TOJ05\(KV!XTIW0%K>79
ME/S2\!-T!4Z&>`-'2O3Q"&>(#(Y/IO@WO^>\N7[!&;>GDMO_`0``__\#`%!+
M`P04``8`"````"$`-Y,MR_`#``#,#P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q.2YX;6R45UV/HS84?:_4_X#\OB$V(;.)0E8S'4V[4BM557?[[`$GL08P
MPLYDYM_WVB8,V#"$ER3<')_[<7P`[[Z]%7GPRFK)19D@O%BB@)6IR'AY3-"/
M?Y^^?$6!5+3,:"Y*EJ!W)M&W_:^_["ZB?I$GQE0`#*5,T$FI:AN&,CVQ@LJ%
MJ%@)_QQ$75`%E_4QE%7-:&86%7E(ELMU6%!>(LNPK6_A$(<#3]FC2,\%*Y4E
MJ5E.%=0O3[R25[8BO86NH/7+N?J2BJ("BF>><_5N2%%0I-OOQU+4]#F'OM_P
MBJ97;G/AT1<\K844![4`NM`6ZO>\"3<A,.UW&8<.]-B#FAT2=(^W#Q%!X7YG
M!O23LXOL_`[D25Q^KWGV)R\93!MTT@H\"_&BH=\S'8+%H;?ZR2CP=QUD[$#/
MN?I'7/Y@_'A2('<,'>G&MMG[(Y,I3!1H%B363*G(H0#X#`JNMP9,A+XEB$!B
MGJE3@J+U(KY;1AC@P3.3ZHEK2A2D9ZE$\9\%85.4Y3*E/5)%][M:7`+0&]"R
MHGKWX"T0#]<"16CLO08G"/8CI)$PP-=]%-_MPE=H.FTP#Q8#GRT&MX@0DK:9
M(=OMF3589]93T:4\V$`W#1E.$_73Z*%'(-WGC>I%@.LT$<5?6WY;@<6LS'2[
M?:W\A&2M%9W(J=>!"O#53BZ*-T[2!K3N@M;+%M0;,&2\?<`:;+*W$[81OS_(
M?3NM!O=IFXCQ6:_<NSF\&MSGM1&_7'WW[&QPK3^)X\7=I!YZ83^%C<2P>SX4
M6H_L[DT_[>?;38/[J6S$[P9#\FX[G_,:=)_X&O+GC[5S.Y.:H&Y\;DJTAC`$
M"1HHVK'Z[1K@QN;=+#;DJ#!B?NRX?Z(G:VFP8&L"0S#8DV/S">;6W!_,36A`
MB%G&U4\09_,TH0$A'._.$,(W,K8A1XAH^%Z$9[G;H)U].^9O[!A\0@C?U88`
MD@T(,<O$V'=Q$_*%((Z-S5,);Q:3-R6SL#^9)N3HL!K6@<PRN4$[V:SO!UIR
M3/ZY#L0W]C4$_WS<7D>V$YGE:X-VVAA[>A/'U\8B&PA.].,;W#`ER-$E'M%E
MEN?URX3C^28TH(OC^8D^?)^3)N3[@\PRM4$[*HR9FCBF-OX`?TT4[YO;$'DB
MK$=$F.5WXON]"?DBZ#?.VY^M!MV?U#7DBQ#-<K1!.]1CCH:S4*]H+0)>DAM>
MG<Q*)XLUO..&C\.#?16T9R=[0"E8?62_L3R702K.^EQ$X,C11MLSV[V9B1M?
M;>_M62YL_X&S5$6/["]:'WDI@YP=@'-IVJGM:<Q>*%%![7"B$@I.4>;G"4[-
M#(X=2WV'/@BAKA?P.`_;<_C^?P```/__`P!02P,$%``&``@````A`$0X%@KJ
M`P``T0\``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&ULE%==;YLP%'V?
MM/^`>%\()LV7DE3MJFZ3-FF:]O'L@I-8!8QLIVG__>ZU"05#0GB!<',XU_<>
M'^"N;E^SU'MA4G&1K_UP-/8]EL<BX?EN[?_Y_?AI[GM*TSRAJ<C9VG]CRK_=
M?/RP.@KYK/:,:0\8<K7V]UH7RR!0\9YE5(U$P7+X9RMD1C5<REV@"LEH8F[*
MTH",Q],@HSSW+<-27L,AMEL>LP<1'S*6:TLB64HUK%_M>:%.;%E\#5U&Y?.A
M^!2+K`"*)YYR_69(?2^+E]]VN9#T*86Z7\,)C4_<YJ)%G_%8"B6V>@1T@5UH
MN^9%L`B`:;-*.%2`;?<DVZ[]NW!Y'Q$_V*Q,@_YR=E2UWY[:B^,7R9/O/&?0
M;=`)%7@2XAFAWQ(,P<U!Z^Y'H\!/Z25L2P^I_B6.7QG?[37(?0,586'+Y.V!
MJ1@Z"C0C<H-,L4AA`7#T,HY;`SI"7\WYR!.]7_MD-KJ9C:,0X-X34_J1(Z7O
MQ0>E1?;/@L*2RI*0D@3.)4DTO98DL`LR]3U033<K*8X>;!I(J0J*6S!<`G%W
M05`)8N\0O/9A4\-:%:CPLHGFXU7P`IV+2\R]Q<"QPH05(H"D56;(=GUF!&-F
M;"TNY=X&ZFE(=YIH2!H$KWTX5HN/YN_+MYDM9F+V2[V>R9!$"(:6PZF6Z;T"
MFZD$U8N,YE%WF;"-KN\F@DWVJITVTBYJ.H06P4U:&VG3SH;0(KA):R-M6GS<
MUC8SNG0"E5W>U'A3D]Y&FMI,NMN^:&:\G`G!S4PVTBXDA"=4O9++O`;=)"Y#
M'<SHSUJ/>I@1[3#;4`>S8VC3_?%BU"M`6'K94-J=7X::$MQT2Q`.<KA!.Q6=
M<S3:<T"O2KO6R["ACEZAWZY7P;H3EE/Y%5\^($P'L^-85('@;N@1NNW=\&3>
M^B-J>D:#088.VXXN0QWU.)[N*:-MYO#D9NA=X_T3#O*N03O[YIQ[B>->H\&D
M5P-S6S-%&6KZ8-:M`1GD;(-VDIUS-G&<?5D#@W:8K</;ZI)!WC5HA_F<=XGC
M7=0@G/=KT#:Q84*KU7TP/Z/!(%_CMY_S="U#'9UR?-VC0=O.Y&1GUP=DD'<-
MVM'@W.N8.-Y%#:;]$K0];(A<"19G)!AD:V(]7'^TEJ&V!)%CZ\L2&'2S466H
M@WF0=2/KT_J:RU`'LV-=8X,(]EW/XMNO9!BO[!NG9H/%^\>_?;3:`<H.&!F3
M._:9I:GR8G'`X8C`R%!%J\'MSLQM;GRRO+,#75#]`P-507?L!Y4[GBLO95O@
M'(]F4(VT(YF]T**`OL-8)32,4N;G'D9G!F/#&+]&MD+HTP6:H1K&-_\!``#_
M_P,`4$L#!!0`!@`(````(0"RW:@`D0(``+L&```9````>&PO=V]R:W-H965T
M<R]S:&5E=#(P+GAM;)25R6[;,!"&[P7Z#@3O$;5XBV`Y<!JD+=`"1='E3%,C
MB8@H"B0=)V_?H>BH=IP6]D7+Z.<W"X>CY<V3:LDC&"MU5]`DBBF!3NA2=G5!
M?_ZXOUI08AWO2M[J#@KZ#);>K-Z_6^ZT>;`-@"-(Z&Q!&^?ZG#$K&E#<1KJ'
M#K]4VBCN\-74S/8&>#DL4BU+XWC&%)<=#83<G,/0524%W&FQ5="Y`#'0<H?Q
MVT;V]H6FQ#DXQ<W#MK\26O6(V,A6NN<!2HD2^>>ZTX9O6LS[*9EP\<(>7D[P
M2@JCK:Y<A#@6`CW-^9I=,R2MEJ7$#'S9B8&JH.LDOUU0MEH.]?DE86</GHEM
M].ZCD>47V0$6&[?);\!&ZP<O_5QZ$RYF)ZOOAPWX9D@)%=^V[KO>?0)9-PYW
M>XH)^;SR\OD.K,""(B9*IYXD=(L!X)4HZ3L#"\*?AOM.EJXI:!I'DW0Z7R2H
M)QNP[EYZ)B5B:YU6OX,JV;,")=U3\+ZG9+-H.H^S,R`L1#0D>,<=7RV-WA%L
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MA!>G>PP<!XAV.#2&QP9_$H`')(Y07&GM7E[0,1M_.ZL_````__\#`%!+`P04
M``8`"````"$`:72$?C0#``#3"P``$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!
M**```0``````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````"<5E%/VS`0?I^T
M_U#E'5*@FC:4!D';":1NH+6P1\M-+JU%8@?;J=K]^IT36A)V]53>DOCN_-UW
M=U\NNMH4>6\-V@@EA\'9:3_H@4Q4*N1R&#S.OY]\#7K&<IGR7$D8!ELPP57\
M^5/TH%4)V@HP/0PAS3!865M>AJ%)5E!P<XK'$D\RI0MN\54O0Y5E(H&Q2JH"
MI`W/^_TO(6PLR!32DW(?,&@B7J[M1X.F*G'XS--\6R+@.+HNRUPDW&*6\0^1
M:&549GN330)Y%+8/(T0W@Z32PF[C?A2V7Z-9PG,88>`XX[F!*'S[$-T"=Z0]
M<*%-'*WMY1H2JW3/B#](VWG06W`##LXP6',MN+0(RYDU+_5S7AJKX]]*/YL5
M@#51B`;-Q_JQ;=M^%H-X\*VVP*>NI8O0(,&#+L:YL#F8^^R!:TM`'GQK8ZY1
M-(@;0+LJ,NP--I$6^6)WLJFV4&WD^QQ&2AJ5BY1;2-D-S[E,@,U<ID>:,X3\
M?Y>9Q8M<HS&5L7MLUB-<3.UC5T>X.(^95<D'7,Z.]!EQ0R.;547!];:&(I92
MX+AAH['K)%&5I%E^G>-M4\>72I2.,A+0&#(AA04V%1E@L5$6EF*1`[LVYD`-
M?RH+!LNUY<[N%^1U[5W';<DKL$50C&P=]49A9W5<29<Q:+'&R5X[7'PA<N%$
MB32=`LX@?72'HE<`F_/-`8.I,I@(:&Q8KG'T]UWMAK@9"5?]YY7*4Y13-D$J
M#R99%,(ZFDW-.B9M43I0=P\!'PM3*H.)*4G>W"&6S367AB?.FDYV5BT,O%1N
M-";K0]7V]Q+=LG0S(:M8?1J*OZ?H6SQ-A5>1!+7+ZX/3K;+/TD_/.8GB`#UC
ML%SD-#]^%YH?/Z<T-+_/!9F.KPYC>D3\+G0Z?A\Z';^.T/?00L)\U6D$Q6O2
MZ3Q?+,J0T4A)4YH(TG2.2U?%<?/92]>;B+V;`!]B0N^\5(R41_<8B:8E?-[0
MAP70N9&AWXL@%;^S/;W;EZ9"/IO'<J[&^$_;+83=CU']KTAQ5=J=OWV(;G$7
MU+D+,EKACQ32G<V_!VY]?6IV]/AL<-J_Z.-FVOH6A:\R@?^/^"\```#__P,`
M4$L#!!0`!@`(````(0`!>:__E0```*D````0````>&PO8V%L8T-H86EN+GAM
M;#R.00H",1`$[X)_&.;N9O6@(DD6%'R!/B!D1Q-()DLFB/[>>/'24#14MY[>
M.<&+JL3"!K?#B$#LRQSY:?!^NVZ."-(<SRX5)H,?$ISL>J6]2_X27&3H!A:#
MH;7EI)3X0-G)4!;BWCQ*S:YUK$\E2R4W2R!J.:G=..Y5[@*TVD,U>#X@Q/X!
M(?U26:W^(_8+``#__P,`4$L#!!0`!@`(````(0`P?G]-,@$``$`"```1``@!
M9&]C4')O<',O8V]R92YX;6P@H@0!**```0``````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````"<D4%/PR`8AN\F_H>&>TMI=3&D98F:G5QBXHR+-X1O*[%0
M`FBW?R_KNCJC)X_D?7EXOH]JOM-M\@G.J\[4B&0Y2L"(3BJSK='S:I'>H,0'
M;B1O.P,UVH-'<W9Y40E+1>?@T7467%#@DT@RG@I;HR8$2S'VH@'-?18;)H:;
MSFD>XM%ML>7BG6\!%WD^PQH"ESQP?`"F=B*B$2G%A+0?KAT`4F!H08,)'I.,
MX.]N`*?]GQ>&Y*RI5=C;.-.H>\Z6XAA.[9U74['O^ZPO!XWH3_!Z^?`TC)HJ
M<]B5`,0.^VFY#\NXRHT">;MGNS?7)MXW%?Z=55(,=E0XX`%D$M^C1[M3\E+>
MW:\6B!4YN4[S,BW)BI2TG-&KXK7"I]9XGTU`/0K\FW@"L,'[YY^S+P```/__
M`P!02P$"+0`4``8`"````"$`^,"D+AD"``"X'@``$P``````````````````
M````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C]0``
M`$P"```+`````````````````%($``!?<F5L<R\N<F5L<U!+`0(M`!0`!@`(
M````(0`I*$,&2@(```,>```:`````````````````'@'``!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+`0(M`!0`!@`(````(0"PUJT`$@0``,H.```/
M``````````````````(+``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`"```
M`"$`$N/@\_0$``!>$@``&`````````````````!!#P``>&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L!`BT`%``&``@````A`!\/A#A7!```%!```!D`````
M````````````:Q0``'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"+0`4
M``8`"````"$`Y<,*K-P#``"D#0``&0````````````````#Y&```>&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+`0(M`!0`!@`(````(0`9WLN2O0(``%@'
M```9``````````````````P=``!X;"]W;W)K<VAE971S+W-H965T-#`N>&UL
M4$L!`BT`%``&``@````A`&E,MV`-`P``.`@``!D``````````````````"``
M`'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"+0`4``8`"````"$`?2\\
MK<L$``"2$0``&0````````````````!$(P``>&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+`0(M`!0`!@`(````(0`NN2E,KQ(``'1K```9````````````
M`````$8H``!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!`BT`%``&``@`
M```A`!/9)`6"`@``W@8``!D`````````````````+#L``'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"+0`4``8`"````"$`&!W4LT$$``"[#@``&```
M``````````````#E/0``>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`
M%``&``@````A`,Y\SP3&`@``!P@``!D`````````````````7$(``'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6Q02P$"+0`4``8`"````"$`+%ZW7J4"``!=
M!@``&0````````````````!910``>&PO=V]R:W-H965T<R]S:&5E=#,S+GAM
M;%!+`0(M`!0`!@`(````(0`9I/8NT0,``"H.```9`````````````````#5(
M``!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!`BT`%``&``@````A`*V&
M2)8W`P``50D``!D`````````````````/4P``'AL+W=O<FMS:&5E=',O<VAE
M970T,BYX;6Q02P$"+0`4``8`"````"$`;]-E,3,"``#V!```&0``````````
M``````"K3P``>&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+`0(M`!0`!@`(
M````(0`H5\I7X`(``*\'```9`````````````````!52``!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L!`BT`%``&``@````A`'P331AC"P``R6,```T`
M````````````````+%4``'AL+W-T>6QE<RYX;6Q02P$"+0`4``8`"````"$`
M]NINP\E?``!Y.0$`%`````````````````"Z8```>&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"+0`4``8`"````"$`QZQY[X,"``"O!@``&```````````````
M``"UP```>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`BT`%``&``@````A
M`-T"HF&2!0``A1<``!@`````````````````;L,``'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+`0(M`!0`!@`(````(0#[8J5ME`8``*<;```3````````
M`````````#;)``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`BT`%``&``@````A
M`$Z"'(S+`@``R@<``!D`````````````````^\\``'AL+W=O<FMS:&5E=',O
M<VAE970T.2YX;6Q02P$"+0`4``8`"````"$`55^R7%,#``#J"0``&0``````
M``````````#]T@``>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+`0(M`!0`
M!@`(````(0!YP1C35@(``"T%```9`````````````````(?6``!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L!`BT`%``&``@````A`#89;A[$`@````<`
M`!D`````````````````%-D``'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q0
M2P$"+0`4``8`"````"$`T!B8@SL*``#\-0``&0`````````````````/W```
M>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+`0(M`!0`!@`(````(0!5"M&1
M6P0``.`0```9`````````````````('F``!X;"]W;W)K<VAE971S+W-H965T
M,S`N>&UL4$L!`BT`%``&``@````A`,-HB,5Z`@``M@4``!D`````````````
M````$^L``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"+0`4``8`"```
M`"$`&>(O8B`%``#4$@``&0````````````````#$[0``>&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+`0(M`!0`!@`(````(0!YMG$2)P4``$`4```9````
M`````````````!OS``!X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L!`BT`
M%``&``@````A`&J]T+E0#P``;5P``!D`````````````````>?@``'AL+W=O
M<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"+0`4``8`"````"$`R)+[$74#```%
M#```&0``````````````````"`$`>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM
M;%!+`0(M`!0`!@`(````(0"H&X4FX`(``$<(```9`````````````````*P+
M`0!X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L!`BT`%``&``@````A`!R6
M/N%;!P``$B(``!D`````````````````PPX!`'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"+0`4``8`"````"$`GZ@Q%Q@.``!030``&```````````
M``````!5%@$`>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`BT`%``&``@`
M```A`'M3L91;!@``=AH``!@`````````````````HR0!`'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0!<`S3X)@4``&H4```8````
M`````````````#0K`0!X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"+0`4
M``8`"````"$`O3OO,"8'``"P'P``&`````````````````"0,`$`>&PO=V]R
M:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&``@````A`*I_Q_S(`@``_@8`
M`!@`````````````````[#<!`'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+
M`0(M`!0`!@`(````(0!/Z""P904``,,5```9`````````````````.HZ`0!X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!`BT`%``&``@````A`,!M2Z(5
M`P``QPD``!D`````````````````AD`!`'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"+0`4``8`"````"$`!=2C%"$'```S'P``&0``````````````
M``#20P$`>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(M`!0`!@`(````
M(0#/4ZU*%PX``)]/```9`````````````````"I+`0!X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L!`BT`%``&``@````A`-UH0.K_`P``D0T``!D`````
M````````````>%D!`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"+0`4
M``8`"````"$`#H:*#]D&``#='```&0````````````````"N70$`>&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+`0(M`!0`!@`(````(0!O4_D"/@@``.0D
M```9`````````````````+YD`0!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L!`BT`%``&``@````A`-%_I`TO"@``-S```!D`````````````````,VT!
M`'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"+0`4``8`"````"$`@E\M
M__X$```B$P``&0````````````````"9=P$`>&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+`0(M`!0`!@`(````(0"YR]`2(P,``",*```9````````````
M`````,Y\`0!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!`BT`%``&``@`
M```A`%26122@!```VA0``!D`````````````````*(`!`'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"+0`4``8`"````"$`-Y,MR_`#``#,#P``&0``
M``````````````#_A`$`>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+`0(M
M`!0`!@`(````(0!$.!8*Z@,``-$/```9`````````````````":)`0!X;"]W
M;W)K<VAE971S+W-H965T,C(N>&UL4$L!`BT`%``&``@````A`++=J`"1`@``
MNP8``!D`````````````````1XT!`'AL+W=O<FMS:&5E=',O<VAE970R,"YX
M;6Q02P$"+0`4``8`"````"$`:72$?C0#``#3"P``$``````````````````/
MD`$`9&]C4')O<',O87!P+GAM;%!+`0(M`!0`!@`(````(0`!>:__E0```*D`
M```0`````````````````'F4`0!X;"]C86QC0VAA:6XN>&UL4$L!`BT`%``&
M``@````A`#!^?TTR`0``0`(``!$`````````````````/)4!`&1O8U!R;W!S
?+V-O<F4N>&UL4$L%!@`````[`#L`!A```*67`0``````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1CAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 16, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommitmentsAndContingenciesTextualAbstract', window );"><strong>Commitments and Contingencies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" onclick="toggleNextSibling(this);">185,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_TerminationOfAgreement', window );">Termination of agreement</a></td>
        <td class="text">180 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_PaymentsForRoyaltiesPeriod', window );">Payments for royalties period</a></td>
        <td class="text">20 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommitmentsAndContingenciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommitmentsAndContingenciesTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_PaymentsForRoyaltiesPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Payments for royalties period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_PaymentsForRoyaltiesPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_TerminationOfAgreement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date of agreement termination.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_TerminationOfAgreement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Definite Life Intangible Assets (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Definite Life Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">$ 186,414</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">$ 231,615</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization expense</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentForAmortization" onclick="toggleNextSibling(this);">$ 14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentForAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentForAmortization" onclick="toggleNextSibling(this);">$ 38,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentForAmortization</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Definite Life Intangible Assets (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Definite Life Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of finite-lived intangible assets, future amortization expense</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: 'times new roman', times, serif;"><br class="apple-interchange-newline" /></font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;"><u>Year ending December 31,</u></font></td><td style="font-size: 10pt; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1240.73864746094px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2015</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2016</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2017</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2018</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2019</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-right: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Thereafter</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">114,509</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">186,414</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGLAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details 2) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current Tax Expense</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">Danish Income Tax</a></td>
        <td class="num"><a title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (177,539)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred Income Tax Expense (Benefit)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets', window );">Excess of Tax over Book Depreciation Fixed Assets</a></td>
        <td class="nump"><a title="pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" onclick="toggleNextSibling(this);">19,259</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ExcessTaxBenefitOverDepreciationFixedAssets</span><span></span></td>
        <td class="nump"><a title="pmhs_ExcessTaxBenefitOverDepreciationFixedAssets" onclick="toggleNextSibling(this);">26,364</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ExcessTaxBenefitOverDepreciationFixedAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ExcessTaxBenefitOverDepreciationPatents', window );">Excess of Tax over Book Depreciation Patents</a></td>
        <td class="nump"><a title="pmhs_ExcessTaxBenefitOverDepreciationPatents" onclick="toggleNextSibling(this);">67,488</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ExcessTaxBenefitOverDepreciationPatents</span><span></span></td>
        <td class="num"><a title="pmhs_ExcessTaxBenefitOverDepreciationPatents" onclick="toggleNextSibling(this);">(105,585)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ExcessTaxBenefitOverDepreciationPatents</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards', window );">Net Operating Loss Carryforwards</a></td>
        <td class="num"><a title="pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" onclick="toggleNextSibling(this);">(523,378)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards</span><span></span></td>
        <td class="num"><a title="pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards" onclick="toggleNextSibling(this);">(190,988)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount', window );">Change in the Valuation allowance</a></td>
        <td class="nump"><a title="pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" onclick="toggleNextSibling(this);">436,631</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount</span><span></span></td>
        <td class="nump"><a title="pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount" onclick="toggleNextSibling(this);">270,209</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total Deferred Tax Expense</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ExcessTaxBenefitOverDepreciationFixedAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess Tax Benefit Over Depreciation Fixed Assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ExcessTaxBenefitOverDepreciationFixedAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ExcessTaxBenefitOverDepreciationPatents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess Tax Benefit Over Depreciation Patents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ExcessTaxBenefitOverDepreciationPatents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income Tax Expense Benefit Operating Loss Carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IncomeTaxExpenseBenefitOperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Valuation Allowance Income Tax Expense Benefit Change in Amount.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ValuationAllowanceIncomeTaxExpenseBenefitChangeInAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509736<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 6<br><br> -Section I<br><br> -Subsection 7<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1GAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Bond Payable - Related Party (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="3">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 16, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
        <th class="th">
          <div>Dec. 01, 2011</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Bond Payable - Related Party [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Convertible bonds, amount borrowed</a></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount" onclick="toggleNextSibling(this);">$ 1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount" onclick="toggleNextSibling(this);">$ 1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Convertible bonds, stated percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Convertible bonds and related accrued interest, intial rate of conversion into common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleConversionPrice1" onclick="toggleNextSibling(this);">$ 9.58</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleConversionPrice1</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Convertible bonds, after conversion estimated fairvalue</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" onclick="toggleNextSibling(this);">1,003,557</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseCommercialPaper', window );">Interest expense for the accertion of discount on note</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseCommercialPaper" onclick="toggleNextSibling(this);">502,465</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseCommercialPaper</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseCommercialPaper" onclick="toggleNextSibling(this);">461,279</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseCommercialPaper</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest</a></td>
        <td class="nump"><a title="us-gaap_InterestReceivable" onclick="toggleNextSibling(this);">179,612</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestReceivable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
        <td class="nump"><a title="us-gaap_DerivativeLiabilities" onclick="toggleNextSibling(this);">$ 673,736</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DerivativeLiabilities</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt', window );">Common stock exchanged during period of conversion</a></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Bond, related accrued interest and derivative liability, converted into shares</a></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" onclick="toggleNextSibling(this);">174,578</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature', window );">Convertible bonds, conversion description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The assumptions used to determine the initial fair value of the conversion feature of the convertible bond were expected volatility of 65%, expected life of two years to twelve months, risk free interest rates of .41%, and no dividend yield.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" onclick="toggleNextSibling(this);">65.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" onclick="toggleNextSibling(this);">0.41%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">2 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock exchanged during period of conversion of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Beneficial Conversion Feature<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505963<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The price per share of the conversion feature embedded in the debt instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 10<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13433-108611<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35750535&amp;loc=d3e13495-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34720828&amp;loc=SL20225862-175312<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 20<br><br> -Section 55<br><br> -Paragraph 10<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36459792&amp;loc=SL20226008-175313<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseCommercialPaper">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest expense incurred during the reporting period on commercial paper.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 7<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseCommercialPaper</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Disposition (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 16, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Disposition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Gain or loss from the Sale and discontinue operations</a></td>
        <td class="nump"><a title="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" onclick="toggleNextSibling(this);">$ 1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of sales or other form of revenues attributable to the disposal group, including a component of the entity (discontinued operation), during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>NOTE 1 &#8212; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Business and Basis of Presentation &#8211;&#160;</b>The consolidated financial statements include the accounts and operations of Dandrit Biotech USA Inc and its wholly owned subsidiary DanDritBioTech A/S.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">DanDrit Biotech USA, Inc. (&#8220;DanDrit USA&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) (formerly Putnam Hills Corp.) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">DanDritBioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (&#8220;DanDrit Denmark&#8221;).&#160;&#160;The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the treatment of cancerin humansusing the dendritic cell technology.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Reverse Acquisition&#160;&#160;- On February 12, 2014, pursuant to aShare Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of approximately 100% of the issued and outstanding capital stock&#160;&#160;of&#160;&#160;DanDrit Denmark (the &#8220;Share Exchange&#8221;) and as a result became DanDrit Denmark&#8217;s parent company (the &#8220;Parent&#8221;). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the &#8220;Common Stock&#8221;) of Parent outstanding.&#160;Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share
 Exchange
 and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent&#8217;s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent&#8217;s Common Stock outstanding immediately following the Share Exchange,&#160;<font style="background-color: white;">including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the&#160;</font>Share Exchange (the &#8220;Non-Consenting Shareholders&#8221;)<font style="background-color: white;">, and deemed issued and outstanding for accounting purposes</font>.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Functional Currency / Foreign currency translation</b>&#160;&#8212;&#160;The functional currency of DanDrit Biotech A/S is the Danish Kroner (&#8220;DKK&#8221;). The Company&#8217;s reporting currency istheU.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years 2014 and 2013. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Cash and Cash Equivalents</b>&#160;&#8212;&#160;The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held inafinancial institution in the United States in excess of federally insured amounts at December 31, 2014 of $2,508,759 and none at December 31, 2013.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Property and Equipment</b>&#160;&#8212;&#160;Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch:
 normal;
 margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Intangible Assets</b>&#160;&#8212;&#160;Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (&#8220;FASB&#8221;) Accounting Standards Codification, (&#8220;ASC&#8221;) Topic 350, &#8220;Goodwill and Other Intangible Assets&#8221; and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Impairment of Long-Lived Assets &#8212;</b>&#160;Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Revenue Recognition and Sales&#160;</b>&#160;&#8212;&#160;The Company&#8217;s sales of its MelCancerVac colorectal cancer treatment have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, &#8220;Revenue Recognition in Financial Statements&#8221; (SAB 101), FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of the resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal;
 font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 18pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Value Added Tax -&#160;</b>In Denmark, Value Added Tax (&#8220;VAT&#8221;) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices. These amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Research and Development Cost</b>&#160;&#8212;&#160;The Company expenses research and development costs for the development of new products as incurred and such costs areincluded in operating expense. There wereno research and development costs for the years ended December 31, 2014 and 2013.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Income Taxes</b>&#160;&#8212;&#160;The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Loss Per Share</b>&#160;&#8212;&#160;The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight:
 normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Derivatives &#8212;&#160;</b>We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, we have entered into certain other financial instruments and contracts, such as debt financing arrangements with features that are either (i)&#160;not afforded equity classification, (ii)&#160;embody risks not clearly and closely related to host contracts, or (iii)&#160;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We estimate fair values of all derivative instruments, such as embedded conversion features utilizing Level 3 inputs (defined below in Note 1: Fair Value of Financial Instruments). We use the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in themarket price of our common stock, which have historically had high volatility. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect the volatility in these estimate and assumption changes.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We report our derivative liabilities at fair value on the accompanying balance sheets as of December 31, 2014 and 2013.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Fair Value of Financial Instruments</b>&#160;&#8212;&#160;The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant:
 normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#9679;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#9679;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#9679;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own
 assumptions.</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Unless otherwise disclosed, the fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Accounting Estimates</b>&#160;&#8212;&#160;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Recent Accounting Pronouncements</b>&#160;&#8212;&#160;In May 2014, the Financial Accounting Standards Board issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective beginning in the first quarter of 2017; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We do not believe the new standard will materially impact our consolidated financial statements.&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#8217;s present or future financial statements.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size:
 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40.5pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Reclassification&#160;&#8212;&#160;</b>The financial statements for the period ended December 31, 2013 have been reclassified to conform to the headings and classifications used in the December 31, 2014 financial statements.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>32
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?86YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L:61A=&5D
M7T)A;&%N8V5?4VAE970\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#(N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y#;VYS;VQI9&%T961?0F%L86YC95]3:&5E=%]087(\+W@Z3F%M
M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S
M+U-H965T,#,N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@
M/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYS;VQI9&%T961?
M4W1A=&5M96YT7V]F7T]P97(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#0N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y#;VYS;VQI9&%T961?4W1A=&5M96YT<U]O9E]/=&@\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VYS;VQI9&%T
M961?4W1A=&5M96YT7V]F7U-T;V,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y#;VYS;VQI9&%T961?4W1A=&5M96YT7V]F7U-T;V,Q
M/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R
M:W-H965T<R]3:&5E=#`W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N<V]L
M:61A=&5D7U-T871E;65N=%]O9E]#87-H/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`X+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O
M=6YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#`Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O
M<&5R='E?86YD7T5Q=6EP;65N=#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,"YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D1E9FEN:71E7TQI9F5?26YT86YG:6)L95]!<W-E=#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S7U!A
M>6%B;&5?4F5L871E9%]087)T>3PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D-O;G9E<G1I8FQE7T)O;F1?4&%Y86)L95]296QA=#PO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E<FEV871I
M=F5?3&EA8FEL:71I97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,30N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y,96%S97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,34N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97,\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE
M9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*
M("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^
M#0H@("`@/'@Z3F%M93Y,;W-S7U!E<E]3:&%R93PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/E-T;V-K:&]L9&5R<U]%<75I='D\+W@Z
M3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE
M971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*
M("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M96YT
M<U]A;F1?0V]N=&EN9V5N8VEE<SPO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q.2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/D1I<W!O<VET:6]N/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4<F%N<V%C=&EO;G,\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C$N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6)S97%U
M96YT7T5V96YT/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2
M968],T0B5V]R:W-H965T<R]3:&5E=#(R+FAT;6PB+SX-"B`@(#PO>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA
M;64^4W5M;6%R>5]O9E]3:6=N:69I8V%N=%]!8V-O=6YT,3PO>#I.86UE/@T*
M("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE
M970R,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E!R;W!E<G1Y7V%N9%]%<75I
M<&UE;G1?5&%B;&5S/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(T+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^1&5F:6YI=&5?3&EF95]);G1A;F=I8FQE7T%S<V5T,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970R-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S7U!A>6%B;&5?
M4F5L871E9%]087)T>5]483PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O
M=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970R-BYH=&UL(B\^#0H@("`\
M+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M("`\>#I.86UE/DEN8V]M95]487AE<U]486)L97,\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,C<N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y,;W-S7U!E<E]3:&%R95]486)L97,\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T,C@N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y3=6UM87)Y
M7V]F7U-I9VYI9FEC86YT7T%C8V]U;G0R/"]X.DYA;64^#0H@("`@/'@Z5V]R
M:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#(Y+FAT;6PB
M+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H
M965T/@T*("`@(#QX.DYA;64^4')O<&5R='E?86YD7T5Q=6EP;65N=%]$971A
M:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B
M5V]R:W-H965T<R]3:&5E=#,P+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4')O
M<&5R='E?86YD7T5Q=6EP;65N=%]$971A:6QS,3PO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970S,2YH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/D1E9FEN:71E7TQI9F5?26YT86YG:6)L
M95]!<W-E=#(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,S(N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y$969I;FET95],:69E7TEN=&%N9VEB;&5?07-S970S/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#,S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X
M8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^3F]T97-?4&%Y86)L95]296QA
M=&5D7U!A<G1Y7T1E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#,T+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX
M.DYA;64^3F]T97-?4&%Y86)L95]296QA=&5D7U!A<G1Y7T1E,3PO>#I.86UE
M/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O
M4VAE970S-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5S7U!A>6%B;&5?
M4F5L871E9%]087)T>5]$93(\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713
M;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,S8N:'1M;"(O/@T*("`@
M/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@
M("`@/'@Z3F%M93Y#;VYV97)T:6)L95]";VYD7U!A>6%B;&5?4F5L870Q/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#,W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^1&5R:79A=&EV
M95],:6%B:6QI=&EE<U]$971A:6QS/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H
M965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#,X+FAT;6PB+SX-
M"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T
M/@T*("`@(#QX.DYA;64^3&5A<V5S7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,SDN
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y);F-O;65?5&%X97-?1&5T86EL<SPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970T,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DEN8V]M95]4
M87AE<U]$971A:6QS7S$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R
M8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#$N:'1M;"(O/@T*("`@/"]X
M.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@
M/'@Z3F%M93Y);F-O;65?5&%X97-?1&5T86EL<U\R/"]X.DYA;64^#0H@("`@
M/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0R
M+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L
M5V]R:W-H965T/@T*("`@(#QX.DYA;64^26YC;VUE7U1A>&5S7T1E=&%I;'-?
M5&5X='5A;#PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970T,RYH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DQO<W-?4&5R7U-H87)E7T1E=&%I;',\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#0N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y3=&]C:VAO;&1E<G-?17%U:71Y7T1E=&%I;',\
M+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K
M<VAE971S+U-H965T-#4N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T
M/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y#;VUM:71M
M96YT<U]A;F1?0V]N=&EN9V5N8VEE<U\\+W@Z3F%M93X-"B`@("`\>#I7;W)K
M<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T-#8N:'1M;"(O
M/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE
M970^#0H@("`@/'@Z3F%M93Y$:7-P;W-I=&EO;E]$971A:6QS/"]X.DYA;64^
M#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3
M:&5E=#0W+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX
M.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^4F5L871E9%]087)T>5]4
M<F%N<V%C=&EO;G-?1&5T/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U
M<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#0X+FAT;6PB+SX-"B`@(#PO
M>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^4W5B<V5Q=65N=%]%=F5N=%]$971A:6QS/"]X.DYA;64^#0H@
M("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E
M=#0Y+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X
M8V5L5V]R:W-H965T<SX-"B`@/'@Z4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS
M:&5E=',O<F5P;W)T+F-S<R(O/@T*("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C
M=&EV95-H965T/@T*("`\>#I0<F]T96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R
M;W1E8W13=')U8W1U<F4^#0H@(#QX.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X
M.E!R;W1E8W17:6YD;W=S/@T*(#PO>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^
M/"%;96YD:69=+2T^#0H\+VAE860^#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P
M86=E('-H;W5L9"!B92!O<&5N960@=VET:"!-:6-R;W-O9G0@17AC96P@6%`@
M;W(@;F5W97(N/"]P/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?
M-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,#$N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$564D%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M
M96YT(&%N9"!%;G1I='D@26YF;W)M871I;VX@*%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ
M,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C
M;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS
M<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,P+"`R,#$U/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,S`L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&]C=6UE;G0@
M86YD($5N=&ET>2!);F9O<FUA=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!296=I<W1R
M86YT($YA;64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D1A;D1R
M:70@0FEO=&5C:"!54T$L($EN8RX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET>2!#96YT<F%L($EN9&5X($ME
M>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,#`P,34R-S<R.#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M06UE;F1M96YT($9L86<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/F9A;'-E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N="!4>7!E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ,"U+/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$;V-U;65N
M="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D1E8R`S,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES8V%L(%EE87(@1F]C
M=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P,30\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1O8W5M
M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/D99/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y%;G1I='D@5V5L;"UK;F]W;B!396%S;VYE9"!)<W-U
M97(\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/DYO/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@
M5F]L=6YT87)Y($9I;&5R<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^3F\\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D5N=&ET>2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/EEE<SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y($9I;&5R($-A
M=&5G;W)Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y3;6%L;&5R
M(%)E<&]R=&EN9R!#;VUP86YY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@4'5B;&EC($9L;V%T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(T+#DU-BPR-C`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5N=&ET
M>2!#;VUM;VX@4W1O8VL@4VAA<F5S($]U='-T86YD:6YG/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY+#4S,RPR.3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q83DT,3-C7S4U9#5?-#-F85\X
M83DW7SEC-#-A-6-E93@R8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\S,6$Y-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(O5V]R:W-H
M965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%,4U!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#$^/'-T<F]N9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E="`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY#=7)R96YT($%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"`H,2D\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,RPP,#@L.#,Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q."PW.30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@:&5L9"!I;B!E<V-R;W<@*#(I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR+#`R.2PU,#(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XW-RPT-C@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]T:&5R(')E8V5I=F%B;&5S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`Q-CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(U+#0U-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E
M<&%I9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3DL-S<T/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@0W5R<F5N="!!<W-E=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#0V+#,T.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,2PT.3(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;W!E<G1Y(&%N9"!%<75I<&UE;G0L(&YE="!A8V-U;75L871E9"!D97!R
M96-I871I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P
M.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY/5$A%4B!!4U-%5%,Z/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E9FEN
M:71E(&QI9F4@:6YT86YG:6)L92!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$X-BPT,30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR,S$L-C$U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$969E<G)E9"!S=&]C:R!O
M9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-C<L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y$97!O<VET<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPQ-#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,"PS-C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!/=&AE<B!!<W-E
M=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$Y,RPU-C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,#@L
M.3<U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&]T86P@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+#(S.2PY,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT-3`L-#8W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-U<G)E;G0@3&EA8FEL
M:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/DYO=&5S('!A>6%B;&4@+2!R96QA=&5D('!A<G1Y+"!C=7)R96YT('!O
M<G1I;VX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDY+#DU,3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<R
M."PP,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E-T;V-K($]F9F5R:6YG($5S8W)O=SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O
M=6YT<R!P87EA8FQE("T@=')A9&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<Q,2PT-#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XU-#@L-3`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE("T@<F5L
M871E9"!P87)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$R
M+#0S.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^-S,S+#@R-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@U."PQ,S4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@
M:6YC;VUE('1A>&5S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($-U<G)E
M;G0@3&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S4W+#8V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,3,T+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;VYG(%1E<FT@3&EA8FEL
M:71I97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F]T97,@<&%Y86)L92`M(')E;&%T960@4&%R='D\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F]T97,@<&%Y86)L92`M1&%N9')I="`H,RD\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L
M($QO;F<M5&5R;2!,:6%B:6QI=&EE<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3&EA
M8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S4W
M+#8V-#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(L,3,T+#8S-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY35$]#2TA/3$1%4E,G($5154E462`H
M1$5&24-)5"DZ/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:SL@<&%R('9A;'5E(#`N,#`P,2P@,3`P+#`P
M,"PP,#`@<VAA<F5S(&%U=&AO<FEZ960L(#DL-3,S+#(Y,"!I<W-U960@86YD
M(&]U='-T86YD:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`V+#`P,"PP
M,#`@<VAA<F5S(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@870@1&5C96UB97(@
M,S$L(#(P,3,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDU,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^061D:71I;VYA;"!P86ED+6EN(&-A<&ET86P\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(U+#`Y."PP-3`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPX-C<L-30V/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/=&AE<B!C
M;VUP<F5H96YS:79E(&EN8V]M92P@;F5T/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-S4L,C0Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,S$L,3DP*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C=6UU;&%T960@1&5F:6-I
M=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$L.#DR+#`P-RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q
M.2PU,C$L,3(V*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(%-T;V-K:&]L9&5R<R<@17%U:71Y("A$969I
M8VET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPT.#(L,C0U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,2PV.#0L,3<P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L($QI86)I;&ET:65S(&%N9"!3=&]C:VAO;&1E
M<G,G("A$969I8VET*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`U+#(S.2PY,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#0U,"PT-C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
M+2TM+2T]7TYE>'1087)T7S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC-#-A
M-6-E93@R8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,6$Y-#$S
M8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(O5V]R:W-H965T<R]3:&5E
M=#`S+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP
M<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U
M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%-D9!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY#;VYS;VQI9&%T960@0F%L86YC92!3:&5E="`H4&%R96YT:&5T:6-A;"D@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^0F%L86YC92!3:&5E="!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E
M<R!A=71H;W)I>F5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$P,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<W1O8VLL('-H87)E<R!I
M<W-U960\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-3,S+#(Y
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@;W5T<W1A;F1I;F<\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-3,S+#(Y,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P
M+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A
M8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?
M,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B#0I#;VYT96YT
M+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?-#-F85\X83DW
M7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,#0N:'1M;`T*0V]N=&5N
M="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N
M="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M
M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M
M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C
M<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@
M1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^
M#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$
M,$59,4%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G-O;&ED871E9"!3
M=&%T96UE;G0@;V8@3W!E<F%T:6]N<R`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1A=&5M96YT
M(&]F($]P97)A=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@4V%L97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,S(L-S8X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;W-T(&]F($=O;V1S
M(%-O;&0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(Y-2PV-C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M,#DL,CDY/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^1W)O<W,@3&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XH,CDU+#8V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W-BPU,S$I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]P97)A=&EN9R!%>'!E
M;G-E<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^1V5N97)A;"!A;F0@861M:6YI<W1R871I=F4@97AP96YS97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-C0T+#DQ.#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,C,S+#8X,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5P<F5C:6%T:6]N(&%N9"!!;6]R=&EZ871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$X+#DX,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,X+#(Y-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N<W5L=&EN9R!E>'!E
M;G-E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#8Y+#8V-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,Y
M,"PT,S<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!/<&5R871I;F<@17AP96YS93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,BPQ,S,L-38U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PV-C(L-#$W/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3&]S<R!F
M<F]M($]P97)A=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M*#(L-#(Y+#(R-BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q+#<S."PY-#@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D]T:&5R($EN8V]M92`H
M17AP96YS92D\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YT97)E<W0@*&5X<&5N<V4I/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@X-"PU-3`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH-C4R+#<P,RD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=A:6X@;VX@9F]R9VEV96YE
M<W,@;V8@9&5B=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^-#DL,#$V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y'86EN("AL;W-S*2!O;B!C=7)R96YC>2!T<F%N
M<V%C=&EO;G,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#0P+#4X
M,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.2PU-#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D=A:6X@;VX@9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-2PW,S(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DEN=&5R97-T(&%N9"!O=&AE<B!I;F-O;64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L.3,W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($]T:&5R($EN8V]M92`H17AP
M96YS92D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Q.2PQ.38I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M-#`X+#0Q,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,;W-S($)E9F]R92!);F-O;64@5&%X97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#(L-30X+#0R,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$T-RPS-C$I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;F-O;64@5&%X($5X<&5N<V4@*$)E;F5F:70I/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@Q-S<L-3,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L,S<P+#@X,RD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@
M*#(L,30W+#,V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D)!4TE#($%.1"!$24Q55$5$($Q/4U,@4$52(%-(05)%
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S(I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y714E'2%1%1"!!5D5204=%($Y534)%4B!/1B!#3TU-3TX@4TA!4D53($]5
M5%-404Y$24Y'+2!"05-)0R!!3D0@1$E,551%1#PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RPU,#`L,30R/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS,S(L-S(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y714E'2%1%1"!!
M5D5204=%($)!4TE#($%.1"!$24Q55$5$($Q/4U,@4$52(%-(05)%/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#`N,S(I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C0I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
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M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14A$04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E;65N=',@
M;V8@3W1H97(@0V]M<')E:&5N<VEV92!,;W-S("A54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY35$%4
M14U%3E13($]&($]42$52($-/35!214A%3E-)5D4@3$]34R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA.
M970@3&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPS
M-S`L.#@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,BPQ-#<L,S8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^*$-U<G)E;F-Y(%1R86YS;&%T:6]N+"!.
M970@;V8@5&%X97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@S
M,#8L-#,Y*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#(Q.2PT-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^*$]T:&5R($-O;7!R96AE;G-I=F4@3&]S<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,BPP-C0L-#0T*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H
M,BPS-C8L.#,Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?-#-F
M85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,#8N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$5)3D))/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,3X\<W1R;VYG/D-O;G-O;&ED
M871E9"!3=&%T96UE;G0@;V8@4W1O8VMH;VQD97)S)R`H1&5F:6-I="D@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y4;W1A;#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y#;VUM
M;VX@4W1O8VL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^061D
M:71I;VYA;"!086ED($EN($-A<&ET86P\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^06-C=6UU;&%T960@16%R;FEN9W,@*$1E9FEC:70I/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D]T:&5R($-O;7!R96AE
M;G-I=F4@26YC;VUE("AL;W-S*3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0F5G:6YN:6YG($)A;&%N8V4@870@1&5C+B`S,2P@,C`Q
M,CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U,S(\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$R+#@Q
M-RPQ,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B0@*#$W+#,W,RPW-C4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#@L,C@P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F,^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y"96=I;FYI;F<@0F%L86YC
M92P@4VAA<F5S(&%T($1E8RX@,S$L(#(P,3(\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4L,S$X+#$U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U960@
M=7!O;B!C;VYV97)S:6]N(&]F(&)O;F0@<&%Y86)L92UR96QA=&5D('!A<G1Y
M(&%N9"!D97)I=F%T:79E(&QI86)I;&ET>2!A="`Y+C`P('!E<B!S:&%R97,L
M($1E8V5M8F5R(#(P,3,L(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(L,S4S+#,R,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M0V]M;6]N('-H87)E<R!I<W-U960@=7!O;B!C;VYV97)S:6]N(&]F(&)O;F0@
M<&%Y86)L92UR96QA=&5D('!A<G1Y(&%N9"!D97)I=F%T:79E(&QI86)I;&ET
M>2!A="`Y+C`P('!E<B!S:&%R97,L($1E8V5M8F5R(#(P,3,L(%-H87)E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8Q+#8V-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N
M('-H87)E<R!I<W-U960@:6X@<&%Y;65N="!O9B!N;W1E<R!P87EA8FQE("T@
M<F5L871E9"!P87)T>2!A="`V+C0R('!E<B!S:&%R97,L($1E8V5M8F5R(#(P
M,3,L(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDR
M-BPS-S(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,@
M:7-S=65D(&EN('!A>6UE;G0@;V8@;F]T97,@<&%Y86)L92`M(')E;&%T960@
M<&%R='D@870@-BXT,B!P97(@<VAA<F5S+"!$96-E;6)E<B`R,#$S+"!3:&%R
M97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PS,C$\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O
M;6UO;B!S:&%R97,@:7-S=65D(&EN('!A>6UE;G0@;V8@;F]T92!P87EA8FQE
M("T@<F5L871E9"!P87)T>2!A="`V+C0R('!E<B!S:&%R97,L($1E8V5M8F5R
M(#(P,3,L(%9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C$L-S<P+#<S,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H
M87)E<R!I<W-U960@:6X@<&%Y;65N="!O9B!N;W1E('!A>6%B;&4@+2!R96QA
M=&5D('!A<G1Y(&%T(#8N-#(@<&5R('-H87)E<RP@1&5C96UB97(@,C`Q,RP@
M4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S4L.#8S
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%<75I='D@061J=7-T;65N="!F;W(@1F]R96EG;B!#=7)R96YC>2!4<F%N
M<VQA=&EO;B!996%R($5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3DL-#<P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,C$Y+#0W,"D\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!,;W-S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#$T-RPS-C$I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPQ-#<L,S8Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')C
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L86YC
M92!A="!$96,N(#,Q+"`R,#$S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M/B@Q+#8X-"PQ-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-C`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3<L.#8W+#4T-CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$Y+#4R,2PQ,C8I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,S$L,3DP
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')C/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0F%L86YC92P@4VAA<F5S(&%T($1E8RX@,S$L(#(P,3,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&\@<F5C;W)D('1H
M92!R96-A<&ET86QI>F%T:6]N(&]F(%-U8G-I9&EA<GD@:6X@8V]N;F5C=&EO
M;B!W:71H('1H92!&96)R=6%R>2`Q,BP@,C`Q-"!3:&%R92!%>&-H86YG92!!
M9W)E96UE;G0@=VAE<F5I;B!$86Y$<FET($)I;W1E8V@@55-!($EN8RX@*")0
M87)E;G0B*2!I<W-U960@-BPP,#`L,#`P(&-O;6UO;B!S:&%R97,@=&\@86-Q
M=6ER92!A(#$P,"4@:6YT97)E<W0@:6X@1&%N1')I="!":6]T96-H($$O4R`H
M(E-U8G-I9&EA<GDB*2!$86Y$<FET($)I;W1E8V@@55-!($EN8RXL("A&;W)M
M97)L>2!0=71N86T@2&EL;',@0V]R<"DL/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR,#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M/B@W.2PT,S8I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;R!R96-O<F0@=&AE(')E8V%P:71A;&EZ871I;VX@;V8@4W5B<VED:6%R
M>2!I;B!C;VYN96-T:6]N('=I=&@@=&AE($9E8G)U87)Y(#$R+"`R,#$T(%-H
M87)E($5X8VAA;F=E($%G<F5E;65N="!W:&5R96EN($1A;D1R:70@0FEO=&5C
M:"!54T$@26YC+B`H(E!A<F5N="(I(&ES<W5E9"`V+#`P,"PP,#`@8V]M;6]N
M('-H87)E<R!T;R!A8W%U:7)E(&$@,3`P)2!I;G1E<F5S="!I;B!$86Y$<FET
M($)I;W1E8V@@02]3("@B4W5B<VED:6%R>2(I($1A;D1R:70@0FEO=&5C:"!5
M4T$@26YC+BP@*$9O<FUE<FQY(%!U=&YA;2!(:6QL<R!#;W)P*2P@4VAA<F5S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#`T,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O
M(')E8V]R9"!T:&4@:7-S=6%N8V4@;V8@-"PP,#`@86YD(#$T,2PP,#`@8V]M
M;6]N('-H87)E<R!O;B!397!T96UB97(@-"P@,C`Q-"!I;B!C;VYN96-T:6]N
M($EN:71I86P@4'5B;&EC($]F9F5R:6YG('9A;'5E9"!A="`D-2!P97(@<VAA
M<F4@;W(@)#0L,#`P(&%N9"`D,30Q+#`P,"P@<F5S<&5C=&9U;&QY+B!.970@
M;V8@<W1O8VL@;V9F97)I;F<@8V]S="!O9B`D-C<L,#`P+"!686QU93PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-3<L.3@U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;R!R96-O<F0@=&AE(&ES<W5A;F-E(&]F(#0L
M,#`P(&%N9"`Q-#$L,#`P(&-O;6UO;B!S:&%R97,@;VX@4V5P=&5M8F5R(#0L
M(#(P,30@:6X@8V]N;F5C=&EO;B!);FET:6%L(%!U8FQI8R!/9F9E<FEN9R!V
M86QU960@870@)#4@<&5R('-H87)E(&]R("0T+#`P,"!A;F0@)#$T,2PP,#`L
M(')E<W!E8W1F=6QL>2X@3F5T(&]F('-T;V-K(&]F9F5R:6YG(&-O<W0@;V8@
M)#8W+#`P,"P@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ-#4L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y4;R!R96-O<F0@=&AE(&ES<W5A;F-E(&]F(#$P,"!C;VUM
M;VX@<VAA<F5S(&]N(%-E<'1E;6)E<B`R-"P@,C`Q-"!I;B!C;VYN96-T:6]N
M($EN:71I86P@4'5B;&EC($]F9F5R:6YG('9A;'5E9"!A="`D-2!P97(@<VAA
M<F4@;W(@)#4P,"P@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C`N,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O(')E8V]R
M9"!T:&4@:7-S=6%N8V4@;V8@,3`P(&-O;6UO;B!S:&%R97,@;VX@4V5P=&5M
M8F5R(#(T+"`R,#$T(&EN(&-O;FYE8W1I;VX@26YI=&EA;"!0=6)L:6,@3V9F
M97)I;F<@=F%L=65D(&%T("0U('!E<B!S:&%R92!O<B`D-3`P+"!3:&%R97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&\@<F5C;W)D
M('1H92!I<W-U86YC92!O9B`X.#DL-CDP(&-O;6UO;B!S:&%R97,@:6X@3V-T
M;V)E<BP@,C`Q-"!I;B!C;VYN96-T:6]N($EN:71I86P@4'5B;&EC($]F9F5R
M:6YG('9A;'5E9"!A="`D-2!P97(@<VAA<F4@;W(@)#0L,S4X+#@W.2!N970@
M;V8@<W1O8VL@;V9F97)I;F<@8V]S="!O9B`D.#DL,S8P('9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L,S4Y+#`P,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^5&\@<F5C;W)D('1H92!I<W-U86YC92!O9B`X
M.#DL-CDP(&-O;6UO;B!S:&%R97,@:6X@3V-T;V)E<BP@,C`Q-"!I;B!C;VYN
M96-T:6]N($EN:71I86P@4'5B;&EC($]F9F5R:6YG('9A;'5E9"!A="`D-2!P
M97(@<VAA<F4@;W(@)#0L,S4X+#@W.2!N970@;V8@<W1O8VL@;V9F97)I;F<@
M8V]S="!O9B`D.#DL,S8P+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C@X.2PV.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E1O(')E8V]R9"!T:&4@:7-S=6%N8V4@;V8@
M-3@L-3`P(&-O;6UO;B!S:&%R97,@;VX@3F]V96UB97(@,3,L(#(P,30@:6X@
M8V]N;F5C=&EO;B!);FET:6%L(%!U8FQI8R!/9F9E<FEN9R!V86QU960@870@
M)#4@<&5R('-H87)E(&]R("0R.3(L-3`P+"!V86QU93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(Y,BPT.30\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/E1O(')E8V]R9"!T:&4@:7-S=6%N8V4@;V8@-3@L-3`P(&-O;6UO
M;B!S:&%R97,@;VX@3F]V96UB97(@,3,L(#(P,30@:6X@8V]N;F5C=&EO;B!)
M;FET:6%L(%!U8FQI8R!/9F9E<FEN9R!V86QU960@870@)#4@<&5R('-H87)E
M(&]R("0R.3(L-3`P+"!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4X+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^5&\@<F5C;W)D('1H92!I<W-U86YC92!O9B`T,#`L
M,#`P(&-O;6UO;B!S:&%R97,@;VX@1&5C96UB97(@,S$L(#(P,30@:6X@8V]N
M;F5C=&EO;B!P<FEV871E('!L86-E;65N="!V86QU960@870@)#4@<&5R('-H
M87)E(&]R("0R+#`P,"PP,#`N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XT,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L.3DY+#DV,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&\@
M<F5C;W)D('1H92!I<W-U86YC92!O9B`T,#`L,#`P(&-O;6UO;B!S:&%R97,@
M;VX@1&5C96UB97(@,S$L(#(P,30@:6X@8V]N;F5C=&EO;B!P<FEV871E('!L
M86-E;65N="!V86QU960@870@)#4@<&5R('-H87)E(&]R("0R+#`P,"PP,#`L
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^17%U:71Y($%D:G5S=&UE;G0@9F]R($9O<F5I9VX@0W5R<F5N8WD@5')A
M;G-L871I;VX@665A<B!%;F1E9"!$96-E;6)E<B`S,2P@,C`Q-#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S`V+#0S.3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N
M8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C,P-BPT,SD\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)O=6YD:6YG/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF
M;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y.970@3&]S<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH,BPS-S`L.#@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N
M8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#(L,S<P+#@X,RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R8SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D)A;&%N8V4@870@1&5C+B`S
M,2P@,C`Q-#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+#0X
M,BPR-#4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#DU,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,C4L,#DX+#`U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,C$L.#DR+#`P-RD\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(W-2PR-#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R8SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)A;&%N8V4L(%-H87)E<R!A="!$96,N(#,Q+"`R,#$T/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XY+#4S,RPR.3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q83DT,3-C7S4U9#5?-#-F85\X
M83DW7SEC-#-A-6-E93@R8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B\S,6$Y-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(O5V]R:W-H
M965T<R]3:&5E=#`W+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1EA!1SX-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY#;VYS;VQI9&%T960@4W1A=&5M96YT(&]F(%-T;V-K:&]L
M9&5R<R<@*$1E9FEC:70I("A087)E;G1H971I8V%L*2`H55-$("0I/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#(^,2!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^4V5P+B`P-"P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y/8W0N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/E-E<"X@,C0L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y.;W8N(#$S+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1A=&5M96YT(&]F(%-T;V-K
M:&]L9&5R<R<@17%U:71Y(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R<VEO;B!O9B!B;VYD('!A
M>6%B;&4@<F5L871E9"!P87)T>2!A;F0@9&5R:79A=&EV92!L:6%B:6QI='D@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYO=&5S('!A>6%B;&4@<F5L871E9"!P87)T>2!P97(@<VAA<F4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-BXT,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T97,@<&%Y86)L
M92!R96QA=&5D('!A<G1Y('!E<B!S:&%R92!O;F4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/B0@-BXT,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC:&%N9V4@86=R965M
M96YT(&%C<75I<VET:6]N('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&5X8VAA;F=E(&%G<F5E;65N
M="!S:&%R97,@:7-S=65D('1O('!A<F5N="!C;VUP86YY/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XV+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O
M;6UO;B!S:&%R97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@X
M.2PV.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4X+#4P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@8V]M;6]N('-H87)E
M<R!O;F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T,2PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DES<W5A;F-E(&]F(&-O;6UO;B!S:&%R97,@=F%L=64\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^27-S=6%N8V4@;V8@
M8V]M;6]N('-H87)E<R!V86QU92!O;F4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$T,2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(%!U8FQI8R!/9F9E<FEN
M9R!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#,U."PX
M-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XR.3(L-3`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y0=6)L:6,@;V9F97)I;F<@=F%L=64@<&5R('-H87)E/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!O9B!O9F9E<FEN9R!C;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XX.2PS-C`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DES<W5A;F-E(&]F(&-O;6UO;B!S:&%R97,@
M='=O/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0
M<FEV871E('!L86-E;65N="!V86QU92!P97(@<VAA<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/B0@-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I=F%T92!0;&%C96UE;G0@5F%L
M=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,BPP,#`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^
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M("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E
M(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T
M('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.
M;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@
M/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P1353
M04<^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P
M86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N<V]L:61A=&5D(%-T871E
M;65N="!O9B!#87-H($9L;W=S("A54T0@)"D\8G(^/"]S=')O;F<^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,3(@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S(&9R
M;VT@3W!E<F%T:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!);F-O;64@*$QO<W,I/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L,S<P+#@X,RD\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(L,30W
M+#,V,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^061J=7-T;65N=',@=&\@<F5C;VYC:6QE(&YE="`H
M;&]S<RD@=&\@;F5T(&-A<V@@<')O=FED960@*'5S960I(&)Y(&]P97)A=&EO
M;G,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT-2PR,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XS."PR.3<\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA'86EN*2],;W-S(&]N
M('-A;&4@;V8@<W5B<VED:6%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,2D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)E=&EO;B!O9B!D:7-C;W5N="!O
M;B!B;VYD('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4P,BPT-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/BA'86EN*2],;W-S(&]N(&1E<FEV871I
M=F4@;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@Q-S4L-S,R*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#:&%N9V5S(&EN(&%S<V5T
M<R!A;F0@;&EA8FEL:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/BA);F-R96%S92D@9&5C<F5A<V4@:6X@86-C;W5N
M="!R96-E:79A8FQE+#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3<L-#0P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-38L,S0V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XH26YC<F5A<V4I(&1E8W)E87-E(&EN('!R97!A:60@
M97AP96YS97,@)F%M<#L@9&5P;W-I=',\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C(R+#DX.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L,3@S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-R96%S92`H9&5C<F5A<V4I(&EN
M(&%C8V]U;G1S('!A>6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$V,BPY-3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M/B@R+#8W-"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E("AD96-R96%S92D@:6X@86-C
M;W5N=',@<&%Y86)L92`M(')E;&%T960@<&%R='D\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C(Q,BPT,S@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN8W)E87-E
M("AD96-R96%S92D@:6X@86-C<G5E9"!E>'!E;G-E<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,3(T+#,P.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,#8L,34R*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($%D
M:G5S=&UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,S8L
M-S`X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,38L-S,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^3F5T($-A<V@@*%5S960I(&)Y($]P97)A=&EN9R!!8W1I
M=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#`S-"PQ
M-S4I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;3XH,BPQ,S`L-C(X*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#87-H($9L;W=S(&9R;VT@26YV97-T
M:6YG($%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!R;V-E960@9G)O;2!S86QE(&]F('-U8G-I9&EA<GD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!D96-R96%S92`H:6YC<F5A<V4I(&EN(&-A<V@@:&5L9"!I;B!E<V-R
M;W<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.34R+#`S-"D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@W
M-RPT-C@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y0=7)C:&%S92!O9B!I;G1A;F=I8FQE(&%S<V5T<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C<L-30X*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!#87-H(%5S960@8GD@26YV97-T:6YG($%C=&EV:71I97,\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L.34R+#`S-"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q,#4L,#$U*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY#87-H($9L;W=S(&9R;VT@1FEN86YC:6YG($%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R
M;V-E961S(&9R;VT@;F]T97,@<&%Y86)L92`M(')E;&%T960@<&%R='D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@Q-"PR.3$\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#<U-"PV-C(\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@<W1O8VL@<V%L97,\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C<L,S<W+#`X.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N="!O
M9B!S=&]C:R!O9F9E<FEN9R!C;W-T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH.#DL,S8P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^*#8W+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&]N(&YO=&5S('!A
M>6%B;&4@+2!R96QA=&5D('!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q+#0S,BPR,3,I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XH,C$X+#$S-BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@0V%S:"!0<F]V:61E
M9"!B>2`H57-E9"!B>2D@1FEN86YC:6YG($%C=&EV:71I97,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8L-C8Y+#@P-SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L-#8Y+#4R-CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^*$=A
M:6XI(&QO<W,@;VX@0W5R<F5N8WD@5')A;G-L871I;VX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C,P-BPT,SD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R,3DL-#<P*3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!);F-R
M96%S92`H1&5C<F5A<V4I(&EN($-A<V@@86YD($-A<V@@17%U:79A;&5N=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.3DP+#`S-SQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#0Q
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A="!"96=I;FYI;F<@;V8@
M4&5R:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ."PW.30\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT
M+#,X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V%S:"!A;F0@0V%S:"!%<75I=F%L96YT<R!A="!%;F0@;V8@4&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#`P."PX,S$\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M."PW.30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0V%S:"!P86ED(&1U<FEN9R!T:&4@>65A<B!F;W(\
M+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^26YT
M97)E<W0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C@R+#@Q-CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R
M+#8S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^26YC;VUE(%1A>&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5P<&QE
M;65N=&%L($1I<V-L;W-U<F4@;V8@3F]N+4-A<V@@26YV97-T:6YG(&%N9"!&
M:6YA;F-I;F<@06-T:79I=&EE<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y!8V-R971I;VX@;V8@9&ES8V]U;G0@;VX@8F]N
M9"!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S
M<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XU,#(L-#8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#:&%N9V4@:6X@9F%I<B!M87)K970@=F%L=64@
M;V8@9&5R:79A=&EV92!L:6%B:6QI='D\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<U+#<S,BD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q83DT,3-C7S4U9#5?-#-F
M85\X83DW7SEC-#-A-6-E93@R8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B\S,6$Y-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(O5V]R
M:W-H965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X]
M,T0R/CQS=')O;F<^4W5M;6%R>2!O9B!3:6=N:69I8V%N="!!8V-O=6YT:6YG
M(%!O;&EC:65S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN
M9R!0;VQI8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#
M3U5.5$E.1R!03TQ)0TE%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/DY/
M5$4@,2`F(S@R,3([(%-534U!4ED@3T8@4TE'3DE&24-!3E0@04-#3U5.5$E.
M1R!03TQ)0TE%4SPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O
M<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R
M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6EN
M9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4]
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M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY$86Y$<FET
M($)I;W1E8V@@55-!+"!);F,N("@F(S@R,C`[1&%N1')I="!54T$F(S@R,C$[
M+"!T:&4@)B,X,C(P.T-O;7!A;GDF(S@R,C$[+"`F(S@R,C`[=V4F(S@R,C$[
M+"`F(S@R,C`[=7,F(S@R,C$[+"`F(S@R,C`[;W5R)B,X,C(Q.RD@*&9O<FUE
M<FQY(%!U=&YA;2!(:6QL<R!#;W)P+BD@=V%S(&]R:6=I;F%L;'D@:6YC;W)P
M;W)A=&5D(&EN('1H92!S=&%T92!O9B!$96QA=V%R92!O;B!*86YU87)Y(#$X
M+"`R,#$Q(&%S(&$@=F5H:6-L92!T;R!P=7)S=64@82!B=7-I;F5S<R!C;VUB
M:6YA=&EO;B!T:')O=6=H('1H92!A8W%U:7-I=&EO;B!O9BP@;W(@;65R9V5R
M('=I=&@L(&%N(&]P97)A=&EN9R!B=7-I;F5S<RX\+V9O;G0^/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O
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M<R!I;F-O<G!O<F%T960@;VX@07!R:6P@,2P@,C`P,2`H)B,X,C(P.T1A;D1R
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M;F]L;V=Y+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/E)E=F5R<V4@06-Q=6ES:71I;VXF
M(S$V,#LF(S$V,#LM($]N($9E8G)U87)Y(#$R+"`R,#$T+"!P=7)S=6%N="!T
M;R!A4VAA<F4@17AC:&%N9V4@06=R965M96YT("AT:&4@(E-H87)E($5X8VAA
M;F=E($%G<F5E;65N="(I+"!$86Y$<FET(%5302!C;VUP;&5T960@=&AE(&%C
M<75I<VET:6]N(&]F(&%P<')O>&EM871E;'D@,3`P)2!O9B!T:&4@:7-S=65D
M(&%N9"!O=71S=&%N9&EN9R!C87!I=&%L('-T;V-K)B,Q-C`[)B,Q-C`[;V8F
M(S$V,#LF(S$V,#M$86Y$<FET($1E;FUA<FL@*'1H92`F(S@R,C`[4VAA<F4@
M17AC:&%N9V4F(S@R,C$[*2!A;F0@87,@82!R97-U;'0@8F5C86UE($1A;D1R
M:70@1&5N;6%R:R8C.#(Q-SMS('!A<F5N="!C;VUP86YY("AT:&4@)B,X,C(P
M.U!A<F5N="8C.#(R,3LI+B!0<FEO<B!T;R!T:&4@4VAA<F4@17AC:&%N9V4@
M=&AE<F4@=V5R92`U+#`P,"PP,#`@<VAA<F5S(&]F('1H92!C;VUM;VX@<W1O
M8VLL('!A<B!V86QU92`D+C`P,#$@<&5R('-H87)E("AT:&4@)B,X,C(P.T-O
M;6UO;B!3=&]C:R8C.#(R,3LI(&]F(%!A<F5N="!O=71S=&%N9&EN9RXF(S$V
M,#M087)E;G0@86YD(&%N(&5X:7-T:6YG('-H87)E:&]L9&5R(&%G<F5E9"!T
M;R!C86YC96P@-"PT,#`L,#`P('-H87)E<R!O9B!I=',@0V]M;6]N(%-T;V-K
M(&%N9"!I<W-U960@,2PT-#`L,#`P('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@
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M(#8L,#`P+#`P,"!S:&%R97,L(')E<W5L=&EN9R!I;B`X+#`T,"PP,#`@<VAA
M<F5S(&]F('1H92!087)E;G0F(S@R,3<[<R!#;VUM;VX@4W1O8VL@;W5T<W1A
M;F1I;F<@:6UM961I871E;'D@9F]L;&]W:6YG('1H92!3:&%R92!%>&-H86YG
M92PF(S$V,#L\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET
M93LG/FEN8VQU9&EN9R`Q.#4L,#4S('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@
M<F5S97)V960@9F]R(&ES<W5A;F-E(&EN(&%C8V]R9&%N8V4@=VET:"!396-T
M:6]N(#<P(&]F('1H92!$86YI<V@@0V]M<&%N:65S($%C="!A;F0@=&AE($%R
M=&EC;&5S(&]F($%S<V]C:6%T:6]N(&]F($1A;D1R:70@1&5N;6%R:R!T;R!T
M:&4@1&%N1')I="!$96YM87)K('-H87)E:&]L9&5R<R!W:&\@:&%V92!N;W0@
M8V]N<V5N=&5D('1O('1H928C,38P.SPO9F]N=#Y3:&%R92!%>&-H86YG92`H
M=&AE("8C.#(R,#M.;VXM0V]N<V5N=&EN9R!3:&%R96AO;&1E<G,F(S@R,C$[
M*3QF;VYT('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^+"!A
M;F0@9&5E;65D(&ES<W5E9"!A;F0@;W5T<W1A;F1I;F<@9F]R(&%C8V]U;G1I
M;F<@<'5R<&]S97,\+V9O;G0^+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^1G5N8W1I
M;VYA;"!#=7)R96YC>2`O($9O<F5I9VX@8W5R<F5N8WD@=')A;G-L871I;VX\
M+V(^)B,Q-C`[)B,X,C$R.R8C,38P.U1H92!F=6YC=&EO;F%L(&-U<G)E;F-Y
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M;F=E(')A=&5S('!R979A:6QI;F<@9'5R:6YG('1H92!Y96%R<R`R,#$T(&%N
M9"`R,#$S+B!4<F%N<VQA=&EO;B!G86EN<R!A;F0@;&]S<V5S(&%R92!D969E
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M871E;65N="!O9B!O<&5R871I;VYS(&%S(&EN8W5R<F5D+CPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[
M(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T
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M<B`S,2P@,C`Q-"!O9B`D,BPU,#@L-S4Y(&%N9"!N;VYE(&%T($1E8V5M8F5R
M(#,Q+"`R,#$S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P
M,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA
M;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$
M)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US
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M<B!T;R!S:7@@>65A<G,@*%-E92!.;W1E(#,I+CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
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M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&(^26YT86YG:6)L92!!<W-E=',\+V(^)B,Q-C`[)B,X,C$R.R8C
M,38P.T1E9FEN:71E(&QI9F4@:6YT86YG:6)L92!A<W-E=',@:6YC;'5D92!P
M871E;G1S+B!4:&4@0V]M<&%N>2!A8V-O=6YT<R!F;W(@9&5F:6YI=&4@;&EF
M92!I;G1A;F=I8FQE(&%S<V5T<R!I;B!A8V-O<F1A;F-E('=I=&@@1FEN86YC
M:6%L($%C8V]U;G1I;F<@4W1A;F1A<F1S($)O87)D+"`H)B,X,C(P.T9!4T(F
M(S@R,C$[*2!!8V-O=6YT:6YG(%-T86YD87)D<R!#;V1I9FEC871I;VXL("@F
M(S@R,C`[05-#)B,X,C(Q.RD@5&]P:6,@,S4P+"`F(S@R,C`[1V]O9'=I;&P@
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M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O
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M+V(^)B,Q-C`[3&]N9RUL:79E9"!A<W-E=',L('-U8V@@87,@<')O<&5R='DL
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M+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M=65S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`S-G!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E
M=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O
M<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SX\8CY2979E;G5E(%)E8V]G;FET:6]N(&%N
M9"!386QE<R8C,38P.SPO8CXF(S$V,#LF(S@R,3([)B,Q-C`[5&AE($-O;7!A
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M(S@R,C$[("A304(@,3`Q*2P@1D%30B!!4T,@-C`U(%)E=F5N=64@4F5C;V=N
M:71I;VXN(%1H92!#;VUP86YY(')E8V]G;FEZ97,@<F5V96YU92!W:&5N(')I
M9VAT<R!A;F0@<FES:R!O9B!O=VYE<G-H:7`@:&%V92!P87-S960@=&\@=&AE
M(&-U<W1O;65R+"!W:&5N('1H97)E(&ES('!E<G-U87-I=F4@979I9&5N8V4@
M;V8@86X@87)R86YG96UE;G0L('!R;V1U8W0@:&%S(&)E96X@<VAI<'!E9"!O
M<B!D96QI=F5R960@=&\@=&AE(&-U<W1O;65R+"!T:&4@<')I8V4@86YD('1E
M<FUS(&%R92!F:6YA;&EZ960L(&%N9"!C;VQL96-T:6]N<R!O9B!T:&4@<F5S
M=6QT:6YG(')E8V5I=F%B;&4@:7,@<F5A<V]N86)L>2!A<W-U<F5D+B!0<F]D
M=6-T<R!A<F4@<')I;6%R:6QY('-H:7!P960@1D]"('-H:7!P:6YG('!O:6YT
M(&%T('=H:6-H('1I;64@=&ET;&4@<&%S<V5S('1O('1H92!C=7-T;VUE<BX\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[#0H@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[
M('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`Q.'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H
M86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
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M,C$[*2!O9B`R-24@;V8@=&AE(&EN=F]I8V4@86UO=6YT(&ES(&-O;&QE8W1E
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M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&(^4F5S96%R8V@@86YD($1E=F5L;W!M96YT($-O<W0\+V(^)B,Q-C`[
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M($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SX\8CY);F-O;64@5&%X97,\+V(^)B,Q-C`[)B,X,C$R.R8C,38P.U1H92!#
M;VUP86YY(&%C8V]U;G1S(&9O<B!I;F-O;64@=&%X97,@:6X@86-C;W)D86YC
M92!W:71H($9!4T(@05-#(%1O<&EC(#<T,"!!8V-O=6YT:6YG(&9O<B!);F-O
M;64@5&%X97,N(%1H:7,@<W1A=&5M96YT(')E<75I<F5S(&%N(&%S<V5T(&%N
M9"!L:6%B:6QI='D@87!P<F]A8V@@9F]R(&%C8V]U;G1I;F<@9F]R(&EN8V]M
M92!T87AE<RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS
M.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C
M;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H
M:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^3&]S<R!097(@4VAA<F4\
M+V(^)B,Q-C`[)B,X,C$R.R8C,38P.U1H92!#;VUP86YY(&-A;&-U;&%T97,@
M96%R;FEN9W,O*&QO<W,I('!E<B!S:&%R92!I;B!A8V-O<F1A;F-E('=I=&@@
M1D%30B!!4T,@,C8P($5A<FYI;F=S(%!E<B!3:&%R92X@0F%S:6,@96%R;FEN
M9W,@<&5R(&-O;6UO;B!S:&%R92`H15!3*2!A<F4@8F%S960@;VX@=&AE('=E
M:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@;W5T<W1A
M;F1I;F<@9'5R:6YG(&5A8V@@<&5R:6]D+B!$:6QU=&5D(&5A<FYI;F=S('!E
M<B!C;VUM;VX@<VAA<F4@87)E(&)A<V5D(&]N('-H87)E<R!O=71S=&%N9&EN
M9R`H8V]M<'5T960@87,@=6YD97(@8F%S:6,@15!3*2!A;F0@<&]T96YT:6%L
M;'D@9&EL=71I=F4@8V]M;6]N('-H87)E<RX@4&]T96YT:6%L(&-O;6UO;B!S
M:&%R97,@:6YC;'5D960@:6X@=&AE(&1I;'5T960@96%R;FEN9W,@<&5R('-H
M87)E(&-A;&-U;&%T:6]N(&EN8VQU9&4@:6XM=&AE+6UO;F5Y('-T;V-K(&]P
M=&EO;G,@=&AA="!H879E(&)E96X@9W)A;G1E9"!B=70@:&%V92!N;W0@8F5E
M;B!E>&5R8VES960N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M
M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M#0H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ
M93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\8CY$97)I=F%T:79E
M<R`F(S@R,3([)B,Q-C`[/"]B/E=E(&=E;F5R86QL>2!D;R!N;W0@=7-E(&1E
M<FEV871I=F4@9FEN86YC:6%L(&EN<W1R=6UE;G1S('1O(&AE9&=E(&5X<&]S
M=7)E<R!T;R!C87-H+69L;W<L(&UA<FME="!O<B!F;W)E:6=N+6-U<G)E;F-Y
M(')I<VMS+B!(;W=E=F5R+"!W92!H879E(&5N=&5R960@:6YT;R!C97)T86EN
M(&]T:&5R(&9I;F%N8VEA;"!I;G-T<G5M96YT<R!A;F0@8V]N=')A8W1S+"!S
M=6-H(&%S(&1E8G0@9FEN86YC:6YG(&%R<F%N9V5M96YT<R!W:71H(&9E871U
M<F5S('1H870@87)E(&5I=&AE<B`H:2DF(S$V,#MN;W0@869F;W)D960@97%U
M:71Y(&-L87-S:69I8V%T:6]N+"`H:6DI)B,Q-C`[96UB;V1Y(')I<VMS(&YO
M="!C;&5A<FQY(&%N9"!C;&]S96QY(')E;&%T960@=&\@:&]S="!C;VYT<F%C
M=',L(&]R("AI:6DI)B,Q-C`[;6%Y(&)E(&YE="UC87-H('-E='1L960@8GD@
M=&AE(&-O=6YT97)P87)T>2X@5&AE<V4@:6YS=')U;65N=',@87)E(')E<75I
M<F5D('1O(&)E(&-A<G)I960@87,@9&5R:79A=&EV92!L:6%B:6QI=&EE<RP@
M870@9F%I<B!V86QU92X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O
M<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
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M979E;"`S(&EN<'5T<R`H9&5F:6YE9"!B96QO=R!I;B!.;W1E(#$Z($9A:7(@
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M92!E<W1I;6%T92!A;F0@87-S=6UP=&EO;B!C:&%N9V5S+CPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/CQB/B8C,38P.SPO8CX\+V9O;G0^/"]P/CQP('-T>6QE
M/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ
M93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY792!R97!O<G0@;W5R
M(&1E<FEV871I=F4@;&EA8FEL:71I97,@870@9F%I<B!V86QU92!O;B!T:&4@
M86-C;VUP86YY:6YG(&)A;&%N8V4@<VAE971S(&%S(&]F($1E8V5M8F5R(#,Q
M+"`R,#$T(&%N9"`R,#$S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M
M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL
M93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^1F%I<B!686QU
M92!O9B!&:6YA;F-I86P@26YS=')U;65N=',\+V(^)B,Q-C`[)B,X,C$R.R8C
M,38P.U1H92!#;VUP86YY(&%C8V]U;G1S(&9O<B!F86ER('9A;'5E(&UE87-U
M<F5M96YT<R!F;W(@9FEN86YC:6%L(&%S<V5T<R!A;F0@9FEN86YC:6%L(&QI
M86)I;&ET:65S(&EN(&%C8V]R9&%N8V4@=VET:"!&05-"($%30R!4;W!I8R`X
M,C`N(%1H92!A=71H;W)I=&%T:79E(&=U:61A;F-E+"!W:&EC:"P@86UO;F<@
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M;&QO=W,Z/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@
M,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:61O=W,Z(#$[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P.R!F;VYT+7-T>6QE
M.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#`N,C5I
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DQE=F5L(#$N($]B<V5R=F%B;&4@
M:6YP=71S('-U8V@@87,@<75O=&5D('!R:6-E<R!I;B!A8W1I=F4@;6%R:V5T
M<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI=&EE<SL\+V9O;G0^
M/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`S
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!W:61T:#H@,34V-W!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=I9&]W<SH@,3L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^
M/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`P
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Y
M-C<Y.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3&5V96P@,BX@26YP=71S+"!O=&AE
M<B!T:&%N('1H92!Q=6]T960@<')I8V5S(&EN(&%C=&EV92!M87)K971S+"!T
M:&%T(&%R92!O8G-E<G9A8FQE(&5I=&AE<B!D:7)E8W1L>2!O<B!I;F1I<F5C
M=&QY.R!A;F0\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:61O=W,Z(#$[(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M=&]P.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQT9"!S
M='EL93TS1"=W:61T:#H@,"XU:6X[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M,T0G=VED=&@Z(#`N,C5I;CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DQE=F5L
M(#,N(%5N;V)S97)V86)L92!I;G!U=',@:6X@=VAI8V@@=&AE<F4@:7,@;&ET
M=&QE(&]R(&YO(&UA<FME="!D871A+"!W:&EC:"!R97%U:7)E('1H92!R97!O
M<G1I;F<@96YT:71Y('1O(&1E=F5L;W`@:71S(&]W;@T*(&%S<W5M<'1I;VYS
M+CPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
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M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UI
M;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M<VAO<G0M=&5R;2!M871U<FET:65S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#LF(S$V,#L\+V9O;G0^
M/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M
M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\
M8CY!8V-O=6YT:6YG($5S=&EM871E<SPO8CXF(S$V,#LF(S@R,3([)B,Q-C`[
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M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`T,'!T.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N
M="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M
M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O
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M,#LF(S@R,3([)B,Q-C`[26X@36%Y(#(P,30L('1H92!&:6YA;F-I86P@06-C
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M;65N=',N)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS
M1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
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M.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US
M=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!T97AT+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
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M(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#0P+C5P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&(^)B,Q-C`[/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US
M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/E)E8VQA<W-I9FEC871I;VXF(S$V
M,#LF(S@R,3([)B,Q-C`[/"]B/E1H92!F:6YA;F-I86P@<W1A=&5M96YT<R!F
M;W(@=&AE('!E<FEO9"!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,R!H879E(&)E
M96X@<F5C;&%S<VEF:65D('1O(&-O;F9O<FT@=&\@=&AE(&AE861I;F=S(&%N
M9"!C;&%S<VEF:6-A=&EO;G,@=7-E9"!I;B!T:&4@1&5C96UB97(@,S$L(#(P
M,30@9FEN86YC:6%L('-T871E;65N=',N/"]F;VYT/CPO<#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N=#QB<CX\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P
M97)T>2!A;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4%)/4$525%D@04Y$($5154E0
M345.5#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M/&(^3D]412`R)B,Q-C`[)B,X,C$R.R8C,38P.U!23U!%4E19($%.1"!%455)
M4$U%3E0\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SY0<F]P97)T>2!A;F0@97%U:7!M96YT(&-O;G-I<W1E
M9"!O9B!T:&4@9F]L;&]W:6YG(&%T($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"!$
M96-E;6)E<B`S,2P@,C`Q,SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0Z(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^57-E9G5L($QI9F4\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@,2XU<'0[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D
M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
M(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG(&-O
M;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,S$M1&5C/&)R("\^,C`Q,SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL
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M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-S-P>#L@=&5X="UA;&EG
M;CH@8V5N=&5R.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^-"TV/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-G!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-G!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3<X+#4T-SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,35P>#L@=&5X
M="UA;&EG;CH@;&5F=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!W:61T:#H@,35P>#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-"TV/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W#0H@<F]M86XG+"!T:6UE<RP-"B!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L
M969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1R
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M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1R
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M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y
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M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
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M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^,C8P+#8S-CPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\
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M,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE.B`Q
M,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1R
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M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH,C,Y+#8Y.#PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
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M:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^*#(V,"PV,S8\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M<VEZ93H@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M<VEZ93H@,3!P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M<W1R971C
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M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#L@8F]R9&5R+6)O='1O
M;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#1P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@9&]U8FQE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.PT*('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T
M<'0[(&9O;G0M<W1R971C:#H-"B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG
M+6)O='1O;3H@-'!T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
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M97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z(&1O
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M/"]T86)L93X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SY$97!R96-I871I;VX@97AP96YS92!A
M;6]U;G1E9"!T;R`D,"!A;F0@)#(L-S`V+"!F;W(@=&AE('EE87(@96YD960@
M1&5C96UB97(@,S$L(#(P,30@86YD(#(P,3,L(')E<W!E8W1I=F5L>2X@5&AE
M($-O;7!A;GDF(S@R,3<[<R!P<F]P97)T>2!A;F0@97%U:7!M96YT(&ES(&AE
M;&0@87,@8V]L;&%T97)A;"!O;B!T:&4@;F]T97,@<&%Y86)L92!R96QA=&5D
M('!A<G1Y+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E
M9FEN:71E($QI9F4@26YT86YG:6)L92!!<W-E=',\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F:6YI=&4@3&EF
M92!);G1A;F=I8FQE($%S<V5T<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1%1DE.251%($Q)1D4@24Y4
M04Y'24),12!!4U-%5%,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
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M:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SX\8CY.3U1%(#,F(S$V,#LF(S@R,3([)B,Q-C`[1$5&24Y)5$4M3$E&
M12!)3E1!3D=)0DQ%($%34T544SPO8CXF(S$V,#L\+V9O;G0^/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R
M=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US
M=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I
M;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY!="!$96-E;6)E<B`S,2P@,C`Q
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M('1H92!Y96%R<R!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,R!W
M87,@)#$T+#,X,2!A;F0@)#,X+#(Y-RP@<F5S<&5C=&EV96QY+B!%>'!E8W1E
M9"!F=71U<F4@86UO<G1I>F%T:6]N(&5X<&5N<V4@9F]R('1H92!Y96%R<R!E
M;F1E9"!A<F4@87,@9F]L;&]W<SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`T,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T;VT[)SX\
M=&0@<W1Y;&4],T0G9F]N="UW96EG:'0Z(&)O;&0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\=3Y996%R(&5N
M9&EN9R!$96-E;6)E<B`S,2P\+W4^/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G
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M=&0@<W1Y;&4],T0G=VED=&@Z(#$R-#`N-S,X-C0W-#8P.31P>#L@9F]N="US
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M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED
M=&@Z(#$T+C4T-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F
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M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S+C8S-C,V,S`R.30X
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^,30L,S@Q/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE
M9G0Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q-SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C$T
M+#,X,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N="!S='EL
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^,30L,S@Q/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG+6)O
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L
M86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O
M;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3$T
M+#4P.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)V9O
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M:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^,3@V+#0Q-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG
M+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0-"B!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\9&EV/B8C,38P.SPO9&EV
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S%A
M.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC
M-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,3(N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-
M13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E<R!087EA8FQE("T@4F5L
M871E9"!087)T>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^/'-T<F]N9SY.;W1E<R!087EA8FQE("T@4F5L871E9"!087)T>2!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DY/5$53(%!!64%"3$4@+2!214Q!5$5$(%!!4E19/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\8CY.3U1%(#0F(S$V
M,#LF(S@R,3([)B,Q-C`[3D]415,@4$%904),12`F(S@R,3$[(%)%3$%4140@
M4$%25%D\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US
M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SY.;W1E<R!P87EA8FQE('1O(')E;&%T960@<&%R=&EE<R!C
M;VYS:7-T<R!O9B!T:&4@9F]L;&]W:6YG(&%S(&]F($1E8V5M8F5R(#,Q+"`R
M,#$T(&%N9"`R,#$S.CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R
M9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO
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M/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[)SX\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT
M97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<@8V]L<W!A;CTS1#8^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SY$96-E;6)E<B`S,2P\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P
M="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D
M9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0Z(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q-#PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B!B;VQD(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A
M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\
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M/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM
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M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W1E>'0M86QI9VXZ(&-E;G1E
M<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G
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M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!W:61T:#H@,30R<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,S@L,C,U/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-7!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H
M.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,30Q<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/C$X+#DV,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!R:6=H=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/C(Q+#4U-SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-B4@
M4')O;6ES<V]R>2!.;W1E('!A>6%B;&4@=&\@3DQ"1$E4(#(P,3`@16YT97)P
M<FES97,L($Q,0SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
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M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
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M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-24@3F]T92!087EA
M8FQE("T@4W5N92!/;'-E;B!(;VQD:6YG($%P4SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
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M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^-3(Q+#,Y,#PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXU)2!.;W1E(%!A>6%B
M;&4@+2!3=6YE($]L<V5N/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E
M>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
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M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXQ.#4L,#4T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E
M>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L-"B!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L#0H@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^5&]T86P@3F]T97,@4&%Y86)L92`F(S@R
M,3$[(%)E;&%T960@4&%R='D\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(')I9VAT.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P
M<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E
M>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^-S(X+#`P,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M
M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU
M<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#DY+#DU,3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^*#<R."PP,#$\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N
M-7!T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M*3PO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N
M.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/DYO=&4@4&%Y86)L97,@)B,X,C$Q.R!296QA=&5D(%!A<G1Y($QO;F<@5&5R
M;3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
M:60[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXM
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
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M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
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M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY4:&4@9F]L;&]W:6YG
M(')E<')E<V5N=',@=&AE(&9U='5R92!M871U<FET:65S(&]F(&QO;F<M=&5R
M;2!D96)T(&%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T.CPO9F]N=#X\+W`^/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL-"B!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[#0H@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$U-C=P>#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
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M:6=N.B!R:6=H=#L@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A;CTS1#(^/&9O
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M=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXR,#$T/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q-G!X.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,30Q
M<'@[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^.3DL.34Q/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('=I9'1H.B`Q-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O
M='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[(&9O
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M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[(&9O
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M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q-SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXM/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M
M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M;&5F=#H@.7!T.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q.#PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R!T97AT+6EN9&5N=#H@,'!X.R!P861D:6YG
M+6)O='1O;3H@,2XU<'0[('!A9&1I;F<M;&5F=#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&AE<F5A9G1E<CPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H=#L-"B!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L#0H@<V5R:68[
M)SXM/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ
M(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US=')E=&-H.B!N
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@9F]N="US=')E
M=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B0\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[(&)O<F1E<BUB
M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P
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M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($9E8G)U87)Y(#$U
M+"`R,#$T(&%N9"!-87)C:"`Q."P@,C`Q-"P@1&%N1')I="!$96YM87)K<F5C
M96EV960@1$M+(#(L-3`P+#`P,"`H)#0V,2PP.#0I(&%N9"!$2TL@,BPS,#`L
M,#`P("@D-#(T+#$Y."D@;&]A;G,@*'1H92`F(S@R,C`[,C`Q-"!,;V%N<R8C
M.#(R,3LI+"!R97-P96-T:79E;'DL(&9R;VT@4&%S96-O07!3+"!A;B!E;G1I
M='D@;W=N960@8GD@82!S:&%R96AO;&1E<B!O9B!T:&4@0V]M<&%N>2`H)B,X
M,C(P.U!A<V5C;R8C.#(R,3LI+B8C,38P.R8C,38P.U1H92`R,#$T($QO86YS
M('=E<F5P87EA8FQE(#$T(&1A>7,@869T97(@=&AE(&-O;7!L971I;VX@;V8@
M=&AE(&-O;G1E;7!L871E9"!P=6)L:6,@;V9F97)I;F<@:6X@1&%N1')I="!5
M4T$@;W(@1F5B<G5A<GD@,2P@,C`Q-2P@86YD(&%C8W)U960@:6YT97)E<W0@
M870@-24@<&5R(&%N;G5M+B!/;B!!<')I;"`R.2P@,C`Q-"P@1&%N1')I="!$
M96YM87)K(&%N9"!087-E8V\@96YT97)E9"!I;G1O(&%N(&%M96YD;65N="!W
M:&5R96)Y('1H92!T97)M<R!O9B!T:&4@,C`Q-"!,;V%N<R!W97)E<&%Y86)L
M92!O;B!&96)R=6%R>2`Q+"`R,#$U(&%N9"!C;W5L9&)E(&5X=&5N9&5D(&%T
M('1H92!#;VUP86YY)B,X,C$W.W,@;W!T:6]N(&9O<B!A;B!A9&1I=&EO;F%L
M('EE87(@=VET:"!A;B!I;F-R96%S92!I;B!T:&4@:6YT97)E<W0@<F%T92!T
M;R`W+C`P)2XF(S$V,#LF(S$V,#M!<R!O9B!/8W1O8F5R(#$W+"`R,#$T+"!T
M:&4@;W5T<W1A;F1I;F<@8F%L86YC92!O;B!T:&4@,C`Q-"!,;V%N<R!I;F-L
M=61I;F<@86-C<G5E9"!I;G1E<F5S="!W87,@)#@S-BPX,S`@8F%S960@;VX@
M=&AE(&-U<G)E;F-Y(&5X8VAA;F=E(')A=&4@;V8@3V-T;V)E<B`Q-RP@,C`Q
M-"X@3VX@3V-T;V)E<B`Q-RP@,C`Q-"!T:&4@0V]M<&%N>2!R97!A:60@=&AE
M(&QO86X@86YD(&EN=&5R97-T(&EN(&ET<R!E;G1I<F5T>2X\+V9O;G0^/"]P
M/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#LG/D1A;D1R:70@1&5N;6%R:R!H87,@<F5C96EV
M960@86X@=6YS96-U<F5D(&QO86X@9F%C:6QI='D@9G)O;2!3=6YE($]L<V5N
M($AO;&1I;F<@07!3("@F(S@R,C`[4W5N92!/;'-E;B!(;VQD:6YG)B,X,C(Q
M.RDL(&$@<VAA<F5H;VQD97(@;V8@=&AE($-O;7!A;GDL('=I=&@@82!G;V%L
M(&]F(&5N<W5R:6YG(&9I;F%N8VEN9R!U;G1I;"!N97<@97%U:71Y(&AA<R!B
M965N(&)R;W5G:'0@:6XN(%5N9&5R('1H92!L;V%N(&9A8VEL:71Y($1A;D1R
M:70@1&5N;6%R:R!H87,@<F5C96EV960@=&AE(&9O;&QO=VEN9R!A;6]U;G1S
M.B!O;B!.;W9E;6)E<B`Q,2P@,C`Q,R!$2TL@,2PU,#`L,#`P/"]F;VYT/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^*"0R-S8L-C4Q*3QF;VYT('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#LG/BP@;VX@3F]V96UB97(@,C`L(#(P,3,@1$M+(#0P-2PP
M,#`@*"0W-"PV.38I+"!A;F0@;VX@1&5C96UB97(@,BP@,C`Q,R!$2TL@.3`P
M+#`P,"@D,38U+#DY,"DN(%1H92!L;V%N<R!W97)E9'5E($UA>2`Q+"`R,#$T
M(&%N9"!A8V-R=65D(&EN=&5R97-T(&%T(#4E('!E<B!Y96%R+B8C,38P.R8C
M,38P.T1U<FEN9R!-87)C:"`R,#$T+"!T:&4@0V]M<&%N>2!E>'1E;F1E9"!M
M871U<FET>2!D871E(&]F('1H92!L;V%N<R!W:71H(%-U;F4@3VQS96X@2&]L
M9&EN9W,@9G)O;2!-87D@,2P@,C`Q-"!T;R`Q-"!D87ES(&%F=&5R('1H92!C
M;VUP;&5T:6]N(&]F('1H92!C;VYT96UP;&%T960@<W1O8VL@;V9F97)I;F<@
M;V8@1&%N1')I="!54T$@;W(@1F5B<G5A<GD@,2P@,C`Q-2X@3VX@3F]V96UB
M97(@,C8L(#(P,30L('1H92!#;VUP86YY(')E<&%I9"!T:&4@;&]A;B!F86-I
M;&ET>2!A;F0@:6YT97)E<W0@=&AE<F5O;BX\+V9O;G0^/"]F;VYT/CPO<#X\
M<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T
M97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O
M<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z
M(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED
M;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
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M(&%M;W5N="!O9B!$2TL@,2PP,#`L,#`P("@D,3@T+#0S-"D@=V%S(&ES<W5E
M9"!O;B!$96-E;6)E<B`R,"P@,C`Q,RX@5&AE(&QO86X@=V%S9'5E($UA>2`Q
M+"`R,#$T(&%N9"!A8V-R=65D(&EN=&5R97-T(&]F(#4E('!E<B!Y96%R+B!$
M=7)I;F<@36%R8V@@,C`Q-"P@=&AE($-O;7!A;GD@97AT96YD961T:&5M871U
M<FET>2!D871E(&]F('1H92!$2TL@,2PP,#`L,#`P(&QO86YS('=I=&@@4W5N
M92!/;'-E;B!F<F]M($UA>2`Q+"`R,#$T('1O(#$T(&1A>7,@869T97(@=&AE
M(&-O;7!L971I;VX@;V8@=&AE(&-O;G1E;7!L871E9"!S=&]C:R!O9F9E<FEN
M9R!O9B!$86Y$<FET(%5302!O<B!&96)R=6%R>2`Q+"`R,#$U+B!/;B!.;W9E
M;6)E<B`R-BP@,C`Q-"!T:&4@0V]M<&%N>2!R97!A:60@=&AE('5N<V5C=7)E
M9"!L;V%N(&%N9"!I;G1E<F5S="!T:&5R96]N+CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F
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M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1'5R:6YG($UA<F-H(#(P
M,30L('1H92!#;VUP86YY(')E8V5I=F5D(&$@,BPP,#`L,#`P($1+2R`H)#,V
M."PX-C@I(&QE='1E<B!O9B!S=7!P;W)T(&9R;VT@4&%S96-O#0H@=&\@9FEN
M86YC92!O<&5R871I;VYS('5N=&EL($9E8G)U87)Y(#$L(#(P,34@=&\@8F4@
M:7-S=65D('=I=&@@=&5R;7,@<W5B<W1A;G1I86QL>2!S:6UI;&%R('1O('1H
M;W-E(&-O;G1A:6YE9"!I;B!T:&4@,C`Q-"!,;V%N<RX@5&AE($-O;7!A;GD@
M:&%S(&%N(&]P=&EO;B!T;R!E>'1E;F0@=&AE(&QO86X-"B!F;W(@;VYE('EE
M87(@8GD@9VEV:6YG(&YO=&EC92!T;R!087-E8V\@8GD@1&5C96UB97(@,S$L
M(#(P,30@=VAE<F5B>2!T:&4@:6YT97)E<W0@<F%T92!W;W5L9"!I;F-R96%S
M92!T;R`W+C`P)2!P97(@86YN=6TN(%1H92!#;VUP86YY(&1I9"!N;W0@97AE
M<F-I<V4@=&AE(&]P=&EO;BX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I
M;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/D1U<FEN9R`R,#$R+"!$2U1)($$O4RP@82!S
M:&%R96AO;&1E<B!O9B!T:&4@0V]M<&%N>2P@=VAI8V@@:7,@8V]N=')O;&QE
M9"!B>2!O9F9I8V5R<R!A;F0@9&ER96-T;W)S(&]F('1H92!#;VUP86YY+"!A
M9W)E960@=&\@;&]A;B!T:&4@0V]M<&%N>2!U<"!T;R!$2TL@-2PP,#`L,#`P
M("AA<'!R;WAI;6%T96QY("0X.#`L,#`P*2!A8V-R=6EN9R!I;G1E<F5S="!A
M="`V)2XF(S$V,#LF(S$V,#M4:&4@;&]A;B!I<R!S96-U<F5D(&)Y(&%L;"!T
M:&4@0V]M<&%N>28C.#(Q-SMS(&EN=&5L;&5C='5A;"!P<F]P97)T>2!R:6=H
M=',L(&EN8VQU9&EN9R!I=',@<&%T96YT<R!A;F0@:71S('!A=&5N="!A<'!L
M:6-A=&EO;G,@8W)E9&ET(&9A8VEL:71Y+B8C,38P.R8C,38P.T1U<FEN9R!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q,B!T:&4@0V]M<&%N>2!B
M;W)R;W=E9"!$2TL@-"PT,S$L.#8R("@D-S@S+#$S.2D@<&QU<R!$2TL@-S$L
M-38S("@D,3(L-C0V*2!I;B!I;G1E<F5S="XF(S$V,#LF(S$V,#M$=7)I;F<@
M=&AE('EE87(@96YD960@1&5C96UB97(@,S$L(#(P,3,L('1H92!#;VUP86YY
M(&)O<G)O=V5D(&%N(&%D9&ET:6]N86P@1$M+(#,Q,"PP,#`@*&%P<')O>&EM
M871E;'D@)#4U+#`P,"D@;VX@=&AE(&QO86X@86YD(&%C8W)U960@:6YT97)E
M<W0@;V8@1$M+(#(S,"PS-S<@*&%P<')O>&EM871E;'D@)#0R+#`P,"DN(%1H
M92!N;W1E<R!W:71H(')E;&%T960@86-C<G5E9"!I;G1E<F5S="!W97)E(&-O
M;G9E<G1E9"!I;G1O(#DV+#(X."!C;VUM;VX@<VAA<F5S(&]F($1A;D1R:70@
M1&5N;6%R:R!O;B!$96-E;6)E<B`Q-BP@,C`Q,R!W:&EC:"!W97)E(&5X8VAA
M;F=E9"!F;W(@,30T+#,R,2!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F('1H
M92!087)E;G0@=7!O;B!T:&4@8VQO<VEN9R!O9B!T:&4@4VAA<F4@17AC:&%N
M9V4N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SY$=7)I;F<@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S
M+"`R,#$R(&%N9"`R,#$Q(%-U;F4@3VQS96X@2&]L9&EN9R8C,38P.VQO86YE
M9"!$86Y$<FET($1E;FUA<FL@1$M+(#$L,C8W+#<R-"`H)#(S,BPX-#$I+"!$
M2TL@,S,X+#<Q.2`H)#4Y+#@U-"D@86YD($1+2R`Q-#,L-S4P("@D,C4L,#$Y
M*2P@<F5S<&5C=&EV96QY+B8C,38P.R8C,38P.U1H92!#;VUP86YY(&%D9&5D
M('1H92!A8V-R=65D(&EN=&5R97-T(&%T(#8E(&%N9"!T:&4@0V]M<&%N>2!R
M96-O<F1E9"!I;G1E<F5S="!E>'!E;G-E(&]F($1+2R`X-BPP-#<@*"0Q-2PX
M,#0I+"!$2TL@,C`L-#8Y("@D,RPV,3<I(&%N9"!$2TL@,BPV.#D@*"0T-C@I
M(&1U<FEN9R!T:&4@>65A<G,@96YD($1E8V5M8F5R(#,Q+"`R,#$S+"`R,#$R
M(&%N9"`R,#$Q+"!R97-P96-T:79E;'DN)B,Q-C`[)B,Q-C`[5&AE(&QO86YS
M(&%R92!P87EA8FQE('5P;VX@=&AR964@;6]N=&AS('=R:71T96X@;F]T:6-E
M(&]F(%-U;F4@3VQS96X@2&]L9&EN9RXF(S$V,#LF(S$V,#M/;B!$96-E;6)E
M<B`Q-BP@,C`Q,RP@=&AE(&YO=&5S('=I=&@@<F5L871E9"!A8V-R=65D(&EN
M=&5R97-T('=E<F4@8V]N=F5R=&5D(&EN=&\@,S4L,3`V('-H87)E<R!O9B!$
M86Y$<FET)B,Q-C`[1&5N;6%R:R8C,38P.W=H:6-H('=E<F4@97AC:&%N9V5D
M(&9O<B`U,BPV,3@@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4@0V]M
M<&%N>2!U<&]N('1H92!C;&]S:6YG(&]F('1H92!3:&%R92!%>&-H86YG92X\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L
M;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N
M=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^3VX@07!R:6P@,30L(#(P,3,L(%-U
M;F4@3VQS96X@2&]L9&EN9RP@82!S:&%R96AO;&1E<B!O9B!T:&4@0V]M<&%N
M>2P@87-S=6UE9"!$2TL@-"PS-S4L.3,R("AA<'!R;WAI;6%T96QY)#<W,RPP
M,#`I(&EN(&QI86)I;&ET:65S(&]W960@8GD@1&%N1')I="!$96YM87)K(&9O
M<B!P87-T(&1U92!R96YT(&9R;VT@82!V96YD;W(@:6X@97AC:&%N9V4@9F]R
M(&$@;F]T92!P87EA8FQE+B`I('=E<F4@8V]N=F5R=&5D(&EN=&\@.#8L,C`T
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M:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[
M('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/B8C,38P.SPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SY/;B!*=6YE(#(P+"`R,#$S+"!3=6YE($]L<V5N($AO;&1I;F<@<&%I9"!$
M2TL@,2PU,#`L,#`P+"`H)#(V-2PP,#`I(&EN(&%C8W)U960@;&5G86P@9F5E
M<R!O=V5D(&)Y('1H92!#;VUP86YY(&EN(&5X8VAA;F=E(&9O<B!A($1+2S$L
M-3`P+#`P,"`H)#(V-2PP,#`I(#4E(&YO=&4@<&%Y86)L92!T;R!3=6YE($]L
M<V5N($AO;&1I;F<N($]N($1E8V5M8F5R(#$V+"`R,#$S+"!T:&4@;F]T92!W
M:71H(')E;&%T960@86-C<G5E9"!I;G1E<F5S="!O9B!$2TL@,C`L.34Y("@D
M,RPX,#0I('=A<R!C;VYV97)T960@:6YT;R`R.2PP,S8@<VAA<F5S(&]F($1A
M;D1R:70F(S$V,#M$96YM87)K)B,Q-C`[8V]M;6]N('-T;V-K+B!3=6-H('-H
M87)E<R!O9B!C;VUM;VX@<W1O8VL@=V5R92!E>&-H86YG960@9F]R(#0S+#4R
M,"!S:&%R97,@;V8@8V]M;6]N('-T;V-K(&]F('1H92!087)E;G0@=7!O;B!T
M:&4@8VQO<VEN9R!O9B!T:&4@4VAA<F4@17AC:&%N9V4N+CPO<#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F
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M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3VX@2G5L>2`R-BP@,C`Q
M,R!A;F0@075G=7-T(#$U+"`R,#$S+"!3=6YE($]L<V5N($AO;&1I;F<@;&]A
M;F5D('1H92!#;VUP86YY(&%N(&%D9&ET:6]N86P@1$M+(#$L,#`P+#`P,"`H
M)#$W-RPR,SDI(&%N9"!$2TL@-S4P+#`P,"`H)#$S,RPS-#,I+"!R97-P96-T
M:79E;'DN)B,Q-C`[)B,Q-C`[5&AE(&YO=&5S(&%C8W)U92!I;G1E<F5S="!A
M="`U)2!A;F0@87)E('!A>6%B;&4@=7!O;B!T:')E92!M;VYT:',@=W)I='1E
M;B!N;W1I8V4@;V8@4W5N92!/;'-E;B!(;VQD:6YG+B!4:&4@;F]T97,@=VET
M:"!R96QA=&5D(&%C8W)U960@:6YT97)E<W0@;V8@1$M+(#$U+#4W-2`H)#(L
M.#(W*2!W97)E(&-O;G9E<G1E9"!I;G1O(#,S+#<P-2!S:&%R97,@;V8@1&%N
M1')I="!$96YM87)K(&-O;6UO;B!S=&]C:R!O;B!$96-E;6)E<B`Q-BP@,C`Q
M,RX@4W5C:"!S:&%R97,@;V8@8V]M;6]N('-T;V-K('=E<F4@97AC:&%N9V5D
M(&9O<B`U,"PU,3@@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!O9B!T:&4-"B!#
M;VUP86YY('5P;VX@=&AE(&-L;W-I;F<@;V8@=&AE(%-H87)E($5X8VAA;F=E
M+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS
M9F]R;3H-"B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SY!<R!O9B!$96-E;6)E<B`S,2P@,C`Q-"P@=&AE(&]U='-T86YD:6YG
M(&)A;&%N8V4@;V8@)#,X+#(S-2!F;W(@<')O9F5S<VEO;F%L(&9E97,@<&%I
M9"!B>2!A('-H87)E:&]L9&5R(&%N9"!A;6]U;G1S(&%D=F%N8V5D('1O('1H
M92!087)E;G0@87)E(')E<&]R=&5D(&%S(&QO86X@<&%Y86)L92`M(')E;&%T
M960@<&%R='DN(%1H92`D,S@L,C,U(&QO86YS('!A>6%B;&4@=V5R92!A8W%U
M:7)E9"!I;B!T:&4@<F5V97)S92!A8W%U:7-I=&EO;BX@5&AE(&%M;W5N=',@
M87)E('5N<V5C=7)E9"P@;F]N+6EN=&5R97-T(&)E87)I;F<@86YD(&AA=F4@
M;F\@<W1I<'5L871E9"!R97!A>6UE;G0@=&5R;7,N/"]F;VYT/CPO<#X\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU
M<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY!(#8E('!R;VUI<W-O
M<GD@;F]T92!P87EA8FQE('1O($Y,0D1)5"`R,#$P($5N=&5R<')I<V5S+"!,
M3$,L(&%N(&5N=&ET>2!C;VYT<F]L;&5D(&)Y(&$@<VAA<F5H;VQD97(@;V8@
M=&AE($-O;7!A;GDL('=A<R!A8W%U:7)E9"!B>2!T:&4@0V]M<&%N>2!I;B!T
M:&4@<F5V97)S92!A8W%U:7-I=&EO;BPF(S$V,#MP87EA8FQE(&]N($9E8G)U
M87)Y(#$R+"`R,#$T('5P;VX@=&AE(&-O;7!L971I;VX@9&%T92!O9B!T:&4@
M4VAA<F4@17AC:&%N9V4N)B,Q-C`[)B,Q-C`[07,@;V8@1&5C96UB97(@,S$L
M(#(P,30L('1H92!O=71S=&%N9&EN9R!B86QA;F-E(&]N('1H92!N;W1E+"!I
M;F-L=61I;F<@86-C<G5E9"!I;G1E<F5S="P@=V%S("0T,BPW-3,N($1U<FEN
M9R!T:&4@=&AR964@86YD('1W96QV92!M;VYT:',@96YD960@1&5C96UB97(@
M,S$L(#(P,30@=&AE($-O;7!A;GD@<F5C;W)D960@<F5L871E9"!P87)T>2!I
M;G1E<F5S="!O;B!T:&4@3F]T92!O9B`D,C$S+"!A;F0@)#8Q.2P@<F5S<&5C
M=&EV96QY+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM
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M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q
M=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R
M<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C
M/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO
M<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$
M<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O
M;G9E<G1I8FQE($)O;F0@4&%Y86)L92`M(%)E;&%T960@4&%R='D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0V]N
M=F5R=&EB;&4@0F]N9"!087EA8FQE("T@4F5L871E9"!087)T>2!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-/3E9%4E1)0DQ%($)/3D0@4$%904),12`M(%)%3$%4140@4$%25%D\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/CQB/DY/5$4@-28C,38P.R8C.#(Q,CLF(S$V,#M#3TY6
M15)424),12!"3TY$(%!!64%"3$4@)B,X,C$Q.R!214Q!5$5$(%!!4E19/"]B
M/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#(W<'0[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY/;B!$96-E;6)E<B`Q+"`R,#$Q
M+"!$86Y$<FET($1E;FUA<FL@8F]R<F]W960@)#$L-3`P+#`P,"!F<F]M($1+
M5$D@02]3(&%N9"!I<W-U960@-B4@8V]N=F5R=&EB;&4@8F]N9',N(%1H92!B
M;VYD<R!M87D@;F]T(&)E(&-O;G9E<G1E9"!D=7)I;F<@=&AE(&9O=7(@=V5E
M:W,@9F]L;&]W:6YG('1H92!P=6)L:6-A=&EO;B!O9B!T:&4@86YN=6%L(')E
M<&]R="X@5&AE(&)O;F1S(&UA>2!N;W0@8F4@<F5P86ED('5N=&EL('1H92!B
M;VYD<R8C.#(Q-SL@97AP:7)A=&EO;B!O;B!$96-E;6)E<B`S,2P@,C`Q-"XF
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q
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M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&AE(&-O;G9E<G-I
M;VXO861J=7-T;65N="!F96%T=7)E<R!H860@86X@97-T:6UA=&5D(&9A:7(@
M=F%L=64@;V8@)#$L,#`S+#4U-R!U<VEN9R!T:&4@0FQA8VLM4V-H;VQE<R!P
M<FEC:6YG(&UO9&5L('5S:6YG('1H92!A<W-U;7!T:6]N<R!S970@9F]R=&@@
M8F5L;W<@86YD('=E<F4@8FEF=7)C871E9"!A;F0@<')O<&5R;'D@8VQA<W-I
M9FEE9"!A<R!D97)I=F%T:79E(&EN<W1R=6UE;G1S(')E<75I<F5D('1O(&)E
M(')E8V]R9&5D(&%T(&9A:7(@=F%L=64@*$YO=&4@-BDN(%1H92!P<F]C965D
M<R!F<F]M('1H92!B;VYD(&AA=F4@8F5E;B!A;&QO8V%T960@=&\@=&AE(&YO
M=&4@86YD(&-O;G9E<G-I;VXO861J=7-T;65N="!F96%T=7)E(&]F('1H92!C
M;VYV97)T:6)L92!B;VYD(&%N9"!R96-O<F1E9"!A="!A(&1I<V-O=6YT('=H
M:6-H('=A<R!A;6]R=&EZ960@=&\@:6YT97)E<W0@97AP96YS92!T:')O=6=H
M(&-O;G9E<G-I;VXN($1U<FEN9R!T:&4@>65A<G,@96YD960@1&5C96UB97(@
M,S$L(#(P,3,@86YD(#(P,3(L('1H92!#;VUP86YY(')E8V]R9&5D(&EN=&5R
M97-T(&5X<&5N<V4@;V8@)#4P,BPT-C4@86YD("0T-C$L,C<Y+"!R97-P96-T
M:79E;'DL(&9O<B!T:&4@86-C<F5T:6]N(&]F('1H92!D:7-C;W5N="!O;B!T
M:&4@;F]T92X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[
M('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET
M92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/D]N($1E8V5M8F5R(#$V+"`R,#$S+"!T:&4@)#$L-3`P+#`P
M,"!C;VYV97)T:6)L92!B;VYD+"!A8V-R=65D(&EN=&5R97-T(&]F("0Q-SDL
M-C$R(&%N9"!T:&4@)#8W,RPW,S8@9&5R:79A=&EV92!L:6%B:6QI='D@=V5R
M92!C;VYV97)T960@:6YT;R`Q-S0L-3<X('-H87)E<R!O9B!$86Y$<FET($1E
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M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C4U
M:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.R8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F
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M<F4@97AP96-T960@=F]L871I;&ET>2!O9B`V-24L(&5X<&5C=&5D(&QI9F4@
M;V8@='=O('EE87)S('1O('1W96QV92!M;VYT:',L(')I<VL@)B,X,C$Q.R!F
M<F5E(&EN=&5R97-T(')A=&5S(&]F("XT,24L(&%N9"!N;R!D:79I9&5N9"!Y
M:65L9"X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^)B,Q-C`[/"]B/CPO9F]N
M=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1E<FEV871I=F4@3&EA
M8FEL:71I97,\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1&5R:79A=&EV92!,:6%B:6QI=&EE<R!;06)S=')A8W1=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1%
M4DE6051)5D4@3$E!0DE,251)15,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L
M:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ
M(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/DY/5$4@
M-B`F(S@R,3([($1%4DE6051)5D4@3$E!0DE,251)15,\+V(^/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT
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M97(@*&DI)B,Q-C`[;F]T(&%F9F]R9&5D(&5Q=6ET>2!C;&%S<VEF:6-A=&EO
M;BP@*&EI*28C,38P.V5M8F]D>2!R:7-K<R!N;W0@8VQE87)L>2!A;F0@8VQO
M<V5L>2!R96QA=&5D('1O(&AO<W0@8V]N=')A8W1S+"!O<B`H:6EI*28C,38P
M.VUA>2!B92!N970M8V%S:"!S971T;&5D(&)Y('1H92!C;W5N=&5R<&%R='DN
M(%1H97-E(&EN<W1R=6UE;G1S(&%R92!R97%U:7)E9"!T;R!B92!C87)R:65D
M(&%S(&1E<FEV871I=F4@;&EA8FEL:71I97,L(&%T(&9A:7(@=F%L=64N/"]F
M;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
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M96UB97(@,S`L(#(P,3,L('1H92!#;VUP86YY(')E8V]R9&5D(&=A:6YS(&]F
M("0T+#$X,"!A;F0@)#0U+#@R,RP@<F5S<&5C=&EV96QY+B!/;B!$96-E;6)E
M<B`Q-BP@,C`Q,RP@=&AE("0Q+#4P,"PP,#`@8V]N=F5R=&EB;&4@8F]N9"P@
M86-C<G5E9"!I;G1E<F5S="!O9B`D,3<Y+#8Q,B!A;F0@=&AE("0V-S,L-S,V
M(&1E<FEV871I=F4@;&EA8FEL:71Y('=E<F4@8V]N=F5R=&5D(&EN=&\@,3<T
M+#4W."!S:&%R97,@;V8@1&%N1')I="!$96YM87)K(&-O;6UO;B!S=&]C:R!O
M<B`R-C$L-C8U('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@;V8@=&AE($-O;7!A
M;GD@=7!O;B!T:&4@8VQO<VEN9R!O9B!T:&4@4VAA<F4@17AC:&%N9V4N/"]F
M;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'10
M87)T7S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8@T*0V]N
M=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,6$Y-#$S8U\U-60U7S0S9F%?
M.&$Y-U\Y8S0S835C964X,F(O5V]R:W-H965T<R]3:&5E=#$U+FAT;6P-"D-O
M;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O
M;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*
M/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT
M96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G
M/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS
M/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H
M96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60]
M,T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&5A<V5S/&)R/CPO
M<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DQE
M87-E<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DQ%05-%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I
M9&]W<SH@,3L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^/&(^3D]412`W)B,Q-C`[)B,X,C$R.R8C,38P.TQ%
M05-%4SPO8CX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/CQB/D]P97)A=&EN9R!,96%S97,\+V(^)B,Q-C`[)B,X
M,C$R.R8C,38P.U1H92!#;VUP86YY(&QE87-E<R!L86)O<F%T;W)Y(&%N9"!P
M<F]D=6-T:6]N('-P86-E('5N9&5R(&]P97)A=&EN9R!L96%S92!A9W)E96UE
M;G1S('=H:6-H(&-A;B!B92!C86YC96QL960@=VET:"`S(&UO;G1H(&YO=&EC
M92XF(S$V,#LF(S$V,#M4:&4@;&5A<V4@8V%L;',@9F]R(&UO;G1H;'D@<&%Y
M;65N=',@;V8@1$M+(#8L,#`P("AA<'!R;WAI;6%T96QY("0Y-C<@870@1&5C
M96UB97(@,S$L(#(P,30I+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I
M;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X
M="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(#$[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($UA<F-H(#(W+"`R,#$T('1H92!#
M;VUP86YY(&5N=&5R960@:6YT;R!A;B!O<&5R871I;F<@;&5A<V4@86=R965M
M96YT(&9O<B!O9F9I8V4@<W!A8V4@9G)O;2!A(')E;&%T960@<&%R='DN(%1H
M92!,96%S92!C86QL<R!F;W(@;6]N=&AL>2!P87EM96YT<R!O9B!$2TL@,3`L
M,#`P("AA<'!R;WAI;6%T96QY("0Q+#8Q,BDL(&EN8W)E87-I;F<@=&\@1$M+
M(#(P+#`P,"`H87!P<F]X:6UA=&5L>2`D,RPR,C4I(&]N($IU;'D@,2P@,C`Q
M-"X@5&AE(&QE87-E(&-A;B!B92!T97)M:6YA=&5D(&)Y(&5I=&AE<B!T:&4@
M0V]M<&%N>2!O<B!T:&4@;&%N9&QO<F0@8GD@9VEV:6YG('1H92!O=&AE<B`S
M(&UO;G1H(&YO=&EC92X@5&AE($-O;7!A;GD@9V%V92!A(&YO=&EC92!T97)M
M:6YA=&EN9R!T:&4@;&5A<V4@86=R965M96YT(&]N($9E8G)U87)Y(#(W+"`R
M,#$U('1H97)E8GD@<F5L96%S:6YG('1H92!#;VUP86YY(&9R;VT@=&AE(&QE
M87-E(&]N($UA>2`S,2P@,C`Q-2X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P
M+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@
M;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DQE87-E(&5X<&5N<V4@8VAA<F=E
M9"!T;R!O<&5R871I;VYS('=A<R`D,S(L,CDW(&%N9"`D-C4L-S`R+"!F;W(@
M=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T+"!A;F0@,C`Q,R!R
M97-P96-T:79E;'DN/"]F;VYT/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*
M#0HM+2TM+2T]7TYE>'1087)T7S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC
M-#-A-6-E93@R8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,6$Y
M-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(O5V]R:W-H965T<R]3
M:&5E=#$V+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E
M9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T
M/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT
M='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[
M(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP
M="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT
M("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA
M<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O
M;F<^26YC;VUE(%1A>&5S/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487AE<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DE.0T]-
M12!405A%4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB
M/DY/5$4@."8C,38P.R8C.#(Q,CLF(S$V,#M)3D-/344@5$%815,\+V(^/"]F
M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&AE($-O
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M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT
M+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D%S(&]F($1E8V5M
M8F5R(#,Q+"`R,#$T('1H92!#;VUP86YY(&AA9"!N970@;W!E<F%T:6YG(&QO
M<W,@8V%R<GEF;W)W87)D<R!O9B!A<'!R;WAI;6%T96QY("0R+#,X,"PQ,#8@
M9F]R($1A;FES:"!T87@@<'5R<&]S97,@=VAI8V@@9&\@;F]T(&5X<&ER92X\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T
M97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[
M("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G
M8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
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M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T
M97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^
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M='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
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M<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@
M9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N
M.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q
M-#(R+C<R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=V]R9"US<&%C:6YG.B`P
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M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M,#$T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M,#$S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#L@9F]N="UW96EG:'0Z(&)O;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS
M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,#@Q+C@Q.#$Q-3(S-#,X
M<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY%>&-E<W,@;V8@5&%X(&]V
M97(@8F]O:R!D97!R96-I871I;VX@1FEX960@87-S971S/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T
M-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B0\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$R."XQ.#$X,#@T-S$V.'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S+C8S-C,V,S`R
M.30X<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C<N,C<R-S(W.38V,S`Y<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^.#<L-3<X/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)W=I9'1H.B`Q,RXV,S8S-C,P,CDT.'!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4]
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/C4R+#`T,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M=`T*('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@
M8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T
M=&]M+7-T>6QE.B!S;VQI9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E
M=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXH
M,BPT-#0L.#4X/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T
M=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N
M;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BD\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E
M=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO
M<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
M8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M:6UE<RP@<V5R:68[)SXH,2PX-#0L,C`T/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/BD\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^
M/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6)O='1O;3H@,2XU<'0[('!A
M9&1I;F<M;&5F=#H@,C!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5&]T86P@1&5F
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
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M:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D#0H@<W1Y;&4],T0G8F]R9&5R+6)O='1O
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M=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
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M9F]N=#X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M
M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@
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M97`@87!P<F]A8V@@=&\@<F5C;V=N:7II;F<@86YD(&UE87-U<FEN9R!T87@@
M8F5N969I=',@86YD(&QI86)I;&ET:65S('=H96X@<F5A;&EZ871I;VX@;V8@
M=&AE('1A>"!P;W-I=&EO;B!I<R!U;F-E<G1A:6XN(%1H92!F:7)S="!S=&5P
M(&ES('1O(&1E=&5R;6EN92!W:&5T:&5R('1H92!T87@@<&]S:71I;VX@;65E
M=',@=&AE(&UO<F4M;&EK96QY+71H86XM;F]T(&-O;F1I=&EO;B!F;W(@<F5C
M;V=N:71I;VX@86YD('1H92!S96-O;F0@<W1E<"!I<R!T;R!D971E<FUI;F4@
M=&AE(&%M;W5N="!T;R!B92!R96-O9VYI>F5D(&)A<V5D(&]N('1H92!C=6UU
M;&%T:79E('!R;V)A8FEL:71Y('1H870@97AC965D<R`U,"4N(%1H92!A;6]U
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M969E<G)E9"!T87@@87-S971S+CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED
M;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^02!R96-O;F-I;&EA=&EO;B!O9B!I;F-O;64@
M=&%X(&5X<&5N<V4@870@=&AE(&9E9&5R86P@<W1A='5T;W)Y(')A=&4@=&\@
M:6YC;VUE('1A>"!E>'!E;G-E(&%T('1H92!#;VUP86YY)B,X,C$W.W,@969F
M96-T:79E(')A=&4@:7,@87,@9F]L;&]W<R!A="!$96-E;6)E<B`S,2P@,C`Q
M-"!A;F0@,C`Q,SH\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H
M86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$T,C(N-S)P>#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E
M.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([
M(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I
M9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[)R!C;VQS
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M<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.@T*("-C8V5E9F8[)SX\=&0@<W1Y;&4]
M,T0G=VED=&@Z(#$P.#$N.#$X,3$U,C,T,SAP>#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN
M92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/D-O;7!U=&5D(%1A>"!A="!%>'!E8W1E9"!3=&%T=71O<GD@
M4F%T93PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N-30U-#4T
M,#(U,C8X-G!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q
M,C@N,3@Q.#`X-#<Q-CAP>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N-30U-#4T,#(U,C8X-G!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H
M.B`Q,RXV,S8S-C,P,CDT.'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(W+C(W,C<R-SDV
M-C,P.7!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B@W-3(L.#@R/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV,S8S-C,P,CDT.'!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3DY
M+#(Y,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^."PS.3`\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D#0H@<W1Y
M;&4],T0G9F]N="US='EL93H-"B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M,C@S+#,X,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4]
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M<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q
M+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^5F%L=6%T:6]N(&%L;&]W86YC93PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C<P+#(P.3PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K
M9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!P
M861D:6YG+6)O='1O;3H@,2XU<'0[('!A9&1I;F<M;&5F=#H@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^26YC;VUE(%1A>"!%>'!E;G-E/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O
M;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E
M<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH-"B!N;W)M86P[(&QI;F4M:&5I9VAT.@T*(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[
M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE
M.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R
M;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S
M.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[
M('1E>'0M:6YD96YT.B`P+C5I;CL@=&5X="UA;&EG;CH@:G5S=&EF>3LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^5&AE(&-O;7!O;F5N=',@;V8@:6YC;VUE('1A>"!E
M>'!E;G-E("AB96YE9FET*2!F<F]M(&-O;G1I;G5I;F<@;W!E<F%T:6]N<R!F
M;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S
M(&-O;G-I<W1E9"!O9B!T:&4@9F]L;&]W:6YG.CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN
M.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$T,C(N
M-S)P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R<^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I
M9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UW96EG:'0Z(&)O
M;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&-E;G1E<CL@8F]R
M9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z
M(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#LG(&-O;'-P86X]
M,T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q,SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M=V5I9VAT.B!B;VQD
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=W
M:61T:#H@,3`V."XT.30R-C(V.34S,7!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T
M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY$86YI<V@@26YC;VUE(%1A>#PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N-30U-#4T,#(U,C8X
M-G!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C@N,3@Q
M.#`X-#<Q-CAP>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,30N-30U-#4T,#(U,C8X-G!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV
M,S8S-C,P,CDT.'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(W+C(W,C<R-SDV-C,P.7!X
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G=VED=&@Z(#$S+C8S-C,V,S`R.30X<'@[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M/D1E9F5R<F5D($EN8V]M92!487@@17AP96YS92`H0F5N969I="D\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE.@T*(#$P<'0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H-"B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<VEZ
M93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P
M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(')I9VAT.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE
M.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
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M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,3DL,C4Y/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^,C8L,S8T/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T
M.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY%>&-E<W,@;V8@5&%X(&]V97(@
M0F]O:R!$97!R96-I871I;VX@4&%T96YT<SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M+"!T:6UE<RP@<V5R:68[)SXH,3`U+#4X-3PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3F5T($]P97)A
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,-"B!N97<@
M<F]M86XG+"!T:6UE<RP-"B!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B@Q.3`L.3@X/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
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M;F<M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R<^/&9O;G0@
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M:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E
M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
M+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z
M(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^1&5F97)R960@:6YC;VUE('1A>"!E>'!E;G-E+RAB96YE9FET*2!R
M97-U;'1S('!R:6UA<FEL>2!F<F]M('1H92!R979E<G-A;"!O9B!T96UP;W)A
M<GD@=&EM:6YG(&1I9F9E<F5N8V5S(&)E='=E96X@=&%X(&%N9"!F:6YA;F-I
M86P@<W1A=&5M96YT(&EN8V]M92X\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A
M7SAA.3=?.6,T,V$U8V5E.#)B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K
M<VAE971S+U-H965T,3<N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY,;W-S(%!E<B!3:&%R93QB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY,;W-S(%!E<B!3:&%R92!;
M06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/DQ/4U,@4$52(%-(05)%/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ
M93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO
M<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X
M="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F
M;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O
M<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^/&(^3D]412`Y)B,Q-C`[)B,X,C$R.R8C,38P.TQ/4U,@
M4$52(%-(05)%/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD
M96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
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M:R!F;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R
M,#$S.CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N
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M:68[(&9O;G0M<VEZ93H@,3!P=#L@=V]R9"US<&%C:6YG.B`P<'@[(&)O<F1E
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M;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[('1E>'0M86QI
M9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG
M(&-O;'-P86X],T0V/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=L
M:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G8F]R9&5R+6)O
M='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E<BUB;W1T;VTM=VED=&@Z(#$N-7!T
M.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L@=&5X="UA;&EG;CH@8V5N
M=&5R.R!L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X.R<@8V]L<W!A
M;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SX\8CXR,#$T/"]B/CPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G;&EN92UH
M96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG(&-O;'-P86X],T0R
M/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^/&(^,C`Q,SPO8CX\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G;&EN
M92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQT9"!S='EL93TS1"=W:61T:#H@,3$Q,'!X.R!L:6YE+6AE:6=H=#H@,34N
M,S,S,S,S,#$U-#0Q.7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SY.970@*$QO<W,I/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&QI;F4M
M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F
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M<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B@R+#,W,"PX.#,\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T
M+C4T-30U-#`R-3(V.#9P>#L@;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T
M,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@
M,3,N-C,V,S8S,#(Y-#AP>#L@;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T
M,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,RXV,S8S-C,P,CDT.'!X.R!L:6YE+6AE:6=H
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M('-T>6QE/3-$)W=I9'1H.B`Q,3,N-C,V,S8P,38X-#4W<'@[('1E>'0M86QI
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M.B`Q,RXV,S8S-C,P,CDT.'!X.R!L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U
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M=&4[)SX\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T
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M;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P
M,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S
M,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/C<L-3`P+#$T,CPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,RPU
M-3<L.#DS/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B
M;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^169F
M96-T(&]F(&1I;'5T:79E('-E8W5R:71I97,L('-T;V-K(&]P=&EO;G,@86YD
M('=A<G)A;G1S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT
M.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
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M;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S
M,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G
M;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I
M9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
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M.B!S;VQI9#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS
M,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/BT\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI
M=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN9RUL969T.B`Q,'!T.R!T97AT+6EN
M9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/E=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R
M97,@86YD('!O=&5N=&EA;"!D:6QU=&EV93PO9F]N=#X\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/CQB<B`O/CQF;VYT('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/F-O
M;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@=7-E9"!I;B!D:6QU=&EV92!E87)N
M:6YG<R!P97(@<VAA<F4\+V9O;G0^/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL
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M9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C<L-3`P+#$T,CPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U
M-#0Q.7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&QI
M;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T
M=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[
M(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!T97AT+6%L:6=N.B!R:6=H
M=#L@;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,RPU
M-3<L.#DS/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q
M-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CPO='(^/"]T86)L93X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M
M86P[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN
M9&5N=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SY&;W(@=&AE('EE87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R
M,#$T(&%N9"`R,#$S+"!T:&4@0V]M<&%N>2!H860@;F\@;W!T:6]N<R!O=71S
M=&%N9&EN9R!T;R!P=7)C:&%S92!C;VUM;VX@<W1O8VL@;V8@=&AE(%!A<F5N
M="X\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?
M-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,3@N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO
M;&1E<B=S($5Q=6ET>3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY3=&]C:VAO;&1E<G,G($5Q=6ET>2!.;W1E(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4U1/0TM(3TQ$15)3)R!%455)5%D\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQD:78^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ
M(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SX\8CY.3U1%(#$P)B,Q-C`[)B,X,C$R.R8C,38P.U-43T-+2$],1$52
M4R8C.#(Q-SL@15%52519/"]B/CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A
M8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/D-O;6UO;B!3=&]C:SPO8CXF
M(S$V,#LF(S@R,3([)B,Q-C`[5&AE($-O;7!A;GD@:&%S(#$P,"PP,#`L,#`P
M(&%U=&AO<FEZ960@<VAA<F5S(&]F($-O;6UO;B!S=&]C:R`D,"XP,#`Q+B8C
M,38P.R8C,38P.T%S(&]F($1E8V5M8F5R(#,Q+"`R,#$T('1H97)E('=E<F4@
M.2PU,S,L,CDP('-H87)E<R!I<W-U960@86YD(&]U='-T86YD:6YG+CPO9F]N
M=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA
M;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!T97AT+6EN9&5N=#H@,"XU-6EN.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SX\8CY3:&%R92!%>&-H86YG92!!9W)E96UE;G0\+V(^+SQB/E)E=F5R<V4@
M06-Q=6ES:71I;VX\+V(^)B,Q-C`[+2!/;B!&96)R=6%R>2`Q,BP@,C`Q-"P@
M:6X@86-C;W)D86YC92!W:71H('1H92!T97)M<R!A;F0@8V]N9&ET:6]N<R!O
M9B!A(%-H87)E($5X8VAA;F=E($%G<F5E;65N="`H=&AE(")3:&%R92!%>&-H
M86YG92!!9W)E96UE;G0B*2P@=V5C;VUP;&5T960@=&AE(&%C<75I<VET:6]N
M(&]F(&%P<')O>&EM871E;'D@,3`P)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S
M=&%N9&EN9R!C87!I=&%L('-T;V-K)B,Q-C`[)B,Q-C`[;V8F(S$V,#LF(S$V
M,#M$86Y$<FET($1E;FUA<FL@*'1H92`F(S@R,C`[4VAA<F4@17AC:&%N9V4F
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M=F%L=64@)"XP,#`Q('!E<B!S:&%R92`H=&AE("8C.#(R,#M#;VUM;VX@4W1O
M8VLF(S@R,C$[*2!F;W(@86X@86=G<F5G871E(&]F(#8L,#`P+#`P,"!S:&%R
M97,L(&EN8VQU9&EN9R`Q.#4L,#4S('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@
M<F5S97)V960@9F]R(&ES<W5A;F-E+"!I;B!A8V-O<F1A;F-E('=I=&@@4V5C
M=&EO;B`W,"!O9B!T:&4@1&%N:7-H($-O;7!A;FEE<R!!8W0@86YD('1H92!!
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M:&%R92!%>&-H86YG92!A9W)E960@=&\@8V%N8V5L(#0L-#`P+#`P,"!S:&%R
M97,@;V8@;W5T<W1A;F1I;F<@0V]M;6]N(%-T;V-K(&]W;F5D(&)Y(&ET(&%N
M9"`H,BD@=&AE(&)O87)D(&]F(&1I<F5C=&]R<R!A;F0@97AE8W5T:79E(&UA
M;F%G96UE;G0@;V8@1&%N1')I="!$96YM87)K('=A<R!A<'!O:6YT960@=&\@
M<V5R=F4@87,@=&AE($)O87)D(&]F($1I<F5C=&]R<R!A;F0@97AE8W5T:79E
M(&UA;F%G96UE;G0@;V8@1&%N1')I="!54T$@969F96-T:79E('5P;VX@=&AE
M(')E<VEG;F%T:6]N(&]F('1H92!S;VQE(&]F9FEC97(@86YD(&1I<F5C=&]R
M(&]F($1A;D1R:70@55-!('!R:6]R('1O('1H92!C;&]S:6YG(&]F('1H92!3
M:&%R92!%>&-H86YG92X\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-35I
M;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[
M('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H
M.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO
M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^0V]M;6]N(%-T;V-K($ES<W5A;F-E
M<R`F(S@R,3$[/"]B/B8C,38P.T]N/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[)SXF(S$V,#M$96-E;6)E<B`S,2P@,C`Q-"P\+V9O
M;G0^)B,Q-C`[=&AE($-O;7!A;GD@<F5C96EV960F(S$V,#L\9F]N="!S='EL
M93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/B0R+#`P,"PP,#`@:6X@
M8V]N;F5C=&EO;B!W:71H(&$@<')I=F%T92!O9F9E<FEN9R!O9B`T,#`L,#`P
M('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@870@86X@;V9F97)I;F<@<')I8V4@
M;V8@)#4N,#`@<&5R('-H87)E+CPO9F]N=#X\+V9O;G0^/"]P/@T*/'`@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI
M;F1E;G0Z(#`N-35I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C4U:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D1U<FEN9R!T:&4@
M>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@<'5R<W5A;G0@=&\F(S$V
M,#L\9F]N="!S='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/G1H
M92!#;VUP86YY)B,X,C$W.W,@;V9F97)I;F<@=7`@=&\@)#$R+#`P,"PP,#`@
M*#(L-#`P+#`P,"!S:&%R97,I(&]F(&-O;6UO;B!S=&]C:R!A="!A;B!O9F9E
M<FEN9R!P<FEC92!O9B`D-2XP,"!P97(@<VAA<F4@:6X@86X@:6YI=&EA;"!P
M=6)L:6,@;V9F97)I;F<@<'5R<W5A;G0@=&\@82!R96=I<W1R871I;VX@<W1A
M=&5M96YT(&5F9F5C=&EV92!O;B!!=6=U<W0@,3(L(#(P,30L('1H92!#;VUP
M86YY('-O;&0@,2PP.3,L,CDP('-H87)E<R!O9B!C;VUM;VX@<W1O8VL@9F]R
M(&=R;W-S('!R;V-E961S(&]F("0U+#0V-BPT-3`@;&5S<R!O9F9E<FEN9R!C
M;W-T<R!O9B`D,34V+#,V,"X\+V9O;G0^/"]F;VYT/CPO<#X-"CQP('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C
M;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD
M96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN
M9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P
M<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^#0H\<"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($1E8V5M8F5R(#$V+"`R
M,#$S+"!$86Y$<FET/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N9"UC;VQO<CH@
M=VAI=&4[)SXF(S$V,#M$96YM87)K/"]F;VYT/B8C,38P.VES<W5E9"`Q-S0L
M-3<X('-H87)E<R!O9B!I=',@8V]M;6]N('-T;V-K('=H:6-H('=E<F4@97AC
M:&%N9V5D(&9O<B`R-C$L-C8U('-H87)E<R!O9B!#;VUM;VX@4W1O8VL@;V8@
M=&AE(%!A<F5N="!U<&]N('1H92!C;&]S:6YG(&]F('1H92!3:&%R92!%>&-H
M86YG92!I;B!P87EM96YT(&]F(&$@)#$L-3`P+#`P,"!C;VYV97)T:6)L92!B
M;VYD+"`D,3<Y+#8Q,B!O9B!A8V-R=65D(&EN=&5R97-T(&%N9"!T:&4@<F5M
M86EN:6YG("0V-S,L-S,V(&]F(&1E<FEV871I=F4@;&EA8FEL:71Y(&%S<V]C
M:6%T960@=VET:"!T:&4@8V]N=F5R<VEO;B!F96%T=7)E(&]F('1H92!B;VYD
M+CPO9F]N=#X\+W`^#0H\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@
M=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A
M;G-F;W)M.B!N;VYE.PT*('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^3VX@1&5C96UB97(@,38L(#(P,3,L($1A;D1R:70\9F]N="!S
M='EL93TS1"=B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/D1E;FUA<FL\+V9O
M;G0^)B,Q-C`[:7-S=65D(#DV+#(X."!S:&%R97,@;V8@:71S(&-O;6UO;B!S
M=&]C:R!W:&EC:"!W97)E(&5X8VAA;F=E9"!F;W(@,30T+#,R,2!S:&%R97,@
M;V8@0V]M;6]N(%-T;V-K(&]F('1H92!087)E;G0@=7!O;B!T:&4@8VQO<VEN
M9R!O9B!T:&4@4VAA<F4@17AC:&%N9V4@:6X@<&%Y;65N="!O9B`D.3(V+#,X
M-B!O9B!N;W1E<R!P87EA8FQE(&%N9"!R96QA=&5D(&%C8W)U960@:6YT97)E
M<W0@<&%Y86)L92!T;R!$2U1)($$O4RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R<^)B,Q-C`[/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT
M+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/"]P/@T*/&1I=B!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF
M>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT
M+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M
M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I
M9'1H.B`P<'@[)SY/;B!$96-E;6)E<B`Q-BP@,C`Q,RP@1&%N1')I=#QF;VYT
M('-T>6QE/3-$)V)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^)B,Q-C`[1&5N
M;6%R:R8C,38P.SPO9F]N=#YI<W-U960@,3@T+#`U,2!S:&%R97,@;V8@:71S
M(&-O;6UO;B!S=&]C:R!W:&EC:"!W97)E(&5X8VAA;F=E9"!F;W(@,C<U+#@V
M,R!S:&%R97,@;V8@0V]M;6]N(%-T;V-K(&]F('1H92!087)E;G0@=7!O;B!T
M:&4@8VQO<VEN9R!O9B!T:&4@4VAA<F4@17AC:&%N9V4@:6X@<&%Y;65N="!O
M9B`D,2PW-S`L-S4W(&]F(&YO=&5S('!A>6%B;&4@86YD(')E;&%T960@86-C
M<G5E9"!I;G1E<F5S="!P87EA8FQE('1O(%-U;F4@3VQS96X@2&]L9&EN9W,@
M07!3(&%N9"!!9'9A;F-E($)I;W1E8V@@26YV97-T($%3+CPO9&EV/@T*/'`@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I
M9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW
M:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P
M/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N
M93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED
M;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T
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M<F5C=&]R<RX\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M
M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P
M,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SX\8CX\:3Y$:79I9&5N9',M)B,Q-C`[/"]I/CPO8CY(
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M+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M
M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT
M<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW
M96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&(^/&D^3&EQ=6ED871I;VX@4FEG:'1S+3PO:3X\+V(^)B,Q-C`[26X@
M=&AE(&5V96YT(&]F(&%N>2!L:7%U:61A=&EO;BP@9&ES<V]L=71I;VX@;W(@
M=VEN9&EN9RUU<"!O9B!A9F9A:7)S(&]F('1H92!#;VUP86YY+"!A9G1E<B!P
M87EM96YT(&]F(&%L;"!O9B!O=7(@9&5B=',@86YD(&QI86)I;&ET:65S+"!T
M:&4@:&]L9&5R<R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS(&-O;6UO;B!S=&]C
M:R!W:6QL(&)E(&5N=&ET;&5D('1O('-H87)E(')A=&%B;'D@:6X@=&AE(&1I
M<W1R:6)U=&EO;B!O9B!A;GD@;V8@;W5R(')E;6%I;FEN9R!A<W-E=',N/"]F
M;VYT/CPO<#X-"CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E
M.#)B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U
M9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,3DN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY#;VUM
M:71M96YT<R!A;F0@0V]N=&EN9V5N8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@
M16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-/34U)5$U%3E13($%.1"!#3TY424Y'
M14Y#2453/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SX\8CY.3U1%(#$Q)B,Q-C`[)B,X,C$R.R8C,38P.T-/34U)5$U%3E13($%.
M1"!#3TY424Y'14Y#2453/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N
M=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C
M,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG
M.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M96YT:71L960@=&\@<F5C96EV92!U<"!T;R`Q.#4L,#4S('-H87)E<R!O9B!C
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M9F]N=#X\+W`^/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T
M97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I
M;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M/&(^/&D^0VQI;FEC86P@5')I86P@06=R965M96YT/"]I/CPO8CXF(S@R,3$[
M3VX@3V-T;V)E<B`Q+"`R,#$T('1H92!#;VUP86YY)B,X,C$W.W,@<W5B<VED
M:6%R>2P@1&%N1')I="!":6]T96-H($$O4R!S:6=N960@82!C;VYT<F%C="!O
M9B!C;VQL86)O<F%T:6]N('=I=&@@=&AE(%5N:79E<G-I='D@2&]S<&ET86P@
M25)#0U,@)B,X,C(P.U-A;B!-87)T:6YO)B,X,C(Q.R`M($E35"`F(S@R,3$[
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M,C`[3D5$)B,X,C(Q.RD@<W1A9V4@258@8V]L;W)E8W1A;"!C86YC97(@*"8C
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M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/CQI/E!A
M=&EE;G0@3F%M92!5<V4@4')O9W)A;3PO:3X\+V(^)B,Q-C`[+2!/;B!$96-E
M;6)E<B`Q-BP@,C`Q,RP@1&%N1')I=#QF;VYT('-T>6QE/3-$)V)A8VMG<F]U
M;F0M8V]L;W(Z('=H:71E.R<^)B,Q-C`[1&5N;6%R:R8C,38P.SPO9F]N=#YE
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M=VAI=&4[)SY$96YM87)K)B,Q-C`[/"]F;VYT/G1O('-E;&P@34-6(&9O<B!A
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M86QT>2!O;B!A(&-O=6YT<GD@=&\@8V]U;G1R>2!B87-I<R!F;W(@,C`@>65A
M<G,@;VX@34-6('-A;&5S('-O;&0@=6YD97(@=&AE(&%G<F5E;65N="X@16ET
M:&5R('!A<G1Y(&UA>2!T97)M:6YA=&4@=&AE(&%G<F5E;65N="!W:71H(#$X
M,"!D87D@=W)I='1E;B!N;W1I8V4N/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z
M(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@
M,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O
M;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E
M;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I
M;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT
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M97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R
M.B`C,#`P,#`P.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T
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M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
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M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N
M;VYE.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M
M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W
M:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/CQI/D5M
M<&QO>6UE;G0@06=R965M96YT<R`M)B,Q-C`[/"]I/CPO8CY4:&4@0V]M<&%N
M>2!A;F0@:71S(%-U8G-I9&EA<GD@:&%V92!E;7!L;WEM96YT(&%G<F5E;65N
M=',@=VET:"!O9F9I8V5R<R!O9B!T:&4@0V]M<&%N>2X\+V9O;G0^/"]P/CQP
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T
M:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E
M>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R
M9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@
M,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!T97AT+6EN9&5N=#H@,"XU:6X[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[
M('=O<F0M<W!A8VEN9SH@,'!X.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
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M;BX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?
M-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,C`N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5-13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$:7-P;W-I
M=&EO;CQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY$:7-P;W-I=&EO;B!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1)4U!/4TE424]./"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT
M.B`P<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R
M;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^3D]412`Q,B8C,38P
M.R8C.#(Q,CLF(S$V,#M$25-03U-)5$E/3CPO8CX\+V9O;G0^/"]P/CQP('-T
M>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@
M;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ
M(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P
M,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R
M+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N
M<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N
M;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M
M=&5X="US=')O:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N
M=#H@,"XU:6X[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/D]N($1E8V5M8F5R(#$V+"`R
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M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
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M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%344^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E
M9"!087)T>2!4<F%N<V%C=&EO;G,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y214Q!5$5$(%!!4E19(%12
M04Y304-424].4SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=CX-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W
M:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/CQB/DY/5$4@,3,F(S$V,#LF(S@R,3([)B,Q-C`[4F5L
M871E9"!087)T>2!4<F%N<V%C=&EO;G,\+V(^/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1'5R:6YG('1H92!Y
M96%R(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S+"!T:&4@0V]M
M<&%N>2!E;G1E<F5D(&EN=&\@=F%R:6]U<R!N;W1E<R!P87EA8FQE('=I=&@@
M<VAA<F5H;VQD97)S(&]F('1H92!#;VUP86YY("A3964@3F]T92`T*2X\+V9O
M;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA
M;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/@T*/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[
M('1E>'0M86QI9VXZ(&IU<W1I9GD[(&-O;&]R.B`C,#`P,#`P.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L971T97(M<W!A
M8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SY/;B!-87)C:"`R-RP@,C`Q-"!T:&4@0V]M<&%N>2!E;G1E<F5D(&EN=&\@
M86X@;W!E<F%T:6YG(&QE87-E(&%G<F5E;65N="!F;W(@;V9F:6-E('-P86-E
M(&9R;VT@82!S:&%R96AO;&1E<B!O9B!T:&4@0V]M<&%N>2`H4V5E($YO=&4@
M-RDN($1U<FEN9R!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"P@
M=&AE($-O;7!A;GD@<&%I9"!T:&4@<F5L871E9"!P87)T>2!$2TL@,3,P+#`P
M,"!O<B!A<'!R;WAI;6%T96QY("0R,RPQ-3(N/"]F;VYT/CPO<#X-"CQP('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y
M.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US
M<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@
M9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED
M=&@Z(#!P>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X-
M"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J
M=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[
M('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@
M=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W
M<SH@,3L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#LG/CPO<#X-"CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I
M;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P+C5I;CL@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@9F]N="US=')E=&-H.B!N;W)M
M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG/D1U<FEN9R!T
M:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@,C`Q-"!A;F0@,C`Q,RP@82!L
M87<@9FER;2!P87)T:6%L;'D@;W=N960@8GD@=&AE($-O;7!A;GDF(S@R,3<[
M<R!#:&%I<FUA;B!O9B!T:&4@0F]A<F0@;V8@1&ER96-T;W)S('!R;W9I9&5D
M(&QE9V%L('-E<G9I8V5S('1O('1H92!#;VUP86YY+B!$=7)I;F<@=&AE('EE
M87)S(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$T(&%N9"`R,#$S('1H92!#;VUP
M86YY(')E8V]R9&5D(&QE9V%L(&5X<&5N<V4@;V8@)#(X."PU-#8@86YD("0S
M,C@L,C`R+"!R97-P96-T:79E;'DN($1U<FEN9R!T:&4@>65A<B!E;F1E9"!$
M96-E;6)E<B`S,2P@,C`Q,R!T:&4@9FER;2!F;W)G879E("0T.2PP,38@:6X@
M;&5G86P@<V5R=FEC97,N($%T($1E8V5M8F5R(#,Q+"`R,#$T+"!T:&4@0V]M
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M<W0@870@1&5C96UB97(@,S$L(#(P,30@86YD(#(P,3,@=V5R92`D,BPP,30L
M.3`Y(&%N9"`D,30L-3DS+"!R97-P96-T:79E;'D\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/BX\+V9O;G0^/"]P/@T*/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/E-U8G-E<75E;G0@179E;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T
M:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N=',@6T%B<W1R
M86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y354)315%514Y4($5614Y4/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@
M,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA
M;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA
M;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@875T;SL@=&5X="UA
M;&EG;CH@<W1A<G0[('1E>'0M:6YD96YT.B`P<'@[('1E>'0M=')A;G-F;W)M
M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M
M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^/&(^3D]412`Q-"8C,38P.R8C.#(Q,CLF(S$V,#M354)315%5
M14Y4($5614Y4/"]B/CPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P
M,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE
M='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R
M<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C
M93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B
M:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI
M;F1E;G0Z(#0P<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H
M.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X
M="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SY4:&4@0V]M<&%N>28C.#(Q-SMS(&UA;F%G96UE;G0@<F5V
M:65W960@;6%T97)I86P@979E;G1S('1H<F]U9V@@36%R8V@@,S`L(#(P,34N
M/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF
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M9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O
M:V4M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4]
M,T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S
M=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY/
M;B!-87)C:"`Q,RP@,C`Q-2P@=&AE($-O;7!A;GDL($1A;D1R:71$96YM87)K
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M;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E
M;6)E<B`S,2P@,C`Q-"`H=&AE("8C.#(R,#M4<F%N<VET:6]N(%!E<FEO9"8C
M.#(R,3LI+B!);B!A8V-O<F1A;F-E('=I=&@@=&AE('1E<FUS(&]F('1H92!!
M9W)E96UE;G0@86YD(&5X8V5P="!A<R!A;65N9&5D(&)Y('1H92!!9W)E96UE
M;G0L('1H92!#1D\@4V5R=FEC92!!9W)E96UE;G0@8F5T=V5E;B!$86Y$<FET
M($1E;FUA<FL@86YD($UR+B!7;VQF92P@9&%T960@87,@;V8@1F5B<G5A<GD@
M,3`L(#(P,30@*'1H92`F(S@R,C`[5V]L9F4@16UP;&]Y;65N="!!9W)E96UE
M;G0F(S@R,C$[*2!W:6QL(')E;6%I;B!I;B!E9F9E8W0@=&AR;W5G:"!/8W1O
M8F5R(#,Q+"`R,#$U("AT:&4@)B,X,C(P.U1E<FUI;F%T:6]N($1A=&4F(S@R
M,C$[*2X@26X@861D:71I;VXL($UR+B!7;VQF92!I<R!E;G1I=&QE9"!T;R!R
M96-E:79E("AI*2!A;&P@<V%L87)Y('!A>6%B;&4@:6X@86-C;W)D86YC92!W
M:71H('1H92!T97)M<R!O9B!T:&4@5V]L9F4@16UP;&]Y;65N="!!9W)E96UE
M;G0L(&%L;VYG('=I=&@@86YY('5N<&%I9"!A8V-R=65D(&5X<&5N<V5S+"!T
M:')O=6=H('1H92!497)M:6YA=&EO;B!$871E.R`H:6DI(&%T=&]R;F5Y(&9E
M97,@;V8@=7`@=&\@82!M87AI;75M(&]F("0T+#`P,#L@*&EI:2D@82!B;VYU
M<R!I;B!A;B!A;6]U;G0@97%U86P@=&\@)#$P+#`P,"!F;VQL;W=I;F<@=&AE
M(&9I;&EN9R!O9B!T:&4@0V]M<&%N>28C.#(Q-SMS($%N;G5A;"!297!O<G0@
M;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E9"!$96-E;6)E<B`S,2P@
M,C`Q-#L@86YD("AI=BD@82!F964@;V8@)#$U,"XP,"!P97(@:&]U<B!F;W(@
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M(#(P,34@=&AR;W5G:"!/8W1O8F5R(#,Q+"`R,#$U('-H86QL(&YO="!B92!B
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M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P
M,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T
M=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P
M:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E
M.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K
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M(#$R+"`R,#$U+B!3=6)J96-T('1O(&%P<')O=F%L(&)Y('1H92!#;VUP86YY
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M<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT
M+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US
M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#`N-6EN.R!B86-K9W)O=6YD+6-O;&]R.B!W:&ET93LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M('1H870@37,N($1E9VX@=VEL;"!R96-E:79E(&$@<V%L87)Y(&]F($1+2R`V
M,"PP,#`@9W)O<W,@<&5R(&UO;G1H+"!T;R!B92!P86ED(&UO;G1H;'D@;VX@
M=&AE(&QA<W0@8G5S:6YE<W,@9&%Y(&]F(&5A8V@@;6]N=&@@86YD('-U8FIE
M8W0@=&\@86YN=6%L(')E=FEE=R!A;F0@:6YC<F5A<V5S(&)Y('1H92!B;V%R
M9"!O9B!D:7)E8W1O<G,@;V8@1&%N1')I="!$96YM87)K+"!A<R!I="!D965M
M<R!A<'!R;W!R:6%T92X\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C
M,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O
M<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E
M8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M
M:6YD96YT.B`P+C5I;CL@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@
M=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
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M;VYT/CPO<#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@,"XU:6X[(&)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF
M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V
M,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;CL@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/D5I=&AE<B!$86Y$<FET($1E;FUA<FL@;W(@37,N($1E9VX@;6%Y('1E<FUI
M;F%T92!T:&4@96UP;&]Y;65N="!I;B!A8V-O<F1A;F-E('=I=&@@=&AE($1A
M;FES:"!386QA<FEE9"!%;7!L;WEE97,@06-T+CPO9F]N=#X\+W`^/'`@<W1Y
M;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@
M:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R!B86-K9W)O=6YD+6-O;&]R
M.B!W:&ET93LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S%A
M.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC
M-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,C,N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$50
M0T%%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U;6UA<GD@;V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H4&]L:6-I97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA
M<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R!;06)S=')A
M8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D)U<VEN97-S(&%N9"!"87-I<R!O9B!0<F5S96YT871I;VX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H
M86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
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M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED
M;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P
M,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T
M97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H
M86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z
M(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD
M96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH
M96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY$86Y$<FET($)I;W1E8V@@55-!+"!);F,N("@F
M(S@R,C`[1&%N1')I="!54T$F(S@R,C$[+"!T:&4@)B,X,C(P.T-O;7!A;GDF
M(S@R,C$[+"`F(S@R,C`[=V4F(S@R,C$[+"`F(S@R,C`[=7,F(S@R,C$[+"`F
M(S@R,C`[;W5R)B,X,C(Q.RD@*&9O<FUE<FQY(%!U=&YA;2!(:6QL<R!#;W)P
M+BD@=V%S(&]R:6=I;F%L;'D@:6YC;W)P;W)A=&5D(&EN('1H92!S=&%T92!O
M9B!$96QA=V%R92!O;B!*86YU87)Y(#$X+"`R,#$Q(&%S(&$@=F5H:6-L92!T
M;R!P=7)S=64@82!B=7-I;F5S<R!C;VUB:6YA=&EO;B!T:')O=6=H('1H92!A
M8W%U:7-I=&EO;B!O9BP@;W(@;65R9V5R('=I=&@L(&%N(&]P97)A=&EN9R!B
M=7-I;F5S<RX\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS
M.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O
M;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[
M('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL
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M:6P@,2P@,C`P,2`H)B,X,C(P.T1A;D1R:70@1&5N;6%R:R8C.#(R,3LI+B8C
M,38P.R8C,38P.U1H92!#;VUP86YY(&5N9V%G97,@:6X@=&AE(')E<V5A<F-H
M(&%N9"!D979E;&]P;65N="P@;6%N=69A8W1U<FEN9R!A;F0@8VQI;FEC86P@
M=')I86QS(&]F('!H87)M86-E=71I8V%L(&%N9"!B:6]L;V=I8V%L('!R;V1U
M8W1S(&9O<B!T:&4@=')E871M96YT(&]F(&-A;F-E<FEN(&AU;6%N<W5S:6YG
M('1H92!D96YD<FET:6,@8V5L;"!T96-H;F]L;V=Y+CPO9F]N=#X\+W`^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/E)E=F5R<V4@06-Q=6ES:71I;VXF(S$V,#LF(S$V,#LM($]N($9E8G)U
M87)Y(#$R+"`R,#$T+"!P=7)S=6%N="!T;R!A4VAA<F4@17AC:&%N9V4@06=R
M965M96YT("AT:&4@(E-H87)E($5X8VAA;F=E($%G<F5E;65N="(I+"!$86Y$
M<FET(%5302!C;VUP;&5T960@=&AE(&%C<75I<VET:6]N(&]F(&%P<')O>&EM
M871E;'D@,3`P)2!O9B!T:&4@:7-S=65D(&%N9"!O=71S=&%N9&EN9R!C87!I
M=&%L('-T;V-K)B,Q-C`[)B,Q-C`[;V8F(S$V,#LF(S$V,#M$86Y$<FET($1E
M;FUA<FL@*'1H92`F(S@R,C`[4VAA<F4@17AC:&%N9V4F(S@R,C$[*2!A;F0@
M87,@82!R97-U;'0@8F5C86UE($1A;D1R:70@1&5N;6%R:R8C.#(Q-SMS('!A
M<F5N="!C;VUP86YY("AT:&4@)B,X,C(P.U!A<F5N="8C.#(R,3LI+B!0<FEO
M<B!T;R!T:&4@4VAA<F4@17AC:&%N9V4@=&AE<F4@=V5R92`U+#`P,"PP,#`@
M<VAA<F5S(&]F('1H92!C;VUM;VX@<W1O8VLL('!A<B!V86QU92`D+C`P,#$@
M<&5R('-H87)E("AT:&4@)B,X,C(P.T-O;6UO;B!3=&]C:R8C.#(R,3LI(&]F
M(%!A<F5N="!O=71S=&%N9&EN9RXF(S$V,#M087)E;G0@86YD(&%N(&5X:7-T
M:6YG('-H87)E:&]L9&5R(&%G<F5E9"!T;R!C86YC96P@-"PT,#`L,#`P('-H
M87)E<R!O9B!I=',@0V]M;6]N(%-T;V-K(&%N9"!I<W-U960@,2PT-#`L,#`P
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M=&]C:RP@9F]R(&$@=&]T86P@;V8@-BPP,#`L,#`P('-H87)E<RP@<F5S=6QT
M:6YG(&EN(#@L,#0P+#`P,"!S:&%R97,@;V8@=&AE(%!A<F5N="8C.#(Q-SMS
M($-O;6UO;B!3=&]C:R!O=71S=&%N9&EN9R!I;6UE9&EA=&5L>2!F;VQL;W=I
M;F<@=&AE(%-H87)E($5X8VAA;F=E+"8C,38P.SQF;VYT('-T>6QE/3-$)V)A
M8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^:6YC;'5D:6YG(#$X-2PP-3,@<VAA
M<F5S(&]F($-O;6UO;B!3=&]C:R!R97-E<G9E9"!F;W(@:7-S=6%N8V4@:6X@
M86-C;W)D86YC92!W:71H(%-E8W1I;VX@-S`@;V8@=&AE($1A;FES:"!#;VUP
M86YI97,@06-T(&%N9"!T:&4@07)T:6-L97,@;V8@07-S;V-I871I;VX@;V8@
M1&%N1')I="!$96YM87)K('1O('1H92!$86Y$<FET($1E;FUA<FL@<VAA<F5H
M;VQD97)S('=H;R!H879E(&YO="!C;VYS96YT960@=&\@=&AE)B,Q-C`[/"]F
M;VYT/E-H87)E($5X8VAA;F=E("AT:&4@)B,X,C(P.TYO;BU#;VYS96YT:6YG
M(%-H87)E:&]L9&5R<R8C.#(R,3LI/&9O;G0@<W1Y;&4],T0G8F%C:V=R;W5N
M9"UC;VQO<CH@=VAI=&4[)SXL(&%N9"!D965M960@:7-S=65D(&%N9"!O=71S
M=&%N9&EN9R!F;W(@86-C;W5N=&EN9R!P=7)P;W-E<SPO9F]N=#XN/"]F;VYT
M/CPO<#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D9U;F-T:6]N86P@0W5R<F5N8WD@+R!&;W)E:6=N(&-U<G)E;F-Y
M('1R86YS;&%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M9&EV('-T>6QE/3-$)W1E>'0M86QI9VXZ(&IU<W1I9GD[(&UA<F=I;CH@,&EN
M(#!I;B`P<'0[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-I>F4],T0R
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86XL=&EM97,[
M)SX\8CY&=6YC=&EO;F%L($-U<G)E;F-Y("\@1F]R96EG;B!C=7)R96YC>2!T
M<F%N<VQA=&EO;CPO8CXF(S$V,#LF(S@R,3([)B,Q-C`[5&AE(&9U;F-T:6]N
M86P@8W5R<F5N8WD@;V9$86Y$<FET($)I;W1E8V@@02]3(&ES('1H92!$86YI
M<V@@2W)O;F5R("@F(S@R,C`[1$M+)B,X,C(Q.RDN(%1H92!#;VUP86YY)B,X
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M<G,@,C`Q-"!A;F0@,C`Q,RX@5')A;G-L871I;VX@9V%I;G,@86YD(&QO<W-E
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M+V9O;G0^/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y#87-H(&%N9"!#87-H($5Q=6EV86QE;G1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@
M(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L
M.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@
M;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@
M;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E+7-P
M86-E.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^0V%S:"!A;F0@0V%S:"!%<75I=F%L
M96YT<SPO8CXF(S$V,#LF(S@R,3([)B,Q-C`[5&AE($-O;7!A;GD@8V]N<VED
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M=',@870@1&5C96UB97(@,S$L(#(P,30@;V8@)#(L-3`X+#<U.2!A;F0@;F]N
M92!A="!$96-E;6)E<B`S,2P@,C`Q,RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@
M86YD($5Q=6EP;65N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!I
M;B`P:6X@,'!T.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S:7IE/3-$
M,B!S='EL93TS1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S
M.R<^/&(^4')O<&5R='D@86YD($5Q=6EP;65N=#PO8CXF(S$V,#LF(S@R,3([
M)B,Q-C`[4')O<&5R='D@86YD(&5Q=6EP;65N="!A<F4@<W1A=&5D(&%T(&-O
M<W0N($5X<&5N9&ET=7)E<R!F;W(@;6%J;W(@<F5N97=A;',@86YD(&)E='1E
M<FUE;G1S('1H870@97AT96YD('1H92!U<V5F=6P@;&EV97,@;V8@<')O<&5R
M='D@86YD(&5Q=6EP;65N="!A<F4@8V%P:71A;&EZ960L('5P;VX@8F5I;F<@
M<&QA8V5D(&EN('-E<G9I8V4N($5X<&5N9&ET=7)E<R!F;W(@;6%I;G1E;F%N
M8V4@86YD(')E<&%I<G,@87)E(&-H87)G960@=&\@97AP96YS92!A<R!I;F-U
M<G)E9"X@1&5P<F5C:6%T:6]N(&ES(&-O;7!U=&5D(&9O<B!F:6YA;F-I86P@
M<W1A=&5M96YT('!U<G!O<V5S(&]N(&$@<W1R86EG:'0M;&EN92!B87-I<R!O
M=F5R('1H92!E<W1I;6%T960@=7-E9G5L(&QI=F5S(&]F('1H92!A<W-E=',@
M=VAI8V@@<F%N9V4@9G)O;2!F;W5R('1O('-I>"!Y96%R<R`H4V5E($YO=&4@
M,RDN/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26YT86YG:6)L92!!<W-E=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG
M;CH@:G5S=&EF>3L@;6%R9VEN.B`P:6X@,&EN(#!P=#L@=&5X="UI;F1E;G0Z
M(#`N-6EN.R<^/&9O;G0@<VEZ93TS1#(@<W1Y;&4],T0G9F]N="UF86UI;'DZ
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M9',@0V]D:69I8V%T:6]N+"`H)B,X,C(P.T%30R8C.#(R,3LI(%1O<&EC(#,U
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M<V4N/"]F;VYT/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^26UP86ER;65N="!O9B!,;VYG+4QI=F5D($%S
M<V5T<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!I;B`P:6X@,'!T
M.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S:7IE/3-$,B!S='EL93TS
M1"=F;VYT+69A;6EL>3H@=&EM97,@;F5W(')O;6%N+'1I;65S.R<^/&(^26UP
M86ER;65N="!O9B!,;VYG+4QI=F5D($%S<V5T<R`F(S@R,3([/"]B/B!,;VYG
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M/CQD:78@<W1Y;&4],T0G=&5X="UA;&EG;CH@:G5S=&EF>3L@;6%R9VEN.B`P
M:6X@,&EN(#!P=#L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^)B,Q-C`[/"]D:78^
M/&1I=B!S='EL93TS1"=T97AT+6%L:6=N.B!J=7-T:69Y.R!M87)G:6XZ(#!I
M;B`P:6X@,'!T.R!T97AT+6EN9&5N=#H@,"XU:6X[)SX\9F]N="!S:7IE/3-$
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M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4F5V96YU92!296-O9VYI=&EO;B!A;F0@4V%L97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS
M.B!A=71O.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO
M<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M;6%R9VEN.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT
M.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R;6%L.R!F
M;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N
M="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG
M:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SX\8CY2979E;G5E(%)E8V]G;FET:6]N(&%N9"!386QE
M<R8C,38P.SPO8CXF(S$V,#LF(S@R,3([)B,Q-C`[5&AE($-O;7!A;GDF(S@R
M,3<[<R!S86QE<R!O9B!I=',@365L0V%N8V5R5F%C(&-O;&]R96-T86P@8V%N
M8V5R('1R96%T;65N="!H879E(&)E96X@;&EM:71E9"!T;R!A(&-O;7!A<W-I
M;VYA=&4@=7-E(&)A<VES(&EN(%-I;F=A<&]R92!A9G1E<B!S=&%G92!)24$@
M=')I86QS(&%N9"!I<R!N;W0@87!P<F]V960@9F]R(&-U<G)E;G0@<V%L92!F
M;W(@86YY(&]T:&5R('5S92!O<B!L;V-A=&EO;BX@5&AE($-O;7!A;GD@86-C
M;W5N=',@9F]R(')E=F5N=64@<F5C;V=N:71I;VX@:6X@86-C;W)D86YC92!W
M:71H('1H92!396-U<FET:65S(&%N9"!%>&-H86YG92!#;VUM:7-S:6]N(%-T
M869F($%C8V]U;G1I;F<@0G5L;&5T:6X@3F\N(#$P,2P@)B,X,C(P.U)E=F5N
M=64@4F5C;V=N:71I;VX@:6X@1FEN86YC:6%L(%-T871E;65N=',F(S@R,C$[
M("A304(@,3`Q*2P@1D%30B!!4T,@-C`U(%)E=F5N=64@4F5C;V=N:71I;VXN
M(%1H92!#;VUP86YY(')E8V]G;FEZ97,@<F5V96YU92!W:&5N(')I9VAT<R!A
M;F0@<FES:R!O9B!O=VYE<G-H:7`@:&%V92!P87-S960@=&\@=&AE(&-U<W1O
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M/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5F%L=64@061D960@5&%X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^/&(^5F%L=64@061D960@5&%X("TF(S$V,#L\+V(^26X@1&5N;6%R:RP@
M5F%L=64@061D960@5&%X("@F(S@R,C`[5D%4)B,X,C(Q.RD@;V8@,C4E(&]F
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M050@:7,@<&%I9"!T;R!T:&4@875T:&]R:71I97,N(%9!5"!O9B`R-24@:7,@
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M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E<V5A<F-H(&%N9"!$979E
M;&]P;65N="!#;W-T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^4F5S
M96%R8V@@86YD($1E=F5L;W!M96YT($-O<W0\+V(^)B,Q-C`[)B,X,C$R.R8C
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M(#,Q+"`R,#$T(&%N9"`R,#$S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O
M;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@
M(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S
M-G!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P
M>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SX\
M8CY);F-O;64@5&%X97,\+V(^)B,Q-C`[)B,X,C$R.R8C,38P.U1H92!#;VUP
M86YY(&%C8V]U;G1S(&9O<B!I;F-O;64@=&%X97,@:6X@86-C;W)D86YC92!W
M:71H($9!4T(@05-#(%1O<&EC(#<T,"!!8V-O=6YT:6YG(&9O<B!);F-O;64@
M5&%X97,N(%1H:7,@<W1A=&5M96YT(')E<75I<F5S(&%N(&%S<V5T(&%N9"!L
M:6%B:6QI='D@87!P<F]A8V@@9F]R(&%C8V]U;G1I;F<@9F]R(&EN8V]M92!T
M87AE<RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3&]S<R!097(@4VAA<F4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S-G!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CY,;W-S(%!E<B!3
M:&%R93PO8CXF(S$V,#LF(S@R,3([)B,Q-C`[5&AE($-O;7!A;GD@8V%L8W5L
M871E<R!E87)N:6YG<R\H;&]S<RD@<&5R('-H87)E(&EN(&%C8V]R9&%N8V4@
M=VET:"!&05-"($%30R`R-C`@16%R;FEN9W,@4&5R(%-H87)E+B!"87-I8R!E
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M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&UA<F=I;CH@,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P
M,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S-G!T
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@
M=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CY$
M97)I=F%T:79E<R`F(S@R,3([)B,Q-C`[/"]B/E=E(&=E;F5R86QL>2!D;R!N
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M:71H(&9E871U<F5S('1H870@87)E(&5I=&AE<B`H:2DF(S$V,#MN;W0@869F
M;W)D960@97%U:71Y(&-L87-S:69I8V%T:6]N+"`H:6DI)B,Q-C`[96UB;V1Y
M(')I<VMS(&YO="!C;&5A<FQY(&%N9"!C;&]S96QY(')E;&%T960@=&\@:&]S
M="!C;VYT<F%C=',L(&]R("AI:6DI)B,Q-C`[;6%Y(&)E(&YE="UC87-H('-E
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M<CH@(S`P,#`P,#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT
M.B`S-G!T.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z
M(#!P>#L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[
M)SXF(S$V,#L\+V9O;G0^/"]P/CQP('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&UA<F=I;CH@
M,'!X.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!C;VQO<CH@(S`P,#`P,#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`S-G!T.R!L971T97(M
M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI=&4M<W!A
M8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
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M979E;"`S(&EN<'5T<R`H9&5F:6YE9"!B96QO=R!I;B!.;W1E(#$Z($9A:7(@
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M92!E<W1I;6%T92!A;F0@87-S=6UP=&EO;B!C:&%N9V5S+CPO9F]N=#X\+W`^
M/'`@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@;6%R9VEN.B`P<'@[(&-O;&]R.B`C,#`P,#`P
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#`N-6EN.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!W;W)D+7-P86-I;F<Z(#!P>#L@=VAI
M=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@9F]N="US=')E=&-H.B!N;W)M86P[)SX\8CXF(S$V
M,#L\+V(^/"]F;VYT/CPO<#X\<"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@8V]L;W(Z(",P,#`P,#`[('1E>'0M
M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,S9P=#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=H:71E+7-P86-E
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M8V]M<&%N>6EN9R!B86QA;F-E('-H965T<R!A<R!O9B!$96-E;6)E<B`S,2P@
M,C`Q-"!A;F0@,C`Q,RX\+V9O;G0^/"]P/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1F%I<B!686QU92!O9B!&:6YA
M;F-I86P@26YS=')U;65N=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q
M,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@
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M,#LF(S@R,3([)B,Q-C`[5&AE($-O;7!A;GD@86-C;W5N=',@9F]R(&9A:7(@
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M.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!O<G!H86YS.B!A=71O.R!T97AT+6%L:6=N.B!S=&%R=#L@=&5X="UT<F%N
M<V9O<FTZ(&YO;F4[('=H:71E+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@
M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
M(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X.R!T97AT
M+6EN9&5N=#H@,S9P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO<#X\=&%B;&4@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=VED=&@Z(#$T,C(N-S)P>#L@=&5X="UT<F%N<V9O
M<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[('=O<F0M<W!A8VEN9SH@,'!X.R!W:61O=W,Z(#$[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R`M=V5B:VET
M+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L
M;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@=&]P
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQT9"!S='EL
M93TS1"=W:61T:#H@,"XU:6X[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M=VED=&@Z(#`N,C5I;CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
M;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H
M.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DQE=F5L(#$N
M($]B<V5R=F%B;&4@:6YP=71S('-U8V@@87,@<75O=&5D('!R:6-E<R!I;B!A
M8W1I=F4@;6%R:V5T<R!F;W(@:61E;G1I8V%L(&%S<V5T<R!O<B!L:6%B:6QI
M=&EE<SL\+V9O;G0^/"]T9#X\+W1R/CPO=&%B;&4^/'`@<W1Y;&4],T0G8V]L
M;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&]R<&AA;G,Z(&%U=&\[('1E>'0M86QI9VXZ('-T87)T.R!T97AT+71R
M86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q
M.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T
M:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E
M>'0M:6YD96YT.B`S-G!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="US='EL93H@
M;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO
M<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]P/CQT86)L
M92!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,30R,BXW,G!X.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z(#!P>#L@;&5T=&5R+7-P86-I;F<Z
M(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P<'@[('=I9&]W<SH@,3L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[("UW96)K
M:70M=&5X="US=')O:V4M=VED=&@Z(#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C
M96QL<&%D9&EN9STS1#`^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!T
M;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/'1D('-T
M>6QE/3-$)W=I9'1H.B`P+C5I;CL@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
M+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US
M=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z
M(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=W:61T:#H@,"XR-6EN.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Y-C<Y.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3&5V96P@
M,BX@26YP=71S+"!O=&AE<B!T:&%N('1H92!Q=6]T960@<')I8V5S(&EN(&%C
M=&EV92!M87)K971S+"!T:&%T(&%R92!O8G-E<G9A8FQE(&5I=&AE<B!D:7)E
M8W1L>2!O<B!I;F1I<F5C=&QY.R!A;F0\+V9O;G0^/"]T9#X\+W1R/CPO=&%B
M;&4^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G
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M(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI
M="UT97AT+7-T<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@;6%R9VEN.B`P<'@[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+`T*('-E<FEF.R!W:61T:#H@
M,30R,BXW,G!X.R!T97AT+71R86YS9F]R;3H@;F]N93L@=&5X="UI;F1E;G0Z
M(#!P>#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@=V]R9"US<&%C:6YG.B`P
M<'@[('=I9&]W<SH@,3L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z(#!P
M>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN9STS1#`^/'1R('-T>6QE
M/3-$)W9E<G1I8V%L+6%L:6=N.B!T;W`[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^/'1D('-T>6QE/3-$)W=I9'1H.B`P+C5I;CL@9F]N
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,"XR-6EN.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Y-C<Y.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^3&5V96P@,RX@56YO8G-E<G9A8FQE(&EN<'5T<R!I
M;B!W:&EC:"!T:&5R92!I<R!L:71T;&4@;W(@;F\@;6%R:V5T(&1A=&$L('=H
M:6-H(')E<75I<F4@=&AE(')E<&]R=&EN9R!E;G1I='D@=&\@9&5V96QO<"!I
M=',@;W=N(&%S<W5M<'1I;VYS+CPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\
M<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE
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M;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E
M>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M
M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W`^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F;VYT+7-I
M>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C:6YG.B!N
M;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U=&\[('1E
M>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O
M=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME
M+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P
M>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V<'0[)SX\
M9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-O=6YT:6YG($5S=&EM871E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!F
M;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&QE='1E<BUS<&%C
M:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&]R<&AA;G,Z(&%U
M=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US<&%C93H@;F]R;6%L
M.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G
M:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#,V
M<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/CQB/D%C8V]U;G1I;F<@17-T:6UA=&5S/"]B/B8C,38P.R8C
M.#(Q,CLF(S$V,#M4:&4@<')E<&%R871I;VX@;V8@9FEN86YC:6%L('-T871E
M;65N=',@:6X@8V]N9F]R;6ET>2!W:71H(&=E;F5R86QL>2!A8V-E<'1E9"!A
M8V-O=6YT:6YG('!R:6YC:7!L97,@<F5Q=6ER97,@;6%N86=E;65N="!T;R!M
M86ME(&5S=&EM871E<R!A;F0@87-S=6UP=&EO;G,@=&AA="!A9F9E8W0@=&AE
M(')E<&]R=&5D(&%M;W5N=',@;V8@87-S971S(&%N9"!L:6%B:6QI=&EE<RP@
M=&AE(&1I<V-L;W-U<F5S(&]F(&-O;G1I;F=E;G0@87-S971S(&%N9"!L:6%B
M:6QI=&EE<R!A="!T:&4@9&%T92!O9B!T:&4@9FEN86YC:6%L('-T871E;65N
M=',@86YD('1H92!R97!O<G1E9"!A;6]U;G0@;V8@<F5V96YU97,@86YD(&5X
M<&5N<V5S(&1U<FEN9R!T:&4@<F5P;W)T:6YG('!E<FEO9"X@06-T=6%L(')E
M<W5L=',@8V]U;&0@9&EF9F5R(&9R;VT@=&AO<V4@97-T:6UA=&5D+CPO9F]N
M=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y296-E;G0@06-C;W5N=&EN9R!0<F]N;W5N8V5M96YT<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@<W1Y;&4],T0G8V]L;W(Z
M(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4Z(#$P<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&]R<&AA;G,Z(&%U=&\[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!W:&ET92US
M<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN9SH@,'!X.R`M
M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG;CH@:G5S=&EF>3L@=&5X
M="UI;F1E;G0Z(#,V<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/CQB/E)E8V5N="!!8V-O=6YT:6YG(%!R
M;VYO=6YC96UE;G1S/"]B/B8C,38P.R8C.#(Q,CLF(S$V,#M);B!-87D@,C`Q
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M92!B96=I;FYI;F<@:6X@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q-SL@96%R
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M('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS9F]R
M;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W;W)D
M+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@,'!X
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M86QI
M9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`T,'!T.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@
M9F]N="UW96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O
M;G0M<VEZ93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]P/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US
M:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@
M;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@
M;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T
M97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED
M;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K
M92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P
M<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`S-G!T.R<^
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M;"!S=&%T96UE;G1S+CPO9F]N=#X\+W`^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296-L87-S:69I8V%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO
M<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R
M;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA
M;#L@;&5T=&5R+7-P86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA
M;#L@;W)P:&%N<SH@875T;SL@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('=H:71E
M+7-P86-E.B!N;W)M86P[('=I9&]W<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^4F5C;&%S<VEF:6-A=&EO;B8C
M,38P.R8C.#(Q,CLF(S$V,#L\+V(^5&AE(&9I;F%N8VEA;"!S=&%T96UE;G1S
M(&9O<B!T:&4@<&5R:6]D(&5N9&5D($1E8V5M8F5R(#,Q+"`R,#$S(&AA=F4@
M8F5E;B!R96-L87-S:69I960@=&\@8V]N9F]R;2!T;R!T:&4@:&5A9&EN9W,@
M86YD(&-L87-S:69I8V%T:6]N<R!U<V5D(&EN('1H92!$96-E;6)E<B`S,2P@
M,C`Q-"!F:6YA;F-I86P@<W1A=&5M96YT<RX\+V9O;G0^/"]P/CQD:78^)B,Q
M-C`[/"]D:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT
M4&%R=%\S,6$Y-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(-"D-O
M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S%A.30Q,V-?-35D-5\T,V9A
M7SAA.3=?.6,T,V$U8V5E.#)B+U=O<FMS:&5E=',O4VAE970R-"YH=&UL#0I#
M;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#
M;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-
M"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N
M=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX
M)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ
M<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO
M:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED
M/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E!R;W!E<G1Y(&%N
M9"!%<75I<&UE;G0@*%1A8FQE<RD\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='D@86YD($5Q=6EP;65N
M="!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-U;6UA<GD@;V8@<')O<&5R='D@86YD(&5Q=6EP;65N=#PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'1A8FQE('-T>6QE/3-$
M)W=I9'1H.B`Q-38W<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=V]R9"US<&%C
M:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9&]W<SH@
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M+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="]N
M;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@8V5N=&5R.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,S$M1&5C
M/&)R("\^,C`Q-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B!B;VQD
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B!B;VQD(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
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M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C,Q+41E8SQB<B`O
M/C(P,3,\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D
M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@
M8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('=I9'1H.B`Q,#`S<'@[('1E>'0M86QI9VXZ(&QE9G0[(&9O
M;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY,86(@97%U:7!M96YT(&%N9"!I;G-T<G5M96YT
M<SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,39P>#L@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!W:61T:#H@,3<S<'@[('1E>'0M86QI9VXZ(&-E;G1E<CL@
M9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/C0M-CPO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!W:61T:#H@,39P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@
M9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q
M-#%P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXQ
M.30L,30S/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q
M-7!X.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI
M9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y
M;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ
M(#$N-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^0V]M<'5T97(@97%U:7!M96YT
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
M="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C0M-CPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
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M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
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M9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
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M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L-"B!B
M;W)D97(M8F]T=&]M+7-T>6QE.B!S;VQI9#L-"B!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R
M9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z
M('-O;&ED.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-C8L-#DS/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
M=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L:6=N.B!B;W1T
M;VT[(&)A8VMG<F]U;F0M8V]L;W(Z("-C8V5E9F8[)SX\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@
M<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N
M="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
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M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^,C,Y+#8Y.#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ92UA
M9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@
M,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
M="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/C(V,"PV,S8\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE+6%D
M:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E
M<G1I8V%L+6%L:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E
M.R<^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`Q,'!T.R!F;VYT+7-I
M>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M
M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-I>F4M861J=7-T.B!N
M;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R
M;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI
M9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R
M+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O
M;&ED.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO
M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#(S.2PV.3@\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M;B<L('1I;65S+"!S97)I9CLG/B@R-C`L-C,V/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BD\+V9O;G0^/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O
M;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M
M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`T<'0[(&9O;G0M<VEZ92UA
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M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@-'!T.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[(&)O<F1E<BUB;W1T;VTM<W1Y
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M;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`T<'0[
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M9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D
M:6YG+6)O='1O;3H@-'!T.PT*(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ#0H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G
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M;F<M8F]T=&]M.B`T<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\+W1R/CPO=&%B;&4^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG
M/D1E9FEN:71E($QI9F4@26YT86YG:6)L92!!<W-E=',@*%1A8FQE<RD\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^
M1&5F:6YI=&4@3&EF92!);G1A;F=I8FQE($%S<V5T<R!;06)S=')A8W1=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D
M=6QE(&]F(&9I;FET92UL:79E9"!I;G1A;F=I8FQE(&%S<V5T<RP@9G5T=7)E
M(&%M;W)T:7IA=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI
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M<SH@,3L@=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M
M=VED=&@Z(#!P>#L@9F]N="US=')E=&-H.B!N;W)M86P[(&UA<F=I;CH@,'!X
M.R!T97AT+6%L:6=N.B!J=7-T:69Y.R!T97AT+6EN9&5N=#H@-#!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^/&)R(&-L87-S/3-$87!P;&4M:6YT97)C:&%N9V4M
M;F5W;&EN92`O/CPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q
M-#(R+C<R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@
M,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=V]R9"US<&%C:6YG.B`P
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M=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@
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M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4]
M,T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@
M(V-C965F9CLG/CQT9"!S='EL93TS1"=W:61T:#H@,3(T,"XW,S@V-#<T-C`Y
M-'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N="!S='EL93TS
M1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/C(P,34\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T
M-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T
M:#H@,3(W+C(W,C<R-SDV-C,P.7!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#EP=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^,C`Q-CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.PT*(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,30L
M,S@Q/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V
M97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E
M969F.R<^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG+6QE9G0Z(#EP=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^,C`Q.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS
M1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D
M:6YG+6)O='1O;3H@,2XU<'0[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M
M;&5F=#H@,'!X.R!P861D:6YG+7)I9VAT.B`P<'@[('1E>'0M:6YD96YT.B`P
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M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q
M-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L
M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
M+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT
M.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
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M<V5R:68[)SXQ,30L-3`Y/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I
M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
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M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O='1O;3H@,2XU
M<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P
M.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L
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M,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X
M=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B#0I#
M;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?-#-F
M85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,C8N:'1M;`T*
M0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*
M0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*
M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O
M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M
M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N
M:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\
M+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I
M9#TS1$E$,$4R1CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E<R!087EA
M8FQE("T@4F5L871E9"!087)T>2`H5&%B;&5S*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E<R!087EA8FQE
M("T@4F5L871E9"!087)T>2!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@;F]T97,@<&%Y
M86)L92!A;F0@<F5L871E9"!P87)T:65S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$U-C=P>#L@=&5X
M="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E<BUS
M<&%C:6YG.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R+6-O
M;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M<W1R
M;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<]
M,T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="]N;W)M
M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUB
M;W1T;VTZ(#$N-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
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M(&-O;'-P86X],T0V/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^1&5C96UB97(@,S$L/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUB;W1T
M;VTZ(#$N-7!T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
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M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N
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M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG+6)O
M='1O;3H@,2XU<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG+6)O='1O;3H@
M,2XU<'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G9F]N=#H@8F]L9"`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!C96YT97([(&)O
M<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H
M.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<VEZ
M92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<@8V]L<W!A
M;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXR,#$S/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0Z(&)O;&0@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y
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M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W1E>'0M86QI9VXZ(&-E;G1E<CL@9F]N="US:7IE.B`Q,'!T.R<@8V]L<W!A
M;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@
M<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[('=I9'1H.B`Q,3DQ<'@[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SY.;VXM26YT97)E<W0@0F5A<FEN9R!,
M;V%N(%!A>6%B;&4@4W5N<FES92!&:6YA;F-I86P@1W)O=7`@26YC+CPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@,39P>#L@9F]N="US
M:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M9CLG/C,X+#(S-3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T
M:#H@,39P>#L@=&5X="UA;&EG;CH@;&5F=#L@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W:61T:#H@
M,35P>#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N
M;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
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M93LG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/C$X+#DV,SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[(&9O;G0M<VEZ92UA9&IU
M<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H-"B`Q
M,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.PT*
M('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@<FEG
M:'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+#LG/C(Q+#4U-SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ
M(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^-B4@4')O;6ES<V]R>2!.;W1E('!A>6%B;&4@=&\@3DQ"1$E4(#(P,3`@
M16YT97)P<FES97,L($Q,0SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&9O;G0M
M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N=#H@,3!P="]N;W)M86P@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@<FEG:'0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO
M;F4[(&9O;G0M<W1R971C:#H@;F]R;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXM
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE
M9G0[(&9O;G0M<VEZ92UA9&IU<W0Z(&YO;F4[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R
M/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O
M=6YD+6-O;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-24@3F]T92!087EA8FQE
M("T@4W5N92!/;'-E;B!(;VQD:6YG($%P4SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
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M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!F
M;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE
M<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^-3(Q+#,Y,#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T
M+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F
M;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
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M=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E
M=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!B;W)D
M97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@
M,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-I>F4M
M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0Z
M(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C
M:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM
M<W1Y;&4Z('-O;&ED.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,#PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O
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M<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[(&)O<F1E<BUB;W1T
M;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@
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M97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@
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M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US
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M=&%L($YO=&5S(%!A>6%B;&4-"B`F(S@R,3$[(%)E;&%T960@4&%R='D\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE+6%D:G5S=#H@
M;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!F;VYT+7-I>F4M861J=7-T.B!N
M;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M-S(X+#`P,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA
M;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!L969T.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O
M='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED
M.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M*#DY+#DU,3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO
M<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
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M;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N
M="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R!B;W)D97(M8F]T=&]M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW
M:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT
M+7-I>F4M861J=7-T.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[('1E>'0M86QI9VXZ(')I9VAT.R!B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-I>F4M861J=7-T.B!N;VYE.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#<R."PP
M,#$\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N=#H@,3!P="]N;W)M86P@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-I>F4M861J=7-T
M.B!N;VYE.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^*3PO9F]N=#X\+W1D/CPO='(^/'1R('-T>6QE/3-$)W9E<G1I8V%L+6%L
M:6=N.B!B;W1T;VT[(&)A8VMG<F]U;F0M8V]L;W(Z('=H:71E.R<^/'1D('-T
M>6QE/3-$)V9O;G0Z(#$P<'0O;F]R;6%L("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M
M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H
M.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/DYO=&4@4&%Y86)L97,@)B,X
M,C$Q.R!296QA=&5D(%!A<G1Y($QO;F<@5&5R;3PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@
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M<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q
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M86QI9VXZ(&QE9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE
M+6%D:G5S=#H@;F]N93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S
M='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT
M.B`Q,'!T+VYO<FUA;"`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R
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M('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US:7IE+6%D:G5S=#H@;F]N
M93L@9F]N="US=')E=&-H.B!N;W)M86P[)SX\9F]N="!S='EL93TS1"=F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C
M,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(&UA
M='5R:71I97,@;V8@;&]N9R!T97)M(&1E8G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N
M="US:7IE.B`Q,'!T.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN
M9SH@;F]R;6%L.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O
M.R!T97AT+71R86YS9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@
M=VED;W=S.B`Q.R!W;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T
M<F]K92UW:61T:#H@,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN
M.B`P<'@[('1E>'0M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I
M;CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^/&)R(&-L87-S/3-$87!P;&4M:6YT97)C
M:&%N9V4M;F5W;&EN92`O/CPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)W=I
M9'1H.B`Q-#(R+C<R<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN
M9&5N=#H@,'!X.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=V]R9"US<&%C
M:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9&]W<SH@
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M/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T.R!P861D:6YG+6)O
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M,T0G=VED=&@Z(#$R-#`N-S,X-C0W-#8P.31P>#L@9F]N="US='EL93H@;F]R
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M/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T
M-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
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M9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S+C8S-C,V,S`R.30X<'@[(&9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL
M969T.B`Y<'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT
M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Y<'0[)SX\9F]N
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.PT*(&QI
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT
M<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD
M+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R!P861D:6YG
M+6QE9G0Z(#EP=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q.#PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
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M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!P861D:6YG+6QE9G0Z(#!P>#L@
M=&5X="UA;&EG;CH@;&5F=#L@=&5X="UI;F1E;G0Z(#!P>#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^5&AE<F5A9G1E<CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
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M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
M<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R
M;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z
M(#$P<'0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D
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M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R.B!B
M;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB;W1T
M;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^
M/"]T9#X\+W1R/CPO=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y
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M("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS
M1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E
M>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@
M5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@
M("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%2T@^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^26YC;VUE(%1A>&5S("A486)L97,I/&)R/CPO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M
M92!487AE<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E-U;6UA<GD@;V8@9&5F97)R960@=&%X(&%S<V5T
M("AL:6%B:6QI=&EE<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQP('-T>6QE/3-$)V-O;&]R.B`C,#`P,#`P.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@9F]N="US:7IE.B`Q,'!T
M.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F
M;VYT+7=E:6=H=#H@;F]R;6%L.R!L971T97(M<W!A8VEN9SH@;F]R;6%L.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!O<G!H86YS.B!A=71O.R!T97AT+71R86YS
M9F]R;3H@;F]N93L@=VAI=&4M<W!A8V4Z(&YO<FUA;#L@=VED;W=S.B`Q.R!W
M;W)D+7-P86-I;F<Z(#!P>#L@+7=E8FMI="UT97AT+7-T<F]K92UW:61T:#H@
M,'!X.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@;6%R9VEN.B`P<'@[('1E>'0M
M86QI9VXZ(&IU<W1I9GD[('1E>'0M:6YD96YT.B`P+C5I;CLG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^/&)R(&-L87-S/3-$87!P;&4M:6YT97)C:&%N9V4M;F5W;&EN
M92`O/CPO9F]N=#X\+W`^/'1A8FQE('-T>6QE/3-$)W=I9'1H.B`Q-#(R+C<R
M<'@[('1E>'0M=')A;G-F;W)M.B!N;VYE.R!T97AT+6EN9&5N=#H@,'!X.R!L
M971T97(M<W!A8VEN9SH@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=V]R9"US<&%C:6YG.B`P<'@[(&)O
M<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I9&]W<SH@,3L@+7=E8FMI="UT
M97AT+7-T<F]K92UW:61T:#H@,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP
M861D:6YG/3-$,#X\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O
M;3LG/CQT9"!S='EL93TS1"=F;VYT+7-I>F4Z(#$P<'0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E
M:6=H=#H@8F]L9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@
M9F]N="UW96EG:'0Z(&)O;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q,SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O
M;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC
M86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG
M/CQT9"!S='EL93TS1"=W:61T:#H@,3`X,2XX,3@Q,34R,S0S.'!X.R!F;VYT
M+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E
M:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE
M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
M;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^17AC97-S(&]F(%1A>"!O=F5R(&)O;VL@
M9&5P<F5C:6%T:6]N($9I>&5D(&%S<V5T<SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,30N-30U-#4T,#(U,C8X-G!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R
M-C@V<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M
M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L
M.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M
M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT
M+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)W=I9'1H.B`Q,C@N,3@Q.#`X-#<Q-CAP>#L@9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(')I9VAT
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXQ,BPW,3$\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G=VED=&@Z(#$T+C4T-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@
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M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV,S8S-C,P,CDT.'!X.R!F
M;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT
M+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@
M;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=W:61T:#H@,3(W+C(W,C<R-SDV-C,P.7!X.R!F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
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M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y
M;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@
M<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US
M='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG
M:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@
M,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[
M)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,BPS.#`L,3`V/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H
M=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^,2PV-#(L-3DX/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
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M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*#(L-#0T+#@U
M.#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXI/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM
M8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R
M9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^*#$L.#0T+#(P-#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D
M:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#L@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!P861D:6YG+6QE
M9G0Z(#(P<'0[)SX\9F]N=`T*('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
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M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^+3PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXD
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M+3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU
M<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L
M:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\+W1R/CPO=&%B;&4^/&1I=CXF(S$V,#L\+V1I=CX\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E)E8V]N8VEL:6%T
M:6]N(&]F(&EN8V]M92!T87@@97AP96YS92!A="!T:&4@9F5D97)A;"!S=&%T
M=71O<GD@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'`@
M<W1Y;&4],T0G8V]L;W(Z(",P,#`P,#`[(&9O;G0M9F%M:6QY.B`G=&EM97,@
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M<W!A8VEN9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UA;&EG
M;CH@:G5S=&EF>3L@=&5X="UI;F1E;G0Z(#`N-6EN.R<^/&9O;G0@<W1Y;&4]
M,T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R
M:68[)SX\8G(@8VQA<W,],T1A<'!L92UI;G1E<F-H86YG92UN97=L:6YE("\^
M/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G=VED=&@Z(#$T,C(N-S)P>#L@
M=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M:6YD96YT.B`P<'@[(&QE='1E
M<BUS<&%C:6YG.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R!W;W)D+7-P86-I;F<Z(#!P>#L@8F]R9&5R
M+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S.B`Q.R`M=V5B:VET+71E>'0M
M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I
M;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R<^
M/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT
M.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4]
M,T0G9F]N="UW96EG:'0Z(&)O;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N
M="UV87)I86YT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!C96YT97([(&)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M
M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L
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M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US
M:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@
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M=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="UW
M96EG:'0Z(&)O;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q,#@Q+C@Q.#$Q-3(S-#,X<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SY#;VUP=71E9"!487@@870@17AP96-T960@4W1A
M='5T;W)Y(%)A=&4\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T
M+C4T-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W
M:61T:#H@,3(X+C$X,3@P.#0W,38X<'@[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^*#@V-BPT-C,\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z
M(#$T+C4T-30U-#`R-3(V.#9P>#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
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M/BD\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T-30U-#`R
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I
M9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H
M=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^,C4U+#,U-CPO9F]N=#X\+W1D/CQT9"!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@
M9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O
M;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I
M9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^,3DY+#(Y,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@
M<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC
M;VQO<CH@(V-C965F9CLG/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M
M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^3F]N+41E9'5C
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M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^."PS.3`\+V9O;G0^/"]T9#X\=&0@
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S
M='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O
M;&]R.B!W:&ET93LG/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
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M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T=&]M
M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[(&9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^-#,V+#8S,3PO9F]N=#X\+W1D/CQT
M9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z
M(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N
M;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[
M(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M=&]M.B`Q+C5P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B
M;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL
M93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
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M86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXR-S`L
M,C`Y/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q
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M9G0[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@<&%D9&EN9RUL969T.B`Q,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP-"B!S97)I9CLG/DEN8V]M92!487@@17AP96YS93PO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA
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M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT
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M9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M<&]N96YT<R!O9B!I;F-O;64@=&%X(&5X<&5N<V4@*&)E;F5F
M:70I(&9R;VT@8V]N=&EN=6EN9R!O<&5R871I;VYS/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M(&9O;G0M<VEZ93H@,3!P=#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A
M<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z(&YO<FUA;#L@;&5T=&5R+7-P
M86-I;F<Z(&YO<FUA;#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@;W)P:&%N<SH@
M875T;SL@=&5X="UA;&EG;CH@<W1A<G0[('1E>'0M=')A;G-F;W)M.B!N;VYE
M.R!W:&ET92US<&%C93H@;F]R;6%L.R!W:61O=W,Z(#$[('=O<F0M<W!A8VEN
M9SH@,'!X.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[(&9O;G0M
M<W1R971C:#H@;F]R;6%L.R!M87)G:6XZ(#!P>#L@=&5X="UI;F1E;G0Z(#`N
M-6EN.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\8G(@8VQA<W,],T1A<'!L92UI;G1E
M<F-H86YG92UN97=L:6YE("\^/"]F;VYT/CPO<#X\=&%B;&4@<W1Y;&4],T0G
M=VED=&@Z(#$T,C(N-S)P>#L@=&5X="UT<F%N<V9O<FTZ(&YO;F4[('1E>'0M
M:6YD96YT.B`P<'@[(&QE='1E<BUS<&%C:6YG.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!W;W)D+7-P
M86-I;F<Z(#!P>#L@8F]R9&5R+6-O;&QA<'-E.B!C;VQL87!S93L@=VED;W=S
M.B`Q.R`M=V5B:VET+71E>'0M<W1R;VME+7=I9'1H.B`P<'@[)R!C96QL<W!A
M8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P/CQT<B!S='EL93TS1"=V97)T:6-A
M;"UA;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)V9O;G0M=V5I9VAT.B!B
M;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE
M+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA
M;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^0W5R<F5N="!4
M87@@17AP96YS93PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F;VYT+7=E:6=H
M=#H@8F]L9#L@9F]N="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO
M<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P=#L@
M;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N97<@
M<F]M86XG+"!T:6UE<RP@<V5R:68[('!A9&1I;F<M8F]T=&]M.B`Q+C5P=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O
M;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N
M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
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M/CPO=&0^/'1D('-T>6QE/3-$)W!A9&1I;F<M8F]T=&]M.B`Q+C5P=#L@9F]N
M="UW96EG:'0Z(&)O;&0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z
M(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M9#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^,C`Q,SPO9F]N=#X\
M+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O;3H@,2XU<'0[(&9O;G0M
M=V5I9VAT.B!B;VQD.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM
M86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C965F9CLG/CQT
M9"!S='EL93TS1"=W:61T:#H@,3`V."XT.30R-C(V.34S,7!X.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@
M<&%D9&EN9RUL969T.B`Q,'!T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI
M;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SY$86YI<V@@
M26YC;VUE(%1A>#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N
M-30U-#4T,#(U,C8X-G!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)W=I9'1H.B`Q-"XU-#4T-30P,C4R-C@V<'@[(&9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!L969T.R<^
M/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG
M+"!T:6UE<RP@<V5R:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I
M9'1H.B`Q,C@N,3@Q.#`X-#<Q-CAP>#L@9F]N="US='EL93H@;F]R;6%L.R!F
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M*3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,30N-30U-#4T,#(U
M,C8X-G!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)W=I9'1H.B`Q,RXV,S8S-C,P,CDT.'!X.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=W:61T:#H@,3(W+C(W
M,C<R-SDV-C,P.7!X.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N
M=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z
M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BT\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G=VED=&@Z(#$S+C8S-C,V,S`R.30X<'@[
M(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M;65S+"!S97)I9CLG/D1E9F5R<F5D($EN8V]M92!487@@17AP96YS92`H0F5N
M969I="D\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US:7IE.B`Q,'!T
M.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M
M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y
M;&4],T0G9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!L969T.R<^/&9O
M;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T
M:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G
M9F]N="US:7IE.B`Q,'!T.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T
M>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M
M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$
M)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
M.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<VEZ93H@
M,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M<VEZ93H@,3!P=#L@=&5X="UA;&EG;CH@<FEG:'0[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=F
M;VYT+7-I>F4Z(#$P<'0[('1E>'0M86QI9VXZ(&QE9G0[)SX\9F]N="!S='EL
M93TS1"=F;VYT+69A;6EL>3H-"B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T<CX\='(@<W1Y;&4],T0G
M=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C:V=R;W5N9"UC;VQO<CH@(V-C
M965F9CLG/CQT9"!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#L@<&%D9&EN9RUL969T.B`Q,'!T
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M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@8F%C
M:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G9F]N="US='EL
M93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW96EG:'0Z
M(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ93H@,3!P
M=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[('1E>'0M86QI9VXZ(&QE9G0[('!A
M9&1I;F<M;&5F=#H@,3!P=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^17AC97-S(&]F
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M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X
M="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M-C<L-#@X/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO
M<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M
M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI
M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T
M.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF
M;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@
M=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
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M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
M.B!L969T.R!P861D:6YG+6QE9G0Z(#$P<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/DYE="!/<&5R871I;F<@3&]S<R!#87)R>69O<G=A<F1S/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT
M.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@
M;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[
M(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF
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M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
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M;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
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M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G9F]N="US='EL93H@;F]R
M;6%L.PT*(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT
M('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM
M97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N.B!R
M:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
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M.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I
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M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
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M="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL
M>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG
M;CH@<FEG:'0[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/C0S-BPV,S$\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G<&%D9&EN9RUB;W1T;VTZ(#$N-7!T.R!F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG
M/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P861D:6YG
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M(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L
M.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I
M9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV
M87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R
M971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N
M;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L
M('-E<FEF.R!T97AT+6%L:6=N.B!R:6=H=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M,C<P+#(P.3PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=P861D:6YG+6)O='1O
M;3H@,2XU<'0[(&9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N
M;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R
M;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T
M97AT+6%L:6=N.B!L969T.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ
M("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O
M;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA;&EG;CH@8F]T
M=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C8V-E969F.R<^/'1D('-T>6QE/3-$
M)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O
M;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT
M+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!T97AT+6%L:6=N
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M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R!P
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M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
M;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S
M+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M+6-O;&]R
M.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O<F1E<BUB
M;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M
M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T
M<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@
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M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@=&5X="UA
M;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/'1D('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I
M86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C
M:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M
M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R!P861D:6YG+6)O='1O;3H@,2XU<'0[)SX\9F]N="!S='EL93TS1"=F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG
M/B8C,38P.SPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
M:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L
M('1I;65S+"!S97)I9CL@=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE
M/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E
M<FEF.R<^)#PO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=B;W)D97(M8F]T=&]M
M+6-O;&]R.B!B;&%C:SL@8F]R9&5R+6)O='1O;2UW:61T:#H@,2XU<'0[(&)O
M<F1E<BUB;W1T;VTM<W1Y;&4Z('-O;&ED.R!F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F
M;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CL@
M=&5X="UA;&EG;CH@;&5F=#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY
M.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F
M;VYT/CPO=&0^/"]T<CX\+W1A8FQE/CQD:78^)B,Q-C`[/"]D:78^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,6$Y-#$S8U\U
M-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E
M.#)B+U=O<FMS:&5E=',O4VAE970R."YH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14U%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/DQO<W,@4&5R(%-H87)E("A486)L97,I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T
M/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/DQO<W,@4&5R(%-H87)E(%M!8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4V-H961U;&4@;V8@8V]M<'5T:6YG
M(&QO<W,@<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<"!S='EL93TS1"=C;VQO<CH@(S`P,#`P,#L@9F]N="UF86UI;'DZ("=T
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M=V]R9"US<&%C:6YG.B`P<'@[("UW96)K:70M=&5X="US=')O:V4M=VED=&@Z
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M9"US<&%C:6YG.B`P<'@[(&)O<F1E<BUC;VQL87!S93H@8V]L;&%P<V4[('=I
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M,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K
M.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US
M='EL93H@<V]L:60[('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z
M(#$U+C,S,S,S,S`Q-30T,3EP>#LG(&-O;'-P86X],T0V/CQF;VYT('-T>6QE
M/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[
M(&9O;G0M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F
M;VYT+7-I>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^1&5C
M96UB97(@,S$L/"]B/CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=L:6YE+6AE
M:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N
M="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF
M(S$V,#L\+V9O;G0^/"]T9#X\+W1R/CQT<B!S='EL93TS1"=V97)T:6-A;"UA
M;&EG;CH@8F]T=&]M.R<^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS
M,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@
M)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/B8C,38P.SPO9F]N
M=#X\+W1D/CQT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,34N,S,S,S,S,#$U
M-#0Q.7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE<R!N
M97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G8F]R9&5R+6)O='1O;2UC;VQO<CH@8FQA8VL[(&)O<F1E
M<BUB;W1T;VTM=VED=&@Z(#$N-7!T.R!B;W)D97(M8F]T=&]M+7-T>6QE.B!S
M;VQI9#L@=&5X="UA;&EG;CH@8V5N=&5R.R!L:6YE+6AE:6=H=#H@,34N,S,S
M,S,S,#$U-#0Q.7!X.R<@8V]L<W!A;CTS1#(^/&9O;G0@<W1Y;&4],T0G9F]N
M="US='EL93H@;F]R;6%L.R!F;VYT+79A<FEA;G0Z(&YO<FUA;#L@9F]N="UW
M96EG:'0Z(&YO<FUA;#L@9F]N="US=')E=&-H.B!N;W)M86P[(&9O;G0M<VEZ
M93H@,3!P=#L@;&EN92UH96EG:'0Z(&YO<FUA;#L@9F]N="UF86UI;'DZ("=T
M:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SX\8CXR,#$T/"]B/CPO
M9F]N=#X\+W1D/CQT9"!S='EL93TS1"=L:6YE+6AE:6=H=#H@,34N,S,S,S,S
M,#$U-#0Q.7!X.R<^/&9O;G0@<W1Y;&4],T0G9F]N="UF86UI;'DZ("=T:6UE
M<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[)SXF(S$V,#L\+V9O;G0^/"]T
M9#X\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP
M>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O
M;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z(&)L86-K.R!B;W)D97(M8F]T
M=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O='1O;2US='EL93H@<V]L:60[
M('1E>'0M86QI9VXZ(&-E;G1E<CL@;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q
M-30T,3EP>#LG(&-O;'-P86X],T0R/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y
M;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT
M.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P
M<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^/&(^,C`Q,SPO8CX\+V9O;G0^
M/"]T9#X\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q-30T
M,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@;F5W
M(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^/"]T
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M970@*$QO<W,I/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q-"XU
M-#4T-30P,C4R-C@V<'@[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y
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M,#,R,C-P>#L@=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS
M,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N
M;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R
M;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L
M:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R
M;VUA;B<L('1I;65S+"!S97)I9CLG/B@R+#,W,"PX.#,\+V9O;G0^/"]T9#X\
M=&0@<W1Y;&4],T0G=VED=&@Z(#$T+C4T-30U-#`R-3(V.#9P>#L@;&EN92UH
M96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^*3PO9F]N=#X\+W1D
M/CQT9"!S='EL93TS1"=W:61T:#H@,3,N-C,V,S8S,#(Y-#AP>#L@;&EN92UH
M96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^
M)B,Q-C`[/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV,S8S
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M:68[)SXD/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,3,N-C,V
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M=&0^/'1D('-T>6QE/3-$)W=I9'1H.B`Q,RXV,S8S-C,P,CDT.'!X.R!L:6YE
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M96EG:'0Z(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O
M;G0M<W1Y;&4Z(&YO<FUA;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M
M=V5I9VAT.B!N;W)M86P[(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I
M>F4Z(#$P<'0[(&QI;F4M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G
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M(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
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M,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G
M=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT
M/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T
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M,T0G=&5X="UA;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P
M,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE
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M1"=V97)T:6-A;"UA;&EG;CH@8F]T=&]M.R!B86-K9W)O=6YD+6-O;&]R.B`C
M8V-E969F.R<^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P
M,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[
M(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F
M;VYT+7-T<F5T8V@Z(&YO<FUA;#L-"B!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^169F96-T(&]F(&1I;'5T:79E('-E8W5R:71I
M97,L('-T;V-K(&]P=&EO;G,@86YD('=A<G)A;G1S/"]F;VYT/CPO=&0^/'1D
M('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\
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M(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL
M93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L
M.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@
M9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A
M;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BT\+V9O
M;G0^/"]T9#X\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S,S`Q
M-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM97,@
M;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO=&0^
M/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[
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M:'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S
M='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R
M;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA
M;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT
M+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/BT\
M+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z(#$U+C,S,S,S
M,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M:6QY.B`G=&EM
M97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[/"]F;VYT/CPO
M=&0^/"]T<CX\='(@<W1Y;&4],T0G=F5R=&EC86PM86QI9VXZ(&)O='1O;3L@
M8F%C:V=R;W5N9"UC;VQO<CH@=VAI=&4[)SX\=&0@<W1Y;&4],T0G<&%D9&EN
M9RUL969T.B`Q,'!T.R!T97AT+6EN9&5N=#H@+3$P<'0[(&QI;F4M:&5I9VAT
M.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N="!S='EL93TS1"=F;VYT+7-T
M>6QE.B!N;W)M86P[(&9O;G0M=F%R:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H
M=#H@;F]R;6%L.R!F;VYT+7-T<F5T8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q
M,'!T.R!L:6YE+6AE:6=H=#H@;F]R;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S
M(&YE=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/E=E:6=H=&5D(&%V97)A9V4@
M;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@86YD('!O=&5N=&EA;"!D:6QU=&EV
M93PO9F]N=#X\9F]N="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE
M=R!R;VUA;B<L('1I;65S+"!S97)I9CLG/CQB<B`O/CQF;VYT('-T>6QE/3-$
M)V9O;G0M<VEZ93H@,3!P=#LG/F-O;6UO;B!S:&%R97,@;W5T<W1A;F1I;F<@
M=7-E9"!I;B!D:6QU=&EV92!E87)N:6YG<R!P97(@<VAA<F4\+V9O;G0^/"]F
M;VYT/CPO=&0^/'1D('-T>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P
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M;&EG;CH@<FEG:'0[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[
M)SX\9F]N="!S='EL93TS1"=F;VYT+7-T>6QE.B!N;W)M86P[(&9O;G0M=F%R
M:6%N=#H@;F]R;6%L.R!F;VYT+7=E:6=H=#H@;F]R;6%L.R!F;VYT+7-T<F5T
M8V@Z(&YO<FUA;#L@9F]N="US:7IE.B`Q,'!T.R!L:6YE+6AE:6=H=#H@;F]R
M;6%L.R!F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I;65S+"!S
M97)I9CLG/C<L-3`P+#$T,CPO9F]N=#X\+W1D/CQT9"!S='EL93TS1"=L:6YE
M+6AE:6=H=#H@,34N,S,S,S,S,#$U-#0Q.7!X.R<^/&9O;G0@<W1Y;&4],T0G
M9F]N="UF86UI;'DZ("=T:6UE<R!N97<@<F]M86XG+"!T:6UE<RP@<V5R:68[
M)SXF(S$V,#L\+V9O;G0^/"]T9#X\=&0@<W1Y;&4],T0G;&EN92UH96EG:'0Z
M(#$U+C,S,S,S,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M9F%M
M:6QY.B`G=&EM97,@;F5W(')O;6%N)RP@=&EM97,L('-E<FEF.R<^)B,Q-C`[
M/"]F;VYT/CPO=&0^/'1D('-T>6QE/3-$)V)O<F1E<BUB;W1T;VTM8V]L;W(Z
M(&)L86-K.R!B;W)D97(M8F]T=&]M+7=I9'1H.B`Q+C5P=#L@8F]R9&5R+6)O
M='1O;2US='EL93H@<V]L:60[(&QI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T
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M,S`Q-30T,3EP>#LG/CQF;VYT('-T>6QE/3-$)V9O;G0M<W1Y;&4Z(&YO<FUA
M;#L@9F]N="UV87)I86YT.B!N;W)M86P[(&9O;G0M=V5I9VAT.B!N;W)M86P[
M(&9O;G0M<W1R971C:#H@;F]R;6%L.R!F;VYT+7-I>F4Z(#$P<'0[(&QI;F4M
M:&5I9VAT.B!N;W)M86P[(&9O;G0M9F%M:6QY.B`G=&EM97,@;F5W(')O;6%N
M)RP@=&EM97,L('-E<FEF.R<^,RPU-3<L.#DS/"]F;VYT/CPO=&0^/'1D('-T
M>6QE/3-$)VQI;F4M:&5I9VAT.B`Q-2XS,S,S,S,P,34T-#$Y<'@[)SX\9F]N
M="!S='EL93TS1"=F;VYT+69A;6EL>3H@)W1I;65S(&YE=R!R;VUA;B<L('1I
M;65S+"!S97)I9CLG/B8C,38P.SPO9F]N=#X\+W1D/CPO='(^/"]T86)L93X\
M9&EV/B8C,38P.SPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E
M.#)B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U
M9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,CDN
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5714)'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-U
M;6UA<GD@;V8@4VEG;FEF:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H1&5T
M86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XQ,B!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D9E8BX@,3(L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E-U;6UA<GD@3V8@4VEG;FEF
M:6-A;G0@06-C;W5N=&EN9R!0;VQI8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=64@861D960@
M=&%X('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(U+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5F%L=64@861D960@=&%X('!A:60@=&\@1&%N:7-H(&%N9"!%
M52!V96YD;W)S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-2XP
M,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-A;&4@;V8@<W5B<VED:6%R>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!E>&-H86YG92!A9W)E96UE
M;G0@86-Q=6ES:71I;VX@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,3`P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC:&%N9V4@86=R965M96YT
M('-H87)E<R!I<W-U960@=&\@<&%R96YT(&-O;7!A;GD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P
M87(@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!R97-E<G9E9"!F;W(@:7-S=6%N
M8V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$X-2PP-3,\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A
M<V@@:6YS=7)E9"!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BPU,#@L-S4Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY3=6UM87)Y($]F
M(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%1E>'1U86PI/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E
M<R!P<FEO<B!T;R!S:&%R92!E>&-H86YG92!A9W)E96UE;G0\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC:&%N
M9V4@86=R965M96YT(&%C<75I<VET:6]N('!E<F-E;G1A9V4\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&5X8VAA;F=E
M(&%G<F5E;65N="!S:&%R97,@:&5L9"!B>2!C;VYS96YT:6YG('-H87)E:&]L
M9&5R<R!O9B!C;VUP86YY/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ+C0Y.#@T,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4VAA<F4@97AC:&%N9V4@86=R965M96YT('-H87)E<R!I
M<W-U960@=&\@<&%R96YT(&-O;7!A;GD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC:&%N9V4@86=R965M96YT
M(&YU;6)E<B!O9B!S:&%R92!C86YC96QL871I;VX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C0L-#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!P87(@
M=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP,#`Q
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VUM;VX@<VAA<F5S(&ES<W5E9"!F;W(@;&5G86P@86YD(&-O;G-U;'1I
M;F<@<V5R=FEC97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-#0P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0V]M;6]N(%-T;V-K(')E<V5R=F5D(&9O<B!I<W-U86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@U+#`U,SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S
M(&]F('!A<F5N="!C;VUM;VX@<W1O8VL@;W5T<W1A;F1I;F<\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/CDL-3,S+#(Y,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4L,S$X
M+#$U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N(%-T;V-K(%M-96UB97)=('P@4&%R96YT($-O;7!A;GD@
M6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY3=6UM87)Y($]F(%-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I
M97,@*%1E>'1U86PI/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E-H87)E<R!O9B!P87)E;G0@8V]M;6]N('-T;V-K(&]U='-T
M86YD:6YG/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX+#`T,"PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L
M93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q
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M#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y
M<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I
M<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O
M($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*
M("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%
M3D5!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L
M<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U
M:7!M96YT("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO;G1H<R!%
M;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT(&%N
M9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%!R;W!E<G1Y(&%N9"!%<75I
M<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B`R,SDL-CDX
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`R-C`L-C,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,97-S.B!!8V-U;75L871E9"!$97!R96-I871I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(S.2PV.3@I/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C8P+#8S-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/DYE="!0<F]P97)T>2!A;F0@17%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQA8B!E
M<75I<&UE;G0@86YD(&EN<W1R=6UE;G1S(%M-96UB97)=/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4')O<&5R='DL(%!L86YT
M(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R;W-S(%!R;W!E<G1Y(&%N9"!%
M<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W."PU
M-#<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.30L,30S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y,86(@97%U:7!M96YT(&%N9"!I;G-T<G5M96YT<R!;365M
M8F5R72!\($UI;FEM=6T@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY0<F]P97)T>2P@4&QA;G0@86YD($5Q=6EP
M;65N="!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^17-T:6UA=&5D('5S969U;"!L:69E("AY96%R<RD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C0@>65A<G,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQA8B!E
M<75I<&UE;G0@86YD(&EN<W1R=6UE;G1S(%M-96UB97)=('P@36%X:6UU;2!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R
M;VYG/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M<W1I;6%T960@=7-E9G5L(&QI9F4@*'EE87)S*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@97%U:7!M96YT(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O
M;F<^4')O<&5R='DL(%!L86YT(&%N9"!%<75I<&UE;G0@6TQI;F4@271E;7-=
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=R
M;W-S(%!R;W!E<G1Y(&%N9"!%<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B`V,2PQ-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#8V+#0Y,SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M<'5T97(@97%U:7!M
M96YT(%M-96UB97)=('P@36EN:6UU;2!;365M8F5R73PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E!R;W!E<G1Y+"!0;&%N="!A
M;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I;6%T960@=7-E9G5L(&QI9F4@
M*'EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^-"!Y96%R
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^0V]M<'5T97(@97%U:7!M96YT(%M-96UB97)=('P@36%X:6UU;2!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/E!R;W!E<G1Y+"!0;&%N="!A;F0@17%U:7!M96YT(%M,:6YE($ET96US73PO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%<W1I
M;6%T960@=7-E9G5L(&QI9F4@*'EE87)S*3PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^-B!Y96%R<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM
M+2TM+3U?3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U
M8V5E.#)B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C
M7S4U9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T
M,S$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R
M:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S
M+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE
M<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA
M<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R
M8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\
M+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS
M1')E<&]R="!I9#TS1$E$,$5'2#X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY0
M<F]P97)T>2!A;F0@17%U:7!M96YT("A$971A:6QS(%1E>'1U86PI("A54T0@
M)"D\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY0<F]P97)T>2!A;F0@17%U:7!M96YT(%M!8G-T<F%C=%T\+W-T
M<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5P<F5C
M:6%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BPW,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
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M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%-DM!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY$969I;FET
M92!,:69E($EN=&%N9VEB;&4@07-S971S("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY$969I;FET92!,:69E($EN=&%N9VEB;&4@07-S971S(%M!
M8G-T<F%C=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q
M-"PS.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/C(P,38\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T
M+#,X,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`Q-SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30L
M,S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$X/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PS
M.#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/C(P,3D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T+#,X
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^5&AE<F5A9G1E<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3$T+#4P.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D9I;FET92U,:79E9"!);G1A;F=I8FQE($%S<V5T<RP@3F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$X-BPT,30\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#(S
M,2PV,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T
M86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T
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M;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT
M+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS
M8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J
M($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D
M/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)
M1#!%2$)!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@
M8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY$969I;FET92!,:69E
M($EN=&%N9VEB;&4@07-S971S("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY$969I;FET92!,:69E($EN=&%N9VEB;&4@07-S971S(%M!8G-T<F%C
M=%T\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1FEN:71E+4QI=F5D($EN=&%N9VEB;&4@07-S971S+"!.970\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,3@V+#0Q-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,C,Q+#8Q-3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO
M<G1I>F%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,30L,S@Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S."PR.3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%1#9!13X-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N
M9SY.;W1E<R!087EA8FQE("T@4F5L871E9"!087)T>2`H1&5T86EL<RD@*%53
M1"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;B!;
M3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^5&]T86P@3F]T97,@4&%Y86)L92`M(%)E;&%T960@4&%R='D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3DL.34Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`W,C@L
M,#`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,97-S($-U<G)E;G0@36%T=7)I=&EE<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;3XH.3DL.34Q*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6T^*#<R."PP,#$I/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F]T92!087EA8FQE
M<R`M(%)E;&%T960@4&%R='D@3&]N9R!497)M/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO;B!)
M;G1E<F5S="!"96%R:6YG($QO86X@4&%Y86)L92!3=6YR:7-E($9I;F%N8VEA
M;"!'<F]U<"!);F,@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N(%M,
M:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y4;W1A;"!.;W1E<R!087EA8FQE("T@4F5L871E9"!087)T>3PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S@L,C,U/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB
M<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y.;W1E(%!A>6%B;&4@34P@1W)O=7`@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y
M(%1R86YS86-T:6]N(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!.;W1E<R!087EA8FQE("T@
M4F5L871E9"!087)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3@L.38S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C$L-34W/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#XV)2!0<F]M:7-S;W)Y($YO=&4@<&%Y86)L92!T;R!.
M3$)$250@,C`Q,"!%;G1E<G!R:7-E<RP@3$Q#(%M-96UB97)=/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4F5L871E9"!087)T
M>2!4<F%N<V%C=&EO;B!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@3F]T97,@4&%Y86)L92`M
M(%)E;&%T960@4&%R='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C0R+#<U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^-24@3F]T92!087EA8FQE("T@4W5N92!/
M;'-E;B!(;VQD:6YG($%P4R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R='D@5')A;G-A8W1I
M;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L($YO=&5S(%!A>6%B;&4@+2!296QA=&5D(%!A
M<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XP/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-3(Q+#,Y,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M-24@3F]T92!087EA8FQE("T@4W5N92!/;'-E;B!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E;&%T960@4&%R
M='D@5')A;G-A8W1I;VX@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L($YO=&5S(%!A>6%B;&4@
M+2!296QA=&5D(%!A<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XD(#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#$X-2PP-30\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%-41!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#$^/'-T<F]N9SY.;W1E
M<R!087EA8FQE("T@4F5L871E9"!087)T>2`H1&5T86EL<R`Q*2`H55-$("0I
M/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^3F]T97,@4&%Y86)L92`M(%)E;&%T960@4&%R='D@6T%B
M<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#XR,#$T/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DY
M+#DU,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^,C`Q-3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB
M<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#XR,#$V/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/C(P,3<\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^,C`Q.#PO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F5U/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&AE<F5A9G1E<CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y.2PY-3$\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%-E!"33X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY.;W1E<R!087EA8FQE("T@4F5L871E9"!087)T>2`H
M1&5T86EL<R!497AT=6%L*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,3(@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^
M,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@
M8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$-#XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Y/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@@8V]L<W!A;CTS1#(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#(^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XQ,B!-;VYT:',@16YD960\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#$V+"`R,#$S
M/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P
M,30\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#$V+"`R,#$S/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S
M,2P@,C`Q-#QB<CY3=6YE($]L<V5N($AO;&1I;F<@07!S(%M-96UB97)=/&)R
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^4W5N92!/;'-E;B!(;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N($]N
M92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#`R+"`R,#$S/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E
M<ET\8G(^3&]A;B!/;F4@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#`R+"`R,#$S/&)R/E-U;F4@
M3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E<ET\8G(^3&]A;B!/;F4@6TUE;6)E
M<ET\8G(^1$M+/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DYO
M=BX@,C`L(#(P,3,\8G(^4W5N92!/;'-E;B!(;VQD:6YG($%P<R!;365M8F5R
M73QB<CY,;V%N($]N92!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,C`L(#(P,3,\8G(^4W5N92!/
M;'-E;B!(;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N($]N92!;365M8F5R
M73QB<CY$2TL\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^3F]V
M+B`Q,2P@,C`Q,SQB<CY3=6YE($]L<V5N($AO;&1I;F<@07!S(%M-96UB97)=
M/&)R/DQO86X@3VYE(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^3F]V+B`Q,2P@,C`Q,SQB<CY3=6YE($]L
M<V5N($AO;&1I;F<@07!S(%M-96UB97)=/&)R/DQO86X@3VYE(%M-96UB97)=
M/&)R/D1+2SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E<ET\
M8G(^3&]A;B!4=V\@6TUE;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`R,"P@,C`Q,SQB<CY3=6YE($]L<V5N($AO;&1I;F<@
M07!S(%M-96UB97)=/&)R/DQO86X@5'=O(%M-96UB97)=/&)R/E531"`H)"D\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`R,"P@,C`Q
M,SQB<CY3=6YE($]L<V5N($AO;&1I;F<@07!S(%M-96UB97)=/&)R/DQO86X@
M5'=O(%M-96UB97)=/&)R/D1+2SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y$96,N(#$V+"`R,#$S/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!
M<',@6TUE;6)E<ET\8G(^3&]A;B!&;W5R(%M-96UB97)=/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3(\8G(^4W5N92!/
M;'-E;B!(;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N($9O=7(@6TUE;6)E
M<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#,Q+"`R,#$R/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE
M;6)E<ET\8G(^3&]A;B!&;W5R(%M-96UB97)=/&)R/D1+2SQB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$Q/&)R/E-U;F4@
M3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E<ET\8G(^3&]A;B!&;W5R(%M-96UB
M97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,3QB<CY3=6YE($]L<V5N($AO;&1I;F<@07!S(%M-
M96UB97)=/&)R/DQO86X@1F]U<B!;365M8F5R73QB<CY$2TL\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY3=6YE
M($]L<V5N($AO;&1I;F<@07!S(%M-96UB97)=/&)R/DQO86X@1F]U<B!;365M
M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3,\8G(^4W5N92!/;'-E;B!(;VQD:6YG($%P<R!;
M365M8F5R73QB<CY,;V%N($9O=7(@6TUE;6)E<ET\8G(^1$M+/&)R/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,38L(#(P,3,\8G(^4W5N
M92!/;'-E;B!(;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N($9I=F4@6TUE
M;6)E<ET\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`P
M,2P@,C`Q,SQB<CY3=6YE($]L<V5N($AO;&1I;F<@07!S(%M-96UB97)=/&)R
M/DQO86X@1FEV92!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^4W5N92!/;'-E
M;B!(;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N($9I=F4@6TUE;6)E<ET\
M8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E
M<ET\8G(^3&]A;B!&:79E(%M-96UB97)=/&)R/D1+2SQB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#$V+"`R,#$S/&)R/E-U;F4@3VQS
M96X@2&]L9&EN9R!!<',@6TUE;6)E<ET\8G(^3&]A;B!3:7@@6TUE;6)E<ET\
M8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#$V+"`R,#$S/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E
M<ET\8G(^3&]A;B!3:7@@6TUE;6)E<ET\8G(^1$M+/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DIU;BX@,C`L(#(P,3,\8G(^4W5N92!/;'-E
M;B!(;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N(%-I>"!;365M8F5R73QB
M<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU
M;BX@,C`L(#(P,3,\8G(^4W5N92!/;'-E;B!(;VQD:6YG($%P<R!;365M8F5R
M73QB<CY,;V%N(%-I>"!;365M8F5R73QB<CY$2TL\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^07!R+B`Q-"P@,C`Q,SQB<CY3=6YE($]L<V5N
M($AO;&1I;F<@07!S(%M-96UB97)=/&)R/DQO86X@4VEX(%M-96UB97)=/&)R
M/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^07!R
M+B`Q-"P@,C`Q,SQB<CY3=6YE($]L<V5N($AO;&1I;F<@07!S(%M-96UB97)=
M/&)R/DQO86X@4VEX(%M-96UB97)=/&)R/D1+2SQB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#$V+"`R,#$S/&)R/E-U;F4@3VQS96X@
M2&]L9&EN9R!!<',@6TUE;6)E<ET\8G(^3&]A;B!3979E;B!;365M8F5R73QB
M<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6PN(#(V+"`R,#$S
M/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E<ET\8G(^3&]A;B!3
M979E;B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DIU;"X@,C8L(#(P,3,\8G(^4W5N92!/;'-E;B!(;VQD
M:6YG($%P<R!;365M8F5R73QB<CY,;V%N(%-E=F5N(%M-96UB97)=/&)R/D1+
M2SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!=6<N(#$U+"`R
M,#$S/&)R/E-U;F4@3VQS96X@2&]L9&EN9R!!<',@6TUE;6)E<ET\8G(^3&]A
M;B!3979E;B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%U9RX@,34L(#(P,3,\8G(^4W5N92!/;'-E;B!(
M;VQD:6YG($%P<R!;365M8F5R73QB<CY,;V%N(%-E=F5N(%M-96UB97)=/&)R
M/D1+2SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q
M+"`R,#$T/&)R/E!A<V5C;R!!<',@6TUE;6)E<ET\8G(^3&]A;B!;365M8F5R
M73QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#$X+"`R
M,#$T/&)R/E!A<V5C;R!!<',@6TUE;6)E<ET\8G(^3&]A;B!;365M8F5R73QB
M<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,3@L(#(P,30\8G(^4&%S96-O($%P<R!;365M8F5R73QB<CY,;V%N(%M-
M96UB97)=/&)R/D1+2SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y&96(N(#$U+"`R,#$T/&)R/E!A<V5C;R!!<',@6TUE;6)E<ET\8G(^3&]A
M;B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D9E8BX@,34L(#(P,30\8G(^4&%S96-O($%P<R!;365M8F5R
M73QB<CY,;V%N(%M-96UB97)=/&)R/D1+2SQB<CX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/E!A<V5C;R!!<',@6TUE
M;6)E<ET\8G(^3&]A;B!4:')E92!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M4&%S96-O($%P<R!;365M8F5R73QB<CY,;V%N(%1H<F5E(%M-96UB97)=/&)R
M/D1+2SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#$V
M+"`R,#$S/&)R/D1+5$D@02]3(%M-96UB97)=/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D1E8RX@,38L(#(P,3,\8G(^1$M422!!+U,@6TUE
M;6)E<ET\8G(^3&]A;B!4:')E92!;365M8F5R73QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/D1+5$D@02]3(%M-
M96UB97)=/&)R/DQO86X@5&AR964@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\
M+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R
M/D1+5$D@02]3(%M-96UB97)=/&)R/DQO86X@5&AR964@6TUE;6)E<ET\8G(^
M1$M+/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,3(\8G(^1$M422!!+U,@6TUE;6)E<ET\8G(^3&]A;B!4:')E92!;365M
M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,S$L(#(P,3(\8G(^1$M422!!+U,@6TUE;6)E<ET\8G(^3&]A
M;B!4:')E92!;365M8F5R73QB<CY$2TL\8G(^/"]T:#X-"B`@("`@("`@/'1H
M(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q-#QB<CY.;&)D:70@5'=O(%IE<F\@
M3VYE(%IE<F\@16YT97)P<FES97,L($QL8R!;365M8F5R73QB<CY,;V%N(%1E
M;B!;365M8F5R73QB<CY54T0@*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^3FQB9&ET(%1W;R!:97)O($]N
M92!:97)O($5N=&5R<')I<V5S+"!,;&,@6TUE;6)E<ET\8G(^3&]A;B!496X@
M6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^/'-T<F]N9SY296QA=&5D(%!A<G1Y(%1R86YS86-T:6]N
M(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y5;G-E8W5R960@;&]A;CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^)"`S."PR,S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$V-2PY.3`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@.3`P+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-S0L-CDV
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M(#0P-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(W-BPV-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#X@,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q.#0L-#,T/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^(#$L,#`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/B0@-#(T+#$Y.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B`R+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#0V,2PP.#0\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@,BPU,#`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S-C@L
M.#8X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#(L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/B0@-#(L-S4S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&EN=&5R97-T(&EN('!E
M<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XV+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XU+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2XP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2XP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C8N,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQO86YS('!A>6%B;&4L(&-U<G)E;G0\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4Y+#@U-#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,S."PW,3D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-2PP,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ-#,L-S4P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^,C,R+#@T,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C$L,C8W+#<R-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(V-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#4P,"PP,#`\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW
M-S,L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-"PS-S4L.3,R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,3<W+#(S.3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#`P+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S,RPS-#,\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW-3`L,#`P
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M.#@P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C4L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M<&%N>2!B;W)R;W=E9"!L;V%N<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S@S+#$S.3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0L-#,Q+#@V,CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M26YT97)E<W0@97AP96YS92P@8F]R<F]W:6YG(&QO86YS/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-2PV,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-BPP-#<\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,BPV-#8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW,2PU-C,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M,3,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV,3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%D9&ET:6]N86P@;&]A;B!O;B!B;W)R;W=I;F=S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-"PP-S4\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XU-2PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,3`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y)
M;F-R96%S960@:6YT97)E<W0@<&5R8V5N=&%G93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-RXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XW+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N,#`E/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-RXP,"4\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+C`P)3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<N,#`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D%C8W)U960@:6YT97)E<W0@<&5R8V5N=&%G93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,RPV,3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PT-CD\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-C@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#8X.3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.#`T
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,C`L.34Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPX,C<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ-2PU-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,S`L,S,W/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T960@:6YT
M;R!C;VUM;VX@<VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XS-2PQ,#8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-2PX-#0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.2PP,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XR.2PP,S8\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-BPR,#0\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX-BPR,#0\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,RPW,#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY
M-BPR.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!E>&-H86YG960@9'5R:6YG('!E<FEO9"!O
M9B!C;VYV97)S:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-C$L-C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,C<U+#@V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C4R+#8Q.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C0S+#4R,#QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0S+#4R,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$R.2PR,#<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,CDL,C`W
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-3`L-3$X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,30T+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$T-"PS,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@3&5G86P@1F5E<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8U+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M1&5B="!);G-T<G5M96YT+"!-871U<FET>2!$871E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#Y-87D@,2P-"@D),C`Q-#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/D9E8B`Q+`T*"0DR,#$U
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'1E;F1E9"!M871U<FET>2!D871E+"!$97-C<FEP=&EO;CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^5&AE($-O;7!A;GD@97AT96YD961T
M:&5M871U<FET>2!D871E(&]F('1H92!$2TL@,2PP,#`L,#`P(&QO86YS('=I
M=&@@4W5N92!/;'-E;B!F<F]M($UA>2`Q+"`R,#$T('1O(#$T(&1A>7,@869T
M97(@=&AE(&-O;7!L971I;VX@;V8@=&AE(&-O;G1E;7!L871E9"!S=&]C:R!O
M9F9E<FEN9R!O9B!$86Y$<FET(%5302!O<B!&96)R=6%R>2`Q+"`R,#$U+CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/E1H
M92!L;V%N<R!A<F4@<&%Y86)L92`Q-"!D87ES(&%F=&5R('1H92!C;VUP;&5T
M:6]N(&]F('1H92!C;VYT96UP;&%T960@<'5B;&EC(&]F9F5R:6YG(&EN($1A
M;D1R:70@0FEO=&5C:"!54T$L($EN8RX@;W(@1F5B<G5A<GD@,2P@,C`Q-2P@
M86YD(&%C8W)U92!I;G1E<F5S="!A="`U)2!P97(@86YN=6TN/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,;V%N<R!P
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,X+#(S
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE
M/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?,S%A
M.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E.#)B#0I#;VYT96YT+4QO
M8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC
M-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T,S<N:'1M;`T*0V]N=&5N="U4
M<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4
M>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-
M"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP
M92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP
M="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@
M3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@
M(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4Q
M1T%'/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS
M<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D-O;G9E<G1I8FQE($)O;F0@
M4&%Y86)L92`M(%)E;&%T960@4&%R='D@*$1E=&%I;',I("A54T0@)"D\8G(^
M/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A
M;CTS1#$^,"!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,SXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`Q
M-BP@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E
M8RX@,S$L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,CQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M:#Y$96,N(#`Q+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#X\<W1R;VYG/D-O;G9E<G1I8FQE($)O;F0@4&%Y86)L92`M(%)E
M;&%T960@4&%R='D@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!B;VYD<RP@86UO=6YT
M(&)O<G)O=V5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,2PU,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!B;VYD<RP@<W1A=&5D
M('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8N
M,#`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VYV97)T:6)L92!B;VYD<R!A;F0@<F5L871E9"!A8V-R=65D(&EN
M=&5R97-T+"!I;G1I86P@<F%T92!O9B!C;VYV97)S:6]N(&EN=&\@8V]M;6]N
M('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y+C4X
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y#;VYV97)T:6)L92!B;VYD<RP@869T97(@8V]N=F5R<VEO;B!E<W1I;6%T
M960@9F%I<G9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ
M+#`P,RPU-3<\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4@9F]R('1H92!A8V-E<G1I;VX@
M;V8@9&ES8V]U;G0@;VX@;F]T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-3`R+#0V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C0V,2PR-SD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@:6YT97)E<W0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W.2PV,3(\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@
M;&EA8FEL:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#8W
M,RPW,S8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!S=&]C:R!E>&-H86YG960@9'5R:6YG('!E<FEO9"!O
M9B!C;VYV97)S:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR
M-C$L-C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y";VYD+"!R96QA=&5D(&%C8W)U960@:6YT97)E<W0@86YD(&1E
M<FEV871I=F4@;&EA8FEL:71Y+"!C;VYV97)T960@:6YT;R!S:&%R97,\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$W-"PU-S@\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I
M8FQE(&)O;F1S+"!C;VYV97)S:6]N(&1E<V-R:7!T:6]N/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#Y4:&4@87-S=6UP=&EO;G,@=7-E9"!T;R!D
M971E<FUI;F4@=&AE(&EN:71I86P@9F%I<B!V86QU92!O9B!T:&4@8V]N=F5R
M<VEO;B!F96%T=7)E(&]F('1H92!C;VYV97)T:6)L92!B;VYD('=E<F4@97AP
M96-T960@=F]L871I;&ET>2!O9B`V-24L(&5X<&5C=&5D(&QI9F4@;V8@='=O
M('EE87)S('1O('1W96QV92!M;VYT:',L(')I<VL@9G)E92!I;G1E<F5S="!R
M871E<R!O9B`N-#$E+"!A;F0@;F\@9&EV:61E;F0@>6EE;&0N/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!E8W1E
M9"!D:79I9&5N9"!Y:65L9"!R871E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X<&5C=&5D('9O;&%T:6QI='D@<F%T
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-C4N,#`E/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y2:7-K
M(&9R964@:6YT97)E<W0@<F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,"XT,24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D5X<&5C=&5D('1E<FT\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/C(@>65A<G,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM
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M<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M
M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H
M87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S
M<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO
M/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,]
M,T1R97!O<G0@:60],T1)1#!%3DY!1SX-"B`@("`@(#QT<CX-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N
M9SY$97)I=F%T:79E($QI86)I;&ET:65S("A$971A:6QS*2`H55-$("0I/&)R
M/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XY($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#$V+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/E-E<"X@,S`L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^4V5P+B`S,"P@,C`Q,SQB<CX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D1E<FEV
M871I=F5S+"!&86ER(%9A;'5E(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$97)I=F%T:79E(&QI86)I
M;&ET:65S(&=A:6X\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M-"PQ.#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#0U+#@R,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^0F]N9"P@<F5L871E9"!A8V-R=65D(&EN=&5R97-T
M(&%N9"!D97)I=F%T:79E(&QI86)I;&ET>2P@8V]N=F5R=&5D(&EN=&\@<VAA
M<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-S0L-3<X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VYV97)T:6)L92!$96)T(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5R:79A=&EV97,L($9A:7(@5F%L=64@
M6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,@:7-S=65D('5P;VX@8V]N=F5R<VEO
M;B!O9B!B;VYD('!A>6%B;&4M<F5L871E9"!P87)T>2!A;F0@9&5R:79A=&EV
M92!L:6%B:6QI='DL('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#4P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D%C8W)U960@26YT97)E<W0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$97)I=F%T
M:79E<RP@1F%I<B!686QU92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U
M960@=7!O;B!C;VYV97)S:6]N(&]F(&)O;F0@<&%Y86)L92UR96QA=&5D('!A
M<G1Y(&%N9"!D97)I=F%T:79E(&QI86)I;&ET>2P@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C$W.2PV,3(\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E<FEV871I=F4@3&EA
M8FEL:71Y(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^1&5R:79A=&EV97,L($9A:7(@5F%L=64@6TQI;F4@271E
M;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D-O;6UO;B!S:&%R97,@:7-S=65D('5P;VX@8V]N=F5R<VEO;B!O9B!B;VYD
M('!A>6%B;&4M<F5L871E9"!P87)T>2!A;F0@9&5R:79A=&EV92!L:6%B:6QI
M='DL('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV-S,L
M-S,V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^/'-T<F]N9SY$97)I=F%T:79E<RP@1F%I<B!686QU
M92!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U960@=7!O;B!C;VYV97)S
M:6]N(&]F(&)O;F0@<&%Y86)L92UR96QA=&5D('!A<G1Y(&%N9"!D97)I=F%T
M:79E(&QI86)I;&ET>2!A="`Y+C`P('!E<B!S:&%R97,L($1E8V5M8F5R(#(P
M,3,L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C8Q
M+#8V-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C(V,2PV-C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,@:7-S=65D('5P;VX@8V]N=F5R
M<VEO;B!O9B!B;VYD('!A>6%B;&4M<F5L871E9"!P87)T>2!A;F0@9&5R:79A
M=&EV92!L:6%B:6QI='DL('9A;'5E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XD(#(V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].
M97AT4&%R=%\S,6$Y-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(-
M"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S%A.30Q,V-?-35D-5\T
M,V9A7SAA.3=?.6,T,V$U8V5E.#)B+U=O<FMS:&5E=',O4VAE970S.2YH=&UL
M#0I#;VYT96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE
M#0I#;VYT96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB
M#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$
M0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T
M9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO
M=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T
M/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T
M(&ED/3-$240P15A)044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3&5A<V5S
M("A$971A:6QS*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$-#XQ,B!-;VYT:',@16YD960\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$-#XQ($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/E531"`H)"D\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY54T0@
M*"0I/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L
M(#(P,30\8G(^3&%B('-P86-E(%M-96UB97)=/&)R/E531"`H)"D\8G(^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CY,
M86(@<W!A8V4@6TUE;6)E<ET\8G(^1$M+/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,C<L(#(P,30\8G(^3V9F:6-E('-P86-E(%M-
M96UB97)=/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@^36%R+B`R-RP@,C`Q-#QB<CY/9F9I8V4@<W!A8V4@6TUE;6)E<ET\
M8G(^1$M+/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DIU;"X@
M,#$L(#(P,30\8G(^3V9F:6-E('-P86-E(%M-96UB97)=/&)R/E-U8G-E<75E
M;G0@179E;G0@6TUE;6)E<ET\8G(^55-$("@D*3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6PN(#`Q+"`R,#$T/&)R/D]F9FEC92!S<&%C
M92!;365M8F5R73QB<CY3=6)S97%U96YT($5V96YT(%M-96UB97)=/&)R/D1+
M2SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY/<&5R871I;F<@3&5A<V5D($%S<V5T<R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4F5N=&%L('!A
M>6UE;G1S(&9O<B!/<&5R871I;F<@3&5A<V5S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#,R+#(Y-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@-C4L-S`R/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Y-C<\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#X@-BPP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L
M-C$R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^(#$P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/B0@,RPR,C4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#X@,C`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/<&5R871I;F<@;&5A<V4@86=R
M965M96YT+"!$97-C<FEP=&EO;CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^5&AE(&QE87-E(&-A;B!B92!T97)M:6YA=&5D(&)Y(&5I=&AE<B!T
M:&4@0V]M<&%N>2!O<B!T:&4@;&%N9&QO<F0@8GD@9VEV:6YG('1H92!O=&AE
M<B`S(&UO;G1H(&YO=&EC92X@5&AE($-O;7!A;GD@9V%V92!A;F]T:6-E('1E
M<FUI;F%T:6YG=&AE(&QE87-E(&%G<F5E;65N="!O;B!&96)R=6%R>2`R-RP@
M,C`Q-2!T:&5R96)Y(')E;&5A<VEN9R!T:&4@0V]M<&%N>2!F<F]M('1H92!L
M96%S92!O;B!-87D@,S$L(#(P,34N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*
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M=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P
M+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C
M:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@
M<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J
M+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S
M/3-$<F5P;W)T(&ED/3-$240P139'04,^#0H@("`@("`\='(^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0Q/CQS=')O
M;F<^26YC;VUE(%1A>&5S("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\
M8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N
M9SY);F-O;64@5&%X97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-E<W,@;V8@5&%X(&]V97(@8F]O
M:R!D97!R96-I871I;VX@1FEX960@87-S971S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XD(#$R+#<Q,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.#<L-3<X/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>&-E<W,@;V8@5&%X
M(&]V97(@8F]O:R!D97!R96-I871I;VX@4&%T96YT<SPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^-3(L,#0Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$T+#`R.#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T($]P97)A=&EN
M9R!,;W-S($-A<G)Y9F]R=V%R9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,BPS.#`L,3`V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PV-#(L-3DX/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y686QU871I;VX@06QL;W=A;F-E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@R+#0T-"PX-3@I/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,2PX
M-#0L,C`T*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/E1O=&%L($1E9F5R<F5D(%1A>"!!<W-E="`H3&EA8FEL:71I
M97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S
M<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#XF;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC-#-A-6-E93@R
M8@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B\S,6$Y-#$S8U\U-60U
M7S0S9F%?.&$Y-U\Y8S0S835C964X,F(O5V]R:W-H965T<R]3:&5E=#0Q+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%2$A!0SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O
M;64@5&%X97,@*$1E=&%I;',@,2D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/DEN8V]M92!487AE
M<R!;06)S=')A8W1=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-O;7!U=&5D(%1A>"!A="!%>'!E8W1E9"!3=&%T=71O<GD@
M4F%T93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@X-C8L-#8S
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H-S4R+#@X,BD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/DYO;BU54R!);F-O;64@5&%X960@870@1&EF9F5R96YT
M(%)A=&5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-34L,S4V
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3DY+#(Y,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^3F]N+41E9'5C=&%B;&4@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C@L,SDP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C@S+#,X,3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5F%L=6%T:6]N(&%L
M;&]W86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,V+#8S
M,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(W,"PR,#D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y);F-O;64@5&%X($5X<&5N<V4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6T^)"`H,3<W+#4S.2D\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF;F)S<#LF;F)S<#L\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B
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M/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N
M=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS
M1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO
M=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-
M"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1TQ!0SX-"B`@
M("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@
M<F]W<W!A;CTS1#(^/'-T<F]N9SY);F-O;64@5&%X97,@*$1E=&%I;',@,BD@
M*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:"!C;VQS<&%N/3-$,CXQ,B!-;VYT:',@16YD960\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$
M96,N(#,Q+"`R,#$S/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#X\<W1R;VYG/D-U<G)E;G0@5&%X($5X<&5N<V4\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&%N:7-H($EN8V]M92!4
M87@\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^)"`H,3<W+#4S.2D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XF
M;F)S<#LF;F)S<#L\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/CQS=')O;F<^1&5F97)R960@26YC;VUE(%1A>"!%>'!E
M;G-E("A"96YE9FET*3PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y%>&-E<W,@;V8@5&%X(&]V97(@0F]O:R!$97!R96-I871I
M;VX@1FEX960@07-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XQ.2PR-3D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XR-BPS-C0\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5X8V5S<R!O9B!487@@;W9E<B!";V]K($1E<')E
M8VEA=&EO;B!0871E;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV-RPT.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M/B@Q,#4L-3@U*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^3F5T($]P97)A=&EN9R!,;W-S($-A<G)Y9F]R
M=V%R9',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#4R,RPS-S@I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH
M,3DP+#DX."D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D-H86YG92!I;B!T:&4@5F%L=6%T:6]N(&%L;&]W86YC93PO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#,V+#8S,3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,"PR,#D\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!$969E<G)E9"!487@@17AP96YS93PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^)FYB<W`[)FYB<W`[/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO
M8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%\S,6$Y-#$S8U\U
M-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(-"D-O;G1E;G0M3&]C871I;VXZ
M(&9I;&4Z+R\O0SHO,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E
M.#)B+U=O<FMS:&5E=',O4VAE970T,RYH=&UL#0I#;VYT96YT+51R86YS9F5R
M+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT96YT+51Y<&4Z('1E
M>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A
M9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E
M;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4]
M,T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M
M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^
M#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14M"04,^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q
M(')O=W-P86X],T0Q/CQS=')O;F<^26YC;VUE(%1A>&5S("A$971A:6QS(%1E
M>'1U86PI("A$86YI<V@@5&%X(%M-96UB97)=+"!54T0@)"D\8G(^/"]S=')O
M;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q
M-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&%N:7-H
M(%1A>"!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#X\<W1R;VYG/DEN8V]M92!487AE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3F5T(&]P97)A=&EN9R!L
M;W-S(&-A<G)Y(&9O<G=A<F1S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#(L,S@P+#$P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?,S%A.30Q,V-?-35D-5\T,V9A7SAA.3=?.6,T,V$U8V5E
M.#)B#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+S,Q83DT,3-C7S4U
M9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8B]7;W)K<VAE971S+U-H965T-#0N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$4S1D%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DQO
M<W,@4&5R(%-H87)E("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y$96,N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,3,\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3$]34R!015(@
M4TA!4D4\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^3F5T($EN8V]M92`H3&]S<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^)"`H,BPS-S`L.#@S*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^)"`H,BPQ-#<L,S8Q*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5V5I9VAT960@879E
M<F%G92!N=6UB97(@;V8@8V]M;6]N('-H87)E<R!U<V5D(&EN(&)A<VEC(&5A
M<FYI;F=S('!E<B!S:&%R93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^-RPU,#`L,30R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;7`^-2PS,S(L-S(Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%9F9E8W0@;V8@9&EL=71I=F4@<V5C
M=7)I=&EE<RP@<W1O8VL@;W!T:6]N<R!A;F0@=V%R<F%N=',\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P.SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/B9N8G-P.R9N8G-P
M.SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E=E:6=H=&5D(&%V97)A9V4@;G5M8F5R(&]F(&-O;6UO;B!S:&%R97,@
M86YD('!O=&5N=&EA;"!D:6QU=&EV92!C;VUM;VX@<VAA<F5S(&]U='-T86YD
M:6YG('5S960@:6X@9&EL=71I=F4@96%R;FEN9W,@<&5R('-H87)E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#4P,"PQ-#(\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4U-RPX.3,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-
M"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7S,Q83DT
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M(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@
M8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@
M='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO
M="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\
M8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%231!
M2SX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A
M;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY3=&]C:VAO;&1E<B=S($5Q=6ET
M>2`H1&5T86EL<RD@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C$R($UO
M;G1H<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P
M86X],T0R/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&@@8V]L<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@
M,38L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C
M+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!
M=6<N(#$R+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H
M/D9E8BX@,3(L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@^1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y$96,N(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US
M73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#
M;VUM;VX@<W1O8VLL('!A<B!V86QU93PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^)"`P+C`P,#$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R
M97,@875T:&]R:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,3`P+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,#`L,#`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-T;V-K+"!S:&%R97,@
M:7-S=65D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4S,RPR
M.3`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XV+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<VAA<F5S(&]U='-T86YD:6YG
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY+#4S,RPR.3`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#`P
M,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D]F9F5R:6YG(&]F(&-O;6UO;B!S=&]C:RP@<VAA<F5S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX.#DL-CDP/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!E>&-H
M86YG92!A9W)E96UE;G0@86-Q=6ES:71I;VX@<&5R8V5N=&%G93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`P+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC:&%N
M9V4@86=R965M96YT('-H87)E<R!I<W-U960@=&\@<&%R96YT(&-O;7!A;GD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N(%-T;V-K(')E<V5R=F5D(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@U+#`U,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U
M960@:6X@<&%Y;65N="!O9B!N;W1E<R!P87EA8FQE("T@<F5L871E9"!P87)T
M>2P@5F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@.3(V
M+#,X-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-H87)E<R!I<W-U960@:6X@<&%Y;65N="!O9B!N;W1E
M('!A>6%B;&4@+2!R96QA=&5D('!A<G1Y+%9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ+#<W,"PW-3<\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN:71I86P@<'5B;&EC(&]F
M9F5R:6YG(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S=')O
M;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D]F9F5R:6YG
M(&]F(&-O;6UO;B!S=&]C:RP@=F%L=64\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$R+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-38L,S8P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!O9B!C;VUM
M;VX@<W1O8VLL('-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPT,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!O9B!C;VUM;VX@<W1O8VL@<')I8V4@
M<&5R('-H87)E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-A;&4@;V8@<W1O8VL@8V]M;6]N('-H87)E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,2PP.3,L,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M('-T;V-K
M(&]F9F5R:6YG+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C4L-#8V+#0U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')I=F%T92!O9F9E<FEN9R!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T
M;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/9F9E<FEN9R!O9B!C;VUM;VX@<W1O8VLL('-H87)E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^3V9F
M97)I;F<@;V8@8V]M;6]N('-T;V-K('!R:6-E('!E<B!S:&%R93PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'<F]S<R!P<F]C965D<R!F
M<F]M('-H87)E(&ES<W5A;F-E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XR+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($1E8G0@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;&%S<R!O
M9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U960@=7!O;B!C
M;VYV97)S:6]N(&]F(&)O;F0@<&%Y86)L92UR96QA=&5D('!A<G1Y(&%N9"!D
M97)I=F%T:79E(&QI86)I;&ET>2P@=F%L=64\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1N=6UP/C$L-3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06-C<G5E9"!);G1E<F5S="!;365M
M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG
M/D-L87-S(&]F(%-T;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S(&ES<W5E
M9"!U<&]N(&-O;G9E<G-I;VX@;V8@8F]N9"!P87EA8FQE+7)E;&%T960@<&%R
M='D@86YD(&1E<FEV871I=F4@;&EA8FEL:71Y+"!V86QU93PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^,3<Y+#8Q,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5R:79A=&EV92!,:6%B
M:6QI='D@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^/'-T<F]N9SY#;&%S<R!O9B!3=&]C:R!;3&EN92!)=&5M<UT\+W-T<F]N
M9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H
M87)E<R!I<W-U960@=7!O;B!C;VYV97)S:6]N(&]F(&)O;F0@<&%Y86)L92UR
M96QA=&5D('!A<G1Y(&%N9"!D97)I=F%T:79E(&QI86)I;&ET>2P@=F%L=64\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8W,RPW,S8\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A<F5N
M="!#;VUP86YY(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@4W1O8VL@6TQI;F4@271E;7-=/"]S
M=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA
M;F=E9"!S:&%R97,@;V8@<&%R96YT)W,@8V]M;6]N('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-C$L-C8U/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S
M(&ES<W5E9"!U<&]N(&-O;G9E<G-I;VX@;V8@8F]N9"!P87EA8FQE+7)E;&%T
M960@<&%R='D@86YD(&1E<FEV871I=F4@;&EA8FEL:71Y(&%T(#DN,#`@<&5R
M('-H87)E<RP@1&5C96UB97(@,C`Q,RP@4VAA<F5S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XQ-S0L-3<X/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S(&ES<W5E
M9"!I;B!P87EM96YT(&]F(&YO=&5S('!A>6%B;&4@+2!R96QA=&5D('!A<G1Y
M("P@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-BPR
M.#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D-O;6UO;B!S:&%R97,@:7-S=65D(&EN('!A>6UE;G0@;V8@;F]T92!P
M87EA8FQE("T@<F5L871E9"!P87)T>3PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,3@T+#`U,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K(%M-96UB97)=/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^0VQA<W,@;V8@
M4W1O8VL@6TQI;F4@271E;7-=/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!S=&]C:RP@<&%R('9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#`N,#`P,3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC
M:&%N9V4@86=R965M96YT(&%C<75I<VET:6]N('!E<F-E;G1A9V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$P,"XP,"4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E(&5X8VAA
M;F=E(&%G<F5E;65N="!N=6UB97(@;V8@<VAA<F4@8V%N8V5L;&%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#0P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D5X8VAA
M;F=E9"!S:&%R97,@;V8@<&%R96YT)W,@8V]M;6]N('-T;V-K/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+C0Y.#@T,CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4@97AC:&%N
M9V4@86=R965M96YT('-H87)E<R!I<W-U960@=&\@<&%R96YT(&-O;7!A;GD\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C8L,#`P+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M
M;6]N(%-T;V-K(')E<V5R=F5D(&9O<B!I<W-U86YC93PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,3@U+#`U,SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U
M960@=7!O;B!C;VYV97)S:6]N(&]F(&)O;F0@<&%Y86)L92UR96QA=&5D('!A
M<G1Y(&%N9"!D97)I=F%T:79E(&QI86)I;&ET>2P@=F%L=64\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C(V/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@<VAA<F5S(&ES<W5E
M9"!U<&]N(&-O;G9E<G-I;VX@;V8@8F]N9"!P87EA8FQE+7)E;&%T960@<&%R
M='D@86YD(&1E<FEV871I=F4@;&EA8FEL:71Y(&%T(#DN,#`@<&5R('-H87)E
M<RP@1&5C96UB97(@,C`Q,RP@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR-C$L-C8U/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;7`^,C8Q+#8V-3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I<W-U
M960@:6X@<&%Y;65N="!O9B!N;W1E<R!P87EA8FQE("T@<F5L871E9"!P87)T
M>2`L(%-H87)E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,30T
M+#,R,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$T-"PS,C$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D-O;6UO;B!S:&%R97,@:7-S=65D(&EN('!A>6UE;G0@
M;V8@;F]T97,@<&%Y86)L92`M(')E;&%T960@<&%R='DL(%9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N('-H87)E<R!I
M<W-U960@:6X@<&%Y;65N="!O9B!N;W1E('!A>6%B;&4@+2!R96QA=&5D('!A
M<G1Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR-S4L.#8S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<U
M+#@V,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^0V]M;6]N('-H87)E<R!I<W-U960@:6X@<&%Y;65N="!O9B!N;W1E
M('!A>6%B;&4@+2!R96QA=&5D('!A<G1Y+%9A;'5E/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(X/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R97,@;V8@<&%R96YT(&-O;6UO
M;B!S=&]C:R!O=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^.2PU,S,L,CDP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-BPP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PS,3@L,34Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O
M8VL@6TUE;6)E<ET@?"!087)E;G0@0V]M<&%N>2!;365M8F5R73PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D-L87-S(&]F(%-T
M;V-K(%M,:6YE($ET96US73PO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3:&%R97,@;V8@<&%R96YT(&-O;6UO;B!S=&]C:R!O
M=71S=&%N9&EN9SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^."PP
M-#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
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M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P13%#04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L
M(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]M;6ET;65N=',@
M86YD($-O;G1I;F=E;F-I97,@*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^
M#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS
M($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/D1E8RX@,38L(#(P,3,\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@,C`Q-#QB<CX\+W1H/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#;VUM:71M96YT<R!A;F0@
M0V]N=&EN9V5N8VEE<R`H5&5X='5A;"D\+W-T<F]N9SX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^0V]M;6]N(%-T;V-K(')E<V5R=F5D(&9O
M<B!I<W-U86YC93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3@U
M+#`U,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^5&5R;6EN871I;VX@;V8@86=R965M96YT/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#XQ.#`@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&%Y;65N=',@9F]R(')O>6%L
M=&EE<R!P97)I;V0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C(P
M('EE87)S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO
M=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R
M=%\S,6$Y-#$S8U\U-60U7S0S9F%?.&$Y-U\Y8S0S835C964X,F(-"D-O;G1E
M;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO,S%A.30Q,V-?-35D-5\T,V9A7SAA
M.3=?.6,T,V$U8V5E.#)B+U=O<FMS:&5E=',O4VAE970T-RYH=&UL#0I#;VYT
M96YT+51R86YS9F5R+45N8V]D:6YG.B!Q=6]T960M<')I;G1A8FQE#0I#;VYT
M96YT+51Y<&4Z('1E>'0O:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH
M=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N
M="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\
M<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO
M*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A
M9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$
M240P15=%/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C
M;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/D1I<W!O<VET:6]N("A$
M971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H/D1E8RX@,38L(#(P,3,\8G(^/"]T:#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/CQS=')O;F<^1&ES<&]S:71I;VX@6T%B<W1R86-T73PO<W1R
M;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y'86EN(&]R
M(&QO<W,@9G)O;2!T:&4@4V%L92!A;F0@9&ES8V]N=&EN=64@;W!E<F%T:6]N
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P159/04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4F5L871E9"!087)T>2!4<F%N<V%C=&EO;G,@
M*$1E=&%I;',I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1H(&-O;'-P86X],T0R/C$R($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/CPO=&@^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/E531"`H)"D\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L
M87-S/3-$=&@^1&5C+B`S,2P@,C`Q,SQB<CY54T0@*"0I/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^1$M+/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/E)E
M;&%T960@4&%R='D@5')A;G-A8W1I;VYS("A497AT=6%L*3PO<W1R;VYG/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y296QA=&5D('!A<G1Y
M('1R86YS86-T:6]N<R!A;6]U;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@,C,L,34R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^(#$S,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DQE9V%L(&5X<&5N<V4\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(X."PU-#8\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS,C@L,C`R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y&;W)G
M879E(&EN(&QE9V%L('-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XT.2PP,38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/E!A>6%B;&4@=&\@<F5L871E9"!P87)T:65S/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,3(L-#,X/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!9&1I=&EO
M;F%L(&QE9V%L('-E<G9I8V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XP/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y"86QA;F-E<R!H96QD(&EN('1R=7-T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#(L,#$T+#DP.3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L-3DS/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P139+04,^#0H@("`@
M("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O
M=W-P86X],T0R/CQS=')O;F<^4W5B<V5Q=65N="!%=F5N="`H1&5T86EL<RD@
M*%-U8G-E<75E;G0@179E;G0@6TUE;6)E<ETL(%531"`D*3QB<CX\+W-T<F]N
M9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XP
M($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#$S+"`R,#$U/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=6)S97%U96YT($5V96YT
M(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS
M=')O;F<^4W5B<V5Q=65N="!%=F5N="`H5&5X='5A;"D\+W-T<F]N9SX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^071T;W)N97D@9F5E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`T+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F]N=7-E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3`L,#`P/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS
M=6QT:6YG(&9E92!P97(@:&]U<CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^,34P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y'<F]S<R!S86QA<GD@<&5R(&UO;G1H/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#8P+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4&5N<VEO;B!C;VYT<FEB
M=71I;VYS('!E<F-E;G1A9V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C$P+C`P)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4W5B<V5Q=65N="!%=F5N="P@1&5S8W)I<'1I;VX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/BAI*2!A;&P@<V%L87)Y('!A
M>6%B;&4@:6X@86-C;W)D86YC92!W:71H('1H92!T97)M<R!O9B!T:&4@5V]L
M9F4@16UP;&]Y;65N="!!9W)E96UE;G0L(&%L;VYG('=I=&@@86YY('5N<&%I
M9"!A8V-R=65D(&5X<&5N<V5S+"!T:')O=6=H('1H92!497)M:6YA=&EO;B!$
M871E.R`H:6DI(&%T=&]R;F5Y(&9E97,@;V8@=7`@=&\@82!M87AI;75M(&]F
M("0T+#`P,#L@*&EI:2D@82!B;VYU<R!I;B!A;B!A;6]U;G0@97%U86P@=&\@
M)#$P+#`P,"!F;VQL;W=I;F<@=&AE(&9I;&EN9R!O9B!T:&4@0V]M<&%N>2=S
M($%N;G5A;"!297!O<G0@;VX@1F]R;2`Q,"U+(&9O<B!T:&4@>65A<B!E;F1E
M9"!$96-E;6)E<B`S,2P@,C`Q-#L@86YD("AI=BD@82!F964@;V8@)#$U,"XP
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M;VT@36%Y(#$L(#(P,34@=&AR;W5G:"!/8W1O8F5R(#,Q+"`R,#$U('-H86QL
M(&YO="!B92!B:6QL86)L92X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM
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M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`R+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970P,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T,#0N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`U
M+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-BYH=&UL(B\^#0H@
M/&\Z1FEL92!(4F5F/3-$(E-H965T,#<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E
M9CTS1")3:&5E=#`X+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P
M.2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3`N:'1M;"(O/@T*
M(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$Q+FAT;6PB+SX-"B`\;SI&:6QE($A2
M968],T0B4VAE970Q,BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T
M,3,N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$T+FAT;6PB+SX-
M"B`\;SI&:6QE($A2968],T0B4VAE970Q-2YH=&UL(B\^#0H@/&\Z1FEL92!(
M4F5F/3-$(E-H965T,38N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E
M=#$W+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q."YH=&UL(B\^
M#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3DN:'1M;"(O/@T*(#QO.D9I;&4@
M2%)E9CTS1")3:&5E=#(P+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970R,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,C(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970R-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,C4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#(V+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970R-RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,C@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#(Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S,"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S$N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#,R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970S,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,S0N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970S-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,S<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#,X+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970S.2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T-#`N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS
M1")3:&5E=#0Q+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970T,BYH
M=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#,N:'1M;"(O/@T*(#QO
M.D9I;&4@2%)E9CTS1")3:&5E=#0T+FAT;6PB+SX-"B`\;SI&:6QE($A2968]
M,T0B4VAE970T-2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T-#8N
M:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#0W+FAT;6PB+SX-"B`\
M;SI&:6QE($A2968],T0B4VAE970T."YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F
M/3-$(E-H965T-#DN:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]7TYE>'1087)T
I7S,Q83DT,3-C7S4U9#5?-#-F85\X83DW7SEC-#-A-6-E93@R8BTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKBAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details Textual) (Danish Tax [Member], USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Danish Tax [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IncomeTaxTextualAbstract', window );"><strong>Income Taxes (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carry forwards</a></td>
        <td class="nump"><a title="us-gaap_OperatingLossCarryforwards[us-gaap_IncomeTaxAuthorityAxis=pmhs_DanishTaxMember]" onclick="toggleNextSibling(this);">$ 2,380,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingLossCarryforwards<br>/ us-gaap_IncomeTaxAuthorityAxis<br>= pmhs_DanishTaxMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IncomeTaxTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IncomeTaxTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EWEBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 12, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary Of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ValueAddedTaxPercentage', window );">Value added tax percentage</a></td>
        <td class="nump"><a title="pmhs_ValueAddedTaxPercentage" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ValueAddedTaxPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ValueAddedTaxPaidToVendors', window );">Value added tax paid to Danish and EU vendors</a></td>
        <td class="nump"><a title="pmhs_ValueAddedTaxPaidToVendors" onclick="toggleNextSibling(this);">25.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ValueAddedTaxPaidToVendors</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ProceedsFromSaleOfSubsidiary', window );">Sale of subsidiary</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementAcquisitionPercentage', window );">Share exchange agreement acquisition percentage</a></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementAcquisitionPercentage" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementAcquisitionPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany', window );">Share exchange agreement shares issued to parent company</a></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock reserved for issuance</a></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" onclick="toggleNextSibling(this);">185,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash insured amount</a></td>
        <td class="nump"><a title="us-gaap_CashFDICInsuredAmount" onclick="toggleNextSibling(this);">$ 2,508,759</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashFDICInsuredAmount</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary Of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementCommonStockShares', window );">Shares prior to share exchange agreement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementCommonStockShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementCommonStockShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementAcquisitionPercentage', window );">Share exchange agreement acquisition percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementAcquisitionPercentage[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementAcquisitionPercentage<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany', window );">Share exchange agreement shares held by consenting shareholders of company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1.498842</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany', window );">Share exchange agreement shares issued to parent company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementSharesIssuedToParentCompany[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementNumberOfShareCancellation', window );">Share exchange agreement number of share cancellation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementNumberOfShareCancellation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,400,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementNumberOfShareCancellation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares', window );">Common shares issued for legal and consulting services</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,440,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">185,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares of parent common stock outstanding</a></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,318,151</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Parent Company [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary Of Significant Accounting Policies (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares of parent common stock outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[dei_LegalEntityAxis=us-gaap_ParentCompanyMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">8,040,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ dei_LegalEntityAxis<br>= us-gaap_ParentCompanyMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ProceedsFromSaleOfSubsidiary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Proceeds from sale of subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ProceedsFromSaleOfSubsidiary</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementAcquisitionPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement acquisition percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementAcquisitionPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement common share in connection with acquisition and offering shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementCommonShareInConnectionWithAcquisitionAndOfferingShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementCommonStockShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock shares prior to the share exchange agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementCommonStockShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementNumberOfShareCancellation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement number of share cancellation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementNumberOfShareCancellation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Exchange Agreement Shares held by consnting shareholders of comany.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementSharesHeldByConsentingShareholdersOfCompany</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Exchange Agreement Shares Issued To Parent Company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ValueAddedTaxPaidToVendors">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value added tax paid to vendors.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ValueAddedTaxPaidToVendors</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ValueAddedTaxPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value added tax percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ValueAddedTaxPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_LossPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of computing loss per share</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;"><br class="apple-interchange-newline" /></font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="6"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>December 31,</b></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>2014</b></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>2013</b></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1110px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Net (Loss)</font></td><td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 114.545448303223px; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(2,370,883</font></td><td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">)</font></td><td style="width: 13.63636302948px; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 113.636360168457px; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(2,214,361</font></td><td style="width: 13.63636302948px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Weighted average number of common shares used in basic earnings per share</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">7,500,142</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">3,557,893</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal;
 font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Effect of dilutive securities, stock options and warrants</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 10pt; text-indent: -10pt; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Weighted average number of common shares and potential dilutive</font><font style="font-family: 'times new roman', times, serif;"><br /><font style="font-size: 10pt;">common shares outstanding used in dilutive earnings per share</font></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">7,500,142</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">3,557,893</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_LossPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_LossPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>LOSS PER SHARE</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,370,883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares used in basic earnings per share</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">7,500,142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">5,332,721</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities, stock options and warrants</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Weighted average number of common shares and potential dilutive common shares outstanding used in dilutive earnings per share</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">7,500,142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" onclick="toggleNextSibling(this);">3,557,893</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENEAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Property and Equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);"> 239,698</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross" onclick="toggleNextSibling(this);">$ 260,636</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated Depreciation</a></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(239,698)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(260,636)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net Property and Equipment</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember', window );">Lab equipment and instruments [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Property and Equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember]" onclick="toggleNextSibling(this);">178,547</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LabEquipmentAndInstrumentsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember]" onclick="toggleNextSibling(this);">194,143</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= pmhs_LabEquipmentAndInstrumentsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember', window );">Lab equipment and instruments [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (years)</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember', window );">Lab equipment and instruments [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross Property and Equipment</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);"> 61,151</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentGross[us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember]" onclick="toggleNextSibling(this);">$ 66,493</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentGross<br>/ us-gaap_PropertyPlantAndEquipmentByTypeAxis<br>= us-gaap_ComputerEquipmentMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member] | Minimum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (years)</a></td>
        <td class="text">4 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment [Member] | Maximum [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (years)</a></td>
        <td class="text">6 years<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 14<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=pmhs_LabEquipmentAndInstrumentsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EGH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
        <td class="nump"><a title="us-gaap_Depreciation" onclick="toggleNextSibling(this);">$ 2,706</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Depreciation</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Depreciation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5SAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statement of Cash Flows (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,370,883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net (loss) to net cash provided (used) by operations:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">45,201</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">38,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary', window );">(Gain)/Loss on sale of subsidiary</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_GainOrLossOnSaleOfStockInSubsidiary" onclick="toggleNextSibling(this);">(1)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionOfDiscount', window );">Accretion of discount on bond payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_AccretionOfDiscount" onclick="toggleNextSibling(this);">502,465</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccretionOfDiscount</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfDerivatives', window );">(Gain)/Loss on derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_GainLossOnSaleOfDerivatives" onclick="toggleNextSibling(this);">(175,732)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GainLossOnSaleOfDerivatives</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in account receivable,</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">17,440</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsReceivable" onclick="toggleNextSibling(this);">56,346</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsReceivable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits', window );">(Increase) decrease in prepaid expenses &amp; deposits</a></td>
        <td class="nump"><a title="pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" onclick="toggleNextSibling(this);">22,988</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits</span><span></span></td>
        <td class="nump"><a title="pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits" onclick="toggleNextSibling(this);">4,183</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in accounts payable</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">162,950</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(2,674)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties', window );">Increase (decrease) in accounts payable - related party</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties" onclick="toggleNextSibling(this);">212,438</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase (decrease) in accrued expenses</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">(124,309)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccruedLiabilities" onclick="toggleNextSibling(this);">(406,152)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities', window );">Total Adjustments</a></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">336,708</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">16,732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash (Used) by Operating Activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(2,034,175)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(2,130,628)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates', window );">Proceed from sale of subsidiary</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_NetIncreaseDecreaseInCashHeldInEscrow', window );">Net decrease (increase) in cash held in escrow</a></td>
        <td class="num"><a title="pmhs_NetIncreaseDecreaseInCashHeldInEscrow" onclick="toggleNextSibling(this);">(1,952,034)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_NetIncreaseDecreaseInCashHeldInEscrow</span><span></span></td>
        <td class="num"><a title="pmhs_NetIncreaseDecreaseInCashHeldInEscrow" onclick="toggleNextSibling(this);">(77,468)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_NetIncreaseDecreaseInCashHeldInEscrow</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Purchase of intangible assets</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquireIntangibleAssets" onclick="toggleNextSibling(this);">(27,548)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquireIntangibleAssets</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Used by Investing Activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(1,952,034)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(105,015)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable - related party</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable" onclick="toggleNextSibling(this);">814,291</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromNotesPayable" onclick="toggleNextSibling(this);">2,754,662</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromNotesPayable</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from stock sales</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" onclick="toggleNextSibling(this);">7,377,089</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of stock offering costs</a></td>
        <td class="num"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">(89,360)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsOfStockIssuanceCosts" onclick="toggleNextSibling(this);">(67,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Payments on notes payable - related party</a></td>
        <td class="num"><a title="us-gaap_ProceedsFromRelatedPartyDebt" onclick="toggleNextSibling(this);">(1,432,213)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromRelatedPartyDebt</span><span></span></td>
        <td class="num"><a title="us-gaap_ProceedsFromRelatedPartyDebt" onclick="toggleNextSibling(this);">(218,136)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromRelatedPartyDebt</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by (Used by) Financing Activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">6,669,807</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">2,469,526</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">(Gain) loss on Currency Translation</a></td>
        <td class="nump"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">306,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
        <td class="num"><a title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" onclick="toggleNextSibling(this);">(219,470)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net Increase (Decrease) in Cash and Cash Equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">2,990,037</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">14,413</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at Beginning of Period</a></td>
        <td class="nump"><a title="us-gaap_CashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">18,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">4,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents at End of Period</a></td>
        <td class="nump"><a title="us-gaap_CashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">3,008,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">18,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CashPaidDuringPeriodsForAbstract', window );"><strong>Cash paid during the year for</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">82,816</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestPaid" onclick="toggleNextSibling(this);">12,632</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestPaid</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental Disclosure of Non-Cash Investing and Financing Activities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_AccretionOfDiscountOnBondPayable', window );">Accretion of discount on bond payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="pmhs_AccretionOfDiscountOnBondPayable" onclick="toggleNextSibling(this);">502,465</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccretionOfDiscountOnBondPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ChangeInFairValueOfDerivativeLiability', window );">Change in fair market value of derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="pmhs_ChangeInFairValueOfDerivativeLiability" onclick="toggleNextSibling(this);">$ (175,732)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ChangeInFairValueOfDerivativeLiability</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_AccretionOfDiscountOnBondPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accretion of discount on bond payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_AccretionOfDiscountOnBondPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CashPaidDuringPeriodsForAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CashPaidDuringPeriodsForAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ChangeInFairValueOfDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Change in fair value of derivative liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ChangeInFairValueOfDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services and deposits that bring economic benefits for future periods.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IncreaseDecreaseInPrepaidExpenseAndDeposits</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_NetIncreaseDecreaseInCashHeldInEscrow">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net increase decrease in cash held in Escrow.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_NetIncreaseDecreaseInCashHeldInEscrow</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionOfDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in standardized measure of discounted future net cash flow as a result of passage of time.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 932<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 35<br><br> -Subparagraph (h)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8451039&amp;loc=d3e62500-109447<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccretionOfDiscount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The sum of adjustments which are added to or deducted from net income or loss, including the portion attributable to noncontrolling interest, to reflect cash provided by or used in operating activities, in accordance with the indirect cash flow method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfDerivatives">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.13(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfDerivatives</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOrLossOnSaleOfStockInSubsidiary">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph ((13)(g))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 13<br><br> -Subparagraph g<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GainOrLossOnSaleOfStockInSubsidiary</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (f)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the obligations due for goods and services provided by the following types of related parties: a parent company and its subsidiaries, subsidiaries of a common parent, an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management, an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableRelatedParties</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of cash paid for interest during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -Subparagraph (e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestPaid</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the deconsolidation of a previously consolidated subsidiary or sale of an entity that is related to it but not strictly controlled.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3179-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Definite Life Intangible Assets (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Definite Life Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2015</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" onclick="toggleNextSibling(this);">$ 14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2016</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2017</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2018</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2019</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" onclick="toggleNextSibling(this);">14,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" onclick="toggleNextSibling(this);">114,509</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-Lived Intangible Assets, Net</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">$ 186,414</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">$ 231,615</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(3)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6GAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Income Taxes (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets', window );">Excess of Tax over book depreciation Fixed assets</a></td>
        <td class="nump"><a title="pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" onclick="toggleNextSibling(this);">$ 12,711</a><span style="display:none;white-space:normal;text-align:left;">pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets</span><span></span></td>
        <td class="nump"><a title="pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets" onclick="toggleNextSibling(this);">$ 87,578</a><span style="display:none;white-space:normal;text-align:left;">pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents', window );">Excess of Tax over book depreciation Patents</a></td>
        <td class="nump"><a title="pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" onclick="toggleNextSibling(this);">52,041</a><span style="display:none;white-space:normal;text-align:left;">pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents</span><span></span></td>
        <td class="nump"><a title="pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents" onclick="toggleNextSibling(this);">114,028</a><span style="display:none;white-space:normal;text-align:left;">pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net Operating Loss Carryforward</a></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">2,380,106</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
        <td class="nump"><a title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" onclick="toggleNextSibling(this);">1,642,598</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation Allowance</a></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(2,444,858)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
        <td class="num"><a title="us-gaap_DeferredTaxAssetsValuationAllowance" onclick="toggleNextSibling(this);">(1,844,204)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredTaxAssetsValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent', window );">Total Deferred Tax Asset (Liabilities)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Tax Asset Excess Tax Over Depreciation Fixed Assets</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_DeferredTaxAssetExcessTaxOverDepreciationFixedAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Deferred Tax Asset Excess Tax Over Depreciation Patents.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_DeferredTaxAssetExcessTaxOverDepreciationPatents</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards, net of deferred tax liability attributable to taxable temporary differences expected to be realized or consumed within one year or operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 25<br><br> -Paragraph 20<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=29652012&amp;loc=d3e28680-109314<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E1MAG">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheet (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash (1)</a></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 3,008,831</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
        <td class="nump"><a title="us-gaap_Cash" onclick="toggleNextSibling(this);">$ 18,794</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Cash</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Cash held in escrow (2)</a></td>
        <td class="nump"><a title="us-gaap_EscrowDeposit" onclick="toggleNextSibling(this);">2,029,502</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EscrowDeposit</span><span></span></td>
        <td class="nump"><a title="us-gaap_EscrowDeposit" onclick="toggleNextSibling(this);">77,468</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EscrowDeposit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Other receivables</a></td>
        <td class="nump"><a title="us-gaap_AccountsAndOtherReceivablesNetCurrent" onclick="toggleNextSibling(this);">8,016</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsAndOtherReceivablesNetCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsAndOtherReceivablesNetCurrent" onclick="toggleNextSibling(this);">25,456</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsAndOtherReceivablesNetCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseCurrent" onclick="toggleNextSibling(this);">19,774</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">5,046,349</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">141,492</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net accumulated depreciation</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>OTHER ASSETS:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Definite life intangible assets</a></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">186,414</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_FiniteLivedIntangibleAssetsNet" onclick="toggleNextSibling(this);">231,615</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FiniteLivedIntangibleAssetsNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred stock offering costs</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_DeferredOfferingCosts" onclick="toggleNextSibling(this);">67,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DeferredOfferingCosts</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deposits</a></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">7,146</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepositsAssetsNoncurrent" onclick="toggleNextSibling(this);">10,360</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepositsAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total Other Assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsNoncurrent" onclick="toggleNextSibling(this);">193,560</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsNoncurrent" onclick="toggleNextSibling(this);">308,975</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">5,239,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">450,467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent', window );">Notes payable - related party, current portion</a></td>
        <td class="nump"><a title="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" onclick="toggleNextSibling(this);">99,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_NotesPayableRelatedPartiesClassifiedCurrent" onclick="toggleNextSibling(this);">728,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockOfferingEscrow', window );">Stock Offering Escrow</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable - trade</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">711,449</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">548,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable - related party</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">212,438</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableRelatedPartiesCurrent</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">733,826</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">858,135</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued income taxes payable</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">1,757,664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">2,134,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long Term Liabilities</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableRelatedPartiesNoncurrent', window );">Notes payable - related Party</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable -Dandrit (3)</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-Term Liabilities</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">1,757,664</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_Liabilities" onclick="toggleNextSibling(this);">2,134,637</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Liabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY (DEFICIT):</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; par value 0.0001, 100,000,000 shares authorized, 9,533,290 issued and outstanding at December 31, 2014 and 6,000,000 shares issued and outstanding at December 31, 2013</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">953</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">25,098,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">17,867,546</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net</a></td>
        <td class="nump"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">275,249</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" onclick="toggleNextSibling(this);">(31,190)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(21,892,007)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(19,521,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity (Deficit)</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">3,482,245</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(1,684,170)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' (Deficit)</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 5,239,909</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 450,467</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockOfferingEscrow">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents stock offering escrow.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockOfferingEscrow</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount due from customers, clients, or other third-parties, or arising from transactions not separately disclosed, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Article 9<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph b(1)<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 12<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 18<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 9<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 18<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.10-17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Cash</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.17)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 17<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.10)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19-26)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Liabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.32)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 25<br><br> -Article 7<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 32<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 21<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22-26)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesClassifiedCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesClassifiedCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableRelatedPartiesNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount for notes payable (written promise to pay), payable to related parties, which are due after one year (or one business cycle).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (d)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Subparagraph 1<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.23)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 23<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NotesPayableRelatedPartiesNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Current Assets<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (g)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 340<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=47804770&amp;loc=d3e5879-108316<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 7<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EI4AK">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholder's Equity (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 16, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Aug. 12, 2014</div>
        </th>
        <th class="th">
          <div>Feb. 12, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering of common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" onclick="toggleNextSibling(this);">889,690</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementAcquisitionPercentage', window );">Share exchange agreement acquisition percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementAcquisitionPercentage" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementAcquisitionPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany', window );">Share exchange agreement shares issued to parent company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" onclick="toggleNextSibling(this);">185,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue', window );">Common shares issued in payment of notes payable - related party, Value</a></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue" onclick="toggleNextSibling(this);">$ 926,386</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne', window );">Common shares issued in payment of note payable - related party,Value</a></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne" onclick="toggleNextSibling(this);">1,770,757</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial public offering [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Offering of common stock, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">12,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">156,360</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering of common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">2,400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering of common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">$ 5.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">1,093,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from stock offering, net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceInitialPublicOffering[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember]" onclick="toggleNextSibling(this);">5,466,450</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceInitialPublicOffering<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_IPOMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private offering [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Offering of common stock, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Offering of common stock price per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesIssuedPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">$ 5.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesIssuedPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Gross proceeds from share issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockConsiderationReceivedOnTransaction[us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember]" onclick="toggleNextSibling(this);">2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= us-gaap_PrivatePlacementMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_ShortTermDebtTypeAxis<br>= us-gaap_ConvertibleDebtMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember', window );">Accrued Interest [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember]" onclick="toggleNextSibling(this);">179,612</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_ShortTermDebtTypeAxis<br>= pmhs_AccruedInterestMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember', window );">Derivative Liability [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember]" onclick="toggleNextSibling(this);">673,736</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_ShortTermDebtTypeAxis<br>= pmhs_DerivativeLiabilityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=us-gaap_ParentCompanyMember', window );">Parent Company [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ExchangedSharesOfParentSCommonStock', window );">Exchanged shares of parent's common stock</a></td>
        <td class="nump"><a title="pmhs_ExchangedSharesOfParentSCommonStock[dei_LegalEntityAxis=us-gaap_ParentCompanyMember]" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ExchangedSharesOfParentSCommonStock<br>/ dei_LegalEntityAxis<br>= us-gaap_ParentCompanyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability[dei_LegalEntityAxis=us-gaap_ParentCompanyMember]" onclick="toggleNextSibling(this);">174,578</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ dei_LegalEntityAxis<br>= us-gaap_ParentCompanyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable', window );">Common shares issued in payment of notes payable - related party , Shares</a></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[dei_LegalEntityAxis=us-gaap_ParentCompanyMember]" onclick="toggleNextSibling(this);">96,288</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ dei_LegalEntityAxis<br>= us-gaap_ParentCompanyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne', window );">Common shares issued in payment of note payable - related party</a></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne[dei_LegalEntityAxis=us-gaap_ParentCompanyMember]" onclick="toggleNextSibling(this);">184,051</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne<br>/ dei_LegalEntityAxis<br>= us-gaap_ParentCompanyMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementAcquisitionPercentage', window );">Share exchange agreement acquisition percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementAcquisitionPercentage[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementAcquisitionPercentage<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementNumberOfShareCancellation', window );">Share exchange agreement number of share cancellation</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementNumberOfShareCancellation[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,400,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementNumberOfShareCancellation<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ExchangedSharesOfParentSCommonStock', window );">Exchanged shares of parent's common stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ExchangedSharesOfParentSCommonStock[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1.498842</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ExchangedSharesOfParentSCommonStock<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany', window );">Share exchange agreement shares issued to parent company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementSharesIssuedToParentCompany[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common Stock reserved for issuance</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">185,053</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">26</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable', window );">Common shares issued in payment of notes payable - related party , Shares</a></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">144,321</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">144,321</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue', window );">Common shares issued in payment of notes payable - related party, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne', window );">Common shares issued in payment of note payable - related party</a></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">275,863</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">275,863</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne', window );">Common shares issued in payment of note payable - related party,Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 28</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares of parent common stock outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,318,151</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Parent Company [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Shares of parent common stock outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[dei_LegalEntityAxis=us-gaap_ParentCompanyMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">8,040,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ dei_LegalEntityAxis<br>= us-gaap_ParentCompanyMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>ommon shares issued in payment of notes payable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable value one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ExchangedSharesOfParentSCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exchanged shares of parents common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ExchangedSharesOfParentSCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementAcquisitionPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement acquisition percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementAcquisitionPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementNumberOfShareCancellation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement number of share cancellation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementNumberOfShareCancellation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Exchange Agreement Shares Issued To Parent Company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares conversion of bond payable related party and derivative liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares value conversion of bond payable related party and derivative liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate number of common shares reserved for future issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Cash received on stock transaction after deduction of issuance costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount per share or per unit of equity securities issued by non-development stage entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=us-gaap_ParentCompanyMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_LegalEntityAxis=us-gaap_ParentCompanyMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EINBI">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Statement of Stockholders' (Deficit) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Total</div>
        </th>
        <th class="th">
          <div>Common Stock</div>
        </th>
        <th class="th">
          <div>Additional Paid In Capital</div>
        </th>
        <th class="th">
          <div>Accumulated Earnings (Deficit)</div>
        </th>
        <th class="th">
          <div>Other Comprehensive Income (loss)</div>
        </th>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 532</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 12,817,122</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (17,373,765)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_OtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">$ 188,280</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_OtherComprehensiveIncomeMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance, Shares at Dec. 31, 2012</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">5,318,151</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">26</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">2,353,322</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue', window );">Common shares issued in payment of notes payable - related party at 6.42 per shares, December 2013, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">926,372</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable', window );">Common shares issued in payment of notes payable - related party at 6.42 per shares, December 2013, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">144,321</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne', window );">Common shares issued in payment of note payable - related party at 6.42 per shares, December 2013, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">28</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,770,730</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne', window );">Common shares issued in payment of note payable - related party at 6.42 per shares, December 2013, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">275,863</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Equity Adjustment for Foreign Currency Translation Year Ended December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" onclick="toggleNextSibling(this);">219,470</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax[us-gaap_StatementEquityComponentsAxis=us-gaap_OtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(219,470)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_OtherComprehensiveIncomeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
        <td class="num"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">(1,684,170)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">600</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">17,867,546</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(19,521,126)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_OtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">(31,190)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_OtherComprehensiveIncomeMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2013</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue', window );">To record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement wherein DanDrit Biotech USA Inc. ("Parent") issued 6,000,000 common shares to acquire a 100% interest in DanDrit Biotech A/S ("Subsidiary") DanDrit Biotech USA Inc., (Formerly Putnam Hills Corp),</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">204</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="num"><a title="pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">(79,436)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares', window );">To record the recapitalization of Subsidiary in connection with the February 12, 2014 Share Exchange Agreement wherein DanDrit Biotech USA Inc. ("Parent") issued 6,000,000 common shares to acquire a 100% interest in DanDrit Biotech A/S ("Subsidiary") DanDrit Biotech USA Inc., (Formerly Putnam Hills Corp), Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">2,040,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue', window );">To record the issuance of 4,000 and 141,000 common shares on September 4, 2014 in connection Initial Public Offering valued at $5 per share or $4,000 and $141,000, respectfully. Net of stock offering cost of $67,000, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">14</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">657,985</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares', window );">To record the issuance of 4,000 and 141,000 common shares on September 4, 2014 in connection Initial Public Offering valued at $5 per share or $4,000 and $141,000, respectfully. Net of stock offering cost of $67,000, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">145,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne', window );">To record the issuance of 100 common shares on September 24, 2014 in connection Initial Public Offering valued at $5 per share or $500, Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">0.01</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">500</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne', window );">To record the issuance of 100 common shares on September 24, 2014 in connection Initial Public Offering valued at $5 per share or $500, Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue', window );">To record the issuance of 889,690 common shares in October, 2014 in connection Initial Public Offering valued at $5 per share or $4,358,879 net of stock offering cost of $89,360 value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">89</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">4,359,001</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares', window );">To record the issuance of 889,690 common shares in October, 2014 in connection Initial Public Offering valued at $5 per share or $4,358,879 net of stock offering cost of $89,360, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">889,690</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne', window );">To record the issuance of 58,500 common shares on November 13, 2014 in connection Initial Public Offering valued at $5 per share or $292,500, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">6</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">292,494</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne', window );">To record the issuance of 58,500 common shares on November 13, 2014 in connection Initial Public Offering valued at $5 per share or $292,500, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">58,500</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue', window );">To record the issuance of 400,000 common shares on December 31, 2014 in connection private placement valued at $5 per share or $2,000,000.</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">40</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">1,999,960</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares', window );">To record the issuance of 400,000 common shares on December 31, 2014 in connection private placement valued at $5 per share or $2,000,000, shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Equity Adjustment for Foreign Currency Translation Year Ended December 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" onclick="toggleNextSibling(this);">306,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax[us-gaap_StatementEquityComponentsAxis=us-gaap_OtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">306,439</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_OtherComprehensiveIncomeMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_AccumulatedEarningsRounding', window );">Rounding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="pmhs_AccumulatedEarningsRounding[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">2</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccumulatedEarningsRounding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">(2,370,883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">(2,370,883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">$ 3,482,245</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 953</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember]" onclick="toggleNextSibling(this);">$ 25,098,050</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_AdditionalPaidInCapitalMember</span><span></span></td>
        <td class="num"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember]" onclick="toggleNextSibling(this);">$ (21,892,007)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_RetainedEarningsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity[us-gaap_StatementEquityComponentsAxis=us-gaap_OtherComprehensiveIncomeMember]" onclick="toggleNextSibling(this);">$ 275,249</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_OtherComprehensiveIncomeMember</span><span></span></td>
      </tr>
      <tr class="rc">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, Shares at Dec. 31, 2014</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharesOutstanding[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharesOutstanding<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_AccumulatedEarningsRounding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accumulated earnings rounding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_AccumulatedEarningsRounding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>ommon shares issued in payment of notes payable value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable value one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayableValueOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares in connection with initial public offering during period shares one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShareOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares in connection with initial public offering during period shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares in connection with initial public offering during period value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares in connection with initial public offering during period value one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithInitialPublicOfferingDuringPeriodValueOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares in connection with private placement during period shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares in connection with private placement during period value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithPrivatePlacementDuringPeriodValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Shares In Connection With Public Offering During Period One.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Common Shares in Connection with Public Offering during Period Shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of Common Shares in Connection with Public Offering during Period Value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Shares In Connection With Public Offering During Period Value One</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement common shares issued for acquisition during period shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement common shares issued for acquisition during period Value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementCommonSharesIssuedForAcquisitionDuringPeriodValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares conversion of bond payable related party and derivative liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares value conversion of bond payable related party and derivative liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares issued which are neither cancelled nor held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E5DAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Notes Payable - Related Party (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable - Related Party [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2014</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" onclick="toggleNextSibling(this);">$ 99,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2015</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2016</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2017</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2018</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" onclick="toggleNextSibling(this);">$ 99,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 3<br><br> -Subparagraph (SX 210.12-04.(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENT</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 14&#160;&#8212;&#160;SUBSEQUENT EVENT</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">The Company&#8217;s management reviewed material events through March 30, 2015.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">On March 13, 2015, the Company, DanDritDenmark and Robert E. Wolfe entered into an Agreement pursuant to which Mr. Wolfe ceased to be Chief Financial Officer of DanDrit Denmark effective as of the date on which a replacement Chief Financial Officer is engaged (the &#8220;Agreement&#8221;). It is currently anticipated that Mr. Wolfe will continue to serve as the Chief Financial Officer of the Company through a transition period that will end following the date that the Company files its Annual Report on Form 10-K for the year ended December 31, 2014 (the &#8220;Transition Period&#8221;). In accordance with the terms of the Agreement and except as amended by the Agreement, the CFO Service Agreement between DanDrit Denmark and Mr. Wolfe, dated as of February 10, 2014 (the &#8220;Wolfe Employment Agreement&#8221;) will remain in effect through October 31, 2015 (the &#8220;Termination Date&#8221;). In addition, Mr. Wolfe is entitled to receive (i) all salary payable in accordance with the terms of the Wolfe Employment Agreement, along with any unpaid accrued expenses, through the Termination Date; (ii) attorney fees of up to a maximum of $4,000; (iii) a bonus in an amount equal to $10,000 following the filing of the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2014; and (iv) a fee of $150.00 per hour for any consulting services that Mr. Wolfe may provide in connection with the filing and completion of the Company&#8217;s current and periodic filings with the Securities and Exchange Commission; provided that the first 100 hours of consultant services provided from May 1, 2015 through October 31, 2015 shall not be billable. Other than as described above, the terms of the Wolfe Employment Agreement will continue to govern Mr. Wolfe&#8217;s relationship with the Company and DanDrit Denmark in all material respects through the Termination Date. In addition, Mr. Wolfe continues to serve as a director of the Company.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">In connection with Mr. Wolfe&#8217;s departure as Chief Financial Officer of DanDrit Denmark, Lone Degn was appointed to serve as Chief Financial Officer of DanDrit Denmark effective as of March 12, 2015. Subject to approval by the Company&#8217;s Board of Directors and Mr. Wolfe&#8217;s resignation as Chief Financial Officer of the Company, it is currently anticipated that Ms. Degn will be appointed to replace Mr. Wolfe upon the effective date of his resignation following the Transition Period.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-family: 'times new roman', times, serif;">In accordance with the terms of a Contract of Employment, dated as of the Effective Date by and between DanDrit Denmark and Ms. Degn (the &#8220;Degn Employment Agreement&#8221;), Ms.
 Degn will be employed by DanDrit Denmark for an indefinite term unless earlier terminated pursuant to the terms therein. The Degn Employment Agreement provides that Ms. Degn will receive a salary of DKK 60,000 gross per month, to be paid monthly on the last business day of each month and subject to annual review and increases by the board of directors of DanDrit Denmark, as it deems appropriate.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">In addition to her salary, Ms. Degn will be entitled to receive reimbursement of all reasonable costs and expenses incurred in connection with the performance of her duties in accordance with the terms of the Degn Employment Agreement In addition, DanDrit Denmark has agreed to contribute an amount equal to 10% of Ms. Degn&#8217;s yearly salary to a pension fund or bank account established for such purpose.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-family: 'times new roman', times, serif;">Either DanDrit Denmark or Ms. Degn may terminate the employment in accordance with the Danish Salaried Employees Act.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in; background-color: white;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">The foregoing descriptions of the Agreement and the Degn Employment Agreement contained herein do not purport to be complete and are qualified in their entirety by reference to the complete text of the&#160;<font style="background-color: white;">Agreement and the Degn Employment Agreement, which are filed as exhibits to this report.</font></font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6PBM">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable - Related Party (Details Textual)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="9">0 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2"></th>
        <th class="th" colspan="2">0 Months Ended</th>
        <th class="th" colspan="4">12 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 16, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Sune Olsen Holding Aps [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 02, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 02, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Nov. 20, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Nov. 20, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Nov. 11, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Nov. 11, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan One [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Two [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 20, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Two [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 20, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Two [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2011

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Four [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Five [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 01, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Five [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Five [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Five [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Six [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Six [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Jun. 20, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Six [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Jun. 20, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Six [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Apr. 14, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Six [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Apr. 14, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Six [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Seven [Member]</div>
        </th>
        <th class="th">
          <div>Jul. 26, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Seven [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Jul. 26, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Seven [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Aug. 15, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Seven [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Aug. 15, 2013

</div>
          <div>Sune Olsen Holding Aps [Member]

</div>
          <div>Loan Seven [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan [Member]</div>
        </th>
        <th class="th">
          <div>Mar. 18, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 18, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Feb. 15, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Feb. 15, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan Three [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014

</div>
          <div>Paseco Aps [Member]

</div>
          <div>Loan Three [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>DKTI A/S [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 16, 2013

</div>
          <div>DKTI A/S [Member]

</div>
          <div>Loan Three [Member]</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>DKTI A/S [Member]

</div>
          <div>Loan Three [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013

</div>
          <div>DKTI A/S [Member]

</div>
          <div>Loan Three [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>DKTI A/S [Member]

</div>
          <div>Loan Three [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2012

</div>
          <div>DKTI A/S [Member]

</div>
          <div>Loan Three [Member]

</div>
          <div>DKK</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2014

</div>
          <div>Nlbdit Two Zero One Zero Enterprises, Llc [Member]

</div>
          <div>Loan Ten [Member]

</div>
          <div>USD ($)</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014

</div>
          <div>Nlbdit Two Zero One Zero Enterprises, Llc [Member]

</div>
          <div>Loan Ten [Member]

</div>
          <div>USD ($)</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured loan</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt" onclick="toggleNextSibling(this);">$ 38,235</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">$ 165,990</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);"> 900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">$ 74,696</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);"> 405,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">$ 276,651</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);"> 1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanTwoMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">$ 184,434</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanTwoMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanTwoMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);"> 1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanTwoMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">$ 424,198</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);"> 2,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">$ 461,084</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);"> 2,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">$ 368,868</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);"> 2,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_UnsecuredDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanTenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember]" onclick="toggleNextSibling(this);">$ 42,753</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_UnsecuredDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanTenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_AccruedInterestInPercentage', window );">Accrued interest in percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanOneMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanOneMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">5.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedInterestInPercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedInterestInPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Loans payable, current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">59,854</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">338,719</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">25,019</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">143,750</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">232,841</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">1,267,724</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">265,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">773,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">4,375,932</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">177,239</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">1,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">133,343</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">750,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">880,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayableCurrent[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">5,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayableCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Company borrowed loans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_OtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">783,139</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">4,431,862</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOtherShortTermBorrowings', window );">Interest expense, borrowing loans</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseOtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFiverMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">15,617</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseOtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFiverMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseOtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFiverMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">86,047</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseOtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFiverMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseOtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">12,646</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseOtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseOtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">71,563</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseOtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseOtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanTenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember]" onclick="toggleNextSibling(this);">213</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseOtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanTenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseOtherShortTermBorrowings[us-gaap_LongtermDebtTypeAxis=pmhs_LoanTenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember]" onclick="toggleNextSibling(this);">619</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseOtherShortTermBorrowings<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanTenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Additional loan on borrowings</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFiverMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">14,075</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFiverMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">55,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">310,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Increased interest percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_UnsecuredDebtMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_PasecoApsMember]" onclick="toggleNextSibling(this);">7.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_PasecoApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateEffectivePercentage[us-gaap_LongtermDebtTypeAxis=pmhs_LoanTenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateEffectivePercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanTenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NlbditTwoZeroOneZeroEnterprisesLlcMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">3,617</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">20,469</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">468</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">2,689</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">3,804</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">20,959</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">2,827</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">15,575</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">42,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseAccruedInterest[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">230,337</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseAccruedInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable', window );">Converted into common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">35,106</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFiverMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">25,844</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFiverMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">29,036</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">29,036</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">86,204</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">86,204</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">33,705</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonSharesIssuedInPaymentOfNotesPayable[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">96,288</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt', window );">Common stock exchanged during period of conversion</a></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">275,863</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanFourMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">52,618</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanFourMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">43,520</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">43,520</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">129,207</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">129,207</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSevenMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">50,518</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSevenMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">144,321</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt[us-gaap_LongtermDebtTypeAxis=pmhs_LoanThreeMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_DktiAsMember]" onclick="toggleNextSibling(this);">144,321</a><span style="display:none;white-space:normal;text-align:left;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanThreeMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_DktiAsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_AccruedLegalFees', window );">Accrued Legal Fees</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_AccruedLegalFees[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">265,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedLegalFees<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="pmhs_AccruedLegalFees[us-gaap_LongtermDebtTypeAxis=pmhs_LoanSixMember;us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AccruedLegalFees<br>/ us-gaap_LongtermDebtTypeAxis<br>= pmhs_LoanSixMember<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SuneOlsenHoldingApsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">May  01,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">Feb.  01,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Extended maturity date, Description</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The Company extendedthematurity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">The loans are payable 14 days after the completion of the contemplated public offering in DanDrit Biotech USA, Inc. or February 1, 2015, and accrue interest at 5% per annum.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Loans payable</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_LoansPayable" onclick="toggleNextSibling(this);">$ 38,235</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LoansPayable</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_AccruedInterestInPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_AccruedInterestInPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_AccruedLegalFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Accrued legal fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_AccruedLegalFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonSharesIssuedInPaymentOfNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares issued in payment of notes payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonSharesIssuedInPaymentOfNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common stock exchanged during period of conversion of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_CommonStockExchangedDuringPeriodOfConversionOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOtherShortTermBorrowings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest expense incurred during the reporting period on other short-term borrowings.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseOtherShortTermBorrowings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LoansPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts at the balance sheet date of short-term borrowings not otherwise specified in the taxonomy having initial terms less than one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19(a)(7))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Article 5<br><br> -Subsection 19, 20, 22<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
        <td class="text"><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Useful Life</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">31-Dec<br />2014</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">31-Dec<br />2013</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Lab equipment and instruments</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 173px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">4-6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">178,547</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">194,143</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Computer equipment</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">4-6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">61,151</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;
 font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">66,493</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">239,698</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">260,636</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Less Accumulated Depreciation</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(239,698</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(260,636</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Net Property and Equipment</font></td><td style="padding-bottom: 4pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt;
 font-size-adjust: none; font-stretch: normal;"><font style="font-family:
 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph b<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EFXAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statement of Stockholders' (Deficit) (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="2">1 Months Ended</th>
        <th class="th" colspan="2">12 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Sep. 04, 2014</div>
        </th>
        <th class="th">
          <div>Oct. 31, 2014</div>
        </th>
        <th class="th">
          <div>Sep. 24, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Nov. 13, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare', window );">Conversion of bond payable related party and derivative liability per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare" onclick="toggleNextSibling(this);">$ 9.00</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_NotesPayableRelatedPartyPerShare', window );">Notes payable related party per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_NotesPayableRelatedPartyPerShare" onclick="toggleNextSibling(this);">$ 6.42</a><span style="display:none;white-space:normal;text-align:left;">pmhs_NotesPayableRelatedPartyPerShare</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_NotesPayableRelatedPartyPerShareOne', window );">Notes payable related party per share one</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_NotesPayableRelatedPartyPerShareOne" onclick="toggleNextSibling(this);">$ 6.42</a><span style="display:none;white-space:normal;text-align:left;">pmhs_NotesPayableRelatedPartyPerShareOne</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementAcquisitionPercentage', window );">Share exchange agreement acquisition percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementAcquisitionPercentage" onclick="toggleNextSibling(this);">100.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementAcquisitionPercentage</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany', window );">Share exchange agreement shares issued to parent company</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_ShareExchangeAgreementSharesIssuedToParentCompany" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonShares', window );">Issuance of common shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonShares" onclick="toggleNextSibling(this);">889,690</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonShares</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonShares" onclick="toggleNextSibling(this);">100</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonShares</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonShares" onclick="toggleNextSibling(this);">4,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonShares</span><span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonShares" onclick="toggleNextSibling(this);">58,500</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonShares</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesOne', window );">Issuance of common shares one</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesOne" onclick="toggleNextSibling(this);">141,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesOne</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesValue', window );">Issuance of common shares value</a></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesValue" onclick="toggleNextSibling(this);">$ 4,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesValue" onclick="toggleNextSibling(this);">$ 500</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesValueOne', window );">Issuance of common shares value one</a></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesValueOne" onclick="toggleNextSibling(this);">141,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesValueOne</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfPublicOfferingCost', window );">Issuance of Public Offering cost</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfPublicOfferingCost" onclick="toggleNextSibling(this);">4,358,879</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfPublicOfferingCost</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfPublicOfferingCost" onclick="toggleNextSibling(this);">292,500</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfPublicOfferingCost</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_PublicOfferingValuePerShare', window );">Public offering value per share</a></td>
        <td class="nump"><a title="pmhs_PublicOfferingValuePerShare" onclick="toggleNextSibling(this);">$ 5.00</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PublicOfferingValuePerShare</span><span></span></td>
        <td class="nump"><a title="pmhs_PublicOfferingValuePerShare" onclick="toggleNextSibling(this);">$ 5</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PublicOfferingValuePerShare</span><span></span></td>
        <td class="nump"><a title="pmhs_PublicOfferingValuePerShare" onclick="toggleNextSibling(this);">$ 5.00</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PublicOfferingValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_PublicOfferingValuePerShare" onclick="toggleNextSibling(this);">$ 5</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PublicOfferingValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_OfferingCostNet', window );">Net of offering cost</a></td>
        <td class="nump"><a title="pmhs_OfferingCostNet" onclick="toggleNextSibling(this);">67,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_OfferingCostNet</span><span></span></td>
        <td class="nump"><a title="pmhs_OfferingCostNet" onclick="toggleNextSibling(this);">89,360</a><span style="display:none;white-space:normal;text-align:left;">pmhs_OfferingCostNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IssuanceOfCommonSharesTwo', window );">Issuance of common shares two</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_IssuanceOfCommonSharesTwo" onclick="toggleNextSibling(this);">400,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IssuanceOfCommonSharesTwo</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_PrivatePlacementValuePerShare', window );">Private placement value per share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_PrivatePlacementValuePerShare" onclick="toggleNextSibling(this);">$ 5</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PrivatePlacementValuePerShare</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_PrivatePlacementValue', window );">Private Placement Value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_PrivatePlacementValue" onclick="toggleNextSibling(this);">$ 2,000,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PrivatePlacementValue</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Conversion of bond payable related party and derivative liability per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ConversionOfBondPayableRelatedPartyAndDerivativeLiabilityPerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Shares</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Shares One</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesTwo">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares two.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesTwo</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of common shares value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfCommonSharesValueOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance Of Common Shares Value One.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfCommonSharesValueOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IssuanceOfPublicOfferingCost">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Issuance of public offering cost.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IssuanceOfPublicOfferingCost</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_NotesPayableRelatedPartyPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notes payable related party per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_NotesPayableRelatedPartyPerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_NotesPayableRelatedPartyPerShareOne">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notes payable related party per share one.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_NotesPayableRelatedPartyPerShareOne</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_OfferingCostNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Offering cost net.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_OfferingCostNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_PrivatePlacementValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Private placement value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_PrivatePlacementValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_PrivatePlacementValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Private placement value per share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_PrivatePlacementValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_PublicOfferingValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Public Offering Value Per Share</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_PublicOfferingValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementAcquisitionPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share exchange agreement acquisition percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementAcquisitionPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ShareExchangeAgreementSharesIssuedToParentCompany">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Share Exchange Agreement Shares Issued To Parent Company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ShareExchangeAgreementSharesIssuedToParentCompany</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6FAC">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Consolidated Balance Sheet (Parenthetical) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Balance Sheet [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockParOrStatedValuePerShare" onclick="toggleNextSibling(this);">$ 0.0001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockParOrStatedValuePerShare</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesAuthorized" onclick="toggleNextSibling(this);">100,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesAuthorized</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesIssued" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesIssued</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockSharesOutstanding" onclick="toggleNextSibling(this);">6,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockSharesOutstanding</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face amount or stated value per share of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Loss Per Share<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_LossPerShareAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER SHARE</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 9&#160;&#8212;&#160;LOSS PER SHARE</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">The following data shows the amounts used in computing loss per share and the effect on income and the weighted average number of shares of potential dilutive common stock for the years ended December 31, 2014 and 2013:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; font-size: 10pt; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="6"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>December 31,</b></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>2014</b></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: center; line-height: 15.3333330154419px;" colspan="2"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>2013</b></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1110px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Net (Loss)</font></td><td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 114.545448303223px; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(2,370,883</font></td><td style="width: 14.5454540252686px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">)</font></td><td style="width: 13.63636302948px; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">$</font></td><td style="width: 113.636360168457px; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">(2,214,361</font></td><td style="width: 13.63636302948px; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;">Weighted average number of common shares used in basic earnings per share</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">7,500,142</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">3,557,893</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Effect of dilutive securities, stock options and warrants</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">-</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="padding-left: 10pt; text-indent: -10pt; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Weighted average number of common shares and potential dilutive</font><font style="font-family: 'times new roman', times, serif;"><br /><font style="font-size: 10pt;">common shares outstanding used in dilutive earnings per share</font></font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">7,500,142</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; line-height: 15.3333330154419px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">3,557,893</font></td><td style="line-height: 15.3333330154419px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">For the years ended December 31, 2014 and 2013, the Company had no options outstanding to purchase common stock of the Parent.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_LossPerShareAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_LossPerShareAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for earnings per share.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1278-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 55<br><br> -Paragraph 52<br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.21)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EVRAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document and Entity Information (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 30, 2015</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">DanDrit Biotech USA, Inc.<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0001527728<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-K<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Dec. 31,  2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2014<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">FY<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Smaller Reporting Company<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityPublicFloat" onclick="toggleNextSibling(this);">$ 24,956,260</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityPublicFloat</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">9,533,290</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityPublicFloat</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_DocumentAndEntityInformationAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_DocumentAndEntityInformationAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Stockholder's Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
        <td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 10&#160;&#8212;&#160;STOCKHOLDERS&#8217; EQUITY</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Common Stock</b>&#160;&#8212;&#160;The Company has 100,000,000 authorized shares of Common stock $0.0001.&#160;&#160;As of December 31, 2014 there were 9,533,290 shares issued and outstanding.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Share Exchange Agreement</b>/<b>Reverse Acquisition</b>&#160;- On February 12, 2014, in accordance with the terms and conditions of a Share Exchange Agreement (the "Share Exchange Agreement"), wecompleted the acquisition of approximately 100% of the issued and outstanding capital stock&#160;&#160;of&#160;&#160;DanDrit Denmark (the &#8220;Share Exchange&#8221;) and as a result became DanDrit Denmark&#8217;s parent company (the &#8220;Parent&#8221;). In connection with the Share Exchange, each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of DanDrit USA&#8217;s common stock, par value $.0001 per share (the &#8220;Common Stock&#8221;) for an aggregate of 6,000,000 shares, including 185,053 shares of Common Stock reserved for issuance, in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, to the DanDrit Denmark shareholders who did not consent to the Share Exchange and deemed issued and outstanding for accounting purposes. In addition, in connection with the Share Exchange (1) the sole shareholder prior to the Share Exchange agreed to cancel 4,400,000 shares of outstanding Common Stock owned by it and (2) the board of directors and executive management of DanDrit Denmark was appointed to serve as the Board of Directors and executive management of DanDrit USA effective upon the resignation of the sole officer and director of DanDrit USA prior to the closing of the Share Exchange.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Common Stock Issuances &#8211;</b>&#160;On<font style="background-color: white;">&#160;December 31, 2014,</font>&#160;the Company received&#160;<font style="background-color: white;">$2,000,000 in connection with a private offering of 400,000 shares of common stock at an offering price of $5.00 per share.</font></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">During the year ended December 31, 2014, pursuant to&#160;<font style="background-color: white;">the Company&#8217;s offering up to $12,000,000 (2,400,000 shares) of common stock at an offering price of $5.00 per share in an initial public offering pursuant to a registration statement effective on August 12, 2014, the Company sold 1,093,290 shares of common stock for gross proceeds of $5,466,450 less offering costs of $156,360.</font></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On December 16, 2013, DanDrit<font style="background-color: white;">&#160;Denmark</font>&#160;issued 174,578 shares of its common stock which were exchanged for 261,665 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of a $1,500,000 convertible bond, $179,612 of accrued interest and the remaining $673,736 of derivative liability associated with the conversion feature of the bond.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none;
 text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On December 16, 2013, DanDrit<font style="background-color: white;">Denmark</font>&#160;issued 96,288 shares of its common stock which were exchanged for 144,321 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of $926,386 of notes payable and related accrued interest payable to DKTI A/S.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<div style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On December 16, 2013, DanDrit<font style="background-color: white;">&#160;Denmark&#160;</font>issued 184,051 shares of its common stock which were exchanged for 275,863 shares of Common Stock of the Parent upon the closing of the Share Exchange in payment of $1,770,757 of notes payable and related accrued interest payable to Sune Olsen Holdings ApS and Advance Biotech Invest AS.</div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Voting-</i></b>&#160;Holders of the Company&#8217;s common stock are entitled to one vote for each share held of record on each matter submitted to a vote of stockholders, including the election of directors, and do not have any right to cumulate votes in the election of directors.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Dividends-&#160;</i></b>Holders of the Company&#8217;s common stock are entitled to receive ratably such dividends as our Board of Directors from time to time may declare out of funds legally available.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Liquidation Rights-</i></b>&#160;In the event of any liquidation, dissolution or winding-up of affairs of the Company, after payment of all of our debts and liabilities, the holders of the Company&#8217;s common stock will be entitled to share ratably in the distribution of any of our remaining assets.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EY1AE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statement of Operations (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statement of Operations [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Net Sales</a></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_SalesRevenueGoodsNet" onclick="toggleNextSibling(this);">$ 32,768</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SalesRevenueGoodsNet</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of Goods Sold</a></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">295,661</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
        <td class="nump"><a title="us-gaap_CostOfGoodsSold" onclick="toggleNextSibling(this);">109,299</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CostOfGoodsSold</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross Loss</a></td>
        <td class="num"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">(295,661)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
        <td class="num"><a title="us-gaap_GrossProfit" onclick="toggleNextSibling(this);">(76,531)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GrossProfit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">1,644,918</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">1,233,683</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">18,981</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationDepletionAndAmortization" onclick="toggleNextSibling(this);">38,297</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationDepletionAndAmortization</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ConsultingExpenses', window );">Consulting expenses</a></td>
        <td class="nump"><a title="pmhs_ConsultingExpenses" onclick="toggleNextSibling(this);">469,666</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ConsultingExpenses</span><span></span></td>
        <td class="nump"><a title="pmhs_ConsultingExpenses" onclick="toggleNextSibling(this);">390,437</a><span style="display:none;white-space:normal;text-align:left;">pmhs_ConsultingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expense</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">2,133,565</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">1,662,417</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(2,429,226)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(1,738,948)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other Income (Expense)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest (expense)</a></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(84,550)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_InterestExpense" onclick="toggleNextSibling(this);">(652,703)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_GainOnForgivenessOfDebt', window );">Gain on forgiveness of debt</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="pmhs_GainOnForgivenessOfDebt" onclick="toggleNextSibling(this);">49,016</a><span style="display:none;white-space:normal;text-align:left;">pmhs_GainOnForgivenessOfDebt</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossRealized', window );">Gain (loss) on currency transactions</a></td>
        <td class="num"><a title="us-gaap_ForeignCurrencyTransactionGainLossRealized" onclick="toggleNextSibling(this);">(40,583)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossRealized</span><span></span></td>
        <td class="nump"><a title="us-gaap_ForeignCurrencyTransactionGainLossRealized" onclick="toggleNextSibling(this);">19,541</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ForeignCurrencyTransactionGainLossRealized</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainOnDerivative', window );">Gain on derivative liability</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="nump"><a title="us-gaap_DerivativeGainOnDerivative" onclick="toggleNextSibling(this);">175,732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DerivativeGainOnDerivative</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest and other income</a></td>
        <td class="nump"><a title="us-gaap_InterestIncomeOther" onclick="toggleNextSibling(this);">5,937</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeOther</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestIncomeOther" onclick="toggleNextSibling(this);">1</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestIncomeOther</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total Other Income (Expense)</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(119,196)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(408,413)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss Before Income Taxes</a></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(2,548,422)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
        <td class="num"><a title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" onclick="toggleNextSibling(this);">(2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">(177,539)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,370,883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">BASIC AND DILUTED LOSS PER SHARE</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.32)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.40)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING- BASIC AND DILUTED</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">7,500,142</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">5,332,721</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_WeightedAverageBasicAndDilutedLossPerShare', window );">WEIGHTED AVERAGE BASIC AND DILUTED LOSS PER SHARE</a></td>
        <td class="num"><a title="pmhs_WeightedAverageBasicAndDilutedLossPerShare" onclick="toggleNextSibling(this);">$ (0.32)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_WeightedAverageBasicAndDilutedLossPerShare</span><span></span></td>
        <td class="num"><a title="pmhs_WeightedAverageBasicAndDilutedLossPerShare" onclick="toggleNextSibling(this);">$ (0.40)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_WeightedAverageBasicAndDilutedLossPerShare</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ConsultingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Consulting expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ConsultingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_GainOnForgivenessOfDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gain on forgiveness of debt.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_GainOnForgivenessOfDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_WeightedAverageBasicAndDilutedLossPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when weighted average basic and diluted loss per share are the same amount and reported as a single line item on the face of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_WeightedAverageBasicAndDilutedLossPerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total costs related to goods produced and sold during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 2<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.2(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainOnDerivative">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativeGainOnDerivative</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossRealized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30690-110894<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450189&amp;loc=d3e30700-110894<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossRealized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1,2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GrossProfit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 940<br><br> -SubTopic 20<br><br> -Section 25<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35710027&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 10<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the cost of borrowed funds accounted for as interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.9)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 9<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of interest income earned from interest bearing assets not separately disclosed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.1(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable - Related Party<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable - Related Party [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_NotesPayableDisclosureTextBlock', window );">NOTES PAYABLE - RELATED PARTY</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 4&#160;&#8212;&#160;NOTES PAYABLE &#8211; RELATED PARTY</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Notes payable to related parties consists of the following as of December 31, 2014 and 2013:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="6"><font style="font-family: 'times new roman', times, serif;">December 31,</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">38,235</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch:
 normal;"><font style="font-family: 'times
 new roman', times, serif;">Note Payable ML Group</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">18,963</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">21,557</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">42,753</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">5% Note Payable - Sune Olsen Holding ApS</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">521,390</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">5% Note Payable - Sune Olsen</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">185,054</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;
 font-stretch: normal;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Total Notes Payable &#8211; Related Party</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">99,951</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">728,001</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Less Current Maturities</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(99,951</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(728,001</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Note Payables &#8211; Related Party Long Term</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The following represents the future maturities of long-term debt as of December 31, 2014:</font></p><p style="font: 10pt/normal 'times new roman', times, serif;
 margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal;
 word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;"><u>Year ending December 31,</u></font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: right; font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1367px; text-align: left; padding-left: 9pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">99,951</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">2015</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">2016</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">2017</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-left: 9pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">2018</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; text-indent: 0px; padding-bottom: 1.5pt; padding-left: 0px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Thereafter</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right;
 border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times,
 serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">99,951</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On February 15, 2014 and March 18, 2014, DanDrit Denmarkreceived DKK 2,500,000 ($461,084) and DKK 2,300,000 ($424,198) loans (the &#8220;2014 Loans&#8221;), respectively, from PasecoApS, an entity owned by a shareholder of the Company (&#8220;Paseco&#8221;).&#160;&#160;The 2014 Loans werepayable 14 days after the completion of the contemplated public offering in DanDrit USA or February 1, 2015, and accrued interest at 5% per annum. On April 29, 2014, DanDrit Denmark and Paseco entered into an amendment whereby the terms of the 2014 Loans werepayable on February 1, 2015 and couldbe extended at the Company&#8217;s option for an additional year with an increase in the interest rate to 7.00%.&#160;&#160;As of October 17, 2014, the outstanding balance on the 2014 Loans including accrued interest was $836,830 based on the currency exchange rate of October 17, 2014. On October 17, 2014 the Company repaid the loan and interest in its entirety.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">DanDrit Denmark has received an unsecured loan facility from Sune Olsen Holding ApS (&#8220;Sune Olsen Holding&#8221;), a shareholder of the Company, with a goal of ensuring financing until new equity has been brought in. Under the loan facility DanDrit Denmark has received the following amounts: on November 11, 2013 DKK 1,500,000</font><font style="font-family: 'times new roman', times, serif;">($276,651)<font style="font-size: 10pt;">, on November 20, 2013 DKK 405,000 ($74,696), and on December 2, 2013 DKK 900,000($165,990). The loans weredue May 1, 2014 and accrued interest at 5% per year.&#160;&#160;During March 2014, the Company extended maturity date of the loans with Sune Olsen Holdings from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014, the Company repaid the loan facility and interest thereon.</font></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">DanDrit Denmark has received an unsecured loan from Sune Olsen, managing member of Sune Olsen Holding, with a goal of ensuring financing until new equity has been brought in. The loan in the amount of DKK 1,000,000 ($184,434) was issued on December 20, 2013. The loan wasdue May 1, 2014 and accrued interest of 5% per year. During March 2014, the Company extendedthematurity date of the DKK 1,000,000 loans with Sune Olsen from May 1, 2014 to 14 days after the completion of the contemplated stock offering of DanDrit USA or February 1, 2015. On November 26, 2014 the Company repaid the unsecured loan and interest thereon.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">During March 2014, the Company received a 2,000,000 DKK ($368,868) letter of support from Paseco
 to finance operations until February 1, 2015 to be issued with terms substantially similar to those contained in the 2014 Loans. The Company has an option to extend the loan
 for one year by giving notice to Paseco by December 31, 2014 whereby the interest rate would increase to 7.00% per annum. The Company did not exercise the option.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">During 2012, DKTI A/S, a shareholder of the Company, which is controlled by officers and directors of the Company, agreed to loan the Company up to DKK 5,000,000 (approximately $880,000) accruing interest at 6%.&#160;&#160;The loan is secured by all the Company&#8217;s intellectual property rights, including its patents and its patent applications credit facility.&#160;&#160;During the year ended December 31, 2012 the Company borrowed DKK 4,431,862 ($783,139) plus DKK 71,563 ($12,646) in interest.&#160;&#160;During the year ended December 31, 2013, the Company borrowed an additional DKK 310,000 (approximately $55,000) on the loan and accrued interest of DKK 230,377 (approximately $42,000). The notes with related accrued interest were converted into 96,288 common shares of DanDrit Denmark on December 16, 2013 which were exchanged for 144,321 shares of common stock of the Parent upon the closing of the Share Exchange.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">During the years ended December 31, 2013, 2012 and 2011 Sune Olsen Holding&#160;loaned DanDrit Denmark DKK 1,267,724 ($232,841), DKK 338,719 ($59,854) and DKK 143,750 ($25,019), respectively.&#160;&#160;The Company added the accrued interest at 6% and the Company recorded interest expense of DKK 86,047 ($15,804), DKK 20,469 ($3,617) and DKK 2,689 ($468) during the years end December 31, 2013, 2012 and 2011, respectively.&#160;&#160;The loans are payable upon three months written notice of Sune Olsen Holding.&#160;&#160;On December 16, 2013, the notes with related accrued interest were converted into 35,106 shares of DanDrit&#160;Denmark&#160;which were exchanged for 52,618 shares of common stock of the Company upon the closing of the Share Exchange.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On April 14, 2013, Sune Olsen Holding, a shareholder of the Company, assumed DKK 4,375,932 (approximately$773,000) in liabilities owed by DanDrit Denmark for past due rent from a vendor in exchange for a note payable. ) were converted into 86,204 shares of DanDrit Denmark , which were exchanged for 129,207 shares of common stock of the Parent upon the closing of the Share Exchange.</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">On June 20, 2013, Sune Olsen Holding paid DKK 1,500,000, ($265,000) in accrued legal fees owed by the Company in exchange for a DKK1,500,000 ($265,000) 5% note payable to Sune Olsen Holding. On December 16, 2013, the note with related accrued interest of DKK 20,959 ($3,804) was converted into 29,036 shares of DanDrit&#160;Denmark&#160;common stock. Such shares of common stock were exchanged for 43,520 shares of common stock of the Parent upon the closing of the Share Exchange..</p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On July 26, 2013 and August 15, 2013, Sune Olsen Holding loaned the Company an additional DKK 1,000,000 ($177,239) and DKK 750,000 ($133,343), respectively.&#160;&#160;The notes accrue interest at 5% and are payable upon three months written notice of Sune Olsen Holding. The notes with related accrued interest of DKK 15,575 ($2,827) were converted into 33,705 shares of DanDrit Denmark common stock on December 16, 2013. Such shares of common stock were exchanged for 50,518 shares of common stock of the
 Company upon the closing of the Share Exchange.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform:
 none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">As of December 31, 2014, the outstanding balance of $38,235 for professional fees paid by a shareholder and amounts advanced to the Parent are reported as loan payable - related party. The $38,235 loans payable were acquired in the reverse acquisition. The amounts are unsecured, non-interest bearing and have no stipulated repayment terms.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">A 6% promissory note payable to NLBDIT 2010 Enterprises, LLC, an entity controlled by a shareholder of the Company, was acquired by the Company in the reverse acquisition,&#160;payable on February 12, 2014 upon the completion date of the Share Exchange.&#160;&#160;As of December 31, 2014, the outstanding balance on the note, including accrued interest, was $42,753. During the three and twelve months ended December 31, 2014 the Company recorded related party interest on the Note of $213, and $619, respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_NotesPayableDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notes payable text block.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_NotesPayableDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Definite Life Intangible Assets<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Definite Life Intangible Assets [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">DEFINITE LIFE INTANGIBLE ASSETS</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 3&#160;&#8212;&#160;DEFINITE-LIFE INTANGIBLE ASSETS</b>&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">At December 31, 2014 and December 31, 2013, definite-life intangible assets, net of accumulated amortization, consist of patents on the Company&#8217;s products and processes of $186,414 and $231,615, respectively. The patents are recorded at cost and amortized over twenty years from the date of application. Amortization expense for the years ended December 31, 2014 and 2013 was $14,381 and $38,297, respectively. Expected future amortization expense for the years ended are as follows:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;"><u>Year ending December 31,</u></font></td><td style="font-size: 10pt; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1240.73864746094px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2015</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2016</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2017</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2018</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2019</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">14,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; text-align: left; padding-left: 0px; padding-right: 0px; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Thereafter</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">114,509</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">186,414</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all or part of the information related to intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPCAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Business and Basis of Presentation</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Business and Basis of Presentation &#8211;&#160;</b>The consolidated financial statements include the accounts and operations of Dandrit Biotech USA Inc and its wholly owned subsidiary DanDritBioTech A/S.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">DanDrit Biotech USA, Inc. (&#8220;DanDrit USA&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;) (formerly Putnam Hills Corp.) was originally incorporated in the state of Delaware on January 18, 2011 as a vehicle to pursue a business combination through the acquisition of, or merger with, an operating business.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">DanDritBioTech A/S, a Danish Corporation was incorporated on April 1, 2001 (&#8220;DanDrit Denmark&#8221;).&#160;&#160;The Company engages in the research and development, manufacturing and clinical trials of pharmaceutical and biological products for the treatment of cancerin humansusing the dendritic cell technology.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Reverse Acquisition&#160;&#160;- On February 12, 2014, pursuant to aShare Exchange Agreement (the "Share Exchange Agreement"), DanDrit USA completed the acquisition of approximately 100% of the issued and outstanding capital stock&#160;&#160;of&#160;&#160;DanDrit Denmark (the &#8220;Share Exchange&#8221;) and as a result became DanDrit Denmark&#8217;s parent company (the &#8220;Parent&#8221;). Prior to the Share Exchange there were 5,000,000 shares of the common stock, par value $.0001 per share (the &#8220;Common Stock&#8221;) of Parent outstanding.&#160;Parent and an existing shareholder agreed to cancel 4,400,000 shares of its Common Stock and issued 1,440,000 shares of Common Stock for legal and consulting services related to the Share Exchange and a future public offering. At the time of the Share Exchange each outstanding share of common stock of DanDrit Denmark was exchanged for 1.498842 shares of Parent&#8217;s Common Stock, for a total of 6,000,000 shares, resulting in 8,040,000 shares of the Parent&#8217;s Common Stock outstanding immediately following the Share Exchange,&#160;<font style="background-color: white;">including 185,053 shares of Common Stock reserved for issuance in accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark to the DanDrit Denmark shareholders who have not consented to the&#160;</font>Share Exchange (the &#8220;Non-Consenting Shareholders&#8221;)<font style="background-color: white;">, and deemed issued and outstanding for accounting purposes</font>.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional Currency / Foreign currency translation</a></td>
        <td class="text"><div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"><font size="2" style="font-family: times new roman,times;"><b>Functional Currency / Foreign currency translation</b>&#160;&#8212;&#160;The functional currency ofDanDrit Biotech A/S is the Danish Kroner (&#8220;DKK&#8221;). The Company&#8217;s reporting currency istheU.S. Dollar for the purpose of these financial statements. The Company&#8217;s balance sheet accounts are translated into U.S. dollars at the period-end exchange rates and all revenue and expenses are translated into U.S. dollars at the average exchange rates prevailing during the years 2014 and 2013. Translation gains and losses are deferred and accumulated as a component of other comprehensive income in stockholders&#8217; equity. Transaction gains and losses that arise from exchange rate fluctuations from transactions denominated in a currency other than the functional currency are included in the statement of operations as incurred.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Cash and Cash Equivalents</b>&#160;&#8212;&#160;The Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents. The Company had balances held inafinancial institution in the United States in excess of federally insured amounts at December 31, 2014 of $2,508,759 and none at December 31, 2013.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
        <td class="text"><div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"><font size="2" style="font-family: times new roman,times;"><b>Property and Equipment</b>&#160;&#8212;&#160;Property and equipment are stated at cost. Expenditures for major renewals and betterments that extend the useful lives of property and equipment are capitalized, upon being placed in service. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed for financial statement purposes on a straight-line basis over the estimated useful lives of the assets which range from four to six years (See Note 3).</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
        <td class="text"><div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"><font size="2" style="font-family: times new roman,times;"><b>Intangible Assets</b>&#160;&#8212;&#160;Definite life intangible assets include patents. The Company accounts for definite life intangible assets in accordance with Financial Accounting Standards Board, (&#8220;FASB&#8221;) Accounting Standards Codification, (&#8220;ASC&#8221;) Topic 350, &#8220;Goodwill and Other Intangible Assets&#8221; and amortized the patents on a straight line basis over the estimated useful life of twenty years. Costs incurred in relation to patent applications are capitalized cost and amortized over the estimated useful life of the patent. If it is determined that a patent will not be issued, the related remaining patent application costs are charged to expense.</font></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
        <td class="text"><div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"><font size="2" style="font-family: times new roman,times;"><b>Impairment of Long-Lived Assets &#8212;</b> Long-lived assets, such as property, plant, and equipment and patents are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed of significantly before the end of its estimated useful life.</font></div><div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;">&#160;</div><div style="text-align: justify; margin: 0in 0in 0pt; text-indent: 0.5in;"><font size="2" style="font-family: times new roman,times;">Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated undiscounted future cash flows, an impairment charge is recognized by the amount by which the carrying amount of the asset exceeds the fair value of the asset. Assets to be disposed of would be separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell, and would no longer be depreciated. The depreciable basis of assets that are impaired and continue in use is their respective fair values.</font></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionSalesOfServices', window );">Revenue Recognition and Sales</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Revenue Recognition and Sales&#160;</b>&#160;&#8212;&#160;The Company&#8217;s sales of its MelCancerVac colorectal cancer treatment have been limited to a compassionate use basis in Singapore after stage IIA trials and is not approved for current sale for any other use or location. The Company accounts for revenue recognition in accordance with the Securities and Exchange Commission Staff Accounting Bulletin No. 101, &#8220;Revenue Recognition in Financial Statements&#8221; (SAB 101), FASB ASC 605 Revenue Recognition. The Company recognizes revenue when rights and risk of ownership have passed to the customer, when there is persuasive evidence of an arrangement, product has been shipped or delivered to the customer, the price and terms are finalized, and collections of the resulting receivable is reasonably assured. Products are primarily shipped FOB shipping point at which time title passes to the customer.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_ValueAddedTaxPolicyTextBlock', window );">Value Added Tax</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Value Added Tax -&#160;</b>In Denmark, Value Added Tax (&#8220;VAT&#8221;) of 25% of the invoice amount is collected in respect of the sales of goods on behalf of tax authorities. The VAT collected is not revenue of the Company; instead, the amount is recorded as a liability on the balance sheet until such VAT is paid to the authorities. VAT of 25% is also paid to Danish and EU vendors on invoices. These amounts are refundable from the respective governmental authority and recorded as other receivables in the accompanying financial statements.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Cost</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Research and Development Cost</b>&#160;&#8212;&#160;The Company expenses research and development costs for the development of new products as incurred and such costs areincluded in operating expense. There wereno research and development costs for the years ended December 31, 2014 and 2013.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Income Taxes</b>&#160;&#8212;&#160;The Company accounts for income taxes in accordance with FASB ASC Topic 740 Accounting for Income Taxes. This statement requires an asset and liability approach for accounting for income taxes.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Share</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Loss Per Share</b>&#160;&#8212;&#160;The Company calculates earnings/(loss) per share in accordance with FASB ASC 260 Earnings Per Share. Basic earnings per common share (EPS) are based on the weighted average number of common shares outstanding during each period. Diluted earnings per common share are based on shares outstanding (computed as under basic EPS) and potentially dilutive common shares. Potential common shares included in the diluted earnings per share calculation include in-the-money stock options that have been granted but have not been exercised.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Derivatives &#8212;&#160;</b>We generally do not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, we have entered into certain other financial instruments and contracts, such as debt financing arrangements with features that are either (i)&#160;not afforded equity classification, (ii)&#160;embody risks not clearly and closely related to host contracts, or (iii)&#160;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We estimate fair values of all derivative instruments, such as embedded conversion features utilizing Level 3 inputs (defined below in Note 1: Fair Value of Financial Instruments). We use the Black-Scholes option valuation technique because it embodies all of the requisite assumptions (including trading volatility, estimated terms and risk free rates) necessary to fair value these instruments. Estimating fair values of derivative financial instruments requires the development of significant and subjective inputs that may, and are likely to, change over the duration of the instrument with related changes in internal and external market factors. In addition, option-based techniques are highly volatile and sensitive to changes in themarket price of our common stock, which have historically had high volatility. Since derivative financial instruments are initially and subsequently carried at fair value, our income will reflect the volatility in these estimate and assumption changes.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 36pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We report our derivative liabilities at fair value on the accompanying balance sheets as of December 31, 2014 and 2013.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Fair Value of Financial Instruments</b>&#160;&#8212;&#160;The Company accounts for fair value measurements for financial assets and financial liabilities in accordance with FASB ASC Topic 820. The authoritative guidance, which, among other things, defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as the exit price, representing the amount that would either be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#9679;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 1. Observable inputs such as quoted prices in active markets for identical assets or liabilities;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#9679;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 2. Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times,
 serif; width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: top; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><td style="width: 0.5in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 0.25in; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#9679;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Unless otherwise disclosed, the fair value of the Company&#8217;s financial instruments including cash, accounts receivable, prepaid expenses, investments, accounts payable, accrued expenses, capital lease obligations and notes payable approximates their recorded values due to their short-term maturities.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Accounting Estimates</b>&#160;&#8212;&#160;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimated.</font></p><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Recent Accounting Pronouncements</b>&#160;&#8212;&#160;In May 2014, the Financial Accounting Standards Board issued a new standard to achieve a consistent application of revenue recognition within the U.S., resulting in a single revenue model to be applied by reporting companies under U.S. generally accepted accounting principles. Under the new model, recognition of revenue occurs when a customer obtains control of promised goods or services in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. In addition, the new standard requires that reporting companies disclose the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The new standard is effective beginning in the first quarter of 2017; early adoption is prohibited. The new standard is required to be applied retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying it recognized at the date of initial application. We do not believe the new standard will materially impact our consolidated financial statements.&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 40pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Other recent accounting pronouncements issued by the FASB did not or are not believed by management to have a material impact on the Company&#8217;s present or future financial statements.</font></p><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 36pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Reclassification&#160;&#8212;&#160;</b>The financial statements for the period ended December 31, 2013 have been reclassified to conform to the headings and classifications used in the December 31, 2014 financial statements.</font></p><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_ValueAddedTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Value Added Tax policy text block.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_ValueAddedTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph n<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41675-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 5<br><br> -Section CC<br><br> -Subsection 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6390181&amp;loc=d3e202-110218<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 19<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 30<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 954<br><br> -SubTopic 740<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 17<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 350<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 13<br><br> -Subparagraph a<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Research and Development<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionSalesOfServices">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for revenue recognition for sales of a service. The entity also may disclose how it recognizes cost of sales for such a service transaction and its treatment of any unearned or deferred revenue that arises from the transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 13<br><br> -Section B<br><br> -Paragraph Question 1<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 605<br><br> -SubTopic 20<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6742685&amp;loc=d3e47769-111627<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RevenueRecognitionSalesOfServices</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 11&#160;&#8212;&#160;COMMITMENTS AND CONTINGENCIES</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Shares held for non-consenting shareholders&#160;</i></b><i>&#8211;&#160;</i>In connection with the Share Exchange agreement certain shareholders of Dandrit Denmark had not been identified or did not consent to the exchange of shares. In accordance with Section 70 of the Danish Companies Act and the Articles of Association of DanDrit Denmark, the Non-Consenting Shareholders that did not exchange the DanDrit Denmark equity interests owned by such Non-Consenting Shareholders for shares of the Company, will be entitled to receive up to 185,053 shares of common stock of the Company that each such Non-Consenting Shareholder would have been entitled to receive if such shareholder had consented to the Share Exchange. The 185,053 shares have been reflected as issued and outstanding in the accompanying financial statements.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Clinical Trial Agreement</i></b>&#8211;On October 1, 2014 the Company&#8217;s subsidiary, DanDrit Biotech A/S signed a contract of collaboration with the University Hospital IRCCS &#8220;San Martino&#8221; - IST &#8211; National Institute for Cancer Research, known as the San Martino Hospital of Genoa. Dr. Alberto Sobrero, the Head of the Medical Oncology Unit at the San Martino Hospital, is principal investigator of the randomized multicenter study. The collaboration relates to a Phase III adjuvant study of DanDrit&#8217;s vaccine in patients with no evident disease (&#8220;NED&#8221;) stage IV colorectal cancer (&#8220;CRC&#8221;). The primary goal of the study is to evaluate the efficacy of DanDrit&#8217;s MelCancerVac&#174; (&#8220;MCV&#8221;) in stage IV CRC patients rendered disease free after the completion of standard treatments in accordance with local practices.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Patient Name Use Program</i></b>&#160;- On December 16, 2013, DanDrit<font style="background-color: white;">&#160;Denmark&#160;</font>entered into an agreement with a Dutch company (the &#8220;MCV Partner&#8221;) regarding a Patient Name Use Program (PNU) for the Company&#8217;s MCV.&#160;&#160;This program will allow DanDrit<font style="background-color: white;">Denmark&#160;</font>to sell MCV for a year of treatment (10 vaccines) to cancer patients through the MCV Partner.&#160;&#160;The MCV Partner offers a worldwide online platform providing access to non-registered medicines for patients with life threatening diseases. The MCV Partner is a turnkey solution and will be in charge of regulatory, recruitment, logistics, and pharmacovigilance.&#160;&#160; The Company will pay the MCV Partner a royalty on a country to country basis for 20 years on MCV sales sold under the agreement. Either party may terminate the agreement with 180 day written notice.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Food and Drug Administration (FDA) -</i></b>&#160;The FDA has extensive regulatory authority over biopharmaceutical products (drugs and biological products), manufacturing protocols and procedures and the facilities in which they will be manufactured. Any new bio product intended for use in humans is subject to rigorous testing requirements imposed by the FDA with respect to product efficacy and safety, possible toxicity and side effects. FDA approval for the use of new bio products (which can never be assured) requires several rounds of extensive preclinical testing and clinical investigations conducted by the sponsoring pharmaceutical company prior to sale and use of the product. At each stage, the approvals granted by the FDA include the manufacturing process utilized to produce the product. Accordingly, the Company&#8217;s cell systems used for the production of therapeutic or bio therapeutic products are subject to significant regulation by the FDA under the Federal Food, Drug and Cosmetic Act, as amended.</font></p><p style="font:
 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Product liability -&#160;</i></b>The contract production services for therapeutic products offered exposes an inherent risk of liability as bio therapeutic substances manufactured, at the request and to the specifications of customers, could foreseeably cause adverse effects. The Company seeks to obtain agreements from contract production customers indemnifying and defending the Company from any potential liability arising from such risk. There can be no assurance, however, that the Company will be successful in obtaining such agreements in the future or that such indemnification agreements will adequately protect the Company against potential claims relating to such contract production services. The Company may also be exposed to potential product liability claims by users of its products. A successful partial or completely uninsured claim against the Company could have a material adverse effect on the Company&#8217;s operations.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Employment Agreements -&#160;</i></b>The Company and its Subsidiary have employment agreements with officers of the Company.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b><i>Contingencies&#160;</i></b>- The Company is from time to time involved in routine legal and administrative proceedings and claims of various types.&#160;&#160;While any proceedings or claim contains an element of uncertainty, management does not expect a material impact on our results of operations or financial position.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for commitments and contingencies.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.25)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 825<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 460<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6398077&amp;loc=d3e12565-110249<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 450<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 440<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Leases<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">LEASES</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 7&#160;&#8212;&#160;LEASES</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>Operating Leases</b>&#160;&#8212;&#160;The Company leases laboratory and production space under operating lease agreements which can be cancelled with 3 month notice.&#160;&#160;The lease calls for monthly payments of DKK 6,000 (approximately $967 at December 31, 2014).</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On March 27, 2014 the Company entered into an operating lease agreement for office space from a related party. The Lease calls for monthly payments of DKK 10,000 (approximately $1,612), increasing to DKK 20,000 (approximately $3,225) on July 1, 2014. The lease can be terminated by either the Company or the landlord by giving the other 3 month notice. The Company gave a notice terminating the lease agreement on February 27, 2015 thereby releasing the Company from the lease on May 31, 2015.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Lease expense charged to operations was $32,297 and $65,702, for the years ended December 31, 2014, and 2013 respectively.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for operating leases of a lessor. This may include a general description of lessor's leasing arrangements for operating leases, including the basis on which contingent rental payments are determined, the existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease arrangements, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452767&amp;loc=d3e37045-112695<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 932<br><br> -SubTopic 235<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8451039&amp;loc=d3e61901-109447<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453916&amp;loc=d3e41460-112716<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6453916&amp;loc=d3e41457-112716<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 840<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6452767&amp;loc=d3e37051-112695<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>61
<FILENAME>0001213900-15-002253-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-15-002253-xbrl.zip
M4$L#!!0````(`&M,?T:K+R)5_[$``'O)"0`1`!P`<&UH<RTR,#$T,3(S,2YX
M;6Q55`D``YFB&E69HAI5=7@+``$$)0X```0Y`0``[%U9<]NXLGZ?JOD/.GXY
M+U<6]\63Y)026QE/',ME>[:[E(NF()DG%*GAXMASJ^YOOP"IA0M(<0$I4H8G
ME8E!@ORZ\:'1`!N-=_]Z69J#9^"XAFV]/V%/F9,!L'1[9EB+]R>_WD^&RLG@
M7Q]^_.'=/X;#P6=@`4?SP&S@N_"&P<7?PS\^WEYMZ@_D4^Z4.64&_\7P(YX=
M<0PK#ACEC.//.&$P_OH_@^%P\ZB/F@L?`^L$#^!.V?`:O/KRZ)C&&?I[`+%9
M[MEJ^>2^/WGRO-79:/3]^_=3AH$/YF294TYU>XE>([`<SY[\^,.ZAFE8WV(U
MT--.;6<![X70T.5'^/Z3P6!;!=TQ,[:5HA6D47@Q=GOJ%=_YX'Y65=51<#5V
MNVO@;H8/9T=_?+VZTY_`4AL:ENMIE@YQQ6`9.:+LJNSJ&*XM<*R<5RN\(UK)
MLBW+7^+KS#QGY+VNP`C>-(1W`<?08W7W5TQ7FH&5`W1$IDR@ZDAS=,<VP6BN
MZ=X0O*Q,S=(\VWF=P-^C#W/`//,IT@A>C<$%7LXK@_?!6U+D\+#D$$-RQ&[7
M;=_RG-?X_2[03Q?V\VA]$;&6'S+L$/(V6M5W'-C_LNJNKP:43U>>`0-?#U[(
MJ`)>]"=\'70%5>+2E0SK&;@>OEIX+4,Z2S-T%U\ON(2JL>EJKJ'C*\$+656\
ME9-1!U[)J.2[PX6FK;;UYIK[&+3S^D*&#M=7AYKG95>%%QWCT?>`FZB*^H>+
MK1=<R7CGBYG3O?^X2I@?WW-R&`^O(HN#+#.R6V=N8(UNP7P0V+&S=2?,MW:C
ME6.O@.,9$/+.OH8/0(*\/W&-Y<K<ECT%71:9]N'&?I^^N+.3P6@S0GRR+0^\
M>(,[H'MH<%D/'N'PH*\O&M!ZK&]\&+L/T_D#PSZ<`_T!M?`]PSR$?^ZGV/*3
MW0.!Y1G>Z^YW8X9*Y@9P!H$^XN)OR/3I\LO)A]UP]&Z4K(P>.,*_`6K+L&>1
M-P:FW(,%`3N#CK>KO;NZ*=G5'\5TDJ^DR9\72!6_:%9:13Q.=;?`1$;Z1G.\
MUWM'LUPM:`[WXVOTROC%<!_N?`M,31=8/]LF<B#&*_<K6#X"Y^'*MA8><);G
MX-&[AVP(;K^R-6MB^TYX3SMM$9:Y8+$$UE93,_A*.+88NN&%6`8S`UX/7:)U
M!SXKKH>3#XC69YG:>#?"OK04&IQ"U^^-JS7G9:.4,@HR%3+1\<ZAS!NN,FR,
MJ]'KVR:=12M`<O-L](6;J_7('5H`+(TIO2F]*QMBOG%#S&4PE>OF6)6P`%Q9
M"\`U90'*:I7V?]K_*;DA6\^_><9X+Y_OH=L.CI3040VTP.&(*M\4B9,^6L]&
MOIASD%(2*>>@O)+H0$8'LF/D*AV7CFM<ZBPG[SRH?"3,Q5\^E."3O5S9%OS5
M#4AV"SS-L,#L0G,L:"/<?G`M5Z:3#SM*XH2CK;]M_?%L9J!.JIDWFC&[M#YI
M*\/3S*,B0:Z,E`M;+L!?E[9UY]GZMZ-J_Y1<M,VW;3[UGH"#RASPA-3[#"XM
MW5[VQ.,H2(!\(?O+AD^^Z]G+!TYZF(!'U.Q\\KO@5\U)E#<\F8*ZI;.I!F93
M.[VVL*3"#QENR$G%EU1@!3ZV!D-V2845'L:K))$AP;'ES1+\SGBA]"9.[ZU6
M&[?%D*;"D!4:L\4L2ZE*J4K.#D.REEC:3K&;K!WFF(=??"M-;FPY)3<E=ZX=
MEH8<TYP=%BE5*57)V6%IR(JE['"<W83ML`1);&+(C2MOF-S@&5B4WN3IO=-K
M&[98CDWW2*]/L)2NE*YD[3$D;#F_.,YPPNL3XL/87V`F?;AR2G!*\+WV6(FY
M&Z3L,?\UC++#&6.>>;@#JWAYI\*3<#:@3-@7K*`.^09\,O5K-':Q]UHM%TS7
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M.&`&5":4'ZUS:E;'!Z<9,,X2\'<^+4:.-\6%;=04E@K8\F:G]/??[6[3J9<3
M^JU6VXE%:2)J*IZ;-!'?R_8MQJ)T?&\K&5_W:Y5^@*8?H/M/8IJ*KX54?&^%
M+C1W'R5/9?+02!=*DKTDH=D!*7U(.>4T2JHSD_+6LPEVA-[)[*D]F\NGESO:
M2#%[>"M`]S[T;^]#9[E*9^!M)\/O3^O3"37E`IT?O]TVI]/=M\6&$G[KM>V!
M&^U5>S3!5_.S8_NK?I"BM$N:)2@E!IX8:"Y]`QP=RAI1W=L)ARLI/Z51)1J]
M3?*\0<K<.#9\E_=Z8T(`8VN&QO(5$N[CZVY11'O<%L-;+B%:QT>_],3&%)!Q
MLTZQ1U)*C00UD%_G>\#97CLB1D1F,#@9WQ072GFNUF9OS$>@.7`P1JM_.U/K
M&"Z8&)9FZ886.GQP/M`/VE1P;BOK@M(K8T'?>%F/X+`3+PW7M9W7R%A^;U^;
MCS/#N_]N_R=P[*D%T/\N4".LD+;=*_-8R49,,WVG'LMMSJ<3XO'^N'*Z*M=.
MFPOHC#>VN=1]#;9YG_>$-,B+O>_NPGZ4=CBXWFC$L-3P=,'P)`)"@F8O$Q"2
MX@GQXQOP-,&5EW"-;C38UO:>"(=?+7B3[X!9?[(UE/:$$HIH+KAA<Q6CU):,
M60.G-JQ)JFP.\TV0%%=.24I)FD52Z.PK38ZX6)9R,J:\T%HG@,TRF\[GA@[N
M5IK>DV^Q)98X\0*V,PSS98=A?LC)30W#?`9WL.6D+=RQ;PALS;JUM2<P;=8:
M7#O;'AJ:8":FO+L1PP(ZE))O[LC5X&0IC)9V)TZ1L?T/=_ZC"_[RT=SF&?ZU
MO3]1WH^>W.1(47RRB-?HSE?!JK:=,4HJ.T;%CP4CG+L$DGE]I%]J22%=CK1F
MS`S->;W33#"=!]/L@*J7-]-^T#-3A!TWMK*TPP>E+!^4!I<.&&%SOEO"YF'*
M.STRJ$,F<FP\Z9&!ZZF6TNQ38\?=%&!?7+&$L^=DL`]7WBF]IMG'-<@^MJ=:
MPK*OG.V+*Y84^X)S1#F,5Q<[\;+:;*WH1]&<:=S1ALL1^&!,;';78IKFT*<K
M:W:;.Y249Q^FNH==J$B5=\J@),PNRS0R9]Z9W7YJ*<4^J*=R9C>A6,)?J_C-
M@:*)&0BFO%-Z3;*/C24B),\^_,'!7==2.F%CN<WS*<4VDQLBU:?7063]T*I0
M-B6!T$[&C?U:I?N7#Y!![&CI0C<\4_)4)@\-B:(DV4L2NJ6:TB>7/O2`^?ZE
M#FKT@'E*;9JO_DCSU;]):M,`TR,/,#T>5M-X#4H&^LV2?K-\V\3/MH(WP4&*
MX,;4=-"?Y!(%3")>,$J3/)H4C^"]TAYM1_-LV`#'NX,#*R1E4&T&[<D`]'"K
M68OPUJ_:B['TET='K^HYD(J/ZALE[DQB3)N4QVWRV+`HC\GQ.*I-RN.Z/,Y(
MOG749KAZXC%J@/M$W*.SNP<B[INUN,E,:ST+DDL&:+:3CH[&O'4CYJVGK4]#
MV"@7:$3:VVUS&F#VMMA`X\7Z%U33:+S843.5TO"M4X,>/$2)00\>ZL'!0\=)
MH[=)GC=(&7KP4*<.'NH;->C!0V^#"_3@H:,[>*BG]*('#_7_X*$N48]N_CC>
MMJ5[.>A>CF/@,=V:\19][O!;W[WV,O:])]O9G'IVKEF&^P2+^]'6>"G673HA
M2]^;E^4W1U:(R>QSZ?*C2F??G4SRL?86@W-O&DTW2!N\6T<'B&6/MTEQA'!8
M*(.G"*Z\NV&A@9*J'R+RC^%P\*ME>(,[$/B:@\%PN"G_\8?+_V/_>_+;S<_@
M!9R+DJS\>0O^,CY</GT#SQ??#.?EN_R3+@B"+HJB?O^_3Q_>?Y[([WYZ?\E.
M?O[Y':N\5T7VXG+R"RO^)`GO?E(4X6RBKE\0(O'1JU'3_'IW?O)A7;@$FNL[
MX(/AV@+'RF?PV@;YYM+F=U0?\S3W27.`FWK@FG;!Q9)/A!@>5NBH$U1Y^^"9
M\0Q;\$/DYFM_"8)=AQ6%2=5'A>?`LI>&A7ML49%BCQC%T>=+OO(C`L=?BRZ5
MT^,_S[]\^6>6:N"U?4]#M+PP`[\SQMAWZ"C5BZ#?W(*%X7IP]N1=:TLP6'/]
M%LSK9$Z%[M`Y])`&'PW;`_K3X->[\7\,H`-U^FZ4]68$=W?M$T3L:.:E-0,O
M7\`K(5A1@Y+YK@V0,=3:#&EN8FH+0@#FFNF"\-VQQV_>^<EWT"FV$\/5-?-/
MH#D7H0DG]/IAZ#6&`++>M<%R;NO!%R,T(A)Z/\L,OX0OCSX\^<*;P/Z2E7SG
M,L??'WM7$LA.-1-8XA*$$@>1>`\>1HB4))#)GS@8D??$N^3OP#2_6/9WZPX:
M&]L"LTO7]>$H3@;,M1WMDAGOB@/ZS39]"_I$KQ/#!`XIK<2!)-Z1,%)A#[H%
M*]OQ#&N!@F&)M<Z?:(#:]ZXXG@#C)TCDA>V0,IEW2\V$3QUL7SQ8'[$=!1=[
M<1S3C?\(_>.):6L>%E&%`^H&:'0+'H*\H,$,Z`8$Z;X_09U+4$6)DY@HN@B$
M1/OMPM(#/\6=^AYR!E'<33[8XH[P#NS:R8K@O;R>G'Q019[GU!C@/%Q(@NWW
M7,U]RL.Y;5`^HZ'Y8DIE%5F%)BOZVDHP"O`M#P;/,(J"#'@6D`M7=^SOYY"I
MKI'+-E**D65!4G9X8N^O!ZRFJCB&4T6&*P!MK.NVC^+UK5D0I'\+=&`\H\]L
M[C7PUE:G#5URHB!*.\"%<#4C2$W=*PQ;1XX;!ZPT8W;QL@*6"UIL`%:%=-X!
MQ^(@`[2\@E]<X\PRS/<GGN.#DU&LW5T7>&Z;>A)808UTK1B`>LAJ,D]D!(D7
MU`+0,L.&("<;TF%.$]9&0Y10$P/>":Z,9^AU0M?/6ABPLX::;$X[<5/(LQ(K
M[IHQ'Q%A[#4YR"J2P`I5L)^#.8!$10?$`A1@],EV/;PS35C=DLPPS`XQ%@<9
MH$1YNA[,W;4R;4MOT08RO!13&1X*,;@U22FS@E0.[2&4RC.**HM)ZTT07]VN
MK?)BM-7WXVM#:P(:]>0DJHI8Z@[`'*^J3&H`CH)!<6SN.I`M$J5B`/>3J;DN
M^K8Q:]&9D3F%82)3JA+PFI2J9CNHJBI6%RJ,042S[XV%#V=/[3E&M1"0]:[7
MTY>U]EIDIB@H8I29>"2$L-8>7U@AYG>7Q9I@9:-:+M[:U5'57;Y@.8%7,O6)
MQ960`\HVNS*T1\,TFE=I?/XO*BPOQL#CP9!#7)>^/*]P4C7$VZBHP]*V!A2B
M]O(PE.-8'L[\(TY0?M,=AF6L+,J2)!0%F3UH-^Z5Y[0O,51D66=;BWO@+*/H
MVM=-911-]<!#$J4ZC*:T<6A#5`=6@Z8G]B5K]^'M-\WTF^I#\=6GZ-I3$D!M
M<'4G4B)?#%Q&AK=6UJ)D19+%Z`)/!AA2>.LZMR*C*HS(E,.KZ_[2#\:;K%Q:
M5[:+EE2G<^@!M:'W(<^R*A/S&LM`;%JZNJTDBUQB2E=5NF0*S,BCSL$<!0^W
MTERL*G(L&_7S]P-K0(R:[3+D6$7E&$:N*D9@OYYL<P8<-TQ:5P@VEP$[4EXI
MRVM^D\D\_$^*3";3Z+L@6WX.TUSCS2FLS')<UR5,9^;,7;OB.R_0GK23^9_X
M%$YA&A:PMK63%(&5#X^R":N0,N3=E*V&54BY=-V4L)Q5B'GZW12HAE5(NH.-
M"%@W@E!0.$YH>CAM*B%\2;>HF[)5-PKI>5,W)2QG%&(S[&X*5,,H)&=1^0)&
M5F7&UNPPCD,RG&`?)N+X28<@E!$@0MT;S9DZ`2]FP6+/#7""6/1&VB"R53`B
MC7#R@3EE8N$)!0"2DX?E'B;@,=TFV/):-J&;\E?G9`ORA!LCUJD8_@8S\KS,
MV*_!,NL?K!1)6"31EVJ%YM$'6[+:T[NT%W<(B!1F$MK>[NVI@[G@IJ26E9VU
M):DN^G;4GH$>)?%Q;\$SL'SPV;9GF4'3\7UT=>,^.3FZBP@'@@#(FGX%4QP@
MBH>>SH,K=]#3:%Z!+*-RJAIM[AB`>MCJ?D=014EB"V'[[-BN>^/8\XR5=*(Z
M&\J2&-U+%WEY=4RUU_83RLH"!2S@:"9T9\>SI6$%200\."U9;T5J@7`<STM*
M9.*V!Q%9\'4_ADN"H+)*)?#G`$X"=4-#,WCX;Q.@?Z"*2[0Y^.^@O`6#J7!J
M9(I6!%0#0M3>**,J;'DA@M!@",CU3;0;>]U&13:=UU6ZR@@HLB,#0#UL-74I
M2*HD2;G8-GJ>KE"^F%8UQTH2)[`1PJ8PU`58.]R6Y\7H5\9B`'=?O5L8KEB9
M5U1!P6#<P:B/LO8`)G`J%_TRLP?E)J=V:R.7)'(R$QFX$@#J8:N[<5H0HZN[
M&&A!__ZL&=;4FMC.`HY1%G#=Z1SE6&U>=X(:[.S.`T$`)-F]K+8#C(45AM?J
MT22Y""!BXRW0S,P5"+)F4!6%R(!7'%IC`M7M[0(C1IW`:A*=@R!!+*1)R)G=
M[RTTB2S*T5"%;"S$$!.E]\9$A,8U^$[1@M+2)BKR_OKPZGX`4*/QMWL07MN6
M'1^A6AN)8.]1!#;2?3*QD`)<M[NSK,JJ4DG`NW%_XMA+!,RP?%AA[1B@;.5@
M#@U'9//*Q0N<@-G.S+`TY_72`\L@@AS6=&S3#-X5MFD+;<2Q@LQ+,<8W)DYW
MM%;;"Q0%18C&M+6J-5A]S<./T/-H:C$IURI7A5&[A\JRR*M)O:>0Q`P*\%J=
MQZ1Z5`Q`L\@:"3OIK#BE(DWRMGRU#7QO`$F7P)8+#B&(O+:1YF643JX!YAXF
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MT)#L+>TN+;H=`BO7+N=LN"?EW$=Y9\/3H,(*P;8L*!B</:,C-*?SC[8U2^?"
M>T53ZFU(R&;[(7[SX_KT49;'<YZ5<)Q_LAWO/GEP>8C+0]GE47F1)`/BFNI-
M2WX$VMUFV`P_.A=*X:!*+$>56T"YF#<6R2:!<@-)1ZS@KJP-'8/P-;(N\&CT
M..:.W/9B55R]M`>W%VJP7PD=&")(>W^<Q$IH;T>#PO=%MT1F":PLB+)R=/IL
MT0IV@*AK>)$M^)<6?`H29SJ/YJ_.SK1;@8#YB8`XB5=V>]C*X",I5J>\KN[)
M4]V10NTK<\?6ON6\'70PW'')3\8G*2Q7KB5B'\8K!V.)!$QYU%9&-BJY'U]C
M5A2)>.=;8&JZP/K9-M%BT7CE;E;=;&OA)6>S5[9FW1DO!:P^VO(G<4QI3A!6
M6QD/HEFU36S?*:8W7F29TF-%/_1V_LTSQGM5=?_D@'0GRUH`E3A%Z9&VB+M6
MK"#P*%BO-QIHN)]!,UVDHX5NJ:@(U$25L^RAXE2&/U(;545Q*%]20>/.RXS8
M(\41F58?TD8??N[;EH$._.*IU<Z,EI5E1A;E2BX_Q$A8NAY/;%L2J4Z^=MC2
M/'.<+5UR0;^T$>N'%EJ>Z!*T40VL5,JB(O%EV[E2$Y/4`YGE;T5@Q-(C%5'9
M#S]<UR=`</O%B_ZD60LP7L#)[#)LB\2C)K8SUB%J-[#,T:7PHDM<APLJ[IN@
MU<>_H:P*NU@,,A+W48,EA\KMTM\;5AFAC]JU!0[O.C1)LNSM)C*3J+!;[:';
M-4L'TWGL(194@`6"18#?#>_IQG\T#7TZGP/TH!Z:XMZ(6=T02Z*L*INU$R+R
M]D][%3_)O5%MD;&_=<7MM/5E!7%G?,E(2I8GQ28*QV!]6Y*TN@$6B1$EM2S2
M)P66L,%<<"H.2[76%5O<`8ID&6)BG:L\0RXA-@/:@\./V&V8X>Y(6]T4"[RH
M,B4-2S&Y>ZO,<JZQHE+='<8X[Y6ZT_ZRHJB26LY2%Q2X$?(<D??<*8%K[+E2
M.4$M-R\O+'F?-5K.?$M4@=VWX1U@3H85%Y6R<]G"$I>=J@3[6,"-J>F!A$?K
M=7="T!I1,"K\D4I.T?:)W$<5EK/3`M58NRL?.0)WVJ\6HODZ2,FZ5=Y8U_VE
M'P3Z;FS<K>UG9W8Y?,[OS6:R'.1=D:YNPK8NR+#7JG44-ZG(O8I[;DL=-$\L
ME[%ZRNS"46LBW^H@&LP5K7X8$:5386,!]@$K+$&6.]X%(?:'ST6B/6`E'99H
MB]SP2=C+&LM)%E'`RD_)S9[N"6?!RD),_AKI_MH2)AK)<V_'8E4[T*09+LHV
M?5XUP0BKA&@:?*+RX;VW/>UZ!U9I.3@A75[_2UH]H%/=PRH\54YD+;D>UFO[
M&1,^SF_*RV#=OV)2!2IY$@O[9A%[8/Y_>W_:W#:2M`N@WSNB_P.N7_<Y=@0D
M$^#>GID(6I*G];9MZ5ARS^W[Q0$"11'3(,#!(EGSZV]F5@$HD*!(2EP`LL;3
MMD1BJ<K*RJTRG]Q4S&J5S!MCV5B7AY.60I@TS/*MU7AZ:Y5Y\DL&NXI_OGRX
MSY,$Z^>JK#S:)44:&Z/O"NSP1)2Z&)<\"Q:T0GR9&"L]AN[UNO-'J?/#V<28
MGR/.2@]@RICCB2$7OZ)56,$K*..`U3ACH4'=SFVQ)\;TPG&7;;75MN!^QUW&
MO*LQ=?FX48AL?=!EW+L:5V]DT#*[?V%/[[]-";I.-Y=S,^]_UK@V)<MZ_69G
MV;C*Y?+M0[!#ZV:)DH#!Y#PY$R%=8RO-!Z)>T*I)YLJGAO3TP+>/;6\6/*#2
M0<@HX>=L&L+MO,6`[PPF01B[_Z5?M]\]H-DS^UVYN_O"L6QNR"\D;ZMM-HRU
MATQ]Z$-L\'#EWU@>L#O'#_1ODF'D.JX5;@;T\&GK+!_V"N/9_/#7I_P3;4,0
M\)O%%#,]=R,[2/P=M!MO-\P6(D`^,8B7CW&C9,*5D]<MCR+OH)>TT6UWY<Z2
M3PQF<V/>*/DN?5A!*V+P#/KWTH<UQ76,OC*;P:@VA=CR=/5NN]-L=0I=PY>.
M:@NS>&G3%:/;DINEKCH+;B?,77P=LJGE.J)Q.AV03(/(C7?1([UE]-+B^C4&
MMJ7)O+@7CMG/@(W6G,WRI=PDJM&2:72ZK5682X(FVN3P7[@*1L?LMU?:',\9
MOW1:Y6Y)\#]+B#YW>"\UD0VSU>RM0>SB`)?.#3N1I(>TVZ+WC$!J=(RVN61&
M,\/:PC1>K"%@71K]YT\C[Y$6W0:@10+?=CU6Z'1^&YQ9T?@Z#.Y=ASD?'K]%
M"(=R!2X?6!C^W<`&.V-'JV9T"M;1)@>_1Z*\D`>:S4ZWT=L^5>`)E6&$$]-H
M-CJF-.O51[>U.;W8K&@T6^``O'1.<+G-F!-]#(/).;H`L1LG(7@%::LGR0F%
M6]$''XU`-("\WL46SJ?WDH'N<,(;<8]X.@SMP1GYC"O\&_-@72\B.PP>=K!Y
MNMU6)[5?5QK3QF?P8K77;^-N67<.&<=P+"^0@Y3&$L+EL>7?8:>Y012Q77A$
M9K?=DL37TA%M>O@;=?H7"*I+GS;CCE6#T6@WC.52M&1P6YO2QMC]97.2!>7&
M$727<GNG8Y;+_EG\VPT,]X4$[QDML[]`4ZTRVNR,)N3Q.)Z+MFLO<B,C>B$E
MN\TN&*?]<E*6#ZI,TJ7A<W$#'M#M0)2(,\M5!K/!0;^4=_F!YMJ#EM9%3M5%
MU/.=V/,]H]DI9Y/9X6QPV"\6S*VF":[(^N->(,`_NCZLSHXUIMGJ@'[I+-4N
M)8/;VI1>N#"=3J??:W1?.J6+T8C9,0@FD1#[%=;SBBQ+<"+P'Y18]R"[_)T$
MT4VCW^I*>WN=X6UQ6B^-7S0ZK6;_Y;,JOX(7ALVZ!SOP<ULM62ZL,[@M3NJE
M8>!^O]%H=C<S+>F&`6S.,'Q,$Y96RE$Q%TS%7&TJK6;/*,YC\7@V//*7<E:O
MVV_M:>@OWNJ-7J_Y++JGL1PL-MS![C4[S<+A0/[R%PSJI9:=V3,ZJPP*P[RW
MU@]T4[9$K*?/KM9\_>8";"7I(U>^5""XNWR7E8:SR7%OCHAGI'7!-K+<D.>>
MC[;5<799]@-/AEEC5)N?Q$;C9#?NG>^.7-O"^CE:9BQ=#SS7!L/S%E[^P0,?
M;3.C^L?_\>+W4RV*'SWV]U=VX`7AK]K_\%3']]H('GLRLB:N]_BK]G]C=P)6
MN<\>-'!;+/__ZAI]HFL1T&PDKH[<_[)?-:,QC=,/\-&_:GX0PIJ)S^ZMT(79
MS7SZP-R[L?2AQV*072?1U$+;6_K<]=G)>.;B()S"8D:_:E82!^\UI,:)Y0$E
M?X7)@6\E/G)]A^&+&],?XI,8.WZ-X"GX+)^]UQ[&;LSHK=*P'UPG>("G&_!C
M$#KYH.A!,/3A7RX\"Q\8Q6'P%SN!.^*Q^%X0`G:O/<Z?.;'".]?GE[SZ/W?Q
M>UP+O#1=CA?2K_RM<ZM42LZU5CX;_!!_^')U>Z$9VO^Q)M/W_],S#?.]=O/M
M\^?!US^UJX_:S>4_OUQ^O#P;?+G5!F=G5]^^W%Y^^:=V??7I\NSRX@:?\FZ8
M/N\=#B/[99K^=$3\6@WNG-D[IVW7/R2.Y:QJ=!KOCYK]JL1K8BM@CH([>IQA
MP&8'R'5`_/<AB>")4:19OJ-]L"(WTH*1=@UF.Q;,4_Y])DV-4FZ]'9/U%X&1
MX&`T41OQD)7EH33AI>Z1YOJVESA,B^%J2V1BT3L#GBL`#\`7G\-'H1MK']P@
M9O98^W8ST,!>IRLQ=?)A''C>HQ8\^/"B*,]4A_O.X3ZX[19O&[R[.56[2.VB
M;>^BXG90S*:8;7O,)D2<+!IUE(VGVIM40IN-["KX-OO4>*^3W)4N$]@8A4ND
MKQ_8HF^2:-$W01)*7[W5WB!OL!"D]742^]9$^\WUO$@[`UXZ?:L]6"#O0Q?6
MT4*!#NH!/@]"4B"N3\,E[4%*@7G6`U8&@C("]S)!@6_T=`W<24.#YUC:/1N[
MM@?:)="F21@EH&.T8:K9[&`RA->0+HO'89#<C84:R@!BX"TZ#$>#\=ZQ$)@V
M'NN@<U+EY-]E3U-J1>UTI584LQT,L\U;SB#YT)YVHS$)ZX";YR2Q"V(:/AM,
M0]?3#!3%#:-4#YTS'^CZEZP93B7^SGY"+R*%E6+^G77'HE0/H"]BA3`V=`(<
M=L^\8(I.A0XKYB<CRXX)8).^MH$JK@VN1PR4]LBE`!8#VM@LB>D+O&KHPIZY
MHU^G8>`D-G@6P'+T-J"[1;GI>*^-F2CP<&V<P+LBU`%W=!6P`/HIKJW9S(.W
M`>E\?.:CT@]JRRK]H)CM8)CM*T,@4Z9)<(IE\OM$N_*UCVP8<NO<).N\I7-S
M'.:$IKG%\3W2M!DM0^_3WJ!,?;7HZU=O=4WR:]"@GP(?@0J:-^,U:PHB_8<[
M`14%?H71:/R"G^*%+J$#\J!3$H-W(=!P.2PP+$Y@_U4VM6!4]NF,@N-3D!1@
M<3(%SPA'0&X+:+;$B[4ALZT)TQ:H3*/[/M*FA&A(,T<-.?LR#GA84++:=>BB
M2@MH[C.D171>ICW@7VT=I`+^IW%LEY1:-F&W<*KH^'[MGI(P7I\V4->#8\1O
MF!L+!WW1;G)RBFEC7)%/0R*_9`R(+XDZOL9^N)0HSM\R#CP'WF@A2S@X*=+,
MGM;26W.CQSBA/`@>/.2+;^BMUNSUA6O1#/"P9STW)P(?5XB&P<)[UX8[0IXT
M6:#LSS]EM(4?:0;:*,$:']@`"'<$[^'(/:?:(.9V!NRTE-8SJ\,L,'9D%N6$
M1GM$6A01+BTP(=IH3#S&H;D8IZU^K]<RI?D6F8782R:!3O=9,#_<%7!]9X9#
M=,&W.#(PC7IZ8XZD.*DEKRE,T)U,F./R+3L*/"]X2`VM(FGTHNJ3A>K0LO^Z
M"Q'B^D1H/%(,7(CQZ#,^T^@!P[>;BY8?;<WP7M#.%:G(.$N,68<._8;1`>V&
MX[UKW48ZW\QDQBV*.:0#FS,S?CD(8PQ0T`L'410(>)FR-11\-?NQM`TH#*Z-
MK7L&<IV2B#%8G['D`O-@ALEFM^V7P#\YXT]".MU(KY-W\5IDUX7)#E+<621^
MB=FR5`/4%],@8E%AZ,=H5*L#6653*YOZ,&WJ[/3U8^+;O$6%=I:$H"_M1^V=
M]C$(X16^9J<?T?IXI#&D+($9HY3278H!E5'^^.Q9DL9)3Q(&[VY`.LM*[/<0
MV"`L!G1^_[UH7TH1FX*2#]D4`=/0LD[?"9;<F'T[O3G5SD&Y@RF9!EN$M!<J
M%'XH.SM>_*JAY9%&CL:,Q=*Q<L@RDM%Q`NA%>KM#;X<+N`DVI2SP$P8:*36:
MM)!JKLF"\SR8RSWS\32!+B&XG-4?#_HY1"S\F6=/X:&6ZR&!'!ZXPHL?&=Z)
M/A.]#),08=[YNFMWENOS@7E!E`[#86!5AD*K6GG+#^Y>V"FT/-(W0)N?/LI:
M<E`X;T+F#5F4,^H>2*PQ*G@3(['L\I'$8Y@Q;#-</V#ZXH2UD9?8<2*.^.G[
M.']8A)&T8(+',_S@QY(XE48,#^=AP#)F1AJ(S(+BL5$:P).R"WCX$N]TCM&>
MJ(V,5Q:%XC9E43S7HL!Z%9+-](-4N;*6X2`U^(A<\CA1&XYAE."@>RX\%=VZ
M80P2%::8\!0O4.8@]R.0Q.0A6[`4>#(3/W+U'C*F@:,=C_'@'S@LBM!?'3+-
MQI&R?*0%?0]NKI/J^4@;,P_EO)6;"3@`-TY(,0D%\,UW49E0GQ4Z1`)]A&^#
M48P83$8D'$0)*<Z)L!G0T[:IXXK6-'CT$N]X;>KM1D_OMOM$563FLFN;2J54
M>),KE:*X3:F4YZJ4ZQ"M:!#C*`!1H]#I^\KZI'`[2V\GTYU,=0?EJ1U$\:E&
MB*0.86/Q`_F)]6_X&VQ]]H"G^71V3WS$-0XY'D!Z)J*L2<1&B0<$N.>1UNGB
M5XM3'R";HR7@)<%S*?R(H.KD2HAX?^F@P.5C/GF>^&!"4PVY0P8*,+SCD5CA
M+Q;\#DW&%D>?&_VQ)!;QYA+G-XN'8K:%!9^'%J[K":XQJ$5*U[YGW)E&8)T)
M$726#N2-<MPEV#3@\8?DGI$S-@H2.B6*W!_""7US`YH:062TYENEUBHL:)1:
M4]RV/K?]_%/Z5/CIR%5;#DNG<5RZE;7:.0-I#0L%0QIA#"I[CI"S:;W+%`3R
MG$^312I1ZCM+GS1W^/@Q4Q1YD2[Z.[YCA4ZD?0C@'[T0O?TXN/E0.(POO?$L
M<*CX%[53\?[!S5GA]MM@ZMI:L]THI(#_,PB<!]?C9^?4`EB;IW#^&!ZUY.TU
M1#*'(%=1VVDK:KL1#R0_P!,>N2X[U3BF5:J`D9AT?D^YX(%X'>:,>&+:T9QU
M@*;)S$A7&$0VEU/M$E,24-D[#"T7;+@M0J;I^XEF>)0[3+-4=)'YR*.Y(4.;
M@^R3N0'3^!89'TI]5UA]'XHP5=I;,=ON-?<$G:[TF.=3X-^=?'(Q<4?@R\I*
MNT2GTPT>W<#5++PEP13S*',:=70&,<M\QGF$WU(MA4(W9/<N>T@SAO)1/8S!
M:T4]@4>(,<4\^:D8:73;#>UD@DDP-GW@H#1G7"U0]IU`&1+Q24IL]/E08>4?
M4V4!OB3J(D1@`557>"9W]$#)>PXFP]]A79,E1IM:)[HV3+@[C,_SW(G+LXA^
M!6\PPP%!S!."Q\H2\C$?"<8Q#<$_+KB7[POW60[/')6FC5?F=5D>Z4XMR[C#
M5/X@C-Z+\[U8'-#R`/'("Q[PTKPD2YP^\O*N/.H\=B-X"@6=Q164S@;+P^!!
M/*T_0,LGD1YBB9RL]#$BFC`S.TH)%&-##6O':559>N1+"T3J'(P%-.G^PI0V
M.L,42Q8%L"!H]KD1.O8.OD*B&EP]9#A6;E_X3IK16&IJ*/VN1*[2[XK9#H;9
MOJ8*C:-?H=KC^IP?%=+Y'TKA)**,4FT"BHG.\8:/(N$%\U!X8NTR/8IN4BY4
M005S7#-4Y3QU.],[D9#VW+>"<=R!;N=%<,/'7/"3J[?LK7@8R<#7GI'I3[Z>
M:I$EVX([>CA_-`!`=_Q7&@E_)?S&+8`%X\FU53H@RK&!-X@\?_F:T]2JXK.7
M5=<#&1BHUQB0GF=P3SEZ2)Z2,Y.GQ6/FX$SSV#]>`;,$^V31HH7RP#Q>TQWQ
MX43,\[B)QD?B!_`L'XT='&@:;<?0^^TX_P##$<,4["3E,)[%Q`2A15*5,!4H
M20H-`IXGY^*A1(0L@6E4^>".LCR\)IG*!R(AE3JN"%\=@SK.W.VO(A'V*]<W
MY/6@>,2V"%$IAMG*24:%C-[(\O(BKL_,.Z,"[#\L6R-.1H_+$U794J4VE<(,
M&?,E'S8U!Z((<T9C[LYQF0^B_`;XP9JBFV6-8BQEBS%3]_)RD!:.\YHQ<MJH
MHC"M"4K=/QPH?8#Q?)ZI2OXB^+(!#\P^$?)/TXI#B9HE87ZJ?V(VYE"Y(BDY
M*]_!JB67YH;Q^]%(#NA_2#S8:?#`+\$I\(-1B-&7K21<FA\IW&2)UW*H_LW-
MX`,^ZZVNX5F"-K@YTSJ-ME;RN.+$,PLERJ:-H1$M1-[DDP*+C:K9$-4KC,;N
ME"\HKEU>9V?#/@LF+-3Y[;R"$59HRK#`E-*9&2+G^SPF@?962,?<'"I`U/G#
MDR/.*?B>*>.N.,-(4%CV+HKC4YR#*KE8..%1'SRJI^,!75@)0'$[0S$3J`6B
M1B[,&_*2Q6:!?0J_/:+AD5!6P'4*0H"/AM>!L($]F@WQX]4'_C.=``0NQE;B
MU+S#,L+8C3U!KVAV#A6Q2'[^2=DD\S:)T3L,-:%LDFKPU5'9)+PIP,#!VH];
MZX=V4F:'7/II!:VNS=X@'W#_,;B=+58WVSET@'\?D!+@#BDE;I'$3X^4R1=,
MK\Z,F+L@<.@L>\C&EC>B[^&]P#SC@"MUKBOAY?(#N=F1:DOQ4*%/WU/&,[/$
M"7$^(-2SH9.6_G@9@'A0YH*CH>#Q$P]\-ZI11,(7JJ,P/OQ>$,/%-/`HR*X5
MQ6)DEWS38+1.$-)T!;GX["*6)UG3><DH\1W2AKP8B.O*U)>^P_"/CSH;2_#%
M0!Y%S""?(;>X<LV:G2Z@#46$HMKBLFHR):*J*Z)41IOB-J40G^^D2T!IYSE0
M&B5!/:O^)ZMY783!)@*Q:3VO_`TH#1QW!K`FY4'34TC[9,E+<A5G?L2;IC&A
M'A&`-7ZPZF!X-C-H)>:4U/9D5;9JAU9WARI]H+A-Z8/G9S=3>3]UNGJ6^"\$
M+0580(Q/*TU*3L."/#>XVVK(,4E\@CP>%.G@3^2%+B&C1N%1?E)*"`.9'T-1
M6`3&F@$,FAV:DN<5WF%*GBMN4_+\N?+\4Q!%VC48L03.]KR"?LNS"2(&#&,K
MQ)*"Z-T;S(%\*R$Z/B7<S4Y#NQ!WYF,YI=8Q=O9,>E@*5LA1(B^N;]Y2`&A(
M$`$B+,4IBQZ!`,OQ$S+3):Q#`=0G0<8)V!R"2>0IHJ?:N>M1'>7B$13>7?+4
M-UDM)G@JB8]PDT.:%!\YIOT&F/;K$GZ`@^_#@%5AF*?:=7K-S/AG46J<LO'R
M@:9KQ$_F>!F1ZY_`72?P0/:8PC].^7D3Y:WD)Z!WL#LI,2F)<XA`^H;]8*'M
M1@K^1@DMI2%+*)471BIVJQV[I3HR[Z%:K`$I.1KZ5YK'2?(\($&).1Q.]@BM
MB#.3`MW$@39F#B&[38.(<`$(D3@:GV"ZIIX62`0$=(=0?B<98AGF.H":^"UX
MP.(0'10@E]*,>B4+-#F;A;&%@3`ZY2@?1)J<&%JV7+U"J#SB#LR@S',@(J[)
M1\SB4`99OB-SZ35OW+<YE2CO933BYRT<!$ZS/4RFD>I#7?D.-AD&CI@?D=+V
M0+=YCZ(M0Q!A9JB$G3S&LDII`@&.H/!$K',9@OYB\0FEPH)/&'MYHBO/E@VG
M5D@`=7305"`0'3:14^ED2$-AZ'(%+RURZF.ZR%-`DSR=4RE*);F4HE3,=C#,
M]J^\9%W.6J>$.<^3A:(D27/E@D<HE#T!<AMK^]!#R?0)N$.>^U]4.I_P2$9K
MPC/`GXJT-X1P@(*;80T?Y27"^XU?->Q]+K(R8`1Y"N)E_O*WI]J_>.XFROP/
MGF7_=7)CCP/*L"`/B.8@ZO"P#8_[GX112P5*UX\U4DR4/^EY>7(>[QE!]0W)
M1'A2;W*8>&!,^O<^0$<,`Y"Z5*TA\@#3U,410ML1N.M;H#]BS6$/#%`Y4M5"
M/*N?3K4+_CP*8A;78JD%D@5+2P[="B68=,XV_+=(KA`+0IH?M"O/7;2D.L5`
M%]6:.<0!.-L95#U/A4F'P>V)5*5+59X(CQ3ZHH4"PC/1+\(H$D6>I[#(FN4X
M+K<E^%*></\\6T:NQ`7LH%@*GHD9(8(MS0G-I4*!Z6QU*N(;%9M9\,Q),KMX
ML2AV@O(XU""^3%KU4\P4ME>P"7G<Q!71`4'W"):)44UG9GG(YH5.8Q/!:RH:
M#=D(DX"(T/D@Q,0B:?/R%B(IZZ844/:*4B%[M%?J.R=/=6-7>VJO9ADOB"2%
M4.Z:%E5'&C\OI#L6<CPIX8::YZK,E]K5!:AST@/@M2HQUC%(T4R+K^!6OCP=
M1I+%`H2`.P)%(%=16XXB-_]0ENK+$VEZ9H-7":39\%PUW"4NW2/<&1V3[$$'
MI$TS\$Q1Y]B""%LK^1S@0UA#SP4EP7N$@",5$:C<*+0F#'B0-\'CDRHZIVD?
M%/@G0A0`#.LB4@%>3Z>Q'*^W+'T'X8WN$)8G0VR8TV<B#HT@11@NQU?#PV#K
MY+]3_>8ICQOP^PA6CX<7+.X.LQ^N\/ZP49W`(DC;K(AZ"?*`.6"`>"L'4V*$
M""5@!?),I("^STHD:%_32//YX3J"CQPZU/%>ZG""@,4/>/R:^J46MH)S@888
M`QA$%%S195)@F86X6CC$$H/QH4?C%'9!PA3,#K?EF(;P]>=>+69/,1*?R,5;
M*.<SSN9&H[1$[2S5P(JN`-2:D(>&LA?RLI24.6>8C9H`G`#?%[;/&'['=-['
MU#.?8N=*-Z::41YRH+`%Q_SP%W`F#@T;!T:_5E'52&>+1VW8'(JJ6<6NB:G(
M29H>'\0[_MKE7";H;+0[W8R.<VM:-!OQND6L5+*ZTMIGE#JQ'+02TN>7TW4)
M6[RBKNCB77]_U>"_3S'<QW_/2!2F]+EG(?5G3QDY#J8OMN!V;W[$3CJ?E!ID
MR-=O(@>Y,V/GB74RU4+M8:'ZG6Y_Q96JU^SJO#3\_,XXU:Z&V`6#(U=P&RP]
M"?Q/$N"A#YG9PHDAKX1;FJ)@`)42RO34"Y*,2G!]GESV=W&8_X@#V+L%I^PW
M9;\I^TW9;_68R$'N3&6_56GPRGZKZN"Y_69BB@T:;?IL)^4EQIN>IP8'N0$H
MXJ2.BR!\WJ-&99?I;P2-KNRY^MES1W70J`PZ9=`I@ZY".U,9=%4:O#+HJCIX
MD5!_JGWS@[F0'-AO&=(_A\3U7"R4XH?GZ=FO8\56>KXJLL=%)CSFG5$YM1_C
M078<I`GEA,$<//@__R0?\)9DC2DSK^IFWC&%[0Z5U:K$5\>03O;-ITXCY#L_
MN!%+$Y[2YISSO5+*`.W+JT7R0B.L;-7SS+(<T10ARQFE'*4@?#KBJK(H%D59
MV3U3ZY'?`)^$"9-O$'U,@?DL!*<?PK*E74Y][)6"."#B=@ZP](/*2_(>)P)Q
M590F.0D3&+$N@E6`XCC!["-@D%B`U*N<XLKMU0/;EK/YFDH;[)W#CD$;9,G%
M$J:=*.!<$UR/Q'I>4UF&44T=0@,?EQ=-<LH*SJ$J0,RS*>$4Y4.9AJ!2W*G'
MI-I0F(IU)Y)&T0_X*Z\?C&8*"%,TB-$HK3[,&W0)[.Z\49:<V$N8"1S/*,T&
MCO(.FW?4,+7TKK3QET,=0+G^+"4%]=V8'Q#>(Q#2HS0MF4/5"G2HHG.3PD0-
M[#BQ/-&<(Q+M41UWA.F\`HX\D.HL%512E45+JW$8HD7IL1HPVZ'IL:_@:<`<
M)'5V'08^_&RS]2ID+GWML_5(I85<%>0%-]+#;Q!FSPJ=2/L0P#^:"[H'A3D-
M-Q)?4MLN>^R"7"^6IH!OX@G<(4GP%_IGH9(4V'K?3F].=:D!$YYP:A'\Y+'L
MUDG@,$_``M'3.;!0KC%X725J*HX%B`]=60ECI,X1``HX07J;7ABO-(W`MI,P
MXGVMK*QQ$[AK"`(5<9"D@+`KP$.;(()?VEDDQ*6]SXYQ_4)]BP`3B`1:$J_9
M$$`9@=0=5`3^>(O3M,<G?>CQ@@N6-AWCR.JH(.?>/X/GD$X\6UD)L8*&-D_F
MU+WF]Q*HB"[F0XP,5W/`"F11PL?B#6)3*A+.5-ZQ%?O`4HT(:O4,9XK;4BF)
M1?N5PD#=2&-D!KF$J`@BPA<\Q$V4,(JU_R3@ZG&42F#[[GM-(%TY`I'$I2[R
M8W?H9IU'9]\Q@TR5LB!(@3!(FZ$0(H>`N<22F#E[1NJT2M\6[\UZR-G)A/`D
M$6:,6WC88"\'JX!W4_VP&\O]9&<,-'&]O!4)FD4`IPV91]MV;N%Y,W1X2,C?
MAMU5[5B@<OA1X+D.X8>4]VI1JK$&JE'988K9E!VV'K-=90VLT+R1;0C9"$O-
M)`%Y2)7!CDN16Y3XF*(E"5^ZKNCU$\B1E<G?3/KZ"P/60J40>"7O0[[W+EH_
M_Z0VR;H2^;1]$-M$(?/4E`,/1$S+[G(!_G:)4YPSZ>VBP&;:IDJ8\N5]JIH2
MLGN8#8&[#2)"G'9M'#."+!3(P(7!YK7S>.$\(M`Z$OYO[Y+HY,ZRIK_>Y$"#
MN:-_#0:]#>[<+3##!R^P__K'SS_]+;WC.L367O'CM8?W^,X%^$"$6WB>18^S
M^\AG@U^^LM'?7YWQG[]__//B>\/X_K^6_QT'?MMH?.?_O[WZWC2^P\R*G[_Z
M1T$8X&S6S/DLL/VL,-E&!NB2_5S._LO2/Q?NP^=MAB]7MQ>:N60+7'^]NK[X
M>ONG-OARKEW\OV^7UY\OOMRN)[WWL6`\0?10EFPMGT:1^X7D3@4</Y%*I5L6
MR72RDRZ"*B'$E7@!0MN<)E@)UT2MX"XV3*&08,-5`>L9J"74'1((T0GVD[:F
M$5`X_:E`X^T7#`R#.`XF^;K,)@[GQMH.EFY1_C(.TW/6VS"""B=\@C`'\K7*
MN;9F4Y/M>IM:4F3\Q&=[(@3$$(&X9[]+=P*G1_$[8?!3O'>[M/H6L5'B:9_<
M$5-\4$L^0(D%HL?_^RMS0W1K&B>@3\E^#;5W^`GJ6<4>:FI'R?G-(V4/J3QE
MJ=VB#6%][\(@\9UTR?_'MAD;E587/L/N3GFET6C.AM0\-MHRO3Y90\D_07_#
MG0%'79$[GC7ESL(PXUZEQ;/FTIU;O51L;'."K9..6J5UY[+;+?9ZZY-JF;.S
M"C'>O=UI&=V>WFYUMSZY]NY7;(?\V#Z@O;6'E=K!WC+VL;?Z+=UHK66=U67%
M=F*@46!Q0^;9/'GV8-:>\9;486ZK;8TW*FNT;VP54[ML#S/=IKEV^`O'MU\E
MXY`__S0S?OA@?X02*JJ2E'J"G3J&;K2-';+286Z9PYQ5301!=8A45R'0T5O]
M[9F^-1("VXU25N3@50WC!<R\?Q[=\%X\H`GM($Q@-OMZI]]3ZZ/V2_TGM(O]
MTFGHG>;V//`JKD\=(VGIQWC13,'%=@Y!$=]K8(OR6,J^GX;,=GF"_TK<\J01
MN7?3HMJC4RZN<G&/RL5]LWO#;0\;YJW:_6KWJ]U?LOMW;H96;?=7*O]N.;E:
MVR;6%Q9KA9*AB_6.>9\8\-ZMNRJ/;0.Z9^N\40_-TUHH49T@&7J+^I54/@UH
M$_IFO[0YV19M?O[I6:(S[X!>GPVB-GT%&5MM^CUL^BI82VL'/A>T('G&[%6-
M]/Y`!4JQ9HY^#>10=8I]+=`R.3K,ZP9Y%*]-O=OHZ!G:S".SP@58,QQW`,O#
M"#PU`Y+D`);E6&&E<`=NI(V9A_CBO/8\1LS4%'.LV'0B9#SR/K7@,<LA9]8!
MD)&!9R[]V/+O7'CC@-#(=X0W<V#@4R6-+@J0!A5"J-J4I/-DQ)OF$L2;\XN/
MEU\N;R]./EU^O-`NO]P.OOSS\L.G"VUP<W-Q>T,,/5Q?@!X^%U6#9];KC+I%
MC7E@"UZEU7T2LVZC2SY8&=A'UQPV0GAE=N*Y(^SKERHKT3M#AU<19K,EG56#
MK@]C][\6Q]L6"$.$$6[%A"_W),9GX"2V:*X!O]@LPLX9</-KH]?16V*DKTT8
M8L=HEYD#Z5L0@C1K$V4AU%'$ZXG%^!#SZ!Z1T!\8XG6C^1&EG39R<.D"J/1`
MFEEFVLCV2[34@-$>P/9X;;3T9L_@4VGV=+/?G9W)!6&>(_HTASJU5GTU3MN*
M!(Y3M!(TD]K5E42GWA$Z5,LT3[OF8BM)`43-9N:F'(OX$VNS^RX`0N=C(ANT
M.A/\X4_AK"%0G"SLB-^2C/-6BO<4)E]^,%B5/.S-HZ`<0N+4]@Y/4QEEMAJG
MW6:OT^JV.HU^2Y+`S]4R>]R+,]F$_<TM%Q@8[=78*!/^I^T6_FF8;;/3Z]2)
ML'O:@`=`N:VIAQ4/0+)=W3TUN_BGW^DT&_W:DI"?R&P*:8%<@_4(V3SM-/%/
MP^RW>K4EXT8-E;VGHM>3_%O536LDF-6!>GLU2JM/GCWO[9H3;&\ZI9;4JIWJ
M6%H*7<<%V*KR6`/7K0[4*Q`&H5F4-*S4_JXYP93ZJ#9[*<]CI\ICC<*V.E!/
M2<(J[^V:$TRICFJSE_(\=JP\^H?%ODH65GEWUYQ@2GE4F[V.WN]8D#^Q3*-0
M>E+Z4<@'4)*9N[G\[MLQ"YDUBEEX8/Q?J02?+2(U5'\EJJ+HU")L17F"]FPW
M5K1=GX;CJ!<5:Z=4UX#%75E]*9M5::%ZK,2><]$4[;>B?'BMCE(^NSC;78@K
MX+CW)4\1G^:ERRN4(&/%\G0RCG[]@C72U[Q$>D>ERCCK78,B/%7E4K-R?'Q"
M7BC<6E(HC!?=:->#/P=8'9Q=`G/X>O%I<'MQ#M]]O?V3&&F8<5V!,17.@L*Z
M.)8U^%*`C(B#`FJ$RZ*T^I4J6+%2DY=E8M6419\M+A1=J7)3K>K>=E9I+66[
MTU6%E*L74E8%;_&`&HD?3I_YSL;PB&;*4X^/*=8)4*F]6J.I566O;JH:&BT@
MQ0QJ:D?`YVLU%#P@9C@<752!893MB[FA[1^THB+4JL@PU*+M^TAUS9!)JC^,
MOC$;--E^4[4O@7]RB4S"HEC[P*P0@T>?`LO71!A>NTG\T(V8]M'U+=]V84;_
M!&),M4O?+L$MW1#J<DJ3SD(TK+V:&,^?RVY7=WN0X3F\U^RL=M#7$#'MFBM"
MT=1KP7;(CNT#VEKM@]Q:<^I@!UMK>T#Z>URK_2<OO[CI0($\Z[<4P3N6'C5E
M*O_S)Z[CM\8+^U_L@^M[6Z>^Q$9/[W?6BE`<]_+4?/@'MQZ[;N-MZ.WV&@`E
M![`\E7+0=TN@SB_8&G'B1E$0/FJDEZ4,D"^?/IQ?WF(*1T.[0+]]BLXY/.'3
MIS,E?ZJP?H<G?UJFWFTK=:VVRP%,J-8N=!57ICY>\X;)T_Y%*SC-)Q@I9]J5
M%S%?^RWP"+Q^,+U18J8*JW5X8J:A5D;ME/I/:`<[I0T.=+-_7/NEX@[T'O*'
MGM+76V.-RN9)[;N5]K.SY6I)I.<VU=XSE78I,@]SIQSFK-3^/X[];_3:>J.]
M5LK\5J3`SS]M?)I8-Z]"':NBA04Q#(I7HZ;F4Z%X6Y2E7F,S<^7%56')#L^+
MZ_?U?GL-N,9C7YZ:#__@UF/'VZ5K]O1&X[CV2SV#'D4HT$*3ZZW0\A.+(NTL
M"4,&3_ELQ4GH(IB$\H&4#Z1\H#DJO=FYW;&'_?)6;7ZU^=7FG]_\N[>BJK;[
M*QWTV`.QY#.D:'$41/L4^'?:+0LG2K0>F6C=7F78`4C472;''>8&.<Q9J6VO
MMOVA;_N%2,H*<'-7@)L*U';OJW%;P*D-V31D$4PSX@"V29R$#,B81B41Q=8#
M4QH&%4XTAPWC1="V6T*T_?FG?2PJO+5FR[K2UE*HMKDG_$QTLI?BV^W@K`:>
MD.`/?S(KU)A/A1!S,*E)QAU+K8(G%7JE\+8*YWJ5@MNJ(@TK=5R72J.F)(V6
M](#=;M'WFEBE"EY+80#5(]-&`0%MPKO=G1C:'M#:_I?ZX%)@ZI2BI`JE*YB<
MM#NYTE%RI3[<J^1*55=&62L%J;(]G*S]+_7!\:Z2*E5=&66MS,B5GI(K]>%>
M)5>JNC*5ME;F#YM6*MEH;#N*>CMF(;-&,0NWQBN539HX\JRBO<B[GW^J!9V*
M-=PJQ6BK9MN:1-C[L:R2@0<C`U5F997*XBN[2U1Z984SO]0:;'4-KGSM(QN&
MB14^:D:;)T1JEN]HGZW0'FM&CW^D:^>6?QZZL7;.?"#K7R&SF7O/'.W\]]\U
M4V\W&CH04'OSNM4Q]$:O]98>PK]LYE^:+=WH]]YJ7@`DUMY@YF9:"64V*'6%
M>LA%V8?&^[>Z%K)HRNP8WN<]ZMH(9J-=6Q&S@\'T1H<7:;`P;ORH!0\^C&CX
MJ%E:-+9"-@X\$*V8](DO.@LF4\M_U-Y(;^2/D=]V6I;TBZFG^>"T!_"J4FA]
M^-"Q'B.-O"QZCPWO`>YP`S]]LPW+PN!#JO*:)D//M>&K$:.>>:Z?T?;;S4`+
M0FE!B/AMG6AIV7:8P/UNVG3/BK7V+]H4WFKY?C(YU6`M!]/0]32SOV#5Z$%\
MSAIU>.3/"Y"&UH3YS@1+^Q_0:P0JXM`Q>S9*Y[&`!($_-V1ZD1TDGC-D&C`P
M/!I>!2.6%B(K@>N^AS=,B6"PZV@LH"GP=]CDCY@+^.#&8_S<]6WP9R.&1,,G
M9;0(@;38Y:![VFC\4KJ$`YK%E1T'F$QH=%,*X6.")(YBB^<;#BW/\FV:U,R4
MX>5>0M?,+<6#%6FO>\V.WFLVX`D1?"?NMPDNP7X$(MACR[]C?*@E0Z'UF_VP
MP+A(<=>ACW#_$(VS(0!%W#BBG0""Y+&DPZ(2J4JMU7<--A8;GQ6)8]B[F3:#
M797X(!X3E(RTR48P90^5"ZF=<J3V@DJ9OZ2HS)[23;J0=-I=`).$[Y@?):0E
M1KR)*OR4P`[W:.;L/PD.#"<P9/"Z(;CDX(J`*#C5OOF.4$?%63PY^[A086%-
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MSK#*BI)7;70E;(]E#98(BESN@NF8R@.4#F]>-SL]O=?!\!91`O=NE$RG01C+
M0:N??T*YP&4JB!>04!8*@T@(U[E0"EP\9*EP))'#@S)1,L2H1>Q:GO>H12Y,
MT0KQZG@<1%RH6*Y/(G$FE,&E:3HA%.$@"40$!N[GHC`STPA$&R8#8HZ",<-'
M[<Z]1Q+Y0>S:%'<1,27X:JZ\NA!.*@9L'C!`E`=UTOB-'-.2!^J`"(-7POA8
M:+MX`\9N:-A*9"F1=<1K($06;#?P9L]_O[W4!N]NEH8:QBX(.#<B21&"V\]C
MYV!YP*8.(S(-'!?$71R$T=S=UEW(,&00<#M"EI#)%#]&D=C.33UK.@V#'R[8
M5@RDU>M>CSY_R^TV'@?/W>=.>0PWMRM!^@DK!J/]GK<PKHQ/A9G9<0*L!B,`
MT0*&'1W9`@GSD"[&3J<P-L23()LH^UV#D7NN+60TB"H'3+'4<WW*N<<A/8I*
M=CPHF1&,9H%FPR`,@P=QGH(VL0&:Q,2X1:^I&\W^6VWJ)1%]VS7T=J>)QK.I
M=UJ=MQ3Z%<1[P7B:>OF`BN%X'$#3*%_3=ILOJ0A]9_9EF6E.)T/-AM[L=N>>
MTR*]*F(O/C4/(+47"IR\^?`[_(-<C/DJZ8E&OZ.;O1X:VQ,8#^V#2#:F4U=*
M]C:,CH@%\:U!CTWC]@XI0:/5TINF(3TO?8&PVFGFUQ9!)"?3]!#`"R)AR^.O
M-WBS=B$>K%274EU'O`8SPBE:+)U(9J(\@1^,DOA%OIHH>?`9,UN=N_!FIZMW
MS1;(3[-IZKV6\5;G4JW9T[M&'SYO]_5>6SK!-EI-O=O&<(4)$L[HSYQ(+U15
MJ2@%\2F"ZV6AXLXO]*(9%P.3@J3KV(\I`\<]E9R]CMYH=5$%M/5>HR5F8#;T
M5@<GT-0[1E<^@>_T^G0T#ZZ)4T+OI=1><<(\*H+"+3T:%B(03`4-I&0\!DD.
M*P)J-?4=2B-1I2^X*A'47&4]5T4TV[K1Z,SK!DES<L[)/UBH&-I`9*.W1"_D
M!I)2#-L42D6QKHBVJB17I%J)5%F>#8:&N!@JBZ8_[7U9491,,GN_V6WK_:8Y
M8PJ_[G:;W*0&$]]SK2'Z'(1M]\`]GUD-AY)H:H&XPP@YV:`4=[*T>Y#R\!T\
M)LM#H50;DIVIM#[5WI;*2=`V9J/UA`VM/V$PFWVXN;MY@UFQJA*%V]O?_XO[
M.3U\*MO>&AVH%)(@=#00.^ULPZ8VB,?N@*PC)NU;V1B8WY/P5$/*J,R>V?ZE
ML%TQR%)B.VE/&TI+[*34-6_H_38W)=&^I..Y&:D`&[O17,]ZDK?^*8P=1,8"
MN5`B2<`(;YN-C0J2&DB2ZNP*Y6X?PAJ0;/,>TV/B)KEX@^0.")3F?Y?+.^%3
MRY)K/C)8.-KO=G43`Y>I&PHN=/I5LZDW6\U5_6CNWW%1-9ME1?'%ESN<*X<:
MTQR&MM[NME$XZSVS6VXVP22[C?839E-1@)5([;5E)%"XO<P+_?FG0_%#828'
MOU^5S-S_&@S*<<.?J!T8::^;/9!^;>Z1A<&(11$7DV0'DO$X5Z="LHPGW8)@
MO<='.?P\/S-L<%^&##,*4#A%_(PEE7TGF=B:8B<A+M32@?#87'HIR0[+_D_B
MAGF"0,A`?$7B\XCD.G]&-JA0RA_2<>%/,L$X9!8%%G$28^L>I2E0W)TF?$14
M+4+5)92\4%F9<OC<K"3*_M=@@%%_$`L3-XJ"\''.K?ORZ</YY2U*F89V@3ML
M&KH1/N/3IS.YX*UX<K_DN!_3?-(=/^^#+A``>LXNI>5>IDCRR4V)/+M13I^<
M-2D65FBM(V;]S*N5C_)G;38^=3Q5[K:;61XH%;>1G4BG+P_,N\],QO(CJ-F4
M2G%&4Y"YDJ'(!T==WU`?F&A7XZM>=XS^K.%;OA'_]FXZ&4>_XB,BT3CNW(W0
M5@/Y>PL,^L$#L^X?/__TMR0ZN;.LZ:_G;!B77,(33'_$7]GH[Z_.^,_?/_YY
M\;UA?/]?R_^.D[MM-+[S_]]>?6\:WV'VQ<]?_:.:@N&IU@XU$POXA"'^\.7J
M]D)KSVZ2GFF8TGXYN_KRQ\77V\L/GRZT#U=?SK7KP9\#_"6[&GL+7GP:W%[@
M=U]O_R36&NZJG.(9BVEV$1'@4%93*=J]KT$A%JJ+L^Q9/SQ+=7J=AUWIW"3-
MI.,983P!%Q2W\/-=5(;#P'=$/BW]"(M"ZAQ3=O-X@'3H/@J2$,QO]E<DE=KA
M%[PNW)+K`C`'%AB!&_P+7B)2^WGN<)Q>(>7`8>Z`&XKG^O-:;6'8A;\*3`K/
MHY?-!6"HHB%_^I('(0T7AE6L/'Q"9*4`RESN5B'X%/."<!?SG[.BZM?]TW:/
M\H?EF^OF;1S2#E12</]K<#M.=Q<&(=Y9#I*&G/$1PUHG>,#8HDQ/V(MT]NQH
M(\L-M7O+2_B^PLAN4V^WNUH2I1+K`X(;G=S8X'!@3"-TJ41L$CC,DZZB@^XI
MSYZ-6(P1D7@,D@M$'\D$"D4,W5$2VEPVP&<\4=<#!\>#V]V1RZ,=X-:X]Q8:
MS;#Q@5K)A/)U0R:\&EXID5GF5BS/X@V9XAV15@IOL!ES1+5L*C=YY(+JV4#J
M!7Q`(@)#/AJ'M7B"DE))5T%'"/&7C\S2'##4J2Y.')ZC?S8!XKC_Y2^=2_X"
M=P5K[*0!%+R9)]/GTE0N<ZZ897&FV>MVP]1;'0[F0<`N9K<_A\82A%EJ6Z&H
M+9N>Y*;531`?D`Q0<GC_:[#X9%ZR/&<EAUYZ"/7:@*W8$2F:](1.MZEWFQU9
M2*8I0X^EYU-&MZ6WN[T5#ZC6/HLR05YT.NVC3HD\).8ML^YKMAP'M!JW,Y95
M$G&CP6%XON+Z3)1;<O>H:,S%!7-PJ>4B]C;J?'C'?0`N'!<J<$.G_8N>?^>Y
M(_Z8AT!8(V@[R:%5L![<Z*]"A&J$,=A"72@)B].6\0L/F/HP*_?>=3!1_=%E
MGK,3*7#T')8%(V>V^U/QP[^]6Q*)+@:K4T5UF1OS`]_YC3F(53%`$Y/2755$
MN_Y,1!'MCB8%LK7SBZ^7?PQN+_^XT#Y=#CY<?KJ\O;RXV6V,6BD7Y2M4<PT*
MP`<!7A[$J.5E^U[@\@#%Y7`(Z-PQB%#2V20UZ2/;BL8G(R]X0#2@\"\6(Y0,
MT)(!W4\RE$K4SM&I]EOP@$?!Q5@!XD040$-M,!,L%QQ^Q(U9,!@1,(&5L['@
M.D(?@B(YPUB"%;+"$,U[?@LEX&6!J7AL\?`P<^DU;]RW.7M26'HTXB$,@4B4
MAHQX*%V'&^0[P/D*'#%/(JGM@:'B<0@RU#)8@9R&J9&2`1@ET@0"'$'AB1B+
M'S)8S?@$:8PQKMC+C]@I!L+"/",G*@:O>$9/(8!E`SGF(UY2_8=>#&TIKTB)
MRF,7E?,>CH@[%-!S*,H@N3[B4N[F<$PU$:"-,$!;$DD1(&FTLWG-ALB=D090
M?,H=B<A0`]D298!HMLV%*@J_*`9A0S%D&$X.![0,RB%/7O'1W2NDKMRP:2SB
MOXTR<(=LA#@X<K=>MW2CUQ"1WK;>,YLS.2I/E)54/WBE[3@>)?M!SW=R9&?I
MBO.%?_<)H9*BJ]$GAJECRC7:@-1R_\M.^$E.^M+JN$S=)4E`GRX&-\IIJO1Z
M*@NANFN3[K5,O&I<ODH;ZNG])[MI'MVJ>=8P@(=A7J\XRW82FTY&B3A:0M#<
M0?9&NHWC:0D'B,Z#;<OGSH!O,\KP)<.CR16]J&9:C,1!S[0MSXOH,(9N`L]&
M).%':1U3IQ3(J=_IHH<QERKT5GD:%>1A)5\JNS9@,PL8T;)^'K,=6!:*!(Z_
M2;A\0H8(6(>2>I]/*^[\!1AN!MKE;_44E).<C2`M"2^[H:F;9ILPWZBN-$TJ
MU&0I1(*,GTO1<(>/:31')H=()/%`:`([.1+.*!4`T/4SXJ\`#WJ'N3M66N>9
MOBZ]?Y:D<A6#6)TV!T`>4@`HG;ST@BQ5B#\K\`GKN9G",*OM5[7MIT1C==>&
MRZDTVPS<Z?".!T`E0&2JVVF:NMGOBM*9MMYMF'G2V5,I;RT]S7EKKEAML[ZO
M+7OHE[X=3-BM]6-'/ODL9ZVU!'/-5E->H.Z3*2?09_=6Z%I^///I`T,(U?S#
M1=SJN3X[&<]<'(33,>R`7S4KB8/BQHEB4&5E7G_YQEG&^26;90E[+]@4\D[?
MBJ/?6^)H7'XYN_I\H=T._K_KNON'SRC58(LR*;X7179@"UZEU9U5[]M;\@*`
MJ&WS`OP18;BAGM%BZP>+!,P4S)<*8BE"\'%P\T$;W)QIM\'4M;5NJZ%K`_X`
M-&CQ$5Q5:;?XB/<BW"#.(*."Q0OJ&(Q]S+U"PYK%FL-&+*232NL'YI_Q8^0\
M5`\/`;M)9,QG>6&CA!+,\)XA\]G(I;ND3'/L?A*$:(KS6B<<J.-B"Q0&\\(.
M,_$#-9D)`M[#DEZ?3XJ0$Y!0]Y;K\2+EW)?"<Q>T%^`6@=Z-!ZR/2(D'*TRK
MM_(>-?BPQ.-U$#`>6/+_%JJRQ!2DTH%YJLPNE39-PFF`T2$7#W6GC%@&W2SR
MW?3\O`$O]JP'6EH&%+#CPM%-`=Q<T!6,(!]F&HG>9OPT7GQUCSX??P)_&CF`
M681)%)%E68.KY=8=F(!1&N7(%KQ*J[L[C;(`7V$FQ\<A.3\C/DE@IO*29&0Q
M"&3JS5Z#P)11[)U;OAN-BV*/2QPGT'@#EZF[8E7F@7&>$C5'MN!56MW]&*\C
M%ZM#A4R0+"(8;A+ZPF@!&?1(J7!W8%R%U-#*Q\XR_AU(JB@9_ALL%S(KX4;V
MP^*170P1H;SA4:!IZ`;4_LIL-+IIA,@M2"/Q2B5X*L>:2O`HP;,IP9,[DY(+
MJ4O^G\A*+CB!_/0H='D;.@[4D:)SE#B];Z1LW+>E9^59\/E7Q7Q'PGPKR9N8
MPA/B'6(^1LLT3[OFXC#WZDEPZS%."=F'F!@:G@!#>M8T@M5*?RJLU[(S(@US
M5L2#__ZJP7^?(EHP_SVC1IB2@M)&;<M+UVL8Q'$PR9<F=I[L`;_=U8N=!<-(
M=\XP\)RUM]T<\\[MX](-M]X2"Z*?<'K"@T_;BF9+:";+#9NR-+)]P<EX(N3U
M$!%09K]+-S41>N8[,=$H\%P'=TF`F\3_^RMS0PN"FF>UI2CG"VW7*T08SL]8
M(\7`:M.K39]M^F:M-GT-MOR[.%S91M&&P!!W89#X3LHC_V/;C(VD,>=KD')*
MHV><]HR>8;3-9JO9DTS:YYKM^]DK'AMM3+1<_`!7C0+,M^!J!4!O?N3GL&G(
M;)<?PWUT?U!M%1ZSK<;VF9E]VF[AGX;9-CN]3IU(OB?9?0"4VQJSOEZ/A&;O
M%'9[K]%K=8U.?;<[M<[>%`D-4^\:AF)%M:WK)A";IYTF_FF8_59]-_,^Q6'W
MU.SBGWX'J-BO+0DW*@][72QJ5IQ8`PN?(MJ+PY-'3/Z5C/AK*\;,M#4B"#4@
MZ3X#+#4@3V7,GUH2;*.*IFWJC=:*AG<MJ:782XDKQ4^'(JX,HZ4WS!4-XUJ2
MJW;V[Q,1[J-?@"\LUB1$$<R@/I,RJ`^+C0LT^_DG)18KML]K3K"-ZI&L3N&`
M":8X3%F^BI\.16(9>J=EZNV^LGTK9/L>8.QWNREC?UA>PN.^`TRJQV+U`^/G
M2F7<;2%M39TJJ46H@CY\8^JM5DOOM5=4B$]E/-:-D)ODYK=*_JJM7RN.58M0
M"?EKZ#V0OV9C`V4F=2/DSN2O"LVO[*!D'^-%OVKF!@L";X/8\K3SM/@7DUD&
MO/CWDU3\J_2H$N&UDCPKYFDJVF]#?9XHK:GBQU45N_GAK=K\2O#NG?9*\%:'
M=]<^5GE'."?I;PKGYNAP;M22']*27\[C3$]#AFC+!+^<(S'?)2Y=4P`M1M!C
MN<<MMI^\\V%1"23+X?T2&"$X2P"!B2\:#*.?S4&:TZ>GJ-387S-^"(!6;,HQ
M22U[O-LWI/#3$V9%HCEG#G/-D<8DK##@%N:7@4H36&H0N?09D"L;&A_6R`TC
M7#X8A$L]33/$9GQBUDJG\)0)0QQJ_'@2A.S$<_]BWN-)#!Q]0HV/`]_A%R)6
MHI@._9YVY8P87E/^UCB'S.8=5C.*.]K0BN#OM']F,DD\WM$3B#=,@<*IK3/[
M83/F1%J[\<LQ@W`3`K>+[9U@QD4R<Z`ZF+7O49=I%G&2.*?:9\NW>,OL[%/1
M+=N-<8*XZ!I?=/S8UW#1Z7MY9SZXGD??<.!-(+;E((A[3!VM<<F(RC`H[#V^
M@,[OTS;?$=P*`_(>@0K4#)>OF94>^A>;[.+JP%=E3SQ&B,[CU"S*F#BZ)1^0
M"/!MT`293)>D=-H70DBJ$7,0$1BA:^.$NFJ2F`*)M/B>,CG-)2_J(;H?)*2%
M"@)%4Z00/!5GKBR,%(*G0O`\NMAPS6A6:S"_>B%X/F^%%/NJ+:^V?+;E%7YG
MI2H\?OY)(7@^;W70\TIBD2X%7M5%V@/P)G/?OH+[M1J[*YBZ(P;XV_<YO,+M
M?"(+N-?IZ*W.BEI+,>.+ZS`.@(0*L+-BK*<`.S<@"+MM4^_U3,6+6Q2#JEI[
M6SA%@7_R[49N!^[028AHFQ:3J:XP.H\J$UFE;E=%MYCMMMYL*ZBBX^8O11[%
M3_605T:_KYO]%4WA6I*K=D!%!U`)O$%3]YPYB<VS-T2^D+)MCU;T*5VQ3UW1
MTYO]Q@$32W%7Y:35##0Q)]!L^]F*D4CQ5&4DEMEKZLV>:IE1(>OV``.[NX+A
MM!0,Y_:%IJKDKX#F4HNP#6W8:G;T3G-%;:A`%8[,"%-2N"HK417658NP%9^D
MV]#-1E])X<J[*@<0B'\N).<F*_SR3!5*+/<CY;\HH5TO<:-0X!0*7%UY5SDL
M2NS6E'65V%5BMZZ\N[:'4D?P3>DD5EX*Z>,RF!I![2BVPKB"R#4*,>N0<8F*
MJUN*5;2A)4=L1/!\IS!CGX,'EF!?O1&8B&\Y)J(=(")G@HB4`>]%'?@<$1$1
MLAZ9%48:(B`Z3R!?$::?&V']ML!=Y(!92,LC9#XE;10DUC8AL8X%PN,L":F\
M['EQO,I3J5KN9$UH5FOX'H78=>SLJ[;\D6UYA=A5FQ/6#*^KTSMM]5MFQ^ST
MVTVCWL`+6SQE/;=\-QI+L`"KL;K"J%%H7?M'J5%H77,D?&-TNWJ[N6*>D&)&
MA=:U=TFH$))>*@<56M>SSR$5$U:XK*OR3M/6B)]U(I_/@M3>?!!G/^LDYN"T
M?_YI1=<!+MQBCI"T`M5*7EHPL(V*I8,E646&45GZ*);:>2RHOBI\BP&?BQ\V
MBRBM`'5*`(36/@3!7]HYFX;,%DVZ/KH(#SF@]GSK,%7U::VR8ZML3=:<8!N&
M6-/-]HIQG%I22[&7$E>*GPY%7)D=O=E9,3>BEM2JG65\R)`Y>[*+KZT8DW(/
MB\N5R*RR$*@YP3:J8SI=O=7K'3"U%'LI<:7XZ5#$U1NCT=;;O?8!TZLN?8%4
ME'B]M?C"8NV*5Y+Y=]JG`"SC,RL,'T=!^&"%CK*`CU9"KK7CL:)W[JD(SGQD
M1-NL6FF;3;W957;P1O/XZD(G):N4^5L3.67T&WI?^>L5,'\/.12\,T#"L['E
MWS'-]0D<0>&K[U2<*K"F"N@TM0@*7_U`6+DV!%-2N"HK417658N@\-5KS<HJ
MEK_K9E"W06QY6E94I##5E:"NJXA1X+[5+ZI5ZE$Y*4KLUH]U?_[IR:-:)7J5
MZ*TT_V[2,ZDCKGK^>1TAMF?@M/>-<ZR6_)"6//-]Y\'4W^5@ZB&+$B^.M&GH
MPF#AZ1Q>'<_[0G;/P@B\:`1'9Y-I$%KA([X($^0<=P2/9[X-XQBR^($QG]Z`
MV.HCU[=\VX4[H]B".Q$,F0_B=`'W_>U=$IW<6=;T5X[^`>[ZN1O97A`E(;L%
M$GWP`ONO?_S\T]_2ZRZLT(=Q1-<LO!E;TD6$#`^_?&6CO[\ZXS]___CGQ?>&
M\?U_+?\[XMG>-AK?^?]OK[XWC>_GS"Y^_NH?A[P?2H#>"T#E%=HTFQ)_\(0A
M97E>W5YH?4D:TD\]TS`E$?GIZN9&N[[XJMW\-OAZ05PZS/CUN$2GZ@EP9`M>
MI=7=G:Z\E7M_:(X56UHTAAF2'K0F08)]29*(E"FU*DDH2]S#+/$I"^%B4$&D
M^_`&!JK1CK7`3U5O^@5?+7B*!9K5NF.:GU!G$E"P]`0JQIP&6'&)VM-Q/7C/
M/35'F<#3HACUVWH]3HZQD<EQ\O!*8JM2K4SF&*>6O4T*;&FT3YOTOX;1;K6,
M_@9-F#5C@A4=UC9"965(^TNGG\/F=Q:3H@;QHZ)]*RN"IPS7RG/,.B?F:E,>
MWJ9\HI=%[39EUD*GKINQ\L-2#+QM!F[6FH&WWWW%,+AA_.Q9UX4IL$[Z#99'
MO[Q;0*58Y!!&+(;<ZC4;3=-LSCJA_'3V"'CTC:DWNPV]UUNQC=565KPNQ%IS
M'\^U#:CXGMC@>.NRHFLVTTA)U#`ZO5:[>\Q2PS1:>K.S8F'2$7/87BIW:T)6
M1`!Y-F'_M?B$(#T$X`<%Z6'$T(I<6V/B-#P_C*BAD5[Y81VE5.SJ[49#-UIF
MK9=.#4LQ^A(B-?5VNZOW^BOZ#)5:NNW%-PY_W2_$:?TH/V^/F)V$;NS2E73H
M'DP1^"*B8_4'*PRME3&1*\4GVXV8'M%4CU)"KIB07U$VJ.BPU$94&_$8-N*V
MH@(EZ%?%A*63$M(?)%>L'#M`(V8^RW!N\5[(%7AX&&KO%I-UII-B<8Q!$D<Q
M#!33+--81V:?K1+NJ-?N4/I`Z0,5HZGDL-2&5!OR2&-)JB+XR,L%U)(?TI)_
M7*MR2*=KSX+)U/(?M;'EP!RR.*ALGL>!-DU">VQ%,Y5*6#<,C[@&^]R/EY?^
M+BSIE>M^;_#)X\`#?1-=_"=QX\<OX,F4%`MOL`[8<>]QI#__5-@2.!7.S^_X
MXB[?!\L7?W:?O;0@IX1OE[%Z.=\NJ[#9H-.(/WS!.EVCL:10]^;VZNSWWZX^
MG5]\O<DNZ+[7+O[?M\O;/XG'GBK<K>J"TIX_F"5=IF?4*NQR8YUQ`4UB5-H@
M3^^SVX(BB&!U&GJ#_X=:=1R$H-L=J8;U3%8#KQNG<*%Q.OL2_&E`E\\K(=`;
M(=;+PE]]O=ULZF:_D3[?C:($HUR@IR0UM$B_5)>]#HJ_U"ZOPBJDNYSL)^WB
MA\T;.`SN0D8P+/F.?Y==^Y5@7N`B&\RIR$7[KDPPG&A7OO:1#<,$46`,DV]4
M'>.REFT#G;`?!!`B'I/1!^2<\$@SV&&.*ZS&D69IB\:FO<'[7BWZ^M5;'>0!
MUM[#8C%>3V_E0Z9G3Z=A\,.=6#'S'E%(_9*:H.4B0[.MJ1L33`U*PQ+Q%(S*
M/CVW_//0C4%L^<"4?_&!IX+3;,Q0/_O">/^61@`"U!*X.]J0V=:$:3-/E&R9
M2)N2^4RH`RA_9U_&K6OY):?:)8(4^#ZSB3+9FA3'I6O,LL<%>G`8`^F\(#7C
M9V?\`'-@XCD.(1(8IZU^K]<R)260WO3M9E"8D/QP':>GW5M>PK37I"8D/(79
MJ19TETQ5'(`%?'@'S'('JX]O[V0:BH\(.=7V$IJGT6OKC79S7F'1HW%M6'@O
M)H:L@ZQ=RNDW@L3=1LII,&DW&@MMZ<+#!W:<X3\,\+3+XV\<1%&0-MF>I[".
M7I5X7H'R-&3A_X`L"C3'1<<,^<./D$_$?3/;"$?@X$9R%NT%HB%,+_$)V@(\
MNFD0L8B8"8_8<*`ZA[]8QEG:&^,M?1P%"#:0CQA1IM`'+1\B[G0'O[21P)[6
MTEN%%40RR2,NK%GPX,/-PT?-Y>1^8_(A#`,K='AR3PBC#D(NE-@/9O.S))"E
MUAT70`L8'<1*X/HQ'QMQ!FYA?/B'].'G:ST<-H3`",%KDFG@"[RM"/19QA$9
M`8/1R+59R-=0O&CV<07"HBN,!!(/*=)9V4G*3E)V4HDWI%T*21]E.L<PWI>9
M0E?^[!">SE?(#8=9/T<O<D%VH1QY@PW/0$XX1=99^>VOS4P1E@AO"R7'/5>9
M(R`0EQKS<K=@$%@H8O,;X`DVJ=S7;=#@N?XND31UXO>#8OCZBIU#6H;SA#9,
M&H-?%(+7T?I"6836W#.WO21!"L9WMFN3*9H+KXU</+PQ9PRNM\_=^60J(_J9
M2QE&TV3HN;9T6SX[\H3N7*`XMWMRP-#<0(*/!\D=<)'D=<H"$HPD1S/T1K\0
M)9H=.MJW0"T$;`L#&RS-B`]<;W4Z>JO=`!Z+)/+8013S*XQV1V]V&K669H=T
M1%!?479`DNS*S\66T='%@:'P2)YM'?'@1[E))-Q6H]O2V]V>M,O=N!A2P(?;
M8QX[+L8HS(ZA=SKM16Y_X;@R=\N>]*90TDVMQ]3#LT!<4"X6"E&PM2B_%1'W
MAH'OZ/!EMZ]W#),NM>TPH;Q&X`<6Y4&"D$TL%P]"M=>=;E/O-CODOC*RTU`>
M>JXU=#TW?@0WE,<0X#&9*\[?&J$P'3$K3GA`A[O"OE-Y[^_GGPYYVRCA5855
MV)SP6DED]3NZV7N>Q#):+;UI&EN46*_[)I@W/9(Q?A`SC#<_$D@HRJ.0>21=
MYH15>A%8<.>_WUYJ@W<WE1<M%6;IHEA09%M=$LC$<MQ[1:[%Y-JFS5:NUU*;
MK=?2&VWC>39;MZWW.@N/:C8A`0V]VVWHW7;W^3+P)O&9=N5%S-=^`V^4:E,&
MTQNZ?^#<TX'1!Q<>#9.\!/L,[AX(@5GQY+(*\:\ROPYD%=+H._[@X@]_!'CF
MR*L:W6Q%9J+NOXE#3[&GRX);Q5@5RA(_=F./G]P!6;5[V((D5NCHF\>JQLRC
M,[R0X=DN1IOHRXF%Q-:B9#AQ8W'X9_$'(%R_E(8JGRP3_+\G(NSRJ:/.C^\"
M.JL=6WB&B+%]3%6F(\]DDJ"8H1=$**$6/DG964J"'/LJS$F0<_?>A9DZT<G,
M"LV(DY<*$7$8IX46EL8\@G@`4>&D+\>\@"`)R_(">%<M=T+F`OT[L1XUA]D>
MI=PD9(J,$GR(Q^XL#YYMW5NNAQ:&VO%JQQ_[*LSM^$_N?Q+7X:=&7U&-1DOL
MATNA4^_36"WH7R]_B`[;.(H"K#!'A1O"S"G-Z"29TM6CD>7."0[0ZB.T$N00
ML.?Q1*40=O<PYAE!:<B6$(7P_O&:<NC!A<<.B[*(FR^I)!(F@X-G:>XPR7(B
M899B.'E@V8HB%B\Q)%+')*_/6;GT1J[706_-C9$XT<!WL`X'!L!\&RBQW:*=
MC6W(8S]O*Y;D&$M*!<ZN/G^^O/U\\>7V1AM\.=?.KK[<7G[YY\67L\N+FZ45
M.4J2[E^?J378@S:[X>$M\D71/P42G(B,WBPQ6XC>IPW<[(ER#EO)'2NEB/.<
M7-)L-@MCT![%_&.>A.K(";.\3A03VYFOH54,2^Z"OH(Y+<A43N-]>1<\GG.\
MPU1KN/X+$/PL)_B-/,UX;,79Z+/AEF5G,U*+68@PRM.2R5%XZB6XZGF0LV!C
ME"G_U!'A:3SS">UEA;AIP@S-AT=`GAX5[*L$&)+"%;2@92-P1_PQ<IXW<H%8
M9GYQ21ZRAE5E,P//WQ2R$08_&)5++$A9%R8/<@I-C-+8YWL/+S1TE*13VN88
MUF!.VYQYX`?80-[;$'=*L3RLU($B/7+E:U=V'-#Y45ZG6>J\1,DP<AW7"A^S
M$Z;L`&3P[D;#2@?<T63PAQ;'7Z76CL-`I`)F.NF;[U)&"PC6WX*(5VQ=?CT[
MNRG47%F^]MD"H>\'4FF0=J)=WMS*^=S:%WHZ/L('!HD3$1`^0TT3:E]9Q*S0
M'NO:7S[([K300WIZ/@88\3^9'UBGVGEXJ@T\H`L>!07#D(4!URJ_,<M)I>]G
MYA#-KWSDR+M'G%>,&96+7J"#W,,42Q!G4[C/I7,C]\X2Y1^4*P22,)A0\>TD
M\4#C49\J8)7$>>0"MDA3?I85\5CV-2$V7%Y>:I;S[^3>(AZ#&R4=65C3>Q"T
MKB^.S\"5Q9ZXM$@P9D81,-220#]XZAMI:;Y<G!>JM4`P@_J\_(/O3!#R,#F;
MDU^^[>SK6;&J#:?#V]0_:G>!Z$N/13(T:)=FQ;"4#./HH@\O4-Q>.*'/S./+
M_H=E"T'5;;TO#.+SV1^%L;M^/GP88$Z($'-Y0^9D%!C!GA+1`9Z6186+P@0A
M%88Q0I`(%O>.R\K+P"7&]%G<'["T2H\I/7;4:S"GQZ[Y[@.9/@$U`9ON.@SN
M0FOR=""0*IEWG`E!<IDG#P2\5#5UK$09SGD"%%U8Y`MB"',<8I^%!7&$Y:XA
MV<(@SA<00WMS_>4;KY%=I*WA\:7H#+=CTD#\,>2%6-@C_46I<N7TH<I*>#Y.
ME"I1>8$$2OA40FIOC$:J@Z*W69UHF,O@>`POO^-&@T2Q!5,K7,,3_[$P&S:%
MYP#S8MT!XDEI4U"9N,.0$*#EB-BVC<4"<4!^.B]@H.6=H(['\=$DBEK2<T>H
MEG`ZC**P0E-$7+/)@W%Q('$2^G\Q*F_@T5S"GA>N()9R@<O$O688`!X>!VAL
M@3X-$QYPU4%_X,A<6YP^3^&.B67#+.Y<#VE72AE-1ON@]TVMQUF:8MU&\&AY
M8)/AR#2J&P:]C*LB?L3.-)P.9D-`3L&E^(S(0L><RC82U)K<BTMWQ*EVX2+\
M!U:&P^/QF`S!!,"O$VI]9N\8O8;FP$4/(9[3^^BDN_;",S,EIY6N/(8UF-.5
M'X.`1U#.P^1.&SBPH?*RJS<?SP=OM24':"@7X#I"`(+!,S^BD_!,^*100"@3
MP&'3AFX@)`Y+".4;):B3V"`0WS@P"'XT!E>AF)*_?JMCX7PR`K,W$75F01Q@
M9UTNQK!^RTE2)&L4"7"I.%Y#R<B3">'SQTQ>YL]C#OAJ(-F0?O#N]*44LZ-R
M/)18240B=IS`?1A^0G_VW]@E!.->[ET`>@;$/[IC,+H0HWXA$U;\!&$3*.07
M"WJ1E(+13L4#TC=F[@G.(K)&+`;Y#7='+L\J_`&J)!;?HC[B%7&@+O"AA'4"
MSDZFUW'(F+]8G!:0FE,#="5\1\N"\`5XZN:\38<.\\.OX&FDO2F`F*_P%'1*
M&C!(YTS`+NF'N6=**"\(^))0Z$X0(9K"QP%?R2)#I/9.!E^`JH$>+J83D\]'
M4X%E2Z.6Z(%Q!SLE0Z3=84^6(N%Y6A97&G,,11H<AN&1]YPM"YMY)7ED<(OW
MJ"\TGVRT7*)'L`$FHC%;NBCB.3FB0VA-:>X8#\=EDC_*E@S#I!+#8:S$158!
M@2!V&SY0FFBN13\RA]81=[O.MSI2\RR()@S?,;#!+$!,BPDQ^^I:\N>?E(S>
MGIY4&G/_JS'O70HYG=?;+4DNX_$V$<^4MCYBQF#\)A4+\SN>O`^&R#$$NL.+
MIQ$"#[>\&]$)CESV-R<[,-X:<_`*6=7I:7P1!7U69!@(J<QL$BL9-I<-S!!,
M**/5IH,?&"^+&*/\$MM"D6PY'"PLTT6RLP"7_D5>43"DL\+,4!?I;V6TR=ZI
M(5M-0-`]IOK%82/F9UFUZ4OH2:0SL@X6$F6`6'0*A!?1J112CT8),A5U(&@_
M/^`*D*,ZC8,'U'TZ/Q6+9WV?(8IB<O=&"6HZ,3<ZE,7G2W,4QU&CA!==AOR)
M=%4Z-T%M^2[N5CNP/ARV#&T=$OS22*P[>"56'&13MCW+G40\GBLP>.E%3[%?
M<;'0KP*]&=#!X@]NM*`6S%XQG6-_\5)0/,`*85;(D7(Q:$N95NB^X7.`$"EJ
M&TPO`=*1\<&?EDU-GJZ=GSI:F(?-Z)2BR'J:J/0HQ3B8,F[7JHAI);2;6H/*
MZ+0+V(@!SU4<Y#)H!;V6B2(0S+CI;[(#/KY16?[@@G`#UT?@E\WF-:B]J?;F
M,:_!_*F\G!S[](X\*:ARMZR\`)SRP+OGC;/`JX\QE$V5!1R#5(K_D(M/D#A4
MM\A=>]+TL&&Q(0,%.QZG>`!9XK+\:^QZO)I)?@IJ?5+P:)&@BD>;EGD9%F+B
MBXPR#'I(,(E.@)2C/"N*ET@&@`NSY8J?9S,C@"H'A<ST/;XVSP`"HX9@*Y>W
M'E@O2UG.;X:OX366]T^@\32Z3`O!\"YZ2L*<JVQX.\IX/K!F'4)T@'\3SO;V
MR^5+-3IZ;"?GVER2<WU^>7-]=7-Y>WGU9;T,ZP-CE&KP@&KDHY9\RTM>FK]0
MFF:'9ZQ@KDONL7:.$X"WWP`%K&G`8\VI+9\^)/_R.F:GVJ?8.=4I?/7:$)I7
M).#Z@88>/"I>#\'UN"&"X:4TDN]DJC`-Y4C^><&.$3V&^/$P)KGE>CT+J`,1
M`@=C#DPD%[\T"3@W`EZJRF6SX"L'C<#3\L=;Y%'+WH$%L!TL"54`)2OCYA)E
M+%:>$B4>-7GME^IF54E:!=]7K4)UD'`7-*,K9-.E'FH1N8<B3[/%2O(SWMPP
MK/J)F=9ZJPKLU88\\E6XHOH#,!O-[GQI1W'#(0(TMX-@!WN4[)ZGY(VH.`$#
MOAI-5)S7%:K#%N[$[MM3;66,;/D14\M-P5.Y]N6Y@^>__PX*FZ.Q8E)IH3_0
M:[.I&VU3[7VU]VN_"HI8*Q)K?;O#TCSK`3Q*3`#G)]H@.[*RWD5'T&=CRT4W
M.Y5U)8A`/)T<'L.C\EF2B$C/2$_)9@7B\L:]!<G(4<VRMV!4W>>I=:_-7D]O
MMSITW^NFV=/-AJFGB8KN/<C(5:4Q?R71"+C@#L\#7[?Z>L/HH'M>G!^E\2T1
MYQ@(L&1\Q>SQJ;<_P21S/@O#U%O-WC/HI.>/Y77WE/J(;PBQV0"FV+&QY8UF
M]55)&Y6TS)HW#XC2-!N1EHJ)ZQ%POT>0E%(!LP0+<ZI]L#R>P$.#R89AE5`K
M7VI"S,06+T#"?J//UQ)^;O>;Q:5\N:Q>%RYFC1!(H<%S,HPP6<F/+Q"I)U(G
M)>JD9.7@3&M)<.;FVX>;B__W[>++K7;Q!_RMCDOVS@@KQ,Y;2"YU6G)$*[[1
MTY+;!3::E'40LGN7/6`!7YIL0#!Q>4DA]XW!E42UVUXI=4GQS@'PCA(71[?D
M620,/03<[07?)"L33R&?T.+^BI@HL79QJOTK\$9L+ER6][B66Y_QPJS/87J7
MC:$T\AN&\+JQRT;:Q^P@\THT@2WI49MW2K.R*+=#+1W34CALLC;U8-5H#(L>
M[:++=&<A\OYL_7F.$%/L,QWC37828J$"(M;ZL8M@);P_-W@N^>0HS3T]1YUK
MI/O$;(O`55P:6QJQ)F_\S8^$^?OH+>#W`5MAH7KJ#SJ\='@FOW_DXCDS)K,.
M?#^!MWYETR`DQ^\C\"%LPI/?LX/G)Z,%L^2ZS4=W3:.;(=M3+=/%E'.6X1V%
M;3:-I<*M-/:072:8]..5=L,=;>D)0Q8_(*;6+./@D[,5THE*CN"AO-%[8\$<
M^;*6Y1,7$`IH13CR*/JT(GD_7<@43DA0LCU/25'YC:0\A_'-$S)K39WS&C'R
M/%#9&_<MH;-&X&B'CUEXX<D&]F(U%D]6AT<&P&8<QL''`@<*1J?=(D3`A6!?
M<W2"V6F]A\'AZ.(X"'T&K,DXBAM'=\,<R!_N))E0P*.EDVZ!&_`.[.J51*+A
MH@B+8"V)Q[L[\MAW<3<`WTN],<HLHQ?NA_>\`[=[C^.#J8@VBHVT1^08\S=Y
MS_9'@HD3Z21Y"*PH.[!4143+%C4@%W.BW-4"TL["FDTNM'A!,>U1UQ9/B20X
M1`;7\;IBO###1:1\T0B;K+W/XWB9@!FY(3:KA-GB3`4<'\V2,);2668WTA')
M9YADN@L6;H]HC`S,\16UH>MQ>'#MBO`2X/T$6.6PR`[=(>[E87`O"F579.=Y
M.7V'M=Q^OAH%*O+Z(YC;V)WF5)-K!69E#C(JO"&SLT6,*GIR>RS<Z>E`HX)&
ML0IMTM<M.5!&W`$8<<IN/[HE+T&T+1=:#L.#'*S1M*(U[&Q=^X0M9,[9'3P=
MI<QT&K@IOFDF>UY@MPNOPQ0Q!BRQ2B$`,K2')XZ<2HZ8"@;>C.!&5`%1C/KD
MJ`N^C[O4X(].!85$\6R!2L(+D01XUK$K)P9W748:8D_)PRP:,7,FMI+MQ[+1
ME6ROSY)K3Z/G;4+H/^F\61J>%*8`L[G%6_1V\9:+3`"AQ8F"EM")GG*=4UDW
MZ[32A\L\8QWO__FGHK3D5;3<O9]])7>8"$I@Y/INS&<)_B8UK@=WS'/1"4BA
MTIQ"K"DG"KH*S/5YYOW"D:;.250FUE.'VDI=:50ZO_^N=;BW"<L-`T)';P*T
M'^LBHD5N,7WB/:;5^YX%CM(PB1`R+R(4-T0>HO9K>"''/I+4(/=+>;2>ER+[
M=D@@>JEF'*9:,.N75JK*$50\!DL`$7M(N4Y#[*.ME,C12Q2E7>K#"QM4(B*X
M@%(&8RE<L.GS]FQI,SCF3H8@;+/B9HN$I!4%/D48[2`2?:#2:"#*+32BG47Q
M+)">N`RDU=`6AB$Y28IOMS1<N5BL%^(HLQH&@?THD]?A.)X^[R3%RD*+1N,7
M\ED$?0K.!<8&L3<>5PX4P,1IDQ&?^-0+9&CY?]$\Z*$1MK!RH[%`3B,D&]!>
M"$JC)'+E=Z&2R(H7=L4+`AIX5G*!T,@D]3Q@L(1-LT!ZBE9"-RBQL%L1EYV,
M]Q12(NCHV4Z)H/KPP@:SQA#_\"X@K'8Z4YMF4(GS1_1/VUT"!0=$"W>_TT[@
M9.6$L7"14YP\#M$3,@VM+=X_C2>^NR$9H$"F1W1X0X:PD2C)A(N?/0#I(L99
MY%V9*$]NFC5FIZ=I)B$=Q/*P"OLQ=H>87$%#HU@NSK1$F,[O)JGGZ*)L<#EE
M_`,BS5^-!MR<A.6Z#CS7?N1_J_SQ`]SIS<Z3&<'/)V'YZ.86JI2BSU`K:?;Z
MAS0$AGN-V!DW[S4'N>#''YF'-=?/4<:>C8#G>62S#`.C@(@MO"_^3AE"*V_J
MF$*)?+L9@.=H9^!_#^,@KX*:1P^!VVX%`HFRG=0NVOHN4L:98K9=,=LLRA*(
M1AUEXVFA;5QZ%7PKG?GP3"SILIEC?+I$^OJ!+?HFB19]$R3%#E%OD#<8AN.N
MD]BW)MIOKN=%VAGPTNE;RF,(0A?6D<I:03T$:(]:$K`2:0]2"LRS'M#$`V4$
M]A+/#NU1LH+!LZ[NV1A[[A*,-)X]X0E1=K@#INDPS>F2<[TL^S^)*T[R@Y&.
MKCR,]PZ;S[IX>%1`&TB?IM2*VNE*K2AF.QAFF[><$7D@ZW#.A3*=$%E144S#
M9X-IZ'H\>;AAE.JA0O,]D3U?AN4KH_'Q6I"LK4$H.N.*U@SWS`NFW/DOMM8I
M=`:*,<>77(J9QC\+.C]EZ>5YUS],GJ8^?UD_IB3*ZCH8^2FNS5OPH$+VJ;>N
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MTUIZ:V[T&">4!\&#AWSQ#;W5FKV^<"V:`7FS@K(2L13HK9RR-/JT$],T&7K8
M<4^@\Q``$=D8L,M2.L_<3RF(,GMR(E,A5[X@94G]#W3TP1_#LUF,TU:_UVN9
MTER+C,(!HZ3I<Z1E"^86\R[WG1GNT(L8S#V],4=.G-22UQ0FZ$ZP=S'?KL5,
M^R)I]&<>)[DIG+)F](#9V\U%2X]V9G@O:(?\0B?U)>?V-R)GJMO(TIY2<QFW
MI\L/[[/3JT$88W""7CB(HL!VK518S:ZAX*G9CPMHH@_C@#>^P5,\9%#FY^RX
MP#288;+9+?LE\$_.^).03C?2Z^0=O!;9=6&N@P1W%HE>8K;L["Q-O(H*0U^.
MGKW:(9Q\;/<Q"$$O^F=436(7,*(&OD._BNK"[9WD.>Y]2L=26R*S-H`!Z;_I
M'+!2V:$S&`!_?V6^*CU]GE'W.OT^<Q[T,?&)$+#]4_)H[S1!,%%_`Q_%.8TD
M)*.G(9#H7#M_?/:L8%0&(.]&\L[Z/0RP]W?!P_S]]Z+"6X2VPH]_2=6GKP35
M,F;?3F].M7.0.%:8>7^"!<6^CE@YH/O"5PTYDAIL6,9BZ9PK9!G%4G`&>KM#
M;X_27HF\'/B$\;I[OE?1U^8G93RW\YYA>6PAI7/5QUO8:1=U3/'94WBHQ:N8
MG5DDNP+FVZDF;0T"W^<#0_A],0SLG$C9I31@VTXFB9>6.UADOL`Z<M\ZH'PJ
M_`B$C6CXB_$%ZB#$U=R,#,(>`M@V.'X\E>'-YT="E0/8D5&`P!8FK(T\</B3
M%-Z?N@9(`@!=^R`M9'"IPWS&J'FQ<[R`EY$&XJBS&,=.(PK2<:>5)^.6"+DY
M5+MG"RU9\IU9T1C[#,$_%T!),.F0H56^@O)"J^V%9OH).9<WEL8?)!Y>2PWE
M_3Y];'".(A*$ZQA&"4:HY\)3T7098M8F3#'A*0R@&T",(%`.A]Q`*(&$-YU'
M;0&>":\=H@XB5!HE<JMPI"P?Z7SKD>$,`*>5:QT<@!LG).>$//F&)5@.&*TD
MO1':Y`>U%(=1C'@3;CI0X[U.>?9\5`[F22BF>KO1T[MMCN")S%QV;7.%3F:K
MB!99%EV'*`SCQVN8?`QWXET4V#TZHRNE!(?Z2,FP,D<7;F?I[;R9>\RU;TRE
M(*?@`DRQLS%ZISSD/;'^'6!+.Q@@QLM%Y2%F,0L4.@L;XL5,^#))Q+##K@?*
MF@?7%[]:Q%6PR;W.JZV'C*Q\+,0FY2A<ZM)18>6V3[84/AE,.,L-N8D!>S"\
MXPY/BBDL:U)@73`H4A_+I>/?:1(+MZ[$G,O<#CS0L#3L3(C2Z@0E%^Q,RHBZ
M%TWN&?#)A"@Z2PBRK\#XH!PE3$D,R>`@\V*$J#-8JN_^$&95#CS?+&L!,:?[
M5]TJ\O:Z],'-NG.''AO0N#Y2Z>8G&+##[SK\?9630.,T6'E+G:>5KIZ+L$[Y
M<\0:I^EL"$`P)](SNQ\YSEGZI+GX0HZ&D/NT*.Y]QPH=`;>@%WRACX.;#X58
M6^F-9X&3-0(OWC^X.2O<?AM,75MKMAN%#(]_!H'#FX;#EN3(/_,4SA_#?8`)
M^E[_%;%:0:[B3M-6W&DC[I8]P!,>^3XZA2E%<;&F+04&HEP0>AV&A+VLV_R,
M:"*Y.#/2%0:1S>54NQP)<`J'\>*/%)'"2M]/-!/023P2HA=:1G"0,I*-<P-.
M2_A*!=\JHF.I&"C(C`G*610L5V':E.QJ]"GP[^@&_H2C4\\Y57#MD1HG1`[!
M\IHL03(!PZ_SZ#J^U75>7FA%F=;441D2DEM1>R(RF-@IN/`91BP%)O/!/(#;
MC*<S*60L=KXE/Y>DBNV&X'YCK,VF#QSD*`F,T+;"D'K6Y9#VA.(%0Z5*)L&P
M"../<0."^SHK/),K.A`T8+3&H7N'J5-66B,O)*2N#1-N#^#S/'?B\F#EKQKB
MJY`XPMZ[+"VF%S8NACT98@&X-BNHU_>%^RR''TY)TZ92_"SURZ/]JV5!?<P6
M",+H?8;")C`<R48?><&#U/T/8?)Y/(%GD.6&_]B-X"ED]XLK*&J.11LVX@IP
MV+6T\6`:'A&AW_0QPIR:F1V=.HBQ\4;$:>):&L2A!2*1,L$NB9[[%T;.*2HA
MEHQZ+Z+JH1W,")1`HAI</60X5B[C?"<]-"D5=XMES.9W;#%XO;77O%0P?$VW
M!'90("X0NIS[>^3$X3HF$86^M0FP-CEC".W!S_!"-\I1`I_:B2CL\V7QJ:5E
M0@%_<<:4<6XD^"4#<KT#Z<`S=01"!3V1%-:RMZ)'R9QHEBN>?#TE3$K2B:LK
MC>IO[`"X[[_22/@KX3<N0Q:,)^?W=$`4=X,WB,-(^9K35!SSV<O,_T`B"G<&
M`G#QHZ:Y/IXSL5ON=8!)P-TGP@P)'G)DJKGAAO+`/)YX&L4"']#SN)#G(_$#
M#:$[X6$XT-1?0>?E=IQ_@$;5,*W(2#F,1S:9(+0(M&:HB3`5%"D\=NZ&4A\.
M:7!E.:SS9L,S+(%B&U(*5'_E2X\B[`:;JUZ-;M)S5!5D5$'&B@89!?-J$O?2
M/B,6+JN!6CWD6#@N$OV&N?;]S+PS2C?\P[)YLRM4_I[(093R$NGP=XC84+DY
ME>H50H9%BP?%`!<>(!/RGLK6*,;$C1B/@2XO!VF:),^0(/N!`_X)8S.U1*BE
M<HJ;RX]!R'3!ULO<3WG"`T[/K$*)F@NJX9>CWJ([.QK)_NV'Q$/075_[$IP"
M/Q@%E[5L)>'2W,.^R4[U9,_US<W@`S[KK:ZA:ZV!?ZQU&FVMY''%B6>J+LJF
MC5:Z%B)O\DF!ZJ?\#:QA"PF^EA84UR[/*K%AGP43%NK\=IZOXQ*V5918=%;&
M$"5+H+2@X@XIXL038T56*^&J$*?@>Z:,6X4,G9*P[%WDUI+)3;D+!.S"2VO]
M-)#'U0U0W"Y4).=9(1R:AN-;1SD6S2-JL(0"=-=IRBT^&EX'PL9%T!8QQ(]7
M'_C/Y!`CA"/J7V$G8.(,P>!P>D6S<U@>IEZJF%"+32?CZ-<_4%D.'(<YM]8/
M=42FM%=-M!?QK4:,JP'G:B=E&NO2SR'I9F^0(X-_#&YGD_C,=IY2Z=\')"ZX
M#4S1=I(-:2R.S,_TZDS=W06!$\VTN8/W`O.,@U`TI4.I"B^7'\@55"I7BPBQ
M[^FDC%DBM)8/*&M#2!D(:=^[#`>P:/6C2O%XF`;?C0*7^KMR(5,8'WXOB.'B
M\6$49->*G!728-\T&*U#8(!^2BX^NXCEAW,4Y$&$*I*;/">!2]74?.=@Z"C=
M,351#.11N"GY#+ENSF5P%A)!;4N$HKRKLJ26A9)SJ3`LVOV\6&/@.^=YJ<8%
MCU=N_-Q!R4XE.S=L^4NU1A(#TT'#LU(,LBRM165,(DR09J#)WX!\P7%G-4K2
M.:<`**7XJS@@D/..\A!F>E2`(D?D?/O!JH-9K9WI*D;74JE0/+K$-+#=6%TX
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MP%TG\$#VF-;]""`X.@?(`X%WL&?HH">)\]H0^H;]8*'M1J4IQC.29XE4D070
M.2S`O86DV$7NL)(]>Y(]TC)KI5(F%T?_2L\;:9]PB$$,$3O9([1B4FN:54NP
MUPY5)4RI-WO$R_NB\0D>*^II*D!`11J8`7^29=MC*!6VWV_!`Z9!Z"!8./<S
MN0NFS4($0!2N<?D@TD,T;-<@Y6E0"K"X`T_Z\A"KZ-0V8A9/6LS.Y1B'B7WC
MOLVI1&'UT8@[Z;R`0;,]C-5+V5BN?`<8VH$CYL?KO#R.;,TQ#H((3S"E0L0Q
M)C%)$PA"WJ4O?R)F=`Q!+K#XA(YLP80A,'%Q(,M/=4-L3_281B<*!*((!=E`
M3I;6'!)B+=$I6^34)'*1TX`F^;'C2L@(:JOO>*NO!26@5F>WJ_.O/`51/K]/
M@?ZE;2?MU5Q\H;M.05V0#)@G13#XJ<0"0\9S_XMB[1-ZY%H3G@&64*2]H8Q5
M%`T,\Z'H8`W>;_RJ?<0A_)$F7N1G:)?YR]^>:O_BAX\H53YXEOW7R8T]#BCP
M2[8+S4'D-"%JBON?A%$%/"4NQ!J)/CH`]+S\=(F7^%.F1S(1-M";O+(7V(7^
MO0_0A$*/3)?R5L1!5GKV-L)*#2I]>PNK@J43HEF`E+\1STK`4^V"/X^\NN):
M+-5QF?=8$N`II+/E36?XHM*"D&X!^:UGX+QISE>@B\RW/&45S.2LNIA'Z--A
M<(V5*@TI8PY3[4-?5+QCKC_](M2N2)B;Z8/)E_*$6];9,G(U(:IHQ%+PH\2(
M4<NT>T)H*R;KS6;Z8:Y\$7N`'_V18N>)=PC<X_'*&7R9M.JG>-1MKV!U<(_'
M%7:]H+O`^_4><]TF*S"=QB:\>=&.:.3QIL),&H286"1M7H[XD+)N2H&=:,1G
MB%>!;'[X\C4S=$MS.I1"K-R"_8N)I#S:BN5F9W'3IC&'POE7X=`O$JW87A+?
M7NP/%V`'8%2D/C_SA-"\@$=E%Z@3LIJ<D*U@!+X\FB_MWTF^5Z*9$CZ1$XO;
M-/]0E@3+SP%Z9H.G&J1'ZER<W"4NW2.,#QU/ZK%QO0``P"B9SBN[L&!1LA#R
MAE(<[P#,GHA*>D:A-6'`@QQAB$^J:$JFF`[P3X39R^CF8X8U7L\;$U*I9MGI
M`Q9VW&%!0I9I/B<#15P"RS,P?(*OAH?!ULE_IW3!4V[E\_NHJ(D[`Q8W7MD/
M5]AJB`0D<JA3R`B1=$'V*D]T%F_E922,:F%$.G1^D!*$68]&S+.@?4TCS>>'
MZP@6;>@0G+"$UI!UR4RM2"OD;8')8A]$Y`KI,BDP5T-<+<Q7B<'XT*-QFBXN
M571E0639`Q&6^=RKQ>S)H_&)7!R?,I]Q-C<:I252-2GE4I2D$_83=^2R%_+<
MEI0Y9YB-*M!/8FS%*<UW#+_CR>MC:D=/$1;,C2E%D3L(Y&3P6@5_`6=&`IDI
M^O4($0>%>`=BAW$%M<^A*9I5(E(QY4D]W\(4=#9:IGG:-3-2+G&+\+IU;.Q9
M<QJ(=6(Y:":DSW^>F4V8L^)=?W_5X+]/T3OGOV=4"E,2W;.0T&]37HZ#Z8OW
MU>[MC]A)YY-2@SNJM9O(06[.V'EBG4RU4'M8J'ZGVU]QI>HUNSHO#0^W&Z?:
MU1`!4'BE!#?"TL#]?Y*`VJB'KIUZ,>26<%-3)#RA4N*(YMP-DJQ*\'V>7/9W
M<9C_B`-0)IPRX90)ITPX9<(=O/I1)EQ=!J],N*H.GIMP)AZ*H]VFSR+#+K'?
M]#Q=+,AM0!$K=5RL^\8>ER&!]O#?"!A&F73U,^F6=8:N"\MOU:;[^2=EU2FK
MK@(3.<CMJ:RZ*@U>6755';S(@SW5OOG!7&@.C+@,JHQ#L7@N9M#S4_3T$-BQ
M8BL]:!5)GR*!-6U!@4&[F+)-11XH8?\$#X6#Y9*$(V7I5=W2.Z;@W:&R6I7X
MZABRRK[Y!)1([O,#MFL1>4\I0O(\U&,9C%IYBG=>'8`%3WJ>8):CHR!0%J/,
MHQ2E04>,%A;%HI(BNV=J/?(;X),06UGE-Z3]`ST$L`6''I8MA9JFA@K48H??
M+C<GS"$:!7J+J"=P$B;P9ERL#06U<8))2&FS"7>5&O*5$TWE[-1O$;L:B2('
M!<^HA$7EA$66@BH!-V3\NE;.*>WZO$ZF#`Z)$+0#'Y<7[37*'<T+7$$*L"E5
MC4O=ZT*0..[48U*]#TS%NA.IA6@D_I77A$0S12%I#>EHE%:4Y/"S`B8JAX&5
MTS^ITI)7EZ<YHU&.0'U'@.*E=Z6PM@XA9'/Q6DJ*M)'AS(#P'@'&%14;DDEM
MQ'++-RW:'V#S+4\@!D8"/MQQL4=FBGP52+4S*Q2N%R67+-.^L`>I+6`8^/"C
MS6>E$N^5U*N5U/L*9@O,01)^189>60)>^MIGZU'T9\8]NDJ_D:R%)PTW$E\2
M\JP]=D$*%-/=Y0X6N9@H0,"B2$T[6IW>G,YTEK6T"'[R6';K)'#`.^>EY_1T
M7KPN-7?,FJ]R'`_J@+BJR$:GWQ$EE#A!>IM>&*\TC<"V$^K$RGA_0(X]"K9?
M3)T(J1`_\$1_I`FB;Z20AV'>1Y@GM<LY\Z*<,!(5^3P//&MFDB.EBQ@"AWM/
M\<[I0X\G<6?]#CF.%XK3N??/5'2F$\]65JI9I:'-DSFUU?F]5%:LB_D0(\/5
MO&05690P&#A8OMS#4D*O1TQ\RCM''9!A&7#-FY)8X$(6!NI&&B.EZ1(:"H@(
M7_`05VAA%&O_2:PPY@@SP/;81I*C*3BB)MFEGAQC=^AF*.RS[YA!/TA9$*1`
M&*0HC523*R!JJ/OVK/:34.?IV^*]&0RR:)M)*+_<'D",Z+Q<%=Y-=6QN+&/K
MSZAS<;V\%:DX6X!S#)E'VW9NX7EK"7A(R-^&2/-V+.IR_0@4ID,5Q.4@DBIZ
M4`/5V&H<AFI4S%8#9CL0.^PJ0];UXZ(-(1MAJ9DD8'6HVM!Q*0Q$/8)")@M?
MNJ[H(Q+,@97)WTSZ^@NC7T*E$$`2[\FR'KSO<WVE8BM/T';7I.+`3"U`&PWH
M7!T?<\XB.W0%`H+RL]3^KM3^EOVL`@,O\:9RM^MV4?PD:R[/;<!R.-VF!.<7
M9D/@]J8(1*4XY&-&:#<"MJPPV+R0$R^<AS181S3@3VD/KM+.7')_TO7V_TIM
M@+<1E2ED**7)1NU.=Q.91NL)G)+M.J0*YQ-$O+>F$3!X^E-AGV\_"6D8Q.!M
MO2])[YG=?(NW_5:S5_`"'*;GK%<S(*APPB<(<SAMYZ)^Q22PFDU9EM\VX2)F
M?,:I<"+TYA"QNF:_2W<(IU/Q.R'8R2'<#PV_\2Z%G]P14WQS%'R#$A%$FX]=
M&S=#SZ9Q`JJ"E'^HO<-/4&LH=E)35COH!3NHJ=AI4=+>4KM+&P(_W(7@?CLI
MB_R/;3,V*LVXYB1\5NEDH]&<=?$\-MH3'3]9PYD6V.X,HM2*W/0L4G1R=[B*
M[+.1.7;G5CL52_N8>.NDHU9U4W.LQA9^O?7)MLS9V5)CS?U,U^CV]':KN_5)
MMZNSPCODZ_81[-T*K>P.]JY1I;W;;^E&:RTKM>XKO!-#E0XI-F2FSI.M0F;_
M&>\;%.8VZ]9XJ4*SWH%L++-/*T2!;9JM%9KFCA>:;^_]1T=J23RA1@^%>AU#
M-]K&#MGNN+;=<<UV8T+FYY^>VBCP[1$0\-`$34=O];?G`AR`H-ENU+HBB01J
M&"]@\NKR[H;W[A%,=(_A&+/9USO]GEI/M1^/>_VJLA\[#;W3W%ZDHT[K6<>(
M:/HQ7E1,:-_QH3ZB>PQL4<]&6<_3D-DN3ZQ>B;N6&<W[-9FJ/3H5'E`Q2!4:
M>`;UWNS>(*W0QGNKI(N2+E4BWL%)EYV;UQ7:>$]*ETKER2XG8VM?1/S"8BTM
MG*-DV8OUTA">GDBU;.HJC6T#.F]O/%,/C==:*+&=(!EZ;#^TVUYZW";T7#5I
M=K)'_7;(FZQLKAL_@(8'5F6^2J@HH:*$REJ!ZAP87L9H6(:S(*,RW-ACYB0>
M"T8?$4B,?<+F[9=^;/EW+CQZ0(BB'PEO9C!!C+/_4DSW@D.`WN+K%:KF`:*]
M+($.6Q]R)>0()G]_A3AU#-X#A.3HA2=P-Q+P%:\JG6?]\KY#FV\AM!YOU1?8
M(^5JK,==>TOL`JAG7D9OD!,3_.%/9H4(T(/(7C)Z#O%;4LZ&JV3T+`C`5"7?
M:/-5X8=PD+:]8%0JH\Q6X[3;['5:W5:GT6])4OJYFFB/>W'FU+F_N>4"0Z"]
M&AMEPO^TW<(_#;-M=GJ=.A%V3QOP`"BW-?6PHJ.6[>KNJ=G%/_U.I]GHUY:$
MW'/<5,5E2V_V5BSK2`G9/.TT\4_#[+=ZM27C1@V5O:<LU9/\6]5-:QSDU8%Z
M>S5*JT^>/>_MFA-L;SJEEM2JG>I86O)3QP78JO)8`S^F#M13LK#*N[OF!%/*
MH]KLI?R.G:J.-=*3ZT`])0FKO+>K0+`TRT4ICP-D,.5Y[%A]]`^+?8].&M9J
M=]><8$IY5)N]CM[S6)`_L4RC4'I2^E'(!Y!G@LG941M:SMLQ"YDUBEEX8/Q?
MJ02?[57*U6`EJJ+HU")L17F"]FPW5K1=G\PJJQD5:Z=4UX!_6UE]*9M5::%Z
MK,2><]$4[;>B?'H=O;5J>SBE?#9>S82_K=B2=I,%3&6%45>CKXPPK:ZM,'Z\
MQ>H2RZ86O%LK?E+-:U]>X[*%6H*5+8BCZ'1W^(T3.QNBYUQ]D6*BYW@>.]SI
MJEGJL>[Y397%J>;":LIJOZRU7U0KX4/5C148QI/=<*M3'5T1:E5D&&K1]AV[
M7Q-:)]4W1G^N!^C^T-^_!/[))3(/BV+M`[-"Q'SX%%B^=FT]4J3E)O%#-V+:
M1]>W?-N%F?X3B#35+GW[=!VEI'I7/S7':G##D?6N;O9TL[DBIL)A+/`.V5JU
MKCZTK5NEUM7;0\"KX-KN/_OOQ2B"^[%M8I:9,9\_<;ME:WQ37<8X@*7<\43W
M*-B,GM[O[+(?YX$N9VVF]?-/:TT,+C^:-=S'EA015T-OM]<`)3C@75BI&$HU
M"-?Y!=M.3-PH"L)'C<R,J3`SXD#[\NG#^>6M9C:,AG:!H94IQD_@"9\^G2EQ
M5\?U/E!15S+3EJEWV\KZ4-OQR->O(MMQESC_U5U)%=B8(5O[%ZT0VSC!0QJF
M77D1\[7?`H^`NP?3&R7>ZKBZQR/>&FHEU4X\[O6KR$YLFX;>[*O]6(.`1X52
M]9ZR0[;&2A6:_UX$X?X37&M)O`/KGKQ+47U<.^ZX9JODBY(OY<?0;;W17JM*
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MUH@JN?:>J#=&/SPAP1_^9%:H,9_J:N8`JY-R-EP%#*]:G4KF1E?206+_@(++
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M4I=K:19D939Q;1A&Z9^JK,2>\\L4[?>=F*9TS\;+E/`WQ[TO>8KXM*R.:;5:
MI/(ZIG,V8F'(G%OKQR"*6!P-?.>3:PU=CQZHRIG$YZJ<294SU:><:5\U(K6K
MJJJ4-5D3FLFRQ6:XR[=26+V%,JS5*V>>,FTJOT**?=665UL^V_(KMOI46W[_
M4;.44QH]X[1G]`RC;39;357LA$^X^&$CTFLPTL!7TP*@-]`X^$MSV#1DMFLA
M=(7VT?W!',TB3VXUMC^`2D=5(UHY9EVW1K1W"KN]U^BUND:GOMM]HY$XP]2[
MQIHEHHH5U;;>OT!4A<HO%8>J9'Z>AKVNWNZNF+*I.%&EE%62_"L9\==6##[V
M&AT<ZD!2E==0Y0U?<X)M5-&T3;W16@-[O7;46HN]L.KH*!E,[3\EL.HAL`RC
MI3?,`ZMFJK<%?)#%>!M:@"\LUJZF+`1CU[_3/@78OLP*P\=1$#Y8H7-8;*R$
M8I5W><T)ME$M8NK-7D,W&@>&PZ,X3$DLQ4]5(=AF[5Z]TS+U=E]9OA6R?`\P
M]KO=E+$_+"_A<=^!YP4/EF^S`^/G2F7<J;*A"N@NM0C;T(=O3+W5:NF]]HH*
M4=5OE=-QC?;&M:"3DK]560DE?RNV")N5OX;>`_EK-C909%(W0NY,_JK`_.H]
M&HL(2.9<.>#//[T`X"B(+4]+RX<IG84*B+4W4OFPTJ1*B-=+]BCP"85Y5%?>
M/=@(LA*[55D))7:K07LE=JO#NVL?J[P0[F<MR)YRU)^+T8C9L7O/+GT[F#!X
MTE<K9E^9'?@V/(:.(Q3TC_A<0?\HZ!\%_7-PF!:5,BIK0K-:XX`HZ)]C9U^U
MY8]LRROHGVHEARGHGV>MS5DPF2:Q.&6Q8NWBQQ3<-_C])K9B<$#"1PW]M]68
M7>%;'#$RR+X#>`KPYXGT@5ZGH[<Z*^HLQ8PO3N`Z`!(JI)^*L9Y"^MF`(.RV
M3;W7,Q4O;E$,JC*/;94W!_[)MQN-GZR@Q8Z`G+%V[HY&+`0'FDQU!>YS5`D,
M*N.C*KK%;+?U9EO5."]^)B:%'CZ'J0VH)%8]));1[^MF?T5CN);DJEV-\P$4
M$6S0V#UG3F+S[`WV8\K\2%FWQROZE*[8IZ[HZ<U^XX")I;A+22O%3X<BK<Q>
M4V_V%-)NA2S;`PSK[@J]QU+H/=L7FJH`J`*:2RW"-K1AJ]G1.TW5>ET984H*
M5WDEJL*Z:A&VXI-T&[K9Z"LI7'E7Y0""\,]%\GEI=5_QB#?/5*'$<C]2'HP2
MV_42.`H^0L%'U)5WE<NBQ&Y-65>)725VZ\J[:_LH+T3M61]RIQRZ!VM!`Q_[
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MP8@T2@"$UCX$P5_:.9N&S.99"=I'%S'L>*^A==BJ^K16*7Q5MB5K3K`-HT#I
M9GO%*$XMJ:782XDKQ4^'(J[,CM[LK)@944MJ'5ADI9;DW[==?&W%F(=[6%RN
M1&:5A4#-";91'=/IZJU>[X"II=A+B2O%3X<BKMX8C;;>[K4/F%YU:5ZBHL3K
MK<47%FM74Q:"V>O?:9\"L(S/K#!\'`7A@Q4ZR@(^6@FI5,I>54K;;.K-KK*!
M-YK!5Q<Z56?;_?Q3)0FD)%5U))71;^A]Y:U7P/@]Y$#P5E'3"E7,5"2ON;X6
MCYFF0*!W*DX5GDP%=)I:!`4"?2"L7!N"*2E<E96H"NNJ15`@T+5F917)WW7'
MFML@MCPM*RA2L,]*4-=5Q"C\T>H7U"KUJ)P4)78/BG65V%5BMZZ\N[97\D+8
MY[7AFLM1G_]%Q&3.`%PCZXY]229#%EZ-;L96R"*%]RP^7Q7ON4K@SH+'_YU$
ML3MZ5(C/+V:N6D)`%UC7:)\VZ7\-H]UJ&0C@LR?SJ:+#VH9E409(NG3Z.;IH
M9S$I:J!N<_F`/X`V8*A?M*:ATQH,RP5"Y3EFG>"BVI2'MRF?@/RMW:;,D,;K
MNADK/RS%P-MFX&:M&7C[(-6&P0WC9\^Z+DR!!25OL([DY:"JE6*10QBQ&'*K
MUVPT3;,YZZCR8-81\.@;4V]V&WJOMR+:_U96O"[$6G,?SZ&K5GQ/;'"\=5G1
M-3&'4Q(UC$ZOU>X>L]0PC9;>[*R8PWG$'+:7(H?#)VMZ5*!9_*Q`\^FP`+%L
M[&`R"7PMHE,#+8G@(M<'ZD6NK3$K]%W_+M*F<"U=44,3O?+#.DJ9V-7;C89N
MM,Q:+YT:EF+T)41JZNUV5^_U5_08*K5TVXMN5&;=TS+E+:P\[^Z,.M9QO03;
M/,.W=A*ZL4M7QG@P'TRQ1C#2+-_1'JPPM%8&CZL4IVPW8GI$4SU*&;EB_E)%
MV:"BPU(;46W$8]B(VXH*E``%%!.63DI(?Y!<L7+T`(V8:8``N*[E95;/W.*]
MD"L\2EE[MYBL,TUGBF,,DCB*8:"(6I9&.S+[;)6`1[UVA]('2A^H*$TEAZ4V
MI-J01QI->F$!Q1J5#U@Z,9V,HU\1CXD-'(<YM]:/:Q9BYA7:,ANIC-`2W^6/
MF"8A>Z4YS'9AA2/,UOI'X]1L_^W=4X-8,$C+=6Z#/YCO!&&TSW'*X\B&>AT&
M-F-.]!'8XL;"5;E)AI'KN%;XN.G!?KLY?Z7]B-Q??=?[^ZLX3-BK=]E`:-4O
M?O""A<%=R-@$J'I&1M\-QM@X6Y2.Z2R)0+#@L#ZRX?RP#+/D\YO8BND5%_])
MW/@Q+^89_'"C[])[/U/"M#0-;H'*5&^\^D>;U\\(PJ\XF263YQ?]QCSG`XS/
MC]`@]^_HTW'@@42->!&2Y9<OU;[)TGGU#^.TU>_U6N:3=%ECGDLH5A`A9PC6
MYGD<O:V*]+G\\O'5/UJMY8RS<%JK[1[\[M*'6?O,QKO^Y<;C@0WCCUS\=>`[
M5Z,1J`%!\VKN,2*6P:FURBY;=])R<9XTLC-KZL:6QZ_YRD!;WC/G8Q!^3&(0
MO9=1E.!RE%)L$'V_&I439G<$Z[4;[6:N?->>V;;(4J8J5E`A.YFF%8T_GE^>
M7?H17.$,)D$"5M7&IT+:L*!#S':CUVWWI6F4C40>*FCO*0OCQVL/+%Q@:62;
M*?+/MXB-$N^3.]J,9?1]X8L^/-X^3AFQYR=KF'T,E\"@0<7C+Q'GUN]?:9_B
MI9^M'^XDF0@N_L=UY\]\TBO,Z2!(X/H%$K0.A`0HLY*8A=EW1[/X*\Q\!VO^
MSQ![.*PBK9H+IMU<45IU&IUF9X4)T(AV/O:-[-<G"6#T6T:K66\"+.#9)^?=
MZ;3Z^YKV2S5LL]_I]RH[]AWP;+?7;G7K38!G\:QAM(WG3'M@V\DD`6^+.7*#
M2/C98\*/`+,LC-W_TN<+'[P+B7PR*Y(W-?B]$>2%V_UD=K]O@R"%OJ'+C8V7
M:MUN0UI@^=TO&-,+R=Q8/J"/8/G$[),+OM>E'X-!Y`X]-H@B!JZM1'"!GO,%
MAGC[P+Q[]AG&.]Z):@!5WI,DQ,L&_/RI_\FL\/8AJ/R,Q3A?.-%QR+80)-C&
M5'&D+YOLQR`):S%7'.@+IXI)&+68*ES[_*D.1F"%['2^1JO=Z#]WPH7A%E2Z
M@Q!5J-<^!J%\X_;56;-G]B5S=.%(-C7<S3+<2L/]%/AWMRR<G+/A3JS`KMEK
M-*1!RN_?\KB^?V5D6UU;8#3=(DR81;'WZ,.C_`U9\5^"F%U;CWC*^]D#LSN9
MKF#&FT:[W:W\U'!_B5-A:98WB<^NO(CYOP4>IJT-IJLX;&W3:/8;=9_R*IXI
MAO!;E9_HE\"_1*P7%L4?0)3".GX*+#^?;^A&#,2RY8,1S-GZTK?+IU]R$EZ1
M2=ZX:58#>$`3-XJ"\%%:UMO@BS=T7+!X@_\?"X,KG^$_%TB6*<X_^N3M8,HO
M%.7]?K^]#2FY0I!CVU+2Z/4[S<I/;9-2<AL"<J>S/8@Y;E`VSAJ)S7;E9[\U
MH5F@1<OLMM?<VV=)&.XJ`OF4\2G&L8EAOC0N^(3P7S+*SU8L2C^_LJGU..'P
MS]?`[+8[M;Q+?Q^QJR>FL_9XGSWQ[4:N5K0<5AOE%L-.FQSG%B-&&QWF]J(?
MFQGFSN,TS]^/"V,TWWPJ.L=SBR>UFV&`&KZ?%^6EGZ^CW1;99=]Q=K&877Y(
M"8H?5-PJ+GVWTY&)59CH`5+@_/??9\WUML@`W1@)S$8Y"4H_KP(3=%N=?N=X
M"##/`ZU&>[,LT##+3;K2SZO``D:GW>\?$07F>:"_!3%02H'2S[=+`3`,5PI<
MM%K-UO%0H$07-#;-!$9[0?YYV>=KD.#:@O<'2R9>&.0JWFW':/0VR0`5GOW\
MXIL;-P2,WO?/5E@R_;+/][[X9LN0DW4.>?8EB]_<].*#VU(Z_=+/-SU]$GGH
M9Z\2W^OT>IU-+GQ%9UZRZ!L7]QOS86>"KCL=V%I!YQ6CJD\LUDKA]YG`ZQP]
MJ")M8-MA0LD8%`6_])=4*,^2QEQ`&O-9I#G_*W8'S^35TL)B3#U<-L\7T@(L
ML_]-2C)+2C_?KL5VX_Y8D2SM[9.E`]/W2LA2]OF6R<+N2S;,O@BSM2/P]0F#
MX=K*[*,*&[[[8I4*FX/[WST;/@O=3(SD:,BRJ3GG)PXP#G'PO,ZYJK%@NL9>
M96AII;31EP]8YJ9[N-0H"1JUFMUV8^ODV*QQNCWF:/=[Q43"(Z+&/',TF[WN
M#O9*=3R7>8;H]8I.]L&38)X+VK.!AHW2P&A]'TS#DB/7LL]W[[25G#=VFT=+
MC9+#1U`?_::Y)7)4W*,O`S9H;X\Y*DZ-%;(3-DN.JL<URDKHNV9S6PJU\O18
MX<ARL\*T_7V0W)4(T[+/*\(@S6:SU3Q6>LPS2+>]$_.KFO&_,@P2L]<RCI0<
M)>+#[(!`7=U?NXK'++P9!V&,*94?@C`,'@CKO5XF>HE-VFL:LEY9--$#)$:)
M2=IJ&KV.N1XUTJB8J'=>BSC%,N'JD*9$O9B=EI0KN>*D#YU.)6K':,M5<'NE
MT_Z%L7O/5E%.0#.CJXCV%-'F.:W7:;3V1[3FYPO,:17NP<R!1>/[#9M6/[G"
M-*JR4^N9G-*1([S/H)^,`I]"XEZ-%F;T""QH<$K%6?),AG669E4]^=9J=*6L
MIL7S?@%UMBG%-FM*M(N!KJ.B1LE)B=%X!CGP]QR#,=U[7V&@O'%H7O=]8`D;
MDL9;BP9;(5[=4CNJ1+R*9LO6@G`U2FE=F(FV<7K:(8.EGTE564$Y5#/?HJQ*
MI;>8:J63/QYJE>2X=WK]"I"KFOD:9<40QA,R[LC)559!T>KLA[U2)\BH^(E=
MB;?=,_?#8G4A6=DI>%OV&W=/,Z-9?K!C='8>%ELMBZ+9:[04P=9(M#`;_785
M%&5U7/2R(JR"AZYH5%Y(VFP^1[Y3@KG4.2OMK.:<)XCE!K:_&SC8B<^_9V$$
M<UD>(32,2J?"E79R-,R^B6[F,\FQ+4JN(<Z6]TLS.T:GTZ[S'/=A?2X@9ANH
MV3L66KY$5BUNZM@TC6,AX-9$%^\FVFR;#47*->W]11N[T3Z>C;U*;5JIOC2[
M[1XF6AP'F63YM]22V)!@$[;:)W9G>1_9T_UYC7:E\\L79]N7SO002?!$BOU"
M&I3;\@)+\O$<QKGSU(87E?C^`U][TFB?R%C!BR=741(\^W00IP]S-S<Z_7,6
MV:$[W5@CE)WAH?WC=LRTM(\]C)3Y#G/B,9N(R6D.+FXPTN`S#7:/9NBP6_`_
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MV>C(7]BVHMTP6YWV2T;^E=G,O5^B!C8GLKI]H/7\>/-1%-D_A`\Q?>>3:PU=
MC]#G=S',3K?9;1;D4LE`9C=JSN)B!S"IQ34)B`B3,9E3+H>V$BXWNJUV=T8*
MK3[.E401YF9'<@Q@HW*(##(+AC,A$R;2D@C,*S"+'88&G0NF,QI?V$X2N%P;
M66ZHW5M>PB2S3(Q+&XF!%;ZA.6C#`,RM!V!%,..GS$83[CX`4PZ7^A%OZ+1_
MT?/O/'?$'_,0:(_,"B,<44R]2+1)@,U(="UTH[_`H&>2_1:"#HOPOM.6\0LW
M\7R8B7OO.N`Z:(\N\YR%1MT*))?7BQ;R`]C!#CHH(`RHO>,@##%^P_N2YY=<
M\WX.@P<K=#X""?]`"@YRJE^(B9^+H7[=E-,Z9QP\T3=C*S/Z(UOE[<UIQN"1
MY?4.YK0U$GX%!O\(_"V;:=LF8(LLQH9<A;SU.<T1<+C\9<-UU@NW<[E.6%]<
M7IM_SI!F*Z,MU]+_M%S_4Q!%5W[^V1=6[@M1\=>"=*J\^&M%?=TR>HTR;;U@
M0"\???_S$T;<VJ-O@W/\S.%?@5D'G_MWGS`W(OH**YAU=M],/LC3AE*[VY!K
MG9\:S<N&+<RCQH*4?[-;\OEU&,![XL=KSP+&]IV+_R3NE/-]'M'#`3A7(W!3
MV,T47.95:K$*-NQ!3GH!6LJ.9RU./8JSSJ7&9F;]_2891NP_"0[L'O[*KI_Y
M?)740=-L*Q(M!X[?"8TV&O.`E97;O5=HV&NLZR=K&,!H@O!Q54G7[QS\I.=9
MM+,>A]+99_&JP1W8D#B:31^"B`,*?(=F6[XV!/>7W&`Z=1@^:LS%HFGR;].#
MJ8#_"H1RO""DJ^[`C_/OZ..`KF]RMQ7<T1AV_JDF'VS=6>#56OR;[&UP>YR-
MQ$JGJ\$TLZ,,L\O/,O`U8&,^:B'#R],7IX^G,Z_\6?`$/`!KYF=3*](W6XIS
M-F)A"(:J]0/,5P:K9;,H@M^NP%L^9],0UIH,X8_N#^;0):O!SKS05NIU*13S
M[#%N?X(OC0N;7</8Z02O@>W]W:R>8;0:YMK+)P:XW9F]<-G:)OG3SYY8[K<4
M[XWR/0L^S)D5AH^C($3W<C<+UFF9[7XA]KGR^+8YK1>NEMGL-8SBF=EFIH7^
M/H\/>%[P@)`!.UFE7JME%NMMEHYK&]-XZ:JT6JU>^REF6W,:TCD#F!G;;83^
M1,QU@^/:2`]E$E)X%IR@07?IV\&$P=B^,AB!#>,B"E/A-S?1^`'D#@(A)]VV
MV>N90HRN/\+M3NZE7>=[G4XKRY1]P>0(T:="JV;T^V8_7;3U!K>].;U4%+7;
MS7;GV7/*3V9+;_H28(Y;8M,YE+A[^^MD]IK-GB$?&Z\\N.W-Z87KU&O*38/7
MG!$M[H)[5M2`FUV@;L-L]`73K3RNK<SDA<O2:G8Z3>,Y,TF74BA%RE@:^,ZG
MP+8\>,0.9-L3BGQ3@WJI)C&ZW;:,%;O2N#(^R=P1\<6Z#N]F>;[3[+0$HZPQ
ML"U-YJ6^>]]L][<XF:?\V<T:8D:CW>ZU5YS*K'^^N6F\<#TZW5:O]\Q)9%*K
MN(O6]%LWO"K]1C^;T-H#W.K47BK2VF:SV7WYU.:5RH)GG5$)UJ7_1*+Q9M>N
MH-R?.<P=3/.EZUC0_"^8YJSOO.#&75L`+Q_.1CSX^6.5+471OF<3'23Q.,!Z
M"%X':?EN-(:/5^IX,!-L6RVV]B_FWHUCT)$@J*T[]B7!%YV[7@*?\03+JR2.
M8LNGBB/GWTD43Q:%45[`$6E.Z!.KL+V1KL4L*XQTX,>N@P-S[]D-UNU0#`I4
MHY>`AX1(IWB@E,2T::]&%U;H(U;P-2((P\.W(RQ+BV<Q-[[7EQ)Z-C+T?=#B
M66M8H`5V4#%:YA9I077)/%]9+DJF[+4O[(&^>;+H%J8K^L_,(+":)9]CO@.,
MWPH?;RR/78WH[216+J^O5D.I;W8DMW^ET6]FNFL?L;]XKN9L?Z5-S99+ILU.
M=WDN?:_7[_27SV9F<'N:SIJKMPAMI[7:"E9^SM>4/LFN/<NFO('58!`V,'NI
MG(+*NU)!MBDC9^U-NK!<K7U:F.JB@5=D=DL7=--3S=_/C23X1;KOTI<JDO>D
M;1:5`#7Z3;,@M]:8R@(2P*1@8&0*!SZOW6+.U5(:[')#EQCS<^IHG0DM:R1P
MR2N0KJGP^RJM^ZZ*W=%N=3HMN=/VRE.00V,<^T7X!:-KBR*W$CS,QF!M"$+D
M`DS%K)X_I`HHRAA;67G)4'$KC'Y3,X6%+>^'8)9\3H%O9&!,8(P?<8J!C]$\
MFK?TQI6W^VFKW^NUS&?,^S;-[4/+.TNQVUBQXC^NC5[C7(RK_%W94$0Q2O0Q
M"+\&CY:'3@)7MAL<CMGX4XQF\>L*$10WF@:1Y?TS#)+II8\N"VP0^!2'Y/H@
M.T5X`$7(/8,/ME#H66)G2UDG:X]0GM\"@(WSA*&4N`WD[S>?\E%2<=`LRNMU
MQE>=>95%E8RV^?)I/0TIM=$0<-/LF7*=3RG$TSKC>2D%>[VVW$IP'G8+=C+F
M+5_Z]-4-"^_!L-L!I5K]AI$F7Y2/H2!1$E987Q`[XD!TX#M?`M_>:GY5D:2&
MV6K*"6RK#2W'.7,<%]G6\M:E^`L'GJ&/E0^@$#>C,\O?F$=&;K(`,'G3&8ZM
M=B$8.#N&EP_PI2L/5_8;_25#Y#2.XR#TV>,R(+N\8*U=U&W-DL\W5W[5DK#H
MI)$6*,PQZCX$?A*MO=E*A[_]:<U4WBV?@CQA)`!\B?:>&R%60$0Y855;/9/@
MC`I^^8*1%PZ1J%`MC.3RYJK-3!04R15%):/.+5_XA$-SQ*$[3*CT>@DFTRXG
M5XIH8*2[[NG!%X()Q?<LJY/:_A3_\<9]JUF>IX'YC-5+*?2;ZR,,6Q`ZE'Y&
M@'U8K(1U4%&*)/*OP!LQ[6(R]0+R([3,H='AD8%_Q^_#:J?$GUINBNSF$**(
M#[M8A^>`S7[''RXY1QIBN+W7WK@X.B'3M!'C,"+)%'%'+&UB_7`GR00_>MU"
M>$&Z`>]`8),DHDG`__FY#\S=\O#&UP;'(AP%>,:=UF6-7$_`!DI56O\WT@:^
MC_=]9=,@Y(5>03C1C,;)[_``7F*&4"@:@2!JH(*(KFDA5^L]P9V\<>]Q5#`!
M&BS?\H1H-PZ2D!Z$5`(6B!(/SUFU*#4DXK$5:Y_#4T'MB05K%`:(1X+3@SM\
MQB-/V1J)F>![Y^'Z\HFE<A^OFY+3Y]KBWBA_6'Y811>F?K66BZ?WZ7@</E8^
MA!"4.`APFA\MFIB;!6_,YI;=.`,`V<[8XLJ.`XF<;0W<?V!6/XBQ!G#H>AYR
MJP0>LWB#P3:$C?C_.3F!%0QB>`)-CFAS<H)[%&;^UZ\C\=TG^$7[01_%L(/^
M_HH)G,M7XM,P\.#3<1Q/?WWW[N'AX?3',/1.P?1]9S8:S7?X]3N\\!4^^MW<
ML^E3O,7]%?^&7___4$L#!!0````(`&M,?T;#5KE$YPP``-K0```5`!P`<&UH
M<RTR,#$T,3(S,5]C86PN>&UL550)``.9HAI5F:(:575X"P`!!"4.```$.0$`
M`.U=67/;.!)^WZK]#R[-LZ/8F=D<-=DIQ4=658[ELIW9W:<43#8M[%"@!B!E
M>W[]`B1U\,)!2B0H^26)':#1W5^CT6@T@5]_>Y[Y1PN@#`?D\^#DS=O!$1`G
M<#%Y_#SX?G]Y_&%P]-L___ZW7WU,_GA`#(YX!\(^#Z9A./\T'#X]/;UY?J#^
MFX`^#D_?OGTW7#8<)"T_/3.<:?WT;MGV9/B?;U=WSA1FZ!@3%B+BK'L),F7]
M3CY^_#B,_Y<W9?@3B_M?!0X*8Q&4?!U5MA`_'2^;'8M?'9^<'K\[>?/,W('0
M`0U\N`7O*![^4_@RA\\#AF=S7[`=_VY*P?L\F,^FC/<_^?GD-.G]TUE`6.!C
M%X7@?D&^D/1N"A`.C@3-[[?C#.-ON6Y^.7W__O3#&R>8#463826%H>#,0;X3
M^;$*KC@?&0[A.03B@KOD49"K/UQL"X&3&<$7V@]H5@GI`+&*/<0>8CU'[/@1
MH?E0*&<(?LB6OXG5=?SV)%7W3^FO?XP8@Y"=190""9<#^.@!_'C8'Q7MABVS
M>8;85,)=\M]YI$8TRQ^BSI(&_V<!IJRQIBV&+)K-8FK'.(39LK]'@YE40>FX
M01F?`76!<F?`?4'$.`_!7-!'_N#H"?#C-.3_-6A;P1>,B_MT#O.`89D=Y-K9
MK_(<PZGN3VW2_<AQ@HB$;$3<23@%>@L.X`5Z\(%=0Z@Q-_7ZVX^5IB`IAN]L
MPO"&PAQA]^)Y#H2!&K.*]O9C5,%XBLG/2DR&N:7T`%;7ZX`XF@OL9M.V3?@2
M$VX?5W@![ICP8/$1\XF7L@4RUE4=+3#J(@1YNU8)8>.B?0X><*'<B<?_YCN*
MLX"%3`)41?M>X%/!NXWK>1IL,(/97]VE)^!4L:^]5A_@NJ!<#=I?`YIL![LU
MTLJ8,LNIC6[\A@9SH.'+#3?(D,>^%W]&>#[C[,J777DWBR&1,VZC1V\>Q]F)
MQ*N_UL/_"J,'[.,0@X9O+&O<ML%>!R&P&_0B]LZWX`O]W2`:L^0CQK"'P55+
M8D2E4S.O!BAO\D8R;7>U**:MQ6]^W(6!\\<RK$W252685#>U7/'5C%OIZ=,4
M5&HA^LFW?`?+45&Q;V..+<=K;O::(E71O9^X50BCG95K%T4:@6NTI$KZ]`>O
M*@E2D'ZQ$*0QX:$8W*-G`Y#*^O0+I#()4I#^\1H75\3%6INCBO;V1,=:4NAU
MM\7FU=D[/7FT8^%#G0%Z=M^^M6]G\VJ!)5?9KV11M2K/MTUOV0\X2OR'>K=W
M4/XCWAA/`Y_KAHD\:/@B,8BRQJU78@6S64!B3GY'?@02=HM-.S7=:E47RK0*
MC-OH3D:NBQ,N;A#F0>L9FN-0L%0=H5?UZ`DNE?Q;FDF*9E$<3<7%3-RHYA2F
M0!A>0++%N`J8*"Z8>'RO(=]8F5'J"YRF<MF8E+J%$&$"[@6B!)-'MB'4.7C8
MD593ZG3N"9@ZHKP6B2G"PA%QC0("==<.8URC_9`%\:Q4^9(@U\[H8#N!9=]@
M*6O9:..QG4]2[D+^IZAPF'B3.=!X!%;OVY1R4KO_2*5\W):-^BOE\<`-#3SI
MJIIIU?J\0SZP6U@`B>!K$+B*VMGRYIW.O1(E%Z99*=<VND%1)CKQ8A[ON%N0
M[E9S+6T'H<"PVM$==Q5?6>$]TI')8_KQ@BQ"*6G;MNE^!<)Y\/GZ-W)GF&`6
M"HX6D'(D<X"JGIV:=B4,>0-7BF&CPSD'OH=U<*P(_F\?8OUR$68!#?%?\>\E
MT.EU[P=^>K)L-W=346,E?%'D*^9^94N[U5W)MKVUG'8M!^M4D\Z"L-FZ]26A
M9OS;N>T655QP]IM,V^C8MQ$]]`"'$M9?XTI5.0D)L@I6AVB2/FT;]IB$0(&%
M:J8++3LU:J7:\Z9=8%_M9HZW$'M\19A,R"67D\>N!!B;>.?P4.;`Y<W[H6RY
M##8>U'$V^=@D*1UQ7NXI(@PY@B\AAO"5MX!\_!?(L@<F1/H!9!W);#R@.P>*
M%_&^,;'*]<_2;5AUIW[!)Y/$QO+PI9-.A(O/A356I$SK?@%4*H)V3?AA1ESK
M,/:2`\#9X]J.N,+7''T!C_NMC4KNB^>0(JY63!!]&7,1XN(TWI-+Z,=8)3!(
MC6V'HW:VG6FX^^UJGK5@`I5;HTTEV+A5W<6&Y(!PEJC"WB)6*_SR-81:[B37
MKOT88S^7C\YBGC+8BW'.#L6WT0NO!$F]QQ>^$Y8G;BM[]`7=$M:;)0^W7'[#
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MNYX:U">2VZB5*?*2?6^`QQ'+NZ:KZF>,2.PMN.:J4-]P9=4,3^\KJC6]5WWW
M%GX#':2XO[=I^5:RG;VFJHD1Y"F]FD1>(ZF!?+#>0'(7+)I:1:'[89I"00TI
M_A^M/O/N+'TF'J9JG!PS(?)Z%*)U9-EP:O3@9*2_B=O^FL5VE=&+:B+;/.N8
M+(`U]:RE1#IX]\4!<.-ZF',<,Q1&%";>NB1XE35-+D(9>1Y?ECDT,I&;D;5Q
M@DH@+WE;IH'PK;SWD'B+7.`EQ/X7^%Q8^0L0FIU[BJ*)B#9^2L1W4.G:,'+^
MC+`H9LL^)2B;MNJ^/4750$+U68(-GYK:MB1>8H)X(-)L22PETN62N'DMN>9R
ME^UBXW210"5;RK*"V;@;V>1VS%@DKE.<T.0D27G_G$[G/4*S2D2;E[3E07[*
MNNJI67FWOF,I%4Y_#>MH>FXD>%\JOD37Z]9W&*7"V7M9K0V1B!B8;Y[$7\)[
M+;@?$R<(0''@YJ-W6=&W$9D.4I\=Y'8[JR2N`6E)VM0T^V55%---SFD/$2\5
MUL;XIILMU1XB7BJLC;6!%YX'#E\[+YZ=*2*/<,M7TPDIUXP$<S,RO4?=3-Q&
MP5/]CT/$2P.$Z\+''N!5<@G%R257/%#@&WP?HD-L-Y^(Z(S<]B5),4-7>"&F
M>C9K)[_@6M6Q]=N>JOG9_$(AK9"[YOC=/X&_@&\!":<R?]"4<*<>0@_>PM50
M#46V,0(TD^F_@.C]4[`ULUC1VWMK6$EJ8U!80Q0^O&RC6YOB81A"(JN-T:*Y
M,)=!)+NRK"[!@S"$1%0;[Z6K(8O\BL&Z!`_##C;O)[3J970S649>"'3KQI"C
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M@5J_"=$#OAEU.0])OF[CK@!1&:3<E>L2:/R=77Z@BV<'&.,_319`-R\GO,3/
MX%9^G]6`5J>SV0RHS!=X]:1MY>-);=9N^!Z_O("K)IV]!W,EJ8T!?D$!JY)B
M\<W]&:+TQ0OH$Z*N+$-@1*6'@->2T\9HO2#`[\B/$A1\/W@27]N8P%S6>Y_@
M+9-/_\;&7<11H0A1S-/#99UW&4EE1^KY`R%-UE7Q35'$&[^LAEC>;I(L#J+<
M5\EF;4H6O#!5"4-F,:TC7"MQ47RG?V/L3*GT!C=3P6P,@2K8OPZ$[XN<4)10
MZ+SA;$"E#_C6$FR[,4_U9;9E'&F%,J8$^H"4J4P=?412S+&<-LD$G;:6"CKM
M*A=D'L@H>S:>?*MM;DJR1M+'B(05VPF3B6@D72LQC(HC14I'N_O>0;6CS(UJ
M6<MR;I20J4NH=]#5D+&5V*2XWE9P>A9_[3DFHUG%BRC-R/4.T-J2=I6/$19V
M`_1NBB@8'VR5==Y-.%,V4ML7ZI(0N]B/Q),G=^"DYY7<^?H1ER9YM78VC\)8
MZHEW@2CA,WC%=>4,V3+]MO>=_X[-D\<"?-5!CW`=S1Z`3KR8ITD4LA`1E_/Y
M!3'LB!<EA(1K\$OT4)=@M_>Q;],X\GO7NAJQL4RO5):4XU@@MB'1^CYE4WO1
MH7A@!J.CDD8%Y$/!RP-BP'_X/U!+`P04````"`!K3']&I]HY;Y07```P>P$`
M%0`<`'!M:',M,C`Q-#$R,S%?9&5F+GAM;%54"0`#F:(:59FB&E5U>`L``00E
M#@``!#D!``#M75MSXS:6?M^J_0]=SK/;+2F9I%/3.R7?)JY26RK;F9V:%Q9$
M0A(W%*D0I-N:7[\`+Q(EX4H"`MCCE\1M`^`YY\/U7/_ZM[=U].$5IBA,XB\7
M@X^?+C[`V$^",%Y^N?C]Y?[REXL/?_N?__ZOOT9A_,<<(/@!=XC1EXM5EFU^
MO;KZ]NW;Q[=Y&GU,TN75\-.GT57=\*)L^>L;"@]:?QO5;0=7__PZ>?97<`TN
MPQAE(/;WO<@PM'Z#SY\_7Q5_Q4U1^"LJ^D\2'V0%"T*Z/C!;D']=ULTNR:\N
M!\/+T>#C&PIV=.$V0;;[3'.`GZ[*/UY\(/("J9\F$7R"BP_5C[\_/9SV"^/L
M*@C75U6;*Q!%^%.$B%^S[09^N4#A>A/!^G>K%"Z8/-8$$-)_(D3_0$:[ZD`-
M_AG&9&I<!G`!\BC32-OIV)HH3=8@C,T06@[=B<YBB,LU7,]AJI/(@W&[4+C"
MQ*1^/H>7.\8UTDD;O0NU<9*-M2Z9:L""IIH@T>";]0KA$08_#H;E;O'#31*C
M)`H#D,'@.</_Q;QFT\5SEOA_K)(HP!ON+5R$?HA7U#&OA,9/>'?\:?CSS\-?
M/OK)^JI@56',CM0_Y^LU2+?)XCE<QB$>$L39V/>3/,[PN3##1/@AQ!_+0!@A
M>0;4ANW(PRQ-\$S+MB`.[O[,PPT1EC+%O$$ZTO>89!!MP!;,(YC"B("Z`?A3
M@2J-HH%TT#DKAW\JAY^1X2LQO,"W+`>1(KGB\3I2?0O3\!7?"%[A)`3S,`JS
M-A.6.TI'"B<07S+423KLUI&&!WS36^.AWB"J9DNF"B=[B*Y[4&-;(VMO-T,4
M]AOF$)WWQSF"?^9X,[A[;;.M,/H75.'+4!B'Y"X[P20<$(<%"^,`!C5Y9"R=
MIT9QS4_\@V]&Y&*=I-3#M#A(%P#-B],T1Y=+`#971%)7,,I0_9M"=I>?!M5-
M^H?JU]Z.&LPH?,`_HOHK$9C#J/BVQV[LX:?*E2V27\CV)4-NT=`;5*3NP1VG
MAT3C^TP]7'6U47HK+-)D+2.PZI.)B-HDQ1/CRP7ND2-,2;(A-)-]X4-Y7_K5
M3V*RT.^BHA]>.'!)?KC8_3U*$`R^7&1I#BWB5"[[FV2]26+\3S1^"Z5F&:V?
M-S2"(N>^S4%UAY0`418C;(#/C=41A;<'SS<*1M3VWL@(-JQ7)0<8EL#I.#&9
M^>[P\6YK#8)9G`[U%*:!VG/%!.S<>&$:UTE<G.]?#[0,%*Q.VGH_FL&'IO4X
MQ8:Y&NB84*EW9^&,@R`L/SX#8?`0WX!-F(%("`JWG_=3CP`2<E*!-7``K2=R
M"8]A<`?2.(R72`@3O8/WEQ[APV:A`F;H`##3;`53PE(*5V23?X7EFU,($+^C
M]W./@!*S4@$V<@"PTV<W]\9]W-C[Q28P:L\F&NT.[6G/*Y!"-,TS8ELC)CT>
M$,=MO<^]P8%&NI8=[%3U0WY3`O^`4`Z#VSPENFN8ADE0TO$/$.7P)HDKH^IT
M<9W$`47A.8Z#4_TB;:F8_J0W^.0ZTF<1@98MM,V,.>]DZ2`D,VJLL\Z3;MQ7
M4^1'$U.D>LT45);4/\28NE)=V[2:%%.=!;W:*-[`C$Y+-Z0MN*J@^LDJ5)U1
M\@:&%%NV`"H8JK#YB_UE-(TUK20\D#>PJCPQM)AJQBK,?K:*F0ZX"H:L:E'T
M(U7S5('TBY$K#"'C[LU?@7@)Q\L4%BR<DGB?I&,?OX90(=;F"<P]N#0-[PVL
M*F#D+RD:V:U0_^PFZF4K<["7K;R!57W.&7%O\+M3-9A`GM!!/'*GBP/J8GR#
MCJ%/OO._8;::Y?,H]*>+!2042J]V+8-[`^=519J9K0'OIEPR!#A_H>L9W1LX
MKY72S6V-N1%-EI:IR;F5Z1K?&_9#1Z65WQIY(QJIKI0:!+W@OQ^Z)EVLUE`;
MT2S)$?E`I`PBHP>ZW#>\83^T4MIYKF>!$:65)FIUG/*2'_&&_5!^Z6>ZG@A&
M-&0ZIVWG4T#Z,]ZP']HU$VS7T\&(\DWG[#4_'>K/>,-^J/!,L%U/!R-J/LD;
M36$?@[,(^(48=#_\1<-[PWZH^72R6\-N1,_7G5`MSW_A^-ZP'WH^K?SN?%D<
M\"EBN:)-$H3NDQ2&R_@F3U,8^]N7%,0H*N+RQ\'_Y2@K`Q?>6OCL*8SN#9W7
M"NKFMIX?1M2"8]_/UWGA'E'[B3XE.<N=3-3%&_9#@2=BH1:Y"QZRCS#;SQO.
MXCIHYXV<UZBQZ:ZES]2,71V&49H(K%2+9G^/K7R/K7R/K7R/K>QE[-Y[;*7;
M^+S'5IX)K_?82JT+!T'_XS)YQ9>UL,0`_W`L>OPK;P*7(+K#]ZILRSAD**T,
M14IJ/5(89&L/(9(5=$D&<QLZ;F(JV%%X,C#D=BK<8VIMS6!EP=K>TEM*V,$]
M>P;2TL-N`^*M<->FM+83*4J;O?2MFD&RCJG.<@HMG[Y3_M.W2N4UGJ,L!7Y&
M$7K[P=P/$NW&FY83@(%>85$8!P$,7L#;#!]FF!&P9%IL&,WMA(=VDRH%(0YW
M!A?0X5=!&+PD_X!QD*1,^PF[AZ7P3<-(G'!H<D7,TL2',$#WF+MG$$',3SY'
M81!BWEB`\/I8BI34#HF01X?21%3TD0?++`U]B-=R84'C::0872Q%1>J$3XI%
MHP'/O#@'0DZ'L)!]=TOAD=H7F@J[)F.0Z70T`E'$UP6%(2P%3)X)/3;+)D.3
MZ;24T^<W&`776Y(0%!9<%K^M\I<4?@KD`:&&J\+`EH(NSX2VJB!,AD#S*"RC
MRUZ2@T=C&\RI`UF*OCPKQFS&389(TREZS(E`,,ODKS?$WR@J?434$&4.8RFJ
M\DQX\MG6$DNMW>R`9]TT+?0/I6>@Q#57HK>E2$H3-UY9;JT&31_[`3;N"N,X
MJ!V`.T9.JWS$4ESE>2_2K82B)\9:^SY0I=(L"7V""*:O1=#X?9[EF,O*^U1N
M5Y`;RU((IN$]0H%W/<'7FF8"0*O[VX>;AQAA,H/QFHB"AS:MO:4@2R.(,OG3
M$S[M0CY&.U&11K125-Z$X<YG<.KD%?PYM]VR(F46$6$WZ)E(N'2*.UMQ\?17
M,,B)1I))G]#Y4W((&VZA<D)G+`D%OGKN0,ID\'K[@K\M<".5Z.V$,ZD"G@RS
MOARC[C@SLAG%7Q:Z-DKTMNZ(*@F)(IZ'#/Y'X6G;R^E\P&IUC&*H'29@OOLV
MI@/?A?$&3_[!+F8@U<^NXZKDNJ$H`V3X<F>Y$4URGL%T1[*,AS&MA]T2(:W@
MDN#(H;3Z3X5RB7]-V;4QY"-[YLO(`3NN02$NU;)O9<J94_H.<2!)CK#U.G):
MD[8K)[RJV!UT9/Z*);?.UT+Y'[2SZRA[-)/I<C^AUYT)_Q6\R8F\V<YNX10Y
MD1_3Z]"6SCRB?D=PD4>3<,'3#TGTMESOI(N62):[/L#Y]Y2?K8#?T7(Q$B,@
M[AESR*^VD0CC%FY2Z(>%BP3^.8*5U72\3M(L_'?Q>R9S'*1U?<)R-9,N<T*K
M"!RJ!<<D]!'R9@2OF^62*$96?LV6R+?W#!:PHJS$IBPKD995D3:D*E)@QPK6
M+,Q4Y$`"?L6KT`8FZFK7`L:@#EUO#_XB;0Y3&,^&;4P&#)%E3)'%GIO)Y+@5
MJ:&D!W'+:*8(->-!K\2\.Z_.)G5".\MI8^MF,C6YB[%ST3C6&2-G%&.&P#J'
MP>L^?(55;`VYME3%L&8`03\9;P16+ZG.=DU?]$5`L71)\V(PIODQB1_P>9I"
ME%U#0+QH)PF(*U*>\S@-$;P/8Q#CMTV$G[KYYB'V^1!U&-*N$4P:N(X<F@R*
M;DRDK^6G16#1VYM*$J,="3;Y1FM)AW7:`?PZ7(<()>FV0<M+\AC-@S![^9;\
M"Z;)-(;D?W=DSFS(Y$"32+"(M'W`3AX492"U\FLR1)J^:>-%#Z<1@O%O241<
M8UN>8\QA+!N$NIUH7*Y,!D8+R.F$D!-6(TVXG%B4N@4YZ[FK3Y)X^0+3]2V<
M\Y2.S6:6;43MM24G3#AD"FK25N8UEX6C:FW9Z*,'E28O#MEY:A(%Y<MYS2W;
M7[K#<\*,Z/@_ESZ^HNE@ER[U\57,S;M:_ETM_ZZ6?U?+OZOE'5;YOJOEW<?H
M72VO(SVLH@J#_:SOA_J=2[]!E;NDI>/8#M`/U3B%:I/J[ML_LG`L$&2S34_4
MVL<DFU1E=]54?V>*Z+/KF?4I`K)*5R$1CTUK;DC';//2RF+3,?5:DT3A_8?>
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MW=L&X@VW!722(WA#9TS0:DBJ\.>0`WRSCF-=TF"Z$-P<V)V\H3.V;S7X!"QI
M>1[K08S0M,]76D^[)\SWW6)!JI?LHC#HEY)6XWA#9PSK:KBJ<ZGEW6X&:C^%
M`,&C^Y<"Q-3^WM"9L*]NT+*Y,ZDX:!00JNJ_/9`@74+2="&(F%`;P!LZ$P>F
M\%I08\^D3J)1VJ<N`Q7<YB2P&N\`81*0*HSQ*TR)G9MY!+8<R1OU+&BL"Y]Z
ME"'\%_@$+D%T#]DUT([;>:.>*3C87.BI-L6SP>_+[^!ME;P>@QG$XV?,<J#\
M7MZHCWH."9Y<JB!U>!Q^!1E>J-GV%G,N?4-H=O)&/=5\"%@2EI)R`K);B/PT
M+"AKA5ZCOS?JJ6Y$GKL:4Q<T)4W%FZ2NT1OU5.=QPD0-!%.S<8:HV%M\-7D%
MY&$W"<$\C/#0$%DJU+:G!=V#,"U*S4XD`F&Y_6Q$P>ZH0`W2KD%$U"3/*PBS
M"?DVQO!ZNV^`+X=%M3]B3[O>_@:#)3Y&\=H-EW'15A0J:^ZC-N)IA9C2UYA9
M(?0\XK:HX$SH(>ERLRVI$9/$I(J/(#*!V\^%N%JSJ--GFE`H[GC-'U$H=)JG
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M&,VESB.[8/R\4Z;;)RV':FN?-QJDX9!C>Y'*=\=,=6.#C2+S36^H`??L4!G(
M<KQYZX-$F4<'2N%-B*NA+:OB=`-3+.AX65`1C!&"&9(Q*_([VLVN2Z5-/IDN
MN[L-6Y]8T(S7MR0_/3?;,8M=7F\E=)X2O5TPX<EB29\)DDRZHSIC$BRE1I/H
M;=U<)PF)(IZ'#/Y'X>F*BM0\L.=(K5MN+A,P3U+29_N\`;XHG0&[BUVCGN1J
MH3PS!"R93%Y6?'FZ6(0^E);]27.[&7B[RIW*CDO6MWR.X)\YL>2_5ER)#*ST
M'H:L;V>\8'`8<QLPL4F.U<>4J4?>9,J6N31(>U;<N2MH1LF5>X%.N!PTGQY1
M*S2?4MM;MNSQUH<41B?F/0>6T^%VCIX(K656`;ZIB=O/KEVPK4)$R)))"]/A
MQ\?+%!;:%'YLCF1/RU8_53Q4N!*9<<Z@GGV(\8\P`V\0!:6.-K-3#&TOL@2A
M&Y"FVT62?@-IH*BO9?:VH;1EDR72UPIZVE75<F4LVIZ8_/1<55NNI!?P-LZS
M54("\`0/)GH'%Q2R$F#146:SY,Z=X91&X0V<U<6ZHI4M;UE\7%2H:D7(E2>2
M/JC.H2*]!7&(5OCK`M^ZPV9V5:&\R4VYHU%H-ZCSW!%7U9H=SU'AP,^2+*N]
M7:UGJRN`D!^'M&AL!EO=U>S4-Q,*7/6*)A%Z<(:G2N$7M4HB3`<J8YDL>97<
M1`"AZ:*@1^9Q0FUOUX>DH.5Z6U`F[SIRTLO&,X0I3886BT]]SQ\=WVU8MP`V
M!M;O<=EG-M.\QV7S67+E]?$>E_T>EZT"!(+^QV7RBF]U88D!_N%8]/A77I%N
M[R[.V-HN2BL7HJZ5SA<&#]K?+;)2+\E@[DG'3:P%0#/D=BK<8VIM36=EP=K>
MWUM*V,$-?`9(Y06R"X*8'='):6TG/)DV>^G[-H-D=ZX\>C)J.%6U6N7MP.+&
MH>A:?4D7;)>G9DI;$AP7"U1K1,?VL:(;)@?/&STI,>SZIG"6!>OMP&+"[:08
M=H._I<4LX*`G:3'L1DRK"9O/A4M'=SY'81""=/L,=C<3"8]Z:A]3\<MGN&5Q
M67(H,KU!WB-8XQ\;^9[%Y[JPL[$*W4H>]FPD&.C)\>70E<PXBL[<U$S!Z>#5
M[6$V%5[7=FTLEVZ77#)T@`Z9,.J=@N4"HED^CT)_NEA`DG9D*JKQS.]EN<I[
M*\'+LN60Q\JLN`#!603\PL`C5IU1.UBN(=]IF7`X<N@&V+#;S$`Z30N37%`D
M?YF1`I@@Y3EA2/2V7+1>T2]#EB&'EEJ#Y#+53N5H^.^](Q,?N>->17'Y/B)&
M9<3-M=9,BJ2"4MFC*%G?7X0:3#CTMCHALU$[3`6B1K>BG'U_<3KFQ*%ZUHQL
M=,5&_0B_%7_A>YI)]/>&5G5.JBZ%TBPY5+Z:FU6P`Y!'`WA#JZGU]"!)X\FA
MNM;-O1W??7V9^R.SCS>TZORD"AB7#8<*4C<?-#D1`?['067?Q@-'4@<E&L8;
M6M5TJ"*IRIF6TM3:P;U)8A0&1>!$$C]!'X:O,)BJHRL>QQM:U:>TAU>2-2T%
MK;5E=/,A#-`]E@*9CJ04"U4KQ%6S2([A#:UJ7A1Q56/+:'WK8KNHJVWO<BR,
M_3_S$!52Q&>#CW\#ELR*\@I#>,,^:%=:<66T2C:=F(,M_X9,HB@"O#PABL-X
MPSYH5EISIJ>:-@.Q70'[ZFVZ*#T7GQNO5A9*$EV+NO?]0$:6&SV%LI763_.J
M])(<N):JK2#.0-ZH#SJ5#KRY5`R[,:=NP";,0%12_P013/%]Z3Y)[_,L3V%]
MZ,HIRN3&\D9]4K^T8T]8<+O3(OV^:F:,^J##.8L4ZEG33>WS/=?E&?5!?61:
M`/4TZ:9Y8DR3:K\[4(Y@\L@)-UT\)AE$%;$LY*4'\$9]T""UX*G&IYORJ"L^
MQ7[4&:1B%&_4!V506\9JN+KI@KK"-8V[@X7'\$9]T.^T8VMG\K>_KG2@50_D
MC7JCZVG'6XV;"UXU*BX`I];R41_T/'SR:S!<<)RYSA%F`^'KT'H>EJ7$GS.X
M:>@.RVP%=73+0US\"3^XN<I6G<-[/_9!@:2=XWJ6,)5,Y\C`=9@1W%+ZK2,J
M)A(9N%A=K"3A.LK$+LJ^16EN(^T63X2,W8Y!>=]3;FFKC.)"FBT&1G*(;ETL
MKZ:WQ(;U#%MLD4MCY&)^+<THN12&I0LN!R.O]!1"L:HQY*X/*8S.DB_XF$RY
MK,'\7G9S!\M?("19,1E./\YPRQAN[R'5)_:DC<5$OV)!4:1[3+L[!T.5/N$Z
MB3$EZ"9/B=5V'`>/2>R7_^#L-^+.=K)$M0)*C2F'XJ3(I,+T$=54B,BYB:;9
MBGM.,'K8*9G5"2P.)P[%1Y75)U.BE2`EHEB>5[SF=JID=<*&Q8:6T"C&03(K
M;XXW^$F;AO.<#(S$?HG\7I:R#K4_;238<2GBZ5C+Q2MB)NYD*7E1IY4BX$84
MUD1115Z1[\P!@O@?_P]02P,$%`````@`:TQ_1K1O-.Y680``L>\%`!4`'`!P
M;6AS+3(P,30Q,C,Q7VQA8BYX;6Q55`D``YFB&E69HAI5=7@+``$$)0X```0Y
M`0``[;UK<QLYEB;\?2/>_X"HZ=FR(^BR7;<N]\[T!B51-J=E42/2U5-;L=&1
M(D$INY*9[,RD;/6O?W'))/,&)("\G*.:_=!=LH1S@`=Y;@`.#O[M?W_9!>21
MQHD?A?_^U=MOWGQ%:+B.-GYX_^]??5I=OOKI*_*___S__8]_"_SPMSLOH801
MA,F_?_60IOL_O7[]^?/G;[[<Q<$W47S_^MLW;[Y[G3?\2K;\TY?$+[7^_%W>
M]NWK__IXM5P_T)WWR@^3U`O7)RK.IHGN[;MW[UZ+O[*FB?^G1-!?16LO%1!:
MQT64+?B_7N7-7O%?O7K[[:OOWG[S)=E\Q><@C@)Z2[=$=/^G]&E/__VKQ-_M
M`SYL\;N'F&Z;QQ#$\6M._SJD]UY*-YS_.\[_[8^<_[]DO[[R[FCP%>$M/]W.
ME7#>E7A)HM=_)F.,\(;&?K29A6Y#K5"/.N9EZL5IAU$7Z$<:]RI*O<!IQ`7*
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MO>VF80RM/F>F)?:".0O0OOR%/K6%0QK"L<,?'0:%^&0-B6A)6%/`X`;E\&WB
ME2$`C.ZH6Q6AT3&KJ895V2D+!#8\&+@,O'L;#UPAA'2]50Q543G^G?`&2'PM
M\*!=G6NW88-ZTT91;W6C9:IAE?'\$,>\)S]9>\$OU(MGX>;"2YLBXYK)4=-"
M>%$-DJK$9$V);$MX8[8`VQ#>'-B98D5AZU,'P@'B6MMT1.E=E83#ZG2^V%XQ
MMC;^M4P'Z5XK")0[)_SO2)PKZ)!=76N708,ZUB81;_6K):)Q5/!X7&?J4Q6$
M$`Y5A4$I);(A%D^*;OBV+K1O`""^4ZL(2L?93#6.RIZ\]27[3>+B0&LL,/C2
M.BZE(!4C,=$8F8]%!:6K[^T3#`J?K%`@8_=<I1]3[:7!42F^TKHU$$-Z["8L
M;4*5.0\`=7\^,%P]>-]`0#VY4E%:O7F=<HRSH;_2(/A+&'T.E]1+HI!NYDER
MH+&-7V]A!'\&K,:H.,/@!*]^XQ0D)R&2!I5+,?J"AL>2*BYCR.#/47`(4R]^
MNO0#9@K-SR=KA'#GDW4,"MDZ-B2R)0KKI?T.+<=C5:I13K3EUN$MW4=QZH?W
MR]1+[18C>C[P-DN)4'7LFFT3'PF(I$!HL/0?S]!>*9B,(7Q"SL_9DOL^BBV2
M*2ID<*:J.GZ%1(EF)&^'(HL"Q\C=$BAZ&3N@<VB4^A;74*890S=O#G>!O[X,
M(J\IZ[O%,)6(X5U`&8M"7F0C(EHAM/4-W\/0P!<I1PDIHMTN"I=IM/YM^>"Q
MS[PXI/S2&+^K9F[D]5P`T^?TZ%1!A:`B@HQ(.E(@1.$3NB.;C`'-,>MN%'"0
M&7D&6M>6GJ=CX68YMEYR)Q`>DE?WGK>7YH,&:9+_IFI'LE__C8>AE._F++:7
M?NB%:]\+;J+$;[F.U&A%[7A"^2M+Y%61/?,"?C&722FEJ>;B"I@O<_FR6A=G
MQ7!L^9TF"4T3TXMS*JJQ_9QR]+5D2-$`Q\TWRT&#>B3SL2Z7L]42W,'HQ;G1
MH2A(8!0PV]UP]1@*)M`N0H5-H:7YEA:4MO:")0<AV_\)Q?FZ-89/M[>SZQ61
MREW#`.Z:M3ICY(N;.8RM^^=>\F#J<F5;*$>;C;0F*.S7"#SJF*-S\:*:\9$7
M;U_V/L:]B"H?>QED%J\GY($&&^*'9)O'KH07V?'3`X]?^X]6]K4:*]WF>KK\
M,"%GL_?SZ^OY]7NRN"0WL]OYXF*@@9\*VO0P[-GUA7K`8+%6T7II(RS1<&S;
M.DL8LL\75.B";3Q5(8:.HZI8:MM`XN\D:X`H:&H;N+"`N6&A$L6+;VL&$3S@
M:!0FHT"C3#GZXF*]C@XA6]V$FT7Z0.-;NJ;^HW<7T.2:IEGX8[SH-V,&MA=@
MB+6V^,CH1-T104D*I!/"B"?YT@1%-.$*5&*+3ZW1>!(K,=4OYHTXC:V&-S'=
M>_YF]F5/PX2JU4YK@Q1,H'V3"EM5^K)V)&L(IE*]@J&R(9ZD&R.),W)<S1Q`
M=\?L=J?A'5)E[/I=+QRNI67(H@PD*6]Q]1]N%JI4CC=LX"UK*R=7HAC?F45L
MB9L^W;`I%@7,_G'P]_Q8BSE8>Y^FXP7OVK1(ZTY!-I\002#KV.4D(HY$M#*S
MQ,9^2W*2,C!D_MOIBU4_5<C0>NOU87<(>*%6LJ%[%C;[HCP?0E??KH^&'E_#
M",;Q7[-Y:3T9TUC5)GK8<*`147-DP$S&L3&6>J8.8!:K#[-;R*,D2_DP=L`-
MQ&-KR:4?^BF]\A_I9AZF;-9]MM+-1F?OC=NX0?OC5K15T9,$KP0%.9&0HWX-
MX)*[N"]K@!=T*TA(X&\I\4\(/8#0'/S;@;MB,W4T<L8MK,8V-$S0*#-UF\66
M_=</[\^C)&V]M]="#.6(55@:E$NT(WE#(EJB\+_6&!*1TAWE2-9-2,"<L5:Z
MM)ZXF7)\[1#'.TDU+K!UP&H^T*Y7@[`N<K(IJ4>QB-:_#H#0N9LVL3-R-$HF
MT"L^UY4>GA6>T<H.S?:I=MQR!U6>(*+</U5+OQED&&FW=1`Y%;0[.(X>1^JZ
MVUA7B]7TBC0GL`.NE-3C%3H(IWU&DFGA>3*2L37ORO?N_,!/?<JS!,0ULH<H
MV+!(@F]XID^V.XWF_*#\D@7BJLP52,4F>9&82&I<EVOZQ,HO%TKBKW.P*!9_
M73#.IV?SJ_EJ/EN2Z?4%6:X6YW_YL+BZF-U^O207L\OY^7QV??X+&N]NJZU:
MKV_,#-`F=;P)I.,$'35H4>JT$?7%("M4.9("$:XK0G9HLGM"!:N"[[)0NVX9
M12L:-F-;B^LHI<F-]\33&F^I.**^\6(QLL!+$G_KTXUERI052Z@XQ@YW+86!
M4Y.,G+S*&!#.X>F8C4AN>'6I^BD_0"33'2W9YV!)G*'=<[0H@I@^/J8"WX3D
MI^;[H;ZF]1Y+-[ARZ5>18%(28301FX-UT@9M-OS,+;'B=6$1$^:'"?+NAFD$
MIJ:'BKLTB*H")BO^'`^Z9#L$018Z"&W/X79%L7KP$T(#42>$6;4]&R/EEU,J
MYW?RKA3(F[B6PF\08BF)H:Y+9=;&\7Y4E1KZ0E0-C?(&5-82YW4G<QBGL(#%
MYQOXAS_,Q,OH7E.%%%A!*N[8[=#;C"?TWH4A\G;5*@9M/K]?B/$>5%>TA@L/
M\+T!&WDV.],P80B@M?&!;NH[&!:>3<4`T+DI,36()6];W'1#Y^*LP4!>/;05
M$C,'IZ`&TI9YN(YV=.5]Z>+85(P0>#,E1I7`^:(Q27GKW,!C-.CZCV=JQ15<
MX`^&'(ZEP8VUD6%K./!!89R-!E^^85H@0;#UV"\`#"?!-HX%@4<I#,'H0IOI
M<1;0[3;38S*CVV&EF`S%?;=^X47A/5G1>`>M4EUDRNV4%,'U./71@7V:L1DO
M?$>CVK3>THE2P][$@&G*_9X9&J"L[TD\EW,SR]QF(T:C^T!F"+D=+`[.VO4U
M\@#W>,W(6H3PP@LWL9^2%]_U7_ZSDX,S1Y/;C:1\$$V./@]14K43K%>FP.`=
MN$:[S/QV$P,4<;+#>A>#0U9A,8Q_4;A;4PQR[6@4ZL(N?PU1O,(0L-L(N=TR
M&#(*.(VBP[H7@<\OX=#H-"[?KAUU)O]0NCODR.']<UWN;9?3`"];=;T9A?$N
ME-5M&?2WG>S0G.[Z++\FL__\-%_]0E[(.S^KEZ-?0^@54.GR$IXJ4QWO*R&Z
MH51X=.]G+SA8K]WK]-`^O`%1[7Y+\3E,T0B5/S='(+)'_Q=/PB&/O"5Y\\V;
M-V_>3LC;-V\F;^3_2"+?C?0.Z4,4^_^DFPEY-_GAN^\FW[Y[0_PDX8?`_%YD
M='IND7@IN:!KNKNC,?F.\>/2(QK]6&5KSN`[=.Y;)?Q&/KQ&/'I"PV8CWACT
M@AO/W\S#<V_OLX#)./E'10Z6^J/$4TM=.+8DO"F9AR1KC,!W.\'@);E?^2%9
M#P3#*7MI`"!P64QZ9='G,"EH`3*8\M*UHF(+LT#[F#[0,/$?J4QJN8H27D=N
ML5UY7QSRFNS80WMZ^_EHR($Z%@.617!*/(AD0EYP-B]%;4(2;0GCA2I>Z#X/
M$ONZA%WFA8FBR>@<MZ,FF":)6?$>VPK<TM3S0[J9>7'((JVD,%Y>-G3=^"I6
MHTTTX005#!BAK(IQ3D1R*O*BJ.$98?\'<_9!@A.\!BS]07DGH83TGO-'`08L
M6#!7,6W<8,`&?O//-DIHX@`="#2BTFWZ?9WO^DW3-/;O#JDXO$\C?B",[<Z.
M$3BY55YH^G62:14-U_T7!G#?\7=#<_I@+P8SX@8/DW9'=D;O_9`;`Y*]OSK^
M,Z4]@&@>.GA4J#9N1H%?`SFV&G8.21,*/@CR)U0('6K5H=@O<8`F2U7JB[?)
M`QU<"1?&^*HGN+4/^+7:HF/(QM!J8:>:=)`G/2S*6<3,T[%`5&Q=W]!8%$7L
M</BC9@D=')KAUAT137A82**82%)Y8D08L2PEB:"<2B]8$XGU>)B$*@H>%!EX
MY&*AF[9G4TI^@/9'#""9'@\D3<,:+0NHB$:/2V]7)`$Y42#8FG+"DVE8[:@9
M16`V*"*P*,5`G[0!BHX>W#;,159!AWBDS`91#%+!9V(?)D0VQ^J0S2"5%<IO
M1(3)$3<)HJWS+?$`5ZK%*3_'V>.6>*!QN65D9CI5H,'II8Q`E;4J4F/"XZ<:
MQ-#.4149C*U4\@!8Q-.[#K?]E6R@/94:7_T\)6O#4R(6>QJ+TID)SF+NYK"R
ME(\3.J05"P9!!.Y_6]3+R/^J>(Q^UNH%-+FECS0\T/=1M%$\W=N<8-Y("W:Y
MHAE)S2)X\M*P:#<AHN4PC_$ZW*@P@\`SO$13-.Y3)T7Z2P9-A./'H$FZV(KN
MEU'@L*"KD$.[QSJ>>ER6"(\HVA#>")7;@`5@EF0T.`!P-Z=0"\/E99EV;)5^
M'T=)<A-'6_-$PQ()E!,KC[LJ-.*O1/X9Q7+09+BE]&0$)\0F8^9C1>-<&V19
MZU.+[<?6NVR)%=[/L@JQKFM/#2-H]ZK#6,M9S]N2O#'6I5HW5/A>WFJ51",_
MIN8RND>C(1M*,`TWT\W.#WT^C-1_I-G`C+U<&QLPS]>*KV:J)87(UBG3Y&*)
M8$GG`&MV/;OE;P-?7Y#IQ<?Y]7RYNIVNYC_/R.R_;F;7RUG_#P8[^?Y.'\PK
M?S!T!<4-U4WOB%MXC&U"+OB+/FM?;(&RGP/*?^"CV_&7RO[9^*I0FYDUXPGM
ML@V15P6V2#8A1T)I<0JDJ!QY#UA;`8)[=QM1-G+T1@P[O_!V'H7)(2C&$VU^
M6TDVMI]6C[^^M9$W.H:'H`[+:>0JA]1YY&UON/4W=)`'VLR$5^,\533@*]G.
M*UAX-]B$J7UMA\J[F4"0"?TU((@NF/6(`MP5*Q7%;8$-I^BG:_.FB^E&4J@%
M=#,.M7H/NR_KLJ(T0\!_3;AL%O(Y$&PK]S=XL#6O1A.TZ]PFNO%?6PBC\C`R
M@^*Z`6W`$-J=FV"N%QD_T1Q-0$;V$NO>M`M062VFBA"=]S266R-OVLYM_%3$
ME#)Q22VWJ6MD4%ZU/OYZYIIL,5B8Z>)*+8;]@BITPWW@'<JT]#%P,`>J$':M
M\ZS2=-YC>N_YX2*\9(#\1QK2)%EL+^B=L?_3\X!R>2W(:B<-K"59A*30EBRV
MA+=&D._K`B8*R;8`)MJ2S1!@VG:G!L8#LF7EH`8&+EG+8&POS$9`_?M0OD&X
M?EK%7IBP:(!]8SY"'K#?4B^PN>5JPQ'*=UNAKDII1DQR:E(@)T*$\X*+.1,4
MCK\39@DKX+"X@JYSZ.F)"Y[5JKU,:_VP!;OQSVUC_U&<'$M[<OJW_6FMFA/T
M:E:+LGY:F?]Q0G)_<OH=JL6K%:X<R^;8B`19C1:0QP*=I<GJZ%7)!FJU*M?.
M8@O!=L5:(H5>M99Q*%=2\ZR*KFB((&G*<OBBK+_8[I'E@-&X*(TX&:T)BW1H
M-E1[VTB%=SDZC%8;IP@6E2Z8LB-&HYU2P-/2H2"!.]!6'>NVZ0MT[YS'RI=L
M`LZCD`WIP$9U.NLZHVS5GQ4H7WE?:#+[PA874;SQ0R]^FJ=T)UX(9)1L<@,!
M2)I"<S<\X!#@W/F0\ZJXBBV7M_*P\M1E\1+]G>@T5S/1[824.B:B9_FVZ*EO
MDG>.(M08<VK%\>]9?=I0;!V,.Q4OKA;+Y4MR-KM<W,[8?ZYGE_,5N;Q=?"3S
MZ_/%QQE93?]K@%1W^Y/]WYN(=#J=>08B`ACN#^[^6I8-P_4/$TJP,6:QS!D-
M:?-E7H-2'0ULH)<>:GP*=\R:YB?,Y$76>O2TK><(R7W=T040JG($YD!0&5DW
MS;98.:EXC+[70E/[Y-,*$=3:I#KVIF(UY17%2,^9V*\%VJ"\X%CPI,N:S'Q3
M(0.`$!ILJ!L_60=1<HCI^X._X0^"#";7*`)T=Q$&BYH;C9\VSBU3C&VL\X>R
M\AKE9U[BKZ?AYL(/#JE].>!6=M"1:CO>JI`='[8[OCY`!)$XJ,G($.V8VP,\
MFR[GY^*"_L7\ZM-J=D'X2I7<S&[)\L/T=H8J+!\>'G@L:*B21C%A&Z^QS<U?
MJ7__P#J>,AGP[NGU@;]6OMB*L15JS+9;H4;CZ\H=*MITGHVJC.>,2,:)2%8\
M2S1[[Z#`;@)MOP:>B]G\_0>NYM.?9[?3]S-R_>GC&5/VQ25A"\"/BVNI]DNR
M^+1:KIA=F%^_?T5J5@)%4-R_@'B9@(120*(M?X)85+66<G)(6",_)'="1&CN
M^_:L;3+,RSO6X??XD\(U91^E;%WG>P'9<(8\EZG<J%`(_#B+QZ8C3.2&+?9#
M\6BZ[>(`OY2!A?/=_)4V[G=DW?E&1:7?"G^^"+%]F\R:+>B]"RO\K8Y6NM+I
MR96*]2BJE\IZ0%UUJ:,O&=QO<G0"OGJ@Q-M%!UEQ/Z1IEI/'7Z8+Q.5G]D/*
M&LDG8(4!H][Z05HQ;N'\D"ORFMF\SP\T))^K%O+N&(IM,OD1?(^6D/#_\1X2
M;W<<"V\>TWT4"T[,/Y&$68J`9]>&K->4[GC6+:?:>FO*ARY^]D,V$N[!DKQ0
M.TQ5E7Z,B,$JR);G^$^#9]]AL95;0&Q<Y]%N'U,F*PF+&[+?JB]]-]<OMV4+
M5N3>&G^M_OUJNII]G%VOECR^7ZP^,`O$HOR;V]F'V?625QD4A@GV^85^/I)!
M2&'+<_3B)#R1L6%`XI"_X<9*(,S]=//W0Y)R6"OOB^V&9"]=0F]:]C-OS34%
M2FS+9P`3TGQM3+(G)_X3?E:,(-(9=K[D(\(%V,+[:Z?H%[:T(;-PP]ST!5U3
ML1CZ[NV$</U`M:TZS(PUS8EXG82'),.D"NZCQ.<K;D2S\*)]&OH_@LWGX6=T
M0C'N=/20;X)G&L"/)GITX&;UU'KH#^`-R.IPV4==;)N#%]7[?6H6@"]`:G`U
MO)6H#BM.0C[!FS]CA_=%4S2%Y9&0H:!`/G#9IF-M[ULJZ0$W`<2#FP]1L&'"
M*J--UWIOADRA%S:FV+4/818IOR99E([R2<QG";?+L@(",'B09*701F&0&4<P
MP[7BOMMZ<S*C`M][S$>OEL%?19.1#0G60;ND,70?-OPV;4G(S79A)0F86DKS
MP$.=*.1G/=,OOG79]Q9F:.('!5:UG&5NY$3!/`JC01DMV(*;C(>NE^!@.'QX
M8@&=,MK%`(V<1D\;+P_B(MIY?M-K2XTV54$,%0FHL"CV_X\-R:^R*8;``!\&
MESBA=Q1@88-6/[310S,EP";F+@K%8N.C.+:R#1P:&$`'"TV8&K8M>9JB:$1^
ME<TPQ02V&%`Y_-X^`+A;5ZJ'X7/B5>JQU7NZV8A,82^X\?S-/#SW]G[J!4I5
M;[1Q+4R@W'D;MJK$G=H33D#F(<E(@`Q`WZCVC."5'Y*U)$'AZ?O[2&A<OI%.
M:5V_GL/8-N*6IBSRH)O\"IE;'*#B`AT,*-%5)2]O2([W0!&&!<9H+NC67_LI
MF:[7A]TAX#D1Y.(0\SLK/$7X@C[2(-J+'1*VX+S'57O8&&41W?&SO<BPX\NJ
MT&N:44BA8($EP=,NL&CC`O8F71LZZPQ+3!%&K^@"5.D"9F*I?Q5.SP)LD_^*
M:;VH=.:\LU_@`.V4&U%ISHIX,UF4$Y,SQH2BE_WY[CC`7:Q:7^PVWT_DHVN\
MN#E;N!AJ?.!>)P0[<V_`4!,HT692+%B`P#F:CYQGK.Q%#N/QSK/8RXH&Q.-T
M)F^`Z(S>^R&/)\F9%_!;C.2%G]_A'B!E7=RA9*H6I\,CF62%,09",0OM*ET9
M8="/'"Y%0F69]%D2-:K.-]O%CNH\20YT(]>T-U*B1$\_>\&!GD<ATY7$C\+%
M]BP*-S?>$\_1N*5BK7C#).^)7PT]/MERE;]68QI=#3\.T+OSP\YP/;;@AE-V
ME^]2R`[SJC:B2W+JDQ>\X;V2K%N2]4M$Q_*:_NDMHBO56T0`P2/`])Z72G+X
M<IH/>_Y4VFE"F3>[XQ.ZEQV]BK,)W8L)%??6&QYW(EY*WGWSYLWI'COSZ,<;
M<$QSOYO(;X>H4`"$;&>3OI&RG141R#[(HY!M]:<@9I^B=L._^Q2;%)K!,L\#
M"OE$?B(T:YVQ?&![R84A!S%LE-!G@%`*E@;M>NSUW+#S:!\&/+,``'`N@7W^
M0&NN-J</+KPZ/]_9PR.H)/?_A'C\Y?<(SJQQ`3]DOYV=>Y9:)88AAS</6??R
M[M1UE-(D&XR(0JQ6];:L01?JUO.@RL.3.I8YWWE(,B;<SPHV1T<[S'+.<2'=
M%_RRB?%#;DWR:XFA@)^;ZE=58YV2'[_Y_MOQ%\`N)SXXY@S?ED#G*;&=$;&@
M1%:3S\VDMB\2+?F.YQJ,EG(6W$!69S9HN]I^Z-53#U@'-?0#K7IL3OUZF"<>
MTZ5B<M*H7,X9P7IN3!$`VE%%)O>XUD'6QEV]M#%G-?)J91$.N6`1W)_1FD7.
M1C_+%L*8/<^EBW86VI3[O^WB99!9FSSOU4NG.:FL8$@4/N]53,'4]KV0X:S'
M<QS-/J.#_QS+373PRSUYAM%]PE"0AW0#SVYI,\A,/:<%4#]V'L2Z=S5;O47^
MO=APT<_LR_J!?0<ZO8^I2#"OC^$RBJ?K?QS\1"P0BZ<M]F<8O?4)FX78V\PU
MIG"3G#4Y\B:-WH/Q)X4.*KD)J`Y$AINR5<1LX3J*-^("*?M17EKV_RDKX//Z
MC8>[Q-_X7OS$+0K3\9"NQ=\^^^F#H+JD=_&!__WMM[(V/E%^B,\/-*:,S847
M7L1^2LY\II?K!_)I.>67S[XA+[Z2%82_>IF;L1\G;]Z\X?^K/$*61L3C6/DC
M.^3MFS?_RK>V&/>$O_)3ZV#Z>LEXG[`P_JHQ3,@+-H\[&@=/Y.:0AMZ.?/"#
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MZ[W>YFE`-X)CL3?83/UN'<A`W\U^'3*\D'=W'9(.R2E5O]93O0;IJ1]P;^&4
M[=9?I\]_'=)\QMOW4@13UMR`TZ9V*&_U+N3;WGS(#[_;!02<I/X.EA%666J]
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M.8`?FG:TKJ-'N:'%;W?VXVZ^???M1&QJ_9Z7*"U2W/,J!>$%^X&,Z[B+%4R[
M8X*LW[,.BSZ?_9IE-+<B<^>?S8E(E]G#Y4Y^EZN2T?S(\1L]K^,3:[,YSNID
MS(-Q43:9W@3>6MPQ&>7N1GN?SV`]8C)SW4XJ90?DV,/S/T%QF3--"F[C'4=^
M'S4O*_/=VT8_L<]F=G^<69V'R.]2#E"I<>ATJ2XB:N(<ZA/Y>SD$,;:+O>5*
MM7:(P"/T?_/"H#/$BP>CN1K4"3RG4PZGV4)C_I_=$J&;</9A_I_A:86Y]>N<
M5=7>4V>+/UTST3J(VG(S+^8OUB:WT4'UX+/:9VKY@,;J>H15Z2ZT)GESDK?'
M$DK;01IL].[!J?LWH?DWB;/VR&)'`WUJCP=U3'JHY>KX6A(S/,+J&`5W/?0"
M5/6U^^PTOV70X;E`'LK).`XZC!MX>MP>I#O%8P@B+^0SA"34ZLT(Z:JK=NVB
MLZDMUG`M]JNQI&K/TLX,-,PRP%H5ZW+]Z[(I',[B.=?\=T;8K*MP1FM\B,B"
M-%.];(_46CD-;D-,3^R-^("$7&8(G8P'AF/R+O!:U(J?IB((>09&B"1DL5!$
M=5!BPF2@BKF%,H"LMS7_PO=]5'-7\$58L5TU`\:E;HL5;4\<L.P*]0&ZH21G
ML?+F?CC0?1<5'P@WLDC&0=5=2W\W,QW(6&4;XJ*$Z2J2Q8O/H]W>"Y^,HAT'
MKH@*=NO1&YNK_,Q05M%=141R(ADKZ,"H/^P-VIL?24GL:9276%X/A+VO\LKC
M?'HD(96S[MO61=:Q'"AIHH>L.)1);C;I"E@B(WLDU;-M1.%._Y\%8[95U^2I
MH=2ZVP4);%<=;"\M(-A.<0)22U7!L7$RV$?!E#_3(3=^P"SWOC+7\6:CVV>8
M/X-T<?N<Y.=Q"=01%[+="`-5<_7G@R8X:V[8FUJY42_*F]I/I_ON0-?6^\34
MK"RHG7ZW3X5D/6^F7;91P!`WI<O7Z\ZC)'6,!9H8(0D&&C'JA*MZ*9:3X`L'
M[&!%=5CK(6#U$1!8(ZO>N.7(T(8$:I6SB0D:N'0V"V6>PMQ8Y;IJZ4'"`3VB
MJDA5%42Z%30YITY@HM+-?E09HH-^'!C';Z!!:J^O(^ZLVT5+<4WMO'R-%M2Q
MUY%41:7DN/DS/UB<=_O0LS>)(J0^VF+N13'#D&+SPPH]:'>]5<*!EN"KSU&'
MU;>@1K3PEFC,%W*L/;27=0)26VBG`P#I:XGM@`7UNKJ@,K9+:D[:/6RN7$]M
M"YS5QJF%$ZC;;4-9B]=JU_%!P^G^@57NQ*.\QS`X-EAG;J1Y[:Y=SV88^V"V
MH&ZFA%E**U`8ZCT";VB+H*($2'R@5IHTB\M&,G/9SH`($%LON1-(#LFK>\_;
MO^8R_YH&:9+_1FC!JS=O7V5ZD/WZ;TOVN43WS`U[R<-E$'U.IG=)&GMKXR6I
M&2\H7VF(M);`F#<7;[`R`B(HR*\YS?]%X"Z?#S:7NXVCH0/SF39:J/6:1HS&
MMBUL4<X'<1-'C_Z&;LZ>/B5T,P\7+'9A/B*\GZY3_]%/?:JS."5[VX7SV#ZZ
MTRPT[4()4<[9D+,GPAGQNEM'5N3$"\Q.#3<'Y]/E!W)YM?CKDES>+CZ2Q<WL
M=KJ:7[\GT_/5_.?Y:CY;_FELPS4@W)/EXE:D\2O7X(X>`777]<8(J0/;L:W<
M=//W0Y)RFYNLHEO*)\\/*!OX/%Q'.WH5)>SWW>V@UG\,,P;HB&V@F:T5<3IU
MP^^C'#OBYQ1$=D5X7_R/:&QPEW@*8%Y360E1SBM_:^E%P'IYR7_/_[7FT[K/
MI_7%@?7VDMP]D4AV&(4PE@Y`YRQBO4$&,+;UO*![)AB^^,C3<#/=17'J_[-Q
M"T'E>K0LH*(^/:ZJJA1;3PC[5T#%[5Y>-:E(.B'74<CT9',0I1@11';N.`4X
MK]`>32QC()/:H$5'/[9^O??\<!%S6[`(EUY`%]LE?^)N'BX/=XF_\;VXZ=JR
MUO`9L82.'<QP5^634Y$75\(U\6*\?K*/LHOVT98(#KR6[(D'HCT@-\0O.-G+
MUR*^X0>,C%"\@S@`PG<284CO>7$1S!C!8PL+K34*%4SXC;YN6J]CX>466Z9G
MZ^@0&F__-))">?IF'`V58F4K+GEY.P3^VV'TFZP=UZ5BQ4<T_ELC65J_W40'
MX:^+>GJJ`FE\;]^(%0;_K,;9XI>7F04O$"%SQ.;0*LZIJ<@N.A?LC*ZI`BQ*
MY]NB@L9.5\5G;+,R#YEI\Q)Z0>5_"YL`Y][>3[W`]@C&AB.4:[9"74N_RXC)
MBYS\I7B!_+C1E['`==+2"?*YJ$TCGLOPDH2FB5BCYYJ*ZKS!7J"UKM^"';SJ
MLCB%QR;)+5U39E%8Z&4;&ICQA(X1#)$;*FY.2T[$B((&1ZPO<KJ7S+=FL)NQ
MD@NFR[&?DD_+*:J`HE_DGJ3EIPT9[01=@&&CT4:1AA'#[M<C:KW<Q'3O^9O9
MEST-$RIJUHO],L-7UFSXP5RAL$*LM$,Y.3\GS!B0C$/VL(;D`7[1HA/<DT)>
M%/2Q@C=Y/1A8A\L8G?"N^)-N1U>S.;J:[!DQ_N(;X\:W_D^/BK$)X;_W=G+_
M9$NB0YJDGG@_A^RBD#X1,5O<D&T>Q>6/;123^RC:)/Q%MX3&C_Z:)MES&G)L
MC*67DCO1*S\%C';^FMS1D&[Y'SG]]I`>8IH-HOZFV=#F?SA)*YG^?29J-!,U
M\C^]W?Y_':<)/'1U-:*:*S06S/"$K5F1\?YBUB-#O`'K";-MM'K3O+D*FD#2
M#>>FB-/+<0)N(G<5NUXBM9P;.CTM/`;@M[^?Z\P6SQY1&WY'#9Z4G@+Q!]BR
M=DE5[1.^5K')J_)+&N#NN*,"6&XGZ7FB4/KXP$*XTUY?+_ZYQA.EBZXC-]=Q
M3DL*Q-CWE&RP5A5:8,W#Z^?AJ15"[>ZLJPR?<[JY<;Y%KWV")6KT.W,MZ<Z-
M:>39$79:322_>R(O1":Y'[YL3"7OWZI$J1=810H#3]^*#X@4.D$3(`RA<?H\
ME#X[Q'OISS;`L.$,'698S4+GRWZH-@>Z09^MB+CG]VDYNR#SZ\9+?N,:PQ&^
ML[#]XL*+R=<%#[3L5=PHW+)@B\2HS<-'F@QRDUG+&=E-9OTL6!FW(ZOG=I/9
M;@ZJ-YGGUS_/EL_I)K,EW,I-YJ:OC">SR%W776XRZ]B.;>78V-:4;I)+-D$7
MOA@7/S=<;.<A4Q3VS\)]`3[.<#/=;MDZV$OM@[EN?4&'=QUGJE[?2+*3ZE%@
MR(^(<Y:EBT=^=@9\8HMHWVF8V9&3\PPN[_2A1D8!4Z>.NC__+M:CE0TR;N(^
MT(`9MEG"9O*S42*0(2>8)^`-43:%.8T)0,(9<F+^#TD.G??3!>,Q`>.%'Q8V
MB\6%_@>.DOV##H/2X3GX#D"/J3[%E),23$F.I"B=E79J7H4W8C-ZH.(]9;MC
MXNGGF(TI9=_+OPOH5.2M6T<C[0S!0PX#S#7/F='P#>>,BIS(B*3#%#BX8&3#
M>^#J*$.EH;#UD.C<%9U_0N<UHH./?$SUTBR\:>6&=QNH_^V?Y[#MT\=VSS/;
M]FC=PS[[I7%[!\&!7C_?57S+NR>C;_D,]G1ZWLO!8J(N_=`+U[W4FG/I`3IX
M<IH5*U-V9(5AYWKXN:ANZ3;!'WT'>P38E8W[R_GU]/J\9>,>/"QSMPE=SNUT
M["%WMJ^CE&KN(#3Z#S4]5%"F0:3<7>9MB6@,=:N@-RC"Z(0""O;\XC;9TT8:
M2F)(#3J^W!/+PA8SMCI+K<O(F7"$CAN,4.N%]/2*4WRL6R-)4;G''I`FHCP>
M/Z!!N#-A++[6)R\*=E![HGEIMVQ4_'$\X]T(/0\P5Z='IMST/%9L/*J@($&0
M1.*&2!Q["D"EQRA'W^0$@`3GO`VT2N_`=0P@G7CA!M+3!;VSW@;0\\+DN!N0
MZAU9\9[>$^$DB);OMLB.UC#$%R]W$#!'9UUCA'=_KN,10B-'9$<(S:@[[[LA
M\/#=`.<'"#>WBY_G%_(0H6FK"<7R_9E"[>V\Q%6(CW>^[IY>&HDQMM,3C<UR
M.3UI8C>V=9ZQ*'2=LC7<E[4HA7C+G,5"Y+M,PPW_#U_</;)E7FB?8V+'&SJ`
MLIR)JKA+<K'7D3$@G`./0H06\-Q5\4.!#:(@JR-Z6?66!%G5V_-#'--P_416
ML1<F`=AC%SV*IT7X9<5X;(5O'L:-*)1537PS#<CL>$*%9);(&P\`F[1X0B0/
MTE`R`46\TA$XCUCFU^>WL^ERQB\H\N@%07#2%54Q7;E<X\+87H/%)RY*K(U0
MK!A"F*S"J*8LF(KC)Q8WJ5XQUYK]-F[0<4@KVD;#5+)''H^\)=%`+Y_+PHK+
MU(M3IW###6233G*P9_3>#T..EH5?4F@'0CP+W3)A^\7+1J%&"AY7F:FK4235
MPFKTI^,/^WT@'IOV@ORQZ7FXC>*=?/G,\B:T,3NHB,D<;^U%\@+EZ45R4B`&
M?"IT2*S\&1VV"CJP89<>8R]"QW/SUU*@M2&$*:_.U_#$5HKG;RY$V6%I!)/+
M*+9-[S1D!A4/F&)M]!R<ADBBS$TDA)'ARL_LA%`4/BY4GGZB7LQ+/X]^Z6ZT
MCP=RSZZ+YA@X>C-.XQ>+E+>)^:!,G7F9!JZV:VGD]4*'V<UZ_G<4;M=PP&@\
M9I-HM!1&+1``5#V-=G3E?>%IE(VRW%9?LDP.O3:NXVDHY<G+#HHF(%+>X_C1
MV/L6<3(M+5JBA=A$XB'I-<//?CS=7`HW#>=PIS#>=E'7O1_(_?&.,Z2\-".>
M<1>U`TZWYOCN1N,EHA-K7)6P!I@@Q=J1+QU9+Z_.S68,C7?L2\E:]ZH[==)Y
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MH9O%U?R\(9L>[LC52H;U)ZYFK`#NW.UIG#[=!'Q@X88G<.QY>.'J5PP80KL7
M$\P-5_`$C=C6.1+@.J(=%1^XQS267--;>"W<T&CF:9/,VHO:\00L'F.#7"7*
M$R(85"2ZN%\]I&MUN';?$?8M?XQF]0N97E^0V7]^FM]\G%VOT+A2%W%NJSUC
MSG!LY7T?19O/?A"P<57+@AJ=5FDMGR5S:'=K.Q=5P;Z@6S_T4[Z#M&TH$(S9
M1SF)@9&_LN,,D).C&)*URS)B!9C!8X"S(4^F(L)XG9(;PHO9Y?QZOIJ1J_DE
MOX:TFEZ_GY]=S<ATN9RM\*SO+.2T+6^HE<_HI1P*]=B<BZDV\H!V*`IDM4MC
MQ5*"Y%6E;@IBKZ'[<F8E+YL8=']1I<#5P:";\8!Y1:45F5ZV\)EO5UB+U6Q)
M;J:_3+FQ9BHSNYJN9A?L-VQA@>`DR_5#Y46%4OYQ[GA3),=5ACJE>0&EA<'8
M7H=7+>J^PE%Q@?8\2G2UD],H?&2+4Q'C%1-IGI,;TG]*(T>D8`$KE-9+$"4Y
MU+)#C:>^=KX;;\O+Y33)',KYXOKGV>U*+"/.%M<7IFX*;''1(G7:!86*=GS-
MR7,>YB%37N&N^4M]'^CFWCX'N\7<=.@*WC%TF:>ZUM:RII"G+_0@)X8.Q;V?
M9Z`[#JZI2Q]P_JO3S&C4I<!/G/MD'%47%O!YPWXG9G8[_WFZFO_,-^*F9_.K
MQEJ%@`ZRNX*T>-$.'8QM+JYXN1[G=+XJ-;1#K*&IRJ9L@-FG-7\0(S=5(1U;
ME!9[&GL\OTB.8[&]HDD2Q1W\C`U'**]BA;HJCD=BD@EFM"62'N'N7B^(KWB)
M.#S.P%YFM:;?@AW8/>_N:R8M*V@7H,>IO0L.5VYH$$1FEV3!'9Z!8-K='D>P
M"&L8BT,*@HX'7.Z!%IFA-.)R:,Z8D#S,:SO^Z_/%QQE93?\+D2,VT9B69`@-
M@\ZGT%=1PDN=+A\\>[>I80!Z;5N!J1:Q\8+=K!T1#8=TDNZ7EPVAA&S9[05D
M?[@+_/7Q=26_^=<"-XOG2,*Y(KO&K)/']JO+C=2C/RO@Q;P>ZW$@U@Y2PP#*
M.^HPU5X#R-H6=0N77[1!<[58+LG-[)8L/TQO9VC<2JN0:7V*FGKT:XW\G;2'
M*-BPCRC?4N0I&*X+N#9NT&NX5K2U2WX%@J^SET3%H[Z8%SYFW]1H[=/""H>T
M=E@+63`$NXIK@=E<?#$?&W5"O%J<_^7#XNIB=KO\6MP;0I1"82V^^BNXQMQ&
MKW<7[79^FA]/G4?B<C`-U[TD5E@RAW8YMG-13[T[TLN:_$4.F+V0DQ"85>:W
MXHQ2^*T=E2U7L$*.MNCMY!WO7E]WX(N/'^<K?LEU*>Z\GB]$%8G9-:H2$F[2
MK:^I:,=R]+PG7H.-C^E`-]DQ7!3RD;(_[*/$"]['T6'OG.E@S1[:H=G/1RV/
M1S3T6U[B`'=@CA_>+/'/DC>`T!>&,0_7P6'#M+)YV%T2_CKW`Y;TUWV&FO7"
M"XCD.2%'KJ3(EISX3A`[Q"$F:+Z\62SGJ_GB&HU#[$M3])E_73L9VWX47WY?
M\7=8F1$3%L[12[;S@W:+!HBKXER^.E4DPNP633^MD1]L989%<#OX."N64.[,
M#K>%)&/>:.P(NGA-BZQNI]?+Z3GW37A6:P[2K/5#-OS&?R#Q+J'_.+!EY.Q1
MK"5=S["4?*!=C`9AO8ILWI3(MI@]2MN7,SNI4C&!ED/[,RDU`[C'.-68#$0/
MU\+$"LRGL^7L/S_-KE=D]C.F^G.M4M;R7J:*>FQM.?,2/UEL*S5DG^3_ZU1'
M:U%,N4);=&/T5;D4A/Q2QXET(HLL/Y%?L_^":=U`D`^)'])$G@H<\=^PT>>9
M?>@<FYUP&[DY0Y9CJ_%E%%/_/CP_Q#$-U^6E7+@1_PSD[D2[9C?:NPX=0#G-
M+G-2%?Z,%\F9E==87".*_-!8@N'GY1`*2O[2=SXUKTD^6^O\5^F)*1H/WEEE
MM![>G3O$XXC\W(_]AV>Q/'H!CT@Z!@"&3*']ORGVQK<-Q>DX_Z%`^DR"@-YQ
MHW/]5E)MEO5BQ!%-67='/V_.#UTY]W;QU99RQZ.Z0\$NXT7CB&U%V*V,.[2B
M5FOZ7HHBY%?^(]W(H=FZ6`.&T.[5!'-K->L)D62O!!T>+1T>.3JG:BS#AO>Z
MV[B-KJ.[O>?'W%HLXOS(?[&]BL)[,2HY3$?'ZL8;[#:XVTS41/K(ALC*)S*_
MAA=#8:RD1A_5'(MBCS4A#9.`QB=WT03];6X7QN,G(3S2\$!OZ3JZ#T6>Y))%
M^\EBNZ3QH[^FB7WZ3"M#:%]M@KF>=B!H2(%H0@29>#XS(X37Z#&`B^!:4*)S
MV\;B;)@RU,:M<U$&\4+N=+.AFY7WQ=+?&C``>12@!5-5PN23UZ*]*+("KD-]
M(T)0_K_C)]G++X+N$0`3[5&_`*"E'M\1)Y3-`]]WNV!F)XC$4G[V94_#A+HM
MFXU8PCMC$]QUKR2IA"LJT)&,$$^(/2;X\R@!V>OJ+H563KF='UBM--<5LY(>
MO$::P4+O6$L,C];UAPDFR+64$I/5J(H8NF92Q^/75G;0#JX=;WM5)3R*U3/4
M<F$V=+[+4%:-_%8;+[A'%ESW>74<X!](,-BB+#3&HV&]PD+CN]JES?`]`O`=
MTTO/C\7*\2/U^#64TXEK1T]FP1C:I]G,02V/CM$2N<%0H,:C?V,`C[;\I-<+
MU[QF9^&%#70.T%K8C5RA.=>QE?M30A?;69+Z.R]M//MH-&Y5*BCG5QM]5019
M`RY[QR9XM,X-SRDW_80)C<MKEB6MFZN0C/[P-?U<R/:/HY#]N!;:F?3BX>SY
M0SLZAQFIO:-+/Q>NSI`R$SP*./0TW-(UWZ)4S@0ZU^>J#&;OC-LR'S_9UH]B
MME3UHPW[<H&7)/[67XL#I^GF[X=$%-&ZH,DZ]O=-IU#J#$A;OG#)M]8ST"#S
M)3H\VCX68C3.V%6>6S)P+9FB29EW=N$F'*&=MA%JJX1Y\NM*O$&.TSL[X5T>
M=CLO?N++@7TQ:9Y")LUW%CT+%VS`;O1Z#NL'NCD$--H6$H1KN<.'E-><W45Q
MZO]3V)KL[%.(J'T)B%[[!*L:T>_,U90E8Y]MW!Q3]$E3"K_HA12[R;,2P,T(
M]-QMY=P%8N[\T]QYV=QMY=QYQ;FCLA\TD<002JJOH-%GAU`F;;%5%71J-5OZ
M@C[6_*&C$X<9T:F4KK(?YJ"ECVDXA3!AE-*$[+TG@9C',7$V+WO&UD>8J>RJ
M&&85JFR9PYF%CQXS7.(I<7DW8D7CW06]2[M%,^9\H2,6BQG0F8'=D0G_5\#8
M$*:;.[)AC,`-`?0$H(L=;,7>*#XP9@JG[!=T2^-8Y%O+L(6MNZY\[\X/Q*C[
M"@4LN\$3$=C.CTXA<EXB@5]R$XZQP`_<,(PU+:=`89//2LIF12P[R(O@Q.HE
MXCC!27DLPP6[/N`,R6R[I6N>#G1,:[UE80Z_J!6NV5C%`JAK!.'2!WPTX30S
M.CMR9$@*#V%SGJ3,=`QCXO3$6[]34P'-)LB7T\(-2K970;R4I`^4;.F&QEY`
MDI0Y9J833R1F'2*,1MS5R3`R<>@`SKB<1[M]%/*SV,7V.-YL.^6,AG3KMZ].
M#&VZ0U=XHA67>=)9FA,__J^"M<FW3U]D7%\BL#4CSE%Y7AK,S8N[?%ZXQI/L
MH0Z>8Q$=G^I`'-@XZYME<&/?#YP-^BOU[Q]2NIDR,?3NZ?5A=T?CQ5;<'&A?
M)[68>ROF\"&-W5SH+$S.B62LB.0E2C@(;N`KHM&F@HG__B#RL`)^!X?9"9)`
MW<'I4URMPA(;SFZV(*'K;^ZCQ]<;ZDLSP'ZH:C_[U=^NZ+T7S)C=3I^F7WSC
MJBN-I%`10C..VI4OWH+()N17W@C/,Q&:+Z'U-4UTP\J+[.@BVGE^:^Y=O?W8
M-KUAQ+5+CYE`R`8@(M$R:1K+4FL\>J(7,UAAR@,<+WSZ2+D9L\[L:F(!O=AH
MQE7+W1*M2-:,_"H;XC$K!E_)+&6I@;YS!:)L<Y1Y/?\^%/F+85JI^<]W_I@?
M/'B!YJ6C>G461\X@-8M<9T&UU;Q@$>6)4RGM/>-%,F::YY)&##6A)N%%Q@UD
MX[TWD=6XA@YL>RXN1F-^`X.%N::>0<\#RC6T(&LK975JC."HRPF+)[#P_9_]
M<%C:2HP-"P>DO)B##ACX;BV#GC7<\S>KZ&<:;J*X]>YJ*SF"TH$5/*VJS=J3
M540R"M#3)U<T!6W@:-*(7'BAGSU%,?M$'@?"UK6DH".X#`[*<H)-VF1:3+!$
MVUG+;^)H3>DFN61CYQ5(61QQN$O\C<]B"BMGKF<$ZM%;,#9<UQ'-"6\OBM&*
M:/-(@L6YN\(2!SF))_=JD^%@N9QRN0!;#@_%/63I^2,ABUY,K$=["*/E,OHY
MF1Q`&JU_NXG]-<UK:AD?A2GIP4Z[U(A4JB0:3XAHKJZA!G%<98EE+Q`@/(%J
MD3+](9.*N/N&'6<S^[)^8!-)I_<Q%74#SJ/=+@I%?_+XRBHP,.8)&B.8(Z_)
M&?\#R4G)D99(8JE+V1DPEM"A(]J$ZU44\RA;J!6A.7HOYX7(!;N#S;Y@(KY@
M4D'.L_!4Z)&Y:4NU;O?8I@P',DB2^P<:;,Z>SJ.0/YWLA_?BMP]1L&$Z(3-R
MO+!I#=.P-=N]%YB3A1YFQ]B<99K/^9*S)W+B3(JL^5(I8PZ_23+<_-15/K</
M#WQ^[IYXIEP^/TEQ?K+\F"'FQWZC!4*`BA.DG!_&&LG&36\62'.$T[F+@>QL
M*6GIW&,S%P2-PN7@?32\$0:"NIDP5H`L(W"19022(A_<D:$]_`8#&1X3(F78
MM!X2OO/FT^]E`OJ.EP>?@6<1,[=:1-?86<UXV$4]_]L\9/XEI.+V_E_]]&&Z
M_L?!3\2C9--PL]AN:9Q['K.SOYY[1!1;N\^:];:!^/L\)*=>".^&%/HAK".2
M]P2RQ3#^O*TB$M-U%&_$`MQ/D@-7%FY2WDZ^?_-F\N;-&W&@^;W\<9TMX67L
MZ8<\[,RG\S.?3L[%*TPIIXWR*7WD)V\;?N?N#S^<=A'Y*ZQ_^"-G+[I@!'_X
M5OX\86-+]HS]]A`$3Y.A/DE/"Z'^/LIY>9;91V&SMF73%(B,;#ZG/-P_!#+>
MSYXX1+L`ZEO+&SQA42Z;Q%(IDG*.42^..KH6VX62:W=CGRP5ML?.O;V?>H$<
M"']U+'ZDF\LHEJ6VYIE1,UUE=>@`.@G;94X4QB<[L\K8Y+L-.2-AC;+Z>3DO
M%(N.H6:">Z(3<E\!&3QOW5DIC++:[;F/;A2\Y.'R8GX^#_EK%9OICB?NFIXU
M*XBA#II56&IBRMI-"&])LJ9$MD5PP&R#@?EM.7IOF-&[E*3H<?Q@A^-:G=">
MC#=3PEVU5A<"YA=`;?V[.5]HMVXQ`R[%LO%=O[+]Y);E!5J8HJG]?O:T8GTK
M;ADKBN<;L()[I\$$IY4$3PBG!+R<[/X5#.RO"1\TPLI'I+SE[%@NOL`2V@:;
MX7827L"+U-V_BX4!-N'7>7N>A7='OJR/PI-]RLO6]8V8=B8@F^@&V&HU'+R[
M@K_G&]P%*N7]Z[%WN1V!'5_`$'KECP',?D^T=VP[089DR])4W=2[D*T<`#86
M]P<FP,=1N55I4+*!]F1J?$WES'C+XHH!Q&+TC8>VX@%WOBU2:+I?U\AC;(VZ
M%0<,%LN8`@'48J4XYEIE47'ZA&S149MD[=+BU!I$&-Q,:HD4VHR6<2A$!&MH
MW_`1C"Q*D6YLP?GHA_[NL#,+XQ5$4-:D.O:JN&1_!W5')O-G8%G*%*,+B?=%
M*R1:K:@00UN8*I::T,B_XXUA&C^&D9TI4Z+9X[KR0SI/Z:[[?FR!$[KMV")*
MR_,$3DH$+1X39OXUW39C3VS0R.FGA&X/P96_M3X4,V();1C-<%ONQ4I:PHD1
M+6[=H,Z2U-^)1]4.$E7`VI$73]2+$3Z<8B'&W?:9"_S0J.K[.$JZNY.,"SI7
MDJ.SU$5!AB!]Q1J7^#W)R<JP\#O$DBRZ.4/)8FSMFJ[7A]U!O)]X0?<Q7<MW
M2MC/`<VR58L/KBI';^LM^^L7VJ7V.(-5G2BP)D7>$W+D+A2ER']"*A9BHM<E
M0`\]X,Q=T23Y$U'-'SH_WK<6&CG[WCH=VV851VOJ_\LT4-Z^,O*JU.ID%,"'
M6XP6W0OF33*B]<LE@K$E6O/H><-SY]?T2[KZ3(-'^C$*TP?C*DA]]0;M<3O/
M5E62)<-7@B,YL<Q>%)V4_&O^4->$<,9$<B:2-2+?VOL<,<G]`9W?[$=OC+QE
MQZYP6Y1?J!>O/D>FSM21.937=9V+?LP$Y\?,1(3`H?<U$4SF?D3CZ3M)NC8D
M<./\##2==6^]O>W<S?.*%HKSTZ?^<Y:HKGGV-RU,+O_XS".#FE8,$!*<^L!O
M(2Z9*`X7#$CNSR<:R&:C1W/`.:*XI=G;9##1^^D9AP1%@>\Y)A"LGX'*L[;#
MQP2RE^<7$F2STZ<)8#3//"!03`H3R7>_@WB@J!`#A0.B"]RF8;IERTR-?>C!
M_E:Z>!YQ075>^K$,'N<*9Q]&F)?5`XVI@-G_?DB4>@%*:,\D$&K4]1ZCH3+_
MT3,=-G\_)"D_L+R,XN+HK%,7U(R@`QL=QEIR0>'/J`(15Q"09Y"N`F-S7*_D
M`E=6YI:*]($;+TZ?5K$7)IZH>)></97^HJ@QT_P@C1MSL#>-'.>B5I\QX\/K
MAV;MB2`@15X37J^^_&=%(1J04`'K9,"]KM1%4_1/+SEQ'OW&HM'8%/=;]=?P
M+#A#>V6K6:A=ARP+>./-65!W/3@Z</]M+\5F-T+-V4+JK;(R4?-=Z@9*L(OH
M32A:)%!Q[1C$G?8X?KB[]4I)TE^RKY-UKF_$5YW9N^3744IOO"?N$V^\A*ZC
MZ5Y=Y$C]-(,A1]!G9$Q1US>P'L6+FVOQ8`RC)!DID;2$$6.J:=()[`__JH"X
MQ'=%V%Z6VY\",6/760.OHW`>LD]+D_2,>KP"^E7DA5EORT,8^PF]]$,O7/M>
M\#Z.#OMYN+8H/M:)/TA=LFXS4A5CQHWD[$C&CW"&1\'.6)(C3R*8,JKU<,IL
M_4K$?XM9L:^'UO^T^/FTW&73$O!IV6?3DF33LCU.R[V8%C]<(ZFAUH-!49=7
MZ\*\!U-Y-,,?)7.'^$3-!#0DT6"K"VG!*W_,]1);V.$,Z*H%$&R0T2:#[7&%
MDD/WM\3\+UG`<L.0^$D2Q4^%WE;1=7"W\=/5Y^C_T#A:A)3_9\;5><_U-KD*
M;`*+'GN#>4.LQ]FJ;=;Z7X[KA!/W<CR]BHCL@2?"$\Z<L$[D#X5N)H1UA"@.
M&7+:?OS7VFSE?C=ELW5U=C%?$2;W;RH3='6.*23!.4-(HI/>;93F0:K>NAIH
MFX7%2W01)#3\$`4;%DKUN>&BX8UPZT4W$^:;,)P+$6Q(QF?8#1GG9VR[3T)U
M<^95,_CGM573J@^NFS9JQD-KMD4\9<@))%8R1>FDJUC*QKN"U.HBFA*<]M*J
M]JQF;)`<K%]IJBRZ''%>C5IKT>6T]$I3<5&9.J*MMHCQ,+U_E%@/U6L2W.4H
M_0JLON15%-ZO:+R[H'?&CRB6::`.S2LCKQ568G]^Q9S-CO`&*([)6T:\XFGA
MPFLE!;=5TAH$J>C]@P`[\F^2?>UA?XD`4E//#W'L4,NND06TOVS&I5?G"<E:
MDH]>>HC]U!__S?@^0-$D,4`"[@(UHF?D]9KH(=7G--6W=.\]B9>(^).1?KCV
M]UXP#PT*5[5:%(=.,+A2E[EI4]83SPDY<>5)TT>^Q`_!ZU2-,C=</%%Z0&>E
M,':9]CV@-A+J6E3&QM2\#TQ>VF)F>K(,,*6IQI@0E-7JNJB!=4!@W`%^8Z`H
M5]7=](Y;I:J[(==58>ID`@:I3C5P4-!2D@I/@;IN`M]?&`!7@,IZF(KZ4_U:
MU]'*4/5KLQ4%F+KH/T0YJE$F!65IND[:,$P<`%*CRGZ4%B5H')D_FS!`48.D
MDQ7`4G&FK\E`59.ND[3W&P2`E%^Q&&5;S:F^K.OXA:?ZLMIMI8A<S,#0M:>T
M9V)C30QLC::!!'>8R,"U6I,J8=\B`;0AE18TQ;,AW]8B?]$R51,H5]DT']%F
M+CH+39?+V;BN8;??049\K;J7P<-FX3I?C>[]$O3%;ZD_M;%]90(0<U<9<^TE
M*/9G,H626_OA_F4U)]/7L`GC;=^YS>J66G>_;NI^6TYS?Q#3I3C-)47W*TH(
M+K6UW=D:!C>VRU=]"*&I1QC@*E5_2^PT"^Y7K#-%737E]D2=%G([K`%)VS*7
M-P4L(F8QL8;;.C5":)%2%@-K7=HV<<&PX]*(SDS0`&MM.4VWY3Y!`XNQQ>]3
MR(+O0\P?J+U+S4)F+2F4/6O&496R8RLA91BB:;OQBYHZ:&)J`QG2VM\FNLYQ
M-I\B%C(X!-,52M"(N8JB41!X+(QM(Z/SP&%CV4;I:0]8RV2]R#"+?BUV,"H4
M(%L8U5$W?GJ^D$-@=OL9,,PN1J-TJ+<QRLW[D4V>X^1H84NTX#:VC*19`'@3
MQ.:JX6.8&:PB82]BP7-<+&U6D03,:)7&W2@#O`5"*U"?<+T9*+3OYX/[CU3]
MQ?5B6Z(%MP-E),TRP*M/X#4##=_"S`P4"7N1BJ7_Q=(*%"C`C$!QU(W?GU=A
MPV<":I.MMP"GYOU\:OJHJ4JC%]@2+;@!*"-I%@#>!+$%:/@89A:@2-B+6,S\
M^P?#S:1F&C`K4!YYHQB()@@M0<.DZVU!D:"7SW[M.^^[%$G!;4$)1Z,,\!:(
M+4']0Y@9@@)=/^M$JY)E%0JX/8PV1[`:LLR8?850HS&G-$12L[-1,%JV+\"J
M@)6VJ&T/Y2K$T&=Q52SZPQ$$&\KV`^?%]=&88ZT,&9T1EBD[F^3I>AT?Q#NR
MHN3^/,RJ[GGWK9=^VNE!S+4>4>TI4]GZ]%3%/"0G`NC=:#<LQ_<E_)#LA\-B
M[Y6ZP4'BJPPT1NVY=,3C9YEX89*5-7.NP=7``MJG->-JBH".5=V.);@0>3@;
M&/L<QKH9!KB_T\B:869,G7YL?5FD#S1>/D1QRN_RG$5Q''WVPWOC9#\U/52"
MC`915<Y$4R+:RI2L4VL$F3(60,ZCW=X+G\B=:)3%AR!5ZBR%1.-:6HG'5I7<
MO\WDV_`6FJ.U(L9LH5V0.?ZJ>![CT(QT0L;4O"[5(WK`3'/,=WES..WL1Q`M
M7)PIS[%U^2:.UI1NDDLV-?,D.7ALVA9;FQ++.@Y0KD^+JG;/+FM,N'B0O#F_
MR#W^KDAW--/-QN=+-B^0#P]&X4G?\#C"=K'3ND(-^=@*Q#N=ATD:B]5RKN:W
M7DIGVRU=IZ>G#IHW7;26R)(YM&.TG8O:)4*>HGUB,#GMVW`>$W+D`K:),RC\
M>;B.J9<4]WC4&SS@7M))\(U\I1UG:(67WZRR]6/J/`V90?E14ZPMBDR\RF8?
M`J?J"JVZ;XFBNE-?8(#M31<5,8@:S#AU/G0YCW:[*%RFT?JWV9?U`YMONKDX
M\+>.F=7RH\UB>QZ%["LG+$I3AMKJXWX7]J`)%D[ST;"QPY@0P84<V1#)ATA&
M9+$E)U;\7Q#OJ8PS$8F8"'J<B(V<B+V<"+9V61]9(;H>#S0#_%\;Q@S9-7IW
M0]&>W./`NZ_3YBMZ[P67E+9NG2N((,^5BV-7.4O1AO!&>`Y=3<8=B'%O62-<
M9ZTU>6D]8#U1]'-Y])`FJ1?R.ELL*.#G3YL;&GI!^F3EF-M8@6<Y:G$V7]L\
M49"<A&0TB-R*&[CH1(',,9@)I>$E534?V)5S5BKQZ8*MZ]V6RV4..-;(%52M
M.UQY>\()P,VR^9>R6&B5R/'(W`5-UK&_;S(V=EM?2J:XMF/5V.V$=$(*U&AW
M7\W1SKZD--PPO[;+46[:4"+;>VV1:H<]5Q5'R"0V4Q]1IH&KME4:N38_#<%N
MJ-%P]\W#!2P#5I>.EO)?!0)83W3IK>ET%QWLLS+5?'#YFQ+"5A?#6Q/9'*U/
MT2*2VRFISU\1OHO"33(AWC!PNJ3Q]`'HF%R'W"W65<S!$Q:80!\TGHY!EZEX
MF=WX+H<+1QS+J1;4M@D$DL60V0-]G-Y906Y0TT2B?`9G>>TB;76@IV$'J[R]
MK341KR\MUY1#+B+[\Y!Z4`VZMWDVJ\9^5HJ0J\/R2`H?XW2T=1/[:_K6S3]J
M&>)PCWK,K3I8()\43\X%!X2NT0YN33N)%VY(3`/A':LI21/^D^\%)&9_KAP?
ML[]$[-_RV/G!B^LG?T@\JH$.6#A4'3<TNGY&0[KUU^S+G<9X2?G^5<=L6],^
M<'EAXYFQ,PXG7D4[D7%#[+^=IZ-I]2L><RN8!68U_)TP)EO/CQ^]X(`]2]=.
M;QS"`<,.@&^L\>08MC1@0[OQ]N;ES]NX0,4$K>C:KZ&=:(@@0N'\W7%E5\W(
M-HI)^D"YL^=2F66"^<E:[&.Q?X81HE-7,RG5.O`6%E!Z=TO7U']4G.(8W<4K
M<H#VN(VHE+)X:H7*3QJ!:$MV!W=O:@&SNI59(!\_L(U9S_Q.RY7OW?F!>#S4
M?,':2`RW.&W&4H\U\W8D;]A_.IG;<M,:0*`"`+@DU$A4R_*OB;)SCN4MY0_=
M^.']1>9YDT5XQF)J4U_0P@0TKU*#K2HTQZ;DV)8L0L);H_`,[G@V1SSBMO$`
M>-QS0_L!A"Q!M$VCVE-#E1P@-G9."\1L_<BO8^5+RJ78<..WO.G&:B?7ABOD
M=JX5^L9MFQ.'X[:-*'IWVLR1;(CD@\35=D3.I76BW,X5>[V;!C<]R79P4MDX
MPKBA:Z\/K;NZ%BS1;.WRTBA)\:)2W_NZZ@Z@EY@N<V*WHRL8\>V0Y[J?:S$3
M#9NYA6W<YW-D:Z$;W?9NE=S'M@W",IWQFAB\LAL-$Q$`3N.87VCD@SY[.C6Y
M\9[XKZ:?O7ASZ?GQSWQ'?LJLVDY\W(1OBJV9X;OP'_T-#3>W%C=/1A@(5`PR
MQAQ7-5(P?'4GBIT4>R6%;LG=$RFVR[HFHF^>,>K'1'1/"OU/2#X"D@]!Y'ZA
MB'D@9OHX'9M\.IY\&FS$,3>:H&<T-=?&2<./XG=A/G^.6,@M8FF%`=5ZM%&&
M!!V^C3/O$$;U-(AAS*I[KC[,G!\GYO$T,5"F%5[O+&+/,<;SK,WMK9_\=AE3
M6DQK!HE6FP?RNXA6%7,\HF'E(R!\".6K"K^_<-5PJL5\;/E\''?R?K^1JD[%
MQXM4&T<!8CKOVA'=V;@#OHW1=&30[B@'&@F*N'2H688(1WG?J+8K1YWAXS2D
M#=.`(^(<5*7-`\UAAC&VD3R.*#EE:B1G7L#+7R\?*$VO>-]LG&=/IP;G49C&
MWCI=L=&=/7V@FWM^ZDL3_SX4;5<VQ16&'`%41#GHK%95]F31$E+H;D*R#HGH
MD>1=3KB!+&0;Y=T2WB_Y5?0"_R+M>/*IC8H&['[\<"A[&H(?T?"A3;_XU@^J
M*)C`!R'-V.KQP_%1%-YRDLD\;XWG!5ZC#V;HIYHX@`O>1<03A<PW'A3D<-L%
M*CR&XB;;X[&Q+1^H9=G83#NVD!5.FOE([%X0;V$";=U4V'0Y"2)3`]WCXD9?
MR\BT-7/H^W5;BX?'%9087K15"DSM+5M(@3&>4HU5TI!U%HUZ)ON3G95IXP*:
M=*Y#9W+7`I^M,?MH[6G-:A9P]WJ2X[KDR@_I/*4[A_L]C4S@[_DT8U/+8%+:
MT_N5$Q%!!6_%K#Z<X36:)@YP@OB>Q7I749(LPM/OKJE#`<)6AM!!F`EFM9!.
M"*<B+SC=2WX#I/@G1HQJP[D;U&->O$\3<L\8H/$(UN)KF/':QFWT!??Z@6X.
M`5UL%WL:LV&$]U?B$;AIDM`TL=J=->,%MA0W0UI;EV=D/%?]2$@D)9&DZ#9"
M;3ZJ?L5NPJC[(QB")3,_4<QIGI9[;TT=XF4M']CG+[0(:^6.I7"=FA/17ADV
M=P9DG_7F@LJ[(\FP.#H\X>'R@8+3!Q+`D-W2-%`K@S<\-$QZ4OS%=NNOJ5[I
MZPM^)2W(+HH:B4)V9%-0Q>Z"(AL^L#[W\!VB`A`D[U*U:(5Z,TM%.'I,>;A+
MZ#\.[,/-'MG_.9\?JMA`+^_4^&K!X[$E$4UQGR'J/YO9*:*"!P(1M#Q)5#,`
M6\!H,!D*'KK3Q+;/I%^=**F!Q<WM1%'!!)FU4SK4FL@A6JX,A@6;T78X'6WF
M,+8&->XO6!]8M'&!,MVMZ&KQM6JG">.1A=FWTYKR%A:PTIC<<N60)2T=#BQ:
MF$';]S:L+:+)+Q$).YG7<AWBA,+=XMNBXPV\@+\UQA>>B2CA6D6,S@D8B:N1
M,]!SZKSA4V8_O8\I;7^?I+Y"-F$#L@UDA*]%H<B1#.ZER]Z1!0*9EY,-^_Z*
M_;91O^B*)7V0["F9*YYZ>\F`1P^)4UO*WXA>>5]$###[LJ9)POZU>*3Q!=W'
M=.V+SWKI?\G#!,N<*I<.@-.MG.:D?NHNV1!&*<-)(CF)7W!>I,B,"&Y9W(G`
MH?<Y%1GN:"N@1QSZ713]QO2VAM\;!K_[215":8!.VW,W&289?0[<QS.#-U[*
MPU2CJ,F>*4@,Y8"]JW!GG*!CK!Z0&UFVH>#:QUUPWQI)7.:JZ.HHS9KC^`FA
MY0$FI[@R2I)S+XZ?V**;WX"V/C&T8@V][V(W#^UBGTR*&Q6,!2GQ0!#"]8/\
MFFFX!BB:X*2#O!OFDIKS!==QGH0N"Q\$0?29WX@VW=(W8@5W$\$$IY'N'BG)
MD10P'ND&<%`L[R26D-[SRNLXT`#>%C%6M)8[(^U\P(U(X548Y@3.#^R/H</U
M$3.NZ,(#%7HCZ\(H)B2CZ=^L1*D7]!,)F()<\2Y)0^S_HL#A)?Y80"O2;F%`
M,\O.6Q+\2?L#SP">A^MH1UEWMY1/!>M*V`E>MBT[*I)/;S9I9GT!Y,(69%O"
M"7\MKR1G0B07(;AE/J+^8GZ:2C)6T#L3O8#G]:\.:::M7GJJHG::E4%J3]IO
M2X!^:R0[$^[ZKMZ;<.#9_<@Y?:!Q%YNEWGFV90UZBF0]#[7C3LX`M=T:$/QU
MQ/];0,^/AE)RX6^9]^5'OIP+IF,BD,^-[`*4F^JWGPE9\AW_U>/&D3$1WM#-
M82WJX&1#--V$L6()]PZY#>[:R0G3Y+6XDUZ4>2[D979L+55D>,I[F^[X.X8H
M*F=WFPENZRY$.WZ]-W_,',\3=0[RW?)HN3F_SN&(HC.C_5&UI;/@"AJ$V*"O
MOVBN<D7@6Z?#`#[!\@:#Y1Y@C/8ID045U@K<'D^8LQR]4J+</3H.L!S9\-JU
M?GCPP_OLZ"D*D^E=(NK9FD8677J`"C0ZS4IM5T0R*T8=>53](N/X4KR=F3$E
M)Z[DUYQO_W>L7,*.0>:E,"%H(I#N:J$-2#JP!S(0?&.'3L,-KW`=U$9L>T1C
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M6[;Z&9)JK?G`WR.=AS*+P2B"<N8-$E&YSX3!?9"F[8Q<]B4_U@)#ADC/4Y%A
M\T.2/E""X<`:WX?W\P]?,W3ND^%P!PKZR\/$HAWMGSHV=66,;,/?]FBNE1WT
MH5P[WEZVI$&/X>PQ-ER74IRI=]\"Z'P9;`A8X`>,AGIH=>5+Q0NN6F8U@+5Z
M/JB5#7SU5A4^34F_VGH'W6M!AI_/L'YK,P^P'/CI(7V(8C]]<GF!0,4%VLDI
MT6F6Y,>F6)\?T'\R(\.H8`$O?'9O#ZCIP:]6U!&9B1RVAP?:/I'9A8$J<?>Z
M;R)1BG%V>2VX2@M;M+*&1)$4Q@4%X8-@O8P?N#!BLS`9U#RL$.*))Z_<'P30
ML,(75UZ9/0W0$%M>H7X?H/5[.@:95PXO!;2=!:[HE_3@!9KT1X-#A!H3'"=[
M=6P:-_XB:_T2,#6Q9TPT.:'"9;3;Q,_BE*G*`8\9[VZ],1IM2UN-(KO7^CP[
M.A6]YXC6G(2H("'T.!T=S>A*-//BD`TDN:'Q\L&+Z9F7^.MIN+GP`UY+1Y0B
MN/"3-?L:!R8TMMZJ<S?06R'N\U/+M,HX$<:*"%X3(KB)*SH9OPF1=3$*+(?T
MBNXU5ON;EZO%<DEN9K=D^6%Z.T/C+7M2$*-])=<^QC86?Z7^_0,;T)2Y`N^>
M7A_X\BT;I!AXLCBD2<KDF:&9;OY^2-)=<PG%1JOJS![*5[O/1U4)<DXD8T4D
MK]PL2'N1D`([<N*'H(YK?S,AZZ3PS-L-)^<%4Q*Z/L2BX."$)&FT_HU%"?(N
M$[><S&_&7D,:+EAPT%%+M)&#*^^Q+<4T3/W\^RV/GV_V91T<-G1SR2905NL3
M&V>+;=4`*K/$M*:ZITZA0XZ^YJZJ646^Y,28Y)P)EVM2X,V5L"EJ&2C/S#T8
M&6K&CE;9RZQR**TRFQ>V!MZQ&4JD73[P)S3]D-R)>([F<\;"?-D"418$^%QQ
MF[V/>&:][P4G(U]N%!4<73ZYQZ;M\PL>-?9J_XQBR'YZ'/UAZ_4#W1P"NM@N
MN6,_>SH/O,0NK4/+`NPM=2VN6BG7K#57%M&>W#T108$NF</@@^G?5-?00[RJ
MSG3&BY^6WG%$+GD<&D;0P80.8TT,O:(((DWC:/UHQH^2-W,970A/_5][._;C
MBJUF$K:Z9V;:+JW#A!.8/31!V2*/V'(\S+^<WB*VLQD]P>AF89<@TD`(;?B*
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MM?/$<&YG@%Q[@C?)DUKY+XKZRI-["GPP>/Y^8$MMU48`*$XO367:^!RSE2&@
M!I]'8>)OLGKWMW1-_4>Z6;2HL-[<V3$']ZN6<]&BU"4>)&="(D"='A3^^YA?
M3-O'T9K232*39H5N$Y\).E1INCX%U,9'6W$>_VQ'?B2>_3C//D[C\9.IT[9@
M".6Q;3#7#TV*0IU3$\4!,@(_W1]8N3DQ&#27=7I_X+)+,UGS"0EI+7L?+`ZQ
MUE%M$&+.K8_'(D3IS?S>S?;&$P]RG8MP3\B3:2!AS@_Z/1L#Q`TO#$BJXR6V
M+9&$9$DDJ=0^%'OTO0#-+S%LR5X0?IV4UN^(RA#UC;0,%%GI=0N--7J8II79
MV/'.V2'Q0YHD;`QW?BBD89G2_73]CX.?^/R?,_93^C0/F:NE23H/Q9]BRK=6
MUER`[HVO7?33%U24U--,514C9TL*?">$<R8%UA,BF9.<NZCAG?&?D%,/""*L
MH2?*.S$B5,Y*]#EDPWSP]Q.^Q:F8"K!XI4\=TX8RO734.<KAYLP7=XB3:;B1
M+P;>TW#MTZ1+`2L;MJ`QCQ7^6G+0B9@P:E(B)QD]KOH>_8+V:J"1EL6R%_/V
M",&"9V<U7=%XEQF)Q79ZSXR`2>$-+2E(<KL21ZTT^ZDA7U`<FT(GLCL!8.&S
M-Q@`^Z1U8PP7,L/V-'B2GDB1I*OK-4.=IJZ@ZZRI-]Z3,`F747P;/7D!OZ4M
M<PJL'*B.#:C#U.*K;5-EC0EK38[-LZP@+-[0#=&6(8J/B/;#(')?^/<'"MDB
MOUV_VCVWAL?H[^OXR3Y*O.!]'!WV\Y!7<V!1!"\&)A_OIIOCV]VW])&R7Y@N
MX%TX0RW7G6:AYJTR)D1PF9`C'U)D1(Z<)B3CA6`9WLL$O/=\%FO$LK*F.!C@
M;VN)XUP>J&].W/(RG%&()V'!71.TRVP'MIUC@%L:\'?5;KPX?2J<CW9:41OS
M!(T.S)%7A3>C)(*TF%HPRD+:^2AA$,#*131@0#$$4&2AA:7:ML<9I@S'#CH4
MX[HX4'ZNNHJ*?S<--^QX0@4:ELB-17E"&`OI<U^DT4M2:H@@ON@)]U[@3HNV
MRFLL%@@61;B(MC9^L&(XMB)?T7LON*3VMR,+A-#IBD4,M=K1_&^$_Q'!9H'Y
M@"G21R1KXF*4`WBBZAP8LP7WO?=(YZ'@N:3QH[]NOSFG)079QE;BJ,I#UI"_
MWBU%(V\+O8]MC8`M+0.!(!D*@?U&=G<02#:Q]7JAWL16T(V^B76@)4?HT^3\
M$/-TF6FXN6:3(?]AZZ2,V4*[,'/\M3TK%C6F42E<]%$Y.W=H-]X3K_K)X<6%
M\+$!'KA?M)1?LT>6#7EV]JG3S49DBWB!O5-5TH)X53626JGS8TMD;M4)`CJ_
M:H%"K/[$N1'_GZ<"A<3/MNB*VM&J"$=_=R%):)I\H(&X;W=([-]0J#.`]IY-
MF&IR)MH0WNB5'[Y*>3-$7M($PID7\-L*"7E@S7@DV@@"W!<J)<RL2GV-&J+H
M-_W'@=F[V2/[/[M2\XVT8'>SFY'4KFL>FQ'1#E])><T7T=\X;B($EJ<K3=V[
MUKKFS7R@[:\&8;NL7<'6PW.<<@N+IF32.7"OBG?KX7`]GFEC`1+&M^)JE2KX
M`]\A4,&=Z@[XC9`$]F:ZI([O6^B[+])3UC*D3S9G-0V$H+D=%0RU$#W[,Y;C
M&JLQ;X<8LWNR1<NP5P\T.W?EV=G9:1,O6?'H;V2Y'9[X)=,WY;J\B!-9UD63
M:K2G5I2H1E^%K]?Q@6[.HO"0&&]U-\;&)IR@UA]&*&L:)8E(1H4@]<$)AF+X
M8&LH<XG3KJ@,V(RM2UR!Q?6IW<Y/$IY2(IY#MEU>*=E`KZ[4^&J'E)3F-^J.
M;;/WPA&X4WL\O&#0(>"7XKC;$>4,']A`T7@?0PDT6B6J>(RM38OMUE^S;\O?
M@F1!06/DH;(QS;10WD>!I*&&IFCV-2DV1%'?QQ"!K#>6>($7/PDEV45A^H#&
M\^@D2NMK&@F[7Z]CK!@C?MLV]N\.(@=16]Q"<Y.HA17L-;LVG+7C=DE`2A1@
MM28&`+8N`5-7C@!<MO6.#=E2S4SY#.[?Z?D`;_%?T&0=^WNK8K\:#DB.C\JH
MVK;W)J30'HTO:O]0-N=)17+QD23,*\;GS^QG]I\[+Z'L#_\_4$L#!!0````(
M`&M,?T9>5B2E$C8``)J\`P`5`!P`<&UH<RTR,#$T,3(S,5]P<F4N>&UL550)
M``.9HAI5F:(:575X"P`!!"4.```$.0$``.U]6W/CMI;N^ZDZ_R'5\YQT).^]
MD]XUF2GYUG&-8[EL9^?,>6'1)"1C0@$*+VX[OWX`7B2*PI4$M4BF7[K=;@#$
MAV\!6%A86.O?__-M$WWSBN($4_+3A]EWWW_X!I&`AIBL?_KPZ]/UMS]^^.8_
M_^/__I]_CS#Y_=E/T#>L`DE^^O"2IMM_?OSXY<N7[]Z>X^@[&J\_SK___NQC
M5?!#4?*?;PD^*/WEK"H[^_C_?KE]#%[0QO\6DR3U2;"OQ9L1U9M]^O3I8_Z_
MK&B"_YGD]6]IX*<Y!&V_OI&6X/_ZMBKV+?_5M[/YMV>S[]Z2\`,?@YA&Z`&M
MOLD__\_T?8M^^I#@S3;BW<Y_]Q*CU4\?MIN7A-6?_6TV+VK_VR4-L@TB#&+(
M_L3I.R8K&F_R/G_XAK?[Z\/-0>>_9^/S]_D//\Q__"Z@FX^\R$=E*Q^[]?""
MDH1&./13%)[[$>?B\06AU+QWTA9ZZMF]'[-1>$$I#ORH>S</FW/8Y\>4_<EI
M6ZZ66Q3G;"7M^BMNJH^^)NP+;##B"[K9QN@%D02_HEN:=.VXO-U^1OPQI<'O
M+S0*V1)WB58XP"TE6M/FR7KO0.IM/M`/K@L_>;F.Z)?NTV#?4L>>/F:;C1^_
MLR'!:X+92/@D700!S=A"2];W[-,!1A;]-6RO8Z_O8\K6@?1]0<*K/S*\Y8-B
MWD=A[8X]XE)$<(IN\0K=\*UJC9\CM$@2E%J,GK*5CCV\HRE*[OUW_YFW$'&!
M8C*?OIOW3MI"]]G"5+&40WVF)-P67XB++VSM^FC05F>F8_S*MB"V?F/_&4<X
MM9H@XNH=^W2+F.IFT8FR?,>OWC"->8.>_#>;3]<K=47-]L][%#^^L*7;`GN]
M5M?5L[:/\*7$1E(%=3O/H\T&I[FZP98V-A/XDLN.-5;RJ6JDZ\S!R98FV%+Y
MKU7J^/WZFO44^R3Q`TNE5-I"YUWX.4%_9&S0KUZMMK)F13?:`%7OWJVU`M-V
M'6D'?FU_?^+;@$6/%6WTJ"G8]M*@+1=:@V`732U[JFG'W4YD.X3'51WN2K:=
M$=0]R8R^1*F/(^<3NFJVA_ELW6-5(SV<1LJFG]!;FMD<6`W:<K3^1&S-P+LU
MP\_7C-!V5$T:Z[^_J>TH6[39T_II/=*ZAOKMY\Q91V=]G6/;SCC#]GH_XUI+
MA'F3?9QXK1=@92M.SK_673JLYDX'L>Z(H*Z3WJ2\1?LI+*KL?'3F789G[GY\
MK#<1>1,.-4A[F194=F[EL-<7I4VXLWGX#7.%=2<-VG)G`;%?/X_K]F0/L>Z:
MKB&WUI$6AQ5A?:M>B6[/HS@N/D#0FN/G=^>?^-WY[!]YO\M?W_K/2+*LU"_B
M/QVT553Z^!_?G**';+W`-+PB[;K:J'W2/C^F3.8Z]+I6_T3]?J*I'[7J<:WF
MB?IZA]J-[:[>J<:4[2JHW9CN:SKL:WK<3^N!W(\@6Z6V,4JX`PQ?56]9-PXZ
MR)0.1$(45EWD#73SJ<D=GVAP\)6(NQK16+=6\]]X5>/<B)$W?K-O?/&<I#';
M'ZJ&(@XS;]XSKNM]_^&;C\:=+$<B'^4$!=^MZ>O'$.&/O-_\AQS`M]_/2I>G
M?V._\HI//Z`UYE\DZ9V_08(>RXIZL[*#=>(6\6%G_3BHFF0_'K%VZ*15EOBX
MS=T4O@U><+0C?!7338L1+/M"]5!HS/2VGSZP.EG".DFWO"FN*I^"A`L&)?:C
M&R:H;_^%WI4L-,IZ\Q'3(,!2\C`[-1$+AB/D6*XC?RTAX*",=S;*@3_"4`[X
M_-0#?I'%'.8U3@(_^F_DQTR[NF3[E63L9<6]OXV2!A6<DI&S4S-2H7EBS4I8
MJ!?Q_C[*D6]"*$?[;U"CO3M:*(1?6-;[QZC'_PA+2<3?H8C8S\5K]IM$0T6C
MM/?#J,D0H"GI^`<L'864F!-2*^_].`%*&GA*4GZ`45-_0U'T7X1^(8_(3RA!
MX4V29"B6$*.LXWT:)3E:3"5!/\(0]"\:96PLX_=K'+%3OY*81EEO]OV(&1&!
M*:GX!'2D*Q2\![2E,;>Q<\=VZ1JFJN+-QGS05F#:G?1@",HEY8+I'FL:JT_<
M!R6]V9@/W,=0*A9.?N`N.G2?/4<XN(ZH+[*6"<MYLW&>O,5`JO$_^?F[G)]T
MLZ$DO[K,KU.399;RYYK\E:AZL5)4]&;C/)0;(JLHDQW0/S9-V<V1<&/>EC[*
M;"4V*S]YSH<[2[Y=^_ZVD!T4I4GUFZ80E;_V:D^VKC%AW<!,;2UO<166<)OJ
M[8WA[6$5'L8&``X+0IG%;8?S4/KE6*1V<89OA=CF7ER)*OJ?=SZM75_!,%EJ
M(L:$-LI#V=GES*@8%'1^`D3R%Z$*WOA_0UGEM<,O9JOJLB-R7E'\3,'HN4K8
M2'VY1+D+CX*G@W)0]ON6A!WU77Y?-9YY5;YJX(_A\A?\#RA`^#5_FW&'TG)L
M5`NF27VHZX*61!MCDM^?C6GNWL=HZ^/PZFV+2(+TE`O+0]U(M*18BD%^`3<F
M2@]&PU3=@;K':#M+FWV7W^99+L<U%[;3S\7B?=1]Y!>GV.J1U!U23TEY-:B[
M$%OM58?!U6X[A)EY1TE@>28YK@)UC]+N6"+N_S1VT.ORE?(K"IO/E-7S5ET1
M[%[&A#DQUP:`)G'>N2R[NERQOS%97]`D%=WP*,N#7>^TYU>.8QK+<WFZ2YHC
MHZ167`7LMJ@+NPHHKI9J>'.@$:W'8S`(\Y(-G4((K@XXD%IR%7=,0Q[8750[
M#:E^P31J>FH/H)D>?_PVTD#G-6W"FP&;EKK=N5C!G(*YL0;8_%)&7LF;`9N=
MK`C4RH`(W03N;B0A*#C@R$\2O,(HU-NJ+%KQ9L"F+`VG8D&P!0A\D)(\CLOG
M0'4\**Y,!*3*BGHS8&N5%7-*%%-8KJN;D%(JS:^##BMX,V!35:OYJ,`R#;-5
M`V!CS;'E6EC=FP.;L%PP+T<VD=NB((@SUM.CH5*3+Z[CS8&-6FT95\!Q=;,T
M")IKT8:,:3ZNX\V!K5M=:);`D;]"LZ,Y&LK9RNI,Y<V!#5RM&)7@D+]@&Z49
MQ>J^4%G/FP/;Q-R>F"4`IW$9(3\0&EFP3:I[<V#[F9Y+V\-R`]PDKAMO*5D_
MH7A31ZU:`03%O?EP3&563$O!N)KD\-NUT706EO?FP[%TV;$J1>/LGG$86[<9
MH]Y\.'8O!]MR#F<*1+:ZO%*,WGPXAK"V-&O0.;O`A'QLLG\&^"\_RE1;;;.H
M=P9L\-+0(^94B&(2FM,B#''1[WL?LX/_A;_%*0<A-WF(:WAGX*_[6A"K`C.-
M0](B"+)-EA\`CE-0%H8>'C/Z#J7+U9/_IK9UV;3DG0%;P-H)1`N0T[CM>.!Q
MD0D*K_R88+).:B.Q2R$JE0U]9>\,V'S62AP,<4UA4Q<EL[-0X;PS8,-9*WXE
M.*;P5$:GRG;P+O/.AF,5<W`:DV/L30Z`XV`<9CO^&A3#\:&(#>\RSOL9YL>%
M?992DW.2K/:XPV<8`IR`.]]1D)Q%EK[0&/^YG[QJ`6C6@HZOX8QX$;!IG+*.
M0.9A#ZWX+FI`!^EPS/4>U#0.298QP4RJ04?Y<,QX`UF/'F``.E1MK)9;%.=?
M24ZM/Q56B%U7#%0F20T(+>G1CU#R@%X1R=!G2D/-`V!1<6@]2#&:DD.F!,0D
M=)V$S84<U".-U/O=04EHG<::1$'_IZ&Z?(YYRL"8KI0&OEHI:!7%FKI&WZ=P
M[UKN/F1=1N@Q"<8HK0.M@5@3JD0R#9_SSX@PC-&"A(MP@TF>D8DGSRT1JV:J
MNB9TK#$E=Y+YJT<TB;O82\1ZR]1OWG?V<X1R:ACJ#0\0_F>1G$U.O$EUZ#!D
M+=@WA06]&TO>^_'C0Q;5(0LHE)2$CCAFP98"P31._D=C8;/30L<8:S'MA!BF
M$'UA!VQ_FV]"Y;XT=%RQ]NK2(88I7'+>44(/T97B:J`/:^N"QQ>S9MH,DJMW
M7+`+\@U)$:,EU6O$C9+@8<7,6!(S+,+25?D5I1[OKOA\]C%9DFOV#::J$Y0D
MR]4E>I8F_I44!X\2UH8L+:`IQ#Y@R!!>D^)58?#^%/LD8</!<'#D?)-Y0'ZD
MN?4T;P0\OEB766L)<QH:\R6*\6M^4"^FPO[?RD.LK!)XM+(N`J"!-0V;5;4W
M%8.3N\\:[,JUTN#1RESLS$T\SM1LT`A5DG%IHUZ#!R7KPK(:E2O-&O)(M3\D
M7K.1NZ"$0<T8VOV%]SE:L?VL%B3BZHT-&\..B1^_W[##2OYFD=5D8*)\H(JI
MH;VB[N6KX-'.K(]Q?0_&%*(_[+"7\^^<Z=CJ*TQ)#?"0:BW%0PQ$G@5Y3)K$
M'4J-K','Y<"CJ-F;:XZZ+\^1/)Z96;V5J=QZS_T$!PL27N(H2Y6G04U-\&!I
MU@2;`)+G8A[3C/V-G6]?&*0%ZX:_1G?9YAG%RU6.NN82:"X+[1H$CZYF+2(=
M<"JR1)_B:"&Q^S4`-3K.5SK%<PC+%L"CK!G3W0:8(O]T1WXA76>3Y>KX96V^
MS\.]0RIH9%0(GOO:/4DR:0G"[[:E1C48UW33<352M";A>JMZGBZR-T<%>^'_
M9$G*QU3]V-]!Z]`NOLZDQ]%8=+[TZ7A/Y^P%3',<#&)'*&I!NQ,[$Q,-QM[<
MCF'?P=1?3E=Q(N`V\I;QJ`SJ@SR6J3KVI`EH>%AP0-NV>CS%\^@8C*/=&BB0
MX0Y/,0!\F:"$*\*+-ZQ2Q93U!K.Y[DC2D"D#,6YN&Z@NZ<;'*A]M8?G![(`R
MCB3&+1F6<5-:>]'Z"^+&&+5:<U@6^BF-E!.IRG+<_PF<C21AW;1\*NM!OYRQ
MY%:+!?K!1#]AR[0<BRM`/XRQ)%<.8AJ^8[(CMY9==47H!S66+.O!3"/P7*E^
ML',JRET73)3B76'HMS76FO!!ST<>I+UKT$#@&WLQ)S+^1+UWI"QM48PI-ZO$
M*=0LM`AG<QSI!?JEC!61PMZ[FHA=F%2EC"PB*5UF/(OB??&-'$<>0>V"$K9?
M)ZS#R]4Y)>%QXH]W?L^X<SJN@A^*9FO?GP1_?F,B*R<9!-B,\6V$[;1RUF%T
MAV(=ZR1BW?##JH;2U_"YP:$6&^Z&,%B%L;B>P4:65Z!%*^`OAXREH04NV-<%
M75GN3##XHR#WW-8?!'5_2``W>9?$T?QE#8$_#.II"E?0G#GD@]#M@NE\)(!M
M<.Y)KE"Y\LIWJ^GQ_E^]!2\^6:/%.D8Y]F-LUS1>!.S`6X0$K:LIRDW:4?/@
MKW?,=3F'@)V]`QB6P!2E^I.8HA3XBYX3BDP-L:N'!$YEAO>?IQU8K@Y0$7:V
M(2A_`?\;3E_NL^<(!\L5ZR5#9KS$.&D<_-F0L;2X@SO,EP-=\:E7%S>M@[]!
M.IFTU/#V]Q`!?&E1Z*ZNV@=_DW3:!:9"7`G-L,R;72'V*"_YP(W%<.D*;"4E
MPS)3FJ&[(4P=\Z->E1>S;WCSL9@XG:.N!&A8%E!',%UH-(8?R7.1_Y5$J`:[
MDJ%AF5M=3I7.VY;Q9[SY6$RU?0"O)&E8EER7,Z9_2:H^X\W'8@_N`W@E2<.R
M&1NJ??F--+J/_"`?/]<&'5WSWGPL-F.7@"N)&9;1N#M")V8=;?O>?"Q&8Z>(
M*Z$!LAK_99["C\#&[!KOSKUM4.M1+8-[]7CB@68RCU==%>]L+.9@'8B*K5''
MI&X7Y>1L!/99><\KXD;^XJ?K2X*S$5A.-=VOF.QL"RU\T*\(5(R0;F\)SD9@
MRU3WOB*RLTU22.3@XGW<Y\/Z@E(<,(A?@W_(,X&U<^?6Q<OKW/!(`X:X`P_Z
MY%TB+G4_PCH:G33HZ@TF<D@+LDVP03]K;TFGPJYJ4'4P(41Z(+6$-\S74D('
MOIJO'@,1<#[6EGZRPB:@HXMT8=D2YB!?+XDQU!TUGVBA#''SB4_DS]YL&X*.
M/>*>>0W80;YK$EM>[2S3T(%&NC`I1S3(]TKB[EI?8/+]9RCW2<Y(*T$-\N&1
MN,<M+@Z+N[&AW.LXXVX':Y#/BA1]MIYZ.]^*H5R?N.6P1#;(QS[[;A\Z+%Q0
M81XG;9WAA`CIQ*$$V"#?WASV-9<XG?%`464X<3M:$*C#-<P',74QNT/2:=<H
M-ISH%RV($F$9T_.3IR_4;HMC%883H,+9]E:A&N8CD*9OC-G2J*HTG#@4;19'
M+;)AOM(0]MN*ON'$E7!%6SV<1/<W$?6H@K#7CA=^\G(=T2^068)V?;"[5CRJ
M!I3_A_?C/J:OF%%R_OYKPJ-6+*M<MHL@Q:\XQ<@$G'UC`[IA%-(AOMUOA]/1
M9>(8,W`"*Y[M^))R?PC,$:TA3H*()EF,/F=LE6.:$T1X],I7,WFB#RB@),`1
M.D#\1-TM%WU\#OK"TZ6H]34^T#?A;H3U$K'>!K@@F(2+#8U3_&?^3X7,*6I!
MWZ+V1;=8N#0#,8%D#Y]]3)8Q'[8E>?0C5*K2-^0Q>TYPB/U8Y4IJ4!OZ\O6T
M`F,X(-/(9K<(@ABEN?/8)=N8:4:4&]EQ:>CKW-/*AF0`8%USW*TB=:'?>PRJ
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M_9K]LW;EP4>`A(O5BFD';*!5:TZ79L&3G;04"+%T=1Z)03[+S[?EAOK(Q^QG
M%+&1NDK8<'^167*,*H.G+W$B!)9X72TID)IVF0***6OYL^:884U]LL;LR+E(
M$B0T\!G7!4]3XG9I,(+;63$9A&W/?."<J"3@&4J<"HHE;F=A`X:GREYCXK.#
MH1M55M'8<-*5N%!E=4"GX+I0U[,TV55U5<`3D+2D4:^`'J&<A)MV'>'N)59<
MN&!HHRCJ*X/G%>E-'!1X)W*Z+36LRGVOQ,O?59KHH:)JX"E"W$J##NDTM,^Z
MT->C:UVB9Y7>H*H&GN*CMU5!B!0V%-6I=4HGNB1XZ@ZG$F*)V]FE(>`9Y&JU
M0@%3P*NP70]L6BQSR\V"A/POOE^^LIV3*'<3FV:&D[3#ZMQA#7$*RXD87I%<
MHFGP4XB'33/#R<]A)1[6$*>P>C30+MCR&<?O5>`5C4#(*PXGBX:U"&A`N;JP
M+^*%LV[&Z<2H'TR>#9?4U_)N=([`!Q[S/]MNHWR$_*@:H1NRHO&FH,H@9()9
M"\-)UV$E"C;H7,7U<QS".E>"?1S64TGQC$`*;HWJP>?NL.!&<,MIA&\"#VVK
M:WN.5>E&NB\&ELS#G!CQ=#T",0ES<>%0^.2_<5.XAL2#DMX9D.FO.X_'.*9A
MX*T6JCM*`O;C_D:4A`++Q.4N[(C!3MRU:>]L.&&U++6USK`'&<Q5\&Y[26K9
M4F0[MZZ>=P9LYW-"F6!+-P(.O"7(M+3<#'5#KGT<%U&&:X^Q=]EOI+J:46WO
M#-A6UQ?O%O![W$5.%&KO,=ML_/A]N7K$:X)7./!Y0HY<V/DV2R,<\`N!TX?D
M:/3`),24M!)$L#WE>#XQKL[9QW]7'86-&H`.JJ<>=,DQV!A9?ZOKB:;7?4RW
MJ$@_QFU`6ZZ/G'HR57VXC_B`USIB,*>T=2&FEK13^S7>9(+9-`,]S8QXD-YM
M6\'LRTAQHAG'\U$2G+*->G7L>WWJ>$*4AE]P%+%1;W;%ZBQFU0[$C)3WRF0B
M&M2&GG_6#$@M2B9(1SX%9<G\3CW]ZOTP<9,6%'>2]+7>L-G,,*D&/25DPR4X
M41D@&;G(%QEH4SZSGRD)MP76N!#^+83P<]<UJTU&7`%B-SGLB<D.(JD!/47D
M0RK>'A0P1G\2.C:A`-@5]IVX(8R,+'?^97OZSRA<MS>5=V@59GI9=]=L#K9O
M%GZB=F)0-IN[#<CHI_PM=V@[^1POOFHP;0\+0LS$73".HBO+U2U*$AK;S3OS
M1J!GV?&`BR>.':*1:XZUR^E3SY3=IZUV.T4M&-/#47?,;`[R:M#S1#/"&B>'
MR>XF-$EV^=FZ'LGKC>E<UT1E(23]RH\)6Q1W?3$1<VD=*!E7CJA8LI481K[Z
M'R=\.WUNLV8/N+7&*+N9JB+(E:NP1W;[@G$;T)N$?O@EEZ\V`$>_:?!\I#BM
M3EX7-+]J1@3"IT'1%3O'/)MV(*:A40=-YJ)=0]`3TIH7\?RT!SWR+9"ARD.Y
MLP9/;@[D;GU\@#,4EH=.2OBP%WWRH\\QS;8FM@3+ED#,?@<]8<>%*`N9:(E[
M;FGZZ]@T]-1MP9[$Y.=@($8^G>L7OD^Q3Q(V8!SMJ>>VK!\&DUE7%6+VROID
M-U$M6H&>DR8DB">A)<C1Z[@\?BKZ(V.-7KT"N!<V/F^4&%M2!>30V.B+T2%1
M5@=ZTJ@&5G(<5$$9^594^K93M6_[5Q_WUA#._00GRU6C4^_%GR83R:P!Z%G5
MQL?='-D$'@5?TQBQ*7:1L=Z2X'"[)F'^SZC0><U%HW6;T`GHVTA+)[!3")LM
M"9%C+"U&]:'SQ;>1#&-@$PEB*WZJ8"X(IDV`)X!O(0LVV*808:SI+7]=/NQX
M98>['+'%FX*CNN`)W5L(@!&H*>0KN]EL?1SGC_?CRJ:V7-U2LL[!%NC-%X4V
MS8$G=6\C'RUQ.LL5!B@R#XB=7S/$4Z>QPQ[O/P_JS"/[HO@5!\J@IMJZX'G<
M6PB#$2A7D<><1JK(']TO0G;<?_+?]+-<6P<\A[H%>T9@7,4&@YVO"6+#^)+G
M<GY%$<TUF3+!LW9[-Z@-G?:\W9PU@@4;7\:QWZ;%-BZI`I[PO)TNIP!3$OQI
MS`0WW?;,>=;4!$]EWH9N$TP[0\Z8:=^_>K%0T.65P+.1MR%;`Z?B>=06NUUT
MI%^0S^]4]W8("QNO:1O@&<=;&76MT%5",6H#WJ\)3Z.3I'BC29!Z6!`^UW<+
M>@40*@Y';76[0U]JPQ%3PGX,<N%-;.>W;5/@";C;R$$KD)6DC-I*=Q]C&A>1
M6!]0$/E)DE^RYYSMTME?HB2(<8Y.:;:W:PH\UW8[^WT+D)6DN#?.G3@$FE^[
ML'CBT3%.[G'QUPF$UNFF;#!^%WT$/9N2?Y,JU!G,#/O+!#Q[#%Y0F$6(KFIW
M<$?7<QE/=;_8T#C%?^:\EY:\G!PC1T.'GX&>S8Y"J+D>DI&O`7EH+4&XJ11D
M_I\\XIK;V;Q<R7S'K6>L:5/0L](LBEL7=!/P;]S#_L5G"TL>M*>X5W]"\89'
M[6HA'V9-07LSMI4/<W2]N2^>/H`+C-(UB3`N>\FY+$EG72LV<Z8PU$+&M9AI
M5BU"+\BM@K]TP#JIY;E(Q)I'7"M'D:=BY2XP)&`CD'/90H#LFX5>MCM*43O`
MT\BIM!^%"[K94H+R_/"[@2@/$N>(L--WFWW?NE5HM_6.LM0*KRMO]F&$J[+5
M"R84M&HO![\AO'YA1X8%X\1?H[ML\XSBY2KO89M=W:*]$06[:HUOY'8,L[>:
MERCU<?3UJ6:;V%AE-KPG2:XW<4%H;;A5>J$C!([F1@2DD%1XBG!=^_UT\895
M/A;*>M`*ZC%)&C)E(,;-;0/5)=WX6'5/+BP/K2!J.1)3*\4R;DIY`"]*\C![
MOR"^9ROH/"H+_2Q1RHF80F'_AT!?@H+OUO3U8XAPP1S[H4D8^Y5WB]9^=,4V
MF/1=LIH*2D$_'=2MG9(NRX_G_8YQT0OITM8L`O7P3C)JQT/;[*Q4WD_N#I+C
MXY/7)^_:M4=0&NJ9FVA4)7X=XDX/8<EQH."QHQ2Z83\::76[PM#/VZQ5N8.>
MN[+T6',G,;*8)<3E1^_,CW16F%:-03]<$_-TR&DW=*!W#D:/3E$<\)%?2[.B
M2XJ#/47K1HB`7!7`X?/GX_")_@N1D,:BQ513`^R%6<\L'F&$OK&1<'D?TP"A
M,+EF`\,?K;.AR)X3'&(V+#(V577`'I$YYU.+LL>+DU-J1`4T?JZ\CW&`=GD_
M%'J1I`K8TS&7W!N!A`WY(U.G>/>NWH(7GZS18AVC7+.HV0V*^PRI`F56'>P!
MF?,);@,8-M*/%>&+X(\,%T'>];J511-@+\9.1+P<-&S,'BOR"Y']&47A^?L%
M)9PF-CSY;\M$)(67`#O2VXF$1<-@#\9.)"BV0^$J\(]CS4\%[B9),J;'T@,;
M4!N!$3;DS8",7R<5$#ETV)A"5N)PX`IQX9,`145T5#MAD#;CS8`L:B<2!37P
M*007JNE+3-*7<6[2"O/#L,%1PJ"V-P,RTO5QJC#%"QN5J,T!@__?#6'[(4'Y
M\Y3?</I24ZD6)%RN6,>KG;+=,<3V(]Y\*C9"]\/B+`02K/VB-J,N_"U._:C`
MR..[Q:\HO*9Q\421[\=\`39;C<S:\N83L%YV0^\LPA*P&/G)R_7ES<4-X4[7
MX6+#1U$E*J+RWGP"QD\]PDG$3RID>YFE2>H3GCE,9?!LEO7F4[)T"M'U%V`)
M,!@*D%/SY**A[%WGY=$_=,[/ADU`NT5WB(QB`W'<;C52?.?O3^S;&N]I@]K@
M/M065(J%P1#D1.6`0]1Z7!O4AO:_-F314@0.\4&)@.PIG/^\7_-X0!FV[&5Y
MS#VIWZ-1/6C_:T,V!&=Q$V03>.O-3=89Z\`.JXF/O:@&M!-W*Z8-,$TA&]A#
M;D]2[\^[,M")6KKOP@=07/$'M-GF6+1SLE8*.K7*P>`K^)F*L_DOF.!-MM%2
M=%`.VL6\P8"8IJ,>CYPH_\V,J'HY:-]Q,Z*:/1[YFB==]V\-WG/H*X.G-^GQ
MG'D($NPM2,]R\&N"5EG$P[2V$81];?#,)X8\6@I!`^`$3BE2J)]CFK1:#?**
MX,E0^N%_CVT*AY=%$&2;+(^.>8E8MX,B7!;[.4+EQ7<],*UT5!12XNH3X&E5
M.LF3TU&8=/KD.]3J,H=5`\_,TL^*4R'K[<G$B:\3Z]C*Z\3RIO7KK6)'0/6E
M1='W>K$1WPXV88P\JEB5(2%BNB7>Q8CW\\"H(<RU^U\F18(B/+\@,/\=X_?I
M"XI>T2^4I"\J';E;P]"3TU$:A.Z#,(%CEMT@_#?RXZ<OU)EDE>U!>P&`"%0-
M^Q3.;"W`L\^KK#DM6X1V)8`3I@K]-!ZPVP_`-<U45OYV#4*[,X")4P7>U0%O
M=-+$RKJ5)E86VF4"3II*\*X>W(])FA8KMC$[%ZF#5J$].$#DZF@$7#WH'ZQP
MJ:V0ZHK07B+]BT@)TM6[_)2F?C1,BTL*8YG\:GCI.`4G;S@I08[;;6B?2?J:
MQO5]1W6?**LS$=N&$E^/,?"`<X`"6;@GFP3T_/W@?XS?DEFT![W(NDX'*H$X
M[B76#*S.?]VX$>A%N#7+8J&Q`SX=2=&^-#LN#&T-MJ-*3_=@GY/Q,W@97X^O
M@.4">.\G**"+K>9-F5%E:$NLF(9#RNS0##$(]!TE3$]D2E"2GB.?QY:YI3XI
M,3QF),8)8@<`GP38CS['--O>D$#-;H<FH>VEQIQWQ#C0*-(U\?VEZ+6.:7%Y
M:/.D!8UR`+#^C;+87;B*+'_/4.,DH?%[#<03O8N>0YP^?:'_'\5T21#_ZXI+
MZI:+9'(;:2:OLP]`VQ^-9<`I8NC;,ZO=FJU3:!DQ<GZF$0\8TW+?EC8#_@:N
MVPZNQ`5]L=6.Z$[T#N2]G"-2C][2`<6%[O6`?6OPG$Y7=4"/Z?H\3=^*WM6-
M]7WE+27K)Q1O+M&SRI!8+P;^4LZ(%S&E1S@<G;1@+X;KJ"ZR.%:_<!*4!G_\
MYHC2.ASHDY-;:NO&8P-NZ\7!7Z(Y(/<(C[,S%]!=ON9>:?;U8LEZY?O%3[,8
MIY@'L&4CF\=GXL_J,0GPUH]NB,4[B$[MCNNBJ3/4"3QVL!H#_5N'-LU!WT3U
M*#03>]!@CUWSGJ%=@]`76'T+C.M'"Z,2&<V+A5;M05^3]2PPTWJ68`]?[4+>
MJCWH2[:^)6923P\LX)N^.VC;)/2M7F]RT]O#`M!C:#E2!_9RT$`7(SV,?O5R
M_.KE^-7+\:N7XU<OQ[^>EZ.UAX3<9V`LWHQ*!`.CQ]#=M.F*.18G0T&_P>ZE
M)0Q<_I[BA6;XZV6@SQ#&8]_L]""]`;LZ^TW.EP_"50_0Q2,MS[<&R9E$Q:']
M\QPKD#*($_#EJ</2ZHOB"M!^>S)VS+C<8QBWXO\K85LZS\.9FZ5TB0H$I<&]
M\>3,B)F481CB8QC^AH/M&IJ$6/5"X%YSIG1(NCXT?9+WD&W?>@9VA<"=W*P9
M..PZ6`8'%0/\EM:`@WTQ<&\T>Q8:G0=3!Q4\\,M//0W[4N"QQZU9:/3=U9V=
M4Q+P*S)A85_,FP%;&.QI:'3>U0682QX>\9N>A5TA;P9L:;#FX+#KKJ):.64`
MO>J>$#6*>3-@RX$]"XW.ESS\,"0>KO#Z17YX$!7S9L!'?6L>FITO>?AQ2#S<
M89.SPKZ4-QO8&5S+0J/O)0F?AD3"D\F2M"ODS4=R?)9T?7=>&ZG]H\]WBG/@
MH_BIWRG.9X"GQQ[,8::&,&\^]&=M<RFIQT"&:`=;!$&<Y=$>\P@G-Z1\1^VO
M18Y-NBK>?)CN"BJ^C#!-X]D#&X_2L<ODD>E1:6\^(,\&R]DH@S.%QPG+]`7%
MCR\T3KD7[#F-8_H%D[5JAY55\>8#\IBPI%B)J;=D=B?DN5J=RB#I+6@W;,&;
M#\AWPU(*;"!.X]W`?4P#A,+DF@WC39)D/@F88JI1L^25O/F`7$`LR=>@FD+X
M%P[FAB1IG/&W#96T/[`1NUJM$!NI72@<L0K7JAUO/J#X3I8R80_469J!`8E)
M$",_00TUUT(\A/6]^8`B1'44"SE`5W9AQ_&_+NAF0\GC"QNHA*]UO-?WQ8NG
MY4H3;<2N`>\,V)+6]E1GA]"5W;D?GE,:_'[U%KSX9(W"RXS'(67+%J;A<G5!
M"?MFPCHKW?9;MN2=#3U2E)IY6ZBNK-Z.1:!<E6[1VH^N$1)I^,)RWMGXS&=R
M('`&<94/698FJ4_X\PFVAW##0GB/6)_2=Z53F;26=S92"YH!K(K`L;KG'JH,
MY4OC]TLV7,:*5+V2=S9><YH&5<7T6"\KY/`N41+$.$?3BO1:?>]LO+8V<X"5
M*(S:\E:W'AO:S+VS\=K0CG!4)':VE!V1>*(P"86VE_(,6<^4A,/)!\4GDE6&
M/7$%B&@)AVO`M1^@Q89FRDLE617HF`?R0359_@YQ3"(@K=QH]ICFJTHW$V.S
M$>CX!MWXUR&;1B#;0\QM]*`#U6#,A#>`N+I#'A*_M0US;RFYCW&`9L9\*]J`
MCI'0C7\-L&D$L)-"/D<$K3#/=K0'?XWX$<!\,S!K#CI\@S,IT6"<QCUTX^:=
MFV#9-L@PW_M;Y=M7=47H.!*V0J!',XUD]CNM!P4(OVI.QL>%H0--M*7U$(&K
MJV+HI3YFD/A-^"WVGW&4QT]4KN6"\M`A)NP7:PF(@=[W/B#^?`"3-0?)#YO)
MDIQ3$@IX4I:'C@YARI,6Q-?[VN-+3.B0$5;DML0'?4GK3KW>PRMU1>Z@4*F/
M=;<%W9G+O"'P*!9M=&I+>,XNBN$E1'B:X)ZL27UR=#A]R=H"C[7A[.RE1.CL
M2AI65/(Y<.XG*&1K*C]VE&S%?$WEXW'^OB]2>D`MOOAQ>.WC^%]^E*$%FS^;
M''O"#RX!FV*7^!6'B(0/Z@ONWK\-'G#$5A1/,R+.[M@G*+K_HA%KAJGT[Q#"
M>_AU\$@M@Q!?P9A,PC/`Z6`]X.3WZQBA^H72J817]&WPZ#:@HBL=$6?>$`-8
M>9_U@_5L,\^YMJ4ZK?3W4?`P0*V$M;^AJ*2T#S/SB;QVA":Z2RA'G:HO^U-&
MLB#ASRA<\]CI_"%1T3\[;Y[6K4*X_.PD+]EW/#GW(_[.[O$%H?26?YOQ?_Z^
M+\!.7GF'>0R4\_<2V25*\)KD97595/K[*+S;42?VQ<M*O\,U[IB\N7<.'^6K
M/S*FBO)UEY)\T-4AM97UH)V7^B5<LG?I!F3<<M)`I8W#+2P/[>.DY4A,K13+
MN"FM739H@W$?E85V5Y)R(J90V/]QT[<+X6"8!$%8'MJ?"&2EE@W$R',E'.'2
M+M*2&M#^15*"#/G<HQCW#*]=V1AE3!"6A_8J4K`C6ZHE*`:6?ZL1&$$=AU-8
M&-H_R)@:-82AI5$XMI&\:W)TR2I`.P;9$:2$,?)8F37M8*<RW!K$3576`_<-
M@M!^]",R&5'YS.;*+4V2)=G_[@Z9&1\E=0?@+*2C3T>["AGP2SU9(E)^;"O<
MF>K.<(6;4]TACOM!"C)_+T@H6!MENT$_7QN`]Y"=X/0]%JZTAA"M,,&\[N<,
MAWSE[%OB\J$[K=AU^^0`W(5<RYZ#`7&US743P)&[SH([\K3=#:UA]OB$\41W
MQ[<\G!_497'Q<8/[W\."$%>Z^U0&RRV*&0%DG7<J7"0)2A/=Y:Q)=>AKUN-!
MEIC6#+&,V\YV'U.&+GV_9P>OE.T8_&YA6[B;&-C5#6I#WX>:TB@6`D.`$Y4!
M(T.Z06WHNT]#%BU%X!#?P"RTA8RS3]*8UWE_W/J!+F>5O`KTC:<A!P)-6@-J
MB$E8BBXO5RL<(&/:CHI#WVYVI4P(:`J)5QZSYP3]D7%/C-=R.'2WU^(:X%>5
MG796!:BQWT4?(]/?1LOJ@%]ARFDRYG6/9-QZ4@.:]DY:6![\XE/%CQ&E1[>?
M(Z53N&J97*RI*X)?G'9:EO781GY%=@@P>>!27<3F45^/*>N!WZ;J:3.A6X1J
MB!KR8:\7ZQ@A?11"PYK@MYRV5-K@ZDU_/I$9]X:P']&3_P9FR]WUP.IACZ*6
MG957ZO93D,>^D,O+U5N`$K;4ORU?47R)&!$!SFFXQF^52,D]@NS;@K;I:L97
M,&':HASB<FB,Y=Y/N<=_9^;+=J!-NSVR7D,X!9M#$W>RWR]HDESX<?R^HC%_
M3:IV*#-N!=KB:R4:+?%-(5GL$61^C5R0%47T2W&C;RX0Q[6A+<=N!$&,J_.U
M^*="``A:<Z>-H8A`[74U.P3H<T.;-0!MCW8C"%)HKH+VIC3U(S#-.N6:=9G[
M8O95M2Y<L?PTXS='NP\]H("2@$E!/OQYZM#BR%S$=98&<+1O:7QJ=3N,0U2J
M\U31G3FW:V5\"K4]OBFHTQ+`=Y0ONUF0O]\JD9NL7/I61JE.6^*#SILA60<D
M*(ST9+L&1J4JVT-SY40ZB(FO7?TU-4:I#2NP3$/]K1N6YW\Q]=?1L^WB1"21
M%/Y\#Y,,DW5I6:'$Q"VZ?:.C4J#=P)U$PKER"/*8-0L2WK(O13:KKE%]:&V[
M&\]*V=$#GX285.89M\M-AU9'J:=WQ`N=SU"BM^^N=DH8+6Y"+9J`UMT[<BC0
M[2W!#]&$HX.@N0XUK`ZMRI^>^AIP6&N.[LA^.!)6=Y[M&H)VR78O"ZV&8*"F
MG&.[A&R<\NQ#-T2:P;I+<]`>W>YEI,-`3.L*U=X\I*D)[2SN5%8L,$_#G%2_
M34U9.QD#\-6HU,5EN[G9Z-ZC:VJ.TCQD@&G<[S)VH[+(TA<:X_1=\SY.7`':
MO&/`D\;,?@1G:KQJG\7)J@S&SG)$D2FE@WTX?ND3G+RPKFKB1AX6@[9_J`98
MH+$*>C_NN25?;&ZM'K1):T-;.5JOIH;8AA;(=2?03X7BJ-#:E.6A+1*&PZ^R
M/`@03>+VHI4/OL+P`F17T))E.R\=/A0'##C&4-VC.(^E9OU43188I-:F;CT0
ME84XNUWY,4_8ONO+N9_@@$<FQ%&6HC#W']R??DRNYUJV"'764[(AGAH=$()>
MP[B1F#M47HGS05/(P4$YZ,->!\K$,G"$SA&SX:X3<!$[?T-X_<)&9<&69W^-
M[C*N@R]7^<`MLS1)?1*RP6R,H4(4VC4(?8AT+C/MAP'Z#K]'N2I1%D%-:Z.P
M"/\G2]*-^FE3RQ:A3\.GD2RS<9C"*\D%27'(T>)7](B"+,X?@%V]!5'&],)K
M-OX\&5=6\+Q<-8=?>HWHM'WH$[ISH7,V*LX\SX%ND_)HX"\T8BB2(O<;4/"+
MXX[<T=3D0DE=$3;0<=ZW\_>+R$\LXAL?U8*^2](/L7B6:2"-VRPZR0RO&L8D
M-']-T7JP67U-T3IT2K^F:!T`?0D*OEO3UX\AP@5S[(<F8>Q7WBU:^]$54]BD
ME_6"4M`:J]5"*NF__.3<[X`7O9"N<\TB4-=`DE$['MIF9Z7"?_+@^#D^/I-]
M(L^EJ"@-=2\C&E7QZB/I]!#6'^@4T=#!>ENI>C(D(X_<ZB[',W2$7AE!AGSN
M48Q[BKK)\0P=>E=!CTS9D\$8F"N8@RS/T,%TC<G18!B:>Y##/,_0R3GM*%+C
M&/L.ESTG.,1^_/[H[S9]@^0@PCK@F2_;*2]*.*XL^5#\[B'=^1OVXU/LD\0/
M.`B],J.M#)Z24DV>A'`S6./6=&[NEUKM9E?&FT';1<PH$?-Y"&.(S\)O>,9:
M/[K/GB,<+%>L&_P!&]&DV5+7\F;0R9C:<&8*;`HQ^^YSO0'=1WZ0V]CUIAQA
M!6\&G9"IR^148()^L^WH2,E5C')X;@U>/@C+>[,QFGWD4%R]IH6_"+KWXV6<
M7Y.%>;[KRM?#[&I(5MN;`1N$Y-1IKXN4F";@#5R#6CB:E0^\_E0ZA"IJ>7-@
M>U$'LH58IK`Y'V$LLL_;,%S4\.;`!J?.[-9P3&1+;B*LN8K:$%RKYLVA0_=U
M9;D)QI5A`Y;J'&`AP)<9/T:PW0C38F.Z0U_R_U&[71G4]^;`=BU;\LU1N5+4
M!BD%A>!W$(-&`]X<V-KE2`Y$L$I!^/O(!:&VH;&39V"BKDOK>'-@JY@UW4HD
M)</_&+/65C=%U-\:E:!O2,TT86C8UC7CS8'M;-928`NN%(P?)B(8%Y0D."R#
M@SV@`.%7%"[M)4/?CC<'MLQU$`U#=*5L_#AFV;B/:8!0F/#W.WP.%.$"!29H
MI6G6L`UO#FS)LY4).V2E/'P:6)S-?(&[>@OR:(^[7,2+X(\,)S@/((OB@).Q
MEB9-L6C"FX_$>M<*V,ZZ,Z@K-#&*@PWN@HMN%/F2);Y-,][92$QWK<%5;`\P
MF'H.HWKLNRI<AA]K=@T9QP95O;.1&.VL`%5<#BT*LE@NZTKI$SWP"+>;O8J&
MO+.1F.TZP*M8'W6:JYHH7_A;G/I1`?N!L18SS?2:QM=9FL6H4E',[+AF;7EG
M([/OM4-8"0J8L4^:[U1AI<IMEH7_<I(_NC^G)+SWW_G-]`.*^"TDFQ+I.W_V
M?^RH*5U(^OND=S82(^%)!J*2N<YVQ1"M,,G5U391A-I(WFF%KL,PC\1*V?<8
M5*+6V<#9BZB52_:!(8[AXQO\<L7C)B0E6IGT&#?@G8W$8-D"5L5Q9ULE+,?Y
MPMJ9Z+P5[VPD-LBVV"K*.YL@'6LMQE"6I#O5K`WO;"2&Q7;(*IJ'9EFTDU@7
M7%<->6=CLC*V@[?S-YK"M;.9E]&Q-\[?1F)C5".HJ!RU5^!YEK`!2)@FNGG&
M)"?B,47;FK&\"+-2O=>\(?E_Q0@I+QA<-N_];22F2^>@*PES']CQ1%'U^!J)
M\S"5"9LX12JK-2(!WJ4`/W5XO5J/%LT>V:1OLFK'+OB>8E^6?-$P?X%Y"]"!
M]JQ'5[(_FZ.=EAL_@$49Z-JA!=6N+,SP&;XE*P5_Z%_N.\O5[E9%MBJ(2T/%
MZ>O,IP;3()/IEL>&A,G8`WWW(QZ#MS`3RDB3UX"*RN>&.#6NWN)<GT@=8GO7
MEA8:()#ZPW?/(J$H"FOY1'D$:=XU/_H<TVQKDB+$LB6(^,,'/;DA/*8U$T=A
MQQ_0*R)""V7[QJ"5J!8,B;?&=M#[TJA.-%?K=S`U'U&H<XNL.P8S55?5R>E$
M]A'#HXEA=>@I93*4@EW-`MTDLJY)\%YFB/O</M'Z_]L+KK`9T/.'!;_B%=86
MZ01.JWG$VFND?*2V*P-Z&NG,[@&,01Y`F+J]]E_1#<F[^L@.O#@0,J,H#7KP
M:,V1!M`4,NNP5>1@!6%'JHLLYD/*=,$[2H+B'RK=UZP%J%CC;F:I!4AGR6Y<
MSN%%&.*B&T:36%(<*HBY@UFL0.3JT3=H@JPD06GR,XKR!XU9HDQVU2P+FKBV
M\]04PG'U?AOJ@,D#.:(_,M;H%3LSIU#II@Y[87*>E%4!23%UV!=M;BE!<>@S
MI6HX)>X($A3CCM_91&603D!<`SQWE(0>,S)K(";'IS[^KJP.>-HH.4O&M$XE
M:50#FC;(I[`\=/(H)3]&E`XKB90S.F\-(GK*JH`GF^JR\AZ@&%HN@B8R,ZNZ
MNA;44<]D_`7'.SV887IC+%)6DJ!WB:WSJ`SH44T_R**#=Z/W$[!.EUE*SBEA
M$&S-9?K*4#FO6G%L!VL*H5*Y(.?^*YL-3OCKO"3/K*V@7%(#*@M6)YX56*9@
M#E^N5CA@W^<1!1!)9,%35,7!\F%UXE6*!#HPJLPKCG62]8-[D<7X.<M-AOJH
M1NI:8,FRVN^N!H"F8-X^,H<F08RWFLDIKP26<JO3%-7@<67RKI]*A-;NC[QW
MSWZ"V#_^%U!+`P04````"`!K3']&R'52QQ,0``!VO0``$0`<`'!M:',M,C`Q
M-#$R,S$N>'-D550)``.9HAI5F:(:575X"P`!!"4.```$.0$``.U=6V_;N!)^
M+]#_(/AE>QY<QTGO:'O@ULFN@6QL)-X+SLN"EFB;J$RZHI3$__X,*<FF1$JB
M+]U*55]:1YP9SGPSO`Q)4>__^[CRG7L<<,+HAT[_^5G'P=1E'J&+#YT_IE?=
M-QWGOQ^?/GG/W25>(2=$P0*'-VB%^1JY^$-G&8;K=[W>P\/#\[.SL_[+\]>O
MS]\\=]FJ=W[6?]$_O^B#1!^O,`VO6+`:XCF*_/!#YVN$?#(GV.LX3Y^`$I2_
M6Z^6W$[@TR>.9,E0/UP\9\$"J,[ZO;]_O[Z3"G><+?$[G]`O&8['6>"G/!<]
M43Q#'*LL@L(+MTPJP\M>7)@A]TOD_WT-%>2%DQ(&0GF(J)M52#,B,;O_]NW;
MGBS=P?..X@4*L5=8Q]M>P'S<2\C4>B+>72"TWG+.$9])KJ1`.J-[UN\*=VAL
M712&Q:Q0&)!9%&*NLKHLHF&PR6+-L?M\P>Y[2:&H]4*OU8V"`**VB#<I+5#9
MP\3,!P4%+/C179IY1$D!$Z'WF(=FMKBLP#J*B,O-?+)(L/5U-DY<,Q,4%+"`
M@\+-&G.CZV1)@6T\7`<%E4%)06T!GA<&YJL>E&:]M`ZP6Q',*'!E/,^1&W;Q
MX]I'%(4LV%S!WQE$&:71RBS("X.>,+4'1%V@P@%Q,[S5C`J3Z#D1I2Q$(72P
M']^C]9K0.1./15-])]2=`I,C?OQQ.RKK_J1I0^9&HB]%U(-_2;@1XH*5%-]Q
M"*!32K&MV,-S0HE4"FIQND[*IOX$$<ZEE.&,=D+>]_(24J$1Q]Z8?I2_P5U<
M:"$(1,>7<"4D)HZ=0#MZ%_ENY!=7T,L@?#CDGQGES">>"+Y/R!<]\MT2XS"&
MN[#4#/4YX'L'J.`$:Y7=2?@=*>`GS#&0$P2]=[C$(0%-RC'/DIH=<&'M`.=9
M1MY_VNR0+6+C^7B-`UDYUYUA)C,[XD69(W8%;.[L1/UT`=C%`5P(RN`S6X&E
M2TPYN<?7C)?YHYC'[)R75L[ATCM"KI,1[`C)/WTEV\%=R-PO2^9[D&-!\D-<
M8A@X*NC-/GIEW8!4F;\XSQ*Q/SNT0L0KQIQ]F,V^>WVL[WX.3D9W?$9\>>6S
MA_*Q:4=E]LX;:^\(28X4U38'W$6K%0HVT`+(@A((2D3#@2OS=$(7$X#+)3AQ
M@R6MV1EO149"N.LS'@58>":6)AO'3IZS$^BD$MOFDTG`8*H4;@;4N_P:D;6(
MTM@#QA(CWOVS/-XI;YP.IMQMPW88ZX6OR1R/1':](#,?#SC'81+EI11FK/MY
MK%,9CA#B[*0XL9BV@7[#0LPG:(,`@EOLB_X7AKUP$P->6&H&^SP/MN1W$@'P
M=R+#D4+:!C6,<??0RD6PS1CUUC$J00S)>@>Z!9T9_HL\_(HDYQ.(^NF)M*<)
MR#U4`PD:03/B@XIXV\68BLQXO]#[EI394;C;ANXU1CR%,_EMQN]E'K^8NFUX
MC2C\Q%/TF(*F/C`C]RJ/7,SB2)ZVX2>60B8XN%M"NI9$G?K$C.!K+?:`QP$F
M1W*U#4,U!Q83T'0L,CPWX_E&RR%VG+]P)^9M&ZJ?V6I%0KF.!VD!C,8B=\)T
ME[:5$9AQUG(U181,'S)"V@8X(+-FG"A;=<H#(Z#G6C*FL+0-/G6*/PT0Y<A5
MMB$*2\W`:IE79LKIJ!+:AO-=-./X:P3&7-YO%Q#R#\VH:BG6CLV1?.W#4JY5
ML?*5+^-JF2V/V1-:MF6_:N8\2W^U;E4Y7>I"RC+95.2D/+N,9B@WNT%+PLR+
M:<ZS6$KK`"];,U.!MZ`S.T#+XBI6V%KK";D89EC-"14O5-"8/:!E@Z7+;JW%
M7TFKU<#7'YM1UC)&->=N+:AJJJVB:GANAE5+'+.)>&N!M9NC#'&(B+_7M"9E
M,;OCB+U`L74N1;?.5Z9)2\8S901&/UQ8[A'^Q'R@0SK%CV&4GBJQH#-[0,M?
M*SS@).):YXETON?#=(]L9WM(3O8\M178$)I]H66]E7/,MC8+"XQ#M7GL06]V
MC98&V[JFM>VE:(Z?:2M51&9G:,EP12;0UE92@6[?R@?]`B=H";&=$YQ^.]U@
M.%YB&L<M:<TNV3=#;GL757T$)=-9V9.;W:.EUK8'5]K;@QG/J0RSLZT2"K,?
MM%S<?*"EO:C'!U0R,&<?F7'5DNJ8J;TX*FMN&3`-SXV(OM#2X^QB7+MQ#04(
MV:F,J<",K);V&I%MX61%C\WSHJ`]+\!62V/-V)ZW%%LU/#-):G&Q&6<M)S7C
MW-;9G;HVGQW+#`5FA+5$,[]JW]8>6#\PEUVB+RPVXZSEDJ9C=>U%6SG\AG+G
MYX;9!*62SHR_ECB6'K=KKR.40W/9)$1_;@9:2P$5SO;"6G3D+H-Q%9$9<"W7
M*SZ>UU[\<V?R<KNMQC(SVH9MU>RQO1\&8_&/N./K%L\=>5G6.W%ESX<.)ZNU
MCSO)LZ6\FDA<1]9-[QS[!TQZ_KCR4Q(AN>3J+NF?/`I)Q:F(Y+:B\LN\0(C<
MUX/^NY<JW^F=P!X`?%][LCZJE34^FNUK#;!@OW:&0%SO:TBN*9S6G%YZ8Q7\
MVMUC!05@"0M"AQIO`BRZQRZ^1/":N5),"8OXJYOR=<6C;O^\>]%__LB]6+$]
MZM]:M&?]*=]^]9OO"+2L.6405;ZTJ*ST6KZ".F5]1L8>]D.>/NGN1-E:77*=
M79DN!K;D=W<G8E\=3#<&VBBA\J5_'*.&Z?)!*SU4QNU?1SA%NYK01HLMD_QU
M1.WZ384VU>^XXI_=G8!]%<C?>FA3?<HC?AQ3=?X.1*NZ4R;Y:[_:JZ[YM.F,
M_"#(<(D>Z:WH!/NOCM'`LBM4:@^/K;G\5DA;;50IESLA^RE7>K^H352D/.+'
M?JVQXJY*&QCR7$<XQGS+YGY*,'ISB![E=YH>/F9*64:?)-<?2UUV]W.*(W_R
M;DWE:LW!C(>!#$N1PXF9X3]VY/'T4EXH_`Z>$;H8A7@E4I^.@Q*J#YTPB,3D
M4U+!=(\P;RKYO"B^7Z_C4.+[8BL[I>60"$*ED2C]-6#1.JV$@/B.T_OH:/;)
M-<#Q?(Z%%I<<6LV#8HZQ5-5^Q:#)HV!CTG^.?&XT()XIAFG1++[&\4/'#;`G
M[EL[@5GB#JC(%ZMIT/HQW=XA(*TR%1YMU,XK.:L\/#N14;\B0L?T"F*:0)J/
M.1_/AWBFAE\AQ;<S[X1.^PN3Q1(&K\$]#M`"?T(PD$-#&A(_@J?ZJ_G2Y'V8
M8A2@`Q.FR6<'8G"JAC?B/,+>,!+-:R)KDEKQ/Y$?X?C@BKCJ?3P7!U<,!Y:$
MH=K1C$V^`7^K6AH15*4(?'.(3X0NE\*^7["*G0I&8Y-B4T<43(GOYU-/T\F0
MRG2U^S$V(J2LC3H$B"8[?DP/][WD_;'<?R`<&A+?.PBDSI>/[A+1!1XL`BP+
M=7M@WC%POT8DV:-3.L-\MW`RB8T(F..MC:E."F`JLDZ!)G06Z(_G&4LHC*(4
MR_W#OTBXG$0SG[AI5E(69B>2UX@@.]96+<1.)?"'"[!LMWXZD:T(L]."5[NA
MTLZ@D=B71?ZI.S);L3]0H%6:?&"W9BWW1PV^0]KI'I);%X+?!,^=Y.:%X40N
M>>")CUS)?()Y7+7$'RCLRJP]="YG(;).@39PW6@5R96T2Q10T)7?LHB*KV$J
MMI=2-2(@#EY$-"R7GT#6D:OHV]V?$R!3]"*OP?!JT@;9E1U-K*AK9)UY\4)9
MIP#%77$4<U&]9E3`E;%6/*W;ZIFZ2#-E\=>!Q%>Y$-U4VES*6Z<.VCSL5(Y+
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M>JBEK/I#<Q.M9CB`>!:EGT74^7Y29P40)9SU-UM9$,AO3"J+_)"5I:LC^Q^*
MW$]NG2"[1K/M+?&@ZHA"]?)%,_X[%CY79U*5I)E9B,=6B-#O-OY>P2P]&53%
ME#:9T4X@%7798*U;9TE?)Q-O&!W1$$/\A)\P$A%VS1!--+^+:$`XOB(4FBM!
MOI0)6;EF^%%2Z@7'UFV_QXH:;"TBJ9,A=R2=#L)<9$4X9\%&T7S*;OP9)(;3
M!_8_'+`QQ>*_2^'#M7`6O_9U+Y]09IV@,K=:B%H\AMZ3_@:C-`2T?7LOX6R0
MV?L:6T<3;7S8$&\5#SJU'EZ&7T(RT'7./JZ3P@=TB\WL]<0`#<KJ,[3L\[JI
M##`;55:>UT[E)4SVS4JK)753^XI%@5%KM:!V2L,@5:"U6E(WM6%F951:>5X[
ME?&]89*@E=1-[4MQ(8-1[4Q)W=2^(05=M5I0-Z6G!0$RK6=XB#U*^>)SG,B.
MS"<]2ZF.6ZD^Y9$*9=TU773*;"J+1<?=8>O<32V',-=I02KQT35>(/\*9Y;A
M]*)&[+W*65D4BO@02<J(REO\O`FFR,_L.%<1'FWMOW`_TBT6_8!XG2@Y*L#C
MLP**F<4DW\S`T^VMY+H0K8\L**]37VDXQ:`G><4T=3)%?J+(NT8S%LAK^.[$
M%6_ZN%5&53]SQO,Y<7&9*0:*.IDQ!LE([)1);;?[)4/,W8"L<QM.-L1VV_K_
MSO@TQ',L>N4I>I3?"H5!%G,.?XUA4!WB=8!=(FN[(H_8BS\GFFE8A[`WH&.T
M-FR"0K%G=`@F6]8&X'$7(J"'WF;[Y:5;[#+J0E\J;;D%6Y(#H9\PQ7.2.?YR
M`',33B:,PR4.#@%D7\8F@%%@CCA-$U_KZ?OL(;XP73U;;,O3!`BV+3UQG%T?
MNA?7CP"#WF5:<S3!_&U09UOQ;F;`./^,@F`S9\$#"CQN:A#VO$V`1&_0!8:F
MIY0'*Y%)Y0[E'22A$3GU$%'"EV"+GKGD2^HT,]ZZH/CD:S&)W2SX7[+#<(&(
M:4>JBK!.SMDNER4OV<[C%Z#OE!6U;`]<35VGA37EHW"#W.?EBJ-Q'Z8:Q><4
M!RM"I;SQ?)M3*G85$:@VI!I]QQ/+\2V>XB6B6[9!OO@P3[R*FSE#4$Q4+W.*
MO@%7''[6'#6*/7%).KJ'`56N4]_AX)ZXF67L(H)&#+P#SY/'6I%?9%XA11/F
M7;GOY96]H%).6*.`'(0A"RC>Y'=3,H^;X)P)S%J!6HQ"`9E)3F[<YZLB/&ZK
M[TCG].)OBWQ\^N3_4$L!`AX#%`````@`:TQ_1JLO(E7_L0``>\D)`!$`&```
M`````0```*2!`````'!M:',M,C`Q-#$R,S$N>&UL550%``.9HAI5=7@+``$$
M)0X```0Y`0``4$L!`AX#%`````@`:TQ_1L-6N43G#```VM```!4`&```````
M`0```*2!2K(``'!M:',M,C`Q-#$R,S%?8V%L+GAM;%54!0`#F:(:575X"P`!
M!"4.```$.0$``%!+`0(>`Q0````(`&M,?T:GVCEOE!<``#![`0`5`!@`````
M``$```"D@8"_``!P;6AS+3(P,30Q,C,Q7V1E9BYX;6Q55`4``YFB&E5U>`L`
M`00E#@``!#D!``!02P$"'@,4````"`!K3']&M&\T[E9A``"Q[P4`%0`8````
M```!````I(%CUP``<&UH<RTR,#$T,3(S,5]L86(N>&UL550%``.9HAI5=7@+
M``$$)0X```0Y`0``4$L!`AX#%`````@`:TQ_1EY6)*42-@``FKP#`!4`&```
M`````0```*2!"#D!`'!M:',M,C`Q-#$R,S%?<')E+GAM;%54!0`#F:(:575X
M"P`!!"4.```$.0$``%!+`0(>`Q0````(`&M,?T;(=5+'$Q```':]```1`!@`
M``````$```"D@6EO`0!P;6AS+3(P,30Q,C,Q+GAS9%54!0`#F:(:575X"P`!
@!"4.```$.0$``%!+!08`````!@`&`!H"``#'?P$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Convertible Bond Payable - Related Party<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Convertible Bond Payable - Related Party [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">CONVERTIBLE BOND PAYABLE - RELATED PARTY</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 5&#160;&#8212;&#160;CONVERTIBLE BOND PAYABLE &#8211; RELATED PARTY</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 27pt; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On December 1, 2011, DanDrit Denmark borrowed $1,500,000 from DKTI A/S and issued 6% convertible bonds. The bonds may not be converted during the four weeks following the publication of the annual report. The bonds may not be repaid until the bonds&#8217; expiration on December 31, 2014.&#160;&#160;The bonds shall not accrue interest after expiration.&#160;&#160;The bonds and related accrued interest are convertible into common shares of the Company at an initial rate of $9.58 per common share.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The conversion/adjustment features had an estimated fair value of $1,003,557 using the Black-Scholes pricing model using the assumptions set forth below and were bifurcated and properly classified as derivative instruments required to be recorded at fair value (Note 6). The proceeds from the bond have been allocated to the note and conversion/adjustment feature of the convertible bond and recorded at a discount which was amortized to interest expense through conversion. During the years ended December 31, 2013 and 2012, the Company recorded interest expense of $502,465 and $461,279, respectively, for the accretion of the discount on the note.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On December 16, 2013, the $1,500,000 convertible bond, accrued interest of $179,612 and the $673,736 derivative liability were converted into 174,578 shares of DanDrit Denmark common stock. Such shares of common stock were exchanged for 261,665 shares of common stock of the Company upon the closing of the Share Exchange.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The assumptions used to determine the initial fair value of the conversion feature of the convertible bond were expected volatility of 65%, expected life of two years to twelve months, risk &#8211; free interest rates of .41%, and no dividend yield.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Liabilities [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITIES</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 6 &#8212; DERIVATIVE LIABILITIES</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The Company does not use derivative financial instruments to hedge exposures to cash-flow, market or foreign-currency risks. However, the Company has entered into certain other financial instruments and contracts, such as debt financing arrangements with features that are either (i)&#160;not afforded equity classification, (ii)&#160;embody risks not clearly and closely related to host contracts, or (iii)&#160;may be net-cash settled by the counterparty. These instruments are required to be carried as derivative liabilities, at fair value.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.55in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">The fair value of the shares to be issued upon conversion of the bond was recorded as a derivative liability, with the change in the fair value recorded as a gain or loss in the accompanying statement of operations.&#160;&#160;During the three and nine months ended September 30, 2013, the Company recorded gains of $4,180 and $45,823, respectively. On December 16, 2013, the $1,500,000 convertible bond, accrued interest of $179,612 and the $673,736 derivative liability were converted into 174,578 shares of DanDrit Denmark common stock or 261,665 shares of common stock of the Company upon the closing of the Share Exchange.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80748-113994<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4K<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708775-113959<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 25<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6886632&amp;loc=d3e76258-113986<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4E<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624181-113959<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6441202&amp;loc=d3e80720-113993<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4H<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624258-113959<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624163-113959<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(n))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4J<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5708773-113959<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35736893&amp;loc=d3e80784-113994<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4D<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624177-113959<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41620-113959<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579245-113959<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1B<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5580258-113959<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5579240-113959<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41641-113959<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=d3e41638-113959<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 8&#160;&#8212;&#160;INCOME TAXES</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">The Company accounts for income taxes in accordance with FASB ASC Topic 740, Accounting for Income Taxes; which requires the Company to provide a net deferred tax asset or liability equal to the expected future tax benefit or expense of temporary reporting differences between book and tax accounting and any available operating loss or tax credit carry forwards. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other future events, the effects of which cannot be determined.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">As of December 31, 2014 the Company had net operating loss carryforwards of approximately $2,380,106 for Danish tax purposes which do not expire.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">The Company files Danish income tax returns, and they are generally no longer subject to tax examinations for years prior to 2007 for their Danish tax returns.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">The temporary differences, tax credits and carry forwards gave rise to the following deferred tax asset (liabilities) at December 31, 2014 and 2013:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height:
 normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over book depreciation Fixed assets</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">12,711</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">87,578</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over book depreciation Patents</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">52,041</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">114,028</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Net Operating Loss Carryforward</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font
 style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,380,106</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,642,598</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">Valuation Allowance</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(2,444,858</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(1,844,204</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt;"><font style="font-family: 'times new roman', times, serif;">Total Deferred Tax Asset (Liabilities)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td
 style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">In accordance with prevailing accounting guidance, the Company is required to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognize and disclose any income tax uncertainties. The guidance provides a two-step approach to recognizing and measuring tax benefits and liabilities when realization of the tax position is uncertain. The first step is to determine whether the tax position meets the more-likely-than-not condition for recognition and the second step is to determine the amount to be recognized based on the cumulative probability that exceeds 50%. The amount of and ultimate realization of the benefits from the deferred tax assets for income tax purposes is dependent, in part, upon the tax laws in effect, the Company&#8217;s future earnings, and other future events, the effects of which can be difficult to determine and can only be estimated. Management estimates that it is more likely than not that the Company will not generate adequate net profits to use the deferred tax assets; and consequently, a valuation allowance was recorded for all deferred tax assets.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">A reconciliation of income tax expense at the federal statutory rate to income tax expense at the Company&#8217;s effective rate is as follows at December 31, 2014 and 2013:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color:
 #cceeff;"><td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Computed Tax at Expected Statutory Rate</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(866,463</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(752,882</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Non-US Income Taxed at Different Rates</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">255,356</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">199,292</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">Non-Deductable expenses</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">8,390</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td
 style="font-style:
 normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">283,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">Valuation allowance</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">436,631</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">270,209</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Income Tax Expense</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing:
 normal; line-height:
 normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in; text-align: justify;"><font style="font-family: 'times new roman', times, serif;">The components of income tax expense (benefit) from continuing operations for the years ended December 31, 2014 and 2013 consisted of the following:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">Current Tax Expense</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1068.49426269531px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Danish Income Tax</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(177,539</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Deferred Income Tax Expense (Benefit)</font></td><td style="font-size:
 10pt;"><font style="font-family:
 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over Book Depreciation Fixed Assets</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">19,259</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">26,364</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over Book Depreciation Patents</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">67,488</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(105,585</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Net Operating Loss Carryforwards</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times
 new roman', times,
 serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(523,378</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(190,988</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Change in the Valuation allowance</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">436,631</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">270,209</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">Total Deferred Tax Expense</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new
 roman', times,
 serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">Deferred income tax expense/(benefit) results primarily from the reversal of temporary timing differences between tax and financial statement income.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ED6AE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Notes Payable - Related Party (Details) (USD $)<br></strong></div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Notes Payable - Related Party</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt" onclick="toggleNextSibling(this);">$ 99,951</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt" onclick="toggleNextSibling(this);">$ 728,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less Current Maturities</a></td>
        <td class="num"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">(99,951)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
        <td class="num"><a title="us-gaap_LongTermDebtCurrent" onclick="toggleNextSibling(this);">(728,001)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebtCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Note Payables - Related Party Long Term</a></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember', window );">Non Interest Bearing Loan Payable Sunrise Financial Group Inc [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Notes Payable - Related Party</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember]" onclick="toggleNextSibling(this);">38,235</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NotePayableMlGroupMember', window );">Note Payable ML Group [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Notes Payable - Related Party</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NotePayableMlGroupMember]" onclick="toggleNextSibling(this);">18,963</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NotePayableMlGroupMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NotePayableMlGroupMember]" onclick="toggleNextSibling(this);">21,557</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_NotePayableMlGroupMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember', window );">6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Notes Payable - Related Party</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember]" onclick="toggleNextSibling(this);">42,753</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember', window );">5% Note Payable - Sune Olsen Holding ApS [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Notes Payable - Related Party</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember]" onclick="toggleNextSibling(this);">521,390</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenMember', window );">5% Note Payable - Sune Olsen [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total Notes Payable - Related Party</a></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenMember]" onclick="toggleNextSibling(this);">$ 0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_FivePercentNotePayableSuneOlsenMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_LongTermDebt[us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenMember]" onclick="toggleNextSibling(this);">$ 185,054</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LongTermDebt<br>/ us-gaap_RelatedPartyTransactionsByRelatedPartyAxis<br>= pmhs_FivePercentNotePayableSuneOlsenMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 7<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 16<br><br> -Article 9<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20, 22<br><br> -Article 5<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.16)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 20<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenHoldingApsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_FivePercentNotePayableSuneOlsenMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NonInterestBearingLoanPayableSunriseFinancialGroupIncMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NotePayableMlGroupMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_NotePayableMlGroupMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=pmhs_SixPercentPromissoryNotePayableToNlbditTwoZeroOneZeroEnterprisesLlcMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Related Party Transactions<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
        <td class="text"><div>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 13&#160;&#8212;&#160;Related Party Transactions</b></font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">During the year ended December 31, 2014 and 2013, the Company entered into various notes payable with shareholders of the Company (See Note 4).</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">On March 27, 2014 the Company entered into an operating lease agreement for office space from a shareholder of the Company (See Note 7). During the year ended December 31, 2014, the Company paid the related party DKK 130,000 or approximately $23,152.</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p>
<p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">During the year ended December 31, 2014 and 2013, a law firm partially owned by the Company&#8217;s Chairman of the Board of Directors provided legal services to the Company. During the years ended December 31, 2014 and 2013 the Company recorded legal expense of $288,546 and $328,202, respectively. During the year ended December 31, 2013 the firm forgave $49,016 in legal services. At December 31, 2014, the Company had a payable to the firm in the amount of $212,438. During the years ended December 31, 2014 and 2013, the firm held funds in trust on behalf of the Company in connection with stock offerings and to facilitate settling outstanding liabilities. Balances held in trust at December 31, 2014 and 2013 were $2,014,909 and $14,593, respectively<font style="font-family: 'times new roman', times, serif;">.</font></p>
</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph b<br><br> -Article 3A<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(k))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph k<br><br> -Article 4<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 850<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E2F">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Notes Payable - Related Party (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable - Related Party [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Summary of notes payable and related parties</a></td>
        <td class="text"><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;"></font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="6"><font style="font-family: 'times new roman', times, serif;">December 31,</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="text-align: center; font-size: 10pt;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1191px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Non-Interest Bearing Loan Payable Sunrise Financial Group Inc.</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">38,235</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Note Payable ML Group</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">18,963</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font:
 10pt/normal 'times new roman', times, serif;
 text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman',;">21,557</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">6% Promissory Note payable to NLBDIT 2010 Enterprises, LLC</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">42,753</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">5% Note Payable - Sune Olsen Holding ApS</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">521,390</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">5% Note Payable - Sune Olsen</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">0</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">185,054</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch:
 normal;"><font style="font-family: 'times new roman', times, serif;">Total Notes Payable
 &#8211; Related Party</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">99,951</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times,; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">728,001</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Less Current Maturities</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(99,951</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(728,001</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Note Payables &#8211; Related Party Long Term</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-size-adjust: none; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of maturities of long term debt</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;"><br class="apple-interchange-newline" /></font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;"><u>Year ending December 31,</u></font></td><td style="font-size: 10pt; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: right;" colspan="2"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1240.73864746094px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">99,951</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2015</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2016</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2017</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt;
 line-height:
 normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 9pt;"><font style="font-family: 'times new roman', times, serif;">2018</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt; padding-left: 0px; text-align: left; text-indent: 0px;"><font style="font-family: 'times new roman', times, serif;">Thereafter</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt; padding-bottom: 1.5pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">99,951</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 470<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6KAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Subsequent Event (Details) (Subsequent Event [Member], USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 13, 2015</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Subsequent Event [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_SubsequentEventTextualAbstract', window );"><strong>Subsequent Event (Textual)</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_AttorneyFees', window );">Attorney fees</a></td>
        <td class="nump"><a title="pmhs_AttorneyFees[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 4,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_AttorneyFees<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrentAndNoncurrent', window );">Bonuses</a></td>
        <td class="nump"><a title="us-gaap_AccruedBonusesCurrentAndNoncurrent[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">10,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccruedBonusesCurrentAndNoncurrent<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeesAndCommissionsOther', window );">Consulting fee per hour</a></td>
        <td class="nump"><a title="us-gaap_FeesAndCommissionsOther[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">150.00</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_FeesAndCommissionsOther<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OfficersCompensation', window );">Gross salary per month</a></td>
        <td class="nump"><a title="us-gaap_OfficersCompensation[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">$ 60,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OfficersCompensation<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_PensionContributionsPercentage', window );">Pension contributions percentage</a></td>
        <td class="nump"><a title="pmhs_PensionContributionsPercentage[us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember]" onclick="toggleNextSibling(this);">10.00%</a><span style="display:none;white-space:normal;text-align:left;">pmhs_PensionContributionsPercentage<br>/ us-gaap_SubsequentEventTypeAxis<br>= us-gaap_SubsequentEventMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventDescription', window );">Subsequent Event, Description</a></td>
        <td class="text">(i) all salary payable in accordance with the terms of the Wolfe Employment Agreement, along with any unpaid accrued expenses, through the Termination Date; (ii) attorney fees of up to a maximum of $4,000; (iii) a bonus in an amount equal to $10,000 following the filing of the Company's Annual Report on Form 10-K for the year ended December 31, 2014; and (iv) a fee of $150.00 per hour for any consulting services that Mr. Wolfe may provide in connection with the filing and completion of the Company's current and periodic filings with the Securities and Exchange Commission; provided that the first 100 hours of consultant services provided from May 1, 2015 through October 31, 2015 shall not be billable.<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_AttorneyFees">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of expense provided in the period for attorney fees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_AttorneyFees</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_PensionContributionsPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Pension contributions percentage.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_PensionContributionsPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_SubsequentEventTextualAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_SubsequentEventTextualAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrentAndNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-03.15(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 210<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-03.15(a))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph a<br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 15<br><br> -Subparagraph 5<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrentAndNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeesAndCommissionsOther">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Fee and commission revenue earned from sources not otherwise specified in the existing taxonomy.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 942<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.9-04.13)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 13<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_FeesAndCommissionsOther</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OfficersCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OfficersCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventDescription">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 855<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsequentEventDescription</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Details 1) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit', window );">Computed Tax at Expected Statutory Rate</a></td>
        <td class="num"><a title="pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" onclick="toggleNextSibling(this);">$ (866,463)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit</span><span></span></td>
        <td class="num"><a title="pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit" onclick="toggleNextSibling(this);">$ (752,882)</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit', window );">Non-US Income Taxed at Different Rates</a></td>
        <td class="nump"><a title="pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" onclick="toggleNextSibling(this);">255,356</a><span style="display:none;white-space:normal;text-align:left;">pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit</span><span></span></td>
        <td class="nump"><a title="pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit" onclick="toggleNextSibling(this);">199,292</a><span style="display:none;white-space:normal;text-align:left;">pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-Deductable expenses</a></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpense" onclick="toggleNextSibling(this);">8,390</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncomeTaxReconciliationNondeductibleExpense" onclick="toggleNextSibling(this);">283,381</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_IncomeTaxReconciliationValuationAllowance', window );">Valuation allowance</a></td>
        <td class="nump"><a title="pmhs_IncomeTaxReconciliationValuationAllowance" onclick="toggleNextSibling(this);">436,631</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IncomeTaxReconciliationValuationAllowance</span><span></span></td>
        <td class="nump"><a title="pmhs_IncomeTaxReconciliationValuationAllowance" onclick="toggleNextSibling(this);">270,209</a><span style="display:none;white-space:normal;text-align:left;">pmhs_IncomeTaxReconciliationValuationAllowance</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense</a></td>
        <td class="num"><a title="us-gaap_IncomeTaxExpenseBenefit" onclick="toggleNextSibling(this);">$ (177,539)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncomeTaxExpenseBenefit</span><span></span></td>
        <td class="text">&nbsp;&nbsp;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_IncomeTaxReconciliationValuationAllowance">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Income Tax Reconciliation Valuation Allowance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_IncomeTaxReconciliationValuationAllowance</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Other Income Tax Reconciliation Rate Expense Benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_OtherIncomeTaxReconciliationRateExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Statutory Income Tax Reconciliation Rate Expense Benefit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StatutoryIncomeTaxReconciliationRateExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Income Tax Expense (or Benefit)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 13<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Consolidated Statements of Other Comprehensive Loss (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>STATEMENTS OF OTHER COMPREHENSIVE LOSS [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">(Net Loss)</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,370,883)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (2,147,361)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">(Currency Translation, Net of Taxes)</a></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" onclick="toggleNextSibling(this);">(306,439)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</span><span></span></td>
        <td class="num"><a title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" onclick="toggleNextSibling(this);">(219,470)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">(Other Comprehensive Loss)</a></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (2,064,444)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
        <td class="num"><a title="us-gaap_ComprehensiveIncomeNetOfTax" onclick="toggleNextSibling(this);">$ (2,366,831)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ComprehensiveIncomeNetOfTax</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35737396<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 10A<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 220<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e640-108580<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Property and Equipment<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
        <td class="text"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 2&#160;&#8212;&#160;PROPERTY AND EQUIPMENT</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Property and equipment consisted of the following at December 31, 2014 and December 31, 2013:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><table style="width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Useful Life</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">31-Dec<br />2014</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;" colspan="2"><font style="font-family: 'times new roman', times, serif;">31-Dec<br />2013</font></td><td style="font: bold 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; width: 1003px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Lab equipment and instruments</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 173px; text-align: center; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">4-6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 16px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 142px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">178,547</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 141px; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">194,143</font></td><td style="font: 10pt/normal 'times new roman', times, serif; width: 15px; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Computer equipment</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: center; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">4-6</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new
 roman', times,
 serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">61,151</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">66,493</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">239,698</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">260,636</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Less Accumulated Depreciation</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 1.5pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(239,698</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">(260,636</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">Net Property and Equipment</font></td><td style="padding-bottom: 4pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="padding-bottom: 4pt; font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif;
 text-align: left; padding-bottom: 4pt; font-stretch:
 normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; padding-bottom: 4pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="font: 10pt/normal 'times new roman', times, serif; text-align: left; padding-bottom: 4pt; font-stretch: normal;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font-family: 'times new roman', times, serif;">Depreciation expense amounted to $0 and $2,706, for the year ended December 31, 2014 and 2013, respectively. The Company&#8217;s property and equipment is held as collateral on the notes payable related party.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2921-110230<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.13-14)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of deferred tax asset (liabilities)</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;"><br class="apple-interchange-newline" /></font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over book depreciation Fixed assets</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">12,711</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">87,578</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over book depreciation Patents</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">52,041</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times
 new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">114,028</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Net Operating Loss Carryforward</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">2,380,106</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">1,642,598</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">Valuation Allowance</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(2,444,858</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(1,844,204</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 20pt;"><font
 style="font-family: 'times new roman', times, serif;">Total Deferred Tax Asset (Liabilities)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of income tax expense at the federal statutory rate</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;"><br class="apple-interchange-newline" /></font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1081.81811523438px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Computed Tax at Expected Statutory Rate</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(866,463</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(752,882</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Non-US Income Taxed at Different Rates</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">255,356</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times,
 serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">199,292</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">Non-Deductable expenses</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">8,390</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">283,381</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">Valuation allowance</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">436,631</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">270,209</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"><font style="font-family: 'times new roman', times,
 serif;">Income Tax Expense</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of income tax expense (benefit) from continuing operations</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;"><br class="apple-interchange-newline" /></font></p><table style="width: 1422.72px; text-transform: none; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman', times, serif; word-spacing: 0px; border-collapse: collapse; widows: 1; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">Current Tax Expense</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2014</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><font style="font-family: 'times new roman', times, serif;">2013</font></td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1068.49426269531px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Danish Income Tax</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 128.18180847168px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(177,539</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="width: 14.5454540252686px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="width: 127.272727966309px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="width: 13.63636302948px; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-weight: bold; font-style: normal; font-variant: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">Deferred Income Tax Expense (Benefit)</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: right;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-size: 10pt; text-align: left;"><font style="font-family:
 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over Book Depreciation Fixed Assets</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">19,259</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">26,364</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Excess of Tax over Book Depreciation Patents</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">67,488</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(105,585</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Net Operating Loss Carryforwards</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(523,378</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal;
 font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">(190,988</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">)</font></td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt;"><font style="font-family: 'times new roman', times, serif;">Change in the Valuation allowance</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">436,631</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">270,209</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">Total Deferred Tax Expense</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; padding-bottom: 1.5pt;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">$</font></td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: right;"><font style="font-family: 'times new roman', times, serif;">-</font></td><td style="padding-bottom: 1.5pt; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; text-align: left;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></td></tr></table><div>&#160;</div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 12<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>117</ContextCount>
  <ElementCount>265</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>36</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Documentandentityinformation</Role>
      <ShortName>Document and Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheet</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheet</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Balance Sheet (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedBalanceSheetParenthetical</Role>
      <ShortName>Consolidated Balance Sheet (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statement of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedStatementOfOperations</Role>
      <ShortName>Consolidated Statement of Operations</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Other Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedStatementsOfOtherComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Other Comprehensive Loss</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statement of Stockholders' (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficit</Role>
      <ShortName>Consolidated Statement of Stockholders' (Deficit)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - Consolidated Statement of Stockholders' (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedStatementOfStockholdersDeficitParenthetical</Role>
      <ShortName>Consolidated Statement of Stockholders' (Deficit) (Parenthetical)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Statement - Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/ConsolidatedStatementOfCashFlows</Role>
      <ShortName>Consolidated Statement of Cash Flows</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Definite Life Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/DefiniteLifeIntangibleAssets</Role>
      <ShortName>Definite Life Intangible Assets</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Notes Payable - Related Party</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.0001527728.com/role/NotesPayableRelatedParty</Role>
      <ShortName>Notes Payable - Related Party</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Convertible Bond Payable - Related Party</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Convertiblebondpayablerelatedparty</Role>
      <ShortName>Convertible Bond Payable - Related Party</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/LossPerShare</Role>
      <ShortName>Loss Per Share</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/StockholdersEquity</Role>
      <ShortName>Stockholder's Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Disposition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Disposition</Role>
      <ShortName>Disposition</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Definite Life Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/DefiniteLifeIntangibleAssetsTables</Role>
      <ShortName>Definite Life Intangible Assets (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Notes Payable - Related Party (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.0001527728.com/role/Notespayablerelatedpartytables</Role>
      <ShortName>Notes Payable - Related Party (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/LossPerShareTables</Role>
      <ShortName>Loss Per Share (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/PropertyAndEquipmentDetailsTextual</Role>
      <ShortName>Property and Equipment (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Definite Life Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Definitelifeintangibleassetsdetails</Role>
      <ShortName>Definite Life Intangible Assets (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Definite Life Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Definitelifeintangibleassetsdetailstextual</Role>
      <ShortName>Definite Life Intangible Assets (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Notes Payable - Related Party (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.0001527728.com/role/Notespayablerelatedpartydetails</Role>
      <ShortName>Notes Payable - Related Party (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Notes Payable - Related Party (Details 1)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.0001527728.com/role/Notespayablerelatedpartydetails1</Role>
      <ShortName>Notes Payable - Related Party (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Notes Payable - Related Party (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.0001527728.com/role/NotesPayableRelatedPartyDetailsTextual</Role>
      <ShortName>Notes Payable - Related Party (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Convertible Bond Payable - Related Party (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Convertiblebondpayablerelatedpartydetails</Role>
      <ShortName>Convertible Bond Payable - Related Party (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/DerivativeLiabilitiesDetails</Role>
      <ShortName>Derivative Liabilities (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Income Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Incometaxesdetails1</Role>
      <ShortName>Income Taxes (Details 1)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Income Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/IncomeTaxesDetails2</Role>
      <ShortName>Income Taxes (Details 2)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/Incometaxesdetailstextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/LossPerShareDetails</Role>
      <ShortName>Loss Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Stockholder's Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholder's Equity (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Disposition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/DispositionDetails</Role>
      <ShortName>Disposition (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.0001527728.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element pmhs_IssuanceOfCommonSharesInConnectionWithPublicOfferingDuringPeriodValueOne had a mix of decimals attribute values: 0 2.</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Consolidated Balance Sheet</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Consolidated Balance Sheet (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 004 - Statement - Consolidated Statement of Operations</Log>
    <Log type="Info">Process Flow-Through: 005 - Statement - Consolidated Statements of Other Comprehensive Loss</Log>
    <Log type="Info">Process Flow-Through: 007 - Statement - Consolidated Statement of Stockholders' (Deficit) (Parenthetical)</Log>
    <Log type="Info">Process Flow-Through: 008 - Statement - Consolidated Statement of Cash Flows</Log>
  </Logs>
  <InputFiles>
    <File>pmhs-20141231.xml</File>
    <File>pmhs-20141231.xsd</File>
    <File>pmhs-20141231_cal.xml</File>
    <File>pmhs-20141231_def.xml</File>
    <File>pmhs-20141231_lab.xml</File>
    <File>pmhs-20141231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENNAG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Derivative Liabilities (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">9 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 16, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Sep. 30, 2013</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Derivative liabilities gain</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DerivativeGainLossOnDerivativeNet" onclick="toggleNextSibling(this);">$ 4,180</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DerivativeGainLossOnDerivativeNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_DerivativeGainLossOnDerivativeNet" onclick="toggleNextSibling(this);">$ 45,823</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DerivativeGainLossOnDerivativeNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Bond, related accrued interest and derivative liability, converted into shares</a></td>
        <td class="nump"><a title="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" onclick="toggleNextSibling(this);">174,578</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember]" onclick="toggleNextSibling(this);">1,500,000</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_ShortTermDebtTypeAxis<br>= us-gaap_ConvertibleDebtMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember', window );">Accrued Interest [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember]" onclick="toggleNextSibling(this);">179,612</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_ShortTermDebtTypeAxis<br>= pmhs_AccruedInterestMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember', window );">Derivative Liability [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember]" onclick="toggleNextSibling(this);">673,736</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_ShortTermDebtTypeAxis<br>= pmhs_DerivativeLiabilityMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability at 9.00 per shares, December 2013, Shares</a></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">261,665</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability', window );">Common shares issued upon conversion of bond payable-related party and derivative liability, value</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 26</a><span style="display:none;white-space:normal;text-align:left;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares conversion of bond payable related party and derivative liability</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockIssuedDuringPeriodSharesConversionOfBondPayableRelatedPartyAndDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Stock issued during period shares value conversion of bond payable related party and derivative liability.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">pmhs_StockIssuedDuringPeriodSharesValueConversionOfBondPayableRelatedPartyAndDerivativeLiability</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>pmhs_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4A<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 815<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4C<br><br> -Subparagraph (a),(c),(d),(e)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=35706170&amp;loc=SL5624171-113959<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=pmhs_AccruedInterestMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=pmhs_DerivativeLiabilityMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EME">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Disposition<br></strong></div>
        </th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Disposition [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSITION</a></td>
        <td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-family: 'times new roman', times, serif;"><b>NOTE 12&#160;&#8212;&#160;DISPOSITION</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-family: 'times new roman', times, serif;">On December 16, 2013,DanDrit Biotech A/S sold its&#8217; Dormant Singapore subsidiary DanDrit Singapore Pte. Ltd., for $1 resulting in no gain or loss from the sale and discontinuing the operations. The Company had no sales or operations for the periods presented in the accompanying financial statements.</font></p><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the facts and circumstances leading to the completed or expected disposal, manner and timing of disposal, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss), amounts of revenues and pretax profit or loss reported in discontinued operations, the segment in which the disposal group was reported, and the classification (whether sold or classified as held for sale) and carrying value of the assets and liabilities comprising the disposal group. Includes all disposal groups, including those classified as components of the entity (discontinued operations).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391110&amp;loc=d3e2941-110230<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e957-107759<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1012-107759<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1510-107760<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6892542&amp;loc=d3e1020-107759<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1436-107760<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 205<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6360339&amp;loc=d3e1474-107760<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=8077374&amp;loc=d3e2443-110228<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
